<SEC-DOCUMENT>0001601485-25-000049.txt : 20250331
<SEC-HEADER>0001601485-25-000049.hdr.sgml : 20250331
<ACCEPTANCE-DATETIME>20250331070746
ACCESSION NUMBER:		0001601485-25-000049
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		121
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250331
DATE AS OF CHANGE:		20250331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Elicio Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001601485
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				113430072
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39990
		FILM NUMBER:		25788822

	BUSINESS ADDRESS:	
		STREET 1:		451 D STREET, 5TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210
		BUSINESS PHONE:		(857) 209-0050

	MAIL ADDRESS:	
		STREET 1:		451 D STREET, 5TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Angion Biomedica Corp.
		DATE OF NAME CHANGE:	20140228
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>angn-20241231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:e62aa408-c713-4974-8057-b2b3ab20d8bb,g:40b09b34-8017-48cd-b202-ee62afe33f17,d:488c1714f53641d3b5e4dbb098e37e6c-->
<html xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2024" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:angn="http://www.angn.com/20241231" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:utr="http://www.xbrl.org/2009/utr" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>angn-20241231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-36">Nasdaq</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-37">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-38">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-39">0001601485</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-40">False</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-57" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-414">0.1</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-57" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-436">0.1</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-131" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-630">3.4</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-131" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-631">4.3</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-131" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-632">3.4</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-131" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-633">4.3</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-134" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-634">3.7</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-134" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-635">4.5</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-134" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="0" id="f-636">0.0368</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-131" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-637">0.0</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-132" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-638">0.0</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-131" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-639">79.5</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-131" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-640">107.8</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-6" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-641">71.7</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-134" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-642">75.5</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-134" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="0" id="f-643">0.7170</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-134" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="0" id="f-644">0.7550</ix:nonFraction><ix:nonNumeric contextRef="c-135" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-645">5.0</ix:nonNumeric><ix:nonNumeric contextRef="c-136" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-646">6.1</ix:nonNumeric><ix:nonNumeric contextRef="c-137" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-647">5.5</ix:nonNumeric><ix:nonNumeric contextRef="c-138" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-648">6.1</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="angn-20241231.xsd"/></ix:references><ix:resources><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="board_member"><xbrli:measure>angn:board_member</xbrli:measure></xbrli:unit><xbrli:unit id="agreement"><xbrli:measure>angn:agreement</xbrli:measure></xbrli:unit><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="day"><xbrli:measure>angn:day</xbrli:measure></xbrli:unit><xbrli:unit id="entity"><xbrli:measure>angn:entity</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:JulyPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:JulyPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:JulyPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">angn:ConversionOfConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">angn:ConversionOfConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">angn:ConversionOfConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">angn:ConversionOfConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">angn:ConversionOfConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:ReverseRecapitalizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="angn:StockIssuanceAxis">angn:AngionStockholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="angn:StockIssuanceAxis">angn:AngionStockholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="angn:StockIssuanceAxis">angn:ServiceAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="angn:StockIssuanceAxis">angn:ServiceAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">angn:FormerElicioEquityHoldersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">angn:FormerAngionEquityHoldersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">angn:AngionCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">angn:AngionCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">angn:FormerElicioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">angn:FormerElicioEquityHoldersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">angn:BridgeLoanBetweenAngionAndFormerElicioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">angn:BridgeLoanBetweenAngionAndFormerElicioDiscountAmountInitialClosingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">angn:BridgeLoanBetweenAngionAndFormerElicioInitialClosingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">angn:BridgeLoanBetweenAngionAndFormerElicioDiscountAmountAdditionalClosingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">angn:BridgeLoanBetweenAngionAndFormerElicioAdditionalClosingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">angn:WarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">angn:WarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">angn:WarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">angn:WarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">angn:WarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:PreFundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:MarchSubscriptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:JulyPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:JulyPreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:JulyPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:JulyPreFundedWarrantsAndJulyCommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:JulyPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">angn:JulySharesAndJulyCommonWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:JulyPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:JulyCommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:JulyPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">angn:MeasurementInputStrikePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">angn:MeasurementInputStrikePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">angn:ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">angn:ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">angn:ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">angn:ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">angn:ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFJuly2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">angn:ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept.2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">angn:ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept.2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">angn:ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept.2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">angn:ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">angn:ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">angn:ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">angn:FormerElicioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">angn:FormerElicioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:RegistrationStatementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:AtTheMarketEquityOfferingSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:AtTheMarketEquityOfferingSalesAgreement2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:AtTheMarketEquityOfferingSalesAgreement2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:A2024RegistrationStatementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:AtTheMarketEquityOfferingSalesAgreement2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:AtTheMarketEquityOfferingSalesAgreement2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:PreFundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:MarchSubscriptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">angn:A2021PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">angn:A2021PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">angn:A2021PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">angn:A2022PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">angn:A2024PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">angn:A2024PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:PreFundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:MarchSubscriptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:PreFundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:MarchSubscriptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:PreFundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:MarchSubscriptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:PreFundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:JulyPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:PreFundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:JulyPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:JulyCommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:JulyPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:JulyPreFundedWarrantsAndJulyCommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:JulyPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:PreFundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:JulyPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:JulyCommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:JulyPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:JulyPreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:JulyCommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:JulyPreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">angn:BostonMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">angn:BostonMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">angn:NewtonMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">angn:NewtonMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">angn:ConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">angn:ConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">angn:SeniorSecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">angn:SeniorSecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-01</xbrli:startDate><xbrli:endDate>2024-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-01</xbrli:startDate><xbrli:endDate>2024-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">angn:SeniorSecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">angn:EmployeeBenefitPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">angn:UnvestedCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">angn:UnvestedCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">angn:ConsultingServicePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">angn:ConsultingServicePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:MarchSubscriptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-19</xbrli:startDate><xbrli:endDate>2024-03-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:JulyPreFundedWarrantsAndJulyCommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:JulyPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">angn:YekaterinaChudnovskyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">angn:PurchaseOfWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-02</xbrli:startDate><xbrli:endDate>2024-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:JulyPreFundedWarrantsAndJulyCommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:JulyPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">angn:JayVenkatesanAndTrustsAffiliatedWithJayVenkatesanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">angn:PurchaseOfWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-02</xbrli:startDate><xbrli:endDate>2024-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">angn:ClinicalTrailMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">angn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">angn:ClinicalTrailMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">angn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">angn:EmployeeRelatedReasearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">angn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">angn:EmployeeRelatedReasearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">angn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">angn:TranslationalMedicineAndCMCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">angn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">angn:TranslationalMedicineAndCMCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">angn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">angn:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">angn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">angn:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">angn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">angn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">angn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">angn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">angn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:PreFundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:PreFundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-29</xbrli:startDate><xbrli:endDate>2025-01-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">angn:SeniorSecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-01</xbrli:startDate><xbrli:endDate>2024-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">angn:SeniorSecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-01</xbrli:startDate><xbrli:endDate>2024-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:PreFundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:PreFundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-05</xbrli:startDate><xbrli:endDate>2025-03-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_1"></div><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_____________________________________________</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_____________________________________________</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.123%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:10pt;padding-left:9pt;padding-right:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-4"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-3">December&#160;31</ix:nonNumeric>, 2024</ix:nonNumeric></span></div><div style="margin-top:10pt;padding-left:9pt;padding-right:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:10pt;padding-left:9pt;padding-right:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.123%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from &#160;&#160;&#160;to </span></div><div style="margin-top:10pt;padding-left:9pt;padding-right:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-39990</ix:nonNumeric></span></div><div style="margin-top:10pt;padding-left:9pt;padding-right:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">Elicio Therapeutics, Inc.</ix:nonNumeric></span></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:10pt;padding-left:9pt;padding-right:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">11-3430072</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">451 D Street, 5th Floor</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">Boston</ix:nonNumeric>,  <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-12">Massachusetts</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">02210</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">857</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">209-0050</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant's telephone number, including area code</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.737%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common Stock, par value $0.01</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">ELTX</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The <ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">Nasdaq</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to section 12(g) of the Act: None. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-19">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-20">No</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-21">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-(&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-22">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.451%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-23">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-24">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="f-25">&#9746;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="f-26">&#9744;</ix:nonNumeric></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="f-27">&#9744;</ix:nonNumeric></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the Registrant included in the filing reflect the correction of an error to previously issued financial statements.  <ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-28">&#9744;</ix:nonNumeric></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the Registrant's executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-29">&#9746;</ix:nonNumeric></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate market value of the voting stock and non-voting common stock held by non-affiliates of the registrant, based on the closing price of a share of the registrant&#8217;s common stock on June 28, 2024, the last business day of the registrant&#8217;s most recently completed second fiscal quarter, as reported by the Nasdaq Capital Market on such date, was approximately $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="6" id="f-30">33.2</ix:nonFraction>&#160;million. Shares of common stock held by each executive officer and director and by each entity affiliated with an executive officer or director have been excluded from this computation. The determination of affiliate status for this purpose is not necessarily a conclusive determination for other purposes.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of the issuer&#8217;s common stock outstanding as of March&#160;25, 2025, was <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-31">15,953,524</ix:nonFraction>.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:10pt;text-align:center"><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-32" escape="true"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portions of the registrant&#8217;s definitive proxy statement to be filed for the registrant&#8217;s 2025 Annual Meeting of Stockholders are incorporated by reference into Part III hereof. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.</span></ix:nonNumeric><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:33.067%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.598%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.589%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.575%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auditor Name: <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-33">Baker Tilly US, LLP</ix:nonNumeric> </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auditor Location:  <ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-34">Tewksbury, Massachusetts</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PCAOB ID: <ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-35">23</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_602"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_608">Forward-Looking Statements</a></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_608">2</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_10">P</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_10">art I</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_13">I</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_13">tem 1. Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_13">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_16">I</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_16">tem 1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_16">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_19">I</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_19">tem 1B. Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_19">90</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_22">I</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_22">tem 1C. Cybersecurity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_22">90</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_25">I</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_25">tem 2. Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_25">91</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_28">I</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_28">tem 3. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_28">91</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_31">I</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_31">tem 4. Mine Safety </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_31">Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_31">91</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_34">P</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_34">art II</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_37">I</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_37">tem 5. Market for Re</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_37">gistrant</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_37">&#8217;</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_37">s Common Equity, Related Stockholder Matters and Issu</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_37">er Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_37">92</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_40">Item 6. [Reserved]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_40">92</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_43">I</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_43">tem 7. Management</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_43">&#8217;</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_43">s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_43">92</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_67">I</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_67">tem 7A. </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_67">Quantitative and Qualitative Disclosu</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_67">res about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_67">100</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_70">I</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_70">tem 8. Financ</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_70">ial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_70">101</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_154">I</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_154">tem 9. Changes in and Disagreements with Accountants </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_154">on Accounti</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_154">ng and Financial Disclosu</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_154">re</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_154">130</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_157">I</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_157">tem 9A. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_157">130</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_160">I</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_160">tem 9B. Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_160">131</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_163">Item 9C. Disclosure Regarding Foreign Jurisdictions that Pre</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_163">vent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_163">131</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_166">P</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_166">art III</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_169">I</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_169">tem 10. Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_169">132</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_175">I</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_175">tem 11. Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_175">132</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_172">I</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_172">tem 12. Security </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_172">O</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_172">w</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_172">ners</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_172">hip of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_172">B</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_172">eneficial </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_172">O</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_172">wners and </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_172">M</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_172">anagement </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_172">and </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_172">R</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_172">elated </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_172">S</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_172">tockholder </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_172">M</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_172">att</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_172">ers</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_172">132</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_178">I</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_178">tem 13. C</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_178">ertain Relationships and Related Transactions</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_178">, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_178">132</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_181">I</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_181">tem 14. Principal Accountant Fees</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_181">132</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_184">P</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_184">art IV</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_187">I</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_187">tem 15. Exhibit</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_187">s and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_187">133</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_190">I</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_190">tem 16. Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_190">135</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_193">S</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_193">IGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_193">136</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_608"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This Annual Report on Form 10-K, including the sections titled &#8220;Business,&#8221; &#8220;Risk Factors,&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Annual Report on Form 10-K other than statements of historical fact, including statements concerning our business strategy and plans, future operating results and financial position, as well as our objectives and expectations for our future operations, are forward-looking statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In some cases, you can identify forward-looking statements by terminology such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;due,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;positioned,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">our financial condition, including our ability to obtain the funding necessary to advance the development of ELI-002 and any other current or future product candidates, our ability to continue as a going concern and our cash runway;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">our ability to utilize our platform to develop a pipeline of product candidates to address unmet needs in cancer;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the timing, progress and results of clinical trials for ELI-002, and other current or future product candidates we may develop, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the studies or trials will become available, and the timing, progress and results of our research and development programs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the timing, scope and likelihood of regulatory filings and approvals, including timing of INDs (as defined below) and U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval of ELI-002 and any current or future product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the timing, scope or likelihood of foreign regulatory filings and approvals;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">our ability to develop and advance our current product candidates and programs into, and successfully complete, clinical studies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">our manufacturing, commercialization, and marketing capabilities and strategy;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the need to hire additional personnel and our ability to attract and retain such personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the size of the market opportunity for our product candidates, including estimates of the number of patients who suffer from the diseases we are targeting;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">expectations regarding the approval and use of our product candidates in combination with other drugs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">expectations regarding potential for accelerated approval or other expedited regulatory designation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">our competitive position and the success of competing therapies that are or may become available;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">our anticipated research and development activities and projected expenditures;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">existing regulations and regulatory developments in the United States, Europe and other jurisdictions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the extent to which global economic and political developments, including the ongoing conflict between Ukraine and Russia, the conflicts in the Middle East, geopolitical tensions with China, and other geopolitical events, will affect our business operations, clinical trials, or financial condition;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">our expectations regarding other macroeconomic trends;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">our intellectual property position, including the scope of protection we are able to establish and maintain for intellectual property rights covering ELI-002, other current or future product candidates we may develop, including the extensions of existing patent terms where available, the validity of intellectual property rights </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">held by third parties, and our ability not to infringe, misappropriate or otherwise violate any third-party intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">our continued reliance on third parties to conduct additional clinical trials of our product candidates, and for the manufacture of our product candidates for clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">our ability to have manufactured sufficient supplies of drug product for clinical testing and commercialization;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">our ability to obtain, and negotiate favorable terms of, any collaboration, licensing or other arrangements that may be necessary or desirable to develop, manufacture or commercialize our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">our projected financial performance;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">our anticipated use of proceeds from financing activities; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our planned operating expenses and capital expenditure requirements; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the potential impact of anticipated funding pressures and the expected effect from U.S. export controls and tariffs; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the impact of laws and regulations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We caution you that the foregoing list may not contain all of the forward-looking statements made in this Annual Report on Form 10-K.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. We discuss these risks in greater detail in the &#8220;Risk Factors&#8221; section in Part I, Item 1A of this Annual Report on Form 10-K. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our management&#8217;s beliefs and assumptions only as of the date of this Annual Report on Form 10-K. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. In addition, statements such as &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this Annual Report on Form 10-K. While we believe that information provides a reasonable basis for these statements, that information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into or review of all relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely on these statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This Annual Report on Form 10-K also contains estimates, projections and other information concerning our industry, our business and the markets for certain drugs, including data regarding the estimated size of those markets, their projected growth rates and the incidence of certain medical conditions. Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources. In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you should assume that other data of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As used in this Annual Report on Form 10-K, unless otherwise stated or the context otherwise indicates, references to &#8220;Elicio,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; or similar terms refer to Elicio Therapeutics, Inc. and our wholly owned subsidiaries.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part I</span></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_13"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Business</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are a clinical-stage biotechnology company pioneering the development of immunotherapies for patients with limited treatment options and poor outcomes suffering from cancer. Our proprietary Amphiphile (&#8220;AMP&#8221;) technology is designed to generate robust anti-tumor T cell responses by preferentially targeting lymph nodes.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Recent advances have identified T cell responses as a key component of effective cancer immunotherapy and we believe our AMP technology can generate a robust T cell response that can potentially provide meaningful clinical benefit. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe the therapeutic utility of currently approved and development stage cancer immunotherapies are limited in many cases due to their inability to sufficiently localize to lymph nodes and adequately engage with the critical immune cells responsible for stimulating adaptive immunity.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our AMP technology is specifically intended to localize payloads to lymph nodes leading to the generation of a robust T cell response that we believe is critical to generate an anticancer immune response.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our lead programs focus on our cancer vaccine product candidates, which target biologically validated driver tumor mutations using common and well-characterized neoantigens. This strategy results in an &#8220;off-the-shelf&#8221; therapeutic option allowing patients to receive treatment without delayed manufacturing timelines and increased costs associated with personalized vaccine approaches.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, currently being evaluated in a Phase 2 study, designed to stimulate an immune response against mutant KRAS cancers, ELI-007, currently being evaluated in preclinical studies for the treatment of mutant b-raf murine sarcoma viral oncogene homolog B1 (&#8220;BRAF&#8221;)-driven cancers, and ELI-008, currently being evaluated in preclinical studies for use in the treatment of mutated tumor protein p53 (&#8220;TP53&#8221;) expressing cancers.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe that each of our immunotherapy product candidates, if approved, has the potential to reduce the risk of recurrence of tumors carrying specific oncogenic driver mutations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strategy</span></div><div style="margin-top:6pt;text-align:justify;text-indent:20pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are focused on mobilizing the immune response to defeat cancer through the development and commercialization of lymph node targeted immunotherapies. Key elements of our strategy are to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Aptos',san-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:12.37pt">Continue advancing ELI-002 in an ongoing randomized Phase 2 trial in pancreatic ductal adenocarcinoma (&#8220;PDAC&#8221;)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. We are developing our first product candidate, ELI-002, for the treatment of patients with solid tumors expressing mutated KRAS. By targeting immunotherapy to the lymph nodes and generating a robust and differentiated T cell response, we believe ELI-002 could improve the long-term prognosis and quality of life for patients suffering from solid tumors. We are currently evaluating ELI-002 in AMPLIFY-7P, a randomized Phase 2 trial to evaluate the efficacy and safety in patients with PDAC. In December 2024, we announced that we completed enrollment in our AMPLIFY-7P trial. We will continue to follow patients for up to 36 months. A disease-free survival event-driven interim analysis is expected in Q3 2025, depending on rate of event accrual. To determine how long patients live without their cancer returning, the study will compare events (cancer detected on an imaging scan or death) in the AMPLIFY-7P versus observation groups once the pre-specific total number of events are observed.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:14.15pt">Expand ELI-002 clinical development for the treatment of other KRAS driven cancers.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our ongoing Phase 2 trial is in adjuvant stage PDAC, but our Phase 1 trials also included patients with colorectal cancer (&#8220;CRC&#8221;) and the preliminary safety, immunogenicity and efficacy data were encouraging in both PDAC and CRC patients.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition to CRC, our platform may be applicable to patients with lung cancer, bile duct and other gastrointestinal cancers driven by KRAS mutations, and there is also unmet need in neoadjuvant stage pancreatic cancer.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are evaluating opportunities to advance ELI-002 in clinical trials for CRC including in collaboration with other organizations.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:14.15pt">Advance development of our internal pipeline, including ELI-007 and ELI-008, for additional oncology targets.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> We have two preclinical programs that employ our AMP technology targeting other key tumor driver mutations, BRAF and TP53.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ELI-007, for mutant BRAF-driven cancers, and ELI-008, for mutant TP53-expressing cancers, are AMP immunotherapies targeting biologically validated neoantigens expressed in high proportions of solid tumors.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have received grants to fund the preclinical development </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">of ELI-007 and ELI-008. We intend to continue to seek collaboration opportunities to advance the development of ELI-007 and ELI-008 into Phase 1 trials.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:14.15pt">Realize the full value of the AMP technology through collaborations. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have published several preclinical proof-of-concept applications where our AMP technology has demonstrated meaningful improvements when applied to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">prophylactic or therapeutic infectious disease </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">vaccine</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">s</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, CAR-T and TCR-T cell therapies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, and therapies</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> for auto-immune disease.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We will look to establish collaborations to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">capitalize on the potential of the technology in these applications including with our AMP CpG (ELI-004; Amph-CpG-7909) adjuvant.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Overview of Immune System and Cancer Immunotherapy</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The immune system is a large network of organs, tissues, white blood cells, proteins and chemicals working together to protect and repair the body from infections, injuries and cellular changes associated with disease.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">One component of the immune system is the adaptive immune response which is responsible for mounting highly specific responses to substances deemed to be foreign.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The adaptive immune response is carried out by white blood cells including B lymphocytes (&#8220;B cells&#8221;) and T lymphocytes (&#8220;T cells&#8221;). B cells are involved in the humoral immune response, differentiating into antibody-secreting plasma cells on activation and recognition of a foreign-specific molecular structure known as an antigen. T cells participate primarily in the cell-mediated immune response and are capable of specific antigen-directed recognition and elimination of aberrant cells arising from pathogenic infection or genetic transformation.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">T cells can be further segregated into distinct cell types, with the primary types being CD8+ T cells, which are also referred to as cytotoxic lymphocytes (&#8220;CTLs&#8221;) and CD4+ &#8220;helper&#8221; T cells. CD8+ T cells specifically recognize and eliminate cells infected with viruses, other pathogens, or cancer-associated mutations. In contrast, CD4+ T cells, which can also exhibit cytotoxic activity, primarily participate in the immune response by directing the activity of other cells, in particular B cells and CD8+ T cells.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The lymphatic system plays a major role in the production, differentiation, and proliferation of both B cells and T cells, and lymph nodes serve a critical role in lymphocytes&#8217; activation and acquisition of essential functionality. The lymph nodes act as the &#8220;school house&#8221; of the adaptive immune response, playing an essential role in the generation of B cells and T cells possessing the specificity and functionality required for effective disease modification.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Specifically, signaling delivered between immune cells residing in the lymph nodes is critical for the generation of a T cell response with the magnitude, potency, persistence, functionality, specificity, and memory capacity required for an effective cell-mediated immune response.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As cancer is the result of genetic transformation of normal cells resulting in uncontrolled growth, the immune system doesn&#8217;t always recognize cancer cells as foreign.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, cancer cells can adopt mechanisms to evade immune system recognition or defenses rendering the adaptive immune response ineffective.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">However, immune cells, referred to as tumor-infiltrating lymphocytes (&#8220;TILs&#8221;), are sometimes found in and around tumors and patients with TILs often have a better prognosis than patients without TILs - supporting the development of drugs such as checkpoint antibodies that target immune cells found in and around tumors rather than directly targeting cancer cells.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the last 15 years, immunotherapy has become a therapeutic mainstay for treating certain cancers.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Several approaches to cancer immunotherapy have been attempted all with the goal of eliciting or enhancing an immune response to identify and attack tumor cells.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">One immunotherapy approach attempted with limited success to date is the development of therapeutic cancer vaccines.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe that cancer immunotherapies, including cancer vaccines, hold the potential to eliminate cancer cells as cancer cells often contain tumor-specific antigens, or neoantigens, not present in normal cells; therapeutic cancer vaccines could facilitate the immune system recognition and response to these neoantigens.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, because an adaptive immune response includes a mechanism to create life-long lymphocytes, cancer vaccines may prevent relapse of cancer long after initial treatment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">While general neoantigen-specific immune activity has been demonstrated by previous cancer vaccine efforts, reduction in tumor loads has not been frequently observed resulting in only two FDA-approved cancer vaccines. Researchers investigating this lack of historical cancer vaccine efficacy have suggested a key reason is the limited generation of tumor-specific T cells as well as impaired fitness of the elicited anti-tumor T cells. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe improved delivery of immunotherapies to the lymph nodes is required to generate the robust and multifunctional adaptive immune response, specifically T cell responses, needed for therapeutic efficacy. Our AMP technology is designed to deliver immunotherapeutic payloads of interest to lymph nodes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Our Approach</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fundamental underpinning of our innovative approach is delivering immunotherapeutic payloads to lymph nodes.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our AMP technology is designed to rapidly deliver peptides, proteins, nucleic acids and small molecules to lymph nodes through reversible interactions with endogenous albumin.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our AMP technology has been flexibly designed to be manufactured with various peptide lengths and sequences optimizing the localization of the AMP-modified molecules to lymph nodes and the subsequent cellular processing required to generate robust T cell response.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">AMP Technology: Lymph node targeting via albumin hitchhiking </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our proprietary AMP technology, and combined expertise in immunology and materials science, allows us to develop AMP immunotherapies capable of generating robust and differentiated immune responses.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our AMP immunotherapies utilize modular conjugation chemistry, potentially allowing for application to multiple therapeutic modalities, including peptides, proteins, nucleic acids, and small molecules as illustrated in the figure below:</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">AMP construction: A molecular conjugation approach for</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">delivery of immune therapeutics to lymph nodes</span></div><div style="margin-top:6pt"><img src="angn-20241231_g1.jpg" alt="amp.jpg" style="height:276px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">AMP molecules are multifunctional constructs with lipid tails linked to a therapeutic payload designed to accumulate in the lymph nodes through the body&#8217;s existing surveillance mechanisms.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">AMP molecules are designed to interact with endogenous albumin, an abundant serum protein that drains through lymphatic capillaries and accumulates in lymph nodes where foreign substances are collected for risk-assessment by sentinel immune cells.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">AMP molecules use their lipid tails to </span><span style="color:#1f1f1f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">target the lymph nodes by hitchhiking on endogenous albumin after subcutaneous injection resulting in precise delivery to immune cells responsible for coordinating protective immune responses.</span><span style="color:#1f1f1f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#1f1f1f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Albumin hitchhiking is a well-established method for targeting molecules to lymph nodes. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our AMP technology preferentially delivers immuno-modulatory cargo to lymph nodes - potentially enhancing the magnitude, functionality, and durability of the immune response. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe this lymph node-targeting technology has the potential to be broadly applicable to address significant unmet medical needs.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#1f1f1f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">AMP Facilitated Albumin Hitchhiking</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><img src="angn-20241231_g2.jpg" alt="AMP technology.jpg" style="height:249px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Targeting Common Validated Tumor Neoantigens</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe a critical strategic benefit of our approach is training the immune system to recognize common neoantigens to generate an effective T cell-mediated anti-tumor response.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Common neoantigens represent an elite class of tumor-specific antigens derived from recurrently mutated driver genes shared across certain types of cancer.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Neoantigens are newly formed antigens generated by tumor cells as a result of various tumor-specific alterations, such as genomic mutation or dysregulated protein synthesis. Neoantigens are recognized as non-self and can readily trigger an immune response. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our most advanced clinical product candidate, ELI-002, is a cancer vaccine that targets the tumor driver gene KRAS, which is mutated in more than 25% of all solid tumors.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our preclinical cancer vaccine candidates, ELI-007 and ELI-008, target two other key neoantigens TP53, the most commonly mutated cancer driver gene, and BRAF, a cancer driver gene found frequently in melanoma, thyroid, and colon cancers. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">   </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Utilizing potent adjuvants</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition to utilizing well-known neoantigens, our product candidates incorporate potent adjuvants as our AMP immunotherapy&#8217;s rapid localization to the lymph nodes supports enhanced delivery to immune cells potentially resulting in higher,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">more robust immune responses with potentially fewer side effects.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Adjuvants are any substance included in an immunotherapy intended to activate immune cells to elicit a stronger immune response.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our current product candidates utilize a modified form of the synthetic oligonucleotide adjuvant, soluble CpG 7909, intended to mimic bacterial DNA that has been extensively studied and incorporated into FDA-approved products. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In previous clinical studies conducted by third parties, CpG-containing oligonucleotides have been shown to be both well tolerated and to exert immune-stimulatory effects. Our AMP-modification is designed to concentrate and retain the CpG adjuvant in the lymphatic system potentially allowing more effective delivery to immune cells and/or reduced side effects. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The result of our approach is the development of therapeutic cancer vaccines targeting common tumor neoantigens found in a significant portion of patients with cancer.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our AMP immunotherapies are manufactured through traditional pharmaceutical methods resulting in an &#8220;off-the-shelf&#8221; drug product. &#8201;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Our Product Candidates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">ELI-002: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">AMP Immunotherapy for mutant KRAS-driven Cancers</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ELI-002 is a multivalent lymph node&#8211;targeted AMP peptide vaccine being developed to target seven KRAS driver mutations that are present in 25% of all solid tumor cancers including 88% of PDAC, 36% of CRC, and 25% of non-small cell lung cancer (&#8220;NSCLC&#8221;). Other cancers with significant proportions of KRAS mutations include bile duct and ovarian cancers. The KRAS protein relays signals from outside of the cell membrane to the cell nucleus influencing expression of downstream genes involved in the regulation of cell growth, cell differentiation, and cell death (also referred to as apoptosis). Mutations to the KRAS gene result in expression of overactive KRAS protein, driving aberrant signaling and unregulated cell growth, which are hallmarks of cancer. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Targeting mutated KRAS using immunotherapy presents several potential advantages. KRAS mutations are categorized as truncal mutations serving as a genetic driver of malignant changes where each tumor cell must maintain the expression of the mutated KRAS protein to remain viable. Such uniform expression across every transformed cell in a particular tumor holds the promise that immunological approaches may enable complete tumor </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">eradication. Mutated KRAS proteins are neoantigens, found exclusively in tumor cells, potentially limiting immunotherapy activity to the targeted tumor cells limiting side effects. ELI-002 is chemically synthesized with traditional manufacturing methods that allow the drug product to be readily available as an &#8220;off-the-shelf&#8221; treatment providing potential cost and time-to-treatment advantages compared to personalized vaccine or cell-therapy treatments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8201;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">AMPLIFY-201: Our First-in-human Phase 1 trial (NCT04853017)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2021, we initiated dosing of the 2-peptide version of ELI-002 (&#8220;ELI-002 2P&#8221;), covering KRAS G12D and G12R mutations, in a Phase 1 dose escalation study intended to evaluate safety and tolerability, as well as provide immunologic and anti-tumor proof of concept in patients with high relapse risk mKRAS-driven solid tumors, following surgery and chemotherapy. In April 2023, we completed enrollment of 25 patients with PDAC or CRC. In August 2024, we ended study visits for this study. Results published in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Nature Medicine</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> in January 2024 from a September 6, 2023 data cutoff, and long term follow up results presented at the ESMO Immuno-Oncology meeting in December 2024 from a September 24, 2024 data cutoff demonstrated (results from both timepoints presented below unless otherwise indicated):</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">ELI-002 2P is generally well-tolerated with no dose limiting toxicities or serious adverse events</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Selection of a recommended Phase 2 dose of 10.0 mg Amph-CpG-7909</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">84% of patients generated mKRAS-specific T cell responses with a 58x average fold-change compared to baseline (September 6, 2023 data cutoff)</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">59% of patient responses included both CD4 and CD8 T cells (September 6, 2023 data cutoff)</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">84% of patients had a decline in their tumor biomarker from baseline (September 6, 2023 data cutoff)</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">100% of the above-median T cell response group (12.75X) achieved tumor biomarker responses to ELI-002; in the below-median group 67% (8/12) responded to ELI-002 (September 6, 2023 data cutoff)</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">At a median follow-up of 19.7 months (September 24, 2024 data cutoff) </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">The median RFS was not reached for the above median T cell responders compared to 4.01 months among the below median T cell responders (HR 0.23, 95% CI 0.06-0.93, P=0.0184); 10 of the 13 of the above median T cell group were free from relapse or death</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">77% reduction in risk of progression or death in the above median T cell responders to ELI-002 (September 24, 2024 data cutoff)</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Median relapse-free survival of 16.3 months for the 25 patient cohort (September 24, 2024 data cutoff)</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">At a median follow-up of 19.7 months, the median overall survival was 28.9 months for the 25 full cohort; the median overall survival for the 20 PDAC subgroup was also 28.9 months (September 24, 2024 data cutoff)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition to ELI-002 2P, we evaluated a 7-peptide version of ELI-002 (&#8220;ELI-002 7P&#8221;), covering seven of the most common KRAS mutations (G12D, G12R, G12V, G12C, G12A, G12S, and G13D), thereby increasing the eligible patient population for ELI-002 and potentially reducing the chance of tumor bypass resistance mechanisms.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">AMPLIFY-7P Phase 1/2 clinical trial (NCT05726864)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This trial is to assess the safety and efficacy of ELI-002 7P as adjuvant monotherapy treatment in patients with solid tumors carrying mutated KRAS. In April 2023, we initiated dosing of the Phase 1A portion of the trial enrolling 14 patients through October 2023 who were evaluated for safety and efficacy of two ELI-002 AMP-peptide total dose levels (1.4mg and 4.9mg) in combination with the 10.0 mg Phase 2 dose of Amph-CpG-7909. In September 2023, the Independent Data Monitoring Committee (&#8220;IDMC&#8221;) reviewed the available Phase 1A data and determined enrollment for the Phase 2 portion of the study could be opened. Preliminary results from the Phase 1A trial were presented at the ASCO Annual Meeting in June 2024 from a December 18, 2023 data cutoff, which demonstrated:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">ELI-002 7P administered as a monotherapy was well tolerated and generated a ~100x mKRAS-specific expanded T cell response relative to baseline levels</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">ELI-002 7P generated a mKRAS-specific T cell response in 100% of patients including responses targeting all mKRAS mutations enrolled (G12D, V, R and G13D)</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">mKRAS-specific T cells were polyfunctional with 85.7% (6/7) of evaluable patients having both CD8+ and CD4+ responses at the 4.9 mg Phase 2 dose level</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Tumor biomarker reductions were observed in 71% (5/7) of evaluable patients at the 4.9 mg Phase 2 dose level</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">ELI-002 7P was shown to induce antigen-spreading with increased T cell responses targeting non-immunizing, personalized tumor neoantigens in 100% (6/6) of evaluable patients at the 4.9 mg Phase 2 dose level</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Recommend Phase 2 dose was selected as 4.9 mg of AMP-peptides and 10.0 mg Amph-CpG-7909 adjuvant</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2024, we announced the first patient had been dosed in the randomized Phase 2 portion of the AMPLIFY-7P trial of ELI-002 7P as an adjuvant monotherapy treatment for patients with KRAS-mutated PDAC. The Phase 2 portion of the trial utilized disease-free survival (&#8220;DFS&#8221;) as the primary endpoint. Patients were randomized in a 2:1 ratio to receive ELI-002 7P (10.0 mg AMP-CpG and 4.9 mg AMP-peptides 7P) or the current standard of care (observation), respectively. Crossover was permitted for patients randomized to the observation arm upon confirmed radiographic relapse via iRECIST. In December 2024, we announced completed enrollment and will continue to follow patients for up to 36 months. The Phase 2 DFS event-driven interim analysis is expected in Q3 2025, depending on rate of event accrual. To determine how long patients live without their cancer returning, the study will compare events (cancer detected on an imaging scan or death) in the AMPLIFY-7P versus observation groups once the pre-specific total number of events are observed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">ELI-007:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"> AMP Immunotherapy for mutant BRAF-driven Cancers</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ELI-007 is a multivalent lymph node&#8211;targeted AMP peptide vaccine developed to target 95% of the BRAF gene mutations found in solid tumors. The BRAF gene is part of an intracellular signaling pathway that drives cell growth and division. BRAF mutations can lead to uncontrolled cell growth and are present in multiple types of cancer, including 40% in melanoma, 9% in CRC, and 2% in lung cancer. High levels of BRAF protein expression in these tumors suggest susceptibility to T cells targeting the mutated protein. We received funding for the initial development of ELI-007 through three grants from the Gastro-Intestinal (&#8220;GI&#8221;) Research Foundation.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At the November 2023 Society for Immunotherapy of Cancer annual meeting, we presented preclinical data demonstrating ELI-007 can generate robust mutant BRAF-specific polyfunctional T cell responses in a murine model. We are currently evaluating opportunities to advance ELI-007 through partnerships, collaborations or additional grants.   </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">ELI-008:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"> AMP Immunotherapy for mutant TP53-expressing Cancers</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ELI-008 is a multivalent lymph node&#8211;targeted AMP peptide vaccine developed to target TP53 hotspot mutations. TP53 is a tumor-suppressing protein that controls DNA replication processes where mutated TP53 protein contributes to uncontrolled cell growth and tumor progression. We designed ELI-008 to target ~30% of the TP53 hotspot mutations found in solid tumor cancers including melanoma, CRC, and NSCLC. We received funding for the initial development of ELI-008 through three grants from the GI Research Foundation.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At the November 2023 Society for Immunotherapy of Cancer annual meeting, we presented preclinical data demonstrating ELI-008 can generate robust mutant TP53-specific polyfunctional T cell responses in a murine model. We are currently evaluating opportunities to advance ELI-008 through partnerships, collaborations or additional grants.   </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">AMP Platform Potential Expansion</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our AMP platform has broad potential applications for the treatment or prevention of cancer and other diseases. These other applications include immune cell therapy AMP-lifiers for CAR T cell therapeutics and TCR T cell therapeutics. We intend to advance additional applications of the AMP platform via out-licensing, co-development, or other partnership arrangements. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">TCR T Cell Therapy Preclinical Data</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2024, data from preclinical studies was published in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Cancer Immunology Research</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> demonstrating our AMP immunotherapy in combination with TCR-T cell therapy led to complete eradication and durable responses against established murine solid tumors refractory to TCR-T cell monotherapy. Our AMP immunotherapy led to enhanced lymph node delivery and correlated with pro-inflammatory lymph node transcriptional reprogramming and increased antigen-presenting cell maturation, resulting in TCR-T cell expansion and functional enhancement. Addition of AMP immunotherapy enhanced the infiltration and function of TCR-T cells in the tumor microenvironment and led to antigen spreading against diverse tumor targets. We are currently evaluating opportunities to advance our AMP immunotherapy application to TCR-T cell therapy through partnerships or collaborations.     </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Licensing, Collaboration and Partnership Agreements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MIT License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On January 27, 2016, we entered into an Exclusive Patent License Agreement with Massachusetts Institute of Technology (&#8220;MIT&#8221;), which has been amended from time to time (the &#8220;MIT License Agreement&#8221;). Pursuant to the MIT </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">License Agreement, we were granted an exclusive, worldwide license, with the right to sublicense, to certain patents and patent applications owned by MIT related to the AMP technology for the diagnosis, treatment or prevention of diseases. The licensed patent claims cover vaccine products in development by us for our current lead programs in tumor indications where mutant KRAS, rearranged Anaplastic lymphoma kinase (&#8220;ALK&#8221;), or certain other proteins that are drivers of disease, as well as programs using CpG as an adjuvant for immune activation in conjunction with an immunostimulatory agent. The MIT License Agreement established annual license payment obligations and intellectual property cost reimbursement obligations for which we are responsible, specific product categories (including immunotherapeutic products and adjuvant products) for which we are required to invest specified minimum amounts of research funding and the timing of such investment, specified development and commercialization milestone obligations, and payments due with respect to the achievement of these milestones.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 21, 2016, the MIT License Agreement was amended to update language around patent rights and MIT procedures. On February 22, 2018, the MIT License Agreement was amended to extend certain milestone dates. On each of January 31, 2019, June 23, 2020 and January 7, 2021, the MIT License Agreement was amended to add certain patent applications owned by MIT and include an additional fee, updates to patent application fees and to annual license maintenance fees. The amendments on June 23, 2020 and January 7, 2021 also adjusted milestone dates and diligence requirements under the MIT License Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the terms of the MIT License Agreement, we are obligated to use commercially reasonable diligent efforts to develop and commercialize licensed products, and to use such efforts to accomplish specified development and commercial launch objectives in accordance with a specified timeline as well as to expend specified resources in the development and commercialization of immunotherapeutic products and adjuvant products. We are obligated to pay an annual license maintenance fee, which can be credited against royalties paid to MIT during the same calendar year. We are also obligated to make milestone payments upon the occurrence of specific development and commercialization achievements on a product-by-product basis during the term of the MIT License Agreement, including those relating to the making of certain regulatory filings, the initiation of certain clinical trials and the achievement of certain sales thresholds. The achievement of each milestone triggers the payment of a set dollar amount to MIT by us. These milestone payments could, in the aggregate, reach a maximum of $27.5 million. We are obligated to make royalty payments based on net sales by it and its sublicensees equal to (i) a fractional to low single digit percentage of net sales of products that would infringe the MIT patent rights and (ii) a fractional percentage of net sales of products that could not have been identified, selected, or determined to have biological activity but for the use or modification of products that would infringe the MIT patent rights. These royalty rates are subject to an upward adjustment if we or a sublicensee commence an action against MIT to declare or render invalid or unenforceable any of the licensed patent rights; and the amount of royalties payable to MIT are subject to a downward adjustment if we are required to secure certain patent licenses from third parties to avoid infringement by the practice of the licensed patent rights. These royalties are payable (1) until the expiration of the last to expire of the MIT patent rights with respect to products that would infringe the MIT patent rights and (2) for 12 years following the first commercial sale of products that could not have been identified, selected, or determined to have biological activity but for the use or modification of products that would infringe the MIT patent rights.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are also obligated to pay a percentage of any revenue that we or our sublicensees earn from the provision of services using licensed products or that utilizes a process that would infringe the MIT patent rights. We are also obligated to pay a percentage of any payments we receive from our sublicenses, with certain exceptions. We are also required to share a portion of any funds we or a sublicensee receives in respect of the sale of a regulatory voucher that is granted by any regulatory authority based upon the regulatory approval of a product subject to the MIT License Agreement for the treatment of a neglected disease. MIT controls the prosecution and maintenance of the licensed patent rights, and we are required to pay all costs and fees associated with patent prosecution and maintenance of the licensed patents. Patent protection for the MIT licensed patents is being sought in the United States and elsewhere, including Australia, Canada, Europe, Hong Kong and Japan.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The term of the MIT License Agreement will continue in effect until the expiration or abandonment of all issued patents and filed patent applications within the licensed patent rights, unless earlier terminated. MIT may terminate the MIT License Agreement upon our uncured material breach of the MIT License Agreement or upon the occurrence of certain events, including if we or a sublicensee commence an action against MIT to declare or render invalid or unenforceable any of the licensed patent rights, or upon specified insolvency or bankruptcy events concerning us. We may terminate the MIT License Agreement without cause upon six months advance written notice to MIT and upon payment of all amounts due MIT through the date such termination takes effect.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Intellectual Property</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Intellectual property is of vital importance in our field and in biotechnology generally. We seek to protect and enhance proprietary technology, inventions, and improvements that are commercially important to the development of our business by seeking, maintaining, and defending patent rights, whether developed internally or licensed from third parties. We will also seek to rely on regulatory protection afforded through inclusion in expedited development and review, data exclusivity, market exclusivity and patent term extensions where available.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have sought patent protection in the United States and internationally related to the AMP platform technology as well as the mKRAS, universal adjuvant, mutant serine/threonine-protein kinase BRAF, and mutant TP53 programs. We have issued patents in Australia, China, Hong Kong, Israel, Japan, Nigeria, Russia, Saudi Arabia, Singapore, Ukraine, and the United States covering clinical product candidates but the patent portfolio owned by us currently largely comprises pending applications. Such applications may not result in issued patents and, even if patents do issue, such patents may not be in a form or scope that will provide us with meaningful protection for our product candidates. We also rely on trade secrets that may be important to the development of our business. Trade secrets are difficult to protect and provide us with only limited protection, as trade secrets do not protect against independent development of a technology by third parties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect to file additional patent applications in support of current and new clinical candidates as well as new platform and core technologies. Our commercial success will depend in part on obtaining and maintaining patent protection and trade secret protection of current and future product candidates and the methods used to develop and manufacture them, as well as successfully defending any such patents against third-party challenges and operating without infringing on the proprietary rights of others. Our ability to stop third parties from making, using, selling, offering to sell or importing our product candidates will depend on the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities. We cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any patents that may be granted in the future will be commercially useful in protecting our product candidates, discovery programs and processes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The terms of individual patents depend upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, including the United States, the patent term is 20 years from the earliest date of filing a non-provisional patent application. In the United States, a patent term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;) in examining and granting a patent or may be shortened if a patent is terminally disclaimed over an earlier filed patent. In the United States, the term of a patent that covers an FDA-approved drug may also be eligible for extension, which permits patent term restoration to account for the patent term lost during the FDA regulatory review process. The Hatch-Waxman Act permits a patent term extension of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the subject drug candidate is under regulatory review. Patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent applicable to an approved drug may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar provisions to extend the term of a patent that covers an approved drug are available in Europe and other foreign jurisdictions. In the future, if and when our products receive FDA approval, we expect to apply for patent term extensions on patents covering those products. We plan to seek patent term extensions to any issued patents we may obtain in any jurisdiction where such patent term extensions are available, however there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment that such extensions should be granted, and if granted, the length of such extensions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In some instances, we have submitted and expect to submit patent applications directly to the USPTO as provisional patent applications. Corresponding non-provisional patent applications must be filed not later than 12 months after the provisional application filing date. While we intend to timely file non-provisional patent applications relating to our provisional patent applications, we cannot predict whether any such patent applications will result in the issuance of patents that provide us with any competitive advantage.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We file U.S. non-provisional applications and Patent Cooperation Treaty (&#8220;PCT&#8221;) applications that claim the benefit of the priority date of earlier filed provisional applications, when applicable. The PCT system allows a single application to be filed within 12 months of the original priority date of the patent application, and to designate all of the PCT member states in which national patent applications can later be pursued based on the international patent application filed under the PCT. The PCT searching authority performs a patentability search and issues a non-binding patentability opinion which can be used to evaluate the chances of success for the national applications in foreign countries prior to having to incur the filing fees. Although a PCT application does not issue as a patent, it allows the applicant to seek protection in any of the member states through national-phase applications. At the end of the period of two and a half years from the first priority date of the patent application, separate patent applications can be pursued in any of the PCT member states either by direct national filing or, in some cases by filing through a regional patent organization, such as the European Patent Office. The PCT system delays expenses, allows a limited evaluation of the chances of success for national/regional patent applications and enables substantial savings where applications are abandoned within the first two and a half years of filing.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For all patent applications, we determine claiming strategy on a case-by-case basis. Advice of counsel and our business model and needs are always considered. We seek to file patents containing claims for protection of all useful applications of our proprietary technologies and any products, as well as all new applications and/or uses that we discover for existing technologies and products, assuming these are strategically valuable. We continuously reassess the number and type of patent applications, as well as the pending and issued patent claims to pursue </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">maximum coverage and value for our processes, and compositions, given existing patent office rules and regulations. Further, claims may be modified during patent prosecution to meet our intellectual property and business needs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We recognize that the ability to obtain patent protection and the degree of such protection depends on a number of factors, including the extent of the prior art, the novelty and non-obviousness of the invention, and the ability to satisfy the enablement requirement of the patent laws. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted or further altered even after patent issuance. Consequently, we may not obtain or maintain adequate patent protection for any of our future product candidates or for our technology platform. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that we hold may be challenged, circumvented or invalidated by third parties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition to patent protection, we also rely on trade secrets, know how, other proprietary information and continuing technological innovation to develop and maintain our competitive position. We seek to protect and maintain the confidentiality of proprietary information to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific collaborators, contract research organizations, contract manufacturing organizations, sponsored researchers, advisors, and other third parties to execute confidentiality agreements upon the commencement of employment, consulting, or service relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual during the course of the individual&#8217;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. Our agreements with employees also provide that all inventions conceived by the employee in the course of employment with us or from the employee&#8217;s use of our confidential information are our exclusive property. In the case of consultants and other third-party service providers, the agreements provide us with certain rights to all inventions arising from the services provided to us by those individuals or entities. However, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technologies and processes. Additionally, such confidentiality agreements and invention assignment agreements can be breached and we may not have adequate remedies for any such breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our consultants, contractors or collaborators use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting trade secrets, know-how and inventions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The patent positions of biotechnology companies are generally uncertain and involve complex legal, scientific and factual questions. Our commercial success will also depend in part on not infringing upon the proprietary rights of third parties. Third-party patents could require us to alter our development or commercial strategies, or our products or processes, obtain licenses or cease certain activities. Our breach of any license agreements or our failure to obtain a license to proprietary rights required to develop or commercialize our future products may have a material adverse impact on us. If third parties prepare and file patent applications in the United States that also claim technology to which we have rights, we may have to participate in interference or derivation proceedings in the USPTO to determine priority of invention. For more information, see &#8220;Risk Factors&#8212;Risks Related to Our Intellectual Property.&#8221;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">When available to expand market exclusivity, our strategy is to obtain, or license additional intellectual property related to current or contemplated development platforms, core elements of technology and/or product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Company-owned Intellectual Property</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We own the following patent families and applications:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have an issued U.S. patent and pending U.S. and Canadian patent applications titled &#8220;ALK polypeptides and methods of use thereof&#8221;, which are related to our products in development for tumor indications where rearranged ALK is a driver of disease.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We also have a patent family titled &#8220;Compounds including a mutant KRAS sequence and a lipid and uses thereof&#8221; with granted patents in Australia, China, Hong Kong, Japan, Russia, Saudi Arabia, Singapore, and the United States and pending applications in the United States, the United Arab Emirates, Brazil, Canada, China, Europe, Hong Kong, Israel, India, Japan, South Korea, Mexico, Malaysia, Nigeria, New Zealand, Thailand, Ukraine, and South Africa. This patent family relates to our products in development for tumor indications where mutant KRAS is a driver of disease.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We also have a patent family titled &#8220;CpG amphiphiles and uses thereof&#8221; with granted patents in Israel, Nigeria, Russia, Saudi Arabia, Singapore, and Ukraine and pending applications in the United States, the United Arab Emirates, Australia, Brazil, Canada, China, Europe, Hong Kong, India, Japan, South Korea, Mexico, Malaysia, New Zealand, Thailand, and South Africa. This patent family relates to our products in development for tumor indications where expression of human papillomavirus protein(s) is a driver of disease.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We also have a patent family titled &#8220;Compositions and methods for inducing an immune response against coronavirus&#8221; with pending applications in the United States, Australia, Canada, China, Europe, Hong Kong, Japan, South Korea, and Mexico. This patent family relates to the use of our AMP technology, including products in development, in methods of inducing an immune response against coronavirus.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We also have a patent family titled &#8220;Uses of amphiphiles in immune cell therapy and compositions therefor&#8221; with pending applications in the United States, Australia, Canada, Europe, Hong Kong, Japan, and New Zealand. This application relates to the use of our AMP technology, including products in development, in immune cell therapy.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We also have a patent family titled &#8220;Compositions containing polynucleotide amphiphiles and methods of use thereof&#8221; with pending applications in the United States, Australia, Canada, Europe, Hong Kong, Japan, and New Zealand.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This application relates to aspects of our AMP technology platform.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We also have a pending PCT international application titled &#8220;Compositions containing polynucleotide and polypeptide amphiphiles and methods of use thereof.&#8221; This application relates to aspects of our AMP technology platform.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We also have a pending PCT international application titled &#8220;Compositions containing mutant P53 peptide amphiphiles and methods of use thereof.&#8221; This application relates to aspects of our AMP technology platform.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have sole ownership of the above patents and patent applications. For these patents and for any patents granted on the pending applications, we anticipate that patent expiration would occur between 2037 and 2044 without taking into consideration patent term adjustments or extensions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We also have a pending U.S. application titled &#8220;Uses of amphiphiles in immune cell therapy and compositions therefor.&#8221; This application relates to aspects of our AMP technology platform in connection with immune cell therapy.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This application is co-owned with the University of Pennsylvania. If we are granted patents on this pending application, it is anticipated that patent expiration would occur in 2043 without taking into consideration patent term adjustments or extensions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We also have a pending PCT international application titled &#8220;Compositions containing BRAF peptide amphiphiles and methods of use thereof.&#8221; This application relates to aspects of our AMP technology platform. This application is co-owned with Cornell University. If we are granted patents on national phase entries of this application, it is anticipated that patent expiration would occur in 2044 without taking into consideration patent term adjustments or extensions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Licensed Intellectual Property</span></div><div style="margin-top:6pt;text-align:justify;text-indent:20pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have an exclusive license from MIT for six patent families related to aspects of our AMP technology platform:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">&#8220;Immunostimulatory compositions and methods of use thereof&#8221;, which contains three patents granted in the United States, patents granted in Europe, Hong Kong, and Japan, as well as pending applications in the United States, Europe, Hong Kong, and Japan, which relates to aspects of our AMP platform technology;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">&#8220;Albumin binding peptide conjugates and methods thereof,&#8221; which contains two patents granted in the United States, as well as pending applications in China, Hong Kong, Japan, and Europe, which relates to certain additional aspects of our AMP platform technology;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">&#8220;Chimeric antigen receptor-targeting ligands and uses thereof&#8221; with a pending application in the United States, which relates to further aspects of our AMP platform technology;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">&#8220;Compositions for chimeric antigen receptor T cell therapy and uses thereof&#8221; which contains a patent granted in Russia, as well as pending applications in the United States, Australia, Canada, China, Europe, Hong Kong, Japan, South Korea, Mexico, and New Zealand, which relates to the use of our AMP platform technology in connection with CAR T therapy;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">&#8220;Uses of amphiphiles in immune cell therapy and compositions therefor&#8221; with pending application in the United States, Europe, Hong Kong, and Japan, which relates to use of our AMP platform technology in connection with immune cell therapy; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">&#8220;Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof&#8221; with a pending application in the United States, which relates to methods of identifying further ligands for use in our AMP platform technology.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For these patents and for any patents granted on the pending applications, we anticipate patent expiration to occur between 2033 and 2041, without taking into consideration patent term adjustments or extensions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We also have an exclusive license from Dr. Roberto Chiarle for a patent family titled Anaplastic lymphoma kinase (ALK) as oncoantigen for lymphoma vaccination,&#8221; which contains two granted U.S. patents. This patent family relates to ALK antigen sequences that may be used in connection with our AMP platform technology. We anticipate patent expiration to occur in 2028 and 2031 without taking into consideration patent term extension.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Manufacturing</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We do not own or operate facilities for clinical drug manufacturing, storage, distribution or quality testing. Currently, all of our clinical manufacturing is outsourced to third-party contract manufacturing organizations. We currently obtain our supplies from these manufacturers on a purchase order basis and do not have long-term committed supply arrangements with respect to our product candidates and other materials. Our product candidates are manufactured using reliable and reproducible synthetic processes from readily available starting materials and are based on chemistry that is amenable to scale up. We expect to continue to develop product candidates that can be produced cost effectively at contract manufacturing facilities. See "Risk Factors &#8212; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">We rely on CMOs to manufacture our nonclinical and clinical pharmaceutical supplies and expect to continue to rely on CMOs to produce commercial supplies of any approved product candidate, and our dependence on CMOs could adversely impact our business.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Competition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The biotechnology and pharmaceutical industries are characterized by rapid evolution of technologies, fierce competition, and strong defense of intellectual property. While we believe our technology, expertise, scientific knowledge, and intellectual property estate provide competitive advantages, we face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical, biotechnology companies, academic institutions, governmental agencies, and public and private research institutions that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization. In addition, many small biotechnology companies have formed collaborations with large, established companies to (i) obtain support for their research, development and commercialization of products or (ii) combine several treatment approaches to develop longer lasting or more efficacious treatments that may directly compete with our current or future product candidates. We anticipate that we will continue to face increasing competition as new therapies and combinations thereof, technologies, and data emerge within the field of immunotherapy and, furthermore, within the treatment of cancer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition to the current standard of care treatments for patients, numerous commercial and academic preclinical studies and clinical trials are being undertaken by many parties to assess novel technologies and product candidates in the field of immunotherapy. In the treatment of mKRAS associated cancers there are two approved therapies for NSCLC, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Amgen Inc.&#8217;s (&#8220;Amgen&#8221;) LUMAKRAS and Mirati Therapeutics, Inc.&#8217;s</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, a wholly owned subsidiary of Bristol Myers Squibb Co. (&#8220;Mirati&#8221;), KRAZATI, both of which are for a single KRAS mutation. Other companies developing clinical stage personalized cancer vaccine therapies or mKRAS-targeted therapies include AstraZeneca Plc (&#8220;AstraZeneca&#8221;), BioNTech SE (&#8220;BioNTech&#8221;), BridgeBio Pharma Inc. (&#8220;BridgeBio&#8221;), Boehringer Ingelheim (&#8220;Boehringer&#8221;), Bristol Myers Squibb Co. (&#8220;Bristol Myers&#8221;), Circio Holding ASA (&#8220;Circio&#8221;), Eli Lilly &amp; Co., Inc. (&#8220;Eli Lilly&#8221;), Geneos Therapeutics, Inc. (&#8220;Geneos&#8221;), Gilead Sciences, Inc. (&#8220;Gilead&#8221;), Hookipa Pharma Inc. (&#8220;Hookipa&#8221;), Merck &amp; Co. (&#8220;Merck&#8221;), Moderna, Inc. (&#8220;Moderna&#8221;), Novartis International AG (&#8220;Novartis&#8221;), Roche Holding Ltd. (&#8221;Roche&#8221;)/Genentech, Inc. (&#8220;Genentech&#8221;), and Revolution Medicines, Inc. (&#8220;Revolution&#8221;). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Many of our competitors, either alone or in combination with their respective strategic partners, have significantly greater financial resources and expertise in research and development, manufacturing, the regulatory approval process, and marketing than we do. Mergers and acquisition activity in the pharmaceutical, biopharmaceutical, and biotechnology sector is likely to result in greater resource concentration among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through sizeable collaborative arrangements with established companies. These competitors also compete with us in the recruiting and retaining of qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, better tolerated, or of greater convenience or economic benefit than any products we may develop. Our competitors also may be in a position to obtain FDA or other regulatory approval for their products more rapidly, resulting in a stronger or dominant market position before we are able to enter the market. The key competitive factors affecting the success of all of our programs are likely to be product safety, efficacy, convenience and treatment cost.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Government Regulation and Product Approval</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Governmental authorities in the United States, at the federal, state, and local level, and in other countries, extensively regulate, among other things, the research, development, testing, approval, manufacturing, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, import, and export of biopharmaceutical products. In addition, sponsors of biopharmaceutical products participating in Medicaid, Medicare, and other government health care programs are required to comply with mandatory price reporting, discount, and rebate requirements. We, along with our third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates. The processes for obtaining regulatory approvals in the United States and in foreign countries, along with compliance with applicable statutes and regulations, requires the expenditure of substantial time and financial resources.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">FDA Regulation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the United States, the FDA regulates biologics under the Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;), the Public Health Services Act (&#8220;PHSA&#8221;), and their implementing regulations. The FDA further has issued a growing body of guidance documents, which, while not binding, provide the agency&#8217;s current interpretation of its statutes and regulations. Failure to comply with the applicable U.S. requirements may subject an applicant to administrative or judicial sanctions, such as FDA refusal to approve pending biologics license applications (&#8220;BLAs&#8221;) or the agency's issuance of warning letters, or the imposition of fines, civil penalties, product recalls, product seizures, total or partial suspension of production or distribution, injunctions and/or criminal prosecution brought by the FDA and the U.S. Department of Justice (&#8220;DOJ&#8221;) or other governmental entities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The process required by the FDA before product candidates may be marketed in the United States generally involves the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">completion of preclinical (or non-clinical) laboratory tests and formulation studies in compliance with the FDA&#8217;s good laboratory practice (&#8220;GLP&#8221;) regulations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">submission to the FDA of an Investigational New Drug application (&#8220;IND&#8221;) which must become effective before human clinical trials may begin at United States clinical trial sites;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">approval by an institutional review board (&#8220;IRB&#8221;) for each clinical site, or centrally, before each trial may be initiated;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">performance of adequate and well-controlled human clinical trials to establish the product candidate&#8217;s safety, purity, potency, and efficacy for its intended use, performed in accordance with good clinical practice (&#8220;GCP&#8221;) as well as IND regulations and other clinical-trial related regulations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">development of manufacturing processes to ensure the product candidate&#8217;s identity, strength, quality, purity, and potency in compliance with current good manufacturing practice (&#8220;cGMP&#8221;) regulations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">submission to the FDA of a BLA;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">satisfactory completion of an FDA advisory committee review, if applicable; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">FDA review and approval of the BLA to permit commercial marketing for particular indications for use.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Preclinical Studies and IND Submission</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The testing and approval process of product candidates requires substantial time, effort, and financial resources. Satisfaction of FDA pre-market approval requirements typically takes many years and the actual time required may vary substantially based upon the type, complexity, and novelty of the product or target indication. Preclinical studies include laboratory evaluation of chemistry, pharmacology, toxicity, and product formulation, and may involve </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">in vitro</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> testing or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">in vivo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> animal studies to assess the potential for toxicity, adverse events, and other safety characteristics of the product candidate, and in some cases to establish a rationale for therapeutic use. Such studies must generally be conducted in accordance with FDA GLP regulations. The Consolidated Appropriations Act for 2023, signed into law on December 29, 2022, (P.L. 117-328) amended the FDCA and the PHSA to specify that non-clinical testing for drugs and biologics may, but is not required to, include </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">in vivo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> animal studies. According to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the amended language, a sponsor may fulfill non-clinical testing requirements by completing various </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">in vitro</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> assays (e.g., cell-based assays, organ chips, or microphysiological systems), </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">in silico</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> studies (i.e., computer modeling), other human or nonhuman biology-based tests (e.g., bioprinting), or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">in vivo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> animal studies.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Prior to commencing the first clinical trial at a U.S. investigational site with a product candidate, an IND sponsor must submit the results of the non-clinical tests, together with manufacturing information, analytical data, any available clinical data or relevant scientific literature (including data from clinical trials conducted outside of the United States), and proposed clinical study protocols among other things, to the FDA as part of an IND. An IND is a request from a clinical study sponsor to obtain authorization from the FDA to administer an investigational drug or biological product to humans in accordance with a specific clinical trial protocol. Some long-term non-clinical testing to further establish the safety profile of the product candidate, as well as manufacturing process development and product quality evaluation, may continue after the IND is submitted.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">An IND goes into effect upon notification by the FDA or automatically 30 days after receipt by the FDA, unless the FDA, within the 30&#8211;day-time period, notifies the sponsor of safety concerns or questions related to one or more proposed clinical trials and places the trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve all outstanding concerns or questions posed by the FDA before the clinical trial can begin. Clinical holds also may be imposed by the FDA at any time before or during clinical trials due to safety concerns or non-compliance with applicable regulations. As a result, submission of an IND may not result in FDA authorization to commence a clinical trial. A separate submission to an existing IND must also be made for each successive clinical trial conducted during product development.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Clinical Trials</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with federal regulations and GCP requirements, which include the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial, as well as review and approval of the trial by an IRB. Investigators must also provide certain information to the clinical trial sponsors to allow the sponsors to make certain financial disclosures to the FDA. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the trial procedures, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A statistical analysis plan will be prepared for analysis of the data collected. A protocol for each clinical trial, and any subsequent protocol amendments, must be submitted to the FDA as part of the IND. In addition, an IRB at each site participating in the clinical trial, or a central IRB, must review and approve the protocol (initial and amendments) for any clinical trial, informed consent forms, and communications and documents provided to trial subjects before a trial commences at that site. An IRB considers, among other things, whether the risks to individuals participating in the trials are minimized and are reasonable in relation to anticipated benefits, and whether the planned human subject protections are adequate. The IRB must continue to oversee the clinical trial while it is being conducted. If a product candidate is being investigated for multiple intended indications, separate INDs may also be required. Status reports summarizing the progress of the clinical trials must be submitted at least annually to the FDA and the IRB and more frequently if suspected unexpected serious adverse reactions occur, findings from other studies suggest a significant risk to humans exposed to the investigational product, findings from animal or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">in vitro</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> testing suggest a significant risk for human subjects, or other significant safety information is found.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The FDA may order the temporary, or permanent, discontinuation of a clinical trial at any time, or impose other sanctions on various grounds, including if the agency believes that the clinical trial either is not being conducted in accordance with regulatory requirements or presents an unacceptable risk to the clinical trial subjects. An IRB may also require performance of the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB&#8217;s requirements or if the trial poses unexpected serious harm to subjects. The FDA or an IRB may also impose conditions on the conduct of a clinical trial. Clinical trial sponsors may also choose to discontinue clinical trials as a result of risks to subjects, a lack of favorable results, or changing business priorities. Some clinical trials also include oversight by an independent group of qualified experts organized by the trial sponsor, known as a data monitoring committee (&#8220;DMC&#8221;) which provides authorization for whether a trial may move forward at designated check points based on review of certain data from the trial, to which only the DMC has access, and may recommend halting the trial if it determines that there is an unacceptable safety risk for subjects or on other grounds, such as no demonstration of efficacy.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Sponsors of clinical trials of certain FDA-regulated products generally must register and disclose certain clinical trial information to a public registry maintained by the National Institutes of Health (&#8220;NIH&#8221;). In particular, information related to the investigational product, patient population, phase of investigation, trial site locations and other aspects of the clinical trial is made public as part of the registration of the clinical trial. Competitors may use this publicly available information to gain knowledge regarding the progress of development programs. Although sponsors are also obligated to disclose the results of their clinical trials after completion, disclosure of the results may be delayed in some cases for up to two years after the date of completion of the trial. Failure to timely register a covered clinical study or to submit study results as provided for in the law can give rise to civil monetary penalties and also prevent </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the non-compliant party from receiving future grant funds from the federal government. The U.S. Department of Health and Human Services&#8217; Final Rule and NIH&#8217;s complementary policy on ClinicalTrials.gov registration and reporting requirements became effective in 2017, and the government has brought enforcement actions against non-compliant clinical trial sponsors. Sponsors or distributors of investigational products for the diagnosis, monitoring, or treatment of one or more serious diseases or conditions must also have a publicly available policy on evaluating and responding to requests for expanded access requests.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The manufacture of investigational biologics for the conduct of human clinical trials is subject to cGMP requirements. Investigational biologics and their therapeutic substances that are imported into the United States are also subject to regulation by the FDA. Further, the export of investigational products outside of the United States is subject to regulatory requirements of the receiving country as well as U.S. export requirements under the FDCA.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In general, for purposes of BLA approval, human clinical trials are typically conducted in three sequential phases, which may overlap or be combined.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.5pt">Phase 1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;The product candidate is initially administered to healthy human volunteers and tested for safety, dosage tolerance, structure-activity relationships, mechanism of action, absorption, metabolism, distribution, and excretion. In the case of some products for severe or life-threatening diseases, such as cancer, especially when the product may be too inherently toxic to administer ethically to healthy volunteers, the initial human testing is often conducted in patients with the target disease or condition. If possible, Phase 1 trials may also be used to gain an initial indication of product effectiveness.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.5pt">Phase 2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;Studies are conducted in limited subject populations with a specified disease or condition to evaluate preliminary efficacy, identify optimal dosages, dosage tolerance and schedule, possible adverse effects and safety risks, and expanded evidence of safety. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more extensive clinical trials.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.5pt">Phase 3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;Clinical trials are undertaken with broader subject populations, generally at geographically dispersed clinical trial sites, to generate sufficient data to provide statistically significant evidence of clinical efficacy and safety of the product candidate, to establish the overall risk-benefit profile of the product candidate, and to provide adequate information for the labeling of the product candidate. Typically, two adequate, well-controlled trials are required by the FDA for biological product approval. Under some limited circumstances, however, the FDA may approve a BLA based upon a single clinical trial plus confirmatory evidence from a post-market trial or, alternatively, a single large, robust, well-controlled multicenter trial without confirmatory evidence.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additional kinds of data may also help to support a BLA, such as patient experience and real-world data. For appropriate indications sought through supplemental BLAs, data summaries may provide marketing application support. For genetically targeted products and variant protein targeted products intended to address an unmet medical need in one or more patient subgroups with a serious or life threatening rare disease or condition, the FDA may allow a sponsor to rely upon data and information previously developed by the sponsor or for which the sponsor has a right of reference, that was submitted previously to support an approved application for a product that incorporates or utilizes the same or similar genetically targeted technology or a product that is the same or utilizes the same variant protein targeted therapeutic agent as the product that is the subject of the application.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The FDA may also require, or companies may voluntarily conduct, additional clinical trials for the same indication after a product is approved. These post-approval trials, generally referred to as Phase 4 clinical trials, are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 trials as a condition of approval of a BLA. The results of Phase 4 studies can confirm or refute the effectiveness of a product candidate and can provide important safety information.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Concurrent with clinical trials, companies usually complete additional non-clinical studies and must also develop additional information about the chemistry and physical characteristics of the product candidate as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, manufacturers must develop methods for testing the identity, strength, quality, potency, and purity of the final product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the Consolidated Appropriations Act for 2023, Congress amended the FDCA to require sponsors of a Phase 3 clinical trial, or other &#8220;pivotal study&#8221; of a new medical product to support marketing authorization, to submit a diversity action plan for such clinical trial. The action plan must include the sponsor&#8217;s diversity goals for enrollment, as well as a rationale for the goals and a description of how the sponsor will meet them. A sponsor must submit a diversity action plan to FDA by the time the sponsor submits the trial protocol to the agency for review. The FDA </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">may grant a waiver for some or all of the requirements for a diversity action plan. If the FDA objects to a sponsor&#8217;s diversity action plan and requires the sponsor to amend the plan or take other actions, it may delay trial initiation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Marketing Application Submission, Review by the FDA, and Marketing Approval</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Assuming successful completion of the required clinical and preclinical testing in accordance with all applicable regulatory requirements, the results of product development, including chemistry, manufacture, and controls information, non-clinical studies, and clinical trial results, including negative or ambiguous results as well as positive findings, are all submitted to the FDA, along with the proposed labeling, as part of a BLA requesting approval to market the product for one or more indications. A BLA must contain sufficient evidence of the biological product candidate&#8217;s safety, purity, potency and efficacy for its proposed indication or indications. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a product&#8217;s use or from a number of alternative sources. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of the FDA. The testing and approval processes require substantial time and effort and there can be no assurance that the FDA will accept the BLA for filing and, even if filed, that any approval will be granted on a timely basis, if at all.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the Prescription Drug User Fee Act, as amended (&#8220;PDUFA&#8221;), each BLA submission is subject to a substantial application user fee, and the sponsor of an approved BLA is also subject to an annual program fee. The FDA adjusts the PDUFA user fees on an annual basis. The application user fee must be paid at the time of the first submission of the application, even if the application is being submitted on a rolling basis. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Product candidates that are designated as orphan products are also not subject to application user fees, unless the application also includes a non-orphan indication.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, under the Pediatric Research Equity Act (&#8220;PREA&#8221;), a BLA or supplement to a BLA for a new active ingredient, indication, dosage form, dosage regimen, or route of administration, must contain data that are adequate to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. A sponsor who is planning to submit a marketing application for a product that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration must submit an initial Pediatric Study Plan (&#8220;PSP&#8221;) within 60 days of an end-of-Phase 2 meeting or, if there is no such meeting, as early as practicable before the initiation of the Phase 3 or Phase 2/3 clinical trial. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including trial objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA and the sponsor must reach an agreement on the PSP. A sponsor can submit amendments to an agreed upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from preclinical studies, early-phase clinical trials or other clinical development programs. Orphan products are exempt from the PREA requirements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The FDA Reauthorization Act of 2017 introduced a provision regarding required pediatric studies. Under this statute, for product candidates intended for the treatment of adult cancer which are directed at molecular targets that the FDA determines to be substantially relevant to the growth or progression of pediatric cancer, original application sponsors must submit, with the marketing application, reports from molecularly targeted pediatric cancer investigations designed to yield clinically meaningful pediatric study data, gathered using appropriate formulations for each applicable age group, to inform potential pediatric labeling. The FDA may, on its own initiative or at the request of the applicant, grant deferrals or waivers of some or all of this data, as above. Unlike PREA, orphan products are not exempt from this requirement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The FDA also may require submission of a risk evaluation and mitigation strategy (&#8220;REMS&#8221;) if it determines that a REMS is necessary to ensure that the benefits of the product candidate outweigh the risks and to assure safe use of the biological product. The REMS plan could include medication guides, physician communication plans, assessment plans and/or elements to assure safe and effective use, such as restricted distribution methods, patient registries, or other risk minimization tools. The FDA determines the requirement for a REMS, as well as the specific REMS provisions, on a case-by-case basis. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS. The FDA will not approve a BLA without a REMS, if required. An assessment of the REMS must also be conducted at set intervals. Following product approval, a REMS may also be required by the FDA if new safety information is discovered and the FDA determines that a REMS is necessary to ensure that the benefits of the product outweigh the risks.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Once the FDA receives a marketing application for a biologic, it has 60 days to review the BLA to determine if it is substantially complete to permit a substantive review, before it accepts the application for filing. The FDA may request additional information rather than accept an application for filing. In this event, the application must be </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the goals and policies agreed to by the FDA under PDUFA, the FDA has set the review goal of completing its review of 90% of BLAs within 10 months of the filing date for a standard application and within six months of the filing date for an application with priority review. For all original BLAs, the 10 and six-month time periods run from the filing date; for all other submissions, including resubmissions, efficacy supplements and other supplements, the FDA&#8217;s stated review time periods, ranging from two to 10 months, run from the submission date. This review goal is referred to as the PDUFA date. The PDUFA date is only a goal, and it is not uncommon for FDA review of a BLA to extend beyond the PDUFA date. The review process and the PDUFA date may also be extended if the FDA requests, or the sponsor otherwise provides, substantial additional information or clarification regarding the submission.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The FDA may also refer certain applications to an advisory committee. Before approving a product candidate for which no active ingredient has previously been approved by the FDA, the FDA must either refer that product candidate to an external advisory committee or provide in an action letter a summary of the reasons why the FDA did not refer the product candidate to an advisory committee. The FDA may also refer other product candidates to an advisory committee if FDA believes that the advisory committee&#8217;s expertise would be beneficial. An advisory committee is typically a panel that includes clinicians and other experts, who review, evaluate, and make a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making product approval decisions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The FDA reviews a BLA to determine, among other things, whether a product candidate meets the agency&#8217;s approval standards, such as whether the application includes sufficient evidence that the product candidate is safe and effective for the proposed indications, and whether the manufacturing methods and controls are adequate to assure and preserve the product&#8217;s identity, strength, quality, potency, and purity. As part of its review, the FDA likely will re-analyze the clinical trial data, which could result in extensive discussions between the FDA and the applicant during the review process. Before approving a marketing application, the FDA typically will inspect the facility or facilities where the product is manufactured, referred to as a pre-approval inspection. The FDA will not approve an application unless it determines that the manufacturing processes and facilities, including contract manufacturers and subcontractors, are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a marketing application the FDA may inspect one or more clinical trial sites to assure compliance with applicable IND trial requirements and GCP. To assure cGMP and GCP compliance, an applicant must incur significant expenditure of time, money and effort in the areas of training, record keeping, production, and quality control.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">After evaluating the marketing application and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a Complete Response Letter (&#8220;CRL&#8221;). A CRL indicates that the review cycle of the application is complete and the application will not be approved in its present form, and it describes all of the specific deficiencies that the FDA identified. A CRL generally contains a statement of specific conditions that must be met in order to secure final approval of the marketing application and may require additional clinical or non-clinical testing for the FDA to reconsider the application. The deficiencies identified may be minor, for example, requiring labeling changes; or major, for example, requiring additional Phase 3 clinical trials. If a CRL is issued, the applicant may either: resubmit the marketing application, addressing all of the deficiencies identified in the letter; withdraw the application; or request an opportunity for a hearing. The FDA&#8217;s goal is to review 90% of application resubmissions in either two or six months of the resubmission date, depending on the type of information included. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#8217;s satisfaction, the FDA may issue an approval letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Even if the FDA approves a product, it may limit the approved indications or populations for use of the product; require that contraindications, warnings, or precautions be included in the product labeling, including a boxed warning; require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a product&#8217;s safety and efficacy after approval; require testing and surveillance programs to monitor the product after commercialization; or impose other conditions, including distribution restrictions or other risk management mechanisms under a REMS which can materially affect the potential market and profitability of the product. The FDA also may not approve label statements that are necessary for successful commercialization and marketing or may prevent or limit further marketing of a product based on the results of post-marketing trials or surveillance programs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements and FDA review </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and approval. The FDA may also withdraw the product approval if compliance with regulatory standards is not maintained or if problems occur after the product reaches the marketplace. Further, should new safety information arise, additional testing, product labeling, or FDA notification may be required.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Patent Term Restoration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Depending upon the timing, duration and specifics of FDA approval of our biological product candidates, some of our U.S. patents may be eligible for limited patent term extension. These patent term extensions permit a patent restoration term of up to five years as compensation for any patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND, and the submission date of a BLA, plus the time between the submission date of a BLA and the approval of that application. Only one patent applicable to an approved biological product is eligible for the extension, and the extension must be applied for prior to expiration of the patent. The USPTO in consultation with the FDA, reviews and approves the application for any patent term extension or restoration.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Biosimilars and Exclusivity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Biologics Price Competition and Innovation Act of 2009 (&#8220;BPCIA&#8221;) created an abbreviated approval pathway for biological products shown to be biosimilar to or interchangeable with an FDA-licensed reference biological product. To date, a number of biosimilars have been licensed under the BPCIA, and numerous biosimilars have been approved in Europe. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Biosimilarity, which requires no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be demonstrated through analytical studies, animal studies, and one or more clinical trials. There must be no difference between the reference product and a biosimilar in mechanism of action, conditions of use, route of administration, dosage form, and strength. A biosimilar product may be deemed interchangeable with the reference product if it meets the higher hurdle of demonstrating that it can be expected to produce the same clinical results as the reference product in any given patient and, for products administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic without such alternation or switching. Upon licensure by the FDA, an interchangeable biosimilar may be substituted for the reference product without the intervention of the health care provider who prescribed the reference product. The FDA approved the first interchangeable biosimilars, including an interchangeable monoclonal antibody biosimilar, in 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A reference biologic is granted 12 years of data exclusivity from the time of first licensure of the product, and the first approved interchangeable biological product will be granted an exclusivity period of up to one year after it is first commercially marketed. However, certain changes and supplements to an approved BLA, and subsequent applications filed by the same sponsor, manufacturer, licensor, predecessor in interest, or other related entity do not qualify for the 12-year exclusivity period. As part of the Consolidated Appropriations Act for 2023, Congress amended the PHSA in order to permit multiple interchangeable products approved on the same day to receive and benefit from the one-year exclusivity period. If pediatric studies are performed and accepted by the FDA as responsive to a written request, the 12-year exclusivity period will be extended for an additional six months. In addition, the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product. &#8220;First licensure&#8221; typically means the initial date the particular product at issue was licensed in the United States. Date of first licensure does not include the date of licensure of (and a new period of exclusivity is not available for) a supplement for the reference product for a subsequent application filed by the same sponsor or manufacturer of the reference product (or licensor, predecessor in interest or other related entity) for a change (not including a modification to the structure of the biological product) that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device, or strength, or for a modification to the structure of the biological product that does not result in a change in safety, purity or potency. Therefore, one must determine whether a new product includes a modification to the structure of a previously licensed product that results in a change in safety, purity or potency to assess whether the licensure of the new product is a first licensure that triggers its own period of exclusivity. Whether a subsequent application, if approved, warrants exclusivity as the &#8220;first licensure&#8221; of a biological product is determined on a case-by-case basis with data submitted by the sponsor.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of litigation. As a result, the ultimate impact, implementation, and impact of the BPCIA is subject to significant uncertainty.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Pediatric Exclusivity</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pediatric exclusivity is a type of non-patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity or listed patents. This six-month exclusivity may be granted if a sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or patent protection cover the product are extended by six months. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot approve another application. The issuance of a written request does not require the sponsor to undertake the described studies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Orphan Product Designation and Exclusivity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Orphan Drug Act provides incentives for the development of products for rare diseases or conditions. Specifically, sponsors may apply for and receive Orphan Drug Designation (&#8220;ODD&#8221;) if a product candidate is intended to treat a rare disease or condition, which is generally a disease or condition affecting less than 200,000 individuals in the United States, or affecting more than 200,000 in the United States and for which there is no reasonable expectation that the cost of developing and making the product available in the United States will be recovered from United States sales. Additionally, sponsors must present a plausible hypothesis for clinical superiority to obtain ODD if there is a product already approved by the FDA that that is considered by the FDA to be the same as the already approved product and is intended for the same indication. This hypothesis for clinical superiority must be demonstrated to obtain orphan exclusivity. Orphan drug designation must be requested before submitting a marketing application for the product candidate and does not convey any advantage in or shorten the duration of the regulatory review and approval process. If granted, ODD entitles the applicant to financial incentives such as opportunities for grant funding towards clinical study costs, tax advantages, and certain user-fee waivers. After the FDA grants ODD, the identity of the therapeutic agent and its potential orphan use will be disclosed publicly by the FDA; the posting will also indicate whether the drug or biologic is no longer designated as an orphan product. More than one product candidate may receive an orphan designation for the same indication.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If a product candidate receives FDA approval for the indication for which it has ODD, the product is generally entitled to orphan exclusivity, which means the FDA may not approve any other application to market a product containing the same active moiety for the same indication for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity. A product is clinically superior if it is safer, more effective or makes a major contribution to patient care. Thus, orphan drug exclusivity could block the approval of one of our potential products for seven years if a competitor obtains approval of the same product, as defined by the FDA, for the same orphan indication and we are not able to show the clinical superiority of our product candidate. In addition, the FDA will not recognize orphan drug exclusivity if a sponsor fails to demonstrate upon approval that the product is clinically superior to a previously approved product containing the same active moiety for the same orphan condition, regardless of whether or not the previously approved product was designated an orphan drug or had orphan drug exclusivity. A product that has received ODD may not receive orphan exclusivity if it is approved for a use that is broader than the indication for which it received the designation. Orphan exclusivity does not prevent the FDA from approving a different drug or biological product for the same disease or condition, or the same product for a different disease or condition. In addition, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The FDA&#8217;s approach to determining the scope of orphan drug exclusivity has been challenged in court, but at this time, the agency continues to apply its long-standing interpretation of the governing regulations and has stated that it does not plan to change any orphan drug implementing regulations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Fast Track, Breakthrough Therapy and Priority Review Designations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The FDA is authorized to designate certain products for expedited development or review if they are intended for the treatment of serious or life-threatening diseases or conditions, and demonstrate the potential to address unmet medical needs or present a significant improvement over existing therapy. These programs include fast track designation, breakthrough therapy designation, and priority review designation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To be eligible for a fast track designation, the FDA must determine, based on the request of a sponsor, that a product candidate is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need by providing a therapy where none exists or a therapy that may be potentially superior to existing therapy based on efficacy or safety factors. Fast track designation provides opportunities for more frequent interactions with the FDA review team to expedite development and review of the product. In addition, the FDA may initiate review of sections of a marketing application before the application is complete. This &#8220;rolling review&#8221; is available if the applicant provides and the FDA approves a schedule for the submission of the application sections and the sponsor pays any required user fees upon submission of the first </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">section of the application. In some cases, a product with fast track designation may be eligible for accelerated approval or priority review if the relevant criteria are met. The FDA may rescind, or the sponsor may forfeit, fast track designation if the designation is no longer supported by data emerging from the clinical trial process.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the provisions of the Food and Drug Administration Safety and Innovation Act (&#8220;FDASIA&#8221;) enacted in 2012, a sponsor may request designation of a product candidate as a &#8220;breakthrough therapy.&#8221; A breakthrough therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drug or biologic, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Products designated as breakthrough therapies are eligible for the same benefits described above for fast track designation, as well as intensive guidance on an efficient development program beginning as early as Phase 1 trials, and a commitment from the FDA to involve senior managers and experienced review staff in a proactive collaborative and cross-disciplinary review. Drugs or biologics designated as breakthrough therapies are also eligible for accelerated approval of their respective marketing applications.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Finally, the FDA may grant priority review designation to product candidates that are intended to treat serious conditions and, if approved, would provide significant improvements in the safety or effectiveness over existing therapies. The FDA determines at the time that the marketing application is submitted, on a case-by-case basis, whether the proposed drug or biologic represents a significant improvement in treatment, prevention or diagnosis of disease when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, or evidence of safety and effectiveness in a new subpopulation. A priority review designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA&#8217;s goal for taking action on a marketing application from 10 months to six months for an original application from the date of filing.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. Furthermore, fast track designation, breakthrough therapy designation, and priority review do not change the standards for approval and may not ultimately expedite the development or approval process.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Accelerated Approval</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval from the FDA and may be approved on the basis of adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. The FDA may also grant accelerated approval for such a drug or biologic when the product has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality (&#8220;IMM&#8221;) and that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA will require that a sponsor of a drug receiving accelerated approval perform post-marketing clinical trials to verify and describe the predicted effect on IMM or other clinical endpoint, and the product may be subject to expedited withdrawal procedures. Drugs and biologics granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. An intermediate clinical endpoint is a measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a drug or biologic, such as an effect on IMM. The FDA has limited experience with accelerated approvals based on intermediate clinical endpoints, but has indicated that such endpoints generally may support accelerated approval when the therapeutic effect measured by the endpoint is not itself a clinical benefit and basis for traditional approval, if there is a basis for concluding that the therapeutic effect is reasonably likely to predict the ultimate long-term clinical benefit of a drug or biologic.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The accelerated approval pathway is most often used in settings in which the course of a disease is long and an extended period of time is required to measure the intended clinical benefit of a drug or biologic, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. For example, accelerated approval has been used extensively in the development and approval of drugs and biologics for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large clinical trials to demonstrate a clinical or survival benefit.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The accelerated approval pathway is usually contingent on a sponsor&#8217;s agreement to conduct, in a diligent manner, post-approval confirmatory studies to verify and describe the drug&#8217;s clinical benefit. As a result, a product </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase 4 or post-approval clinical trials to establish the effect on the clinical endpoint. Failure to conduct required post-approval studies, or to confirm the predicted clinical benefit of the product during post-marketing studies, would allow the FDA to withdraw approval of the drug or biologic. As part of the Consolidated Appropriations Act for 2023, Congress provided the FDA additional statutory authority to mitigate potential risks to patients from continued marketing of ineffective drugs or biologics previously being considered for accelerated approval. Under the act&#8217;s amendments to the FDCA, the FDA may require the sponsor of a product granted accelerated approval to have a confirmatory trial underway prior to approval. The sponsor must also submit progress reports on a confirmatory trial every six months until the trial is complete, and such reports are published on the FDA&#8217;s website. The amendments also give the FDA the option of using expedited procedures to withdraw product approval if the sponsor&#8217;s confirmatory trial fails to verify the claimed clinical benefits of the product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">All promotional materials for product candidates being considered and approved under the accelerated approval program are subject to prior review by the FDA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Post-approval Requirements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Any products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, monitoring and record-keeping requirements, reporting of adverse experiences with the product, periodic reporting requirements, providing the FDA with updated safety and efficacy information, product sampling and distribution requirements, as well as advertising and promotion requirements, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting products for uses or in patient populations that are not described in the product&#8217;s approved uses (known as off-label uses), limitations on industry-sponsored scientific and educational activities, and requirements for promotional activities involving the Internet.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA review and approval of a new BLA or a supplement, which may require the applicant to develop additional data or conduct additional non-clinical studies and clinical trials. The FDA may also place other conditions on approvals, including the requirement for a REMS, to assure the safe use of the product. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, quality control and manufacturing procedures must continue to conform to applicable manufacturing requirements after approval to ensure the quality and long-term stability of the product. The cGMP regulations include requirements relating to organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, records and reports and returned or salvaged products. The manufacturing facilities for our product candidates must meet cGMP requirements and satisfy the FDA or comparable foreign regulatory authorities before any product is approved and our commercial products can be manufactured. We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of our products in accordance with cGMP regulations. These third-party manufacturers must comply with cGMP regulations that require, among other things, quality control and quality assurance, the maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Manufacturers, including third-party manufacturers, and other entities involved in the manufacture and distribution of approved biologics are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. Future inspections by the FDA and other regulatory agencies may identify compliance issues at the facilities of our contract manufacturers that may disrupt production or distribution or require substantial resources to correct. In addition, the discovery of conditions that violate these rules, including failure to conform to cGMP regulations, could result in enforcement actions, and the discovery of problems with a product after approval may result in restrictions on a product, manufacturer, or holder of an approved BLA, including, among other things, voluntary recall and regulatory sanctions as described further below.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The FDA also strictly regulates marketing, labeling, advertising, and promotion of products that are placed on the market. A company can make only those claims relating to a product that are approved by the FDA. Physicians, in their independent professional medical judgment, may prescribe legally available products for unapproved indications that are not described in the product&#8217;s labeling and that differ from those tested and approved by the FDA. Biopharmaceutical companies, however, are required to promote their products only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability, including, but not limited to, criminal and civil penalties under the FDCA and False Claims Act, exclusion from participation in federal health care programs, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">mandatory compliance programs under corporate integrity agreements, suspension and debarment from government contracts, and refusal of orders under existing government contracts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Moreover, the Drug Supply Chain Security Act (&#8220;DSCSA&#8221;) was enacted with the aim of building an electronic system to identify and trace certain prescription drugs distributed in the United States, including most biological products. The DSCSA imposes phased-in and resource-intensive obligations on biopharmaceutical manufacturers, wholesale distributors, and dispensers related to product tracking and tracing over a 10-year period which culminated in November 2023. Among the requirements of this legislation, manufacturers are required to provide certain information regarding the products to wholesale distributors and dispensers to which product ownership is transferred, label products with a product identifier, and keep certain records regarding the product. A manufacturer must also verify that purchasers of the manufacturer&#8217;s products are appropriately licensed. Further, under this legislation, manufacturers have product investigation, quarantine, disposition, and notification responsibilities related to counterfeit, diverted, stolen, and intentionally adulterated products that would result in serious adverse health consequences of death to humans, as well as products that are the subject of fraudulent transactions or which are otherwise unfit for distribution such that they would be reasonably likely to result in serious health consequences or death. After an additional one-year stabilization period to give entities subject to the DSCSA additional time to finalize interoperable tracking systems and to ensure supply chain continuity, the applicable requirements under the DSCSA became fully enforceable as of November 27, 2024.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">FDA&#8217;s post-market requirements are continuously evolving and additional requirements may apply. For instance, in March 2020, the U.S. Congress passed the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;), which includes various provisions regarding FDA drug shortage reporting requirements, as well as provisions regarding supply chain security, such as risk management plan requirements, and the promotion of supply chain redundancy and domestic manufacturing. Any changes of law may require that we modify how we conduct our business and may require additional expenditure to ensure that we are in compliance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in significant regulatory actions. Such actions may include refusal to approve pending applications, product license or approval suspension or revocation, imposition of a clinical hold or termination of clinical trials, warning letters, untitled letters, modification of promotional materials or labeling, provision of corrective information, imposition of post-market requirements including the need for additional testing, imposition of distribution or other restrictions under a REMS, product recalls, product seizures or detentions, refusal to allow imports or exports, total or partial suspension of production or distribution, FDA debarment, injunctions, fines, consent decrees, corporate integrity agreements, suspension and debarment from government contracts, and refusal of orders under existing government contracts, exclusion from participation in federal and state health care programs, restitution, disgorgement, or civil or criminal penalties, including fines and imprisonment, and adverse publicity, among other adverse consequences.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Additional Controls for Biologics</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To help reduce the increased risk of the introduction of adventitious agents, the PHSA emphasizes the importance of manufacturing controls for products whose attributes cannot be precisely defined. The PHSA also provides authority to the FDA to immediately suspend licenses in situations where there exists a danger to public health, to prepare or procure products in the event of shortages and critical public health needs, and to authorize the creation and enforcement of regulations to prevent the introduction or spread of communicable diseases in the United States and between states.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">After a BLA is approved, the product may also be subject to official lot release as a condition of approval. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing the results of all of the manufacturer&#8217;s tests performed on the lot. The FDA may also perform certain confirmatory tests on lots of some products before releasing the lots for distribution by the manufacturer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency, and effectiveness of biological products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Fraud and Abuse, Data Privacy and Security, and Transparency Laws and Regulations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Although we currently do not have any products on the market, our business activities and current and future arrangements with investigators, health care professionals, consultants, third-party payors and customers may be subject to regulation and enforcement by numerous federal and state regulatory and law enforcement authorities in the United States in addition to the FDA, including potentially the DOJ, the Department of Health and Human Services and its various divisions, including the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) and the Health Resources and Services Administration, the Department of Veterans Affairs, the Department of Defense, and state and local governments. Our business activities must comply with numerous health care laws, including but not </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">limited to, anti-kickback and false claims laws and regulations as well as data privacy and security laws and regulations, which are described below, as well as state and federal consumer protection and unfair competition laws.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The federal Anti-Kickback Statute, which regulates, among other things, marketing practices, educational programs, pricing policies, and relationships with health care providers or other entities, prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting, or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering, or arranging for or recommending the purchase, lease, or order, or the referral to another for the furnishing or arranging for the furnishing of any item or service reimbursable under Medicare, Medicaid, or other federal health care programs, in whole or in part. The term &#8220;remuneration&#8221; has been interpreted broadly to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between biopharmaceutical industry members on one hand and prescribers, purchasers, formulary managers, and beneficiaries on the other. There are certain statutory exceptions and regulatory safe harbors protecting some common activities from prosecution. The exceptions and safe harbors are drawn narrowly, and practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases, or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal health care covered business, including purchases of products paid by federal health care programs, the statute has been violated. The Patient Protection and Affordable Care Act (&#8221;ACA&#8221;) of 2010, as amended, also modified the intent requirement under the Anti-Kickback Statute to a stricter standard, such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the ACA also provided that a violation of the federal Anti-Kickback Statute is grounds for the government or a whistleblower to assert that a claim for payment of items or services resulting from such violation constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The federal civil False Claims Act (&#8220;FCA&#8221;) prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment to, or approval by, the federal government, knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government, or avoiding, decreasing, or concealing an obligation to pay money to the federal government. A claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. The FCA has been used to assert liability on the basis of kickbacks and other improper referrals, improperly reported government pricing metrics such as Best Price or Average Manufacturer Price, improper use of Medicare provider or supplier numbers when detailing a provider of services, improper promotion of off-label uses, and allegations as to misrepresentations with respect to products, contract requirements, and services rendered. Intent to deceive is not required to establish liability under the FCA. Actions under the FCA may be brought by the government or may be brought by private individuals on behalf of the government, called &#8220;qui tam&#8221; actions. If the government decides to intervene in a qui tam action and prevails in the lawsuit, the individual will share in the proceeds from any fines or settlement funds. If the government declines to intervene, the individual may pursue the case alone. The FCA provides for treble damages and a civil penalty for each false claim, such as an invoice or pharmacy claim for reimbursement, which can aggregate into millions of dollars. For these reasons, since 2004, FCA lawsuits against biopharmaceutical companies have increased significantly in volume and breadth, leading to several substantial civil and criminal settlements regarding certain sales practices and promoting off label uses. FCA liability may further be imposed for known Medicare or Medicaid overpayments, for example, overpayments caused by understated rebate amounts that are not refunded within 60 days of discovering the overpayment, even if the overpayment was not caused by a false or fraudulent act. In addition, conviction or civil judgment for violating the FCA may result in exclusion from federal health care programs, and suspension and debarment from government contracts, and refusal of orders under existing government contracts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The government may further prosecute conduct constituting a false claim under the criminal False Claims Act. The criminal False Claims Act prohibits the making or presenting of a claim to the government knowing such claim to be false, fictitious, or fraudulent and, unlike the False Claims Act, requires proof of intent to submit a false claim.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The civil monetary penalties statute is another potential statute under which biopharmaceutical companies may be subject to enforcement. Among other things, the civil monetary penalties statue imposes fines against any person who is determined to have knowingly presented, or caused to be presented, claims to a federal health care program that the person knows, or should know, is for an item or service that was not provided as claimed or is false or fraudulent.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) also created federal criminal statutes that prohibit, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">property owned by, or under the custody or control of, a health care benefit program, regardless of whether the payor is public or private, in connection with the delivery or payment for health care benefits, knowingly and willfully embezzling or stealing from a health care benefit program, willfully obstructing a criminal investigation of a health care offense and knowingly and willfully falsifying, concealing, or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, health care benefits, items, or services relating to health care matters. Additionally, the ACA amended the intent requirement of certain of these criminal statutes under HIPAA so that a person or entity no longer needs to have actual knowledge of the statute, or the specific intent to violate it, to have committed a violation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the federal Physician Payments Sunshine Act and its implementing regulations, manufacturers of biologics for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program (with certain exceptions) must make annual reports to CMS regarding payments and other transfers of value made to or at the request of covered recipients, such as, but not limited to, physicians, certain advanced non-physician health care providers, and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family. Certain payments for clinical trials are included within the ambit of this law. CMS makes the reported information publicly available.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Further, we may be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (the &#8220;HITECH Act&#8221;) and its implementing regulations impose requirements on covered entities relating to the privacy, security, and transmission of individually identifiable health information, known as protected health information. Among other things, the HITECH Act, through its implementing regulations, makes HIPAA&#8217;s security standards and certain privacy standards directly applicable to business associates, defined as a person or organization, other than a member of a covered entity&#8217;s workforce, that creates, receives, maintains, or transmits protected health information on behalf of a covered entity for a function or activity regulated by HIPAA. The HITECH Act also strengthened the civil and criminal penalties that may be imposed against covered entities, business associates, and individuals, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. We are not a covered entity or a business associate under HIPAA, however, we are indirectly affected by HIPAA because the protected health information held by investigators conducting our clinical trials is subject to HIPAA and can only be used for our research consistent with HIPAA requirements imposed on those investigators.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, numerous federal and state laws and regulations, including state data breach notification laws, and federal and state consumer protection laws govern the collection, use, disclosure, and protection of health-related and other personal information. For example, California enacted the California Consumer Privacy Act (&#8220;CCPA&#8221;), which took effect on January 1, 2020, and in 2020, California voters passed the California Privacy Rights Act (the &#8220;CPRA&#8221;), which became effective as of January 1, 2023, and significantly amends the CCPA and imposes additional data protection obligations on companies doing business in California, in addition to establishing a new regulatory agency, the California Privacy Protection Agency.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Many states have also adopted fraud and abuse laws similar to each of the above federal laws, which may be broader in scope and apply to items or services reimbursed by any third-party payor, including commercial insurers. Certain state laws also regulate sponsors&#8217; use of prescriber-identifiable data. Certain states also require implementation of commercial compliance programs and compliance with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government, or otherwise restrict payments or the provision of other items of value that may be made to health care providers and other potential referral sources; impose restrictions on marketing practices; or require sponsors to track and report information related to payments, gifts, and other items of value to physicians and other health care providers. Furthermore, to distribute products commercially, we must comply with state laws requiring the registration of manufacturers and wholesale distributors of drug and biological products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Recently, states have enacted or are considering legislation intended to make drug prices more transparent and deter significant price increases, typically as consumer protection laws. These laws may affect our future sales, marketing, and other promotional activities by imposing administrative and compliance burdens.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If our operations are found to be in violation of any of the laws or regulations described above or any other laws that apply to us, we may be subject to penalties or other enforcement actions, including criminal and significant civil monetary penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government health care programs, corporate integrity agreements, suspension and debarment from government contracts and non-procurement transactions such as grants, and refusal of orders under existing government contracts, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. Any action against </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To the extent that any of our products are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws, and implementation of corporate compliance programs and reporting of payments or transfers of value to health care professionals.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Coverage and Reimbursement Generally</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The commercial success of our product candidates and our ability to commercialize any approved product candidates successfully will depend in part on the extent to which governmental payor programs at the federal and state levels, including Medicare and Medicaid, private health insurers, and other third-party payors provide coverage for and establish adequate reimbursement levels for our product candidates. Government authorities, private health insurers, and other organizations generally decide which therapeutics they will pay for and establish reimbursement levels for health care. A growing trend in recent years is the containment of health care costs. Accordingly, governmental payors are increasingly trying to control therapeutic prices through reimbursement restrictions, rebates, mandatory discounts, and formulary restrictions, among other strategies.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Medicare is a federal health care program administered by the federal government that covers individuals aged 65 and over as well as individuals with certain disabilities. Drugs and biologics may be covered under one or more sections of Medicare depending on the nature of the product and the conditions associated with and site of administration. For example, under Part D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities which provide coverage for outpatient prescription drugs. Part D plans include both stand-alone prescription drug benefit plans and prescription drug coverage as a supplement to Medicare Advantage plans. Unlike Medicare Parts A and B, Part D coverage is not standardized. Part D prescription drug plan sponsors are not required to pay for all covered Part D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Medicare Part B covers most injectable drugs and biologics given in an in-patient setting and some products administered by a licensed medical provider in hospital outpatient departments and doctors&#8217; offices. Medicare Part B is administered by Medicare Administrative Contractors, which generally have the responsibility of making coverage decisions. Subject to certain payment adjustments and limits, Medicare generally pays for a Part B-covered drug or biologic based on a percentage of manufacturer-reported Average Sales Price, which is regularly updated. We believe that our product candidates, which are intended to be administered by a health care professional in a clinical environment, will be subject to the Medicare Part B rules.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the United States, the European Union, and other markets for our product candidates, government authorities and third-party payors are increasingly attempting to limit or regulate the price of medical products and services, particularly for new and innovative products and therapies, which often has resulted in average selling prices lower than they would otherwise be and sometimes at or below the provider&#8217;s acquisition cost. In the United States, it is also common for government and private health plans to use coverage determinations to leverage rebates from sponsors in order to reduce the plans&#8217; net costs. These restrictions and limitations influence the purchase of health care services and products and lower the realization on sponsors&#8217; sales of prescription therapeutics. Third-party payors are developing increasingly sophisticated methods of controlling health care costs. Third-party payors may limit coverage to specific therapeutic products on an approved list, or formulary, which might not include all of the FDA-approved products for a particular indication or might impose high copayment amounts to influence patient choice. Third-party payors also control costs by requiring prior authorization or imposing other dispensing restrictions before covering certain products and by broadening therapeutic classes to increase competition. Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. Absent clinical differentiators, third-party payors may treat products as therapeutically equivalent and base formulary decisions on net cost. To lower the prescription cost, sponsors frequently rebate a portion of the prescription price to the third-party payors. Recently, purchasers and third-party payors have begun to focus on value of new therapeutics and have sought agreements in which price is based on achievement of performance metrics.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Federal programs also impose price controls through mandatory ceiling prices on purchases by federal agencies and federally funded hospitals and clinics and mandatory rebates on retail pharmacy prescriptions covered by such programs. By example, payment or reimbursement of prescription therapeutics by Medicaid or Medicare requires sponsors to submit certified pricing information to CMS. The Medicaid Drug Rebate statute and state statutes require sponsors to calculate and report price points, which are used to determine mandatory rebate payments or negotiate supplemental rebate payments on both the state and federal level and Medicaid payment rates for certain therapeutics. For therapeutics paid under Medicare Part B, sponsors must also calculate and report their Average Sales Price, which is used to determine the Medicare Part B payment rate. Furthermore, as a condition of receiving Medicare Part B reimbursement for eligible drugs or biologicals, the manufacturer is required to participate in other government health care programs, including the Medicaid Drug Rebate Program and the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">340B Drug Pricing Program. The Medicaid Drug Rebate Program requires biopharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the Secretary of Department of Health &amp; Human Services (&#8220;DHHS&#8221;) as a condition for states to receive federal matching funds for the manufacturer&#8217;s outpatient therapeutic products furnished to Medicaid patients. Under the 340B Drug Pricing Program, the manufacturer must extend discounts to entities that participate in the program. In addition, therapeutics covered by certain government payor programs are subject to an additional inflation penalty which can substantially increase rebate payments. Certain states have also enacted laws requiring manufacturers to report certain pricing information, including drug price increases. States laws may also limit the amount that prices may be increased or require negotiation of supplemental rebates for new drugs entering the market at price points determined to be high. Refusal to negotiate supplemental rebates can negatively affect market access and provider reimbursement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Private payors often rely on the lead of the governmental payors in rendering coverage and reimbursement determinations. Therefore, achieving favorable CMS coverage and reimbursement is usually a significant gating issue for successful introduction of a new product. In addition, government programs as a condition of participation mandate fixed discounts or rebates from sponsors regardless of formulary position or utilization and may utilize mechanisms such as formulary placement to attain further price reductions, which can greatly reduce realization on the sale.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Further, the increased emphasis on managed health care in the United States and on country and regional pricing and reimbursement controls in the European Union will put additional pressure on product pricing, reimbursement, and utilization, which may adversely affect our future product sales and results of operations. These pressures can arise from rules and practices of managed care groups, competition within therapeutic classes, laws, regulations and judicial decisions related to governmental health benefit programs, health care reform, biopharmaceutical coverage and reimbursement policies, and pricing in general. Patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated health care costs. Sales of our product candidates will therefore depend substantially, both domestically and abroad, on the extent to which the costs of our products will be paid by health maintenance, managed care, pharmacy benefit and similar health care management organizations, or reimbursed by government health administration authorities, private health insurers, and other third-party payors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. Some countries provide that drug products may be marketed only after a reimbursement price has been agreed upon. Some countries may require the completion of additional studies that compare the cost-effectiveness of our product candidate to currently available therapies (so called health technology assessment (&#8220;HTA&#8221;)) in order to obtain reimbursement or pricing approval. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Other member states allow companies to fix their own prices for drug products but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products that may be approved for commercialization in such countries. Historically, products launched in the European Union do not follow price structures of the United States, and prices generally tend to be significantly lower in the European Union.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As a result of the above, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain marketing approvals in the United States and in other jurisdictions. Our product candidates may not be considered medically necessary or cost-effective, or the rebate percentages required to secure coverage may not yield an adequate margin over cost. Additionally, companies are increasingly finding it necessary to establish bridge programs to assist patient access to new therapies during protracted initial coverage determination periods.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Moreover, a payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved or that significant price concessions will not be required to avoid restrictive conditions. High health plan co-payment requirements may result in patients refusing prescriptions or seeking alternative therapies. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in therapeutic development. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. Legislative proposals to reform health care or reduce costs under government insurance programs may result in lower reimbursement for our products and product candidates or exclusion of our products and product candidates from coverage. The cost containment measures that health care payors and providers are instituting and any health care reform could significantly reduce our revenues from the sale of any products for which we may obtain approval. We cannot provide any assurances that we will be able </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">to obtain and maintain third-party coverage or adequate reimbursement for our product candidates in whole or in part.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Health Care Reform Measures</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the United States and some foreign jurisdictions, there have been, and continue to be, legislative and regulatory changes and proposed changes regarding the health care system that could prevent or delay marketing approval of product and therapeutic candidates, restrict or regulate post-approval activities, and affect the ability to profitably sell therapeutic products that obtain marketing approval. The FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product and therapeutic candidates. In addition, future legislative and regulatory proposals may materially impact the ability of the FDA and other regulatory agencies to operate as they have historically operated. We cannot be sure whether additional legislative changes will be enacted, or whether any of the FDA&#8217;s regulations, guidances or interpretations will be changed, or what the impact of such changes on the FDA and its scientific review staff, if any, may be. For example, the next FDA user fee reauthorization package is expected to enter stakeholder negotiations beginning in mid-2025, with any agreement sent to Congress in early 2027 for purposes of initiating the legislative process. Reauthorization of the prescription drug user fee program would need to be finalized by Congress by the end of September 2027 in order to avoid a disruption in FDA&#8217;s review goals for BLAs and other activities supported by user fees assessed against industry. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we otherwise may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition and results of operations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in health care systems with the stated goals of containing health care costs, improving quality and/or expanding access. For example, the ACA has had a significant impact on the health care industry in the United States. The ACA expanded coverage for the uninsured while at the same time containing overall health care costs. With regard to biopharmaceutical products, the ACA, among other things, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by such manufacturers under the rebate program and extended the program to individuals enrolled in Medicaid managed care organizations; established annual fees on manufacturers of certain branded prescription drugs; and created a new Medicare Part D coverage gap discount program. Additionally, the CREATES Act, which became law on December 20, 2019, aims to address the concern articulated by both the FDA and others in the industry that some brand manufacturers have improperly restricted the distribution of their products, including by invoking the existence of a REMS for certain products, to deny generic product developers access to samples of brand products. Because generic product developers need samples to conduct certain comparative testing required by the FDA, some have attributed the inability to timely obtain samples as a cause of delay in the entry of generic products. To remedy this concern, the CREATES Act establishes a private cause of action that permits a generic product developer to sue the brand manufacturer to compel it to furnish the necessary samples on &#8220;commercially reasonable, market-based terms.&#8221; Although lawsuits have been filed under the CREATES Act since its enactment, those lawsuits have settled privately; therefore to date no federal court has reviewed or opined on the statutory language and there continues to be uncertainty regarding the scope and application of the law.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Legislative and regulatory changes under the ACA are possible, but it is unknown what form any such changes or any law would take and how or whether it may affect the biopharmaceutical industry as a whole or our business in the future. We expect that changes or additions to the ACA, the Medicare and Medicaid programs, and changes stemming from other health care reform measures, especially with regard to health care access, financing or other legislation in individual states, could have a material adverse effect on the health care industry in the United States. Moreover, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2022, the Inflation Reduction Act of 2022 (the &#8220;IRA&#8221;) was signed into law. Among other things, the IRA has multiple provisions that may impact the prices of drug products that are both sold into the Medicare program and throughout the United States. For example, a manufacturer of a drug or biological product covered by Medicare Parts B or D must pay a rebate to the federal government if the drug product&#8217;s price increases faster than the rate of inflation. This calculation is made on a product-by-product basis and the amount of the rebate owed to the federal government is directly dependent on the volume of a drug or biological product that is paid for by Medicare Parts B or D. Additionally, starting in payment year 2026, CMS will negotiate drug prices annually for a select number of single-source Part D drugs without generic or biosimilar competition. CMS will also negotiate drug prices for a select number of Part B drugs starting for payment year 2028. If a drug product is selected by CMS for </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">negotiation, it is expected that the revenue generated from such drug will decrease. CMS has begun to implement these new authorities and entered into the first set of agreements with drug and biological product manufacturers for negotiated prices of 10 products, which will become applicable for payment year 2026. However, the IRA&#8217;s impact on the pharmaceutical industry in the United States remains uncertain, in part because multiple large pharmaceutical companies and other stakeholders (e.g., the U.S. Chamber of Commerce) have initiated federal lawsuits against CMS arguing the program is unconstitutional for a variety of reasons, among other complaints. Those lawsuits are currently ongoing.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. For example, in recent years, several states have formed prescription drug affordability boards (&#8220;PDABs&#8221;). Much like the IRA&#8217;s drug price negotiation program, these PDABs have attempted to implement upper payment limits (&#8220;UPLs&#8221;) on drugs sold in their respective states in both public and commercial health plans. For example, in August 2023, Colorado&#8217;s PDAB announced a list of five prescription drugs that would undergo an affordability review. The effects of these efforts remain uncertain pending the outcomes of several federal lawsuits challenging state authority to regulate prescription drug payment limits. In December 2020, the U.S. Supreme Court held unanimously that federal law does not preempt the states&#8217; ability to regulate pharmaceutical benefit managers (&#8220;PBMs&#8221;) and other members of the health care and pharmaceutical supply chain, an important decision that may lead to further and more aggressive efforts by states in this area. In mid-2022, the Federal Trade Commission also launched sweeping investigations into the practices of the PBM industry that could lead to additional federal and state legislative or regulatory proposals targeting such entities&#8217; operations, pharmacy networks, or financial arrangements. Significant efforts to change the PBM industry as it currently exists in the U.S. may affect the entire pharmaceutical supply chain and the business of other stakeholders, including biopharmaceutical developers like us.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. We expect that additional state and federal health care reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for health care products and services, including any future drug products for which we secure marketing approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">The Foreign Corrupt Practices Act</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Foreign Corrupt Practices Act (&#8220;FCPA&#8221;) prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party, or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. Activities that violate the FCPA, even if they occur wholly outside the United States, can result in criminal and civil fines, imprisonment, disgorgement, oversight, and suspension and debarment from government contracts, and refusal of orders under existing government contracts. However, in February 2025, President Trump issued an executive order directing the DOJ to pause enforcement of the FCPA and to issue new enforcement guidelines that take into consideration U.S. national security and the competitiveness of U.S. companies abroad. It is unclear how this presidential directive may affect the biopharmaceutical industry as a whole or our business in particular.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">European Union Drug Development</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the European Union (&#8220;European Union&#8221; or the &#8220;EU&#8221;), our product candidates and products, should they receive marketing authorization in the EU, will be subject to extensive regulatory requirements. As in the United States, medicinal products can be marketed only if a marketing authorization from the competent regulatory agencies has been obtained. Similar to the United States, the various phases of preclinical and clinical research in the European Union are subject to significant regulatory controls. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2014, the Clinical Trials Regulation, (EU) No 536/2014, was adopted and it became effective on January 31, 2022. The Clinical Trials Regulation will be directly applicable in all of the European Union Member States (&#8220;EU Member States&#8221;), repealing the current Clinical Trials Directive 2001/20/EC. The extent to which ongoing clinical trials will be governed by the Clinical Trials Regulation will depend on when the clinical trial is initiated or on the duration of an ongoing trial. As of January 2023, all new clinical trials must comply with the Clinical Trials Regulation. In addition, any clinical trial that was already under way as of January 1, 2023 and continues for more than three years from the day on which the Clinical Trials Regulation becomes applicable (i.e., January 31, 2025), the Clinical Trials Regulation will at that time begin to apply to the clinical trial.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Clinical Trials Regulation aims to simplify and streamline the approval of clinical trials in the European Union. The main characteristics of the regulation include: a streamlined application procedure via a single entry point, the &#8220;EU portal&#8221; or Clinical Trial Information System (&#8220;CTIS&#8221;); a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts. Part I is assessed by the competent authorities of all EU Member States in which an application for authorization of a clinical trial has been submitted (Member States concerned). Part II is assessed separately by each EU Member State concerned. Strict deadlines have been established for the assessment of clinical trial applications. The role of the relevant ethics committees in the assessment procedure will continue to be governed by the national law of the concerned EU Member State.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To obtain a marketing authorization of a medicinal product in the European Union, we may submit marketing authorization applications (&#8220;MAA&#8221;) either under the so-called centralized or national authorization procedures. Before granting the marketing authorization under any such procedures, described below, the European Medicines Agency (&#8220;EMA&#8221;) or the competent authorities of the individual member states assess the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline">Centralized procedure</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The centralized procedure provides for the grant of a single marketing authorization following a favorable opinion by the EMA that is valid in all EU Member States, as well as Iceland, Liechtenstein and Norway. The centralized procedure is compulsory for medicines produced by specified biotechnological processes, products designated as orphan medicinal products, advanced-therapy medicines (such as gene-therapy, somatic cell-therapy or tissue-engineered medicines) and products with a new active substance indicated for the treatment of specified diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative disorders or autoimmune diseases and other immune dysfunctions and viral diseases. The centralized procedure is optional for products that represent a significant therapeutic, scientific or technical innovation, or whose authorization would be in the interest of public health. Under the centralized procedure the maximum timeframe for the evaluation of an MAA by the EMA is 210 days, excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the Committee for Medicinal Products for Human Use (&#8220;CHMP&#8221;). Accelerated assessment might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest, particularly from the point of view of therapeutic innovation. The timeframe for the evaluation of an MAA under the accelerated assessment procedure is 150 days, excluding stop-clocks.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline">National authorization procedures</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There are also two other possible routes to authorize medicinal products in several EU countries, which are available for investigational medicinal products that fall outside the scope of the centralized procedure:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Decentralized procedure. Using the decentralized procedure, an applicant may apply for simultaneous authorization in more than one EU Member State of medicinal products that have not yet been authorized in any EU Member State and that do not fall within the mandatory scope of the centralized procedure.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Mutual recognition procedure. In the mutual recognition procedure, a medicine is first authorized in one EU Member State, in accordance with the national procedures of that country. Following this, further marketing authorizations may be sought from other EU Member States in a procedure whereby the countries concerned agree to recognize the validity of the original, national marketing authorization</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Only products for which marketing authorizations have been granted may be promoted in the European Union. A marketing authorization is valid for five years in principle and the marketing authorization may be renewed after the initial five-year period on the basis of a re-evaluation of the risk-benefit balance by the EMA or by the competent authority of the authorizing member state. To this end, the marketing authorization holder must provide the EMA, or the applicable competent authority, with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted, at least six months before the marketing authorization ceases to be valid. Once renewed, the marketing authorization is valid for an unlimited period, unless the European Commission, or the applicable competent authority, decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal. Any marketing authorization which is not followed by the actual placing of the drug on the market in the European Union (in case of centralized procedure) or on the market in the authorizing member state within three years after authorization ceases to be valid (the so-called sunset clause).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2023, the European Commission issued a proposal that will revise and replace the existing general pharmaceutical legislation. As of March 2025, the Council of the EU is conducting a technical examination of the proposal. If adopted and implemented as currently proposed, these revisions will significantly change several aspects of drug development and approval in the European Union.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">European Data Collection</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The collection, use, disclosure, transfer or other processing of personal data, including personal health data, in the EU is governed by the General Data Protection Regulation (&#8220;GDPR&#8221;). The GDPR applies to any company established in the European Economic Area (&#8220;EEA&#8221;) and to companies established outside the EEA that process personal data in connection with the offering of goods or services to data subjects in the EEA or the monitoring of the behavior of data subjects in the EEA. The GDPR establishes stringent requirements applicable to the processing of personal data, including strict requirements relating to the validity of consent of data subjects, expanded disclosures about how personal data is used, requirements to conduct data protection impact assessments for &#8220;high risk&#8221; processing, limitations on retention of personal data, special provisions affording greater protection to and requiring additional compliance measures for &#8220;special categories of personal data&#8221; including health and genetic information of data subjects, mandatory data breach notification (in certain circumstances), &#8220;privacy by design&#8221; requirements, and direct obligations on service providers acting as processors. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The GDPR also prohibits the international transfer of personal data from the EEA to &#8220;non-adequate&#8221; countries outside of the EEA unless a valid data transfer mechanism has been put in place to safeguard the personal data, such as the Standard Contractual Clauses or certification under the newly-adopted Data Privacy Framework. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The GDPR also enhances enforcement authority and imposes large penalties for non-compliance, including the potential for fines of up to &#8364;20 million or 4% of annual global turnover</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">of the infringer, whichever is greater.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, the GDPR confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">United Kingdom Regulation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of January 1, 2021, EU law no longer directly applies in the United Kingdom (&#8220;United Kingdom&#8221; or the &#8220;UK&#8221;). The United Kingdom has adopted existing EU medicines regulation as standalone UK legislation with some amendments to reflect procedural and other requirements with respect to marketing authorizations and other regulatory provisions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In order to market medicines in the United Kingdom, manufacturers must hold a UK authorization. On January 1, 2021, all EU marketing authorizations were converted to UK marketing authorizations subject to a manufacturer opt-out. UK medicines legislation is subject to future regulatory change under the Medicines and Medical Devices Act 2021, which sets out a framework for the adoption of medicines regulation. Guidance issued by the Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;) states that the United Kingdom will have the power to take into account marketing authorizations made under the EU decentralized and mutual recognition procedures. In addition, the MHRA&#8217;s guidance has been updated to refer to UK-specific licensing procedures including routes of evaluation for novel and biotechnological products. In some cases, medicinal products may be eligible for submission through the International Recognition Procedure, which was launched by MHRA in January 2024 to provide an expedited authorization pathway for products that have received positive marketing authorization decisions from trusted partner agencies, such as the EMA or the FDA. In Northern Ireland, however, marketing applications granted by the European Commission continue to apply.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Different rules apply in Northern Ireland following implementation of the Northern Ireland Protocol, under which European Union central marketing applications continue to apply there. However, in March 2023, the United Kingdom government and the European Commission reached agreement on a regulatory framework to replace the Northern Ireland Protocol, referred to as the Windsor Framework. The Windsor Framework is effective as of January 1, 2025 and requires changes to the system that was previously in effect under the Northern Ireland Protocol, including the regulation of pharmaceutical products in the United Kingdom. Specifically, the MHRA will be responsible for approving all medicines intended to be marketed in the United Kingdom (including Northern Ireland), while the EMA will no longer be involved in approving medicines intended for sale in Northern Ireland.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Trade and Cooperation Agreement between the EU and the United Kingdom contains an Annex in relation to medicinal products with the objective of facilitating availability of medicines, promotion of public health and consumer protection in respect of medicinal products. The Annex provides for mutual recognition of cGMP inspections and certificates, meaning that manufacturing facilities do not need to undergo duplicate inspections for the two markets. The Annex establishes a Working Group on Medicinal Products to deal with matters under the Trade and Cooperation Agreement, facilitate co-operation and for the carrying out of technical discussions. It is expected that further bilateral discussions will continue with respect to regulatory areas not the subject of the Trade and Cooperation Agreement, including pharmacovigilance. The Trade and Cooperation Agreement also does not include reciprocal arrangements for the recognition of batch testing certification. However, the United Kingdom has listed approved countries, including the EEA which will enable UK importers and wholesales to recognize certain certification and regulatory standards. The European Commission has not adopted such recognition procedures.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Relatedly, following the United Kingdom&#8217;s withdrawal from the EU, the GDPR&#8217;s requirements have been implemented in the United Kingdom (referred to as the &#8220;UK GDPR&#8221;). The UK GDPR sits alongside the amended UK Data Protection Act 2018 which implements certain derogations in the EU GDPR into United Kingdom law. Under the UK GDPR, companies not established in the United Kingdom but who process personal data in relation to the offering of goods or services to individuals in the United Kingdom, or to monitor their behavior will be subject to the UK GDPR &#8211; the requirements of which are (at this time) largely aligned with those under the EU GDPR and as such, may lead to similar compliance and operational costs with potential fines of up to &#163;17.5 million or 4% of global turnover. In June</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2021, the European Commission issued a decision, valid for four years from its entry into force, that the United Kingdom ensures an adequate level of protection for personal data transferred under the EU GDPR from the EU to the United Kingdom. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Rest of the World Regulation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For other countries outside of the EU and the United States, such as countries in Eastern Europe, Latin America, Asia, as well as Australia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement, and data privacy vary from country to country. Additionally, clinical trials to support applications for marketing authorization in such jurisdictions must be conducted in accordance with GCP requirements and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Human Capital</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December 31, 2024, we had 32 employees, all of whom were full-time, 10 of whom have Ph.D. or M.D. degrees, and 26 of whom are engaged in research and development and manufacturing activities. We do not have any employees represented by a labor union or covered under a collective bargaining agreement.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Talent Acquisition and Retention</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are committed to pioneering the development of immunotherapies for patients with limited treatment options and poor outcomes suffering from cancer. To that end, we recognize that our industry is specialized and dynamic, and a significant aspect of our success is our continued ability to execute our human capital strategy of attracting, engaging, developing and retaining highly skilled talent. We offer competitive compensation packages including base salary, annual incentive bonuses, and long-term equity incentive awards. We also offer comprehensive and robust employee benefits, such as life, disability, and health insurance, health savings accounts, paid time off, and a 401(k) plan. We also provide flexible work arrangements consisting of remote, hybrid, and onsite work. We believe that our non-lab-based employees can be highly productive working remotely and we are building a culture that closely connects all employees, regardless of location, based on open and frequent communication, transparency, and employing people with a desire to participate in company events, frequent video face to face discussions, and other activities designed to eliminate &#8220;remoteness&#8221; from working remotely. We pride ourselves on our strong company culture and initiatives aligned with our mission, vision, and values. In addition, we strive to provide a collegial atmosphere where teamwork and collaboration are emphasized and valued. We use internal and external resources to recruit highly skilled candidates for open positions. It is our express intent to be an employer of choice in our industry by providing market-competitive compensation and benefits packages and we believe we are able to attract and retain superior talent as measured by our minimal turnover rate and high employee service tenure. We are an equal opportunity employer and cultivate a highly collaborative and entrepreneurial culture. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Training and Development</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe in encouraging employees to become lifelong learners by providing ongoing learning and leadership training opportunities. We strive to provide real-time recognition of employee performance. In addition, we have formal mid-year and annual review processes to determine individual contributions that may lead to pay and equity adjustments. The mid-year and annual review processes also help us identify areas where training and development may be needed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Corporate Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Elicio Therapeutics, Inc. (&#8220;Elicio&#8221; or the &#8220;Company&#8221;) was incorporated in Delaware as Vedantra Pharmaceuticals Inc. in August 2011. On January 17, 2023, the Company entered into a definitive merger agreement (the &#8220;Merger Agreement&#8221;) with Angion Biomedica Corp. (&#8220;Angion&#8221;), a clinical-stage biotechnology company, Arkham Merger Sub, Inc., a wholly owned subsidiary of Angion (&#8220;Merger Sub&#8221;), and Elicio Operating Company, Inc. (&#8220;Former Elicio&#8221;), pursuant to which Merger Sub merged with and into Former Elicio, with Former Elicio surviving the merger as a wholly owned subsidiary of Angion (the &#8220;Merger&#8221;). On June 1, 2023, the Company </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">completed the Merger in accordance with the terms and conditions of the Merger Agreement and Angion changed its name from &#8220;Angion Biomedica Corp.&#8221; to &#8220;Elicio Therapeutics, Inc.&#8221; </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We and Former Elicio each have a principal executive office at 451 D Street, Suite 501, Boston, MA 02210. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Available Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We file electronically with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). The SEC maintains an Internet site that contains reports, proxy information and information statements, and other information regarding issuers that file electronically with the SEC. The address of that website is http://www.sec.gov.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We maintain a public website at https://www.elicio.com and use our website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Our website includes an Investors section through which we make available, free of charge, our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, Proxy Statements and Forms 3, 4 and 5 filed on behalf of directors and executive officers, as well as any amendments to those reports filed or furnished pursuant to the Exchange Act as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. The members of our board of directors are reflected on the signature page of this Annual Report on Form 10-K. We also make available on our website the charters for our board of directors&#8217; Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee, as well as our Code of Business Conduct and Ethics, and other related materials. The information on our website is not part of this Annual Report.</span></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_16"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Investing in our securities involves a high degree of risk. You should carefully consider the risk factors set forth below as updated by our subsequent filings under the Exchange Act, before deciding whether to purchase our securities. The risks and uncertainties we describe below are not the only ones we face. Additional risks and uncertainties not presently known to us could adversely affect our business, operating results and financial condition, as well as adversely affect the value of an investment in our securities, and the occurrence of any of these risks might cause you to lose all or part of your investment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Summary Risk Factors</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are subject to a number of risks that if realized could affect our business, financial condition, results of operations and cash flows. As a clinical stage biopharmaceutical company, certain elements of risk are inherent to our business. Accordingly, we encounter risks as part of the normal course of our business. Some of the more significant challenges and risks include the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">We will require substantial additional capital to finance our operations, and a failure to obtain this necessary capital when needed, on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our research and development programs, commercialization efforts or cease operations.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">We have identified conditions and events that raise substantial doubt about our ability to continue as a going concern. Our independent registered public accounting firm has included an explanatory paragraph relating to our ability to continue as a going concern in its report on our audited consolidated financial statements for the year ended December 31, 2024 included in this Annual Report on Form 10-K filed with the SEC.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">We have incurred losses since inception, have never generated any revenue from product sales, have a limited operating history on which to assess our business, and anticipate that we will continue to incur significant losses for the foreseeable future.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">We have identified material weaknesses in our internal control over financial reporting related to our control environment. If we do not remediate the material weaknesses in our internal control over financial reporting, or if we fail to establish and maintain effective internal control, we may not be able to accurately report our financial results, which may cause investors to lose confidence in our reported financial information and may lead to a decline in the market price of our stock.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Our product candidates are at an early stage of development and, except for our AMPLIFY-201 and AMPLIFY-7P clinical trials, we have not previously conducted clinical trials with our product candidates. We may not be able to effectively design and execute a clinical trial that supports marketing approval and may not successfully develop or commercialize our product candidates</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Our clinical trial results may not support approval by the FDA or comparable foreign regulatory authorities and such failure to obtain regulatory approval of our product candidates would significantly harm our business, results of operations, and prospects.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">We may be unable to use and expand our discovery engine to build a pipeline of product candidates and progress such product candidates through preclinical or clinical development, which may result in us abandoning our development efforts, or we may not be able to identify, discover, develop, or commercialize additional product candidates, which would have a material adverse effect on our business and could potentially cause us to cease operations. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Due to our limited financial and managerial resources, we may focus on research programs and product candidates we identify for specific indications and may forego or delay other opportunities that may have greater commercial potential.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">There are a number of factors that can impact the enrollment of patients in our clinical trials. If we experience difficulties in enrolling patients, we could experience significant delays and we may need to abandon one or more clinical trials, or we may need to increase development costs for our product candidates which could materially impair our ability to generate revenues.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Our product candidates may cause undesirable side effects, may not achieve the desired efficacy threshold, or have other properties or characteristics that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">We may form or seek strategic partnerships or collaborations or enter into additional licensing arrangements with third parties and we may not realize the benefits of such transactions or arrangements. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">We rely on contract manufacturing organizations (&#8220;CMOs&#8221;) to manufacture our product candidates and perform other manufacturing-related services. If these third parties do not successfully carry out their contractual duties, meet expected timelines, or otherwise conduct the trials as required or perform and comply with regulatory requirements, we may not be able to successfully complete clinical development, obtain regulatory approval or commercialize our product candidates when expected or at all, and our business could be substantially harmed. We face significant competition, and our competitors may achieve regulatory approval before us or develop safer, more advanced or effective therapies than we might develop.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Our AMP platform is novel and any current or future product candidates may be too complex to manufacture and such complexities could lead to regulatory delays or production problems that could harm our business.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Our success depends on our ability to obtain and maintain our intellectual property for our product candidates and their formulations. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">We are substantially dependent on patents we license from MIT and if the licensed patent rights lack legal effect or if there is a dispute under the license agreement or changes to the scope of the agreement, it could lead to a material adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Even if we obtain regulatory approval for our product candidates, we will remain subject to ongoing regulatory requirements. Maintaining compliance with ongoing regulatory requirements may result in significant additional expense to us, and any failure to maintain such compliance could subject us to penalties and cause our business to suffer.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Healthcare and other legislative reform measures may have a materially negative impact on our business.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Cybersecurity incidents, loss of data and other disruptions, including from cyberattacks, could compromise sensitive information related to our business, prevent us from accessing critical information or expose us to liability, which could adversely affect our business and our reputation. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">The instability of the global credit and financial markets may adversely affect our business strategy, including our ability to secure necessary and timely financings, which may impact our financial performance, stock price and development of our product candidates. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">We will continue to incur significant legal, accounting and other expenses in order to comply with the laws, rules, and regulations associated with being a public company.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The above list is not exhaustive, and we face additional challenges and risks. Please carefully consider all of the information in this Annual Report on Form 10-K including matters set forth in this &#8220;Risk Factors&#8221; section.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Risks Related to Our Operating History, Financial Position and Capital Requirements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We will require substantial additional capital to finance our operations, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our research and development programs, commercialization efforts or cease operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our operations have consumed substantial amounts of cash. During the years ended December 31, 2024 and 2023, we incurred research and development expenses of $33.7&#160;million and $23.8&#160;million, respectively, and net losses of $51.9&#160;million and $35.2&#160;million, respectively. We will require substantial additional funds to support our continued research and development activities, including the anticipated costs of nonclinical studies and clinical trials, regulatory approvals and potential commercialization. Additionally, our estimates on future financial needs may be based on assumptions that prove to be wrong, and we may spend our available financial resources much faster than we expect.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Until such time, if ever, that we can generate sufficient product revenue and achieve profitability, we expect to seek to finance future cash needs through the sale of common stock in public offerings and/or private placements, debt financings, or through other capital sources, including licensing arrangements, partnerships and collaborations with other companies or other strategic transactions. We currently have no other commitments or agreements relating to any of these types of transactions, other than our Capital on Demand</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Sales Agreement with JonesTrading Institutional Services LLC and obligations related to the exercise of previously issued warrants, and cannot be certain that additional funding will be available to us on acceptable terms, or at all. To the extent that we raise additional capital through the sale of equity, convertible debt or other securities convertible into equity, the ownership interest of our stockholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect rights of our stockholders. Debt financing, if available at all, would likely involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, completing acquisitions or declaring or paying dividends.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Furthermore, the impact of macroeconomic factors, including the current inflationary environment and the imposition of tariffs, in addition to geopolitical instability and tensions, could make the terms of any available financing less attractive to us and more dilutive to our existing stockholders. If we are unable to raise additional capital, we will have to delay, curtail or eliminate one or more of our research and development programs or cease operations. In addition, securing additional financing would require a substantial amount of time and attention from our management and may divert a disproportionate amount of their attention away from day-to-day activities, which may adversely affect our management&#8217;s ability to oversee the development of our product candidates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our recurring losses from operations have raised substantial doubt regarding our ability to continue as a going concern.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe there is substantial doubt about our ability to continue as a going concern as of the date of this Annual Report on Form 10-K. Our independent registered public accounting firm has included an explanatory paragraph relating to our ability to continue as a going concern in its report on our audited consolidated financial statements for the year ended December 31, 2024 included in this Annual Report on Form 10-K. This going concern opinion could materially limit our ability to raise additional funds through the issuance of new debt or equity securities or otherwise. Future reports on our financial statements may include an explanatory paragraph with respect to our ability to continue as a going concern. We have incurred significant losses since our inception and have never been profitable, and it is possible we will never achieve profitability. We have devoted a majority of our resources to developing ELI-002, but this product candidate cannot be marketed or commercialized until regulatory approvals have been obtained. Meaningful revenues will likely not be available unless ELI-002 or any of our current or future product candidates are approved by the FDA or comparable regulatory agencies in other countries and successfully marketed, either by us or a partner, an outcome which may not occur. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe that our cash on hand will enable us to fund our operations into the fourth quarter of 2025 based on our current plan. This period could be shortened if there are any significant increases in planned or actual spending on development programs or more rapid progress of development programs than anticipated. There is no assurance that financing will be available when needed to allow us to continue as a going concern. If we are unable to obtain additional capital and continue as a going concern, we might have to further scale back our operations or liquidate </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">our assets and cease operations entirely, and the values we receive for our assets in liquidation or dissolution could be significantly lower than the values reflected in our financial statements. Our lack of capital resources and our conclusion that we may be unable to continue as a going concern may materially adversely affect our share price and our ability to raise new capital or to enter into critical contractual relations with third parties.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We may be unsuccessful in raising the capital necessary to address our going concern issues, or if we are successful, it may be on terms that are highly dilutive to existing stockholders.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Historically, we have funded our operations by raising capital from external sources and from the Merger (as defined below). However, we are currently facing significant challenges to our ability to raise capital through the sale of common stock, including the following factors:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">in general, it is difficult for development stage companies to raise capital under current market conditions, especially those with early-stage programs like ours;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the perception that we may be unable to continue as a going concern may impede our ability to attract further equity investment; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our common stock has limited trading volume, which limits the demand for our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Given these factors, there can be no assurances we will be successful at raising sufficient capital to address our going concern issues. Even if we are successful in raising capital, it may be on terms that are very highly dilutive to existing stockholders. In addition, if we are unable to raise additional capital, we may have to delay, curtail or eliminate one or more of our research and development programs or cease operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We have a history of operating losses that are expected to continue for the foreseeable future, and we are unable to predict the extent of future losses, or whether we will generate significant revenues or achieve or sustain profitability.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are focused on product development and we have not generated any revenues to date. Additionally, we expect to continue to incur operating losses for the foreseeable future. These operating losses have adversely affected and are likely to continue to adversely affect our working capital, total assets and stockholders&#8217; deficit.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Since we are a clinical-stage biotechnology company, our prospects must be considered in light of the uncertainties, risks, expenses, and difficulties frequently encountered by companies in their early stages of operations. Specifically, we have generated net losses each year since our inception, including $51.9&#160;million and $35.2&#160;million for the years ended December 31, 2024 and 2023, respectively. We expect to make substantial expenditures and incur increasing operating costs in the future and our accumulated deficit is expected to increase significantly as we expand development and clinical trial activities for our product candidates. Because of the risks and uncertainties associated with product development, we are unable to predict the extent of any future losses, whether we will ever generate significant revenues or if we will ever achieve or sustain profitability.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe that our cash on hand will enable us to fund our operations into the fourth quarter of 2025 based on our current plan. We are dependent on obtaining, and are continuing to pursue, necessary funding from outside sources, including obtaining additional funding from the issuance of securities in order to continue our operations. Without adequate funding, we may not be able to meet our financial obligations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have not demonstrated an ability to perform the functions necessary for the successful commercialization of any products. The successful commercialization of any of our products will require us to perform a variety of functions, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">continuing to undertake preclinical and clinical development;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">engaging in the development of product candidate formulations and manufacturing processes;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">interacting with the applicable regulatory authorities and pursuing other required steps for regulatory approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">engaging with payors and other pricing and reimbursement authorities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">submitting marketing applications to and receiving approval from the applicable regulatory authorities; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">manufacturing the applicable products and product candidates in accordance with regulatory requirements and, if ultimately approved, conducting sales and marketing activities in accordance with health care, FDA and similar foreign regulatory authority laws and regulations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We have never generated revenue from product sales and may never become profitable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have no products approved for commercialization and have never generated any product revenue. Our ability to generate product sales and achieve profitability depends on our ability, alone or with collaborative partners, to successfully complete the development of, and obtain the regulatory approvals necessary to commercialize our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">current and future product candidates. We do not anticipate generating product sales for the next several years, if ever.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our product candidates will require additional clinical, manufacturing, and non-clinical development, regulatory approval, commercial manufacturing arrangements, establishment of a commercial organization, significant marketing efforts, and further investment before they generate any product sales. We cannot guarantee that we will meet our timelines for our development programs, which may be delayed or may not be completed for a number of reasons. Our ability to generate future revenues from product sales depends heavily on our, or our collaborators&#8217;, ability to successfully:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">complete research and obtain favorable results from nonclinical and clinical development of our current and future product candidates, including addressing any clinical holds that may be placed on our development activities in the future by regulatory authorities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">seek and obtain regulatory and marketing approvals for any of our product candidates for which we complete clinical trials, as well as their manufacturing facilities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">seek and maintain grants that may be necessary for continuing operations; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">launch and commercialize any of our product candidates for which we obtain regulatory and marketing approval by establishing a sales force, marketing, and distribution infrastructure or, alternatively, collaborating with a commercialization partner;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">qualify for coverage and establish adequate reimbursement by government and third-party payors for any of our product candidates for which we obtain regulatory and marketing approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">develop, maintain, and enhance a sustainable, scalable, reproducible, and transferable manufacturing process for the product candidates we may develop;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">establish and maintain supply and manufacturing capabilities or capacities internally or with third parties that can provide adequate, in both amount and quality, products, and services to support clinical development and the market demand for any of our product candidates for which we obtain regulatory and marketing approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">obtain market acceptance of current or any future product candidates as viable treatment options and effectively compete with other therapies to establish market share;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">maintain a continued acceptable safety and efficacy profile of our product candidates following launch;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">address competing technological and market developments;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">implement internal systems and infrastructure, as needed;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">negotiate favorable terms in any collaboration, licensing, or other arrangements into which we may enter and perform our obligations in such collaborations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">maintain, protect, enforce, defend, and expand our portfolio of intellectual property rights, including patents, trade secrets, and know-how;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">avoid and defend against third-party interference, infringement, and other intellectual property claims; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">attract, hire, and retain qualified personnel.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Even if one or more of our current and future product candidates are approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. Our expenses could increase beyond our expectations if we are required by the FDA or other regulatory authorities to perform clinical and other studies in addition to those that we currently anticipate. If we are required to conduct additional clinical trials or other testing of our product candidates that we develop beyond those that we currently expect, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive, or if there are safety concerns, we may be delayed in obtaining marketing approval for our product candidates, not obtain marketing approval at all, or obtain more limited approvals. Even if we are able to generate revenues from the sale of any approved product candidates, we may not become profitable and may need to obtain additional funding to continue operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease our value and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in our value also could cause our stockholders to lose all or part of their investment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We have a limited operating history and we expect a number of factors to cause our operating results to fluctuate on a quarterly and annual basis, which may make it difficult to predict our future performance.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are a clinical stage biopharmaceutical company with a limited operating history. Our operations to date have been primarily limited to organizing and staffing our company, acquiring, developing and securing our proprietary technology, and preclinical and clinical development of our product candidates. While we ended study visits for the Phase 1 trial of ELI-002 in August 2024, we have not yet successfully completed any other clinical trials for our product candidates, manufactured our product candidates at commercial scale or conducted sales and marketing activities that will be necessary to successfully commercialize our product candidates, if approved. Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had a longer operating history or commercialized products. Our financial condition has varied significantly in the past and will continue to fluctuate from quarter-to-quarter or year-to-year due to a variety of factors, many of which are beyond our control. Factors relating to our business that may contribute to these fluctuations include other factors described elsewhere herein and also include, among other things:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to obtain additional funding to develop our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to conduct and complete nonclinical studies and clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">delays in the commencement, enrollment and timing of clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the success of our nonclinical studies and clinical trials through all phases of development;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">any delays in regulatory review and approval of product candidates in clinical development;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to obtain and maintain regulatory approval for our product candidates in the United States and foreign jurisdictions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">potential toxicity and/or side effects of our product candidates that could delay or prevent commercialization, limit the indications for any approved products, require the establishment of risk evaluation and mitigation strategies, cause an approved drug to be taken off the market or an inability to establish efficacy needed for approvals;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to establish or maintain partnerships, collaborations, licensing or other arrangements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">market acceptance of our product candidates, if approved;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">competition from existing products, new products or new therapeutic approaches that may emerge;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the ability of patients or health care providers to obtain coverage of or sufficient reimbursement for our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to leverage our proprietary AMP technology platform to discover and develop additional product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability and our licensors&#8217; abilities to successfully obtain, maintain, defend and enforce intellectual property rights important to our business; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">potential product liability claims.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Accordingly, the results of any quarterly or annual periods should not be relied upon as indications of future operating performance.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We have identified material weaknesses in our internal control over financial reporting related to our control environment. If we do not remediate the material weaknesses in our internal control over financial reporting, or if we fail to establish and maintain effective internal control, we may not be able to accurately report our financial results, which may cause investors to lose confidence in our reported financial information and may lead to a decline in the market price of our stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As a public company, we are required to maintain internal control over financial reporting and to report any material weaknesses in such internal controls. Pursuant to Section 404 (&#8220;Section 404&#8221;) of the Sarbanes-Oxley Act of 2002, as amended (the &#8220;Sarbanes-Oxley Act&#8221;), we are required to furnish a report by our management on our internal control over financial reporting in our periodic reports filed with the SEC. However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section 404. If we identify additional material weaknesses, it could result in an adverse </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented, or detected and corrected on a timely basis. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In our 2023 Form 10-K, we identified material weaknesses in our internal control over financial reporting related to our control environment. More specifically, we determined that we had not ensured calculations used in financial reporting were properly reviewed, including earnings per share (&#8220;EPS&#8221;) and weighted average shares outstanding (&#8220;WASO&#8221;) calculations as a result of a lack of finance and accounting staff with the appropriate U.S. GAAP technical expertise needed to identify, evaluate, and review such calculations. This material weakness was remediated as of December 31, 2024. Additionally, in our 2023 Form 10-K, we determined that we had not maintained adequate formal accounting policies, processes and controls related to complex transactions as a result of a lack of finance and accounting staff with the appropriate U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) technical expertise needed to identify, evaluate and account for complex and non-routine transactions. We also determined that we had insufficient financial reporting and close controls to ensure that incurred expenses are accrued at period end. Although we initiated efforts to remediate these material weaknesses, the material weaknesses have not been fully remediated as of December 31, 2024. Our remediation efforts are intended to address the identified material weaknesses. However, these material weaknesses will not be considered remediated until the applicable remedial actions operate effectively for a sufficient period of time.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have implemented additional measures to address the remaining material weaknesses identified, however, these material weaknesses will not be considered remediated until the applicable remedial actions operate effectively for a sufficient period of time. As part of these additional measures, we engaged SEC compliance and technical accounting consultants to assist in evaluating transactions for conformity with U.S. GAAP. Also, we hired additional finance and accounting personnel, including a Staff Accountant, to augment accounting staff and to provide more resources for complex accounting matters and financial reporting. We designed additional controls around identification, documentation and application of technical accounting guidance with particular emphasis on complex and non-routine transactions. These controls include an additional review process to ensure that the correct conclusions are reached with respect to complex and non-routine transactions and avoid the potential for a material misstatement of our financial statements. However, we cannot assure you that we will be successful in remediating the material weaknesses we identified or that our internal control over financial reporting, as modified, will enable us to identify or avoid material weaknesses in the future. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Any failure to remediate the material weaknesses we identified or any failure to develop or maintain effective controls, or any difficulties encountered in their implementation or improvement, could harm our operating results or cause us to fail to meet our reporting obligations and may result in a restatement of our financial statements for prior periods. Any failure to remediate the material weaknesses we identified or any failure to implement and maintain effective internal control over financial reporting could also adversely affect the results of management reports and independent registered public accounting firm audits of our internal control over financial reporting that we will eventually be required to include in our periodic reports that will be filed with the SEC. Ineffective disclosure controls and procedures, and internal control over financial reporting could also cause investors to lose confidence in our reported financial and other information, which would likely have a negative effect on the market price of our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Failure to maintain effective internal controls in accordance with Section 404 of the Sarbanes-Oxley Act could have a material adverse effect on our stock price. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Section 404 of the Sarbanes-Oxley Act and the related rules and regulations of the SEC require annual management assessments of the effectiveness of our internal control over financial reporting. If we fail to maintain the adequacy of our internal control over financial reporting, as such standards are modified, supplemented or amended from time to time, we may not be able to ensure that we can conclude on an ongoing basis that we have effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act and the related rules and regulations of the SEC. If we cannot favorably assess the effectiveness of our internal control over financial reporting, investor confidence in the reliability of our financial reports may be adversely affected, which could have a material adverse effect on our stock price. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We hold a portion of our cash and cash equivalents that we use to meet our working capital and operating expense needs in deposit accounts that could be adversely affected if the financial institutions holding such funds fail. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We hold a portion of our cash and cash equivalents that we use to meet our working capital and operating expense needs in deposit accounts. The balance held in these accounts may exceed the Federal Deposit Insurance Corporation standard deposit insurance limit of $250,000. If a financial institution in which we hold such funds fails or is subject to significant adverse conditions in the financial or credit markets, we could be subject to a risk of loss of all or a portion of such uninsured funds or be subject to a delay in accessing all or a portion of such uninsured </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">funds. Any loss or lack of access to these funds could adversely impact our short-term liquidity and ability to meet our operating expense obligations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Changes in interpretation or application of U.S. GAAP may adversely affect our operating results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We prepare our consolidated financial statements to conform to U.S. GAAP. These principles are subject to interpretation by the Financial Accounting Standards Board (&#8220;FASB&#8221;), the American Institute of Certified Public Accountants, the SEC and various other regulatory and accounting bodies. A change in interpretations of, or our application of, these principles can have a significant effect on our reported results and may even affect our reporting of transactions completed before a change is announced. In addition, when we are required to adopt new accounting standards, our methods of accounting for certain items may change, which could cause our results of operations to fluctuate from period to period and make it more difficult to compare our financial results to prior periods.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Risks Related to the Development of our Product Candidates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our product candidates are at an early stage of development and may not be successfully developed or commercialized.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2023, we completed enrollment of the AMPLIFY-201 trial for ELI-002, our 2-peptide formulation, targeting Kirsten rat sarcoma viral oncogene homolog (&#8220;KRAS&#8221;) gene mutations, which product candidate also includes ELI-004, our universal AMP-modified CpG adjuvant. In October 2023, we completed enrollment of the AMPLIFY-7P Phase 1 portion of the trial for ELI-002, our 7-peptide formulation, and initiated enrollment of the AMPLIFY-7P Phase 2 portion of the trial in January 2024.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2024, we completed enrollment in our AMPLIFY-7P Phase 2 portion of the ELI-002 trial.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">All of our other product candidates are in preclinical development and will require substantial further capital expenditures, development, testing, and regulatory approval prior to commercialization. With the limited data on ELI-002, we may not be able to effectively design and execute clinical studies that ultimately support marketing approval. In addition, we have not initiated or submitted for any marketing authorization to any health authorities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The time required to obtain approval from the FDA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of regulatory authorities. The outcome of studies is also inherently uncertain. Of the large number of drugs in development, only a small percentage successfully complete the regulatory approval process and are commercialized. The results of nonclinical studies, interim or top-line study results, and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Failure can occur at any time during the clinical trial process. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy despite having progressed through nonclinical studies and initial clinical trials. Nonclinical and early clinical studies may also reveal unfavorable product candidate characteristics, including safety concerns. A number of companies have suffered significant setbacks in advanced clinical trials, notwithstanding promising results in earlier trials. In some instances, there can be significant variability in results between different clinical trials of the same product candidate due to numerous factors, including, among other things, differences in trial procedures set forth in protocols, differences in the type of the patient populations, changes in and adherence to the clinical trial protocols, the rate of dropout among clinical trial participants, and evolving standards of treatment from newly approved drugs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Accordingly, even if we are able to obtain the requisite financing to fund our development programs, we cannot assure you that our product candidates will be successfully developed or commercialized. Our failure to develop, manufacture or receive regulatory approval for or successfully commercialize any of our product candidates could result in the failure of our business and a loss of all of our stockholders&#8217; investment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our product candidates are in various stages of development and we will not be able to commercialize our product candidates if our nonclinical and clinical studies do not produce successful results and/or our clinical trials do not demonstrate the safety and efficacy of our product candidates; early results and early understanding of product candidate potential may not be predictive of later success. Any product candidates currently in clinical development or that we advance into clinical development are subject to extensive regulation, which can be costly and time-consuming, and we may experience unanticipated delays or be unable to receive the required approvals to commercialize our product candidates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Product candidates are susceptible to the risks of failure inherent at any stage of product development, including the occurrence of unexpected or unacceptable adverse events or the failure to demonstrate efficacy in clinical trials. Clinical development is expensive and can take many years to complete, and its outcome is inherently uncertain. The results of nonclinical studies, preliminary clinical trial results, and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Our product candidates may not perform as we expect, may ultimately have a different than expected impact or no impact at all, may have a different mechanism of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">action than we initially understand or than we expect in humans, and may not ultimately prove to be safe or effective.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The nonclinical and clinical development, manufacturing, packaging, labeling, storage, record-keeping, advertising, promotion, post-approval monitoring and reporting, import, export, marketing and distribution, among other activities, of our product candidates are subject to extensive regulation by the FDA and by comparable health authorities in foreign markets. We are not permitted to market or promote our product candidates in the United States until we receive approval from the FDA of a BLA, or in any jurisdictions outside of the United States until we receive similar authorization from analogous foreign authorities, and we may never receive such regulatory approvals for any of our product candidates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Some of our product candidates have only been tested in a nonclinical setting and while those studies have been subject to certain regulatory requirements in order to support product development and regulatory progression, as such product candidates progress they will require clinical trials (which are subject to much more extensive requirements, including GCP standards), as well as additional manufacturing development, before we will be able to submit marketing applications to the applicable regulatory authorities. Even if our product candidates are approved, they may be subject to limitations on the indicated uses and populations for which they may be marketed. They may also be subject to other conditions of approval, may contain significant safety warnings, including boxed warnings, contraindications, and precautions, may not be approved with label statements necessary or desirable for successful commercialization, or may be subject to requirements for costly post-market testing and surveillance, or other requirements, including the submission of a REMS to monitor the safety or efficacy of the products. If we do not receive regulatory authority approval for, and successfully commercialize our product candidates, we will not be able to generate revenue from these product candidates in the foreseeable future, or at all. Any significant delays in obtaining approval for and commercializing our product candidates could have a material adverse impact on our business and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The process of product candidate development and obtaining marketing approval is expensive, often takes many years and can vary substantially based upon the type, complexity and novelty of the products involved and the conditions that they are intended to treat. The number and nature of nonclinical studies and clinical trials that will be required for regulatory approval also varies depending on the product candidate, the disease or condition that the product candidate is designed to address and the regulations applicable to any particular product candidate. We have not previously submitted a marketing application to the FDA, or a similar marketing application to any comparable foreign authorities, for any product candidate, and we cannot be certain that our product candidates will be successful in clinical trials or receive regulatory approval.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition to significant clinical testing requirements, our ability to obtain marketing approval for our product candidates depends on obtaining the final results of required nonclinical testing, including characterization of the manufactured components of our product candidates and validation of our manufacturing processes. Regulatory authorities may determine that our product manufacturing processes, testing procedures or facilities are insufficient to justify approval. Approval policies or regulations, or the type and amount of data necessary to gain approval, may change and may vary among jurisdictions. Moreover, regulatory authorities have substantial discretion in the biopharmaceutical approval process, including the ability to refuse to accept an application and to delay, limit or deny approval of a product candidate for many reasons, such as a determination that our data is insufficient for approval or that additional nonclinical studies, clinical trials or other data or development work is necessary. Despite the time and expense invested in the development of product candidates, regulatory approval is never guaranteed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our product candidates may fail at any stage of preclinical or clinical development, and may also reveal unfavorable product candidate characteristics, including safety concerns or the failure to demonstrate efficacy in initial clinical trials. Further, our product candidates may not receive regulatory approval even if they are successful in clinical trials. Although we have completed preclinical validation, including toxicology testing, for our lead product candidate ELI-002 and anticipate completing the preclinical development necessary to file additional IND applications for other product candidates in the future, we may experience numerous unforeseen events before, during, or as a result of clinical trials that could delay or prevent our ability to commence or complete development, commence or complete clinical trials, receive marketing approval or commercialize our product candidates, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">we may be unable to generate sufficient nonclinical, toxicology, or other in vivo or in vitro data to support the initiation of clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">regulators or IRB or Independent Ethics Committees (&#8220;IECs&#8221;) may not authorize us or our investigators to commence or continue a clinical trial, conduct a clinical trial at a prospective trial site, or amend trial protocols, or may require that we modify or amend our clinical trial protocols;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">we, regulators, IDMC, IRBs, or IECs may recommend or require the suspension or termination of clinical research for various reasons, including non-compliance with regulatory requirements or a finding that </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">participants are being exposed to unacceptable health risks, undesirable side effects, or a failure of the product candidate to demonstrate any benefit to patients, or other unexpected characteristics (alone or in combination with other products) of the product candidate, or due to findings of undesirable effects caused by a chemically or mechanistically similar therapeutic or therapeutic candidate;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">new information may emerge regarding our product candidates or technology platform that result in continued development of some or all of our product candidates being deemed undesirable;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">we may have delays identifying, recruiting and training suitable clinical investigators or investigators may withdraw from our studies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">we may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites or contract research organizations (&#8220;CROs&#8221;). Contractual terms can be subject to extensive negotiation, may be subject to modification from time to time and may vary significantly among different CROs and trial sites;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">we may have delays in adding new clinical trial sites, or we may experience a withdrawal of clinical trial sites;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">potential delays in patient enrollment for clinical trials due to public health emergencies pandemics, natural disasters, staffing shortages, or other events, which may affect our ability to initiate, conduct ongoing clinical trials, and delay initiation of planned and future clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, or participants may drop out of these clinical trials or be lost to follow-up at a higher rate than we anticipate for a number of reasons, such as adverse events, lack of treatment effectiveness, fatigue with the clinical trial process or personal issues, electing to participate in alternative clinical trials sponsored by our competitors with product candidates that treat the same indications as our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">patients who enroll in our studies may misrepresent their eligibility or may otherwise not comply with clinical trial protocols, resulting in the need to increase the enrollment size for those studies, or extend the duration of those studies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">there may be flaws in our study design, which may not become apparent until a study is well advanced;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">our contractors may fail to comply with regulatory requirements or clinical trial protocols, or meet their contractual obligations to us in a timely manner, or at all, or we may be required to engage in additional clinical trial site monitoring;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">regulatory authorities or IRBs or IECs may disagree with the design, including endpoints, scope, or implementation of our clinical trials, or regulatory authorities may disagree with the study patient population against our intended indications or our interpretation of data from nonclinical studies or clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">regulatory authorities may disagree with the formulation for our product candidates, or our product candidate dose or dosing schedule;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">we may be unable to demonstrate to the satisfaction of regulatory authorities that a product candidate is safe, pure, and potent for any indication;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">regulatory authorities may not accept, or we or our clinical trials may not meet, the criteria required to submit clinical data from trials which are conducted outside of their jurisdictions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the results of clinical trials may be negative or inconclusive, may not meet the level of statistical significance required for, or may not otherwise be sufficient to support marketing approval, and we may decide, or regulatory authorities may require us, to conduct additional clinical trials, analyses, reports, or nonclinical studies, or abandon product development programs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">our product candidates may have undesirable or unintended side effects, toxicities, or other properties or characteristics that preclude marketing approval or prevent or limit commercial use;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks or otherwise provide an advantage over current standard of care (&#8220;SOC&#8221;) or current or future competitive therapies in development;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the SOC for the indications we are investigating may change, which changes could impact the meaningfulness of our resulting study data or require the initiation of new studies or which may necessitate changes to our ongoing or planned studies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">regulatory authorities may require us to amend our studies, perform additional or unanticipated clinical trials or nonclinical studies or manufacturing development work to obtain approval or initiate clinical trials, or we may decide to do so or abandon product development programs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">regulatory authorities may find that we or our third-party manufacturers do not satisfy regulatory requirements and standards for the facilities and operations used in the manufacture of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the cost of clinical trials of our product candidates may be greater than we anticipate, or we may have insufficient funds for a clinical trial or to pay the substantial user fees required by the FDA or other regulatory authorities upon the filing of a marketing application;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">regulatory authorities may take longer than we anticipate to make a decision on our product candidates; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">we may be unable to demonstrate the efficacy and safety of our product candidates to the FDA or other regulatory authorities, due to inaccurate or inconsistent potency assessments, potentially resulting in regulatory delays, additional testing requirements, or even rejection of our product candidates; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">changes in regulatory guidelines of the FDA or other regulatory authorities may necessitate modifications to any future biological potency assays we may develop, requiring additional validation studies and potential delays in the development or commercialization of our product candidates; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">changes in or the enactment of the approval policies, statutes, or regulations of the applicable regulatory authorities may significantly change in a manner rendering our nonclinical or clinical data insufficient for approval.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, our clinical trials, to date, have been open-label trials. Our Phase 2 study of AMPLIFY-7P is an open-label, randomized study, where both the patient and investigator know whether the patient is receiving our product candidate or is under observation, which may introduce study bias. Most typically, open-label clinical trials test only the product candidate and sometimes do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when or if they are receiving treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received product candidate and may interpret the information of the treated group more favorably given this knowledge. Positive results observed in open-label trials may not be replicated in later clinical trials. Additionally, as patients become aware that they are not receiving our product candidate as part of the trial, they may elect to withdraw from our study and enroll in clinical trials sponsored by our competitors, which may extend our study timeline.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. While we take steps to assess for conflicts of interest, it remains possible that these relationships and any related compensation could result in perceived or actual conflicts of interest, or a regulatory authority may conclude that the financial relationship may have affected the interpretation of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of the marketing application we submit. Any such delay or rejection could prevent or delay us from commercializing our current or future product candidates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Furthermore, we expect to rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and data analysis from such trials. Although we expect to enter into agreements governing our CROs&#8217; committed activities, we have limited influence over their actual performance.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A clinical trial may be suspended or terminated by us, our partners, the IRBs of the institutions in which such trials are being conducted, the IDMC for such trial or by the FDA or other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug or therapeutic biologic, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If we experience delays in the completion of, or termination of, any clinical trial of any of our current or potential future product candidates, the commercial prospects of such product candidate will be harmed, and our ability to generate product revenue from such product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow our product development and approval process and jeopardize our ability to commence product sales and generate revenue, and we may not have the financial resources to continue development of the product candidate that is affected or any of our other product candidates. We may also lose, or be unable to enter into, collaborative arrangements for the affected product candidate and for other product candidates that we are developing. Any of these occurrences may materially and adversely affect our business, financial condition, results of operations and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our potential future product candidates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Preliminary results from our nonclinical studies and clinical trials that we announce or publish from time to time may change as more patient data becomes available and as the data undergoes audit and verification procedures.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">From time to time, we may publish interim, topline, or preliminary results from our nonclinical studies and clinical trials. Preliminary and interim results from our clinical trials are not necessarily predictive of final results and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary, interim and topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, preliminary, interim and topline data should be viewed with caution until the final data are available. Material adverse changes in the final data compared to the preliminary, interim or topline data could significantly harm our business prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or therapeutic product, if any, and us in general. In addition, the information we choose to publicly disclose regarding a particular nonclinical study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular therapeutic product, if any, product candidate or our business. If the preliminary, interim and topline data that we report differs from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">The FDA or comparable foreign regulatory authorities may disagree with our regulatory plans and we may fail to obtain regulatory approval of our product candidates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The FDA standard for approval of a biologic generally requires two adequate, well-controlled clinical trials, each convincingly demonstrating the product candidate&#8217;s safety and effectiveness, or one large and robust, well-controlled trial providing substantial evidence that the product candidate is safe and effective for its proposed indication. Phase 3 clinical trials typically involve hundreds of patients, have significant costs and take years to complete. Product candidates studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may be eligible for accelerated approval and may be approved on the basis of adequate and well-controlled clinical trials establishing that the product candidate has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA usually requires a sponsor of a drug or biologic receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the drug or biologic may be subject to withdrawal procedures by the FDA that are more accelerated than those available for regular approvals.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our clinical trial results may not support either accelerated or regular approval. The results of nonclinical studies and clinical trials may not be predictive of the results of later-stage clinical trials, and product candidates in later </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">stages of clinical trials may fail to show the desired safety and efficacy despite having progressed through nonclinical studies and initial clinical trials. In addition, our product candidates could fail to receive regulatory approval for many reasons, including the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the population studied in the clinical program may not be sufficiently broad or representative to assure safety in the full population for which we seek approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">we may be unable to demonstrate that the clinical and other benefits of our product candidates outweigh their safety risks;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">we may be unable to demonstrate that our product candidates&#8217; risk-benefit ratios for their proposed indications are acceptable;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from nonclinical studies or clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the data collected from clinical trials of our product candidates may not be sufficient to satisfy the FDA or comparable foreign regulatory authorities or to support the submission of a BLA or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes, our own manufacturing facilities, or a third-party manufacturer&#8217;s facilities with which we contract for clinical and commercial supplies; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the FDA or comparable foreign regulatory authorities may fail to approve our analytical testing methods, particularly with respect to bioassay potency testing; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">we may fail to develop a potency assay for ELI-002 that is satisfactory for the FDA or comparable foreign regulatory authorities; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Failure to obtain regulatory approval to market any of our product candidates would significantly harm our business, results of operations, and prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We may not be successful in our efforts to use and expand our discovery engine to build a pipeline of product candidates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A key element of our strategy is to use and expand our discovery engine to build a pipeline of product candidates and progress these product candidates through preclinical and clinical development for the treatment of various diseases. Although our research efforts to date suggest that complex amphiphilic molecules can deliver conventional immunomodulatory payloads including peptides, proteins and nucleic acids directly and preferentially to lymph nodes, this hypothesis may prove incorrect, or we may not be able to identify a product candidate that is safe or effective as a treatment for various cancers or for other diseases. We also may not be able to identify an amphiphile product candidate that we can demonstrate to be safe or effective, and we may not be able to develop any other product candidates. Our scientific research that forms the basis of our efforts to discover product candidates based on our discovery engine is ongoing. Further, the scientific evidence to support the feasibility of developing viable product candidates based on our platform has not been established. Our discovery engine may not be proven to be superior to competing technologies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Even if we are successful in building our pipeline of product candidates, the potential product candidates that we identify may not be suitable for clinical development or generate acceptable clinical data, including as a result of being shown to have unacceptable toxicity or other characteristics that indicate that they are unlikely to be products that will receive marketing approval from the FDA or other regulatory authorities or achieve market acceptance. Investment in biopharmaceutical product development involves significant risk that any potential product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval, and become commercially viable. We cannot provide you any assurance that we will be able to successfully advance any of these additional product candidates through the development process. Our research programs may initially show </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">promise in identifying potential product candidates, yet fail to yield product candidates for clinical development or commercialization for many reasons, including the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">our platform may not be successful in identifying additional product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">we may not be able or willing to assemble sufficient resources to acquire or discover additional product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">our product candidates may not succeed in nonclinical or clinical testing;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">a product candidate may upon further study demonstrate harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">competitors may develop alternatives that render our product candidates obsolete or less attractive;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">product candidates we develop may nevertheless be covered by third parties&#8217; patents or other exclusive rights;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the market for a product candidate may change during our program so that the continued development of that product candidate is no longer reasonable;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors, if applicable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If any of these events occur, we may be forced to abandon our development efforts for a program or programs, or we may not be able to identify, discover, develop, or commercialize additional product candidates, which would have a material adverse effect on our business and could potentially cause us to cease operations. Even if we receive FDA approval to market additional product candidates, whether for the treatment of cancers or other diseases, we cannot assure you that any such product candidates will be successfully commercialized, widely accepted in the marketplace or more effective than other commercially available alternatives.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our ELI-002 clinical trials are designed to require, as part of screening to determine whether patients meet inclusion criteria, the use of an investigational in vitro diagnostic device. If we are not able to successfully collaborate or partner with a third-party company for the development and authorization of such a device, we may not be able to receive marketing authorization for ELI-002.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The clinical trials for ELI-002 (AMPLIFY-201 and AMPLIFY-7P) employ an investigational in vitro diagnostic device (&#8220;IVD&#8221;), that identifies gene mutations in KRAS and neuroblastoma rat sarcoma viral oncogene homolog (&#8220;NRAS&#8221;) genes and detects circulating tumor DNA (&#8220;ctDNA&#8221;), to identify patients who show signs of minimal residual disease in their blood, but before relapse is detected in traditional radiographic scans. Based on our Phase 2 study design, we must account for and address the investigational status of this device from a regulatory perspective through the course of clinical development (for example, through the compliance with any applicable investigational device exemption requirements). An IVD used to select patients who may be appropriate to receive our commercial product will be considered a companion diagnostic device. Companion diagnostic devices are subject to regulation by the FDA and comparable foreign regulatory authorities as medical devices and we anticipate that separate regulatory marketing authorization will be required for the device prior to commercialization of ELI-002. We plan to collaborate with appropriate companion diagnostic developers to seek marketing authorization from the FDA&#8217;s Center for Devices and Radiological Health. If our companion diagnostic partner experiences any delays in development or is not able to successfully develop and obtain marketing authorization for its companion diagnostic, or does not comply with the FDA&#8217;s medical device regulations:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the development and commercialization of ELI-002 may also be delayed because in most circumstances, FDA expects the companion diagnostic and its corresponding therapeutic product to be approved contemporaneously by the FDA;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">ELI-002 may not receive marketing approval if its safe and effective use depends on a companion diagnostic, and none is commercially available; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">we may not realize the full commercial potential of ELI-002 if it receives marketing approval and, among other reasons, we are unable to appropriately identify patients or types of tumors with the specific genetic alterations targeted by ELI-002.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Even if ELI-002 and any associated companion diagnostics are approved for marketing, the need for companion diagnostics may slow or limit adoption of ELI-002. Although we believe genetic testing is becoming more prevalent in the diagnosis and treatment of cancer, ELI-002 may be perceived negatively compared to alternative treatments that do not require the use of companion diagnostics, either due to the additional cost of the companion diagnostic or the need to complete additional procedures to identify relevant biomarkers prior to administering our product candidates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If any of these events were to occur, our business and growth prospects would be harmed, possibly materially.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We may seek designations under FDA programs designed to facilitate and potentially expedite product candidate development, such as fast track or breakthrough therapy designation. Our product candidates may not receive any such designations or if they do receive such designations it may not lead to faster development or regulatory review or approval and it does not increase the likelihood that our product candidates will receive marketing approval.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We may seek designations under the FDA&#8217;s expedited programs for serious conditions, such as fast track or breakthrough therapy designation, which are intended to facilitate and expedite the development or regulatory review or approval process for product candidates. Descriptions of the fast track and breakthrough therapy designations are included under &#8220;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Description of Our Business&#8212;Government Regulation and Product Approval&#8212;Fast Track, Breakthrough Therapy and Priority Review Designations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.&#8221;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The granting of fast track or breakthrough therapy designation to an investigational product is entirely within the FDA&#8217;s discretion. Accordingly, even if we believe one of our product candidates meets the criteria for a designation, the FDA may disagree and instead determine not to grant such designation. In any event, the receipt of a fast track or breakthrough therapy designation for a product candidate may not result in a faster development process, review, or approval compared to product candidates considered for approval under conventional FDA procedures and does not assure ultimate marketing approval by the FDA. In addition, the FDA may later decide that the product candidate no longer meets the designation conditions, in which case any granted designations may be revoked, or the agency may decide that the time period for review or approval of the product candidate will not be shortened.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">If we are unable to obtain approval via the accelerated approval pathway, we may be required to conduct additional nonclinical studies or clinical trials. Even if we receive accelerated approval from the FDA, the FDA may seek to withdraw accelerated approval.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We may seek an accelerated approval development pathway for our product candidates. See &#8220;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Description of Our Business&#8212;Government Regulation and Product Approval&#8212;Accelerated Approval</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; for a description of the accelerated approval pathway.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we choose to pursue accelerated approval, we intend to seek feedback from the FDA or will otherwise evaluate our ability to seek and receive such accelerated approval. After our evaluation of the feedback from the FDA or other factors, we may decide not to pursue or submit a BLA for accelerated approval or any other form of expedited development, review or approval. Furthermore, if we submit an application for accelerated approval, there can be no assurance that such application will be accepted or that approval will be granted on a timely basis, or at all. The FDA also could require us to conduct further studies or trials prior to considering our application or granting approval of any type, and may require us to have a confirmatory trial to verify the clinical benefit of the product underway and partially or fully enrolled before granting approval. We might not be able to fulfill the FDA&#8217;s requirements in a timely manner, which would cause delays, or approval might not be granted because our submission is deemed incomplete by the FDA.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Even if we receive accelerated approval from the FDA, we will be subject to rigorous post-marketing requirements, including the completion of confirmatory post-market clinical trials, submission to the FDA of periodic progress reports on confirmatory trials, and submission to the FDA of all promotional materials prior to their dissemination. The FDA could seek to withdraw accelerated approval for multiple reasons, including if we fail to conduct any required post-market study with due diligence; a post-market study does not confirm the predicted clinical benefit; other evidence shows that the product is not safe or effective under the conditions of use; or we disseminate promotional materials that are found by the FDA to be false and misleading. Under the Consolidated Appropriations Act for 2023, the FDA may use expedited procedures to withdraw any product for which we receive accelerated approval if our confirmatory trials fail to verify the purported clinical benefits.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A failure to obtain accelerated approval or any other form of expedited development, review or approval for a product candidate that we may choose to develop would delay our commercialization of such product candidate, could increase the cost of development of such product candidate and could harm our competitive position in the marketplace.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">If we apply for orphan drug designation from the FDA, there is no guarantee that we will be able to obtain or maintain this designation, receive this designation for any of our other product candidates, or receive or maintain any corresponding benefits, including periods of exclusivity.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States when there is no reasonable expectation that the cost of developing and making available the drug or biologic in the United States will be recovered from sales in the United States for that drug or biologic. Orphan drug designation for a biologic must be requested before submitting a BLA. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and user-fee waivers. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If a biologic that has orphan drug designation subsequently receives the first FDA approval for a particular active ingredient for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a BLA, to market the same biologic for the same indication for seven years, except in limited circumstances such as a showing of clinical superiority to the product with orphan drug exclusivity or if FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the product was designated. As a result, even if one of our product candidates receives orphan exclusivity, the FDA can still approve other drugs or biologics that have a different active ingredient for use in treating the same indication or disease. Furthermore, the FDA can waive orphan exclusivity if we are unable to manufacture sufficient supply of our product.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We may seek orphan drug designation for some or all of our product candidates in specific orphan indications for which there is a medically plausible basis for their use, but exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective or if we are unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. In addition, although we intend to seek orphan drug designation for other product candidates, we may never receive such designations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Any future product candidates for which we intend to seek approval as biological products may face competition sooner than anticipated.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Even if we are successful in achieving regulatory approval to commercialize a product candidate ahead of our competitors, our product candidates may face competition from biosimilar products. In the United States, our amphiphile product candidates are expected to be regulated by the FDA as biological products, and we intend to seek approval for these product candidates pursuant to the BLA pathway. The enactment of the BPCIA created an abbreviated pathway for the approval of biosimilar and interchangeable biological products based on a previously licensed reference product. Under the BPCIA, an application for a biosimilar biological product cannot be approved by the FDA until 12 years after the original reference biological product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our product candidates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe that any of our product candidates approved as a biological product under a BLA should qualify for the 12-year period of exclusivity available to reference biological products. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference biological products pursuant to its interpretation of the exclusivity provisions of the BPCIA for competing products, potentially creating the opportunity for generic follow-on biosimilar competition sooner than anticipated. Moreover, the extent to which a biosimilar product, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing including whether a future competitor seeks an interchangeability designation for a biosimilar of one of our products. Under the BPCIA as well as state pharmacy laws, only interchangeable biosimilar products are considered substitutable for the reference biological product without the intervention of the health care provider who prescribed the original biological product. However, as with all prescribing decisions made in the context of a patient-provider relationship and a patient&#8217;s specific medical needs, health care providers are not restricted from prescribing biosimilar products in an off-label manner. In addition, a competitor could decide to forego the abbreviated approval pathway available for biosimilar products and to submit a full BLA for product licensure after completing its own nonclinical studies and clinical trials. In such a situation, any exclusivity for which our products candidates may be eligible under the BPCIA would not prevent the competitor from marketing a product similar or identical to our biological product as soon as it is approved.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In Europe, the European Commission has granted marketing authorizations for several biosimilar products pursuant to a set of general and product class-specific guidelines for biosimilar approvals issued over the past few years. In addition, companies may be developing biosimilar products in other countries that could compete with our products, if approved.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If competitors are able to obtain marketing approval for biosimilars referencing our product candidates, our future products may become subject to competition from such biosimilars, whether or not they are designated as interchangeable, with the attendant competitive pressure and potential adverse consequences. Such competitive products may be able to immediately compete with us in each indication for which our product candidates may have received approval.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of subjects who remain in the trial until its conclusion. We may not be able to initiate or continue conducting clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible subjects to participate in these trials. The enrollment of patients depends on many factors, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the number of clinical trials for other product candidates in the same therapeutic area that are currently in clinical development, and our ability to compete with such trials for subjects and clinical trial sites;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the severity of the disease under investigation and the existence of current treatments;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the perceived risks and benefits of the product candidate, including the potential advantages or disadvantages of the product candidate being studied in relation to other available therapies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the subject eligibility criteria defined in the protocol, as well as our ability to compensate subjects, as applicable, for their time and effort;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the size and nature of the patient population;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the proximity and availability of clinical trial sites for prospective subjects;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the design of the trial, including factors such as frequency of required assessments, length of the study and ongoing monitoring requirements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">subjects&#8217; and investigators&#8217; ability to comply with the specific instructions related to the trial protocol, proper documentation, and use of the product candidate;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">patient referral practices of physicians and the effectiveness of publicity created by clinical trials sites regarding the trial;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the ability to adequately monitor subjects during and after treatment and compensate them, as applicable, for their time and effort;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the ability of our clinical study sites, CROs, and other applicable third parties to facilitate timely enrollment;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the ability of clinical trial sites to enroll subjects that meet all inclusion criteria and any patient exclusion due to erroneous enrollment;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">our ability to obtain and maintain subject informed consents;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the ability of clinical trial sites to enroll patients due to public health emergencies or pandemics, natural disasters, staffing shortages, or other events; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the risk that subjects enrolled in clinical trials will drop out of the trials before completion of the study or not return for post-study follow-up, especially subjects in control groups, due to reasons such as, adverse events, lack of treatment effectiveness, fatigue with the clinical trial process or personal issues, electing to participate in alternative clinical trials sponsored by our competitors with product candidates that treat the same indications as our product candidates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Because the number of qualified clinical investigators is limited, we may conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites. Moreover, because our product candidates represent a departure from more commonly used methods for cancer treatment, potential patients and their doctors may be inclined to use conventional therapies, such as chemotherapy, rather than enroll patients in any of our future clinical trials.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our inability to enroll a sufficient number of subjects for our clinical trials would result in significant delays and could require us to abandon one or more clinical trials altogether. Moreover, a significant number of withdrawn subjects would compromise the quality of our data. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, or the inability to complete development of our product candidates, which could cause our value to decline, limit our ability to obtain additional financing, and materially impair our ability to generate revenues.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Any product candidate we advance into clinical trials may cause unacceptable adverse events or have other properties that may delay or prevent our regulatory approval or commercialization or limit our commercial potential.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As with most biological products, use of our product candidates could be associated with side effects or adverse events, which can vary in severity from minor reactions to death and in frequency from infrequent to prevalent. Undesirable side effects caused by any current or future product candidate could cause regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other regulatory authorities. We initiated dosing of the AMPLIFY-201 trial of our 2-peptide formulation of ELI-002 in October 2021, and our 7-peptide formulation of ELI-002, the AMPLIFY-7P trial, began dosing in April 2023. We initiated enrollment of the Phase 2 of the AMPLIFY-7P trial in January 2024 and we have not yet initiated clinical trials for any other product candidates. ELI-002, through the course of the AMPLIFY-201 trial to August 2024, when we stopped the disease free survival follow up for this study, and the AMPLIFY-7P trial to date, has shown to induce mild to moderate side effects, such as fatigue, malaise, injection site reactions and myalgia.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we initiate future clinical trials for any other current or future product candidates or continue to advance the AMPLIFY-7P study, it is likely that there will be new or additional side effects associated with the use of our product candidates. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of these side effects. In such an event, our trials could be suspended or terminated, and the FDA or other regulatory authorities could place a clinical hold or order us to cease further development of or deny approval of a product candidate for any or all targeted indications. Such side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may materially and adversely affect our business and financial condition and impair our ability to generate revenues.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Further, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of patients and limited duration of exposure, rare and severe side effects of a product candidate may only be uncovered when a significantly larger number of patients are exposed to the product candidate or when patients are exposed for a longer period of time.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, including during any long-term follow-up observation period recommended or required for patients who receive treatment using our products, a number of potentially significant negative consequences could result, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">regulatory authorities may withdraw or limit their approvals of such products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">regulatory authorities may require the addition of labeling statements, specific warnings or contraindications;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">we may be required to create a REMS plan, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for health care providers, and/or other elements to assure safe use;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">we may be required to change the way such products are distributed or administered, or change the labeling of the products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the FDA or a comparable foreign regulatory authority may require us to conduct additional clinical trials or costly post-marketing testing and surveillance to monitor the safety and efficacy of the products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">we may decide to recall such products from the marketplace after they are approved;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">we could be sued and held liable for harm caused to individuals exposed to or taking our products; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">our reputation may suffer.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, adverse side effects caused by any therapeutics that may be similar in nature to our product candidates could delay or prevent regulatory approval of our product candidates, limit the commercial profile of an approved label for our product candidates, or result in significant negative consequences for our product candidates following marketing approval.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Any of these events could prevent us from achieving or maintaining market acceptance of the affected product candidates and could substantially increase the costs of commercializing our product candidates, if approved, and significantly impact our ability to successfully commercialize our product candidates and generate revenues.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We may form or seek strategic partnerships or enter into additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">From time to time, we may form or seek strategic partnerships or collaborations or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates and any future product candidates that we may develop. Any such relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. These relationships also may result in a delay in the development of our product candidates if we become dependent upon the other party and such other party does not prioritize the development of our product candidates relative to our other development activities. Additionally, any collaborations, or licensing arrangements would be subject to the same product candidate development and compliance risks and obligations as we would be if we were to develop the product candidate on our own. Should any third party with which we enter into any of these arrangements not comply with the applicable regulatory requirements, we or they may be subject to regulatory enforcement action and we or they may be delayed or prevented from obtaining marketing approval for the applicable product candidate. Any collaborations, or licensing arrangements may pose a number of risks, including the following: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">any third party with which we enter into any of these arrangements often have significant discretion in determining the efforts and resources that they will apply to the arrangement and may not commit sufficient resources to the development, marketing or commercialization of the product or products that are subject to the arrangement; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">third parties may not perform their obligations as expected or may breach or terminate their agreements with us or otherwise fail to conduct their collaborative or licensing activities successfully and in a timely manner;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">any such collaboration, partnership, or licensing arrangement may significantly limit our share of potential future profits from the associated program, and may require us to relinquish potentially valuable rights to our current product candidates, potential products or proprietary technologies or grant licenses on terms that are not favorable to us;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">third parties may cease to devote resources to the development or commercialization of our product candidates if the partners view our product candidates as competitive with their own products or product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">disagreements with third parties, including disagreements over proprietary rights, contract interpretation or the course of development, might cause delays or termination of the development or commercialization of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">product candidates, and might result in legal proceedings, which would be time consuming, distracting and expensive;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">third parties may be impacted by changes in their strategic focus or available funding, or business combinations involving them, which could cause them to divert resources away from the arrangement;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">third parties may infringe the intellectual property rights of other third parties, which may expose us to litigation and potential liability;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the collaborations, partnerships, or licensing arrangements may not result in us achieving revenues sufficient to justify such transactions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">by entering into certain collaborations, partnerships, or licensing arrangements, we may forego opportunities to collaborate with other third parties who do not wish to be associated with our existing third-party strategic partners; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">such arrangements may be terminated and, if terminated, may result in a need for us to raise additional capital to pursue further development or commercialization of the applicable product candidate.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangement for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort, and third parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy. If we license products or acquire businesses, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture. Any licensed products or acquired businesses may also subject us to the risk of regulatory enforcement should the product or business not be compliant with applicable regulatory requirements. We cannot be certain that, following a strategic transaction or licensing arrangement, we will achieve the revenue or specific net income that justifies such a transaction.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We rely on CMOs to manufacture our nonclinical and clinical pharmaceutical supplies and expect to continue to rely on CMOs to produce commercial supplies of any approved product candidate, and our dependence on CMOs could adversely impact our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We rely on CMOs for the manufacture of nonclinical and clinical supplies of our product candidates and plan to continue to do so for commercial supplies should we receive marketing approval for any of our product candidates. This reliance also results in our reduced control over the manufacture of our product candidates and the protection of our trade secrets and know-how from misappropriation or inadvertent disclosure, which may adversely affect our future business prospects. Nevertheless, as the developer of the product candidates and sponsor of clinical trials involving such product candidates, we continue to have regulatory obligations to maintain oversight of the CMOs to ensure compliance with, among other things, contractual obligations, specifications, and cGMP.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In complying with the manufacturing regulations of the FDA and other comparable foreign regulatory authorities, we and our third-party suppliers must spend significant time, money and effort in the areas of design and development, testing,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">including but not limited to, several complex release tests, including tests for biological potency, production, record-keeping and quality control to assure that the products meet applicable specifications and other regulatory requirements. Although our agreements with our CMOs require them to perform according to certain cGMP, such as those relating to quality control, quality assurance and qualified personnel, we cannot control the conduct of our CMOs to implement and maintain these standards. If our CMOs do not successfully carry out their contractual duties, meet expected deadlines or manufacture our product candidates in accordance with regulatory requirements, if there are disagreements between us and such parties, or if such parties are unable to support the commercialization of any of our product candidates for which we obtain marketing approval, we may not be able to produce, or may be delayed in producing sufficient product to meet our supply requirements. Any delays in obtaining adequate supplies on adequate terms with respect to our product candidates and components, due to manufacturing issues, global trade policies, or for other reasons, may delay the development, approval, or commercialization of our product candidates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We may not succeed in our efforts to establish manufacturing relationships on commercially reasonable terms. Our product candidates may compete with other products and product candidates for access to manufacturing facilities, of which there are a limited number that operate under cGMP conditions and that are both capable of manufacturing our product candidates and willing to do so. Even if we do establish such collaborations or arrangements, our CMOs may breach, terminate, or not renew these agreements. These facilities may also be affected by general economic conditions, including but not limited to political unrest, global trade wars, natural disasters, such as floods or fires, acts of war, terrorism, or disease outbreaks, or such facilities could face manufacturing issues, such as </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">contamination or adverse regulatory findings following a regulatory inspection. CMOs may also be subject to power failures and/or other utility failures or experience the breakdown, failure, substandard performance or improper installation or operation of equipment in the manufacturing process. Further, our CMOs may be temporarily unable to manufacture our product candidates due to government restrictions, requirements, or limitations. If our CMOs cease to manufacture our product candidates for any reason, we would experience delays in obtaining sufficient quantities of our product for us to meet commercial demand if we receive marketing approval or in advancing our development programs while we identify and qualify replacement suppliers. We could also incur added costs and delays in identifying and qualifying any such replacements and transferring any necessary technology and processes. The terms of a new arrangement may also be less favorable than any prior arrangements, if we are able to negotiate a new arrangement at all. The addition of a new or alternative CMO may also require FDA approval and may have a material adverse effect on our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We or our CMOs may also encounter shortages in the raw materials or substances necessary to produce our product candidates in the quantities and at the quality needed for our nonclinical studies and clinical trials or, if any of our product candidates are approved for commercialization, to produce our products on a commercial scale, meet an increase in demand, or compete effectively. Such shortages may occur for a variety of reasons, including capacity constraints, delays or disruptions in the market, and shortages caused by the purchase of such materials by our competitors or others. Our or our third-party manufacturers&#8217; failure to obtain the raw materials or substances necessary to manufacture sufficient quantities of our product candidates may have a material adverse effect on our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Moreover, any problems or delays we experience in preparing for commercial-scale manufacturing of a product candidate or component, including manufacturing validation, may result in a delay in a future marketing approval, if any, or commercial launch of any of our product candidates, should they receive regulatory approval, or may impair our ability to manufacture commercial quantities or manufacture such quantities at an acceptable cost, which could result in the delay, prevention, or impairment of commercialization of our product candidates, if approved, and could adversely affect our business. Furthermore, if the future manufacturers of the commercial supplies of our products, if approved, fail to deliver the required commercial quantities of our product candidates on a timely basis and at commercially reasonable prices, we would likely be unable to meet demand for our products and we could lose potential revenues. The manufacture of biological products requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of biologics often encounter difficulties in production, particularly in scaling up initial production. These problems include difficulties with production costs and yields, quality control, including stability of the product candidate and quality assurance testing, shortages of qualified personnel, and compliance with strictly enforced federal, state, and foreign regulations. If our manufacturers were to encounter any of these difficulties and were unable to perform as agreed, our ability to provide our product candidates for use in nonclinical studies or our current and planned clinical trials, or, if any of our product candidates are approved, our ability to produce our product for commercial use, could be jeopardized.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, all manufacturers of our product candidates used in clinical trials and of our products for commercial supply, should any of our product candidates receive regulatory approval, must comply with cGMP regulations promulgated by the FDA and equivalent foreign regulatory authorities that are applicable to both finished products and their active components used both for clinical and commercial supply. Regulatory authorities enforce these requirements through facility inspections. CMO facilities must be satisfactory to the FDA and equivalent foreign regulatory authorities as determined by inspections that will be conducted after we submit our marketing applications to the appropriate agencies and prior to product approval and commercialization. Our CMOs will also be subject to continuing, periodic regulatory authority inspections should our product candidates receive marketing approval. Further, we, in cooperation with our CMOs, must supply all necessary chemistry, manufacturing, and control documentation to the FDA and equivalent foreign regulatory authorities in support of a marketing application on a timely basis.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The cGMP include quality control, quality assurance, and the maintenance of records and documentation. Manufacturers of our product candidates may be unable to comply with our specifications, cGMP or with other applicable regulatory requirements. Poor control of production processes can lead to the introduction of adventitious agents or other contaminants, or to inadvertent changes in the properties or stability of a product candidate that may not be detectable in final product testing. If our CMOs cannot successfully manufacture material that conforms to our specifications and the applicable regulatory requirements, they may not be able to secure or maintain regulatory acceptance of their manufacturing facilities for the purpose of producing our product candidates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Deviations from manufacturing requirements may also require reporting and remedial measures that may be costly and/or time-consuming for us or a third party to implement and that may include the temporary or permanent suspension of a clinical trial or commercial sales, if any of our product candidates receives regulatory approval, or the temporary or permanent closure of a facility. Any such remedial measure could materially harm our business. Any delay in obtaining products or product candidates that comply with the applicable regulatory requirements may </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">result in delays to nonclinical studies and clinical trials, or potential product approvals or commercialization. Any such delay may also require that we conduct additional studies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">While we are ultimately responsible for the manufacture and regulatory compliance of our products and product candidates, we have little control over our CMOs&#8217; compliance with these regulations and standards other than through our contractual arrangements. If the FDA or a comparable foreign regulatory authority does not find these facilities satisfactory for the manufacture of our products, if approved, or product candidates, or if such authorities find such facilities to be noncompliant in the future, we may need to find alternative manufacturing facilities, which would significantly impact our</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ability to develop, obtain and maintain regulatory approval for or market our product candidates, if approved. Any new manufacturers would need to either obtain or develop the necessary manufacturing know-how, and obtain the necessary equipment and materials, which may take substantial time and investment. We must also receive FDA or other relevant comparable regulatory authority approval for the use of any new manufacturers for commercial supply.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our failure, or the failure of our CMOs, to comply with applicable regulatory requirements may result in regulatory enforcement actions against our CMOs or us, including fines and civil and criminal penalties, suspension of or restrictions on production, injunctions, delay, withdrawal or denial of product approval or supplements to approved products, clinical holds or termination of clinical studies, warning or untitled letters, regulatory authority communications warning the public about safety issues with a product, refusal to permit the import or export of a product, product seizure, detention, or recall, operating restrictions, civil penalties, criminal prosecution, corporate integrity agreements, or consent decrees and equivalent foreign sanctions. Depending on the severity of any potential regulatory action, supplies of our product candidates or products, if approved, could be interrupted or limited, which could have a material adverse effect on our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A portion of the manufacturing for our product candidates takes place in China through third-party manufacturers. A significant disruption in the operation of those manufacturers, a trade war or political unrest in China, or a change in the regulatory framework in the United States or China, could materially adversely affect our business, financial condition and results of operations. The recently proposed BIOSECURE Act was aimed at discouraging federal contracting with certain Chinese biotechnology companies for biotechnology equipment or services. Although the proposed BIOSECURE Act was not enacted before Congress adjourned at the end of December 2024, it or similar legislation if enacted with substantially similar provisions in the future has the potential to impact supply of our product candidates. If the BIOSECURE Act, or any similar legislation, is enacted and implemented and we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable laws and regulations. We anticipate that the complexity of the manufacturing process for our biological product candidates may impact the amount of time it may take to secure a replacement manufacturer and such delays could negatively affect our ability to develop product candidates in a timely manner or within budget, which could materially adversely affect our business, financial condition and results of operations. Additionally, there may be increased competition to find CMOs in regions outside of China, which may cause us to face challenges finding available CMOs or CMOs that can manufacture our product candidates in a timely manner or within budget. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The demand for glucagon-like peptide-1 (&#8220;GLP-1&#8221;) agonists and other drugs or product candidates containing peptide active pharmaceutical ingredient (&#8220;API&#8221;) increased substantially in 2024. As ELI-002 and our other product candidates use similar peptide API manufacturing methods to GLP-1 drugs, the manufacturers that we utilize may face capacity challenges, which may impact the amount of time it takes to manufacture ELI-002 and/or our other product candidates. Any scheduling delays or interruptions in manufacturing could negatively affect our ability to produce adequate supplies of our product candidates. Additionally, with the increased demand, manufacturers may increase the cost of their services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These potential delays and additional costs could materially affect our business, financial conditions and results of operations. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We rely on third parties to conduct some of our nonclinical studies and all of our clinical trials. If these third parties do not meet our deadlines or otherwise conduct the trials as required, our development programs could be delayed or unsuccessful and we may not be able to obtain regulatory approval for or commercialize our product candidates when expected or at all.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We do not have the ability to conduct all aspects of our clinical trials ourselves and do not currently plan to independently conduct clinical trials. We use third parties, such as CROs, to conduct, supervise, and monitor our past trials, such as the AMPLIFY-201 trial, and our current trials, such as the AMPLIFY-7P trial, and will rely upon such CROs, as well as medical institutions, investigators and consultants, to conduct current trials and any future clinical trials that we may conduct in accordance with our protocols and applicable laws and regulations. In addition, we occasionally use third parties to conduct our nonclinical studies. Our CROs, investigators and other service providers play a significant role in the conduct of these trials and the subsequent collection and analysis of data from such trials.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our service providers are not our employees and, except for remedies available to us under our agreements with such third parties, we will have less control over the timing, quality and other aspects of such nonclinical studies and clinical trials than we would have if we were to conduct them on our own. If these third parties do not successfully carry out their contractual duties to us, meet our expected timelines or conduct our nonclinical studies or clinical trials in accordance with regulatory requirements or our stated protocols, if they need to be replaced or if the quality or accuracy of the data they obtain is compromised due to their failure to adhere to our protocols or applicable regulatory requirements or for other reasons, our trials may need to be repeated, extended, delayed, or terminated. Further, we may not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates, we may fail or be delayed in our efforts to successfully commercialize our product candidates, if approved. Such failures may also subject us or our third-party service providers to regulatory enforcement actions. As a result, our results of operations and the commercial prospects for our product candidates could be harmed, our costs could increase and our ability to generate revenues could be delayed. To the extent we are unable to successfully identify and manage the performance of service providers in the future, our business may be materially and adversely affected. Our third-party service providers may also have relationships with other entities, some of which may be our competitors, for whom they may also be conducting trials or other therapeutic development activities that could harm our competitive position. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Agreements with third parties conducting or otherwise assisting with our nonclinical studies or clinical trials might terminate for a variety of reasons, including a failure to perform by such parties. If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with suitable alternative providers or do so on commercially reasonable terms. Switching or adding third parties involves additional cost and requires management time and focus. There is also a natural transition period when a new third party commences work. As a result, if we need to enter into alternative arrangements, we may need to delay our product development activities and our business could be adversely affected. Although we carefully manage our relationships with our third parties, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects, and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our reliance on third parties for development activities will reduce our control over these activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards and our reliance on third parties does not relieve us of our oversight and regulatory responsibilities. For example, we will remain responsible for ensuring that each of our trials is conducted in accordance with the general investigational plan and protocols for that trial. We must also ensure that our nonclinical studies are conducted in accordance with GLP requirements, as appropriate. Moreover, the FDA and comparable foreign regulatory authorities require us to comply with established GCP standards for conducting, recording, and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity, and confidentiality of trial participants are protected. In addition, our clinical trials must be conducted with product candidates that were produced under cGMP conditions. Regulatory authorities enforce these requirements through periodic inspections of trial sponsors, clinical and nonclinical investigators, manufacturers, and trial sites. If we or any of our third-party service providers fail to comply with applicable regulatory requirements, we or they may be subject to enforcement or other legal actions, the data generated in our trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional studies, which may significantly delay our clinical development plans and the regulatory approval process. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that we, our third-party service providers, or clinical trial sites is in substantial compliance with the applicable regulatory requirements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, we will be required to report certain financial interests of our third-party investigators if these relationships exceed certain financial thresholds or meet other criteria. The FDA or comparable foreign regulatory authorities may question the integrity of the data from those clinical trials conducted by investigators who may have conflicts of interest. We are also required to register certain clinical trials and post the results of certain completed clinical trials on a government-sponsored database, clinicaltrials.gov, within specified timeframes. Failure to do so can result in enforcement actions and adverse publicity.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We rely on other third parties to store and distribute our product candidates for nonclinical studies and clinical trials that we conduct.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We also rely on other third parties to store and distribute our product candidates for the nonclinical studies and clinical trials that we are conducting or plan to conduct. Any performance failure, or failure to comply with applicable regulations, on the part of our distributors could delay development, the regulatory approval process, or potential commercialization of our product candidates, producing additional losses and depriving us of potential product revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We may incur substantial product liability or indemnification claims relating to the clinical testing of our product candidates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials, and claims could be brought against us if the use or misuse of one of our product candidates causes, or merely appears to have caused, personal injury or death. We will face an even greater risk of product liability if we receive marketing approval for and commercialize any of our product candidates. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our product candidates and approved products, if any. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. Product liability claims might be brought against us by consumers, health care providers or others using, administering or selling our products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There is a risk that our future product candidates may induce adverse events. Patients with the diseases targeted by our product candidates may already be in severe or advanced stages of disease and have both known and unknown significant preexisting and potentially life-threatening health risks. During the course of treatment, patients may suffer adverse events, including death, for reasons that may be related to our product candidates. Such events could subject us to costly litigation, require us to pay substantial amounts of money to injured patients, delay, negatively impact or end our opportunity to receive or maintain regulatory approval to market our products, or require us to suspend or abandon our commercialization efforts. Even in a circumstance in which an adverse event is unrelated to our product candidates, the investigation into the circumstance may be time-consuming or inconclusive. These investigations may delay our regulatory approval process or impact and limit the type of regulatory approvals our product candidates receive or maintain. As a result of these factors, a product liability claim, even if successfully defended, could have a material adverse effect on our business, financial condition or results of operations. Any claims against us, regardless of their merit, could severely harm our financial condition, strain our management and other resources or destroy the prospects for commercialization of the product which is the subject of any such claim. For instance, product liability claims may result in:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">loss of revenue from decreased demand for our products and/or product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">impairment of our business reputation or financial stability;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">incurred costs and time of related litigation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">substantial monetary awards to patients or other claimants, and loss of revenue;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">diversion of management attention;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">withdrawal of clinical trial participants and potential termination of clinical trial sites or entire clinical programs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the inability to commercialize our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">significant negative media attention;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">decrease in our stock price;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">initiation of investigations, and enforcement actions by regulators; and/or</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">product recalls, withdrawals, revocation of approvals, or labeling, marketing or promotional restrictions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we cannot successfully defend ourselves against these claims, we will incur substantial liabilities or be required to limit development or commercialization of our products or product candidates. Although we maintain product liability and clinical trial insurance coverage, it may be inadequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage as we continue clinical development of our product candidates and if we successfully commercialize any medicine. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Risks Related to Our Business, Industry and Future Commercialization</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">If any product candidate that we successfully develop does not achieve broad market acceptance among physicians, patients, health care payors and the medical community, the revenues that we generate from sales will be limited.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Even if our product candidates receive regulatory approval, they may not gain market acceptance among physicians, patients, health care payors and the medical community. Market acceptance of our products by the medical community, patients, and third-party payors will depend on a number of factors, some of which are beyond its control, including:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the efficacy of our products and the prevalence and severity of any adverse events;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">any potential advantages or disadvantages when compared to alternative treatments;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">interactions of our products with other medicines patients are taking and any restrictions on the use of our products together with other medications;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the clinical indications for which the products are approved and the approved claims that we may make for the products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">limitations or warnings contained in the product&#8217;s FDA-approved labeling, including potential limitations or warnings for such products that may be more restrictive than other competitive products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">changes in the standard of care for the targeted indications for such product candidates, which could reduce the marketing impact of any claims that we could make following approval, if obtained;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the safety, efficacy, and other potential advantages over alternative treatments, such as relative convenience and ease of administration of such products, and the availability of alternative treatments already used or that may later be approved;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">cost of treatment versus economic and clinical benefit in relation to alternative treatments or therapies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the availability of formulary coverage and adequate coverage or reimbursement by third parties, such as insurance companies and other health care payors, and by U.S. and international government health care programs, including Medicaid and Medicare;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the price concessions required by third-party payors and government health care programs to obtain coverage and payment;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the extent and strength of our marketing and distribution of such products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">distribution and use restrictions imposed by the FDA and equivalent foreign regulatory authorities with respect to such products or to which we agree, for instance, as part of a REMS or voluntary risk management plan;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the timing of market introduction of such products, as well as competitive products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">our ability to offer such products for sale at competitive prices;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">our ability to offer programs to facilitate market acceptance and insurance coverage from public and private insurance companies, provide patient assistance, and transition patient coverage;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the extent and strength of our third-party manufacturer and supplier support;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the approval of other new products, including biosimilar products that may be priced at a substantially lower price than we expect to offer our product candidates for, if approved;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">adverse publicity about the product or favorable publicity about competitive products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">support from patient advocacy groups;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the success of any efforts to educate the medical community and third-party payors regarding our products, which efforts may require significant resources and may not be successful; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">potential product liability claims.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If any product candidate is approved but does not achieve an adequate level of acceptance by physicians, hospitals, health care payors and patients, we may not generate sufficient revenue from these products and may not become or remain profitable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our ability to negotiate, secure and maintain third-party coverage and reimbursement for our product candidates may be affected by political, economic and regulatory developments in the United States, the European Union and other jurisdictions. Governments continue to impose cost containment measures, and third-party payors are </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">increasingly challenging prices charged for medicines and examining their cost effectiveness, in addition to their safety and efficacy. These and other similar developments could significantly limit the degree of market acceptance of any drug or biologic candidate of ours that receives marketing approval in the future. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market any product candidates we may develop, we may not be successful in commercializing those product candidates if and when they are approved.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We do not have a sales or marketing infrastructure and we have limited experience in the sale, marketing, or distribution of pharmaceutical products. To achieve commercial success for any approved medicine for which we retain sales and marketing responsibilities, we must either develop a sales and marketing organization or outsource these functions to third parties. In the future, we may choose to build a focused sales, marketing, and commercial support infrastructure to sell, or participate in sales activities with our collaborators for, some of our current and future product candidates if and when they are approved.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There are risks involved with both establishing and managing our own commercial capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force or reimbursement specialists is expensive and time-consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing and other commercialization capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our commercialization personnel.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Factors that may inhibit our efforts to commercialize product candidates on our own include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">our inability to recruit and retain adequate numbers of effective sales, marketing, reimbursement, customer service, medical affairs, and other support personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the inability of sales personnel to obtain access to physicians to discuss our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the inability of reimbursement professionals to negotiate arrangements for formulary access, reimbursement, and other acceptance by payors, and to secure adequate coverage;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">reduced realization on government sales from mandatory discounts, rebates and fees, and from price concessions to private health plans and pharmacy benefit managers necessitated by competition for access to managed formularies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the clinical indications for which the products are approved and the claims that we may make for the products, as well as any limitations on use or warnings;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the costs associated with training sales and marketing personnel on legal and regulatory compliance matters and monitoring their actions, and any liability for sales or marketing personnel who fail to comply with the applicable legal and regulatory requirements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">restricted or closed distribution channels that make it difficult to distribute our products to different segments of the patient population;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the lack of complementary medicines to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">unforeseen costs and expenses associated with creating an independent commercialization organization.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we enter into arrangements with third parties to perform sales, marketing, commercial support, and distribution services, our product revenues or the profitability of these product revenues to us may be lower than if we were to market and sell any product we may develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to commercialize our products or may be unable to do so on terms that are favorable to us. We may have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish commercialization capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing any products we may develop.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We face significant competition in an environment of rapid technological change, and there is a possibility that our competitors may achieve regulatory approval before us or develop therapies that are safer or more advanced or effective than ours, which may harm our financial condition and our ability to successfully market or commercialize any product candidates we may develop.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The development and commercialization of new therapeutic biologics is highly competitive. Moreover, the immunotherapy field is characterized by rapidly changing technologies, significant competition, and a strong emphasis on intellectual property. We will likely face competition with respect to any product candidates that we may seek to develop or commercialize in the future from numerous pharmaceutical and biotechnology organizations, as well as from academic institutions, government agencies and other public and private research organizations for our current and future product candidates. Our commercial success may be reduced or eliminated and our business, financial condition, results of operations, and prospects may be harmed if our competitors develop products that are safer, more effective or less costly than ours.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A number of well-resourced pharmaceutical and biotechnology companies are developing products to inhibit RAS mutated cancers. These products, as well as marketing campaigns by competitors and clinical trial results with competitive products, could significantly diminish our ability to market and sell ELI-002 for RAS mutated cancers, if approved. For example, Amgen, Mirati, and Revolution, among others, have developed small molecule therapies for the treatment of KRAS mutated cancer including G12C and other alleles. Other companies in the immunotherapy and cancer vaccine sector include AstraZeneca, BioNTech, BridgeBio, Boehringer, Bristol Myers, Circio, Eli Lilly, Geneos, Gilead, Hookipa, Moderna, Merck, Novartis, Roche/Genentech. Closest in mechanism to ELI-002 is the Hookipa HB-700 vaccine for KRAS mutated tumors, which is currently anticipated for Phase 1 clinical development in mid-2025. While many of these programs are in preclinical stages or Phase 1 clinical trials, Amgen and Mirati have products that are approved by the FDA for the treatment of adult patients with KRAS G12C mutated locally advanced or metastatic NSCLC, who have received at least one prior systemic therapy. Moderna and Merck are in a combined Phase 3 trial of their personalized cancer vaccine targeting melanoma (mRNA-4157) and BioNTech and Roche/Genentech are in Phase 2 trials of their personalized cancer vaccine targeting pancreatic cancer, colorectal cancer, and melanoma (BNT122, RO7198457). Although ELI-002 is being evaluated as an earlier line of therapy (before metastatic disease can be observed on radiographs), it may compete with existing and new therapies that may be approved in the future.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Many of our current or potential competitors, either alone or with their collaboration partners, may have significantly greater financial resources and expertise in research and development, manufacturing, nonclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize product candidates that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than the product candidates we may develop or that would render any of our product candidates obsolete or non-competitive. Our competitors also may obtain FDA or other regulatory approval for their product candidates more rapidly than we may obtain approval for our product candidates, which could result in our competitors establishing a strong market position before we are able to enter the market.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our commercial opportunity may also be reduced or limited if we or our partners are unable to scale up the manufacture of our product candidates to meet clinical or commercial requirements. ELI-002 is comprised of eight APIs, including peptides and nucleotides with a lipid modification. The compositions we seek to develop may exhibit poor pharmaceutical properties, and formulation, purification and stable storage could be challenging.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, we could face litigation with respect to the validity and/or scope of patents relating to our competitors&#8217; products. The availability of competitive products could limit the demand and the price we are able to charge for our products. Further, intellectual property protection for the amphiphile components of our product candidates is dynamic and rapidly evolving. The scope of intellectual property protection for our AMP platform may be limited, and its commercial opportunity may be reduced or limited if our competitors are able to acquire or develop the same or similar technologies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Corporate and academic collaborators may take actions to delay, prevent, or undermine the success of our products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our operating and financial strategy for the development, clinical testing, manufacture, and commercialization of product candidates is heavily dependent on us entering into collaborations with corporations, academic institutions, licensors, licensees, and other parties and we may not be successful in establishing such collaborations. Some of our existing collaborations are, and future collaborations may be, terminable at the sole discretion of the collaborator. Replacement collaborators might not be available on attractive terms, or at all. The activities of any collaborator will not be within our control and may not be within our power to influence. Any collaborators may not perform their obligations to our satisfaction, or at all, we may not derive any revenue or profits from such collaborations, and any collaborators may ultimately compete with us. If any collaboration is not pursued, we may </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">require substantially greater capital to undertake development and marketing of our proposed products and may not be able to develop and market such products effectively, if at all. In addition, a lack of development and marketing collaborations may lead to significant delays in introducing proposed products into certain markets and/or reduced sales of proposed products in such markets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, we expect that changing policies of and actions by the U.S. government may adversely affect the ability of certain of our current, or potential, collaborators to maintain or retain our product candidates. In particular, upon taking office in January 2025, the Trump Administration implemented a freeze that prevented the NIH from reviewing and awarding grants, or paying out funds under already awarded grants, including for research or other projects. If this hold on government grants continues, or if the U.S. government takes any other actions to limit funds available for life science or healthcare research or other projects, it may affect certain of our current, or potential, collaborators and may have a material and adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Data provided by collaborators and others upon which we rely that has not been independently verified could turn out to be false, misleading, or incomplete.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We rely on third-party vendors, scientists and collaborators to provide us with significant data and other information related to our projects, clinical trials and our business. If such third parties provide inaccurate, misleading or incomplete data, our business, prospects and results of operations could be materially adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Even if we are able to commercialize any product candidates, such products may become subject to unfavorable pricing regulations, reimbursement practices, or health care reform initiatives, which would harm our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The regulations that govern pricing and reimbursement for new medicines vary widely from country to country, and current and future legislation may change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Outside the United States, some countries require approval of the sale price of a medicine before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product candidate in a particular country, but then be subject to price regulations that delay or might even prevent our commercial launch of the product candidate, possibly for lengthy time periods, and negatively impact the revenues we are able to generate from the sale of the product candidate in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates we may develop, even if any such product candidates obtain marketing approval.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our ability to commercialize any product candidates successfully also will depend in part on the extent to which reimbursement for these product candidates and related treatments will be available from government authorities or health care programs, private health plans, and other organizations. Even if we succeed in bringing one or more products to the market, these products may not be considered medically necessary and/or cost-effective, and the amount reimbursed for any products may be insufficient to allow us to sell our products on a competitive basis. In addition, reduction in Medicaid or other healthcare reimbursements may impact our future potential domestic customers which may eventually have an adverse impact on us. At this time, we are unable to determine their cost effectiveness or the likely level or method of reimbursement for our product candidates. Government authorities and third-party payors, such as private health plans, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. health care industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are challenging the prices charged for medical products and requiring that biopharmaceutical companies provide them with predetermined discounts from list prices. Novel medical products, if covered at all, may be subject to enhanced utilization management controls designed to ensure that the products are used only when medically necessary. Such utilization management controls may discourage the prescription or use of a medical product by increasing the administrative burden associated with its prescription or creating coverage uncertainties for prescribers and patients. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, that the level of reimbursement will be adequate. Reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We currently expect that any drugs we develop may need to be administered under the supervision of a physician on an outpatient basis. Under currently applicable U.S. law, certain therapeutic products that are not usually self-administered (such as most injectable drugs and biologics) may be eligible for coverage under the Medicare Part B program if:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">they are incident to a physician&#8217;s services;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">they are reasonable and necessary for the diagnosis or treatment of the illness or injury for which they are administered according to accepted standards of medical practice; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">they have been approved by the FDA and meet other requirements of the statute.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There may be significant delays in obtaining reimbursement for newly approved product candidates, and coverage may be more limited than the purposes for which the product candidate is approved by the FDA or other regulatory authorities. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to pay all or part of the costs associated with their prescription medications. Patients are unlikely to use our products unless coverage is provided and payment is adequate to cover all or a significant portion of the cost of our products. Therefore, coverage and adequate payment is critical to new product acceptance. Coverage decisions may depend upon clinical and economic standards that disfavor new products when more established or lower cost therapeutic alternatives are already available or subsequently become available. Moreover, eligibility for reimbursement does not imply that any product candidate will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale, and distribution. Interim reimbursement levels for new product candidates, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the product candidate and reimbursement in the clinical setting in which it is used may be based on reimbursement levels already set for lower cost therapies or medicines and may be incorporated into existing payments for other services. Net prices for product candidates may be reduced by mandatory discounts or rebates required by government health care programs or private payors and by any future relaxation of laws that presently restrict imports of medicines from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates. However, no uniform policy requirement for coverage and reimbursement for drug products exists among third-party payors in the United States. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for any approved product candidates we may develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize medicines, and our overall financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe that the efforts of governments and third-party payors to contain or reduce the cost of health care and legislative and regulatory proposals to broaden the availability of health care will continue to affect the business and financial condition of pharmaceutical and biopharmaceutical companies. A number of legislative and regulatory changes in the health care system in the United States and other major health care markets have been proposed and/or adopted in recent years, and such efforts have expanded substantially in recent years.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In particular, in March 2010, the ACA was signed into law. This legislation changed the system of health care insurance and benefits and was intended to broaden access to health care coverage, enhance remedies against fraud and abuse, add transparency requirements for the health care and health insurance industries, impose taxes and fees on the health care industry, impose health policy reforms, and control costs. This law also contains provisions that affect companies in the pharmaceutical industry and other health care related industries by imposing additional costs and changes to business practices. Since its enactment, there have been judicial and congressional challenges to certain aspects of the ACA. The uncertainty around the future of the ACA, and in particular the impact to reimbursement levels, may lead to uncertainty or delay in the purchasing decisions of our customers, which may in turn negatively impact our product sales. We continue to evaluate the effect that the ACA has or any potential changes to the ACA could have on our business. Additional federal and state legislative and regulatory developments are likely, and we expect ongoing initiatives in the United States to increase pressure on drug and biologic pricing and reimbursement. Such reforms could have an adverse effect on anticipated revenues from product candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">If the market opportunities for any of our product candidates are smaller than we believe they are, our potential revenues may be adversely affected, and our business may suffer.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We focus certain research and product development pipelines and our product candidates on lymph node-directed immunotherapies for cancer. ELI-002 is a KRAS therapeutic vaccine in clinical development for the potential treatment of several cancer types with KRAS mutations. ELI-002 targets six position 12 and one position 13 KRAS mutations, representing approximately 25% of solid tumors. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">While we believe that the cancer types to be included in our early-stage clinical trials have a large KRAS mutation positive patient population in the United States, our understanding of both the number of patients who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, is based on estimates. These estimates may prove to be incorrect and new studies may </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">reduce the estimated incidence or prevalence of these diseases. By example, because some of the cancer indications that we are targeting are rare, certain estimates are based upon studies with small patient populations. Moreover, because our product candidates, such as ELI-002, target specific positions on a mutation, not all patients with the mutation will be treatment candidates. As a result, the number of patients in the United States may turn out to be lower than expected, may not be otherwise eligible for treatment with ELI-002, or patients may become increasingly difficult to identify and access for clinical trials, all of which could adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">If we or any CMOs and suppliers we engage fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We and any CMOs and suppliers we engage are subject to numerous federal, state, and local environmental, health, and safety laws, regulations, and permitting requirements, including those governing laboratory procedures; the generation, handling, use, storage, treatment, and disposal of hazardous and regulated materials and wastes; the emission and discharge of hazardous materials into the ground, air, and water; and employee health and safety.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste. We generally contract with third parties for the disposal of these materials and wastes. Although we believe that the safety procedures utilized by us and such third parties for handling and disposing of these materials and wastes generally comply with the standards prescribed by applicable laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. Under certain environmental laws, we could be held responsible for costs relating to any contamination at our current or past facilities and at third-party facilities. We also could incur significant costs associated with civil or criminal fines and penalties.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our research and product development efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty, and general liability insurance policies (which provide for adequate and reasonable amounts of coverage for a company in our industry and at our size and stage) specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, we may incur substantial costs in order to comply with current or future environmental, health, and safety laws, regulations, and permitting requirements. These current or future laws, regulations, and permitting requirements may impair our research, development, or production efforts. Failure to comply with these laws, regulations, and permitting requirements also may result in substantial fines, penalties, or other sanctions or business disruptions, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Any CMOs and suppliers we engage will also be subject to these and other environmental, health, and safety laws and regulations. Liabilities they incur pursuant to these laws and regulations could result in significant costs or an interruption in operations, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our technologies are novel, and any product candidates we develop may be complex and difficult to manufacture on a clinical or commercial scale. We could experience delays in satisfying regulatory authorities or production problems that result in delays in our development or commercialization programs, limit the supply of our product candidates we may develop, or otherwise harm our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our AMP platform is novel, and the manufacture of products on the basis of our platform is untested at a large scale. Any current and future product candidates will likely require processing steps that are more complex than those required for most chemical pharmaceuticals. Problems with the manufacturing process, even minor deviations from the normal process, could result in product defects or manufacturing failures that result in lot failures, product recalls, product liability claims, insufficient inventory, or potentially delay progression of our regulatory filings. Even if we successfully develop product candidates, we may encounter problems achieving adequate quantities and quality of clinical-grade materials that meet FDA or other comparable applicable foreign standards or specifications with consistent and acceptable production yields and costs. If we or our CMOs are unable to scale our manufacturing at </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the same levels of quality and efficiency, we may not be able to supply the required number of doses for our current or planned clinical trials or for commercial supply, if any of our product candidates receive regulatory approval, and our business could be harmed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As product candidates proceed through nonclinical studies to clinical trials towards potential approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are tested and then altered along the way in an effort to optimize processes and results. We have updated ELI-002, with two peptides (ELI-002-2P), to a new version of ELI-002, with seven peptides (ELI-002-7P), as part of our product development activities, and, may continue to update ELI-002 in the future if needed and subject to receipt of additional funding. Any such changes could cause any product candidates we may develop to perform differently and affect the results of clinical trials conducted with the materials manufactured using altered processes. Such changes may also require a new IND to be filed, additional testing, FDA notification, and FDA authorization. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commence sales and generate revenue. For instance, the FDA may require that we conduct a comparability study that evaluates the potential differences in the product candidate resulting from the change. Delays in designing and completing such a study to the satisfaction of the FDA could delay or preclude our development and commercialization plans, and the regulatory approval of our product candidates. Any of the foregoing could limit our future revenues and growth. Any changes would also require that we devote time and resources to manufacturing development and would also likely require additional testing and regulatory actions on our part, which may delay the development of our product candidates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, the FDA and other regulatory authorities may require us to submit samples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, a regulatory authority may require that we do not distribute a lot until the agency authorizes its release. Slight deviations in the manufacturing process, including those affecting quality attributes and stability, may result in unacceptable changes in the product that could result in lot failures or product recalls. Lot failures or product recalls could cause us to delay clinical trials or product launches, which could be costly to us and otherwise harm our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We also may encounter problems hiring and retaining the experienced scientific, quality control, and manufacturing personnel needed to manage our manufacturing process, which could result in delays in our production or difficulties in maintaining compliance with applicable regulatory requirements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The manufacture of biopharmaceutical products is complex and requires significant expertise, including the development of advanced manufacturing techniques and process controls. For example, given the aseptic controls required for the manufacture of our product candidates, if contaminants are discovered in our supply of product candidates or in the manufacturing facilities, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. Any such contamination could materially harm our ability to produce product candidates on schedule and could delay our development programs and results of operations and cause reputational damage. We cannot assure that any such issues relating to the manufacture of ELI-002 or any other product candidate will not occur in the future or that significant delays would not occur as a result of any such issue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ELI-002 drug substances and drug products are supplied by multiple manufacturers at present. Any problems in our manufacturing process or the facilities with which we contract to make, store, test, release, or ship our product candidates or any problems caused by it, our vendors or other factors not in our control could result in the loss of usable product or prevent or delay the delivery of product candidates to patients in our clinical trials, including the AMPLIFY-7P trial. Any such loss or delay could materially delay our development timelines and harm our business, financial condition and results of operations. Such losses or delays could also make us a less attractive collaborator for potential partners, including larger pharmaceutical companies and academic research institutions, which could limit our access to additional attractive development programs. Problems with third-party manufacturing processes or facilities also could restrict our ability to ensure sufficient clinical material for any clinical trials we may be conducting or plan to conduct and meet market demand for any product candidates we may develop, obtain regulatory approval for, and commercialize.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our insurance policies are expensive and protect us only from some business risks, which will leave us exposed to significant uninsured liabilities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We carry insurance for most categories of risk that our business may encounter; however, we may not have adequate levels of coverage. The insurance policies that we currently maintain include general liability, property, workers&#8217; compensation, products liability and directors&#8217; and officers&#8217; insurance, along with an umbrella policy. We may not be able to maintain existing insurance at current or adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our cash position and results of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Business interruptions could adversely affect future operations, revenues, and financial conditions, and may increase our costs and expenses.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our operations, and those of our directors, advisors, contractors, consultants, CROs, and collaborators, could be adversely affected by earthquakes, floods, hurricanes, typhoons, extreme weather conditions, fires, water shortages, power failures, business systems failures, medical epidemics and other natural and man-made disaster or business interruptions. Our phones, electronic devices and computer systems and those of our directors, advisors, contractors, consultants, CROs, and collaborators are vulnerable to damages, theft and accidental loss, negligence, unauthorized access, terrorism, war, electronic and telecommunications failures, and other natural and man-made disasters. Operating as a company where a portion of our employees have worked and are working remotely, results in our employees conducting business outside of our headquarters. These locations may be subject to additional security risks and other risk factors. If such an event as described above were to occur in the future, it may cause interruptions in our operations, delay research and development programs, clinical trials, regulatory activities, manufacturing and quality assurance activities, future sales and marketing activities, hiring, training of employees and persons within associated third parties, and other business activities. For example, the loss of clinical trial data from current or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Likewise, we will rely on third parties to manufacture our product candidates and conduct clinical trials, and similar events as those described in the prior paragraph relating to their business systems, equipment and facilities could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our product candidates could be delayed or altogether terminated.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Indemnity provisions in various agreements potentially expose us to substantial liability for intellectual property infringement, data protection, and other losses.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our agreements with third parties may include indemnification provisions under which we agree to indemnify them for losses suffered or incurred as a result of claims of intellectual property infringement or other liabilities relating to or arising from our contractual obligations. Large indemnity payments could harm our business, financial condition, results of operations and growth prospects. Although we normally contractually limit our liability with respect to such obligations, we may still incur substantial liability. Any dispute with a third party with respect to such obligations could have adverse effects on our relationship with that third party and relationships with other existing or new partners, harming our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our success will depend upon intellectual property and proprietary technologies, and we may be unable to protect our intellectual property.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our success will depend, in large part, on obtaining and maintaining patent protection and trade secret protection for our product candidates and their formulations and uses, as well as successfully defending these patents against third-party challenges. If we or our licensors fail to appropriately prosecute and maintain patent protection for our product candidates, our ability to develop and commercialize these product candidates may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products. This failure to properly protect the intellectual property rights relating to these product candidates could have a material adverse effect on our financial condition and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have sought patent protection in the United States and internationally related to the AMP platform technology as well as the mKRAS, universal adjuvant, mutant serine/threonine-protein kinase BRAF and mutant TP53 programs. We have issued patents in Australia, China, Hong Kong, Israel, Japan, Nigeria, Russia, Saudi Arabia, Singapore, Ukraine, and the United States, covering clinical product candidates but the patent portfolio owned by us currently largely comprises pending applications. The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or our partners will be successful in protecting our product candidates by obtaining and defending patents. These risks and uncertainties include the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">pending patent applications may not result in any patents being issued;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">patents that may be issued or in-licensed may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable, or otherwise may not provide barriers to entry or any competitive advantage;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that before a potential product can be commercialized, any related patent may expire, or remain in existence for only a short period following commercialization, reducing or eliminating any advantage of the patent;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our competitors, many of which have substantially greater resources than us or our partners do, and many of which have made significant investments in competing technologies, may seek, or may already have sought or obtained, patents that will limit, interfere with, or eliminate our ability to make, use, and sell our potential products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">others may design around our patent claims to produce competitive technologies, products or uses which fall outside of the scope of our patents or other intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">others may identify prior art or other bases which could render unpatentable our patent applications or invalidate our patents;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">there may be significant pressure on the U.S. government and other international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful as a matter of public policy regarding worldwide health concerns;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">countries other than the United States may have patent laws less favorable to patentees than those upheld by United States courts, allowing foreign competitors a better opportunity to create, develop, and market competing products; and/or</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">we may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The pending application directed to the mutant BRAF program is co-owned by Cornell University. Cornell University has the right to make decisions, including decisions on patent prosecution and licensing, independent of us. These decisions may be detrimental to us, including to our ability to commercialize a mutant BRAF product.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition to patents, we also rely on trade secrets and proprietary know-how. Although we have taken steps to protect our trade secrets and unpatented know-how, including entering into confidentiality agreements with third parties, and confidential information and inventions agreements with employees, consultants and advisors, third parties may still obtain this information or come upon this same or similar information independently. We may become subject to claims that we, our employees, consultants, advisors or independent contractors that we may engage to assist us in developing our product candidates have wrongfully or inadvertently disclosed to us or used trade secrets or other proprietary information of their former employers or their other clients.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We may be forced to litigate to enforce or defend our intellectual property rights, and/or the intellectual property rights of our licensors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We may be forced to litigate to enforce or defend our intellectual property rights against infringement by competitors, and to protect our trade secrets against unauthorized use. In so doing, we may place our intellectual property at risk of being invalidated, rendered unenforceable, or limited or narrowed in scope such that we may no longer be used to adequately prevent the manufacture and sale of competitive products. Further, an adverse result in any litigation or other proceedings before government agencies such as the USPTO, may place pending applications at risk of non-issuance. Further, interference proceedings, derivation proceedings, entitlement proceedings, ex parte reexamination, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">inter partes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> reexamination, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">inter partes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> review, post-grant review, and opposition proceedings provoked by third parties or brought by the USPTO or any foreign patent authority may be used to challenge the inventorship, ownership, claim scope, or validity of our patents or patent applications. Additionally, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential and proprietary information or trade secrets could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We have rights in some intellectual property that have been discovered through United States government funded programs and thus are subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements, and a preference for U.S. industry.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have rights in some intellectual property that have been discovered through U.S. government funded programs and thus are subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements, and a preference for U.S. industry. Compliance with such regulations may limit our exclusive rights, subject us to expenditure of resources with respect to reporting requirements, and limit our ability to contract with non-U.S. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">manufacturers. Some of the intellectual property rights in-licensed to us have been generated through the use of U.S. government funding and are therefore subject to certain federal regulations. For example, all of the intellectual property rights licensed to us under our license agreement with MIT have been generated using U.S. government funds. As a result, the U.S. government has certain rights to intellectual property embodied in our current or future products pursuant to the Bayh-Dole Act of 1980. These U.S. government rights in certain inventions developed under government-funded programs include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if the government determines that: (i) adequate steps have not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;). The U.S. government also has the right to take title to these inventions if we fail, or the applicable licensor fails, to disclose the invention to the government, elect title, and file an application to register the intellectual property within specified time limits. In addition, the U.S. government may acquire title to these inventions in any country in which a patent application is not filed within specified time limits. Intellectual property generated under U.S. government funded programs is also subject to certain reporting requirements, compliance with which may require us, or the applicable licensor, to expend substantial resources. In addition, the U.S. government requires that any products embodying the subject invention or produced through the use of the subject invention be manufactured substantially in the U.S. This requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that, under the circumstances, domestic manufacture is not commercially feasible. This preference for U.S. manufacturing may limit our ability to license the applicable patent rights on an exclusive basis under certain circumstances.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we enter into future arrangements involving government funding, and we make inventions as a result of such funding, our intellectual property rights to such discoveries may be subject to the applicable provisions of the Bayh-Dole Act. To the extent any of our current or future intellectual property is generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply. Any exercise by the government of certain of its rights could harm our competitive position, business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We are substantially dependent on patents we license from MIT, and if such licensed patent rights lack legal effect or if a dispute arises under such license agreement and our licensed rights are narrowed or this license is terminated, that could cause significant impairment to our ability to develop and commercialize certain of our product candidates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our business is substantially dependent upon technology licensed from MIT. Pursuant to our license agreement with MIT, we were granted an exclusive, worldwide license, including the right to sublicense, patents and patent applications owned by MIT related to the &#8220;Amphiphile&#8221; technology for the diagnosis, treatment or prevention of diseases. The patent rights licensed from MIT cover products in development by us for all of our current lead programs in tumor indications where mutant KRAS, mutant BRAF, or mutant TP53 are a driver of disease, as well as programs using CpG as an adjuvant for immune activation. Therefore, our ability to develop and commercialize several of our product candidates, including ELI-002, are substantially dependent on the legal effectiveness of the MIT patent rights licensed under this agreement and continuation of this agreement. MIT has the right to control the preparation, filing and prosecution of the patent applications, and to maintain the patents, covering the patent rights we licensed from MIT under this license agreement. Therefore, we cannot be certain that these patents and patent applications will be prosecuted, maintained and enforced in a manner consistent with the best interests of our business. If MIT fails to maintain such patents, or loses rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated and its right to develop and commercialize any of our products that are the subject of such licensed patent rights could be adversely affected, and we may not be able to prevent competitors from making, using or selling competing products. MIT also has the right to control defense of any claims asserting the invalidity of these licensed patent rights and, even if we are permitted to pursue such defense, we cannot ensure the cooperation of MIT. We cannot be certain that MIT will allocate sufficient resources or prioritize their or our enforcement of such patent rights or their defense of such claims to protect our interests in the licensed patent rights. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it might prevent us from continuing to license intellectual property that we may need to operate our business. In addition, although we have the right to control enforcement of the licensed patents, we may be adversely affected or prejudiced by actions or inactions of MIT and their counsel that took place prior to or after us assuming control.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The license agreement with MIT is complex, and certain provisions in this license agreement may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow or eliminate what we believe to be the scope of our rights to the licensed patent rights or increase what we believe to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">be our financial or other obligations under the license agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">If we or our partners are sued for infringing on the intellectual property rights of third parties, it could be costly and time-consuming, and an unfavorable outcome in any such litigation could have a material adverse effect on our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our success also depends upon our ability and the ability of any of our future collaborators to develop, manufacture, market and sell our product candidates without infringing on the proprietary rights of third parties. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing products, some of which may have issued or pending claims that overlap with the subject matter of our intellectual property or our product candidates. Because patent applications can take many years to issue, there may be currently pending applications, unknown to us, which may later result in issued patents that our product candidates or proprietary technologies may infringe upon. Similarly, there may be issued patents relevant to our product candidates of which we are not aware.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, third parties may sue us for infringing on their patents. Even if we are successful in defending any claims of infringement, the defense of such claims may be costly and present a time-consuming distraction. In the event of a successful claim of infringement against us, we may be required to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">pay substantial damages;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">stop using certain technologies and methods;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">stop certain research and development efforts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">develop non-infringing products or methods; and/or</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">obtain one or more licenses from third parties.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If required, we cannot assure you that we will be able to obtain such licenses on acceptable terms, or at all. If we are sued for infringement, we could encounter substantial delays in the development, manufacture and commercialization of our product candidates. Any litigation, whether to enforce our patent rights or to defend against allegations that we infringed third-party rights, could be costly, time-consuming, and may distract management from other important tasks.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As is commonplace in the biotechnology and pharmaceutical industry, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. To the extent that our employees are involved in endeavors which are similar to those that they were involved in at their former employers, we may be subject to claims that such employees have inadvertently or otherwise used or disclosed the alleged trade secrets or other proprietary information of such former employers and/or that we have inadvertently or otherwise used the alleged trade secrets or other proprietary information. Litigation may be necessary to defend against such claims, which could result in substantial costs, be a distraction to management and ultimately have a material adverse effect on us, even if we are successful in defending such claims.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">The biotechnology and pharmaceutical industries have experienced substantial litigation and other proceedings concerning intellectual property rights, and third parties may initiate legal proceedings alleging that we are infringing, misappropriating, or otherwise violating their intellectual property rights, the outcome of which could be uncertain and may prevent, delay or otherwise interfere with our product discovery and development efforts.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our commercial success depends upon our ability and the ability of our collaborators and licensors to develop, manufacture, market, and sell ELI-002 and other Amphiphile immunotherapies. The biotechnology and pharmaceutical industries are characterized by extensive litigation regarding patents and other intellectual property rights as well as administrative proceedings for challenging patents, including interference, derivation,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> inter partes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> review, post grant review, and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. We may be subject to and may in the future become party to, or threatened with, adversarial proceedings or litigation concerning intellectual property rights with respect to our Amphiphile platform and any product candidates we may develop, including interference proceedings, post-grant review,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> inter partes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> review, and derivation proceedings before the USPTO and similar proceedings in foreign jurisdictions such as oppositions before the European Patent Office (&#8220;EPO&#8221;). Numerous U.S. and foreign issued patents and pending patent applications that are owned by third parties exist in the fields in which we are developing our product candidates and infringement claims may be asserted against us or our partners based on existing patents or patents that may be granted in the future, regardless of their merit.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our AMP platform and product candidates may give rise to claims of infringement of the patent rights of others. Moreover, it is not always clear to industry participants, including us, which patents cover various types of therapies, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">products or their methods of use or manufacture. As with many technology-based products, there may be third-party patent applications that, if issued, may be construed to cover components of our AMP platform and product candidates. There may also be third-party patents or pending patents of which we are currently unaware with claims covering our technologies, compositions, methods of manufacture, or methods of use.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Because of the large number of patents issued and patent applications filed in our fields, third parties may allege they have patent rights encompassing our product candidates, technologies or methods. Third parties may assert that we are employing their proprietary technology without authorization and may file patent infringement claims or lawsuits against us, and if we are found to be infringing on any such third-party patents, we may be required to pay damages, cease commercialization of the infringing technology, or obtain a license from such third party, which may not be available on commercially reasonable terms or at all.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our ability to commercialize our product candidates in the United States and abroad may be adversely affected if we cannot successfully defend infringement claims, or obtain a license on commercially reasonable terms to relevant third-party patents that cover our product candidates. Even if we believe third-party intellectual property claims are without merit, there can be no assurance that a court would find in our favor on questions of infringement, validity, enforceability, or priority. A court of competent jurisdiction could hold that these third-party patents are valid and enforceable and have been infringed by us, which could materially and adversely affect our ability to commercialize ELI-002 or any other product candidates and any other product candidates or technologies covered by the asserted third-party patents. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claims, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. If we are found to be infringing on a third party&#8217;s intellectual property rights, and we are unsuccessful in demonstrating that any such patents are invalid or unenforceable, we could be required to obtain a license from such third party to continue developing, manufacturing, and marketing ELI-002 or any other product candidates and our technologies. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain such a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies as us. The license, if available, could require us to make substantial licensing and royalty payments. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, we may be unable to commercialize our AMP platform or product candidates or such commercialization efforts may be significantly delayed, which could in turn significantly harm our business. We also could be forced, including by court order, to cease developing, manufacturing, and commercializing the allegedly infringing technology or product candidates. In addition, we could be found liable for significant monetary damages, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed on a patent or other intellectual property right. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The defense of third-party claims of infringement, misappropriation, or violation of intellectual property rights often involves substantial litigation expense and could be a substantial diversion of management and employee time and resources from our business. Some third parties may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations or could otherwise have a material adverse effect on our business, financial condition, results of operations, and prospects. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, this could have a substantial adverse effect on the price of our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Periodic maintenance fees, renewal fees, annuity fees, and various other government fees on patents and patent applications are due to be paid to the USPTO and foreign patent agencies outside of the United States over the lifetime of our owned or licensed patents and patent applications. For our in-licensed patents and patent applications, we generally rely on our licensor, MIT, to pay these fees due to USPTO and non-U.S. patent agencies; however, we reimburse MIT for these fees as required by our license agreement with MIT. For our owned patent applications, we rely on our outside patent counsel in the United States and foreign countries to monitor these deadlines and to pay these fees when so instructed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The USPTO and foreign patent agencies require compliance with several procedural, documentary, fee payment, and other similar provisions, such as the requirement to disclose known prior art, during the patent application process. We depend on our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property, and for our owned patent applications, we engage counsel and other professionals to help us comply with these requirements. While certain inadvertent lapses can be cured by payment </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">of a late fee or by other means in accordance with the applicable rules, there are situations in which non-compliance can result in a partial or complete loss of patent rights in the relevant jurisdiction. Were a non-compliance event to occur, our competitors might be able to enter the market with similar or identical products or technology, which could have a material adverse effect on its business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Changes in patent law in the United States and in non-U.S. jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our technologies and product candidates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As is the case with other biotech and pharmaceutical companies, our success is heavily dependent on intellectual property, and particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity, and are therefore costly, time-consuming and inherently uncertain.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Changes in either the patent laws or interpretation of the patent laws could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of our issued patents. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce our existing patents and patents that we obtain in the future.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the Leahy-Smith America Invents Act (&#8220;AIA&#8221;), the United States adopted a &#8220;first-inventor-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. A third party that filed or files a patent application with the USPTO after March 16, 2013 but before we filed an application could therefore have been granted a patent covering an invention of ours even if we had made the invention before it was made by the third party. Since patent applications in the United States and most other countries are confidential at least 18 months after filing, we cannot be certain that we were the first to file any patent application related to our product candidates. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The AIA also provides a process known as inter partes review (&#8220;IPR&#8221;), which has been used by many third parties to challenge and invalidate patents. The IPR process is not limited to patents filed after the AIA was enacted and would therefore be available to a third party seeking to invalidate any of our U.S. patents, even those issued or filed before March 16, 2013. Because of a lower evidentiary standard in USPTO proceedings, where IPRs are conducted, compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a U.S. federal court action. Accordingly, a third party may attempt to use the USPTO procedures, e.g., an IPR, to invalidate our patent claims that would not have been invalidated if first challenged by the third party in a U.S. federal court action.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Patents have a limited lifespan. The terms of individual patents depend upon the legal term for patents in the countries in which they are granted. In most countries, including the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest non-provisional filing date in the applicable country. However, the actual protection afforded by a patent varies from country to country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent. Various extensions including patent term extension (&#8220;PTE&#8221;) and patent term adjustment (&#8220;PTA&#8221;) may be available, but the lives of such extensions, and the protections they afford, are limited. Although we will likely seek patent term extensions in the U.S. and in one or more foreign jurisdictions where available, we cannot provide any assurances that any such patent term extensions will be granted and, if so, for how long. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including biosimilars and generics. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting our product candidates might expire before or shortly after we or our partners commercialize those candidates. As a result, our owned and licensed patent portfolio may not provide us with sufficient future rights to exclude others from commercializing products similar or identical to ours.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position could be harmed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition to seeking patents for our technologies and product candidates, we also rely on trade secret protection, as well as confidentiality agreements, non-disclosure agreements and invention assignment agreements with our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">employees, consultants and third parties to protect our know-how and other confidential and proprietary information, especially where we do not believe patent protection is appropriate or obtainable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">It is our policy to require our employees, corporate collaborators, outside scientific collaborators, CROs, CMOs, consultants, advisors, and other third parties to execute confidentiality agreements upon the commencement of employment, consulting, or service relationships with us. These agreements generally provide that all confidential information concerning our business or financial affairs developed by or made known to an individual or entity during the course of that party&#8217;s relationship with us is to be kept confidential and not disclosed to third parties, except in certain specified circumstances. In the case of employees, the agreements provide that all inventions conceived by the individual, and that are related to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment or proprietary information, are our exclusive property. In the case of consultants and other third-party service providers, the agreements provide us with certain rights to all inventions arising from the services provided to us by those individuals or entities. However, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technologies and processes. Additionally, the assignment of intellectual property rights may not be self-executing, or assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. We may not be able to obtain adequate remedies for any breaches of such agreements. Ultimately, enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive, and time-consuming, and the outcome is unpredictable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition to contractual measures, we try to protect the confidential nature of our proprietary information through other appropriate precautions, such as physical and technological security measures. However, trade secrets and know-how can be difficult to protect. These measures may not, for example, in the case of misappropriation of a trade secret by an employee or third party with authorized access, provide adequate protection for our proprietary information. Our security measures may not prevent an employee or consultant from misappropriating our trade secrets and providing them to a competitor, and any recourse we might take against this type of misconduct may not provide an adequate remedy to protect our interests fully. In addition, our trade secrets may be independently developed by others in a manner that could prevent us from receiving legal recourse. If any of our confidential or proprietary information, such as our trade secrets, were to be disclosed or misappropriated, or if any of that information was independently developed by a competitor, our competitive position could be harmed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, courts inside and outside the United States are sometimes less willing or unwilling to protect trade secrets. If we chose to go to court to stop a third party from using any of our trade secrets, we may incur substantial costs. Even if we are successful, these types of lawsuits may consume significant amounts of our time and other resources. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Third parties may assert that our employees, consultants, or advisors have wrongfully used or disclosed confidential information or misappropriated trade secrets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As is common in the biotechnology and pharmaceutical industries, we employ individuals that are currently or were previously employed at universities, research institutions or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants, and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these individuals have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. We may then be involved in litigation proceedings to defend against these claims. If we fail in defending against any such claims, in addition to potentially paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, that perception could have a substantial adverse effect on the price of our common stock. Ultimately, any such litigation could substantially increase our operating losses and reduce our resources available for development activities, and we may not have sufficient financial or other resources to adequately engage in such litigation. For example, some of our competitors may be able to sustain the costs of such litigation more effectively than we can because of their substantially greater financial resources. In any case, uncertainties resulting from the initiation and continuation of intellectual property litigation or other intellectual property related proceedings could adversely affect our ability to compete in the marketplace.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Any trademarks we may obtain may be infringed or successfully challenged, resulting in harm to our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect to rely on trademarks as one means to distinguish any of our product candidates that are approved for marketing from the products of our competitors. However, our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversions of resources and could adversely affect our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, any proprietary name we propose to use with any product candidate in the United States must be approved by the FDA, regardless of whether we have registered it or applied to register it as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of the potential for confusion with other product names. If the FDA objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify an alternate proprietary product name that would qualify under applicable trademark laws, not infringe the existing rights of third parties, and be acceptable to the FDA.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Intellectual property rights do not necessarily address all potential threats.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">any of our current and future product candidates, if approved, may eventually become commercially available in generic or biosimilar product forms;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">others may be able to make immunotherapies that are similar to any of our current and future product candidates or utilize lymph node targeting technology but that are not covered by the claims of the patents that we license or may own in the future;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">we, or our licensors or current or future collaborators, might not have been the first to make the inventions covered by the issued patent or pending patent applications that we license or may own in the future, potentially resulting in the invalidation of such patents or refusal of such applications;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">we, or our licensors or current or future collaborators, might not have been the first to file patent applications covering certain of our or their inventions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">we, or our licensors or current or future collaborators, may fail to meet the obligations to the U.S. government regarding any in-licensed patents and patent applications funded by U.S. government grants, leading to the loss or unenforceability of patent rights;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing on our owned or licensed intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">it is possible that our pending, owned or licensed patent applications or those that we may own or license in the future will not lead to issued patents;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">it is possible that there are prior public disclosures that could invalidate our owned or in-licensed patents, or parts of our owned or in-licensed patents;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">it is possible that there are unpublished applications or patent applications maintained in secrecy that may later issue with claims covering our product candidates or technology similar to ours;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">it is possible that our owned or in-licensed patents or patent applications omit individual(s) that should be listed as inventor(s) or include individual(s) that should not be listed as inventor(s), which may cause these patents or patents issuing from these patent applications to be held invalid or unenforceable;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">issued patents that we hold rights to may be held invalid, unenforceable, or narrowed in scope, including as a result of legal challenges by our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the claims of our owned or in-licensed issued patents or patent applications, if and when issued, may not cover our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the laws of foreign countries may not protect our proprietary rights or the proprietary rights of our licensors or current or future collaborators to the same extent as the laws of the United States;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the inventors of our owned or in-licensed patents or patent applications may become involved with competitors, develop products or processes that design around our patents, or become hostile to us or the patents or patent applications on which they are named as inventors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in major commercial markets;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">we have engaged in scientific collaborations in the past and we intend to continue to do so in the future, and our collaborators may develop adjacent or competing products that are outside the scope of our patents;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">we may not develop additional proprietary technologies that are patentable;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">any product candidates we develop may be covered by third-party patents or other exclusive rights;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the patents of others may prohibit or otherwise harm our business; and/or</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">we may choose not to file a patent, or we may choose not to extend patent coverage in a particular region, in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Risks Related to Regulatory and Compliance Matters</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">The FDA regulatory approval process is lengthy, time-consuming, and inherently unpredictable, and we may experience significant delays in the clinical development and regulatory approval, if any, of our product candidates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The research, testing, manufacturing, labeling, approval, selling, import, export, adverse event reporting, record keeping, advertising, promotion, and distribution of drug products, including biologics, are subject to extensive regulation by the FDA and other regulatory authorities in the United States. We are not permitted to market any biological product in the United States until we receive a biologics license from the FDA. We have not previously submitted a BLA to the FDA, or similar approval filings to comparable foreign authorities. A BLA must include extensive nonclinical and clinical data and supporting information to establish that the product candidate is safe, pure, potent, and effective for each desired indication. The BLA must also include significant information regarding the chemistry, manufacturing, and controls for the product, and the manufacturing facilities must complete a successful pre-license inspection. The FDA may also require a panel of experts, referred to as an Advisory Committee, to deliberate on the adequacy of the safety and efficacy data to support licensure. The opinion of the Advisory Committee, although not binding, may have a significant impact on our ability to obtain licensure of the product candidates based on the completed clinical trials. Accordingly, the regulatory approval pathway for our product candidates may be uncertain, complex, expensive, and lengthy, and approval may not be obtained.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Even if we receive regulatory approval of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If our product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies, and submission of safety, efficacy, and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Manufacturers and manufacturers&#8217; facilities must comply with extensive FDA, and comparable foreign regulatory authority, requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations. As such, we and our CMOs will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any BLA, other marketing applications, and previous responses to inspection observations. Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production, and quality control.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Any regulatory approvals that we receive for our product candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require a REMS program as a condition of approval of our product candidates, which could entail requirements for long-term patient follow-up, a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, we will have to comply with requirements including submissions of safety and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">other post-marketing information and reports, registration, as well as continued compliance with cGMP and GCP for any clinical trials that we conduct post-approval.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The FDA strictly regulates marketing, labeling, advertising, and promotion of products that are placed on the market. Drugs and biologics may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements may result in revisions to the approved labeling to add new safety information; imposition of post-market studies; clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">fines, restitution, disgorgement of profits or revenues, warning letters or other enforcement-related letters or clinical holds on post-approval clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">refusal of the FDA to approve pending BLAs or supplements to approved BLAs, or suspension or revocation of product approvals or suspension of any ongoing clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">product seizure or detention, recalls or refusal to permit the import or export of products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">injunctions or the imposition of civil or criminal penalties; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">consent decrees, corporate integrity agreements, debarment, or exclusion from federal health care programs; or mandated modification of promotional materials and labeling and the issuance of corrective information.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The policies of the FDA and of other regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Additional regulatory burdens and other risks and uncertainties in foreign markets may limit our growth.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our future growth may depend, in part, on our ability to develop and commercialize product candidates in foreign markets for which we may rely on strategic partnership with third parties. We will not be permitted to market or promote any product candidate before we receive regulatory approval from the applicable regulatory authority in a foreign market, and we may never receive such regulatory approval. To obtain separate regulatory approval in foreign countries, we generally must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of a product candidate, and we cannot predict success in these jurisdictions. In particular, the European Commission issued a proposal in April 2023 for a new Directive and a new Regulation, which will revise and replace the existing general pharmaceutical legislation. If adopted and implemented as currently proposed, these revisions will significantly change several aspects of drug development and approval in the EU. If we obtain approval of any of our potential future product candidates and ultimately commercialize any such product candidate in foreign markets, we would be subject to risks and uncertainties, including the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements and the reduced protection of intellectual property rights in some foreign countries.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, but a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional nonclinical studies or clinical trials as trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our relationships with health care providers, physicians, and third-party payors will be subject to applicable anti-kickback, fraud and abuse, anti-bribery and other health care laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, and diminished profits and future earnings.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Physicians, other health care providers and third-party payors will play a primary role in the recommendation and prescription of ELI-002 or any other product candidates for which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other health care laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our product candidates for which we obtain marketing approval. Violations of the fraud and abuse laws are punishable by criminal and civil sanctions, including, in some instances, exclusion from participation in federal and state health care programs, including Medicare and Medicaid. Restrictions under applicable domestic and foreign health care laws and regulations include but are not limited to the following: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase order or recommendation of a good or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs; a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">federal civil and criminal false claims laws and civil monetary penalties laws, including the federal False Claims Act, which impose criminal and civil penalties against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government; actions may be brought by the government or a whistleblower and may include an assertion that a claim for payment by federal health care programs for items and services which results from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the HIPAA which imposes criminal and civil liability for executing a scheme to defraud any health care benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for health care benefits, items or services; similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the federal transparency requirements, sometimes referred to as the &#8220;Sunshine Act,&#8221; enacted as part of the ACA, which require, among other things, manufacturers of drugs, devices, biologics and medical supplies that are reimbursed under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to the CMS information related to payments and other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain advanced non-physician health care practitioners (such as physician assistants and nurse practitioners) and teaching hospitals, as well as physician ownership and investment interests, including such ownership and investment interests held by a physician&#8217;s immediate family members;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">analogous state and foreign laws and regulations relating to health care fraud and abuse, such as state anti-kickback and false claims laws, that may apply to sales or marketing arrangements and claims involving health care items or services reimbursed by non-governmental third-party payors, including private insurers;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">analogous state and foreign laws that require pharmaceutical companies to track, report and disclose to the government and/or the public information related to payments, gifts, and other transfers of value or remuneration to physicians and other health care providers, marketing activities or expenditures, or product pricing or transparency information, or that require pharmaceutical companies to implement compliance programs that meet certain standards or to restrict or limit interactions between pharmaceutical manufacturers and members of the health care industry;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the U.S. federal laws that require pharmaceutical manufacturers to report certain calculated product prices to the government or provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement under federal health care programs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">HIPAA, which imposes obligations on certain covered entity health care providers, health plans, and health care clearinghouses as well as their business associates that perform certain services involving the use or disclosure of protected health information, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of protected health information; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">state and foreign laws which govern the privacy and security of health information and personal data in certain circumstances, including state security breach notification laws, state health information privacy laws and federal and state consumer protection laws, many of which differ from each other in significant ways or conflict with each other and often are not preempted by HIPAA, thus complicating compliance efforts. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. In addition, recent health care reform legislation has strengthened these laws. For example, the ACA, among other things, amends the intent requirement of the federal Anti-Kickback and criminal health care fraud statutes. As a result of such amendment, a person or entity no longer needs to have actual knowledge of these statutes or specific intent to violate them in order to have committed a violation. Moreover, the ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Efforts to ensure that our business arrangements with third parties will comply with applicable health care laws and regulations will involve substantial costs. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance or reporting requirements increases the possibility that a health care company may run afoul of one or more of the requirements. If our operations are found to be in violation of any applicable laws or any other government regulations that apply to us, we may be subject to penalties, including criminal and significant civil monetary penalties, damages, fines, individual imprisonment, disgorgement, contractual damages, reputational harm, exclusion from participation in government health care programs, integrity obligations, injunctions, recall or seizure of products, total or partial suspension of production, denial or withdrawal of pre-marketing product approvals, private qui tam actions brought by individual whistleblowers in the name of the government, refusal to allow us to enter into supply contracts, including government contracts, additional reporting requirements and oversight if subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We intend to develop and implement a comprehensive corporate compliance program prior to the commercialization of our product candidates. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to us in terms of money, time and resources. Moreover, federal, state or foreign laws or regulations are subject to change, and while we, our collaborators, manufacturers and/or service providers currently may be compliant, that could change due to changes in interpretation, prevailing industry standards or other reasons.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Health care and other reform legislation may increase the difficulty and cost for us and any collaborators we may have to obtain marketing approval of and commercialize our product candidates and affect the prices we, or they, may obtain.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">All aspects of our business, including research and development, manufacturing, marketing, pricing, sales, litigation, and intellectual property rights, are subject to extensive legislation and regulation. Changes in applicable U.S. federal and state laws and agency regulation, as well as foreign laws and regulations, could have a materially negative impact on our business. In the United States and in some other jurisdictions, there have been a number of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">legislative and regulatory changes and proposed changes regarding the health care system that could prevent or delay marketing approval of our product candidates or any of our potential future product candidates, restrict or regulate post-approval activities, or affect our ability to profitably sell any product candidates for which we obtain marketing approval. Increased scrutiny by the U.S. Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements. We cannot be sure whether additional legislative changes will be enacted, or whether any of the FDA&#8217;s regulations, guidances or interpretations will be changed, or what the impact of such changes on the agency and its scientific review staff, if any, may be. Congress also must reauthorize the FDA&#8217;s user fee programs every five years and often makes changes to those programs in addition to policy or procedural changes that may be negotiated between the FDA and industry stakeholders as part of this periodic reauthorization process. The next FDA user fee reauthorization package is expected to enter stakeholder negotiations beginning in mid-2025, with any agreement sent to Congress in early 2027 for purposes of initiating the legislative process. Reauthorization of the prescription drug user fee program would need to be finalized by Congress by the end of September 2027 in order to avoid a disruption in FDA&#8217;s review goals for BLAs and other activities supported by user fees assessed against industry.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in health care systems with the stated goals of containing health care costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a focus of these efforts and has been significantly affected by major legislative initiatives. In March 2010, Congress passed the ACA, which substantially changed the way health care is financed by both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Aspects of the ACA have been the subject of judicial and Congressional challenges, and as a result certain sections of the ACA have not been fully implemented or have been effectively repealed. Following several years of litigation, the U.S. Supreme Court upheld the ACA in June 2021 when it dismissed a legal challenge to the law&#8217;s constitutionality. Further legislative and regulatory changes under the ACA remain possible, although it is unknown what form any such changes or any law would take, and how or whether it may affect the pharmaceutical industry as a whole or our business in the future. We expect that changes or additions to the ACA, the Medicare and Medicaid programs, and changes stemming from other health care reform measures, especially with regard to health care access, financing or other legislation in individual states, could have a material adverse effect on the health care industry in the United States.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, the DSCSA enacted in 2013 imposed obligations on manufacturers of pharmaceutical products related to product tracking and tracing, and the applicable requirements under the law became fully enforceable as of November 27, 2024. As another example, on December 20, 2019, a piece of bipartisan legislation called the CREATES Act, which establishes a private cause of action that permits a generic or biosimilar product developer to sue the brand manufacturer to compel it to furnish the necessary samples on &#8220;commercially reasonable, market-based terms,&#8221;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">was signed into law as part of the Further Consolidated Appropriations Act for 2020 (P.L. 116-94). Although lawsuits have been filed under the CREATES Act since its enactment, those lawsuits have settled privately; therefore to date no federal court has reviewed or opined on the statutory language and there continues to be uncertainty regarding the scope and application of the law. Other legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We are unsure whether additional legislative changes will be enacted, or whether the current regulations, guidance or interpretations will be changed, or whether such changes will have any impact on our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices considering the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. For example, state legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In December 2020, the U.S. Supreme Court held unanimously that federal law does not preempt the states&#8217; ability to regulate PBMs and other members of the health care and pharmaceutical supply chain, an important decision that may lead to further and more aggressive efforts by states in this area.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The U.S. Federal Trade Commission (&#8220;FTC&#8221;) in mid-2022 also launched sweeping investigations into the practices of the PBM industry that could lead to additional federal and state legislative or regulatory proposals targeting such entities&#8217; operations, pharmacy networks, or financial arrangements. Both the U.S. Congress and state legislatures are increasingly scrutinizing the industry and proposing novel regulatory approaches to address various perceived public policy concerns. Significant efforts to change the PBM industry as it currently exists in the United States may </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">affect the entire pharmaceutical supply chain and the business of other stakeholders, including biopharmaceutical product developers like us. Further, in September 2023, the FTC issued a policy statement articulating its view that certain &#8220;improper&#8221; patent listings by drug developers in FDA&#8217;s Orange Book represent an unfair trade practice and indicated that industry should be prepared for potential enforcement actions based on its analysis. The FTC followed that action in November 2023 by publicly calling out over 100 &#8220;improper&#8221; patent listings made by ten large pharmaceutical companies and initiating an FDA administrative process with respect to those patents. Initial federal court decisions appear to support the FTC&#8217;s policy challenging such patent listing practices, but it remains to be seen whether the FTC, other governmental agencies, pharmaceutical manufacturers, or other stakeholders continue to prioritize the policy issue of &#8220;improper&#8221; patent listings and whether additional significant litigation will develop in this area. Accordingly, regulatory and government interest in biopharmaceutical industry business practices continues to expand and pose a risk of uncertainty.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2022, the IRA was signed into law. The IRA includes multiple provisions that may impact the prices of drug products throughout the United States. Under the IRA, a manufacturer of a drug or biological product covered by Medicare Parts B or D must pay a rebate to the federal government if the product&#8217;s price increases faster than the rate of inflation. This calculation is made on a product-by-product basis and the amount of the rebate owed to the federal government is directly dependent on the volume of a drug or biological product that is paid for by Medicare Parts B or D. Starting in payment year 2026, CMS will negotiate drug prices annually for a select number of single source Part D drugs without generic or biosimilar competition, and starting in payment year 2028, CMS will begin negotiating drug prices for a select number of Part B drugs. If a drug product is selected by CMS for negotiation, it is expected that the revenue generated from such drug will decrease. CMS has begun to implement these new authorities and entered into the first set of agreements with drug and biological product manufacturers for negotiated prices of 10 products, which will become applicable for payment year 2026. Ultimately, the IRA&#8217;s impact on the biopharmaceutical industry in the United States remains uncertain, in part because of multiple ongoing lawsuits against CMS brought by large pharmaceutical companies and other stakeholders (e.g., the U.S. Chamber of Commerce).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Any additional federal or state health care reform measures could limit the amounts that third-party payers will pay for future health care products and services, and, in turn, could significantly reduce the projected value of certain development projects and reduce our profitability.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our employees, principal investigators, consultants, and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are exposed to the risk of fraud or other misconduct by our employees, consultants, and commercial partners, and, our principal investigators. Misconduct by these parties could include intentional failures to comply with FDA regulations or the regulations applicable in the European Union and other jurisdictions, provide accurate information to the FDA or other regulatory authorities, comply with health care fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately, or disclose unauthorized activities to us. In particular, sales, marketing, and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA or other regulatory authorities, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial condition, results of operations, and prospects, including the imposition of significant fines or other sanctions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Laws and regulations governing any international operations we may have in the future may preclude us from developing, manufacturing and selling certain product candidates outside of the United States and require us to develop and implement costly compliance programs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We will be subject to numerous laws and regulations in each jurisdiction outside the United States in which we operate in the future. The creation, implementation and maintenance of international business practices compliance programs is costly and such programs are difficult to enforce, particularly where reliance on third parties is required.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The FCPA prohibits any U.S. individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. The anti-bribery provisions of the FCPA are enforced primarily by the DOJ.  The SEC is involved with enforcement of the books and records provisions of the FCPA. However, in February 2025, President Trump issued an executive order directing the DOJ to pause enforcement of the FCPA and to issue new enforcement guidelines that take into consideration U.S. national security and the competitiveness of U.S. companies abroad. It is unclear how this presidential directive may affect the biopharmaceutical industry as a whole or our business in particular.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Similarly, the U.K. Bribery Act 2010 has extra-territorial effect for companies and individuals having a connection with the United Kingdom. The U.K. Bribery Act prohibits inducements both to public officials and private individuals and organizations. Compliance with the FCPA and the U.K. Bribery Act is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If we expand our business outside of the United States, we will be required to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our development costs. The failure to comply with laws governing international business practices may result in substantial penalties, including suspension or debarment from government contracting. Violations of the FCPA can result in significant civil and criminal penalties. Indictment alone under the FCPA can lead to suspension of the right to do business with the U.S. government until the pending claims are resolved. A conviction under the FCPA can result in long-term disqualification as a government contractor. The termination of a government contract or relationship as a result of our failure to satisfy any of our obligations under laws governing international business practices could have a negative impact on our operations and harm our reputation and ability to procure government contracts. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We are subject to, and may in the future become subject to, U.S. federal and state, and foreign, stringent privacy laws, information security laws, regulations, policies and contractual obligations related to data privacy, artificial intelligence, and security and changes in such laws, regulations, policies and contractual obligations could adversely affect our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We and our current and potential collaborators may be subject to federal, state and foreign data protection laws and regulations (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">i.e.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, laws and regulations that address privacy and data security). In the United States, numerous federal and state laws and regulations, including federal health information privacy laws (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">e.g.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, HIPAA as amended by the HITECH Act), state data breach notification laws, state health information privacy laws and federal and state consumer protection laws (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">e.g.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, Section 5 of the Federal Trade Commission Act), that govern the collection, use, disclosure and protection of health-related and other personal information could apply to our operations or the operations of our collaborators. In addition, we may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under HIPAA, as amended by HITECH, or other privacy and data security laws. Depending on the facts and circumstances, we could be subject to criminal penalties if we knowingly obtain, use, or disclose protected health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. However, determining whether protected health information has been handled in compliance with applicable privacy standards and our contractual obligations can be complex and may be subject to changing interpretation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we are unable to properly protect the privacy and security of protected health information or other personal, sensitive, or confidential information in our possession, we could be found to have breached our contracts. Further, if we fail to comply with applicable privacy laws, including applicable HIPAA privacy and security standards, we could face significant administrative, civil and criminal penalties. Enforcement activity can also result in financial liability and reputational harm, and responses to such enforcement activity can consume significant internal and outside resources. Furthermore, state attorneys general are authorized to enforce HIPAA and to bring civil actions seeking either injunctions or damages in response to violations that threaten the privacy of state residents. In addition to the risks associated with enforcement activities and potential contractual liabilities, our ongoing efforts to comply with evolving privacy and data security laws and regulations at the federal and state level may be costly and require ongoing modifications to our policies, procedures and systems.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Many state laws govern the privacy and security of health information and personal data in specified circumstances, many of which differ from each other in significant ways, are often not pre-empted by HIPAA, and may have a more prohibitive effect than HIPAA, thus complicating compliance efforts. For example, the California Confidentiality of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Medical Information Act (&#8220;CMIA&#8221;) imposes restrictive requirements regulating the use and disclosure of health information and other personally identifiable information. In addition to fines and penalties imposed upon violators, some of these state laws also afford private rights of action to individuals who believe their personal information has been misused. California&#8217;s patient privacy laws, for example, provide for penalties of up to $250,000 and permit injured parties to sue for damages. In addition to the CMIA, in 2018, California enacted the CCPA which creates new individual privacy rights for California consumers (as defined in the law) and places increased privacy and security obligations on certain entities handling personal data of consumers or households. The CCPA requires covered companies to provide new disclosure to consumers about such companies&#8217; data collection, use and sharing practices, provide such consumers new ways to opt-out of certain sales or transfers of personal information, and provide consumers with additional causes of action. While there is currently an exception for protected health information that is subject to HIPAA and clinical trial regulations, as currently written, the CCPA may impact our business activities. In addition, the CPRA was recently enacted to strengthen elements of the CCPA and became effective on January 1, 2023. A number of other states continue to introduce similar privacy proposals, with states like Colorado, Connecticut, Delaware, Florida, Indiana, Iowa, Montana, Oregon, Tennessee, Texas, Utah and Virginia enacting their own omnibus privacy laws. These privacy laws may impact our business activities and exemplify the vulnerability of our business to the evolving regulatory environment related to personal data.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Numerous other federal and state laws, including consumer protection laws and regulations, govern the collection, dissemination, use, access to, confidentiality and security of patient health information. For example, Washington state recently enacted the &#8220;My Health My Data&#8221; Act which regulates a broad category called &#8220;consumer health data,&#8221; defined as &#8220;personal information that is linked or reasonably linkable to a consumer and that identifies a consumer&#8217;s past, present, or future physical or mental health.&#8221; Notably, the &#8220;My Health My Data&#8221; Act contains a private right of action, which is expected to increase litigation. In addition, Congress and some states are considering new laws and regulations that further protect the privacy and security of medical records or medical information. With the recent increase in publicity regarding data breaches resulting in improper dissemination of consumer information, all 50 states have passed laws regulating the actions that a business must take if it experiences a data breach, as defined by state law, including prompt disclosure within a specified amount of time to affected individuals. In addition to data breach notification laws, some states have enacted statutes and rules requiring businesses to reasonably protect certain types of personal information they hold or to otherwise comply with certain specified data security requirements for personal information. Congress has also been considering similar federal legislation relating to data privacy and data protection.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the European Union, we may be subject to the GDPR which went into effect in May 2018 and which imposes obligations on companies that operate in our industry with respect to the processing of personal data and the cross-border transfer of such data. The GDPR applies to any company established in the EEA (which includes the European Union Member States plus Iceland, Liechtenstein, and Norway) and to companies established outside the EEA that process personal data in connection with the offering of goods or services to data subjects in the EEA or the monitoring of the behavior of data subjects in the EEA. The GDPR establishes stringent requirements applicable to the processing of personal data, including strict requirements relating to the validity of consent of data subjects, expanded disclosures about how personal data is used, requirements to conduct data protection impact assessments for &#8220;high risk&#8221; processing, limitations on retention of personal data, special provisions affording greater protection to and requiring additional compliance measures for &#8220;special categories of personal data&#8221; including health and genetic information of data subjects, mandatory data breach notification (in certain circumstances), &#8220;privacy by design&#8221; requirements, and direct obligations on service providers acting as processors. The GDPR also prohibits the international transfer of personal data from the EEA to countries outside of the EEA unless made to a country deemed to have adequate data privacy laws by the European Commission or a data transfer mechanism has been put in place. If we or our partners&#8217; or service providers&#8217; privacy or data security measures fail to comply with the GDPR requirements, we may be subject to litigation, regulatory investigations, enforcement notices requiring us to change the way we use personal data and/or fines of up to 20 million Euros or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, as well as compensation claims by affected individuals, negative publicity, reputational harm and a potential loss of business and goodwill.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The GDPR may also impose additional compliance obligations relating to the transfer of data between us and our affiliates, collaborators, or other business partners. For example, on July 16, 2020, the Court of Justice of the European Union (&#8220;CJEU&#8221;), issued a landmark opinion in the case </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Maximilian Schrems vs. Facebook</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (Case C-311/18), called </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Schrems II.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> This decision (a) called into question commonly relied upon data transfer mechanisms as between the European Union Member States and the United States (such as the Standard Contractual Clauses) and (b) invalidated the European Union-U.S. Privacy Shield on which many companies had relied as an acceptable mechanism for transferring such data from the European Union to the United States. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 10, 2023, the European Commission adopted an adequacy decision for a new mechanism for transferring data from the EU to the United States &#8211; the EU-US Data Privacy Framework (the &#8220;Framework&#8221;).</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Framework provides EU individuals with several new rights, including the right to obtain access to their data, or obtain correction or deletion of incorrect or unlawfully handled data. The adequacy decision followed the signing of an </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">executive order introducing new binding safeguards to address the points raised in the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Schrems II</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> decision. Notably, the new obligations were geared to ensure that data can be accessed by US intelligence agencies only to the extent necessary and proportionate and to establish an independent and impartial redress mechanism to handle complaints from Europeans concerning the collection of their data for national security purposes. The Commission will continually review developments in the US along with its adequacy decision. Adequacy decisions can be adapted or even withdrawn in the event of developments affecting the level of protection in the applicable jurisdiction.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Future actions of EU data protection authorities are difficult to predict. Some patients or other service providers may respond to these evolving laws and regulations by asking us to make certain privacy or data-related contractual commitments that we are unable or unwilling to make. This could lead to the loss of current or prospective patients or other business relationships.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Relatedly, following the United Kingdom&#8217;s withdrawal from the European Union (i.e., Brexit), and the expiry of the Brexit transition period, which ended on December 31, 2020, the European Union GDPR has been implemented in the United Kingdom (as the &#8220;UK GDPR&#8221;). The UK GDPR sits alongside the UK Data Protection Act 2018 which implements certain derogations in the European Union GDPR into United Kingdom law. Under the UK GDPR, companies not established in the UK but who process personal data in relation to the offering of goods or services to individuals in the UK, or to monitor their behavior will be subject to the UK GDPR &#8211; the requirements of which are (at this time) largely aligned with those under the EU GDPR and as such, may lead to similar compliance and operational costs with potential fines of up to &#163;17.5 million or 4% of global turnover.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Inadequate funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent our product candidates from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business rely, which could negatively impact our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Future legislative and regulatory proposals may materially impact the ability of the FDA and other regulatory agencies to operate as they have historically operated. We cannot be sure whether additional legislative changes or executive orders will be enacted, or whether any of the FDA&#8217;s regulations, guidances or interpretations will be changed, or what the impact of such changes on the agency and its scientific review staff, if any, may be. For example, the next FDA user fee reauthorization package is expected to enter stakeholder negotiations beginning in mid-2025, with any agreement sent to Congress in early 2027 for purposes of initiating the legislative process. Reauthorization of the prescription drug user fee program would need to be finalized by Congress by the end of September 2027 in order to avoid a disruption in FDA&#8217;s review goals for BLAs and other activities supported by user fees assessed against industry.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, disruptions at the FDA and other agencies may slow the time necessary for new drugs and biologic products to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, political disputes in Congress may result in a shutdown of the U.S. government, and in such cases certain regulatory agencies, such as the FDA and the SEC, would have to furlough employees and cease critical activities. If a prolonged government shutdown or slowdown occurs, it could significantly affect the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Risks Related to Employee and Operations Matters, Managing Growth and Information Technology</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our business, operations and clinical development timelines and plans are subject to risks arising from epidemic or pandemic diseases.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The COVID-19 worldwide pandemic presented substantial public health and economic challenges and affected our employees, patients, physicians and other healthcare providers, CMOs, communities and business operations, as well as the U.S. and global economies and financial markets. To date we have not experienced material disruptions in our business operations due to COVID-19. Measures taken by the governmental authorities to respond to any future epidemic or pandemic disease outbreaks could disrupt the supply chain and the manufacture or shipment of drug substances and finished drug products for clinical products for use in our clinical trials and research and nonclinical studies and, delay, limit or prevent our employees and CROs from continuing research and development activities, impede our clinical trial initiation and recruitment and the ability of patients to continue in clinical trials, including due to measures taken that may limit social interaction or prevent reopening of high-transmission settings, impede testing, monitoring, data collection and analysis and other related activities, any of which could delay our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">nonclinical studies and clinical trials and increase our development costs, and have a material adverse effect on our business, financial condition and results of operations. Any future epidemic or pandemic disease outbreak could also potentially further affect the business of the FDA, the EMA or other regulatory authorities, which could result in delays in meetings related to our planned clinical trials. Any future epidemic disease outbreak may have an adverse impact on global economic conditions which could have an adverse effect on our business and financial condition, including impairing our ability to raise capital when needed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our future success depends on our ability to retain our key executives and to attract, retain, and motivate qualified personnel.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are highly dependent on the principal members of our senior management and scientific teams. Such principal members are employed &#8220;at will,&#8221; meaning we or they may terminate the employment relationship at any time. The loss of the services of any of these persons could impede the achievement of our research, development, and commercialization objectives.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Recruiting and retaining qualified scientific, clinical, manufacturing, business development, general and administrative and sales and marketing personnel will also be critical to our success. We may not be able to attract and retain these personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors, including our scientific co-founder, may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. In addition, inflation has had, and we expect that it will continue to have, an impact on the costs that we incur to attract and retain qualified personnel, and may make it more difficult for us to attract and retain such personnel. The inability to recruit, or loss of services of certain executives, key employees, consultants, or advisors, may impede the progress of our research, development, and commercialization objectives and have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">If we are unable to hire additional qualified personnel, our ability to grow our business may be harmed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Over time we will need to hire additional qualified personnel with expertise in drug development, product registration, clinical, preclinical and nonclinical research, quality compliance, government regulation, formulation and manufacturing, financial matters and sales and marketing. We compete for qualified individuals with numerous biopharmaceutical companies, universities and other research institutions. There is currently a shortage of highly qualified personnel in our industry, which is likely to continue. As a result, competition for personnel is intense and the turnover rate can be high. Attracting and retaining qualified personnel will be critical to our success. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for individuals with similar skill sets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, failure to succeed in development and commercialization of our product candidates may make it more challenging to recruit and retain qualified personnel. The inability to recruit and retain qualified personnel may impede the progress of our research, development and commercialization objectives and would negatively impact our ability to succeed in our product development strategy.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We expect to expand our development, regulatory, and future sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December 31, 2024, we had 32 full-time employees and, in connection with the growth and advancement of our pipeline and becoming a public company, we expect to continue to increase the number of our employees and the scope of our operations, particularly in the areas of product development, regulatory affairs, and sales and marketing. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational, and financial systems, expand our facilities, and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expected expansion of our operations or recruit and train additional qualified personnel. Moreover, the expected physical expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As a growing biotechnology company, we are actively pursuing new platforms and product candidates in many therapeutic areas and across a wide range of diseases. Successfully developing product candidates for and fully understanding the regulatory and manufacturing pathways to all of these therapeutic areas and disease states requires a significant depth of talent, resources and corporate processes in order to allow simultaneous execution across multiple areas. Due to our limited resources, we may not be able to effectively manage this simultaneous execution and the expansion of our operations or recruit and train additional qualified personnel. This may result in weaknesses in our infrastructure, give rise to operational mistakes, legal or regulatory compliance failures, loss of business opportunities, loss of employees and reduced productivity among remaining employees. The physical </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">expansion of our operations may lead to significant costs and may divert financial resources from other projects, such as the development of our product candidates. If our management is unable to effectively manage our expected development and expansion, our expenses may increase more than expected, our ability to generate or increase our revenue could be reduced, and we may not be able to implement our business strategy. Our future financial performance and our ability to compete effectively and commercialize our product candidates, if approved, will depend in part on our ability to effectively manage our future development and expansion.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our internal information technology systems, or those of our vendors, collaborators or other contractors or consultants, may fail or suffer cybersecurity incidents, loss of data, and other disruptions, which could result in a material disruption of our product development programs, compromise sensitive information related to our business or prevent us from accessing critical information, potentially exposing us to liability or otherwise adversely affecting our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the ordinary course of our business, we collect and store sensitive data, intellectual property, and proprietary business information. This data encompasses a wide variety of business-critical information including research and development information, clinical trial information, personal information, commercial information, and business and financial information. We face risks relative to protecting this critical information, including loss of access, unauthorized access or disclosure, unauthorized modification, and inadequate monitoring of our controls over these risks.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Despite the implementation of security measures, our internal information technology (&#8220;IT&#8221;) systems and those of our current and any future third-party vendors, collaborators and other contractors or consultants are vulnerable to risks and damages from a variety of sources, including, interruption, failure, damage, cybersecurity incidents, or data theft from computer viruses, computer hackers, malicious code, employee theft or misuse, malware, including ransomware, social engineering (including phishing attacks), denial-of-service attacks, sophisticated nation-state and nation-state-supported actors, unauthorized access, cyber-attacks, phishing schemes, breaches,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">interruptions due to employee error or malfeasance, damage from natural disasters, terrorism, war and telecommunication, network, and electrical failures. As use of digital technologies has increased, cybersecurity incidents, including deliberate attacks and attempts to gain unauthorized access to IT systems and networks, have increased in frequency and sophistication. These threats pose a risk to the security of our IT systems and networks and the confidentiality, availability, and integrity of our data.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There can be no assurance that we will be successful in detecting or preventing cybersecurity incidents, or successfully mitigating their effects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Any such disruption or security incident could cause interruptions in our operations, and result in a disruption of our development programs and our business operations. For example, the loss of clinical trial data from future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. If we were to experience a significant cybersecurity incident that impacts our IT systems or data, the costs associated with the investigation, remediation and potential notification of the cybersecurity incident to counterparties, regulatory authorities, and data subjects could be material. In addition, our remediation efforts may not be successful. Cybersecurity incidents could also lead to significant business disruption, including transaction errors, supply chain or manufacturing interruptions, processing inefficiencies, data loss or the loss of or damage to intellectual property or other proprietary information. In addition, our remote workforce could increase our cybersecurity risk, create data accessibility concerns, and make us more susceptible to communication disruption. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To the extent that any disruption or cybersecurity incident were to result in a loss of, or damage to, our or our third-party vendors&#8217;, collaborators&#8217; or other contractors&#8217; or consultants&#8217; data or applications, or inappropriate disclosure of confidential, proprietary, or other critical or sensitive information or data, we could incur liability including litigation exposure, penalties and fines, we could become the subject of regulatory actions or investigations, our competitive position could be harmed and the further development and commercialization of our product candidates could be delayed. For example, any such event that leads to unauthorized access, use or disclosure of personal information, including personal information regarding our patients, to the extent we have such information, or our employees, could harm our reputation, require us to comply with federal and/or state data breach notification laws and foreign law equivalents, and potential contractual obligations, and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information. Despite our implementation of security and other protective measures, sustained or repeated IT system failures that interrupt our ability to generate and maintain data could adversely affect our ability to operate our business. Any of the above could have a material adverse effect on our business, financial condition, reputation, competitive advantage, results of operations or prospects. While we maintain cyber-liability insurance (covering security and privacy matters), such insurance may not be adequate to cover any losses experienced as a result of a cybersecurity incident.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">General Risk Factors</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The global credit and financial markets have periodically experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. The financial markets and the global economy may also be adversely affected by the current or anticipated impact of military conflict, including the conflicts in the Middle East and between Russia and Ukraine, geopolitical tensions with China, terrorism or other geopolitical events, including the imposition of tariffs. Sanctions imposed by the United States and other countries in response to such conflicts, including the ones in the Middle East and in Ukraine, may also adversely impact the financial markets and the global economy, and any economic countermeasures by the affected countries or others could exacerbate market and economic instability. Additionally, the imposition of substantial tariffs by the United States on imports from various countries, including China, Canada, and Mexico, and the possible countermeasures by these countries could increase costs, disrupt the global supply chain, and create additional operational challenges. The uncertainty surrounding future trade relationships and the potential for increased market volatility and currency exchange rate fluctuations along with tariffs and trade regulations could have an adverse effect on our business. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market our product candidates even if we would otherwise prefer to develop and market such product candidates ourselves, or on less favorable terms than we would otherwise choose. In addition, one or more of our current service providers, manufacturers and other partners may not survive an economic downturn, which could directly affect our ability to attain our clinical development goals on schedule and on budget.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Uncertainty about global economic conditions could result in increased costs related to the manufacture of our product candidates and, if our product candidates are approved and made available for sale, customers may postpone purchases of our product candidates in response to tighter credit, unemployment, negative financial news and/or declines in income or asset values and other macroeconomic factors, which could have a material adverse effect on demand for our product candidates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Inflation could adversely affect our business and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">While inflation in the United States has reduced recently, during 2021 and 2022, the economy in the United States encountered a material level of inflation. The impact of COVID-19, geopolitical developments such as the Russia-Ukraine and Middle East conflicts, geopolitical tensions with China, and global supply chain disruptions continue to increase uncertainty in the outlook of near-term and long-term economic activity. Increases in inflation raise our costs for commodities, labor, materials and services and other costs required to grow and operate our business, and failure to secure these on reasonable terms may adversely impact our financial condition. Additionally, increases in inflation, geopolitical and macroeconomic developments, and global supply chain disruptions, have caused, and may in the future cause, global economic uncertainty and uncertainty about the interest rate environment, which may make it more difficult, costly or dilutive for us to secure additional financing. A failure to adequately respond to these risks could have a material adverse impact on our financial condition, results of operations or cash flows.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We have broad discretion in the use of our financial resources and may not use them effectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our management has broad discretion in the application of our financial resources. Because of the number and variability of factors that determine our use of our financial resources, their ultimate use may vary substantially from their currently intended use. Our management may not apply our financial resources in ways that ultimately increase the value of any investment in our securities or enhance stockholder value. The failure by our management to apply these funds effectively could harm our business. We have invested and may in the future invest our cash in interest-bearing securities. These investments may not yield a favorable return to our stockholders. If we do not invest or apply our cash in ways that enhance stockholder value, we may fail to achieve expected financial results, which may result in a decline in the price of our shares of common stock, and, therefore, may negatively impact our ability to raise capital, invest in or expand our business, acquire additional licenses, commercialize our product candidates, or continue our operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">U.S. federal income tax reform could adversely affect our business and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The rules dealing with U.S. federal, state, and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many such changes have been made and changes are likely to continue to occur in the future. For example, on March 27, 2020, President Trump signed into law the CARES Act which included certain changes in tax law intended to stimulate the U.S. economy in light of the COVID-19 outbreak, including temporary beneficial changes to the treatment of net operating losses (&#8220;NOLs&#8221;), interest deductibility limitations and payroll tax </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">matters. Additionally, on December 22, 2017, President Trump signed into law the Tax Cuts and Jobs Act of 2017 (&#8220;TCJA&#8221;), which significantly reformed the Internal Revenue Code. The TCJA included significant changes to corporate and individual taxation, some of which could adversely impact an investment in our common stock. Under the TCJA, in general, NOLs generated in taxable years beginning after December 31, 2017 may offset no more than 80 percent of such year&#8217;s taxable income and there is no ability for such NOLs to be carried back to a prior taxable year. The CARES Act modifies the TCJA with respect to the TCJA&#8217;s limitation on the deduction of NOLs and provides that NOLs arising in taxable years beginning after December 31, 2017 and before January 1, 2021, may be carried back to each of the five taxable years preceding the tax year of such loss, but NOLs arising in taxable years beginning after December 31, 2020 may not be carried back. In addition, the CARES Act eliminates the limitation on the deduction of NOLs to 80 percent of current year taxable income for taxable years beginning before January 1, 2021. As a result of such limitation, we may be required to pay federal income tax in some future year notwithstanding that we had a net loss for all years in the aggregate. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. We urge investors to consult with their legal and tax advisers regarding the implications of potential changes in tax laws on an investment in our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">The market price of our common stock is expected to be volatile, and the market price of our common stock may drop.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The market price of our common stock could be subject to significant fluctuations. Market prices for securities of early-stage pharmaceutical, biotechnology and other life sciences companies have historically been particularly volatile. Some of the factors that may cause the market price of our common stock to fluctuate include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">our ability to obtain regulatory approvals for our product candidates, and delays or failures to obtain such approvals;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">failure of any of our product candidates, if approved, to achieve commercial success;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">failure by us to maintain our existing third-party license and supply agreements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">failure by us or our licensors to prosecute, maintain, or enforce our intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">changes in laws or regulations applicable to our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">any inability to obtain adequate supply of our product candidates or the inability to do so at acceptable prices;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">adverse regulatory authority decisions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">adverse results, clinical holds, or delays in the clinical trials of our product candidates or any future clinical trials we may conduct, or changes in the development status of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">introduction of new products, services or technologies by our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">failure to meet or exceed financial and development projections we may provide to the public;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">failure to meet or exceed the financial and development projections of the investment community;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by us or our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">disputes or other developments relating to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our technologies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">additions or departures of key personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">significant lawsuits, including patent or stockholder litigation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">if securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our business and stock;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">changes in the market valuations of similar companies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">general market or macroeconomic conditions;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">sales of our common stock by us or our stockholders in the future;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">trading volume of our common stock;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">failure to maintain compliance with the listing requirements of the Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;);</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">announcements by commercial partners or competitors of new commercial products, clinical progress or the lack thereof, significant contracts, commercial relationships or capital commitments;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">adverse publicity generally, including with respect to other products and potential products in such markets;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the introduction of technological innovations or new therapies that compete with our potential products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">changes in the structure of health care payment systems;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">disruptions in the financial markets;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the impact of political instability and military conflict,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">which has resulted in instability in the global financial markets and export control; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">period-to-period fluctuations in our financial results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management attention and resources, which could significantly harm our profitability and reputation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, a decrease in our stock price may cause our common stock to no longer satisfy the continued listing standards of Nasdaq. If we are not able to maintain the requirements for listing on Nasdaq, we could be delisted, which could have a materially adverse effect on our ability to raise additional funds as well as the price and liquidity of our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We will continue to incur costs and demands upon management as a result of complying with the laws, rules and regulations affecting public companies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We will continue to incur significant legal, accounting and other expenses that we did not incur as a private company, including costs associated with public company reporting requirements. We will also incur costs associated with corporate governance requirements, including requirements under the laws, rules and regulations of the SEC as well as the Nasdaq rules. These laws, rules and regulations are expected to increase our legal and financial compliance costs and to make some activities more time consuming and costly. For example, some members of our management team have not previously managed and operated a public company. These executive officers and other personnel will need to devote substantial time to gaining expertise regarding operations as a public company and compliance with applicable laws and regulations. These laws, rules and regulations also may make it difficult and expensive for us to maintain directors&#8217; and officers&#8217; liability insurance. As a result, it may be more difficult for us to attract and retain qualified individuals to serve on our board of directors or as executive officers, which may adversely affect investor confidence and could cause our business or stock price to suffer.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We may become involved in securities litigation that could divert management&#8217;s attention and harm our business, and insurance coverage may not be sufficient to cover all costs and damages.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We may be exposed to securities litigation even if no wrongdoing occurred. Litigation is usually expensive and diverts management&#8217;s attention and resources, which could adversely affect our business and cash resources. We may become involved in such litigation, and our stock price may fluctuate for many reasons, including as a result of public announcements regarding the progress of our development efforts or the development efforts of current or future collaboration partners or competitors, the addition or departure of our key personnel, variations in our quarterly operating results and changes in market valuations of biopharmaceutical and biotechnology companies. This risk is especially relevant to us because biopharmaceutical and biotechnology companies have experienced significant stock price volatility in recent years. When the market price of a stock has been volatile, as our stock price may be, holders of that stock have occasionally brought securities class action litigation against the company that issued the stock. If any of our stockholders were to bring a lawsuit of this type against us, even if the lawsuit is without merit, it could result in substantial costs for defending the lawsuit and diversion of the time, attention and resources of our board of directors and management, which could significantly harm our profitability and reputation. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our management.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws may delay or prevent an acquisition or a change in management. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law (&#8220;DGCL&#8221;), which prohibits stockholders owning in excess of 15% of our outstanding voting stock from merging or combining with us. Although we believe these provisions collectively will provide for an opportunity to receive higher bids by requiring potential acquirors to negotiate with our board of directors, they would apply even if the offer may be considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove then current management by making it more difficult for stockholders to replace members of the board of directors, which is responsible for appointing the members of management.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or other employees, and could make it more costly for stockholders to bring a claim against us.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our amended and restated certificate of incorporation and amended and restated bylaws, provide, among other things, that that the Court of Chancery of the State of Delaware (or, in the event that the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of Delaware) generally will be the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of fiduciary duty, any action asserting a claim against us arising pursuant to the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine; provided that, the exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction; and provided further that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated certificate of incorporation and the amended and restated bylaws further provide that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). However, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims, and investors cannot waive compliance with the federal laws and rules and regulations thereunder. While the Delaware courts have determined that such choice of forum provisions are facially valid and several state trial courts have enforced such provisions and required that suits asserting Securities Act claims be filed in federal court, there is no guarantee that courts of appeal will affirm the enforceability of such provisions and a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation and amended and restated bylaws. This may require significant additional costs associated with resolving such action in other jurisdictions and there is uncertainty that the provision would be enforced by a court in those other jurisdictions. If a court were to find either exclusive forum provision in our amended and restated certificate of incorporation or amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with litigating Securities Act claims in state court, or both state and federal court, which could seriously harm our business, financial condition, results of operations, and prospects. This exclusive forum provision may make it more expensive for stockholders to bring a claim than if the stockholders were permitted to select another jurisdiction and may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">or our directors, officers or other employees or stockholders, which may discourage such lawsuits against us and our directors, officers and other employees and stockholders. Alternatively, if a court were to find the choice of forum provision contained in our amended and restated certificate of incorporation or amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could materially and adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We do not anticipate that we will pay any cash dividends in the foreseeable future.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The current expectation is that we will retain our future earnings, if any, to fund the development and growth of our business. As a result, capital appreciation, if any, of our common stock will be our stockholders&#8217; sole source of gain, if any, for the foreseeable future.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our stockholders may experience future dilution as a result of future equity offerings.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition to the (i) &#8220;at-the-market&#8221; offering program entered into in June 2024 under which we may offer and sell, from time to time, up to $40 million of shares of common stock through JonesTrading Institutional Services LLC, as agent, (ii) March 2024 private placement of pre-funded warrants to purchase up to 1,032,702 shares of our common stock, (iii) July 2024 underwritten offering of 500,000 shares of our common stock, pre-funded warrants to purchase up to 1,800,000 shares of our common stock and common warrants to purchase up to 2,300,000 shares of our common stock, and (iv) January 2025 underwritten offering of 1,261,830 shares of our common stock and common warrants to purchase up to 1,261,830 shares of our common stock, we may offer additional shares of our common stock or other securities convertible into or exchangeable for our common stock in order to raise additional capital in the future. We cannot assure our stockholders that we will be able to sell shares or other securities in any other offering at a price per share that is equal to or greater than the price per share our stockholders paid for our shares. Investors purchasing shares or other securities in the future could have rights, preferences or privileges senior to those of our stockholders and our stockholders may experience dilution. Our stockholders may incur additional dilution upon the exercise of any outstanding stock options or warrants, the issuance of shares of restricted stock, the vesting of restricted stock units, or the issuance, vesting or exercise of other equity awards.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">An active trading market for our common stock may not develop and our stockholders may not be able to resell their shares of common stock for a profit, if at all.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">An active trading market for our shares of common stock may never develop or be sustained. If an active market for our common stock does not develop or is not sustained, it may be difficult for our stockholders to sell their shares at an attractive price or at all.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Future sales of a substantial number of shares by existing stockholders, or the perception that such sales could occur, could cause our stock price to decline.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the trading price of our common stock could decline. We are unable to predict the effect that sales may have on the prevailing market price of our common stock. In addition, shares of our common stock that are either subject to outstanding options or reserved for future issuance under our equity incentive plan will be eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our largest stockholder has significant influence over us, including influence over decisions that require the approval of stockholders, which could limit our stockholders&#8217; ability to influence the outcome of key transactions, including a change of control.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Yekaterina (Katie) Chudnovsky, a member of our board of directors, and GKCC, LLC (&#8220;GKCC&#8221;), an entity controlled by Ms. Chudnovsky, together beneficially own 34.1% of our outstanding common stock. Additionally, GKCC holds common warrants to purchase approximately 1.6 million shares of common stock and pre-funded warrants to purchase approximately 2.6 million shares of common stock, which could result in GKCC owning an even greater percentage of our outstanding common stock if exercised. Although we are not a &#8220;controlled company&#8221; within the meaning of the corporate governance standards of Nasdaq, Ms. Chudnovsky, through her control of GKCC, is able to significantly influence our decisions, including the election of directors, the approval of significant corporate transactions, such as mergers and related party transactions. Ms. Chudnovsky, through her control of GKCC, has the ability to delay or perhaps even block, by ownership of our stock, an unsolicited tender offer. This concentration of ownership could have the effect of delaying, deterring or preventing a change in control of our company that stockholders might view favorably. Additionally, our largest stockholder&#8217;s interests may not align with the interests of our other stockholders. Our largest stockholder may make investments in companies and may acquire and hold interests in businesses that compete directly or indirectly with us and our largest stockholder may also pursue acquisition opportunities that may be complementary to our business, and, as a result, those acquisition opportunities may not be available to us.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Although we do not expect to rely on the &#8220;controlled company&#8221; exemption, we may soon become a &#8220;controlled company&#8221; within the meaning of the Nasdaq listing standards, and we would qualify for exemptions from certain corporate governance requirements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A &#8220;controlled company,&#8221; as defined in the Nasdaq listing standards, is a company of which more than 50% of the voting power for the election of directors is held by an individual, a group or another company. Controlled companies are not required to comply with certain Nasdaq listing standards relating to corporate governance, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the requirement that a majority of a company&#8217;s board of directors consist of independent directors;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the requirement that a company&#8217;s nominating and corporate governance committee be composed entirely of independent directors with a written charter addressing the committee&#8217;s purpose and responsibilities; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the requirement that a company&#8217;s compensation committee be composed entirely of independent directors with a written charter addressing the committee&#8217;s purpose and responsibilities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If our largest stockholder were to obtain a majority of the voting power for the election of our directors, we would meet the definition of a &#8220;controlled company.&#8221; As a result, these requirements would not apply to us as long as we remain a &#8220;controlled company.&#8221;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Although we may soon qualify as a &#8220;controlled company,&#8221; we currently do not, and we do not expect to, rely on this exemption and we currently comply with, and we expect to continue to comply with, all relevant corporate governance requirements under the Nasdaq listing standards. However, if we were to utilize some or all of these exemptions, our stockholders may not have the same protections afforded to stockholders of companies that are subject to all of the Nasdaq listing standards that relate to corporate governance.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The trading market for our common stock is influenced by the research and reports that equity research analysts publish about us and our business. Equity research analysts may elect not to provide research coverage of our common stock, and such lack of research coverage may adversely affect the market price of our common stock. In the event we do have equity research analyst coverage, we will not have any control over the analysts, or the content and opinions included in their reports. The price of our common stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of us or fails to publish reports on us regularly, demand for our common stock could decrease, which in turn could cause our stock price or trading volume to decline.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We are expected to take advantage of reduced disclosure and governance requirements applicable to smaller reporting companies and emerging growth companies, which could result in our common stock being less attractive to investors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have a public float of less than $250 million and therefore qualify as a smaller reporting company under the rules of the SEC. As a smaller reporting company, we are able to take advantage of reduced disclosure requirements, such as simplified executive compensation disclosures and reduced financial statement disclosure requirements in our SEC filings. Decreased disclosures in our SEC filings due to our status as a smaller reporting company may make it harder for investors to analyze our results of operations and financial prospects.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We cannot predict if investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. We may take advantage of the reporting exemptions applicable to a smaller reporting company until we are no longer a smaller reporting company, which status would end once we have a public float greater than $250 million. In that event, we could still be a smaller reporting company if our annual revenues were below $100 million and we have a public float of less than $700 million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are an emerging growth company (&#8220;EGC&#8221;), as defined in the Jumpstart Our Business Startups Act of 2012, as amended. For as long as we continue to be an EGC, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not EGCs, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding nonbinding advisory votes on executive compensation and stockholder approval of any golden parachute payments not previously approved. We may remain an EGC or until the earlier of (a) December 31, 2026, (b) the last day of the fiscal year in which we have total annual gross revenue of at least $1.235 billion or more, (c) the date we are deemed to be a large accelerated filer, which requires the market value of our common stock that is held by non-affiliates to exceed $700.0 million as of the prior June 30th, and (d) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Changes in tax laws may materially adversely affect our business, prospects, financial condition and operating results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">New tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business, prospects, financial condition and operating results. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, the Tax Act, the CARES Act, and the IRA enacted many significant changes to the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to such legislation may affect us, and certain aspects of such legislation could be repealed or modified in future legislation. Such tax law changes could have a material adverse impact on us. In addition, it is uncertain if and to what extent various states will conform to newly </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">enacted federal tax legislation. While it is too early to assess the overall impact of these changes, as these and other tax laws and related regulations are revised, enacted, and implemented, our financial condition, results of operations, and cash flows could be materially adversely impacted.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our ability to use NOL carryforwards and other tax attributes may be limited.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have incurred losses during our history, and we do not expect to become profitable in the near future and may never achieve profitability. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire, if at all. As of December 31, 2024, we had U.S. federal NOL carryforwards and state NOL carryforwards of approximately $261.8&#160;million and $145.2&#160;million, respectively. Under current law, U.S. federal NOL carryforwards generated in taxable periods beginning after December 31, 2017, may be carried forward indefinitely, but the deductibility of such NOL carryforwards is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to federal law. In addition, under Sections 382 and 383 of the Code, federal NOL carryforwards and other tax attributes may become subject to an annual limitation in the event of certain cumulative changes in ownership. An &#8220;ownership change&#8221; pursuant to Section 382 of the Code generally occurs if one or more stockholders or groups of stockholders who own at least 5% of a company&#8217;s stock increase their ownership by more than 50 percentage points over their lowest ownership percentage within a rolling three-year period. Our ability to utilize our NOL carryforwards and other tax attributes to offset future taxable income or tax liabilities may be limited as a result of ownership changes or other transactions. Similar rules may apply under state tax laws. If we earn taxable income, such limitations could result in increased future income tax liability to us, and our future cash flows could be adversely affected.</span></div><div><span><br/></span></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_19"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B. Unresolved Staff Comments</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">None.</span></div><div><span><br/></span></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_22"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1C. Cybersecurity</span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="f-41" continuedAt="f-41-1" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="f-42" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We recognize the critical importance of protecting the confidentiality, integrity and availability of our business operations and systems. With this in mind, we have implemented and maintain ongoing cybersecurity risk management practices, in accordance with our risk profile and business size, under the oversight of our Audit Committee that are designed to identify, assess, and mitigate cybersecurity risk. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true" id="f-43">Our cybersecurity program is informed by the National Institute of Standards and Technology Cybersecurity Framework, and other applicable industry standards.</ix:nonNumeric> We <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true" id="f-44">engage <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true" id="f-45">third-party</ix:nonNumeric></ix:nonNumeric> service providers and vendors to assist us in managing our cybersecurity programs and systems.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Cybersecurity Risk Management and Strategy; Effect of Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To identify and assess material risks from cybersecurity threats, we maintain a cybersecurity program to develop and implement effective systems and prepare for information security risks. We consider risks from cybersecurity threats alongside other company risks as part of our overall risk assessment process. We employ a range of tools and services, including regular network and endpoint monitoring to inform our risk identification and assessment, as well as undertaking the following activities: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">monitor emerging data protection laws and implement changes to our processes that are designed to comply with such laws;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">through our policies, practices and contracts (as applicable), require employees, as well as third parties that provide services on our behalf, to treat confidential information and data with care;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">employ technical safeguards that are designed to protect our information systems from cybersecurity threats, including firewalls, device encryption, multi-factor authentication, advanced threat protection for emails, anti-virus and anti-malware functionality and access controls, which are evaluated and improved from time to time; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">employ multiple backup systems for our data stored on our servers or other information systems.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We face risks from cybersecurity threats that, if realized, are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false" id="f-46">During the reporting period, we have not identified any risks from cybersecurity threats, including as a result of previous cyber security incidents, that we believe have materially affected, or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition.</ix:nonNumeric> For more information, see the section in our risk factors under the heading &#8220;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Our internal information technology systems, or those of our vendors, collaborators or other contractors or consultants, may fail or suffer cybersecurity incidents, loss of data, and other disruptions, which could result in a material disruption of our product development programs, compromise sensitive information related to our business </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><ix:continuation id="f-41-1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">or prevent us from accessing critical information, potentially exposing us to liability or otherwise adversely affecting our business</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.&#8221; which disclosures are incorporated by reference herein.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Cybersecurity Governance; Management</span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="f-49" continuedAt="f-49-1" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="f-48" continuedAt="f-48-1" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="f-47" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cybersecurity is an important part of our risk management processes and is an area of focus for our board of directors and management. Our <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true" id="f-50">board</ix:nonNumeric> of directors has delegated the oversight of cybersecurity risks to our Audit Committee, which oversees management&#8217;s implementation of our cybersecurity program.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-52" continuedAt="f-52-1" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-51" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our Audit Committee receives periodic updates from our General Counsel regarding our cybersecurity program and risks, including, as necessary, any material cybersecurity threat risks or incidents, as well as the steps management has taken to respond to such risks. Members of our Audit Committee are also encouraged to engage in conversations with management on cybersecurity-related news events and discuss any updates to our cybersecurity risk management and strategy programs. The Audit Committee reports to the full board of directors regarding its activities and risk management functions, including those related to cybersecurity.</span></div></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="f-52-1"><ix:continuation id="f-49-1"><ix:continuation id="f-48-1"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="f-53" escape="true">Oversight of our cybersecurity program, which is discussed in greater detail above, is led by our <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true" id="f-54">General Counsel</ix:nonNumeric> who, along with a contracted third party managed security service provider, is responsible for helping to integrate cybersecurity risk considerations into the Company&#8217;s overall risk management strategy and to help prepare for and respond to cybersecurity incidents.</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="f-55" escape="true">Our third party managed security service provider has over 25 years of experience in cybersecurity and is informed about and monitors our cybersecurity risk through participation in the cybersecurity risk management and strategy processes described above.</ix:nonNumeric>  Additionally, our legal and operations teams review and assess potential improvements to our cybersecurity policies and procedures with input from third-party vendors, as appropriate. As discussed above, the General Counsel reports to the Audit Committee of our board of directors about cybersecurity related matters, periodically.</ix:continuation></ix:continuation></ix:continuation> </span></div><div><span><br/></span></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_25"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Properties</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2021, we entered into a lease agreement for approximately 13,424 square feet of office and laboratory space in Boston, Massachusetts, which serves as our corporate headquarters.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The lease commenced in February 2022. The lease term is for eight years and expires February 28, 2030 and does not contain an option to renew. The initial annual rent was $1,235,008 with a 3% annual increase. We believe substantially all of our property and equipment is in good condition and that we have sufficient capacity to meet our current operational needs. See Note 11 to our consolidated financial statements included in Item 8 of this Annual Report on Form 10-K for additional information.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_28"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Legal Proceedings</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">From time to time, we may be subject to various legal proceedings, claims and administrative proceedings that arise in the ordinary course of our business activities or otherwise. Although the results of any litigation and claims cannot be predicted with certainty, as of the date of this report, we do not believe we are party to any claim, proceeding or litigation the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business. The outcome of any future litigation is uncertain. Such litigation, if not resolved, could result in substantial costs to us, including any costs associated with the indemnification of directors and officers.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_31"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Not applicable.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part II</span></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_37"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Market Information</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our common stock trades under the symbol &#8220;ELTX&#8221; on the Nasdaq Capital Market and has been publicly traded under this symbol since June 1, 2023, prior to which it was traded under the symbol &#8220;ANGN&#8221;.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Holders of Record </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of March&#160;25, 2025 there were approximately 459 holders of record of shares of our common stock. This number does not reflect the beneficial holders of our common stock who hold shares in street name through brokerage accounts or other nominees. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Unregistered Sales of Equity Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">None.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Repurchases of Equity Securities </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">None. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Dividend Policy</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have never declared or paid cash dividends on our common stock. We intend to retain all available funds and any future earnings, if any, to fund the development and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to dividend policy will be made at the discretion of our board of directors after considering our financial condition, results of operations, capital requirements, business prospects and other factors the board of directors deems relevant, and subject to the restrictions contained in any future financing instruments.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_40"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. [Reserved]</span></div><div style="margin-top:4pt;text-indent:22.5pt"><span><br/></span></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_43"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes appearing elsewhere in this Annual Report on Form 10-K. In addition to the historical financial information, this discussion contains forward-looking statements that involve risks, assumptions and uncertainties, such as statements of our plans, objectives, expectations, intentions, forecasts and projections. Our actual results and the timing of selected events could differ materially from those discussed in these forward-looking statements as a result of several factors, including those set forth under the section of this Annual Report on Form 10-K titled "Risk Factors," which you should read carefully to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements. Please also see the section titled "Forward-Looking Statements" at the beginning of this report.</span></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_46"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Overview</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are a clinical-stage biotechnology company pioneering the development of immunotherapies for patients with limited treatment options and poor outcomes suffering from cancer. Our proprietary Amphiphile (&#8220;AMP&#8221;) technology is designed to generate robust anti-tumor T lymphocytes (&#8220;T cell&#8221;) responses by preferentially targeting lymph nodes.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Recent advances have identified T cell responses as a key component of effective cancer immunotherapy and we believe our AMP technology can generate a robust T cell response that can potentially provide meaningful clinical benefit. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe the therapeutic utility of currently approved and development stage cancer immunotherapies are limited in many cases due to their inability to sufficiently localize to lymph nodes and adequately engage with the critical immune cells responsible for stimulating adaptive immunity.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our AMP technology is specifically intended to localize payloads to lymph nodes leading to the generation of a robust T cell response that we believe is critical to generate an anticancer immune response.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our lead programs focus on our cancer vaccine product candidates, which target biologically validated driver tumor mutations using common and well-characterized neoantigens.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This strategy results in an &#8220;off-the-shelf&#8221; therapeutic option allowing patients to receive treatment without delayed manufacturing timelines and increased costs associated with personalized vaccine approaches.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, currently being evaluated in a Phase 2 study, designed to stimulate an immune response against mutant KRAS cancers, ELI-007, currently being evaluated in preclinical studies for the treatment of mutant b-raf murine sarcoma viral oncogene homolog B1-driven cancers, and ELI-008, currently being evaluated in preclinical studies for use in the treatment of mutated tumor protein p53 expressing cancers.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe that each of our immunotherapy product candidates, if approved, has the potential to reduce the risk of recurrence of tumors carrying specific oncogenic driver mutations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our operations to date have been financed primarily by aggregate net proceeds of $182.9 million from the issuance of common stock, pre-funded warrants, convertible preferred stock, convertible notes, the exercise of stock options and common stock warrants, the private placement of our securities, at-the-market offerings, and proceeds from the Merger. Since inception, we have had significant annual operating losses. Our net loss was $51.9 million and $35.2 million for the years ended December&#160;31, 2024 and 2023, respectively. As of December&#160;31, 2024, we had an accumulated deficit of $194.1 million and $17.6 million in cash and cash equivalents.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Elicio Operating Company, Inc. (&#8220;Former Elicio&#8221;) was incorporated in Delaware as Vedantra Pharmaceuticals Inc. in August 2011. In December 2018, Former Elicio formed a wholly owned subsidiary, Elicio Securities Corporation, a Massachusetts corporation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On January 17, 2023, Former Elicio entered into a definitive merger agreement (the &#8220;Merger Agreement&#8221;) with Angion Biomedica Corp. (&#8220;Angion&#8221;) and Arkham Merger Sub, Inc., a wholly owned subsidiary of Angion (&#8220;Merger Sub&#8221;), pursuant to which Merger Sub merged with and into Former Elicio, with Former Elicio surviving the merger as a wholly owned subsidiary of Angion (the &#8220;Merger&#8221;). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 1, 2023, the Merger was completed in accordance with the terms and conditions of the Merger Agreement and Angion changed its name from &#8220;Angion Biomedica Corp.&#8221; to &#8220;Elicio Therapeutics, Inc.&#8221; Following the Merger, Former Elicio and Elicio Australia Pty Ltd. (&#8220;Elicio Pty&#8221;), an Australian subsidiary established in August 2019 for the purpose of qualifying for research credits for studies conducted in Australia, became our wholly owned subsidiaries.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are currently facing substantial doubt about our ability to continue as a going concern, given our cash position and cash runway. As of the filing date of this Annual Report on Form 10-K, we believe that our cash on hand will enable us to fund our operations into the fourth quarter of 2025 based on our current financial operating plan. This period could be shortened or lengthened if there are any significant increases or decreases in planned or actual spending on development programs or more rapid progress of development programs than anticipated. There is no assurance that financing will be available when needed to allow us to continue as a going concern. Our losses from operations, negative operating cash flows and accumulated deficit, as well as the additional capital needed to fund operations for at least twelve months following the issuance of the consolidated financial statements, raise substantial doubt about our ability to continue as a going concern. We expect to incur substantial expenditures in the foreseeable future for the development of our product candidates and will require additional financing to continue this development. We plan to address this condition through the sale of common stock or other securities in public offerings and/or private placements, debt financings, or through other capital sources, including licensing arrangements, partnerships and collaborations with other companies or other strategic transactions, but there is no assurance these plans will be completed successfully or at all.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we are unable to obtain additional capital when and as needed to continue as a going concern, we might have to further reduce or scale back our operations and/or liquidate our assets, and the values we receive for our assets in liquidation or dissolution could be significantly lower than the values reflected in our financial statements. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K have been prepared on a basis that assumes that we will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Our consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our accounts payable and accrued expenses. We expect to continue to incur net losses for the foreseeable future, and we expect our research and development expenses, general and administrative expenses, and capital expenditures will continue to increase. In particular, we expect our expenses to increase as we continue our development of, and seek regulatory approvals for, our product candidates, as well as hire additional personnel, pay fees to outside consultants, attorneys and accountants, and incur other increased costs associated with being a public company. In addition, if and when we seek and obtain regulatory approval to commercialize any product candidate, we will also incur increased expenses in connection with commercialization and marketing of any such product. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical trials and our expenditures on other research and development activities. We anticipate that our expenses will increase significantly in connection with our ongoing activities, as we:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226; advance our lead product candidate, ELI-002, to late-stage clinical trials;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226; advance our preclinical programs to clinical trials;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226; expand our pipeline of product candidates;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226; seek regulatory approval for our investigational medicines;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226; maintain, expand, protect and defend our intellectual property portfolio;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226; acquire or in-license technology;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226; expand our clinical, scientific, management and administrative teams; and</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226; operate as a public company.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of the filing date of this Annual Report on Form 10-K, we believe that our cash on hand will enable us to fund our operations into the fourth quarter of 2025 based on our current plan. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. To finance our operations beyond that point we will need to raise additional capital, which cannot be assured. Our losses from operations, negative operating cash flows and accumulated deficit, as well as the additional capital needed to fund operations for at least twelve months following the issuance of the consolidated financial statements, raise substantial doubt about our ability to continue as a going concern.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have not had any products approved for sale. We do not expect to generate any product sales unless and until we successfully complete development and obtain regulatory approval for one or more of our product candidates. If we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. As a result, until such time, if ever, that we can generate substantial product revenue, we expect to finance our cash needs through equity offerings, debt financings or other capital sources, including collaborations, licenses or similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed or on favorable terms, if at all. Any failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies, including our research and development activities. If we are unable to raise capital, we will need to delay, reduce or terminate planned activities to reduce costs.</span></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_49"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Components of Results of Operations</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following discussion summarizes the key factors our management believes are necessary for an understanding of our financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Operating Expenses</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our operating expenses since inception have consisted primarily of research and development expenses and general and administrative costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our research and development expenses consist primarily of costs incurred for the development of our product candidates and our drug discovery efforts, which include:</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226; personnel costs, which include salaries, benefits, and equity-based compensation expense;</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226; expenses incurred under agreements with consultants and contract organizations that conduct research and </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">development activities on our behalf;</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226; costs related to sponsored research service agreements;</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226; costs related to production of preclinical and clinical materials, including fees paid to contract manufacturers;</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226; laboratory and vendor expenses related to the execution of preclinical studies and planned clinical trials; and</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226; laboratory supplies and equipment used for internal research and development activities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expense all research and development costs in the periods in which they are incurred. Costs for certain research and development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and service providers.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our research and development expenses are not currently tracked on a program-by-program basis. We use our personnel and infrastructure resources across multiple research and development programs directed toward identifying and developing product candidates. Substantially all our research and development costs are incurred on the development of ELI-002 and our preclinical candidates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect our research and development expenses to increase substantially for the foreseeable future as we continue to invest in research and development activities related to developing our product candidates, including investments in conducting clinical trials, manufacturing and otherwise advancing our programs. The process of conducting the clinical research necessary to obtain regulatory approval is costly and time-consuming, and the successful development of our product candidates is highly uncertain. At this time, we cannot reasonably estimate the nature, timing and costs of the efforts that will be needed to complete the development of, or the period, if any, in which material net cash inflows may commence from ELI-002 or any of our preclinical candidates. This is due to the numerous risks and uncertainties associated with developing drugs, including the uncertainty of:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the scope, rate of progress and expense of our research and development activities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">clinical trials and early-stage results;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the terms and timing of regulatory approvals; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the ability to market, commercialize and achieve market acceptance for ELI-002, or any of our preclinical candidates that we or our future collaboration partners may develop in the future. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Any of these variables with respect to the development of ELI-002, or any other of our preclinical candidates that we may develop could result in a significant change in the costs and timing associated with the development of such candidates. For example, if the U.S. Food and Drug Administration (&#8220;FDA&#8221;) or other regulatory authority were to require us to conduct preclinical and clinical studies beyond those which we currently anticipate will be required for the completion of clinical development or if we experience significant delays in enrollment in any clinical trials, we could be required to expend significant additional financial resources and time on the completion of our clinical development programs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our general and administrative expenses consist primarily of personnel costs, including equity-based compensation, and other expenses for outside professional services, including marketing, legal, audit and accounting, facility-related costs not otherwise included in research and development expenses, and recruiting. We expect our general and administrative expenses to increase over the next several years to support our continued research and development activities, manufacturing activities, increased costs of expanding our operations and operating as a public company. These increases will likely include increases related to the hiring of additional personnel and legal, regulatory and other fees and services associated with maintaining compliance with the Nasdaq Stock Market LLC Listing Rules and Securities and Exchange Commission (&#8220;SEC&#8221;) requirements, accounting and audit fees, director and officer insurance costs and investor relations costs associated with being a public company.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Other (Expense) Income </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the years ended December&#160;31, 2024 and 2023, other income and expense consisted primarily of interest income and expense, foreign exchange transaction gains and losses, gain on sale of equipment, gain on extinguishment of the promissory note payable, and gains and losses related to the re-measurement of our warrant liabilities. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_52"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison for the Years Ended December&#160;31, 2024 and 2023</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the periods indicated:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">$ Change</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">% Change</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(In thousands, except percentages)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Operating expenses:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">33,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23,849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,807&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11,896&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(566)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total operating expenses</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">44,986&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">35,745&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9,241&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">25.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loss from operations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(44,986)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(35,745)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(9,241)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">25.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other (expense) income, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(6,912)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,462)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1356.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Net loss</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(51,898)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(35,195)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(16,703)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________</span></div><div style="margin-top:1pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Research and development expenses increased by $9.8&#160;million, or 41.1%, for the year ended December&#160;31, 2024 compared to the year ended December&#160;31, 2023. The net increase in research and development expenses was primarily due to an increase in external costs associated with ELI-002 manufacturing and clinical trials.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">General and administrative expenses decreased by $0.6&#160;million, or 4.8%, for the year ended December&#160;31, 2024 compared to the year ended December&#160;31, 2023. The decrease was primarily due to a decrease in external costs related to the Merger.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Other (expense) Income</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other (expense) income for the year ended December&#160;31, 2024 was $6.9&#160;million compared to other (expense) income of</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$0.6&#160;million for the year ended December&#160;31, 2023. The increase of $7.5&#160;million was primarily due to the change in fair value and loss on issuance associated with the pre-funded warrants and common warrants.</span></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_55"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Sources and Uses of Liquidity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our operations through December&#160;31, 2024 have been financed primarily by aggregate net proceeds of $182.9 million from the issuance of common stock, pre-funded warrants, convertible preferred stock, convertible notes, the exercise of stock options and common stock warrants, the private placement of our securities, at-the-market offerings, and proceeds from the Merger. Since inception, we have had significant operating losses. Our net loss was $51.9 million and $35.2 million for the years ended December&#160;31, 2024 and 2023, respectively. As of December&#160;31, 2024, we had an accumulated deficit of $194.1 million and $17.6 million in cash and cash equivalents. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our losses from operations, negative operating cash flows and accumulated deficit, as well as the additional capital needed to fund operations for at least twelve months following the issuance of the consolidated financial statements, raise substantial doubt about our ability to continue as a going concern. We expect to incur substantial expenditures in the foreseeable future for the development of our product candidates and will require additional financing to continue this development. The consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K have been prepared on a basis that assumes that we will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern. We plan to address this condition through the sale of common stock or other securities in public offerings and/or private placements, debt financings, or through other capital sources, including licensing arrangements, partnerships and collaborations with other companies or other strategic transactions. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">However, there is no assurance that we will be successful in raising additional capital or that such additional funds will be available on acceptable terms, if at all. Should we be unable to raise this amount of capital our operating plans will be limited to the amount of capital that we can access. We may also consider steps to reduce our operating expenses. There can be no assurances that we will be successful in any of the foregoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Summary Statement of Cash Flows</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table sets forth a summary of our net cash flow activity for the years ended December&#160;31, 2024 and 2023 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.913%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Year Ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net cash provided by (used in)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating activities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(37,068)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(32,694)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Investing activities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financing activities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">42,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38,613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Effect of foreign currency on cash</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net increase in cash</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,191&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,887&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Operating activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the year ended December&#160;31, 2024, net cash used in operating activities was $37.1&#160;million, which primarily consisted of a net loss of $51.9 million and a change in net operating assets and liabilities of $3.9 million partially offset by net non-cash charges of $10.9 million. The change in net operating assets and liabilities of $3.9 million was the result of a $0.5 million increase in the deferred research obligation, a $0.8 million decrease in prepaid assets, a $2.2 million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">decrease in other long-term prepaid assets, a $0.9 million decrease in the operating lease liability, and a net increase in accounts payable and accrued expenses of $1.3 million. The $10.9 million of net non-cash charges were related to $3.9 million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">of change in the fair value of warrant liability, $3.5 million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">loss on the issuance of the pre-funded warrants and common warrants, $1.5 million of stock-based compensation expense, $0.9 million related to amortization of the right-of-use (&#8220;ROU&#8221;) asset, $0.5 million related to issuance costs for the pre-funded warrants and common warrants, $0.3 million of depreciation, $0.2 million of non-cash interest expense, and $0.1 million of amortization of debt discount.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the year ended December&#160;31, 2023, net cash used in operating activities was $32.7&#160;million, which primarily consisted of a net loss of $35.2&#160;million and a change in net operating assets and liabilities of $0.1 million partially offset by net non-cash charges of $2.6 million. The change in net operating assets and liabilities of $0.1 million was the result of a $0.7&#160;million decrease in the deferred research obligation, a $0.8 million decrease in prepaid assets, and a $0.8&#160;million decrease in the operating lease liability offset by an increase in accounts payable and accrued expenses of $2.2 million. The $2.6 million of net non-cash charges were related to $1.1 million of interest expense related to the accretion of the promissory note payable, $1.2 million of stock-based compensation expense, $0.8 million related to amortization of the ROU asset, $0.4 million of depreciation, $0.1&#160;million loss on disposal of property and equipment partially offset by $0.4 million increase in the fair value of the embedded derivative associated with the promissory notes payable and $0.6&#160;million of gain on the extinguishment of the promissory notes payable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Investing activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the years ended December&#160;31, 2024 and 2023, net cash provided by or used in investing activities was immaterial.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Financing activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the year ended December&#160;31, 2024, net cash provided by financing activities was $42.3 million, comprised of $19.7 million of net proceeds from the issuance of the convertible note, $17.5 million of proceeds from the issuance of common stock warrants, and $5.6 million of proceeds from the sale of common stock, offset by $0.5 million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">of issuance costs for the pre-funded warrants and common warrants. For the year ended December&#160;31, 2023, net cash provided by financing activities was $38.6 million, comprised of $31.6 million of net proceeds from the Merger and $7.0 million of net proceeds from the sale of common stock.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Future Cash Needs and Funding Requirements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Based on our current operating plan, we believe our cash and cash equivalents will be sufficient to fund our planned operations into the fourth quarter of 2025. However, we have based our projections of operating capital requirements on assumptions that may prove to be incorrect and we may use all our available capital resources </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">sooner than we expect. We are unable to estimate the exact amount of our operating capital requirements. The amount and timing of our future funding requirements will depend on many factors, including, but not limited to:</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:25.26pt">the scope, progress, results and costs of researching and developing product candidates, and conducting preclinical studies and clinical trials;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:25.26pt">the outcome of any future clinical trials, for any existing or future product candidates;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:25.26pt">whether we are able to take advantage of any FDA expedited development and approval programs for any of our product candidates;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:25.26pt">the outcome, costs and timing of seeking and obtaining and maintaining FDA and any foreign regulatory approvals;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:25.26pt">the costs associated with any delays we may encounter as a result of evolving regulatory requirements or adverse results with respect to any of our product candidates;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:25.26pt">the number and characteristics of product candidates we pursue, including product candidates in preclinical development;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:25.26pt">the ability of our product candidates to progress through clinical development successfully;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:25.26pt">our need to expand our research and development activities, including to conduct additional clinical trials;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:25.26pt">market acceptance of our product candidates, including physician adoption, market access, pricing and reimbursement;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:25.26pt">the costs of acquiring, licensing or investing in businesses, products, product candidates and technologies;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:25.26pt">our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments potentially required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:25.26pt">our need and ability to hire additional personnel, including management, clinical development, medical and commercial personnel;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:25.26pt">the effect of competing technological, market developments and government policy;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:25.26pt">the costs associated with being a public company, including our need to implement additional internal systems and infrastructure, including financial and reporting systems;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:25.26pt">the costs associated with securing and establishing commercialization and manufacturing capabilities, as well as those associated with packaging, warehousing and distribution;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:25.26pt">the economic and other terms, timing of and success of our existing licensing arrangements and any collaboration, licensing or other arrangements into which we may enter in the future and timing and amount of payments thereunder; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:25.26pt">the timing, receipt and amount of sales and general commercial success of any future approved products, if any.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Until such time as we can generate significant revenue from sales of product candidates, if ever, we expect to finance our operations through the sale of common stock or other securities in public offerings and/or private placements, debt financings, or through other capital sources, including licensing arrangements, partnerships and collaborations with other companies or other strategic transactions. Adequate funding may not be available to us on acceptable terms, or at all. To the extent we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through additional collaborations, or other similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to and/or may reduce the value of our common stock. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts or grant rights to develop and market our product candidates even if we would otherwise prefer to develop and market such product candidates ourselves.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_58"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">While our significant accounting policies are described in more detail in Note 2 to our consolidated financial statements in this Annual Report on Form 10-K, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Accrued Research and Development Costs</span></div><div style="margin-top:6pt;text-align:justify;text-indent:20pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We incur, and expect to continue to incur, substantial expenses associated with manufacturing and clinical trials. Accounting for clinical trials relating to activities performed by contract research organizations (&#8220;CROs&#8221;) and other external vendors requires management to exercise significant estimates in regard to the timing and accounting for these expenses. We estimate costs of research and development activities conducted by service providers, which include the conduct of sponsored research, preclinical studies and contract manufacturing activities. The diverse nature of services being provided under CROs and other arrangements, the different compensation arrangements that exist for each type of service and the lack of timely information related to certain clinical activities complicates the estimation of accruals for services rendered by CROs and other vendors in connection with clinical trials. We record the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and include these costs in the accrued expenses on the balance sheets and within research and development expense on the consolidated statements of operations and comprehensive loss. In estimating the duration of a clinical study, we evaluate the start-up, treatment and wrap-up periods, compensation arrangements and services rendered attributable to each clinical trial and fluctuations are regularly tested against payment plans and trial completion assumptions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:20pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We estimate these costs based on factors such as estimates of the work completed and budget provided and in accordance with agreements established with our collaboration partners and third-party service providers. We make significant judgments and estimates in determining the accrued liabilities balances in each reporting period. As actual costs become known, we adjust our accrued liabilities. We have not experienced any material differences between accrued costs and actual costs incurred since our inception.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:20pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our expenses related to clinical trials will be based on estimates of patient enrollment and related expenses at clinical investigator sites as well as estimates for the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that may be used to conduct and manage clinical trials on our behalf. We will accrue expenses related to clinical trials based on contracted amounts applied to the level of patient enrollment and activity. If timelines or contracts are modified based upon changes in the clinical trial protocol or scope of work to be performed, we will modify our estimates of accrued expenses accordingly on a prospective basis.</span></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_61"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">See Note 2, &#8220;Summary of Significant Accounting Policies&#8221; in the Notes to the Consolidated Financial Statements set forth in Item 8 of this Annual Report on Form 10-K for a full description of recent accounting standards.</span></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_64"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Emerging Growth Company and Smaller Reporting Company Status</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are a smaller reporting company and an emerging growth company, as defined under the Jumpstart Our Business Startup (&#8220;JOBS&#8221;) Act. Under the JOBS Act, emerging growth companies can delay the adoption of new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. Other exemptions and reduced reporting requirements under the JOBS Act for emerging growth companies include presentation of only two years of audited financial statements in a registration statement for an initial public offering, an exemption from the requirement to provide an auditor's report on internal controls over financial reporting pursuant to Sarbanes-Oxley Act of 2002, as amended (&#8220;Sarbanes-Oxley&#8221;), an exemption from any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation, and less extensive disclosure about our executive compensation arrangements. We have elected to use the extended transition period for complying with new or revised accounting </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">standards that have different effective dates for public and private companies until the earlier of the date that (i) we are no longer an emerging growth company or (ii) we affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our consolidated financial statements may not be comparable to companies that comply with new or revised accounting standards as of public company effective dates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We will remain an emerging growth company until the earliest of (i) December 31, 2026, (ii) the last day of our first fiscal year in which we have total annual gross revenue of $1.235 billion or more, (iii) the date on which we are deemed to be a "large accelerated filer," as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), which means the market value of equity securities that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter and (iv) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Even after we no longer qualify as an emerging growth company, we may still qualify as a "smaller reporting company" and/or &#8220;non-accelerated filer&#8221; which may allow us to take advantage of many of the same exemptions from disclosure requirements including not being required to comply for a period of time with the auditor attestation requirements of Section 404 of Sarbanes-Oxley, and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements.</span></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_67"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_70"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8. Financial Statements and Supplementary Data.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements of Elicio Therapeutics, Inc., listed below are set forth in Item 8 of this Annual Report for the years ended December 31, 2024 and 2023:</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELICIO THERAPEUTICS, INC.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_73">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Baker Tilly US, LLP, Tewksbury, Massachusetts, PCAOB ID: 23)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_73">102</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_76">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_76">103</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_82">Consolidated Statements of Operations and Comprehensive Loss </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_82">104</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_85">Consolidated Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_85">105</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_91">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_91">107</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_94">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_94">109</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_73"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Elicio Therapeutics, Inc.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Elicio Therapeutics, Inc. and its subsidiaries (the &#8220;Company&#8221;) as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders&#8217; equity (deficit), and cash flows, for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of their operations and their cash flows for each of the two years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern Uncertainty</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has suffered losses and negative cash flow from operations, and has an accumulated deficit as of December 31, 2024, that raises substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures to respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Baker Tilly US, LLP</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company's auditor since 2019.</span></div><div style="margin-top:10pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Tewksbury, Massachusetts</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2025</span></div><div style="margin-top:10pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_76"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELICIO THERAPEUTICS, INC. </span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets </span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:72.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-56">17,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-57">12,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Restricted cash, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="3" id="f-58">1,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="f-59">722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-60">1,897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-61">2,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:17pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-62">20,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-63">16,348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-64">483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-65">717</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Operating lease, right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-66">5,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-67">6,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Restricted cash, noncurrent</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="f-68">696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="f-69">685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Other long-term prepaid assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseOtherNoncurrent" scale="3" id="f-70">600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidExpenseOtherNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-71">2,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-72">28,178</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-73">27,146</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Liabilities, convertible preferred stock, and stockholders&#8217; (deficit) equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-74">1,038</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-75">4,369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-76">8,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-77">3,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Deferred research obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-78">1,169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="f-79">694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Operating lease liability, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-80">901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-81">910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Unvested option exercise liability, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="f-82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent" scale="3" id="f-83">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:17pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-84">11,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-85">9,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Warrant liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="angn:WarrantLiability" format="ixt:num-dot-decimal" scale="3" id="f-86">2,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="angn:WarrantLiability" scale="3" id="f-87">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Operating lease liability, noncurrent</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-88">5,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-89">6,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Convertible note - related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ConvertibleLongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-90">20,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ConvertibleLongTermNotesPayable" format="ixt:fixed-zero" scale="3" id="f-91">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-92">39,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-93">15,773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Commitments and contingencies&#8212;Note 10</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-94"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-5" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-95"></ix:nonFraction></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Stockholders' (deficit) equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-96"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-97">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-98"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-99">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt-sec:numwordsen" scale="3" id="f-100"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt-sec:numwordsen" scale="3" id="f-101"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt-sec:numwordsen" scale="3" id="f-102"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt-sec:numwordsen" scale="3" id="f-103">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-104">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-105">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-106"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-107">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-108"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-109">300,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-110">11,043,837</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-111">9,618,178</ix:nonFraction> shares issued at December 31, 2024 and 2023, respectively; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-112">11,029,382</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-113">9,603,723</ix:nonFraction> shares outstanding as of December 31, 2024 and 2023, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-114">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-115">96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Treasury stock, at cost, <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-116"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-117">14,455</ix:nonFraction></ix:nonFraction> shares outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:TreasuryStockCommonValue" scale="3" id="f-118">150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:TreasuryStockCommonValue" scale="3" id="f-119">150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-120">183,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-121">153,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-122">175</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-123">197</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-124">194,101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-125">142,203</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Total stockholders' (deficit) equity</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-126">11,312</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-127">11,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Total liabilities, convertible preferred stock, and stockholders&#8217; (deficit) equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-128">28,178</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-129">27,146</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_82"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELICIO THERAPEUTICS, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations and Comprehensive Loss </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Operating expenses:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Research and development</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-130">33,656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-131">23,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">General and administrative</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-132">11,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-133">11,896</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Total operating expenses</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-134">44,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-135">35,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Loss from operations</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-136">44,986</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-137">35,745</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Other (expense) income</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Change in fair value of warrant liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="3" id="f-138">3,886</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="f-139">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Loss on issuance of pre-funded warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="angn:GainLossOnIssuanceOfWarrants" format="ixt:num-dot-decimal" scale="3" id="f-140">3,502</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="angn:GainLossOnIssuanceOfWarrants" format="ixt:fixed-zero" scale="3" id="f-141">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Change in fair value of derivative liability</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:fixed-zero" scale="3" id="f-142">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="f-143">429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Gain on extinguishment of promissory notes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-144">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="f-145">605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Gain on sale of equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" scale="3" id="f-146">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" format="ixt:fixed-zero" scale="3" id="f-147">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Foreign exchange transaction gain</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="f-148">151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="f-149">204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Interest income</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestIncomeOperatingAndNonoperating" scale="3" id="f-150">777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InterestIncomeOperatingAndNonoperating" scale="3" id="f-151">373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Interest expense</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseNonoperating" scale="3" id="f-152">455</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-153">1,059</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Total other (expense) income, net</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-154">6,912</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="f-155">550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Provision for income taxes</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-156">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-157">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Net loss</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-158">51,898</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-159">35,195</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Other comprehensive gain (loss):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:30.6pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Foreign currency translation adjustment</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-160">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-161">197</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Comprehensive loss</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-162">51,876</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-163">35,392</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Net loss per common share, basic and diluted</span></div></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-164"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-165">4.25</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-166"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-167">6.96</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Weighted average common shares outstanding, basic and diluted</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-168"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-169">12,202,996</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-170"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-171">5,056,225</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_85"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELICIO THERAPEUTICS, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share amounts)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.384%"><tr><td style="width:1.0%"/><td style="width:17.812%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.272%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.583%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.401%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.928%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.238%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.196%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">Total Convertible Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">Common Stock</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">Treasury Stock</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">Additional</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">Paid-in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">Capital</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">Accumulated Other Comprehensive Loss</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">Accumulated </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">Deficit</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">Total </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">Stockholders'</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">(Deficit) Equity</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">Shares</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">Par Value</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">Shares</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">Amount</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">Balance as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-172">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-173">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-174">9,618,178</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-175">96</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-176">14,455</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-177">150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-178">153,827</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-179">197</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-180">142,203</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-181">11,373</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Issuance of common stock from At-the-Market offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="f-182">118</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-183">703,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-184">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-185">5,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-186">5,635</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-187">9,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-188">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-189">39</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Issuance of common stock upon settlement of restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="f-190">1,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-191">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-192">25</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Issuance of common stock from July Public Offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="f-193">517</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-194">510,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-195">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-196">1,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-197">1,080</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Issuance of common stock from the exercise of Pre-funded Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="angn:StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants" format="ixt:num-dot-decimal" scale="0" id="f-198">200,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="3" id="f-199">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" format="ixt:num-dot-decimal" scale="3" id="f-200">1,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" format="ixt:num-dot-decimal" scale="3" id="f-201">1,016</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Reclassification of liability-classified warrants to equity classified warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="angn:ReclassLiabilityClassifiedWarrantsToEquityClassifiedWarrants" format="ixt:num-dot-decimal" scale="3" id="f-202">19,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="angn:ReclassLiabilityClassifiedWarrantsToEquityClassifiedWarrants" format="ixt:num-dot-decimal" scale="3" id="f-203">19,944</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-204">1,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-205">1,452</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-206">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-207">22</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-208">51,898</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-209">51,898</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Balance as of December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-210">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="0" id="f-211">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-212">11,043,837</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-213">110</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-23" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-214">14,455</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-215">150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-216">183,004</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-217">175</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-218">194,101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-219">11,312</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELICIO THERAPEUTICS, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share amounts)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.384%"><tr><td style="width:1.0%"/><td style="width:17.812%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.272%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.583%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.401%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.928%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.238%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.196%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="12" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="padding:0 1pt"/></tr><tr style="height:19pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">Total Convertible Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">Common Stock</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">Treasury Stock</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">Additional</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">Paid-in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">Capital</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">Accumulated Other Comprehensive Loss</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">Accumulated </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">Deficit</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">Total </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">Stockholders'</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">(Deficit) Equity</span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">Shares</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">Par Value</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">Shares</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">Amount</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">Balance as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-220">4,997,920</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-221">111,060</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-222">320,281</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-223">3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:fixed-zero" scale="0" id="f-224">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-225">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-226">4,860</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-227">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-228">107,008</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-229">102,145</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">Exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-34" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-230">16,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-231">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-232">126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-233">127</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">Vesting of restricted common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-34" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="f-234">5,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-235">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-236">67</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">Conversion of preferred stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="shares" contextRef="c-36" decimals="INF" name="angn:TemporaryEquitySharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-237">4,997,920</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="angn:TemporaryEquityValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-238">111,060</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-37" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-239">4,997,920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="f-240">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-241">111,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-242">111,060</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">Issuance of common stock to Angion stockholders as a result of Merger and reset to par of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-243">0.01</ix:nonFraction>, net of transaction costs of $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-244">2.4</ix:nonFraction> million</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-34" decimals="INF" name="angn:StockIssuedDuringPeriodSharesReverseRecapitalization" format="ixt:num-dot-decimal" scale="0" id="f-245">3,012,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="angn:StockIssuedDuringPeriodValueReverseRecapitalization" scale="3" id="f-246">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="angn:StockIssuedDuringPeriodValueReverseRecapitalization" format="ixt:num-dot-decimal" scale="3" id="f-247">19,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="angn:StockIssuedDuringPeriodValueReverseRecapitalization" format="ixt:num-dot-decimal" scale="3" id="f-248">19,526</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">Settlement of promissory notes in connection with Merger</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-249">10,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-250">10,027</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">Issuance of common stock upon accelerated vesting of restricted stock units due to Merger</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="f-251">41,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">Return of common stock to pay withholding taxes on restricted stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="shares" contextRef="c-43" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-252">14,455</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-253">150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-254">150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">Issuance of common stock related to stock purchase agreement</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-34" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-255">1,213,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-256">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-257">6,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-258">6,999</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">Issuance of common stock related to service agreement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-34" decimals="INF" name="angn:StockIssuedDuringPeriodSharesServiceAgreement" format="ixt:num-dot-decimal" scale="0" id="f-259">11,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="angn:StockIssuedDuringPeriodValueServiceAgreement" scale="3" id="f-260">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="angn:StockIssuedDuringPeriodValueServiceAgreement" scale="3" id="f-261">75</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-262">1,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-263">1,179</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-264">197</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-265">197</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-266">35,195</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-267">35,195</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">Balance as of December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-268">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-269">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-270">9,618,178</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-271">96</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-272">14,455</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-273">150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-274">153,827</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-275">197</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-276">142,203</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-277">11,373</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_91"></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELICIO THERAPEUTICS, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Cash flows from operating activities</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Net loss</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-278">51,898</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-279">35,195</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Adjustments to reconcile net loss to net cash used in operating activities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Depreciation </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-280">321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-281">382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Amortization of right-of-use assets, operating leases</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="f-282">857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="f-283">788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Amortization of debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="f-284">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:fixed-zero" scale="3" id="f-285">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Non-cash interest expense</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="angn:InterestExpenseNoncash" scale="3" id="f-286">232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="angn:InterestExpenseNoncash" format="ixt:num-dot-decimal" scale="3" id="f-287">1,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Costs expensed upon the issuance of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="angn:CostsExpensedUponTheIssuanceOfWarrants" scale="3" id="f-288">549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="angn:CostsExpensedUponTheIssuanceOfWarrants" format="ixt:fixed-zero" scale="3" id="f-289">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Change in fair value of embedded derivative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" format="ixt:fixed-zero" scale="3" id="f-290">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="3" id="f-291">429</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Change in fair value of warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="3" id="f-292">3,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="f-293">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Loss on issuance of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="angn:GainLossOnIssuanceOfWarrants" format="ixt:num-dot-decimal" scale="3" id="f-294">3,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="angn:GainLossOnIssuanceOfWarrants" format="ixt:fixed-zero" scale="3" id="f-295">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-296">1,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-297">1,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Non-cash professional services expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="angn:ProfessionalServicesExpenseNoncash" format="ixt:fixed-zero" scale="3" id="f-298">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="angn:ProfessionalServicesExpenseNoncash" scale="3" id="f-299">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Gain on extinguishment of promissory notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-300">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="f-301">605</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(Gain) loss on disposal of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="f-302">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="f-303">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Changes in operating assets and liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:17pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-304">835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-305">729</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:17pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Other long-term prepaid assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-306">2,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:fixed-zero" scale="3" id="f-307">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:17pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-308">3,331</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="f-309">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:17pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Accrued expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="angn:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-310">4,658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="angn:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-311">2,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:17pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Deferred research obligation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="f-312">475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="f-313">742</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:17pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Operating lease liability</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-314">911</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-315">825</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Net cash used in operating activities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-316">37,068</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-317">32,694</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Cash flows from investing activities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:17pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Purchases of property and equipment</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-318">87</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-319">66</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:17pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Proceeds from sale of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="f-320">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="f-321">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Net cash used in investing activities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-322">84</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-323">32</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Cash flows from financing activities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:17pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Cash acquired in connection with the reverse merger</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashAcquiredInExcessOfPaymentsToAcquireBusiness" format="ixt:fixed-zero" scale="3" id="f-324">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashAcquiredInExcessOfPaymentsToAcquireBusiness" format="ixt:num-dot-decimal" scale="3" id="f-325">24,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:17pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Merger transaction costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-326">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-327">2,364</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:17pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Proceeds from issuance of promissory notes payable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" format="ixt:fixed-zero" scale="3" id="f-328">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-329">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:17pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Proceeds from issuance of common stock warrants from March PIPE</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfWarrants" format="ixt:num-dot-decimal" scale="3" id="f-330">5,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfWarrants" format="ixt:fixed-zero" scale="3" id="f-331">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:17pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Proceeds from issuance of common stock warrants from July Public Offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="angn:ProceedsFromIssuanceOfCommonStockWarrantsFromJulyPublicOffering" format="ixt:num-dot-decimal" scale="3" id="f-332">11,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="angn:ProceedsFromIssuanceOfCommonStockWarrantsFromJulyPublicOffering" format="ixt:fixed-zero" scale="3" id="f-333">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:17pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Proceeds from issuance of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-334">4,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-335">6,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:17pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Proceeds from issuance of common stock from July Public Offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="angn:ProceedsFromIssuanceOfCommonStockFromJulyPublicOffering" format="ixt:num-dot-decimal" scale="3" id="f-336">1,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="angn:ProceedsFromIssuanceOfCommonStockFromJulyPublicOffering" format="ixt:fixed-zero" scale="3" id="f-337">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:17pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Payment of warrant issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="angn:PaymentOfWarrantIssuanceCosts" scale="3" id="f-338">549</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="angn:PaymentOfWarrantIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-339">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:17pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Proceeds from issuance of senior note, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-340">19,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt" format="ixt:fixed-zero" scale="3" id="f-341">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:17pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Payment of employee withholding taxes on restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfEquity" format="ixt:fixed-zero" scale="3" id="f-342">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfEquity" scale="3" id="f-343">150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:17pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-344">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-345">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Net cash provided by financing activities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-346">42,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-347">38,613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Effect of foreign currency on cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-348">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="3" id="f-349">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Net increase in cash, cash equivalents and restricted cash</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-350">5,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-351">5,887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Cash, cash equivalents and restricted cash at the beginning of the year</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-352">14,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-353">8,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Cash, cash equivalents and restricted cash at the end of the year</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-354">19,492</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-355">14,301</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Components of cash, cash equivalents and restricted cash:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-356">17,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-357">12,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-358">1,874</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-359">1,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-360">19,492</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-361">14,301</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="margin-top:2pt;text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Contents</a></span></div></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELICIO THERAPEUTICS, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows (continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.786%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Supplemental disclosure of noncash investing and financing activities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Fair value of pre-funded warrants at issuance date</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="angn:FairValueOfPreFundedWarrants" format="ixt:num-dot-decimal" scale="3" id="f-362">13,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="angn:FairValueOfPreFundedWarrants" format="ixt:fixed-zero" scale="3" id="f-363">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Fair value of common warrants at issuance date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="angn:FairValueOfCommonStockWarrants" format="ixt:num-dot-decimal" scale="3" id="f-364">6,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="angn:FairValueOfCommonStockWarrants" format="ixt:fixed-zero" scale="3" id="f-365">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Accretion of promissory note discount from embedded derivative</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="angn:AccretionOfPromissoryNoteDiscountFromEmbeddedDerivative" format="ixt:fixed-zero" scale="3" id="f-366">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="angn:AccretionOfPromissoryNoteDiscountFromEmbeddedDerivative" format="ixt:num-dot-decimal" scale="3" id="f-367">10,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Accretion of promissory note to face value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="angn:AccretionOfPromissoryNoteToFaceValue" scale="3" id="f-368">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="angn:AccretionOfPromissoryNoteToFaceValue" scale="3" id="f-369">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Settlement of promissory notes payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="angn:SettlementOfPromissoryNotesPayable" format="ixt:fixed-zero" scale="3" id="f-370">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="angn:SettlementOfPromissoryNotesPayable" scale="3" id="f-371">897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Non-cash vesting of restricted common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="angn:VestingOfRestrictedCommonStockNoncash" scale="3" id="f-372">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="angn:VestingOfRestrictedCommonStockNoncash" scale="3" id="f-373">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Non-cash issuance of common stock from conversion of preferred stock</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ConversionOfStockAmountIssued1" format="ixt:fixed-zero" scale="3" id="f-374">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ConversionOfStockAmountIssued1" format="ixt:num-dot-decimal" scale="3" id="f-375">111,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Non-cash issuance of common stock to Angion stockholders</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="3" id="f-376">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="3" id="f-377">19,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Non-cash issuance of common stock related to service agreement</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="3" id="f-378">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:StockIssued1" scale="3" id="f-379">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:2pt;text-align:center"><span><br/></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_94"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELICIO THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:1pt"><span><br/></span></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_97"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Note 1&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-380" continuedAt="f-380-1" escape="true">Description of the Business and Financial Condition</ix:nonNumeric></span></div><ix:continuation id="f-380-1"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Elicio Therapeutics, Inc. (&#8220;Elicio&#8221; or the &#8220;Company&#8221;) was incorporated in Delaware as Vedantra Pharmaceuticals Inc., in August 2011. Elicio is a clinical-stage biotechnology company pioneering the development of immunotherapies for patients with limited treatment options and poor outcomes suffering from cancer. In December 2018, Elicio formed a wholly-owned subsidiary, Elicio Securities Corporation (&#8220;ESC&#8221;), a Massachusetts corporation. ESC is an investment company. Elicio, ESC, Former Elicio (as defined below) and Elicio Pty (as defined below) are collectively referred to as &#8220;Elicio&#8221; throughout these consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Reverse Merger Transaction</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On January 17, 2023, the Company entered into a definitive merger agreement (the &#8220;Merger Agreement&#8221;) with Angion Biomedica Corp. (&#8220;Angion&#8221;), a clinical-stage biotechnology company, Arkham Merger Sub, Inc., a wholly owned subsidiary of Angion (&#8220;Merger Sub&#8221;), and Elicio Operating Company, Inc. (&#8220;Former Elicio&#8221;), pursuant to which Merger Sub merged with and into Former Elicio, with Former Elicio surviving the merger as a wholly owned subsidiary of Angion (the &#8220;Merger&#8221;). Following the Merger, Former Elicio and Elicio Australia Pty Ltd. (&#8220;Elicio Pty&#8221;), an Australian subsidiary established in August 2019 for the purpose of qualifying for research credits for studies conducted in Australia, became wholly owned subsidiaries of Elicio.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 1, 2023, the Company completed the Merger in accordance with the terms and conditions of the Merger Agreement and Angion changed its name from &#8220;Angion Biomedica Corp.&#8221; to &#8220;Elicio Therapeutics, Inc.&#8221; Immediately following the consummation of the Merger, there were approximately <ix:nonFraction unitRef="shares" contextRef="c-50" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="f-381">9.7</ix:nonFraction>&#160;million shares of the Company&#8217;s common stock outstanding on a fully-diluted basis, with Former Elicio equity holders collectively owning approximately <ix:nonFraction unitRef="number" contextRef="c-51" decimals="3" name="angn:ReverseRecapitalizationOwnershipPercentage" scale="-2" id="f-382">65.2</ix:nonFraction>% of the Company and Angion equity holders collectively owning approximately <ix:nonFraction unitRef="number" contextRef="c-52" decimals="3" name="angn:ReverseRecapitalizationOwnershipPercentage" scale="-2" id="f-383">34.8</ix:nonFraction>% of the Company, in each case on a fully diluted basis.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Merger was accounted for as a reverse recapitalization, with Former Elicio being treated as the acquirer for accounting purposes. See discussions of the transactions in connection with the Merger at Note 3 - Merger and Related Transactions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Liquidity and Going Concern</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has experienced net losses and negative cash flows from operating activities since inception. As of December&#160;31, 2024, the Company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-384">194.1</ix:nonFraction>&#160;million. The Company expects that its operating losses and negative operating cash flows will continue for the foreseeable future as the Company continues to develop its product candidates. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December&#160;31, 2024, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-385">17.6</ix:nonFraction>&#160;million in cash and cash equivalents. The Company&#8217;s losses from operations, negative operating cash flows and accumulated deficit, as well as the additional capital needed to fund operations for at least twelve months following the issuance of the consolidated financial statements, raise substantial doubt about the Company&#8217;s ability to continue as a going concern. The Company expects to incur substantial expenditures in the foreseeable future for the development of its product candidates and will require additional financing to continue this development. The Company plans to address this condition through the sale of Company common stock or other securities in public offerings and/or private placements, debt financings, or through other capital sources, including licensing arrangements, partnerships and collaborations with other companies or other strategic transactions, but there is no assurance these plans will be completed successfully or at all.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If the Company is unable to obtain additional capital when and as needed to continue as a going concern, it might have to further reduce or scale back its operations and/or liquidate its assets, and the values it receives for its assets in liquidation or dissolution could be significantly lower than the values reflected in its financial statements. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The accompanying consolidated financial statements have been prepared on a basis that assumes that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></div></ix:continuation><div id="i488c1714f53641d3b5e4dbb098e37e6c_100"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Note 2&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-386" continuedAt="f-386-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-387" continuedAt="f-387-1" escape="true"><ix:continuation id="f-386-1" continuedAt="f-386-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company's consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable </span></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELICIO THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-386-2" continuedAt="f-386-3"><ix:continuation id="f-387-1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">guidance is meant to refer to the authoritative accounting principles generally accepted in the United States as found in the Accounting Standard Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-388" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Elicio Pty, ESC, and Former Elicio. All significant intercompany balances and transactions have been eliminated in consolidation.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Since Former Elicio was determined to be the accounting acquirer in connection with the Merger, for periods prior to the Merger, the consolidated financial statements were prepared on a stand-alone basis for Former Elicio and did not include the combined entities activity or financial position. Subsequent to the Merger, the consolidated financial statements include the acquired business and assets and liabilities at their acquisition date fair value. Historical share and per share figures of Former Elicio have been retroactively restated to reflect the impact of the reverse stock split of Angion&#8217;s common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-53" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-389">0.01</ix:nonFraction> per share (&#8220;Angion common stock&#8221;), at a ratio of 10:1 (the &#8220;Reverse Stock Split&#8221;) completed in connection with and prior to the closing of the Merger, based on the exchange ratio of <ix:nonFraction unitRef="number" contextRef="c-54" decimals="INF" name="angn:RecapitalizationExchangeRatio" scale="0" id="f-390">0.0181</ix:nonFraction> (the &#8220;Exchange Ratio&#8221;).</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="f-391" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Financial Statement Reclassification</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Certain account balances from prior periods have been reclassified in these consolidated financial statements to conform to current period classifications. The warrant liability was reclassified from current to noncurrent liabilities. These reclassifications had no effect on the reported results of operations or financial position.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-392" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Segments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the Chief Operating Decision Maker (&#8220;CODM&#8221;), or decision-making group, in deciding how to allocate resources and in assessing performance. The Chief Executive Officer serves as the CODM. The Company operates as a single operating and reportable segment, reflecting the integrated nature of the Company&#8217;s business.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-393" continuedAt="f-393-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Use of Estimates</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="f-393-1">The Company&#8217;s management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could materially differ from those estimates. Significant estimates reflected in these consolidated financial statements include but are not limited to, the accrual of research and development expenses, the valuation of stock-based awards, the valuation of warrants, the valuation of embedded derivatives and convertible debt, the operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liability, and forecasts utilized in management&#8217;s going concern assessment.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="f-394" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Foreign Currency Translation and Transactions</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Australian Dollar (&#8220;AUD&#8221;) is the functional currency for Elicio Pty. Accordingly, nonmonetary assets and liabilities originally acquired or assumed in other currencies are recorded in AUD at the date they were acquired or assumed. As part of the consolidation process, the Elicio Pty results are translated from AUD into the reporting currency of US Dollars using average rates for profit and loss transactions and applicable spot rates for period-end balances. The effect of translating our functional currency into our reporting currency is reported separately in Accumulated Other Comprehensive Loss.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-395" continuedAt="f-395-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Concentrations of Credit Risk and Off-Balance Sheet Risk</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="f-395-1">Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash, cash equivalents, and restricted cash. At times, cash balances deposited at major financial banking institutions exceed the federally insured limit. The Company regularly monitors the financial condition of the institutions in which it has depository accounts and believes the risk of loss is minimal. The Company has not experienced any losses in such accounts.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="f-396" continuedAt="f-396-1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Cash and Cash Equivalents</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash and cash equivalents are comprised of deposits at major financial banking institutions and highly liquid investments with an original maturity of three months or less at the date of purchase. As of December&#160;31, 2024 and 2023, the Company&#8217;s cash equivalents were held in institutions in the United States and include deposits in a money market fund which were unrestricted as to withdrawal or use.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Restricted Cash</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELICIO THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-386-3" continuedAt="f-386-4"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="f-396-1">Restricted cash consists of cash securing a collateral letter of credit issued in connection with the Company&#8217;s research grant and facility operating lease.</ix:continuation> See Notes 6 and 11 for further discussion. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-397" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Fair Value Measurement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company follows the guidance prescribed by ASC Topic 820, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Fair Value Measurements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, which establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The standard provides a consistent definition of fair value that focuses on an exit price which is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The standard establishes a three-level hierarchy for fair value measurements based on the nature of inputs used in the valuation of an asset or liability as of the measurement date.</span></div><div style="margin-top:6pt;padding-left:76.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Level 1:&#160;&#160;&#160;&#160;Observable inputs such as unadjusted quoted prices in active markets for identical assets or liabilities at measurement. </span></div><div style="margin-top:6pt;padding-left:76.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Level 2:&#160;&#160;&#160;&#160;Inputs (other than quoted prices included in Level 1) that are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. </span></div><div style="margin-top:6pt;padding-left:76.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Level 3:&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The carrying amounts of financial instruments reflected in the consolidated balance sheets for cash and cash equivalents, current and non-current restricted cash, accounts payable, and accrued expenses approximate their respective fair values because of the short-term maturity of those financial assets and liabilities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-398" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Property and Equipment</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of the asset. Upon sale or retirement, the cost and accumulated depreciation are eliminated from their respective accounts, and the resulting gain or loss is recorded in the consolidated statement of operations and comprehensive loss. Repair and maintenance expenditures are expensed as incurred. Construction in process is not depreciated until the asset is placed into service.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-399" continuedAt="f-399-1" escape="true"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:67.668%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Estimated Useful Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-55" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-400">5</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furniture and fixtures</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-56" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-401">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Leasehold improvements</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Shorter of useful life or lease term</span></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="f-402" continuedAt="f-402-1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Impairment of Long-Lived Assets</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="f-402-1">The Company evaluates its long-lived assets, which consist primarily of property and equipment, and right-of-use asset, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset.</ix:continuation> During the years ended December&#160;31, 2024 and 2023, <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt-sec:numwordsen" scale="0" id="f-403"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt-sec:numwordsen" scale="0" id="f-404">no</ix:nonFraction></ix:nonFraction> impairments have occurred.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtPolicyTextBlock" id="f-405" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Debt Issuance Costs</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These deferred costs will be amortized and recognized as additional interest expense over the term of the Company&#8217;s convertible note using the effective interest method. The Company will present debt issuance costs as a direct deduction from the convertible note liability on its financial statements. See Note 12 for further discussion of the Company&#8217;s accounting for its outstanding debt and related issuance costs.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-406" continuedAt="f-406-1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Income Taxes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company accounts for income taxes in accordance with ASC Topic 740, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Income Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELICIO THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-386-4" continuedAt="f-386-5"><ix:continuation id="f-406-1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and liabilities using enacted tax rates and laws in effect in the years in which the differences are expected to reverse. A valuation allowance is provided if, based upon the weighted available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is required to recognize the financial statement effects of a tax position when it is more likely than not, based on the technical merits, the position will be sustained upon examination. As of December&#160;31, 2024, there were no accruals for interest or penalties related to uncertain tax provisions.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-407" continuedAt="f-407-1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Research and Development</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Research and development costs are charged to expense as incurred and consist of expenses incurred in performing research and development activities, including salaries and benefits, materials and supplies, preclinical expenses, stock-based compensation expense, depreciation of equipment, contract services, and other outside expenses. The Company accrues for costs incurred by external service providers, based on estimates of services performed and costs. The Company expenses all research and development costs in the periods in which they are incurred. Costs for certain research and development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and service providers. Based on the timing of payments to service providers, the Company may also record prepaid expenses for those service providers that will be recognized as expenses in future periods as the related services are rendered. Research and development costs may be offset by research grants and research and development refundable tax rebates received by Elicio Pty.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-408" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Leases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ASC Topic 842, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Leases,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (&#8220;ASC 842&#8221;) requires a lessee to recognize a ROU asset and corresponding lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the consolidated statements of operations and comprehensive loss as well as the reduction of the ROU asset. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances, the existence of an identified asset(s), if any, and the Company&#8217;s control over the use of the identified asset(s), if applicable. Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of future lease payments over the expected lease term. When the interest rate implicit in lease contracts is not readily determinable, the Company will utilize its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has elected to combine lease and non-lease components as a single component. Operating leases are recognized on the consolidated balance sheet as ROU lease assets, current lease liabilities and non-current lease liabilities. Fixed rents are included in the calculation of the lease balances, while variable costs paid for certain operating and pass-through costs are excluded. Lease expense is recognized over the expected term on a straight-line basis.</span></div></ix:nonNumeric><ix:continuation id="f-407-1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Research Grant </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company analogizes to the guidance provided by International Accounting Standards 20, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Accounting for Government Grants and Disclosure of Government Assistance </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(&#8220;IAS 20&#8221;) for funds received from grants from entities that are not customers nor government agencies. The Company recognizes the amount of grant income based on the activity in allowable expenses covered under the grant and has elected to recognize the funds earned as an offset to the related research expenses recorded in operations. Advances from the grant that have yet to be recognized are recorded as restricted cash if the grant requires the funds to be isolated from general cash and cash equivalents. The Company records a liability for any research activity that is required under the grant but has not yet been performed. The liability is recorded as a deferred research obligation on the consolidated balance sheets.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-409" continuedAt="f-409-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Stock-Based Compensation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company issues stock-based awards to employees and non-employees, generally in the form of stock options. The Company accounts for stock-based awards in accordance with ASC 718,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> Compensation&#8212;Stock Compensation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, which requires all stock-based payments to be recognized in the consolidated statements of operations and comprehensive loss based on their fair values. The expense is recognized on a straight-line basis over the requisite service period, which is generally the vesting period. The Company has elected to account for option forfeitures as they occur. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company uses the Black-Scholes option-pricing model (&#8220;Black-Scholes&#8221;) to determine the fair value of options granted, which uses as inputs the fair value of the Company common stock, assumptions the Company </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELICIO THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-386-5" continuedAt="f-386-6"><ix:continuation id="f-409-1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">makes for the volatility of its Company common stock, the expected term of its stock options, the risk-free interest rate for a period that approximates the expected term of its stock options and its expected dividend yield. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Compensation cost of awards that contain a performance condition are recognized when success is considered probable during the performance period. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Prior to the Merger, there was no public market for Former Elicio&#8217;s common stock. The estimated fair value of the Company&#8217;s common stock underlying Former Elicio&#8217;s stock-based awards was determined by Former Elicio&#8217;s board of directors as of the grant date of each option grant. To determine the fair value of Former Elicio&#8217;s common stock underlying option grants, Former Elicio&#8217;s board of directors considered, among other things, input from management and valuations of Former Elicio's common stock prepared by third-party valuation firms performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants' Accounting and Valuation Guide, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Valuation of Privately-Held-Company Equity Securities Issued as Compensation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Following the Merger, the fair value of the Company&#8217;s common stock is based on the closing stock price on the date of grant as reported on the Nasdaq Capital Market.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="angn:WarrantsAndDerivativesPolicyTextBlock" id="f-410" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Warrants and Derivatives</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s common stock warrants are evaluated pursuant to ASC 480, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (&#8220;ASC 480&#8221;), and ASC 815, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (&#8220;ASC 815&#8221;). The Company classifies its freestanding warrants as (i) liabilities, if the warrant terms allow settlement of the warrant exercise in cash, or (ii) equity, if the warrant terms only allow settlement in shares of common stock. Please refer to Note 9 below for the application to the Company&#8217;s pre-funded and common warrants.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-411" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Net Loss Per Share</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Basic net loss per share of Company common stock is computed by dividing net loss attributable to Company common stockholders by the weighted average number of shares of Company common stock and pre-funded warrants outstanding for the period. Pre-funded warrants are considered outstanding for the purposes of computing basic and diluted net loss per share because shares may be issued for little or no additional consideration and are fully vested and exercisable after the original issuance date of the pre-funded warrants. Diluted net loss per share excludes the potential impact of Company common stock options, warrants and unvested shares of restricted stock because their effect would be anti-dilutive due to the Company's net loss. Since the Company had net losses for the years ended December&#160;31, 2024 and 2023, basic and diluted net loss per common share are the same.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="f-412" continuedAt="f-412-1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Other Comprehensive Gain (Loss)</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="f-412-1">Other comprehensive gain (loss) is defined as a change in equity during a period from foreign exchange transactions and other events and circumstances from non-owner sources.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-413" continuedAt="f-413-1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Recently Adopted Accounting Standards During the Period</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2023, the FASB finalized ASU No. 2023-07, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (&#8220;ASU 2023-07&#8221;). ASU 2023-07 requires enhanced disclosures about reportable segments and the CODM. The new guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company adopted ASU 2023-07 on January 1, 2024. There was no impact on the Company's reportable segments identified and additional required disclosures have been included in Note 17.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Recently Issued Accounting Standards Not Yet Adopted</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Except as noted below, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its consolidated financial statements and disclosures. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This ASU requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as additional information on income taxes paid. The standard requires entities to disclose federal, state, and foreign income taxes in their rate reconciliation tables and elaborate on reconciling items that exceed a quantitative threshold. Additionally, it requires an annual disclosure of income taxes paid, net of refunds, categorized by jurisdiction based on a quantitative threshold. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is permitted. This ASU will result in the required additional disclosures being included in the Company&#8217;s consolidated financial statements, once adopted. </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELICIO THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-413-1"><ix:continuation id="f-386-6"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2024, the FASB issued ASU No. 2024-03, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This ASU requires enhanced disclosures of disaggregated income statement expenses. Disclosure within the notes of the financial statements for each annual and interim period should include: employee compensation, depreciation, and intangible asset amortization, included in each relevant expense caption; certain amount that are already required to be disclosed under current GAAP in the same disclosure as the other disaggregation requirement; a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively; and the total amount of selling expenses and, in annual reporting periods, an entity&#8217;s definition of selling expenses. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning December 15, 2027. Early adoption is permitted. The Company is currently evaluating the effect that adoption of ASU 2024-03 will have on its consolidated financial statements. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2024, the FASB issued ASU No. 2024-04, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. This new guidance clarifies the accounting treatment of whether the settlement of convertible debt should be accounted for as an induced conversion or extinguishment of convertible debt. This guidance is effective for annual reporting periods beginning after December 15, 2025. The Company is evaluating the potential impact of this adoption on the consolidated financial statements and related disclosures.</span></div></ix:continuation></ix:continuation><div id="i488c1714f53641d3b5e4dbb098e37e6c_103"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Note 3&#8212;<ix:nonNumeric contextRef="c-1" name="angn:ReverseRecapitalizationDisclosureTextBlock" id="f-415" continuedAt="f-415-1" escape="true">Merger and Related Transactions</ix:nonNumeric></span></div><ix:continuation id="f-415-1" continuedAt="f-415-2"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As described in Note 1, Former Elicio merged with a wholly owned subsidiary of Angion on June 1, 2023. The Merger was accounted for as a reverse recapitalization under U.S. GAAP. Former Elicio was considered the accounting acquirer for financial reporting purposes. This determination was based on the facts that, immediately following the Merger: (i) Former Elicio stockholders owned a substantial majority of the voting rights; (ii) Former Elicio designated a majority (<ix:nonFraction unitRef="board_member" contextRef="c-58" decimals="INF" name="angn:NumberOfMembersOfTheBoardOfDirectors" format="ixt-sec:numwordsen" scale="0" id="f-416">six</ix:nonFraction> of <ix:nonFraction unitRef="board_member" contextRef="c-54" decimals="INF" name="angn:NumberOfMembersOfTheBoardOfDirectors" format="ixt-sec:numwordsen" scale="0" id="f-417">nine</ix:nonFraction>) of the initial members of the board of directors of the combined company; (iii) Former Elicio&#8217;s executive management team became the management team of the combined company; and (iv) the Company was named Elicio Therapeutics, Inc. and is headquartered in Boston, Massachusetts. Accordingly, for accounting purposes, the Merger was treated as the equivalent of Former Elicio issuing stock to acquire the net assets of Angion. As a result of the Merger, the net assets of Angion were recorded at their acquisition-date fair value, which approximated book value due to the short-term nature of the instruments, in the financial statements of Former Elicio and the reported operating results prior to the Merger are those of Former Elicio. Historical common share amounts of Former Elicio have been retroactively restated based on the Exchange Ratio. It was concluded that any in-process research and development assets that remained as of the Merger would be </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">de minimis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> when compared to the cash and investments obtained through the Merger.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Prior to the effective time of the Merger, on June 1, 2023, in connection with the transactions contemplated by the Merger Agreement, the Company effected the Reverse Stock Split. At the effective time of the Merger, each outstanding share of Former Elicio capital stock (after giving effect to the automatic conversion of all shares of Former Elicio preferred stock into shares of Former Elicio common stock and excluding any shares held as treasury stock by Former Elicio or held or owned by Angion or any subsidiary of Angion or Former Elicio and any dissenting shares) was converted into the right to receive <ix:nonFraction unitRef="number" contextRef="c-54" decimals="INF" name="angn:RecapitalizationExchangeRatio" scale="0" id="f-418">0.0181</ix:nonFraction> shares of Angion common stock, which resulted in the issuance by Angion of an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-59" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-419">5,375,751</ix:nonFraction> shares of Angion common stock to the stockholders of Former Elicio (the &#8220;Exchange Shares&#8221;), and a total of <ix:nonFraction unitRef="shares" contextRef="c-54" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-420"><ix:nonFraction unitRef="shares" contextRef="c-54" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-421">8,387,025</ix:nonFraction></ix:nonFraction> shares of the Company common stock being issued and outstanding immediately following the effective time of the Merger. In addition, Angion assumed the Former Elicio 2022 Equity Incentive Plan and the Former Elicio 2012 Equity Incentive Plan (the &#8220;Former Elicio Plans&#8221;) and each outstanding and unexercised option to purchase Former Elicio common stock and each outstanding and unexercised warrant to purchase Former Elicio capital stock were adjusted with such stock options and warrants henceforth representing the right to purchase a number of shares of the Company&#8217;s common stock equal to the Exchange Ratio multiplied by the number of shares of Former Elicio common stock previously represented by such options, and warrants at an exercise price equal to the exercise price of Former Elicio capital stock divided by the Exchange Ratio.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the execution of the Merger Agreement, Angion made a bridge loan to Former Elicio pursuant to a note purchase agreement and promissory notes up to an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-422">12.5</ix:nonFraction>&#160;million, issued with a <ix:nonFraction unitRef="number" contextRef="c-60" decimals="INF" name="angn:DebtInstrumentIssuanceDiscountPercent" scale="-2" id="f-423">20</ix:nonFraction>% original issue discount, with an initial closing held substantially concurrently with the execution of the Merger Agreement for a principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-4" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-424">6.25</ix:nonFraction>&#160;million in exchange for cash of $<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-425">5.0</ix:nonFraction>&#160;million and an additional closing for a principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-4" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-426">6.25</ix:nonFraction>&#160;million in exchange for cash of $<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-427">5.0</ix:nonFraction>&#160;million upon delivery by Former Elicio to Angion of Former Elicio&#8217;s audited financial statements for the year ended December 31, 2022 (the &#8220;Bridge Loan&#8221;).</span></div><ix:nonNumeric contextRef="c-1" name="angn:ScheduleOfReverseRecapitalizationTableTextBlock" id="f-428" continuedAt="f-428-1" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of the recapitalization, the Company obtained the assets and liabilities listed below (in thousands):</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELICIO THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-415-2" continuedAt="f-415-3"><ix:continuation id="f-428-1"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.315%"><tr><td style="width:1.0%"/><td style="width:22.463%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.708%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.529%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="angn:CashAndCashEquivalentsAcquiredThroughReverseRecapitalization" format="ixt:num-dot-decimal" scale="3" id="f-429">24,001</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="angn:OtherCurrentAssetsAcquiredThroughReverseRecapitalization" scale="3" id="f-430">540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Promissory notes</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="angn:PromissoryNotesAcquiredThroughReverseRecapitalization" format="ixt:num-dot-decimal" scale="3" id="f-431">10,027</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="angn:AccruedLiabilitiesAssumedThroughReverseRecapitalization" format="ixt:num-dot-decimal" scale="3" id="f-432">2,438</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="angn:NetAssetsAcquiredThroughReverseRecapitalization" format="ixt:num-dot-decimal" scale="3" id="f-433">32,130</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Per the terms of the Merger Agreement, upon completion of the Merger, all obligations owed by Former Elicio related to the Bridge Loan were automatically forgiven and the amount advanced by Angion, along with any accrued and unpaid interest, was credited towards the net cash balance used to calculate the assets and liabilities listed above. Upon settlement of the Bridge Loan, the Company recognized a gain of $<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-434">0.6</ix:nonFraction>&#160;million related to the fair value of the embedded derivatives associated with the Bridge Loan. </span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="f-415-3">The Company recognized the net assets acquired, excluding the promissory notes and transaction costs of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="angn:ReverseRecapitalizationTransactionCosts" scale="6" id="f-435">2.9</ix:nonFraction> million,</ix:continuation> as an increase to additional paid-in capital in the consolidated statements of convertible preferred stock and stockholders&#8217; equity (deficit) for the year ended December 31, 2023.</span></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_109"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-437" continuedAt="f-437-1" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-438" escape="true"><ix:continuation id="f-437-1" continuedAt="f-437-2"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following tables present the Company's financial assets and liabilities measured at fair value on a recurring basis and their assigned levels within the fair value hierarchy (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Level 3</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Money market funds </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-439">12,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-440">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-441">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-442">12,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total assets</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-443">12,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-444">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-445">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-446">12,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Warrant liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="angn:WarrantsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-447">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="angn:WarrantsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-448">2,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="angn:WarrantsFairValueDisclosure" scale="3" id="f-449">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="angn:WarrantsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-450">2,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-451">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-452">2,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="f-453">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-454">2,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Level 3</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Money market funds </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-455">5,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-456">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-457">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-458">5,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total assets</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-459">5,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-460">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-461">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-462">5,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Warrant liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="angn:WarrantsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-463">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="angn:WarrantsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-464">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="angn:WarrantsFairValueDisclosure" scale="3" id="f-465">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="angn:WarrantsFairValueDisclosure" scale="3" id="f-466">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-467">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-468">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="f-469">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="f-470">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">___________________</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Included in cash, cash equivalents, and restricted cash on the consolidated balance sheets. This balance includes cash requirements settled on a nightly basis.</span></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELICIO THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-437-2" continuedAt="f-437-3"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash equivalents at December&#160;31, 2024 and 2023 were held in U.S. Treasury securities.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There were no transfers made among the three levels in the fair value hierarchy during the periods presented.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of the Merger transaction, Former Elicio assumed Angion&#8217;s warrant liabilities. The fair value of the assumed Angion warrants was classified as Level 3 with key Level 3 inputs of exercise price, term, and volatility. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="f-471" continuedAt="f-471-1" escape="true">The following table presents a summary of changes in Level 3 in the fair value of the Company&#8217;s common stock warrant liability (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-471-1"><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Balance, beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="f-472">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="3" id="f-473">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Existing Angion warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" format="ixt:fixed-zero" scale="3" id="f-474">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" scale="3" id="f-475">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="f-476">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="f-477">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Balance, end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="f-478">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="f-479">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with assets and liabilities within the Level 3 category include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long-dated volatilities) inputs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair value of the Angion warrants assumed by the Company has been estimated using a Black-Scholes option pricing model. The underlying equity included in Black-Scholes was valued based on the equity value implied from sales of preferred and common stock at each measurement date, as applicable. The fair value of the warrants was impacted by the model selected as well as assumptions surrounding unobservable inputs including the underlying equity value, expected volatility of the underlying equity, risk free interest rate, and the expected term.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2024, the Company entered into a subscription agreement (the &#8220;March Subscription Agreement&#8221;) with GKCC, LLC (&#8220;GKCC&#8221;), an entity controlled by a member of the Company&#8217;s board of directors, providing for the issuance and sale by the Company to GKCC of pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;) to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-78" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-480">1,032,702</ix:nonFraction> shares of the Company&#8217;s common stock, at a purchase price per Pre-Funded Warrant of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-78" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-481">5.81</ix:nonFraction> (the &#8220;March Offering&#8221;). The Company identified these warrants as liabilities and measured them at fair value on March 19, 2024, and subsequently remeasures the fair value of these warrant liabilities on a quarterly basis. The Company is able to calculate the fair value measurement based on directly observable inputs for the asset from active markets, therefore these warrants are classified as Level 2. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2024, the Company closed an underwritten public offering (the &#8220;Public Offering&#8221;), which resulted in net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-482">10.9</ix:nonFraction>&#160;million to the Company, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The Public Offering consisted of (i) <ix:nonFraction unitRef="shares" contextRef="c-79" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-483">500,000</ix:nonFraction> shares of the Company&#8217;s common stock (the &#8220;July Shares&#8221;) and (ii) <ix:nonFraction unitRef="shares" contextRef="c-80" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-484">1,800,000</ix:nonFraction> pre-funded warrants exercisable for shares of common stock (the &#8220;July Pre-Funded Warrants&#8221;), together with common warrants (the &#8220;July Common Warrants&#8221;) to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-81" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-485">2,300,000</ix:nonFraction> shares of common stock. Each July Share and accompanying July Common Warrant were sold together at a combined offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-82" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="f-486">5.00</ix:nonFraction> per July Share and accompanying July Common Warrant, and each July Pre-Funded Warrant and accompanying July Common Warrant were sold together at a combined offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-81" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="f-487">4.99</ix:nonFraction> per July Pre-Funded Warrant and accompanying July Common Warrant, which represented the combined purchase price per July Pre-Funded Warrant and accompanying July Common Warrant less the $<ix:nonFraction unitRef="usdPerShare" contextRef="c-80" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-488">0.01</ix:nonFraction> per share exercise price for each such July Pre-Funded Warrant. The July Common Warrants have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-83" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-489">5.00</ix:nonFraction> per share, are immediately exercisable and will expire <ix:nonNumeric contextRef="c-83" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="f-490">five years</ix:nonNumeric> from the issuance date. The Company identified these warrants as liabilities and measured them at fair value on July 1, 2024, and subsequently remeasures the fair value of these warrant liabilities on a quarterly basis. The Company is able to calculate the fair value measurement based on directly observable inputs for the asset from active markets, therefore these warrants are classified as Level 2.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At the Company&#8217;s Annual Shareholder&#8217;s Meeting in November 2024, the Company obtained stockholder approval for a shareholder, together with its affiliates, to exceed the <ix:nonFraction unitRef="number" contextRef="c-4" decimals="4" name="angn:SaleOfStockBeneficialOwnershipLimitationPercentage" scale="-2" id="f-491">19.99</ix:nonFraction>% beneficial ownership limitation pursuant to the rules and regulations of the Nasdaq Stock Market LLC (&#8220;Stockholder Approval&#8221;). As such, the Company remeasured the July Common Warrants held by that shareholder at fair value and recognized the loss from change in fair value on the consolidated financial statements during the year ended December 31, 2024. As a result of obtaining Stockholder Approval, the Common Warrants held by that shareholder met the equity classification requirements under ASC 815. During the quarter ended December 31, 2024, the Company reclassified the July Common Warrants held by the stockholder from a liability to equity. The Company will re-assess the liability classification for the remaining July Common Warrants at each period end.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELICIO THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-437-3"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company records the change in the fair value of common stock warrants in change in fair value of warrant liability in the consolidated statements of operations and comprehensive loss.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="f-492" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair value of the assumed Angion common stock warrant liability was estimated using the following assumptions:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.274%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted average strike price</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-84" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="f-493">76.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-85" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="f-494">76.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contractual term (years)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-86" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="f-495">3.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-87" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="f-496">4.7</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Volatility (annual)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-88" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-497">74.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-89" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-498">94.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free rate</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-90" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-499">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-91" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-500">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dividend yield (per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-92" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-501">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-93" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-502">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:3pt"><span><br/></span></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_112"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Note 5&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="f-503" continuedAt="f-503-1" escape="true">Balance Sheet Components</ix:nonNumeric></span></div><ix:continuation id="f-503-1" continuedAt="f-503-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Prepaid and Other Current Assets</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> <ix:nonNumeric contextRef="c-1" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="f-504" continuedAt="f-504-1" escape="true">Prepaid and other current assets consisted of the following (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-504-1"><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid research and development contract services</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="angn:PrepaidResearchAndDevelopmentExpenses" format="ixt:num-dot-decimal" scale="3" id="f-505">1,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="angn:PrepaidResearchAndDevelopmentExpenses" format="ixt:num-dot-decimal" scale="3" id="f-506">1,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Advanced professional fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="angn:AdvancedProfessionalFees" scale="3" id="f-507">243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="angn:AdvancedProfessionalFees" scale="3" id="f-508">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid insurance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidInsurance" scale="3" id="f-509">347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidInsurance" scale="3" id="f-510">376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="angn:OtherPrepaidExpensesAndOtherAssetsCurrent" scale="3" id="f-511">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="angn:OtherPrepaidExpensesAndOtherAssetsCurrent" scale="3" id="f-512">173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total prepaid and other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-513">1,897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-514">2,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><ix:continuation id="f-399-1"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net was comprised of the following (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-515">1,661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-516">1,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furniture and fixtures</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-517">242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-518">242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Leasehold improvements</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-519">132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-520">132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total property and equipment</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-521">2,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-522">1,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Less: accumulated depreciation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-523">1,552</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-524">1,231</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-525">483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-526">717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Depreciation expense for the years ended December&#160;31, 2024 and 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-527">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-528">0.4</ix:nonFraction> million, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELICIO THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-503-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Other long-term prepaid assets</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other long-term prepaid assets consisted of the advance payments for clinical trial services, totaling $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:PrepaidExpenseOtherNoncurrent" scale="6" id="f-529">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:PrepaidExpenseOtherNoncurrent" scale="6" id="f-530">2.8</ix:nonFraction> million as of December&#160;31, 2024 and December&#160;31, 2023, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Accrued Expenses</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-531" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Accrued expenses consisted of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued professional fees</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-532">1,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="f-533">945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-534">2,312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-535">1,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued research and development</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="angn:AccruedResearchAndDevelopmentCurrent" format="ixt:num-dot-decimal" scale="3" id="f-536">4,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="angn:AccruedResearchAndDevelopmentCurrent" scale="3" id="f-537">912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other accrued expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="angn:AccruedOtherOperatingLiabilitiesCurrent" scale="3" id="f-538">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="angn:AccruedOtherOperatingLiabilitiesCurrent" scale="3" id="f-539">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-540">8,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-541">3,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="i488c1714f53641d3b5e4dbb098e37e6c_115"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" id="f-542" continuedAt="f-542-1" escape="true">Research Grant</ix:nonNumeric></span></div><ix:continuation id="f-542-1" continuedAt="f-542-2"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2022, Former Elicio entered into a grant agreement with the Gastro-Intestinal (&#8220;GI&#8221;) Research Foundation, a not-for-profit organization focused on supporting research to treat, cure, and prevent digestive diseases. Of the $<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="angn:ResearchAndDevelopmentArrangementGrant" scale="6" id="f-543">2.8</ix:nonFraction> million award, $<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="angn:ResearchAndDevelopmentArrangementGrantReceived" format="ixt:num-dot-decimal" scale="6" id="f-544">2.3</ix:nonFraction>&#160;million was received in September 2022 and the remaining $<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="angn:ResearchAndDevelopmentArrangementGrantReceived" format="ixt:num-dot-decimal" scale="6" id="f-545">0.5</ix:nonFraction>&#160;million was received in June 2023 with the completion of the development efforts as defined in the grant agreement. The final $<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="angn:ResearchAndDevelopmentArrangementGrantReceived" format="ixt:num-dot-decimal" scale="6" id="f-546">0.5</ix:nonFraction>&#160;million payment was applied as a credit to the second grant agreement described below. For the years ended December&#160;31, 2024 and 2023, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="f-547">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-548">1.9</ix:nonFraction> million, respectively, in research and development expenses related to this project. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2023, the Company entered into a second grant agreement with the GI Research Foundation for $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="angn:ResearchAndDevelopmentArrangementGrant" scale="6" id="f-549">3.1</ix:nonFraction> million, with such amount received net of the $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="angn:ResearchAndDevelopmentArrangementCredit" format="ixt:num-dot-decimal" scale="6" id="f-550">0.5</ix:nonFraction>&#160;million credit, described above. As of the years ended December&#160;31, 2024 and 2023, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-551">2.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-552">1.9</ix:nonFraction> million, respectively, in research and development expenses related to this project. As of December&#160;31, 2024, the grant funds available for the second grant agreement were $<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="0" name="angn:ResearchAndDevelopmentArrangementGrantReceived" scale="0" id="f-553">0</ix:nonFraction> and the deferred research obligation was $<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="0" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" id="f-554">0</ix:nonFraction>, as the grant agreement was completed in the third quarter of 2024.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2024, the Company entered into a third grant agreement with the GI Research Foundation for $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="angn:ResearchAndDevelopmentArrangementGrant" scale="6" id="f-555">1.5</ix:nonFraction> million. The grant funds available as of December&#160;31, 2024 were $<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="f-556">1.2</ix:nonFraction> million, which are reflected in restricted cash in the accompanying consolidated balance sheets. The deferred research obligation as of December&#160;31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> was </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="f-557">1.2</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, which was reflected in the deferred research obligation in the accompanying consolidated balance sheets. For the year ended </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December&#160;31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, the Company incurred </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-558">0.3</ix:nonFraction> million in research and development expenses related to this project, of which</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-5" name="angn:ResearchAndDevelopmentArrangementReimbursementFromGrantFunds" scale="6" id="f-559">0.3</ix:nonFraction> million was applied against the grant funds received. </span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="f-542-2">The award money for the <ix:nonFraction unitRef="agreement" contextRef="c-4" decimals="INF" name="angn:NumberOfResearchGrantAgreements" format="ixt-sec:numwordsen" scale="0" id="f-560">three</ix:nonFraction> agreements was earned and recognized as a contra research and development expense as the expenses were incurred.</ix:continuation>  </span></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_118"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-561" continuedAt="f-561-1" escape="true">Convertible Preferred Stock, Common Stock and Stockholders' Equity</ix:nonNumeric></span></div><ix:continuation id="f-561-1" continuedAt="f-561-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Authorized Shares</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company's current Amended and Restated Certificate of Incorporation, as amended, authorizes <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-562">300,000,000</ix:nonFraction> shares of common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-563">0.01</ix:nonFraction> per share, and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-564">10,000,000</ix:nonFraction> shares of preferred stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-565">0.01</ix:nonFraction> per share.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Convertible Preferred Stock of Former Elicio</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Former Elicio&#8217;s convertible preferred stock consisted of Series A preferred stock (&#8220;Series A Preferred Shares&#8221;), Series B preferred stock (&#8220;Series B Preferred Shares&#8221;) and Series C preferred stock (&#8220;Series C Preferred Shares&#8221; and collectively with the Series A Preferred Shares and the Series B Preferred Shares, the &#8220;Convertible Preferred Stock&#8221;).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Conversion of Convertible Preferred Stock</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 1, 2023, Former Elicio completed the Merger with Angion in accordance with the Merger Agreement. Under the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each share of Former Elicio&#8217;s Convertible Preferred Stock was converted into a share of Former Elicio&#8217;s common stock. At the closing of the Merger, the Company issued an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-59" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-566">5,375,751</ix:nonFraction> shares of its common stock to Former Elicio </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELICIO THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-561-2" continuedAt="f-561-3"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">stockholders, based on the Exchange Ratio. <ix:nonFraction unitRef="shares" contextRef="c-109" decimals="INF" name="angn:TemporaryEquitySharesIssuedDuringPeriod" format="ixt:fixed-zero" scale="0" id="f-567"><ix:nonFraction unitRef="shares" contextRef="c-110" decimals="INF" name="angn:TemporaryEquitySharesIssuedDuringPeriod" format="ixt:fixed-zero" scale="0" id="f-568">No</ix:nonFraction></ix:nonFraction> shares of Convertible Preferred Stock were issued during the years ended December&#160;31, 2024 and 2023, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As a result of the Merger, the aggregate amount of <ix:nonFraction unitRef="shares" contextRef="c-111" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-569">276,128,177</ix:nonFraction> shares of Convertible Preferred Stock (retroactively restated for the reverse recapitalization as described in Note 3) were converted </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">int</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">o <ix:nonFraction unitRef="shares" contextRef="c-112" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-570">4,997,920</ix:nonFraction> </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">shares of Former Elicio's common stock to be exchanged for the same number of shares of the Company&#8217;s common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">At-The-Market Equity Programs</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2022, the Company filed a registration statement on Form S-3 (the &#8220;Prior Shelf Registration St</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">atement&#8221;) with the SEC that registered the offering, issuance, and sale of an amount of common stock, preferred stock, debt securities, and warrants to purchase common stock, preferred stock and/or debt securities, not to exceed an aggregate initial offering price of $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-6" name="angn:SaleOfStockAggregateInitialOfferingPrice" scale="6" id="f-571">100</ix:nonFraction> million. Simultaneously, the Company entered into an At-the-Market Equity Offering Sales Agreement with Stifel, Nicolaus &amp; Company, Incorporated and Virtu Americas LLC, as sales agents, pursuant to which the Company was able to offer, issue or sell shares of its common stock having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-6" name="angn:SaleOfStockAggregateInitialOfferingPrice" scale="6" id="f-572">21</ix:nonFraction> million from time to time in &#8220;at-the-market&#8221; offerings under the Prior Shelf Registration Statement and related prospectus filed with the Prior Shelf Registration Statement (the &#8220;2022 ATM Program"). During the year ended December&#160;31, 2024, the Company issued and sold a total of <ix:nonFraction unitRef="shares" contextRef="c-115" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-573">650,179</ix:nonFraction> shares of common stock under the 2022 ATM Program for aggregate net sale proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-574">5.4</ix:nonFraction> million after deducting sales commissions. <ix:nonFraction unitRef="shares" contextRef="c-116" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt-sec:numwordsen" scale="0" id="f-575">No</ix:nonFraction> sales were made under the 2022 ATM Program during the year ended December&#160;31, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2024, the 2022 ATM Program was terminated by the Company. In June 2024, the Company filed a registration statement on Form S-3 (the &#8220;2024 Registration Statement&#8221;) with the SEC that registered the offering, issuance, and sale of an amount of common stock, preferred stock, debt securities, warrants to purchase common stock, preferred stock and/or debt securities, and/or units consisting of any combination of such securities, not to exceed an aggregate initial offering price of $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-6" name="angn:SaleOfStockAggregateInitialOfferingPrice" format="ixt:num-dot-decimal" scale="6" id="f-576">200</ix:nonFraction>&#160;million. Simultaneously, the Company entered into the Capital on Demand</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Sales Agreement with JonesTrading Institutional Services, LLC, as agent, to provide for the issuance and sale of up to $<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-6" name="angn:SaleOfStockAggregateInitialOfferingPrice" format="ixt:num-dot-decimal" scale="6" id="f-577">40</ix:nonFraction>&#160;million of common stock from time to time in &#8220;at-the-market&#8221; offerings under the 2024 Registration Statement and related prospectus filed with the 2024 Registration Statement (the &#8220;2024 ATM Program&#8221;). During the year ended December&#160;31, 2024, the Company issued and sold <ix:nonFraction unitRef="shares" contextRef="c-119" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-578">53,795</ix:nonFraction> shares of common stock, for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-579">0.3</ix:nonFraction> million, under the 2024 ATM Program.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Private Placement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2024, the Company entered into the March Subscription Agreement with GKCC, an entity controlled by a member of the Company&#8217;s board of directors, for purposes of the March Offering. Each Pre-Funded Warrant issued and sold in the March Offering is exercisable at an exercise price equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-120" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-580">0.01</ix:nonFraction> per share, subject to certain adjustments and limitations as provided under the terms of the Pre-Funded Warrants. The Pre-Funded Warrants were classified as a liability at issuance due to the need for the Company to obtain stockholder approval to settle the instruments in shares in an amount exceeding the <ix:nonFraction unitRef="number" contextRef="c-78" decimals="4" name="angn:SaleOfStockBeneficialOwnershipLimitationPercentage" scale="-2" id="f-581">19.99</ix:nonFraction>% beneficial ownership limit. Such stockholder approval was obtained in November 2024. See Note 16 - Related Party Transactions for a discussion of the March Offering.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Public Offering</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2024, the Company closed its Public Offering, which resulted in net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-582">10.9</ix:nonFraction>&#160;million to the Company, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The Public Offering consisted of (i) the July Shares, together with the July Common Warrants, and (ii) the July Pre-Funded Warrants, together with the July Common Warrants. Each July Share and accompanying July Common Warrant were sold together at a combined offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-82" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="f-583">5.00</ix:nonFraction> per July Share and accompanying July Common Warrant, and each July Pre-Funded Warrant and accompanying July Common Warrant were sold together at a combined offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-81" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="f-584">4.99</ix:nonFraction> per July Pre-Funded Warrant and accompanying July Common Warrant, which represented the combined purchase price per July Pre-Funded Warrant and accompanying July Common Warrant less the $<ix:nonFraction unitRef="usdPerShare" contextRef="c-80" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-585">0.01</ix:nonFraction> per share exercise price for each such July Pre-Funded Warrant. </span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-561-3">The July Common Warrants have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-83" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-586">5.00</ix:nonFraction> per share, are immediately exercisable and will expire <ix:nonNumeric contextRef="c-83" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="f-587">five years</ix:nonNumeric> from the issuance date. Refer to Note 16 &#8212; Related Party Transactions, of our consolidated financial statements for additional information.</ix:continuation>   </span></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_121"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-588" continuedAt="f-588-1" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="f-588-1" continuedAt="f-588-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">2012 Plan and 2022 Plan</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the Merger Agreement, the Company assumed the Former Elicio Plans and all stock options issued and outstanding under the Former Elicio Plans. Each outstanding and unexercised option to purchase Former Elicio common stock was adjusted with such Company stock options henceforth representing the right to </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELICIO THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-588-2" continuedAt="f-588-3"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">purchase a number of shares of the Company&#8217;s common stock based on the Exchange Ratio. Any restriction on the exercise of any Former Elicio stock options assumed by the Company continued in full force and effect and the term, exercisability, vesting schedule, accelerated vesting provisions, and any other provisions of such Former Elicio stock options otherwise remained unchanged.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">2015 Plan </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2019, Angion approved an Amended and Restated 2015 Equity Incentive Plan (the &#8220;2015 Plan&#8221;) permitting the granting of incentive stock options, non-statutory stock options, restricted stock and other stock-based awards. Following the effectiveness of the 2021 Incentive Award Plan (&#8220;2021 Plan&#8221;), Angion ceased making grants under the 2015 Plan. However, the 2015 Plan continues to govern the terms and conditions of the outstanding awards granted under it. Shares of common stock subject to awards granted under the 2015 Plan that cease to be subject to such awards by forfeiture or otherwise after the termination of the 2015 Plan will be available for issuance under the 2021 Plan.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">2021 Plan and Amendment to 2021 Plan</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2021, Angion&#8217;s board of directors approved the 2021 Plan which permits the granting of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards to employees, directors, officers and consultants. The 2021 Plan provides that the number of shares reserved and available for issuance will automatically increase each January 1st by the lesser of <ix:nonFraction unitRef="number" contextRef="c-121" decimals="2" name="angn:CommonStockCapitalSharesReservedForFutureIssuanceIncreasePercentageOfCommonStockOutstanding" scale="-2" id="f-589">5</ix:nonFraction>% of the Company&#8217;s common stock outstanding on the immediately preceding December 31st, or such lesser number of shares as determined by the Company&#8217;s board of directors. In March 2023, Angion&#8217;s board of directors approved an amendment to the 2021 Plan to increase the cumulative number of shares of common stock reserved for issuance thereunder by <ix:nonFraction unitRef="shares" contextRef="c-122" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-590">30,113</ix:nonFraction> shares. The Company has a policy of issuing shares out of respective plan pools (to the extent available) to satisfy share option exercises and restricted stock vesting.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December&#160;31, 2024, <ix:nonFraction unitRef="shares" contextRef="c-123" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-591">298,795</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="c-124" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-592">175,283</ix:nonFraction> shares remain available for future grants under the 2021 Plan and Former Elicio 2022 Equity Incentive Plan, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">2024 Inducement Incentive Award Plan</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2024, the Company&#8217;s board of directors approved the Company&#8217;s 2024 Inducement Incentive Award Plan (the &#8220;2024 Inducement Plan&#8221;) which permits the granting of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock-based awards to employees as an inducement pursuant to Listing Rule 5635(c)(4) of the corporate governance rules of the Nasdaq Stock Market, LLC. The 2024 Inducement Plan provides for an overall share limit of <ix:nonFraction unitRef="shares" contextRef="c-125" decimals="INF" name="angn:ShareBasedCompensationArrangementByShareBasedPaymentAwardShareLimit" format="ixt:num-dot-decimal" scale="0" id="f-593">500,000</ix:nonFraction> shares of the Company&#8217;s common stock. As of December&#160;31, 2024, <ix:nonFraction unitRef="shares" contextRef="c-126" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-594">387,332</ix:nonFraction> shares remain available for future grants under the 2024 Inducement Plan.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Stock Options</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-595" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes information and activity related to the Company&#8217;s stock options:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Number of <br/>Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Weighted Average <br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Weighted Average <br/>Remaining Contractual Life <br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Total <br/>Intrinsic Value <br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Outstanding as of December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-596">1,305,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-597">21.27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-598">7.43</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-599">2,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-600">798,934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-601">3.59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-602">9,757</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-603">3.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Forfeited (unvested)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-604">204,169</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-605">10.43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Outstanding as of December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-606">1,890,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-607">15.69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-608">6.78</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="f-609">920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and exercisable</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-610">860,803</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-611">28.28</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-612">4.78</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="f-613">428</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The aggregate intrinsic value in the above table is calculated as the difference between the estimated fair value of the Company's common stock price and the exercise price of the stock options. <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-614">798,934</ix:nonFraction> stock options were granted during the year ended December&#160;31, 2024. The weighted average grant date fair value per share for the stock option grants during the year ended December&#160;31, 2024 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-615">3.59</ix:nonFraction>. As of December&#160;31, 2024, the total unrecognized compensation expense related to unvested stock option awards granted was $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="f-616">3.1</ix:nonFraction> million, which the Company expects to recognize over a weighted-average period of approximately <ix:nonNumeric contextRef="c-1" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-617">2.2</ix:nonNumeric> years.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELICIO THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-588-3"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Stock-based Compensation Expense</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-618" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes total stock-based compensation expense recorded in the consolidated statements of operations (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-619">582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-620">552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-621">870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-622">627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-623">1,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-624">1,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair value of each option is estimated on the date of grant using a Black-Scholes option pricing model with the assumptions noted in the table below. The fair value of an award with only a service condition is amortized as compensation expense on a straight-line basis over the requisite service period of the awards, which is generally the vesting period. Compensation cost of awards that contain a performance condition are recognized when success is considered probable during the performance period. The Company has elected to account for forfeitures as they occur, rather than estimating the number of awards that are expected to vest. The risk-free interest rate is estimated using the weighted average rate of return on U.S. Treasury notes with a life that approximates the expected life of the option. The expected term of options granted to employees was calculated using the simplified method, which represents the average of the contractual term of the option and the weighted-average vesting period of the option. The Company uses the simplified method because it does not have sufficient historical option exercise data to provide a reasonable basis upon which to estimate expected term. The contractual life of the option was used for the expected life of options granted to non-employees. Expected volatility is based on the weighted average of the historical volatility of a peer group of publicly traded companies, using the daily closing prices during the equivalent period of the calculated expected term of stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of the Company&#8217;s stock price becomes available, or until circumstances change, such that the identified entities are no longer comparable companies. The assumed dividend yield is based upon the Company's expectation of not paying dividends in the foreseeable future.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-625" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair value of each employee and non-employee stock option grant was estimated on the date of grant using Black-Scholes based on the following assumptions. </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.4% - 4.3%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.7% - 4.5%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-131" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-626">0.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-132" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-627">0.0</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">79.5% - 107.8%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">71.7% - 75.5%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected term in years (employees)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.0  -  6.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.5 - 6.1</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2021 and June 2022, certain employees of the Company early exercised options to purchase shares of the Company&#8217;s common stock. The shares had not fully vested at the time of exercise and were recorded as an unvested option exercise liability. As the shares vested, the Company recognized the shares and related expense as issuance of common stock upon settlement of restricted stock in the consolidated financial statements for the years ended December&#160;31, 2024 and 2023.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2021, the board of directors of Angion approved the Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The ESPP was effective on the date immediately prior to the effectiveness of Angion's registration statement relating to the initial public offering. The offering period and purchase period was determined by Angion&#8217;s board of directors. No offering periods or purchasing periods were active as of December&#160;31, 2024. As of December&#160;31, 2024, <ix:nonFraction unitRef="shares" contextRef="c-133" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-628">165,015</ix:nonFraction> shares under the ESPP remain available for purchase and <ix:nonFraction unitRef="shares" contextRef="c-133" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:fixed-zero" scale="0" id="f-629">no</ix:nonFraction> offerings have been authorized.</span></div></ix:continuation><div id="i488c1714f53641d3b5e4dbb098e37e6c_127"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9&#8212;<ix:nonNumeric contextRef="c-1" name="angn:WarrantsAndRightsOutstandingTextBlock" id="f-649" continuedAt="f-649-1" escape="true">Warrants</ix:nonNumeric></span></div><ix:continuation id="f-649-1" continuedAt="f-649-2"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In accordance with ASC 815, the warrants classified as liabilities are recorded at fair value at the issuance date, with subsequent changes in the fair value recognized in the consolidated statements of operations and </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELICIO THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-649-2" continuedAt="f-649-3"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">comprehensive loss at the end of each reporting period. Refer to Note 4 for changes in the fair value recognized during the periods reported. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As disclosed in Note 4, in March 2024, the Company entered into the March Subscription Agreement with GKCC, an entity controlled by a member of the Company&#8217;s board of directors, for purposes of the March Offering. Each Pre-Funded Warrant issued and sold in the March Offering is exercisable at an exercise price equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-78" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-650">0.01</ix:nonFraction> per share, subject to certain adjustments and limitations as provided under the terms of the Pre-Funded Warrants. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Upon issuance, the fair value of the Pre-Funded Warrants was $<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-5" name="angn:FairValueOfCommonStockWarrants" format="ixt:num-dot-decimal" scale="6" id="f-651">6.6</ix:nonFraction>&#160;million. The Company recorded the $<ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-5" name="angn:GainLossOnIssuanceOfWarrants" format="ixt:num-dot-decimal" scale="6" id="f-652">0.6</ix:nonFraction>&#160;million difference between the proceeds and the grant date fair value as a loss on issuance of warrants in the statements of operations and comprehensive loss during the three months ended March 31, 2024. The fair value of the Pre-Funded Warrants was measured using the Black-Scholes option pricing model as of the grant date. For the year ended December&#160;31, 2024, the Company recognized a gain of $<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-5" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" scale="6" id="f-653">1.3</ix:nonFraction> million in fair value remeasurement of the Pre-Funded Warrants. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As disclosed in Notes 4 and 7, in July 2024, the Company closed its Public Offering consisting of (i) the July Shares, (ii) the July Pre-Funded Warrants, and (iii) the July Common Warrants. Each July Pre-Funded Warrant issued and sold in the Public Offering is exercisable at an exercise price equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-142" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-654">0.01</ix:nonFraction> per share, subject to certain adjustments and limitations as provided under the terms of the July Pre-Funded Warrants. Each July Common Warrant is exercisable at an exercise price equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-83" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-655">5.00</ix:nonFraction> per share, subject to certain adjustments and limitations as provided under the terms of the July Common Warrants. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Upon issuance, the fair value of the July Pre-Funded Warrants and July Common Warrants was $<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="angn:FairValueOfCommonStockWarrants" format="ixt:num-dot-decimal" scale="6" id="f-656">6.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-5" name="angn:FairValueOfCommonStockWarrants" format="ixt:num-dot-decimal" scale="6" id="f-657">6.5</ix:nonFraction>&#160;million, respectively. The Company recorded the $<ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-5" name="angn:GainLossOnIssuanceOfWarrants" format="ixt:num-dot-decimal" scale="6" id="f-658">2.9</ix:nonFraction>&#160;million difference between the proceeds and the grant date fair value as a loss on the issuance of warrants in the statements of operations and comprehensive loss during the three months ended September 30, 2024. The fair value of the July Pre-Funded Warrants and July Common Warrants was measured using the Black-Scholes option pricing model as of the grant date. For the year ended December&#160;31, 2024, the Company recognized a loss of $<ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-5" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" scale="6" id="f-659">2.4</ix:nonFraction> million in fair value remeasurement of the July Pre-Funded Warrants. For the year ended December&#160;31, 2024, the Company recognized a loss of $<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-5" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" scale="6" id="f-660">2.8</ix:nonFraction> million in fair value remeasurement of the July Common Warrants.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Following receipt of Stockholder Approval in November 2024, the Company remeasured the July Common Warrants held by that shareholder at fair value and recognized the loss from change in fair value on the consolidated financial statements during the year ended December 31, 2024. As a result of obtaining Stockholder Approval, the Common Warrants held by that shareholder met the equity classification requirements under ASC 815. During the quarter ended December 31, 2024, the Company reclassified the July Common Warrants held by the stockholder from a liability to equity. The Company will re-assess the liability classification for the remaining July Common Warrants at each period end.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="f-661" continuedAt="f-661-1" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes the issuances of warrants by the Company throughout 2024:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.174%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.131%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Number of Warrants Issued</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Date of Issuance</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Expiration Date</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pre-Funded Warrants</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-148" decimals="INF" name="angn:WarrantsIssuedShares" format="ixt:num-dot-decimal" scale="0" id="f-662">1,032,702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">July Pre-Funded Warrants</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-149" decimals="INF" name="angn:WarrantsIssuedShares" format="ixt:num-dot-decimal" scale="0" id="f-663">1,800,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">July Common Warrants</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-150" decimals="INF" name="angn:WarrantsIssuedShares" format="ixt:num-dot-decimal" scale="0" id="f-664">2,300,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total Warrants Issued</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="angn:WarrantsIssuedShares" format="ixt:num-dot-decimal" scale="0" id="f-665">5,132,702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Pre-funded warrants have been purchased and have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-151" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-666"><ix:nonFraction unitRef="usdPerShare" contextRef="c-152" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-667">.01</ix:nonFraction></ix:nonFraction> per share. These warrants do not have an expiration date. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes warrant activity regarding the Pre-Funded Warrants and Common Warrants outstanding at December&#160;31, 2024:</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELICIO THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-661-1"><ix:continuation id="f-649-3"><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.174%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.131%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted <br/>Average <br/>Exercise <br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average Life (years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Outstanding at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-668">148,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-669">54.19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-5" name="angn:ClassOfWarrantOrRightWeightedAverageLife" format="ixt-sec:duryear" id="f-670">5.5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Issued</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="angn:ClassOfWarrantOrRightIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-671">5,132,702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="INF" name="angn:ClassOfWarrantOrRightWeightedAverageExercisePriceIssuedInPeriod" scale="0" id="f-672">2.34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="angn:ClassOfWarrantOrRightExercisedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-673">200,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="INF" name="angn:ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod" scale="0" id="f-674">0.01</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Outstanding at December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-675">5,081,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-676">3.85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-4" name="angn:ClassOfWarrantOrRightWeightedAverageLife" format="ixt-sec:duryear" id="f-677">4.5</ix:nonNumeric></span></td></tr></table></div></ix:continuation></ix:continuation><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_130"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-678" continuedAt="f-678-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="f-678-1" continuedAt="f-678-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Legal Proceedings </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">From time to time, the Company may be involved in legal proceedings, or may be subject to various demands, claims and threatened litigation, which arise in the normal course of its business or otherwise. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The outcome of any future litigation is uncertain. Such litigation, if not resolved, could result in substantial costs to the Company, including any costs associated with the indemnification of directors and officers, and could lead to a diversion of management resources among other factors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company may be exposed to litigation in connection with its products under development and operations. The Company&#8217;s policy is to assess the likelihood of any adverse judgments or outcomes related to legal matters, as well as ranges of probable losses. As of the time of this report, the Company does not believe it is a party to any claim, proceeding or litigation, the outcome of which, if determined adversely to the Company, would individually or in the aggregate be reasonably expected to have a material adverse effect on its business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">License Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2016, Former Elicio entered into a license agreement to license certain intellectual property from a university, which agreement has been amended from time to time to license additional intellectual property and to adjust fees, milestone dates, and diligence requirements. The Company is required to pay certain contractual maintenance and milestone payments related to clinical trials and royalties on product sales over the term of the contract, with minimum annual royalty payments commencing in the calendar year after commercialization. The license term for the January 2016 license agreement extends until terminated by either party under certain provisions. During the year ended December&#160;31, 2024, in accordance with the terms of the license agreement, the Company achieved a milestone related to the ongoing clinical trials and recorded license expense of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="angn:LicenseExpense" format="ixt:num-dot-decimal" scale="6" id="f-679">0.4</ix:nonFraction>&#160;million. No commercialization royalties have been achieved to date. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, the Company is required to pay a total of up to $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="angn:OperatingLeaseFutureMinimumAnnualMaintenancePayments" format="ixt:num-dot-decimal" scale="6" id="f-680">20.9</ix:nonFraction>&#160;million upon achievement of certain late-stage developmental and commercial milestones. The developmental milestone payment will be recorded when the milestone is achieved, and the commercial milestone payment and royalties will be recorded when the sales occur.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="f-678-2">Future minimum annual maintenance payments are $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="angn:OperatingLeaseFutureMinimumAnnualMaintenancePaymentsDueThereafter" format="ixt:num-dot-decimal" scale="6" id="f-681">0.1</ix:nonFraction>&#160;million for the year ended December&#160;31, 2024 and for each year thereafter. Future minimum annual payments are due until the termination of the agreement.</ix:continuation> </span></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_133"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-682" continuedAt="f-682-1" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="f-682-1" continuedAt="f-682-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Operating Leases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2021, the Company signed an operating lease for office and laboratory space in Boston, Massachusetts (the &#8220;Boston Lease&#8221;).</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Boston Lease commenced in February 2022 with the term set to expire in February 2030. The Boston Lease has rent payments escalating annually, which total $<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="f-683">11.1</ix:nonFraction>&#160;million in the aggregate. As a result, at the commencement of the Boston Lease, the Company recognized a ROU lease asset of $<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="f-684">8.0</ix:nonFraction>&#160;million with a corresponding lease liability of $<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-685">8.0</ix:nonFraction>&#160;million based on the present value of the minimum rental payments. In addition, the Company will make payments for operating expenses and real estate taxes. In June 2023, the Company secured a letter of credit for the deposit on the Boston Lease and has a deposit in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-5" name="us-gaap:ProceedsFromSecuredLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="f-686">0.7</ix:nonFraction>&#160;million, which was reported as restricted cash, noncurrent on the consolidated balance sheets as of December&#160;31, 2024 and 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of the Merger Agreement, the Company also assumed a lease for clinical and regulatory space in Newton, Massachusetts, comprising approximately <ix:nonFraction unitRef="sqft" contextRef="c-156" decimals="0" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="f-687">6,157</ix:nonFraction> square feet for approximately $<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-5" name="angn:LesseeOperatingLeaseAnnualRentExpense" format="ixt:num-dot-decimal" scale="6" id="f-688">0.2</ix:nonFraction>&#160;million per year, under a non-cancelable operating lease that expired on June 30, 2024. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELICIO THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-682-2" continuedAt="f-682-3"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Lease expense for all leases for the years ended December&#160;31, 2024 and 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="f-689">1.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="f-690">1.5</ix:nonFraction>&#160;million, respectively.</span></div><ix:nonNumeric contextRef="c-1" name="angn:ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock" id="f-691" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes quantitative information about the Company's operating leases (dollars in thousands):</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating cash outflows from operating leases</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-692">1,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-693">1,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted-average remaining lease term&#8212;operating leases (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-694">5.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-5" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-695">5.6</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted-average discount rate&#8212;operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-696">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-697">7.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-698" continuedAt="f-698-1" escape="true"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, maturities of lease liabilities were as follows (in thousands):</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt"><ix:continuation id="f-698-1"><ix:continuation id="f-682-3"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-699">1,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-700">1,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-701">1,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-702">1,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="f-703">1,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Thereafter</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="f-704">253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-705">7,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Less present value discount</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-706">1,384</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating lease liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-707">6,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Less: operating lease liability, current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-708">901</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating lease liability, noncurrent portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-709">5,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_136"></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-710" continuedAt="f-710-1" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="f-710-1" continuedAt="f-710-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Note Payable</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with execution of the Merger Agreement, Angion made the Bridge Loan to Former Elicio pursuant to a note purchase agreement and promissory notes up to an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-711">12.5</ix:nonFraction>&#160;million, issued with a <ix:nonFraction unitRef="number" contextRef="c-60" decimals="INF" name="angn:DebtInstrumentIssuanceDiscountPercent" scale="-2" id="f-712">20</ix:nonFraction>% original issue discount. An initial closing held substantially concurrently with the execution of the Merger Agreement for a principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-4" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-713">6.25</ix:nonFraction>&#160;million in exchange for cash of $<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-714">5.0</ix:nonFraction>&#160;million and an additional closing for a principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-4" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-715">6.25</ix:nonFraction>&#160;million in exchange for cash of $<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-716">5.0</ix:nonFraction>&#160;million occurred upon delivery by Former Elicio to Angion of Former Elicio&#8217;s audited financial statements for the year ended December 31, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The promissory notes included multiple settlement options depending on the outcome of the Merger. Former Elicio evaluated all the settlement features, included within the promissory note agreement, under FASB ASC Topic 815, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, and determined the settlement features met the definition of a derivative and required bifurcation from the promissory notes. The bifurcated embedded derivative of $<ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-5" name="us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" scale="6" id="f-717">0.4</ix:nonFraction> million was recorded as a liability at fair value at the date of issuance based on the probability of occurrence of a triggering event taking place during the term of the promissory notes and was recorded as a discount to the carrying value of the promissory note. During the year ended December&#160;31, 2023, Former Elicio recorded other expense of $<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="6" id="f-718">2.3</ix:nonFraction> million related to the accretion of the discount of the promissory notes derivative.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the year ended December&#160;31, 2023, per the terms of the Merger Agreement, upon completion of the Merger, all obligations owed by Former Elicio related to the promissory notes were automatically forgiven and the amount advanced by Angion, along with any accrued and unpaid interest, was credited towards the net cash balance used to calculate the assets and liabilities listed above.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Senior Secured Convertible Note Financing</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2024, the Company entered into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) with GKCC, an entity controlled by a member of the Company&#8217;s board of directors, pursuant to which the Company issued a <ix:nonFraction unitRef="number" contextRef="c-160" decimals="2" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-719">3</ix:nonFraction>% Senior Secured Convertible Promissory Note due February 15, 2026 (the &#8220;Convertible Note&#8221;) in the principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="f-720">20.0</ix:nonFraction> million (the &#8220;Note Financing&#8221;). Unless earlier converted in accordance with </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELICIO THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-710-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the terms of the Convertible Note, the Convertible Note will mature on February 15, 2026. Interest on the Convertible Note accrues and is payable quarterly in cash on the principal amount equal to <ix:nonFraction unitRef="number" contextRef="c-160" decimals="2" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-721">3</ix:nonFraction>% per annum, with the initial interest payment date to be June 30, 2025. The Convertible Note is secured by a (i) first priority lien on substantially all assets of the Company and its subsidiaries, pursuant to a security agreement and (ii) first priority lien on intellectual property of the Company, pursuant to an intellectual property security agreement. The Convertible Note will be convertible into shares of the Company&#8217;s common stock, in whole or in part, at the option of GKCC at any time, based on an initial conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-160" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-722">5.81</ix:nonFraction> (the &#8220;Conversion Price&#8221;) per share of common stock, subject to adjustments and satisfaction of certain conversion conditions; provided that the Company was not able to effect any conversion of the Convertible Note and GKCC did not have any right to convert any portion of the Convertible Note until the Company received Stockholder Approval. The Company received Stockholder Approval in November 2024. If at any time from and after the date of the Securities Purchase Agreement and for so long as certain conversion conditions are satisfied, the closing price of the common stock on Nasdaq equals or exceeds <ix:nonFraction unitRef="number" contextRef="c-161" decimals="2" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="f-723">135</ix:nonFraction>% of the Conversion Price for <ix:nonFraction unitRef="day" contextRef="c-161" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="f-724">20</ix:nonFraction> trading days in a <ix:nonFraction unitRef="day" contextRef="c-161" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="f-725">30</ix:nonFraction> trading day period, then the Company has the right to require GKCC to convert all or any portion of the Convertible Note, including any accrued but unpaid interest into shares of common stock, as further described in the Convertible Note. The Convertible Note contains customary terms and covenants and customary events of default. The Company granted GKCC certain customary registration rights with respect to the shares of common stock issuable upon conversion of the Convertible Note.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company received net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-5" name="us-gaap:ProceedsFromConvertibleDebt" scale="6" id="f-726">19.7</ix:nonFraction> million from the Note Financing, after deducting debt issuance costs. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Convertible Note includes multiple conversion features. The Company evaluated all conversion features included within the Convertible Note, under FASB ASC Topic 815, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Derivatives and Hedging,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and determined that the default interest feature met the definition of a derivative, but the value was de minimis. During the year ended December&#160;31, 2024, the Company recorded other expense of $<ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="6" id="f-727">0.1</ix:nonFraction> million related to the accretion of the discount of Convertible Note debt issuance costs. As of and for the year ended December&#160;31, 2024, the Company recorded accrued interest expense of $<ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-5" name="us-gaap:InterestExpenseDebt" scale="6" id="f-728">0.2</ix:nonFraction> million related to the interest due on the Convertible Note but not yet payable.</span></div></ix:continuation><div style="margin-top:1pt"><span><br/></span></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_139"></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 13&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-729" continuedAt="f-729-1" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-730" escape="true"><ix:continuation id="f-729-1" continuedAt="f-729-2"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The components of the Company&#8217;s provision for income taxes for the years ended December&#160;31, 2024 and 2023 consists of the following (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"/><td style="width:72.451%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.828%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-731">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-732">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">United States</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-733">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-734">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-735">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-736">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total Current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-737">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-738">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-739">11,236</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-740">7,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-741">1,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-742">3,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-743">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-744">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Change in valuation allowance</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" format="ixt:num-dot-decimal" scale="3" id="f-745">10,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" format="ixt:num-dot-decimal" scale="3" id="f-746">10,859</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total Deferred</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-747">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-748">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total tax provision</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-749">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-750">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELICIO THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span><br/></span></div><ix:continuation id="f-729-2" continuedAt="f-729-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-751" escape="true"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliations between the federal statutory income tax rate and the Company's effective income tax rate were as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"/><td style="width:72.451%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.828%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Statutory federal income tax rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-752">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-753">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">State tax, net of federal benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-754">2.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-755">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Permanent differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="angn:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" scale="-2" id="f-756">3.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" sign="-" name="angn:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" scale="-2" id="f-757">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Federal research and development credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="angn:EffectiveIncomeTaxRateReconciliationTaxCreditFederalResearchAndDevelopmentPercent" scale="-2" id="f-758">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="angn:EffectiveIncomeTaxRateReconciliationTaxCreditFederalResearchAndDevelopmentPercent" scale="-2" id="f-759">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">State research and development credits</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="angn:EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent" scale="-2" id="f-760">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="angn:EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent" scale="-2" id="f-761">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other differences</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-762">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-763">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-764">19.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-765">30.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Effective income tax rate</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-766">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-767">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-768" escape="true"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal components of the Company's net deferred tax asset at December&#160;31, 2024 and 2023 were as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred tax assets (liabilities):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net operating loss carryforwards</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-769">64,646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-770">60,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development tax credit carryovers</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-771">15,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-772">12,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Capitalized research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-773">17,585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-774">13,686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lease liability</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="angn:DeferredTaxAssetsOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-775">1,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="angn:DeferredTaxAssetsOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-776">1,897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="f-777">2,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="f-778">2,732</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ROU asset</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-779">1,470</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-780">1,800</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="f-781">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="f-782">33</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total deferred tax assets</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="angn:DeferredTaxAssetsNetBeforeValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-783">100,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="angn:DeferredTaxAssetsNetBeforeValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-784">90,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Less: Deferred tax asset valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-785">100,117</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-786">90,118</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net deferred tax asset</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-787">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-788">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net operating losses (&#8220;NOL&#8221;) generated before December 31, 2017 can be carried forward 20 years under the Internal Revenue Code (&#8220;IRC&#8221;). Use of NOLs arising in tax years ended after December 31, 2017 are limited to 80% of taxable income in any one tax year, and are carried forward indefinitely. The Company has <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="INF" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt-sec:numwordsen" scale="0" id="f-789"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt-sec:numwordsen" scale="0" id="f-790">no</ix:nonFraction></ix:nonFraction> income tax expense due to operating losses incurred for the years ended December&#160;31, 2024 and 2023. The Company has provided a valuation allowance for the full amount of the net deferred tax assets as, based on all available evidence, it is considered more likely than not that all the recorded deferred tax assets will not be realized in a future period. The increase in the net deferred tax assets and valuation allowance is primarily due to increases in federal and state NOLs, federal and state research credits, and capitalized research expenditures. At December&#160;31, 2024, Elicio has federal NOLs of $<ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-791">261.8</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-792">19.1</ix:nonFraction> million was generated before the tax year ended December 31, 2018, and state NOLs of $<ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-793">145.2</ix:nonFraction> million. If not utilized, certain NOLs for federal and state tax purposes will start to expire beginning in 2032. At December&#160;31, 2024, Elicio has $<ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-794">12.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-795">2.6</ix:nonFraction> million of federal and state research and development credit carryforwards, respectively, that start to expire in 2027.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As the Company has not yet achieved profitable operations, management believes the tax benefits as of December&#160;31, 2024 did not satisfy the realization criteria set forth in ASC Topic 740, Income Taxes and, therefore, has recorded a full valuation allowance for the entire deferred tax asset. The valuation allowance increased in 2024 by $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="f-796">10.0</ix:nonFraction> million due to the increase in the deferred tax assets by the same amount, primarily due to NOL carryforwards. The Company&#8217;s effective income tax rate differed from the federal statutory rate primarily due to state taxes and the Company&#8217;s full valuation allowance, the latter of which reduced the Company&#8217;s effective federal income tax rate to <ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt-sec:numwordsen" scale="-2" id="f-797">zero</ix:nonFraction>.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ownership changes, as defined in the IRC, may limit the amount of NOL carryforwards that can be utilized annually to offset future taxable income pursuant to IRC Section 382 or similar provisions. Subsequent ownership </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELICIO THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-729-3"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">changes could further affect the limitation in future years. The Company has not completed a study to assess whether a change of control has occurred or whether there have been multiple changes of control since the Company&#8217;s formation due to the significant complexity and cost associated with such study and because there could be additional changes in control in the future. As a result, the Company is not able to estimate the effect of the change in control, if any, on the Company&#8217;s ability to utilize NOL and research and development credit carryforwards in the future.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company files tax returns in the United States, Australia, California, Connecticut, Florida, Massachusetts, Michigan, Missouri, New Hampshire, New Jersey, North Carolina, Pennsylvania, and Tennessee. All tax years from 2021 to 2024 remain open to examination by the major taxing jurisdictions to which the Company is subject, as carryforward attributes generated in years past may still be adjusted upon examination by the Internal Revenue Service (&#8220;IRS&#8221;) or other authorities if they have or will be used in a future period. To its knowledge, the Company is not currently under examination by the IRS or any other jurisdictions for any tax years.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December&#160;31, 2024, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="f-798">4.1</ix:nonFraction> million of uncertain tax positions related to prior research tax credits that may not be substantiated upon audit. The Company does not anticipate that uncertain tax positions will decrease within the next 12 months. The Company has elected to recognize interest and penalties related to income tax matters as a component of income tax expense, of which <ix:nonFraction unitRef="usd" contextRef="c-4" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="0" id="f-799"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="0" id="f-800">no</ix:nonFraction></ix:nonFraction> interest or penalties were recorded for the years ended December&#160;31, 2024 and 2023.</span></div></ix:continuation><div id="i488c1714f53641d3b5e4dbb098e37e6c_142"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 14&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:DefinedContributionPlanTextBlock" id="f-801" continuedAt="f-801-1" escape="true">Employee Benefit Plan</ix:nonNumeric></span></div><ix:continuation id="f-801-1" continuedAt="f-801-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Employee Benefit Plan</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company provides a retirement savings plan through the Vendantra Pharmaceuticals Inc. 401(k) Plan (the &#8220;Elicio Retirement Plan&#8221;), subject to certain limitations. As allowed under Section 401(k) of the IRC, the Elicio Retirement Plan allows tax deferred salary deductions for eligible employees. An employee&#8217;s interest in his or her salary deferral contributions is <ix:nonFraction unitRef="number" contextRef="c-169" decimals="INF" name="us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" scale="-2" id="f-802">100</ix:nonFraction>% vested when contributed.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="f-801-2">Pursuant to the Merger Agreement, the Company assumed the retirement savings plan sponsored by Angion (the &#8220;Angion Retirement Plan&#8221;). The Angion Retirement Plan is intended to qualify for favorable tax treatment under Section 401(a) of the IRC, and contains a cash or deferred feature that is intended to meet the requirements of Section 401(k) of the IRC. Currently, no employees are contributing under the Angion Retirement Plan.</ix:continuation> </span></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_145"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 15&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-803" continuedAt="f-803-1" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><ix:continuation id="f-803-1" continuedAt="f-803-2"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has reported losses since inception and has computed basic net loss per share attributable to common stockholders by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock and pre-funded warrants outstanding for the period, without consideration for potentially dilutive securities. The Company computes diluted net loss per share of common stock after giving consideration to all potentially dilutive shares of common stock, including options to purchase common stock and preferred stock outstanding during the period determined using the treasury-stock and if-converted methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential shares of common stock and preferred stock have been anti-dilutive and basic and diluted loss per share were the same for all periods presented.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-804" continuedAt="f-804-1" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Basic and diluted net loss per share attributable to common stockholders was calculated for the years ended December&#160;31, 2024 and 2023 as follows (in thousands, except share and per share data):</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELICIO THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-803-2"><ix:continuation id="f-804-1"><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Numerator:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-805">51,898</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-806">35,195</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Weighted-average shares used in computing net loss per share, basic and diluted</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-807"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-808">12,202,996</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-809"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-810">5,056,225</ix:nonFraction></ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-811"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-812">4.25</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-813"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-814">6.96</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-815" continuedAt="f-815-1" escape="true">The table below provides potentially dilutive securities not included in the calculation of the diluted net loss per share because to do so would be anti-dilutive:</ix:nonNumeric></span></div><ix:continuation id="f-815-1"><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2023</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Shares issuable upon exercise of stock options</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-170" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-816">1,890,932</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-171" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-817">1,305,924</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Shares issuable upon the exercise of warrants</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-172" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-818">2,448,764</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-173" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-819">148,764</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Unvested common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-174" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-820">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-175" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-821">1,933</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Total</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-822">4,339,696</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-823">1,456,621</ix:nonFraction></span></td></tr></table></div></ix:continuation></ix:continuation><div style="margin-top:3pt;text-indent:22.5pt"><span><br/></span></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_148"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 16&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="f-824" continuedAt="f-824-1" escape="true">Related Party Transactions</ix:nonNumeric></span></div><ix:continuation id="f-824-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Consulting Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company paid $<ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="0" id="f-825">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="6" id="f-826">0.8</ix:nonFraction> million for the years ended December&#160;31, 2024 and 2023, respectively, for consulting services provided by an entity affiliated with the Company&#8217;s former interim chief financial officer and former board member. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Private Placement and Subscription Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2024, the Company entered into the March Subscription Agreement with GKCC, an entity controlled by a member of the Company&#8217;s board of directors, for purposes of the March Offering. Each Pre-Funded Warrant issued and sold in the March Offering is exercisable at an exercise price equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-78" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-827">0.01</ix:nonFraction> per share, subject to certain adjustments and limitations as provided under the terms of the Pre-Funded Warrants. Refer to Note 7 for further detail about the March Offering. The gross proceeds to the Company from the March Offering were approximately $<ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfWarrants" format="ixt:num-dot-decimal" scale="6" id="f-828">6.0</ix:nonFraction>&#160;million. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Public Offering</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of the Public Offering described in Note 7, Yekaterina Chudnovsky, a member of the Company&#8217;s board of directors, and Jay Venkatesan, a member of the Company&#8217;s board of directors, and trusts affiliated with Jay Venkatesan, purchased <ix:nonFraction unitRef="shares" contextRef="c-179" decimals="0" name="angn:ClassOfWarrantOrRightIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-829">1,600,000</ix:nonFraction> July Pre-Funded Warrants and accompanying July Common Warrants and <ix:nonFraction unitRef="shares" contextRef="c-180" decimals="0" name="angn:ClassOfWarrantOrRightIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-830">200,000</ix:nonFraction> July Pre-Funded Warrants and accompanying July Common Warrants, respectively, with such July Pre-Funded Warrants and July Common Warrants subject to the terms and conditions of the July Pre-Funded Warrants and July Common Warrants, as further detailed in Note 7 above.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Senior Secured Convertible Note Financing</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2024, the Company entered into the Securities Purchase Agreement with GKCC, pursuant to which the Company issued the Convertible Note in the principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="f-831">20.0</ix:nonFraction> million pursuant to the Note Financing. The Company received net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-5" name="us-gaap:ProceedsFromConvertibleDebt" scale="6" id="f-832">19.7</ix:nonFraction> million from the Note Financing, after deducting debt issuance costs. Refer to Note 12 for further detail regarding the Note Financing.</span></div></ix:continuation><div id="i488c1714f53641d3b5e4dbb098e37e6c_151"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 17&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-833" continuedAt="f-833-1" escape="true">Segment Reporting</ix:nonNumeric></span></div><ix:continuation id="f-833-1" continuedAt="f-833-2"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has <ix:nonFraction unitRef="entity" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" id="f-834">one</ix:nonFraction> reportable segment relating to the development of immunotherapies for patients with limited treatment options and poor outcomes suffering from cancer. The Company&#8217;s CODM, its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis, assesses performance for the operating segment and decides how to allocate resources based on consolidated net loss, which is reported on the consolidated statements of operations and comprehensive loss. Depreciation expense, amortization expense, stock-based compensation expense, and the change in fair value of warrants are significant noncash items included in consolidated net loss reviewed by the CODM and are reported on the consolidated statements of cash flows. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELICIO THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-833-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other segment items include interest revenue, interest expense, change in the fair value of derivatives, and change in the fair value of warrants. Expenditures for additions to long-lived assets, which include purchases of property and equipment, are included in total consolidated assets reviewed by the CODM and are reported on the consolidated statements of cash flows. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-835" continuedAt="f-835-1" escape="true">The following table presents certain financial data for the Company&#8217;s reportable segment (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-835-1"><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-836">15,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-837">7,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee related research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-838">8,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-839">7,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chemistry, manufacturing and controls expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-840">4,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-841">7,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-842">5,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-843">5,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract and grant reimbursements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" sign="-" name="us-gaap:RecoveryOfDirectCosts" format="ixt:num-dot-decimal" scale="3" id="f-844">1,027</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" sign="-" name="us-gaap:RecoveryOfDirectCosts" format="ixt:num-dot-decimal" scale="3" id="f-845">3,800</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee related general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-846">3,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-847">3,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees and other general and administrative expenses </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:OtherGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-848">7,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:OtherGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-849">8,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other segment items </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:SegmentReportingOtherItemAmount" format="ixt:num-dot-decimal" scale="3" id="f-850">6,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" sign="-" name="us-gaap:SegmentReportingOtherItemAmount" scale="3" id="f-851">445</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-852">51,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-853">35,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-854">28,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-855">27,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:continuation><div id="i488c1714f53641d3b5e4dbb098e37e6c_584"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 18&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-856" continuedAt="f-856-1" escape="true">Subsequent Events</ix:nonNumeric></span></div><ix:continuation id="f-856-1"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has completed an evaluation of all subsequent events after the consolidated balance sheet date as of December&#160;31, 2024 through the date these consolidated financial statements were issued to ensure that these consolidated financial statements include appropriate disclosure of events both recognized in the consolidated financial statements as of December&#160;31, 2024, and events which occurred subsequently but were not recognized in the consolidated financial statements. Non-recognizable subsequent events are summarized below.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">January Offering</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On January 29, 2025, the Company entered into a Securities Purchase Agreement (the &#8220;January Purchase Agreement&#8221;) with certain institutional investors (each an &#8220;Investor&#8221; and, collectively, the &#8220;Investors&#8221;), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Investors (the &#8220;January Offering&#8221;): (i) an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-193" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-857">1,261,830</ix:nonFraction> shares of common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-193" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-858">0.01</ix:nonFraction> per share, of the Company and (ii) common warrants to purchase up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-193" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-859">1,261,830</ix:nonFraction> shares of Common Stock (the &#8220;January Common Warrants&#8221;). Each share of common stock and accompanying January Common Warrant were sold together at a combined offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-193" decimals="3" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-860">7.925</ix:nonFraction>. The January Common Warrants have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-193" decimals="1" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-861">7.80</ix:nonFraction> per share, are immediately exercisable and will expire five years from the initial exercise date. The aggregate gross proceeds to the Company from the January Offering were approximately $<ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-6" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-862">10</ix:nonFraction>&#160;million before deducting the placement agent&#8217;s fees and related offering expenses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Convertible Note Conversion</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As previously described, in August 2024, the Company entered into the Securities Purchase Agreement with GKCC, pursuant to which the Company issued the Convertible Note in the principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-863">20.0</ix:nonFraction>&#160;million pursuant to the Note Financing. Under the terms of the Convertible Note, if at any time from and after the date of the Convertible Note and for so long as the closing price of the Company&#8217;s common stock on The Nasdaq Capital Market equals or exceeds <ix:nonFraction unitRef="number" contextRef="c-161" decimals="2" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="f-864">135</ix:nonFraction>% of the initial conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-160" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-865">5.81</ix:nonFraction> for <ix:nonFraction unitRef="entity" contextRef="c-195" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="f-866">20</ix:nonFraction> trading days in a <ix:nonFraction unitRef="entity" contextRef="c-196" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="f-867">30</ix:nonFraction> trading day period, then the Company had the right to require GKCC to convert all or any portion of the Convertible Note, including any accrued but unpaid interest into shares of Company common stock. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 3, 2025, the Company exercised its right under the Convertible Note to require GKCC to convert the full amount of the Convertible Note, including all accrued and unpaid interest, into shares of Company common stock. On March 5, 2025, the Company issued <ix:nonFraction unitRef="shares" contextRef="c-197" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-868">3,500,573</ix:nonFraction> shares of common stock to GKCC in exchange for the principal balance of $<ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-6" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-869">20</ix:nonFraction>&#160;million plus $<ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-5" name="angn:AccruedInterestPremiumForConvertiblePreferredStock" format="ixt:num-dot-decimal" scale="6" id="f-870">0.3</ix:nonFraction>&#160;million in accrued interest, in satisfaction in full of the Convertible Note.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129</span></div></div></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_154"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_157"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A. Controls and Procedures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Definition and Limitations of Disclosure Controls</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed under the Exchange Act, such as this Annual Report on Form 10-K, is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures are also designed to ensure that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Our management evaluates these controls and procedures on an ongoing basis.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There are inherent limitations to the effectiveness of any system of disclosure controls and procedures. These limitations include the possibility of human error, the circumvention or overriding of the controls and procedures and reasonable resource constraints. In addition, because we have designed our system of controls based on certain assumptions, which we believe are reasonable, about the likelihood of future events, our system of controls may not achieve its desired purpose under all possible future conditions. Accordingly, our disclosure controls and procedures provide reasonable assurance, but not absolute assurance, of achieving their objectives.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our management, with the participation of our President and Chief Executive Officer, our principal executive officer, principal accounting officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of December&#160;31, 2024.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Based on the evaluation of our disclosure controls and procedures, our President and Chief Executive Officer concluded that our disclosure controls and procedures were not effective as of December&#160;31, 2024 as a result of our material weaknesses in our internal control over financial reporting.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">However, our management, including our Chief Executive Officer, has concluded that, notwithstanding the identified material weaknesses in our internal control over financial reporting, the financial statements in this Annual Report on Form 10-K fairly present, in all material respects, our financial position, results of operations and cash flows for the periods presented in conformity with U.S. GAAP.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f)) under the Exchange Act) that occurred during the year ended December&#160;31, 2024, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting, except as follows:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Material Weakness Remediation Plan</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As previously reported, in connection with the preparation of our consolidated financial statements, we identified control deficiencies in the design and operation of our internal control over financial reporting that constituted material weaknesses. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our financial statements will not be prevented or detected on a timely basis.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The material weaknesses identified in our internal control over financial reporting related to (i) insufficient resources with knowledge and expertise in U.S. GAAP to properly evaluate certain complex transactions, including debt instruments and equity instruments; and (ii) insufficient financial reporting and close controls to ensure that incurred expenses are accrued at period end and deliverables from third party contractors are reviewed for accuracy.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We initiated several steps to remediate these material weaknesses, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;engaging SEC compliance and technical accounting consultants to assist in evaluating transactions for conformity with U.S. GAAP;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;hiring additional finance and accounting personnel to augment accounting staff and to provide more resources for complex accounting matters and financial reporting; and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;strengthening our financial reporting and close relating to incurred expenses by ensuring our data capture procedures are clearly defined and that responsible personnel, including supervisory personnel, have adequate training regarding the process and expectation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Although we have initiated efforts to remediate these material weaknesses, the material weaknesses have not been fully remediated as of December 31, 2024. Our remediation efforts are intended to address the identified material weaknesses. However, these material weaknesses will not be considered remediated until the applicable remedial actions operate effectively for a sufficient period of time. Management is committed to continuous improvement of our internal control over financial reporting and will continue to diligently review our internal control over financial reporting. However, we cannot assure you that we will be successful in remediating the material weaknesses we identified or that our internal control over financial reporting, as modified, will enable us to identify or avoid material weaknesses in the future.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Remediation of Previously Reported Material Weakness</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the year ended December 31, 2024, we completed control enhancements and testing necessary to conclude that the previously identified material weakness in our internal control over financial reporting related to insufficient resources to ensure that calculations used in financial reporting are properly reviewed, including earnings per share and weighted average shares outstanding calculations was remediated. In addressing this material weakness, we have undertaken actions in each of the steps identified below: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">engaging SEC compliance consultants to provide preparation support for the financial reporting process; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">hiring sufficient resources to have a separate reviewer and preparer for the financial reporting calculations and schedules.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Management&#8217;s Report on Internal Control Over Financial Reporting </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our internal control over financial reporting is a process designed by, or under the supervision of, the Company&#8217;s principal executive and principal accounting and financial officer and effected by the Company&#8217;s board of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our management assessed the effectiveness of our internal control over financial reporting as of December&#160;31, 2024. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;) in Internal Control-Integrated Framework (2013). Based on our assessment, management concluded our internal control over financial reporting was not effective as of December&#160;31, 2024, based on the COSO criteria.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Inherent Limitation on the Effectiveness Over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The effectiveness of any system of internal control over financial reporting, including ours, is subject to inherent limitations, including the exercise of judgment in designing, implementing, operating, and evaluating the controls and procedures, and the inability to eliminate misconduct completely. Accordingly, any system of internal control over financial reporting, including ours, no matter how well designed and operated, can only provide reasonable, not absolute assurances. In addition, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. We intend to continue to monitor and upgrade our internal controls as necessary or appropriate for our business, but there can be no assurance that such improvements will be sufficient to provide us with effective internal control over financial reporting.</span></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_160"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. Other Information </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the three months ended December 31, 2024, no director or officer of the Company <ix:nonNumeric contextRef="c-199" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-871"><ix:nonNumeric contextRef="c-199" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-872">adopted</ix:nonNumeric></ix:nonNumeric>, modified or <ix:nonNumeric contextRef="c-199" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-873"><ix:nonNumeric contextRef="c-199" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-874">terminated</ix:nonNumeric></ix:nonNumeric> a &#8220;Rule 10b5-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as each term is defined in Item 408(a) of Regulation S-K.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_163"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131</span></div></div></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_166"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part III</span></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_169"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10. Directors, Executive Officers and Corporate Governance </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement related to the 2025 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K pursuant to General Instruction G(3) of Form 10-K.</span></div><div><span><br/></span></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_175"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11. Executive Compensation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement related to the 2025 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K pursuant to General Instruction G(3) of Form 10-K.</span></div><div style="padding-left:18pt"><span><br/></span></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_172"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement related to the 2025 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K pursuant to General Instruction G(3) of Form 10-K.</span></div><div style="padding-left:36pt"><span><br/></span></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_178"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13. Certain Relationships and Related Transactions, and Director Independence</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The information <ix:nonNumeric contextRef="c-1" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true" id="f-875">required by this Item is incorporated herein by reference</ix:nonNumeric> to the information that will be contained in our proxy statement related to the 2025 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K pursuant to General Instruction G(3) of Form 10-K.</span></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_181"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14. Principal Accountant Fees</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement related to the 2025 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K pursuant to General Instruction G(3) of Form 10-K.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">132</span></div></div></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_184"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part IV</span></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_187"></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15. Exhibits and Financial Statement Schedules</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.73pt">Financial Statements: See &#8220;Index to Consolidated Financial Statements&#8221; in Part II, Item 8 of this Annual Report on Form 10-K</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.26pt">Exhibits.</span></div><div style="padding-left:9pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:8.178%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.009%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.450%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.009%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.000%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.014%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Exhibit</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Number</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Description</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Incorporated by</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Reference</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Filed Herewith</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Form</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Date</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Number</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">2.1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000114036123001714/ny20006674x1_ex2-1.htm">Agreement and Plan of Merger and Reorganization, dated January 17, 2023, by and among Angion Biomedica Corp., Arkham Merger Sub, Inc. and Elicio Therapeutics, Inc</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">1/17/2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">2.1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">3.1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000110465921016652/tm215755d1_ex3-1.htm">Amended and Restated Certificate of Incorporation</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">2/9/2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">3.1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">3.2</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000114036123028077/brhc20053890_ex3-3.htm">Certificate of Amendment (Reverse Stock Split) to the Amended and Restated Certificate of Incorporation, dated June 1, 2023.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">6/2/2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">3.3</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">3.3</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000114036123028077/brhc20053890_ex3-4.htm">Certificate of Amendment (Officer Exculpation) to the Amended and Restated Certificate, dated June 1, 2023.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">6/2/2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">3.4</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">3.4</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000114036123028077/brhc20053890_ex3-5.htm">Certificate of Amendment (Name Change) to the Amended and Restated Certificate of Incorporation, dated June 1, 2023.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">6/2/2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">3.5</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">3.5</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000110465921016652/tm215755d1_ex3-2.htm">Amended and Restated Bylaws</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">2/9/2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">3.2</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">4.1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Reference is made to exhibits 3.1 through 3.5.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">4.2</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000234/a2242860zex-4_2.htm">Form of Common Stock Certificate.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">S-1/A</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">2/1/2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">4.2</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">4.3</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000107/a2242765zex-4_3.htm">Form of Warrant to Purchase Common Stock.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">S-1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">1/15/2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">4.3</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">4.4</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000107/a2242765zex-4_6.htm">Amended and Restated Registration Rights Agreement, dated as of March 31, 2020, by and among Angion Biomedica Corp. and the investors party thereto.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">S-1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">1/15/2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">4.6</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">4.5</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000160148522000022/angion-descriptionofsecuri.htm">Description of Registrant&#8217;s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">3/30/2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">4.5</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">4.6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000119312525016455/d914999dex41.htm">Form of Common Warrant</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">1/30/2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">4.7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000114036124036848/ef20033947_ex4-1.htm">Form of Senior Secured Convertible Promissory Note due February 15, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000114036124036848/ef20033947_ex4-1.htm">6</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000114036124036848/ef20033947_ex4-1.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">8/12/2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">4.8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000114036124031811/ny20031755x4_ex4-1.htm">Form of Common Warrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">6/28/2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">4.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000114036124031811/ny20031755x4_ex4-2.htm">Form of Pre-Funded Warrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">6/28/2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">4.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">4.10</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001601485/000160148524000015/angn-20240318.htm">Form of Pre-Funded Warrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">3/18/2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">10.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">10.1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000114036123014578/ny20006674x9_ex10-34.htm">Lease Between Elicio Therapeutics, Inc. and RREF II 451D, LLC dated July 21, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">S-4/A</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">3/29/2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">10.34</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">10.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000119312525016455/d914999dex101.htm">Form of Securities Purchase Agreement, dated as of January 29, 2025, by and among Elicio Therapeutics, Inc. and the purchasers party thereto</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">1/30/2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">10.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000114036124036848/ef20033947_ex10-1.htm">Securities Purchase Agreement, dated August 12, 2024, by and between the Company and GKCC, LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">8/12/2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">10.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000114036124036848/ef20033947_ex10-2.htm">Security Agreement, dated August 12, 2024, by and between the Company and GKCC, LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">8/12/2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">10.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">10.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000114036124036848/ef20033947_ex10-3.htm">IP Security Agreement, dated August 12, 2024, by and between the Company and GKCC, LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">8/12/2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">10.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">10.6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000114036124036848/ef20033947_ex10-4.htm">Subsidiary Guarantee, dated August 12, 2024, among Elicio Operating Company, Inc., Elicio Securities Corp. and GKCC, LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">8/12/2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">10.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">10.7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001601485/000160148524000015/angn-20240318.htm">Subscription Agreement, dated as of March 18, 2024, by and between Elicio Therapeutics, Inc. and GKCC, LLC.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">3/18/2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">10.8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001601485/000160148524000045/angn-20240630.htm">Capital on DemandTM Sales Agreement, dated as of June 3, 2024, by and between Elicio Therapeutics, Inc. and JonesTrading Institutional Services LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">S-3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">6/3/2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">1.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">10.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000114036123028077/brhc20053890_ex10-8.htm">Form of Indemnification Agreement between Elicio Therapeutics, Inc. and each of its directors and officers.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">6/2/2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">10.8</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">10.10</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000114036123028077/brhc20053890_ex10-13.htm">Information Rights Letter, dated May 30, 2023, by and between Clal Biotechnology Industries Ltd. and Elicio Therapeutics, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">6/2/2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">10.13</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">10.11#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000114036123014578/ny20006674x9_ex10-29.htm">Employment Agreement between Elicio Therapeutics, Inc. and Robert Connelly, dated as of November 15, 2018.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">S-4/A</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">3/29/2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">10.29+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">133</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:8.178%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.009%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.450%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.009%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.000%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.014%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">10.12#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000114036123014578/ny20006674x9_ex10-30.htm">Offer Letter between Elicio Therapeutics, Inc. and Dr. Christopher Haqq, dated as of September 29, 2019.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">S-4/A</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">3/29/2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">10.30+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">10.13#</span></div><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000114036123014578/ny20006674x9_ex10-32.htm">Employment Letter, by and between Elicio Therapeutics, Inc. and Peter DeMuth, dated as of April 13, 2022.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">S-4/A</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">3/29/2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">10.32+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">10.14#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000160148525000022/confidential-elicioemplo.htm">Employ</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000160148525000022/confidential-elicioemplo.htm">ment Agreement, dated March 21, 2025, by and between Elicio Therapeutics, Inc. and Preetam Shah.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">3/24/2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">10.1+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">10.15</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000160148523000086/eltxpipesubscriptionagmt.htm">Subscription Agreement, dated as of December 22, 2023, by and between the Company and GKCC, LLC.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">12/22/2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">10.1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">10.16#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000114036123014578/ny20006674x9_ex10-27.htm">Elicio Therapeutics, Inc. 2012 Equity Incentive Plan, as amended.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">S-4/A</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">3/29/2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">10.27+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">10.17#</span></div><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000114036123014578/ny20006674x9_ex10-28.htm">Elicio Therapeutics, Inc. 2022 Equity Incentive Plan, as amended.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">S-4/A</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">3/29/2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">10.28+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">10.18&#8224;</span></div><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000114036123014578/ny20006674x9_ex10-25.htm">Exclusive Patent License Agreement, dated January 22, 2016, by and between Elicio Therapeutics, Inc. and the Massachusetts Institute of Technology, as amended.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">S-4/A</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">3/29/2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">10.25+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">10.19</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000114036123001714/ny20006674x1_ex10-1.htm">Note Purchase Agreement, dated January 17, 2023, by and between Elicio Therapeutics and Angion Biomedica Corp., and Form of Promissory Note.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">1/17/2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">10.1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">10.20#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000160148524000023/elicio-amendedandrestate.htm">Amended and Restated Non-Employee Director Compensation Policy.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">3/29/2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">10.14</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">10.21#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000160148524000023/elicio-executiveseveranc.htm">Executive Severance Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">2/2/2024</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">10.22#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000107/a2242765zex-10_5a.htm">Second Amended and Restated 2015 Equity Incentive Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">S-1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">1/15/2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">10.5(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">10.23#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000107/a2242765zex-10_5b.htm">Form of Incentive Stock Option Grant under 2015 Equity Incentive Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">S-1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">1/15/2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">10.5(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">10.24#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000107/a2242765zex-10_5c.htm">Form of Non-Qualified Stock Option Grant under 2015 Equity Incentive Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">S-1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">1/15/2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">10.5(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">10.25#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000107/a2242765zex-10_5d.htm">Form of Stock Option Exercise under 2015 Equity Incentive Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">S-1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">1/15/2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">10.5(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">10.26#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000234/a2242860zex-10_6a.htm">2021 Incentive Award Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">S-1/A</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">2/1/2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">10.6(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">10.27#</span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000234/a2242860zex-10_6b.htm">Form of Stock Option Grant Notice and Stock Option Agreement under the 2021 Incentive Award Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">2/1/2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">10.6(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">10.28#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000234/a2242860zex-10_6c.htm">Form of Restricted Stock Award Grant Notice and Restricted Stock Award Agreement under the 2021 Incentive Award Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">S-1/A</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">2/1/2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">10.6(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">10.29#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000234/a2242860zex-10_6d.htm">Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2021 Incentive Award Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">S-1/A</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">2/1/2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">10.6(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">10.30#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000234/a2242860zex-10_7.htm">2021 Employee Stock Purchase Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">S-1/A</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">2/1/2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">10.7</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">10.31#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000160148524000023/elicio-inducementincenti.htm">Elicio Therapeutics, Inc. 2024 Inducement Incentive Award Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">3/29/2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">10.19</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">10.32#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000160148524000023/elicio-formofoptionagree.htm">Form of Stock Option Grant Notice and Stock Option Agreement under the 2024 Inducement Incentive Award Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">3/29/2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">10.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">10.33#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000160148524000023/elicio-formofinducements.htm">Form of Inducement Stock Option Grant Notice and Agreement.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">3/29/2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">10.21</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">19.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="elicio-insidertradingcom.htm"><ix:nonNumeric contextRef="c-1" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true" id="f-876">2021 Insider Trading Compliance Policy, as amended</ix:nonNumeric></a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">X</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">21.1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit2112024.htm">Subsidiaries of the registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">X</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">23.1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="eliciotherapeuticsinc123.htm">Consent of independent registered public accounting firm.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">X</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">24.1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="elicio-powerofattorney20.htm">Power of Attorney (reference is made to the signature page hereto).</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">X</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">31.1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="elicio-exhibit311.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">X</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">32.1&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="elicio-exhibit321.htm">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">X</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">97.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="elicio_clawbackpolicynas.htm">Elicio Therapeutics, Inc. Clawback Policy (effective October 31, 2023).</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">101.INS</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Inline XBRL Instance Document</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">X</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">101.SCH</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Inline XBRL Taxonomy Extension Schema Document</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">X</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">101.CAL</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">X</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">101.DEF</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">X</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">101.LAB</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">X</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:8.178%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.009%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.450%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.009%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.000%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.014%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">101.PRE</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">X</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">104</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Cover Page Interactive Data File</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">X</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________________________</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#8224;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">       </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Portions of this exhibit have been omitted in accordance with Item 601(b)(10) of Regulation S-K.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">#</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">       </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Indicates management contract or compensatory plan.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#x5E;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">       </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">The certification that accompanies the Annual Report on Form 10-K pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, is not deemed &#8220;filed&#8221; by the Registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:10pt"><span><br/></span></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_190"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16. Form 10-K Summary</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135</span></div></div></div><div id="i488c1714f53641d3b5e4dbb098e37e6c_193"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Date: March&#160;31, 2025 </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="padding-left:184.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELICIO THERAPEUTICS, INC.  </span></div><div><span><br/></span></div><div style="padding-left:184.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> /s/ Robert Connelly </span></div><div style="padding-left:180pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Robert Connelly </span></div><div style="padding-left:180pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer </span></div><div style="padding-left:180pt;text-indent:36pt"><span><br/></span></div><div style="padding-left:180pt;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Power of Attorney</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Robert Connelly, as his or her true and lawful attorney-in-fact and agent, with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K and to file the same, with all exhibits thereto and other documents in connection therewith, with the SEC, granting unto said attorney-in-fact and agent, with full power to act alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed by the following persons in the capacities and on the dates indicated. </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"><tr><td style="width:1.0%"/><td style="width:33.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.140%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.516%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.898%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Signature</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Title</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Date</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">/s/ Robert Connelly</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Robert Connelly</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Chief Executive Officer, President and Director</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(Principal Executive Officer, Principal Financial Officer, and Principal Accounting Officer)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">/s/ Jay Venkatesan, M.D.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Director</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Jay Venkatesan, M.D.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">/s/ Julian Adams, Ph.D.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Director</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Julian Adams, Ph.D.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">/s/ Carol Ashe</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Director</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Carol Ashe</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">/s/ Yekaterina (Katie) Chudnovsky</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Director</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Yekaterina (Katie) Chudnovsky</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i488c1714f53641d3b5e4dbb098e37e6c_602">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"><tr><td style="width:1.0%"/><td style="width:33.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.140%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.516%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.898%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">/s/ Robert R. Ruffolo, Jr., Ph.D.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Director</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Robert R. Ruffolo, Jr., Ph.D.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">/s/ Karen Wilson</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Director</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Karen Wilson</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">/s/ Allen Nissenson, M.D.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Director</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Allen Nissenson, M.D.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">137</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>2
<FILENAME>elicio-insidertradingcom.htm
<DESCRIPTION>EX-19.1
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>elicio-insidertradingcom</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- elicio-insidertradingcom001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="elicio-insidertradingcom001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">US-DOCS\114338280.5   ELICIO THERAPEUTICS, INC.  INSIDER TRADING COMPLIANCE POLICY  (Adopted January 5, 2021, Effective as of February 4, 2021)  (Amended by the Board of Directors on December 7, 2023 and March 16, 2025)  This Insider Trading Compliance Policy (this &#8220;Policy&#8221;) consists of six sections:  &#8226; Section I provides an overview;   &#8226; Section II sets forth Elicio Therapeutics, Inc.&#8217;s (the &#8220;Company&#8221;) policies  prohibiting insider trading;   &#8226; Section III explains insider trading;   &#8226; Section IV consists of procedures that have been put in place by the  Company to prevent insider trading;   &#8226; Section V sets forth additional transactions that are prohibited by this  Policy; and  &#8226; Section VI refers to the execution and return of a compliance certificate.  I. OVERVIEW  Preventing insider trading is necessary to comply with securities laws and to preserve the  reputation and integrity of the Company as well as that of all persons affiliated with the Company.  &#8220;Insider trading&#8221; occurs when any person purchases or sells a security (e.g., common stock) while  in possession of &#8220;inside information&#8221; relating to the security. As explained in Section III below,  &#8220;inside information&#8221; is information that is both &#8220;material&#8221; and &#8220;non-public.&#8221; Insider trading  violates several laws, including civil and criminal laws. The penalties for violating insider trading  laws include imprisonment, disgorgement of profits, civil fines, and criminal fines of up to $5  million for individuals and $25 million for entities. Insider trading is also prohibited by this Policy,  and violation of this Policy may result in Company-imposed sanctions, including removal or  dismissal for cause.  This Policy applies to all officers, directors, employees and consultants of the Company  and its subsidiaries (&#8220;Company Personnel&#8221;). The restrictions in this Policy also apply to any  Company Personnel&#8217;s (1) immediate family members who reside with them, (2) others living in  their household (whether or not related to them), (3) family members who do not live in their  household but whose transactions in the Company&#8217;s securities are directed by them or are subject  to their influence or control (e.g., parents or children who consult with them before they trade in  the Company&#8217;s securities) and (4) any entities that they influence or control, including any  corporations, limited liability companies, partnerships or trusts (each person or entity identified in  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- elicio-insidertradingcom002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="elicio-insidertradingcom002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">US-DOCS\114338280.5 clauses (1) &#8211; (4), a &#8220;Related Person&#8221;).  Securities and Exchange Commission (&#8220;SEC&#8221;) regulations  specifically provide that any material non-public information about the Company communicated  to any spouse, parent, child or sibling is considered to have been communicated under a duty of  trust or confidence; and that any trading in the Company&#8217;s securities by such family members  while they are aware of such information may, therefore, violate insider trading laws and  regulations.  Company Personnel are expected to be responsible for the compliance of all Related  Persons with this Policy. This means that, to the extent such Related Persons of Company  Personnel intend to trade in the Company&#8217;s securities, the Related Persons need to comply with  the black-out periods and all other restrictions in this Policy. Furthermore, Company Personnel  should not participate in any investment club (i.e., groups of people who pool their money to make  investments) that may invest in the Company&#8217;s securities. Notwithstanding the foregoing, the pre- clearance policy, blackout periods and prohibited transactions of this Policy, do not apply to  venture capital entities or other institutional investors who have implemented procedures to ensure  compliance with the requirements of Rule 10b5-1(c)(2) under the Securities Exchange Act of  1934, as amended.   This Policy extends to all activities within and outside an individual&#8217;s Company duties. All  Company Personnel must review this Policy.    Questions regarding the Policy should be directed to the Company&#8217;s General Counsel (or  the Chief Financial Officer in the absence of a General Counsel), or such other person as the  Company&#8217;s Board of Directors (the &#8220;Board of Directors&#8221;) may designate from time to time (the  &#8220;Compliance Officer&#8221;).  II. STATEMENT OF POLICIES PROHIBITING INSIDER TRADING  No officer, director, employee or consultant, or any immediate family member or any  Related Person of any such person, shall purchase or sell any securities of the Company while in  possession of material, non-public information (subject to the specific exceptions noted below).    This Policy also applies with equal force to information relating to any other company,  including our customers or suppliers, obtained by Company Personnel during the course of their  service to or employment by the Company.  Specifically, no Company Personnel who, in the  course of work on behalf of the Company, learns of material non-public information about a  company with which the Company does business may trade in the other company&#8217;s securities until  the information becomes public or is no longer material.   In addition, no Company Personnel shall directly or indirectly engage in any other action  to take advantage of, or pass on to others, communicate (or &#8220;tip&#8221;) material, non-public information  to anyone outside the Company (except in accordance with the Company&#8217;s policies regarding the  protection or authorized external disclosure of Company information) or to anyone within the  Company other than on a need-to-know basis.  III. EXPLANATION OF INSIDER TRADING  &#8220;Insider trading&#8221; refers to the purchase or sale of a security by someone who is in  possession of &#8220;material,&#8221; &#8220;non-public&#8221; information relating to the security.  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- elicio-insidertradingcom003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="elicio-insidertradingcom003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">US-DOCS\114338280.5 &#8220;Insider&#8221; refers to employees, officers, directors and consultants of the Company and  anyone else within the Company who has material, non-public information about the Company.  &#8220;Securities&#8221; includes stocks, bonds, notes, debentures, options, warrants and other  convertible securities, as well as derivative instruments.  &#8220;Purchase&#8221; and &#8220;sale&#8221; are defined broadly under the federal securities law. &#8220;Purchase&#8221;  includes not only the actual purchase of a security, but any contract to purchase or otherwise  acquire a security.   &#8220;Sale&#8221; includes not only the actual sale of a security, but any contract to sell or otherwise  dispose of a security.   These definitions extend to a broad range of transactions, including conventional cash-for- stock transactions, conversions, the exercise of stock options, and acquisitions and exercises of  warrants or puts, calls or other derivative securities.  It is generally understood that insider trading includes the following:  &#8226; trading by insiders while in possession of material, non-public information;  &#8226; trading by persons other than insiders while in possession of material, non-public  information, if the information either was given in breach of an insider&#8217;s duty to  keep it confidential or was misappropriated; and  &#8226; communicating or tipping material, non-public information to others, including  recommending the purchase or sale of a security while in possession of such  information.  A. What Facts are Material?  The materiality of a fact depends upon the circumstances. A fact is considered &#8220;material&#8221;  if there is a substantial likelihood that a reasonable investor would consider it important in making  a decision to buy, sell or hold a security, or if the fact is likely to have a significant effect on the  market price of the security. Material information can be positive or negative and can relate to  virtually any aspect of a company&#8217;s business or to any type of security, debt or equity.  Examples of material information include (but are not limited to) information about the  results of clinical trials; communications sent to or received from the U.S. Food and Drug  Administration; dividends; corporate earnings or earnings forecasts; mergers, acquisitions, tender  offers or dispositions; major new products or product developments; important business  developments such as major contract awards or cancellations; management or control changes;  significant borrowing or financing developments including pending public sales or offerings of  debt or equity securities; defaults on borrowings; bankruptcies; significant pending or threatened  litigation or the resolution of such litigation, or significant regulatory actions or developments, or  other items that require the filing of a Current Report on Form 8-K with the SEC. Moreover,  material information does not have to be related to a company&#8217;s business. For example, the  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- elicio-insidertradingcom004.jpg -->
<DIV style="padding-top:2em;">
<IMG src="elicio-insidertradingcom004.jpg" title="slide4" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">US-DOCS\114338280.5 contents of a forthcoming newspaper column that is expected to affect the market price of a  security can be material.  A good general rule of thumb: When in doubt, do not trade.  B. What is Non-public?  Information is &#8220;non-public&#8221; if it is not available to the general public. In order for  information to be considered public, it must be widely disseminated in a manner making it  generally available to investors through such media as Dow Jones, Business Wire, Reuters, The  Wall Street Journal, Associated Press, or United Press International (all of which generally are  accessible via a nationally recognized service such as Global News Wire, Business Wire, or PR  Newswire), a broadcast on widely available radio or television programs, publication in a widely  available newspaper, magazine or news web site, a Regulation FD-compliant conference call, or  public disclosure documents filed with the SEC that are available on the SEC&#8217;s web site.  The circulation of rumors, even if accurate and reported in the media, does not constitute  effective public dissemination. In addition, even after a public announcement, a reasonable period  of time must lapse in order for the market to react to the information. Generally, the Company  allows trading to begin at the beginning of the second trading day following the date of publication  to provide for a reasonable waiting period before such information is deemed to be public.  C. Who is an Insider?  &#8220;Insiders&#8221; include employees, officers, directors and consultants of a company and anyone  else within a company who has material, non-public information about a company.  Insiders have  independent fiduciary duties to their company and its stockholders not to trade on material, non- public information relating to the company&#8217;s securities. All officers, directors, employees and  consultants of the Company should consider themselves insiders with respect to material, non- public information about the Company&#8217;s business, activities and securities. Officers, directors,  employees and consultants may not trade in the Company&#8217;s securities while in possession of  material, non-public information relating to the Company, nor may they tip such information to  anyone outside the Company (except in accordance with the Company&#8217;s policies regarding the  protection or authorized external disclosure of Company information) or to anyone within the  Company other than on a need-to-know basis.  The restrictions in this Policy also apply to any Company Personnel&#8217;s Related Persons, and  Company Personnel subject to this Policy are responsible for ensuring that such Related Persons  comply with this Policy.   D. Trading by Persons Other than Insiders  Insiders may be liable for communicating or tipping material, non-public information to a  third party (&#8220;tippee&#8221;), and insider trading violations are not limited to trading or tipping by insiders.  Persons other than insiders also can be liable for insider trading, including tippees who trade on  material, non-public information tipped to them or individuals who trade on material, non-public  information that has been misappropriated.  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- elicio-insidertradingcom005.jpg -->
<DIV style="padding-top:2em;">
<IMG src="elicio-insidertradingcom005.jpg" title="slide5" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">US-DOCS\114338280.5 Tippees inherit an insider&#8217;s duties and are liable for trading on material, non-public  information illegally tipped to them by an insider. Similarly, just as insiders are liable for the  insider trading of their tippees, so are tippees who pass the information along to others who trade.  In other words, a tippee&#8217;s liability for insider trading is no different from that of an insider. Tippees  can obtain material, non-public information by receiving overt tips from others or through, among  other things, conversations at social, business, or other gatherings.  E. Penalties for Engaging in Insider Trading  Penalties for trading on or tipping material, non-public information can extend significantly  beyond any profits made or losses avoided, both for individuals engaging in such unlawful conduct  and their employers. The SEC and Department of Justice have made the civil and criminal  prosecution of insider trading violations a top priority. Enforcement remedies available to the  government or private plaintiffs (e.g., the Company&#8217;s stockholders) under the federal securities  laws include:  &#8226; SEC administrative sanctions;  &#8226; securities industry self-regulatory organization sanctions;  &#8226; civil injunctions;  &#8226; damage awards to private plaintiffs;  &#8226; disgorgement of all profits;  &#8226; civil fines for the violator of up to three times the amount of profit gained or loss  avoided;  &#8226; civil fines of up to three times the amount of profit gained or loss avoided by the  violator;  &#8226; criminal fines for individual violators of up to $5,000,000 ($25,000,000 for an  entity); and  &#8226; jail sentences of up to 20 years.  In addition, insider trading could result in serious sanctions by the Company, including  dismissal. Insider trading violations are not limited to violations of the federal securities laws.  Other federal and state civil or criminal laws, such as the laws prohibiting mail and wire fraud and  the Racketeer Influenced and Corrupt Organizations Act (&#8220;RICO&#8221;), also may be violated in  connection with insider trading.  Any of the above consequences, including an SEC investigation that does not result in  prosecution, can tarnish the Company&#8217;s or an individual&#8217;s reputation and irreparably damage a  career.  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- elicio-insidertradingcom006.jpg -->
<DIV style="padding-top:2em;">
<IMG src="elicio-insidertradingcom006.jpg" title="slide6" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">US-DOCS\114338280.5 F. Size of Transaction and Reason for Transaction Do Not Matter  The size of the transaction or the amount of profit received does not have to be significant  to result in prosecution. The SEC has the ability to monitor even the smallest trades, and the SEC  performs routine market surveillance. Brokers and dealers are required by law to inform the SEC  of any possible violations by people who may have material, non-public information. The SEC  aggressively investigates and prosecutes even small insider trading violations.  G. Examples of Insider Trading  Examples of insider trading cases include actions brought against corporate officers,  directors, employees and consultants who traded in a company&#8217;s securities after learning of  significant confidential corporate developments; friends, business associates, family members and  other tippees of such officers, directors, employees and consultants who traded in the securities  after receiving such information; government employees who learned of such information in the  course of their employment; and other persons who misappropriated, and took advantage of,  confidential information from their employers.  The following are illustrations of insider trading violations. These illustrations are  hypothetical and, consequently, not intended to reflect on the actual activities or business of the  Company or any other entity.  Trading by Insider  An officer of X Corporation learns that earnings to be reported by X Corporation will  increase dramatically. Prior to the public announcement of such earnings, the officer  purchases X Corporation&#8217;s stock. The officer, an insider, is liable for all profits as well as  penalties of up to three times the amount of all profits. The officer also is subject to, among  other things, criminal prosecution, including up to $5,000,000 in additional fines and 20  years in jail. Depending upon the circumstances, X Corporation and the individual to whom  the officer reports also could be liable as controlling persons.  Trading by Tippee  An officer of X Corporation tells a friend that X Corporation is about to publicly announce  that it has concluded an agreement for a major acquisition. This tip causes the friend to  purchase X Corporation&#8217;s stock in advance of the announcement. The officer is jointly  liable with his friend for all of the friend&#8217;s profits, and each is liable for all civil penalties  of up to three times the amount of the friend&#8217;s profits. The officer and his friend are also  subject to criminal prosecution and other remedies and sanctions, as described above.  IV. STATEMENT OF PROCEDURES PREVENTING INSIDER TRADING  While it is never permissible to trade based on material non-public information, we  are implementing the following procedures to help prevent inadvertent violations of this  Policy and avoid even the appearance of an improper transaction (which could result, for  example, where Company Personnel engage in a trade while unaware of a pending major  development).    </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- elicio-insidertradingcom007.jpg -->
<DIV style="padding-top:2em;">
<IMG src="elicio-insidertradingcom007.jpg" title="slide7" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">US-DOCS\114338280.5 All Company Personnel are required to follow these procedures.  A. Black-Out Periods  &#8226; No officer, director, employee or consultant listed on Schedule I (as amended  from time to time by the Compliance Officer), or any Related Person of such  person shall purchase or sell any security of the Company during the period  beginning on the 15th day prior to the last trading day of any fiscal quarter of  the Company until the beginning of the second trading day after the public  release of the Company&#8217;s financial results for each fiscal quarter  and, in the  case of the fourth quarter, financial results for the year end, whether or not  the Company or any Company Personnel or Related Person  is in possession  of material, non-public information.   &#8226; Additionally, from time to time, the Company, through the Board of Directors, the  Company&#8217;s disclosure committee or the Compliance Officer, may recommend that  some or all Company Personnel, Related Persons or others suspend trading in the  Company&#8217;s securities because of developments that have not yet been disclosed to the  public. Individuals affected by such an event-specific blackout may be notified by the  Company that they are subject to the blackout (or the Compliance Officer may  determine in their discretion to rely instead on the pre-clearance requirement provided  for in Section IV.B of this policy). All those affected should not trade in the  Company&#8217;s securities while the event-specific blackout is in effect, and in the event  that a press release is issued by the Company in connection with the event that resulted  in the event-specific blackout (or the event or circumstances go away), such  suspension shall continue until the beginning of the second trading day after the date  of public release (or the event or circumstances go away).  Additionally, those subject  to the event-specific blackout should not disclose to others that we have suspended  trading, as the blackout itself is material non-public information. Events that may give  rise to event-specific blackouts may include consideration of major strategic  transactions (e.g., acquisitions, dispositions, joint ventures or financings), product  developments, interim earnings or sales releases, significant legal proceedings and  other circumstances that potentially implicate material non-public information.  These prohibitions do not apply to::  &#8226; purchases of the Company&#8217;s securities from the Company (e.g., Employee Stock  Purchase Plan or exercise of an option) or sales of the Company&#8217;s securities to the  Company, or the surrender to, or withholding by, the Company of the Company&#8217;s  securities (e.g., to cover withholding obligations upon the vesting or settlement of  equity-based awards).   This Policy does apply, however, to any sale of stock as  part of a broker-assisted cashless exercise of an option, or any other market sale  of stock for the purpose of generating the cash needed to pay the exercise price  and/or taxes upon the exercise of an option or the vesting of restricted stock units;    </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- elicio-insidertradingcom008.jpg -->
<DIV style="padding-top:2em;">
<IMG src="elicio-insidertradingcom008.jpg" title="slide8" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">US-DOCS\114338280.5 &#8226; bona fide gifts of the Company&#8217;s securities, unless the person making the gift (the  donor) has reason to believe that the recipient of the gift intends to sell the  Company&#8217;s securities while the donor is in possession of material non-public  information;   &#8226; Transactions in mutual funds and exchange traded funds that are invested in the  Company&#8217;s securities; or  &#8226; Notwithstanding the restrictions and prohibitions on trading in the Company&#8217;s  securities set forth in this Policy, persons subject to this Policy are permitted to  effect transactions in the Company&#8217;s securities pursuant to approved Trading Plans,  which may include transactions during the prohibited periods discussed above.  In  order to comply with this policy, the Company must pre-approve any such 10b5-1  Plan prior to its effectiveness in accordance with the Elicio Therapeutics, Inc. Rule  10b5-1 Trading Plan Policy.  Exceptions to the black-out period policy may be approved only by the Compliance Officer  or, in their absence, the Chief Financial Officer.  .  For purposes of clarity, the Company shall periodically review and update Schedule I.  B. Pre-Clearance of All Trades by All Executive Officers and Directors and Certain  Employees and Consultants  To provide assistance in preventing inadvertent violations of applicable securities laws and to  avoid the appearance of impropriety in connection with the purchase and sale of the Company&#8217;s  securities, all transactions in the Company&#8217;s securities (including without limitation,  acquisitions and dispositions of Company stock, broker-assisted  &#8220;net&#8221; or &#8220;cashless&#8221; exercises  of stock options, and the sale of Company stock issued upon exercise of stock options) by all  officers, directors, employees and consultants listed on Schedule II (as amended from time to  time by the Compliance Officer) or any Related Person of such persons must be pre-cleared  by the Compliance Officer. As part of the pre-clearance process, the individual requesting pre- clearance must confirm that he or she is not in possession of material, non-public information. Pre- clearance does not relieve anyone of their responsibility under SEC rules.   For clarity, transactions in the Company&#8217;s securities pursuant to a Rule 10b5-1 plan, which  was approved in advance of entering into the plan in accordance with the Elicio Therapeutics, Inc.  Rule 10b5-1 Trading Plan Policy, are considered pre-cleared. For purposes of clarity, the Company  shall periodically review and update Schedule II.  C. Post-Termination Transactions  With the exception of the pre-clearance requirement under this Policy, the insider trading  laws continue to apply to transactions in the Company&#8217;s securities even after termination of service  to the Company. If an individual is in possession of material, non-public information when their  service terminates, that individual may not trade in the Company&#8217;s securities until that information  has become public or is no longer material, and it would be prudent for the individual, if they are  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- elicio-insidertradingcom009.jpg -->
<DIV style="padding-top:2em;">
<IMG src="elicio-insidertradingcom009.jpg" title="slide9" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">US-DOCS\114338280.5 subject to a black-out period upon termination of service, to refrain from trading until those  restrictions no longer apply to Company Personnel.  D. Information Relating to the Company  1. Access to Information  Access to material, non-public information about the Company, including the Company&#8217;s  business, earnings or prospects, should be limited to officers, directors, employees and consultants  of the Company on a need-to-know basis. In addition, such information should not be  communicated to anyone outside the Company under any circumstances (except in accordance  with the Company&#8217;s policies regarding the protection or authorized external disclosure of  Company information) or to anyone within the Company on an other than need-to-know basis.  In communicating material, non-public information to employees of the Company, all  officers, directors, employees and consultants must take care to emphasize the need for  confidential treatment of such information and adherence to the Company&#8217;s policies with regard  to confidential information.  2. Inquiries From Third Parties  Inquiries from third parties, such as industry analysts or members of the media, about the  Company should be directed to the Compliance Officer, the Chief Financial Officer or head of  Investor Relations (if any).  E. Limitations on Access to Company Information  The following procedures are designed to maintain confidentiality with respect to the  Company&#8217;s business operations and activities.  All officers, directors, employees and consultants should take all steps and precautions  necessary to restrict access to, and secure, material, non-public information by, among other  things:  &#8226; maintaining the confidentiality of Company-related transactions;  &#8226; conducting their business and social activities so as not to risk inadvertent  disclosure of confidential information. Review of confidential documents in public  places should be conducted so as to prevent access by unauthorized persons;  &#8226; restricting access to documents and files (including computer files) containing  material, non-public information to individuals on a need-to-know basis (including  maintaining control over the distribution of documents and drafts of documents);  &#8226; promptly removing and cleaning up all confidential documents and other materials  from conference rooms following the conclusion of any meetings (including  erasing any whiteboards or other viewable information);  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- elicio-insidertradingcom010.jpg -->
<DIV style="padding-top:2em;">
<IMG src="elicio-insidertradingcom010.jpg" title="slide10" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">US-DOCS\114338280.5 &#8226; disposing of all confidential documents and other papers, after there is no longer  any business or other legally required need, through shredders when appropriate;  &#8226; restricting access to areas likely to contain confidential documents or material, non- public information, including individual offices that may contain such information;  &#8226; safeguarding laptop computers, mobile devices, tablets, memory sticks, and other  items that contain confidential information, including complying with Company IT  policies to prevent unauthorized access to your devices and/or electronic  information you have access to; and  &#8226; avoiding the discussion of material, non-public information in places where the  information could be overheard by others such as in elevators, restrooms, hallways,  restaurants, airplanes or taxicabs.  Personnel involved with material, non-public information, to the extent feasible, should  conduct their business and activities in areas separate from other Company activities.  V. ADDITIONAL PROHIBITED TRANSACTIONS  The Company has determined that there is a heightened legal risk and/or the appearance of  improper or inappropriate conduct if the persons subject to this Policy engage in short-term or  speculative transactions involving the Company&#8217;s securities. Therefore, Company Personnel shall  comply with the following policies with respect to certain transactions in the Company securities:  A. Short Sales   Short sales of the Company&#8217;s securities evidence an expectation on the part of the seller  that the securities will decline in value, and therefore signal to the market that the seller may not  have confidence in the Company or its short-term prospects. In addition, short sales may reduce  the seller&#8217;s incentive to improve the Company&#8217;s performance. For these reasons, short sales of the  Company&#8217;s securities are prohibited by this Policy. In addition, as noted below, Section 16(c) of the  1934 Act absolutely prohibits Section 16 reporting persons from making short sales of the Company&#8217;s  equity securities, i.e., sales of shares that the insider does not own at the time of sale, or sales of owned  shares against which the insider does not deliver the shares within 20 days after the sale.  B. Publicly Traded Options  A transaction in options is, in effect, a bet on the short-term movement of the Company&#8217;s  stock and therefore may create the appearance that an officer, director, employee or consultant is  trading based on inside information. Transactions in options also may focus an officer&#8217;s, director&#8217;s,  employee&#8217;s or consultant&#8217;s attention on short-term performance at the expense of the Company&#8217;s  long-term objectives. Accordingly, transactions in puts, calls or other derivative securities involving  the Company&#8217;s equity securities, on an exchange or in any other organized market, are prohibited by  this Policy.  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- elicio-insidertradingcom011.jpg -->
<DIV style="padding-top:2em;">
<IMG src="elicio-insidertradingcom011.jpg" title="slide11" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">US-DOCS\114338280.5 C. Hedging Transactions  Certain forms of hedging or monetization transactions, such as zero-cost collars and forward  sale contracts, allow an insider to lock in much of the value of their stock holdings, often in exchange  for all or part of the potential for upside appreciation in the stock. These transactions allow the insider  to continue to own the covered securities, but without the full risks and rewards of ownership. When  that occurs, the insider may no longer have the same objectives as the Company&#8217;s other stockholders.  Therefore, hedging transactions involving the Company&#8217;s equity securities, including but not limited  to zero-cost collars and forward sale contracts, are prohibited by this Policy.  D. Purchases of the Company&#8217;s Securities on Margin; Pledging the Company&#8217;s  Securities to Secure Margin or Other Loans  Purchasing on margin means borrowing from a brokerage firm, bank or other entity in  order to purchase the Company&#8217;s securities (other than in connection with a cashless exercise of  stock options under the Company&#8217;s equity plans). Margin purchases of the Company&#8217;s securities  are prohibited by this Policy. Pledging the Company&#8217;s securities as collateral to secure loans is  prohibited. This prohibition means, among other things, that you cannot hold the Company&#8217;s  securities in a &#8220;margin account&#8221; (which would allow you to borrow against your holdings to buy  securities).  E. Trading on a Short-Term Basis  Any shares of Company securities purchased in the open market must be held for a minimum  of six months and ideally longer.   VI. EXECUTION AND RETURN OF CERTIFICATION OF COMPLIANCE  After reading this Policy, all Company Personnel should execute and return to the Compliance  Officer the Certification of Compliance form attached hereto as Attachment A.    * * * * *  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>exhibit2112024.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i02c1367d05994948a8b6962adf1e0d5a_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.628%"><tr><td style="width:1.0%"></td><td style="width:38.173%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.174%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of Subsidiary</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elicio Operating Company, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elicio Australia Pty Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elicio Securities Corp.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Massachusetts</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>eliciotherapeuticsinc123.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>eliciotherapeuticsinc123</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- eliciotherapeuticsinc123001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="eliciotherapeuticsinc123001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">      CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM    We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (File No.  333-264994, 333-278373, 333-279925, and 333-283199) and Form S-8 (File No. 333-252906, 333-264995,  333-270676, 333-274217, 333-278374) of Elicio Therapeutics, Inc. of our report dated March 31, 2025, relating  to the consolidated financial statements, which includes an explanatory paragraph relating to the Company's  ability to continue as going concern, which appears in this Form 10-K.    /s/ BAKER TILLY US, LLP      Tewksbury, Massachusetts  March 31, 2025      </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24.1
<SEQUENCE>5
<FILENAME>elicio-powerofattorney20.htm
<DESCRIPTION>EX-24.1
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>elicio-powerofattorney20</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- elicio-powerofattorney20001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="elicio-powerofattorney20001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  SIGNATURES    Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has  duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.    Date: March 31, 2025    ELICIO THERAPEUTICS, INC.   By:  /s/ Robert Connelly        Robert Connelly       Chief Executive Officer    Power of Attorney  KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby  constitutes and appoints Robert Connelly, as his or her true and lawful attorneys-in-fact and agents, with full power of  substitution, for him or her in any and all capacities, to sign any and all amendments to this Annual Report on Form  10-K and to file the same, with all exhibits thereto and other documents in connection therewith, with the SEC,  granting unto said attorney-in-fact and agent, with full power to act alone, full power and authority to do and perform  each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and  purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or  his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed  by the following persons in the capacities and on the dates indicated.    Signature  Title  Date        /s/ Robert Connelly  Robert Connelly   Chief Executive Officer, President and  Director  March 31, 2025    (Principal Executive Officer)          /s/ Jay Venkatesan, M.D.  Director  March 31, 2025  Jay Venkatesan, M.D.            /s/ Julian Adams, Ph.D.  Director  March 31, 2025  Julian Adams, Ph.D.            /s/ Carol Ashe  Director  March 31, 2025  Carol Ashe            /s/ Yekaterina (Katie) Chudnovsky   Director  March 31, 2025  Yekaterina (Katie) Chudnovksy            /s/ Robert R. Ruffolo, Jr., Ph.D.  Director  March 31, 2025  Robert R. Ruffolo, Jr., Ph.D.            /s/ Karen Wilson  Director  March 31, 2025  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- elicio-powerofattorney20002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="elicio-powerofattorney20002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">Karen Wilson            /s/ Allen Nissenson, M.D.  Director  March 31, 2025  Allen Nissenson, M.D.                </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>elicio-exhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>elicio-exhibit311</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- elicio-exhibit311001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="elicio-exhibit311001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">    Exhibit 31.1  CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL  FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY  ACT OF 2002  I, Robert Connelly, certify that:  1. I have reviewed this Annual Report on Form 10-K of Elicio Therapeutics, Inc.;  2. Based on my knowledge, this report does not contain any untrue statement of a  material fact or omit to state a material fact necessary to make the statements made, in light of  the circumstances under which such statements were made, not misleading with respect to the  period covered by this report;  3. Based on my knowledge, the financial statements, and other financial information  included in this report, fairly present in all material respects the financial condition, results of  operations and cash flows of the registrant as of, and for, the periods presented in this report;  4. I am responsible for establishing and maintaining disclosure controls and  procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over  financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant  and have:  a. Designed such disclosure controls and procedures, or caused such  disclosure controls and procedures to be designed under my supervision, to ensure that material  information relating to the registrant, including its consolidated subsidiaries, is made known to  me by others within those entities, particularly during the period in which this report is being  prepared;  b. Designed such internal control over financial reporting, or caused such  internal control over financial reporting to be designed under my supervision, to provide  reasonable assurance regarding the reliability of financial reporting and the preparation of  financial statements for external purposes in accordance with generally accepted accounting  principles;  c. Evaluated the effectiveness of the registrant&#8217;s disclosure controls and  procedures and presented in this report our conclusions about the effectiveness of the disclosure  controls and procedures, as of the end of the period covered by this report based on such  evaluation; and  d. Disclosed in this report any change in the registrant&#8217;s internal control over  financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s  fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably  likely to materially affect, the registrant&#8217;s internal control over financial reporting; and  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- elicio-exhibit311002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="elicio-exhibit311002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">    5. I have disclosed, based on my most recent evaluation of internal control over  financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board  of directors (or persons performing the equivalent functions):  a. All significant deficiencies and material weaknesses in the design or  operation of internal control over financial reporting which are reasonably likely to adversely  affect the registrant&#8217;s ability to record, process, summarize and report financial information; and  b. Any fraud, whether or not material, that involves management or other  employees who have a significant role in the registrant&#8217;s internal control over financial reporting.  ELICIO THERAPEUTICS, INC.  By:  /s/ Robert Connelly   Robert Connelly  President and Chief Executive Officer  (Principal Executive Officer, Principal  Financial Officer, and Principal   Accounting Officer)    Date:  March 31, 2025      </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>elicio-exhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>elicio-exhibit321</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- elicio-exhibit321001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="elicio-exhibit321001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">    Exhibit 32.1  CERTIFICATIONS PURSUANT TO  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002  (18 U.S.C. SECTION 1350)  The undersigned officer of Elicio Therapeutics, Inc. (the &#8220;Company&#8221;) certifies to such  officer&#8217;s knowledge, pursuant to 18 U.S.C. &sect; 1350, as adopted pursuant to &sect; 906 of the Sarbanes- Oxley Act of 2002, that:  1. The Annual Report on Form 10-K of the Company for the period ended December  31, 2024 (the &#8220;Annual Report&#8221;), as filed with the Securities and Exchange Commission, fully  complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934,  and  2. The information contained in this Annual Report fairly presents, in all material  respects, the financial condition and results of operations of the Company.    ELICIO THERAPEUTICS, INC.  By:  /s/ Robert Connelly   Robert Connelly  President and Chief Executive Officer  (Principal Executive Officer, Principal  Financial Officer, and Principal   Accounting Officer)  Date:  March 31, 2025    </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>8
<FILENAME>elicio_clawbackpolicynas.htm
<DESCRIPTION>EX-97.1
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>elicio_clawbackpolicynas</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- elicio_clawbackpolicynas001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="elicio_clawbackpolicynas001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">    ELICIO THERAPEUTICS, INC.  CLAWBACK POLICY  I. Introduction  The Board of Directors (the &#8220;Board&#8221;) of Elicio Therapeutics, Inc. (the &#8220;Company&#8221;) believes that it is in the  best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and  accountability and that reinforces the Company&#8217;s pay-for-performance compensation philosophy.  The Board has  therefore adopted this policy which provides for the recoupment of certain executive compensation in the event of an  accounting restatement resulting from material noncompliance with financial reporting requirements under the federal  securities laws (the &#8220;Policy&#8221;).  This Policy is designed to comply with Section 10D of the Securities Exchange Act of  1934, as amended (the &#8220;Exchange Act&#8221;) and final rules and amendments adopted by the Securities and Exchange  Commission (the &#8220;SEC&#8221;) to implement the aforementioned legislation.  II. Administration  This Policy shall be administered by the Board or, if so designated by the Board, the Compensation  Committee of the Board, in which case references herein to the Board shall be deemed references to the Compensation  Committee. Any determinations made by the Board shall be final and binding on all affected individuals.  III. Covered Executives  This Policy applies to the Company&#8217;s current and former executive officers, as determined by the Board in  accordance with the requirements of Section 10D of the Exchange Act and any applicable rules or standards adopted  by the SEC and any national securities exchange on which the Company&#8217;s securities are listed, and such other  employees who may from time to time be deemed subject to the Policy by the Board (&#8220;Covered Executives&#8221;).  IV. Incentive-Based Compensation  For purposes of this Policy, incentive-based compensation (&#8220;Incentive-Based Compensation&#8221;) includes any  compensation that is granted, earned, or vested based wholly or in part upon the attainment of any financial reporting  measures that are determined and presented in accordance with the accounting principles (&#8220;GAAP Measures&#8221;) used  in preparing the Company&#8217;s financial statements and any measures derived wholly or in part from such measures, as  well as non-GAAP Measures, stock price, and total shareholder return (collectively, &#8220;Financial Reporting  Measures&#8221;); however, it does not include: (i) base salaries; (ii) discretionary cash bonuses; (iii) awards (either cash  or equity) that are solely based upon subjective, strategic or operational standards or standards unrelated to Financial  Reporting Measures, and (iv) equity awards that vest solely on completion of a specified employment period or  without any performance condition.  Incentive-Based Compensation is considered received in the fiscal period during  which the applicable reporting measure is attained, even if the payment or grant of such award occurs after the end of  that period.  If an award is subject to both time-based and performance-based vesting conditions, the award is  considered received upon satisfaction of the performance-based conditions, even if such an award continues to be  subject to the time-based vesting conditions.  For the purposes of this Policy, Incentive-Based Compensation may include, among other things, any of the  following:  &#61623; Annual bonuses and other short- and long-term cash incentives.  &#61623; Stock options.  &#61623; Stock appreciation rights.  &#61623; Restricted stock or restricted stock units.  &#61623; Performance shares or performance units.    For purposes of this Policy, Financial Reporting Measures may include, among other things, any of the  following:  &#61623; Company stock price.   &#61623; Total shareholder return.  &#61623; Revenues.  &#61623; Net income.  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- elicio_clawbackpolicynas002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="elicio_clawbackpolicynas002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  2  &#61623; Earnings before interest, taxes, depreciation, and amortization (EBITDA).  &#61623; Funds from operations.  &#61623; Liquidity measures such as working capital or operating cash flow.  &#61623; Return measures such as return on invested capital or return on assets.  &#61623; Earnings measures such as earnings per share.  V. Recoupment; Accounting Restatement  In the event the Company is required to prepare an accounting restatement of its financial statements due to  the Company&#8217;s material noncompliance with any financial reporting requirement under U.S. securities laws, including  any required accounting restatement to correct an error in previously issued financial statements that (i) is material to  the previously issued financial statements or (ii) is not material to previously issued financial statements, but that  would result in a material misstatement if the error were corrected in the current period or left uncorrected in the  current period, the Board will require reimbursement or forfeiture of any excess Incentive-Based Compensation  received by any Covered Executive during the three completed fiscal years immediately preceding the date on which  the Company is required to prepare the accounting restatement (the &#8220;Look-Back Period&#8221;).  For the purposes of this  Policy, the date on which the Company is required to prepare an accounting restatement is the earlier of (i) the date  the Board concludes or reasonably should have concluded that the Company is required to prepare a restatement to  correct a material error, and (ii) the date a court, regulator, or other legally authorized body directs the Company to  restate its previously issued financial statements to correct a material error. The Company&#8217;s obligation to recover  erroneously awarded compensation is not dependent on if or when the restated financial statements are filed.  Recovery of the Incentive-Based Compensation is only required when the excess award is received by a  Covered Executive (i) after the beginning of their service as a Covered Executive, (ii) who served as an executive  officer at any time during the performance period for that Incentive-Based Compensation, (iii) while the Company  has a class of securities listed on a national securities exchange or a national securities association, and (iv) during the  Look-Back Period immediately preceding the date on which the Company is required to prepare an accounting  restatement.  VI. Excess Incentive Compensation: Amount Subject to Recovery  The amount of Incentive-Based Compensation subject to recovery is the amount the Covered Executive  received in excess of the amount of Incentive-Based Compensation that would have been paid to the Covered  Executive had it been based on the restated financial statements, as determined by the Board.  The amount subject to  recovery will be calculated on a pre-tax basis.  For Incentive-Based Compensation received as cash awards, the erroneously awarded compensation is the  difference between the amount of the cash award that was received (whether payable in a lump sum or over time) and  the amount that should have been received applying the restated Financial Reporting Measure.  For cash awards paid  from bonus pools, the erroneously awarded Incentive-Based Compensation is the pro rata portion of any deficiency  that results from the aggregate bonus pool that is reduced based on applying the restated Financial Reporting Measure.  For Incentive-Based Compensation received as equity awards that are still held at the time of recovery, the  amount subject to recovery is the number of shares or other equity awards received or vested in excess of the number  that should have been received or vested applying the restated Financial Reporting Measure.  If the equity award has  been exercised, but the underlying shares have not been sold, the erroneously awarded compensation is the number of  shares underlying the award.  In instances where the Company is not able to determine the amount of erroneously awarded Incentive-Based  Compensation directly from the information in the accounting restatement, the amount will be based on the Company&#8217;s  reasonable estimate of the effect of the accounting restatement on the applicable measure.  In such instances, the  Company will maintain documentation of the determination of that reasonable estimate.  VII. Method of Recoupment  The Board will determine, in its sole discretion, subject to applicable law, the method for recouping Incentive- Based Compensation hereunder, which may include, without limitation:  &#61623; requiring reimbursement of cash Incentive-Based Compensation previously paid;  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- elicio_clawbackpolicynas003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="elicio_clawbackpolicynas003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  3  &#61623; seeking recovery of any gain realized on the vesting, exercise, settlement, sale, transfer, or other  disposition of any equity-based awards;  &#61623; offsetting the recouped amount from any compensation otherwise owed by the Company to the Covered  Executive;  &#61623; cancelling outstanding vested or unvested equity awards; and/or  &#61623; taking any other remedial and recovery action permitted by law, as determined by the Board.  VIII. No Indemnification; Successors  The Company shall not indemnify any Covered Executives against the loss of any incorrectly awarded  Incentive-Based Compensation.  This Policy shall be binding and enforceable against all Covered Executives and their  beneficiaries, heirs, executors, administrators or other legal representatives.  IX. Exception to Enforcement  The Board shall recover any excess Incentive-Based Compensation in accordance with this Policy unless  such recovery would be impracticable, as determined by the Board in accordance with Rule 10D-1 of the Exchange  Act and any applicable rules or standards adopted by the SEC and the listing standards of any national securities  exchange on which the Company&#8217;s securities are listed.  X. Interpretation  The Board is authorized to interpret and construe this Policy and to make all determinations necessary,  appropriate, or advisable for the administration of this Policy.  It is intended that this Policy be interpreted in a manner  that is consistent with the requirements of Section 10D of the Exchange Act and any applicable rules or standards  adopted by the SEC and any national securities exchange on which the Company&#8217;s securities are listed.  XI. Effective Date  This Policy shall be effective as of the date it is adopted by the Board  (the &#8220;Effective Date&#8221;) and shall apply  to Incentive-Based Compensation that is received by a Covered Executive on or after October 2, 2023, as determined  by the Board in accordance with applicable rules or standards adopted by the SEC and the listing standards of any  national securities exchange on which the Company&#8217;s securities are listed.  XII. Amendment; Termination  The Board may amend this Policy from time to time in its discretion and shall amend this Policy as it deems  necessary to comply with any rules or standards adopted by the SEC and the listing standards of any national securities  exchange on which the Company&#8217;s securities are listed. The Board may terminate this Policy at any time.  XIII. Other Recoupment Rights  Any right of recoupment under this Policy is in addition to, and not in lieu of, any other remedies or rights  of recoupment that may be available to the Company pursuant to the terms of any similar policy in any employment  agreement, equity award agreement, or similar agreement and any other legal remedies available to the Company.  506031948v.1  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>angn-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:e62aa408-c713-4974-8057-b2b3ab20d8bb,g:40b09b34-8017-48cd-b202-ee62afe33f17-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:angn="http://www.angn.com/20241231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.angn.com/20241231">
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/cyd-af-sub/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="angn-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="angn-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="angn-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="angn-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.angn.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.angn.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.angn.com/role/ConsolidatedBalanceSheets">
        <link:definition>9952151 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.angn.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>9952152 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>9952153 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity" roleURI="http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity">
        <link:definition>9952154 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquityParenthetical" roleURI="http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquityParenthetical">
        <link:definition>9952155 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.angn.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>9952156 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionoftheBusinessandFinancialCondition" roleURI="http://www.angn.com/role/DescriptionoftheBusinessandFinancialCondition">
        <link:definition>9952157 - Disclosure - Description of the Business and Financial Condition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.angn.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>9952158 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergerandRelatedTransactions" roleURI="http://www.angn.com/role/MergerandRelatedTransactions">
        <link:definition>9952159 - Disclosure - Merger and Related Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.angn.com/role/FairValueMeasurements">
        <link:definition>9952160 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponents" roleURI="http://www.angn.com/role/BalanceSheetComponents">
        <link:definition>9952161 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchGrant" roleURI="http://www.angn.com/role/ResearchGrant">
        <link:definition>9952162 - Disclosure - Research Grant</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredStockCommonStockandStockholdersEquity" roleURI="http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquity">
        <link:definition>9952163 - Disclosure - Convertible Preferred Stock, Common Stock and Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.angn.com/role/StockBasedCompensation">
        <link:definition>9952164 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Warrants" roleURI="http://www.angn.com/role/Warrants">
        <link:definition>9952165 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.angn.com/role/CommitmentsandContingencies">
        <link:definition>9952166 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.angn.com/role/Leases">
        <link:definition>9952167 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.angn.com/role/Debt">
        <link:definition>9952168 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.angn.com/role/IncomeTaxes">
        <link:definition>9952169 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlan" roleURI="http://www.angn.com/role/EmployeeBenefitPlan">
        <link:definition>9952170 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.angn.com/role/NetLossPerShare">
        <link:definition>9952171 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.angn.com/role/RelatedPartyTransactions">
        <link:definition>9952172 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReporting" roleURI="http://www.angn.com/role/SegmentReporting">
        <link:definition>9952173 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.angn.com/role/SubsequentEvents">
        <link:definition>9952174 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.angn.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergerandRelatedTransactionsTables" roleURI="http://www.angn.com/role/MergerandRelatedTransactionsTables">
        <link:definition>9955513 - Disclosure - Merger and Related Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.angn.com/role/FairValueMeasurementsTables">
        <link:definition>9955514 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsTables" roleURI="http://www.angn.com/role/BalanceSheetComponentsTables">
        <link:definition>9955515 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.angn.com/role/StockBasedCompensationTables">
        <link:definition>9955516 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsTables" roleURI="http://www.angn.com/role/WarrantsTables">
        <link:definition>9955517 - Disclosure - Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.angn.com/role/LeasesTables">
        <link:definition>9955518 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.angn.com/role/IncomeTaxesTables">
        <link:definition>9955519 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.angn.com/role/NetLossPerShareTables">
        <link:definition>9955520 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTables" roleURI="http://www.angn.com/role/SegmentReportingTables">
        <link:definition>9955521 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionoftheBusinessandFinancialConditionDetails" roleURI="http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails">
        <link:definition>9955522 - Disclosure - Description of the Business and Financial Condition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.angn.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>9955523 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails" roleURI="http://www.angn.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails">
        <link:definition>9955524 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergerandRelatedTransactionsNarrativeDetails" roleURI="http://www.angn.com/role/MergerandRelatedTransactionsNarrativeDetails">
        <link:definition>9955525 - Disclosure - Merger and Related Transactions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergerandRelatedTransactionsScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" roleURI="http://www.angn.com/role/MergerandRelatedTransactionsScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails">
        <link:definition>9955526 - Disclosure - Merger and Related Transactions - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" roleURI="http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails">
        <link:definition>9955527 - Disclosure - Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails" roleURI="http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails">
        <link:definition>9955528 - Disclosure - Fair Value Measurements - Schedule of Fair Value, Liabilities, Measured on Recurring Basis, Unobservable Input Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.angn.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>9955529 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails" roleURI="http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails">
        <link:definition>9955530 - Disclosure - Fair Value Measurements - Schedule of Fair Value Measurement Inputs and Valuation Techniques (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofPrepaidandOtherCurrentAssetsDetails" roleURI="http://www.angn.com/role/BalanceSheetComponentsScheduleofPrepaidandOtherCurrentAssetsDetails">
        <link:definition>9955531 - Disclosure - Balance Sheet Components - Schedule of Prepaid and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" roleURI="http://www.angn.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails">
        <link:definition>9955532 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsNarrativeDetails" roleURI="http://www.angn.com/role/BalanceSheetComponentsNarrativeDetails">
        <link:definition>9955533 - Disclosure - Balance Sheet Components - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofAccruedExpensesDetails" roleURI="http://www.angn.com/role/BalanceSheetComponentsScheduleofAccruedExpensesDetails">
        <link:definition>9955534 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchGrantDetails" roleURI="http://www.angn.com/role/ResearchGrantDetails">
        <link:definition>9955535 - Disclosure - Research Grant (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredStockCommonStockandStockholdersEquityDetails" roleURI="http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails">
        <link:definition>9955536 - Disclosure - Convertible Preferred Stock, Common Stock and Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.angn.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>9955537 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofShareOptionActivityDetails" roleURI="http://www.angn.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails">
        <link:definition>9955538 - Disclosure - Stock-Based Compensation - Schedule of Share Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails" roleURI="http://www.angn.com/role/StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails">
        <link:definition>9955539 - Disclosure - Stock-Based Compensation - Components of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofAssumptionsUsedtoEstimateFairValueofStockOptionAwardsDetails" roleURI="http://www.angn.com/role/StockBasedCompensationScheduleofAssumptionsUsedtoEstimateFairValueofStockOptionAwardsDetails">
        <link:definition>9955540 - Disclosure - Stock-Based Compensation - Schedule of Assumptions Used to Estimate Fair Value of Stock Option Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsNarrativeDetails" roleURI="http://www.angn.com/role/WarrantsNarrativeDetails">
        <link:definition>9955541 - Disclosure - Warrants - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsScheduleofIssuanceofWarrantsDetails" roleURI="http://www.angn.com/role/WarrantsScheduleofIssuanceofWarrantsDetails">
        <link:definition>9955542 - Disclosure - Warrants - Schedule of Issuance of Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsScheduleofOutstandingWarrantsDetails" roleURI="http://www.angn.com/role/WarrantsScheduleofOutstandingWarrantsDetails">
        <link:definition>9955543 - Disclosure - Warrants - Schedule of Outstanding Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.angn.com/role/CommitmentsandContingenciesDetails">
        <link:definition>9955544 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.angn.com/role/LeasesNarrativeDetails">
        <link:definition>9955545 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofQuantitativeInformationaboutOperatingLeasesDetails" roleURI="http://www.angn.com/role/LeasesScheduleofQuantitativeInformationaboutOperatingLeasesDetails">
        <link:definition>9955546 - Disclosure - Leases - Schedule of Quantitative Information about Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails" roleURI="http://www.angn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails">
        <link:definition>9955547 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails_1" roleURI="http://www.angn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails_1">
        <link:definition>9955547 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtDetails" roleURI="http://www.angn.com/role/DebtDetails">
        <link:definition>9955548 - Disclosure - Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails" roleURI="http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails">
        <link:definition>9955549 - Disclosure - Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>9955550 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>9955551 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.angn.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>9955552 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlanDetails" roleURI="http://www.angn.com/role/EmployeeBenefitPlanDetails">
        <link:definition>9955553 - Disclosure - Employee Benefit Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareScheduleofNetLossPerShareBasicandDilutedDetails" roleURI="http://www.angn.com/role/NetLossPerShareScheduleofNetLossPerShareBasicandDilutedDetails">
        <link:definition>9955554 - Disclosure - Net Loss Per Share - Schedule of Net Loss Per Share, Basic and Diluted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofNetLossperShareDetails" roleURI="http://www.angn.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofNetLossperShareDetails">
        <link:definition>9955555 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded From Computation of Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.angn.com/role/RelatedPartyTransactionsDetails">
        <link:definition>9955556 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingDetails" roleURI="http://www.angn.com/role/SegmentReportingDetails">
        <link:definition>9955557 - Disclosure - Segment Reporting (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.angn.com/role/SubsequentEventsDetails">
        <link:definition>9955558 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="angn_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="angn_WarrantLiability" abstract="false" name="WarrantLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_GainLossOnIssuanceOfWarrants" abstract="false" name="GainLossOnIssuanceOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_ConversionOfConvertiblePreferredStockMember" abstract="true" name="ConversionOfConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="angn_ConversionOfConvertibleDebtMember" abstract="true" name="ConversionOfConvertibleDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="angn_ReverseRecapitalizationMember" abstract="true" name="ReverseRecapitalizationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="angn_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_JulyPublicOfferingMember" abstract="true" name="JulyPublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_TemporaryEquitySharesConversionOfConvertibleSecurities" abstract="false" name="TemporaryEquitySharesConversionOfConvertibleSecurities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="angn_TemporaryEquityValueConversionOfConvertibleSecurities" abstract="false" name="TemporaryEquityValueConversionOfConvertibleSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants" abstract="false" name="StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="angn_ReclassLiabilityClassifiedWarrantsToEquityClassifiedWarrants" abstract="false" name="ReclassLiabilityClassifiedWarrantsToEquityClassifiedWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_StockIssuedDuringPeriodSharesReverseRecapitalization" abstract="false" name="StockIssuedDuringPeriodSharesReverseRecapitalization" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="angn_StockIssuedDuringPeriodValueReverseRecapitalization" abstract="false" name="StockIssuedDuringPeriodValueReverseRecapitalization" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_StockIssuedDuringPeriodSharesServiceAgreement" abstract="false" name="StockIssuedDuringPeriodSharesServiceAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="angn_StockIssuedDuringPeriodValueServiceAgreement" abstract="false" name="StockIssuedDuringPeriodValueServiceAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_InterestExpenseNoncash" abstract="false" name="InterestExpenseNoncash" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_CostsExpensedUponTheIssuanceOfWarrants" abstract="false" name="CostsExpensedUponTheIssuanceOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_ProfessionalServicesExpenseNoncash" abstract="false" name="ProfessionalServicesExpenseNoncash" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" abstract="false" name="IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_ProceedsFromIssuanceOfCommonStockWarrantsFromJulyPublicOffering" abstract="false" name="ProceedsFromIssuanceOfCommonStockWarrantsFromJulyPublicOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_ProceedsFromIssuanceOfCommonStockFromJulyPublicOffering" abstract="false" name="ProceedsFromIssuanceOfCommonStockFromJulyPublicOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_PaymentOfWarrantIssuanceCosts" abstract="false" name="PaymentOfWarrantIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_StockIssuanceAxis" abstract="true" name="StockIssuanceAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="angn_StockIssuanceDomain" abstract="true" name="StockIssuanceDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_AngionStockholdersMember" abstract="true" name="AngionStockholdersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_ServiceAgreementMember" abstract="true" name="ServiceAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_FairValueOfPreFundedWarrants" abstract="false" name="FairValueOfPreFundedWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_FairValueOfCommonStockWarrants" abstract="false" name="FairValueOfCommonStockWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_AccretionOfPromissoryNoteDiscountFromEmbeddedDerivative" abstract="false" name="AccretionOfPromissoryNoteDiscountFromEmbeddedDerivative" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_AccretionOfPromissoryNoteToFaceValue" abstract="false" name="AccretionOfPromissoryNoteToFaceValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_SettlementOfPromissoryNotesPayable" abstract="false" name="SettlementOfPromissoryNotesPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_VestingOfRestrictedCommonStockNoncash" abstract="false" name="VestingOfRestrictedCommonStockNoncash" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_ReverseRecapitalizationAbstract" abstract="true" name="ReverseRecapitalizationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="angn_ReverseRecapitalizationDisclosureTextBlock" abstract="false" name="ReverseRecapitalizationDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="angn_WarrantsAndRightsOutstandingAbstract" abstract="true" name="WarrantsAndRightsOutstandingAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="angn_WarrantsAndRightsOutstandingTextBlock" abstract="false" name="WarrantsAndRightsOutstandingTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="angn_WarrantsAndDerivativesPolicyTextBlock" abstract="false" name="WarrantsAndDerivativesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="angn_ScheduleOfReverseRecapitalizationTableTextBlock" abstract="false" name="ScheduleOfReverseRecapitalizationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="angn_ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock" abstract="false" name="ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="angn_FormerElicioEquityHoldersMember" abstract="true" name="FormerElicioEquityHoldersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="angn_FormerAngionEquityHoldersMember" abstract="true" name="FormerAngionEquityHoldersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="angn_ReverseRecapitalizationOwnershipPercentage" abstract="false" name="ReverseRecapitalizationOwnershipPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="angn_AngionCommonStockMember" abstract="true" name="AngionCommonStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="angn_RecapitalizationExchangeRatio" abstract="false" name="RecapitalizationExchangeRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="angn_ScheduleOfReverseRecapitalizationTable" abstract="true" name="ScheduleOfReverseRecapitalizationTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="angn_FormerElicioMember" abstract="true" name="FormerElicioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="angn_BridgeLoanBetweenAngionAndFormerElicioMember" abstract="true" name="BridgeLoanBetweenAngionAndFormerElicioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountInitialClosingMember" abstract="true" name="BridgeLoanBetweenAngionAndFormerElicioDiscountAmountInitialClosingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="angn_BridgeLoanBetweenAngionAndFormerElicioInitialClosingMember" abstract="true" name="BridgeLoanBetweenAngionAndFormerElicioInitialClosingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountAdditionalClosingMember" abstract="true" name="BridgeLoanBetweenAngionAndFormerElicioDiscountAmountAdditionalClosingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="angn_BridgeLoanBetweenAngionAndFormerElicioAdditionalClosingMember" abstract="true" name="BridgeLoanBetweenAngionAndFormerElicioAdditionalClosingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="angn_ReverseRecapitalizationLineItems" abstract="true" name="ReverseRecapitalizationLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="angn_NumberOfMembersOfTheBoardOfDirectors" abstract="false" name="NumberOfMembersOfTheBoardOfDirectors" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="angn_DebtInstrumentIssuanceDiscountPercent" abstract="false" name="DebtInstrumentIssuanceDiscountPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="angn_ReverseRecapitalizationTransactionCosts" abstract="false" name="ReverseRecapitalizationTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_CashAndCashEquivalentsAcquiredThroughReverseRecapitalization" abstract="false" name="CashAndCashEquivalentsAcquiredThroughReverseRecapitalization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_OtherCurrentAssetsAcquiredThroughReverseRecapitalization" abstract="false" name="OtherCurrentAssetsAcquiredThroughReverseRecapitalization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_PromissoryNotesAcquiredThroughReverseRecapitalization" abstract="false" name="PromissoryNotesAcquiredThroughReverseRecapitalization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_AccruedLiabilitiesAssumedThroughReverseRecapitalization" abstract="false" name="AccruedLiabilitiesAssumedThroughReverseRecapitalization" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_NetAssetsAcquiredThroughReverseRecapitalization" abstract="false" name="NetAssetsAcquiredThroughReverseRecapitalization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_WarrantsFairValueDisclosure" abstract="false" name="WarrantsFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_WarrantLiabilityMember" abstract="true" name="WarrantLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="angn_PreFundedWarrantMember" abstract="true" name="PreFundedWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember" abstract="true" name="JulyPreFundedWarrantsAndJulyCommonWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_JulyPreFundedWarrantsMember" abstract="true" name="JulyPreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_JulyCommonWarrantsMember" abstract="true" name="JulyCommonWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_MarchSubscriptionAgreementMember" abstract="true" name="MarchSubscriptionAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_JulySharesAndJulyCommonWarrantMember" abstract="true" name="JulySharesAndJulyCommonWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_SaleOfStockBeneficialOwnershipLimitationPercentage" abstract="false" name="SaleOfStockBeneficialOwnershipLimitationPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="angn_MeasurementInputStrikePriceMember" abstract="true" name="MeasurementInputStrikePriceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="angn_PrepaidResearchAndDevelopmentExpenses" abstract="false" name="PrepaidResearchAndDevelopmentExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_AdvancedProfessionalFees" abstract="false" name="AdvancedProfessionalFees" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_OtherPrepaidExpensesAndOtherAssetsCurrent" abstract="false" name="OtherPrepaidExpensesAndOtherAssetsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_AccruedResearchAndDevelopmentCurrent" abstract="false" name="AccruedResearchAndDevelopmentCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_AccruedOtherOperatingLiabilitiesCurrent" abstract="false" name="AccruedOtherOperatingLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept2022Member" abstract="true" name="ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFJuly2023Member" abstract="true" name="ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFJuly2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept.2023Member" abstract="true" name="ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept.2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFAugust2024Member" abstract="true" name="ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFAugust2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_ResearchAndDevelopmentArrangementGrant" abstract="false" name="ResearchAndDevelopmentArrangementGrant" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_ResearchAndDevelopmentArrangementGrantReceived" abstract="false" name="ResearchAndDevelopmentArrangementGrantReceived" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_ResearchAndDevelopmentArrangementCredit" abstract="false" name="ResearchAndDevelopmentArrangementCredit" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_ResearchAndDevelopmentArrangementReimbursementFromGrantFunds" abstract="false" name="ResearchAndDevelopmentArrangementReimbursementFromGrantFunds" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_NumberOfResearchGrantAgreements" abstract="false" name="NumberOfResearchGrantAgreements" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="angn_RegistrationStatementMember" abstract="true" name="RegistrationStatementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_AtTheMarketEquityOfferingSalesAgreementMember" abstract="true" name="AtTheMarketEquityOfferingSalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_A2024RegistrationStatementMember" abstract="true" name="A2024RegistrationStatementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_AtTheMarketEquityOfferingSalesAgreement2022Member" abstract="true" name="AtTheMarketEquityOfferingSalesAgreement2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_AtTheMarketEquityOfferingSalesAgreement2024Member" abstract="true" name="AtTheMarketEquityOfferingSalesAgreement2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_TemporaryEquitySharesIssuedDuringPeriod" abstract="false" name="TemporaryEquitySharesIssuedDuringPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="angn_SaleOfStockAggregateInitialOfferingPrice" abstract="false" name="SaleOfStockAggregateInitialOfferingPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_A2021PlanMember" abstract="true" name="A2021PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="angn_A2022PlanMember" abstract="true" name="A2022PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_A2024PlanMember" abstract="true" name="A2024PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_CommonStockCapitalSharesReservedForFutureIssuanceIncreasePercentageOfCommonStockOutstanding" abstract="false" name="CommonStockCapitalSharesReservedForFutureIssuanceIncreasePercentageOfCommonStockOutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareLimit" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardShareLimit" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="angn_PreFundedWarrantsMember" abstract="true" name="PreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_WarrantsIssuedShares" abstract="false" name="WarrantsIssuedShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="angn_ClassOfWarrantOrRightRollForward" abstract="true" name="ClassOfWarrantOrRightRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="angn_ClassOfWarrantOrRightIssuedInPeriod" abstract="false" name="ClassOfWarrantOrRightIssuedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="angn_ClassOfWarrantOrRightExercisedInPeriod" abstract="false" name="ClassOfWarrantOrRightExercisedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="angn_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" abstract="true" name="ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="angn_ClassOfWarrantOrRightWeightedAverageExercisePriceIssuedInPeriod" abstract="false" name="ClassOfWarrantOrRightWeightedAverageExercisePriceIssuedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod" abstract="false" name="ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="angn_ClassOfWarrantOrRightWeightedAverageLifeRollForward" abstract="true" name="ClassOfWarrantOrRightWeightedAverageLifeRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="angn_ClassOfWarrantOrRightWeightedAverageLife" abstract="false" name="ClassOfWarrantOrRightWeightedAverageLife" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="angn_LicenseExpense" abstract="false" name="LicenseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_OperatingLeaseFutureMinimumAnnualMaintenancePayments" abstract="false" name="OperatingLeaseFutureMinimumAnnualMaintenancePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_OperatingLeaseFutureMinimumAnnualMaintenancePaymentsDueThereafter" abstract="false" name="OperatingLeaseFutureMinimumAnnualMaintenancePaymentsDueThereafter" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_BostonMassachusettsMember" abstract="true" name="BostonMassachusettsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="angn_NewtonMassachusettsMember" abstract="true" name="NewtonMassachusettsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="angn_LesseeOperatingLeaseAnnualRentExpense" abstract="false" name="LesseeOperatingLeaseAnnualRentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_ConvertibleNotesMember" abstract="true" name="ConvertibleNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_SeniorSecuredConvertiblePromissoryNoteMember" abstract="true" name="SeniorSecuredConvertiblePromissoryNoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="angn_EffectiveIncomeTaxRateReconciliationTaxCreditFederalResearchAndDevelopmentPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationTaxCreditFederalResearchAndDevelopmentPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="angn_EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="angn_DeferredTaxAssetsOperatingLeaseLiability" abstract="false" name="DeferredTaxAssetsOperatingLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_DeferredTaxAssetsNetBeforeValuationAllowance" abstract="false" name="DeferredTaxAssetsNetBeforeValuationAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_EmployeeBenefitPlanMember" abstract="true" name="EmployeeBenefitPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="angn_UnvestedCommonStockMember" abstract="true" name="UnvestedCommonStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_ConsultingServicePaymentsMember" abstract="true" name="ConsultingServicePaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="angn_PurchaseOfWarrantsMember" abstract="true" name="PurchaseOfWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_YekaterinaChudnovskyMember" abstract="true" name="YekaterinaChudnovskyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_JayVenkatesanAndTrustsAffiliatedWithJayVenkatesanMember" abstract="true" name="JayVenkatesanAndTrustsAffiliatedWithJayVenkatesanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_ClinicalTrailMember" abstract="true" name="ClinicalTrailMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_EmployeeRelatedReasearchAndDevelopmentMember" abstract="true" name="EmployeeRelatedReasearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_TranslationalMedicineAndCMCMember" abstract="true" name="TranslationalMedicineAndCMCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_OtherMember" abstract="true" name="OtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_ReportableSegmentMember" abstract="true" name="ReportableSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_AccruedInterestPremiumForConvertiblePreferredStock" abstract="false" name="AccruedInterestPremiumForConvertiblePreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>angn-20241231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:e62aa408-c713-4974-8057-b2b3ab20d8bb,g:40b09b34-8017-48cd-b202-ee62afe33f17-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.angn.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="angn-20241231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.angn.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9bb70916-6c5f-4619-90a3-02c83697b843" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a71cd6f3-7a56-4a91-be6d-2c4080df452b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9bb70916-6c5f-4619-90a3-02c83697b843" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a71cd6f3-7a56-4a91-be6d-2c4080df452b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_05ab0dee-79aa-480e-9cd7-2ac2f5ea7e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9bb70916-6c5f-4619-90a3-02c83697b843" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_05ab0dee-79aa-480e-9cd7-2ac2f5ea7e7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_bdd82177-eff6-404d-ae20-c9715263f142" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9bb70916-6c5f-4619-90a3-02c83697b843" xlink:to="loc_us-gaap_AssetsCurrent_bdd82177-eff6-404d-ae20-c9715263f142" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_bfd23069-251b-47d8-91a0-e5d32130755b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9bb70916-6c5f-4619-90a3-02c83697b843" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_bfd23069-251b-47d8-91a0-e5d32130755b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseOtherNoncurrent_75e15685-df39-4aea-846c-bf3fb542cf42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseOtherNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9bb70916-6c5f-4619-90a3-02c83697b843" xlink:to="loc_us-gaap_PrepaidExpenseOtherNoncurrent_75e15685-df39-4aea-846c-bf3fb542cf42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3091ebaf-ba0b-4e61-824f-498257518a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1b54efa9-2665-4104-8865-63cfc399e00c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3091ebaf-ba0b-4e61-824f-498257518a6d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1b54efa9-2665-4104-8865-63cfc399e00c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fd0549a4-b99f-46b8-bef1-b12187d1a47b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3091ebaf-ba0b-4e61-824f-498257518a6d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fd0549a4-b99f-46b8-bef1-b12187d1a47b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_ab1eae6b-cd27-4bab-8e6c-293a1d955e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3091ebaf-ba0b-4e61-824f-498257518a6d" xlink:to="loc_us-gaap_RestrictedCashCurrent_ab1eae6b-cd27-4bab-8e6c-293a1d955e0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_512d3ad3-5c13-4343-91eb-37a316e35e80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_9c3b5eaa-2f1d-4420-99b0-cee0025fa6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_512d3ad3-5c13-4343-91eb-37a316e35e80" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_9c3b5eaa-2f1d-4420-99b0-cee0025fa6a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2e350fd6-ed60-45bd-adc2-3bbf72d9d608" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_512d3ad3-5c13-4343-91eb-37a316e35e80" xlink:to="loc_us-gaap_LiabilitiesCurrent_2e350fd6-ed60-45bd-adc2-3bbf72d9d608" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantLiability_cac1adf3-9db9-4bdd-87f2-4f4cb9d27a45" xlink:href="angn-20241231.xsd#angn_WarrantLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_512d3ad3-5c13-4343-91eb-37a316e35e80" xlink:to="loc_angn_WarrantLiability_cac1adf3-9db9-4bdd-87f2-4f4cb9d27a45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f4ec2285-c618-4996-bf42-d424792030d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_512d3ad3-5c13-4343-91eb-37a316e35e80" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f4ec2285-c618-4996-bf42-d424792030d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_856b01c9-7f91-426d-87ea-11d697a8463e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_6ab3f1c0-e5f0-4661-a456-4abc6dfa3a16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_856b01c9-7f91-426d-87ea-11d697a8463e" xlink:to="loc_us-gaap_CommitmentsAndContingencies_6ab3f1c0-e5f0-4661-a456-4abc6dfa3a16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e38c3fe5-26bf-424c-ade8-cdb7a4e538ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_856b01c9-7f91-426d-87ea-11d697a8463e" xlink:to="loc_us-gaap_StockholdersEquity_e38c3fe5-26bf-424c-ade8-cdb7a4e538ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d85c3a40-21cb-4ab1-81ee-6abc70cb23de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_856b01c9-7f91-426d-87ea-11d697a8463e" xlink:to="loc_us-gaap_Liabilities_d85c3a40-21cb-4ab1-81ee-6abc70cb23de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_35bb834b-6636-42c7-b8a9-4db0f5e84ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_5d5f0654-afe2-414a-a6fa-362323ddd132" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_35bb834b-6636-42c7-b8a9-4db0f5e84ab1" xlink:to="loc_us-gaap_PreferredStockValue_5d5f0654-afe2-414a-a6fa-362323ddd132" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_c376725a-6eef-4e2a-a050-59563b24873e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_35bb834b-6636-42c7-b8a9-4db0f5e84ab1" xlink:to="loc_us-gaap_TreasuryStockCommonValue_c376725a-6eef-4e2a-a050-59563b24873e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_8b386c2d-5c84-403e-b52c-16543aa1d974" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_35bb834b-6636-42c7-b8a9-4db0f5e84ab1" xlink:to="loc_us-gaap_CommonStockValue_8b386c2d-5c84-403e-b52c-16543aa1d974" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0f8dc63a-e530-4876-a666-440aaa45f867" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_35bb834b-6636-42c7-b8a9-4db0f5e84ab1" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0f8dc63a-e530-4876-a666-440aaa45f867" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fe2bbfa5-0d6f-46d9-ae36-44c774bc112c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_35bb834b-6636-42c7-b8a9-4db0f5e84ab1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fe2bbfa5-0d6f-46d9-ae36-44c774bc112c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_63e98495-4756-42c8-abae-b6edc40956e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_35bb834b-6636-42c7-b8a9-4db0f5e84ab1" xlink:to="loc_us-gaap_AdditionalPaidInCapital_63e98495-4756-42c8-abae-b6edc40956e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_0ba88545-4aea-4854-82c3-b5112017f010" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_73aa8e60-21e0-446f-99f5-88d665dbb832" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0ba88545-4aea-4854-82c3-b5112017f010" xlink:to="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_73aa8e60-21e0-446f-99f5-88d665dbb832" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_2044272c-e0b1-42c1-a4f9-7ad3e6999c76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0ba88545-4aea-4854-82c3-b5112017f010" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_2044272c-e0b1-42c1-a4f9-7ad3e6999c76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_62661abe-4073-4083-9918-6c0690ce8e36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0ba88545-4aea-4854-82c3-b5112017f010" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_62661abe-4073-4083-9918-6c0690ce8e36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c13e66a5-2851-4346-b350-2be4d0e33d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0ba88545-4aea-4854-82c3-b5112017f010" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c13e66a5-2851-4346-b350-2be4d0e33d2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_58b1d4a1-678b-4f3d-bdec-cbe717689762" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0ba88545-4aea-4854-82c3-b5112017f010" xlink:to="loc_us-gaap_AccountsPayableCurrent_58b1d4a1-678b-4f3d-bdec-cbe717689762" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="angn-20241231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ff58c4e9-3294-486d-91fe-92eb61ecf1dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_26f9d96e-b5a6-4507-ab6a-e69aff8ba463" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_ff58c4e9-3294-486d-91fe-92eb61ecf1dd" xlink:to="loc_us-gaap_CostsAndExpenses_26f9d96e-b5a6-4507-ab6a-e69aff8ba463" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f5aca2c1-3b61-40b1-881a-220791a6fc46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_bbc77569-bdff-43a8-a989-6c16a782bb3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f5aca2c1-3b61-40b1-881a-220791a6fc46" xlink:to="loc_us-gaap_OperatingIncomeLoss_bbc77569-bdff-43a8-a989-6c16a782bb3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_fdd55e5d-7e4d-4af0-bd43-bb1b7db72b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f5aca2c1-3b61-40b1-881a-220791a6fc46" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_fdd55e5d-7e4d-4af0-bd43-bb1b7db72b9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1fc91016-4f9b-4ad3-afb5-77a9078d9558" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f5aca2c1-3b61-40b1-881a-220791a6fc46" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1fc91016-4f9b-4ad3-afb5-77a9078d9558" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_bfa62fe3-20c4-414e-8ef4-44e767bf368e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_c1a12583-0669-4651-9975-645c0e444b17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_bfa62fe3-20c4-414e-8ef4-44e767bf368e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_c1a12583-0669-4651-9975-645c0e444b17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_64c2cb61-5a47-48af-954b-69af5acb687d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_bfa62fe3-20c4-414e-8ef4-44e767bf368e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_64c2cb61-5a47-48af-954b-69af5acb687d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_f30bf0ae-3fa1-4e06-b57c-7281d3e0e136" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_ac7a006c-bf7d-46ad-8d53-ca5ea819e806" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f30bf0ae-3fa1-4e06-b57c-7281d3e0e136" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_ac7a006c-bf7d-46ad-8d53-ca5ea819e806" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_ece916de-c7b1-42bb-84e1-e6e0e48750f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f30bf0ae-3fa1-4e06-b57c-7281d3e0e136" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_ece916de-c7b1-42bb-84e1-e6e0e48750f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_53ca8151-6b45-444c-b206-37315ea9b21f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f30bf0ae-3fa1-4e06-b57c-7281d3e0e136" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_53ca8151-6b45-444c-b206-37315ea9b21f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_GainLossOnIssuanceOfWarrants_d3c64fd4-f720-4773-be08-77ff0b911b38" xlink:href="angn-20241231.xsd#angn_GainLossOnIssuanceOfWarrants"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f30bf0ae-3fa1-4e06-b57c-7281d3e0e136" xlink:to="loc_angn_GainLossOnIssuanceOfWarrants_d3c64fd4-f720-4773-be08-77ff0b911b38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperatingAndNonoperating_ad5a6202-b6c9-420c-965c-1dba4be62b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOperatingAndNonoperating"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f30bf0ae-3fa1-4e06-b57c-7281d3e0e136" xlink:to="loc_us-gaap_InterestIncomeOperatingAndNonoperating_ad5a6202-b6c9-420c-965c-1dba4be62b7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_0059fadd-fef2-42cf-8f6c-4239ba06549b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f30bf0ae-3fa1-4e06-b57c-7281d3e0e136" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_0059fadd-fef2-42cf-8f6c-4239ba06549b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_bf67c839-d2a1-4bf8-81f2-6365ffb5f727" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f30bf0ae-3fa1-4e06-b57c-7281d3e0e136" xlink:to="loc_us-gaap_InterestExpenseNonoperating_bf67c839-d2a1-4bf8-81f2-6365ffb5f727" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_f9ad6d28-f478-45fa-a84f-431a3ca46fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f30bf0ae-3fa1-4e06-b57c-7281d3e0e136" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_f9ad6d28-f478-45fa-a84f-431a3ca46fdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_ce2cef59-8ec8-49aa-8955-12fe24b02249" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_dc56e62a-bfb9-4ce5-8166-93c8a9f50dae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_ce2cef59-8ec8-49aa-8955-12fe24b02249" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_dc56e62a-bfb9-4ce5-8166-93c8a9f50dae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7b4ce17f-63f1-4d93-a20e-ee3967107402" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_ce2cef59-8ec8-49aa-8955-12fe24b02249" xlink:to="loc_us-gaap_NetIncomeLoss_7b4ce17f-63f1-4d93-a20e-ee3967107402" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angn.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="angn-20241231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.angn.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e6b75115-9ac1-48e3-aed1-3c4cc569e269" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_39c35161-f4cb-4ff4-9f4c-ff82a62e2fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e6b75115-9ac1-48e3-aed1-3c4cc569e269" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_39c35161-f4cb-4ff4-9f4c-ff82a62e2fd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_293d67f6-2c1b-4878-9c42-952977fca3a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e6b75115-9ac1-48e3-aed1-3c4cc569e269" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_293d67f6-2c1b-4878-9c42-952977fca3a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1775aca-3f6d-4c45-ad62-5c75a842b15f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_7ba2c31b-5e05-482e-ba4d-cf522abee242" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1775aca-3f6d-4c45-ad62-5c75a842b15f" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_7ba2c31b-5e05-482e-ba4d-cf522abee242" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_InterestExpenseNoncash_df5c0cc1-0fbd-4b6a-8e85-083c0bc6b8ae" xlink:href="angn-20241231.xsd#angn_InterestExpenseNoncash"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1775aca-3f6d-4c45-ad62-5c75a842b15f" xlink:to="loc_angn_InterestExpenseNoncash_df5c0cc1-0fbd-4b6a-8e85-083c0bc6b8ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_a1fef268-28bb-4183-b461-73a8cac345e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1775aca-3f6d-4c45-ad62-5c75a842b15f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_a1fef268-28bb-4183-b461-73a8cac345e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bd00d438-f885-4a95-830c-0bfd29af2b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1775aca-3f6d-4c45-ad62-5c75a842b15f" xlink:to="loc_us-gaap_NetIncomeLoss_bd00d438-f885-4a95-830c-0bfd29af2b4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_GainLossOnIssuanceOfWarrants_c44b3c40-95f8-4465-bc5b-fca57be3e111" xlink:href="angn-20241231.xsd#angn_GainLossOnIssuanceOfWarrants"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1775aca-3f6d-4c45-ad62-5c75a842b15f" xlink:to="loc_angn_GainLossOnIssuanceOfWarrants_c44b3c40-95f8-4465-bc5b-fca57be3e111" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_b256a510-7d79-45ac-8379-67ce6ddac116" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1775aca-3f6d-4c45-ad62-5c75a842b15f" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_b256a510-7d79-45ac-8379-67ce6ddac116" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_87c289fe-7f69-4198-96b4-67a325eef1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1775aca-3f6d-4c45-ad62-5c75a842b15f" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_87c289fe-7f69-4198-96b4-67a325eef1f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ProfessionalServicesExpenseNoncash_d06a1e57-93eb-459a-8046-5cae6da6d32f" xlink:href="angn-20241231.xsd#angn_ProfessionalServicesExpenseNoncash"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1775aca-3f6d-4c45-ad62-5c75a842b15f" xlink:to="loc_angn_ProfessionalServicesExpenseNoncash_d06a1e57-93eb-459a-8046-5cae6da6d32f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_CostsExpensedUponTheIssuanceOfWarrants_b48e8900-312f-4ac5-a01f-b0aea03ac8ac" xlink:href="angn-20241231.xsd#angn_CostsExpensedUponTheIssuanceOfWarrants"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1775aca-3f6d-4c45-ad62-5c75a842b15f" xlink:to="loc_angn_CostsExpensedUponTheIssuanceOfWarrants_b48e8900-312f-4ac5-a01f-b0aea03ac8ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_54c3aa7d-c0a2-4e9e-97bb-3b7c2363ee3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1775aca-3f6d-4c45-ad62-5c75a842b15f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_54c3aa7d-c0a2-4e9e-97bb-3b7c2363ee3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_66e3064a-52d2-4cc7-89eb-83053a5cf516" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1775aca-3f6d-4c45-ad62-5c75a842b15f" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_66e3064a-52d2-4cc7-89eb-83053a5cf516" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_2dccb8ab-2581-48c5-8411-c9f3f043ceb8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1775aca-3f6d-4c45-ad62-5c75a842b15f" xlink:to="loc_us-gaap_Depreciation_2dccb8ab-2581-48c5-8411-c9f3f043ceb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_314622c9-bd60-440a-97e7-1b17a6f81dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1775aca-3f6d-4c45-ad62-5c75a842b15f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_314622c9-bd60-440a-97e7-1b17a6f81dfb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_6b03b5a9-380b-46fe-a97e-4a78e0732252" xlink:href="angn-20241231.xsd#angn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1775aca-3f6d-4c45-ad62-5c75a842b15f" xlink:to="loc_angn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_6b03b5a9-380b-46fe-a97e-4a78e0732252" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ca587ae7-6ae6-46c0-8a49-1b2dfaf906c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1775aca-3f6d-4c45-ad62-5c75a842b15f" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ca587ae7-6ae6-46c0-8a49-1b2dfaf906c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_731c8f35-9c78-4891-afe8-1c1ee6e7952e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1775aca-3f6d-4c45-ad62-5c75a842b15f" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_731c8f35-9c78-4891-afe8-1c1ee6e7952e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_c3d31310-1ffa-4b2f-8038-f06c259dd706" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1775aca-3f6d-4c45-ad62-5c75a842b15f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_c3d31310-1ffa-4b2f-8038-f06c259dd706" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_cba16f31-5de6-4d07-a4d0-75477f9938cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1775aca-3f6d-4c45-ad62-5c75a842b15f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_cba16f31-5de6-4d07-a4d0-75477f9938cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_679e498f-bfbb-4b15-9922-f90063d3db3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1775aca-3f6d-4c45-ad62-5c75a842b15f" xlink:to="loc_us-gaap_ShareBasedCompensation_679e498f-bfbb-4b15-9922-f90063d3db3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d41091f4-c168-4d18-9daa-45656093f0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ProceedsFromIssuanceOfCommonStockWarrantsFromJulyPublicOffering_f516a3e5-6713-45f4-8315-20712436dc35" xlink:href="angn-20241231.xsd#angn_ProceedsFromIssuanceOfCommonStockWarrantsFromJulyPublicOffering"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d41091f4-c168-4d18-9daa-45656093f0e4" xlink:to="loc_angn_ProceedsFromIssuanceOfCommonStockWarrantsFromJulyPublicOffering_f516a3e5-6713-45f4-8315-20712436dc35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness_b9eaed10-3e0d-4ac6-a08e-4a713b3fe107" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d41091f4-c168-4d18-9daa-45656093f0e4" xlink:to="loc_us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness_b9eaed10-3e0d-4ac6-a08e-4a713b3fe107" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_f441a0ed-b699-4eee-b18d-a36b27fcf22a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d41091f4-c168-4d18-9daa-45656093f0e4" xlink:to="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_f441a0ed-b699-4eee-b18d-a36b27fcf22a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_e66004c1-844d-4a82-b64c-64d355311ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d41091f4-c168-4d18-9daa-45656093f0e4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_e66004c1-844d-4a82-b64c-64d355311ee4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d919df97-b8d4-4a47-9980-3b6fd066bab0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d41091f4-c168-4d18-9daa-45656093f0e4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d919df97-b8d4-4a47-9980-3b6fd066bab0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ProceedsFromIssuanceOfCommonStockFromJulyPublicOffering_c07c3cb2-5995-4fcb-903b-687fc4e8b384" xlink:href="angn-20241231.xsd#angn_ProceedsFromIssuanceOfCommonStockFromJulyPublicOffering"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d41091f4-c168-4d18-9daa-45656093f0e4" xlink:to="loc_angn_ProceedsFromIssuanceOfCommonStockFromJulyPublicOffering_c07c3cb2-5995-4fcb-903b-687fc4e8b384" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_e740bb48-5629-478d-b2ff-c24fe312f9bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d41091f4-c168-4d18-9daa-45656093f0e4" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_e740bb48-5629-478d-b2ff-c24fe312f9bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_277f7c93-532d-4c21-9521-4d7f733801e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d41091f4-c168-4d18-9daa-45656093f0e4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_277f7c93-532d-4c21-9521-4d7f733801e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfEquity_e509e0bb-36a8-4b42-a21a-8c7279882f18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfEquity"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d41091f4-c168-4d18-9daa-45656093f0e4" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfEquity_e509e0bb-36a8-4b42-a21a-8c7279882f18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_PaymentOfWarrantIssuanceCosts_c67eab5f-9375-4592-a7dd-58ed31241f40" xlink:href="angn-20241231.xsd#angn_PaymentOfWarrantIssuanceCosts"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d41091f4-c168-4d18-9daa-45656093f0e4" xlink:to="loc_angn_PaymentOfWarrantIssuanceCosts_c67eab5f-9375-4592-a7dd-58ed31241f40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_2dd705b6-3035-42f3-a95c-6db89b19f2ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d41091f4-c168-4d18-9daa-45656093f0e4" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_2dd705b6-3035-42f3-a95c-6db89b19f2ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_23d69317-584c-4384-a5a1-cce7b109e47f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_168eb231-a43b-487d-a95a-941aba6b263a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_23d69317-584c-4384-a5a1-cce7b109e47f" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_168eb231-a43b-487d-a95a-941aba6b263a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0146317e-51a7-438f-a080-7714b4ad6e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_23d69317-584c-4384-a5a1-cce7b109e47f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0146317e-51a7-438f-a080-7714b4ad6e5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_aa63f767-8a9a-44f5-a3e2-6e4bb6ed8a12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0d42984b-d668-4bf6-ba8b-5968cccbd4cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_aa63f767-8a9a-44f5-a3e2-6e4bb6ed8a12" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0d42984b-d668-4bf6-ba8b-5968cccbd4cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5ff5f41-9ead-41d6-ab5c-ebe919a9f0c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_aa63f767-8a9a-44f5-a3e2-6e4bb6ed8a12" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5ff5f41-9ead-41d6-ab5c-ebe919a9f0c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_48e7c990-cf28-4799-be40-9568f7d201d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_aa63f767-8a9a-44f5-a3e2-6e4bb6ed8a12" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_48e7c990-cf28-4799-be40-9568f7d201d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ed25ae08-747d-47df-963c-67bf5f9c4152" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_aa63f767-8a9a-44f5-a3e2-6e4bb6ed8a12" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ed25ae08-747d-47df-963c-67bf5f9c4152" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angn.com/role/MergerandRelatedTransactionsScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#MergerandRelatedTransactionsScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://www.angn.com/role/MergerandRelatedTransactionsScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_angn_NetAssetsAcquiredThroughReverseRecapitalization_4145f293-2683-439d-9584-68e48d1c64bc" xlink:href="angn-20241231.xsd#angn_NetAssetsAcquiredThroughReverseRecapitalization"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_CashAndCashEquivalentsAcquiredThroughReverseRecapitalization_da1ff2dd-72ff-4f2f-9ad3-a7973989225e" xlink:href="angn-20241231.xsd#angn_CashAndCashEquivalentsAcquiredThroughReverseRecapitalization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_angn_NetAssetsAcquiredThroughReverseRecapitalization_4145f293-2683-439d-9584-68e48d1c64bc" xlink:to="loc_angn_CashAndCashEquivalentsAcquiredThroughReverseRecapitalization_da1ff2dd-72ff-4f2f-9ad3-a7973989225e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AccruedLiabilitiesAssumedThroughReverseRecapitalization_eaa110bd-8f1f-483e-98a7-a24593e5b055" xlink:href="angn-20241231.xsd#angn_AccruedLiabilitiesAssumedThroughReverseRecapitalization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_angn_NetAssetsAcquiredThroughReverseRecapitalization_4145f293-2683-439d-9584-68e48d1c64bc" xlink:to="loc_angn_AccruedLiabilitiesAssumedThroughReverseRecapitalization_eaa110bd-8f1f-483e-98a7-a24593e5b055" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_PromissoryNotesAcquiredThroughReverseRecapitalization_949a1431-281c-4b1f-a058-80e12bc63d86" xlink:href="angn-20241231.xsd#angn_PromissoryNotesAcquiredThroughReverseRecapitalization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_angn_NetAssetsAcquiredThroughReverseRecapitalization_4145f293-2683-439d-9584-68e48d1c64bc" xlink:to="loc_angn_PromissoryNotesAcquiredThroughReverseRecapitalization_949a1431-281c-4b1f-a058-80e12bc63d86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_OtherCurrentAssetsAcquiredThroughReverseRecapitalization_060ed627-9e06-4aa4-b03f-c76693b450b5" xlink:href="angn-20241231.xsd#angn_OtherCurrentAssetsAcquiredThroughReverseRecapitalization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_angn_NetAssetsAcquiredThroughReverseRecapitalization_4145f293-2683-439d-9584-68e48d1c64bc" xlink:to="loc_angn_OtherCurrentAssetsAcquiredThroughReverseRecapitalization_060ed627-9e06-4aa4-b03f-c76693b450b5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_a9ce3446-c3bd-48c7-a612-3adb8241ad7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_754d0f45-69c2-4196-9dc3-385d792e37ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_a9ce3446-c3bd-48c7-a612-3adb8241ad7e" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_754d0f45-69c2-4196-9dc3-385d792e37ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_65dbac83-e149-42d5-bbb4-55769bc285ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsFairValueDisclosure_ee9a1229-27b0-4cc0-970f-6ab3d42096db" xlink:href="angn-20241231.xsd#angn_WarrantsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_65dbac83-e149-42d5-bbb4-55769bc285ae" xlink:to="loc_angn_WarrantsFairValueDisclosure_ee9a1229-27b0-4cc0-970f-6ab3d42096db" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angn.com/role/BalanceSheetComponentsScheduleofPrepaidandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#BalanceSheetComponentsScheduleofPrepaidandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.angn.com/role/BalanceSheetComponentsScheduleofPrepaidandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ab15531d-05e7-423d-a51d-6c45500edbda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_da163902-ecca-444e-995d-9ad03d0013d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ab15531d-05e7-423d-a51d-6c45500edbda" xlink:to="loc_us-gaap_PrepaidInsurance_da163902-ecca-444e-995d-9ad03d0013d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AdvancedProfessionalFees_f2850454-f554-4919-8a6e-cf901a73bace" xlink:href="angn-20241231.xsd#angn_AdvancedProfessionalFees"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ab15531d-05e7-423d-a51d-6c45500edbda" xlink:to="loc_angn_AdvancedProfessionalFees_f2850454-f554-4919-8a6e-cf901a73bace" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_OtherPrepaidExpensesAndOtherAssetsCurrent_97e5c318-a615-4a5e-9738-4744d95ff035" xlink:href="angn-20241231.xsd#angn_OtherPrepaidExpensesAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ab15531d-05e7-423d-a51d-6c45500edbda" xlink:to="loc_angn_OtherPrepaidExpensesAndOtherAssetsCurrent_97e5c318-a615-4a5e-9738-4744d95ff035" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_PrepaidResearchAndDevelopmentExpenses_97fabf17-251a-4f22-b5c9-006574b438fa" xlink:href="angn-20241231.xsd#angn_PrepaidResearchAndDevelopmentExpenses"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ab15531d-05e7-423d-a51d-6c45500edbda" xlink:to="loc_angn_PrepaidResearchAndDevelopmentExpenses_97fabf17-251a-4f22-b5c9-006574b438fa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angn.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://www.angn.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a15d0e27-258a-4e45-9426-f49a968142fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_0a2b84ca-7067-43ef-a8d1-84b977813d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_a15d0e27-258a-4e45-9426-f49a968142fa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_0a2b84ca-7067-43ef-a8d1-84b977813d1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_30faa3dd-c50c-44c6-bb1d-81229f78391c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_a15d0e27-258a-4e45-9426-f49a968142fa" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_30faa3dd-c50c-44c6-bb1d-81229f78391c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angn.com/role/BalanceSheetComponentsScheduleofAccruedExpensesDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#BalanceSheetComponentsScheduleofAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.angn.com/role/BalanceSheetComponentsScheduleofAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3557850b-16c9-4954-9288-a346db74f6da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AccruedOtherOperatingLiabilitiesCurrent_a3d445d3-a7e4-4d47-8457-66d9519ba8ac" xlink:href="angn-20241231.xsd#angn_AccruedOtherOperatingLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3557850b-16c9-4954-9288-a346db74f6da" xlink:to="loc_angn_AccruedOtherOperatingLiabilitiesCurrent_a3d445d3-a7e4-4d47-8457-66d9519ba8ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AccruedResearchAndDevelopmentCurrent_9116a631-e57e-4276-9a75-4e92d8809de5" xlink:href="angn-20241231.xsd#angn_AccruedResearchAndDevelopmentCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3557850b-16c9-4954-9288-a346db74f6da" xlink:to="loc_angn_AccruedResearchAndDevelopmentCurrent_9116a631-e57e-4276-9a75-4e92d8809de5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a50128c5-e502-439f-9789-56e46589f87f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3557850b-16c9-4954-9288-a346db74f6da" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a50128c5-e502-439f-9789-56e46589f87f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_59029a00-f9d9-4dc2-9c1b-87bc2c4e6e32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3557850b-16c9-4954-9288-a346db74f6da" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_59029a00-f9d9-4dc2-9c1b-87bc2c4e6e32" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.angn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1f71cb3d-94b7-4581-8c8a-c33f8aa19145" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_3e8c4762-c25d-4f89-a294-271e12dc1d05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1f71cb3d-94b7-4581-8c8a-c33f8aa19145" xlink:to="loc_us-gaap_OperatingLeaseLiability_3e8c4762-c25d-4f89-a294-271e12dc1d05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_aba79ef5-21c1-4896-9f45-e6bb2f1f1e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1f71cb3d-94b7-4581-8c8a-c33f8aa19145" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_aba79ef5-21c1-4896-9f45-e6bb2f1f1e9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_4fcf2738-c2f9-4988-9ff8-df2ffe865a34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_762aa119-9ab1-4fd3-9c3a-29b8552a4d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_4fcf2738-c2f9-4988-9ff8-df2ffe865a34" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_762aa119-9ab1-4fd3-9c3a-29b8552a4d4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_39e68b71-130e-435d-8a32-15d72d2f5811" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_4fcf2738-c2f9-4988-9ff8-df2ffe865a34" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_39e68b71-130e-435d-8a32-15d72d2f5811" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="angn-20241231.xsd#LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.angn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_abba5b65-998c-412d-9b70-16ae148f27cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_78761f55-afae-4f5f-b3e7-1d3781a42dca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_abba5b65-998c-412d-9b70-16ae148f27cb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_78761f55-afae-4f5f-b3e7-1d3781a42dca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_cc28a4f7-309d-4c06-b5f8-5ff2ca39334a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_abba5b65-998c-412d-9b70-16ae148f27cb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_cc28a4f7-309d-4c06-b5f8-5ff2ca39334a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_981f072d-0e4c-4930-aa07-bc404feb93c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_abba5b65-998c-412d-9b70-16ae148f27cb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_981f072d-0e4c-4930-aa07-bc404feb93c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_cf464fbb-466b-4225-a685-a57179d1a8ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_abba5b65-998c-412d-9b70-16ae148f27cb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_cf464fbb-466b-4225-a685-a57179d1a8ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6df45c23-17e6-483a-a76b-cbc5a7a41b80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_abba5b65-998c-412d-9b70-16ae148f27cb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6df45c23-17e6-483a-a76b-cbc5a7a41b80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7580883c-7b1a-44ce-a5cb-c5c92f13b29a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_abba5b65-998c-412d-9b70-16ae148f27cb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7580883c-7b1a-44ce-a5cb-c5c92f13b29a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:calculationLink xlink:role="http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_0421321e-a715-4578-a9c5-8a0d99bdb03c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_16562189-26b8-44be-853f-e448e1458af4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_0421321e-a715-4578-a9c5-8a0d99bdb03c" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_16562189-26b8-44be-853f-e448e1458af4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_b90f7a06-2e4d-4a10-afbc-6dc111111bed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_0421321e-a715-4578-a9c5-8a0d99bdb03c" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_b90f7a06-2e4d-4a10-afbc-6dc111111bed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_46eb969d-3271-4e55-b352-a02357fa96c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_0421321e-a715-4578-a9c5-8a0d99bdb03c" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_46eb969d-3271-4e55-b352-a02357fa96c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_43896d84-3539-4a07-a990-c294daa10eed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8e6dc208-61f4-4a88-afa4-d8cd5919501f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_43896d84-3539-4a07-a990-c294daa10eed" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8e6dc208-61f4-4a88-afa4-d8cd5919501f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ed49e7f9-a115-4ed2-8a08-d089b909d32c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_43896d84-3539-4a07-a990-c294daa10eed" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ed49e7f9-a115-4ed2-8a08-d089b909d32c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_14d599d0-5346-4697-b388-46d1973c2f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_b990e22d-a1d5-4d84-9628-fc95f7def44c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_14d599d0-5346-4697-b388-46d1973c2f5d" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_b990e22d-a1d5-4d84-9628-fc95f7def44c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_f0017902-6cc2-4a2f-bccb-02531f7c149e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_14d599d0-5346-4697-b388-46d1973c2f5d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_f0017902-6cc2-4a2f-bccb-02531f7c149e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_e75f4771-252d-4583-84a8-508ba83cd11b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_14d599d0-5346-4697-b388-46d1973c2f5d" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_e75f4771-252d-4583-84a8-508ba83cd11b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_a8e7af84-96cb-4dc3-acc5-ead14feb142a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_14d599d0-5346-4697-b388-46d1973c2f5d" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_a8e7af84-96cb-4dc3-acc5-ead14feb142a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_dc8beb31-1b70-4a1e-adc6-d7cd9229b9f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_d838ba71-cb25-4ea7-9fec-995d608b1b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_dc8beb31-1b70-4a1e-adc6-d7cd9229b9f9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_d838ba71-cb25-4ea7-9fec-995d608b1b4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_EffectiveIncomeTaxRateReconciliationTaxCreditFederalResearchAndDevelopmentPercent_529f676a-7e15-4a13-86bc-e3ba705891d0" xlink:href="angn-20241231.xsd#angn_EffectiveIncomeTaxRateReconciliationTaxCreditFederalResearchAndDevelopmentPercent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_dc8beb31-1b70-4a1e-adc6-d7cd9229b9f9" xlink:to="loc_angn_EffectiveIncomeTaxRateReconciliationTaxCreditFederalResearchAndDevelopmentPercent_529f676a-7e15-4a13-86bc-e3ba705891d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent_2634929a-6585-4ddd-aa23-8958b90d639f" xlink:href="angn-20241231.xsd#angn_EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_dc8beb31-1b70-4a1e-adc6-d7cd9229b9f9" xlink:to="loc_angn_EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent_2634929a-6585-4ddd-aa23-8958b90d639f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_6e7e62ca-dc0e-478f-ad10-5cade7e2f988" xlink:href="angn-20241231.xsd#angn_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_dc8beb31-1b70-4a1e-adc6-d7cd9229b9f9" xlink:to="loc_angn_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_6e7e62ca-dc0e-478f-ad10-5cade7e2f988" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_5f1366c5-89b9-4e5c-bfd4-25cb8e6ce097" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_dc8beb31-1b70-4a1e-adc6-d7cd9229b9f9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_5f1366c5-89b9-4e5c-bfd4-25cb8e6ce097" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1ea0d886-7eb9-48e8-aa1e-a5db5dc95349" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_dc8beb31-1b70-4a1e-adc6-d7cd9229b9f9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1ea0d886-7eb9-48e8-aa1e-a5db5dc95349" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_4ee9e3c2-aa51-430a-ad28-d83880feced9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_dc8beb31-1b70-4a1e-adc6-d7cd9229b9f9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_4ee9e3c2-aa51-430a-ad28-d83880feced9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_77cd5e73-b967-45e5-a9f1-34b663ad1084" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_631e424f-b1bc-45a1-a1eb-b32eae7ecd25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_77cd5e73-b967-45e5-a9f1-34b663ad1084" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_631e424f-b1bc-45a1-a1eb-b32eae7ecd25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_DeferredTaxAssetsNetBeforeValuationAllowance_f3ffd524-2c7b-4c23-8be6-a2abc0c70e53" xlink:href="angn-20241231.xsd#angn_DeferredTaxAssetsNetBeforeValuationAllowance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_77cd5e73-b967-45e5-a9f1-34b663ad1084" xlink:to="loc_angn_DeferredTaxAssetsNetBeforeValuationAllowance_f3ffd524-2c7b-4c23-8be6-a2abc0c70e53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_DeferredTaxAssetsNetBeforeValuationAllowance_3420f98f-8317-41f8-b733-11df6619a361" xlink:href="angn-20241231.xsd#angn_DeferredTaxAssetsNetBeforeValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_dcc213f7-56aa-47e9-87da-4965a69d6900" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_angn_DeferredTaxAssetsNetBeforeValuationAllowance_3420f98f-8317-41f8-b733-11df6619a361" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_dcc213f7-56aa-47e9-87da-4965a69d6900" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_98e02955-6253-4282-9b52-8ad3ed967adf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_angn_DeferredTaxAssetsNetBeforeValuationAllowance_3420f98f-8317-41f8-b733-11df6619a361" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_98e02955-6253-4282-9b52-8ad3ed967adf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_f5080d79-a005-4be8-9e84-e8922b1172a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_angn_DeferredTaxAssetsNetBeforeValuationAllowance_3420f98f-8317-41f8-b733-11df6619a361" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_f5080d79-a005-4be8-9e84-e8922b1172a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_b1be3f91-04c4-48cf-a636-c4ba49b29bba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_angn_DeferredTaxAssetsNetBeforeValuationAllowance_3420f98f-8317-41f8-b733-11df6619a361" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_b1be3f91-04c4-48cf-a636-c4ba49b29bba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_c04e697c-d560-41dc-8cb2-36c6f142179d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_angn_DeferredTaxAssetsNetBeforeValuationAllowance_3420f98f-8317-41f8-b733-11df6619a361" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_c04e697c-d560-41dc-8cb2-36c6f142179d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_3baab870-c49a-49e3-a6df-7a289d526f98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_angn_DeferredTaxAssetsNetBeforeValuationAllowance_3420f98f-8317-41f8-b733-11df6619a361" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_3baab870-c49a-49e3-a6df-7a289d526f98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_DeferredTaxAssetsOperatingLeaseLiability_f1d83a11-1258-46be-9f5a-61de2967c5f5" xlink:href="angn-20241231.xsd#angn_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_angn_DeferredTaxAssetsNetBeforeValuationAllowance_3420f98f-8317-41f8-b733-11df6619a361" xlink:to="loc_angn_DeferredTaxAssetsOperatingLeaseLiability_f1d83a11-1258-46be-9f5a-61de2967c5f5" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>angn-20241231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:e62aa408-c713-4974-8057-b2b3ab20d8bb,g:40b09b34-8017-48cd-b202-ee62afe33f17-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity" xlink:type="simple" xlink:href="angn-20241231.xsd#ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_20b58b54-aee4-4c3d-b2dc-bdf6fe3b7dad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_efc0ec3c-5b07-45c5-a7aa-5a364fd8b19b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_20b58b54-aee4-4c3d-b2dc-bdf6fe3b7dad" xlink:to="loc_us-gaap_StatementTable_efc0ec3c-5b07-45c5-a7aa-5a364fd8b19b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_51eb319e-4295-4490-9930-9500b53609f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_efc0ec3c-5b07-45c5-a7aa-5a364fd8b19b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_51eb319e-4295-4490-9930-9500b53609f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_51eb319e-4295-4490-9930-9500b53609f5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_51eb319e-4295-4490-9930-9500b53609f5" xlink:to="loc_us-gaap_EquityComponentDomain_51eb319e-4295-4490-9930-9500b53609f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7c2b17cb-f6ab-426a-b6dc-e506c6850dae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_51eb319e-4295-4490-9930-9500b53609f5" xlink:to="loc_us-gaap_EquityComponentDomain_7c2b17cb-f6ab-426a-b6dc-e506c6850dae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f948d2e7-33d7-4f60-a8aa-c7ae4dbfe5ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7c2b17cb-f6ab-426a-b6dc-e506c6850dae" xlink:to="loc_us-gaap_CommonStockMember_f948d2e7-33d7-4f60-a8aa-c7ae4dbfe5ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_354e474a-f619-41f6-9575-038baecc0200" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7c2b17cb-f6ab-426a-b6dc-e506c6850dae" xlink:to="loc_us-gaap_TreasuryStockCommonMember_354e474a-f619-41f6-9575-038baecc0200" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_d1c5daee-904b-42ff-b75a-afbb0a2736b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7c2b17cb-f6ab-426a-b6dc-e506c6850dae" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_d1c5daee-904b-42ff-b75a-afbb0a2736b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1d10451d-43c1-4cd2-adcd-4ff72e935330" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7c2b17cb-f6ab-426a-b6dc-e506c6850dae" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1d10451d-43c1-4cd2-adcd-4ff72e935330" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_71c164ae-04dc-4edb-9797-b839e642052e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7c2b17cb-f6ab-426a-b6dc-e506c6850dae" xlink:to="loc_us-gaap_RetainedEarningsMember_71c164ae-04dc-4edb-9797-b839e642052e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_455e212f-3802-435e-9f75-359ffbb21739" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7c2b17cb-f6ab-426a-b6dc-e506c6850dae" xlink:to="loc_us-gaap_PreferredStockMember_455e212f-3802-435e-9f75-359ffbb21739" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_26c5d5db-525f-473d-b092-52717b528c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_efc0ec3c-5b07-45c5-a7aa-5a364fd8b19b" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_26c5d5db-525f-473d-b092-52717b528c9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_26c5d5db-525f-473d-b092-52717b528c9e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_26c5d5db-525f-473d-b092-52717b528c9e" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_26c5d5db-525f-473d-b092-52717b528c9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_c7386733-75ac-480c-963f-0abe031de6a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_26c5d5db-525f-473d-b092-52717b528c9e" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_c7386733-75ac-480c-963f-0abe031de6a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ConversionOfConvertiblePreferredStockMember_015e168a-897a-48a3-b2c5-bd498cfd0b53" xlink:href="angn-20241231.xsd#angn_ConversionOfConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_c7386733-75ac-480c-963f-0abe031de6a8" xlink:to="loc_angn_ConversionOfConvertiblePreferredStockMember_015e168a-897a-48a3-b2c5-bd498cfd0b53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ConversionOfConvertibleDebtMember_66faf15e-f01a-474f-ad1b-e6c8094a2abb" xlink:href="angn-20241231.xsd#angn_ConversionOfConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_c7386733-75ac-480c-963f-0abe031de6a8" xlink:to="loc_angn_ConversionOfConvertibleDebtMember_66faf15e-f01a-474f-ad1b-e6c8094a2abb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_97ebe95f-b5db-462e-8001-44e520460d56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_efc0ec3c-5b07-45c5-a7aa-5a364fd8b19b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_97ebe95f-b5db-462e-8001-44e520460d56" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_97ebe95f-b5db-462e-8001-44e520460d56_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_97ebe95f-b5db-462e-8001-44e520460d56" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_97ebe95f-b5db-462e-8001-44e520460d56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0c9d50c3-3129-48f6-9fae-ae1da1e466a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_97ebe95f-b5db-462e-8001-44e520460d56" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0c9d50c3-3129-48f6-9fae-ae1da1e466a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ReverseRecapitalizationMember_4466e73a-0d73-483e-a4ed-54074c58cbf8" xlink:href="angn-20241231.xsd#angn_ReverseRecapitalizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0c9d50c3-3129-48f6-9fae-ae1da1e466a9" xlink:to="loc_angn_ReverseRecapitalizationMember_4466e73a-0d73-483e-a4ed-54074c58cbf8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AtTheMarketOfferingMember_87d549f9-3eee-4d74-bcc9-8c4115950fed" xlink:href="angn-20241231.xsd#angn_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0c9d50c3-3129-48f6-9fae-ae1da1e466a9" xlink:to="loc_angn_AtTheMarketOfferingMember_87d549f9-3eee-4d74-bcc9-8c4115950fed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_JulyPublicOfferingMember_92d61e75-a926-441d-acfc-d2a4f3be88d4" xlink:href="angn-20241231.xsd#angn_JulyPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0c9d50c3-3129-48f6-9fae-ae1da1e466a9" xlink:to="loc_angn_JulyPublicOfferingMember_92d61e75-a926-441d-acfc-d2a4f3be88d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9578339b-3fd5-487c-8a05-cc7c64c01a41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_20b58b54-aee4-4c3d-b2dc-bdf6fe3b7dad" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9578339b-3fd5-487c-8a05-cc7c64c01a41" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_c05d0b64-0504-4a6c-a6db-879e073cfe48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9578339b-3fd5-487c-8a05-cc7c64c01a41" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_c05d0b64-0504-4a6c-a6db-879e073cfe48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_e9afc6b0-d70a-4141-8867-cc2c70e2b40b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9578339b-3fd5-487c-8a05-cc7c64c01a41" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_e9afc6b0-d70a-4141-8867-cc2c70e2b40b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_TemporaryEquitySharesConversionOfConvertibleSecurities_6b70b38f-7a7b-4344-9f73-cb86b2c7d87a" xlink:href="angn-20241231.xsd#angn_TemporaryEquitySharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9578339b-3fd5-487c-8a05-cc7c64c01a41" xlink:to="loc_angn_TemporaryEquitySharesConversionOfConvertibleSecurities_6b70b38f-7a7b-4344-9f73-cb86b2c7d87a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_TemporaryEquityValueConversionOfConvertibleSecurities_b5f46a40-d8fa-4889-a1bd-0559730dbb85" xlink:href="angn-20241231.xsd#angn_TemporaryEquityValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9578339b-3fd5-487c-8a05-cc7c64c01a41" xlink:to="loc_angn_TemporaryEquityValueConversionOfConvertibleSecurities_b5f46a40-d8fa-4889-a1bd-0559730dbb85" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_373681b7-18e7-4186-929a-1f3e8e0d77a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_08fb9f16-05c8-4b9d-ba7e-d3cf892f2d36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_20b58b54-aee4-4c3d-b2dc-bdf6fe3b7dad" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d1f418c6-63ee-4764-9139-d2d74d9fe37e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d1f418c6-63ee-4764-9139-d2d74d9fe37e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_33aae4d9-9669-4924-acc5-44e4df829c17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_us-gaap_StockholdersEquity_33aae4d9-9669-4924-acc5-44e4df829c17" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_fb2bbcc1-432e-416e-abf2-ebff44a6223a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_us-gaap_TreasuryStockCommonShares_fb2bbcc1-432e-416e-abf2-ebff44a6223a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d3e68e6f-d97f-4830-b8af-f11dd9ce7271" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d3e68e6f-d97f-4830-b8af-f11dd9ce7271" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_aaea2154-fb10-44dc-9dd4-57f41aca8f98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_aaea2154-fb10-44dc-9dd4-57f41aca8f98" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b52d6370-c7f9-4788-a35a-b5ac93c81415" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b52d6370-c7f9-4788-a35a-b5ac93c81415" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b83d9dd5-266d-413e-9ba3-d41912921dec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b83d9dd5-266d-413e-9ba3-d41912921dec" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_1127650d-c454-4d02-bfb0-9b12dcff2280" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_1127650d-c454-4d02-bfb0-9b12dcff2280" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_2dbf3379-4e59-4fc2-a680-bc263f2b80dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_2dbf3379-4e59-4fc2-a680-bc263f2b80dc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants_01c759c2-ca65-45ba-b33e-da115f5456af" xlink:href="angn-20241231.xsd#angn_StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_angn_StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants_01c759c2-ca65-45ba-b33e-da115f5456af" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_5c847108-bf6a-4478-abd0-f3bf0b168a12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_5c847108-bf6a-4478-abd0-f3bf0b168a12" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ReclassLiabilityClassifiedWarrantsToEquityClassifiedWarrants_fe75b87e-b3d9-4f6d-acec-5865281a3649" xlink:href="angn-20241231.xsd#angn_ReclassLiabilityClassifiedWarrantsToEquityClassifiedWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_angn_ReclassLiabilityClassifiedWarrantsToEquityClassifiedWarrants_fe75b87e-b3d9-4f6d-acec-5865281a3649" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_6769606a-5061-419b-a838-5284429625e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_6769606a-5061-419b-a838-5284429625e9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_2dcd9e9d-4e4d-4bc8-b89e-dd66de547f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_2dcd9e9d-4e4d-4bc8-b89e-dd66de547f7f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_StockIssuedDuringPeriodSharesReverseRecapitalization_65660d0c-141a-4243-b18e-8e6302500f63" xlink:href="angn-20241231.xsd#angn_StockIssuedDuringPeriodSharesReverseRecapitalization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_angn_StockIssuedDuringPeriodSharesReverseRecapitalization_65660d0c-141a-4243-b18e-8e6302500f63" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_StockIssuedDuringPeriodValueReverseRecapitalization_81d33fc8-7ba3-484a-a2a8-60c5145bb33f" xlink:href="angn-20241231.xsd#angn_StockIssuedDuringPeriodValueReverseRecapitalization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_angn_StockIssuedDuringPeriodValueReverseRecapitalization_81d33fc8-7ba3-484a-a2a8-60c5145bb33f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_d827140b-4870-4f9f-9a09-4bc87774cefc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_d827140b-4870-4f9f-9a09-4bc87774cefc" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_4f498706-30a3-4543-98ad-1b849d202bde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_4f498706-30a3-4543-98ad-1b849d202bde" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7a7f7a38-0553-4412-900a-64f03987a6f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7a7f7a38-0553-4412-900a-64f03987a6f8" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_55e9db0c-c927-48b4-9439-458f99cb416a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_55e9db0c-c927-48b4-9439-458f99cb416a" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_StockIssuedDuringPeriodSharesServiceAgreement_a07f3a98-1fb6-4355-a04c-f753125484d2" xlink:href="angn-20241231.xsd#angn_StockIssuedDuringPeriodSharesServiceAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_angn_StockIssuedDuringPeriodSharesServiceAgreement_a07f3a98-1fb6-4355-a04c-f753125484d2" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_StockIssuedDuringPeriodValueServiceAgreement_a3b86f39-82b9-4694-8446-74ad06069190" xlink:href="angn-20241231.xsd#angn_StockIssuedDuringPeriodValueServiceAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_angn_StockIssuedDuringPeriodValueServiceAgreement_a3b86f39-82b9-4694-8446-74ad06069190" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1288c983-77ef-42ab-bfdc-7b98ec591eec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1288c983-77ef-42ab-bfdc-7b98ec591eec" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_502c2bfc-f229-44a5-9bc0-8c5a68a2980f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_502c2bfc-f229-44a5-9bc0-8c5a68a2980f" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3d4893f8-5433-46ae-ac0d-5963b2165599" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_us-gaap_NetIncomeLoss_3d4893f8-5433-46ae-ac0d-5963b2165599" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_56b0c333-79f6-4851-b274-04e2cadcb836" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bef80b23-45d2-4c6b-9741-e1fcbd5c02c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_2a426845-9fd5-453a-87a8-625b615bab0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquityParenthetical" xlink:type="simple" xlink:href="angn-20241231.xsd#ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquityParenthetical"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1d27c3f8-b5e7-48a1-94be-4e5a3ff29058" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8d463a22-9ee1-4c3a-a73e-c999b5cc9650" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1d27c3f8-b5e7-48a1-94be-4e5a3ff29058" xlink:to="loc_us-gaap_StatementTable_8d463a22-9ee1-4c3a-a73e-c999b5cc9650" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_29f8a9c6-f31a-4c47-ba57-38898872a02c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8d463a22-9ee1-4c3a-a73e-c999b5cc9650" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_29f8a9c6-f31a-4c47-ba57-38898872a02c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_29f8a9c6-f31a-4c47-ba57-38898872a02c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_29f8a9c6-f31a-4c47-ba57-38898872a02c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_29f8a9c6-f31a-4c47-ba57-38898872a02c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2d508c9c-75e7-409c-88c4-c413b283b981" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_29f8a9c6-f31a-4c47-ba57-38898872a02c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2d508c9c-75e7-409c-88c4-c413b283b981" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_JulyPublicOfferingMember_cbab655b-e571-4988-8c15-d9464ed2e8c5" xlink:href="angn-20241231.xsd#angn_JulyPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2d508c9c-75e7-409c-88c4-c413b283b981" xlink:to="loc_angn_JulyPublicOfferingMember_cbab655b-e571-4988-8c15-d9464ed2e8c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_1f74dff6-d42b-4c58-b60f-2d0179436a74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1d27c3f8-b5e7-48a1-94be-4e5a3ff29058" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_1f74dff6-d42b-4c58-b60f-2d0179436a74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_896c7ff2-3bff-44c9-b0e9-ab1f2aa97c38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1d27c3f8-b5e7-48a1-94be-4e5a3ff29058" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_896c7ff2-3bff-44c9-b0e9-ab1f2aa97c38" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="angn-20241231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7c8a8326-6ba9-4663-80df-341c46f315c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c2046131-f464-4515-9a66-5458538c2b45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_7c8a8326-6ba9-4663-80df-341c46f315c5" xlink:to="loc_us-gaap_StatementTable_c2046131-f464-4515-9a66-5458538c2b45" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_36ef13ed-0945-45bd-929c-4d553c0815a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c2046131-f464-4515-9a66-5458538c2b45" xlink:to="loc_us-gaap_StatementClassOfStockAxis_36ef13ed-0945-45bd-929c-4d553c0815a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_36ef13ed-0945-45bd-929c-4d553c0815a5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_36ef13ed-0945-45bd-929c-4d553c0815a5" xlink:to="loc_us-gaap_ClassOfStockDomain_36ef13ed-0945-45bd-929c-4d553c0815a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_56e2240e-1e4c-4024-8a6d-ea255346a595" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_36ef13ed-0945-45bd-929c-4d553c0815a5" xlink:to="loc_us-gaap_ClassOfStockDomain_56e2240e-1e4c-4024-8a6d-ea255346a595" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_44950e48-3514-4600-9beb-b68e5c197425" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_56e2240e-1e4c-4024-8a6d-ea255346a595" xlink:to="loc_us-gaap_CommonStockMember_44950e48-3514-4600-9beb-b68e5c197425" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_StockIssuanceAxis_e766a0a4-6ba7-4320-8683-b6d470969117" xlink:href="angn-20241231.xsd#angn_StockIssuanceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c2046131-f464-4515-9a66-5458538c2b45" xlink:to="loc_angn_StockIssuanceAxis_e766a0a4-6ba7-4320-8683-b6d470969117" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_StockIssuanceDomain_e766a0a4-6ba7-4320-8683-b6d470969117_default" xlink:href="angn-20241231.xsd#angn_StockIssuanceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_angn_StockIssuanceAxis_e766a0a4-6ba7-4320-8683-b6d470969117" xlink:to="loc_angn_StockIssuanceDomain_e766a0a4-6ba7-4320-8683-b6d470969117_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_StockIssuanceDomain_34b2b835-90ee-48b4-829c-b8df8c13aae2" xlink:href="angn-20241231.xsd#angn_StockIssuanceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_angn_StockIssuanceAxis_e766a0a4-6ba7-4320-8683-b6d470969117" xlink:to="loc_angn_StockIssuanceDomain_34b2b835-90ee-48b4-829c-b8df8c13aae2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AngionStockholdersMember_97b034be-e303-4da6-acb6-68785782651e" xlink:href="angn-20241231.xsd#angn_AngionStockholdersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_angn_StockIssuanceDomain_34b2b835-90ee-48b4-829c-b8df8c13aae2" xlink:to="loc_angn_AngionStockholdersMember_97b034be-e303-4da6-acb6-68785782651e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ServiceAgreementMember_b5e6a8d5-5382-47cd-81bd-9019781c3f6f" xlink:href="angn-20241231.xsd#angn_ServiceAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_angn_StockIssuanceDomain_34b2b835-90ee-48b4-829c-b8df8c13aae2" xlink:to="loc_angn_ServiceAgreementMember_b5e6a8d5-5382-47cd-81bd-9019781c3f6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FairValueOfPreFundedWarrants_261d991a-2ccf-417d-9b50-bf1a057b0eba" xlink:href="angn-20241231.xsd#angn_FairValueOfPreFundedWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7c8a8326-6ba9-4663-80df-341c46f315c5" xlink:to="loc_angn_FairValueOfPreFundedWarrants_261d991a-2ccf-417d-9b50-bf1a057b0eba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FairValueOfCommonStockWarrants_1a0389d5-96df-424c-b80b-d80ea2c368ab" xlink:href="angn-20241231.xsd#angn_FairValueOfCommonStockWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7c8a8326-6ba9-4663-80df-341c46f315c5" xlink:to="loc_angn_FairValueOfCommonStockWarrants_1a0389d5-96df-424c-b80b-d80ea2c368ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AccretionOfPromissoryNoteDiscountFromEmbeddedDerivative_0056194d-2b2d-4033-8a2d-f7919b0fcea3" xlink:href="angn-20241231.xsd#angn_AccretionOfPromissoryNoteDiscountFromEmbeddedDerivative"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7c8a8326-6ba9-4663-80df-341c46f315c5" xlink:to="loc_angn_AccretionOfPromissoryNoteDiscountFromEmbeddedDerivative_0056194d-2b2d-4033-8a2d-f7919b0fcea3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AccretionOfPromissoryNoteToFaceValue_4452270f-8282-400b-83b5-f0263737493a" xlink:href="angn-20241231.xsd#angn_AccretionOfPromissoryNoteToFaceValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7c8a8326-6ba9-4663-80df-341c46f315c5" xlink:to="loc_angn_AccretionOfPromissoryNoteToFaceValue_4452270f-8282-400b-83b5-f0263737493a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_SettlementOfPromissoryNotesPayable_d013e7fe-ebbd-43a7-9b53-56d78702e871" xlink:href="angn-20241231.xsd#angn_SettlementOfPromissoryNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7c8a8326-6ba9-4663-80df-341c46f315c5" xlink:to="loc_angn_SettlementOfPromissoryNotesPayable_d013e7fe-ebbd-43a7-9b53-56d78702e871" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_VestingOfRestrictedCommonStockNoncash_10d25ace-583f-4e00-b8d4-d7c6da45ed88" xlink:href="angn-20241231.xsd#angn_VestingOfRestrictedCommonStockNoncash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7c8a8326-6ba9-4663-80df-341c46f315c5" xlink:to="loc_angn_VestingOfRestrictedCommonStockNoncash_10d25ace-583f-4e00-b8d4-d7c6da45ed88" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1_18ccb5ce-3cdc-49ab-a597-4ea84bb2a139" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7c8a8326-6ba9-4663-80df-341c46f315c5" xlink:to="loc_us-gaap_ConversionOfStockAmountIssued1_18ccb5ce-3cdc-49ab-a597-4ea84bb2a139" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_fa579077-2ec7-4574-b511-60569c168d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7c8a8326-6ba9-4663-80df-341c46f315c5" xlink:to="loc_us-gaap_StockIssued1_fa579077-2ec7-4574-b511-60569c168d1c" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#DescriptionoftheBusinessandFinancialConditionDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_b3725cc6-8f06-47a5-98a2-1bcff3653a90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_3430381f-4a09-42b4-b9c2-77b6c1c97a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_b3725cc6-8f06-47a5-98a2-1bcff3653a90" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_3430381f-4a09-42b4-b9c2-77b6c1c97a6e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_664e84fc-0317-4ff1-ad66-24c3ec3d133b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_3430381f-4a09-42b4-b9c2-77b6c1c97a6e" xlink:to="loc_srt_OwnershipAxis_664e84fc-0317-4ff1-ad66-24c3ec3d133b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_664e84fc-0317-4ff1-ad66-24c3ec3d133b_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_664e84fc-0317-4ff1-ad66-24c3ec3d133b" xlink:to="loc_srt_OwnershipDomain_664e84fc-0317-4ff1-ad66-24c3ec3d133b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_f5083559-46ba-4ec3-a9c6-9bc0e6935545" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_664e84fc-0317-4ff1-ad66-24c3ec3d133b" xlink:to="loc_srt_OwnershipDomain_f5083559-46ba-4ec3-a9c6-9bc0e6935545" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FormerElicioEquityHoldersMember_1dbfe387-db75-4eea-b5a3-d0249686a400" xlink:href="angn-20241231.xsd#angn_FormerElicioEquityHoldersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_f5083559-46ba-4ec3-a9c6-9bc0e6935545" xlink:to="loc_angn_FormerElicioEquityHoldersMember_1dbfe387-db75-4eea-b5a3-d0249686a400" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FormerAngionEquityHoldersMember_70d3560a-6649-401c-adf2-1791b50f8e79" xlink:href="angn-20241231.xsd#angn_FormerAngionEquityHoldersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_f5083559-46ba-4ec3-a9c6-9bc0e6935545" xlink:to="loc_angn_FormerAngionEquityHoldersMember_70d3560a-6649-401c-adf2-1791b50f8e79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7a5f6242-572b-42ff-ae5f-8c6013943739" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_b3725cc6-8f06-47a5-98a2-1bcff3653a90" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7a5f6242-572b-42ff-ae5f-8c6013943739" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ReverseRecapitalizationOwnershipPercentage_3f47b796-5320-4e52-99ad-b92f7affc2df" xlink:href="angn-20241231.xsd#angn_ReverseRecapitalizationOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_b3725cc6-8f06-47a5-98a2-1bcff3653a90" xlink:to="loc_angn_ReverseRecapitalizationOwnershipPercentage_3f47b796-5320-4e52-99ad-b92f7affc2df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_09e3119d-6c65-4f49-bbd1-155e32c753cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_b3725cc6-8f06-47a5-98a2-1bcff3653a90" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_09e3119d-6c65-4f49-bbd1-155e32c753cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0c3d3ca5-e2ad-42b3-a0d0-4d908a4cb86a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_b3725cc6-8f06-47a5-98a2-1bcff3653a90" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0c3d3ca5-e2ad-42b3-a0d0-4d908a4cb86a" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_07b0ac51-3f68-4673-bd60-739cebf0448a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_7439bf93-6057-4c53-96b7-6280b53130ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_07b0ac51-3f68-4673-bd60-739cebf0448a" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_7439bf93-6057-4c53-96b7-6280b53130ac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_456c3c45-223c-4472-b05b-752e5ad8a5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7439bf93-6057-4c53-96b7-6280b53130ac" xlink:to="loc_us-gaap_StatementClassOfStockAxis_456c3c45-223c-4472-b05b-752e5ad8a5e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_456c3c45-223c-4472-b05b-752e5ad8a5e7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_456c3c45-223c-4472-b05b-752e5ad8a5e7" xlink:to="loc_us-gaap_ClassOfStockDomain_456c3c45-223c-4472-b05b-752e5ad8a5e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2d35706e-5749-493d-9cc3-a88275f3dfb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_456c3c45-223c-4472-b05b-752e5ad8a5e7" xlink:to="loc_us-gaap_ClassOfStockDomain_2d35706e-5749-493d-9cc3-a88275f3dfb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AngionCommonStockMember_03ec359d-d25c-4201-8f0d-a2f90a9617ef" xlink:href="angn-20241231.xsd#angn_AngionCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2d35706e-5749-493d-9cc3-a88275f3dfb7" xlink:to="loc_angn_AngionCommonStockMember_03ec359d-d25c-4201-8f0d-a2f90a9617ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_8cce5aba-f603-47ce-8fd2-950a513bfc2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_07b0ac51-3f68-4673-bd60-739cebf0448a" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_8cce5aba-f603-47ce-8fd2-950a513bfc2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_80965695-aa4c-43e9-bccf-255bcba1938d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_07b0ac51-3f68-4673-bd60-739cebf0448a" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_80965695-aa4c-43e9-bccf-255bcba1938d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_RecapitalizationExchangeRatio_8b871d52-f477-42e1-b1d2-7d318438ba6d" xlink:href="angn-20241231.xsd#angn_RecapitalizationExchangeRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_07b0ac51-3f68-4673-bd60-739cebf0448a" xlink:to="loc_angn_RecapitalizationExchangeRatio_8b871d52-f477-42e1-b1d2-7d318438ba6d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_6c550a8e-7c1e-4baa-a1ad-16c4a7ed3fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_07b0ac51-3f68-4673-bd60-739cebf0448a" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_6c550a8e-7c1e-4baa-a1ad-16c4a7ed3fb7" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a8350a69-669f-497b-8468-80ce5ecc7651" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8e195495-0ce8-41a7-91c6-3d3ab32f50aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a8350a69-669f-497b-8468-80ce5ecc7651" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8e195495-0ce8-41a7-91c6-3d3ab32f50aa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8e876d43-bf68-4d00-8c5d-c47c69457e30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8e195495-0ce8-41a7-91c6-3d3ab32f50aa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8e876d43-bf68-4d00-8c5d-c47c69457e30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8e876d43-bf68-4d00-8c5d-c47c69457e30_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8e876d43-bf68-4d00-8c5d-c47c69457e30" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8e876d43-bf68-4d00-8c5d-c47c69457e30_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2c33a154-ccfd-41f4-9955-4cfe6196555d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8e876d43-bf68-4d00-8c5d-c47c69457e30" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2c33a154-ccfd-41f4-9955-4cfe6196555d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_6560e72b-5232-4c67-903e-38bdf8878b70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2c33a154-ccfd-41f4-9955-4cfe6196555d" xlink:to="loc_us-gaap_EquipmentMember_6560e72b-5232-4c67-903e-38bdf8878b70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_3d493426-3e68-48c6-a604-2718758a6c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2c33a154-ccfd-41f4-9955-4cfe6196555d" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_3d493426-3e68-48c6-a604-2718758a6c8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_8827fd90-4f8a-4366-9958-8cd141245b46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a8350a69-669f-497b-8468-80ce5ecc7651" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_8827fd90-4f8a-4366-9958-8cd141245b46" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/MergerandRelatedTransactionsNarrativeDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#MergerandRelatedTransactionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/MergerandRelatedTransactionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_angn_ReverseRecapitalizationLineItems_4079921b-2c0b-41b2-948d-c2fd46e2b9e3" xlink:href="angn-20241231.xsd#angn_ReverseRecapitalizationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ScheduleOfReverseRecapitalizationTable_180a1a1b-fd9e-4159-ab76-edc371aef685" xlink:href="angn-20241231.xsd#angn_ScheduleOfReverseRecapitalizationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_angn_ReverseRecapitalizationLineItems_4079921b-2c0b-41b2-948d-c2fd46e2b9e3" xlink:to="loc_angn_ScheduleOfReverseRecapitalizationTable_180a1a1b-fd9e-4159-ab76-edc371aef685" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_2bd27172-cc25-4a87-84e2-8735854365f6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_angn_ScheduleOfReverseRecapitalizationTable_180a1a1b-fd9e-4159-ab76-edc371aef685" xlink:to="loc_dei_LegalEntityAxis_2bd27172-cc25-4a87-84e2-8735854365f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2bd27172-cc25-4a87-84e2-8735854365f6_default" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2bd27172-cc25-4a87-84e2-8735854365f6" xlink:to="loc_dei_EntityDomain_2bd27172-cc25-4a87-84e2-8735854365f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ec445f75-7893-4fe3-9770-b6009c5aadd7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2bd27172-cc25-4a87-84e2-8735854365f6" xlink:to="loc_dei_EntityDomain_ec445f75-7893-4fe3-9770-b6009c5aadd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FormerElicioMember_3efefcd6-e953-459f-9beb-714ec5144c74" xlink:href="angn-20241231.xsd#angn_FormerElicioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_ec445f75-7893-4fe3-9770-b6009c5aadd7" xlink:to="loc_angn_FormerElicioMember_3efefcd6-e953-459f-9beb-714ec5144c74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6b7182a5-3915-405f-8072-2cc6bbd20347" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_angn_ScheduleOfReverseRecapitalizationTable_180a1a1b-fd9e-4159-ab76-edc371aef685" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6b7182a5-3915-405f-8072-2cc6bbd20347" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6b7182a5-3915-405f-8072-2cc6bbd20347_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6b7182a5-3915-405f-8072-2cc6bbd20347" xlink:to="loc_us-gaap_ClassOfStockDomain_6b7182a5-3915-405f-8072-2cc6bbd20347_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_334ae451-85c3-44bc-851e-4b24c8a03200" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6b7182a5-3915-405f-8072-2cc6bbd20347" xlink:to="loc_us-gaap_ClassOfStockDomain_334ae451-85c3-44bc-851e-4b24c8a03200" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AngionCommonStockMember_04844387-5dbb-48a9-8142-7574e3c3ce3c" xlink:href="angn-20241231.xsd#angn_AngionCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_334ae451-85c3-44bc-851e-4b24c8a03200" xlink:to="loc_angn_AngionCommonStockMember_04844387-5dbb-48a9-8142-7574e3c3ce3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a3d4aae4-f8f5-4b82-a42a-a44e47ca83cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_angn_ScheduleOfReverseRecapitalizationTable_180a1a1b-fd9e-4159-ab76-edc371aef685" xlink:to="loc_us-gaap_DebtInstrumentAxis_a3d4aae4-f8f5-4b82-a42a-a44e47ca83cd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a3d4aae4-f8f5-4b82-a42a-a44e47ca83cd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_a3d4aae4-f8f5-4b82-a42a-a44e47ca83cd" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a3d4aae4-f8f5-4b82-a42a-a44e47ca83cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b4d8763a-1f91-4f4e-b107-bf71808a9087" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_a3d4aae4-f8f5-4b82-a42a-a44e47ca83cd" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b4d8763a-1f91-4f4e-b107-bf71808a9087" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_BridgeLoanBetweenAngionAndFormerElicioMember_29284872-34ae-4b71-b90a-fb2e49cd6862" xlink:href="angn-20241231.xsd#angn_BridgeLoanBetweenAngionAndFormerElicioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b4d8763a-1f91-4f4e-b107-bf71808a9087" xlink:to="loc_angn_BridgeLoanBetweenAngionAndFormerElicioMember_29284872-34ae-4b71-b90a-fb2e49cd6862" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountInitialClosingMember_ef16bfe2-8860-432b-a46f-f524b9aa851a" xlink:href="angn-20241231.xsd#angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountInitialClosingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b4d8763a-1f91-4f4e-b107-bf71808a9087" xlink:to="loc_angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountInitialClosingMember_ef16bfe2-8860-432b-a46f-f524b9aa851a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_BridgeLoanBetweenAngionAndFormerElicioInitialClosingMember_72c8498b-f403-42cb-8112-8a465ebcdb21" xlink:href="angn-20241231.xsd#angn_BridgeLoanBetweenAngionAndFormerElicioInitialClosingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b4d8763a-1f91-4f4e-b107-bf71808a9087" xlink:to="loc_angn_BridgeLoanBetweenAngionAndFormerElicioInitialClosingMember_72c8498b-f403-42cb-8112-8a465ebcdb21" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountAdditionalClosingMember_8928f007-6fd9-46cf-a283-f6f9068def23" xlink:href="angn-20241231.xsd#angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountAdditionalClosingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b4d8763a-1f91-4f4e-b107-bf71808a9087" xlink:to="loc_angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountAdditionalClosingMember_8928f007-6fd9-46cf-a283-f6f9068def23" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_BridgeLoanBetweenAngionAndFormerElicioAdditionalClosingMember_24954b7b-1d92-4582-8346-b8a45f1abd01" xlink:href="angn-20241231.xsd#angn_BridgeLoanBetweenAngionAndFormerElicioAdditionalClosingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b4d8763a-1f91-4f4e-b107-bf71808a9087" xlink:to="loc_angn_BridgeLoanBetweenAngionAndFormerElicioAdditionalClosingMember_24954b7b-1d92-4582-8346-b8a45f1abd01" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b1d5b504-8bd2-45e0-8688-e25f4c29f9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_angn_ScheduleOfReverseRecapitalizationTable_180a1a1b-fd9e-4159-ab76-edc371aef685" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b1d5b504-8bd2-45e0-8688-e25f4c29f9ec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b1d5b504-8bd2-45e0-8688-e25f4c29f9ec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b1d5b504-8bd2-45e0-8688-e25f4c29f9ec" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b1d5b504-8bd2-45e0-8688-e25f4c29f9ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_175a5074-21ba-49dc-9959-3c3415f95ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b1d5b504-8bd2-45e0-8688-e25f4c29f9ec" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_175a5074-21ba-49dc-9959-3c3415f95ee3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_cd6b9f8c-5a43-4e8c-9fb2-1952a925a104" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_175a5074-21ba-49dc-9959-3c3415f95ee3" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_cd6b9f8c-5a43-4e8c-9fb2-1952a925a104" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_NumberOfMembersOfTheBoardOfDirectors_3f95e5b9-8814-4bd0-a166-3c525d94188f" xlink:href="angn-20241231.xsd#angn_NumberOfMembersOfTheBoardOfDirectors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_angn_ReverseRecapitalizationLineItems_4079921b-2c0b-41b2-948d-c2fd46e2b9e3" xlink:to="loc_angn_NumberOfMembersOfTheBoardOfDirectors_3f95e5b9-8814-4bd0-a166-3c525d94188f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_RecapitalizationExchangeRatio_ca5dfcb9-469d-49b3-aa56-f70e5db68b51" xlink:href="angn-20241231.xsd#angn_RecapitalizationExchangeRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_angn_ReverseRecapitalizationLineItems_4079921b-2c0b-41b2-948d-c2fd46e2b9e3" xlink:to="loc_angn_RecapitalizationExchangeRatio_ca5dfcb9-469d-49b3-aa56-f70e5db68b51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_cba004e5-208e-4cdb-8305-86b8017c1c17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_angn_ReverseRecapitalizationLineItems_4079921b-2c0b-41b2-948d-c2fd46e2b9e3" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_cba004e5-208e-4cdb-8305-86b8017c1c17" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_34bb0957-4641-49e7-8903-8f165d37e8a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_angn_ReverseRecapitalizationLineItems_4079921b-2c0b-41b2-948d-c2fd46e2b9e3" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_34bb0957-4641-49e7-8903-8f165d37e8a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_83d95a45-7092-4bfc-aedf-bcf23af6b920" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_angn_ReverseRecapitalizationLineItems_4079921b-2c0b-41b2-948d-c2fd46e2b9e3" xlink:to="loc_us-gaap_CommonStockSharesIssued_83d95a45-7092-4bfc-aedf-bcf23af6b920" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_23f603d1-be7c-4730-9ef1-86434ca86e56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_angn_ReverseRecapitalizationLineItems_4079921b-2c0b-41b2-948d-c2fd46e2b9e3" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_23f603d1-be7c-4730-9ef1-86434ca86e56" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_c082f47b-6894-4cef-8833-4677b8e2a964" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_angn_ReverseRecapitalizationLineItems_4079921b-2c0b-41b2-948d-c2fd46e2b9e3" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_c082f47b-6894-4cef-8833-4677b8e2a964" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_DebtInstrumentIssuanceDiscountPercent_be560898-ab00-417d-a192-2955d198693d" xlink:href="angn-20241231.xsd#angn_DebtInstrumentIssuanceDiscountPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_angn_ReverseRecapitalizationLineItems_4079921b-2c0b-41b2-948d-c2fd46e2b9e3" xlink:to="loc_angn_DebtInstrumentIssuanceDiscountPercent_be560898-ab00-417d-a192-2955d198693d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a8ed4a23-9222-42b5-b6ad-963db85d71ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_angn_ReverseRecapitalizationLineItems_4079921b-2c0b-41b2-948d-c2fd46e2b9e3" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a8ed4a23-9222-42b5-b6ad-963db85d71ae" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ReverseRecapitalizationTransactionCosts_a987b251-b300-4fc9-bfdd-d551781ccb06" xlink:href="angn-20241231.xsd#angn_ReverseRecapitalizationTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_angn_ReverseRecapitalizationLineItems_4079921b-2c0b-41b2-948d-c2fd46e2b9e3" xlink:to="loc_angn_ReverseRecapitalizationTransactionCosts_a987b251-b300-4fc9-bfdd-d551781ccb06" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3157fabf-3ef3-4519-bc72-a53204ca860c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_c2f73bf6-34d2-4861-a22e-00ddd6a4c30d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3157fabf-3ef3-4519-bc72-a53204ca860c" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_c2f73bf6-34d2-4861-a22e-00ddd6a4c30d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_db237d67-52cb-44d2-a1ae-4f46938ebd10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_c2f73bf6-34d2-4861-a22e-00ddd6a4c30d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_db237d67-52cb-44d2-a1ae-4f46938ebd10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_db237d67-52cb-44d2-a1ae-4f46938ebd10_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_db237d67-52cb-44d2-a1ae-4f46938ebd10" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_db237d67-52cb-44d2-a1ae-4f46938ebd10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6c11a871-3668-4707-9827-46be0239c6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_db237d67-52cb-44d2-a1ae-4f46938ebd10" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6c11a871-3668-4707-9827-46be0239c6cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_3b7dc291-0708-4cae-b00f-6f8c014612c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6c11a871-3668-4707-9827-46be0239c6cf" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_3b7dc291-0708-4cae-b00f-6f8c014612c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_3a957a9c-53bc-47ea-9fc3-8c7930013db3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6c11a871-3668-4707-9827-46be0239c6cf" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_3a957a9c-53bc-47ea-9fc3-8c7930013db3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_82fe3a3f-3f31-412b-832e-2a869b800d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6c11a871-3668-4707-9827-46be0239c6cf" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_82fe3a3f-3f31-412b-832e-2a869b800d9a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_224688f9-2a8c-4c96-92b0-0aaef0c7d1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_c2f73bf6-34d2-4861-a22e-00ddd6a4c30d" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_224688f9-2a8c-4c96-92b0-0aaef0c7d1f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_224688f9-2a8c-4c96-92b0-0aaef0c7d1f7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_224688f9-2a8c-4c96-92b0-0aaef0c7d1f7" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_224688f9-2a8c-4c96-92b0-0aaef0c7d1f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_92157dd6-96ad-4833-9339-1ad2a683dbac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_224688f9-2a8c-4c96-92b0-0aaef0c7d1f7" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_92157dd6-96ad-4833-9339-1ad2a683dbac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_03c6a233-b7ee-47f3-9ebe-3d7731c5325e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_92157dd6-96ad-4833-9339-1ad2a683dbac" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_03c6a233-b7ee-47f3-9ebe-3d7731c5325e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_2dd1e676-2e36-4b66-8bb5-223e5aced136" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3157fabf-3ef3-4519-bc72-a53204ca860c" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_2dd1e676-2e36-4b66-8bb5-223e5aced136" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_79ac8da3-2a31-4381-8b05-bc8424c42107" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_2dd1e676-2e36-4b66-8bb5-223e5aced136" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_79ac8da3-2a31-4381-8b05-bc8424c42107" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_c9a8be86-4ff0-4c32-bdc8-821af0a4efee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_2dd1e676-2e36-4b66-8bb5-223e5aced136" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_c9a8be86-4ff0-4c32-bdc8-821af0a4efee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_d563f392-16ce-4631-8e57-6afc4feb925a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3157fabf-3ef3-4519-bc72-a53204ca860c" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_d563f392-16ce-4631-8e57-6afc4feb925a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsFairValueDisclosure_6d31b621-99dc-4bf4-b8c6-ded30cd3a641" xlink:href="angn-20241231.xsd#angn_WarrantsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_d563f392-16ce-4631-8e57-6afc4feb925a" xlink:to="loc_angn_WarrantsFairValueDisclosure_6d31b621-99dc-4bf4-b8c6-ded30cd3a641" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_d5325e7d-fb7e-49cf-9ab3-cdf6f935e639" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_d563f392-16ce-4631-8e57-6afc4feb925a" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_d5325e7d-fb7e-49cf-9ab3-cdf6f935e639" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#FairValueMeasurementsScheduleofFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_c0afa857-aaf1-4b89-9708-63228952e397" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a9fae550-b161-413a-8bc3-1ccab2de7436" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_c0afa857-aaf1-4b89-9708-63228952e397" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a9fae550-b161-413a-8bc3-1ccab2de7436" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_f449f4d9-2bb3-4e82-8c33-3f2f0b4aa86d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a9fae550-b161-413a-8bc3-1ccab2de7436" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_f449f4d9-2bb3-4e82-8c33-3f2f0b4aa86d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_f449f4d9-2bb3-4e82-8c33-3f2f0b4aa86d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_f449f4d9-2bb3-4e82-8c33-3f2f0b4aa86d" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_f449f4d9-2bb3-4e82-8c33-3f2f0b4aa86d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_39896801-ca50-45be-9f00-cbb61b4fdcb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_f449f4d9-2bb3-4e82-8c33-3f2f0b4aa86d" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_39896801-ca50-45be-9f00-cbb61b4fdcb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantLiabilityMember_dc06d3cb-6457-41bb-a319-e7219527c759" xlink:href="angn-20241231.xsd#angn_WarrantLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_39896801-ca50-45be-9f00-cbb61b4fdcb5" xlink:to="loc_angn_WarrantLiabilityMember_dc06d3cb-6457-41bb-a319-e7219527c759" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6555aa64-56d7-4be0-bab2-5ca4329ca69c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_c0afa857-aaf1-4b89-9708-63228952e397" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6555aa64-56d7-4be0-bab2-5ca4329ca69c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_12b40503-57eb-4ebb-8ef8-d681230b4ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6555aa64-56d7-4be0-bab2-5ca4329ca69c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_12b40503-57eb-4ebb-8ef8-d681230b4ee8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_16efa29a-f85c-4ca6-9e0a-4da30cd2832a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6555aa64-56d7-4be0-bab2-5ca4329ca69c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_16efa29a-f85c-4ca6-9e0a-4da30cd2832a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c83e6613-0e38-4cb6-91f4-4f9fe214f6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6555aa64-56d7-4be0-bab2-5ca4329ca69c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c83e6613-0e38-4cb6-91f4-4f9fe214f6ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_78098f4d-ea44-418d-9543-26d028d2d952" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_510c9a33-8a60-40d8-8711-7b4a883f691e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_68665112-b16c-42fb-9a9c-3edef6fea4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_510c9a33-8a60-40d8-8711-7b4a883f691e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_68665112-b16c-42fb-9a9c-3edef6fea4a6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_2422c698-d169-476e-91cd-a1b810e3d4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_68665112-b16c-42fb-9a9c-3edef6fea4a6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_2422c698-d169-476e-91cd-a1b810e3d4dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_2422c698-d169-476e-91cd-a1b810e3d4dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2422c698-d169-476e-91cd-a1b810e3d4dd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_2422c698-d169-476e-91cd-a1b810e3d4dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_aa129020-e754-4e6c-9dc9-1ee53cb7deda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2422c698-d169-476e-91cd-a1b810e3d4dd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_aa129020-e754-4e6c-9dc9-1ee53cb7deda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_PreFundedWarrantMember_e73ef36d-1d29-4b3c-a3d8-871364e8579f" xlink:href="angn-20241231.xsd#angn_PreFundedWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_aa129020-e754-4e6c-9dc9-1ee53cb7deda" xlink:to="loc_angn_PreFundedWarrantMember_e73ef36d-1d29-4b3c-a3d8-871364e8579f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember_bbfe7e9f-e302-409e-bda8-717ace6de20e" xlink:href="angn-20241231.xsd#angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_aa129020-e754-4e6c-9dc9-1ee53cb7deda" xlink:to="loc_angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember_bbfe7e9f-e302-409e-bda8-717ace6de20e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_JulyPreFundedWarrantsMember_37d48eeb-a240-4375-8ad2-c1b7db806c18" xlink:href="angn-20241231.xsd#angn_JulyPreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember_bbfe7e9f-e302-409e-bda8-717ace6de20e" xlink:to="loc_angn_JulyPreFundedWarrantsMember_37d48eeb-a240-4375-8ad2-c1b7db806c18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_JulyCommonWarrantsMember_f7cd4beb-94a0-4d0c-9c6f-45faad9e7ae8" xlink:href="angn-20241231.xsd#angn_JulyCommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember_bbfe7e9f-e302-409e-bda8-717ace6de20e" xlink:to="loc_angn_JulyCommonWarrantsMember_f7cd4beb-94a0-4d0c-9c6f-45faad9e7ae8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_154c01c8-a3bd-4086-a2a5-4f2dd6ce714b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_68665112-b16c-42fb-9a9c-3edef6fea4a6" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_154c01c8-a3bd-4086-a2a5-4f2dd6ce714b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_154c01c8-a3bd-4086-a2a5-4f2dd6ce714b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_154c01c8-a3bd-4086-a2a5-4f2dd6ce714b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_154c01c8-a3bd-4086-a2a5-4f2dd6ce714b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_65ddec05-580b-4a86-915b-23ee2415cde0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_154c01c8-a3bd-4086-a2a5-4f2dd6ce714b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_65ddec05-580b-4a86-915b-23ee2415cde0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_MarchSubscriptionAgreementMember_3c57a12a-b875-4759-918b-620a366ee70b" xlink:href="angn-20241231.xsd#angn_MarchSubscriptionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_65ddec05-580b-4a86-915b-23ee2415cde0" xlink:to="loc_angn_MarchSubscriptionAgreementMember_3c57a12a-b875-4759-918b-620a366ee70b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_JulyPublicOfferingMember_87559132-e436-4c22-a5cd-89a9824b5fc4" xlink:href="angn-20241231.xsd#angn_JulyPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_65ddec05-580b-4a86-915b-23ee2415cde0" xlink:to="loc_angn_JulyPublicOfferingMember_87559132-e436-4c22-a5cd-89a9824b5fc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ebb76922-e9d2-48b5-81cc-b75bd082f498" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_68665112-b16c-42fb-9a9c-3edef6fea4a6" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ebb76922-e9d2-48b5-81cc-b75bd082f498" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ebb76922-e9d2-48b5-81cc-b75bd082f498_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ebb76922-e9d2-48b5-81cc-b75bd082f498" xlink:to="loc_us-gaap_ClassOfStockDomain_ebb76922-e9d2-48b5-81cc-b75bd082f498_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_655e383a-de74-487e-8189-91f39917d88d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ebb76922-e9d2-48b5-81cc-b75bd082f498" xlink:to="loc_us-gaap_ClassOfStockDomain_655e383a-de74-487e-8189-91f39917d88d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_JulySharesAndJulyCommonWarrantMember_0cebe5b5-6e43-469d-8c11-e474f726ae42" xlink:href="angn-20241231.xsd#angn_JulySharesAndJulyCommonWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_655e383a-de74-487e-8189-91f39917d88d" xlink:to="loc_angn_JulySharesAndJulyCommonWarrantMember_0cebe5b5-6e43-469d-8c11-e474f726ae42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_79804130-df65-49a5-bc50-c4c56cf9700f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_510c9a33-8a60-40d8-8711-7b4a883f691e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_79804130-df65-49a5-bc50-c4c56cf9700f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_178aecde-e15e-4508-99f2-4db55792a78d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_510c9a33-8a60-40d8-8711-7b4a883f691e" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_178aecde-e15e-4508-99f2-4db55792a78d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_c04e41fc-85bb-4206-9141-8ffd5619a59e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_510c9a33-8a60-40d8-8711-7b4a883f691e" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_c04e41fc-85bb-4206-9141-8ffd5619a59e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1dcde385-454f-432f-9acc-7559c6c84304" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_510c9a33-8a60-40d8-8711-7b4a883f691e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1dcde385-454f-432f-9acc-7559c6c84304" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_f1dd1483-896d-4ae0-ac33-94ef23ba62d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_510c9a33-8a60-40d8-8711-7b4a883f691e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_f1dd1483-896d-4ae0-ac33-94ef23ba62d0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_806ddab7-f7f2-49a2-ab4b-e6bd905cea7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_510c9a33-8a60-40d8-8711-7b4a883f691e" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_806ddab7-f7f2-49a2-ab4b-e6bd905cea7f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e27ac4ad-2a3b-431f-bd22-5ce70b6e6203" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_510c9a33-8a60-40d8-8711-7b4a883f691e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e27ac4ad-2a3b-431f-bd22-5ce70b6e6203" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_08a3156e-a8df-43d3-833f-dc4119ecb7b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_510c9a33-8a60-40d8-8711-7b4a883f691e" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_08a3156e-a8df-43d3-833f-dc4119ecb7b5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_SaleOfStockBeneficialOwnershipLimitationPercentage_a0b127b1-e1ce-44cb-ae28-60cdca580801" xlink:href="angn-20241231.xsd#angn_SaleOfStockBeneficialOwnershipLimitationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_510c9a33-8a60-40d8-8711-7b4a883f691e" xlink:to="loc_angn_SaleOfStockBeneficialOwnershipLimitationPercentage_a0b127b1-e1ce-44cb-ae28-60cdca580801" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_697038ba-1d36-4f3b-8710-59f18a4b14ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_21e1f062-299f-4dce-a781-d4849dd5e13c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_697038ba-1d36-4f3b-8710-59f18a4b14ef" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_21e1f062-299f-4dce-a781-d4849dd5e13c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8fa36441-f55a-4e63-a2cc-117973a56813" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_21e1f062-299f-4dce-a781-d4849dd5e13c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8fa36441-f55a-4e63-a2cc-117973a56813" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8fa36441-f55a-4e63-a2cc-117973a56813_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8fa36441-f55a-4e63-a2cc-117973a56813" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8fa36441-f55a-4e63-a2cc-117973a56813_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2a948eb0-8f64-403a-8a38-c7bb77b5eb23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8fa36441-f55a-4e63-a2cc-117973a56813" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2a948eb0-8f64-403a-8a38-c7bb77b5eb23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3407fe92-98cb-4761-bb52-029cfd16ad6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2a948eb0-8f64-403a-8a38-c7bb77b5eb23" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3407fe92-98cb-4761-bb52-029cfd16ad6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_c89d4e61-fc2a-42eb-8318-a940fbea8c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_21e1f062-299f-4dce-a781-d4849dd5e13c" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_c89d4e61-fc2a-42eb-8318-a940fbea8c6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_c89d4e61-fc2a-42eb-8318-a940fbea8c6e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_c89d4e61-fc2a-42eb-8318-a940fbea8c6e" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_c89d4e61-fc2a-42eb-8318-a940fbea8c6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_d4f9242c-2dad-4ed3-84a3-8fb6a6596b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_c89d4e61-fc2a-42eb-8318-a940fbea8c6e" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_d4f9242c-2dad-4ed3-84a3-8fb6a6596b4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_MeasurementInputStrikePriceMember_777e271a-1621-4a40-bc47-3c1acc146f1e" xlink:href="angn-20241231.xsd#angn_MeasurementInputStrikePriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d4f9242c-2dad-4ed3-84a3-8fb6a6596b4f" xlink:to="loc_angn_MeasurementInputStrikePriceMember_777e271a-1621-4a40-bc47-3c1acc146f1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_2a5e50fe-9aae-4599-9ffd-7a8c15925640" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d4f9242c-2dad-4ed3-84a3-8fb6a6596b4f" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_2a5e50fe-9aae-4599-9ffd-7a8c15925640" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_9f346b13-57d5-4e86-b211-61dfaa3d1f73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d4f9242c-2dad-4ed3-84a3-8fb6a6596b4f" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_9f346b13-57d5-4e86-b211-61dfaa3d1f73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_5b490e2f-2455-4e47-a530-6fec3c2629bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d4f9242c-2dad-4ed3-84a3-8fb6a6596b4f" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_5b490e2f-2455-4e47-a530-6fec3c2629bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_91613815-3613-4f5c-98a6-57f2e0f8536d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_697038ba-1d36-4f3b-8710-59f18a4b14ef" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_91613815-3613-4f5c-98a6-57f2e0f8536d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_c5d5a142-8247-4c84-96cf-92185a34bfc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_697038ba-1d36-4f3b-8710-59f18a4b14ef" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_c5d5a142-8247-4c84-96cf-92185a34bfc4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_13a95c5e-3089-43c5-b64f-fb23ece0be59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a2a35a21-cb85-4b89-987b-d979ab9ba319" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_13a95c5e-3089-43c5-b64f-fb23ece0be59" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a2a35a21-cb85-4b89-987b-d979ab9ba319" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ea887f78-8874-4605-b682-798f3c17db8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a2a35a21-cb85-4b89-987b-d979ab9ba319" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ea887f78-8874-4605-b682-798f3c17db8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ea887f78-8874-4605-b682-798f3c17db8d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ea887f78-8874-4605-b682-798f3c17db8d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ea887f78-8874-4605-b682-798f3c17db8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8ad51b3e-28cd-486a-acc7-1592c2fffd33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ea887f78-8874-4605-b682-798f3c17db8d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8ad51b3e-28cd-486a-acc7-1592c2fffd33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_2137dbd9-9dda-48a5-b67e-797961e49501" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8ad51b3e-28cd-486a-acc7-1592c2fffd33" xlink:to="loc_us-gaap_EquipmentMember_2137dbd9-9dda-48a5-b67e-797961e49501" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_10327786-e010-405f-ae3a-920c72b826f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8ad51b3e-28cd-486a-acc7-1592c2fffd33" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_10327786-e010-405f-ae3a-920c72b826f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_b000fec8-0a80-45a4-900a-9a2da62ce9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8ad51b3e-28cd-486a-acc7-1592c2fffd33" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_b000fec8-0a80-45a4-900a-9a2da62ce9ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_ca95226b-9440-45fe-bfd4-a6e2b316b476" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_13a95c5e-3089-43c5-b64f-fb23ece0be59" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_ca95226b-9440-45fe-bfd4-a6e2b316b476" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c16f0db5-d3e8-4097-8597-b558378155d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_13a95c5e-3089-43c5-b64f-fb23ece0be59" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c16f0db5-d3e8-4097-8597-b558378155d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6df5b5c8-7022-417c-be9d-0acb12644deb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_13a95c5e-3089-43c5-b64f-fb23ece0be59" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6df5b5c8-7022-417c-be9d-0acb12644deb" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/ResearchGrantDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#ResearchGrantDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/ResearchGrantDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9d9c34af-dc93-4332-a8d2-a428d218b45f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_123ca317-7a99-4bf5-9376-3e72875db1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9d9c34af-dc93-4332-a8d2-a428d218b45f" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_123ca317-7a99-4bf5-9376-3e72875db1a2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_530b0563-5e03-4a98-86ce-dae228af709a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_123ca317-7a99-4bf5-9376-3e72875db1a2" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_530b0563-5e03-4a98-86ce-dae228af709a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_530b0563-5e03-4a98-86ce-dae228af709a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_530b0563-5e03-4a98-86ce-dae228af709a" xlink:to="loc_us-gaap_ProjectMember_530b0563-5e03-4a98-86ce-dae228af709a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_5e7915bb-3154-4598-8ca1-19ce240f8174" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_530b0563-5e03-4a98-86ce-dae228af709a" xlink:to="loc_us-gaap_ProjectMember_5e7915bb-3154-4598-8ca1-19ce240f8174" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept2022Member_9eb2dfdc-b719-4bf2-95d4-33ac1b2a048f" xlink:href="angn-20241231.xsd#angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_5e7915bb-3154-4598-8ca1-19ce240f8174" xlink:to="loc_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept2022Member_9eb2dfdc-b719-4bf2-95d4-33ac1b2a048f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFJuly2023Member_d308850b-aede-4549-a407-cc2c16af2dc6" xlink:href="angn-20241231.xsd#angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFJuly2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_5e7915bb-3154-4598-8ca1-19ce240f8174" xlink:to="loc_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFJuly2023Member_d308850b-aede-4549-a407-cc2c16af2dc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept.2023Member_f4e39f7c-7cd1-4ba3-b671-b0bd27d46f68" xlink:href="angn-20241231.xsd#angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept.2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_5e7915bb-3154-4598-8ca1-19ce240f8174" xlink:to="loc_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept.2023Member_f4e39f7c-7cd1-4ba3-b671-b0bd27d46f68" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFAugust2024Member_5dac8bfd-1d09-445e-9428-e16190ca43bf" xlink:href="angn-20241231.xsd#angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFAugust2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_5e7915bb-3154-4598-8ca1-19ce240f8174" xlink:to="loc_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFAugust2024Member_5dac8bfd-1d09-445e-9428-e16190ca43bf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ResearchAndDevelopmentArrangementGrant_3434fdf6-9d64-4fbd-8713-9ccb31543574" xlink:href="angn-20241231.xsd#angn_ResearchAndDevelopmentArrangementGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9d9c34af-dc93-4332-a8d2-a428d218b45f" xlink:to="loc_angn_ResearchAndDevelopmentArrangementGrant_3434fdf6-9d64-4fbd-8713-9ccb31543574" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ResearchAndDevelopmentArrangementGrantReceived_91ad14b7-cade-4234-8b5d-11837ba583fa" xlink:href="angn-20241231.xsd#angn_ResearchAndDevelopmentArrangementGrantReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9d9c34af-dc93-4332-a8d2-a428d218b45f" xlink:to="loc_angn_ResearchAndDevelopmentArrangementGrantReceived_91ad14b7-cade-4234-8b5d-11837ba583fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6b63dc5a-0bf4-4ede-901b-bd138f9a0938" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9d9c34af-dc93-4332-a8d2-a428d218b45f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6b63dc5a-0bf4-4ede-901b-bd138f9a0938" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ResearchAndDevelopmentArrangementCredit_1541ae3d-6488-491f-8b06-ab1e4bcb68fe" xlink:href="angn-20241231.xsd#angn_ResearchAndDevelopmentArrangementCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9d9c34af-dc93-4332-a8d2-a428d218b45f" xlink:to="loc_angn_ResearchAndDevelopmentArrangementCredit_1541ae3d-6488-491f-8b06-ab1e4bcb68fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a83aad80-ee46-43a3-83b7-aad36bf8fbb4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9d9c34af-dc93-4332-a8d2-a428d218b45f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a83aad80-ee46-43a3-83b7-aad36bf8fbb4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_6b3ff915-5e65-4d50-b739-0edc075cd318" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9d9c34af-dc93-4332-a8d2-a428d218b45f" xlink:to="loc_us-gaap_RestrictedCashCurrent_6b3ff915-5e65-4d50-b739-0edc075cd318" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ResearchAndDevelopmentArrangementReimbursementFromGrantFunds_4c7dde0d-e502-4a52-9675-4ae499d7d763" xlink:href="angn-20241231.xsd#angn_ResearchAndDevelopmentArrangementReimbursementFromGrantFunds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9d9c34af-dc93-4332-a8d2-a428d218b45f" xlink:to="loc_angn_ResearchAndDevelopmentArrangementReimbursementFromGrantFunds_4c7dde0d-e502-4a52-9675-4ae499d7d763" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_NumberOfResearchGrantAgreements_b35e72cc-b2ed-47d6-a137-9fef8e10b950" xlink:href="angn-20241231.xsd#angn_NumberOfResearchGrantAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9d9c34af-dc93-4332-a8d2-a428d218b45f" xlink:to="loc_angn_NumberOfResearchGrantAgreements_b35e72cc-b2ed-47d6-a137-9fef8e10b950" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#ConvertiblePreferredStockCommonStockandStockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_13d1a269-01aa-4573-919d-7ce5fdce739a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_349acfc4-b9fc-4488-933e-fe92ab791ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_13d1a269-01aa-4573-919d-7ce5fdce739a" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_349acfc4-b9fc-4488-933e-fe92ab791ad0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f4424d95-1a2c-4a04-ac4f-88a4b8142e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_349acfc4-b9fc-4488-933e-fe92ab791ad0" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f4424d95-1a2c-4a04-ac4f-88a4b8142e1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f4424d95-1a2c-4a04-ac4f-88a4b8142e1c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f4424d95-1a2c-4a04-ac4f-88a4b8142e1c" xlink:to="loc_us-gaap_ClassOfStockDomain_f4424d95-1a2c-4a04-ac4f-88a4b8142e1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_037b3419-d38a-47ef-9e0e-ebca4664ba12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f4424d95-1a2c-4a04-ac4f-88a4b8142e1c" xlink:to="loc_us-gaap_ClassOfStockDomain_037b3419-d38a-47ef-9e0e-ebca4664ba12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_38f2d618-ac04-49be-bd97-2948bc3d26dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_037b3419-d38a-47ef-9e0e-ebca4664ba12" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_38f2d618-ac04-49be-bd97-2948bc3d26dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_JulySharesAndJulyCommonWarrantMember_a5bb08d7-5b8d-43ee-9a30-a64b092c0882" xlink:href="angn-20241231.xsd#angn_JulySharesAndJulyCommonWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_037b3419-d38a-47ef-9e0e-ebca4664ba12" xlink:to="loc_angn_JulySharesAndJulyCommonWarrantMember_a5bb08d7-5b8d-43ee-9a30-a64b092c0882" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_c6e14886-288d-4b23-8f2d-cb0c7f6f5629" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_349acfc4-b9fc-4488-933e-fe92ab791ad0" xlink:to="loc_dei_LegalEntityAxis_c6e14886-288d-4b23-8f2d-cb0c7f6f5629" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_c6e14886-288d-4b23-8f2d-cb0c7f6f5629_default" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_c6e14886-288d-4b23-8f2d-cb0c7f6f5629" xlink:to="loc_dei_EntityDomain_c6e14886-288d-4b23-8f2d-cb0c7f6f5629_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f309b630-1715-430e-8619-6461d9164c54" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_c6e14886-288d-4b23-8f2d-cb0c7f6f5629" xlink:to="loc_dei_EntityDomain_f309b630-1715-430e-8619-6461d9164c54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FormerElicioMember_9cdc3ebb-e4ca-42d2-8a5a-9c1fc081e0e2" xlink:href="angn-20241231.xsd#angn_FormerElicioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_f309b630-1715-430e-8619-6461d9164c54" xlink:to="loc_angn_FormerElicioMember_9cdc3ebb-e4ca-42d2-8a5a-9c1fc081e0e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_13543f12-add6-47da-b4d7-9f354f636602" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_349acfc4-b9fc-4488-933e-fe92ab791ad0" xlink:to="loc_srt_CounterpartyNameAxis_13543f12-add6-47da-b4d7-9f354f636602" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_13543f12-add6-47da-b4d7-9f354f636602_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_13543f12-add6-47da-b4d7-9f354f636602" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_13543f12-add6-47da-b4d7-9f354f636602_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_270cbd16-eb38-4493-99b2-776f771f414b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_13543f12-add6-47da-b4d7-9f354f636602" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_270cbd16-eb38-4493-99b2-776f771f414b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FormerElicioEquityHoldersMember_af1adcf0-916d-42cc-92ae-eaed20d78a0a" xlink:href="angn-20241231.xsd#angn_FormerElicioEquityHoldersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_270cbd16-eb38-4493-99b2-776f771f414b" xlink:to="loc_angn_FormerElicioEquityHoldersMember_af1adcf0-916d-42cc-92ae-eaed20d78a0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2fe22c86-d5af-4334-a860-3f462f82f697" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_349acfc4-b9fc-4488-933e-fe92ab791ad0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2fe22c86-d5af-4334-a860-3f462f82f697" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2fe22c86-d5af-4334-a860-3f462f82f697_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2fe22c86-d5af-4334-a860-3f462f82f697" xlink:to="loc_us-gaap_EquityComponentDomain_2fe22c86-d5af-4334-a860-3f462f82f697_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_adb223c7-2f7e-484d-9ca2-2528091c1bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2fe22c86-d5af-4334-a860-3f462f82f697" xlink:to="loc_us-gaap_EquityComponentDomain_adb223c7-2f7e-484d-9ca2-2528091c1bf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_05e16113-f2b6-42de-b5e2-0b236e924f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_adb223c7-2f7e-484d-9ca2-2528091c1bf5" xlink:to="loc_us-gaap_CommonStockMember_05e16113-f2b6-42de-b5e2-0b236e924f7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_56cde6be-9dd2-46f0-a898-0342d36665a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_349acfc4-b9fc-4488-933e-fe92ab791ad0" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_56cde6be-9dd2-46f0-a898-0342d36665a1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_56cde6be-9dd2-46f0-a898-0342d36665a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_56cde6be-9dd2-46f0-a898-0342d36665a1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_56cde6be-9dd2-46f0-a898-0342d36665a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e363c3a8-51ad-42c5-890e-4448e057f076" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_56cde6be-9dd2-46f0-a898-0342d36665a1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e363c3a8-51ad-42c5-890e-4448e057f076" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_RegistrationStatementMember_bd255414-84b8-4889-8090-3c2f2e33e855" xlink:href="angn-20241231.xsd#angn_RegistrationStatementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e363c3a8-51ad-42c5-890e-4448e057f076" xlink:to="loc_angn_RegistrationStatementMember_bd255414-84b8-4889-8090-3c2f2e33e855" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AtTheMarketEquityOfferingSalesAgreementMember_f4901024-68f8-4fbb-bb56-e39e2861be16" xlink:href="angn-20241231.xsd#angn_AtTheMarketEquityOfferingSalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e363c3a8-51ad-42c5-890e-4448e057f076" xlink:to="loc_angn_AtTheMarketEquityOfferingSalesAgreementMember_f4901024-68f8-4fbb-bb56-e39e2861be16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_A2024RegistrationStatementMember_5a071662-35cf-4d5c-944a-2484e54f6c9a" xlink:href="angn-20241231.xsd#angn_A2024RegistrationStatementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e363c3a8-51ad-42c5-890e-4448e057f076" xlink:to="loc_angn_A2024RegistrationStatementMember_5a071662-35cf-4d5c-944a-2484e54f6c9a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AtTheMarketEquityOfferingSalesAgreement2022Member_f34c1e91-050a-4073-ac99-49464366f79f" xlink:href="angn-20241231.xsd#angn_AtTheMarketEquityOfferingSalesAgreement2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e363c3a8-51ad-42c5-890e-4448e057f076" xlink:to="loc_angn_AtTheMarketEquityOfferingSalesAgreement2022Member_f34c1e91-050a-4073-ac99-49464366f79f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_MarchSubscriptionAgreementMember_3175e9ca-3f0e-45ed-acfc-5351ba33b09c" xlink:href="angn-20241231.xsd#angn_MarchSubscriptionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e363c3a8-51ad-42c5-890e-4448e057f076" xlink:to="loc_angn_MarchSubscriptionAgreementMember_3175e9ca-3f0e-45ed-acfc-5351ba33b09c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_JulyPublicOfferingMember_6faf7e2b-52f8-4f47-b40b-8c5c6665719d" xlink:href="angn-20241231.xsd#angn_JulyPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e363c3a8-51ad-42c5-890e-4448e057f076" xlink:to="loc_angn_JulyPublicOfferingMember_6faf7e2b-52f8-4f47-b40b-8c5c6665719d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AtTheMarketEquityOfferingSalesAgreement2024Member_e5c53acb-f408-47df-96d1-3a303c0c395a" xlink:href="angn-20241231.xsd#angn_AtTheMarketEquityOfferingSalesAgreement2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e363c3a8-51ad-42c5-890e-4448e057f076" xlink:to="loc_angn_AtTheMarketEquityOfferingSalesAgreement2024Member_e5c53acb-f408-47df-96d1-3a303c0c395a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_97ff51b7-68fb-4c72-9691-2ce3360618e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_349acfc4-b9fc-4488-933e-fe92ab791ad0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_97ff51b7-68fb-4c72-9691-2ce3360618e3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_97ff51b7-68fb-4c72-9691-2ce3360618e3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_97ff51b7-68fb-4c72-9691-2ce3360618e3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_97ff51b7-68fb-4c72-9691-2ce3360618e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_5557e18d-ca08-4239-be59-3bccd6e819c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_97ff51b7-68fb-4c72-9691-2ce3360618e3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_5557e18d-ca08-4239-be59-3bccd6e819c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_PreFundedWarrantMember_013f802b-1192-49bb-aaad-145c8bb3301f" xlink:href="angn-20241231.xsd#angn_PreFundedWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5557e18d-ca08-4239-be59-3bccd6e819c7" xlink:to="loc_angn_PreFundedWarrantMember_013f802b-1192-49bb-aaad-145c8bb3301f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember_b53fe6b3-dcf7-4f57-9083-52e9b277ef5e" xlink:href="angn-20241231.xsd#angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5557e18d-ca08-4239-be59-3bccd6e819c7" xlink:to="loc_angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember_b53fe6b3-dcf7-4f57-9083-52e9b277ef5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_JulyPreFundedWarrantsMember_eca3c3fc-6796-494e-9d47-9c19e730a413" xlink:href="angn-20241231.xsd#angn_JulyPreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5557e18d-ca08-4239-be59-3bccd6e819c7" xlink:to="loc_angn_JulyPreFundedWarrantsMember_eca3c3fc-6796-494e-9d47-9c19e730a413" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_JulyCommonWarrantsMember_06f9fab6-5af6-4a7f-aaae-c00c6bbfe549" xlink:href="angn-20241231.xsd#angn_JulyCommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5557e18d-ca08-4239-be59-3bccd6e819c7" xlink:to="loc_angn_JulyCommonWarrantsMember_06f9fab6-5af6-4a7f-aaae-c00c6bbfe549" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_e417468f-dbe0-44c7-9450-0de2f9a62089" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_13d1a269-01aa-4573-919d-7ce5fdce739a" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_e417468f-dbe0-44c7-9450-0de2f9a62089" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_fb34cac0-97e2-45e6-9773-c58edf210de5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_13d1a269-01aa-4573-919d-7ce5fdce739a" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_fb34cac0-97e2-45e6-9773-c58edf210de5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_b6864a3b-9068-4c50-985d-028ec386a215" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_13d1a269-01aa-4573-919d-7ce5fdce739a" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_b6864a3b-9068-4c50-985d-028ec386a215" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_514e4083-3387-41d5-bd75-9829c418daa4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_13d1a269-01aa-4573-919d-7ce5fdce739a" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_514e4083-3387-41d5-bd75-9829c418daa4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ae79cba4-ad99-4165-bf2b-b30c8e63af82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_13d1a269-01aa-4573-919d-7ce5fdce739a" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ae79cba4-ad99-4165-bf2b-b30c8e63af82" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_TemporaryEquitySharesIssuedDuringPeriod_9befabf6-91e1-42a7-81a6-54555a8e4793" xlink:href="angn-20241231.xsd#angn_TemporaryEquitySharesIssuedDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_13d1a269-01aa-4573-919d-7ce5fdce739a" xlink:to="loc_angn_TemporaryEquitySharesIssuedDuringPeriod_9befabf6-91e1-42a7-81a6-54555a8e4793" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_0dd4d0c1-3571-447e-82b1-5dd9ddc7990c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_13d1a269-01aa-4573-919d-7ce5fdce739a" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_0dd4d0c1-3571-447e-82b1-5dd9ddc7990c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_410e2806-6081-4b92-a5e6-5602fd9e38d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_13d1a269-01aa-4573-919d-7ce5fdce739a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_410e2806-6081-4b92-a5e6-5602fd9e38d5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_SaleOfStockAggregateInitialOfferingPrice_5d7c3f47-b9fa-4ac1-a296-c2f95cae12c2" xlink:href="angn-20241231.xsd#angn_SaleOfStockAggregateInitialOfferingPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_13d1a269-01aa-4573-919d-7ce5fdce739a" xlink:to="loc_angn_SaleOfStockAggregateInitialOfferingPrice_5d7c3f47-b9fa-4ac1-a296-c2f95cae12c2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_0dda4ed6-bf8f-4370-87c3-4126b0af8dda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_13d1a269-01aa-4573-919d-7ce5fdce739a" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_0dda4ed6-bf8f-4370-87c3-4126b0af8dda" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_SaleOfStockBeneficialOwnershipLimitationPercentage_aeee9c3e-a45f-4fd8-9f08-379c765d44ba" xlink:href="angn-20241231.xsd#angn_SaleOfStockBeneficialOwnershipLimitationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_13d1a269-01aa-4573-919d-7ce5fdce739a" xlink:to="loc_angn_SaleOfStockBeneficialOwnershipLimitationPercentage_aeee9c3e-a45f-4fd8-9f08-379c765d44ba" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_eb5ed0ab-b8b0-49c3-90aa-417193726d42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_13d1a269-01aa-4573-919d-7ce5fdce739a" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_eb5ed0ab-b8b0-49c3-90aa-417193726d42" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b11d2bfc-5e1f-4188-995e-e98ec635f2d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_13d1a269-01aa-4573-919d-7ce5fdce739a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b11d2bfc-5e1f-4188-995e-e98ec635f2d7" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_8da5adfb-9ad8-45a5-be56-e74355ce31f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_13d1a269-01aa-4573-919d-7ce5fdce739a" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_8da5adfb-9ad8-45a5-be56-e74355ce31f1" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2888821-0e3f-4b39-8f04-b433beba9fba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_51932c88-479b-4d90-8cc2-90c6db4b79d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2888821-0e3f-4b39-8f04-b433beba9fba" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_51932c88-479b-4d90-8cc2-90c6db4b79d4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_1c826fc0-89ce-42a3-9951-fc989dbd7fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_51932c88-479b-4d90-8cc2-90c6db4b79d4" xlink:to="loc_us-gaap_PlanNameAxis_1c826fc0-89ce-42a3-9951-fc989dbd7fbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_1c826fc0-89ce-42a3-9951-fc989dbd7fbc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1c826fc0-89ce-42a3-9951-fc989dbd7fbc" xlink:to="loc_us-gaap_PlanNameDomain_1c826fc0-89ce-42a3-9951-fc989dbd7fbc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_fbe4593f-4378-46ca-9282-bad0c6382a55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1c826fc0-89ce-42a3-9951-fc989dbd7fbc" xlink:to="loc_us-gaap_PlanNameDomain_fbe4593f-4378-46ca-9282-bad0c6382a55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_A2021PlanMember_789733e8-6476-4249-88ad-89f3a634e511" xlink:href="angn-20241231.xsd#angn_A2021PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_fbe4593f-4378-46ca-9282-bad0c6382a55" xlink:to="loc_angn_A2021PlanMember_789733e8-6476-4249-88ad-89f3a634e511" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_A2022PlanMember_cb12a1e3-a7cf-4fc2-a510-e3b7a91cf373" xlink:href="angn-20241231.xsd#angn_A2022PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_fbe4593f-4378-46ca-9282-bad0c6382a55" xlink:to="loc_angn_A2022PlanMember_cb12a1e3-a7cf-4fc2-a510-e3b7a91cf373" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_A2024PlanMember_46d0b11f-0415-4bb6-83ec-7bb5e48b0e97" xlink:href="angn-20241231.xsd#angn_A2024PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_fbe4593f-4378-46ca-9282-bad0c6382a55" xlink:to="loc_angn_A2024PlanMember_46d0b11f-0415-4bb6-83ec-7bb5e48b0e97" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e744faef-187d-4eed-a80e-704dc31388a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_51932c88-479b-4d90-8cc2-90c6db4b79d4" xlink:to="loc_us-gaap_AwardTypeAxis_e744faef-187d-4eed-a80e-704dc31388a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e744faef-187d-4eed-a80e-704dc31388a4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e744faef-187d-4eed-a80e-704dc31388a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e744faef-187d-4eed-a80e-704dc31388a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_864f6a7e-2892-4fd5-8e1e-3791dc6d7fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e744faef-187d-4eed-a80e-704dc31388a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_864f6a7e-2892-4fd5-8e1e-3791dc6d7fc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_aa94520e-2e15-4ac5-bd7a-a801a59b2921" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_864f6a7e-2892-4fd5-8e1e-3791dc6d7fc8" xlink:to="loc_us-gaap_EmployeeStockMember_aa94520e-2e15-4ac5-bd7a-a801a59b2921" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d59f5e13-e2ac-4e64-ae21-d21b4069d2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_864f6a7e-2892-4fd5-8e1e-3791dc6d7fc8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d59f5e13-e2ac-4e64-ae21-d21b4069d2e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2e42abda-1288-4f2c-a6f3-b14213c8e631" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_51932c88-479b-4d90-8cc2-90c6db4b79d4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2e42abda-1288-4f2c-a6f3-b14213c8e631" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2e42abda-1288-4f2c-a6f3-b14213c8e631_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2e42abda-1288-4f2c-a6f3-b14213c8e631" xlink:to="loc_us-gaap_EquityComponentDomain_2e42abda-1288-4f2c-a6f3-b14213c8e631_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b3681adc-221c-49ee-86d8-f40030a82299" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2e42abda-1288-4f2c-a6f3-b14213c8e631" xlink:to="loc_us-gaap_EquityComponentDomain_b3681adc-221c-49ee-86d8-f40030a82299" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_f37eed83-9009-4a2a-8252-90a0d1ff652f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b3681adc-221c-49ee-86d8-f40030a82299" xlink:to="loc_us-gaap_TreasuryStockCommonMember_f37eed83-9009-4a2a-8252-90a0d1ff652f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8dde41c8-202c-453b-bbc3-6ff47d8cf830" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_51932c88-479b-4d90-8cc2-90c6db4b79d4" xlink:to="loc_srt_RangeAxis_8dde41c8-202c-453b-bbc3-6ff47d8cf830" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8dde41c8-202c-453b-bbc3-6ff47d8cf830_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8dde41c8-202c-453b-bbc3-6ff47d8cf830" xlink:to="loc_srt_RangeMember_8dde41c8-202c-453b-bbc3-6ff47d8cf830_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_af226979-26c2-45f8-9247-da5c2bed9097" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8dde41c8-202c-453b-bbc3-6ff47d8cf830" xlink:to="loc_srt_RangeMember_af226979-26c2-45f8-9247-da5c2bed9097" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fcd07b38-ad13-48dd-9e74-ea436046ada8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_af226979-26c2-45f8-9247-da5c2bed9097" xlink:to="loc_srt_MinimumMember_fcd07b38-ad13-48dd-9e74-ea436046ada8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2236e494-7697-4049-8c57-cb5184f65566" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_af226979-26c2-45f8-9247-da5c2bed9097" xlink:to="loc_srt_MaximumMember_2236e494-7697-4049-8c57-cb5184f65566" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_CommonStockCapitalSharesReservedForFutureIssuanceIncreasePercentageOfCommonStockOutstanding_a5b3380e-8b67-4c89-ba00-5297f64b2a25" xlink:href="angn-20241231.xsd#angn_CommonStockCapitalSharesReservedForFutureIssuanceIncreasePercentageOfCommonStockOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2888821-0e3f-4b39-8f04-b433beba9fba" xlink:to="loc_angn_CommonStockCapitalSharesReservedForFutureIssuanceIncreasePercentageOfCommonStockOutstanding_a5b3380e-8b67-4c89-ba00-5297f64b2a25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_55edac4a-c453-473a-9e99-bc67ae29e141" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2888821-0e3f-4b39-8f04-b433beba9fba" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_55edac4a-c453-473a-9e99-bc67ae29e141" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_53328f49-44cd-44d5-9500-93ef2b02630c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2888821-0e3f-4b39-8f04-b433beba9fba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_53328f49-44cd-44d5-9500-93ef2b02630c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_710e8763-a90c-40f8-bd74-e3f24740e17f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2888821-0e3f-4b39-8f04-b433beba9fba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_710e8763-a90c-40f8-bd74-e3f24740e17f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_de8ff025-a72e-4f28-8cf5-94fcf4718821" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2888821-0e3f-4b39-8f04-b433beba9fba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_de8ff025-a72e-4f28-8cf5-94fcf4718821" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_d8200ecc-aee4-40af-9b37-ffd27f38b106" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2888821-0e3f-4b39-8f04-b433beba9fba" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_d8200ecc-aee4-40af-9b37-ffd27f38b106" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1b6d5fdd-574c-4afe-a17d-97ba95472b63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2888821-0e3f-4b39-8f04-b433beba9fba" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1b6d5fdd-574c-4afe-a17d-97ba95472b63" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_7b8a38b3-075f-470b-ac09-977b861866de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2888821-0e3f-4b39-8f04-b433beba9fba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_7b8a38b3-075f-470b-ac09-977b861866de" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareLimit_81dcc856-739f-42d6-a7b3-e442cb0b46fe" xlink:href="angn-20241231.xsd#angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2888821-0e3f-4b39-8f04-b433beba9fba" xlink:to="loc_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareLimit_81dcc856-739f-42d6-a7b3-e442cb0b46fe" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_60396159-9e1e-4b72-b8e0-d4251b4e99a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2888821-0e3f-4b39-8f04-b433beba9fba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_60396159-9e1e-4b72-b8e0-d4251b4e99a6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_51734e42-d71c-4d5a-8b83-a9ed8692213d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2888821-0e3f-4b39-8f04-b433beba9fba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_51734e42-d71c-4d5a-8b83-a9ed8692213d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_9f3bdb97-6286-42dc-9718-932407c80909" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2888821-0e3f-4b39-8f04-b433beba9fba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_9f3bdb97-6286-42dc-9718-932407c80909" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_e159e797-b937-46e9-a6af-cd79eca9e6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2888821-0e3f-4b39-8f04-b433beba9fba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_e159e797-b937-46e9-a6af-cd79eca9e6f7" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_207b3092-c33f-42ac-9793-4f3feaa88a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2888821-0e3f-4b39-8f04-b433beba9fba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_207b3092-c33f-42ac-9793-4f3feaa88a9f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_14f741c6-b92a-473b-8073-71b8d5ebd3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2888821-0e3f-4b39-8f04-b433beba9fba" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_14f741c6-b92a-473b-8073-71b8d5ebd3b8" xlink:type="arc" order="14"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5ec4ce50-d749-4303-8a04-7837f50bc6d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_15e0d16d-87e9-458f-a43b-dc77a7530827" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5ec4ce50-d749-4303-8a04-7837f50bc6d2" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_15e0d16d-87e9-458f-a43b-dc77a7530827" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3d6a8692-cbbb-4ef3-b46c-61259dd3055c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_15e0d16d-87e9-458f-a43b-dc77a7530827" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3d6a8692-cbbb-4ef3-b46c-61259dd3055c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3d6a8692-cbbb-4ef3-b46c-61259dd3055c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3d6a8692-cbbb-4ef3-b46c-61259dd3055c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3d6a8692-cbbb-4ef3-b46c-61259dd3055c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_cf5bb1a8-e25b-4def-8ca6-15af0c91f24c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3d6a8692-cbbb-4ef3-b46c-61259dd3055c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_cf5bb1a8-e25b-4def-8ca6-15af0c91f24c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c82f0f01-4117-47db-8a09-79b8cb45d975" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_cf5bb1a8-e25b-4def-8ca6-15af0c91f24c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c82f0f01-4117-47db-8a09-79b8cb45d975" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_006b43ed-e54d-4fa8-917a-c8036d9fbfe7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_cf5bb1a8-e25b-4def-8ca6-15af0c91f24c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_006b43ed-e54d-4fa8-917a-c8036d9fbfe7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7c1f85df-76ef-455b-8224-0cb1967f4ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5ec4ce50-d749-4303-8a04-7837f50bc6d2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_7c1f85df-76ef-455b-8224-0cb1967f4ca9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/StockBasedCompensationScheduleofAssumptionsUsedtoEstimateFairValueofStockOptionAwardsDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#StockBasedCompensationScheduleofAssumptionsUsedtoEstimateFairValueofStockOptionAwardsDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/StockBasedCompensationScheduleofAssumptionsUsedtoEstimateFairValueofStockOptionAwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bf7a333-ff5a-436d-8a51-487add540a72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7ca2417f-f3b3-4824-85f0-129f931552d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bf7a333-ff5a-436d-8a51-487add540a72" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7ca2417f-f3b3-4824-85f0-129f931552d2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e32d8def-5e66-433b-8f26-d09a9fe1814d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7ca2417f-f3b3-4824-85f0-129f931552d2" xlink:to="loc_us-gaap_AwardTypeAxis_e32d8def-5e66-433b-8f26-d09a9fe1814d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e32d8def-5e66-433b-8f26-d09a9fe1814d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e32d8def-5e66-433b-8f26-d09a9fe1814d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e32d8def-5e66-433b-8f26-d09a9fe1814d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_477219f6-912d-438e-a89d-6dca77c04dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e32d8def-5e66-433b-8f26-d09a9fe1814d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_477219f6-912d-438e-a89d-6dca77c04dfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_eef027f1-870a-47de-b4f1-d3a6eddbea62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_477219f6-912d-438e-a89d-6dca77c04dfb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_eef027f1-870a-47de-b4f1-d3a6eddbea62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_036104f8-5c9c-4952-9e83-68569e1c9794" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bf7a333-ff5a-436d-8a51-487add540a72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_036104f8-5c9c-4952-9e83-68569e1c9794" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/WarrantsNarrativeDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#WarrantsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/WarrantsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_bf85226d-2809-4980-a0f2-f794fb63d7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_2c9ced73-7e9f-4130-9255-bbcc52cb8bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_bf85226d-2809-4980-a0f2-f794fb63d7a3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_2c9ced73-7e9f-4130-9255-bbcc52cb8bcd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_6bc2b99d-d63b-4e10-8c71-d4a4aa00f3a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_2c9ced73-7e9f-4130-9255-bbcc52cb8bcd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_6bc2b99d-d63b-4e10-8c71-d4a4aa00f3a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_6bc2b99d-d63b-4e10-8c71-d4a4aa00f3a8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_6bc2b99d-d63b-4e10-8c71-d4a4aa00f3a8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_6bc2b99d-d63b-4e10-8c71-d4a4aa00f3a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_e8398620-1a5b-4713-9024-db8ab9764610" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_6bc2b99d-d63b-4e10-8c71-d4a4aa00f3a8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_e8398620-1a5b-4713-9024-db8ab9764610" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_PreFundedWarrantMember_ad0519ad-8f93-47c6-a1b0-cfe770b1bce8" xlink:href="angn-20241231.xsd#angn_PreFundedWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_e8398620-1a5b-4713-9024-db8ab9764610" xlink:to="loc_angn_PreFundedWarrantMember_ad0519ad-8f93-47c6-a1b0-cfe770b1bce8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_JulyCommonWarrantsMember_5142cff5-b8d2-40c7-8c2c-a163ef9cc7e1" xlink:href="angn-20241231.xsd#angn_JulyCommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_e8398620-1a5b-4713-9024-db8ab9764610" xlink:to="loc_angn_JulyCommonWarrantsMember_5142cff5-b8d2-40c7-8c2c-a163ef9cc7e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember_7908377b-1c85-4414-9e02-e26aec2a0cb9" xlink:href="angn-20241231.xsd#angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_e8398620-1a5b-4713-9024-db8ab9764610" xlink:to="loc_angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember_7908377b-1c85-4414-9e02-e26aec2a0cb9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8e05fece-fe73-4f01-af9b-fa10adf23da3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_2c9ced73-7e9f-4130-9255-bbcc52cb8bcd" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_8e05fece-fe73-4f01-af9b-fa10adf23da3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8e05fece-fe73-4f01-af9b-fa10adf23da3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8e05fece-fe73-4f01-af9b-fa10adf23da3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8e05fece-fe73-4f01-af9b-fa10adf23da3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bb39bc9e-65b6-4499-bca4-1cda0076ec2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8e05fece-fe73-4f01-af9b-fa10adf23da3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bb39bc9e-65b6-4499-bca4-1cda0076ec2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_MarchSubscriptionAgreementMember_70536509-e87b-4f9d-8574-dec88d122c8b" xlink:href="angn-20241231.xsd#angn_MarchSubscriptionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bb39bc9e-65b6-4499-bca4-1cda0076ec2b" xlink:to="loc_angn_MarchSubscriptionAgreementMember_70536509-e87b-4f9d-8574-dec88d122c8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_JulyPublicOfferingMember_92a1440a-958f-4c5b-bceb-15d46a07af0e" xlink:href="angn-20241231.xsd#angn_JulyPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bb39bc9e-65b6-4499-bca4-1cda0076ec2b" xlink:to="loc_angn_JulyPublicOfferingMember_92a1440a-958f-4c5b-bceb-15d46a07af0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_137015f8-bdd7-4c44-b7e3-52a4d11027cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_bf85226d-2809-4980-a0f2-f794fb63d7a3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_137015f8-bdd7-4c44-b7e3-52a4d11027cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FairValueOfCommonStockWarrants_a365318d-6ffd-4f88-9b4f-6ce6e38d8246" xlink:href="angn-20241231.xsd#angn_FairValueOfCommonStockWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_bf85226d-2809-4980-a0f2-f794fb63d7a3" xlink:to="loc_angn_FairValueOfCommonStockWarrants_a365318d-6ffd-4f88-9b4f-6ce6e38d8246" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_GainLossOnIssuanceOfWarrants_b41fa8ff-e2ae-45bb-9cfc-16d755e19906" xlink:href="angn-20241231.xsd#angn_GainLossOnIssuanceOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_bf85226d-2809-4980-a0f2-f794fb63d7a3" xlink:to="loc_angn_GainLossOnIssuanceOfWarrants_b41fa8ff-e2ae-45bb-9cfc-16d755e19906" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_62d8e749-ddad-434e-b31d-212f0d5bc900" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_bf85226d-2809-4980-a0f2-f794fb63d7a3" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_62d8e749-ddad-434e-b31d-212f0d5bc900" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_SaleOfStockBeneficialOwnershipLimitationPercentage_571a2c05-416c-4dd9-a9d3-31933b657af6" xlink:href="angn-20241231.xsd#angn_SaleOfStockBeneficialOwnershipLimitationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_bf85226d-2809-4980-a0f2-f794fb63d7a3" xlink:to="loc_angn_SaleOfStockBeneficialOwnershipLimitationPercentage_571a2c05-416c-4dd9-a9d3-31933b657af6" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/WarrantsScheduleofIssuanceofWarrantsDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#WarrantsScheduleofIssuanceofWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/WarrantsScheduleofIssuanceofWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_12a9b0cc-a070-42f1-98da-94307dc39593" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_a3080701-23d0-48a2-b45f-bf09bbaab6da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_12a9b0cc-a070-42f1-98da-94307dc39593" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_a3080701-23d0-48a2-b45f-bf09bbaab6da" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_000dfb29-9005-44c2-9ca6-e8a1667d664c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_a3080701-23d0-48a2-b45f-bf09bbaab6da" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_000dfb29-9005-44c2-9ca6-e8a1667d664c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_000dfb29-9005-44c2-9ca6-e8a1667d664c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_000dfb29-9005-44c2-9ca6-e8a1667d664c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_000dfb29-9005-44c2-9ca6-e8a1667d664c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_b56b863f-c6da-4c89-838b-ba7bb4d19998" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_000dfb29-9005-44c2-9ca6-e8a1667d664c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_b56b863f-c6da-4c89-838b-ba7bb4d19998" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_PreFundedWarrantsMember_ba85fc49-94f7-46fe-adec-a65e0050958d" xlink:href="angn-20241231.xsd#angn_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_b56b863f-c6da-4c89-838b-ba7bb4d19998" xlink:to="loc_angn_PreFundedWarrantsMember_ba85fc49-94f7-46fe-adec-a65e0050958d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_JulyPreFundedWarrantsMember_1e98f091-a9c4-45a8-8221-aede61ab9aa9" xlink:href="angn-20241231.xsd#angn_JulyPreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_b56b863f-c6da-4c89-838b-ba7bb4d19998" xlink:to="loc_angn_JulyPreFundedWarrantsMember_1e98f091-a9c4-45a8-8221-aede61ab9aa9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_JulyCommonWarrantsMember_09570474-df51-4184-8de5-77a637af673e" xlink:href="angn-20241231.xsd#angn_JulyCommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_b56b863f-c6da-4c89-838b-ba7bb4d19998" xlink:to="loc_angn_JulyCommonWarrantsMember_09570474-df51-4184-8de5-77a637af673e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsIssuedShares_75b0bdd7-4636-4eae-92e3-c7d3d7c95964" xlink:href="angn-20241231.xsd#angn_WarrantsIssuedShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_12a9b0cc-a070-42f1-98da-94307dc39593" xlink:to="loc_angn_WarrantsIssuedShares_75b0bdd7-4636-4eae-92e3-c7d3d7c95964" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6bf1d4bb-942a-4faa-a0d1-199fa5eb5035" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_12a9b0cc-a070-42f1-98da-94307dc39593" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6bf1d4bb-942a-4faa-a0d1-199fa5eb5035" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_bb805b86-cb48-424f-83e2-faabd454653b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_71210771-3317-4956-9dc6-a9867542cd0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bb805b86-cb48-424f-83e2-faabd454653b" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_71210771-3317-4956-9dc6-a9867542cd0e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_a692cb65-aed9-4102-8ced-372bfe5493eb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_71210771-3317-4956-9dc6-a9867542cd0e" xlink:to="loc_srt_StatementGeographicalAxis_a692cb65-aed9-4102-8ced-372bfe5493eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a692cb65-aed9-4102-8ced-372bfe5493eb_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_a692cb65-aed9-4102-8ced-372bfe5493eb" xlink:to="loc_srt_SegmentGeographicalDomain_a692cb65-aed9-4102-8ced-372bfe5493eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a95f9f99-caaa-4e65-b2c2-937d6632393f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_a692cb65-aed9-4102-8ced-372bfe5493eb" xlink:to="loc_srt_SegmentGeographicalDomain_a95f9f99-caaa-4e65-b2c2-937d6632393f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_BostonMassachusettsMember_a8951079-8eb1-4532-9cd2-e015d71565a3" xlink:href="angn-20241231.xsd#angn_BostonMassachusettsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a95f9f99-caaa-4e65-b2c2-937d6632393f" xlink:to="loc_angn_BostonMassachusettsMember_a8951079-8eb1-4532-9cd2-e015d71565a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_NewtonMassachusettsMember_a3fa196e-fbdc-419c-a869-e80d3d6323cb" xlink:href="angn-20241231.xsd#angn_NewtonMassachusettsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a95f9f99-caaa-4e65-b2c2-937d6632393f" xlink:to="loc_angn_NewtonMassachusettsMember_a3fa196e-fbdc-419c-a869-e80d3d6323cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_8a37eff7-08ea-4b4d-86b6-b68aa82e2ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bb805b86-cb48-424f-83e2-faabd454653b" xlink:to="loc_us-gaap_OperatingLeaseExpense_8a37eff7-08ea-4b4d-86b6-b68aa82e2ecf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6611fe7b-5608-4256-af74-ae4e7145dc73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bb805b86-cb48-424f-83e2-faabd454653b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6611fe7b-5608-4256-af74-ae4e7145dc73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_93fe90c7-e44f-4b4d-9c57-f84f14c98d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bb805b86-cb48-424f-83e2-faabd454653b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_93fe90c7-e44f-4b4d-9c57-f84f14c98d0d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSecuredLinesOfCredit_bba281d2-a107-4bfe-be08-af5b702add89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSecuredLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bb805b86-cb48-424f-83e2-faabd454653b" xlink:to="loc_us-gaap_ProceedsFromSecuredLinesOfCredit_bba281d2-a107-4bfe-be08-af5b702add89" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_997cf687-fbab-4877-9596-434329565865" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bb805b86-cb48-424f-83e2-faabd454653b" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_997cf687-fbab-4877-9596-434329565865" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_LesseeOperatingLeaseAnnualRentExpense_1c1a92d5-9a1d-4788-9dfd-9d3deddb8b0c" xlink:href="angn-20241231.xsd#angn_LesseeOperatingLeaseAnnualRentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bb805b86-cb48-424f-83e2-faabd454653b" xlink:to="loc_angn_LesseeOperatingLeaseAnnualRentExpense_1c1a92d5-9a1d-4788-9dfd-9d3deddb8b0c" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/DebtDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#DebtDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/DebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5c85ee09-e40a-467c-89e7-e8b8df1e8eae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_52bc6910-777b-4929-99f9-04f8d53030bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c85ee09-e40a-467c-89e7-e8b8df1e8eae" xlink:to="loc_us-gaap_DebtInstrumentTable_52bc6910-777b-4929-99f9-04f8d53030bc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7949a471-296d-45eb-a3e1-f87ce18df9dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_52bc6910-777b-4929-99f9-04f8d53030bc" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7949a471-296d-45eb-a3e1-f87ce18df9dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7949a471-296d-45eb-a3e1-f87ce18df9dc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7949a471-296d-45eb-a3e1-f87ce18df9dc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7949a471-296d-45eb-a3e1-f87ce18df9dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e266fa5d-2895-4e04-a9d5-0ba981d49bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7949a471-296d-45eb-a3e1-f87ce18df9dc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e266fa5d-2895-4e04-a9d5-0ba981d49bd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_ca2dc095-2c70-41d6-8a49-eb0f52dda2a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e266fa5d-2895-4e04-a9d5-0ba981d49bd8" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_ca2dc095-2c70-41d6-8a49-eb0f52dda2a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_31de7d90-2cc1-4a57-affc-cdc1a6d12539" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e266fa5d-2895-4e04-a9d5-0ba981d49bd8" xlink:to="loc_us-gaap_ConvertibleDebtMember_31de7d90-2cc1-4a57-affc-cdc1a6d12539" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3cb9442b-67b7-4bd1-a4e8-2554e425429d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_52bc6910-777b-4929-99f9-04f8d53030bc" xlink:to="loc_us-gaap_DebtInstrumentAxis_3cb9442b-67b7-4bd1-a4e8-2554e425429d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3cb9442b-67b7-4bd1-a4e8-2554e425429d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_3cb9442b-67b7-4bd1-a4e8-2554e425429d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3cb9442b-67b7-4bd1-a4e8-2554e425429d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d6742329-91d3-4ad5-8d2c-d9a5858a16d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_3cb9442b-67b7-4bd1-a4e8-2554e425429d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d6742329-91d3-4ad5-8d2c-d9a5858a16d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_BridgeLoanBetweenAngionAndFormerElicioMember_08994bee-3836-4152-a842-68c2f473d9b0" xlink:href="angn-20241231.xsd#angn_BridgeLoanBetweenAngionAndFormerElicioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6742329-91d3-4ad5-8d2c-d9a5858a16d9" xlink:to="loc_angn_BridgeLoanBetweenAngionAndFormerElicioMember_08994bee-3836-4152-a842-68c2f473d9b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ConvertibleNotesMember_78e0ad24-7e45-43b9-b6e0-e7a2066e61be" xlink:href="angn-20241231.xsd#angn_ConvertibleNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6742329-91d3-4ad5-8d2c-d9a5858a16d9" xlink:to="loc_angn_ConvertibleNotesMember_78e0ad24-7e45-43b9-b6e0-e7a2066e61be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountInitialClosingMember_7237864f-9a40-46ea-ad0c-6185b3475054" xlink:href="angn-20241231.xsd#angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountInitialClosingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6742329-91d3-4ad5-8d2c-d9a5858a16d9" xlink:to="loc_angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountInitialClosingMember_7237864f-9a40-46ea-ad0c-6185b3475054" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_BridgeLoanBetweenAngionAndFormerElicioInitialClosingMember_906310e9-2d17-4773-a085-8d5b61a72967" xlink:href="angn-20241231.xsd#angn_BridgeLoanBetweenAngionAndFormerElicioInitialClosingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6742329-91d3-4ad5-8d2c-d9a5858a16d9" xlink:to="loc_angn_BridgeLoanBetweenAngionAndFormerElicioInitialClosingMember_906310e9-2d17-4773-a085-8d5b61a72967" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountAdditionalClosingMember_15221b02-86f9-48ec-ae11-c5c30a948820" xlink:href="angn-20241231.xsd#angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountAdditionalClosingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6742329-91d3-4ad5-8d2c-d9a5858a16d9" xlink:to="loc_angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountAdditionalClosingMember_15221b02-86f9-48ec-ae11-c5c30a948820" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_BridgeLoanBetweenAngionAndFormerElicioAdditionalClosingMember_e932ac74-4e62-4c75-a038-39fd501bbe92" xlink:href="angn-20241231.xsd#angn_BridgeLoanBetweenAngionAndFormerElicioAdditionalClosingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6742329-91d3-4ad5-8d2c-d9a5858a16d9" xlink:to="loc_angn_BridgeLoanBetweenAngionAndFormerElicioAdditionalClosingMember_e932ac74-4e62-4c75-a038-39fd501bbe92" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_SeniorSecuredConvertiblePromissoryNoteMember_659072b2-0b82-45de-98a9-1657a7e7cae8" xlink:href="angn-20241231.xsd#angn_SeniorSecuredConvertiblePromissoryNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6742329-91d3-4ad5-8d2c-d9a5858a16d9" xlink:to="loc_angn_SeniorSecuredConvertiblePromissoryNoteMember_659072b2-0b82-45de-98a9-1657a7e7cae8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_6ea3248b-ba87-4e8f-8f77-2f7b2abf88c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c85ee09-e40a-467c-89e7-e8b8df1e8eae" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_6ea3248b-ba87-4e8f-8f77-2f7b2abf88c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_DebtInstrumentIssuanceDiscountPercent_8fb02785-f02a-4ded-a062-d8d1af1bc40d" xlink:href="angn-20241231.xsd#angn_DebtInstrumentIssuanceDiscountPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c85ee09-e40a-467c-89e7-e8b8df1e8eae" xlink:to="loc_angn_DebtInstrumentIssuanceDiscountPercent_8fb02785-f02a-4ded-a062-d8d1af1bc40d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_55209243-50ab-47c4-9b25-9b8b17ab1210" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c85ee09-e40a-467c-89e7-e8b8df1e8eae" xlink:to="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_55209243-50ab-47c4-9b25-9b8b17ab1210" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_559dc550-4281-4643-9547-054d9edee53e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c85ee09-e40a-467c-89e7-e8b8df1e8eae" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_559dc550-4281-4643-9547-054d9edee53e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_bc7ab3f0-c7d8-4005-98d6-2b08524e6d23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c85ee09-e40a-467c-89e7-e8b8df1e8eae" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_bc7ab3f0-c7d8-4005-98d6-2b08524e6d23" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_d032422e-b795-4cb6-a644-046c1756341c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c85ee09-e40a-467c-89e7-e8b8df1e8eae" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_d032422e-b795-4cb6-a644-046c1756341c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_c8fb6545-b601-4be7-b5d6-840eddc0ae74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c85ee09-e40a-467c-89e7-e8b8df1e8eae" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_c8fb6545-b601-4be7-b5d6-840eddc0ae74" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_7640ae6d-3e22-4835-bf8e-c2d8e859a95f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c85ee09-e40a-467c-89e7-e8b8df1e8eae" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_7640ae6d-3e22-4835-bf8e-c2d8e859a95f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_cc56b2fd-8107-4f64-a8d9-b0bc12d9ef52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c85ee09-e40a-467c-89e7-e8b8df1e8eae" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_cc56b2fd-8107-4f64-a8d9-b0bc12d9ef52" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_fb2a36c9-371e-49cb-a17c-d3a068729646" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c85ee09-e40a-467c-89e7-e8b8df1e8eae" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_fb2a36c9-371e-49cb-a17c-d3a068729646" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_445a66e0-eb58-4726-bd4a-f8a27c0457a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c85ee09-e40a-467c-89e7-e8b8df1e8eae" xlink:to="loc_us-gaap_InterestExpenseDebt_445a66e0-eb58-4726-bd4a-f8a27c0457a8" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_8273fd3b-d1db-4016-9c4d-a7a6bc6443d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_fe2e5207-863d-460b-9bd4-9ba5c6dc7936" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_8273fd3b-d1db-4016-9c4d-a7a6bc6443d1" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_fe2e5207-863d-460b-9bd4-9ba5c6dc7936" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_c8ef3e77-e4d1-4211-8e93-4006c7097652" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_fe2e5207-863d-460b-9bd4-9ba5c6dc7936" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_c8ef3e77-e4d1-4211-8e93-4006c7097652" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_c8ef3e77-e4d1-4211-8e93-4006c7097652_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_c8ef3e77-e4d1-4211-8e93-4006c7097652" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_c8ef3e77-e4d1-4211-8e93-4006c7097652_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_ba2e6e88-3d97-414f-a2cc-5b154c57aa13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_c8ef3e77-e4d1-4211-8e93-4006c7097652" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_ba2e6e88-3d97-414f-a2cc-5b154c57aa13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_4e1a068c-8281-40ae-b32b-8cb7f33a51e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_ba2e6e88-3d97-414f-a2cc-5b154c57aa13" xlink:to="loc_us-gaap_DomesticCountryMember_4e1a068c-8281-40ae-b32b-8cb7f33a51e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_0d383b55-e844-40cd-ae52-a6802780bedd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_ba2e6e88-3d97-414f-a2cc-5b154c57aa13" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_0d383b55-e844-40cd-ae52-a6802780bedd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_9443a4c4-7aac-4943-96f9-2354dc06ac92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_fe2e5207-863d-460b-9bd4-9ba5c6dc7936" xlink:to="loc_us-gaap_TaxPeriodAxis_9443a4c4-7aac-4943-96f9-2354dc06ac92" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_9443a4c4-7aac-4943-96f9-2354dc06ac92_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_9443a4c4-7aac-4943-96f9-2354dc06ac92" xlink:to="loc_us-gaap_TaxPeriodDomain_9443a4c4-7aac-4943-96f9-2354dc06ac92_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_ada12aed-70f7-4ffe-8f34-4870f0aa3042" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_9443a4c4-7aac-4943-96f9-2354dc06ac92" xlink:to="loc_us-gaap_TaxPeriodDomain_ada12aed-70f7-4ffe-8f34-4870f0aa3042" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxYear2017Member_eb4e39e6-23af-4757-9bff-e90b41744fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxYear2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_ada12aed-70f7-4ffe-8f34-4870f0aa3042" xlink:to="loc_us-gaap_TaxYear2017Member_eb4e39e6-23af-4757-9bff-e90b41744fbc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_dd0f62df-d01f-4ba2-be19-13f260665d20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_fe2e5207-863d-460b-9bd4-9ba5c6dc7936" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_dd0f62df-d01f-4ba2-be19-13f260665d20" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_dd0f62df-d01f-4ba2-be19-13f260665d20_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_dd0f62df-d01f-4ba2-be19-13f260665d20" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_dd0f62df-d01f-4ba2-be19-13f260665d20_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_99895f64-2de0-4774-b131-8f9004908273" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_dd0f62df-d01f-4ba2-be19-13f260665d20" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_99895f64-2de0-4774-b131-8f9004908273" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_aaceffbf-41a2-4cff-b75f-837a5725ab76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_99895f64-2de0-4774-b131-8f9004908273" xlink:to="loc_us-gaap_ResearchMember_aaceffbf-41a2-4cff-b75f-837a5725ab76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_759d7a26-4927-4280-b1b1-583ffde3dea9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_8273fd3b-d1db-4016-9c4d-a7a6bc6443d1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_759d7a26-4927-4280-b1b1-583ffde3dea9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_46704af0-4f23-4580-8beb-b70d8cc80624" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_8273fd3b-d1db-4016-9c4d-a7a6bc6443d1" xlink:to="loc_us-gaap_OperatingLossCarryforwards_46704af0-4f23-4580-8beb-b70d8cc80624" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_e5a2041a-c2dd-45b0-a9ef-e3027c86e546" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_8273fd3b-d1db-4016-9c4d-a7a6bc6443d1" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_e5a2041a-c2dd-45b0-a9ef-e3027c86e546" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_becd73c1-9889-42ed-b7ed-09e3ec04e5d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_8273fd3b-d1db-4016-9c4d-a7a6bc6443d1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_becd73c1-9889-42ed-b7ed-09e3ec04e5d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_cdd36925-3b8d-48e3-a310-3e587554ad28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_8273fd3b-d1db-4016-9c4d-a7a6bc6443d1" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_cdd36925-3b8d-48e3-a310-3e587554ad28" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_f2a53d13-9002-41d1-a3e0-7b03f72472bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_8273fd3b-d1db-4016-9c4d-a7a6bc6443d1" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_f2a53d13-9002-41d1-a3e0-7b03f72472bb" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/EmployeeBenefitPlanDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#EmployeeBenefitPlanDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/EmployeeBenefitPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_cc1cd026-c664-42f3-ad24-cdae0b6da403" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTable_1d0e05e1-10b7-45a1-aab3-d63002a6e187" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_cc1cd026-c664-42f3-ad24-cdae0b6da403" xlink:to="loc_us-gaap_DefinedContributionPlanTable_1d0e05e1-10b7-45a1-aab3-d63002a6e187" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_963c8fbc-47e2-4be4-a03d-37c14b7e64ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedContributionPlanTable_1d0e05e1-10b7-45a1-aab3-d63002a6e187" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_963c8fbc-47e2-4be4-a03d-37c14b7e64ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_963c8fbc-47e2-4be4-a03d-37c14b7e64ec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_963c8fbc-47e2-4be4-a03d-37c14b7e64ec" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_963c8fbc-47e2-4be4-a03d-37c14b7e64ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_c132af07-a186-4535-aee1-75de378ace07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_963c8fbc-47e2-4be4-a03d-37c14b7e64ec" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_c132af07-a186-4535-aee1-75de378ace07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_EmployeeBenefitPlanMember_3d8c64c5-1326-43f0-886e-108b61a0cabc" xlink:href="angn-20241231.xsd#angn_EmployeeBenefitPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_c132af07-a186-4535-aee1-75de378ace07" xlink:to="loc_angn_EmployeeBenefitPlanMember_3d8c64c5-1326-43f0-886e-108b61a0cabc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_7ad6cb26-7f53-4e51-8bd6-a998698c7082" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_cc1cd026-c664-42f3-ad24-cdae0b6da403" xlink:to="loc_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_7ad6cb26-7f53-4e51-8bd6-a998698c7082" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofNetLossperShareDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofNetLossperShareDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofNetLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ee9a0519-c68a-4b07-8e55-7cbcc9070239" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b7e4a9fc-6424-4d8d-8e7c-cd951d446c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ee9a0519-c68a-4b07-8e55-7cbcc9070239" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b7e4a9fc-6424-4d8d-8e7c-cd951d446c8d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_52d41a0e-4d6b-4ad6-9375-6939f66ddd89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b7e4a9fc-6424-4d8d-8e7c-cd951d446c8d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_52d41a0e-4d6b-4ad6-9375-6939f66ddd89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_52d41a0e-4d6b-4ad6-9375-6939f66ddd89_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_52d41a0e-4d6b-4ad6-9375-6939f66ddd89" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_52d41a0e-4d6b-4ad6-9375-6939f66ddd89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2788f6f0-087b-45eb-af6f-6fc3fd1d4749" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_52d41a0e-4d6b-4ad6-9375-6939f66ddd89" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2788f6f0-087b-45eb-af6f-6fc3fd1d4749" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_487ef8b1-f821-411a-8075-5ae51aa007b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2788f6f0-087b-45eb-af6f-6fc3fd1d4749" xlink:to="loc_us-gaap_EmployeeStockOptionMember_487ef8b1-f821-411a-8075-5ae51aa007b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_85539334-5364-4523-9177-cb43520f841a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2788f6f0-087b-45eb-af6f-6fc3fd1d4749" xlink:to="loc_us-gaap_WarrantMember_85539334-5364-4523-9177-cb43520f841a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_UnvestedCommonStockMember_c0963c8d-8b2a-444f-9085-719aed1c8c0f" xlink:href="angn-20241231.xsd#angn_UnvestedCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2788f6f0-087b-45eb-af6f-6fc3fd1d4749" xlink:to="loc_angn_UnvestedCommonStockMember_c0963c8d-8b2a-444f-9085-719aed1c8c0f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0f58429f-21dd-4105-a1bf-0c7b0049b241" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ee9a0519-c68a-4b07-8e55-7cbcc9070239" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0f58429f-21dd-4105-a1bf-0c7b0049b241" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_53bd7601-f7cb-4b1e-b627-8746b3bba572" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6e42ee65-0a97-4634-a38b-e002856a7adc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_53bd7601-f7cb-4b1e-b627-8746b3bba572" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6e42ee65-0a97-4634-a38b-e002856a7adc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_29eb4b7a-2b3e-4f72-8da8-fe879f5cc194" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6e42ee65-0a97-4634-a38b-e002856a7adc" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_29eb4b7a-2b3e-4f72-8da8-fe879f5cc194" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_29eb4b7a-2b3e-4f72-8da8-fe879f5cc194_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_29eb4b7a-2b3e-4f72-8da8-fe879f5cc194" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_29eb4b7a-2b3e-4f72-8da8-fe879f5cc194_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_81b37bb6-b3f2-4f74-aa73-0b802597e338" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_29eb4b7a-2b3e-4f72-8da8-fe879f5cc194" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_81b37bb6-b3f2-4f74-aa73-0b802597e338" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ConsultingServicePaymentsMember_8a6aeb9a-a553-42cd-ba0a-167bfbe35a80" xlink:href="angn-20241231.xsd#angn_ConsultingServicePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_81b37bb6-b3f2-4f74-aa73-0b802597e338" xlink:to="loc_angn_ConsultingServicePaymentsMember_8a6aeb9a-a553-42cd-ba0a-167bfbe35a80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_PurchaseOfWarrantsMember_c2877fbb-38ce-40dd-b529-5c6ea32c4d9e" xlink:href="angn-20241231.xsd#angn_PurchaseOfWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_81b37bb6-b3f2-4f74-aa73-0b802597e338" xlink:to="loc_angn_PurchaseOfWarrantsMember_c2877fbb-38ce-40dd-b529-5c6ea32c4d9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_b9675ba9-73d4-488e-bfa8-8a52f4bc340d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6e42ee65-0a97-4634-a38b-e002856a7adc" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_b9675ba9-73d4-488e-bfa8-8a52f4bc340d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b9675ba9-73d4-488e-bfa8-8a52f4bc340d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b9675ba9-73d4-488e-bfa8-8a52f4bc340d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b9675ba9-73d4-488e-bfa8-8a52f4bc340d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_26419a41-e03c-40a7-949e-5bd72fbc407b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b9675ba9-73d4-488e-bfa8-8a52f4bc340d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_26419a41-e03c-40a7-949e-5bd72fbc407b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_MarchSubscriptionAgreementMember_10e43093-f352-4324-b47d-6d58a555309f" xlink:href="angn-20241231.xsd#angn_MarchSubscriptionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_26419a41-e03c-40a7-949e-5bd72fbc407b" xlink:to="loc_angn_MarchSubscriptionAgreementMember_10e43093-f352-4324-b47d-6d58a555309f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_JulyPublicOfferingMember_1aa860d2-b2bd-41e5-b848-de2185c53056" xlink:href="angn-20241231.xsd#angn_JulyPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_26419a41-e03c-40a7-949e-5bd72fbc407b" xlink:to="loc_angn_JulyPublicOfferingMember_1aa860d2-b2bd-41e5-b848-de2185c53056" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_5d9cbc07-2cbd-4892-9488-38d719eff764" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6e42ee65-0a97-4634-a38b-e002856a7adc" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_5d9cbc07-2cbd-4892-9488-38d719eff764" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_5d9cbc07-2cbd-4892-9488-38d719eff764_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_5d9cbc07-2cbd-4892-9488-38d719eff764" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_5d9cbc07-2cbd-4892-9488-38d719eff764_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_2e8de2ab-0b90-40b5-9a93-fb2cb1cb4913" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_5d9cbc07-2cbd-4892-9488-38d719eff764" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_2e8de2ab-0b90-40b5-9a93-fb2cb1cb4913" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_PreFundedWarrantMember_29406f0d-dbe8-42d6-9cb8-76cc3d5544c2" xlink:href="angn-20241231.xsd#angn_PreFundedWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2e8de2ab-0b90-40b5-9a93-fb2cb1cb4913" xlink:to="loc_angn_PreFundedWarrantMember_29406f0d-dbe8-42d6-9cb8-76cc3d5544c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember_04fcefcf-d6cb-415d-8c40-cd3f00903ec4" xlink:href="angn-20241231.xsd#angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2e8de2ab-0b90-40b5-9a93-fb2cb1cb4913" xlink:to="loc_angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember_04fcefcf-d6cb-415d-8c40-cd3f00903ec4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4c7ebbad-e575-4465-9ea0-4460a2706988" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6e42ee65-0a97-4634-a38b-e002856a7adc" xlink:to="loc_srt_CounterpartyNameAxis_4c7ebbad-e575-4465-9ea0-4460a2706988" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4c7ebbad-e575-4465-9ea0-4460a2706988_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_4c7ebbad-e575-4465-9ea0-4460a2706988" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4c7ebbad-e575-4465-9ea0-4460a2706988_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_00797e23-c5b7-46af-9544-f0d5ff4e751b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_4c7ebbad-e575-4465-9ea0-4460a2706988" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_00797e23-c5b7-46af-9544-f0d5ff4e751b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_YekaterinaChudnovskyMember_b7865a02-3fe9-4581-9587-dd3acc67c3f3" xlink:href="angn-20241231.xsd#angn_YekaterinaChudnovskyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_00797e23-c5b7-46af-9544-f0d5ff4e751b" xlink:to="loc_angn_YekaterinaChudnovskyMember_b7865a02-3fe9-4581-9587-dd3acc67c3f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_JayVenkatesanAndTrustsAffiliatedWithJayVenkatesanMember_37d87fa2-1899-4859-8ee1-a7f0003afe86" xlink:href="angn-20241231.xsd#angn_JayVenkatesanAndTrustsAffiliatedWithJayVenkatesanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_00797e23-c5b7-46af-9544-f0d5ff4e751b" xlink:to="loc_angn_JayVenkatesanAndTrustsAffiliatedWithJayVenkatesanMember_37d87fa2-1899-4859-8ee1-a7f0003afe86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6ebf1560-973e-41d9-a43e-85703fe49aed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6e42ee65-0a97-4634-a38b-e002856a7adc" xlink:to="loc_us-gaap_DebtInstrumentAxis_6ebf1560-973e-41d9-a43e-85703fe49aed" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6ebf1560-973e-41d9-a43e-85703fe49aed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_6ebf1560-973e-41d9-a43e-85703fe49aed" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6ebf1560-973e-41d9-a43e-85703fe49aed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f14266c1-affd-42c1-a4a4-872235105fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_6ebf1560-973e-41d9-a43e-85703fe49aed" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f14266c1-affd-42c1-a4a4-872235105fa1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_SeniorSecuredConvertiblePromissoryNoteMember_9b8f0c14-94b8-471b-a7b1-dd462743d88e" xlink:href="angn-20241231.xsd#angn_SeniorSecuredConvertiblePromissoryNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f14266c1-affd-42c1-a4a4-872235105fa1" xlink:to="loc_angn_SeniorSecuredConvertiblePromissoryNoteMember_9b8f0c14-94b8-471b-a7b1-dd462743d88e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_0a4bccbe-7a02-4a23-994f-1cfa45c82de2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6e42ee65-0a97-4634-a38b-e002856a7adc" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_0a4bccbe-7a02-4a23-994f-1cfa45c82de2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0a4bccbe-7a02-4a23-994f-1cfa45c82de2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0a4bccbe-7a02-4a23-994f-1cfa45c82de2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0a4bccbe-7a02-4a23-994f-1cfa45c82de2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_08f31638-b629-4cb9-b4aa-4fc2a8b96301" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0a4bccbe-7a02-4a23-994f-1cfa45c82de2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_08f31638-b629-4cb9-b4aa-4fc2a8b96301" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_33494c39-6283-49f0-9feb-12d966a94bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_08f31638-b629-4cb9-b4aa-4fc2a8b96301" xlink:to="loc_us-gaap_ConvertibleDebtMember_33494c39-6283-49f0-9feb-12d966a94bd2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_1eb895c3-d773-4ead-81ff-02216043ce77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_53bd7601-f7cb-4b1e-b627-8746b3bba572" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_1eb895c3-d773-4ead-81ff-02216043ce77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_085cc358-29c5-490a-8221-9688313c59da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_53bd7601-f7cb-4b1e-b627-8746b3bba572" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_085cc358-29c5-490a-8221-9688313c59da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_73055ef5-1c00-4c73-b508-385a891303b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_53bd7601-f7cb-4b1e-b627-8746b3bba572" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_73055ef5-1c00-4c73-b508-385a891303b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ClassOfWarrantOrRightIssuedInPeriod_9ed395b6-fb84-4bc3-bc65-f1783a76d59c" xlink:href="angn-20241231.xsd#angn_ClassOfWarrantOrRightIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_53bd7601-f7cb-4b1e-b627-8746b3bba572" xlink:to="loc_angn_ClassOfWarrantOrRightIssuedInPeriod_9ed395b6-fb84-4bc3-bc65-f1783a76d59c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_0d948bd6-7cc1-428a-9c92-dcb5ccf67a79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_53bd7601-f7cb-4b1e-b627-8746b3bba572" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_0d948bd6-7cc1-428a-9c92-dcb5ccf67a79" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_b93f6440-f510-40f5-bebc-85c00b2eb7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_53bd7601-f7cb-4b1e-b627-8746b3bba572" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_b93f6440-f510-40f5-bebc-85c00b2eb7d9" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/SegmentReportingDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#SegmentReportingDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/SegmentReportingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_bd84da68-1388-4774-8686-89b05e8c0300" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_55a8d58b-2278-4342-b733-276a6a0c89b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bd84da68-1388-4774-8686-89b05e8c0300" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_55a8d58b-2278-4342-b733-276a6a0c89b1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_59df21e2-93f6-43e1-ac72-c493ea7a02c5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_55a8d58b-2278-4342-b733-276a6a0c89b1" xlink:to="loc_srt_ProductOrServiceAxis_59df21e2-93f6-43e1-ac72-c493ea7a02c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_59df21e2-93f6-43e1-ac72-c493ea7a02c5_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_59df21e2-93f6-43e1-ac72-c493ea7a02c5" xlink:to="loc_srt_ProductsAndServicesDomain_59df21e2-93f6-43e1-ac72-c493ea7a02c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1d4d68a8-5f8f-4f1e-9a80-9af21a7b7379" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_59df21e2-93f6-43e1-ac72-c493ea7a02c5" xlink:to="loc_srt_ProductsAndServicesDomain_1d4d68a8-5f8f-4f1e-9a80-9af21a7b7379" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ClinicalTrailMember_ab8a6e78-8c27-4d4d-8d84-4624d37b382f" xlink:href="angn-20241231.xsd#angn_ClinicalTrailMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1d4d68a8-5f8f-4f1e-9a80-9af21a7b7379" xlink:to="loc_angn_ClinicalTrailMember_ab8a6e78-8c27-4d4d-8d84-4624d37b382f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_EmployeeRelatedReasearchAndDevelopmentMember_86b686f1-050b-4dd5-9693-1568ee665859" xlink:href="angn-20241231.xsd#angn_EmployeeRelatedReasearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1d4d68a8-5f8f-4f1e-9a80-9af21a7b7379" xlink:to="loc_angn_EmployeeRelatedReasearchAndDevelopmentMember_86b686f1-050b-4dd5-9693-1568ee665859" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_TranslationalMedicineAndCMCMember_751b8008-405c-4e4f-bf2f-47c3aad4264b" xlink:href="angn-20241231.xsd#angn_TranslationalMedicineAndCMCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1d4d68a8-5f8f-4f1e-9a80-9af21a7b7379" xlink:to="loc_angn_TranslationalMedicineAndCMCMember_751b8008-405c-4e4f-bf2f-47c3aad4264b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_OtherMember_b8643275-4775-4344-9d28-7a6b556bb1eb" xlink:href="angn-20241231.xsd#angn_OtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1d4d68a8-5f8f-4f1e-9a80-9af21a7b7379" xlink:to="loc_angn_OtherMember_b8643275-4775-4344-9d28-7a6b556bb1eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_9b48ae89-468d-42c6-90db-e894cf9132e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_55a8d58b-2278-4342-b733-276a6a0c89b1" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_9b48ae89-468d-42c6-90db-e894cf9132e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_9b48ae89-468d-42c6-90db-e894cf9132e2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_9b48ae89-468d-42c6-90db-e894cf9132e2" xlink:to="loc_us-gaap_SegmentDomain_9b48ae89-468d-42c6-90db-e894cf9132e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a7b61a03-4706-4d0a-bca8-faa415f3aba1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_9b48ae89-468d-42c6-90db-e894cf9132e2" xlink:to="loc_us-gaap_SegmentDomain_a7b61a03-4706-4d0a-bca8-faa415f3aba1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ReportableSegmentMember_bf0894b2-4b51-4526-9e75-59654c233e44" xlink:href="angn-20241231.xsd#angn_ReportableSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_a7b61a03-4706-4d0a-bca8-faa415f3aba1" xlink:to="loc_angn_ReportableSegmentMember_bf0894b2-4b51-4526-9e75-59654c233e44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e3bd11ad-8344-4f8a-97ce-095b4c4f050f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bd84da68-1388-4774-8686-89b05e8c0300" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e3bd11ad-8344-4f8a-97ce-095b4c4f050f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecoveryOfDirectCosts_76451350-bf30-4f9f-835e-4aab836701f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RecoveryOfDirectCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bd84da68-1388-4774-8686-89b05e8c0300" xlink:to="loc_us-gaap_RecoveryOfDirectCosts_76451350-bf30-4f9f-835e-4aab836701f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_2e62631d-fc89-4755-9697-debba3a6ed3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bd84da68-1388-4774-8686-89b05e8c0300" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_2e62631d-fc89-4755-9697-debba3a6ed3c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_02867247-a887-4be6-89ac-71d8e06ce8b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bd84da68-1388-4774-8686-89b05e8c0300" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_02867247-a887-4be6-89ac-71d8e06ce8b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_61bcee2e-f935-4a3e-86d9-8c8185f7a04d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bd84da68-1388-4774-8686-89b05e8c0300" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_61bcee2e-f935-4a3e-86d9-8c8185f7a04d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c03b0482-0020-4a10-9d1e-07299c0b0c33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bd84da68-1388-4774-8686-89b05e8c0300" xlink:to="loc_us-gaap_NetIncomeLoss_c03b0482-0020-4a10-9d1e-07299c0b0c33" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ef2ed3dc-f703-4977-9e64-6f6eda080652" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bd84da68-1388-4774-8686-89b05e8c0300" xlink:to="loc_us-gaap_Assets_ef2ed3dc-f703-4977-9e64-6f6eda080652" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_a9e034b2-3488-4caa-8f02-3a9b967743cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_94bf28fc-a988-4db0-849d-852ae4fa348a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_a9e034b2-3488-4caa-8f02-3a9b967743cc" xlink:to="loc_us-gaap_SubsequentEventTable_94bf28fc-a988-4db0-849d-852ae4fa348a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_da5ee83e-7375-47ca-b330-e98a14a1c0c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_94bf28fc-a988-4db0-849d-852ae4fa348a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_da5ee83e-7375-47ca-b330-e98a14a1c0c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_da5ee83e-7375-47ca-b330-e98a14a1c0c4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_da5ee83e-7375-47ca-b330-e98a14a1c0c4" xlink:to="loc_us-gaap_EquityComponentDomain_da5ee83e-7375-47ca-b330-e98a14a1c0c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_08686b6c-871c-41dc-b2f8-4a663fd0ecd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_da5ee83e-7375-47ca-b330-e98a14a1c0c4" xlink:to="loc_us-gaap_EquityComponentDomain_08686b6c-871c-41dc-b2f8-4a663fd0ecd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a02b75f2-aaf3-48f5-8238-5fbc4df73eef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_08686b6c-871c-41dc-b2f8-4a663fd0ecd4" xlink:to="loc_us-gaap_CommonStockMember_a02b75f2-aaf3-48f5-8238-5fbc4df73eef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_61cc1d4f-48d0-4922-aafe-f69ecfd93885" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_94bf28fc-a988-4db0-849d-852ae4fa348a" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_61cc1d4f-48d0-4922-aafe-f69ecfd93885" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_61cc1d4f-48d0-4922-aafe-f69ecfd93885_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_61cc1d4f-48d0-4922-aafe-f69ecfd93885" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_61cc1d4f-48d0-4922-aafe-f69ecfd93885_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f0254a83-8d6c-4cb9-bbdc-9846a49894a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_61cc1d4f-48d0-4922-aafe-f69ecfd93885" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f0254a83-8d6c-4cb9-bbdc-9846a49894a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_0e7a7c2f-4948-4ab9-a8d6-1e55b10aecc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_f0254a83-8d6c-4cb9-bbdc-9846a49894a6" xlink:to="loc_us-gaap_SubsequentEventMember_0e7a7c2f-4948-4ab9-a8d6-1e55b10aecc4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_ed466df4-4f78-48d9-91ee-b64f6f5430ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_94bf28fc-a988-4db0-849d-852ae4fa348a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_ed466df4-4f78-48d9-91ee-b64f6f5430ae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_ed466df4-4f78-48d9-91ee-b64f6f5430ae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_ed466df4-4f78-48d9-91ee-b64f6f5430ae" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_ed466df4-4f78-48d9-91ee-b64f6f5430ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_a5b20801-ac5c-44db-af27-344916f5eceb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_ed466df4-4f78-48d9-91ee-b64f6f5430ae" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_a5b20801-ac5c-44db-af27-344916f5eceb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_PreFundedWarrantMember_99dffa2c-6e84-4cfb-b8f6-cc1180caa0ec" xlink:href="angn-20241231.xsd#angn_PreFundedWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a5b20801-ac5c-44db-af27-344916f5eceb" xlink:to="loc_angn_PreFundedWarrantMember_99dffa2c-6e84-4cfb-b8f6-cc1180caa0ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4c508184-a95a-463a-8f9e-49efe2871595" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_94bf28fc-a988-4db0-849d-852ae4fa348a" xlink:to="loc_us-gaap_DebtInstrumentAxis_4c508184-a95a-463a-8f9e-49efe2871595" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4c508184-a95a-463a-8f9e-49efe2871595_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_4c508184-a95a-463a-8f9e-49efe2871595" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4c508184-a95a-463a-8f9e-49efe2871595_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_19c2c804-5f27-44d6-8d22-f40071706b94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_4c508184-a95a-463a-8f9e-49efe2871595" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_19c2c804-5f27-44d6-8d22-f40071706b94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_SeniorSecuredConvertiblePromissoryNoteMember_43f81470-25ce-46cb-b78a-896a8cb2fdee" xlink:href="angn-20241231.xsd#angn_SeniorSecuredConvertiblePromissoryNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_19c2c804-5f27-44d6-8d22-f40071706b94" xlink:to="loc_angn_SeniorSecuredConvertiblePromissoryNoteMember_43f81470-25ce-46cb-b78a-896a8cb2fdee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6d0d69b0-491f-4dce-8a8e-ccd965cf89ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_94bf28fc-a988-4db0-849d-852ae4fa348a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6d0d69b0-491f-4dce-8a8e-ccd965cf89ff" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6d0d69b0-491f-4dce-8a8e-ccd965cf89ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6d0d69b0-491f-4dce-8a8e-ccd965cf89ff" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6d0d69b0-491f-4dce-8a8e-ccd965cf89ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_302345d8-e56c-4deb-b375-0370a5286215" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6d0d69b0-491f-4dce-8a8e-ccd965cf89ff" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_302345d8-e56c-4deb-b375-0370a5286215" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_aa549113-fe9a-4551-a9f6-453b5589ba93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_302345d8-e56c-4deb-b375-0370a5286215" xlink:to="loc_us-gaap_ConvertibleDebtMember_aa549113-fe9a-4551-a9f6-453b5589ba93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_485b034f-ddfe-4789-a418-9623705f5fd9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_94bf28fc-a988-4db0-849d-852ae4fa348a" xlink:to="loc_srt_RangeAxis_485b034f-ddfe-4789-a418-9623705f5fd9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_485b034f-ddfe-4789-a418-9623705f5fd9_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_485b034f-ddfe-4789-a418-9623705f5fd9" xlink:to="loc_srt_RangeMember_485b034f-ddfe-4789-a418-9623705f5fd9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0c9c92e7-7475-485d-9be7-8fa5a2a45233" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_485b034f-ddfe-4789-a418-9623705f5fd9" xlink:to="loc_srt_RangeMember_0c9c92e7-7475-485d-9be7-8fa5a2a45233" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9643c7e4-7943-49c4-aa04-8fbab25a6b31" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0c9c92e7-7475-485d-9be7-8fa5a2a45233" xlink:to="loc_srt_MinimumMember_9643c7e4-7943-49c4-aa04-8fbab25a6b31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9bfc0ef0-bfa8-40e8-b189-1049b2e08e97" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0c9c92e7-7475-485d-9be7-8fa5a2a45233" xlink:to="loc_srt_MaximumMember_9bfc0ef0-bfa8-40e8-b189-1049b2e08e97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_e048fe1e-8cc1-41d9-a48c-d8a134af9ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_a9e034b2-3488-4caa-8f02-3a9b967743cc" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_e048fe1e-8cc1-41d9-a48c-d8a134af9ff1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_71181bf3-bba9-4f25-90f5-0484451d2e76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_a9e034b2-3488-4caa-8f02-3a9b967743cc" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_71181bf3-bba9-4f25-90f5-0484451d2e76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_b86ec689-7caa-486e-a3b6-e99b96658cac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_a9e034b2-3488-4caa-8f02-3a9b967743cc" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_b86ec689-7caa-486e-a3b6-e99b96658cac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7371a90c-dd10-472b-a58a-10aa09e5049d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_a9e034b2-3488-4caa-8f02-3a9b967743cc" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7371a90c-dd10-472b-a58a-10aa09e5049d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_f78e7d0c-f5a0-408e-acc9-1e85b74ff35c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_a9e034b2-3488-4caa-8f02-3a9b967743cc" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_f78e7d0c-f5a0-408e-acc9-1e85b74ff35c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_d9cef12c-ba6d-4e93-93eb-78ea4ee19601" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_a9e034b2-3488-4caa-8f02-3a9b967743cc" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_d9cef12c-ba6d-4e93-93eb-78ea4ee19601" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_8f218d31-d4e2-4c31-ac00-aae0038d8051" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_a9e034b2-3488-4caa-8f02-3a9b967743cc" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_8f218d31-d4e2-4c31-ac00-aae0038d8051" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_c304ebbf-f6fc-40e6-a41e-fc24d18dc71a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_a9e034b2-3488-4caa-8f02-3a9b967743cc" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_c304ebbf-f6fc-40e6-a41e-fc24d18dc71a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_c2f88db0-994f-4326-b270-fd7b640c26b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_a9e034b2-3488-4caa-8f02-3a9b967743cc" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_c2f88db0-994f-4326-b270-fd7b640c26b6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AccruedInterestPremiumForConvertiblePreferredStock_c0b9e1ec-8887-4d30-b0af-39fc3510a72a" xlink:href="angn-20241231.xsd#angn_AccruedInterestPremiumForConvertiblePreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_a9e034b2-3488-4caa-8f02-3a9b967743cc" xlink:to="loc_angn_AccruedInterestPremiumForConvertiblePreferredStock_c0b9e1ec-8887-4d30-b0af-39fc3510a72a" xlink:type="arc" order="9"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>angn-20241231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:e62aa408-c713-4974-8057-b2b3ab20d8bb,g:40b09b34-8017-48cd-b202-ee62afe33f17-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_fc44e28a-f664-45a2-b00b-12a08f4d8a0b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock warrants from March PIPE</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ResearchAndDevelopmentArrangementGrant_0d13d02c-4e50-4bdd-b3ac-c8912f807f30_terseLabel_en-US" xlink:label="lab_angn_ResearchAndDevelopmentArrangementGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant award</link:label>
    <link:label id="lab_angn_ResearchAndDevelopmentArrangementGrant_label_en-US" xlink:label="lab_angn_ResearchAndDevelopmentArrangementGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Grant</link:label>
    <link:label id="lab_angn_ResearchAndDevelopmentArrangementGrant_documentation_en-US" xlink:label="lab_angn_ResearchAndDevelopmentArrangementGrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ResearchAndDevelopmentArrangementGrant" xlink:href="angn-20241231.xsd#angn_ResearchAndDevelopmentArrangementGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ResearchAndDevelopmentArrangementGrant" xlink:to="lab_angn_ResearchAndDevelopmentArrangementGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_OtherPrepaidExpensesAndOtherAssetsCurrent_60440eaf-1bab-4b7b-81f8-704c745a88c5_terseLabel_en-US" xlink:label="lab_angn_OtherPrepaidExpensesAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other prepaid expenses and other current assets</link:label>
    <link:label id="lab_angn_OtherPrepaidExpensesAndOtherAssetsCurrent_label_en-US" xlink:label="lab_angn_OtherPrepaidExpensesAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Prepaid Expenses And Other Assets, Current</link:label>
    <link:label id="lab_angn_OtherPrepaidExpensesAndOtherAssetsCurrent_documentation_en-US" xlink:label="lab_angn_OtherPrepaidExpensesAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Prepaid Expenses And Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_OtherPrepaidExpensesAndOtherAssetsCurrent" xlink:href="angn-20241231.xsd#angn_OtherPrepaidExpensesAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_OtherPrepaidExpensesAndOtherAssetsCurrent" xlink:to="lab_angn_OtherPrepaidExpensesAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0e7f8723-1e2e-4af5-9221-b41e5d356445_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_AccruedLiabilitiesAssumedThroughReverseRecapitalization_8cba9e2e-9be9-44dd-a952-b465931d13fa_negatedTerseLabel_en-US" xlink:label="lab_angn_AccruedLiabilitiesAssumedThroughReverseRecapitalization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_angn_AccruedLiabilitiesAssumedThroughReverseRecapitalization_label_en-US" xlink:label="lab_angn_AccruedLiabilitiesAssumedThroughReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities Assumed Through Reverse Recapitalization</link:label>
    <link:label id="lab_angn_AccruedLiabilitiesAssumedThroughReverseRecapitalization_documentation_en-US" xlink:label="lab_angn_AccruedLiabilitiesAssumedThroughReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Liabilities Assumed Through Reverse Recapitalization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AccruedLiabilitiesAssumedThroughReverseRecapitalization" xlink:href="angn-20241231.xsd#angn_AccruedLiabilitiesAssumedThroughReverseRecapitalization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_AccruedLiabilitiesAssumedThroughReverseRecapitalization" xlink:to="lab_angn_AccruedLiabilitiesAssumedThroughReverseRecapitalization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1a5904d0-0707-43e3-bc4a-59aa410f4bdb_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_JulyPreFundedWarrantsMember_4af7130c-504f-418e-8538-c952d255f649_terseLabel_en-US" xlink:label="lab_angn_JulyPreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">July Pre-Funded Warrants</link:label>
    <link:label id="lab_angn_JulyPreFundedWarrantsMember_label_en-US" xlink:label="lab_angn_JulyPreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">July Pre-Funded Warrants [Member]</link:label>
    <link:label id="lab_angn_JulyPreFundedWarrantsMember_documentation_en-US" xlink:label="lab_angn_JulyPreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">July Pre-Funded Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_JulyPreFundedWarrantsMember" xlink:href="angn-20241231.xsd#angn_JulyPreFundedWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_JulyPreFundedWarrantsMember" xlink:to="lab_angn_JulyPreFundedWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_ea208abc-6450-4cd5-bc24-a4b1f6c13b46_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_cd9a41c8-25b9-490e-a4e9-b91d4674871b_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_099d2ca4-77ff-43e3-a28e-43f1a8c97939_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Prepaid and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_9082c752-4b36-4f5c-b488-1255969810f2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ReverseRecapitalizationTransactionCosts_d75fbaf5-5557-482d-b03e-4e96ffb7987c_terseLabel_en-US" xlink:label="lab_angn_ReverseRecapitalizationTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_angn_ReverseRecapitalizationTransactionCosts_label_en-US" xlink:label="lab_angn_ReverseRecapitalizationTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reverse Recapitalization, Transaction Costs</link:label>
    <link:label id="lab_angn_ReverseRecapitalizationTransactionCosts_documentation_en-US" xlink:label="lab_angn_ReverseRecapitalizationTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reverse Recapitalization, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ReverseRecapitalizationTransactionCosts" xlink:href="angn-20241231.xsd#angn_ReverseRecapitalizationTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ReverseRecapitalizationTransactionCosts" xlink:to="lab_angn_ReverseRecapitalizationTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3a593b3a-cd42-47ee-8947-41d2d19fed76_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f96a3666-16a8-4d47-b867-dffabd428444_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_6b4e4d27-301a-484f-8f01-474a9113a128_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ClassOfWarrantOrRightRollForward_4dd76862-57b5-402e-8e4d-ed62488d08ae_terseLabel_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_angn_ClassOfWarrantOrRightRollForward_label_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Roll Forward]</link:label>
    <link:label id="lab_angn_ClassOfWarrantOrRightRollForward_documentation_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ClassOfWarrantOrRightRollForward" xlink:href="angn-20241231.xsd#angn_ClassOfWarrantOrRightRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ClassOfWarrantOrRightRollForward" xlink:to="lab_angn_ClassOfWarrantOrRightRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_2045138e-137b-4a48-9779-2b987acf4206_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_5a55a51d-97c7-4856-8af9-2f1f2e88bd3f_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ClassOfWarrantOrRightWeightedAverageLife_42769b5c-25e6-4f22-b342-51739ced8b5a_periodStartLabel_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightWeightedAverageLife" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding beginning balance (in years)</link:label>
    <link:label id="lab_angn_ClassOfWarrantOrRightWeightedAverageLife_9378d39f-6db3-47d0-ac17-bf0aaebf4649_periodEndLabel_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightWeightedAverageLife" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding ending balance (in years)</link:label>
    <link:label id="lab_angn_ClassOfWarrantOrRightWeightedAverageLife_label_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightWeightedAverageLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant Or Right, Weighted Average Life</link:label>
    <link:label id="lab_angn_ClassOfWarrantOrRightWeightedAverageLife_documentation_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightWeightedAverageLife" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant Or Right, Weighted Average Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ClassOfWarrantOrRightWeightedAverageLife" xlink:href="angn-20241231.xsd#angn_ClassOfWarrantOrRightWeightedAverageLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ClassOfWarrantOrRightWeightedAverageLife" xlink:to="lab_angn_ClassOfWarrantOrRightWeightedAverageLife" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_NumberOfResearchGrantAgreements_2d6fc08e-355a-4064-a5b0-c5c99eca2746_terseLabel_en-US" xlink:label="lab_angn_NumberOfResearchGrantAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of research grant agreements</link:label>
    <link:label id="lab_angn_NumberOfResearchGrantAgreements_label_en-US" xlink:label="lab_angn_NumberOfResearchGrantAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Research Grant Agreements</link:label>
    <link:label id="lab_angn_NumberOfResearchGrantAgreements_documentation_en-US" xlink:label="lab_angn_NumberOfResearchGrantAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Research Grant Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_NumberOfResearchGrantAgreements" xlink:href="angn-20241231.xsd#angn_NumberOfResearchGrantAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_NumberOfResearchGrantAgreements" xlink:to="lab_angn_NumberOfResearchGrantAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_4b8d41e4-8486-4e48-bbe0-6eb32f34d16b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Net Loss Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_StockIssuedDuringPeriodSharesReverseRecapitalization_d6655e72-3c10-4982-8bfe-dd5e65fffbc9_terseLabel_en-US" xlink:label="lab_angn_StockIssuedDuringPeriodSharesReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, net of issuance costs (in shares)</link:label>
    <link:label id="lab_angn_StockIssuedDuringPeriodSharesReverseRecapitalization_label_en-US" xlink:label="lab_angn_StockIssuedDuringPeriodSharesReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Recapitalization</link:label>
    <link:label id="lab_angn_StockIssuedDuringPeriodSharesReverseRecapitalization_documentation_en-US" xlink:label="lab_angn_StockIssuedDuringPeriodSharesReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Recapitalization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_StockIssuedDuringPeriodSharesReverseRecapitalization" xlink:href="angn-20241231.xsd#angn_StockIssuedDuringPeriodSharesReverseRecapitalization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_StockIssuedDuringPeriodSharesReverseRecapitalization" xlink:to="lab_angn_StockIssuedDuringPeriodSharesReverseRecapitalization" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_338fe31f-f082-4fc2-8810-8d54ddcb0f79_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of preferred stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_PurchaseOfWarrantsMember_4c540b88-5947-4d40-bbee-9102a57eefbf_terseLabel_en-US" xlink:label="lab_angn_PurchaseOfWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Of Warrants</link:label>
    <link:label id="lab_angn_PurchaseOfWarrantsMember_label_en-US" xlink:label="lab_angn_PurchaseOfWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Of Warrants [Member]</link:label>
    <link:label id="lab_angn_PurchaseOfWarrantsMember_documentation_en-US" xlink:label="lab_angn_PurchaseOfWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_PurchaseOfWarrantsMember" xlink:href="angn-20241231.xsd#angn_PurchaseOfWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_PurchaseOfWarrantsMember" xlink:to="lab_angn_PurchaseOfWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingCostsAndExpensesAbstract_c3a9ce89-a3ff-4b6d-8e64-cf8209db5087_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingCostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="lab_us-gaap_OperatingCostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_3f7e8624-e48c-4946-bbfd-6d97122667d7_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_122e80a0-d4bf-4ee1-b36c-369d42a9a260_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description of the Business and Financial Condition</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_f491fc7d-b827-4538-bf99-ec31e1c0d907_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_f1d474a3-e3e8-49d5-b5b6-df855669ea05_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting of restricted common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_f9531af4-8d2f-4455-83d3-d0824c6cf009_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_8e55982a-3383-4629-b007-63703dc471d6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_8fa4c54e-0c50-4099-8f12-e624de56e8a0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_474883be-0d18-4b20-b45f-1d43d294a2e0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_d57e877e-cec4-40a0-89a2-9373a0efc7dd_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_TemporaryEquitySharesIssuedDuringPeriod_1850c2c4-44e0-4d5c-b9df-7b057883cc7a_terseLabel_en-US" xlink:label="lab_angn_TemporaryEquitySharesIssuedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued during period (in shares)</link:label>
    <link:label id="lab_angn_TemporaryEquitySharesIssuedDuringPeriod_label_en-US" xlink:label="lab_angn_TemporaryEquitySharesIssuedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares Issued During Period</link:label>
    <link:label id="lab_angn_TemporaryEquitySharesIssuedDuringPeriod_documentation_en-US" xlink:label="lab_angn_TemporaryEquitySharesIssuedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares Issued During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_TemporaryEquitySharesIssuedDuringPeriod" xlink:href="angn-20241231.xsd#angn_TemporaryEquitySharesIssuedDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_TemporaryEquitySharesIssuedDuringPeriod" xlink:to="lab_angn_TemporaryEquitySharesIssuedDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_5ec683df-14ce-4904-876b-9610a89d14aa_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_55809fc6-f7c5-42f1-9a8e-b511cfdb6f5b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_f6ae5f79-3c1e-410a-a341-247e930315c1_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_8101cb8f-22c0-4282-b18d-c900e6677c83_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_5e747b9f-86d1-40e6-b7cb-68a5b7195524_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_e3133338-7832-42f9-a89c-aa5d3d961cb2_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4c77dd3f-9706-45a1-9b80-444572ad8c30_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares available for future grants (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_9f925c2d-03df-4623-9e62-01e3aaa53b90_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability, noncurrent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_85f259ad-7ad0-4f94-8a10-e4b4e6c2f2f1_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability, noncurrent portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_be5921d4-6a08-44d8-b76c-8170ea53980c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_c4bbbe4a-7b86-4548-91f8-11b3de8ff7d3_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ReverseRecapitalizationDisclosureTextBlock_eec42489-d0dc-460f-a25e-6cd22173930d_terseLabel_en-US" xlink:label="lab_angn_ReverseRecapitalizationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Merger and Related Transactions</link:label>
    <link:label id="lab_angn_ReverseRecapitalizationDisclosureTextBlock_label_en-US" xlink:label="lab_angn_ReverseRecapitalizationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reverse Recapitalization Disclosure [Text Block]</link:label>
    <link:label id="lab_angn_ReverseRecapitalizationDisclosureTextBlock_documentation_en-US" xlink:label="lab_angn_ReverseRecapitalizationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reverse Recapitalization Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ReverseRecapitalizationDisclosureTextBlock" xlink:href="angn-20241231.xsd#angn_ReverseRecapitalizationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ReverseRecapitalizationDisclosureTextBlock" xlink:to="lab_angn_ReverseRecapitalizationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_130a5cd0-edea-4f44-bb54-fd5c7447a572_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development tax credit carryovers</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_1a815493-d658-49fa-88fe-3cdd2d866945_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, contractual term</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_2f0333ce-d6c6-4a53-88a5-c65374a2b7e4_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred research obligation</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_0eeb6f43-562c-47c8-9b31-915d3a6ecde0_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_ac95e9d9-5028-47db-bbb1-6eb9b6793780_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_AdvancedProfessionalFees_a332d0c2-d1da-452a-8e67-ad446179bd54_terseLabel_en-US" xlink:label="lab_angn_AdvancedProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advanced professional fees</link:label>
    <link:label id="lab_angn_AdvancedProfessionalFees_label_en-US" xlink:label="lab_angn_AdvancedProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advanced Professional Fees</link:label>
    <link:label id="lab_angn_AdvancedProfessionalFees_documentation_en-US" xlink:label="lab_angn_AdvancedProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Advanced Professional Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AdvancedProfessionalFees" xlink:href="angn-20241231.xsd#angn_AdvancedProfessionalFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_AdvancedProfessionalFees" xlink:to="lab_angn_AdvancedProfessionalFees" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_67810eb6-de16-4951-b943-b6b24aca20c4_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_JulySharesAndJulyCommonWarrantMember_4aebb9aa-f6b5-4253-9137-286cfac99bf5_terseLabel_en-US" xlink:label="lab_angn_JulySharesAndJulyCommonWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">July Share And July Common Warrant</link:label>
    <link:label id="lab_angn_JulySharesAndJulyCommonWarrantMember_label_en-US" xlink:label="lab_angn_JulySharesAndJulyCommonWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">July Shares And July Common Warrant [Member]</link:label>
    <link:label id="lab_angn_JulySharesAndJulyCommonWarrantMember_documentation_en-US" xlink:label="lab_angn_JulySharesAndJulyCommonWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">July Shares And July Common Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_JulySharesAndJulyCommonWarrantMember" xlink:href="angn-20241231.xsd#angn_JulySharesAndJulyCommonWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_JulySharesAndJulyCommonWarrantMember" xlink:to="lab_angn_JulySharesAndJulyCommonWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_5b21bd74-8cc9-4021-9b36-317e61bf676c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_d5fa5024-1340-4717-b9da-4834de437f5a_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_6ace715c-6684-47ee-a85a-7f36cc04e8c0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_c8f812b1-2f12-4b94-8950-ffb283a1bf75_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized research and development</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_4653a1b4-01ea-45af-8a87-b911215383b5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from convertible debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3a04bbc6-3774-4d24-9edd-750597758cd5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_c2907e43-c6b9-4122-b26d-f049c00bab4d_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross proceeds from offering</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ad2a2d9f-f942-49fc-8d32-73c851fbb6bc_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_85df13c0-d6b0-4b66-a847-d2dfdfe25c4d_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_WarrantsIssuedShares_af672dd1-bc07-4333-8637-7ae205af0962_terseLabel_en-US" xlink:label="lab_angn_WarrantsIssuedShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-funded warrants (in shares)</link:label>
    <link:label id="lab_angn_WarrantsIssuedShares_label_en-US" xlink:label="lab_angn_WarrantsIssuedShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Issued Shares</link:label>
    <link:label id="lab_angn_WarrantsIssuedShares_documentation_en-US" xlink:label="lab_angn_WarrantsIssuedShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Issued Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsIssuedShares" xlink:href="angn-20241231.xsd#angn_WarrantsIssuedShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_WarrantsIssuedShares" xlink:to="lab_angn_WarrantsIssuedShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProjectMember_2663e94c-5735-4778-ad0a-ad0e57408964_terseLabel_en-US" xlink:label="lab_us-gaap_ProjectMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Project [Domain]</link:label>
    <link:label id="lab_us-gaap_ProjectMember_label_en-US" xlink:label="lab_us-gaap_ProjectMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Project [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProjectMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProjectMember" xlink:to="lab_us-gaap_ProjectMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_584ff8a8-1eb5-40b0-a4f3-c54f60686c71_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_543eb242-9119-4fc5-a837-0780e8d35103_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c05f92fd-944d-4b36-b5ad-69459c8de7f0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_89f8bcae-30db-43f1-88fe-f7e359f6fd97_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development and Research Grant</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanTextBlock_2f17a0c9-328f-4710-80d9-ee971acedf30_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Benefit Plan</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanTextBlock_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanTextBlock" xlink:to="lab_us-gaap_DefinedContributionPlanTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ServiceAgreementMember_5db96df5-703b-4681-b60f-f526ed83b3ce_terseLabel_en-US" xlink:label="lab_angn_ServiceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service Agreement</link:label>
    <link:label id="lab_angn_ServiceAgreementMember_label_en-US" xlink:label="lab_angn_ServiceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service Agreement [Member]</link:label>
    <link:label id="lab_angn_ServiceAgreementMember_documentation_en-US" xlink:label="lab_angn_ServiceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Service Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ServiceAgreementMember" xlink:href="angn-20241231.xsd#angn_ServiceAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ServiceAgreementMember" xlink:to="lab_angn_ServiceAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_5d4e95df-f17a-4051-a6ae-5819bbd60012_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_3c0b2b60-c138-46ea-966c-3140beac3dc6_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_DeferredTaxAssetsOperatingLeaseLiability_d737eb29-c9a1-4953-b43b-90b113873a80_terseLabel_en-US" xlink:label="lab_angn_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_angn_DeferredTaxAssetsOperatingLeaseLiability_label_en-US" xlink:label="lab_angn_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Lease, Liability</link:label>
    <link:label id="lab_angn_DeferredTaxAssetsOperatingLeaseLiability_documentation_en-US" xlink:label="lab_angn_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_DeferredTaxAssetsOperatingLeaseLiability" xlink:href="angn-20241231.xsd#angn_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_DeferredTaxAssetsOperatingLeaseLiability" xlink:to="lab_angn_DeferredTaxAssetsOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_WarrantsAndRightsOutstandingAbstract_label_en-US" xlink:label="lab_angn_WarrantsAndRightsOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding [Abstract]</link:label>
    <link:label id="lab_angn_WarrantsAndRightsOutstandingAbstract_documentation_en-US" xlink:label="lab_angn_WarrantsAndRightsOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsAndRightsOutstandingAbstract" xlink:href="angn-20241231.xsd#angn_WarrantsAndRightsOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_WarrantsAndRightsOutstandingAbstract" xlink:to="lab_angn_WarrantsAndRightsOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_3b62e871-4d58-458d-b504-c506b46d5ae7_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_8574d284-7713-4eb1-9aff-e2c9f94e1310_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4a98893a-0e9f-425b-af53-4572c74bb221_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, total intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept2022Member_83ebfbfb-5d40-4777-bbf7-8b3acc6d67d2_terseLabel_en-US" xlink:label="lab_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Grant Agreement with GIRF Sept. 2022</link:label>
    <link:label id="lab_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept2022Member_label_en-US" xlink:label="lab_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Grant Agreement With The Gastro-Intestinal Research Foundation (&#8220;GIRF&#8221;) Sept. 2022 [Member]</link:label>
    <link:label id="lab_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept2022Member_documentation_en-US" xlink:label="lab_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research Grant Agreement With The Gastro-Intestinal Research Foundation (&#8220;GIRF&#8221;) Sept. 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept2022Member" xlink:href="angn-20241231.xsd#angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept2022Member" xlink:to="lab_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_af400b66-a437-46e8-8fe7-e24798863852_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_f3ef1e93-a7e6-4d64-a0ac-581b2ff92e53_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_77f881dc-01ec-4d68-b246-4f86f240da5e_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5036b8af-755b-4586-a761-0ce3771c65a7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_20c53673-a6bb-486a-8c99-4305fc81f883_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance increase</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_1b609ecd-45ca-41fc-a840-35d8b8d942ad_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c94288c5-eb32-4240-9024-1dcd61e15485_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_FormerAngionEquityHoldersMember_97495ed2-19c8-4bbb-b56e-db176de3565e_terseLabel_en-US" xlink:label="lab_angn_FormerAngionEquityHoldersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Former Angion Equity Holders</link:label>
    <link:label id="lab_angn_FormerAngionEquityHoldersMember_label_en-US" xlink:label="lab_angn_FormerAngionEquityHoldersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Former Angion Equity Holders [Member]</link:label>
    <link:label id="lab_angn_FormerAngionEquityHoldersMember_documentation_en-US" xlink:label="lab_angn_FormerAngionEquityHoldersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Former Angion Equity Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FormerAngionEquityHoldersMember" xlink:href="angn-20241231.xsd#angn_FormerAngionEquityHoldersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_FormerAngionEquityHoldersMember" xlink:to="lab_angn_FormerAngionEquityHoldersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_882ad7fe-b563-446d-b0a1-93a81fda25a6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ResearchAndDevelopmentArrangementGrantReceived_7dc3cdfa-c923-46e7-b1b1-03091d470f4d_terseLabel_en-US" xlink:label="lab_angn_ResearchAndDevelopmentArrangementGrantReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant award received</link:label>
    <link:label id="lab_angn_ResearchAndDevelopmentArrangementGrantReceived_label_en-US" xlink:label="lab_angn_ResearchAndDevelopmentArrangementGrantReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Grant Received</link:label>
    <link:label id="lab_angn_ResearchAndDevelopmentArrangementGrantReceived_documentation_en-US" xlink:label="lab_angn_ResearchAndDevelopmentArrangementGrantReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Grant Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ResearchAndDevelopmentArrangementGrantReceived" xlink:href="angn-20241231.xsd#angn_ResearchAndDevelopmentArrangementGrantReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ResearchAndDevelopmentArrangementGrantReceived" xlink:to="lab_angn_ResearchAndDevelopmentArrangementGrantReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_448c6c6e-f9d6-42e3-84d2-58b4e8f3ba14_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares of common stock to purchase (up to) (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_344b3ed2-498d-4785-b9d4-f80e1907b9af_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f2f48aee-d3a1-4034-be94-4d790cb66746_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock related to stock purchase agreement (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_1880d4f4-509a-4b0a-a5e0-93dfb5c4e5a6_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_d5209a0d-518e-4de2-8618-3a541e5d1484_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6c6fdba8-f8ad-4537-9286-958c5688f1ee_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_62e3a0ad-0f18-4a05-ba85-e69c40c4000c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_1eab1c2c-0e70-449b-bef7-182948041db1_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield (per share)</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ProceedsFromIssuanceOfCommonStockFromJulyPublicOffering_28288f4b-631e-4f66-9c86-1301a1068d11_terseLabel_en-US" xlink:label="lab_angn_ProceedsFromIssuanceOfCommonStockFromJulyPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock from July Public Offering</link:label>
    <link:label id="lab_angn_ProceedsFromIssuanceOfCommonStockFromJulyPublicOffering_label_en-US" xlink:label="lab_angn_ProceedsFromIssuanceOfCommonStockFromJulyPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance of Common Stock From July Public Offering</link:label>
    <link:label id="lab_angn_ProceedsFromIssuanceOfCommonStockFromJulyPublicOffering_documentation_en-US" xlink:label="lab_angn_ProceedsFromIssuanceOfCommonStockFromJulyPublicOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance of Common Stock From July Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ProceedsFromIssuanceOfCommonStockFromJulyPublicOffering" xlink:href="angn-20241231.xsd#angn_ProceedsFromIssuanceOfCommonStockFromJulyPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ProceedsFromIssuanceOfCommonStockFromJulyPublicOffering" xlink:to="lab_angn_ProceedsFromIssuanceOfCommonStockFromJulyPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_f60cd0b3-51b4-4d86-9635-81394f2b18bd_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_43de44ee-e198-450b-8d33-a786118007a0_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_StockIssuanceDomain_34b93e0e-9af9-466c-a71f-b0002ccddc31_terseLabel_en-US" xlink:label="lab_angn_StockIssuanceDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issuance [Domain]</link:label>
    <link:label id="lab_angn_StockIssuanceDomain_label_en-US" xlink:label="lab_angn_StockIssuanceDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issuance [Domain]</link:label>
    <link:label id="lab_angn_StockIssuanceDomain_documentation_en-US" xlink:label="lab_angn_StockIssuanceDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issuance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_StockIssuanceDomain" xlink:href="angn-20241231.xsd#angn_StockIssuanceDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_StockIssuanceDomain" xlink:to="lab_angn_StockIssuanceDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_49051877-ac13-454b-943d-435a957f835d_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at the beginning of the year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3f88c19d-02f8-443e-95a7-075565f01314_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at the end of the year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_09259224-2f75-44ff-95e7-6107fdce8abf_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_JulyCommonWarrantsMember_05442727-d46d-4630-9fbb-a2786cd324ed_terseLabel_en-US" xlink:label="lab_angn_JulyCommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">July Common Warrants</link:label>
    <link:label id="lab_angn_JulyCommonWarrantsMember_label_en-US" xlink:label="lab_angn_JulyCommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">July Common Warrants [Member]</link:label>
    <link:label id="lab_angn_JulyCommonWarrantsMember_documentation_en-US" xlink:label="lab_angn_JulyCommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">July Common Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_JulyCommonWarrantsMember" xlink:href="angn-20241231.xsd#angn_JulyCommonWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_JulyCommonWarrantsMember" xlink:to="lab_angn_JulyCommonWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_610a2fc6-6dca-43d6-8f66-6ad9674efb6c_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ReverseRecapitalizationLineItems_d6378775-3041-42e4-9a00-b13638dcb348_terseLabel_en-US" xlink:label="lab_angn_ReverseRecapitalizationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reverse Recapitalization [Line Items]</link:label>
    <link:label id="lab_angn_ReverseRecapitalizationLineItems_label_en-US" xlink:label="lab_angn_ReverseRecapitalizationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reverse Recapitalization [Line Items]</link:label>
    <link:label id="lab_angn_ReverseRecapitalizationLineItems_documentation_en-US" xlink:label="lab_angn_ReverseRecapitalizationLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reverse Recapitalization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ReverseRecapitalizationLineItems" xlink:href="angn-20241231.xsd#angn_ReverseRecapitalizationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ReverseRecapitalizationLineItems" xlink:to="lab_angn_ReverseRecapitalizationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_a87885c0-0ada-48fc-8d7f-33615a40ca07_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareLimit_5e177ecc-60ed-4d43-b1e9-8d5746abce8e_terseLabel_en-US" xlink:label="lab_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Share Limit</link:label>
    <link:label id="lab_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareLimit_label_en-US" xlink:label="lab_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Share Limit</link:label>
    <link:label id="lab_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareLimit_documentation_en-US" xlink:label="lab_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareLimit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Share Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareLimit" xlink:href="angn-20241231.xsd#angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareLimit" xlink:to="lab_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_AccruedOtherOperatingLiabilitiesCurrent_33a4dac4-4dd3-4a78-9611-f3c30aa7f7ec_terseLabel_en-US" xlink:label="lab_angn_AccruedOtherOperatingLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_angn_AccruedOtherOperatingLiabilitiesCurrent_label_en-US" xlink:label="lab_angn_AccruedOtherOperatingLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Other Operating Liabilities, Current</link:label>
    <link:label id="lab_angn_AccruedOtherOperatingLiabilitiesCurrent_documentation_en-US" xlink:label="lab_angn_AccruedOtherOperatingLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Other Operating Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AccruedOtherOperatingLiabilitiesCurrent" xlink:href="angn-20241231.xsd#angn_AccruedOtherOperatingLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_AccruedOtherOperatingLiabilitiesCurrent" xlink:to="lab_angn_AccruedOtherOperatingLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_aeb9dd1b-a32d-45cf-b911-71a644205f02_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_a5298333-4fc7-4dc9-80db-0b63e5f8f9f2_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_d7acce1f-e668-4d0d-a11a-8992a7f22408_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_SettlementOfPromissoryNotesPayable_d4530b0e-5af4-4420-99bf-43b48ce45d48_terseLabel_en-US" xlink:label="lab_angn_SettlementOfPromissoryNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settlement of promissory notes payable</link:label>
    <link:label id="lab_angn_SettlementOfPromissoryNotesPayable_label_en-US" xlink:label="lab_angn_SettlementOfPromissoryNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Settlement Of Promissory Notes Payable</link:label>
    <link:label id="lab_angn_SettlementOfPromissoryNotesPayable_documentation_en-US" xlink:label="lab_angn_SettlementOfPromissoryNotesPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Settlement Of Promissory Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_SettlementOfPromissoryNotesPayable" xlink:href="angn-20241231.xsd#angn_SettlementOfPromissoryNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_SettlementOfPromissoryNotesPayable" xlink:to="lab_angn_SettlementOfPromissoryNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_ff8b7bbf-50e7-43a3-89bc-d81b431f7c78_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_29aae101-64bf-499a-a93e-ce73cf759b83_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_640ecb17-6721-4db3-a691-9be5c40486e7_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares issuable upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_PromissoryNotesAcquiredThroughReverseRecapitalization_c4648e08-22ba-4cab-806d-75b897294ebb_terseLabel_en-US" xlink:label="lab_angn_PromissoryNotesAcquiredThroughReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Promissory notes</link:label>
    <link:label id="lab_angn_PromissoryNotesAcquiredThroughReverseRecapitalization_label_en-US" xlink:label="lab_angn_PromissoryNotesAcquiredThroughReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Promissory Notes Acquired Through Reverse Recapitalization</link:label>
    <link:label id="lab_angn_PromissoryNotesAcquiredThroughReverseRecapitalization_documentation_en-US" xlink:label="lab_angn_PromissoryNotesAcquiredThroughReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Promissory Notes Acquired Through Reverse Recapitalization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_PromissoryNotesAcquiredThroughReverseRecapitalization" xlink:href="angn-20241231.xsd#angn_PromissoryNotesAcquiredThroughReverseRecapitalization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_PromissoryNotesAcquiredThroughReverseRecapitalization" xlink:to="lab_angn_PromissoryNotesAcquiredThroughReverseRecapitalization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_74641b84-51df-4245-a44e-eae188bbe559_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_062985af-cb80-4be9-a810-8827e80a032c_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f0ae587c-2caa-4ef8-833b-9494f7cb02e1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d49434ff-47cf-4b3c-96c7-02bc895a075f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_65fd4e46-d4df-4f94-9165-1fb2051e34db_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_NewtonMassachusettsMember_632dc7ba-9107-492f-a83d-1ac2b6fb87b9_terseLabel_en-US" xlink:label="lab_angn_NewtonMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Newton, Massachusetts</link:label>
    <link:label id="lab_angn_NewtonMassachusettsMember_label_en-US" xlink:label="lab_angn_NewtonMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Newton, Massachusetts [Member]</link:label>
    <link:label id="lab_angn_NewtonMassachusettsMember_documentation_en-US" xlink:label="lab_angn_NewtonMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Newton, Massachusetts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_NewtonMassachusettsMember" xlink:href="angn-20241231.xsd#angn_NewtonMassachusettsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_NewtonMassachusettsMember" xlink:to="lab_angn_NewtonMassachusettsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_4816b0f2-3b43-47c3-b100-306d7a9b238e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_e7499097-f96e-4305-a307-7feed20873d8_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other differences</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_PreFundedWarrantsMember_389d4a4b-cd0a-4883-b713-bc9dd80ab684_terseLabel_en-US" xlink:label="lab_angn_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-funded Warrants</link:label>
    <link:label id="lab_angn_PreFundedWarrantsMember_label_en-US" xlink:label="lab_angn_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-funded Warrants [Member]</link:label>
    <link:label id="lab_angn_PreFundedWarrantsMember_documentation_en-US" xlink:label="lab_angn_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre-funded Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_PreFundedWarrantsMember" xlink:href="angn-20241231.xsd#angn_PreFundedWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_PreFundedWarrantsMember" xlink:to="lab_angn_PreFundedWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_47864b85-b5e5-45a0-8a9d-c977d32aff19_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issuable upon the exercise of warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_e5828225-d1cb-4097-a7c6-f29e3fa5ff20_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_e7093d85-a637-44de-8f82-98919c3a7e29_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_524871b0-a94c-4378-bb15-c892a2c25605_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_AccretionOfPromissoryNoteToFaceValue_92c303f3-263a-4008-a846-e6c867459922_terseLabel_en-US" xlink:label="lab_angn_AccretionOfPromissoryNoteToFaceValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accretion of promissory note to face value</link:label>
    <link:label id="lab_angn_AccretionOfPromissoryNoteToFaceValue_label_en-US" xlink:label="lab_angn_AccretionOfPromissoryNoteToFaceValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion Of Promissory Note To Face Value</link:label>
    <link:label id="lab_angn_AccretionOfPromissoryNoteToFaceValue_documentation_en-US" xlink:label="lab_angn_AccretionOfPromissoryNoteToFaceValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accretion Of Promissory Note To Face Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AccretionOfPromissoryNoteToFaceValue" xlink:href="angn-20241231.xsd#angn_AccretionOfPromissoryNoteToFaceValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_AccretionOfPromissoryNoteToFaceValue" xlink:to="lab_angn_AccretionOfPromissoryNoteToFaceValue" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_MeasurementInputStrikePriceMember_e86b6289-b0b0-4018-b301-13c1adbea2dc_terseLabel_en-US" xlink:label="lab_angn_MeasurementInputStrikePriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average strike price</link:label>
    <link:label id="lab_angn_MeasurementInputStrikePriceMember_label_en-US" xlink:label="lab_angn_MeasurementInputStrikePriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Strike Price [Member]</link:label>
    <link:label id="lab_angn_MeasurementInputStrikePriceMember_documentation_en-US" xlink:label="lab_angn_MeasurementInputStrikePriceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Measurement Input, Strike Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_MeasurementInputStrikePriceMember" xlink:href="angn-20241231.xsd#angn_MeasurementInputStrikePriceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_MeasurementInputStrikePriceMember" xlink:to="lab_angn_MeasurementInputStrikePriceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_NumberOfMembersOfTheBoardOfDirectors_dc83b4dd-a24c-4fea-a12b-b1e4e92fb639_terseLabel_en-US" xlink:label="lab_angn_NumberOfMembersOfTheBoardOfDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of members of the board of directors</link:label>
    <link:label id="lab_angn_NumberOfMembersOfTheBoardOfDirectors_label_en-US" xlink:label="lab_angn_NumberOfMembersOfTheBoardOfDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Members Of The Board Of Directors</link:label>
    <link:label id="lab_angn_NumberOfMembersOfTheBoardOfDirectors_documentation_en-US" xlink:label="lab_angn_NumberOfMembersOfTheBoardOfDirectors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Members Of The Board Of Directors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_NumberOfMembersOfTheBoardOfDirectors" xlink:href="angn-20241231.xsd#angn_NumberOfMembersOfTheBoardOfDirectors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_NumberOfMembersOfTheBoardOfDirectors" xlink:to="lab_angn_NumberOfMembersOfTheBoardOfDirectors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_540b4c50-7fea-4dd7-9f32-b2d40c0383d6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_73835779-ee48-4c1a-aee1-8f5bd36a0b1f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_4ec402f1-677f-47c6-b222-20b2113d5228_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Grant</link:label>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research, Development, and Computer Software Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept.2023Member_26095c85-3794-4ec6-9d19-26e10eaae445_terseLabel_en-US" xlink:label="lab_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept.2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Grant Agreement With The Gastro-Intestinal Research Foundation (&#8220;GIRF&#8221;) Sept. 2023</link:label>
    <link:label id="lab_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept.2023Member_label_en-US" xlink:label="lab_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept.2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Grant Agreement With The Gastro-Intestinal Research Foundation (&#8220;GIRF&#8221;) Sept. 2023 [Member]</link:label>
    <link:label id="lab_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept.2023Member_documentation_en-US" xlink:label="lab_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept.2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research Grant Agreement With The Gastro-Intestinal Research Foundation (&#8220;GIRF&#8221;) Sept. 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept.2023Member" xlink:href="angn-20241231.xsd#angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept.2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept.2023Member" xlink:to="lab_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept.2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants_77b5e5dd-9b4e-41f3-8742-9a5e3b985c2b_terseLabel_en-US" xlink:label="lab_angn_StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock from the exercise of Pre-funded Warrants (in shares)</link:label>
    <link:label id="lab_angn_StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants_label_en-US" xlink:label="lab_angn_StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock and Warrants Issued During Period, Share, Preferred Stock and Warrants</link:label>
    <link:label id="lab_angn_StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants_documentation_en-US" xlink:label="lab_angn_StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock and Warrants Issued During Period, Share, Preferred Stock and Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants" xlink:href="angn-20241231.xsd#angn_StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants" xlink:to="lab_angn_StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_73e4ff10-2468-4700-a26f-717083da78fc_terseLabel_en-US" xlink:label="lab_angn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_angn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_label_en-US" xlink:label="lab_angn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_angn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_documentation_en-US" xlink:label="lab_angn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Accrued Expenses and Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:href="angn-20241231.xsd#angn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:to="lab_angn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_314e9c7a-18ae-419c-9925-5184f0987687_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_a1019ef8-bf88-4dd7-92eb-42a2a94a9531_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_42370841-12ec-4bfd-925f-140333e9f2f5_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_c560192f-dea2-43e1-88e5-38a88f0a3c12_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_FormerElicioEquityHoldersMember_6b140146-4756-4805-9b7c-d5887f2334d1_terseLabel_en-US" xlink:label="lab_angn_FormerElicioEquityHoldersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Former Elicio Equity Holders</link:label>
    <link:label id="lab_angn_FormerElicioEquityHoldersMember_label_en-US" xlink:label="lab_angn_FormerElicioEquityHoldersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Former Elicio Equity Holders [Member]</link:label>
    <link:label id="lab_angn_FormerElicioEquityHoldersMember_documentation_en-US" xlink:label="lab_angn_FormerElicioEquityHoldersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Former Elicio Equity Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FormerElicioEquityHoldersMember" xlink:href="angn-20241231.xsd#angn_FormerElicioEquityHoldersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_FormerElicioEquityHoldersMember" xlink:to="lab_angn_FormerElicioEquityHoldersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_c71a4a14-eab1-4e55-9ca8-ff853e739477_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_CommonStockCapitalSharesReservedForFutureIssuanceIncreasePercentageOfCommonStockOutstanding_4b321af1-88e3-424b-ad32-ba85defc352d_terseLabel_en-US" xlink:label="lab_angn_CommonStockCapitalSharesReservedForFutureIssuanceIncreasePercentageOfCommonStockOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of outstanding stock</link:label>
    <link:label id="lab_angn_CommonStockCapitalSharesReservedForFutureIssuanceIncreasePercentageOfCommonStockOutstanding_label_en-US" xlink:label="lab_angn_CommonStockCapitalSharesReservedForFutureIssuanceIncreasePercentageOfCommonStockOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance, Increase, Percentage Of Common Stock Outstanding</link:label>
    <link:label id="lab_angn_CommonStockCapitalSharesReservedForFutureIssuanceIncreasePercentageOfCommonStockOutstanding_documentation_en-US" xlink:label="lab_angn_CommonStockCapitalSharesReservedForFutureIssuanceIncreasePercentageOfCommonStockOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance, Increase, Percentage Of Common Stock Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_CommonStockCapitalSharesReservedForFutureIssuanceIncreasePercentageOfCommonStockOutstanding" xlink:href="angn-20241231.xsd#angn_CommonStockCapitalSharesReservedForFutureIssuanceIncreasePercentageOfCommonStockOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_CommonStockCapitalSharesReservedForFutureIssuanceIncreasePercentageOfCommonStockOutstanding" xlink:to="lab_angn_CommonStockCapitalSharesReservedForFutureIssuanceIncreasePercentageOfCommonStockOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_f497a629-96a9-4357-a7b3-faba799bbd97_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options vested and exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_87c4f5cc-89d0-4dcc-bc74-1a5c608d90a3_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_0cda1210-83a3-4a84-8daf-29ccaf4c7433_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_12d2dc5d-61d2-48ac-b393-3c2049ee40c0_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_33a06232-decd-4e51-be77-731996932661_negatedLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9500aaa6-18f5-408f-9874-33cec8560aea_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_578b5762-425c-4b26-bfda-d6f904053662_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Translation and Transactions</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_BridgeLoanBetweenAngionAndFormerElicioInitialClosingMember_d0870b47-af13-4738-a83c-a411d5e7d6ef_terseLabel_en-US" xlink:label="lab_angn_BridgeLoanBetweenAngionAndFormerElicioInitialClosingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bridge Loan Between Angion And Former Elicio, Initial Closing</link:label>
    <link:label id="lab_angn_BridgeLoanBetweenAngionAndFormerElicioInitialClosingMember_label_en-US" xlink:label="lab_angn_BridgeLoanBetweenAngionAndFormerElicioInitialClosingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bridge Loan Between Angion And Former Elicio, Initial Closing [Member]</link:label>
    <link:label id="lab_angn_BridgeLoanBetweenAngionAndFormerElicioInitialClosingMember_documentation_en-US" xlink:label="lab_angn_BridgeLoanBetweenAngionAndFormerElicioInitialClosingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bridge Loan Between Angion And Former Elicio, Initial Closing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_BridgeLoanBetweenAngionAndFormerElicioInitialClosingMember" xlink:href="angn-20241231.xsd#angn_BridgeLoanBetweenAngionAndFormerElicioInitialClosingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_BridgeLoanBetweenAngionAndFormerElicioInitialClosingMember" xlink:to="lab_angn_BridgeLoanBetweenAngionAndFormerElicioInitialClosingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d4f665e8-21d1-4d3d-871e-eae48735578c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_NetAssetsAcquiredThroughReverseRecapitalization_f5e06e90-894c-45ba-9a74-2da58b8e3b57_totalLabel_en-US" xlink:label="lab_angn_NetAssetsAcquiredThroughReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net assets acquired</link:label>
    <link:label id="lab_angn_NetAssetsAcquiredThroughReverseRecapitalization_label_en-US" xlink:label="lab_angn_NetAssetsAcquiredThroughReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Assets Acquired Through Reverse Recapitalization</link:label>
    <link:label id="lab_angn_NetAssetsAcquiredThroughReverseRecapitalization_documentation_en-US" xlink:label="lab_angn_NetAssetsAcquiredThroughReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Assets Acquired Through Reverse Recapitalization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_NetAssetsAcquiredThroughReverseRecapitalization" xlink:href="angn-20241231.xsd#angn_NetAssetsAcquiredThroughReverseRecapitalization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_NetAssetsAcquiredThroughReverseRecapitalization" xlink:to="lab_angn_NetAssetsAcquiredThroughReverseRecapitalization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_0e6ea85c-ba35-4365-8272-a699bdfb3a67_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_fda8ae32-e1da-4ab3-bbf5-a250d243b6f4_negatedLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: operating lease liability, current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_9da1e070-31d6-4abf-83cb-e0074a29a903_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_bab18b29-1cd3-4956-ac78-e92063e43294_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consecutive trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_2c25fc88-36cf-4970-a97b-5965aed8e486_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_FairValueOfPreFundedWarrants_b4ae59a0-6d75-430d-b3dc-7c16131a71a5_terseLabel_en-US" xlink:label="lab_angn_FairValueOfPreFundedWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of pre-funded warrants at issuance date</link:label>
    <link:label id="lab_angn_FairValueOfPreFundedWarrants_label_en-US" xlink:label="lab_angn_FairValueOfPreFundedWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Pre Funded Warrants</link:label>
    <link:label id="lab_angn_FairValueOfPreFundedWarrants_documentation_en-US" xlink:label="lab_angn_FairValueOfPreFundedWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Of Pre Funded Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FairValueOfPreFundedWarrants" xlink:href="angn-20241231.xsd#angn_FairValueOfPreFundedWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_FairValueOfPreFundedWarrants" xlink:to="lab_angn_FairValueOfPreFundedWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_5558af0e-8bb8-45a8-b27b-2efd9b09ea38_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_37a04907-1191-4621-8f7c-ed04f3ccfacd_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_c208fabe-c7d5-4969-a6aa-2de9dcda3ed5_verboseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4c0e56e1-1cb6-4afc-b7ad-70086d0c19fc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_b1a4597a-d8db-4949-80dd-05448b41c85f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_c6e3e739-444c-4aee-85ee-89e4fcef0be8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidInsurance_25dc4e5b-2e98-4017-80cb-8a43aa01778b_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid insurance</link:label>
    <link:label id="lab_us-gaap_PrepaidInsurance_label_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1a637980-8ceb-4e5f-80be-b0d881ec4d24_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5054d45d-b074-4090-9a53-52f6a89eeed2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ClassOfWarrantOrRightIssuedInPeriod_00196acb-2c3f-49f1-b071-4d7f54e11139_verboseLabel_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issued (in shares)</link:label>
    <link:label id="lab_angn_ClassOfWarrantOrRightIssuedInPeriod_337c265b-d1c3-49fd-9572-04f860ee4a40_terseLabel_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued in period</link:label>
    <link:label id="lab_angn_ClassOfWarrantOrRightIssuedInPeriod_label_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Issued In Period</link:label>
    <link:label id="lab_angn_ClassOfWarrantOrRightIssuedInPeriod_documentation_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Issued In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ClassOfWarrantOrRightIssuedInPeriod" xlink:href="angn-20241231.xsd#angn_ClassOfWarrantOrRightIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ClassOfWarrantOrRightIssuedInPeriod" xlink:to="lab_angn_ClassOfWarrantOrRightIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_15f23346-c5d6-425b-a9c1-ba17ca640bb8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0f71037c-afd0-4e24-ad5a-866ef4b8e34b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_519107fe-cb86-4cdc-b94f-3d2022b3b76f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_96e78d67-9745-416b-adcc-907f80e6bd46_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_68c64185-9a57-4cc9-a9ba-98a1b64fe2d4_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_JayVenkatesanAndTrustsAffiliatedWithJayVenkatesanMember_43f10f00-2e97-40e1-a65b-26d098b7b1f2_terseLabel_en-US" xlink:label="lab_angn_JayVenkatesanAndTrustsAffiliatedWithJayVenkatesanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Jay Venkatesan and Trusts Affiliated With Jay Venkatesan</link:label>
    <link:label id="lab_angn_JayVenkatesanAndTrustsAffiliatedWithJayVenkatesanMember_label_en-US" xlink:label="lab_angn_JayVenkatesanAndTrustsAffiliatedWithJayVenkatesanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Jay Venkatesan and Trusts Affiliated With Jay Venkatesan [Member]</link:label>
    <link:label id="lab_angn_JayVenkatesanAndTrustsAffiliatedWithJayVenkatesanMember_documentation_en-US" xlink:label="lab_angn_JayVenkatesanAndTrustsAffiliatedWithJayVenkatesanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Jay Venkatesan and Trusts Affiliated With Jay Venkatesan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_JayVenkatesanAndTrustsAffiliatedWithJayVenkatesanMember" xlink:href="angn-20241231.xsd#angn_JayVenkatesanAndTrustsAffiliatedWithJayVenkatesanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_JayVenkatesanAndTrustsAffiliatedWithJayVenkatesanMember" xlink:to="lab_angn_JayVenkatesanAndTrustsAffiliatedWithJayVenkatesanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f0eeaf17-c52c-43bc-acd1-b81ea36736eb_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ae231b1a-e528-4718-9a54-0c609565166a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_edcfe6a9-50a4-4f85-b2be-c9c7bd2ea5a1_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares used in computing net loss per share, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSecuredLinesOfCredit_44ca1dd7-f5a0-4e72-90bf-ebbc0130782b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSecuredLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Letter of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSecuredLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSecuredLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Secured Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSecuredLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSecuredLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSecuredLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromSecuredLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_RegistrationStatementMember_d268ca09-2d60-4323-9a26-bc6898562a9e_terseLabel_en-US" xlink:label="lab_angn_RegistrationStatementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Registration Statement</link:label>
    <link:label id="lab_angn_RegistrationStatementMember_label_en-US" xlink:label="lab_angn_RegistrationStatementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Registration Statement [Member]</link:label>
    <link:label id="lab_angn_RegistrationStatementMember_documentation_en-US" xlink:label="lab_angn_RegistrationStatementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Registration Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_RegistrationStatementMember" xlink:href="angn-20241231.xsd#angn_RegistrationStatementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_RegistrationStatementMember" xlink:to="lab_angn_RegistrationStatementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_7162a7e5-6f53-4b6e-a6a5-e1a2f57c6ef9_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_391c782f-9540-4b46-8dce-466e87f7b208_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' (deficit) equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_4b80fb53-5dd2-4d74-9314-6b0cee3ec56d_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_ff2b4d4b-3506-46d5-86aa-175d01771266_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_c17fab9f-3242-402c-affa-b013d56fdb77_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_PreFundedWarrantMember_14a31cc5-aa35-4b31-9b34-b27b8cfc826a_terseLabel_en-US" xlink:label="lab_angn_PreFundedWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrant</link:label>
    <link:label id="lab_angn_PreFundedWarrantMember_label_en-US" xlink:label="lab_angn_PreFundedWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrant [Member]</link:label>
    <link:label id="lab_angn_PreFundedWarrantMember_documentation_en-US" xlink:label="lab_angn_PreFundedWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_PreFundedWarrantMember" xlink:href="angn-20241231.xsd#angn_PreFundedWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_PreFundedWarrantMember" xlink:to="lab_angn_PreFundedWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_RecapitalizationExchangeRatio_be1f6314-898f-461d-8f4d-ebc33f43bfac_terseLabel_en-US" xlink:label="lab_angn_RecapitalizationExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recapitalization exchange ratio</link:label>
    <link:label id="lab_angn_RecapitalizationExchangeRatio_label_en-US" xlink:label="lab_angn_RecapitalizationExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recapitalization Exchange Ratio</link:label>
    <link:label id="lab_angn_RecapitalizationExchangeRatio_documentation_en-US" xlink:label="lab_angn_RecapitalizationExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Recapitalization Exchange Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_RecapitalizationExchangeRatio" xlink:href="angn-20241231.xsd#angn_RecapitalizationExchangeRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_RecapitalizationExchangeRatio" xlink:to="lab_angn_RecapitalizationExchangeRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_d25e3423-de19-47a2-9a69-5c0fd6b2c367_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_label_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseNonoperating" xlink:to="lab_us-gaap_InterestExpenseNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_6f523a50-78c4-452b-ad0f-2d002769108c_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_CashAndCashEquivalentsAcquiredThroughReverseRecapitalization_e477a8d5-12ef-40f4-aa92-0d1bbf6ade22_terseLabel_en-US" xlink:label="lab_angn_CashAndCashEquivalentsAcquiredThroughReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_angn_CashAndCashEquivalentsAcquiredThroughReverseRecapitalization_label_en-US" xlink:label="lab_angn_CashAndCashEquivalentsAcquiredThroughReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents Acquired Through Reverse Recapitalization</link:label>
    <link:label id="lab_angn_CashAndCashEquivalentsAcquiredThroughReverseRecapitalization_documentation_en-US" xlink:label="lab_angn_CashAndCashEquivalentsAcquiredThroughReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents Acquired Through Reverse Recapitalization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_CashAndCashEquivalentsAcquiredThroughReverseRecapitalization" xlink:href="angn-20241231.xsd#angn_CashAndCashEquivalentsAcquiredThroughReverseRecapitalization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_CashAndCashEquivalentsAcquiredThroughReverseRecapitalization" xlink:to="lab_angn_CashAndCashEquivalentsAcquiredThroughReverseRecapitalization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_19548cf3-40bc-4f02-b553-95b2e6330649_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value measurements, recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_944d0067-a1b3-429e-9d85-977a8337b558_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion price</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6ff8c866-dd39-4354-84b7-5256debe9892_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ResearchAndDevelopmentArrangementCredit_9b4ff658-195c-4d5d-ab39-141a39b8cbf8_terseLabel_en-US" xlink:label="lab_angn_ResearchAndDevelopmentArrangementCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit</link:label>
    <link:label id="lab_angn_ResearchAndDevelopmentArrangementCredit_label_en-US" xlink:label="lab_angn_ResearchAndDevelopmentArrangementCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Credit</link:label>
    <link:label id="lab_angn_ResearchAndDevelopmentArrangementCredit_documentation_en-US" xlink:label="lab_angn_ResearchAndDevelopmentArrangementCredit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ResearchAndDevelopmentArrangementCredit" xlink:href="angn-20241231.xsd#angn_ResearchAndDevelopmentArrangementCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ResearchAndDevelopmentArrangementCredit" xlink:to="lab_angn_ResearchAndDevelopmentArrangementCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_3d264efb-e160-474b-a8d3-4b3e3c973aec_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Conversion Description [Axis]</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Conversion Description [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxYear2017Member_24d19c71-be12-4dea-8177-7aab3f8b4202_terseLabel_en-US" xlink:label="lab_us-gaap_TaxYear2017Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Year 2017</link:label>
    <link:label id="lab_us-gaap_TaxYear2017Member_label_en-US" xlink:label="lab_us-gaap_TaxYear2017Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Year 2017 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxYear2017Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxYear2017Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxYear2017Member" xlink:to="lab_us-gaap_TaxYear2017Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6e18db92-e9e8-4129-87cd-ba7142c4f430_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_34ab6c0c-e662-4583-b887-19e710f3c35c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_ceae8605-a032-4870-a632-a2a11e84b7c1_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_fe1d9dd9-f99a-4e51-8279-7aad738affd3_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract_765ea1f3-3707-4aa6-9aa1-965df8b18b76_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive gain (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent, Alternative [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ProceedsFromIssuanceOfCommonStockWarrantsFromJulyPublicOffering_170cd465-27de-4ce8-ad16-7e8c17683f06_terseLabel_en-US" xlink:label="lab_angn_ProceedsFromIssuanceOfCommonStockWarrantsFromJulyPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock warrants from July Public Offering</link:label>
    <link:label id="lab_angn_ProceedsFromIssuanceOfCommonStockWarrantsFromJulyPublicOffering_label_en-US" xlink:label="lab_angn_ProceedsFromIssuanceOfCommonStockWarrantsFromJulyPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance of Common Stock Warrants From July Public Offering</link:label>
    <link:label id="lab_angn_ProceedsFromIssuanceOfCommonStockWarrantsFromJulyPublicOffering_documentation_en-US" xlink:label="lab_angn_ProceedsFromIssuanceOfCommonStockWarrantsFromJulyPublicOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance of Common Stock Warrants From July Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ProceedsFromIssuanceOfCommonStockWarrantsFromJulyPublicOffering" xlink:href="angn-20241231.xsd#angn_ProceedsFromIssuanceOfCommonStockWarrantsFromJulyPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ProceedsFromIssuanceOfCommonStockWarrantsFromJulyPublicOffering" xlink:to="lab_angn_ProceedsFromIssuanceOfCommonStockWarrantsFromJulyPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_DeferredTaxAssetsNetBeforeValuationAllowance_83d88ba1-3a43-4d03-8093-9b142ce95385_totalLabel_en-US" xlink:label="lab_angn_DeferredTaxAssetsNetBeforeValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_angn_DeferredTaxAssetsNetBeforeValuationAllowance_label_en-US" xlink:label="lab_angn_DeferredTaxAssetsNetBeforeValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net, Before Valuation Allowance</link:label>
    <link:label id="lab_angn_DeferredTaxAssetsNetBeforeValuationAllowance_documentation_en-US" xlink:label="lab_angn_DeferredTaxAssetsNetBeforeValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net, Before Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_DeferredTaxAssetsNetBeforeValuationAllowance" xlink:href="angn-20241231.xsd#angn_DeferredTaxAssetsNetBeforeValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_DeferredTaxAssetsNetBeforeValuationAllowance" xlink:to="lab_angn_DeferredTaxAssetsNetBeforeValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent_db1d9de0-59b8-4fee-a9c9-250a4f2c8f16_terseLabel_en-US" xlink:label="lab_angn_EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State research and development credits</link:label>
    <link:label id="lab_angn_EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent_label_en-US" xlink:label="lab_angn_EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, State Research And Development, Percent</link:label>
    <link:label id="lab_angn_EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent_documentation_en-US" xlink:label="lab_angn_EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, State Research And Development, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent" xlink:href="angn-20241231.xsd#angn_EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent" xlink:to="lab_angn_EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_9dc023fc-173c-4ae4-aa4a-83892392c4f3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, weighted average remaining contractual life (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_b139f04d-55ec-4626-8a77-94c1be23009f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_fdfe9911-f895-4018-80d9-8e4d194980b4_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_a906d2f1-cf06-4b69-ae71-40e9587004f0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ScheduleOfReverseRecapitalizationTable_4b5b795d-cc87-4298-bd32-d5b725527746_terseLabel_en-US" xlink:label="lab_angn_ScheduleOfReverseRecapitalizationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reverse Recapitalization [Table]</link:label>
    <link:label id="lab_angn_ScheduleOfReverseRecapitalizationTable_label_en-US" xlink:label="lab_angn_ScheduleOfReverseRecapitalizationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Reverse Recapitalization [Table]</link:label>
    <link:label id="lab_angn_ScheduleOfReverseRecapitalizationTable_documentation_en-US" xlink:label="lab_angn_ScheduleOfReverseRecapitalizationTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Reverse Recapitalization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ScheduleOfReverseRecapitalizationTable" xlink:href="angn-20241231.xsd#angn_ScheduleOfReverseRecapitalizationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ScheduleOfReverseRecapitalizationTable" xlink:to="lab_angn_ScheduleOfReverseRecapitalizationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6609311e-49b0-46c0-b3fb-5a7fe164bb48_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_TemporaryEquitySharesConversionOfConvertibleSecurities_f2b15db5-0821-4494-b8b4-058de5e44802_negatedTerseLabel_en-US" xlink:label="lab_angn_TemporaryEquitySharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Conversion of preferred stock (in shares)</link:label>
    <link:label id="lab_angn_TemporaryEquitySharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_angn_TemporaryEquitySharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares, Conversion Of Convertible Securities</link:label>
    <link:label id="lab_angn_TemporaryEquitySharesConversionOfConvertibleSecurities_documentation_en-US" xlink:label="lab_angn_TemporaryEquitySharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares, Conversion Of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_TemporaryEquitySharesConversionOfConvertibleSecurities" xlink:href="angn-20241231.xsd#angn_TemporaryEquitySharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_TemporaryEquitySharesConversionOfConvertibleSecurities" xlink:to="lab_angn_TemporaryEquitySharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_306d04aa-cab3-4c1f-9bd8-bef9884c016e_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash, current</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_60879eb6-fa51-4e8f-bb17-f5b90d619550_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_f1587611-43b9-4177-9a66-d3fbfffb625e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_21390601-6c81-4bc3-b010-1f9f6980ef01_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_6fc8dfdc-daa3-4f15-b1f7-63e1f3a38eea_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options vested and exercisable, weighted average remaining contractual life (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_YekaterinaChudnovskyMember_724f171a-394f-4387-abd5-d43285abfdce_terseLabel_en-US" xlink:label="lab_angn_YekaterinaChudnovskyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Yekaterina Chudnovsky</link:label>
    <link:label id="lab_angn_YekaterinaChudnovskyMember_label_en-US" xlink:label="lab_angn_YekaterinaChudnovskyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Yekaterina Chudnovsky [Member]</link:label>
    <link:label id="lab_angn_YekaterinaChudnovskyMember_documentation_en-US" xlink:label="lab_angn_YekaterinaChudnovskyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Yekaterina Chudnovsky</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_YekaterinaChudnovskyMember" xlink:href="angn-20241231.xsd#angn_YekaterinaChudnovskyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_YekaterinaChudnovskyMember" xlink:to="lab_angn_YekaterinaChudnovskyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_f6f07cc7-ff72-494b-8bae-50bf136295a8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other (expense) income</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_BridgeLoanBetweenAngionAndFormerElicioMember_40420d62-2fd7-4093-9e6d-f862bb89d711_terseLabel_en-US" xlink:label="lab_angn_BridgeLoanBetweenAngionAndFormerElicioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bridge Loan Between Angion And Former Elicio</link:label>
    <link:label id="lab_angn_BridgeLoanBetweenAngionAndFormerElicioMember_label_en-US" xlink:label="lab_angn_BridgeLoanBetweenAngionAndFormerElicioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bridge Loan Between Angion And Former Elicio [Member]</link:label>
    <link:label id="lab_angn_BridgeLoanBetweenAngionAndFormerElicioMember_documentation_en-US" xlink:label="lab_angn_BridgeLoanBetweenAngionAndFormerElicioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bridge Loan Between Angion And Former Elicio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_BridgeLoanBetweenAngionAndFormerElicioMember" xlink:href="angn-20241231.xsd#angn_BridgeLoanBetweenAngionAndFormerElicioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_BridgeLoanBetweenAngionAndFormerElicioMember" xlink:to="lab_angn_BridgeLoanBetweenAngionAndFormerElicioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_GainLossOnIssuanceOfWarrants_73bca3a1-387b-4706-8b83-18cecb1bbbc2_terseLabel_en-US" xlink:label="lab_angn_GainLossOnIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on issuance of pre-funded warrants</link:label>
    <link:label id="lab_angn_GainLossOnIssuanceOfWarrants_3a99f1a1-dc9d-4f53-a2d6-69ae12e1c6d1_negatedLabel_en-US" xlink:label="lab_angn_GainLossOnIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss on issuance of warrants</link:label>
    <link:label id="lab_angn_GainLossOnIssuanceOfWarrants_1a61dee8-e62e-457f-b55c-642f2bd5f54b_negatedTerseLabel_en-US" xlink:label="lab_angn_GainLossOnIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on issuance of pre-funded warrants</link:label>
    <link:label id="lab_angn_GainLossOnIssuanceOfWarrants_label_en-US" xlink:label="lab_angn_GainLossOnIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain Loss On Issuance Of Warrants</link:label>
    <link:label id="lab_angn_GainLossOnIssuanceOfWarrants_documentation_en-US" xlink:label="lab_angn_GainLossOnIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain Loss On Issuance Of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_GainLossOnIssuanceOfWarrants" xlink:href="angn-20241231.xsd#angn_GainLossOnIssuanceOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_GainLossOnIssuanceOfWarrants" xlink:to="lab_angn_GainLossOnIssuanceOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_3e7e9453-bbd4-4ac8-a56d-84907ef39587_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_ad9612e1-7c1f-4656-ae2d-6ae00182a7c6_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_0a6955f4-b932-4f7b-bac3-4d36e70b3fb2_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Project [Axis]</link:label>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_label_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Project [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_071276b0-ea00-4e42-a41f-402175f2c920_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_e1edf79c-3247-4d72-8521-a58762d2a738_verboseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_27471f4b-959e-4b76-b2a0-3dda66e9a617_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_5b7538db-4863-4823-b571-2bf0ff8a4328_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_72ad07b5-72ee-4ad0-9f54-69a6c95db6a9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_d935069a-1cab-4d34-9054-1a5e79db784f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ResearchAndDevelopmentArrangementReimbursementFromGrantFunds_bc0d7230-0900-4d6b-ba01-bdf3e6945613_terseLabel_en-US" xlink:label="lab_angn_ResearchAndDevelopmentArrangementReimbursementFromGrantFunds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reimbursement from grant funds</link:label>
    <link:label id="lab_angn_ResearchAndDevelopmentArrangementReimbursementFromGrantFunds_label_en-US" xlink:label="lab_angn_ResearchAndDevelopmentArrangementReimbursementFromGrantFunds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Reimbursement from Grant Funds</link:label>
    <link:label id="lab_angn_ResearchAndDevelopmentArrangementReimbursementFromGrantFunds_documentation_en-US" xlink:label="lab_angn_ResearchAndDevelopmentArrangementReimbursementFromGrantFunds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Reimbursement from Grant Funds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ResearchAndDevelopmentArrangementReimbursementFromGrantFunds" xlink:href="angn-20241231.xsd#angn_ResearchAndDevelopmentArrangementReimbursementFromGrantFunds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ResearchAndDevelopmentArrangementReimbursementFromGrantFunds" xlink:to="lab_angn_ResearchAndDevelopmentArrangementReimbursementFromGrantFunds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_c7d9d4c0-e864-4418-9d18-15c2c2196336_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_af58c1ff-8690-48f5-8d36-895506de0553_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Price per share of shares issued (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f0fc9ee1-144a-4de2-9e95-4b579629ce75_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Assumptions Used to Estimate Fair Value of Stock Option Awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_626cd954-3a63-42a8-bc03-6481471b8665_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_6c4197bb-a433-4356-b459-9131afa48e24_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_ca4b711b-8b61-4ab4-8293-6ddbbe5034bd_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related party transaction, amounts of transaction</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0cc2decd-1522-4645-905c-e18c7a4f7c89_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less present value discount</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_403f46b3-0bcf-4464-b18f-a6ee78512e3d_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_384e3683-e4a4-4f7b-9bd6-c94ef3435b8b_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-funded warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_741e60ea-0b2e-4548-9a09-6d3555047818_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_a700d0d9-923d-4305-bf2a-12ed970ebcdf_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_199481a2-5db0-4e4b-a3a3-2f32ee7dcaa9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_04257e3f-f9b7-40bd-8258-bef061ce6ac4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock_06d7636a-f3ef-4dde-9fd4-8ec1e8c3bf46_terseLabel_en-US" xlink:label="lab_angn_ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Quantitative Information On Operating Leases</link:label>
    <link:label id="lab_angn_ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock_label_en-US" xlink:label="lab_angn_ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Quantitative Information On Operating Leases [Table Text Block]</link:label>
    <link:label id="lab_angn_ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock_documentation_en-US" xlink:label="lab_angn_ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Quantitative Information On Operating Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock" xlink:href="angn-20241231.xsd#angn_ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock" xlink:to="lab_angn_ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_02ecaf83-f07c-4c7e-9e04-659381382863_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded From Computation of Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_f545117b-4b52-47bf-bf5b-08b12440f5ab_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockAmountIssued1_eaf037d4-616d-4d2a-a0ac-5fe9a01a614c_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash issuance of common stock from conversion of preferred stock</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockAmountIssued1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Amount Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountIssued1" xlink:to="lab_us-gaap_ConversionOfStockAmountIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_5ae5d064-19c9-4507-b13f-a671b80cb764_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_230b3533-7182-4615-a557-cbd88b44dfed_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_1f5ca9bb-a6f4-47b8-8cb7-5f7fe1fd4160_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash, noncurrent</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod_69b8a8c2-071d-471d-9f0b-a3169c5f8fcc_terseLabel_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod_label_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Weighted Average Exercise Price, Exercises In Period</link:label>
    <link:label id="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod_documentation_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Weighted Average Exercise Price, Exercises In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod" xlink:href="angn-20241231.xsd#angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod" xlink:to="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_9c404b43-0025-479a-9fd0-f447685d43f3_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently Adopted Accounting Standards During the Period and Recently Issued Accounting Standards Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherGeneralAndAdministrativeExpense_f0994425-2207-4c12-a027-d52d8851d7e0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Professional fees and other general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_OtherGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_EmployeeRelatedReasearchAndDevelopmentMember_98c2c13d-5dac-4e0d-81b3-5702b3ff36bb_terseLabel_en-US" xlink:label="lab_angn_EmployeeRelatedReasearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee related research and development expenses</link:label>
    <link:label id="lab_angn_EmployeeRelatedReasearchAndDevelopmentMember_label_en-US" xlink:label="lab_angn_EmployeeRelatedReasearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Related Reasearch and Development [Member]</link:label>
    <link:label id="lab_angn_EmployeeRelatedReasearchAndDevelopmentMember_documentation_en-US" xlink:label="lab_angn_EmployeeRelatedReasearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Related Reasearch and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_EmployeeRelatedReasearchAndDevelopmentMember" xlink:href="angn-20241231.xsd#angn_EmployeeRelatedReasearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_EmployeeRelatedReasearchAndDevelopmentMember" xlink:to="lab_angn_EmployeeRelatedReasearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_c027e32c-f4c4-48f8-8f05-30c5f7a6ca86_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_993dd58e-6876-49bb-84d2-d02019ad1842_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per common share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_2f6417c3-244d-44ba-a0aa-55e914012bc0_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_992c7df0-a12b-4f96-a663-b822ece9e319_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_24b4a861-a287-40a2-a4fb-f72f44adbe97_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of right-of-use assets, operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_a04fb284-5ce8-4fa1-90e4-6d389b6b0c36_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_InterestExpenseNoncash_79eab3ec-31a4-41c0-a3a7-af5c7aa6ea2e_terseLabel_en-US" xlink:label="lab_angn_InterestExpenseNoncash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_angn_InterestExpenseNoncash_label_en-US" xlink:label="lab_angn_InterestExpenseNoncash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Noncash</link:label>
    <link:label id="lab_angn_InterestExpenseNoncash_documentation_en-US" xlink:label="lab_angn_InterestExpenseNoncash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Expense, Noncash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_InterestExpenseNoncash" xlink:href="angn-20241231.xsd#angn_InterestExpenseNoncash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_InterestExpenseNoncash" xlink:to="lab_angn_InterestExpenseNoncash" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_faf8e14c-3780-489d-b36e-2f513837e7e9_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_83655fa6-f68c-4e72-b121-cd64f55d671f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred research obligation</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_a638cd43-0af6-4940-9452-0b4cb011903e_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Current</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_327f6740-50af-4868-b45f-a0ec84499748_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_b9131339-5fc3-449b-9f60-478c3f7339da_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Outstanding Warrants</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_WarrantsAndRightsOutstandingTextBlock_6d2e1355-0e90-413f-ae8d-f2f00db23fb3_terseLabel_en-US" xlink:label="lab_angn_WarrantsAndRightsOutstandingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_angn_WarrantsAndRightsOutstandingTextBlock_label_en-US" xlink:label="lab_angn_WarrantsAndRightsOutstandingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants And Rights Outstanding [Text Block]</link:label>
    <link:label id="lab_angn_WarrantsAndRightsOutstandingTextBlock_documentation_en-US" xlink:label="lab_angn_WarrantsAndRightsOutstandingTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants And Rights Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsAndRightsOutstandingTextBlock" xlink:href="angn-20241231.xsd#angn_WarrantsAndRightsOutstandingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_WarrantsAndRightsOutstandingTextBlock" xlink:to="lab_angn_WarrantsAndRightsOutstandingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_789d5961-65ec-4eb4-b513-20db3a47d489_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_d7caba68-b881-413c-bddb-099ef2916a98_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrant liability</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_20c65b11-f9ae-4ec6-a3f5-36fc102af7c8_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on fair value of warrants</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_bd423fa2-d792-4c5c-8317-af22f2598285_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange transaction gain</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_0c2e3f8e-ccde-49db-affb-c4be341b5c6c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_4fdf2577-603b-4d34-b6ea-f8b3e65e6015_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_75136843-9010-4716-a616-d7082f410eb3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Merger transaction costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Merger Related Costs, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:to="lab_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_fc0e4959-ca28-4bac-9077-c86946a0a553_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_27536722-ebe0-4a94-8d0e-ef1a07f22e80_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_4adb3e94-88a6-418f-be63-093a4139da9a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_f7b7b97b-9398-4b0e-be34-6d660ba0bb05_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on sale of equipment</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_91677b1a-4648-427c-a7dd-d6a62e61f080_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_46bca7d1-34d6-4954-9e0a-0018e7a4eca6_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total tax provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_1adcb59d-54ab-4435-bf14-ede11646af79_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income tax expenses</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_e045e661-f528-4777-8ab1-5e6155bb24d7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible notes accrue interest, percent</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_db68639e-24f4-46f6-b25c-876b1672b48b_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of noncash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_CostsExpensedUponTheIssuanceOfWarrants_30fe8e62-9350-4c95-b099-88dd2fbb8574_terseLabel_en-US" xlink:label="lab_angn_CostsExpensedUponTheIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs expensed upon the issuance of warrants</link:label>
    <link:label id="lab_angn_CostsExpensedUponTheIssuanceOfWarrants_label_en-US" xlink:label="lab_angn_CostsExpensedUponTheIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs Expensed Upon The Issuance Of Warrants</link:label>
    <link:label id="lab_angn_CostsExpensedUponTheIssuanceOfWarrants_documentation_en-US" xlink:label="lab_angn_CostsExpensedUponTheIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Costs Expensed Upon The Issuance Of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_CostsExpensedUponTheIssuanceOfWarrants" xlink:href="angn-20241231.xsd#angn_CostsExpensedUponTheIssuanceOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_CostsExpensedUponTheIssuanceOfWarrants" xlink:to="lab_angn_CostsExpensedUponTheIssuanceOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ClassOfWarrantOrRightExercisedInPeriod_b572989e-89eb-4f57-91b6-dc85266fb87c_negatedTerseLabel_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightExercisedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_angn_ClassOfWarrantOrRightExercisedInPeriod_label_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Exercised In Period</link:label>
    <link:label id="lab_angn_ClassOfWarrantOrRightExercisedInPeriod_documentation_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Exercised In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ClassOfWarrantOrRightExercisedInPeriod" xlink:href="angn-20241231.xsd#angn_ClassOfWarrantOrRightExercisedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ClassOfWarrantOrRightExercisedInPeriod" xlink:to="lab_angn_ClassOfWarrantOrRightExercisedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0d1191e7-8e7e-420c-8f87-cb13e14f6d8b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation related to unvested stock option awards, period for recognition (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_d04943a1-3b81-4976-9f58-4d5e6fa91820_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ScheduleOfReverseRecapitalizationTableTextBlock_8f8a3100-4c58-4bcd-b1f4-13ba2e3082cd_terseLabel_en-US" xlink:label="lab_angn_ScheduleOfReverseRecapitalizationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reverse Recapitalization</link:label>
    <link:label id="lab_angn_ScheduleOfReverseRecapitalizationTableTextBlock_label_en-US" xlink:label="lab_angn_ScheduleOfReverseRecapitalizationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Reverse Recapitalization [Table Text Block]</link:label>
    <link:label id="lab_angn_ScheduleOfReverseRecapitalizationTableTextBlock_documentation_en-US" xlink:label="lab_angn_ScheduleOfReverseRecapitalizationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Reverse Recapitalization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ScheduleOfReverseRecapitalizationTableTextBlock" xlink:href="angn-20241231.xsd#angn_ScheduleOfReverseRecapitalizationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ScheduleOfReverseRecapitalizationTableTextBlock" xlink:to="lab_angn_ScheduleOfReverseRecapitalizationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_6f0ad860-0399-4d9b-8ebd-e51c1f9e4d95_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_25ccc389-a713-4e5c-8ed1-27c79b235c5e_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_79312bb3-e9cd-4cbd-bdab-fa88e45e1d22_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_01717477-daf7-461c-be05-965fe397ca9f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_5fbe5902-f2de-4615-bb05-12b459837266_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_ed536064-274a-40ed-8ac7-66d61e541bfe_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_b31a0144-ba1f-41fb-831d-1a65bf0caf3e_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_2f12ca38-c008-4017-9987-b091d80f6da3_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities, convertible preferred stock, and stockholders&#8217; (deficit) equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_cc2083f1-8853-4e7c-8e54-912724959d1d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_e2fdeed7-4755-407f-bef1-dcbd95fa0d0b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_28da0f83-454e-4a2a-a4e4-3de6531b0a84_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f473a0f7-b415-4e0c-8425-dd5f7038406e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_c93e0ce9-60be-4625-8314-f217234563ee_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_a395e5e1-ce6e-4f2e-88ad-905817a71cd3_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_SeniorSecuredConvertiblePromissoryNoteMember_4200fcae-8d19-4151-96cb-077d36db2a74_terseLabel_en-US" xlink:label="lab_angn_SeniorSecuredConvertiblePromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Secured Convertible Promissory Note</link:label>
    <link:label id="lab_angn_SeniorSecuredConvertiblePromissoryNoteMember_label_en-US" xlink:label="lab_angn_SeniorSecuredConvertiblePromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Secured Convertible Promissory Note [Member]</link:label>
    <link:label id="lab_angn_SeniorSecuredConvertiblePromissoryNoteMember_documentation_en-US" xlink:label="lab_angn_SeniorSecuredConvertiblePromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Secured Convertible Promissory Note</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_SeniorSecuredConvertiblePromissoryNoteMember" xlink:href="angn-20241231.xsd#angn_SeniorSecuredConvertiblePromissoryNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_SeniorSecuredConvertiblePromissoryNoteMember" xlink:to="lab_angn_SeniorSecuredConvertiblePromissoryNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_600bcf9d-1b3b-4cdb-a266-f3c4d17e8461_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_DebtInstrumentIssuanceDiscountPercent_1301c803-770e-4a62-ba3b-c745b4e8656d_terseLabel_en-US" xlink:label="lab_angn_DebtInstrumentIssuanceDiscountPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, issuance discount percent</link:label>
    <link:label id="lab_angn_DebtInstrumentIssuanceDiscountPercent_label_en-US" xlink:label="lab_angn_DebtInstrumentIssuanceDiscountPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Issuance Discount Percent</link:label>
    <link:label id="lab_angn_DebtInstrumentIssuanceDiscountPercent_documentation_en-US" xlink:label="lab_angn_DebtInstrumentIssuanceDiscountPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Issuance Discount Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_DebtInstrumentIssuanceDiscountPercent" xlink:href="angn-20241231.xsd#angn_DebtInstrumentIssuanceDiscountPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_DebtInstrumentIssuanceDiscountPercent" xlink:to="lab_angn_DebtInstrumentIssuanceDiscountPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_5fde79c2-1c89-4c09-b2f5-530708bf7780_terseLabel_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_label_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label id="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_documentation_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xlink:href="angn-20241231.xsd#angn_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xlink:to="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_b2a25f8a-d8a0-4cbc-b9bc-7204a08bf990_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of promissory notes payable</link:label>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_label_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable" xlink:to="lab_us-gaap_ProceedsFromNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanDisclosureLineItems_0364b89a-1402-43b8-846e-35e38fabd624_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_62fb3d27-e714-4568-8d97-5db2167a3bab_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_14d003bb-c3a9-45a2-ac8b-7aadb6351e61_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_f7b90333-47d4-43bd-a999-5914472c47c7_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_54a5d31a-5cf7-44b4-8665-30cab0120ba3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Return of common stock to pay withholding taxes on restricted stock</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_20bf0ef8-592f-43f0-aadd-34192cc7fd7b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting of restricted common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_dfcea4b2-a490-4eaf-a8f0-fbef6d7c30ab_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_bc21a10f-bc9f-4c62-ac5c-dc4b266b847f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (unvested) (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_abaf2e72-4094-4e07-917a-7d6dd77c6e42_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_abc2cdb1-83e6-4f7e-937c-9a016fe65386_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_3977f40b-e9d1-45d8-811d-f3b088a01210_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_cb5ddbd8-dd5b-48f9-834b-93f6350d75d0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_1ee5dea5-0154-4d6d-9a12-7650e5c654da_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_StockIssuedDuringPeriodValueReverseRecapitalization_88a29eb5-d398-41dc-8d20-665aee60a4fc_terseLabel_en-US" xlink:label="lab_angn_StockIssuedDuringPeriodValueReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, net of issuance costs</link:label>
    <link:label id="lab_angn_StockIssuedDuringPeriodValueReverseRecapitalization_label_en-US" xlink:label="lab_angn_StockIssuedDuringPeriodValueReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Reverse Recapitalization</link:label>
    <link:label id="lab_angn_StockIssuedDuringPeriodValueReverseRecapitalization_documentation_en-US" xlink:label="lab_angn_StockIssuedDuringPeriodValueReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Reverse Recapitalization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_StockIssuedDuringPeriodValueReverseRecapitalization" xlink:href="angn-20241231.xsd#angn_StockIssuedDuringPeriodValueReverseRecapitalization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_StockIssuedDuringPeriodValueReverseRecapitalization" xlink:to="lab_angn_StockIssuedDuringPeriodValueReverseRecapitalization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_b62270aa-2029-4ecc-b07d-2464af24c97a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_eb0fafa0-b96c-4a75-b838-313a0f97453c_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_BridgeLoanBetweenAngionAndFormerElicioAdditionalClosingMember_f15641ed-0514-4dc2-826a-dd5244e83734_terseLabel_en-US" xlink:label="lab_angn_BridgeLoanBetweenAngionAndFormerElicioAdditionalClosingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bridge Loan Between Angion And Former Elicio, Additional Closing</link:label>
    <link:label id="lab_angn_BridgeLoanBetweenAngionAndFormerElicioAdditionalClosingMember_label_en-US" xlink:label="lab_angn_BridgeLoanBetweenAngionAndFormerElicioAdditionalClosingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bridge Loan Between Angion And Former Elicio, Additional Closing [Member]</link:label>
    <link:label id="lab_angn_BridgeLoanBetweenAngionAndFormerElicioAdditionalClosingMember_documentation_en-US" xlink:label="lab_angn_BridgeLoanBetweenAngionAndFormerElicioAdditionalClosingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bridge Loan Between Angion And Former Elicio, Additional Closing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_BridgeLoanBetweenAngionAndFormerElicioAdditionalClosingMember" xlink:href="angn-20241231.xsd#angn_BridgeLoanBetweenAngionAndFormerElicioAdditionalClosingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_BridgeLoanBetweenAngionAndFormerElicioAdditionalClosingMember" xlink:to="lab_angn_BridgeLoanBetweenAngionAndFormerElicioAdditionalClosingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountInitialClosingMember_72e83e45-38e0-4e20-b0fa-27ed64cd4069_terseLabel_en-US" xlink:label="lab_angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountInitialClosingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bridge Loan Between Angion And Former Elicio, Discount Amount, Initial Closing</link:label>
    <link:label id="lab_angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountInitialClosingMember_label_en-US" xlink:label="lab_angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountInitialClosingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bridge Loan Between Angion And Former Elicio, Discount Amount, Initial Closing [Member]</link:label>
    <link:label id="lab_angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountInitialClosingMember_documentation_en-US" xlink:label="lab_angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountInitialClosingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bridge Loan Between Angion And Former Elicio, Discount Amount, Initial Closing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountInitialClosingMember" xlink:href="angn-20241231.xsd#angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountInitialClosingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountInitialClosingMember" xlink:to="lab_angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountInitialClosingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ProfessionalServicesExpenseNoncash_a62fb7b6-014b-4fb4-a901-d939431c14e9_terseLabel_en-US" xlink:label="lab_angn_ProfessionalServicesExpenseNoncash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash professional services expense</link:label>
    <link:label id="lab_angn_ProfessionalServicesExpenseNoncash_label_en-US" xlink:label="lab_angn_ProfessionalServicesExpenseNoncash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Professional Services Expense, Noncash</link:label>
    <link:label id="lab_angn_ProfessionalServicesExpenseNoncash_documentation_en-US" xlink:label="lab_angn_ProfessionalServicesExpenseNoncash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Professional Services Expense, Noncash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ProfessionalServicesExpenseNoncash" xlink:href="angn-20241231.xsd#angn_ProfessionalServicesExpenseNoncash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ProfessionalServicesExpenseNoncash" xlink:to="lab_angn_ProfessionalServicesExpenseNoncash" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_WarrantLiability_068e992a-c13f-419b-bc0b-9afcfcd9b17b_terseLabel_en-US" xlink:label="lab_angn_WarrantLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant liabilities</link:label>
    <link:label id="lab_angn_WarrantLiability_label_en-US" xlink:label="lab_angn_WarrantLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Liability</link:label>
    <link:label id="lab_angn_WarrantLiability_documentation_en-US" xlink:label="lab_angn_WarrantLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantLiability" xlink:href="angn-20241231.xsd#angn_WarrantLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_WarrantLiability" xlink:to="lab_angn_WarrantLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_680b92bb-acb7-4f8b-a799-cfd0aa0e8d77_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_8be590ee-9acf-45aa-b348-3f265b667a13_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5482d626-53be-411e-ad99-f534cb91a4a9_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities, convertible preferred stock, and stockholders&#8217; (deficit) equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_JulyPublicOfferingMember_f4ae95b4-0215-4b10-8a32-bf9535ae318e_terseLabel_en-US" xlink:label="lab_angn_JulyPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">July Public Offering</link:label>
    <link:label id="lab_angn_JulyPublicOfferingMember_label_en-US" xlink:label="lab_angn_JulyPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">July Public Offering [Member]</link:label>
    <link:label id="lab_angn_JulyPublicOfferingMember_documentation_en-US" xlink:label="lab_angn_JulyPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_JulyPublicOfferingMember" xlink:href="angn-20241231.xsd#angn_JulyPublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_JulyPublicOfferingMember" xlink:to="lab_angn_JulyPublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1bce1ae7-69c4-4909-a719-377e6ef693b5_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, beginning of the period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_49348c79-0f8c-44eb-9f38-eaca612a6ef1_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, end of the period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_345f6d7a-4901-4407-ae47-178c049d593e_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_a6ad5b81-7bcc-4b6c-bd1f-11d8b8267f68_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_4357318d-9462-4388-840f-d4184a8ad376_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, measurement input</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_WarrantLiabilityMember_2ed7bfe9-f176-4264-9304-20c9ffc06d8d_terseLabel_en-US" xlink:label="lab_angn_WarrantLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant Liability</link:label>
    <link:label id="lab_angn_WarrantLiabilityMember_label_en-US" xlink:label="lab_angn_WarrantLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Liability [Member]</link:label>
    <link:label id="lab_angn_WarrantLiabilityMember_documentation_en-US" xlink:label="lab_angn_WarrantLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantLiabilityMember" xlink:href="angn-20241231.xsd#angn_WarrantLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_WarrantLiabilityMember" xlink:to="lab_angn_WarrantLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d1120a6a-4907-4d00-9c29-89e92b8d809f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_80639e3e-47d3-49eb-b858-c5f8e85e30a4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5396cf6f-8936-4883-bef1-8992f79aeb5f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ca9cd370-6763-4c1e-ac17-67120406f0a7_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_08934f0b-a718-47ac-99ee-0cd5d9cd5b0c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0275be13-fe98-47c6-9fe5-56f48cfb1858_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_72eba8f7-0eb3-496e-9acf-9e5cca450b08_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_688233e6-6028-40ed-a1cb-20b39ba7f782_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodAxis_bd473007-5f47-4649-9cf1-d2b15cc7244c_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodAxis_label_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_fe6606b8-1ac8-4e0e-8cd7-35c1130e5723_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statutory federal income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_514739a9-587d-4cfa-9b5a-cc02d3ab41ce_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_50843639-fbe7-4ba6-b3db-f201daa81951_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_A2024RegistrationStatementMember_97d107c3-40de-48ea-b14a-2da2d9085da2_terseLabel_en-US" xlink:label="lab_angn_A2024RegistrationStatementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 Registration Statement</link:label>
    <link:label id="lab_angn_A2024RegistrationStatementMember_label_en-US" xlink:label="lab_angn_A2024RegistrationStatementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2024 Registration Statement [Member]</link:label>
    <link:label id="lab_angn_A2024RegistrationStatementMember_documentation_en-US" xlink:label="lab_angn_A2024RegistrationStatementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2024 Registration Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_A2024RegistrationStatementMember" xlink:href="angn-20241231.xsd#angn_A2024RegistrationStatementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_A2024RegistrationStatementMember" xlink:to="lab_angn_A2024RegistrationStatementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_85a6c96b-f1ea-4871-86de-3e92e45861b4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock related to stock purchase agreement</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_9fb1c19a-6bab-4e18-8cb7-08a357140bc5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_5b2f6b1d-090e-4649-a184-ed15418b80f3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7883c23d-8215-437f-96b5-68cc17ca9a4b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_EmployeeBenefitPlanMember_2de85e32-b2ed-4be2-bd5f-24c5856f7fbb_terseLabel_en-US" xlink:label="lab_angn_EmployeeBenefitPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Benefit Plan</link:label>
    <link:label id="lab_angn_EmployeeBenefitPlanMember_label_en-US" xlink:label="lab_angn_EmployeeBenefitPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Benefit Plan [Member]</link:label>
    <link:label id="lab_angn_EmployeeBenefitPlanMember_documentation_en-US" xlink:label="lab_angn_EmployeeBenefitPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Benefit Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_EmployeeBenefitPlanMember" xlink:href="angn-20241231.xsd#angn_EmployeeBenefitPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_EmployeeBenefitPlanMember" xlink:to="lab_angn_EmployeeBenefitPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_EffectiveIncomeTaxRateReconciliationTaxCreditFederalResearchAndDevelopmentPercent_8bb9ada3-9d97-4895-87b2-92b0962ca763_terseLabel_en-US" xlink:label="lab_angn_EffectiveIncomeTaxRateReconciliationTaxCreditFederalResearchAndDevelopmentPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal research and development credits</link:label>
    <link:label id="lab_angn_EffectiveIncomeTaxRateReconciliationTaxCreditFederalResearchAndDevelopmentPercent_label_en-US" xlink:label="lab_angn_EffectiveIncomeTaxRateReconciliationTaxCreditFederalResearchAndDevelopmentPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Federal Research And Development, Percent</link:label>
    <link:label id="lab_angn_EffectiveIncomeTaxRateReconciliationTaxCreditFederalResearchAndDevelopmentPercent_documentation_en-US" xlink:label="lab_angn_EffectiveIncomeTaxRateReconciliationTaxCreditFederalResearchAndDevelopmentPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Federal Research And Development, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_EffectiveIncomeTaxRateReconciliationTaxCreditFederalResearchAndDevelopmentPercent" xlink:href="angn-20241231.xsd#angn_EffectiveIncomeTaxRateReconciliationTaxCreditFederalResearchAndDevelopmentPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_EffectiveIncomeTaxRateReconciliationTaxCreditFederalResearchAndDevelopmentPercent" xlink:to="lab_angn_EffectiveIncomeTaxRateReconciliationTaxCreditFederalResearchAndDevelopmentPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_61eaec25-f152-4c03-8e91-498e437bc906_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic Tax Jurisdiction</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ReportableSegmentMember_9073b3cf-f4d4-4db0-84a6-f5b7303e1ccb_terseLabel_en-US" xlink:label="lab_angn_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:label id="lab_angn_ReportableSegmentMember_label_en-US" xlink:label="lab_angn_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reportable Segment [Member]</link:label>
    <link:label id="lab_angn_ReportableSegmentMember_documentation_en-US" xlink:label="lab_angn_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ReportableSegmentMember" xlink:href="angn-20241231.xsd#angn_ReportableSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ReportableSegmentMember" xlink:to="lab_angn_ReportableSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_e98de17b-a81b-4a7c-b253-47b91eeb7055_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_8a5b4355-58f4-43bc-8ad0-f8b560ecd8f8_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_OtherCurrentAssetsAcquiredThroughReverseRecapitalization_ed2b66a2-daa4-4769-a0b4-3f6f5703153c_terseLabel_en-US" xlink:label="lab_angn_OtherCurrentAssetsAcquiredThroughReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_angn_OtherCurrentAssetsAcquiredThroughReverseRecapitalization_label_en-US" xlink:label="lab_angn_OtherCurrentAssetsAcquiredThroughReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Assets Acquired Through Reverse Recapitalization</link:label>
    <link:label id="lab_angn_OtherCurrentAssetsAcquiredThroughReverseRecapitalization_documentation_en-US" xlink:label="lab_angn_OtherCurrentAssetsAcquiredThroughReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Current Assets Acquired Through Reverse Recapitalization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_OtherCurrentAssetsAcquiredThroughReverseRecapitalization" xlink:href="angn-20241231.xsd#angn_OtherCurrentAssetsAcquiredThroughReverseRecapitalization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_OtherCurrentAssetsAcquiredThroughReverseRecapitalization" xlink:to="lab_angn_OtherCurrentAssetsAcquiredThroughReverseRecapitalization" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_AngionStockholdersMember_1667969d-e7c2-49a9-aa9e-3b58228f6039_terseLabel_en-US" xlink:label="lab_angn_AngionStockholdersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Angion Stockholders</link:label>
    <link:label id="lab_angn_AngionStockholdersMember_label_en-US" xlink:label="lab_angn_AngionStockholdersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Angion Stockholders [Member]</link:label>
    <link:label id="lab_angn_AngionStockholdersMember_documentation_en-US" xlink:label="lab_angn_AngionStockholdersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Angion Stockholders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AngionStockholdersMember" xlink:href="angn-20241231.xsd#angn_AngionStockholdersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_AngionStockholdersMember" xlink:to="lab_angn_AngionStockholdersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_TranslationalMedicineAndCMCMember_6666ee80-1cf4-41b5-96f2-88acd675c1b9_terseLabel_en-US" xlink:label="lab_angn_TranslationalMedicineAndCMCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Chemistry, manufacturing and controls expenses</link:label>
    <link:label id="lab_angn_TranslationalMedicineAndCMCMember_label_en-US" xlink:label="lab_angn_TranslationalMedicineAndCMCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Translational Medicine and CMC [Member]</link:label>
    <link:label id="lab_angn_TranslationalMedicineAndCMCMember_documentation_en-US" xlink:label="lab_angn_TranslationalMedicineAndCMCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Translational Medicine and CMC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_TranslationalMedicineAndCMCMember" xlink:href="angn-20241231.xsd#angn_TranslationalMedicineAndCMCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_TranslationalMedicineAndCMCMember" xlink:to="lab_angn_TranslationalMedicineAndCMCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_fb94eb0d-a04f-4a86-a619-38ea0a56aa10_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' (deficit) equity:</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c50b9ccd-5283-4dac-b062-54a4fb78a3f5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_5681ed3c-3505-424a-8262-e3dec7174b6d_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_506ea6fe-6dcb-4692-a05a-d646e436050c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other long-term prepaid assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_88c9a5e5-b202-45a4-8577-1ed9509f432e_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, at cost, 14,455 shares outstanding</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonValue" xlink:to="lab_us-gaap_TreasuryStockCommonValue" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ClassOfWarrantOrRightWeightedAverageLifeRollForward_96543156-aa87-4c1b-b356-2bcafc2d3353_terseLabel_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightWeightedAverageLifeRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Life (years)</link:label>
    <link:label id="lab_angn_ClassOfWarrantOrRightWeightedAverageLifeRollForward_label_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightWeightedAverageLifeRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Weighted Average Life [Roll Forward]</link:label>
    <link:label id="lab_angn_ClassOfWarrantOrRightWeightedAverageLifeRollForward_documentation_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightWeightedAverageLifeRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Weighted Average Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ClassOfWarrantOrRightWeightedAverageLifeRollForward" xlink:href="angn-20241231.xsd#angn_ClassOfWarrantOrRightWeightedAverageLifeRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ClassOfWarrantOrRightWeightedAverageLifeRollForward" xlink:to="lab_angn_ClassOfWarrantOrRightWeightedAverageLifeRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfEquity_b4dfbfb7-83df-4ffa-b324-a337f8f33433_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfEquity" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of employee withholding taxes on restricted stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfEquity_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfEquity" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_MarchSubscriptionAgreementMember_1d87a4cc-12a6-41ed-9dd5-7d4692b53a54_terseLabel_en-US" xlink:label="lab_angn_MarchSubscriptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">March Subscription Agreement</link:label>
    <link:label id="lab_angn_MarchSubscriptionAgreementMember_label_en-US" xlink:label="lab_angn_MarchSubscriptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">March Subscription Agreement [Member]</link:label>
    <link:label id="lab_angn_MarchSubscriptionAgreementMember_documentation_en-US" xlink:label="lab_angn_MarchSubscriptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">March Subscription Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_MarchSubscriptionAgreementMember" xlink:href="angn-20241231.xsd#angn_MarchSubscriptionAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_MarchSubscriptionAgreementMember" xlink:to="lab_angn_MarchSubscriptionAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_d240b7a0-614d-4f5f-b077-2cf142c03957_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_69a7b3ad-97bf-4df3-a486-b1d511892890_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash issuance of stock</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c3ff8912-55c5-46ef-b72a-350657ae4d04_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_3094bf1a-a76d-48b0-ba9a-f9f8430b736c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_44e3b863-eed9-477e-b067-d8ee1070bf04_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility (annual)</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2867e4e4-6538-4fb3-a59d-16d476ff212a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_e90ad288-a6ff-4fbb-a896-3645be82b75c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of senior note, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Senior Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_UnvestedCommonStockMember_59757ccb-0e85-4cb0-835d-2e595db89e54_terseLabel_en-US" xlink:label="lab_angn_UnvestedCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested common stock</link:label>
    <link:label id="lab_angn_UnvestedCommonStockMember_label_en-US" xlink:label="lab_angn_UnvestedCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unvested Common Stock [Member]</link:label>
    <link:label id="lab_angn_UnvestedCommonStockMember_documentation_en-US" xlink:label="lab_angn_UnvestedCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unvested Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_UnvestedCommonStockMember" xlink:href="angn-20241231.xsd#angn_UnvestedCommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_UnvestedCommonStockMember" xlink:to="lab_angn_UnvestedCommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_3b1c90fa-4a46-4b24-b3e6-b20fcaf391bc_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_7032b329-2b9f-4316-bdb6-070b7b4ccc5a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: Deferred tax asset valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_b71f34c7-11d7-43a3-ba68-813ddad5acfb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_0285e0fe-5ffa-472b-889d-81f5d4953d03_terseLabel_en-US" xlink:label="lab_angn_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Permanent differences</link:label>
    <link:label id="lab_angn_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_label_en-US" xlink:label="lab_angn_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Permanent Differences, Percent</link:label>
    <link:label id="lab_angn_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_documentation_en-US" xlink:label="lab_angn_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Permanent Differences, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:href="angn-20241231.xsd#angn_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:to="lab_angn_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_eb226b6c-e6b9-42c3-97ad-c8633db0fc1d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_SaleOfStockAggregateInitialOfferingPrice_5f203106-f6b9-4fa0-acf9-c021061780a6_terseLabel_en-US" xlink:label="lab_angn_SaleOfStockAggregateInitialOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, aggregate offering price (up to)</link:label>
    <link:label id="lab_angn_SaleOfStockAggregateInitialOfferingPrice_label_en-US" xlink:label="lab_angn_SaleOfStockAggregateInitialOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Aggregate Initial Offering Price</link:label>
    <link:label id="lab_angn_SaleOfStockAggregateInitialOfferingPrice_documentation_en-US" xlink:label="lab_angn_SaleOfStockAggregateInitialOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Aggregate Initial Offering Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_SaleOfStockAggregateInitialOfferingPrice" xlink:href="angn-20241231.xsd#angn_SaleOfStockAggregateInitialOfferingPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_SaleOfStockAggregateInitialOfferingPrice" xlink:to="lab_angn_SaleOfStockAggregateInitialOfferingPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_77eab970-74df-4cda-889a-e7929f7b8e88_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Option Activity, Additional Disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness_c7ef4878-1577-4b20-9720-0fc81bb426bd_terseLabel_en-US" xlink:label="lab_us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash acquired in connection with the reverse merger</link:label>
    <link:label id="lab_us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness_label_en-US" xlink:label="lab_us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Acquired in Excess of Payments to Acquire Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness" xlink:to="lab_us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d0482071-4f9c-4089-ad74-984309a2b886_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_24545e67-6745-4797-8769-6da8345fa271_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_PrepaidResearchAndDevelopmentExpenses_b0294229-08ff-4bab-8d6d-d5b02238125a_terseLabel_en-US" xlink:label="lab_angn_PrepaidResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid research and development contract services</link:label>
    <link:label id="lab_angn_PrepaidResearchAndDevelopmentExpenses_label_en-US" xlink:label="lab_angn_PrepaidResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Research And Development Expenses</link:label>
    <link:label id="lab_angn_PrepaidResearchAndDevelopmentExpenses_documentation_en-US" xlink:label="lab_angn_PrepaidResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaid Research And Development Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_PrepaidResearchAndDevelopmentExpenses" xlink:href="angn-20241231.xsd#angn_PrepaidResearchAndDevelopmentExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_PrepaidResearchAndDevelopmentExpenses" xlink:to="lab_angn_PrepaidResearchAndDevelopmentExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_aa4a0e87-2ced-4197-8f37-a76385f83697_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_e4157a19-a62d-461b-9402-9d5695dd5e4b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_065922ea-c4fc-49ad-9c31-c6cd9b3f6f0e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_173a212f-a74c-4799-ae18-49164396f39b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_db094489-4412-429e-b099-63d4a9c5ca01_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_33fca25c-1c3d-445e-9d65-d2b9f723f259_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFAugust2024Member_6d4b0dc4-bc1b-49b8-8a28-7d2e01473577_terseLabel_en-US" xlink:label="lab_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFAugust2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Grant Agreement With The Gastro-Intestinal Research Foundation (&#8220;GIRF&#8221;) August 2024</link:label>
    <link:label id="lab_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFAugust2024Member_label_en-US" xlink:label="lab_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFAugust2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Grant Agreement With The Gastro-Intestinal Research Foundation (&#8220;GIRF&#8221;) August 2024 [Member]</link:label>
    <link:label id="lab_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFAugust2024Member_documentation_en-US" xlink:label="lab_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFAugust2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research Grant Agreement With The Gastro-Intestinal Research Foundation (&#8220;GIRF&#8221;) August 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFAugust2024Member" xlink:href="angn-20241231.xsd#angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFAugust2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFAugust2024Member" xlink:to="lab_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFAugust2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_FairValueOfCommonStockWarrants_5d3594ea-54e5-4844-af44-c1b722d77d3e_negatedTerseLabel_en-US" xlink:label="lab_angn_FairValueOfCommonStockWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Fair value of common warrants at issuance date</link:label>
    <link:label id="lab_angn_FairValueOfCommonStockWarrants_c0256b45-229d-4303-b9f7-adf5dafdbc1a_terseLabel_en-US" xlink:label="lab_angn_FairValueOfCommonStockWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of common warrants at issuance date</link:label>
    <link:label id="lab_angn_FairValueOfCommonStockWarrants_label_en-US" xlink:label="lab_angn_FairValueOfCommonStockWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Common Stock Warrants</link:label>
    <link:label id="lab_angn_FairValueOfCommonStockWarrants_documentation_en-US" xlink:label="lab_angn_FairValueOfCommonStockWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Of Common Stock Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FairValueOfCommonStockWarrants" xlink:href="angn-20241231.xsd#angn_FairValueOfCommonStockWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_FairValueOfCommonStockWarrants" xlink:to="lab_angn_FairValueOfCommonStockWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_dfb1f01a-ac16-48d6-b6e6-14e54053dfe2_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of long lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_c37189c6-0d03-4e62-ae48-3805fc247387_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_bef92e8c-adec-4bcf-91dd-5f85a3a5f45b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_ddfce8bc-ac80-474c-8ee4-266a47f1c238_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock split, conversion ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_ff2fc43b-d5d9-4e69-984c-def4c7a99435_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_87cf7ccc-a79f-4771-8d95-d4f6131bbc80_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_496b13bb-a7b3-472b-ab07-bfb3dff331c9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_AngionCommonStockMember_fc63355a-181a-4dca-b12d-b678b6a023eb_terseLabel_en-US" xlink:label="lab_angn_AngionCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Angion Common Stock</link:label>
    <link:label id="lab_angn_AngionCommonStockMember_label_en-US" xlink:label="lab_angn_AngionCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Angion Common Stock [Member]</link:label>
    <link:label id="lab_angn_AngionCommonStockMember_documentation_en-US" xlink:label="lab_angn_AngionCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Angion Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AngionCommonStockMember" xlink:href="angn-20241231.xsd#angn_AngionCommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_AngionCommonStockMember" xlink:to="lab_angn_AngionCommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_6d9c969e-998f-471b-b915-4a452f54cb0b_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_801a5363-1d5b-4885-a10a-c6adffc102e2_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_95cd8d6e-0e1a-457b-ab54-5a8be7ea8c92_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issuance costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_526f0696-f9dc-4d05-a8a5-4921391cc945_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Return of common stock to pay withholding taxes on restricted stock (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_e31bf3d4-676a-4ad6-8bc8-6b0d6dbb1db3_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_c006c6a7-f78b-476a-8750-20c63d052fcf_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other segment items</link:label>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_label_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Other Segment Item, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:to="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_77c7bb5e-2566-4518-b76e-e3e8dc385074_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_ab06952f-2b11-4474-ab21-c5e9f9d8ef83_terseLabel_en-US" xlink:label="lab_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock from the exercise of Pre-funded Warrants</link:label>
    <link:label id="lab_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_label_en-US" xlink:label="lab_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="lab_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_FormerElicioMember_b6b78e1b-4695-4966-8a91-4ad41d8ac28a_terseLabel_en-US" xlink:label="lab_angn_FormerElicioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Former Elicio</link:label>
    <link:label id="lab_angn_FormerElicioMember_label_en-US" xlink:label="lab_angn_FormerElicioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Former Elicio [Member]</link:label>
    <link:label id="lab_angn_FormerElicioMember_documentation_en-US" xlink:label="lab_angn_FormerElicioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Former Elicio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FormerElicioMember" xlink:href="angn-20241231.xsd#angn_FormerElicioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_FormerElicioMember" xlink:to="lab_angn_FormerElicioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_38e998fb-f598-4588-83a5-3edba68f1d85_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_96ad4294-8ae1-460e-89eb-84391cc494e4_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits, income tax penalties and interest accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9b31bb51-e88a-496a-aa04-3ac0ee780dd3_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_d2f98603-982d-4a20-a355-1c62c5ab3f55_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_32ea1064-1d28-42db-ab3e-bd0d0ec28af7_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Common Stock and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RecoveryOfDirectCosts_4f64ca9f-0f5c-475a-9200-bac4a64c2e84_terseLabel_en-US" xlink:label="lab_us-gaap_RecoveryOfDirectCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract and grant reimbursements</link:label>
    <link:label id="lab_us-gaap_RecoveryOfDirectCosts_label_en-US" xlink:label="lab_us-gaap_RecoveryOfDirectCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Direct Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecoveryOfDirectCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RecoveryOfDirectCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RecoveryOfDirectCosts" xlink:to="lab_us-gaap_RecoveryOfDirectCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_0cda8764-5bec-4619-b1c7-98654e22bfb1_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2bc0ab20-b523-4e2d-a7fd-00aa02e42722_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_051f4b57-77e0-499f-95b0-8448df6fa353_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_75569fc2-e54c-459f-a653-04c7f8bd8244_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_32d4f231-928a-4195-bc60-e1a1b82bd366_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_74a52524-3def-4422-b8fd-ef45232d1e8a_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_OperatingLeaseFutureMinimumAnnualMaintenancePaymentsDueThereafter_f7070db9-268c-43d2-8f9a-41c99b53e17d_terseLabel_en-US" xlink:label="lab_angn_OperatingLeaseFutureMinimumAnnualMaintenancePaymentsDueThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future minimum payments, thereafter</link:label>
    <link:label id="lab_angn_OperatingLeaseFutureMinimumAnnualMaintenancePaymentsDueThereafter_label_en-US" xlink:label="lab_angn_OperatingLeaseFutureMinimumAnnualMaintenancePaymentsDueThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Future Minimum, Annual Maintenance Payments, Due Thereafter</link:label>
    <link:label id="lab_angn_OperatingLeaseFutureMinimumAnnualMaintenancePaymentsDueThereafter_documentation_en-US" xlink:label="lab_angn_OperatingLeaseFutureMinimumAnnualMaintenancePaymentsDueThereafter" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Future Minimum, Annual Maintenance Payments, Due Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_OperatingLeaseFutureMinimumAnnualMaintenancePaymentsDueThereafter" xlink:href="angn-20241231.xsd#angn_OperatingLeaseFutureMinimumAnnualMaintenancePaymentsDueThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_OperatingLeaseFutureMinimumAnnualMaintenancePaymentsDueThereafter" xlink:to="lab_angn_OperatingLeaseFutureMinimumAnnualMaintenancePaymentsDueThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_9f5336f1-39ae-48ec-95e5-1bf6fd0efeaa_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of cash, cash equivalents and restricted cash:</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_AtTheMarketOfferingMember_3a5c4d1b-d572-4494-9fe0-7f75dd71bdd9_terseLabel_en-US" xlink:label="lab_angn_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At-the-Market Offering</link:label>
    <link:label id="lab_angn_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_angn_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At-the-Market Offering [Member]</link:label>
    <link:label id="lab_angn_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_angn_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At-the-Market Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AtTheMarketOfferingMember" xlink:href="angn-20241231.xsd#angn_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_AtTheMarketOfferingMember" xlink:to="lab_angn_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember_3d9efbb9-38cc-4b64-9cfa-f458f920c976_terseLabel_en-US" xlink:label="lab_angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">July Pre-Funded Warrants and July Common Warrants</link:label>
    <link:label id="lab_angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember_label_en-US" xlink:label="lab_angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">July Pre-Funded Warrants and July Common Warrants [Member]</link:label>
    <link:label id="lab_angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember_documentation_en-US" xlink:label="lab_angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">July Pre-Funded Warrants and July Common Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember" xlink:href="angn-20241231.xsd#angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember" xlink:to="lab_angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9bc5d02c-02af-4f2a-87ba-d8b72ccbb063_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_32bb2093-6ca7-4316-8ff0-16b06b9843e1_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_259da81f-cd77-43b8-bb80-23322527d7ab_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_1b4f0677-3ee7-477b-925c-e5df15531942_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_ae9517c1-437f-4eba-8768-ca7d2fa96bd8_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_c9567eaf-ebb6-4234-acdc-af66b9a19068_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Comprehensive Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_8bf1684d-f243-4160-aab7-33e4a9cc8b9d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanTable_a24edb54-66ed-4545-8ac7-0c145a24074b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan [Table]</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanTable_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanTable" xlink:to="lab_us-gaap_DefinedContributionPlanTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_194b674e-1f45-48f5-8f06-32c570f818b7_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_eefbd08a-bd22-4dc0-9428-6ae6b69e714a_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_e2d84330-0dee-480e-8f19-7e56b767015a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_06481e69-d0a7-4b2b-b148-9fa9af4702bb_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_8dd8df70-f88c-4e48-96f1-c235d9514ac3_verboseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_1ea3c60c-75f9-4dfc-9c02-4411da991f71_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_1895dfbb-0891-42db-8eba-8343a7ba75c8_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_da895c7e-aaf6-4408-be00-88693a7749cc_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_ca635000-122e-445e-b089-55b2d37ae696_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_6ab0cc7a-bd68-4e12-adeb-ff27aff16d2a_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_label_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_PaymentOfWarrantIssuanceCosts_f82d0148-a6f1-4148-8270-bb59171bd18d_negatedTerseLabel_en-US" xlink:label="lab_angn_PaymentOfWarrantIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of warrant issuance costs</link:label>
    <link:label id="lab_angn_PaymentOfWarrantIssuanceCosts_label_en-US" xlink:label="lab_angn_PaymentOfWarrantIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment Of Warrant Issuance Costs</link:label>
    <link:label id="lab_angn_PaymentOfWarrantIssuanceCosts_documentation_en-US" xlink:label="lab_angn_PaymentOfWarrantIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment Of Warrant Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_PaymentOfWarrantIssuanceCosts" xlink:href="angn-20241231.xsd#angn_PaymentOfWarrantIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_PaymentOfWarrantIssuanceCosts" xlink:to="lab_angn_PaymentOfWarrantIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_f4043ba1-f6ee-4e73-aa9c-a8e722c0edc0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_f9e46df8-42b8-4f5d-9927-581c236c6403_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountAdditionalClosingMember_ba6a9127-6408-40c1-b004-71f8f2cbbd3a_terseLabel_en-US" xlink:label="lab_angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountAdditionalClosingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bridge Loan Between Angion And Former Elicio, Discount Amount, Additional Closing</link:label>
    <link:label id="lab_angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountAdditionalClosingMember_label_en-US" xlink:label="lab_angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountAdditionalClosingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bridge Loan Between Angion And Former Elicio, Discount Amount, Additional Closing [Member]</link:label>
    <link:label id="lab_angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountAdditionalClosingMember_documentation_en-US" xlink:label="lab_angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountAdditionalClosingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bridge Loan Between Angion And Former Elicio, Discount Amount, Additional Closing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountAdditionalClosingMember" xlink:href="angn-20241231.xsd#angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountAdditionalClosingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountAdditionalClosingMember" xlink:to="lab_angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountAdditionalClosingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ConversionOfConvertiblePreferredStockMember_5cb9714e-7f14-43a4-9dbf-980c1cb56e79_terseLabel_en-US" xlink:label="lab_angn_ConversionOfConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Convertible Preferred Stock</link:label>
    <link:label id="lab_angn_ConversionOfConvertiblePreferredStockMember_label_en-US" xlink:label="lab_angn_ConversionOfConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion Of Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_angn_ConversionOfConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_angn_ConversionOfConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conversion Of Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ConversionOfConvertiblePreferredStockMember" xlink:href="angn-20241231.xsd#angn_ConversionOfConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ConversionOfConvertiblePreferredStockMember" xlink:to="lab_angn_ConversionOfConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_a5beef79-0bfc-4cb0-8484-6dbe4595134e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceIssuedInPeriod_3fabd723-7c07-46ad-90c7-63de082171e7_terseLabel_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued (in dollars per share)</link:label>
    <link:label id="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceIssuedInPeriod_label_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Weighted Average Exercise Price, Issued In Period</link:label>
    <link:label id="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceIssuedInPeriod_documentation_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Weighted Average Exercise Price, Issued In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceIssuedInPeriod" xlink:href="angn-20241231.xsd#angn_ClassOfWarrantOrRightWeightedAverageExercisePriceIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceIssuedInPeriod" xlink:to="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodDomain_2e66382e-9076-41a2-81dd-b459b8b8a350_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodDomain_label_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ReverseRecapitalizationOwnershipPercentage_ff8bbace-924c-419c-8eba-5595c67f4173_terseLabel_en-US" xlink:label="lab_angn_ReverseRecapitalizationOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_angn_ReverseRecapitalizationOwnershipPercentage_label_en-US" xlink:label="lab_angn_ReverseRecapitalizationOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reverse Recapitalization Ownership Percentage</link:label>
    <link:label id="lab_angn_ReverseRecapitalizationOwnershipPercentage_documentation_en-US" xlink:label="lab_angn_ReverseRecapitalizationOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reverse Recapitalization Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ReverseRecapitalizationOwnershipPercentage" xlink:href="angn-20241231.xsd#angn_ReverseRecapitalizationOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ReverseRecapitalizationOwnershipPercentage" xlink:to="lab_angn_ReverseRecapitalizationOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_76d0fb68-84f4-4a3b-8456-30b6fde89c18_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options vested and exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_StockIssuanceAxis_234a3982-b9d6-4210-9f2c-49ac54b9a357_terseLabel_en-US" xlink:label="lab_angn_StockIssuanceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issuance [Axis]</link:label>
    <link:label id="lab_angn_StockIssuanceAxis_label_en-US" xlink:label="lab_angn_StockIssuanceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issuance [Axis]</link:label>
    <link:label id="lab_angn_StockIssuanceAxis_documentation_en-US" xlink:label="lab_angn_StockIssuanceAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_StockIssuanceAxis" xlink:href="angn-20241231.xsd#angn_StockIssuanceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_StockIssuanceAxis" xlink:to="lab_angn_StockIssuanceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_5b1c7fdc-389c-442e-b6a8-eebdd054e240_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_705cdc1d-4947-44f8-b1f0-9453207f0689_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_WarrantsFairValueDisclosure_3582ac92-4d00-415e-aaff-64936d53a169_terseLabel_en-US" xlink:label="lab_angn_WarrantsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant liability</link:label>
    <link:label id="lab_angn_WarrantsFairValueDisclosure_label_en-US" xlink:label="lab_angn_WarrantsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants, Fair Value Disclosure</link:label>
    <link:label id="lab_angn_WarrantsFairValueDisclosure_documentation_en-US" xlink:label="lab_angn_WarrantsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsFairValueDisclosure" xlink:href="angn-20241231.xsd#angn_WarrantsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_WarrantsFairValueDisclosure" xlink:to="lab_angn_WarrantsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_07f631d5-16df-4a05-8755-8bb6408ef1c7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value Measurement Inputs and Valuation Techniques</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_f1d5be6a-8a48-4f48-af74-67b41c155c93_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_58645efb-884a-4f9f-b84e-86756531507d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_782dc59c-2a7d-4df8-a49a-2431116b2718_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_67708f67-6ea0-4f35-88b5-88b0a152fe5a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOperatingAndNonoperating_d7be4770-f8bb-46fc-aeb7-b6cbcee56059_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOperatingAndNonoperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOperatingAndNonoperating_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOperatingAndNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income, Operating and Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperatingAndNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOperatingAndNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOperatingAndNonoperating" xlink:to="lab_us-gaap_InterestIncomeOperatingAndNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_eb3043f1-e512-417e-a5e4-cb0ca94f0b2e_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_a12cd045-c93f-4e39-96ed-0fe0ff3bd1ad_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_c951f5b1-c88b-4d90-8ccc-3282a3e56e55_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_56a97021-710e-493d-bc40-cfe66e0bd40e_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_5e2c6aa4-c700-4c70-98b8-370a8c5c2118_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_15ebf49d-1d6b-4ed2-88c3-039553368355_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee related general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_A2022PlanMember_d5dd3121-f324-476d-bcfe-f23b38bd02c1_terseLabel_en-US" xlink:label="lab_angn_A2022PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022 Plan</link:label>
    <link:label id="lab_angn_A2022PlanMember_label_en-US" xlink:label="lab_angn_A2022PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2022 Plan [Member]</link:label>
    <link:label id="lab_angn_A2022PlanMember_documentation_en-US" xlink:label="lab_angn_A2022PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2022 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_A2022PlanMember" xlink:href="angn-20241231.xsd#angn_A2022PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_A2022PlanMember" xlink:to="lab_angn_A2022PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_OperatingLeaseFutureMinimumAnnualMaintenancePayments_37e0163e-6785-4752-a7a5-69572bbd1f30_terseLabel_en-US" xlink:label="lab_angn_OperatingLeaseFutureMinimumAnnualMaintenancePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future minimum payments</link:label>
    <link:label id="lab_angn_OperatingLeaseFutureMinimumAnnualMaintenancePayments_label_en-US" xlink:label="lab_angn_OperatingLeaseFutureMinimumAnnualMaintenancePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Future Minimum, Annual Maintenance Payments</link:label>
    <link:label id="lab_angn_OperatingLeaseFutureMinimumAnnualMaintenancePayments_documentation_en-US" xlink:label="lab_angn_OperatingLeaseFutureMinimumAnnualMaintenancePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Future Minimum, Annual Maintenance Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_OperatingLeaseFutureMinimumAnnualMaintenancePayments" xlink:href="angn-20241231.xsd#angn_OperatingLeaseFutureMinimumAnnualMaintenancePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_OperatingLeaseFutureMinimumAnnualMaintenancePayments" xlink:to="lab_angn_OperatingLeaseFutureMinimumAnnualMaintenancePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_eeb69842-52c1-4c6d-a63d-585b69a7bd77_terseLabel_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs</link:label>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock" xlink:to="lab_us-gaap_DebtPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_daee15cc-4c42-49a2-9f35-922dc90ef880_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of embedded derivative</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_label_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Embedded Derivative, Gain (Loss) on Embedded Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:to="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_8b983277-3c8e-4233-95ac-90ff412549ff_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average discount rate&#8212;operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_76bda802-dbb5-4489-9f35-d02a301d6cd7_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_SaleOfStockBeneficialOwnershipLimitationPercentage_e53c76e6-02f1-4eee-96f6-0845a9768e96_terseLabel_en-US" xlink:label="lab_angn_SaleOfStockBeneficialOwnershipLimitationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Beneficial ownership limitation, percentage</link:label>
    <link:label id="lab_angn_SaleOfStockBeneficialOwnershipLimitationPercentage_label_en-US" xlink:label="lab_angn_SaleOfStockBeneficialOwnershipLimitationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Beneficial Ownership Limitation, Percentage</link:label>
    <link:label id="lab_angn_SaleOfStockBeneficialOwnershipLimitationPercentage_documentation_en-US" xlink:label="lab_angn_SaleOfStockBeneficialOwnershipLimitationPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Beneficial Ownership Limitation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_SaleOfStockBeneficialOwnershipLimitationPercentage" xlink:href="angn-20241231.xsd#angn_SaleOfStockBeneficialOwnershipLimitationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_SaleOfStockBeneficialOwnershipLimitationPercentage" xlink:to="lab_angn_SaleOfStockBeneficialOwnershipLimitationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_d262d396-1495-42b4-8355-ac1b09c56cc4_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_b968b256-bb9b-4ace-8de9-7efabb653e4d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockNameDomain_5f3afc51-c817-4295-a3ca-fde5a28eeab9_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockNameDomain_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockNameDomain" xlink:to="lab_us-gaap_ConversionOfStockNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_f3cb1256-be8f-40b0-85f4-b7f4dcc1e7ec_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_04853ca0-aad4-4be0-9d74-9fc2e953158f_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_148219ac-20c9-4a83-a7bd-f4140beb40a8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">(Gain) loss on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_StockIssuedDuringPeriodValueServiceAgreement_87cdf57a-8e22-4375-bd1e-e788289a113a_terseLabel_en-US" xlink:label="lab_angn_StockIssuedDuringPeriodValueServiceAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock related to service agreement</link:label>
    <link:label id="lab_angn_StockIssuedDuringPeriodValueServiceAgreement_label_en-US" xlink:label="lab_angn_StockIssuedDuringPeriodValueServiceAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Service Agreement</link:label>
    <link:label id="lab_angn_StockIssuedDuringPeriodValueServiceAgreement_documentation_en-US" xlink:label="lab_angn_StockIssuedDuringPeriodValueServiceAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Service Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_StockIssuedDuringPeriodValueServiceAgreement" xlink:href="angn-20241231.xsd#angn_StockIssuedDuringPeriodValueServiceAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_StockIssuedDuringPeriodValueServiceAgreement" xlink:to="lab_angn_StockIssuedDuringPeriodValueServiceAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_559f7e52-85e7-495a-81bd-3892f1032db3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_92974229-e98f-43d7-ad23-c46577e7bdac_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_05dbc93d-adc1-469a-a938-7f7dfbbaaafc_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_c544dbb9-9684-415c-8ac8-9815eef3b358_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_c0ea97b2-f619-4f92-87f2-49210d985317_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares sold in offering (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_bf9f0bca-1193-4120-b61c-e15e1bb606c2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_70a1baee-d4d2-45f9-b138-e14e0e4579af_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested option exercise liability, current</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Compensation Share-Based Arrangements, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:to="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_10a244cf-ed8e-4c70-9d72-087f6fc600a9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_91a97bfb-67c0-4373-b798-f166f831d796_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_d22b53f6-ed7e-4ce8-a1cf-f6b5ebd6d21d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_4920b5bd-037c-40f0-bc8d-113e665f3127_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_A2021PlanMember_03166575-608c-4a2c-be72-152017a4e5c0_terseLabel_en-US" xlink:label="lab_angn_A2021PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021 Plan</link:label>
    <link:label id="lab_angn_A2021PlanMember_label_en-US" xlink:label="lab_angn_A2021PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2021 Plan [Member]</link:label>
    <link:label id="lab_angn_A2021PlanMember_documentation_en-US" xlink:label="lab_angn_A2021PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2021 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_A2021PlanMember" xlink:href="angn-20241231.xsd#angn_A2021PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_A2021PlanMember" xlink:to="lab_angn_A2021PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_58ef1646-cad5-4ff2-aa70-b3c1fccbddd9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_3896b8a0-2fd0-4a61-933e-db86bede2d4c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_dad9fc5c-7874-40da-b36e-1606f51cb701_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_576fd53b-394d-4c28-a798-91b68e86117c_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:to="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_5c8940e4-df79-41d1-9e4c-23de88656ba5_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ReverseRecapitalizationMember_ce86fda2-514e-4a83-ae29-bfe77d675bed_terseLabel_en-US" xlink:label="lab_angn_ReverseRecapitalizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reverse Recapitalization</link:label>
    <link:label id="lab_angn_ReverseRecapitalizationMember_label_en-US" xlink:label="lab_angn_ReverseRecapitalizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reverse Recapitalization [Member]</link:label>
    <link:label id="lab_angn_ReverseRecapitalizationMember_documentation_en-US" xlink:label="lab_angn_ReverseRecapitalizationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reverse Recapitalization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ReverseRecapitalizationMember" xlink:href="angn-20241231.xsd#angn_ReverseRecapitalizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ReverseRecapitalizationMember" xlink:to="lab_angn_ReverseRecapitalizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_6dc958c0-defe-430d-b7f8-b17671b67c9a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.01 par value; 300,000,000 shares authorized; 11,043,837 and 9,618,178 shares issued at December 31, 2024 and 2023, respectively; 11,029,382 and 9,603,723 shares outstanding as of December 31, 2024 and 2023, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_8d4323f8-8350-4231-a710-35a24144ff37_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ClinicalTrailMember_8ca78cbc-25a7-411a-b75e-2d23db76d856_terseLabel_en-US" xlink:label="lab_angn_ClinicalTrailMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical trial expenses</link:label>
    <link:label id="lab_angn_ClinicalTrailMember_label_en-US" xlink:label="lab_angn_ClinicalTrailMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Trail [Member]</link:label>
    <link:label id="lab_angn_ClinicalTrailMember_documentation_en-US" xlink:label="lab_angn_ClinicalTrailMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical Trail</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ClinicalTrailMember" xlink:href="angn-20241231.xsd#angn_ClinicalTrailMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ClinicalTrailMember" xlink:to="lab_angn_ClinicalTrailMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_a5297f2b-eb51-4511-967f-7170afbe25c3_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_5f888cf7-8229-4373-907f-dd26d852b60e_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State tax, net of federal benefits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_ccc18305-2b70-4a59-9e0e-96de86d1ffda_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_afcedd8a-dc3b-4085-8fc9-68f0a37664e7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_f599118a-7b94-4c00-8ce7-bf619c06934b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_f5b1cbd2-5125-48bd-94c5-b85a62db3ce9_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employers matching contribution annual vesting (in percentage)</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:to="lab_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_75e7c48d-8504-443d-86bb-cd4760065302_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_LicenseExpense_7f91da68-249d-4054-b811-cc15a3f20081_terseLabel_en-US" xlink:label="lab_angn_LicenseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License expense</link:label>
    <link:label id="lab_angn_LicenseExpense_label_en-US" xlink:label="lab_angn_LicenseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Expense</link:label>
    <link:label id="lab_angn_LicenseExpense_documentation_en-US" xlink:label="lab_angn_LicenseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_LicenseExpense" xlink:href="angn-20241231.xsd#angn_LicenseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_LicenseExpense" xlink:to="lab_angn_LicenseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_d34b7aa5-6c84-4fee-87dd-d6a8c578d343_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on extinguishment of promissory notes payable</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_41a2504b-0ec0-40e4-a74a-14409f6c02d8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gain on extinguishment of promissory notes</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_WarrantsAndDerivativesPolicyTextBlock_bab0e901-3821-4321-813c-2d29cb3003da_terseLabel_en-US" xlink:label="lab_angn_WarrantsAndDerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and Derivatives</link:label>
    <link:label id="lab_angn_WarrantsAndDerivativesPolicyTextBlock_label_en-US" xlink:label="lab_angn_WarrantsAndDerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Derivatives [Policy Text Block]</link:label>
    <link:label id="lab_angn_WarrantsAndDerivativesPolicyTextBlock_documentation_en-US" xlink:label="lab_angn_WarrantsAndDerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants and Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsAndDerivativesPolicyTextBlock" xlink:href="angn-20241231.xsd#angn_WarrantsAndDerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_WarrantsAndDerivativesPolicyTextBlock" xlink:to="lab_angn_WarrantsAndDerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_841d3290-31e1-4ccd-9722-c43fcaf7136d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_26862667-2caa-421d-a70d-0a74520ec0d2_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_45fbf4c3-9c78-40e5-aab7-80b6de06c467_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.01 par value; 10,000,000 shares authorized; no shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseOtherNoncurrent_319aa65a-474e-4337-96f4-fa802d7bdc8c_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseOtherNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term prepaid assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseOtherNoncurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseOtherNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense Other, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseOtherNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseOtherNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseOtherNoncurrent" xlink:to="lab_us-gaap_PrepaidExpenseOtherNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_d49744d6-9ad2-4346-8749-9b74c4b33142_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, useful life (in years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_912fdb47-3464-4996-8e40-50ba6f407ead_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Stock Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_2f07a8eb-f212-4e45-8b09-198f49fdb354_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_28c090cd-680a-44d7-bb9f-f27b85ce337d_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible note - related party</link:label>
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_label_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Notes Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleLongTermNotesPayable" xlink:to="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_9aa274da-1076-42a6-9a1c-cb0edb77dbfb_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per common share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_6ee0338c-f4b0-431f-bf5d-5de6413b7d6b_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_d4cb677b-96eb-4ea2-82c5-7c253d1a3eeb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_41cb16dd-5555-433b-a326-a31b1d508e4e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_1fed6355-9478-474b-a785-89deb762d1a4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating cash outflows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_AccruedResearchAndDevelopmentCurrent_e5ee9e71-0504-4a6f-828e-40009a07116b_terseLabel_en-US" xlink:label="lab_angn_AccruedResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued research and development</link:label>
    <link:label id="lab_angn_AccruedResearchAndDevelopmentCurrent_label_en-US" xlink:label="lab_angn_AccruedResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Research And Development, Current</link:label>
    <link:label id="lab_angn_AccruedResearchAndDevelopmentCurrent_documentation_en-US" xlink:label="lab_angn_AccruedResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Research And Development, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AccruedResearchAndDevelopmentCurrent" xlink:href="angn-20241231.xsd#angn_AccruedResearchAndDevelopmentCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_AccruedResearchAndDevelopmentCurrent" xlink:to="lab_angn_AccruedResearchAndDevelopmentCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_AccruedInterestPremiumForConvertiblePreferredStock_5099daff-d806-4ade-87a3-50e137d42f69_terseLabel_en-US" xlink:label="lab_angn_AccruedInterestPremiumForConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_angn_AccruedInterestPremiumForConvertiblePreferredStock_label_en-US" xlink:label="lab_angn_AccruedInterestPremiumForConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Interest Premium For Convertible Preferred Stock</link:label>
    <link:label id="lab_angn_AccruedInterestPremiumForConvertiblePreferredStock_documentation_en-US" xlink:label="lab_angn_AccruedInterestPremiumForConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Interest Premium For Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AccruedInterestPremiumForConvertiblePreferredStock" xlink:href="angn-20241231.xsd#angn_AccruedInterestPremiumForConvertiblePreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_AccruedInterestPremiumForConvertiblePreferredStock" xlink:to="lab_angn_AccruedInterestPremiumForConvertiblePreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_5ca40224-38d3-4a9a-9d98-cf628479803f_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_b4032e1c-f68d-4bcd-aef9-c115c145ebc3_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation, Less-than-Wholly-Owned Subsidiary, Parent Ownership Interest, Effect of Change [Table]</link:label>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_label_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Less-than-Wholly-Owned Subsidiary, Parent Ownership Interest, Effect of Change [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1be23222-156a-4e18-a5fd-70ee9af28a7c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_3f54b7ef-5d6d-4625-8869-7193795bd940_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_7c1d1912-c8f9-4f38-a709-ee441ea79489_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_d43354c1-e184-4b53-896b-067cf8fe4a40_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_7b4ff303-d258-4592-829c-7e7c6178794f_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_099bf57c-ad87-4bcf-9167-166f025c4680_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation related to unvested stock option awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_13ff06a2-bf7f-4089-aed2-61eb2927d88d_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_9cb25e0d-c258-45c9-af73-f6d9533ef7a3_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total segment assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_ea61f21a-5557-4867-bd97-c09923d55e0b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentrations of Credit Risk and Off-Balance Sheet Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_StockIssuedDuringPeriodSharesServiceAgreement_4d9fa772-52be-4fb9-9b7d-9c9051f12e2d_terseLabel_en-US" xlink:label="lab_angn_StockIssuedDuringPeriodSharesServiceAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock related to service agreement (in shares)</link:label>
    <link:label id="lab_angn_StockIssuedDuringPeriodSharesServiceAgreement_label_en-US" xlink:label="lab_angn_StockIssuedDuringPeriodSharesServiceAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Service Agreement</link:label>
    <link:label id="lab_angn_StockIssuedDuringPeriodSharesServiceAgreement_documentation_en-US" xlink:label="lab_angn_StockIssuedDuringPeriodSharesServiceAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Service Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_StockIssuedDuringPeriodSharesServiceAgreement" xlink:href="angn-20241231.xsd#angn_StockIssuedDuringPeriodSharesServiceAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_StockIssuedDuringPeriodSharesServiceAgreement" xlink:to="lab_angn_StockIssuedDuringPeriodSharesServiceAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_LesseeOperatingLeaseAnnualRentExpense_fdd854bb-decd-47f1-9788-b5514297f4fb_terseLabel_en-US" xlink:label="lab_angn_LesseeOperatingLeaseAnnualRentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, payment per year</link:label>
    <link:label id="lab_angn_LesseeOperatingLeaseAnnualRentExpense_label_en-US" xlink:label="lab_angn_LesseeOperatingLeaseAnnualRentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Annual Rent Expense</link:label>
    <link:label id="lab_angn_LesseeOperatingLeaseAnnualRentExpense_documentation_en-US" xlink:label="lab_angn_LesseeOperatingLeaseAnnualRentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Annual Rent Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_LesseeOperatingLeaseAnnualRentExpense" xlink:href="angn-20241231.xsd#angn_LesseeOperatingLeaseAnnualRentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_LesseeOperatingLeaseAnnualRentExpense" xlink:to="lab_angn_LesseeOperatingLeaseAnnualRentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3d4f3267-7cad-42a0-b7e0-f2eadff8f6fd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_88267e71-b318-4016-8398-693126f000a7_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies&#8212;Note 10</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_58383868-3f17-4882-91db-98da143988ac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_TemporaryEquityValueConversionOfConvertibleSecurities_38b22d54-ee58-4ee4-b608-dfe581285498_negatedTerseLabel_en-US" xlink:label="lab_angn_TemporaryEquityValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Conversion of preferred stock</link:label>
    <link:label id="lab_angn_TemporaryEquityValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_angn_TemporaryEquityValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Value, Conversion Of Convertible Securities</link:label>
    <link:label id="lab_angn_TemporaryEquityValueConversionOfConvertibleSecurities_documentation_en-US" xlink:label="lab_angn_TemporaryEquityValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Value, Conversion Of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_TemporaryEquityValueConversionOfConvertibleSecurities" xlink:href="angn-20241231.xsd#angn_TemporaryEquityValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_TemporaryEquityValueConversionOfConvertibleSecurities" xlink:to="lab_angn_TemporaryEquityValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_OtherMember_3a22d7f1-e948-4ee1-895b-70b8f8373a10_terseLabel_en-US" xlink:label="lab_angn_OtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other research and development expenses</link:label>
    <link:label id="lab_angn_OtherMember_label_en-US" xlink:label="lab_angn_OtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other [Member]</link:label>
    <link:label id="lab_angn_OtherMember_documentation_en-US" xlink:label="lab_angn_OtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_OtherMember" xlink:href="angn-20241231.xsd#angn_OtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_OtherMember" xlink:to="lab_angn_OtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_8fcc9e84-76b8-4ce6-8745-282205f91243_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1599f0fa-e194-4a00-b271-86bcbd951d46_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_fb342ea8-407c-4b6a-8ece-aed805f9a776_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_492c9d57-121b-4387-b344-e2a10e943004_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1ce7483d-6a68-4a37-a4b4-890656dba1fe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ec63c720-20e4-412e-9327-d832cce7a5d9_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9730fed0-1a69-4e4a-b367-c3a30e64eb38_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4cb99603-1425-432c-a233-c968e04f7b3c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b6288fae-088b-4084-bce6-36da7ba70d45_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4e4e9a4c-925e-4f50-978d-781638ff246d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_400f851c-ecdb-41c1-9477-849acf7341e3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of stock price trigger</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFJuly2023Member_6107aae9-5bd2-4b1c-8a72-0f3f0d2fae90_terseLabel_en-US" xlink:label="lab_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFJuly2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Grant Agreement with GIRF July 2023</link:label>
    <link:label id="lab_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFJuly2023Member_label_en-US" xlink:label="lab_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFJuly2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Grant Agreement With The Gastro-Intestinal Research Foundation (&#8220;GIRF&#8221;) July 2023 [Member]</link:label>
    <link:label id="lab_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFJuly2023Member_documentation_en-US" xlink:label="lab_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFJuly2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research Grant Agreement With The Gastro-Intestinal Research Foundation (&#8220;GIRF&#8221;) July 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFJuly2023Member" xlink:href="angn-20241231.xsd#angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFJuly2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFJuly2023Member" xlink:to="lab_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFJuly2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_be4772de-fb72-4a29-93f2-601193b922e1_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_fc1336ba-023f-4602-9bc2-2088523aa027_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ConversionOfConvertibleDebtMember_1d19f9f4-a73a-40bb-a6ee-4821e6714feb_terseLabel_en-US" xlink:label="lab_angn_ConversionOfConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Convertible Debt</link:label>
    <link:label id="lab_angn_ConversionOfConvertibleDebtMember_label_en-US" xlink:label="lab_angn_ConversionOfConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion Of Convertible Debt [Member]</link:label>
    <link:label id="lab_angn_ConversionOfConvertibleDebtMember_documentation_en-US" xlink:label="lab_angn_ConversionOfConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conversion Of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ConversionOfConvertibleDebtMember" xlink:href="angn-20241231.xsd#angn_ConversionOfConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ConversionOfConvertibleDebtMember" xlink:to="lab_angn_ConversionOfConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_6fc07f79-8c05-4a29-bcd4-f99c2bf85693_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_bde86650-f19c-49b8-9f3f-16524f4189b1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2a0b735c-618d-483e-8f8c-331dcf41d291_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_AuditInformationAbstract_label_en-US" xlink:label="lab_angn_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_angn_AuditInformationAbstract_documentation_en-US" xlink:label="lab_angn_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AuditInformationAbstract" xlink:href="angn-20241231.xsd#angn_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_AuditInformationAbstract" xlink:to="lab_angn_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_eeba67db-5a5b-4108-9fac-fe9638251946_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_976e2b39-2438-4ac7-ba08-a2c0d8e18c9b_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_8489de25-0952-48aa-9242-dbe9b10ea593_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_39e3125d-8929-4fa3-96a7-6d566d7c41b0_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_55fb1cd7-3a48-46f2-92d9-b60aa918a9b7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of preferred stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_37349fe7-0a72-47a6-af33-0f811dc2cc7b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_54f3cf2e-5d71-46f6-a8d1-0d2f82c67e82_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_7310fc5b-83c3-4da1-959b-1122ae23435c_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Area of office space (in sqft)</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ConsultingServicePaymentsMember_22015e67-6e76-4ce3-a25b-f214c546b413_terseLabel_en-US" xlink:label="lab_angn_ConsultingServicePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consulting Service Payments</link:label>
    <link:label id="lab_angn_ConsultingServicePaymentsMember_label_en-US" xlink:label="lab_angn_ConsultingServicePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consulting Service Payments [Member]</link:label>
    <link:label id="lab_angn_ConsultingServicePaymentsMember_documentation_en-US" xlink:label="lab_angn_ConsultingServicePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consulting Service Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ConsultingServicePaymentsMember" xlink:href="angn-20241231.xsd#angn_ConsultingServicePaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ConsultingServicePaymentsMember" xlink:to="lab_angn_ConsultingServicePaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_3ab87198-cb04-4a42-98f4-e38ccb080e83_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_a1d84823-6541-49bf-836d-dab7bcb600ce_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">ROU asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_aa7cc444-c7cc-427a-8a68-2ee1e696d1cf_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ReclassLiabilityClassifiedWarrantsToEquityClassifiedWarrants_24d2d530-3169-4e9a-899c-5c74e4fdd98f_terseLabel_en-US" xlink:label="lab_angn_ReclassLiabilityClassifiedWarrantsToEquityClassifiedWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification of liability-classified warrants to equity classified warrants</link:label>
    <link:label id="lab_angn_ReclassLiabilityClassifiedWarrantsToEquityClassifiedWarrants_label_en-US" xlink:label="lab_angn_ReclassLiabilityClassifiedWarrantsToEquityClassifiedWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclass Liability-Classified Warrants to Equity Classified Warrants</link:label>
    <link:label id="lab_angn_ReclassLiabilityClassifiedWarrantsToEquityClassifiedWarrants_documentation_en-US" xlink:label="lab_angn_ReclassLiabilityClassifiedWarrantsToEquityClassifiedWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reclass Liability-Classified Warrants to Equity Classified Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ReclassLiabilityClassifiedWarrantsToEquityClassifiedWarrants" xlink:href="angn-20241231.xsd#angn_ReclassLiabilityClassifiedWarrantsToEquityClassifiedWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ReclassLiabilityClassifiedWarrantsToEquityClassifiedWarrants" xlink:to="lab_angn_ReclassLiabilityClassifiedWarrantsToEquityClassifiedWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_4c10af2f-9c98-4a98-b35d-9556fbef7eaa_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_a8ddad08-fc87-49ee-9740-8df73f129ea5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_6733e21d-e765-4c44-a066-746d2abaabfd_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_3d1a607f-1f90-4729-9600-078030f15b77_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_662a92c2-d00d-45c7-836f-3efd886f52b8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5c9f0867-5ab0-41a5-8fa0-f09086333484_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of foreign currency on cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_82418f97-f305-4277-84b6-a024ee0428ef_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_a6e546f8-f2ac-478b-a08a-8e836a184ab6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options vested and exercisable, total intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_262d0679-e67b-42cb-a313-86dd78881a57_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining lease term&#8212;operating leases (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_AtTheMarketEquityOfferingSalesAgreement2022Member_3c5a3dfa-297b-420c-b24a-4e7feb5404b9_terseLabel_en-US" xlink:label="lab_angn_AtTheMarketEquityOfferingSalesAgreement2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At-The-Market Equity Offering Sales Agreement 2022</link:label>
    <link:label id="lab_angn_AtTheMarketEquityOfferingSalesAgreement2022Member_label_en-US" xlink:label="lab_angn_AtTheMarketEquityOfferingSalesAgreement2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At-The-Market Equity Offering Sales Agreement 2022 [Member]</link:label>
    <link:label id="lab_angn_AtTheMarketEquityOfferingSalesAgreement2022Member_documentation_en-US" xlink:label="lab_angn_AtTheMarketEquityOfferingSalesAgreement2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At-The-Market Equity Offering Sales Agreement 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AtTheMarketEquityOfferingSalesAgreement2022Member" xlink:href="angn-20241231.xsd#angn_AtTheMarketEquityOfferingSalesAgreement2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_AtTheMarketEquityOfferingSalesAgreement2022Member" xlink:to="lab_angn_AtTheMarketEquityOfferingSalesAgreement2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_294296a2-7232-40ea-9793-d85ee1692a6e_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_d6a5fe7d-4c0d-4015-8aff-4637e4fd075d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_9976704a-c6d5-416b-8da9-315342e70d95_terseLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Embedded derivative, fair value of embedded derivative liability</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Embedded Derivative, Fair Value of Embedded Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:to="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_A2024PlanMember_d317f68f-b8c6-40f6-8440-00e36d8b3d67_terseLabel_en-US" xlink:label="lab_angn_A2024PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 Plan</link:label>
    <link:label id="lab_angn_A2024PlanMember_label_en-US" xlink:label="lab_angn_A2024PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2024 Plan [Member]</link:label>
    <link:label id="lab_angn_A2024PlanMember_documentation_en-US" xlink:label="lab_angn_A2024PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2024 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_A2024PlanMember" xlink:href="angn-20241231.xsd#angn_A2024PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_A2024PlanMember" xlink:to="lab_angn_A2024PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_57aeb46e-67b8-442a-88c9-f985fab27578_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_34ebf4bf-9e6d-44e7-9f29-5034a45548e6_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Components</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_b9e05b1d-884c-485f-b7ca-e9c93e196286_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Existing Angion warrant liability</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_08df5fd7-9576-4a97-8799-5e02a264c25c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_88c10df8-9e04-4a93-9a1d-762b58cf6ebe_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_dc9bbe1a-410c-439c-b373-1b09e0056fbf_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d24794a1-b8ba-4545-a75e-ca8d523feb5b_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_7dfd9551-01c1-470a-9938-86b17d433016_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Statement Reclassification</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_b5210872-6dc8-415d-b659-c4e7b36e7a88_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_585c4a89-f092-4945-a76b-65511c7c6e0a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_8a129aad-c181-47a3-8e79-3add490fa097_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_13c03af7-353c-4483-892a-37dfced62b2b_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_25d81e6e-4f15-42d8-8cf5-b67ee671a3aa_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_BostonMassachusettsMember_2ba4d289-08f5-4f90-84f7-850bc6f3ab71_terseLabel_en-US" xlink:label="lab_angn_BostonMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Boston, Massachusetts</link:label>
    <link:label id="lab_angn_BostonMassachusettsMember_label_en-US" xlink:label="lab_angn_BostonMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Boston, Massachusetts [Member]</link:label>
    <link:label id="lab_angn_BostonMassachusettsMember_documentation_en-US" xlink:label="lab_angn_BostonMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Boston, Massachusetts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_BostonMassachusettsMember" xlink:href="angn-20241231.xsd#angn_BostonMassachusettsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_BostonMassachusettsMember" xlink:to="lab_angn_BostonMassachusettsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ReverseRecapitalizationAbstract_label_en-US" xlink:label="lab_angn_ReverseRecapitalizationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reverse Recapitalization [Abstract]</link:label>
    <link:label id="lab_angn_ReverseRecapitalizationAbstract_documentation_en-US" xlink:label="lab_angn_ReverseRecapitalizationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reverse Recapitalization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ReverseRecapitalizationAbstract" xlink:href="angn-20241231.xsd#angn_ReverseRecapitalizationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ReverseRecapitalizationAbstract" xlink:to="lab_angn_ReverseRecapitalizationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4a7d2a34-22f2-4fa1-ace3-fc6ebe6c084a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6abbc9b5-328d-4bd7-b800-27f77b76f15e_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares used in computing net loss per share, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_AtTheMarketEquityOfferingSalesAgreement2024Member_f46396c8-0473-44c5-bd83-8e83cea7fcdf_terseLabel_en-US" xlink:label="lab_angn_AtTheMarketEquityOfferingSalesAgreement2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At-The-Market Equity Offering Sales Agreement 2024</link:label>
    <link:label id="lab_angn_AtTheMarketEquityOfferingSalesAgreement2024Member_label_en-US" xlink:label="lab_angn_AtTheMarketEquityOfferingSalesAgreement2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At-The-Market Equity Offering Sales Agreement 2024 [Member]</link:label>
    <link:label id="lab_angn_AtTheMarketEquityOfferingSalesAgreement2024Member_documentation_en-US" xlink:label="lab_angn_AtTheMarketEquityOfferingSalesAgreement2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At-The-Market Equity Offering Sales Agreement 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AtTheMarketEquityOfferingSalesAgreement2024Member" xlink:href="angn-20241231.xsd#angn_AtTheMarketEquityOfferingSalesAgreement2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_AtTheMarketEquityOfferingSalesAgreement2024Member" xlink:to="lab_angn_AtTheMarketEquityOfferingSalesAgreement2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_VestingOfRestrictedCommonStockNoncash_f2b5d575-7479-4db7-ac6f-ad43fbc4db00_terseLabel_en-US" xlink:label="lab_angn_VestingOfRestrictedCommonStockNoncash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash vesting of restricted common stock</link:label>
    <link:label id="lab_angn_VestingOfRestrictedCommonStockNoncash_label_en-US" xlink:label="lab_angn_VestingOfRestrictedCommonStockNoncash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Of Restricted Common Stock, Noncash</link:label>
    <link:label id="lab_angn_VestingOfRestrictedCommonStockNoncash_documentation_en-US" xlink:label="lab_angn_VestingOfRestrictedCommonStockNoncash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vesting Of Restricted Common Stock, Noncash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_VestingOfRestrictedCommonStockNoncash" xlink:href="angn-20241231.xsd#angn_VestingOfRestrictedCommonStockNoncash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_VestingOfRestrictedCommonStockNoncash" xlink:to="lab_angn_VestingOfRestrictedCommonStockNoncash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_028effa5-467a-4077-9c1a-2de046099fdc_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_c9d2ac86-ca2d-473b-a574-1eb2a793d4ce_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets (liabilities):</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_2fb79b4d-2470-4031-a882-ccdd148628c5_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ConvertibleNotesMember_3488e3ed-12d2-4fc5-9a19-19bc9799b3eb_terseLabel_en-US" xlink:label="lab_angn_ConvertibleNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Notes</link:label>
    <link:label id="lab_angn_ConvertibleNotesMember_label_en-US" xlink:label="lab_angn_ConvertibleNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Notes [Member]</link:label>
    <link:label id="lab_angn_ConvertibleNotesMember_documentation_en-US" xlink:label="lab_angn_ConvertibleNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ConvertibleNotesMember" xlink:href="angn-20241231.xsd#angn_ConvertibleNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ConvertibleNotesMember" xlink:to="lab_angn_ConvertibleNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_7a6f9972-9810-4383-8775-ce3354237330_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (unvested) (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_AccretionOfPromissoryNoteDiscountFromEmbeddedDerivative_9b51e1d1-6a92-4422-aa03-d74943987304_terseLabel_en-US" xlink:label="lab_angn_AccretionOfPromissoryNoteDiscountFromEmbeddedDerivative" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accretion of promissory note discount from embedded derivative</link:label>
    <link:label id="lab_angn_AccretionOfPromissoryNoteDiscountFromEmbeddedDerivative_label_en-US" xlink:label="lab_angn_AccretionOfPromissoryNoteDiscountFromEmbeddedDerivative" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion Of Promissory Note Discount From Embedded Derivative</link:label>
    <link:label id="lab_angn_AccretionOfPromissoryNoteDiscountFromEmbeddedDerivative_documentation_en-US" xlink:label="lab_angn_AccretionOfPromissoryNoteDiscountFromEmbeddedDerivative" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accretion Of Promissory Note Discount From Embedded Derivative</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AccretionOfPromissoryNoteDiscountFromEmbeddedDerivative" xlink:href="angn-20241231.xsd#angn_AccretionOfPromissoryNoteDiscountFromEmbeddedDerivative"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_AccretionOfPromissoryNoteDiscountFromEmbeddedDerivative" xlink:to="lab_angn_AccretionOfPromissoryNoteDiscountFromEmbeddedDerivative" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_08bd3f44-1703-4557-87b2-882fdb5263fe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_c7b25eb7-1c59-4662-89ac-f424edb8d7d8_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_AtTheMarketEquityOfferingSalesAgreementMember_e40fc41d-46f2-4d3e-bd28-c475236abdae_terseLabel_en-US" xlink:label="lab_angn_AtTheMarketEquityOfferingSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At-The-Market Equity Offering Sales Agreement</link:label>
    <link:label id="lab_angn_AtTheMarketEquityOfferingSalesAgreementMember_label_en-US" xlink:label="lab_angn_AtTheMarketEquityOfferingSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At-The-Market Equity Offering Sales Agreement [Member]</link:label>
    <link:label id="lab_angn_AtTheMarketEquityOfferingSalesAgreementMember_documentation_en-US" xlink:label="lab_angn_AtTheMarketEquityOfferingSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At-The-Market Equity Offering Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AtTheMarketEquityOfferingSalesAgreementMember" xlink:href="angn-20241231.xsd#angn_AtTheMarketEquityOfferingSalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_AtTheMarketEquityOfferingSalesAgreementMember" xlink:to="lab_angn_AtTheMarketEquityOfferingSalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_f1cda609-fa2d-4793-bf60-2c8be1e250fa_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>angn-20241231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:e62aa408-c713-4974-8057-b2b3ab20d8bb,g:40b09b34-8017-48cd-b202-ee62afe33f17-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.angn.com/role/Cover" xlink:type="simple" xlink:href="angn-20241231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_be552fff-d576-4a64-be3a-1b4125800503" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b0535fed-5b25-4e7f-b551-87b07c8505c6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be552fff-d576-4a64-be3a-1b4125800503" xlink:to="loc_dei_DocumentType_b0535fed-5b25-4e7f-b551-87b07c8505c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_61457115-a1e6-4896-bc15-df6ebd5d5bdf" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be552fff-d576-4a64-be3a-1b4125800503" xlink:to="loc_dei_DocumentAnnualReport_61457115-a1e6-4896-bc15-df6ebd5d5bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_48e83494-b89f-42cd-9754-e4d6b6106013" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be552fff-d576-4a64-be3a-1b4125800503" xlink:to="loc_dei_DocumentPeriodEndDate_48e83494-b89f-42cd-9754-e4d6b6106013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_c8510ca5-c2b6-459a-a94f-41d17fd7633a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be552fff-d576-4a64-be3a-1b4125800503" xlink:to="loc_dei_CurrentFiscalYearEndDate_c8510ca5-c2b6-459a-a94f-41d17fd7633a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_3a05d5c6-844f-4336-85ff-53973699b880" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be552fff-d576-4a64-be3a-1b4125800503" xlink:to="loc_dei_DocumentTransitionReport_3a05d5c6-844f-4336-85ff-53973699b880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_9348617e-b5f6-492d-b001-2d8125f70ee2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be552fff-d576-4a64-be3a-1b4125800503" xlink:to="loc_dei_EntityFileNumber_9348617e-b5f6-492d-b001-2d8125f70ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_f64ca761-f921-46a4-b56d-46ee019d9e3c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be552fff-d576-4a64-be3a-1b4125800503" xlink:to="loc_dei_EntityRegistrantName_f64ca761-f921-46a4-b56d-46ee019d9e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_0536d471-c112-4534-96b9-463d79aea3df" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be552fff-d576-4a64-be3a-1b4125800503" xlink:to="loc_dei_EntityIncorporationStateCountryCode_0536d471-c112-4534-96b9-463d79aea3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_e0fb9318-fc34-4453-95e7-4064b467c3b1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be552fff-d576-4a64-be3a-1b4125800503" xlink:to="loc_dei_EntityTaxIdentificationNumber_e0fb9318-fc34-4453-95e7-4064b467c3b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_35d0b4a6-9ed3-47af-b1c1-ce3fdb694c01" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be552fff-d576-4a64-be3a-1b4125800503" xlink:to="loc_dei_EntityAddressAddressLine1_35d0b4a6-9ed3-47af-b1c1-ce3fdb694c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_1bdfee0f-fa63-44df-8f05-d8128726065e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be552fff-d576-4a64-be3a-1b4125800503" xlink:to="loc_dei_EntityAddressCityOrTown_1bdfee0f-fa63-44df-8f05-d8128726065e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_465e3206-1c82-4f0d-8a2f-e8227e45cc55" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be552fff-d576-4a64-be3a-1b4125800503" xlink:to="loc_dei_EntityAddressStateOrProvince_465e3206-1c82-4f0d-8a2f-e8227e45cc55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_709efdb0-81ed-4cb5-bb0f-816e6b74cad3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be552fff-d576-4a64-be3a-1b4125800503" xlink:to="loc_dei_EntityAddressPostalZipCode_709efdb0-81ed-4cb5-bb0f-816e6b74cad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_081f3a29-7619-47fc-8711-63d5503d5b65" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be552fff-d576-4a64-be3a-1b4125800503" xlink:to="loc_dei_CityAreaCode_081f3a29-7619-47fc-8711-63d5503d5b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_f3b81924-463c-48a1-bae2-d30a931d0c3d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be552fff-d576-4a64-be3a-1b4125800503" xlink:to="loc_dei_LocalPhoneNumber_f3b81924-463c-48a1-bae2-d30a931d0c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_f2fc58af-a167-42bf-a0b3-44e13dca28f8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be552fff-d576-4a64-be3a-1b4125800503" xlink:to="loc_dei_Security12bTitle_f2fc58af-a167-42bf-a0b3-44e13dca28f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_45aabe84-68eb-4ae7-a1ec-422984c99c48" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be552fff-d576-4a64-be3a-1b4125800503" xlink:to="loc_dei_TradingSymbol_45aabe84-68eb-4ae7-a1ec-422984c99c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_6e9f01e7-4d19-4bbc-9554-a53929640bfa" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be552fff-d576-4a64-be3a-1b4125800503" xlink:to="loc_dei_SecurityExchangeName_6e9f01e7-4d19-4bbc-9554-a53929640bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_a1f0bdc8-df47-4c85-9fb4-94a31d05eaa4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be552fff-d576-4a64-be3a-1b4125800503" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_a1f0bdc8-df47-4c85-9fb4-94a31d05eaa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_07af9d74-39c7-493a-a084-9d70d1dd0538" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be552fff-d576-4a64-be3a-1b4125800503" xlink:to="loc_dei_EntityVoluntaryFilers_07af9d74-39c7-493a-a084-9d70d1dd0538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_3c9ed0b9-92d9-4beb-be6c-9f8780c4b708" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be552fff-d576-4a64-be3a-1b4125800503" xlink:to="loc_dei_EntityCurrentReportingStatus_3c9ed0b9-92d9-4beb-be6c-9f8780c4b708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_a9ed2da3-ca20-4edf-b5f1-3fca4d786873" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be552fff-d576-4a64-be3a-1b4125800503" xlink:to="loc_dei_EntityInteractiveDataCurrent_a9ed2da3-ca20-4edf-b5f1-3fca4d786873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_08072b4d-aa6a-4ed9-9c7b-9c3f561e4217" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be552fff-d576-4a64-be3a-1b4125800503" xlink:to="loc_dei_EntityFilerCategory_08072b4d-aa6a-4ed9-9c7b-9c3f561e4217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_26aec3c9-8623-4993-a78f-09eb3375c723" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be552fff-d576-4a64-be3a-1b4125800503" xlink:to="loc_dei_EntitySmallBusiness_26aec3c9-8623-4993-a78f-09eb3375c723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_092298c3-f956-4704-b5a0-fdf931424303" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be552fff-d576-4a64-be3a-1b4125800503" xlink:to="loc_dei_EntityEmergingGrowthCompany_092298c3-f956-4704-b5a0-fdf931424303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_bcf320c5-4a51-460e-80d4-a37336854956" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be552fff-d576-4a64-be3a-1b4125800503" xlink:to="loc_dei_EntityExTransitionPeriod_bcf320c5-4a51-460e-80d4-a37336854956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_79eb5ced-ba4c-4883-8218-e0ccf1e1fdda" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be552fff-d576-4a64-be3a-1b4125800503" xlink:to="loc_dei_IcfrAuditorAttestationFlag_79eb5ced-ba4c-4883-8218-e0ccf1e1fdda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_e72df13d-17ab-4e12-bfd0-d4a3df3476ef" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be552fff-d576-4a64-be3a-1b4125800503" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_e72df13d-17ab-4e12-bfd0-d4a3df3476ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_f46adc36-e657-4f43-b9b6-a9b26d4488d2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be552fff-d576-4a64-be3a-1b4125800503" xlink:to="loc_dei_EntityShellCompany_f46adc36-e657-4f43-b9b6-a9b26d4488d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_42091ced-1923-4f0d-ac1b-b3a5e076e0e5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be552fff-d576-4a64-be3a-1b4125800503" xlink:to="loc_dei_EntityPublicFloat_42091ced-1923-4f0d-ac1b-b3a5e076e0e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_35b77f1e-f376-4ca4-a986-1e6ea2ae582b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be552fff-d576-4a64-be3a-1b4125800503" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_35b77f1e-f376-4ca4-a986-1e6ea2ae582b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_a106deb3-51e0-40ce-8c86-a7e4ced42cf9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be552fff-d576-4a64-be3a-1b4125800503" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_a106deb3-51e0-40ce-8c86-a7e4ced42cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_64b0c914-2b5e-4d26-889f-deb05e7ffb2f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be552fff-d576-4a64-be3a-1b4125800503" xlink:to="loc_dei_DocumentFiscalYearFocus_64b0c914-2b5e-4d26-889f-deb05e7ffb2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_27bf5940-29de-4ebc-8d8e-2cd285f9b18c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be552fff-d576-4a64-be3a-1b4125800503" xlink:to="loc_dei_DocumentFiscalPeriodFocus_27bf5940-29de-4ebc-8d8e-2cd285f9b18c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_071dfb27-a174-4948-987d-2a8c305492b1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be552fff-d576-4a64-be3a-1b4125800503" xlink:to="loc_dei_EntityCentralIndexKey_071dfb27-a174-4948-987d-2a8c305492b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_18baad45-28d6-4b1a-940c-eced0c6727f5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be552fff-d576-4a64-be3a-1b4125800503" xlink:to="loc_dei_AmendmentFlag_18baad45-28d6-4b1a-940c-eced0c6727f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/AuditInformation" xlink:type="simple" xlink:href="angn-20241231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_angn_AuditInformationAbstract_84253234-501d-40a3-a881-bac44463645e" xlink:href="angn-20241231.xsd#angn_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_d46f6619-6bb9-47dc-afd6-c51e90a861c5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_AuditInformationAbstract_84253234-501d-40a3-a881-bac44463645e" xlink:to="loc_dei_AuditorName_d46f6619-6bb9-47dc-afd6-c51e90a861c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_c433ebd9-3c4f-403a-be92-60293c325724" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_AuditInformationAbstract_84253234-501d-40a3-a881-bac44463645e" xlink:to="loc_dei_AuditorLocation_c433ebd9-3c4f-403a-be92-60293c325724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_fd66ac13-9c64-4e58-8f94-6efabab0e3b8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_AuditInformationAbstract_84253234-501d-40a3-a881-bac44463645e" xlink:to="loc_dei_AuditorFirmId_fd66ac13-9c64-4e58-8f94-6efabab0e3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="angn-20241231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_d2f7e171-8dc1-4110-ada1-3731b6ec7bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_fb462804-34b2-472b-bc96-70f23e429b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d2f7e171-8dc1-4110-ada1-3731b6ec7bbe" xlink:to="loc_us-gaap_AssetsAbstract_fb462804-34b2-472b-bc96-70f23e429b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_8da0b553-9530-43f2-95e1-97395b1ce9e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_fb462804-34b2-472b-bc96-70f23e429b5e" xlink:to="loc_us-gaap_AssetsCurrentAbstract_8da0b553-9530-43f2-95e1-97395b1ce9e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7e26423a-fdc0-4345-bee9-095bd1ca158d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8da0b553-9530-43f2-95e1-97395b1ce9e6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7e26423a-fdc0-4345-bee9-095bd1ca158d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_bd07f7f6-e7db-41aa-be81-459f5de73f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8da0b553-9530-43f2-95e1-97395b1ce9e6" xlink:to="loc_us-gaap_RestrictedCashCurrent_bd07f7f6-e7db-41aa-be81-459f5de73f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_66fdf347-f35f-487a-9f65-d34cd2a5c105" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8da0b553-9530-43f2-95e1-97395b1ce9e6" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_66fdf347-f35f-487a-9f65-d34cd2a5c105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b5dab4ae-fb4f-426c-a916-9eb383c58e49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8da0b553-9530-43f2-95e1-97395b1ce9e6" xlink:to="loc_us-gaap_AssetsCurrent_b5dab4ae-fb4f-426c-a916-9eb383c58e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6ea5c880-342f-4fd3-be9b-1c5b74d9c3f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_fb462804-34b2-472b-bc96-70f23e429b5e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6ea5c880-342f-4fd3-be9b-1c5b74d9c3f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_34ccdad4-1ef0-44e4-9024-9f66a294119d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_fb462804-34b2-472b-bc96-70f23e429b5e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_34ccdad4-1ef0-44e4-9024-9f66a294119d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_84789ee3-0b6e-4efd-beb1-bd5416c73471" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_fb462804-34b2-472b-bc96-70f23e429b5e" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_84789ee3-0b6e-4efd-beb1-bd5416c73471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseOtherNoncurrent_a34b869d-c9bc-4eca-ab51-6f4cd127a711" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseOtherNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_fb462804-34b2-472b-bc96-70f23e429b5e" xlink:to="loc_us-gaap_PrepaidExpenseOtherNoncurrent_a34b869d-c9bc-4eca-ab51-6f4cd127a711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0dadef47-302d-460b-b201-787756b8eabf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_fb462804-34b2-472b-bc96-70f23e429b5e" xlink:to="loc_us-gaap_Assets_0dadef47-302d-460b-b201-787756b8eabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0d79c40-4df2-4de0-a2e1-b639b93048b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d2f7e171-8dc1-4110-ada1-3731b6ec7bbe" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0d79c40-4df2-4de0-a2e1-b639b93048b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_af32a843-e19f-47b3-a5b3-25f702fd521e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0d79c40-4df2-4de0-a2e1-b639b93048b6" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_af32a843-e19f-47b3-a5b3-25f702fd521e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_881edc90-e414-483b-bf83-99513d960765" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_af32a843-e19f-47b3-a5b3-25f702fd521e" xlink:to="loc_us-gaap_AccountsPayableCurrent_881edc90-e414-483b-bf83-99513d960765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_9d76336b-9bba-4bd5-bb58-5f17f613fc4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_af32a843-e19f-47b3-a5b3-25f702fd521e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_9d76336b-9bba-4bd5-bb58-5f17f613fc4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_bcdb5641-5987-409c-ae56-f8f8664e5286" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_af32a843-e19f-47b3-a5b3-25f702fd521e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_bcdb5641-5987-409c-ae56-f8f8664e5286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_35bff6c2-f775-4543-bde8-ff1251556f90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_af32a843-e19f-47b3-a5b3-25f702fd521e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_35bff6c2-f775-4543-bde8-ff1251556f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_571b8c33-12f7-4444-899e-770c663c19ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_af32a843-e19f-47b3-a5b3-25f702fd521e" xlink:to="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_571b8c33-12f7-4444-899e-770c663c19ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_67092b99-b30c-49b7-8daa-1e123a14f675" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_af32a843-e19f-47b3-a5b3-25f702fd521e" xlink:to="loc_us-gaap_LiabilitiesCurrent_67092b99-b30c-49b7-8daa-1e123a14f675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantLiability_ecb3796e-4fa6-425c-a7a5-d1349f9a7828" xlink:href="angn-20241231.xsd#angn_WarrantLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0d79c40-4df2-4de0-a2e1-b639b93048b6" xlink:to="loc_angn_WarrantLiability_ecb3796e-4fa6-425c-a7a5-d1349f9a7828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_745a78e2-004d-4118-9fab-dd65134855a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0d79c40-4df2-4de0-a2e1-b639b93048b6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_745a78e2-004d-4118-9fab-dd65134855a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_5a7737f0-688a-40b2-b7e3-92a406f3a9a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0d79c40-4df2-4de0-a2e1-b639b93048b6" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_5a7737f0-688a-40b2-b7e3-92a406f3a9a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7d40c128-214c-4719-915f-2fd79023c089" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0d79c40-4df2-4de0-a2e1-b639b93048b6" xlink:to="loc_us-gaap_Liabilities_7d40c128-214c-4719-915f-2fd79023c089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f21b69ee-126d-4588-ad71-13e2e5524555" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0d79c40-4df2-4de0-a2e1-b639b93048b6" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f21b69ee-126d-4588-ad71-13e2e5524555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_fe47c016-ad57-4184-b876-87b838a34607" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0d79c40-4df2-4de0-a2e1-b639b93048b6" xlink:to="loc_us-gaap_StatementOfStockholdersEquityAbstract_fe47c016-ad57-4184-b876-87b838a34607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_4dbcce4b-f17a-4b8c-bee7-387ef2700880" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_fe47c016-ad57-4184-b876-87b838a34607" xlink:to="loc_us-gaap_PreferredStockValue_4dbcce4b-f17a-4b8c-bee7-387ef2700880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b65018ca-7fa9-421c-9dd3-89389b5b1dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_fe47c016-ad57-4184-b876-87b838a34607" xlink:to="loc_us-gaap_CommonStockValue_b65018ca-7fa9-421c-9dd3-89389b5b1dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_b635f2bd-8b5e-438c-900a-accec3bf02f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_fe47c016-ad57-4184-b876-87b838a34607" xlink:to="loc_us-gaap_TreasuryStockCommonValue_b635f2bd-8b5e-438c-900a-accec3bf02f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_03c0bb28-7c4a-4d30-a4f3-6c959206d0b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_fe47c016-ad57-4184-b876-87b838a34607" xlink:to="loc_us-gaap_AdditionalPaidInCapital_03c0bb28-7c4a-4d30-a4f3-6c959206d0b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0e350a23-033f-4229-88ad-8f377d277755" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_fe47c016-ad57-4184-b876-87b838a34607" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0e350a23-033f-4229-88ad-8f377d277755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ef834167-8bc1-43e1-98af-a283e75797be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_fe47c016-ad57-4184-b876-87b838a34607" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ef834167-8bc1-43e1-98af-a283e75797be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bba9abc1-70fb-4605-babb-57575d8ea695" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_fe47c016-ad57-4184-b876-87b838a34607" xlink:to="loc_us-gaap_StockholdersEquity_bba9abc1-70fb-4605-babb-57575d8ea695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d9a1ef6e-52c8-4089-b26e-05b668d286dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0d79c40-4df2-4de0-a2e1-b639b93048b6" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_d9a1ef6e-52c8-4089-b26e-05b668d286dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_cf1a5c5d-0d2f-40ba-94c8-b7ebe9d6ec09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d2f7e171-8dc1-4110-ada1-3731b6ec7bbe" xlink:to="loc_us-gaap_TreasuryStockCommonShares_cf1a5c5d-0d2f-40ba-94c8-b7ebe9d6ec09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="angn-20241231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_04da5782-1e66-4ff9-b22e-6564a963dc3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_abfff166-2f09-4d05-b7a0-426650519f10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_04da5782-1e66-4ff9-b22e-6564a963dc3b" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_abfff166-2f09-4d05-b7a0-426650519f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_6d3c70ee-77bb-4d59-96b4-7488eac49451" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_04da5782-1e66-4ff9-b22e-6564a963dc3b" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_6d3c70ee-77bb-4d59-96b4-7488eac49451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_ff955e9b-0328-4d49-aa59-25ba37b07030" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_04da5782-1e66-4ff9-b22e-6564a963dc3b" xlink:to="loc_us-gaap_PreferredStockSharesIssued_ff955e9b-0328-4d49-aa59-25ba37b07030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_ed7482da-930c-43b1-8c09-4595bd8990c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_04da5782-1e66-4ff9-b22e-6564a963dc3b" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_ed7482da-930c-43b1-8c09-4595bd8990c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_a7bbd9bb-9f36-40a3-ba14-8711b22dec4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_04da5782-1e66-4ff9-b22e-6564a963dc3b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_a7bbd9bb-9f36-40a3-ba14-8711b22dec4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_11001bb2-b01d-4e07-86f3-3656066e15a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_04da5782-1e66-4ff9-b22e-6564a963dc3b" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_11001bb2-b01d-4e07-86f3-3656066e15a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_dacdcf78-fec1-4cd5-9e58-7e8eca6d49cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_04da5782-1e66-4ff9-b22e-6564a963dc3b" xlink:to="loc_us-gaap_CommonStockSharesIssued_dacdcf78-fec1-4cd5-9e58-7e8eca6d49cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_57651dad-3179-471b-92cb-925015872337" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_04da5782-1e66-4ff9-b22e-6564a963dc3b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_57651dad-3179-471b-92cb-925015872337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_e56a3ffe-0dc8-458b-9303-6ec99466f9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_04da5782-1e66-4ff9-b22e-6564a963dc3b" xlink:to="loc_us-gaap_TreasuryStockCommonShares_e56a3ffe-0dc8-458b-9303-6ec99466f9ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="angn-20241231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_4b3f0fc8-7698-4d1f-ad9f-3a2c1177a7bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract_f01fccfd-9f93-452c-b9c2-eadccb75aa6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4b3f0fc8-7698-4d1f-ad9f-3a2c1177a7bd" xlink:to="loc_us-gaap_OperatingCostsAndExpensesAbstract_f01fccfd-9f93-452c-b9c2-eadccb75aa6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_98aa8e99-e5cd-4ef6-b46a-9ea0762e1182" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_f01fccfd-9f93-452c-b9c2-eadccb75aa6f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_98aa8e99-e5cd-4ef6-b46a-9ea0762e1182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_0d0369a2-f306-4df3-a9dc-b6f855430126" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_f01fccfd-9f93-452c-b9c2-eadccb75aa6f" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_0d0369a2-f306-4df3-a9dc-b6f855430126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_48c16cbe-ae27-4540-b0d6-f6b92cc06813" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_f01fccfd-9f93-452c-b9c2-eadccb75aa6f" xlink:to="loc_us-gaap_CostsAndExpenses_48c16cbe-ae27-4540-b0d6-f6b92cc06813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_958ad713-6c33-438a-9c26-fa91b6894b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4b3f0fc8-7698-4d1f-ad9f-3a2c1177a7bd" xlink:to="loc_us-gaap_OperatingIncomeLoss_958ad713-6c33-438a-9c26-fa91b6894b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_5d47aee0-8a18-4c32-bedb-e57f2d4c53e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4b3f0fc8-7698-4d1f-ad9f-3a2c1177a7bd" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_5d47aee0-8a18-4c32-bedb-e57f2d4c53e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_d8c03ef2-059c-424a-8efb-e5e5c8b36baa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_5d47aee0-8a18-4c32-bedb-e57f2d4c53e5" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_d8c03ef2-059c-424a-8efb-e5e5c8b36baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_GainLossOnIssuanceOfWarrants_5a4fc964-1bd2-4131-90bb-c146805c3e5c" xlink:href="angn-20241231.xsd#angn_GainLossOnIssuanceOfWarrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_5d47aee0-8a18-4c32-bedb-e57f2d4c53e5" xlink:to="loc_angn_GainLossOnIssuanceOfWarrants_5a4fc964-1bd2-4131-90bb-c146805c3e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_9b8beffb-3b6e-4353-8678-c1dac3e04b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_5d47aee0-8a18-4c32-bedb-e57f2d4c53e5" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_9b8beffb-3b6e-4353-8678-c1dac3e04b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a4dd2b4b-a155-4e03-b1d9-090961f3f05d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_5d47aee0-8a18-4c32-bedb-e57f2d4c53e5" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a4dd2b4b-a155-4e03-b1d9-090961f3f05d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_4e3b6a24-e80b-47f0-8e88-11621c2aa13b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_5d47aee0-8a18-4c32-bedb-e57f2d4c53e5" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_4e3b6a24-e80b-47f0-8e88-11621c2aa13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_c0eb2349-f1ef-4a02-882d-90cfefbb505e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_5d47aee0-8a18-4c32-bedb-e57f2d4c53e5" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_c0eb2349-f1ef-4a02-882d-90cfefbb505e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperatingAndNonoperating_8c82bf91-c10b-4cc6-8c85-f81c5b531d97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOperatingAndNonoperating"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_5d47aee0-8a18-4c32-bedb-e57f2d4c53e5" xlink:to="loc_us-gaap_InterestIncomeOperatingAndNonoperating_8c82bf91-c10b-4cc6-8c85-f81c5b531d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_ce41e37e-baf3-40c0-ba64-fffa1e889d69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_5d47aee0-8a18-4c32-bedb-e57f2d4c53e5" xlink:to="loc_us-gaap_InterestExpenseNonoperating_ce41e37e-baf3-40c0-ba64-fffa1e889d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_dd593e6e-d134-491c-83d1-c0884e1b4599" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_5d47aee0-8a18-4c32-bedb-e57f2d4c53e5" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_dd593e6e-d134-491c-83d1-c0884e1b4599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_38f59f72-645c-417d-8526-9c0df5989c14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_5d47aee0-8a18-4c32-bedb-e57f2d4c53e5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_38f59f72-645c-417d-8526-9c0df5989c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2b39d51f-7321-4b44-8a4f-e28fcce6ef24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4b3f0fc8-7698-4d1f-ad9f-3a2c1177a7bd" xlink:to="loc_us-gaap_NetIncomeLoss_2b39d51f-7321-4b44-8a4f-e28fcce6ef24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract_7aeeb21c-76fa-4d69-9e52-c77ea77ace89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4b3f0fc8-7698-4d1f-ad9f-3a2c1177a7bd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract_7aeeb21c-76fa-4d69-9e52-c77ea77ace89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_6ced1c87-d85c-4f82-a360-d5fbce9b2ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract_7aeeb21c-76fa-4d69-9e52-c77ea77ace89" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_6ced1c87-d85c-4f82-a360-d5fbce9b2ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_c249e39d-1934-46c0-b1b2-0b1b677b42a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4b3f0fc8-7698-4d1f-ad9f-3a2c1177a7bd" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_c249e39d-1934-46c0-b1b2-0b1b677b42a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_1f06f575-fb91-465b-afe9-8b01edf90ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4b3f0fc8-7698-4d1f-ad9f-3a2c1177a7bd" xlink:to="loc_us-gaap_EarningsPerShareBasic_1f06f575-fb91-465b-afe9-8b01edf90ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_fe5e4b8c-c7b1-408f-ad9d-c0adc75f7a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4b3f0fc8-7698-4d1f-ad9f-3a2c1177a7bd" xlink:to="loc_us-gaap_EarningsPerShareDiluted_fe5e4b8c-c7b1-408f-ad9d-c0adc75f7a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4d24a22e-9b1f-4eb2-b096-a0ce1c94023c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4b3f0fc8-7698-4d1f-ad9f-3a2c1177a7bd" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4d24a22e-9b1f-4eb2-b096-a0ce1c94023c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ea26ca7f-aa65-4abc-b52b-2f22d194fe9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4b3f0fc8-7698-4d1f-ad9f-3a2c1177a7bd" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ea26ca7f-aa65-4abc-b52b-2f22d194fe9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity" xlink:type="simple" xlink:href="angn-20241231.xsd#ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_2f7620b2-891f-4c29-9100-46cad7675393" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_efc0ec3c-5b07-45c5-a7aa-5a364fd8b19b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_2f7620b2-891f-4c29-9100-46cad7675393" xlink:to="loc_us-gaap_StatementTable_efc0ec3c-5b07-45c5-a7aa-5a364fd8b19b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_51eb319e-4295-4490-9930-9500b53609f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_efc0ec3c-5b07-45c5-a7aa-5a364fd8b19b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_51eb319e-4295-4490-9930-9500b53609f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7c2b17cb-f6ab-426a-b6dc-e506c6850dae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_51eb319e-4295-4490-9930-9500b53609f5" xlink:to="loc_us-gaap_EquityComponentDomain_7c2b17cb-f6ab-426a-b6dc-e506c6850dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f948d2e7-33d7-4f60-a8aa-c7ae4dbfe5ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7c2b17cb-f6ab-426a-b6dc-e506c6850dae" xlink:to="loc_us-gaap_CommonStockMember_f948d2e7-33d7-4f60-a8aa-c7ae4dbfe5ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_354e474a-f619-41f6-9575-038baecc0200" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7c2b17cb-f6ab-426a-b6dc-e506c6850dae" xlink:to="loc_us-gaap_TreasuryStockCommonMember_354e474a-f619-41f6-9575-038baecc0200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_d1c5daee-904b-42ff-b75a-afbb0a2736b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7c2b17cb-f6ab-426a-b6dc-e506c6850dae" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_d1c5daee-904b-42ff-b75a-afbb0a2736b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1d10451d-43c1-4cd2-adcd-4ff72e935330" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7c2b17cb-f6ab-426a-b6dc-e506c6850dae" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1d10451d-43c1-4cd2-adcd-4ff72e935330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_71c164ae-04dc-4edb-9797-b839e642052e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7c2b17cb-f6ab-426a-b6dc-e506c6850dae" xlink:to="loc_us-gaap_RetainedEarningsMember_71c164ae-04dc-4edb-9797-b839e642052e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_455e212f-3802-435e-9f75-359ffbb21739" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7c2b17cb-f6ab-426a-b6dc-e506c6850dae" xlink:to="loc_us-gaap_PreferredStockMember_455e212f-3802-435e-9f75-359ffbb21739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_26c5d5db-525f-473d-b092-52717b528c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_efc0ec3c-5b07-45c5-a7aa-5a364fd8b19b" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_26c5d5db-525f-473d-b092-52717b528c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_c7386733-75ac-480c-963f-0abe031de6a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_26c5d5db-525f-473d-b092-52717b528c9e" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_c7386733-75ac-480c-963f-0abe031de6a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ConversionOfConvertiblePreferredStockMember_015e168a-897a-48a3-b2c5-bd498cfd0b53" xlink:href="angn-20241231.xsd#angn_ConversionOfConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_c7386733-75ac-480c-963f-0abe031de6a8" xlink:to="loc_angn_ConversionOfConvertiblePreferredStockMember_015e168a-897a-48a3-b2c5-bd498cfd0b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ConversionOfConvertibleDebtMember_66faf15e-f01a-474f-ad1b-e6c8094a2abb" xlink:href="angn-20241231.xsd#angn_ConversionOfConvertibleDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_c7386733-75ac-480c-963f-0abe031de6a8" xlink:to="loc_angn_ConversionOfConvertibleDebtMember_66faf15e-f01a-474f-ad1b-e6c8094a2abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_97ebe95f-b5db-462e-8001-44e520460d56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_efc0ec3c-5b07-45c5-a7aa-5a364fd8b19b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_97ebe95f-b5db-462e-8001-44e520460d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0c9d50c3-3129-48f6-9fae-ae1da1e466a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_97ebe95f-b5db-462e-8001-44e520460d56" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0c9d50c3-3129-48f6-9fae-ae1da1e466a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ReverseRecapitalizationMember_4466e73a-0d73-483e-a4ed-54074c58cbf8" xlink:href="angn-20241231.xsd#angn_ReverseRecapitalizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0c9d50c3-3129-48f6-9fae-ae1da1e466a9" xlink:to="loc_angn_ReverseRecapitalizationMember_4466e73a-0d73-483e-a4ed-54074c58cbf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AtTheMarketOfferingMember_87d549f9-3eee-4d74-bcc9-8c4115950fed" xlink:href="angn-20241231.xsd#angn_AtTheMarketOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0c9d50c3-3129-48f6-9fae-ae1da1e466a9" xlink:to="loc_angn_AtTheMarketOfferingMember_87d549f9-3eee-4d74-bcc9-8c4115950fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_JulyPublicOfferingMember_92d61e75-a926-441d-acfc-d2a4f3be88d4" xlink:href="angn-20241231.xsd#angn_JulyPublicOfferingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0c9d50c3-3129-48f6-9fae-ae1da1e466a9" xlink:to="loc_angn_JulyPublicOfferingMember_92d61e75-a926-441d-acfc-d2a4f3be88d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_20b58b54-aee4-4c3d-b2dc-bdf6fe3b7dad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_efc0ec3c-5b07-45c5-a7aa-5a364fd8b19b" xlink:to="loc_us-gaap_StatementLineItems_20b58b54-aee4-4c3d-b2dc-bdf6fe3b7dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9578339b-3fd5-487c-8a05-cc7c64c01a41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_20b58b54-aee4-4c3d-b2dc-bdf6fe3b7dad" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9578339b-3fd5-487c-8a05-cc7c64c01a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_c05d0b64-0504-4a6c-a6db-879e073cfe48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9578339b-3fd5-487c-8a05-cc7c64c01a41" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_c05d0b64-0504-4a6c-a6db-879e073cfe48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_e9afc6b0-d70a-4141-8867-cc2c70e2b40b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9578339b-3fd5-487c-8a05-cc7c64c01a41" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_e9afc6b0-d70a-4141-8867-cc2c70e2b40b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_TemporaryEquitySharesConversionOfConvertibleSecurities_6b70b38f-7a7b-4344-9f73-cb86b2c7d87a" xlink:href="angn-20241231.xsd#angn_TemporaryEquitySharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9578339b-3fd5-487c-8a05-cc7c64c01a41" xlink:to="loc_angn_TemporaryEquitySharesConversionOfConvertibleSecurities_6b70b38f-7a7b-4344-9f73-cb86b2c7d87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_TemporaryEquityValueConversionOfConvertibleSecurities_b5f46a40-d8fa-4889-a1bd-0559730dbb85" xlink:href="angn-20241231.xsd#angn_TemporaryEquityValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9578339b-3fd5-487c-8a05-cc7c64c01a41" xlink:to="loc_angn_TemporaryEquityValueConversionOfConvertibleSecurities_b5f46a40-d8fa-4889-a1bd-0559730dbb85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_373681b7-18e7-4186-929a-1f3e8e0d77a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9578339b-3fd5-487c-8a05-cc7c64c01a41" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_373681b7-18e7-4186-929a-1f3e8e0d77a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_08fb9f16-05c8-4b9d-ba7e-d3cf892f2d36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9578339b-3fd5-487c-8a05-cc7c64c01a41" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_08fb9f16-05c8-4b9d-ba7e-d3cf892f2d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_20b58b54-aee4-4c3d-b2dc-bdf6fe3b7dad" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d1f418c6-63ee-4764-9139-d2d74d9fe37e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d1f418c6-63ee-4764-9139-d2d74d9fe37e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_33aae4d9-9669-4924-acc5-44e4df829c17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_us-gaap_StockholdersEquity_33aae4d9-9669-4924-acc5-44e4df829c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_fb2bbcc1-432e-416e-abf2-ebff44a6223a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_us-gaap_TreasuryStockCommonShares_fb2bbcc1-432e-416e-abf2-ebff44a6223a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d3e68e6f-d97f-4830-b8af-f11dd9ce7271" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d3e68e6f-d97f-4830-b8af-f11dd9ce7271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_aaea2154-fb10-44dc-9dd4-57f41aca8f98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_aaea2154-fb10-44dc-9dd4-57f41aca8f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b52d6370-c7f9-4788-a35a-b5ac93c81415" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b52d6370-c7f9-4788-a35a-b5ac93c81415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b83d9dd5-266d-413e-9ba3-d41912921dec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b83d9dd5-266d-413e-9ba3-d41912921dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_1127650d-c454-4d02-bfb0-9b12dcff2280" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_1127650d-c454-4d02-bfb0-9b12dcff2280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_2dbf3379-4e59-4fc2-a680-bc263f2b80dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_2dbf3379-4e59-4fc2-a680-bc263f2b80dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants_01c759c2-ca65-45ba-b33e-da115f5456af" xlink:href="angn-20241231.xsd#angn_StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_angn_StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants_01c759c2-ca65-45ba-b33e-da115f5456af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_5c847108-bf6a-4478-abd0-f3bf0b168a12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_5c847108-bf6a-4478-abd0-f3bf0b168a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ReclassLiabilityClassifiedWarrantsToEquityClassifiedWarrants_fe75b87e-b3d9-4f6d-acec-5865281a3649" xlink:href="angn-20241231.xsd#angn_ReclassLiabilityClassifiedWarrantsToEquityClassifiedWarrants"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_angn_ReclassLiabilityClassifiedWarrantsToEquityClassifiedWarrants_fe75b87e-b3d9-4f6d-acec-5865281a3649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_6769606a-5061-419b-a838-5284429625e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_6769606a-5061-419b-a838-5284429625e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_2dcd9e9d-4e4d-4bc8-b89e-dd66de547f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_2dcd9e9d-4e4d-4bc8-b89e-dd66de547f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_StockIssuedDuringPeriodSharesReverseRecapitalization_65660d0c-141a-4243-b18e-8e6302500f63" xlink:href="angn-20241231.xsd#angn_StockIssuedDuringPeriodSharesReverseRecapitalization"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_angn_StockIssuedDuringPeriodSharesReverseRecapitalization_65660d0c-141a-4243-b18e-8e6302500f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_StockIssuedDuringPeriodValueReverseRecapitalization_81d33fc8-7ba3-484a-a2a8-60c5145bb33f" xlink:href="angn-20241231.xsd#angn_StockIssuedDuringPeriodValueReverseRecapitalization"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_angn_StockIssuedDuringPeriodValueReverseRecapitalization_81d33fc8-7ba3-484a-a2a8-60c5145bb33f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_d827140b-4870-4f9f-9a09-4bc87774cefc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_d827140b-4870-4f9f-9a09-4bc87774cefc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_4f498706-30a3-4543-98ad-1b849d202bde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_4f498706-30a3-4543-98ad-1b849d202bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7a7f7a38-0553-4412-900a-64f03987a6f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7a7f7a38-0553-4412-900a-64f03987a6f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_55e9db0c-c927-48b4-9439-458f99cb416a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_55e9db0c-c927-48b4-9439-458f99cb416a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_StockIssuedDuringPeriodSharesServiceAgreement_a07f3a98-1fb6-4355-a04c-f753125484d2" xlink:href="angn-20241231.xsd#angn_StockIssuedDuringPeriodSharesServiceAgreement"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_angn_StockIssuedDuringPeriodSharesServiceAgreement_a07f3a98-1fb6-4355-a04c-f753125484d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_StockIssuedDuringPeriodValueServiceAgreement_a3b86f39-82b9-4694-8446-74ad06069190" xlink:href="angn-20241231.xsd#angn_StockIssuedDuringPeriodValueServiceAgreement"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_angn_StockIssuedDuringPeriodValueServiceAgreement_a3b86f39-82b9-4694-8446-74ad06069190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1288c983-77ef-42ab-bfdc-7b98ec591eec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1288c983-77ef-42ab-bfdc-7b98ec591eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_502c2bfc-f229-44a5-9bc0-8c5a68a2980f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_502c2bfc-f229-44a5-9bc0-8c5a68a2980f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3d4893f8-5433-46ae-ac0d-5963b2165599" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_us-gaap_NetIncomeLoss_3d4893f8-5433-46ae-ac0d-5963b2165599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_56b0c333-79f6-4851-b274-04e2cadcb836" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_56b0c333-79f6-4851-b274-04e2cadcb836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bef80b23-45d2-4c6b-9741-e1fcbd5c02c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_us-gaap_StockholdersEquity_bef80b23-45d2-4c6b-9741-e1fcbd5c02c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_2a426845-9fd5-453a-87a8-625b615bab0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80cb1c47-9292-44c0-b550-42f758e68bef" xlink:to="loc_us-gaap_TreasuryStockCommonShares_2a426845-9fd5-453a-87a8-625b615bab0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquityParenthetical" xlink:type="simple" xlink:href="angn-20241231.xsd#ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_5b777aed-b99d-4065-8a58-56238c81618e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8d463a22-9ee1-4c3a-a73e-c999b5cc9650" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_5b777aed-b99d-4065-8a58-56238c81618e" xlink:to="loc_us-gaap_StatementTable_8d463a22-9ee1-4c3a-a73e-c999b5cc9650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_29f8a9c6-f31a-4c47-ba57-38898872a02c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8d463a22-9ee1-4c3a-a73e-c999b5cc9650" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_29f8a9c6-f31a-4c47-ba57-38898872a02c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2d508c9c-75e7-409c-88c4-c413b283b981" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_29f8a9c6-f31a-4c47-ba57-38898872a02c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2d508c9c-75e7-409c-88c4-c413b283b981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_JulyPublicOfferingMember_cbab655b-e571-4988-8c15-d9464ed2e8c5" xlink:href="angn-20241231.xsd#angn_JulyPublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2d508c9c-75e7-409c-88c4-c413b283b981" xlink:to="loc_angn_JulyPublicOfferingMember_cbab655b-e571-4988-8c15-d9464ed2e8c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1d27c3f8-b5e7-48a1-94be-4e5a3ff29058" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8d463a22-9ee1-4c3a-a73e-c999b5cc9650" xlink:to="loc_us-gaap_StatementLineItems_1d27c3f8-b5e7-48a1-94be-4e5a3ff29058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_1f74dff6-d42b-4c58-b60f-2d0179436a74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1d27c3f8-b5e7-48a1-94be-4e5a3ff29058" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_1f74dff6-d42b-4c58-b60f-2d0179436a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_896c7ff2-3bff-44c9-b0e9-ab1f2aa97c38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1d27c3f8-b5e7-48a1-94be-4e5a3ff29058" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_896c7ff2-3bff-44c9-b0e9-ab1f2aa97c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="angn-20241231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_237eccde-3f7e-4788-af9e-756e8cbf7043" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_42f705d0-5d79-4557-9151-d2d35eae564c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_237eccde-3f7e-4788-af9e-756e8cbf7043" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_42f705d0-5d79-4557-9151-d2d35eae564c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bf5ee50d-0de3-4dc7-a9df-b9ae9bec7eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_42f705d0-5d79-4557-9151-d2d35eae564c" xlink:to="loc_us-gaap_NetIncomeLoss_bf5ee50d-0de3-4dc7-a9df-b9ae9bec7eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_59df87f9-72ec-416e-bd85-b77dd17aa1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_42f705d0-5d79-4557-9151-d2d35eae564c" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_59df87f9-72ec-416e-bd85-b77dd17aa1a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_d301dcd8-f182-4b02-a7a3-6bc916cecbb6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_59df87f9-72ec-416e-bd85-b77dd17aa1a4" xlink:to="loc_us-gaap_Depreciation_d301dcd8-f182-4b02-a7a3-6bc916cecbb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_754981bf-a4c3-4f43-ac8e-bcc8f278480a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_59df87f9-72ec-416e-bd85-b77dd17aa1a4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_754981bf-a4c3-4f43-ac8e-bcc8f278480a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_05a21d79-1054-4e97-9d51-0112716534a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_59df87f9-72ec-416e-bd85-b77dd17aa1a4" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_05a21d79-1054-4e97-9d51-0112716534a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_InterestExpenseNoncash_f31bcea3-9cd0-425f-a2de-9d872d1e836a" xlink:href="angn-20241231.xsd#angn_InterestExpenseNoncash"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_59df87f9-72ec-416e-bd85-b77dd17aa1a4" xlink:to="loc_angn_InterestExpenseNoncash_f31bcea3-9cd0-425f-a2de-9d872d1e836a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_CostsExpensedUponTheIssuanceOfWarrants_8c71ddac-fe27-495a-b1d0-aa34a0486c17" xlink:href="angn-20241231.xsd#angn_CostsExpensedUponTheIssuanceOfWarrants"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_59df87f9-72ec-416e-bd85-b77dd17aa1a4" xlink:to="loc_angn_CostsExpensedUponTheIssuanceOfWarrants_8c71ddac-fe27-495a-b1d0-aa34a0486c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_12f40e01-a471-41c1-a010-cc12dc1d565d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_59df87f9-72ec-416e-bd85-b77dd17aa1a4" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_12f40e01-a471-41c1-a010-cc12dc1d565d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_282d44dc-48e1-4908-ad14-5683b069af50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_59df87f9-72ec-416e-bd85-b77dd17aa1a4" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_282d44dc-48e1-4908-ad14-5683b069af50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_GainLossOnIssuanceOfWarrants_1291bb3b-9e10-4f39-b015-c2ddb491bcc9" xlink:href="angn-20241231.xsd#angn_GainLossOnIssuanceOfWarrants"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_59df87f9-72ec-416e-bd85-b77dd17aa1a4" xlink:to="loc_angn_GainLossOnIssuanceOfWarrants_1291bb3b-9e10-4f39-b015-c2ddb491bcc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_afc86b38-8491-4be8-b58f-b0fac3cf3dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_59df87f9-72ec-416e-bd85-b77dd17aa1a4" xlink:to="loc_us-gaap_ShareBasedCompensation_afc86b38-8491-4be8-b58f-b0fac3cf3dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ProfessionalServicesExpenseNoncash_814a30d7-ab80-4d4c-9fef-7e66c4f0ee6b" xlink:href="angn-20241231.xsd#angn_ProfessionalServicesExpenseNoncash"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_59df87f9-72ec-416e-bd85-b77dd17aa1a4" xlink:to="loc_angn_ProfessionalServicesExpenseNoncash_814a30d7-ab80-4d4c-9fef-7e66c4f0ee6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1470def7-97a1-4691-bede-6c9ee788139b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_59df87f9-72ec-416e-bd85-b77dd17aa1a4" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1470def7-97a1-4691-bede-6c9ee788139b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_288f604a-f952-40f5-be88-508ad98d3d45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_59df87f9-72ec-416e-bd85-b77dd17aa1a4" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_288f604a-f952-40f5-be88-508ad98d3d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a9d75532-22d6-40a3-b356-51d545d4538d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_59df87f9-72ec-416e-bd85-b77dd17aa1a4" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a9d75532-22d6-40a3-b356-51d545d4538d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3b41d60a-3d2f-4553-b464-962a7520086e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a9d75532-22d6-40a3-b356-51d545d4538d" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3b41d60a-3d2f-4553-b464-962a7520086e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_40f98cfd-fc5a-4a3c-b767-b8530ec2d745" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a9d75532-22d6-40a3-b356-51d545d4538d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_40f98cfd-fc5a-4a3c-b767-b8530ec2d745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a901c116-49c7-46a3-a8e8-0be634b43773" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a9d75532-22d6-40a3-b356-51d545d4538d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a901c116-49c7-46a3-a8e8-0be634b43773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_3170517c-67b2-4b18-8708-ac0d4f3d7064" xlink:href="angn-20241231.xsd#angn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a9d75532-22d6-40a3-b356-51d545d4538d" xlink:to="loc_angn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_3170517c-67b2-4b18-8708-ac0d4f3d7064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_f3b0d3a6-c8d9-4713-80d0-b14e8e5d499f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a9d75532-22d6-40a3-b356-51d545d4538d" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_f3b0d3a6-c8d9-4713-80d0-b14e8e5d499f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_9aee3057-488f-4644-a102-dab049dd2ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a9d75532-22d6-40a3-b356-51d545d4538d" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_9aee3057-488f-4644-a102-dab049dd2ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a4ef7400-d71d-4f2e-94ea-65fcf2699e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_42f705d0-5d79-4557-9151-d2d35eae564c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a4ef7400-d71d-4f2e-94ea-65fcf2699e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6a5b39ba-6222-47f7-adbd-eef4ca840917" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_237eccde-3f7e-4788-af9e-756e8cbf7043" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6a5b39ba-6222-47f7-adbd-eef4ca840917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_296a2d48-4511-4295-ab75-ec3d5e1f6aba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6a5b39ba-6222-47f7-adbd-eef4ca840917" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_296a2d48-4511-4295-ab75-ec3d5e1f6aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_cc91cc82-0ea6-4dba-9bc7-051d9b200ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6a5b39ba-6222-47f7-adbd-eef4ca840917" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_cc91cc82-0ea6-4dba-9bc7-051d9b200ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0ee64c26-85ff-4d8d-9f3c-3440b8adc213" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6a5b39ba-6222-47f7-adbd-eef4ca840917" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0ee64c26-85ff-4d8d-9f3c-3440b8adc213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0a5df6b6-230c-45f6-a148-e8f1357ef485" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_237eccde-3f7e-4788-af9e-756e8cbf7043" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0a5df6b6-230c-45f6-a148-e8f1357ef485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness_dfc58f88-7030-45bd-a64d-b860ce0f6373" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0a5df6b6-230c-45f6-a148-e8f1357ef485" xlink:to="loc_us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness_dfc58f88-7030-45bd-a64d-b860ce0f6373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_e194fb97-a881-4611-9108-9d10be0d7ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0a5df6b6-230c-45f6-a148-e8f1357ef485" xlink:to="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_e194fb97-a881-4611-9108-9d10be0d7ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_b141c3be-66cb-4132-9f1b-182446e9c92f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0a5df6b6-230c-45f6-a148-e8f1357ef485" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_b141c3be-66cb-4132-9f1b-182446e9c92f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_81e9bbb6-462e-4840-b8be-484463d5ec94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0a5df6b6-230c-45f6-a148-e8f1357ef485" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_81e9bbb6-462e-4840-b8be-484463d5ec94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ProceedsFromIssuanceOfCommonStockWarrantsFromJulyPublicOffering_bb4f6d8d-6d1b-4b04-ae16-04ec9ce08bec" xlink:href="angn-20241231.xsd#angn_ProceedsFromIssuanceOfCommonStockWarrantsFromJulyPublicOffering"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0a5df6b6-230c-45f6-a148-e8f1357ef485" xlink:to="loc_angn_ProceedsFromIssuanceOfCommonStockWarrantsFromJulyPublicOffering_bb4f6d8d-6d1b-4b04-ae16-04ec9ce08bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d282d875-d266-467e-9e71-8a98be1699bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0a5df6b6-230c-45f6-a148-e8f1357ef485" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d282d875-d266-467e-9e71-8a98be1699bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ProceedsFromIssuanceOfCommonStockFromJulyPublicOffering_4d92b4f6-cc6f-4ded-8a29-ce5859a4f984" xlink:href="angn-20241231.xsd#angn_ProceedsFromIssuanceOfCommonStockFromJulyPublicOffering"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0a5df6b6-230c-45f6-a148-e8f1357ef485" xlink:to="loc_angn_ProceedsFromIssuanceOfCommonStockFromJulyPublicOffering_4d92b4f6-cc6f-4ded-8a29-ce5859a4f984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_PaymentOfWarrantIssuanceCosts_3d4cbeb2-ec56-4d51-867e-ec8e19087c0f" xlink:href="angn-20241231.xsd#angn_PaymentOfWarrantIssuanceCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0a5df6b6-230c-45f6-a148-e8f1357ef485" xlink:to="loc_angn_PaymentOfWarrantIssuanceCosts_3d4cbeb2-ec56-4d51-867e-ec8e19087c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_74259d3d-0766-48b8-82ba-53456665b8fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0a5df6b6-230c-45f6-a148-e8f1357ef485" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_74259d3d-0766-48b8-82ba-53456665b8fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfEquity_6019fd01-c4b6-43b2-bb36-bbe91cd3fb60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0a5df6b6-230c-45f6-a148-e8f1357ef485" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfEquity_6019fd01-c4b6-43b2-bb36-bbe91cd3fb60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_e01095cd-5401-4fbe-8fd5-a0a4c0bec2d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0a5df6b6-230c-45f6-a148-e8f1357ef485" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_e01095cd-5401-4fbe-8fd5-a0a4c0bec2d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_667fc932-c7f3-4e98-8b6e-97297db9e387" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0a5df6b6-230c-45f6-a148-e8f1357ef485" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_667fc932-c7f3-4e98-8b6e-97297db9e387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4673e058-3c54-444c-b28a-f079bbfe9341" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_237eccde-3f7e-4788-af9e-756e8cbf7043" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4673e058-3c54-444c-b28a-f079bbfe9341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a675f704-f9f0-48ab-932c-047b39bbf1c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_237eccde-3f7e-4788-af9e-756e8cbf7043" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a675f704-f9f0-48ab-932c-047b39bbf1c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_929c25d9-0748-4664-8cf6-caef49fe4a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_237eccde-3f7e-4788-af9e-756e8cbf7043" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_929c25d9-0748-4664-8cf6-caef49fe4a8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_98640b1b-7e3a-4236-982f-38517add1124" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_237eccde-3f7e-4788-af9e-756e8cbf7043" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_98640b1b-7e3a-4236-982f-38517add1124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_570b2b16-7a49-43af-80e2-4323784261ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_237eccde-3f7e-4788-af9e-756e8cbf7043" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_570b2b16-7a49-43af-80e2-4323784261ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_630951c4-f455-4660-91b5-ee6f8b1a8dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_570b2b16-7a49-43af-80e2-4323784261ed" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_630951c4-f455-4660-91b5-ee6f8b1a8dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_be17d9e9-10de-49b0-a138-73229d723ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_570b2b16-7a49-43af-80e2-4323784261ed" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_be17d9e9-10de-49b0-a138-73229d723ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_90ed4f36-3756-440b-b2b6-dce5e1aafd03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_570b2b16-7a49-43af-80e2-4323784261ed" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_90ed4f36-3756-440b-b2b6-dce5e1aafd03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_52c101b3-34a1-4071-9d3d-c4c3102baa02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_237eccde-3f7e-4788-af9e-756e8cbf7043" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_52c101b3-34a1-4071-9d3d-c4c3102baa02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c2046131-f464-4515-9a66-5458538c2b45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_52c101b3-34a1-4071-9d3d-c4c3102baa02" xlink:to="loc_us-gaap_StatementTable_c2046131-f464-4515-9a66-5458538c2b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_36ef13ed-0945-45bd-929c-4d553c0815a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c2046131-f464-4515-9a66-5458538c2b45" xlink:to="loc_us-gaap_StatementClassOfStockAxis_36ef13ed-0945-45bd-929c-4d553c0815a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_56e2240e-1e4c-4024-8a6d-ea255346a595" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_36ef13ed-0945-45bd-929c-4d553c0815a5" xlink:to="loc_us-gaap_ClassOfStockDomain_56e2240e-1e4c-4024-8a6d-ea255346a595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_44950e48-3514-4600-9beb-b68e5c197425" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_56e2240e-1e4c-4024-8a6d-ea255346a595" xlink:to="loc_us-gaap_CommonStockMember_44950e48-3514-4600-9beb-b68e5c197425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_StockIssuanceAxis_e766a0a4-6ba7-4320-8683-b6d470969117" xlink:href="angn-20241231.xsd#angn_StockIssuanceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c2046131-f464-4515-9a66-5458538c2b45" xlink:to="loc_angn_StockIssuanceAxis_e766a0a4-6ba7-4320-8683-b6d470969117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_StockIssuanceDomain_34b2b835-90ee-48b4-829c-b8df8c13aae2" xlink:href="angn-20241231.xsd#angn_StockIssuanceDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_StockIssuanceAxis_e766a0a4-6ba7-4320-8683-b6d470969117" xlink:to="loc_angn_StockIssuanceDomain_34b2b835-90ee-48b4-829c-b8df8c13aae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AngionStockholdersMember_97b034be-e303-4da6-acb6-68785782651e" xlink:href="angn-20241231.xsd#angn_AngionStockholdersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_StockIssuanceDomain_34b2b835-90ee-48b4-829c-b8df8c13aae2" xlink:to="loc_angn_AngionStockholdersMember_97b034be-e303-4da6-acb6-68785782651e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ServiceAgreementMember_b5e6a8d5-5382-47cd-81bd-9019781c3f6f" xlink:href="angn-20241231.xsd#angn_ServiceAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_StockIssuanceDomain_34b2b835-90ee-48b4-829c-b8df8c13aae2" xlink:to="loc_angn_ServiceAgreementMember_b5e6a8d5-5382-47cd-81bd-9019781c3f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7c8a8326-6ba9-4663-80df-341c46f315c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c2046131-f464-4515-9a66-5458538c2b45" xlink:to="loc_us-gaap_StatementLineItems_7c8a8326-6ba9-4663-80df-341c46f315c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FairValueOfPreFundedWarrants_261d991a-2ccf-417d-9b50-bf1a057b0eba" xlink:href="angn-20241231.xsd#angn_FairValueOfPreFundedWarrants"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7c8a8326-6ba9-4663-80df-341c46f315c5" xlink:to="loc_angn_FairValueOfPreFundedWarrants_261d991a-2ccf-417d-9b50-bf1a057b0eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FairValueOfCommonStockWarrants_1a0389d5-96df-424c-b80b-d80ea2c368ab" xlink:href="angn-20241231.xsd#angn_FairValueOfCommonStockWarrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7c8a8326-6ba9-4663-80df-341c46f315c5" xlink:to="loc_angn_FairValueOfCommonStockWarrants_1a0389d5-96df-424c-b80b-d80ea2c368ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AccretionOfPromissoryNoteDiscountFromEmbeddedDerivative_0056194d-2b2d-4033-8a2d-f7919b0fcea3" xlink:href="angn-20241231.xsd#angn_AccretionOfPromissoryNoteDiscountFromEmbeddedDerivative"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7c8a8326-6ba9-4663-80df-341c46f315c5" xlink:to="loc_angn_AccretionOfPromissoryNoteDiscountFromEmbeddedDerivative_0056194d-2b2d-4033-8a2d-f7919b0fcea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AccretionOfPromissoryNoteToFaceValue_4452270f-8282-400b-83b5-f0263737493a" xlink:href="angn-20241231.xsd#angn_AccretionOfPromissoryNoteToFaceValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7c8a8326-6ba9-4663-80df-341c46f315c5" xlink:to="loc_angn_AccretionOfPromissoryNoteToFaceValue_4452270f-8282-400b-83b5-f0263737493a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_SettlementOfPromissoryNotesPayable_d013e7fe-ebbd-43a7-9b53-56d78702e871" xlink:href="angn-20241231.xsd#angn_SettlementOfPromissoryNotesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7c8a8326-6ba9-4663-80df-341c46f315c5" xlink:to="loc_angn_SettlementOfPromissoryNotesPayable_d013e7fe-ebbd-43a7-9b53-56d78702e871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_VestingOfRestrictedCommonStockNoncash_10d25ace-583f-4e00-b8d4-d7c6da45ed88" xlink:href="angn-20241231.xsd#angn_VestingOfRestrictedCommonStockNoncash"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7c8a8326-6ba9-4663-80df-341c46f315c5" xlink:to="loc_angn_VestingOfRestrictedCommonStockNoncash_10d25ace-583f-4e00-b8d4-d7c6da45ed88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1_18ccb5ce-3cdc-49ab-a597-4ea84bb2a139" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7c8a8326-6ba9-4663-80df-341c46f315c5" xlink:to="loc_us-gaap_ConversionOfStockAmountIssued1_18ccb5ce-3cdc-49ab-a597-4ea84bb2a139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_fa579077-2ec7-4574-b511-60569c168d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7c8a8326-6ba9-4663-80df-341c46f315c5" xlink:to="loc_us-gaap_StockIssued1_fa579077-2ec7-4574-b511-60569c168d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/DescriptionoftheBusinessandFinancialCondition" xlink:type="simple" xlink:href="angn-20241231.xsd#DescriptionoftheBusinessandFinancialCondition"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/DescriptionoftheBusinessandFinancialCondition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1e39e489-baef-4787-b35b-ac3550d39833" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1a4a94b0-e9e3-4b66-bb4a-0012f5baa340" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1e39e489-baef-4787-b35b-ac3550d39833" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1a4a94b0-e9e3-4b66-bb4a-0012f5baa340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="angn-20241231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4cc3804a-69c2-4a13-a469-3e5b430addcb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_6a7893bf-2185-45fd-80d9-cd0e164c4584" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4cc3804a-69c2-4a13-a469-3e5b430addcb" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_6a7893bf-2185-45fd-80d9-cd0e164c4584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/MergerandRelatedTransactions" xlink:type="simple" xlink:href="angn-20241231.xsd#MergerandRelatedTransactions"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/MergerandRelatedTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_angn_ReverseRecapitalizationAbstract_942bcd1b-9d68-4455-ac7c-e1b324621b95" xlink:href="angn-20241231.xsd#angn_ReverseRecapitalizationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ReverseRecapitalizationDisclosureTextBlock_8a160f53-e7e7-4adc-9fef-cdd449d30e25" xlink:href="angn-20241231.xsd#angn_ReverseRecapitalizationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_ReverseRecapitalizationAbstract_942bcd1b-9d68-4455-ac7c-e1b324621b95" xlink:to="loc_angn_ReverseRecapitalizationDisclosureTextBlock_8a160f53-e7e7-4adc-9fef-cdd449d30e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="angn-20241231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_203d9329-00c2-4815-b1cc-c6589ef0848a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_2805d834-264f-48fe-93b8-6044e2037abc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_203d9329-00c2-4815-b1cc-c6589ef0848a" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_2805d834-264f-48fe-93b8-6044e2037abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/BalanceSheetComponents" xlink:type="simple" xlink:href="angn-20241231.xsd#BalanceSheetComponents"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/BalanceSheetComponents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eb6b33d4-5145-42bb-a21c-ac86178658b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_0285f181-4179-4e92-808f-47b0fa9a3f61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eb6b33d4-5145-42bb-a21c-ac86178658b4" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_0285f181-4179-4e92-808f-47b0fa9a3f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/ResearchGrant" xlink:type="simple" xlink:href="angn-20241231.xsd#ResearchGrant"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/ResearchGrant" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_0102c785-0873-476c-9e09-1e8c39e8006e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_12f85a49-4a16-4781-b56c-727782e092bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_0102c785-0873-476c-9e09-1e8c39e8006e" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_12f85a49-4a16-4781-b56c-727782e092bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquity" xlink:type="simple" xlink:href="angn-20241231.xsd#ConvertiblePreferredStockCommonStockandStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f2d4ca67-e0a1-4baf-8707-d8f5a42c4ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_d02eeaef-206c-4a3a-85b3-d3a5caaa74de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f2d4ca67-e0a1-4baf-8707-d8f5a42c4ddb" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_d02eeaef-206c-4a3a-85b3-d3a5caaa74de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="angn-20241231.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f2a6124d-5dd6-41f0-8c6e-d5dc0eb1c850" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_00d0c46d-14c1-435f-8fcb-b84a42650a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f2a6124d-5dd6-41f0-8c6e-d5dc0eb1c850" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_00d0c46d-14c1-435f-8fcb-b84a42650a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/Warrants" xlink:type="simple" xlink:href="angn-20241231.xsd#Warrants"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/Warrants" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsAndRightsOutstandingAbstract_f0f656b3-044f-44aa-af50-107572a64f31" xlink:href="angn-20241231.xsd#angn_WarrantsAndRightsOutstandingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsAndRightsOutstandingTextBlock_aa0f43b5-ce1f-4dd5-9d3c-5efbca54ed3a" xlink:href="angn-20241231.xsd#angn_WarrantsAndRightsOutstandingTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_WarrantsAndRightsOutstandingAbstract_f0f656b3-044f-44aa-af50-107572a64f31" xlink:to="loc_angn_WarrantsAndRightsOutstandingTextBlock_aa0f43b5-ce1f-4dd5-9d3c-5efbca54ed3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="angn-20241231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e1bab21a-6fa5-47a8-a68a-782a63f7b7aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_58d0b1b3-2ba3-40f7-951a-fb3c9adb602c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e1bab21a-6fa5-47a8-a68a-782a63f7b7aa" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_58d0b1b3-2ba3-40f7-951a-fb3c9adb602c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/Leases" xlink:type="simple" xlink:href="angn-20241231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_93344993-fe60-4850-b11e-3f7a3773b8f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_e3970816-f4a1-4eec-adaf-3a92afc461f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_93344993-fe60-4850-b11e-3f7a3773b8f4" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_e3970816-f4a1-4eec-adaf-3a92afc461f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/Debt" xlink:type="simple" xlink:href="angn-20241231.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_fac807b5-5f21-41c7-a438-908559a7a37a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_b195c9a5-d657-4cab-82e7-8b59df0397bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fac807b5-5f21-41c7-a438-908559a7a37a" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_b195c9a5-d657-4cab-82e7-8b59df0397bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/IncomeTaxes" xlink:type="simple" xlink:href="angn-20241231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d8b2f76c-b001-45be-9954-1d0bc12e02f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_12eeeafe-017e-44c7-bdc5-c2094def09e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d8b2f76c-b001-45be-9954-1d0bc12e02f7" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_12eeeafe-017e-44c7-bdc5-c2094def09e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/EmployeeBenefitPlan" xlink:type="simple" xlink:href="angn-20241231.xsd#EmployeeBenefitPlan"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/EmployeeBenefitPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e1dd56ef-a395-4404-b069-3831287899ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTextBlock_52fa0496-8f72-4906-b37d-e6b1440b82ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e1dd56ef-a395-4404-b069-3831287899ae" xlink:to="loc_us-gaap_DefinedContributionPlanTextBlock_52fa0496-8f72-4906-b37d-e6b1440b82ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/NetLossPerShare" xlink:type="simple" xlink:href="angn-20241231.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a3740166-9287-488b-b4bb-40bd15cac30c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_b9fd7e17-f21a-4be8-a008-aec83318181f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a3740166-9287-488b-b4bb-40bd15cac30c" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_b9fd7e17-f21a-4be8-a008-aec83318181f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="angn-20241231.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_ee8d5780-0245-489e-b68d-62fb7a20b061" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_24de4e24-96dc-4c80-8759-102519f524d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_ee8d5780-0245-489e-b68d-62fb7a20b061" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_24de4e24-96dc-4c80-8759-102519f524d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/SegmentReporting" xlink:type="simple" xlink:href="angn-20241231.xsd#SegmentReporting"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/SegmentReporting" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_81a5bd7e-0ff1-4221-bd1e-82d84b7d8ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_6aa167df-3b4a-4a44-8c9d-da99e08b8387" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_81a5bd7e-0ff1-4221-bd1e-82d84b7d8ad9" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_6aa167df-3b4a-4a44-8c9d-da99e08b8387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/SubsequentEvents" xlink:type="simple" xlink:href="angn-20241231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_e9094de7-c6bd-437d-8f87-0ee80542a764" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_f464041b-3841-459d-b443-93357dde4492" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_e9094de7-c6bd-437d-8f87-0ee80542a764" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_f464041b-3841-459d-b443-93357dde4492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="angn-20241231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0b2274be-257d-4029-8703-5c3b3498b863" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7b2acb95-9a0c-470a-8f7b-ee89e1db8552" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0b2274be-257d-4029-8703-5c3b3498b863" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7b2acb95-9a0c-470a-8f7b-ee89e1db8552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_612065f2-f304-451a-b405-586f7d48d07a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0b2274be-257d-4029-8703-5c3b3498b863" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_612065f2-f304-451a-b405-586f7d48d07a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_6cea063d-dc5c-4fa2-8c3c-03eb94037c38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0b2274be-257d-4029-8703-5c3b3498b863" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_6cea063d-dc5c-4fa2-8c3c-03eb94037c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_5a41caca-d397-4681-875e-05539f1097f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0b2274be-257d-4029-8703-5c3b3498b863" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_5a41caca-d397-4681-875e-05539f1097f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_9beb5bb1-45d9-4ac0-adaf-15907691dfeb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0b2274be-257d-4029-8703-5c3b3498b863" xlink:to="loc_us-gaap_UseOfEstimates_9beb5bb1-45d9-4ac0-adaf-15907691dfeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_ad6e0484-424c-43a5-8675-544888611b0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0b2274be-257d-4029-8703-5c3b3498b863" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_ad6e0484-424c-43a5-8675-544888611b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_16c5bac7-0de5-4d7a-815b-9961238cbed5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0b2274be-257d-4029-8703-5c3b3498b863" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_16c5bac7-0de5-4d7a-815b-9961238cbed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_ab9da679-95ac-46d8-8322-658f8fbbdd8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0b2274be-257d-4029-8703-5c3b3498b863" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_ab9da679-95ac-46d8-8322-658f8fbbdd8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_76860cb2-51f6-4e60-b91d-5bc88dfdefcb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0b2274be-257d-4029-8703-5c3b3498b863" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_76860cb2-51f6-4e60-b91d-5bc88dfdefcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_ac38220e-a40e-495c-b15a-dd941226504a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0b2274be-257d-4029-8703-5c3b3498b863" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_ac38220e-a40e-495c-b15a-dd941226504a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_a60e060b-b2cd-4d79-ab9a-62aaca0bcaa7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0b2274be-257d-4029-8703-5c3b3498b863" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_a60e060b-b2cd-4d79-ab9a-62aaca0bcaa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock_05679a54-ca3d-4e50-98f4-0288336eb517" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0b2274be-257d-4029-8703-5c3b3498b863" xlink:to="loc_us-gaap_DebtPolicyTextBlock_05679a54-ca3d-4e50-98f4-0288336eb517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_5801f92f-d47e-4a69-9dc3-bafe722f4d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0b2274be-257d-4029-8703-5c3b3498b863" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_5801f92f-d47e-4a69-9dc3-bafe722f4d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_b796976b-07b2-45cf-a091-3455dbad2430" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0b2274be-257d-4029-8703-5c3b3498b863" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_b796976b-07b2-45cf-a091-3455dbad2430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_e24c4604-dd91-45c4-b329-36248f477779" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0b2274be-257d-4029-8703-5c3b3498b863" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_e24c4604-dd91-45c4-b329-36248f477779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_e29a3fe7-b363-44cd-b32d-88151460c068" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0b2274be-257d-4029-8703-5c3b3498b863" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_e29a3fe7-b363-44cd-b32d-88151460c068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsAndDerivativesPolicyTextBlock_4f0cbb88-30b5-432b-812c-ff52b54c8a57" xlink:href="angn-20241231.xsd#angn_WarrantsAndDerivativesPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0b2274be-257d-4029-8703-5c3b3498b863" xlink:to="loc_angn_WarrantsAndDerivativesPolicyTextBlock_4f0cbb88-30b5-432b-812c-ff52b54c8a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_2704795d-e118-47b0-bfdd-5df912be9cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0b2274be-257d-4029-8703-5c3b3498b863" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_2704795d-e118-47b0-bfdd-5df912be9cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_5076d1fd-a707-43a3-ba4e-e104033a6e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0b2274be-257d-4029-8703-5c3b3498b863" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_5076d1fd-a707-43a3-ba4e-e104033a6e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0bac948a-7c1c-417d-897d-0e85ab7cda69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0b2274be-257d-4029-8703-5c3b3498b863" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0bac948a-7c1c-417d-897d-0e85ab7cda69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="angn-20241231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_128352ea-14c7-47c8-8560-a439faf8f4ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_0053ab93-4484-4fce-b939-691f252432ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_128352ea-14c7-47c8-8560-a439faf8f4ac" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_0053ab93-4484-4fce-b939-691f252432ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/MergerandRelatedTransactionsTables" xlink:type="simple" xlink:href="angn-20241231.xsd#MergerandRelatedTransactionsTables"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/MergerandRelatedTransactionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_angn_ReverseRecapitalizationAbstract_8f3fc4a5-61a0-42c6-a066-5fa3800ab30c" xlink:href="angn-20241231.xsd#angn_ReverseRecapitalizationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ScheduleOfReverseRecapitalizationTableTextBlock_921cd341-86af-44dd-be9d-232ed1426505" xlink:href="angn-20241231.xsd#angn_ScheduleOfReverseRecapitalizationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_ReverseRecapitalizationAbstract_8f3fc4a5-61a0-42c6-a066-5fa3800ab30c" xlink:to="loc_angn_ScheduleOfReverseRecapitalizationTableTextBlock_921cd341-86af-44dd-be9d-232ed1426505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="angn-20241231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_761ef6c7-b9ab-4fdc-be22-61325f2eee3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1b1fbd20-7f9f-40df-893c-26d997091321" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_761ef6c7-b9ab-4fdc-be22-61325f2eee3f" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1b1fbd20-7f9f-40df-893c-26d997091321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_c02952b5-8b48-4378-af23-4690c55fa6b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_761ef6c7-b9ab-4fdc-be22-61325f2eee3f" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_c02952b5-8b48-4378-af23-4690c55fa6b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_b487412b-d45a-476e-b0f6-d3510a910dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_761ef6c7-b9ab-4fdc-be22-61325f2eee3f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_b487412b-d45a-476e-b0f6-d3510a910dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/BalanceSheetComponentsTables" xlink:type="simple" xlink:href="angn-20241231.xsd#BalanceSheetComponentsTables"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/BalanceSheetComponentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0efdc452-84be-4345-be5d-f4bef6b80284" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_78f19eb9-db49-463b-8173-126ee43b6771" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0efdc452-84be-4345-be5d-f4bef6b80284" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_78f19eb9-db49-463b-8173-126ee43b6771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_de3bd385-2528-4f9c-a1f1-d3456dcef2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0efdc452-84be-4345-be5d-f4bef6b80284" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_de3bd385-2528-4f9c-a1f1-d3456dcef2e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_33d9e809-b2c1-493e-9a1c-26e08e4f95a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0efdc452-84be-4345-be5d-f4bef6b80284" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_33d9e809-b2c1-493e-9a1c-26e08e4f95a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="angn-20241231.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_065bfcab-7c3d-4e33-82d2-84f7f2d5e201" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_bc1907a4-7afb-4cf8-bd2e-523994a01c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_065bfcab-7c3d-4e33-82d2-84f7f2d5e201" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_bc1907a4-7afb-4cf8-bd2e-523994a01c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_c0c45a4c-60a5-477f-b555-95ad38a4440f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_065bfcab-7c3d-4e33-82d2-84f7f2d5e201" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_c0c45a4c-60a5-477f-b555-95ad38a4440f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_dde506a3-2fa0-4064-b92e-3b521825a0c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_065bfcab-7c3d-4e33-82d2-84f7f2d5e201" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_dde506a3-2fa0-4064-b92e-3b521825a0c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/WarrantsTables" xlink:type="simple" xlink:href="angn-20241231.xsd#WarrantsTables"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/WarrantsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsAndRightsOutstandingAbstract_3f07c819-61c4-4253-b8b9-12cda4fbfa17" xlink:href="angn-20241231.xsd#angn_WarrantsAndRightsOutstandingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_5b24a12b-8659-4090-bf8d-63a9c0e22e69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_WarrantsAndRightsOutstandingAbstract_3f07c819-61c4-4253-b8b9-12cda4fbfa17" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_5b24a12b-8659-4090-bf8d-63a9c0e22e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/LeasesTables" xlink:type="simple" xlink:href="angn-20241231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e7e96aa9-ed89-406e-a23b-3993390ed4a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock_c7187ee8-3c0e-409d-bd6f-5f82773c70e6" xlink:href="angn-20241231.xsd#angn_ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e7e96aa9-ed89-406e-a23b-3993390ed4a5" xlink:to="loc_angn_ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock_c7187ee8-3c0e-409d-bd6f-5f82773c70e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_09485e36-f660-45e3-af2f-279cb8e4ea84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e7e96aa9-ed89-406e-a23b-3993390ed4a5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_09485e36-f660-45e3-af2f-279cb8e4ea84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="angn-20241231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1611862f-7175-4299-ab1e-a283c624fd13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_66143111-34e6-4cbe-b118-225db21a826c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1611862f-7175-4299-ab1e-a283c624fd13" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_66143111-34e6-4cbe-b118-225db21a826c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_52ce5dd3-5d9a-4225-9201-f1ebe90a3a95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1611862f-7175-4299-ab1e-a283c624fd13" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_52ce5dd3-5d9a-4225-9201-f1ebe90a3a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0f59877f-c459-4264-a43a-21c747f0dca8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1611862f-7175-4299-ab1e-a283c624fd13" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0f59877f-c459-4264-a43a-21c747f0dca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="angn-20241231.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_75a5b00f-84e1-4bfc-8c93-b510518961dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7237fd85-4362-4411-84c1-08ce45a704bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_75a5b00f-84e1-4bfc-8c93-b510518961dc" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7237fd85-4362-4411-84c1-08ce45a704bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_89c9a2f7-28d3-400f-9ef7-f5e35703977e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_75a5b00f-84e1-4bfc-8c93-b510518961dc" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_89c9a2f7-28d3-400f-9ef7-f5e35703977e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="angn-20241231.xsd#SegmentReportingTables"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/SegmentReportingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_62c5d676-5112-463d-bfce-bbb2c47dbbbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_1d3ddeba-0352-440e-a18b-81d55c2a9deb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_62c5d676-5112-463d-bfce-bbb2c47dbbbc" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_1d3ddeba-0352-440e-a18b-81d55c2a9deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#DescriptionoftheBusinessandFinancialConditionDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7e964ca1-fb4c-424d-87f5-6eca1f8dfa0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_3430381f-4a09-42b4-b9c2-77b6c1c97a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7e964ca1-fb4c-424d-87f5-6eca1f8dfa0c" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_3430381f-4a09-42b4-b9c2-77b6c1c97a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_664e84fc-0317-4ff1-ad66-24c3ec3d133b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_3430381f-4a09-42b4-b9c2-77b6c1c97a6e" xlink:to="loc_srt_OwnershipAxis_664e84fc-0317-4ff1-ad66-24c3ec3d133b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_f5083559-46ba-4ec3-a9c6-9bc0e6935545" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_664e84fc-0317-4ff1-ad66-24c3ec3d133b" xlink:to="loc_srt_OwnershipDomain_f5083559-46ba-4ec3-a9c6-9bc0e6935545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FormerElicioEquityHoldersMember_1dbfe387-db75-4eea-b5a3-d0249686a400" xlink:href="angn-20241231.xsd#angn_FormerElicioEquityHoldersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_f5083559-46ba-4ec3-a9c6-9bc0e6935545" xlink:to="loc_angn_FormerElicioEquityHoldersMember_1dbfe387-db75-4eea-b5a3-d0249686a400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FormerAngionEquityHoldersMember_70d3560a-6649-401c-adf2-1791b50f8e79" xlink:href="angn-20241231.xsd#angn_FormerAngionEquityHoldersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_f5083559-46ba-4ec3-a9c6-9bc0e6935545" xlink:to="loc_angn_FormerAngionEquityHoldersMember_70d3560a-6649-401c-adf2-1791b50f8e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_b3725cc6-8f06-47a5-98a2-1bcff3653a90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_3430381f-4a09-42b4-b9c2-77b6c1c97a6e" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_b3725cc6-8f06-47a5-98a2-1bcff3653a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7a5f6242-572b-42ff-ae5f-8c6013943739" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_b3725cc6-8f06-47a5-98a2-1bcff3653a90" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7a5f6242-572b-42ff-ae5f-8c6013943739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ReverseRecapitalizationOwnershipPercentage_3f47b796-5320-4e52-99ad-b92f7affc2df" xlink:href="angn-20241231.xsd#angn_ReverseRecapitalizationOwnershipPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_b3725cc6-8f06-47a5-98a2-1bcff3653a90" xlink:to="loc_angn_ReverseRecapitalizationOwnershipPercentage_3f47b796-5320-4e52-99ad-b92f7affc2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_09e3119d-6c65-4f49-bbd1-155e32c753cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_b3725cc6-8f06-47a5-98a2-1bcff3653a90" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_09e3119d-6c65-4f49-bbd1-155e32c753cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0c3d3ca5-e2ad-42b3-a0d0-4d908a4cb86a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_b3725cc6-8f06-47a5-98a2-1bcff3653a90" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0c3d3ca5-e2ad-42b3-a0d0-4d908a4cb86a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3fa57eb3-d8df-49a2-99c1-74d511adad4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_7439bf93-6057-4c53-96b7-6280b53130ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3fa57eb3-d8df-49a2-99c1-74d511adad4c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_7439bf93-6057-4c53-96b7-6280b53130ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_456c3c45-223c-4472-b05b-752e5ad8a5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7439bf93-6057-4c53-96b7-6280b53130ac" xlink:to="loc_us-gaap_StatementClassOfStockAxis_456c3c45-223c-4472-b05b-752e5ad8a5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2d35706e-5749-493d-9cc3-a88275f3dfb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_456c3c45-223c-4472-b05b-752e5ad8a5e7" xlink:to="loc_us-gaap_ClassOfStockDomain_2d35706e-5749-493d-9cc3-a88275f3dfb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AngionCommonStockMember_03ec359d-d25c-4201-8f0d-a2f90a9617ef" xlink:href="angn-20241231.xsd#angn_AngionCommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2d35706e-5749-493d-9cc3-a88275f3dfb7" xlink:to="loc_angn_AngionCommonStockMember_03ec359d-d25c-4201-8f0d-a2f90a9617ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_07b0ac51-3f68-4673-bd60-739cebf0448a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7439bf93-6057-4c53-96b7-6280b53130ac" xlink:to="loc_us-gaap_ClassOfStockLineItems_07b0ac51-3f68-4673-bd60-739cebf0448a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_8cce5aba-f603-47ce-8fd2-950a513bfc2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_07b0ac51-3f68-4673-bd60-739cebf0448a" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_8cce5aba-f603-47ce-8fd2-950a513bfc2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_80965695-aa4c-43e9-bccf-255bcba1938d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_07b0ac51-3f68-4673-bd60-739cebf0448a" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_80965695-aa4c-43e9-bccf-255bcba1938d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_RecapitalizationExchangeRatio_8b871d52-f477-42e1-b1d2-7d318438ba6d" xlink:href="angn-20241231.xsd#angn_RecapitalizationExchangeRatio"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_07b0ac51-3f68-4673-bd60-739cebf0448a" xlink:to="loc_angn_RecapitalizationExchangeRatio_8b871d52-f477-42e1-b1d2-7d318438ba6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_6c550a8e-7c1e-4baa-a1ad-16c4a7ed3fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_07b0ac51-3f68-4673-bd60-739cebf0448a" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_6c550a8e-7c1e-4baa-a1ad-16c4a7ed3fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d5f90917-162e-487f-9c21-3564e90d5747" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8e195495-0ce8-41a7-91c6-3d3ab32f50aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d5f90917-162e-487f-9c21-3564e90d5747" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8e195495-0ce8-41a7-91c6-3d3ab32f50aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8e876d43-bf68-4d00-8c5d-c47c69457e30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8e195495-0ce8-41a7-91c6-3d3ab32f50aa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8e876d43-bf68-4d00-8c5d-c47c69457e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2c33a154-ccfd-41f4-9955-4cfe6196555d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8e876d43-bf68-4d00-8c5d-c47c69457e30" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2c33a154-ccfd-41f4-9955-4cfe6196555d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_6560e72b-5232-4c67-903e-38bdf8878b70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2c33a154-ccfd-41f4-9955-4cfe6196555d" xlink:to="loc_us-gaap_EquipmentMember_6560e72b-5232-4c67-903e-38bdf8878b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_3d493426-3e68-48c6-a604-2718758a6c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2c33a154-ccfd-41f4-9955-4cfe6196555d" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_3d493426-3e68-48c6-a604-2718758a6c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a8350a69-669f-497b-8468-80ce5ecc7651" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8e195495-0ce8-41a7-91c6-3d3ab32f50aa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a8350a69-669f-497b-8468-80ce5ecc7651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_8827fd90-4f8a-4366-9958-8cd141245b46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a8350a69-669f-497b-8468-80ce5ecc7651" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_8827fd90-4f8a-4366-9958-8cd141245b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/MergerandRelatedTransactionsNarrativeDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#MergerandRelatedTransactionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/MergerandRelatedTransactionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_angn_ReverseRecapitalizationAbstract_beaee32f-9044-4a03-9ddb-5f40c80bf186" xlink:href="angn-20241231.xsd#angn_ReverseRecapitalizationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ScheduleOfReverseRecapitalizationTable_180a1a1b-fd9e-4159-ab76-edc371aef685" xlink:href="angn-20241231.xsd#angn_ScheduleOfReverseRecapitalizationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_ReverseRecapitalizationAbstract_beaee32f-9044-4a03-9ddb-5f40c80bf186" xlink:to="loc_angn_ScheduleOfReverseRecapitalizationTable_180a1a1b-fd9e-4159-ab76-edc371aef685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_2bd27172-cc25-4a87-84e2-8735854365f6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_ScheduleOfReverseRecapitalizationTable_180a1a1b-fd9e-4159-ab76-edc371aef685" xlink:to="loc_dei_LegalEntityAxis_2bd27172-cc25-4a87-84e2-8735854365f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ec445f75-7893-4fe3-9770-b6009c5aadd7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2bd27172-cc25-4a87-84e2-8735854365f6" xlink:to="loc_dei_EntityDomain_ec445f75-7893-4fe3-9770-b6009c5aadd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FormerElicioMember_3efefcd6-e953-459f-9beb-714ec5144c74" xlink:href="angn-20241231.xsd#angn_FormerElicioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_ec445f75-7893-4fe3-9770-b6009c5aadd7" xlink:to="loc_angn_FormerElicioMember_3efefcd6-e953-459f-9beb-714ec5144c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6b7182a5-3915-405f-8072-2cc6bbd20347" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_ScheduleOfReverseRecapitalizationTable_180a1a1b-fd9e-4159-ab76-edc371aef685" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6b7182a5-3915-405f-8072-2cc6bbd20347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_334ae451-85c3-44bc-851e-4b24c8a03200" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6b7182a5-3915-405f-8072-2cc6bbd20347" xlink:to="loc_us-gaap_ClassOfStockDomain_334ae451-85c3-44bc-851e-4b24c8a03200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AngionCommonStockMember_04844387-5dbb-48a9-8142-7574e3c3ce3c" xlink:href="angn-20241231.xsd#angn_AngionCommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_334ae451-85c3-44bc-851e-4b24c8a03200" xlink:to="loc_angn_AngionCommonStockMember_04844387-5dbb-48a9-8142-7574e3c3ce3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a3d4aae4-f8f5-4b82-a42a-a44e47ca83cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_ScheduleOfReverseRecapitalizationTable_180a1a1b-fd9e-4159-ab76-edc371aef685" xlink:to="loc_us-gaap_DebtInstrumentAxis_a3d4aae4-f8f5-4b82-a42a-a44e47ca83cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b4d8763a-1f91-4f4e-b107-bf71808a9087" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_a3d4aae4-f8f5-4b82-a42a-a44e47ca83cd" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b4d8763a-1f91-4f4e-b107-bf71808a9087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_BridgeLoanBetweenAngionAndFormerElicioMember_29284872-34ae-4b71-b90a-fb2e49cd6862" xlink:href="angn-20241231.xsd#angn_BridgeLoanBetweenAngionAndFormerElicioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b4d8763a-1f91-4f4e-b107-bf71808a9087" xlink:to="loc_angn_BridgeLoanBetweenAngionAndFormerElicioMember_29284872-34ae-4b71-b90a-fb2e49cd6862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountInitialClosingMember_ef16bfe2-8860-432b-a46f-f524b9aa851a" xlink:href="angn-20241231.xsd#angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountInitialClosingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b4d8763a-1f91-4f4e-b107-bf71808a9087" xlink:to="loc_angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountInitialClosingMember_ef16bfe2-8860-432b-a46f-f524b9aa851a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_BridgeLoanBetweenAngionAndFormerElicioInitialClosingMember_72c8498b-f403-42cb-8112-8a465ebcdb21" xlink:href="angn-20241231.xsd#angn_BridgeLoanBetweenAngionAndFormerElicioInitialClosingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b4d8763a-1f91-4f4e-b107-bf71808a9087" xlink:to="loc_angn_BridgeLoanBetweenAngionAndFormerElicioInitialClosingMember_72c8498b-f403-42cb-8112-8a465ebcdb21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountAdditionalClosingMember_8928f007-6fd9-46cf-a283-f6f9068def23" xlink:href="angn-20241231.xsd#angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountAdditionalClosingMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b4d8763a-1f91-4f4e-b107-bf71808a9087" xlink:to="loc_angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountAdditionalClosingMember_8928f007-6fd9-46cf-a283-f6f9068def23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_BridgeLoanBetweenAngionAndFormerElicioAdditionalClosingMember_24954b7b-1d92-4582-8346-b8a45f1abd01" xlink:href="angn-20241231.xsd#angn_BridgeLoanBetweenAngionAndFormerElicioAdditionalClosingMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b4d8763a-1f91-4f4e-b107-bf71808a9087" xlink:to="loc_angn_BridgeLoanBetweenAngionAndFormerElicioAdditionalClosingMember_24954b7b-1d92-4582-8346-b8a45f1abd01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b1d5b504-8bd2-45e0-8688-e25f4c29f9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_ScheduleOfReverseRecapitalizationTable_180a1a1b-fd9e-4159-ab76-edc371aef685" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b1d5b504-8bd2-45e0-8688-e25f4c29f9ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_175a5074-21ba-49dc-9959-3c3415f95ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b1d5b504-8bd2-45e0-8688-e25f4c29f9ec" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_175a5074-21ba-49dc-9959-3c3415f95ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_cd6b9f8c-5a43-4e8c-9fb2-1952a925a104" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_175a5074-21ba-49dc-9959-3c3415f95ee3" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_cd6b9f8c-5a43-4e8c-9fb2-1952a925a104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ReverseRecapitalizationLineItems_4079921b-2c0b-41b2-948d-c2fd46e2b9e3" xlink:href="angn-20241231.xsd#angn_ReverseRecapitalizationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_ScheduleOfReverseRecapitalizationTable_180a1a1b-fd9e-4159-ab76-edc371aef685" xlink:to="loc_angn_ReverseRecapitalizationLineItems_4079921b-2c0b-41b2-948d-c2fd46e2b9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_NumberOfMembersOfTheBoardOfDirectors_3f95e5b9-8814-4bd0-a166-3c525d94188f" xlink:href="angn-20241231.xsd#angn_NumberOfMembersOfTheBoardOfDirectors"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_ReverseRecapitalizationLineItems_4079921b-2c0b-41b2-948d-c2fd46e2b9e3" xlink:to="loc_angn_NumberOfMembersOfTheBoardOfDirectors_3f95e5b9-8814-4bd0-a166-3c525d94188f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_RecapitalizationExchangeRatio_ca5dfcb9-469d-49b3-aa56-f70e5db68b51" xlink:href="angn-20241231.xsd#angn_RecapitalizationExchangeRatio"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_ReverseRecapitalizationLineItems_4079921b-2c0b-41b2-948d-c2fd46e2b9e3" xlink:to="loc_angn_RecapitalizationExchangeRatio_ca5dfcb9-469d-49b3-aa56-f70e5db68b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_cba004e5-208e-4cdb-8305-86b8017c1c17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_ReverseRecapitalizationLineItems_4079921b-2c0b-41b2-948d-c2fd46e2b9e3" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_cba004e5-208e-4cdb-8305-86b8017c1c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_34bb0957-4641-49e7-8903-8f165d37e8a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_ReverseRecapitalizationLineItems_4079921b-2c0b-41b2-948d-c2fd46e2b9e3" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_34bb0957-4641-49e7-8903-8f165d37e8a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_83d95a45-7092-4bfc-aedf-bcf23af6b920" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_ReverseRecapitalizationLineItems_4079921b-2c0b-41b2-948d-c2fd46e2b9e3" xlink:to="loc_us-gaap_CommonStockSharesIssued_83d95a45-7092-4bfc-aedf-bcf23af6b920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_23f603d1-be7c-4730-9ef1-86434ca86e56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_ReverseRecapitalizationLineItems_4079921b-2c0b-41b2-948d-c2fd46e2b9e3" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_23f603d1-be7c-4730-9ef1-86434ca86e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_c082f47b-6894-4cef-8833-4677b8e2a964" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_ReverseRecapitalizationLineItems_4079921b-2c0b-41b2-948d-c2fd46e2b9e3" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_c082f47b-6894-4cef-8833-4677b8e2a964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_DebtInstrumentIssuanceDiscountPercent_be560898-ab00-417d-a192-2955d198693d" xlink:href="angn-20241231.xsd#angn_DebtInstrumentIssuanceDiscountPercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_ReverseRecapitalizationLineItems_4079921b-2c0b-41b2-948d-c2fd46e2b9e3" xlink:to="loc_angn_DebtInstrumentIssuanceDiscountPercent_be560898-ab00-417d-a192-2955d198693d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a8ed4a23-9222-42b5-b6ad-963db85d71ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_ReverseRecapitalizationLineItems_4079921b-2c0b-41b2-948d-c2fd46e2b9e3" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a8ed4a23-9222-42b5-b6ad-963db85d71ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ReverseRecapitalizationTransactionCosts_a987b251-b300-4fc9-bfdd-d551781ccb06" xlink:href="angn-20241231.xsd#angn_ReverseRecapitalizationTransactionCosts"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_ReverseRecapitalizationLineItems_4079921b-2c0b-41b2-948d-c2fd46e2b9e3" xlink:to="loc_angn_ReverseRecapitalizationTransactionCosts_a987b251-b300-4fc9-bfdd-d551781ccb06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/MergerandRelatedTransactionsScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#MergerandRelatedTransactionsScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/MergerandRelatedTransactionsScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_angn_ReverseRecapitalizationAbstract_dfe59fa8-1a83-4816-9f40-dbb325df1568" xlink:href="angn-20241231.xsd#angn_ReverseRecapitalizationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_CashAndCashEquivalentsAcquiredThroughReverseRecapitalization_4abd91eb-1bcf-43e2-962a-1549db87132d" xlink:href="angn-20241231.xsd#angn_CashAndCashEquivalentsAcquiredThroughReverseRecapitalization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_ReverseRecapitalizationAbstract_dfe59fa8-1a83-4816-9f40-dbb325df1568" xlink:to="loc_angn_CashAndCashEquivalentsAcquiredThroughReverseRecapitalization_4abd91eb-1bcf-43e2-962a-1549db87132d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_OtherCurrentAssetsAcquiredThroughReverseRecapitalization_08059886-18f6-44aa-b021-02d1f816387b" xlink:href="angn-20241231.xsd#angn_OtherCurrentAssetsAcquiredThroughReverseRecapitalization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_ReverseRecapitalizationAbstract_dfe59fa8-1a83-4816-9f40-dbb325df1568" xlink:to="loc_angn_OtherCurrentAssetsAcquiredThroughReverseRecapitalization_08059886-18f6-44aa-b021-02d1f816387b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_PromissoryNotesAcquiredThroughReverseRecapitalization_1f2546e1-1e26-4f61-bd87-8e61ab60ed25" xlink:href="angn-20241231.xsd#angn_PromissoryNotesAcquiredThroughReverseRecapitalization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_ReverseRecapitalizationAbstract_dfe59fa8-1a83-4816-9f40-dbb325df1568" xlink:to="loc_angn_PromissoryNotesAcquiredThroughReverseRecapitalization_1f2546e1-1e26-4f61-bd87-8e61ab60ed25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AccruedLiabilitiesAssumedThroughReverseRecapitalization_21099673-728d-4f27-a203-7fc0cb6ba60a" xlink:href="angn-20241231.xsd#angn_AccruedLiabilitiesAssumedThroughReverseRecapitalization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_ReverseRecapitalizationAbstract_dfe59fa8-1a83-4816-9f40-dbb325df1568" xlink:to="loc_angn_AccruedLiabilitiesAssumedThroughReverseRecapitalization_21099673-728d-4f27-a203-7fc0cb6ba60a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_NetAssetsAcquiredThroughReverseRecapitalization_c7fbd3ec-07bc-4a28-b59a-8b6532c35bd3" xlink:href="angn-20241231.xsd#angn_NetAssetsAcquiredThroughReverseRecapitalization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_ReverseRecapitalizationAbstract_dfe59fa8-1a83-4816-9f40-dbb325df1568" xlink:to="loc_angn_NetAssetsAcquiredThroughReverseRecapitalization_c7fbd3ec-07bc-4a28-b59a-8b6532c35bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ccac17bb-e5e2-4d13-93ba-9c5c8c4c925d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_c2f73bf6-34d2-4861-a22e-00ddd6a4c30d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ccac17bb-e5e2-4d13-93ba-9c5c8c4c925d" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_c2f73bf6-34d2-4861-a22e-00ddd6a4c30d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_db237d67-52cb-44d2-a1ae-4f46938ebd10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_c2f73bf6-34d2-4861-a22e-00ddd6a4c30d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_db237d67-52cb-44d2-a1ae-4f46938ebd10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6c11a871-3668-4707-9827-46be0239c6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_db237d67-52cb-44d2-a1ae-4f46938ebd10" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6c11a871-3668-4707-9827-46be0239c6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_3b7dc291-0708-4cae-b00f-6f8c014612c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6c11a871-3668-4707-9827-46be0239c6cf" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_3b7dc291-0708-4cae-b00f-6f8c014612c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_3a957a9c-53bc-47ea-9fc3-8c7930013db3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6c11a871-3668-4707-9827-46be0239c6cf" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_3a957a9c-53bc-47ea-9fc3-8c7930013db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_82fe3a3f-3f31-412b-832e-2a869b800d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6c11a871-3668-4707-9827-46be0239c6cf" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_82fe3a3f-3f31-412b-832e-2a869b800d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_224688f9-2a8c-4c96-92b0-0aaef0c7d1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_c2f73bf6-34d2-4861-a22e-00ddd6a4c30d" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_224688f9-2a8c-4c96-92b0-0aaef0c7d1f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_92157dd6-96ad-4833-9339-1ad2a683dbac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_224688f9-2a8c-4c96-92b0-0aaef0c7d1f7" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_92157dd6-96ad-4833-9339-1ad2a683dbac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_03c6a233-b7ee-47f3-9ebe-3d7731c5325e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_92157dd6-96ad-4833-9339-1ad2a683dbac" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_03c6a233-b7ee-47f3-9ebe-3d7731c5325e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3157fabf-3ef3-4519-bc72-a53204ca860c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_c2f73bf6-34d2-4861-a22e-00ddd6a4c30d" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3157fabf-3ef3-4519-bc72-a53204ca860c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_2dd1e676-2e36-4b66-8bb5-223e5aced136" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3157fabf-3ef3-4519-bc72-a53204ca860c" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_2dd1e676-2e36-4b66-8bb5-223e5aced136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_79ac8da3-2a31-4381-8b05-bc8424c42107" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_2dd1e676-2e36-4b66-8bb5-223e5aced136" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_79ac8da3-2a31-4381-8b05-bc8424c42107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_c9a8be86-4ff0-4c32-bdc8-821af0a4efee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_2dd1e676-2e36-4b66-8bb5-223e5aced136" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_c9a8be86-4ff0-4c32-bdc8-821af0a4efee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_d563f392-16ce-4631-8e57-6afc4feb925a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3157fabf-3ef3-4519-bc72-a53204ca860c" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_d563f392-16ce-4631-8e57-6afc4feb925a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsFairValueDisclosure_6d31b621-99dc-4bf4-b8c6-ded30cd3a641" xlink:href="angn-20241231.xsd#angn_WarrantsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_d563f392-16ce-4631-8e57-6afc4feb925a" xlink:to="loc_angn_WarrantsFairValueDisclosure_6d31b621-99dc-4bf4-b8c6-ded30cd3a641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_d5325e7d-fb7e-49cf-9ab3-cdf6f935e639" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_d563f392-16ce-4631-8e57-6afc4feb925a" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_d5325e7d-fb7e-49cf-9ab3-cdf6f935e639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#FairValueMeasurementsScheduleofFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_21e2ebe3-6caa-4ebc-a5fa-665968f5a9e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a9fae550-b161-413a-8bc3-1ccab2de7436" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_21e2ebe3-6caa-4ebc-a5fa-665968f5a9e4" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a9fae550-b161-413a-8bc3-1ccab2de7436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_f449f4d9-2bb3-4e82-8c33-3f2f0b4aa86d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a9fae550-b161-413a-8bc3-1ccab2de7436" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_f449f4d9-2bb3-4e82-8c33-3f2f0b4aa86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_39896801-ca50-45be-9f00-cbb61b4fdcb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_f449f4d9-2bb3-4e82-8c33-3f2f0b4aa86d" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_39896801-ca50-45be-9f00-cbb61b4fdcb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantLiabilityMember_dc06d3cb-6457-41bb-a319-e7219527c759" xlink:href="angn-20241231.xsd#angn_WarrantLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_39896801-ca50-45be-9f00-cbb61b4fdcb5" xlink:to="loc_angn_WarrantLiabilityMember_dc06d3cb-6457-41bb-a319-e7219527c759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_c0afa857-aaf1-4b89-9708-63228952e397" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a9fae550-b161-413a-8bc3-1ccab2de7436" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_c0afa857-aaf1-4b89-9708-63228952e397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6555aa64-56d7-4be0-bab2-5ca4329ca69c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_c0afa857-aaf1-4b89-9708-63228952e397" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6555aa64-56d7-4be0-bab2-5ca4329ca69c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_12b40503-57eb-4ebb-8ef8-d681230b4ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6555aa64-56d7-4be0-bab2-5ca4329ca69c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_12b40503-57eb-4ebb-8ef8-d681230b4ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_16efa29a-f85c-4ca6-9e0a-4da30cd2832a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6555aa64-56d7-4be0-bab2-5ca4329ca69c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_16efa29a-f85c-4ca6-9e0a-4da30cd2832a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c83e6613-0e38-4cb6-91f4-4f9fe214f6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6555aa64-56d7-4be0-bab2-5ca4329ca69c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c83e6613-0e38-4cb6-91f4-4f9fe214f6ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_78098f4d-ea44-418d-9543-26d028d2d952" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6555aa64-56d7-4be0-bab2-5ca4329ca69c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_78098f4d-ea44-418d-9543-26d028d2d952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a5a85588-07fb-40b4-b260-f4e6dc6f241a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_68665112-b16c-42fb-9a9c-3edef6fea4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a5a85588-07fb-40b4-b260-f4e6dc6f241a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_68665112-b16c-42fb-9a9c-3edef6fea4a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_2422c698-d169-476e-91cd-a1b810e3d4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_68665112-b16c-42fb-9a9c-3edef6fea4a6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_2422c698-d169-476e-91cd-a1b810e3d4dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_aa129020-e754-4e6c-9dc9-1ee53cb7deda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2422c698-d169-476e-91cd-a1b810e3d4dd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_aa129020-e754-4e6c-9dc9-1ee53cb7deda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_PreFundedWarrantMember_e73ef36d-1d29-4b3c-a3d8-871364e8579f" xlink:href="angn-20241231.xsd#angn_PreFundedWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_aa129020-e754-4e6c-9dc9-1ee53cb7deda" xlink:to="loc_angn_PreFundedWarrantMember_e73ef36d-1d29-4b3c-a3d8-871364e8579f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember_bbfe7e9f-e302-409e-bda8-717ace6de20e" xlink:href="angn-20241231.xsd#angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_aa129020-e754-4e6c-9dc9-1ee53cb7deda" xlink:to="loc_angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember_bbfe7e9f-e302-409e-bda8-717ace6de20e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_JulyPreFundedWarrantsMember_37d48eeb-a240-4375-8ad2-c1b7db806c18" xlink:href="angn-20241231.xsd#angn_JulyPreFundedWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember_bbfe7e9f-e302-409e-bda8-717ace6de20e" xlink:to="loc_angn_JulyPreFundedWarrantsMember_37d48eeb-a240-4375-8ad2-c1b7db806c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_JulyCommonWarrantsMember_f7cd4beb-94a0-4d0c-9c6f-45faad9e7ae8" xlink:href="angn-20241231.xsd#angn_JulyCommonWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember_bbfe7e9f-e302-409e-bda8-717ace6de20e" xlink:to="loc_angn_JulyCommonWarrantsMember_f7cd4beb-94a0-4d0c-9c6f-45faad9e7ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_154c01c8-a3bd-4086-a2a5-4f2dd6ce714b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_68665112-b16c-42fb-9a9c-3edef6fea4a6" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_154c01c8-a3bd-4086-a2a5-4f2dd6ce714b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_65ddec05-580b-4a86-915b-23ee2415cde0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_154c01c8-a3bd-4086-a2a5-4f2dd6ce714b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_65ddec05-580b-4a86-915b-23ee2415cde0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_MarchSubscriptionAgreementMember_3c57a12a-b875-4759-918b-620a366ee70b" xlink:href="angn-20241231.xsd#angn_MarchSubscriptionAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_65ddec05-580b-4a86-915b-23ee2415cde0" xlink:to="loc_angn_MarchSubscriptionAgreementMember_3c57a12a-b875-4759-918b-620a366ee70b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_JulyPublicOfferingMember_87559132-e436-4c22-a5cd-89a9824b5fc4" xlink:href="angn-20241231.xsd#angn_JulyPublicOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_65ddec05-580b-4a86-915b-23ee2415cde0" xlink:to="loc_angn_JulyPublicOfferingMember_87559132-e436-4c22-a5cd-89a9824b5fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ebb76922-e9d2-48b5-81cc-b75bd082f498" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_68665112-b16c-42fb-9a9c-3edef6fea4a6" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ebb76922-e9d2-48b5-81cc-b75bd082f498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_655e383a-de74-487e-8189-91f39917d88d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ebb76922-e9d2-48b5-81cc-b75bd082f498" xlink:to="loc_us-gaap_ClassOfStockDomain_655e383a-de74-487e-8189-91f39917d88d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_JulySharesAndJulyCommonWarrantMember_0cebe5b5-6e43-469d-8c11-e474f726ae42" xlink:href="angn-20241231.xsd#angn_JulySharesAndJulyCommonWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_655e383a-de74-487e-8189-91f39917d88d" xlink:to="loc_angn_JulySharesAndJulyCommonWarrantMember_0cebe5b5-6e43-469d-8c11-e474f726ae42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_510c9a33-8a60-40d8-8711-7b4a883f691e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_68665112-b16c-42fb-9a9c-3edef6fea4a6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_510c9a33-8a60-40d8-8711-7b4a883f691e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_79804130-df65-49a5-bc50-c4c56cf9700f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_510c9a33-8a60-40d8-8711-7b4a883f691e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_79804130-df65-49a5-bc50-c4c56cf9700f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_178aecde-e15e-4508-99f2-4db55792a78d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_510c9a33-8a60-40d8-8711-7b4a883f691e" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_178aecde-e15e-4508-99f2-4db55792a78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_c04e41fc-85bb-4206-9141-8ffd5619a59e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_510c9a33-8a60-40d8-8711-7b4a883f691e" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_c04e41fc-85bb-4206-9141-8ffd5619a59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1dcde385-454f-432f-9acc-7559c6c84304" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_510c9a33-8a60-40d8-8711-7b4a883f691e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1dcde385-454f-432f-9acc-7559c6c84304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_f1dd1483-896d-4ae0-ac33-94ef23ba62d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_510c9a33-8a60-40d8-8711-7b4a883f691e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_f1dd1483-896d-4ae0-ac33-94ef23ba62d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_806ddab7-f7f2-49a2-ab4b-e6bd905cea7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_510c9a33-8a60-40d8-8711-7b4a883f691e" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_806ddab7-f7f2-49a2-ab4b-e6bd905cea7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e27ac4ad-2a3b-431f-bd22-5ce70b6e6203" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_510c9a33-8a60-40d8-8711-7b4a883f691e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e27ac4ad-2a3b-431f-bd22-5ce70b6e6203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_08a3156e-a8df-43d3-833f-dc4119ecb7b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_510c9a33-8a60-40d8-8711-7b4a883f691e" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_08a3156e-a8df-43d3-833f-dc4119ecb7b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_SaleOfStockBeneficialOwnershipLimitationPercentage_a0b127b1-e1ce-44cb-ae28-60cdca580801" xlink:href="angn-20241231.xsd#angn_SaleOfStockBeneficialOwnershipLimitationPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_510c9a33-8a60-40d8-8711-7b4a883f691e" xlink:to="loc_angn_SaleOfStockBeneficialOwnershipLimitationPercentage_a0b127b1-e1ce-44cb-ae28-60cdca580801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a0702765-a7e3-4fdd-bdf0-083c13f97952" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_21e1f062-299f-4dce-a781-d4849dd5e13c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a0702765-a7e3-4fdd-bdf0-083c13f97952" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_21e1f062-299f-4dce-a781-d4849dd5e13c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8fa36441-f55a-4e63-a2cc-117973a56813" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_21e1f062-299f-4dce-a781-d4849dd5e13c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8fa36441-f55a-4e63-a2cc-117973a56813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2a948eb0-8f64-403a-8a38-c7bb77b5eb23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8fa36441-f55a-4e63-a2cc-117973a56813" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2a948eb0-8f64-403a-8a38-c7bb77b5eb23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3407fe92-98cb-4761-bb52-029cfd16ad6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2a948eb0-8f64-403a-8a38-c7bb77b5eb23" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3407fe92-98cb-4761-bb52-029cfd16ad6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_c89d4e61-fc2a-42eb-8318-a940fbea8c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_21e1f062-299f-4dce-a781-d4849dd5e13c" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_c89d4e61-fc2a-42eb-8318-a940fbea8c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_d4f9242c-2dad-4ed3-84a3-8fb6a6596b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_c89d4e61-fc2a-42eb-8318-a940fbea8c6e" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_d4f9242c-2dad-4ed3-84a3-8fb6a6596b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_MeasurementInputStrikePriceMember_777e271a-1621-4a40-bc47-3c1acc146f1e" xlink:href="angn-20241231.xsd#angn_MeasurementInputStrikePriceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d4f9242c-2dad-4ed3-84a3-8fb6a6596b4f" xlink:to="loc_angn_MeasurementInputStrikePriceMember_777e271a-1621-4a40-bc47-3c1acc146f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_2a5e50fe-9aae-4599-9ffd-7a8c15925640" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d4f9242c-2dad-4ed3-84a3-8fb6a6596b4f" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_2a5e50fe-9aae-4599-9ffd-7a8c15925640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_9f346b13-57d5-4e86-b211-61dfaa3d1f73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d4f9242c-2dad-4ed3-84a3-8fb6a6596b4f" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_9f346b13-57d5-4e86-b211-61dfaa3d1f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_5b490e2f-2455-4e47-a530-6fec3c2629bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d4f9242c-2dad-4ed3-84a3-8fb6a6596b4f" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_5b490e2f-2455-4e47-a530-6fec3c2629bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_697038ba-1d36-4f3b-8710-59f18a4b14ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_21e1f062-299f-4dce-a781-d4849dd5e13c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_697038ba-1d36-4f3b-8710-59f18a4b14ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_91613815-3613-4f5c-98a6-57f2e0f8536d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_697038ba-1d36-4f3b-8710-59f18a4b14ef" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_91613815-3613-4f5c-98a6-57f2e0f8536d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_c5d5a142-8247-4c84-96cf-92185a34bfc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_697038ba-1d36-4f3b-8710-59f18a4b14ef" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_c5d5a142-8247-4c84-96cf-92185a34bfc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/BalanceSheetComponentsScheduleofPrepaidandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#BalanceSheetComponentsScheduleofPrepaidandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/BalanceSheetComponentsScheduleofPrepaidandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df30678a-140d-45c1-ba9c-c21c2390eaee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_PrepaidResearchAndDevelopmentExpenses_a3787f2d-7263-482c-be4d-56ce3b9498ce" xlink:href="angn-20241231.xsd#angn_PrepaidResearchAndDevelopmentExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df30678a-140d-45c1-ba9c-c21c2390eaee" xlink:to="loc_angn_PrepaidResearchAndDevelopmentExpenses_a3787f2d-7263-482c-be4d-56ce3b9498ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AdvancedProfessionalFees_64232695-38c5-42f6-af4a-e23ccd763787" xlink:href="angn-20241231.xsd#angn_AdvancedProfessionalFees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df30678a-140d-45c1-ba9c-c21c2390eaee" xlink:to="loc_angn_AdvancedProfessionalFees_64232695-38c5-42f6-af4a-e23ccd763787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_25f70000-1ef9-4a9b-8717-50c3567cad41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df30678a-140d-45c1-ba9c-c21c2390eaee" xlink:to="loc_us-gaap_PrepaidInsurance_25f70000-1ef9-4a9b-8717-50c3567cad41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_OtherPrepaidExpensesAndOtherAssetsCurrent_df860f8b-8592-4ddc-bd46-159c22a32ae4" xlink:href="angn-20241231.xsd#angn_OtherPrepaidExpensesAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df30678a-140d-45c1-ba9c-c21c2390eaee" xlink:to="loc_angn_OtherPrepaidExpensesAndOtherAssetsCurrent_df860f8b-8592-4ddc-bd46-159c22a32ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a53d6b24-e08e-4d7b-8941-47c672d938a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df30678a-140d-45c1-ba9c-c21c2390eaee" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a53d6b24-e08e-4d7b-8941-47c672d938a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_79d37fb3-1e53-4995-a88c-b9d5ce0e1fda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a2a35a21-cb85-4b89-987b-d979ab9ba319" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_79d37fb3-1e53-4995-a88c-b9d5ce0e1fda" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a2a35a21-cb85-4b89-987b-d979ab9ba319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ea887f78-8874-4605-b682-798f3c17db8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a2a35a21-cb85-4b89-987b-d979ab9ba319" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ea887f78-8874-4605-b682-798f3c17db8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8ad51b3e-28cd-486a-acc7-1592c2fffd33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ea887f78-8874-4605-b682-798f3c17db8d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8ad51b3e-28cd-486a-acc7-1592c2fffd33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_2137dbd9-9dda-48a5-b67e-797961e49501" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8ad51b3e-28cd-486a-acc7-1592c2fffd33" xlink:to="loc_us-gaap_EquipmentMember_2137dbd9-9dda-48a5-b67e-797961e49501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_10327786-e010-405f-ae3a-920c72b826f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8ad51b3e-28cd-486a-acc7-1592c2fffd33" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_10327786-e010-405f-ae3a-920c72b826f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_b000fec8-0a80-45a4-900a-9a2da62ce9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8ad51b3e-28cd-486a-acc7-1592c2fffd33" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_b000fec8-0a80-45a4-900a-9a2da62ce9ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_13a95c5e-3089-43c5-b64f-fb23ece0be59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a2a35a21-cb85-4b89-987b-d979ab9ba319" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_13a95c5e-3089-43c5-b64f-fb23ece0be59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_ca95226b-9440-45fe-bfd4-a6e2b316b476" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_13a95c5e-3089-43c5-b64f-fb23ece0be59" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_ca95226b-9440-45fe-bfd4-a6e2b316b476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c16f0db5-d3e8-4097-8597-b558378155d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_13a95c5e-3089-43c5-b64f-fb23ece0be59" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c16f0db5-d3e8-4097-8597-b558378155d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6df5b5c8-7022-417c-be9d-0acb12644deb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_13a95c5e-3089-43c5-b64f-fb23ece0be59" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6df5b5c8-7022-417c-be9d-0acb12644deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/BalanceSheetComponentsNarrativeDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#BalanceSheetComponentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/BalanceSheetComponentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5ab08bf5-f9c0-4d3f-b3a9-d36f21e5a48f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_b00ab19e-e283-4df1-b569-d9f15b65917b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5ab08bf5-f9c0-4d3f-b3a9-d36f21e5a48f" xlink:to="loc_us-gaap_Depreciation_b00ab19e-e283-4df1-b569-d9f15b65917b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseOtherNoncurrent_3fde8bbd-501d-411e-bca6-a73c2d809725" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseOtherNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5ab08bf5-f9c0-4d3f-b3a9-d36f21e5a48f" xlink:to="loc_us-gaap_PrepaidExpenseOtherNoncurrent_3fde8bbd-501d-411e-bca6-a73c2d809725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/BalanceSheetComponentsScheduleofAccruedExpensesDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#BalanceSheetComponentsScheduleofAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/BalanceSheetComponentsScheduleofAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0da9644f-f690-4c2d-9091-595ce60a1423" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_08dbdaca-b108-443b-ac1f-c7af0ee7453c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0da9644f-f690-4c2d-9091-595ce60a1423" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_08dbdaca-b108-443b-ac1f-c7af0ee7453c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0bba26be-334a-48ba-9bf1-7074ccf5a9b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0da9644f-f690-4c2d-9091-595ce60a1423" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0bba26be-334a-48ba-9bf1-7074ccf5a9b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AccruedResearchAndDevelopmentCurrent_a8f6c5ce-7573-497e-ae8f-365cee5d575d" xlink:href="angn-20241231.xsd#angn_AccruedResearchAndDevelopmentCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0da9644f-f690-4c2d-9091-595ce60a1423" xlink:to="loc_angn_AccruedResearchAndDevelopmentCurrent_a8f6c5ce-7573-497e-ae8f-365cee5d575d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AccruedOtherOperatingLiabilitiesCurrent_ca044deb-0f2d-47a3-99d7-7183f2ab1814" xlink:href="angn-20241231.xsd#angn_AccruedOtherOperatingLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0da9644f-f690-4c2d-9091-595ce60a1423" xlink:to="loc_angn_AccruedOtherOperatingLiabilitiesCurrent_ca044deb-0f2d-47a3-99d7-7183f2ab1814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2b9e3335-31af-4452-b4e0-67821ea105c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0da9644f-f690-4c2d-9091-595ce60a1423" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_2b9e3335-31af-4452-b4e0-67821ea105c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/ResearchGrantDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#ResearchGrantDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/ResearchGrantDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_ea6afc3c-de8d-4b1d-91ab-176d597b595e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_123ca317-7a99-4bf5-9376-3e72875db1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_ea6afc3c-de8d-4b1d-91ab-176d597b595e" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_123ca317-7a99-4bf5-9376-3e72875db1a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_530b0563-5e03-4a98-86ce-dae228af709a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_123ca317-7a99-4bf5-9376-3e72875db1a2" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_530b0563-5e03-4a98-86ce-dae228af709a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_5e7915bb-3154-4598-8ca1-19ce240f8174" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_530b0563-5e03-4a98-86ce-dae228af709a" xlink:to="loc_us-gaap_ProjectMember_5e7915bb-3154-4598-8ca1-19ce240f8174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept2022Member_9eb2dfdc-b719-4bf2-95d4-33ac1b2a048f" xlink:href="angn-20241231.xsd#angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept2022Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_5e7915bb-3154-4598-8ca1-19ce240f8174" xlink:to="loc_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept2022Member_9eb2dfdc-b719-4bf2-95d4-33ac1b2a048f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFJuly2023Member_d308850b-aede-4549-a407-cc2c16af2dc6" xlink:href="angn-20241231.xsd#angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFJuly2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_5e7915bb-3154-4598-8ca1-19ce240f8174" xlink:to="loc_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFJuly2023Member_d308850b-aede-4549-a407-cc2c16af2dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept.2023Member_f4e39f7c-7cd1-4ba3-b671-b0bd27d46f68" xlink:href="angn-20241231.xsd#angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept.2023Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_5e7915bb-3154-4598-8ca1-19ce240f8174" xlink:to="loc_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept.2023Member_f4e39f7c-7cd1-4ba3-b671-b0bd27d46f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFAugust2024Member_5dac8bfd-1d09-445e-9428-e16190ca43bf" xlink:href="angn-20241231.xsd#angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFAugust2024Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_5e7915bb-3154-4598-8ca1-19ce240f8174" xlink:to="loc_angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFAugust2024Member_5dac8bfd-1d09-445e-9428-e16190ca43bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9d9c34af-dc93-4332-a8d2-a428d218b45f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_123ca317-7a99-4bf5-9376-3e72875db1a2" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9d9c34af-dc93-4332-a8d2-a428d218b45f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ResearchAndDevelopmentArrangementGrant_3434fdf6-9d64-4fbd-8713-9ccb31543574" xlink:href="angn-20241231.xsd#angn_ResearchAndDevelopmentArrangementGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9d9c34af-dc93-4332-a8d2-a428d218b45f" xlink:to="loc_angn_ResearchAndDevelopmentArrangementGrant_3434fdf6-9d64-4fbd-8713-9ccb31543574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ResearchAndDevelopmentArrangementGrantReceived_91ad14b7-cade-4234-8b5d-11837ba583fa" xlink:href="angn-20241231.xsd#angn_ResearchAndDevelopmentArrangementGrantReceived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9d9c34af-dc93-4332-a8d2-a428d218b45f" xlink:to="loc_angn_ResearchAndDevelopmentArrangementGrantReceived_91ad14b7-cade-4234-8b5d-11837ba583fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6b63dc5a-0bf4-4ede-901b-bd138f9a0938" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9d9c34af-dc93-4332-a8d2-a428d218b45f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6b63dc5a-0bf4-4ede-901b-bd138f9a0938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ResearchAndDevelopmentArrangementCredit_1541ae3d-6488-491f-8b06-ab1e4bcb68fe" xlink:href="angn-20241231.xsd#angn_ResearchAndDevelopmentArrangementCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9d9c34af-dc93-4332-a8d2-a428d218b45f" xlink:to="loc_angn_ResearchAndDevelopmentArrangementCredit_1541ae3d-6488-491f-8b06-ab1e4bcb68fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a83aad80-ee46-43a3-83b7-aad36bf8fbb4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9d9c34af-dc93-4332-a8d2-a428d218b45f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a83aad80-ee46-43a3-83b7-aad36bf8fbb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_6b3ff915-5e65-4d50-b739-0edc075cd318" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9d9c34af-dc93-4332-a8d2-a428d218b45f" xlink:to="loc_us-gaap_RestrictedCashCurrent_6b3ff915-5e65-4d50-b739-0edc075cd318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ResearchAndDevelopmentArrangementReimbursementFromGrantFunds_4c7dde0d-e502-4a52-9675-4ae499d7d763" xlink:href="angn-20241231.xsd#angn_ResearchAndDevelopmentArrangementReimbursementFromGrantFunds"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9d9c34af-dc93-4332-a8d2-a428d218b45f" xlink:to="loc_angn_ResearchAndDevelopmentArrangementReimbursementFromGrantFunds_4c7dde0d-e502-4a52-9675-4ae499d7d763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_NumberOfResearchGrantAgreements_b35e72cc-b2ed-47d6-a137-9fef8e10b950" xlink:href="angn-20241231.xsd#angn_NumberOfResearchGrantAgreements"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9d9c34af-dc93-4332-a8d2-a428d218b45f" xlink:to="loc_angn_NumberOfResearchGrantAgreements_b35e72cc-b2ed-47d6-a137-9fef8e10b950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#ConvertiblePreferredStockCommonStockandStockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_228642e8-7c18-45c5-baac-d90a28b0d440" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_349acfc4-b9fc-4488-933e-fe92ab791ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_228642e8-7c18-45c5-baac-d90a28b0d440" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_349acfc4-b9fc-4488-933e-fe92ab791ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f4424d95-1a2c-4a04-ac4f-88a4b8142e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_349acfc4-b9fc-4488-933e-fe92ab791ad0" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f4424d95-1a2c-4a04-ac4f-88a4b8142e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_037b3419-d38a-47ef-9e0e-ebca4664ba12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f4424d95-1a2c-4a04-ac4f-88a4b8142e1c" xlink:to="loc_us-gaap_ClassOfStockDomain_037b3419-d38a-47ef-9e0e-ebca4664ba12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_38f2d618-ac04-49be-bd97-2948bc3d26dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_037b3419-d38a-47ef-9e0e-ebca4664ba12" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_38f2d618-ac04-49be-bd97-2948bc3d26dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_JulySharesAndJulyCommonWarrantMember_a5bb08d7-5b8d-43ee-9a30-a64b092c0882" xlink:href="angn-20241231.xsd#angn_JulySharesAndJulyCommonWarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_037b3419-d38a-47ef-9e0e-ebca4664ba12" xlink:to="loc_angn_JulySharesAndJulyCommonWarrantMember_a5bb08d7-5b8d-43ee-9a30-a64b092c0882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_c6e14886-288d-4b23-8f2d-cb0c7f6f5629" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_349acfc4-b9fc-4488-933e-fe92ab791ad0" xlink:to="loc_dei_LegalEntityAxis_c6e14886-288d-4b23-8f2d-cb0c7f6f5629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f309b630-1715-430e-8619-6461d9164c54" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_c6e14886-288d-4b23-8f2d-cb0c7f6f5629" xlink:to="loc_dei_EntityDomain_f309b630-1715-430e-8619-6461d9164c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FormerElicioMember_9cdc3ebb-e4ca-42d2-8a5a-9c1fc081e0e2" xlink:href="angn-20241231.xsd#angn_FormerElicioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_f309b630-1715-430e-8619-6461d9164c54" xlink:to="loc_angn_FormerElicioMember_9cdc3ebb-e4ca-42d2-8a5a-9c1fc081e0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_13543f12-add6-47da-b4d7-9f354f636602" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_349acfc4-b9fc-4488-933e-fe92ab791ad0" xlink:to="loc_srt_CounterpartyNameAxis_13543f12-add6-47da-b4d7-9f354f636602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_270cbd16-eb38-4493-99b2-776f771f414b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_13543f12-add6-47da-b4d7-9f354f636602" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_270cbd16-eb38-4493-99b2-776f771f414b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FormerElicioEquityHoldersMember_af1adcf0-916d-42cc-92ae-eaed20d78a0a" xlink:href="angn-20241231.xsd#angn_FormerElicioEquityHoldersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_270cbd16-eb38-4493-99b2-776f771f414b" xlink:to="loc_angn_FormerElicioEquityHoldersMember_af1adcf0-916d-42cc-92ae-eaed20d78a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2fe22c86-d5af-4334-a860-3f462f82f697" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_349acfc4-b9fc-4488-933e-fe92ab791ad0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2fe22c86-d5af-4334-a860-3f462f82f697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_adb223c7-2f7e-484d-9ca2-2528091c1bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2fe22c86-d5af-4334-a860-3f462f82f697" xlink:to="loc_us-gaap_EquityComponentDomain_adb223c7-2f7e-484d-9ca2-2528091c1bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_05e16113-f2b6-42de-b5e2-0b236e924f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_adb223c7-2f7e-484d-9ca2-2528091c1bf5" xlink:to="loc_us-gaap_CommonStockMember_05e16113-f2b6-42de-b5e2-0b236e924f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_56cde6be-9dd2-46f0-a898-0342d36665a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_349acfc4-b9fc-4488-933e-fe92ab791ad0" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_56cde6be-9dd2-46f0-a898-0342d36665a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e363c3a8-51ad-42c5-890e-4448e057f076" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_56cde6be-9dd2-46f0-a898-0342d36665a1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e363c3a8-51ad-42c5-890e-4448e057f076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_RegistrationStatementMember_bd255414-84b8-4889-8090-3c2f2e33e855" xlink:href="angn-20241231.xsd#angn_RegistrationStatementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e363c3a8-51ad-42c5-890e-4448e057f076" xlink:to="loc_angn_RegistrationStatementMember_bd255414-84b8-4889-8090-3c2f2e33e855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AtTheMarketEquityOfferingSalesAgreementMember_f4901024-68f8-4fbb-bb56-e39e2861be16" xlink:href="angn-20241231.xsd#angn_AtTheMarketEquityOfferingSalesAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e363c3a8-51ad-42c5-890e-4448e057f076" xlink:to="loc_angn_AtTheMarketEquityOfferingSalesAgreementMember_f4901024-68f8-4fbb-bb56-e39e2861be16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_A2024RegistrationStatementMember_5a071662-35cf-4d5c-944a-2484e54f6c9a" xlink:href="angn-20241231.xsd#angn_A2024RegistrationStatementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e363c3a8-51ad-42c5-890e-4448e057f076" xlink:to="loc_angn_A2024RegistrationStatementMember_5a071662-35cf-4d5c-944a-2484e54f6c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AtTheMarketEquityOfferingSalesAgreement2022Member_f34c1e91-050a-4073-ac99-49464366f79f" xlink:href="angn-20241231.xsd#angn_AtTheMarketEquityOfferingSalesAgreement2022Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e363c3a8-51ad-42c5-890e-4448e057f076" xlink:to="loc_angn_AtTheMarketEquityOfferingSalesAgreement2022Member_f34c1e91-050a-4073-ac99-49464366f79f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_MarchSubscriptionAgreementMember_3175e9ca-3f0e-45ed-acfc-5351ba33b09c" xlink:href="angn-20241231.xsd#angn_MarchSubscriptionAgreementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e363c3a8-51ad-42c5-890e-4448e057f076" xlink:to="loc_angn_MarchSubscriptionAgreementMember_3175e9ca-3f0e-45ed-acfc-5351ba33b09c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_JulyPublicOfferingMember_6faf7e2b-52f8-4f47-b40b-8c5c6665719d" xlink:href="angn-20241231.xsd#angn_JulyPublicOfferingMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e363c3a8-51ad-42c5-890e-4448e057f076" xlink:to="loc_angn_JulyPublicOfferingMember_6faf7e2b-52f8-4f47-b40b-8c5c6665719d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AtTheMarketEquityOfferingSalesAgreement2024Member_e5c53acb-f408-47df-96d1-3a303c0c395a" xlink:href="angn-20241231.xsd#angn_AtTheMarketEquityOfferingSalesAgreement2024Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e363c3a8-51ad-42c5-890e-4448e057f076" xlink:to="loc_angn_AtTheMarketEquityOfferingSalesAgreement2024Member_e5c53acb-f408-47df-96d1-3a303c0c395a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_97ff51b7-68fb-4c72-9691-2ce3360618e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_349acfc4-b9fc-4488-933e-fe92ab791ad0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_97ff51b7-68fb-4c72-9691-2ce3360618e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_5557e18d-ca08-4239-be59-3bccd6e819c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_97ff51b7-68fb-4c72-9691-2ce3360618e3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_5557e18d-ca08-4239-be59-3bccd6e819c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_PreFundedWarrantMember_013f802b-1192-49bb-aaad-145c8bb3301f" xlink:href="angn-20241231.xsd#angn_PreFundedWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5557e18d-ca08-4239-be59-3bccd6e819c7" xlink:to="loc_angn_PreFundedWarrantMember_013f802b-1192-49bb-aaad-145c8bb3301f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember_b53fe6b3-dcf7-4f57-9083-52e9b277ef5e" xlink:href="angn-20241231.xsd#angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5557e18d-ca08-4239-be59-3bccd6e819c7" xlink:to="loc_angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember_b53fe6b3-dcf7-4f57-9083-52e9b277ef5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_JulyPreFundedWarrantsMember_eca3c3fc-6796-494e-9d47-9c19e730a413" xlink:href="angn-20241231.xsd#angn_JulyPreFundedWarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5557e18d-ca08-4239-be59-3bccd6e819c7" xlink:to="loc_angn_JulyPreFundedWarrantsMember_eca3c3fc-6796-494e-9d47-9c19e730a413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_JulyCommonWarrantsMember_06f9fab6-5af6-4a7f-aaae-c00c6bbfe549" xlink:href="angn-20241231.xsd#angn_JulyCommonWarrantsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5557e18d-ca08-4239-be59-3bccd6e819c7" xlink:to="loc_angn_JulyCommonWarrantsMember_06f9fab6-5af6-4a7f-aaae-c00c6bbfe549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_13d1a269-01aa-4573-919d-7ce5fdce739a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_349acfc4-b9fc-4488-933e-fe92ab791ad0" xlink:to="loc_us-gaap_ClassOfStockLineItems_13d1a269-01aa-4573-919d-7ce5fdce739a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_e417468f-dbe0-44c7-9450-0de2f9a62089" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_13d1a269-01aa-4573-919d-7ce5fdce739a" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_e417468f-dbe0-44c7-9450-0de2f9a62089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_fb34cac0-97e2-45e6-9773-c58edf210de5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_13d1a269-01aa-4573-919d-7ce5fdce739a" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_fb34cac0-97e2-45e6-9773-c58edf210de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_b6864a3b-9068-4c50-985d-028ec386a215" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_13d1a269-01aa-4573-919d-7ce5fdce739a" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_b6864a3b-9068-4c50-985d-028ec386a215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_514e4083-3387-41d5-bd75-9829c418daa4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_13d1a269-01aa-4573-919d-7ce5fdce739a" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_514e4083-3387-41d5-bd75-9829c418daa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ae79cba4-ad99-4165-bf2b-b30c8e63af82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_13d1a269-01aa-4573-919d-7ce5fdce739a" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ae79cba4-ad99-4165-bf2b-b30c8e63af82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_TemporaryEquitySharesIssuedDuringPeriod_9befabf6-91e1-42a7-81a6-54555a8e4793" xlink:href="angn-20241231.xsd#angn_TemporaryEquitySharesIssuedDuringPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_13d1a269-01aa-4573-919d-7ce5fdce739a" xlink:to="loc_angn_TemporaryEquitySharesIssuedDuringPeriod_9befabf6-91e1-42a7-81a6-54555a8e4793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_0dd4d0c1-3571-447e-82b1-5dd9ddc7990c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_13d1a269-01aa-4573-919d-7ce5fdce739a" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_0dd4d0c1-3571-447e-82b1-5dd9ddc7990c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_410e2806-6081-4b92-a5e6-5602fd9e38d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_13d1a269-01aa-4573-919d-7ce5fdce739a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_410e2806-6081-4b92-a5e6-5602fd9e38d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_SaleOfStockAggregateInitialOfferingPrice_5d7c3f47-b9fa-4ac1-a296-c2f95cae12c2" xlink:href="angn-20241231.xsd#angn_SaleOfStockAggregateInitialOfferingPrice"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_13d1a269-01aa-4573-919d-7ce5fdce739a" xlink:to="loc_angn_SaleOfStockAggregateInitialOfferingPrice_5d7c3f47-b9fa-4ac1-a296-c2f95cae12c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_0dda4ed6-bf8f-4370-87c3-4126b0af8dda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_13d1a269-01aa-4573-919d-7ce5fdce739a" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_0dda4ed6-bf8f-4370-87c3-4126b0af8dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_SaleOfStockBeneficialOwnershipLimitationPercentage_aeee9c3e-a45f-4fd8-9f08-379c765d44ba" xlink:href="angn-20241231.xsd#angn_SaleOfStockBeneficialOwnershipLimitationPercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_13d1a269-01aa-4573-919d-7ce5fdce739a" xlink:to="loc_angn_SaleOfStockBeneficialOwnershipLimitationPercentage_aeee9c3e-a45f-4fd8-9f08-379c765d44ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_eb5ed0ab-b8b0-49c3-90aa-417193726d42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_13d1a269-01aa-4573-919d-7ce5fdce739a" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_eb5ed0ab-b8b0-49c3-90aa-417193726d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b11d2bfc-5e1f-4188-995e-e98ec635f2d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_13d1a269-01aa-4573-919d-7ce5fdce739a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b11d2bfc-5e1f-4188-995e-e98ec635f2d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_8da5adfb-9ad8-45a5-be56-e74355ce31f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_13d1a269-01aa-4573-919d-7ce5fdce739a" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_8da5adfb-9ad8-45a5-be56-e74355ce31f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7b58c652-feb3-46ab-8edf-aa9a6fa53e65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_51932c88-479b-4d90-8cc2-90c6db4b79d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7b58c652-feb3-46ab-8edf-aa9a6fa53e65" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_51932c88-479b-4d90-8cc2-90c6db4b79d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_1c826fc0-89ce-42a3-9951-fc989dbd7fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_51932c88-479b-4d90-8cc2-90c6db4b79d4" xlink:to="loc_us-gaap_PlanNameAxis_1c826fc0-89ce-42a3-9951-fc989dbd7fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_fbe4593f-4378-46ca-9282-bad0c6382a55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1c826fc0-89ce-42a3-9951-fc989dbd7fbc" xlink:to="loc_us-gaap_PlanNameDomain_fbe4593f-4378-46ca-9282-bad0c6382a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_A2021PlanMember_789733e8-6476-4249-88ad-89f3a634e511" xlink:href="angn-20241231.xsd#angn_A2021PlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_fbe4593f-4378-46ca-9282-bad0c6382a55" xlink:to="loc_angn_A2021PlanMember_789733e8-6476-4249-88ad-89f3a634e511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_A2022PlanMember_cb12a1e3-a7cf-4fc2-a510-e3b7a91cf373" xlink:href="angn-20241231.xsd#angn_A2022PlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_fbe4593f-4378-46ca-9282-bad0c6382a55" xlink:to="loc_angn_A2022PlanMember_cb12a1e3-a7cf-4fc2-a510-e3b7a91cf373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_A2024PlanMember_46d0b11f-0415-4bb6-83ec-7bb5e48b0e97" xlink:href="angn-20241231.xsd#angn_A2024PlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_fbe4593f-4378-46ca-9282-bad0c6382a55" xlink:to="loc_angn_A2024PlanMember_46d0b11f-0415-4bb6-83ec-7bb5e48b0e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e744faef-187d-4eed-a80e-704dc31388a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_51932c88-479b-4d90-8cc2-90c6db4b79d4" xlink:to="loc_us-gaap_AwardTypeAxis_e744faef-187d-4eed-a80e-704dc31388a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_864f6a7e-2892-4fd5-8e1e-3791dc6d7fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e744faef-187d-4eed-a80e-704dc31388a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_864f6a7e-2892-4fd5-8e1e-3791dc6d7fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_aa94520e-2e15-4ac5-bd7a-a801a59b2921" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_864f6a7e-2892-4fd5-8e1e-3791dc6d7fc8" xlink:to="loc_us-gaap_EmployeeStockMember_aa94520e-2e15-4ac5-bd7a-a801a59b2921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d59f5e13-e2ac-4e64-ae21-d21b4069d2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_864f6a7e-2892-4fd5-8e1e-3791dc6d7fc8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d59f5e13-e2ac-4e64-ae21-d21b4069d2e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2e42abda-1288-4f2c-a6f3-b14213c8e631" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_51932c88-479b-4d90-8cc2-90c6db4b79d4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2e42abda-1288-4f2c-a6f3-b14213c8e631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b3681adc-221c-49ee-86d8-f40030a82299" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2e42abda-1288-4f2c-a6f3-b14213c8e631" xlink:to="loc_us-gaap_EquityComponentDomain_b3681adc-221c-49ee-86d8-f40030a82299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_f37eed83-9009-4a2a-8252-90a0d1ff652f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b3681adc-221c-49ee-86d8-f40030a82299" xlink:to="loc_us-gaap_TreasuryStockCommonMember_f37eed83-9009-4a2a-8252-90a0d1ff652f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8dde41c8-202c-453b-bbc3-6ff47d8cf830" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_51932c88-479b-4d90-8cc2-90c6db4b79d4" xlink:to="loc_srt_RangeAxis_8dde41c8-202c-453b-bbc3-6ff47d8cf830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_af226979-26c2-45f8-9247-da5c2bed9097" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8dde41c8-202c-453b-bbc3-6ff47d8cf830" xlink:to="loc_srt_RangeMember_af226979-26c2-45f8-9247-da5c2bed9097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fcd07b38-ad13-48dd-9e74-ea436046ada8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_af226979-26c2-45f8-9247-da5c2bed9097" xlink:to="loc_srt_MinimumMember_fcd07b38-ad13-48dd-9e74-ea436046ada8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2236e494-7697-4049-8c57-cb5184f65566" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_af226979-26c2-45f8-9247-da5c2bed9097" xlink:to="loc_srt_MaximumMember_2236e494-7697-4049-8c57-cb5184f65566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2888821-0e3f-4b39-8f04-b433beba9fba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_51932c88-479b-4d90-8cc2-90c6db4b79d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2888821-0e3f-4b39-8f04-b433beba9fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_CommonStockCapitalSharesReservedForFutureIssuanceIncreasePercentageOfCommonStockOutstanding_a5b3380e-8b67-4c89-ba00-5297f64b2a25" xlink:href="angn-20241231.xsd#angn_CommonStockCapitalSharesReservedForFutureIssuanceIncreasePercentageOfCommonStockOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2888821-0e3f-4b39-8f04-b433beba9fba" xlink:to="loc_angn_CommonStockCapitalSharesReservedForFutureIssuanceIncreasePercentageOfCommonStockOutstanding_a5b3380e-8b67-4c89-ba00-5297f64b2a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_55edac4a-c453-473a-9e99-bc67ae29e141" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2888821-0e3f-4b39-8f04-b433beba9fba" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_55edac4a-c453-473a-9e99-bc67ae29e141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_53328f49-44cd-44d5-9500-93ef2b02630c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2888821-0e3f-4b39-8f04-b433beba9fba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_53328f49-44cd-44d5-9500-93ef2b02630c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_710e8763-a90c-40f8-bd74-e3f24740e17f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2888821-0e3f-4b39-8f04-b433beba9fba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_710e8763-a90c-40f8-bd74-e3f24740e17f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_de8ff025-a72e-4f28-8cf5-94fcf4718821" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2888821-0e3f-4b39-8f04-b433beba9fba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_de8ff025-a72e-4f28-8cf5-94fcf4718821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_d8200ecc-aee4-40af-9b37-ffd27f38b106" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2888821-0e3f-4b39-8f04-b433beba9fba" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_d8200ecc-aee4-40af-9b37-ffd27f38b106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1b6d5fdd-574c-4afe-a17d-97ba95472b63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2888821-0e3f-4b39-8f04-b433beba9fba" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1b6d5fdd-574c-4afe-a17d-97ba95472b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_7b8a38b3-075f-470b-ac09-977b861866de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2888821-0e3f-4b39-8f04-b433beba9fba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_7b8a38b3-075f-470b-ac09-977b861866de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareLimit_81dcc856-739f-42d6-a7b3-e442cb0b46fe" xlink:href="angn-20241231.xsd#angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareLimit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2888821-0e3f-4b39-8f04-b433beba9fba" xlink:to="loc_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareLimit_81dcc856-739f-42d6-a7b3-e442cb0b46fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_60396159-9e1e-4b72-b8e0-d4251b4e99a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2888821-0e3f-4b39-8f04-b433beba9fba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_60396159-9e1e-4b72-b8e0-d4251b4e99a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_51734e42-d71c-4d5a-8b83-a9ed8692213d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2888821-0e3f-4b39-8f04-b433beba9fba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_51734e42-d71c-4d5a-8b83-a9ed8692213d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_9f3bdb97-6286-42dc-9718-932407c80909" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2888821-0e3f-4b39-8f04-b433beba9fba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_9f3bdb97-6286-42dc-9718-932407c80909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_e159e797-b937-46e9-a6af-cd79eca9e6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2888821-0e3f-4b39-8f04-b433beba9fba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_e159e797-b937-46e9-a6af-cd79eca9e6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_207b3092-c33f-42ac-9793-4f3feaa88a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2888821-0e3f-4b39-8f04-b433beba9fba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_207b3092-c33f-42ac-9793-4f3feaa88a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_14f741c6-b92a-473b-8073-71b8d5ebd3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2888821-0e3f-4b39-8f04-b433beba9fba" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_14f741c6-b92a-473b-8073-71b8d5ebd3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#StockBasedCompensationScheduleofShareOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7b8b81cb-6c9f-4c87-b50f-0e0a0feff3f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_071b6f7b-3988-4428-b3da-000a1e4f8cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7b8b81cb-6c9f-4c87-b50f-0e0a0feff3f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_071b6f7b-3988-4428-b3da-000a1e4f8cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bd7291fe-2416-4b26-bf8f-b4d6a8e0f6ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_071b6f7b-3988-4428-b3da-000a1e4f8cf9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bd7291fe-2416-4b26-bf8f-b4d6a8e0f6ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a29f27e4-1ca7-4fca-9185-94a86cb3db2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_071b6f7b-3988-4428-b3da-000a1e4f8cf9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a29f27e4-1ca7-4fca-9185-94a86cb3db2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_eddbda70-e0b1-4252-94e4-bba1e2f3e45a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_071b6f7b-3988-4428-b3da-000a1e4f8cf9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_eddbda70-e0b1-4252-94e4-bba1e2f3e45a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4167ed7e-5307-403c-be13-772cc365009c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_071b6f7b-3988-4428-b3da-000a1e4f8cf9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4167ed7e-5307-403c-be13-772cc365009c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fe94320f-1f07-49ff-89e7-75be4a5cbc60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_071b6f7b-3988-4428-b3da-000a1e4f8cf9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fe94320f-1f07-49ff-89e7-75be4a5cbc60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_86a0f349-b606-486e-afed-28c9426683e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7b8b81cb-6c9f-4c87-b50f-0e0a0feff3f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_86a0f349-b606-486e-afed-28c9426683e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d3ad6a10-b9f7-431c-a6ac-be9c21ba38dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7b8b81cb-6c9f-4c87-b50f-0e0a0feff3f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d3ad6a10-b9f7-431c-a6ac-be9c21ba38dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_98b68717-51ac-4ca6-a782-1a3c91db2e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d3ad6a10-b9f7-431c-a6ac-be9c21ba38dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_98b68717-51ac-4ca6-a782-1a3c91db2e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_fa8cfba1-c6ae-4bad-a101-0ca04f02c660" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d3ad6a10-b9f7-431c-a6ac-be9c21ba38dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_fa8cfba1-c6ae-4bad-a101-0ca04f02c660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_84879643-801f-40f6-b351-59f315dfc4da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d3ad6a10-b9f7-431c-a6ac-be9c21ba38dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_84879643-801f-40f6-b351-59f315dfc4da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_3d9e5d8f-2390-4a89-8265-c829b254d034" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d3ad6a10-b9f7-431c-a6ac-be9c21ba38dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_3d9e5d8f-2390-4a89-8265-c829b254d034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a27909ed-0c90-4723-b03f-4fc32c8af152" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d3ad6a10-b9f7-431c-a6ac-be9c21ba38dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a27909ed-0c90-4723-b03f-4fc32c8af152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_eb005e0f-ab1c-4bf7-ad6f-ea1c84fdb11d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7b8b81cb-6c9f-4c87-b50f-0e0a0feff3f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_eb005e0f-ab1c-4bf7-ad6f-ea1c84fdb11d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1925c27c-9e44-40fb-a3f7-baa5a10b2966" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7b8b81cb-6c9f-4c87-b50f-0e0a0feff3f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1925c27c-9e44-40fb-a3f7-baa5a10b2966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4f46ab00-6ea1-409d-958f-67b01780ee05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1925c27c-9e44-40fb-a3f7-baa5a10b2966" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4f46ab00-6ea1-409d-958f-67b01780ee05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_03787f76-e82b-420f-8aee-694e1faf2a62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1925c27c-9e44-40fb-a3f7-baa5a10b2966" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_03787f76-e82b-420f-8aee-694e1faf2a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_5aa40f78-0fc8-4a78-a502-0c25d5325db9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1925c27c-9e44-40fb-a3f7-baa5a10b2966" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_5aa40f78-0fc8-4a78-a502-0c25d5325db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_b679231a-a7b1-4151-9794-d6140cf3a710" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1925c27c-9e44-40fb-a3f7-baa5a10b2966" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_b679231a-a7b1-4151-9794-d6140cf3a710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1d9b09ad-c9b5-410c-8679-82a41ffc3c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_15e0d16d-87e9-458f-a43b-dc77a7530827" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1d9b09ad-c9b5-410c-8679-82a41ffc3c0a" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_15e0d16d-87e9-458f-a43b-dc77a7530827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3d6a8692-cbbb-4ef3-b46c-61259dd3055c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_15e0d16d-87e9-458f-a43b-dc77a7530827" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3d6a8692-cbbb-4ef3-b46c-61259dd3055c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_cf5bb1a8-e25b-4def-8ca6-15af0c91f24c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3d6a8692-cbbb-4ef3-b46c-61259dd3055c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_cf5bb1a8-e25b-4def-8ca6-15af0c91f24c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c82f0f01-4117-47db-8a09-79b8cb45d975" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_cf5bb1a8-e25b-4def-8ca6-15af0c91f24c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c82f0f01-4117-47db-8a09-79b8cb45d975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_006b43ed-e54d-4fa8-917a-c8036d9fbfe7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_cf5bb1a8-e25b-4def-8ca6-15af0c91f24c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_006b43ed-e54d-4fa8-917a-c8036d9fbfe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5ec4ce50-d749-4303-8a04-7837f50bc6d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_15e0d16d-87e9-458f-a43b-dc77a7530827" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5ec4ce50-d749-4303-8a04-7837f50bc6d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7c1f85df-76ef-455b-8224-0cb1967f4ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5ec4ce50-d749-4303-8a04-7837f50bc6d2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_7c1f85df-76ef-455b-8224-0cb1967f4ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/StockBasedCompensationScheduleofAssumptionsUsedtoEstimateFairValueofStockOptionAwardsDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#StockBasedCompensationScheduleofAssumptionsUsedtoEstimateFairValueofStockOptionAwardsDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/StockBasedCompensationScheduleofAssumptionsUsedtoEstimateFairValueofStockOptionAwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9263eb2f-603a-4d53-8ca5-8f3887841b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7ca2417f-f3b3-4824-85f0-129f931552d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9263eb2f-603a-4d53-8ca5-8f3887841b9f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7ca2417f-f3b3-4824-85f0-129f931552d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e32d8def-5e66-433b-8f26-d09a9fe1814d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7ca2417f-f3b3-4824-85f0-129f931552d2" xlink:to="loc_us-gaap_AwardTypeAxis_e32d8def-5e66-433b-8f26-d09a9fe1814d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_477219f6-912d-438e-a89d-6dca77c04dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e32d8def-5e66-433b-8f26-d09a9fe1814d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_477219f6-912d-438e-a89d-6dca77c04dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_eef027f1-870a-47de-b4f1-d3a6eddbea62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_477219f6-912d-438e-a89d-6dca77c04dfb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_eef027f1-870a-47de-b4f1-d3a6eddbea62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bf7a333-ff5a-436d-8a51-487add540a72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7ca2417f-f3b3-4824-85f0-129f931552d2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bf7a333-ff5a-436d-8a51-487add540a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_036104f8-5c9c-4952-9e83-68569e1c9794" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bf7a333-ff5a-436d-8a51-487add540a72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_036104f8-5c9c-4952-9e83-68569e1c9794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/WarrantsNarrativeDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#WarrantsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/WarrantsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsAndRightsOutstandingAbstract_1b6bbdd3-82cd-4b77-8c69-70fdcb7bf855" xlink:href="angn-20241231.xsd#angn_WarrantsAndRightsOutstandingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_2c9ced73-7e9f-4130-9255-bbcc52cb8bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_WarrantsAndRightsOutstandingAbstract_1b6bbdd3-82cd-4b77-8c69-70fdcb7bf855" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_2c9ced73-7e9f-4130-9255-bbcc52cb8bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_6bc2b99d-d63b-4e10-8c71-d4a4aa00f3a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_2c9ced73-7e9f-4130-9255-bbcc52cb8bcd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_6bc2b99d-d63b-4e10-8c71-d4a4aa00f3a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_e8398620-1a5b-4713-9024-db8ab9764610" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_6bc2b99d-d63b-4e10-8c71-d4a4aa00f3a8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_e8398620-1a5b-4713-9024-db8ab9764610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_PreFundedWarrantMember_ad0519ad-8f93-47c6-a1b0-cfe770b1bce8" xlink:href="angn-20241231.xsd#angn_PreFundedWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_e8398620-1a5b-4713-9024-db8ab9764610" xlink:to="loc_angn_PreFundedWarrantMember_ad0519ad-8f93-47c6-a1b0-cfe770b1bce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_JulyCommonWarrantsMember_5142cff5-b8d2-40c7-8c2c-a163ef9cc7e1" xlink:href="angn-20241231.xsd#angn_JulyCommonWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_e8398620-1a5b-4713-9024-db8ab9764610" xlink:to="loc_angn_JulyCommonWarrantsMember_5142cff5-b8d2-40c7-8c2c-a163ef9cc7e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember_7908377b-1c85-4414-9e02-e26aec2a0cb9" xlink:href="angn-20241231.xsd#angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_e8398620-1a5b-4713-9024-db8ab9764610" xlink:to="loc_angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember_7908377b-1c85-4414-9e02-e26aec2a0cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8e05fece-fe73-4f01-af9b-fa10adf23da3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_2c9ced73-7e9f-4130-9255-bbcc52cb8bcd" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_8e05fece-fe73-4f01-af9b-fa10adf23da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bb39bc9e-65b6-4499-bca4-1cda0076ec2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8e05fece-fe73-4f01-af9b-fa10adf23da3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bb39bc9e-65b6-4499-bca4-1cda0076ec2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_MarchSubscriptionAgreementMember_70536509-e87b-4f9d-8574-dec88d122c8b" xlink:href="angn-20241231.xsd#angn_MarchSubscriptionAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bb39bc9e-65b6-4499-bca4-1cda0076ec2b" xlink:to="loc_angn_MarchSubscriptionAgreementMember_70536509-e87b-4f9d-8574-dec88d122c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_JulyPublicOfferingMember_92a1440a-958f-4c5b-bceb-15d46a07af0e" xlink:href="angn-20241231.xsd#angn_JulyPublicOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bb39bc9e-65b6-4499-bca4-1cda0076ec2b" xlink:to="loc_angn_JulyPublicOfferingMember_92a1440a-958f-4c5b-bceb-15d46a07af0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_bf85226d-2809-4980-a0f2-f794fb63d7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_2c9ced73-7e9f-4130-9255-bbcc52cb8bcd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_bf85226d-2809-4980-a0f2-f794fb63d7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_137015f8-bdd7-4c44-b7e3-52a4d11027cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_bf85226d-2809-4980-a0f2-f794fb63d7a3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_137015f8-bdd7-4c44-b7e3-52a4d11027cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FairValueOfCommonStockWarrants_a365318d-6ffd-4f88-9b4f-6ce6e38d8246" xlink:href="angn-20241231.xsd#angn_FairValueOfCommonStockWarrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_bf85226d-2809-4980-a0f2-f794fb63d7a3" xlink:to="loc_angn_FairValueOfCommonStockWarrants_a365318d-6ffd-4f88-9b4f-6ce6e38d8246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_GainLossOnIssuanceOfWarrants_b41fa8ff-e2ae-45bb-9cfc-16d755e19906" xlink:href="angn-20241231.xsd#angn_GainLossOnIssuanceOfWarrants"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_bf85226d-2809-4980-a0f2-f794fb63d7a3" xlink:to="loc_angn_GainLossOnIssuanceOfWarrants_b41fa8ff-e2ae-45bb-9cfc-16d755e19906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_62d8e749-ddad-434e-b31d-212f0d5bc900" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_bf85226d-2809-4980-a0f2-f794fb63d7a3" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_62d8e749-ddad-434e-b31d-212f0d5bc900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_SaleOfStockBeneficialOwnershipLimitationPercentage_571a2c05-416c-4dd9-a9d3-31933b657af6" xlink:href="angn-20241231.xsd#angn_SaleOfStockBeneficialOwnershipLimitationPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_bf85226d-2809-4980-a0f2-f794fb63d7a3" xlink:to="loc_angn_SaleOfStockBeneficialOwnershipLimitationPercentage_571a2c05-416c-4dd9-a9d3-31933b657af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/WarrantsScheduleofIssuanceofWarrantsDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#WarrantsScheduleofIssuanceofWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/WarrantsScheduleofIssuanceofWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_f163d466-5d11-4de8-9c2d-4b4f48949d91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_a3080701-23d0-48a2-b45f-bf09bbaab6da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_f163d466-5d11-4de8-9c2d-4b4f48949d91" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_a3080701-23d0-48a2-b45f-bf09bbaab6da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_000dfb29-9005-44c2-9ca6-e8a1667d664c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_a3080701-23d0-48a2-b45f-bf09bbaab6da" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_000dfb29-9005-44c2-9ca6-e8a1667d664c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_b56b863f-c6da-4c89-838b-ba7bb4d19998" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_000dfb29-9005-44c2-9ca6-e8a1667d664c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_b56b863f-c6da-4c89-838b-ba7bb4d19998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_PreFundedWarrantsMember_ba85fc49-94f7-46fe-adec-a65e0050958d" xlink:href="angn-20241231.xsd#angn_PreFundedWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_b56b863f-c6da-4c89-838b-ba7bb4d19998" xlink:to="loc_angn_PreFundedWarrantsMember_ba85fc49-94f7-46fe-adec-a65e0050958d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_JulyPreFundedWarrantsMember_1e98f091-a9c4-45a8-8221-aede61ab9aa9" xlink:href="angn-20241231.xsd#angn_JulyPreFundedWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_b56b863f-c6da-4c89-838b-ba7bb4d19998" xlink:to="loc_angn_JulyPreFundedWarrantsMember_1e98f091-a9c4-45a8-8221-aede61ab9aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_JulyCommonWarrantsMember_09570474-df51-4184-8de5-77a637af673e" xlink:href="angn-20241231.xsd#angn_JulyCommonWarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_b56b863f-c6da-4c89-838b-ba7bb4d19998" xlink:to="loc_angn_JulyCommonWarrantsMember_09570474-df51-4184-8de5-77a637af673e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_12a9b0cc-a070-42f1-98da-94307dc39593" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_a3080701-23d0-48a2-b45f-bf09bbaab6da" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_12a9b0cc-a070-42f1-98da-94307dc39593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsIssuedShares_75b0bdd7-4636-4eae-92e3-c7d3d7c95964" xlink:href="angn-20241231.xsd#angn_WarrantsIssuedShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_12a9b0cc-a070-42f1-98da-94307dc39593" xlink:to="loc_angn_WarrantsIssuedShares_75b0bdd7-4636-4eae-92e3-c7d3d7c95964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6bf1d4bb-942a-4faa-a0d1-199fa5eb5035" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_12a9b0cc-a070-42f1-98da-94307dc39593" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6bf1d4bb-942a-4faa-a0d1-199fa5eb5035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/WarrantsScheduleofOutstandingWarrantsDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#WarrantsScheduleofOutstandingWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/WarrantsScheduleofOutstandingWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsAndRightsOutstandingAbstract_c50c383b-57dd-422b-aae8-9ea809df5d12" xlink:href="angn-20241231.xsd#angn_WarrantsAndRightsOutstandingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ClassOfWarrantOrRightRollForward_73aaf4f4-8aff-4bb0-8d50-14a12dfc5ca6" xlink:href="angn-20241231.xsd#angn_ClassOfWarrantOrRightRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_WarrantsAndRightsOutstandingAbstract_c50c383b-57dd-422b-aae8-9ea809df5d12" xlink:to="loc_angn_ClassOfWarrantOrRightRollForward_73aaf4f4-8aff-4bb0-8d50-14a12dfc5ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_c70aa955-75a1-4fd4-bd79-4ef632035683" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_ClassOfWarrantOrRightRollForward_73aaf4f4-8aff-4bb0-8d50-14a12dfc5ca6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_c70aa955-75a1-4fd4-bd79-4ef632035683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ClassOfWarrantOrRightIssuedInPeriod_f72cc893-e2f5-419a-8c81-3f960fb7d107" xlink:href="angn-20241231.xsd#angn_ClassOfWarrantOrRightIssuedInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_ClassOfWarrantOrRightRollForward_73aaf4f4-8aff-4bb0-8d50-14a12dfc5ca6" xlink:to="loc_angn_ClassOfWarrantOrRightIssuedInPeriod_f72cc893-e2f5-419a-8c81-3f960fb7d107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ClassOfWarrantOrRightExercisedInPeriod_4ab7d9fb-8bbf-496f-aa0b-99490622af83" xlink:href="angn-20241231.xsd#angn_ClassOfWarrantOrRightExercisedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_ClassOfWarrantOrRightRollForward_73aaf4f4-8aff-4bb0-8d50-14a12dfc5ca6" xlink:to="loc_angn_ClassOfWarrantOrRightExercisedInPeriod_4ab7d9fb-8bbf-496f-aa0b-99490622af83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_9baf9bda-a919-4931-9f58-1a72ab286d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_ClassOfWarrantOrRightRollForward_73aaf4f4-8aff-4bb0-8d50-14a12dfc5ca6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_9baf9bda-a919-4931-9f58-1a72ab286d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_d0c83a40-cdbe-4fb9-b6b6-103c712d7918" xlink:href="angn-20241231.xsd#angn_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_WarrantsAndRightsOutstandingAbstract_c50c383b-57dd-422b-aae8-9ea809df5d12" xlink:to="loc_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_d0c83a40-cdbe-4fb9-b6b6-103c712d7918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9ffc9378-a18e-4058-a523-6f42334344b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_d0c83a40-cdbe-4fb9-b6b6-103c712d7918" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9ffc9378-a18e-4058-a523-6f42334344b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceIssuedInPeriod_3999a28c-0e69-4865-a9f3-f78114969772" xlink:href="angn-20241231.xsd#angn_ClassOfWarrantOrRightWeightedAverageExercisePriceIssuedInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_d0c83a40-cdbe-4fb9-b6b6-103c712d7918" xlink:to="loc_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceIssuedInPeriod_3999a28c-0e69-4865-a9f3-f78114969772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod_c1f53a55-09f8-4dff-974d-68196ab59182" xlink:href="angn-20241231.xsd#angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_d0c83a40-cdbe-4fb9-b6b6-103c712d7918" xlink:to="loc_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod_c1f53a55-09f8-4dff-974d-68196ab59182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_d0ca863c-ffde-4bbe-8eeb-01f176da3026" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_d0c83a40-cdbe-4fb9-b6b6-103c712d7918" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_d0ca863c-ffde-4bbe-8eeb-01f176da3026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ClassOfWarrantOrRightWeightedAverageLifeRollForward_a87414a8-877b-4823-96b8-8a296b6060c9" xlink:href="angn-20241231.xsd#angn_ClassOfWarrantOrRightWeightedAverageLifeRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_WarrantsAndRightsOutstandingAbstract_c50c383b-57dd-422b-aae8-9ea809df5d12" xlink:to="loc_angn_ClassOfWarrantOrRightWeightedAverageLifeRollForward_a87414a8-877b-4823-96b8-8a296b6060c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ClassOfWarrantOrRightWeightedAverageLife_ed175da6-1ad6-4eef-ab29-65a38f0ef71c" xlink:href="angn-20241231.xsd#angn_ClassOfWarrantOrRightWeightedAverageLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_ClassOfWarrantOrRightWeightedAverageLifeRollForward_a87414a8-877b-4823-96b8-8a296b6060c9" xlink:to="loc_angn_ClassOfWarrantOrRightWeightedAverageLife_ed175da6-1ad6-4eef-ab29-65a38f0ef71c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ClassOfWarrantOrRightWeightedAverageLife_a1df342d-a15d-4a43-b3c3-9e0cdae97dad" xlink:href="angn-20241231.xsd#angn_ClassOfWarrantOrRightWeightedAverageLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_ClassOfWarrantOrRightWeightedAverageLifeRollForward_a87414a8-877b-4823-96b8-8a296b6060c9" xlink:to="loc_angn_ClassOfWarrantOrRightWeightedAverageLife_a1df342d-a15d-4a43-b3c3-9e0cdae97dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e6261e03-2766-436c-ab30-b667284ee030" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_LicenseExpense_c784070d-0e6a-4089-95d5-60f8c7c167d4" xlink:href="angn-20241231.xsd#angn_LicenseExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e6261e03-2766-436c-ab30-b667284ee030" xlink:to="loc_angn_LicenseExpense_c784070d-0e6a-4089-95d5-60f8c7c167d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_OperatingLeaseFutureMinimumAnnualMaintenancePayments_6292854e-d2df-4242-a7d5-c5735af5fe6c" xlink:href="angn-20241231.xsd#angn_OperatingLeaseFutureMinimumAnnualMaintenancePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e6261e03-2766-436c-ab30-b667284ee030" xlink:to="loc_angn_OperatingLeaseFutureMinimumAnnualMaintenancePayments_6292854e-d2df-4242-a7d5-c5735af5fe6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_OperatingLeaseFutureMinimumAnnualMaintenancePaymentsDueThereafter_ba740875-0d2d-46ab-a3ad-1b3bbbd5f9d6" xlink:href="angn-20241231.xsd#angn_OperatingLeaseFutureMinimumAnnualMaintenancePaymentsDueThereafter"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e6261e03-2766-436c-ab30-b667284ee030" xlink:to="loc_angn_OperatingLeaseFutureMinimumAnnualMaintenancePaymentsDueThereafter_ba740875-0d2d-46ab-a3ad-1b3bbbd5f9d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_4b0bfe72-a561-4dda-8882-3ca0a1e31601" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_71210771-3317-4956-9dc6-a9867542cd0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4b0bfe72-a561-4dda-8882-3ca0a1e31601" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_71210771-3317-4956-9dc6-a9867542cd0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_a692cb65-aed9-4102-8ced-372bfe5493eb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_71210771-3317-4956-9dc6-a9867542cd0e" xlink:to="loc_srt_StatementGeographicalAxis_a692cb65-aed9-4102-8ced-372bfe5493eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a95f9f99-caaa-4e65-b2c2-937d6632393f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_a692cb65-aed9-4102-8ced-372bfe5493eb" xlink:to="loc_srt_SegmentGeographicalDomain_a95f9f99-caaa-4e65-b2c2-937d6632393f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_BostonMassachusettsMember_a8951079-8eb1-4532-9cd2-e015d71565a3" xlink:href="angn-20241231.xsd#angn_BostonMassachusettsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a95f9f99-caaa-4e65-b2c2-937d6632393f" xlink:to="loc_angn_BostonMassachusettsMember_a8951079-8eb1-4532-9cd2-e015d71565a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_NewtonMassachusettsMember_a3fa196e-fbdc-419c-a869-e80d3d6323cb" xlink:href="angn-20241231.xsd#angn_NewtonMassachusettsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a95f9f99-caaa-4e65-b2c2-937d6632393f" xlink:to="loc_angn_NewtonMassachusettsMember_a3fa196e-fbdc-419c-a869-e80d3d6323cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_bb805b86-cb48-424f-83e2-faabd454653b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_71210771-3317-4956-9dc6-a9867542cd0e" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_bb805b86-cb48-424f-83e2-faabd454653b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_8a37eff7-08ea-4b4d-86b6-b68aa82e2ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bb805b86-cb48-424f-83e2-faabd454653b" xlink:to="loc_us-gaap_OperatingLeaseExpense_8a37eff7-08ea-4b4d-86b6-b68aa82e2ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6611fe7b-5608-4256-af74-ae4e7145dc73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bb805b86-cb48-424f-83e2-faabd454653b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6611fe7b-5608-4256-af74-ae4e7145dc73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_93fe90c7-e44f-4b4d-9c57-f84f14c98d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bb805b86-cb48-424f-83e2-faabd454653b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_93fe90c7-e44f-4b4d-9c57-f84f14c98d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSecuredLinesOfCredit_bba281d2-a107-4bfe-be08-af5b702add89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSecuredLinesOfCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bb805b86-cb48-424f-83e2-faabd454653b" xlink:to="loc_us-gaap_ProceedsFromSecuredLinesOfCredit_bba281d2-a107-4bfe-be08-af5b702add89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_997cf687-fbab-4877-9596-434329565865" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bb805b86-cb48-424f-83e2-faabd454653b" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_997cf687-fbab-4877-9596-434329565865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_LesseeOperatingLeaseAnnualRentExpense_1c1a92d5-9a1d-4788-9dfd-9d3deddb8b0c" xlink:href="angn-20241231.xsd#angn_LesseeOperatingLeaseAnnualRentExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bb805b86-cb48-424f-83e2-faabd454653b" xlink:to="loc_angn_LesseeOperatingLeaseAnnualRentExpense_1c1a92d5-9a1d-4788-9dfd-9d3deddb8b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/LeasesScheduleofQuantitativeInformationaboutOperatingLeasesDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#LeasesScheduleofQuantitativeInformationaboutOperatingLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/LeasesScheduleofQuantitativeInformationaboutOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b1a7a54e-f9d1-4c03-947c-9b54de55c484" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_f37fbdd6-e5c1-43c5-8d9f-b09c2c46756e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b1a7a54e-f9d1-4c03-947c-9b54de55c484" xlink:to="loc_us-gaap_OperatingLeasePayments_f37fbdd6-e5c1-43c5-8d9f-b09c2c46756e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6b740817-7aba-4f48-af29-0676aec8d106" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b1a7a54e-f9d1-4c03-947c-9b54de55c484" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6b740817-7aba-4f48-af29-0676aec8d106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_42c9a9f4-1f4d-41f3-8177-7f2a98c9bb48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b1a7a54e-f9d1-4c03-947c-9b54de55c484" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_42c9a9f4-1f4d-41f3-8177-7f2a98c9bb48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_07cb6fa1-916e-44cb-8f46-f6823e6c15bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9b463687-e9cb-4730-b42b-3d7bd636e9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_07cb6fa1-916e-44cb-8f46-f6823e6c15bf" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9b463687-e9cb-4730-b42b-3d7bd636e9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3c4ab945-2d9c-4fa4-a5e8-f2d0721c5f71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_07cb6fa1-916e-44cb-8f46-f6823e6c15bf" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3c4ab945-2d9c-4fa4-a5e8-f2d0721c5f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_183fc45c-957b-493e-92e8-802291e76ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_07cb6fa1-916e-44cb-8f46-f6823e6c15bf" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_183fc45c-957b-493e-92e8-802291e76ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3fcdf761-6964-4754-b3bb-c60eafdbf776" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_07cb6fa1-916e-44cb-8f46-f6823e6c15bf" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3fcdf761-6964-4754-b3bb-c60eafdbf776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_cf00888d-61a7-4246-913f-488451abd791" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_07cb6fa1-916e-44cb-8f46-f6823e6c15bf" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_cf00888d-61a7-4246-913f-488451abd791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_56edccf3-6ff5-4f63-9b7f-615822ec7017" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_07cb6fa1-916e-44cb-8f46-f6823e6c15bf" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_56edccf3-6ff5-4f63-9b7f-615822ec7017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_756d6c81-ec0a-491e-809a-9da0dd6858d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_07cb6fa1-916e-44cb-8f46-f6823e6c15bf" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_756d6c81-ec0a-491e-809a-9da0dd6858d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ec1314d5-a834-49d9-8e06-2b4aa24a4a64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_07cb6fa1-916e-44cb-8f46-f6823e6c15bf" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ec1314d5-a834-49d9-8e06-2b4aa24a4a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_d9267c15-3810-47d1-b5b6-27088f6c2a54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_07cb6fa1-916e-44cb-8f46-f6823e6c15bf" xlink:to="loc_us-gaap_OperatingLeaseLiability_d9267c15-3810-47d1-b5b6-27088f6c2a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_028a1147-9a47-4e4d-b6f2-05ef69e13b01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_07cb6fa1-916e-44cb-8f46-f6823e6c15bf" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_028a1147-9a47-4e4d-b6f2-05ef69e13b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8f9e9af5-161d-425e-b697-8f31b8089953" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_07cb6fa1-916e-44cb-8f46-f6823e6c15bf" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8f9e9af5-161d-425e-b697-8f31b8089953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/DebtDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#DebtDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/DebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5e4dd19c-511b-4e2f-9a27-d64cea201d51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_52bc6910-777b-4929-99f9-04f8d53030bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5e4dd19c-511b-4e2f-9a27-d64cea201d51" xlink:to="loc_us-gaap_DebtInstrumentTable_52bc6910-777b-4929-99f9-04f8d53030bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7949a471-296d-45eb-a3e1-f87ce18df9dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_52bc6910-777b-4929-99f9-04f8d53030bc" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7949a471-296d-45eb-a3e1-f87ce18df9dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e266fa5d-2895-4e04-a9d5-0ba981d49bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7949a471-296d-45eb-a3e1-f87ce18df9dc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e266fa5d-2895-4e04-a9d5-0ba981d49bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_ca2dc095-2c70-41d6-8a49-eb0f52dda2a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e266fa5d-2895-4e04-a9d5-0ba981d49bd8" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_ca2dc095-2c70-41d6-8a49-eb0f52dda2a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_31de7d90-2cc1-4a57-affc-cdc1a6d12539" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e266fa5d-2895-4e04-a9d5-0ba981d49bd8" xlink:to="loc_us-gaap_ConvertibleDebtMember_31de7d90-2cc1-4a57-affc-cdc1a6d12539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3cb9442b-67b7-4bd1-a4e8-2554e425429d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_52bc6910-777b-4929-99f9-04f8d53030bc" xlink:to="loc_us-gaap_DebtInstrumentAxis_3cb9442b-67b7-4bd1-a4e8-2554e425429d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d6742329-91d3-4ad5-8d2c-d9a5858a16d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_3cb9442b-67b7-4bd1-a4e8-2554e425429d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d6742329-91d3-4ad5-8d2c-d9a5858a16d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_BridgeLoanBetweenAngionAndFormerElicioMember_08994bee-3836-4152-a842-68c2f473d9b0" xlink:href="angn-20241231.xsd#angn_BridgeLoanBetweenAngionAndFormerElicioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6742329-91d3-4ad5-8d2c-d9a5858a16d9" xlink:to="loc_angn_BridgeLoanBetweenAngionAndFormerElicioMember_08994bee-3836-4152-a842-68c2f473d9b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ConvertibleNotesMember_78e0ad24-7e45-43b9-b6e0-e7a2066e61be" xlink:href="angn-20241231.xsd#angn_ConvertibleNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6742329-91d3-4ad5-8d2c-d9a5858a16d9" xlink:to="loc_angn_ConvertibleNotesMember_78e0ad24-7e45-43b9-b6e0-e7a2066e61be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountInitialClosingMember_7237864f-9a40-46ea-ad0c-6185b3475054" xlink:href="angn-20241231.xsd#angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountInitialClosingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6742329-91d3-4ad5-8d2c-d9a5858a16d9" xlink:to="loc_angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountInitialClosingMember_7237864f-9a40-46ea-ad0c-6185b3475054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_BridgeLoanBetweenAngionAndFormerElicioInitialClosingMember_906310e9-2d17-4773-a085-8d5b61a72967" xlink:href="angn-20241231.xsd#angn_BridgeLoanBetweenAngionAndFormerElicioInitialClosingMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6742329-91d3-4ad5-8d2c-d9a5858a16d9" xlink:to="loc_angn_BridgeLoanBetweenAngionAndFormerElicioInitialClosingMember_906310e9-2d17-4773-a085-8d5b61a72967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountAdditionalClosingMember_15221b02-86f9-48ec-ae11-c5c30a948820" xlink:href="angn-20241231.xsd#angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountAdditionalClosingMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6742329-91d3-4ad5-8d2c-d9a5858a16d9" xlink:to="loc_angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountAdditionalClosingMember_15221b02-86f9-48ec-ae11-c5c30a948820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_BridgeLoanBetweenAngionAndFormerElicioAdditionalClosingMember_e932ac74-4e62-4c75-a038-39fd501bbe92" xlink:href="angn-20241231.xsd#angn_BridgeLoanBetweenAngionAndFormerElicioAdditionalClosingMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6742329-91d3-4ad5-8d2c-d9a5858a16d9" xlink:to="loc_angn_BridgeLoanBetweenAngionAndFormerElicioAdditionalClosingMember_e932ac74-4e62-4c75-a038-39fd501bbe92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_SeniorSecuredConvertiblePromissoryNoteMember_659072b2-0b82-45de-98a9-1657a7e7cae8" xlink:href="angn-20241231.xsd#angn_SeniorSecuredConvertiblePromissoryNoteMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6742329-91d3-4ad5-8d2c-d9a5858a16d9" xlink:to="loc_angn_SeniorSecuredConvertiblePromissoryNoteMember_659072b2-0b82-45de-98a9-1657a7e7cae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5c85ee09-e40a-467c-89e7-e8b8df1e8eae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_52bc6910-777b-4929-99f9-04f8d53030bc" xlink:to="loc_us-gaap_DebtInstrumentLineItems_5c85ee09-e40a-467c-89e7-e8b8df1e8eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_6ea3248b-ba87-4e8f-8f77-2f7b2abf88c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c85ee09-e40a-467c-89e7-e8b8df1e8eae" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_6ea3248b-ba87-4e8f-8f77-2f7b2abf88c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_DebtInstrumentIssuanceDiscountPercent_8fb02785-f02a-4ded-a062-d8d1af1bc40d" xlink:href="angn-20241231.xsd#angn_DebtInstrumentIssuanceDiscountPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c85ee09-e40a-467c-89e7-e8b8df1e8eae" xlink:to="loc_angn_DebtInstrumentIssuanceDiscountPercent_8fb02785-f02a-4ded-a062-d8d1af1bc40d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_55209243-50ab-47c4-9b25-9b8b17ab1210" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c85ee09-e40a-467c-89e7-e8b8df1e8eae" xlink:to="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_55209243-50ab-47c4-9b25-9b8b17ab1210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_559dc550-4281-4643-9547-054d9edee53e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c85ee09-e40a-467c-89e7-e8b8df1e8eae" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_559dc550-4281-4643-9547-054d9edee53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_bc7ab3f0-c7d8-4005-98d6-2b08524e6d23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c85ee09-e40a-467c-89e7-e8b8df1e8eae" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_bc7ab3f0-c7d8-4005-98d6-2b08524e6d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_d032422e-b795-4cb6-a644-046c1756341c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c85ee09-e40a-467c-89e7-e8b8df1e8eae" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_d032422e-b795-4cb6-a644-046c1756341c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_c8fb6545-b601-4be7-b5d6-840eddc0ae74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c85ee09-e40a-467c-89e7-e8b8df1e8eae" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_c8fb6545-b601-4be7-b5d6-840eddc0ae74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_7640ae6d-3e22-4835-bf8e-c2d8e859a95f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c85ee09-e40a-467c-89e7-e8b8df1e8eae" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_7640ae6d-3e22-4835-bf8e-c2d8e859a95f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_cc56b2fd-8107-4f64-a8d9-b0bc12d9ef52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c85ee09-e40a-467c-89e7-e8b8df1e8eae" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_cc56b2fd-8107-4f64-a8d9-b0bc12d9ef52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_fb2a36c9-371e-49cb-a17c-d3a068729646" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c85ee09-e40a-467c-89e7-e8b8df1e8eae" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_fb2a36c9-371e-49cb-a17c-d3a068729646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_445a66e0-eb58-4726-bd4a-f8a27c0457a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c85ee09-e40a-467c-89e7-e8b8df1e8eae" xlink:to="loc_us-gaap_InterestExpenseDebt_445a66e0-eb58-4726-bd4a-f8a27c0457a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6ce8752d-9321-4d01-8eff-03cd759f94c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_f768ed8f-8399-457b-bb80-39bb93bf7d26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6ce8752d-9321-4d01-8eff-03cd759f94c8" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_f768ed8f-8399-457b-bb80-39bb93bf7d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_5ed89684-4e01-4418-a8b6-7d0ac5313263" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_f768ed8f-8399-457b-bb80-39bb93bf7d26" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_5ed89684-4e01-4418-a8b6-7d0ac5313263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_b27fef27-d893-4506-96fe-b56149917060" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_f768ed8f-8399-457b-bb80-39bb93bf7d26" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_b27fef27-d893-4506-96fe-b56149917060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_ec2a2b6c-2bea-4cd0-b15e-edfc4ece0d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_f768ed8f-8399-457b-bb80-39bb93bf7d26" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_ec2a2b6c-2bea-4cd0-b15e-edfc4ece0d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c1b80bf8-1556-452a-987f-cea84f9ef128" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_f768ed8f-8399-457b-bb80-39bb93bf7d26" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c1b80bf8-1556-452a-987f-cea84f9ef128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_6a98f637-97da-46c8-afd9-508c21ee7b96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6ce8752d-9321-4d01-8eff-03cd759f94c8" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_6a98f637-97da-46c8-afd9-508c21ee7b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2f63ae7d-cebc-4890-86b2-d7c1e5ef85aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_6a98f637-97da-46c8-afd9-508c21ee7b96" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2f63ae7d-cebc-4890-86b2-d7c1e5ef85aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_5231cccc-a3f6-479a-810d-860178c033d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_6a98f637-97da-46c8-afd9-508c21ee7b96" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_5231cccc-a3f6-479a-810d-860178c033d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_264fee8d-f58a-4cf4-aa20-21862753c36a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_6a98f637-97da-46c8-afd9-508c21ee7b96" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_264fee8d-f58a-4cf4-aa20-21862753c36a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_0e0a5a90-90cd-47ef-8080-d321dd4e07f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_6a98f637-97da-46c8-afd9-508c21ee7b96" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_0e0a5a90-90cd-47ef-8080-d321dd4e07f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ae7d8e26-d6f1-4b36-ace7-892549f1f0ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_6a98f637-97da-46c8-afd9-508c21ee7b96" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ae7d8e26-d6f1-4b36-ace7-892549f1f0ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a4147a09-2209-459b-8cfb-a730f7a2c7a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6ce8752d-9321-4d01-8eff-03cd759f94c8" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a4147a09-2209-459b-8cfb-a730f7a2c7a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_98fd289d-2b3a-4c23-98d5-7b65fd91ff63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_fcc43d89-dd06-47d2-be10-2d75d714b688" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_98fd289d-2b3a-4c23-98d5-7b65fd91ff63" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_fcc43d89-dd06-47d2-be10-2d75d714b688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_b7ef6314-ab59-4064-880b-225690766dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_98fd289d-2b3a-4c23-98d5-7b65fd91ff63" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_b7ef6314-ab59-4064-880b-225690766dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_285c1134-8761-4207-aa0d-13e65d7d0476" xlink:href="angn-20241231.xsd#angn_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_98fd289d-2b3a-4c23-98d5-7b65fd91ff63" xlink:to="loc_angn_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_285c1134-8761-4207-aa0d-13e65d7d0476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_EffectiveIncomeTaxRateReconciliationTaxCreditFederalResearchAndDevelopmentPercent_6097ca8b-7f6b-4d1b-bfd1-d43f79ae4826" xlink:href="angn-20241231.xsd#angn_EffectiveIncomeTaxRateReconciliationTaxCreditFederalResearchAndDevelopmentPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_98fd289d-2b3a-4c23-98d5-7b65fd91ff63" xlink:to="loc_angn_EffectiveIncomeTaxRateReconciliationTaxCreditFederalResearchAndDevelopmentPercent_6097ca8b-7f6b-4d1b-bfd1-d43f79ae4826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent_2d9a2fde-511e-4d30-b1db-427574262630" xlink:href="angn-20241231.xsd#angn_EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_98fd289d-2b3a-4c23-98d5-7b65fd91ff63" xlink:to="loc_angn_EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent_2d9a2fde-511e-4d30-b1db-427574262630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_432e8c2b-3f50-44f4-b4de-e266417a2b43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_98fd289d-2b3a-4c23-98d5-7b65fd91ff63" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_432e8c2b-3f50-44f4-b4de-e266417a2b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_6328d758-9214-4b03-975e-aad8b83c3286" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_98fd289d-2b3a-4c23-98d5-7b65fd91ff63" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_6328d758-9214-4b03-975e-aad8b83c3286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_623caf70-3d28-4c76-8573-6de6b4683714" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_98fd289d-2b3a-4c23-98d5-7b65fd91ff63" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_623caf70-3d28-4c76-8573-6de6b4683714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2b35461b-5f0e-4e61-80da-b74d0fc8e856" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_9b03e90e-5c39-4fc8-bb97-0b4703b94399" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2b35461b-5f0e-4e61-80da-b74d0fc8e856" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_9b03e90e-5c39-4fc8-bb97-0b4703b94399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_a6a4fed5-4365-4ca3-9810-cc0e874e14df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_9b03e90e-5c39-4fc8-bb97-0b4703b94399" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_a6a4fed5-4365-4ca3-9810-cc0e874e14df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_421f6f00-8406-499e-a848-6872bd8c945a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_9b03e90e-5c39-4fc8-bb97-0b4703b94399" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_421f6f00-8406-499e-a848-6872bd8c945a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_ec54bc4d-84ca-48a5-88b2-0cc0dcc42f12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_9b03e90e-5c39-4fc8-bb97-0b4703b94399" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_ec54bc4d-84ca-48a5-88b2-0cc0dcc42f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_DeferredTaxAssetsOperatingLeaseLiability_ec9044f9-23ae-48da-be58-afbfcd1aebd3" xlink:href="angn-20241231.xsd#angn_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_9b03e90e-5c39-4fc8-bb97-0b4703b94399" xlink:to="loc_angn_DeferredTaxAssetsOperatingLeaseLiability_ec9044f9-23ae-48da-be58-afbfcd1aebd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_114f20ad-718c-4ea3-9c68-4c96a6f0c816" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_9b03e90e-5c39-4fc8-bb97-0b4703b94399" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_114f20ad-718c-4ea3-9c68-4c96a6f0c816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_ff85bf1f-66a6-486f-9435-886e1dfb2208" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_9b03e90e-5c39-4fc8-bb97-0b4703b94399" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_ff85bf1f-66a6-486f-9435-886e1dfb2208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_4696eee2-4356-4d6b-8945-af46cdf79c25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_9b03e90e-5c39-4fc8-bb97-0b4703b94399" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_4696eee2-4356-4d6b-8945-af46cdf79c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_DeferredTaxAssetsNetBeforeValuationAllowance_a3d448fc-99df-4a55-8f01-8f82fd80ff0e" xlink:href="angn-20241231.xsd#angn_DeferredTaxAssetsNetBeforeValuationAllowance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_9b03e90e-5c39-4fc8-bb97-0b4703b94399" xlink:to="loc_angn_DeferredTaxAssetsNetBeforeValuationAllowance_a3d448fc-99df-4a55-8f01-8f82fd80ff0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_25d1f18b-fcd0-4c28-a397-f43dc79ed84c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2b35461b-5f0e-4e61-80da-b74d0fc8e856" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_25d1f18b-fcd0-4c28-a397-f43dc79ed84c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_45014cd9-4622-4b0d-91ab-5861a83aa1eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2b35461b-5f0e-4e61-80da-b74d0fc8e856" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_45014cd9-4622-4b0d-91ab-5861a83aa1eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_61885e11-6f80-4c4a-bae9-cb8d43c94bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_fe2e5207-863d-460b-9bd4-9ba5c6dc7936" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_61885e11-6f80-4c4a-bae9-cb8d43c94bd2" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_fe2e5207-863d-460b-9bd4-9ba5c6dc7936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_c8ef3e77-e4d1-4211-8e93-4006c7097652" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_fe2e5207-863d-460b-9bd4-9ba5c6dc7936" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_c8ef3e77-e4d1-4211-8e93-4006c7097652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_ba2e6e88-3d97-414f-a2cc-5b154c57aa13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_c8ef3e77-e4d1-4211-8e93-4006c7097652" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_ba2e6e88-3d97-414f-a2cc-5b154c57aa13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_4e1a068c-8281-40ae-b32b-8cb7f33a51e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_ba2e6e88-3d97-414f-a2cc-5b154c57aa13" xlink:to="loc_us-gaap_DomesticCountryMember_4e1a068c-8281-40ae-b32b-8cb7f33a51e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_0d383b55-e844-40cd-ae52-a6802780bedd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_ba2e6e88-3d97-414f-a2cc-5b154c57aa13" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_0d383b55-e844-40cd-ae52-a6802780bedd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_9443a4c4-7aac-4943-96f9-2354dc06ac92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_fe2e5207-863d-460b-9bd4-9ba5c6dc7936" xlink:to="loc_us-gaap_TaxPeriodAxis_9443a4c4-7aac-4943-96f9-2354dc06ac92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_ada12aed-70f7-4ffe-8f34-4870f0aa3042" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_9443a4c4-7aac-4943-96f9-2354dc06ac92" xlink:to="loc_us-gaap_TaxPeriodDomain_ada12aed-70f7-4ffe-8f34-4870f0aa3042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxYear2017Member_eb4e39e6-23af-4757-9bff-e90b41744fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxYear2017Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_ada12aed-70f7-4ffe-8f34-4870f0aa3042" xlink:to="loc_us-gaap_TaxYear2017Member_eb4e39e6-23af-4757-9bff-e90b41744fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_dd0f62df-d01f-4ba2-be19-13f260665d20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_fe2e5207-863d-460b-9bd4-9ba5c6dc7936" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_dd0f62df-d01f-4ba2-be19-13f260665d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_99895f64-2de0-4774-b131-8f9004908273" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_dd0f62df-d01f-4ba2-be19-13f260665d20" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_99895f64-2de0-4774-b131-8f9004908273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_aaceffbf-41a2-4cff-b75f-837a5725ab76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_99895f64-2de0-4774-b131-8f9004908273" xlink:to="loc_us-gaap_ResearchMember_aaceffbf-41a2-4cff-b75f-837a5725ab76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_8273fd3b-d1db-4016-9c4d-a7a6bc6443d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_fe2e5207-863d-460b-9bd4-9ba5c6dc7936" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_8273fd3b-d1db-4016-9c4d-a7a6bc6443d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_759d7a26-4927-4280-b1b1-583ffde3dea9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_8273fd3b-d1db-4016-9c4d-a7a6bc6443d1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_759d7a26-4927-4280-b1b1-583ffde3dea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_46704af0-4f23-4580-8beb-b70d8cc80624" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_8273fd3b-d1db-4016-9c4d-a7a6bc6443d1" xlink:to="loc_us-gaap_OperatingLossCarryforwards_46704af0-4f23-4580-8beb-b70d8cc80624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_e5a2041a-c2dd-45b0-a9ef-e3027c86e546" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_8273fd3b-d1db-4016-9c4d-a7a6bc6443d1" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_e5a2041a-c2dd-45b0-a9ef-e3027c86e546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_becd73c1-9889-42ed-b7ed-09e3ec04e5d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_8273fd3b-d1db-4016-9c4d-a7a6bc6443d1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_becd73c1-9889-42ed-b7ed-09e3ec04e5d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_cdd36925-3b8d-48e3-a310-3e587554ad28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_8273fd3b-d1db-4016-9c4d-a7a6bc6443d1" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_cdd36925-3b8d-48e3-a310-3e587554ad28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_f2a53d13-9002-41d1-a3e0-7b03f72472bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_8273fd3b-d1db-4016-9c4d-a7a6bc6443d1" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_f2a53d13-9002-41d1-a3e0-7b03f72472bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/EmployeeBenefitPlanDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#EmployeeBenefitPlanDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/EmployeeBenefitPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0b3a5a9c-781b-4af9-99ff-b036ba571b86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTable_1d0e05e1-10b7-45a1-aab3-d63002a6e187" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0b3a5a9c-781b-4af9-99ff-b036ba571b86" xlink:to="loc_us-gaap_DefinedContributionPlanTable_1d0e05e1-10b7-45a1-aab3-d63002a6e187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_963c8fbc-47e2-4be4-a03d-37c14b7e64ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_1d0e05e1-10b7-45a1-aab3-d63002a6e187" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_963c8fbc-47e2-4be4-a03d-37c14b7e64ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_c132af07-a186-4535-aee1-75de378ace07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_963c8fbc-47e2-4be4-a03d-37c14b7e64ec" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_c132af07-a186-4535-aee1-75de378ace07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_EmployeeBenefitPlanMember_3d8c64c5-1326-43f0-886e-108b61a0cabc" xlink:href="angn-20241231.xsd#angn_EmployeeBenefitPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_c132af07-a186-4535-aee1-75de378ace07" xlink:to="loc_angn_EmployeeBenefitPlanMember_3d8c64c5-1326-43f0-886e-108b61a0cabc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_cc1cd026-c664-42f3-ad24-cdae0b6da403" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_1d0e05e1-10b7-45a1-aab3-d63002a6e187" xlink:to="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_cc1cd026-c664-42f3-ad24-cdae0b6da403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_7ad6cb26-7f53-4e51-8bd6-a998698c7082" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_cc1cd026-c664-42f3-ad24-cdae0b6da403" xlink:to="loc_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_7ad6cb26-7f53-4e51-8bd6-a998698c7082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/NetLossPerShareScheduleofNetLossPerShareBasicandDilutedDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#NetLossPerShareScheduleofNetLossPerShareBasicandDilutedDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/NetLossPerShareScheduleofNetLossPerShareBasicandDilutedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5a4aa178-8b95-47cb-8393-62eab6f9aebd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_22fd2bb2-9704-4eaf-a1bd-30ac4d03718c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5a4aa178-8b95-47cb-8393-62eab6f9aebd" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_22fd2bb2-9704-4eaf-a1bd-30ac4d03718c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_84eb9d6f-eeae-4e35-81ef-fe17b8b1a4e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_22fd2bb2-9704-4eaf-a1bd-30ac4d03718c" xlink:to="loc_us-gaap_NetIncomeLoss_84eb9d6f-eeae-4e35-81ef-fe17b8b1a4e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_372e4904-868c-4cba-a9bd-da45c1290d83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5a4aa178-8b95-47cb-8393-62eab6f9aebd" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_372e4904-868c-4cba-a9bd-da45c1290d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f9ca6416-e540-4268-93eb-279baaa5ef7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_372e4904-868c-4cba-a9bd-da45c1290d83" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f9ca6416-e540-4268-93eb-279baaa5ef7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b05154d6-9f4a-4d29-ad7e-6863d2730bba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_372e4904-868c-4cba-a9bd-da45c1290d83" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b05154d6-9f4a-4d29-ad7e-6863d2730bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7143cf5e-3de1-4610-bfa4-1539c78ede6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_372e4904-868c-4cba-a9bd-da45c1290d83" xlink:to="loc_us-gaap_EarningsPerShareBasic_7143cf5e-3de1-4610-bfa4-1539c78ede6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_d615ded4-af76-46de-8f7f-fec4fea40cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_372e4904-868c-4cba-a9bd-da45c1290d83" xlink:to="loc_us-gaap_EarningsPerShareDiluted_d615ded4-af76-46de-8f7f-fec4fea40cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofNetLossperShareDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofNetLossperShareDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofNetLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_df8448f4-0a2d-42fb-818a-b073f8e95146" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b7e4a9fc-6424-4d8d-8e7c-cd951d446c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_df8448f4-0a2d-42fb-818a-b073f8e95146" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b7e4a9fc-6424-4d8d-8e7c-cd951d446c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_52d41a0e-4d6b-4ad6-9375-6939f66ddd89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b7e4a9fc-6424-4d8d-8e7c-cd951d446c8d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_52d41a0e-4d6b-4ad6-9375-6939f66ddd89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2788f6f0-087b-45eb-af6f-6fc3fd1d4749" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_52d41a0e-4d6b-4ad6-9375-6939f66ddd89" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2788f6f0-087b-45eb-af6f-6fc3fd1d4749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_487ef8b1-f821-411a-8075-5ae51aa007b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2788f6f0-087b-45eb-af6f-6fc3fd1d4749" xlink:to="loc_us-gaap_EmployeeStockOptionMember_487ef8b1-f821-411a-8075-5ae51aa007b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_85539334-5364-4523-9177-cb43520f841a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2788f6f0-087b-45eb-af6f-6fc3fd1d4749" xlink:to="loc_us-gaap_WarrantMember_85539334-5364-4523-9177-cb43520f841a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_UnvestedCommonStockMember_c0963c8d-8b2a-444f-9085-719aed1c8c0f" xlink:href="angn-20241231.xsd#angn_UnvestedCommonStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2788f6f0-087b-45eb-af6f-6fc3fd1d4749" xlink:to="loc_angn_UnvestedCommonStockMember_c0963c8d-8b2a-444f-9085-719aed1c8c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ee9a0519-c68a-4b07-8e55-7cbcc9070239" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b7e4a9fc-6424-4d8d-8e7c-cd951d446c8d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ee9a0519-c68a-4b07-8e55-7cbcc9070239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0f58429f-21dd-4105-a1bf-0c7b0049b241" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ee9a0519-c68a-4b07-8e55-7cbcc9070239" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0f58429f-21dd-4105-a1bf-0c7b0049b241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_b2e3b501-f0f9-4041-b7fa-b6e8ff37e3c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6e42ee65-0a97-4634-a38b-e002856a7adc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_b2e3b501-f0f9-4041-b7fa-b6e8ff37e3c8" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6e42ee65-0a97-4634-a38b-e002856a7adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_29eb4b7a-2b3e-4f72-8da8-fe879f5cc194" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6e42ee65-0a97-4634-a38b-e002856a7adc" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_29eb4b7a-2b3e-4f72-8da8-fe879f5cc194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_81b37bb6-b3f2-4f74-aa73-0b802597e338" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_29eb4b7a-2b3e-4f72-8da8-fe879f5cc194" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_81b37bb6-b3f2-4f74-aa73-0b802597e338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ConsultingServicePaymentsMember_8a6aeb9a-a553-42cd-ba0a-167bfbe35a80" xlink:href="angn-20241231.xsd#angn_ConsultingServicePaymentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_81b37bb6-b3f2-4f74-aa73-0b802597e338" xlink:to="loc_angn_ConsultingServicePaymentsMember_8a6aeb9a-a553-42cd-ba0a-167bfbe35a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_PurchaseOfWarrantsMember_c2877fbb-38ce-40dd-b529-5c6ea32c4d9e" xlink:href="angn-20241231.xsd#angn_PurchaseOfWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_81b37bb6-b3f2-4f74-aa73-0b802597e338" xlink:to="loc_angn_PurchaseOfWarrantsMember_c2877fbb-38ce-40dd-b529-5c6ea32c4d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_b9675ba9-73d4-488e-bfa8-8a52f4bc340d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6e42ee65-0a97-4634-a38b-e002856a7adc" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_b9675ba9-73d4-488e-bfa8-8a52f4bc340d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_26419a41-e03c-40a7-949e-5bd72fbc407b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b9675ba9-73d4-488e-bfa8-8a52f4bc340d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_26419a41-e03c-40a7-949e-5bd72fbc407b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_MarchSubscriptionAgreementMember_10e43093-f352-4324-b47d-6d58a555309f" xlink:href="angn-20241231.xsd#angn_MarchSubscriptionAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_26419a41-e03c-40a7-949e-5bd72fbc407b" xlink:to="loc_angn_MarchSubscriptionAgreementMember_10e43093-f352-4324-b47d-6d58a555309f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_JulyPublicOfferingMember_1aa860d2-b2bd-41e5-b848-de2185c53056" xlink:href="angn-20241231.xsd#angn_JulyPublicOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_26419a41-e03c-40a7-949e-5bd72fbc407b" xlink:to="loc_angn_JulyPublicOfferingMember_1aa860d2-b2bd-41e5-b848-de2185c53056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_5d9cbc07-2cbd-4892-9488-38d719eff764" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6e42ee65-0a97-4634-a38b-e002856a7adc" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_5d9cbc07-2cbd-4892-9488-38d719eff764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_2e8de2ab-0b90-40b5-9a93-fb2cb1cb4913" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_5d9cbc07-2cbd-4892-9488-38d719eff764" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_2e8de2ab-0b90-40b5-9a93-fb2cb1cb4913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_PreFundedWarrantMember_29406f0d-dbe8-42d6-9cb8-76cc3d5544c2" xlink:href="angn-20241231.xsd#angn_PreFundedWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2e8de2ab-0b90-40b5-9a93-fb2cb1cb4913" xlink:to="loc_angn_PreFundedWarrantMember_29406f0d-dbe8-42d6-9cb8-76cc3d5544c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember_04fcefcf-d6cb-415d-8c40-cd3f00903ec4" xlink:href="angn-20241231.xsd#angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2e8de2ab-0b90-40b5-9a93-fb2cb1cb4913" xlink:to="loc_angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember_04fcefcf-d6cb-415d-8c40-cd3f00903ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4c7ebbad-e575-4465-9ea0-4460a2706988" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6e42ee65-0a97-4634-a38b-e002856a7adc" xlink:to="loc_srt_CounterpartyNameAxis_4c7ebbad-e575-4465-9ea0-4460a2706988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_00797e23-c5b7-46af-9544-f0d5ff4e751b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_4c7ebbad-e575-4465-9ea0-4460a2706988" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_00797e23-c5b7-46af-9544-f0d5ff4e751b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_YekaterinaChudnovskyMember_b7865a02-3fe9-4581-9587-dd3acc67c3f3" xlink:href="angn-20241231.xsd#angn_YekaterinaChudnovskyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_00797e23-c5b7-46af-9544-f0d5ff4e751b" xlink:to="loc_angn_YekaterinaChudnovskyMember_b7865a02-3fe9-4581-9587-dd3acc67c3f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_JayVenkatesanAndTrustsAffiliatedWithJayVenkatesanMember_37d87fa2-1899-4859-8ee1-a7f0003afe86" xlink:href="angn-20241231.xsd#angn_JayVenkatesanAndTrustsAffiliatedWithJayVenkatesanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_00797e23-c5b7-46af-9544-f0d5ff4e751b" xlink:to="loc_angn_JayVenkatesanAndTrustsAffiliatedWithJayVenkatesanMember_37d87fa2-1899-4859-8ee1-a7f0003afe86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6ebf1560-973e-41d9-a43e-85703fe49aed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6e42ee65-0a97-4634-a38b-e002856a7adc" xlink:to="loc_us-gaap_DebtInstrumentAxis_6ebf1560-973e-41d9-a43e-85703fe49aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f14266c1-affd-42c1-a4a4-872235105fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_6ebf1560-973e-41d9-a43e-85703fe49aed" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f14266c1-affd-42c1-a4a4-872235105fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_SeniorSecuredConvertiblePromissoryNoteMember_9b8f0c14-94b8-471b-a7b1-dd462743d88e" xlink:href="angn-20241231.xsd#angn_SeniorSecuredConvertiblePromissoryNoteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f14266c1-affd-42c1-a4a4-872235105fa1" xlink:to="loc_angn_SeniorSecuredConvertiblePromissoryNoteMember_9b8f0c14-94b8-471b-a7b1-dd462743d88e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_0a4bccbe-7a02-4a23-994f-1cfa45c82de2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6e42ee65-0a97-4634-a38b-e002856a7adc" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_0a4bccbe-7a02-4a23-994f-1cfa45c82de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_08f31638-b629-4cb9-b4aa-4fc2a8b96301" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0a4bccbe-7a02-4a23-994f-1cfa45c82de2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_08f31638-b629-4cb9-b4aa-4fc2a8b96301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_33494c39-6283-49f0-9feb-12d966a94bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_08f31638-b629-4cb9-b4aa-4fc2a8b96301" xlink:to="loc_us-gaap_ConvertibleDebtMember_33494c39-6283-49f0-9feb-12d966a94bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_53bd7601-f7cb-4b1e-b627-8746b3bba572" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6e42ee65-0a97-4634-a38b-e002856a7adc" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_53bd7601-f7cb-4b1e-b627-8746b3bba572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_1eb895c3-d773-4ead-81ff-02216043ce77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_53bd7601-f7cb-4b1e-b627-8746b3bba572" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_1eb895c3-d773-4ead-81ff-02216043ce77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_085cc358-29c5-490a-8221-9688313c59da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_53bd7601-f7cb-4b1e-b627-8746b3bba572" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_085cc358-29c5-490a-8221-9688313c59da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_73055ef5-1c00-4c73-b508-385a891303b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_53bd7601-f7cb-4b1e-b627-8746b3bba572" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_73055ef5-1c00-4c73-b508-385a891303b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ClassOfWarrantOrRightIssuedInPeriod_9ed395b6-fb84-4bc3-bc65-f1783a76d59c" xlink:href="angn-20241231.xsd#angn_ClassOfWarrantOrRightIssuedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_53bd7601-f7cb-4b1e-b627-8746b3bba572" xlink:to="loc_angn_ClassOfWarrantOrRightIssuedInPeriod_9ed395b6-fb84-4bc3-bc65-f1783a76d59c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_0d948bd6-7cc1-428a-9c92-dcb5ccf67a79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_53bd7601-f7cb-4b1e-b627-8746b3bba572" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_0d948bd6-7cc1-428a-9c92-dcb5ccf67a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_b93f6440-f510-40f5-bebc-85c00b2eb7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_53bd7601-f7cb-4b1e-b627-8746b3bba572" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_b93f6440-f510-40f5-bebc-85c00b2eb7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/SegmentReportingDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#SegmentReportingDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/SegmentReportingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_ef10e4b2-4d4a-4589-af32-c915b5131814" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_37e4fae6-af6d-4a29-b370-f2d849958c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_ef10e4b2-4d4a-4589-af32-c915b5131814" xlink:to="loc_us-gaap_NumberOfReportableSegments_37e4fae6-af6d-4a29-b370-f2d849958c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_55a8d58b-2278-4342-b733-276a6a0c89b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_ef10e4b2-4d4a-4589-af32-c915b5131814" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_55a8d58b-2278-4342-b733-276a6a0c89b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_59df21e2-93f6-43e1-ac72-c493ea7a02c5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_55a8d58b-2278-4342-b733-276a6a0c89b1" xlink:to="loc_srt_ProductOrServiceAxis_59df21e2-93f6-43e1-ac72-c493ea7a02c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1d4d68a8-5f8f-4f1e-9a80-9af21a7b7379" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_59df21e2-93f6-43e1-ac72-c493ea7a02c5" xlink:to="loc_srt_ProductsAndServicesDomain_1d4d68a8-5f8f-4f1e-9a80-9af21a7b7379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ClinicalTrailMember_ab8a6e78-8c27-4d4d-8d84-4624d37b382f" xlink:href="angn-20241231.xsd#angn_ClinicalTrailMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1d4d68a8-5f8f-4f1e-9a80-9af21a7b7379" xlink:to="loc_angn_ClinicalTrailMember_ab8a6e78-8c27-4d4d-8d84-4624d37b382f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_EmployeeRelatedReasearchAndDevelopmentMember_86b686f1-050b-4dd5-9693-1568ee665859" xlink:href="angn-20241231.xsd#angn_EmployeeRelatedReasearchAndDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1d4d68a8-5f8f-4f1e-9a80-9af21a7b7379" xlink:to="loc_angn_EmployeeRelatedReasearchAndDevelopmentMember_86b686f1-050b-4dd5-9693-1568ee665859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_TranslationalMedicineAndCMCMember_751b8008-405c-4e4f-bf2f-47c3aad4264b" xlink:href="angn-20241231.xsd#angn_TranslationalMedicineAndCMCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1d4d68a8-5f8f-4f1e-9a80-9af21a7b7379" xlink:to="loc_angn_TranslationalMedicineAndCMCMember_751b8008-405c-4e4f-bf2f-47c3aad4264b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_OtherMember_b8643275-4775-4344-9d28-7a6b556bb1eb" xlink:href="angn-20241231.xsd#angn_OtherMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1d4d68a8-5f8f-4f1e-9a80-9af21a7b7379" xlink:to="loc_angn_OtherMember_b8643275-4775-4344-9d28-7a6b556bb1eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_9b48ae89-468d-42c6-90db-e894cf9132e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_55a8d58b-2278-4342-b733-276a6a0c89b1" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_9b48ae89-468d-42c6-90db-e894cf9132e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a7b61a03-4706-4d0a-bca8-faa415f3aba1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_9b48ae89-468d-42c6-90db-e894cf9132e2" xlink:to="loc_us-gaap_SegmentDomain_a7b61a03-4706-4d0a-bca8-faa415f3aba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ReportableSegmentMember_bf0894b2-4b51-4526-9e75-59654c233e44" xlink:href="angn-20241231.xsd#angn_ReportableSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_a7b61a03-4706-4d0a-bca8-faa415f3aba1" xlink:to="loc_angn_ReportableSegmentMember_bf0894b2-4b51-4526-9e75-59654c233e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_bd84da68-1388-4774-8686-89b05e8c0300" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_55a8d58b-2278-4342-b733-276a6a0c89b1" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_bd84da68-1388-4774-8686-89b05e8c0300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e3bd11ad-8344-4f8a-97ce-095b4c4f050f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bd84da68-1388-4774-8686-89b05e8c0300" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e3bd11ad-8344-4f8a-97ce-095b4c4f050f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecoveryOfDirectCosts_76451350-bf30-4f9f-835e-4aab836701f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RecoveryOfDirectCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bd84da68-1388-4774-8686-89b05e8c0300" xlink:to="loc_us-gaap_RecoveryOfDirectCosts_76451350-bf30-4f9f-835e-4aab836701f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_2e62631d-fc89-4755-9697-debba3a6ed3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bd84da68-1388-4774-8686-89b05e8c0300" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_2e62631d-fc89-4755-9697-debba3a6ed3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_02867247-a887-4be6-89ac-71d8e06ce8b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bd84da68-1388-4774-8686-89b05e8c0300" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_02867247-a887-4be6-89ac-71d8e06ce8b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_61bcee2e-f935-4a3e-86d9-8c8185f7a04d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bd84da68-1388-4774-8686-89b05e8c0300" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_61bcee2e-f935-4a3e-86d9-8c8185f7a04d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c03b0482-0020-4a10-9d1e-07299c0b0c33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bd84da68-1388-4774-8686-89b05e8c0300" xlink:to="loc_us-gaap_NetIncomeLoss_c03b0482-0020-4a10-9d1e-07299c0b0c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ef2ed3dc-f703-4977-9e64-6f6eda080652" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bd84da68-1388-4774-8686-89b05e8c0300" xlink:to="loc_us-gaap_Assets_ef2ed3dc-f703-4977-9e64-6f6eda080652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="angn-20241231.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0fde61bf-d51b-46c8-b963-1e13c7d81b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_94bf28fc-a988-4db0-849d-852ae4fa348a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0fde61bf-d51b-46c8-b963-1e13c7d81b4d" xlink:to="loc_us-gaap_SubsequentEventTable_94bf28fc-a988-4db0-849d-852ae4fa348a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_da5ee83e-7375-47ca-b330-e98a14a1c0c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_94bf28fc-a988-4db0-849d-852ae4fa348a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_da5ee83e-7375-47ca-b330-e98a14a1c0c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_08686b6c-871c-41dc-b2f8-4a663fd0ecd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_da5ee83e-7375-47ca-b330-e98a14a1c0c4" xlink:to="loc_us-gaap_EquityComponentDomain_08686b6c-871c-41dc-b2f8-4a663fd0ecd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a02b75f2-aaf3-48f5-8238-5fbc4df73eef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_08686b6c-871c-41dc-b2f8-4a663fd0ecd4" xlink:to="loc_us-gaap_CommonStockMember_a02b75f2-aaf3-48f5-8238-5fbc4df73eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_61cc1d4f-48d0-4922-aafe-f69ecfd93885" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_94bf28fc-a988-4db0-849d-852ae4fa348a" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_61cc1d4f-48d0-4922-aafe-f69ecfd93885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f0254a83-8d6c-4cb9-bbdc-9846a49894a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_61cc1d4f-48d0-4922-aafe-f69ecfd93885" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f0254a83-8d6c-4cb9-bbdc-9846a49894a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_0e7a7c2f-4948-4ab9-a8d6-1e55b10aecc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_f0254a83-8d6c-4cb9-bbdc-9846a49894a6" xlink:to="loc_us-gaap_SubsequentEventMember_0e7a7c2f-4948-4ab9-a8d6-1e55b10aecc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_ed466df4-4f78-48d9-91ee-b64f6f5430ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_94bf28fc-a988-4db0-849d-852ae4fa348a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_ed466df4-4f78-48d9-91ee-b64f6f5430ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_a5b20801-ac5c-44db-af27-344916f5eceb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_ed466df4-4f78-48d9-91ee-b64f6f5430ae" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_a5b20801-ac5c-44db-af27-344916f5eceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_PreFundedWarrantMember_99dffa2c-6e84-4cfb-b8f6-cc1180caa0ec" xlink:href="angn-20241231.xsd#angn_PreFundedWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a5b20801-ac5c-44db-af27-344916f5eceb" xlink:to="loc_angn_PreFundedWarrantMember_99dffa2c-6e84-4cfb-b8f6-cc1180caa0ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4c508184-a95a-463a-8f9e-49efe2871595" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_94bf28fc-a988-4db0-849d-852ae4fa348a" xlink:to="loc_us-gaap_DebtInstrumentAxis_4c508184-a95a-463a-8f9e-49efe2871595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_19c2c804-5f27-44d6-8d22-f40071706b94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_4c508184-a95a-463a-8f9e-49efe2871595" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_19c2c804-5f27-44d6-8d22-f40071706b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_SeniorSecuredConvertiblePromissoryNoteMember_43f81470-25ce-46cb-b78a-896a8cb2fdee" xlink:href="angn-20241231.xsd#angn_SeniorSecuredConvertiblePromissoryNoteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_19c2c804-5f27-44d6-8d22-f40071706b94" xlink:to="loc_angn_SeniorSecuredConvertiblePromissoryNoteMember_43f81470-25ce-46cb-b78a-896a8cb2fdee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6d0d69b0-491f-4dce-8a8e-ccd965cf89ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_94bf28fc-a988-4db0-849d-852ae4fa348a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6d0d69b0-491f-4dce-8a8e-ccd965cf89ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_302345d8-e56c-4deb-b375-0370a5286215" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6d0d69b0-491f-4dce-8a8e-ccd965cf89ff" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_302345d8-e56c-4deb-b375-0370a5286215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_aa549113-fe9a-4551-a9f6-453b5589ba93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_302345d8-e56c-4deb-b375-0370a5286215" xlink:to="loc_us-gaap_ConvertibleDebtMember_aa549113-fe9a-4551-a9f6-453b5589ba93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_485b034f-ddfe-4789-a418-9623705f5fd9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_94bf28fc-a988-4db0-849d-852ae4fa348a" xlink:to="loc_srt_RangeAxis_485b034f-ddfe-4789-a418-9623705f5fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0c9c92e7-7475-485d-9be7-8fa5a2a45233" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_485b034f-ddfe-4789-a418-9623705f5fd9" xlink:to="loc_srt_RangeMember_0c9c92e7-7475-485d-9be7-8fa5a2a45233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9643c7e4-7943-49c4-aa04-8fbab25a6b31" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0c9c92e7-7475-485d-9be7-8fa5a2a45233" xlink:to="loc_srt_MinimumMember_9643c7e4-7943-49c4-aa04-8fbab25a6b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9bfc0ef0-bfa8-40e8-b189-1049b2e08e97" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0c9c92e7-7475-485d-9be7-8fa5a2a45233" xlink:to="loc_srt_MaximumMember_9bfc0ef0-bfa8-40e8-b189-1049b2e08e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_a9e034b2-3488-4caa-8f02-3a9b967743cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_94bf28fc-a988-4db0-849d-852ae4fa348a" xlink:to="loc_us-gaap_SubsequentEventLineItems_a9e034b2-3488-4caa-8f02-3a9b967743cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_e048fe1e-8cc1-41d9-a48c-d8a134af9ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_a9e034b2-3488-4caa-8f02-3a9b967743cc" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_e048fe1e-8cc1-41d9-a48c-d8a134af9ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_71181bf3-bba9-4f25-90f5-0484451d2e76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_a9e034b2-3488-4caa-8f02-3a9b967743cc" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_71181bf3-bba9-4f25-90f5-0484451d2e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_b86ec689-7caa-486e-a3b6-e99b96658cac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_a9e034b2-3488-4caa-8f02-3a9b967743cc" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_b86ec689-7caa-486e-a3b6-e99b96658cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7371a90c-dd10-472b-a58a-10aa09e5049d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_a9e034b2-3488-4caa-8f02-3a9b967743cc" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7371a90c-dd10-472b-a58a-10aa09e5049d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_f78e7d0c-f5a0-408e-acc9-1e85b74ff35c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_a9e034b2-3488-4caa-8f02-3a9b967743cc" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_f78e7d0c-f5a0-408e-acc9-1e85b74ff35c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_d9cef12c-ba6d-4e93-93eb-78ea4ee19601" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_a9e034b2-3488-4caa-8f02-3a9b967743cc" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_d9cef12c-ba6d-4e93-93eb-78ea4ee19601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_8f218d31-d4e2-4c31-ac00-aae0038d8051" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_a9e034b2-3488-4caa-8f02-3a9b967743cc" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_8f218d31-d4e2-4c31-ac00-aae0038d8051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_c304ebbf-f6fc-40e6-a41e-fc24d18dc71a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_a9e034b2-3488-4caa-8f02-3a9b967743cc" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_c304ebbf-f6fc-40e6-a41e-fc24d18dc71a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_c2f88db0-994f-4326-b270-fd7b640c26b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_a9e034b2-3488-4caa-8f02-3a9b967743cc" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_c2f88db0-994f-4326-b270-fd7b640c26b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AccruedInterestPremiumForConvertiblePreferredStock_c0b9e1ec-8887-4d30-b0af-39fc3510a72a" xlink:href="angn-20241231.xsd#angn_AccruedInterestPremiumForConvertiblePreferredStock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_a9e034b2-3488-4caa-8f02-3a9b967743cc" xlink:to="loc_angn_AccruedInterestPremiumForConvertiblePreferredStock_c0b9e1ec-8887-4d30-b0af-39fc3510a72a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>angn-20241231_g1.jpg
<TEXT>
begin 644 angn-20241231_g1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'X!. # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,<8:555@2Q/\*]O>O(S#+89A9WLT?H&2\1O+\4Z.$I+DE]_J<#^P9\(=4O\
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MA1114#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ORI*K,<GT KUG187M=(L8)!B2.!$8>A"@&JTY?,G6Y=HHHJ2@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $KR_X=_%
MR\\9?%;Q[X2GL(+>W\.20I%<1L2\V]0?F!X&/:O4*\7^%/P]USPW\</B?XAO
M[58=+UJ6!K*8."9 J 'CMS5*UG<EWNK'M-%%%24%%%% !1110 4444 %%%%
M!1110 4C'M2TR:188S([!$499F.  .I)H \-MH?!/Q _::GNX_[0;Q?X2LQ"
MY S:['R1D_WOF->Z+TKQ3]G_ .&MSX9\3_$+Q9>ZC8ZG/XFU(312Z=.)8O(3
M(C&1_%AN:]KJY6OH3$6BBBH*"BBB@ HHHH **** "BBB@ HHI* %HINZE'-
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M,8\HQ@KCZ4O:AR'S_P#L>_$;Q-X\TCQ'!KGDZE9Z9>?9K+7H;3[,M^@&-VW
M)^IKZ)J*"".WC2.*-8HU& J   ?2I:RE+F=T:15E8****D84444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOQ/?%FO-<OOFFE9CDA?[HKUGH**6H;;W*"D8;A2T4@$Q2T44 %%%% #2N?\
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M_?0H^V0?\]X_^^Q7S[YS_P!XU!>:A%86LES=7*6]O&I9Y96"JH]R:E9Y%Z*
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M=65_9L=CZ,^V6_\ SWC_ .^Q1]MM_P#GO'_WV*^>_,(ZG]*-YQP>:S_MV/\
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MK)'I_B%5RJJ?W5T!U9,]#ZKUK*^#'AW5=-_:&^+^HWFGW%M87LUL;:XE3"3
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M[*J=.*^;S7#\[C5EJD-'D4</Q#_:8E=KG[1X$^'K'Y8%RM[?)ZG^Z#77ZO\
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M\?O&=W=S&9+V*^AN(50CRQ),2.?H:]'\;^+]!_9+\-ZG9:3?#5?$^K/FWMF
M_<* 0&<#H!G\37!1I3K35.FKMGU.:9S0RVG.M.5E:/X'RW\?/!_AKP[\(_"/
MA.&Q;_A,M/>6X:9L!X+=SD0R>I)Y [5Q/[(OCCP_X)^-&C-XM@WZ4\GEQR2'
MY;:<\)(1Z9_GFO7O@%\'=7_:#^(%QK>O>=/HR3^?J%Y(2/M$F<^6I_GCH*Z7
M]N[]DV&UL6^(/@^Q6.""-8]3TRUCP%0# E0#I@#FO5QU.G@7&E1E[]O>/D^&
M\UJ\0QJK,X+V,W[E]UYG9:GJ'BJX^/WB>T;3)1H:V]U+]N$9V-$;<X(;H02:
M\Q^ (_XLC\9>.?L]O_[/71?L5_M1V?B;0&^%WC6^,5T]N;;2]2F;/FQLI7R6
M<_Q 'Y<]1QVKUA?V9S\)/@]\0[+2+N?7+O6(0R1; &"IG:H'<X)K:ACH2AR2
M5G[OX,^6S?AW%8'%73YHKG?W[6'?L _\DHU >FH/_(5]/U\X_L/>&=6\-_"V
M[CU6PGT^6:^=T2X3:Q7&,XKZ-&:\K,I*6+J2CM<]?(X2IY=1C-6=A:J:EJEG
MH]G)=W]S%9VT?WIIG"J/Q-6Z^6?VQ;S_ (3[Q-X%^%4-ZEBFL7;7E_.T@01Q
M1JVW)SW.>/I7#&/,['MR=E<^G[.^M]2M8KFTFCN;>4;DEB8,K#U!'6G3W$=K
M;R3S.L44:EW=C@* ,DFODW]EKXK?\(-\%O'&DZH[7DW@2XN%CC# EX 28P#Z
M<=?]JNA^''Q!^+7CKPXGBGQ!I.@_\(-J^FW%TMO%(WVB"/RV,08'KNP 1VS5
M.FXMB4DSZ"T#Q-I7BK3EO]'OX-2LF9D%Q;.'0D'!&1W!J!O&FBQ^*H?#3ZA"
MNNS6[726);]XT0."^/3-?('@?X^W?@/]G7P;#X.\-Z?:>(/$FM7=A8V2R-Y,
M;+,P:1LDDD_6K'A35O'%O^V#97'CK3K--=L?"-XR#2W+QW2 A@5]#G(Q5>SW
M)YT?:.12U\R_ /X[>,/B]XACNI=3\.06)NI8;KPW\R:A9HN</R?F.<<8Z'-?
M3(K*47%V9HG<6BBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 444E &/XH\11^'=/,[C=(W")ZFOF/XB_M*7&D>(Y-#M++4O$&IQQ?:K
MFSTM ?LT79F)(_*O8_BK.9-4MHS]V-./QZU\C^)O[8^'OQF\1:OX873]>N]:
MTU#>Z9<W(AFM%C&!+D]4QR17RF-Q$YXATD[)%(^A/AM\9AXJ\/V^L:;.;[3I
MP4:*<892#\RD=B#FNYU+P;;^(-.75-&PC.N3;CIGN*^>?@!X?B\/_#FW$6H0
M:FU[/+>2W%J<Q>8[$E4]A7TK\*;EI+&\MR?W<;*5_'/^%<V$E]8JO#U=5T[B
M/E[XM?LW:)XVU!=4MQ-X7\6VQS#JNG_NWR.F\#AN?6N'L?C1XT^#.HQZ3\4]
M.:_TAB$A\4V*93V,JCI]:^^/$WA.SU^W/F*(YE!VRKU%>'ZYI-M>1WMA>P17
MEMAT:*9 RMP>H-9XJA+"R4*GO1>W<9\Y^./BEJ?QVUS_ (03X;73+I<B ZOX
MCB!V11'JB'^\17M/PY^'>C_"_P +VVA:+ ([>$9>5A\\S]W8]R:\H_8WL;>P
M\#^(X[>&.!%UNX0!%QP&.!]!7OV?F&>E>=B)<K]C3T0_(GL=/GU"X6&VB:1V
M/89 KT_PO\/H-+VW%Z!-<=0IY536IX+TBUL-%MI8HE665-S/CDUT%?4X#+*=
M%*I/5DGE?[2?Q1U'X-_"NY\2:3;P7-W%=VUN(YQ\FV20(>GL:[EM+L/%N@VP
MU6PM[Z*>%7:*XB5U!9<G (XZUYU^U3\.-:^*OP?NO#^@0QSZE)>VLRI*X1=J
M2AFY/L*]3T:W>TTFRMY!B2*%$8>X !KZ&48RA9HE74CQ+Q-^R+X8O(R= N;C
M0VSD1;C-%^3'=^M>2Z]^RSXXT>65K5+/6+5!\K6\NR9_I&PP/^^J^U,45\IC
M.&<MQCYI4[/NM#W<+G6.P>E.H[>9\7>$OV6?%WB"Z@.L00Z+I;<3":4/.5[J
M$7@9'?=7L6O?LL^ ;7PK?Q:=HUQ]JCMF\A3J5T4WA>#M\S;U[8Q7M^!Z4A4-
MU&:Z<#D>$RZE*E17Q;MF&+S/%8VHJM:5VC\W+/P_J]ZJB+3+VX8'8QBMG;YN
MAZ"NMTGX%^/=:GCC@\-7,"2#*W-XZ1PC_>.2P_[YK[SBMXH%(BC2,9Y"*!_*
MI,5\S3X'P7,Y59MGORXKQ_(H0LK'S-X#_9%V-#<^+KZ.X089M.LLA,_W6?J1
M] *^E+2TBL;6*W@C6*&)0B(HP% & !4NT45]I@<MPV70Y,-&Q\OBL77QD_:5
MY795O=)LM2,1N[2"Z\IM\?G1A]C>HR.#5A8UC554;57H!T%/HKT>57O;4XQ*
M6BBJ **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!",T;12T4 (JA
M>E+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "5Y1\-OBOJ7
MC#XN?$'PM=6\,=EX>EA2WE0$.X=03NKU>O'/A9\--;\+_&OXF>)+^&./2]<E
M@:R99 68*@!R.W-7&UG<EWT/9*JZE'YMG*O^R:M4R1=Z$>U2G9W"2YDT?/W@
M^X_L7XQQJYV1W"O%SW)' _.OH2OG/XG6[^'?&-EJ<?RF&=9 V/0U]!:?>)?V
M<%Q&<I(@<?0BO1QBYN6HNJ/$RR7(ZE%]&6J***\T]T0C=UHVBEHH 3:*3:*=
M10!PDWP>T*Y^)T?CN<W$VLQP"WB5W!B1>>BXZ\FNYVBEQ2U<IRE:[V,H4H4[
M\BM?5C=@HV"G45!J-VBEVBEHH 3:*6BB@ I*6DH XCXS:E_9OP_U$J5#RA8@
M&/7) ./PS7._ NQ\G2_,(^]TS6;^T)JHN+C1]'0Y9I//8?H/YFN[^&NE_P!G
M:# "NTXYKU%^[POJ>!?VV8:;11V-%%%>6>^%%%% !2,2.E+36[4 ?&_[1'[<
MT'PO^(>M>#E\%0ZM?:48S#?74P,>YHU?=LVY&-V.O:ODGQ5X^^*_[9'BRUT^
M."XU-(W(@TZQ39:6^>I8].G=CVXK]%/&7[(/PS^(7CZ\\7>(=&EU/4[LJ9XY
M;@^1)M4*,J/8#O7I_A+P/X?\"Z9%I_A[1[/2+.-=JQ6L03CW/4_C5\Q[U#&8
M7"P4J5*]3NSQK]E7]E;2_P!GW0WN[LIJ'BV^C N[S'RQ#_GG'[>I[U] $=:7
M:/2BI/'K5IUYNI4=VSP3]HW]F.P^,$(U733'8>)H4VI.1A)U'(23'Z'K7Q]H
MWBCXF_LRZ]<0E+K2X]V)+>Y4O:2X/4=A]1@U^GFT'M5+4]$T_68?*O[*WO(O
M[MQ$KC]17MX7-)4:?L:T>>'9GQ69<.T\56^M86;I5>ZZ^I^>FL?MH^-=8BD@
MT>STW2+ZZXEN;&W#3R'U'J?KFHOA/^S+XS^,NN#5?$/VS3])D?S)K^_),T_.
M2$!Y_/@5]]V7P[\,:;-YMMH&FPR@[@Z6J @^H.*Z!8U1<* %Z "NJ6;PI1<<
M)24&^O4\^'#-;$U%/,\0ZB73H87@?P/I/P]\-VFB:-;BVLK9=JCNQ[L3W)K;
MN+6*ZADBFC66)U*O&X!5@>H([BI:*^;E)R?-+<^\IPC2BH05DC\X?VJOV&]9
M\.ZQ=>+/AS9/>Z5-*9Y]+MCB:T8G):(=USV'([5YYX!_;D^*?PDT^/0-1>/5
M(K5?+CBUJ-A/&!T!8X8_CFOU@Q6#JGP_\,ZY,TVH>'],O9FZR3VD;,?Q(S1<
M^BI9HG35/%4U-+[SY&_8S_:<\=_'SXO:W#K]Q"NBVVEF6*TM(=L22^:HR6ZD
MX)[_ (5]KBLS1_#&C^'PPTO2[/3@WWOLL"1Y^NT"M/%)GE8FK"M4YJ<>5=@S
M7SQK'[+\'Q*^-?B;Q3\0+:UU70G@AMM&M(;B17C55^<OC&#G/0GK7T128%.,
MG'8Y&D]SY<C_ &2)_#7Q"\0P^%19Z9\/_$>BMIU]:M.[3P2XR)4# [N0!RW0
MFM/X6?"_XP^%?#]MX.UG5/#[^$M.L)[*W>VWM<W*E"L0DR %QG)(STKZ0P*,
M5?M)/<GD2V/D*W_9'\76OP6\(Z5;:GIUKXW\+ZM<ZG9RJS-;2"24L$9MN1P1
MVZUU?@_X,_$^3XV6WQ$\5ZKHLMXNBW&G+!8AMEL[8\O:"/G7(R22.M?26!2;
M1Z4>TE:P<B/F+2/@#XX\0_&;PUXR\3P^&=%&AN\C7'A\.L^H9! $HV@#K[^E
M?3RT;1Z4M1*3EN4E8****D84444 %%%% !1110 UV$:EB< <G-><>*OB-*EQ
M):Z:0JKPT_?\*[/Q3,8/#]\Z]1&:^=/$OBK2/!ND3:IKFH0Z=91*6,LS@9]@
M.YKYW-<55I.-*ENQG8#QIK2J!]N=O]INOXURD_[16E6WBA/#LOBZSCUEAQ:M
M(,Y]/K7S]<?$+QW^T1/<Z?X#@F\*^#\[)O$5XFV:=<\B%3T^M=+;_LB> (_!
MLFBW%E+=7\K>:^MO(?MGF_WP_4<]J\+VM2"_?5'?R*LCZ''C76B,B^;'TI?^
M$TUGK]M;\J^3U\0?$;]FT10:U%/X]\#1G:NH0#=>6B?[8ZL!ZU[CX+^(WASX
M@Z(NJZ'JT%Y:[=TAW /%ZAP>A%93J8F.L9MH+'?_ /"::S_S^M^5<]XO^.EO
MX LTNO$/B2#2XI&"IYS ,Q/H*\1\>?M&O<ZX?"OPUT__ (2[Q(QVR7$?_'I:
M=LN_0X]*3P3^S1%>:M)XE^)E[_PF7B*="/L\_-I:@C[L:=./6M(U*T5S5JC7
MD*Q]"Z7\2KS7K&*^T[6$O;.9=R30L&4_B*N?\)KK/3[:WY5\KZA\$_%OP5U"
MYUSX4Z@;K37)DN?"VH.6B<=_*)^Z?2NX^%G[0F@_$29M*O$D\/>*(?DGT?4!
ML?=WV$_>%3.I7MSTYMH#V_\ X3363_R^M^51W'CS5;.%YI]1\F%!EY)" %'K
MFO*/BC\;/#/PIL0=3NFN=4E&+?2[3]Y<2MV 4=*\KA\#_$']HSR;OQI<R>#?
M!K'?%H5FV+FX7J/-;M]*FG4Q#7/.;2"Q]$>%?V@=/\;7EW::%XKMM2N;5MLL
M4+@L#].XKI_^$TUK_G];\J^<_&/[*N@36NGWO@>1O!?B/3%"VM]9$@2X[2C^
M+/<FJ7@W]H+5/".O1^$?BO8_V'JA.RVUN,'['=]@=W\)-7*I5J*]&HWY#L?3
M/_"::U_S^M^5(WC;6%!9K\A0.6.!BN \9?$CPYX!\/MK&MZK;VMCLW(P8,TW
MH$ ^\37AS7?C_P#:>WQVOVCP+\/';!G(*WM\GMW4$5%.>(E[TYM(+'T/HO[0
M^E^(?$%SHFG>++2[U2W.)+:.0;L^WK75?\)IK.?^/U_RKYWUW]DGP1=^&;+3
M]$AF\/ZK8_-:ZU:.1<[_ .\[=6Y]:Y_3_C!XS^!^HP:-\4K-]2T)B([?Q78H
M67'0><HZ'WK5U:E1?N:C;[!8^J!XTUG_ )_&_*D;QKK7_/ZWZ5QEOXRT&\\/
M_P!NQ:Q9OHVS>;WSAY0'N:\.UCXS>*OC/JMQX?\ A5:M;Z6K&.Z\57:%8D'0
M^4#]X^]8PJ8J3UDTD*Q[WK'[1&E>'O$5MH>H^++6UU6XXCMI)!N_'T_&NI7Q
MQK#*"M\7!&0PY!%?/'A_]D?P79^&+W3];BE\0ZMJ!\RYUJZ<FY\S^\C?P\GH
M*Y8P_$C]F= (#-X^\ QGE&^:^LT_]F %;NK.:M3JN_YA8^L?^$UUG_G\?\J&
M\::SVOG_ "KS;X>?%3PW\4=(%_H.HI<;5S+;R'9+">X=3R,5P?Q(_:/M='U8
M>&?!=@_B_P 62':+>U^:&V/K(XX'TKG53%N7+S,#VSQ5\:$\#Z8VH:]X@BTR
MT7^.=@,_0=ZM:'\59_%&F0ZCI6M1ZA8S#*30,&4U\[^%?V<KSQ9K:^*?BQJ
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MKC4KF"TM0P4RW#A4R3@#)]ZN1LLBJR$,I&01TKYY_;P4_P##/&H<G_D)6/\
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MX*\RJP_$'%>NZ',]SH]A-*Q>22!&9CW)4$FJL^6XM+E^BBBI&%%%% !1110
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M&,M*BCW85EZEXPT724#7>J6L /3=*.::C)[(F52$=9,V::S!02>E>7:S\?\
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ME@>XB#-&P.003Z&MC%$K/8%<6N)^+WC:Z\!^"YM1L;9;F\DFCM8?,'[N-G.
M[_[([UVU>4_M*C59/AG<1:=#<3V\D\:WZVJ;I!;9^<@#G'3)'(%2:TTG))GS
M0UC?W.O7&IW%['NNLM<0V\(C21S_ ! 9./H*T%5X\@-D=>>35;3;JWFA MI5
M>%5&S:<C%27%P\*N5C+JHSD>N/2@^HBDE9$Y;G&,-5=8YUF=MRE2,!3VI-/V
MM LN=S,,EB:LL3M..:"B#;.LF[*L,?<'^-;_ ,-[?^TOB=X71U\E5G:3=&,R
M953@9_N\\_A6.K;P<Y![UN> M<'AGX@Z!J!7Y9)C9R''1)<9/MRJ\T'/7_AN
MQ]>K3J:J[<]Z=0?,A12<_6N*;XU> EU9]+;QEHBZBDIA:U-[&) X."I&>N>U
M.S>PKG;45''(LJJZ.KHPR&4Y!]ZDI#"BHKBXBM8C+-(L,:]7<X _&GQR"10R
ML&5N0RG((H =15'6]:M/#NDW>I7\RVUE:QM--,W1% R35;PGXLTKQQX=LM<T
M2\CU#2[Q/,@N(_NN,D']01^% &O1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %)2TE 'G'Q_^$\GQJ^'%QX7BU!=,>6Y@N/M#IO \N0/C'OBN]TVU^PV%K:E
MM_DQ+'N]<#&:X/X_?%E_@I\.;CQ0FG#5&BN8+?[,9-@/F2!,Y]LYKO=-NC?:
M?:W)789HEDV^F0#5:V\A:7+5%%%2,**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% 'SO^WA_P F[W^,_P#(2L>G_7=:]V\._P#(!TW_ *]H_P#T
M$4NM:/INNV+6FJ6EO?6;,&,-T@="P.0<'C(-78E2-%5  BC 5>@'I5<WNV%;
M6Y)1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_?7\Z7SD_OK^=?/_ -LG'_+>0?\  S1]MN/^>\O_ '\-?.?VXOY!GT!YT?\
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MG_[;<_\ />7_ +^&C[;<_P#/>7_OX:/[<7\@6/H#SH_[Z_G1YT?]]?SKY_\
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M\%44?ZNX+S^\/]=LT\ON/O;_ (;]\$_] O5/^_0_QI/^&_?!/_0+U3_OT/\
M&O@JBC_5W!>?WA_KMFGE]Q]Z_P##?O@G_H%ZI_WZ'^-'_#?O@G_H%ZI_WZ'^
M-?!5%'^KN"\_O#_7;-/+[C[V_P"&_/!7_0+U3_OT/\:7_AOOP5_T"]4Q_P!<
MQ_C7P1BE[>]'^KN"\_O#_7;-/+[C]#/#/[</@/7]4ALKB.]TSSF")-<1_)N)
MQR0>!7T)!<)<1I)&ZO&X#*RG((/>OQL?/EOSVK];_ADQ?X?^'F)RQL8>O^Z*
M^5SG+*6 Y94GHS]!X5S[$9PZD,0E>/8ZFBBBOF#]""BBB@ HHHH **** "BB
MB@ HHHH *X7XM?\ (%M/^O@?^@FNZKA?BUSHMI_UW_\ 937GX_\ W:?H,\P:
MEI*6OS<84444#"BBB@ HHHH *3COUJUI5B^IZE;6J#)D< _3J37;>)OL^M:)
M?):1*LFERA<J.2N.37?0PCK4Y5$]A'"_8Y]L;""3;(<1G:<.?0>M1R0O#(R2
M(R.IP588(KO(0/[)\(X''V@&FZMX6LM7UN_CCU'_ (F!+.+?;\OK@GUKI>7M
MPO!ZZ <'[4O/89K6O- -GX=BU$R,97E,31D# Q_^JM-?!*R:M;V0N6_?6PGW
M%1]['3Z5R_4ZS=K?TQ'*T*K2N%12S'HJCFNN7P;I\U@]U'JQ,<#;+DE.GT]:
M6/PU_9NM:1/8WADMKIOW<K("5/TK3ZA537-L,Y%E*L58%6'!4C!H'IWKL+CP
MS'?S:K>WE\81;S[)&V#!&,YQZUEZ]X;&G?8I+*9[VWNE)C.WYLCJ,5-3!58)
MRMH!BPP2W#,L<;2E1N(09( ZD^U,KK/ MF\6JZA%<*;?=9N,RC&!QS]*@O/"
M]J-&DO\ 3[YKL0L%E#+C'N*J."G*G&: YR2-XV =&0]<,,<4E=IJV@RZMXHM
MK&>[+$VN\2; ,8&<$>E9]YX5M3I-Q>6&H&[>W8+*NT 9/'%$L#5UY=@.<CC>
M9U1$9W8X"J,DTYK69/,#Q.I3A\J?E^M=KI/A>ST?5M/6?42NHDK)Y.SY>>V?
M6GWUO.W_  E$B7'E1K)EH]@.>/7M6JP$N2\GJ!P6*7\:[!?!=A UBESJ;1/=
M(&C54!.3V^E4E\)+;-J+W]RT-O9N$+1IN9R>F!6'U&OIH!SG'I1D?2MOQ+H=
MKH;6WV>YDG::,28=0,*>A^M7K6-?^%=W#[1O%U]['; J%A9<\H2>J5QG,K&\
MB,RJS*OWF X'UIF<5T&F6\\G@_5I5FVQ+(FZ/:/FR?7M6@W@FQANK6&YU1HY
M+I%,*A!DD]CZ#-6L%4FE*'8#D?+?87VL4!P6QP*6*&2:18XXVDD8X"J,DUT_
M]E7.F^']8@,X58[A8FC"@[O?-:&A>&+32-8T@W&H%;]\3+;[?E(P>,^M:QP$
MY2BOO$<.RM&Y1U*.O!4]125I>)/^0]??]=3_ #K-KSZL/9S<>PPHHHK( HHH
MH **** &M7M7@/\ Y%>R^A_F:\5:O:O ?_(KV?T/\S7T61_QI>A/0Z"BBBOM
MA'D'[4WQ,UKX1_".Z\1: \":E'>VL"FXB\Q-LDJJW&?0UZCHUU)>:793R8\R
M6%)&(XY*@G%>9?M0?#'6/BY\)+KP[H9A_M&2\MIU^T/M7;'*&;GUP*].TFU>
MRTNR@DP9(H4C;;TR% -7IR^9.MR[1114%'(_%C_DG/B#_KSD_P#037Y\1_=%
M?H/\6CM^''B _P#3G)_Z":_/E?NBOQ3CW_>*7H?K7!7\&KZH;WHI:2ORH_20
MHHHH **** "BBB@ HHHH 5<UUD?PK\6S6*WB:#=O;N@D5T0G<I&00*Y/L:^N
MM1AU&TUCP3JO_"1PZ3H=KIT#7=O-<!!)\G7;WSQ7U>2Y71S"-255M<MMO/J?
M,9QFE7+Y4XTDGS7W\O3N?),D;0R-'(ICD4X96&"#Z&K_ (?T"[\4:M;Z78HK
M75PVU-QP#7NNOZ7X/:SU[XA7U@^KV<]X8;2UC;8C <%S]?Z5)HG@O2++QEX!
M\5Z# ]CIVJNRO9R/N,<F">#Z8!KKCP[+VR7.FKK1;\K=KG)/B&/L6U!J5GJ]
MN9*]CP#5],FT75+O3[H 7%K*T,B@\;AUJB*]V\3>"],\76/CVXM(&'B/3=5D
M=F#9+Q%O3T[5H:=\*?"\?C+2/#=_:.T\6C27FH,CG<9=H/'TYK*?#M>56U-K
ME;T?S_,TAQ#0C23J)\R6J^5[^A\]KZ4<5] 6>@_#?6/ =]XDBT2^M[71IO+D
MC\X%[KL 3VSD5#>?"WPWXN\2^";C1[>73-,UV%YI;8MDJ$Z@'MFD^&Z]E[.<
M97[?F-<14$_WD)17=]TK_D>"^PZ^].53)(B#[SMM ]2>U?0GB[X5Z++X1URY
M&B+X;N=..;21;M9#<(#SN&>IK.\?>'? _@/0],B72;FXU;5+6-HY%DPL+$CY
M^>Y-*7#M:BVYS7*BH<0T:J2IP?,]+?J>0^(_"NJ>$KF*VU6W-K+(@D1=P;*G
MITK(W8Z5](:]\+=-UKXE*+V2YFT;3](6\N$>4L['G"@GH#@UY#X^UKPKK"VS
M>'M%GT>:-BLJM(&5U[$>]89AD[PD74<DET75F^ S?ZVXTU%M]6MD8"^'-2DT
M-]8%I(=-63RS<*/E#>E26WA75+SP[=:Y#;%]-M7$<LVX?*QZ#%>HV/R_LP7Q
MSG_B8_\ LRUB^']'BN/@9XBU!I)A+'J%O&%20A""P!RO0FM8Y3!RC%=8<WSL
M92S6<8RDU:T^7Y7/,1R!V]JV])\'ZCKFA:KJ]LBFSTU0]P6." >.*]WF\$_#
M[0?%/A_P_=Z-<W5[KT";)A+^[@)&,X]2:K_#?P,;S1/B9X6LI@H:9;6.68@
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MK\D9O]6_TK];OA=_R3KPY_UXP_\ H(KXGB?X*?J?K?A__%K^B.IHHHKX _:
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M*_0"BC^W\=_,ON#_ %,RC^1_>?G_ /\ # GC_P#Z"^B?]_)/_B*/^&!/'_\
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MON.RCPGDN(@ITXNWJ? '_# OC_\ Z"^B?]_)/_B*/^&!?'__ $%]$_[^2?\
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MOT HH_M_'?S+[@_U-RC^1_>?G_\ \,">/_\ H+Z)_P!_)/\ XBC_ (8$\?\
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M2NRQ-S?HKSR^^.GA6QL;.Z\ZZN([V[ELK5+>W9WGEC.'50.O/\JQQ^TUX+:
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MK0'BS7?ACI/PZN]6U<:EX?U)X[*_N)XEC^SM)$#"Q('0$$9]Z7*%SW&BO/\
MX0^*-:\:Z=K6MZB$CTZXU*:/28E4?\>L9"!R>N6=7//8"N_'2IV*%HHHI %%
M%% !1110 4444 %%%% !1110!YY\0/\ D?? O_7U+_Z!7H5>>_$#_D?? O\
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M^'=.GU0'=]I>!2Q/J>Q/N>:Z95V\#IZ42ES#2L+1114#"BBB@ HHHH ****
M$K*\-?\ (-;_ *[2?^AFM6LKPU_R#6_Z[2?^AFLG\: UJ***U X#XV?">U^-
M'@&?PO>7LFGPRW$-P9X5!8&-PX&#ZXKM=/M18V=O; [A#&L88]\#&:\W_:.^
M*=]\&?A?=>)M.M8;RZBNK> 13YVD22!2>/8UZ/I=RU]IMI<N,--$DA4=!D _
MUJM>7R%I<MT445(SEOBA_P B!KO_ %ZO_*M?PW_R+^G?]>\?_H(K(^*'_(@:
M[_UZO_*M?PW_ ,B_IW_7O'_Z"*X5_O3_ ,*_-G2_X"]7^2-*BBBNXY@HHHH
M*:PR*=24 >-:UX>\0_"_Q)>ZUX<L3K>AZB_F7NE*VUXW[NG8Y]*6/XL3061L
M?#'@?4Q>L2%AEMQ!"C'J20?7\Z]?GFCMXVDE=8T49+,< #US6=:^)-&NYEBM
M]2M)IGZ)',I)_ &O!E@U2FU3J\J?333T/46(]I%.=/F:ZZZ^IR?PO\ WN@RW
MVN:]*MSXBU-@]PR_=B7M&OL*[R]M4OK.>VDSY<T;1MCT(P?YU*&!Q@TZO6P]
M&&'@H0.&K5E6FYR.(TGX1Z)HL?A%+<38\+I+'8;GSQ(H5MWKP*=<?"?1;G0=
M:TAO.%KJUY]NN/FY\S<K<>V4%=K173=F)X]J/PAN_$7Q/\4ZM)J&IZ'#/8V=
MK:WFG7&PR(%D$J%>1U*\XR.QKJM%^$>@>';CPQ)80R0CP]#+#9KOR") 0Y;U
M)R3FNVHI\S%9'FWB#X&Z;KFJ:O=P:KJFDP:SC^T[.RG"Q7.!C)R"5)'!QBKW
MC+X,^'/&WA32O#MW;/;:;I<D,EHMLVUHQ'@!,_W2  1WKO**.9A8XCQ-\*[#
M7]:T_6;2\N]"UFQMS:17FGL%)@.#Y; @@@8X]*Z/0]%;1=+CLGO;G467.ZYN
MG!D?/J0!6I12N,\RA^!=@U]8OJ.NZSK&G6-P+JWTR^N0\*R Y4MQE\'D!B:B
MOOV?=%O+K4T34=2M=%U2Z-Y>Z+#,!;32DY8XQD!CR0"!7J5%/F8K')WGPUT:
M^FUIIHG,>K6B65Q&&POEJ" %]#S6!X;^!>EZ!X@T?6IM6U75K[2(FM[(WD^Y
M8HB -NT #@#KUKTNBE=A9'D-K^S5X>LXVLDU'53HDUZ;^XTEKC-O/-OW[F&,
MXW8X!QQ78:E\,])U1/$2RB0+KBPK=!3C B7:NWTXKKJ*?,PLCE=2^'.DZM=Z
MQ/<H\AU6Q6PN5SP8UZ8]^:X?XF?"N[?X#ZSX/TU[SQ'=W$:06AO'7?%\R@$-
MQ@( 3GK7L5)2NT!C^#?#Z>$_"NDZ/'RME;)"6SG+ ?,<^YR?QK9HHI#"BBB@
M HHHH **** "BBB@ HHHH **** ///B!_P C[X%_Z^I?_0*]"KSWX@?\C[X%
M_P"OJ7_T"O0JX,/_ !:OK^ATU?@AZ?J+1117><PA.*X#P3\)+7P9\0O&'BN*
M^FN)_$;QO);N %BV+CY37?\ 7BO+/AS\6+_QA\6OB!X4N;2&&T\.R0I!-&3O
MD#J"=WYU2O9V$['JE%%%2,P_'/\ R)NM_P#7G+_Z :Y_X%_\DD\*_P#7A'_*
MN@\<_P#(FZW_ -><O_H!KG_@7_R23PK_ ->$?\JV7\-^IR/^.O1G>4445B=8
M4444 %%%% !1110 4444 %)2TAZ4 9^O>(--\,Z;-J&JWD-C90C+S3N%5?Q-
M>7K^U9\+6NQ&/$<(W/Y8F,3B//\ OXQ7G_B"33?C%\8?$$?BW4(X? OA"6.V
M^PS2[(KB\;O)Z@=A7J7Q)O\ P%\._ \MWJ^DZ:UBR^7!9);1EKAB,!$7')/M
M7HQHPA:,TVWV/!EBZM;FG2<8QCWZGH6DZQ8ZY80WNGW45Y:3#='-"P96!]"*
MN5\J_"6\O/A7\2O#NG0Z==Z/X7\:P/-#HURV\Z?=*,[5.>%(YQ[BOJHUSUZ/
ML966S._!XGZS3NU9K1A1FO$_B]\6->\*^,[.'1!"VC:1'%=:Z'3<QCEE6-57
MT(!9\^BUWOBSXH:%X+?2H+R2:XN]3!-I:6<+32RJ!N9@JCH!SFL.5G=<Z_-+
M7S5X'^,VHZ_X;\4ZG?>)'TJV3QE_9NGSS61D86[. D!3@@MTR>E>XM\0-%CC
M\1,UPP7P^<:A\A_=_NQ)QZ_*0>*.5H+HZ2BN6TCXDZ%K6I"QMKIO/.GQZH-Z
M%0;=P=K9/TY':L:Y^.'AV/2+/4[:/4=0L[J)YXY;2RD<>6K%6<D#@9!I68ST
M*D) ZUP^J?&;POI.E:'J$EY)/;ZVI.G_ &>%Y&N"%SM  SFN3\:_M&:5I?PZ
MO_$>AV\U_<6EZMA/:30.KV\I8;ED7&5.#D>N13Y6*Z/9*6N&U7XO:+H]OI9F
MM]1>ZU%7>"RCLW:?:IPS%,9 'O796-XE_9PW,88)*H<!U*L ?4'H:5F,GHHH
MI %%%% !1110 4444 %%%% !1110 4444 ><?M _\DSO?^OBU_\ 1\=>@67_
M !YP?[B_RKS_ /:!_P"29WO_ %\6O_H^.O0++_CS@_W%_E6\OX2]6<</]XGZ
M(GHHHK [ HHHH **** "BBB@ HHHH **** "L#5/^1ITG_<D_D*WZP-4_P"1
MITG_ ')/Y"L*WPC-^BBBMQ!1110 4444 1W%PEK"\LC!(U&68] *Y7_A)-7U
MIB='L%%L#@7%P<!OH*?\0YG_ +-M;<';'/<*DA_V<]*E3Q1;:3<3V-W UDEN
MF8F;[LB@=O>N"K4]_E<K)#(;?Q1?:7<1PZY9K;I(=JW41W)GW]*ZI6#*"#D'
MO7'00W?BBUO;J_7R-.DC806S#DCJ'/O6OX-G>?PW9-(VY@NW<>^#BBC4ES<K
MU3V V6E2,@,RKN.!DXR:?7CG[0<C1ZU\+=KLN[Q9: [3C/7@UT7BKQY?>%/B
M9H&G77DKX=U2SG D*_.MS&"^,^A3]17H6N3<]!HKP:W^*WC;Q!I?A!]+BTVV
MN/$E[=+%)<J62*U0_NY,#[Q(YQ[UAZA\8OB1H_A'Q3XBNDT5K+PA>M:WL<:-
MYFI!63<4[1_*XQ[U7*Q7/I6J\VH6UM<002SQQS7!*Q1LP#2$#)"CO@5XM??$
MKQIXJ^*MUX3\,2:;IELFA6^L"ZOXFE93(<;,#KR17-:IXQ\4^/I/A7>V4%CI
MWB7^TM0M+AIR7@B=(2KN .6Z9 HY6%SZ6IGG(69 ZEUZJ#R/PK@?A'XTU;Q-
M#X@T[7#;RZKH>H-8S7%JA2*88#*P!Z<$9KQGQ!->^#/C;XK^(%I/.;32[NVL
M]6M=Q:-K.1%S)M[%&P<^A-"C?0&SZD219,[6#8X.#T-/KYOT'X@W?AG3?&UU
MHODW^H:MXL^PZ:TSDP[I8XR'/^R%RV.];VJ?%OQ-\+]0U[3O%OV+5VMM$?6+
M*\LHS$'*N$,3KV^9@<^E'*PYM#VBZU2SL;BV@N+F*":Z8I!'(X#2L!DA1W./
M2K-?,OB63QK_ ,+,^#D_BV?2[F*?4)[B,Z<C(87-N28SG[RA<_-ZU83]HG6M
M3N+O5M-FM)M/AU1K*'1%M9'N+B%9#&TGF#A6/4#ICK1R,+GTA),D*[G947NS
M' %-AN8KA=T4BRK_ 'D8$?I7D?[5DW_%BM<?R7F#/;9A3AG!F3*_B./QK@/A
M?J%KX;\=>,]?TW0[CP?H6DZ&IN?#MQ\DEQ-]];@1Y^4;05SWS0HW5PN?3]&:
M^=?"7QP\5:MK7AJ.:2QU&/Q!(\4EG96DF[2B4+1NTAX=00 WUXJEX%^('B[P
M/X)^)'B/Q!K%OKL&FZQ>VUM;^6RGSEFVCYCTCYX7MBGR,.8^F*3->$>$?C'X
M@FUB\T^\GMM;B.CS:BM[9VCPQVLT8R8GS]X'C'?BF>'_ (F?$&.X\!:CKB:3
M_97BN7[(+2U5O-M6:)GCD+'AL[>1VS2Y6.Y[O-.EO&TDCK&B@EF8X  [DTL,
MR7$2R1.LD;#*LIR"/4&OG?X?WGBV;PU\5KCQ%JUIKVEV>H:C;BSFA;EEC0[0
M3TCP<;?<UOV'C+Q'J4WA'PMX733M%DN-#75)[F:(O'&@(18HT^IZGM1RB3/;
M**^<;C]H+Q0^GZ;I=K;:=_PE4?BK_A%]0\Q6%MO()65>^"N#@?2NY^$OQ"U[
M6O&WC3P?XC-I=:CX>DMR+ZR0QQS1S1AP-IZ$9Q2Y6AW/5:***D84444 %%%%
M !1110 E97AK_D&M_P!=I/\ T,UJUE^&O^0:W_7:3_T(UD_C0&K1116H'C/[
M6GP_UWXG?!N[T+PY:+>ZG)>VLRPM(L8*I*K,<GC@"O6-$A>UT>Q@E7;)' B,
M/0A0#6)\1OB-H?PL\,2Z_P"(IY+;3(Y8X6DCC,A#.P51M'/4UT5K<)>6\4\7
MS12*'4GC@C(JKOEL397N3T445)1RWQ0_Y$#7?^O5_P"5:_AO_D7]._Z]X_\
MT$5D?%#_ )$#7?\ KU?^5:_AO_D7]._Z]X__ $$5PK_>G_A7YLZ7_ 7J_P D
M:5%%%=QS!1110 4R1A&"QZ 9I]0W49E@D0<;D('XBIDVHMH:WU/$8K&Z^.WB
M74FOKN>S\(Z=<&WBM8)-ANI%^\6(["KGCGX4_#CPOX?^TWD']B;2%BNK5V$Q
M;MC'+&N>\(Z%-XB\.:EX8@OWT7Q-H.HRW%LZL06RQ968=P<XKI?!_P /=?\
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MQ C#4;*3:6"3$\,NX[0?:L+X+^'1J4G@>]GUO0=.\1VUVTM['#%*-1N)#O\
M,BE).#D^O' I<J'<^O:6D7O2UF4%%%% !1110 4444 >>?$#_D?? O\ U]2_
M^@5Z%7GOQ _Y'WP+_P!?4O\ Z!7H0K@P_P#%J^OZ'35^"'I^HM%%%=YS"$XK
MQ?X4_#O7O#?QQ^*'B+4+18-)UJ6![&82*QD"H >!R/QKVAJY;PW\2M"\5>*]
M?\.:?<22:KH;(M]&T14(6&1ACP>/2J3=G83.JHHHJ1F'XY_Y$W6_^O.7_P!
M-<_\"_\ DDGA7_KPC_E70>./^1-UK_KSE_\ 0#6!\#/^22^%?^O"/^5;+^&_
M4Y'_ !UZ,[NBBBL3K"BBB@ HHHH **** "BBB@ I/6EHH ^6;C1]%\)_&#QO
MX4\96ZIX<\;LM[:7DQQ&TX&&3=_"PZ@^U=+\/_V<8/#OB"WU?Q3XBD\3V6C@
MIH<-V^4M(NH+9X9AT!]*]>\;^ ="^(FBR:5KUA'?VCG(#\,C>JGJ#[BO)?\
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M]N*BL?AW8V^K^*KNX8WD/B *MQ;2+\H4)L*_B*ZZBE<9XUH/[,^C>'?A_?\
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M!R:@&EV:W9NA:0BY/6;RQO\ SZU:HH C6&-&9E0*S=6 Y-"V\<;LZHJNWWF
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MBN6_X6AX6_Z#5M_WU1_PM#PM_P!!JV_[ZH^L4OYD'LJG\K.IHKEO^%H>%O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
-110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>angn-20241231_g2.jpg
<TEXT>
begin 644 angn-20241231_g2.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &]!)D# 2(  A$! Q$!_\0
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MR/G?^(@8G_GQ'[V?J_\ \+D\ ?\ 0\^&_P#P;V__ ,71_P +D\ ?]#SX;_\
M!O;_ /Q=?E!11_JU2_Y^/[D'_$0,3_SXC][/U?\ ^%R> /\ H>?#?_@WM_\
MXNC_ (7)X _Z'GPW_P"#>W_^+K\H**/]6J7_ #\?W(/^(@8G_GQ'[V?J_P#\
M+D\ ?]#SX;_\&]O_ /%T?\+D\ ?]#SX;_P#!O;__ !=?E!11_JU2_P"?C^Y!
M_P 1 Q/_ #XC][/U?_X7)X _Z'GPW_X-[?\ ^+H_X7)X _Z'GPW_ .#>W_\
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MR> /^AY\-_\ @WM__BZ_*"BG_JU2_P"?C^Y"_P"(@8G_ )\1^]GZO_\ "Y/
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M .+H_P"%R> /^AY\-_\ @WM__BZ_*"BC_5JE_P _']R#_B(&)_Y\1^]GZO\
M_"Y/ '_0\^&__!O;_P#Q='_"Y/ '_0\^&_\ P;V__P 77Y044?ZM4O\ GX_N
M0?\ $0,3_P ^(_>S]7_^%R> /^AY\-_^#>W_ /BZ/^%R> /^AY\-_P#@WM__
M (NOR@HH_P!6J7_/Q_<@_P"(@8G_ )\1^]GZO_\ "Y/ '_0\^&__  ;V_P#\
M71_PN3P!_P!#SX;_ /!O;_\ Q=?E!11_JU2_Y^/[D'_$0,3_ ,^(_>S]7_\
MA<G@#_H>?#?_ (-[?_XNC_A<G@#_ *'GPW_X-[?_ .+K\H**/]6J7_/Q_<@_
MXB!B?^?$?O9^K_\ PN3P!_T//AO_ ,&]O_\ %T?\+D\ ?]#SX;_\&]O_ /%U
M^4%%'^K5+_GX_N0?\1 Q/_/B/WL_5_\ X7)X _Z'GPW_ .#>W_\ BZ/^%R>
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M^>Q_[Y_^O1_8*_\ /8_]\_\ UZUJ* ,G^P5_Y['_ +Y_^O1_8*_\]C_WS_\
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M'C_QKZPHH_MC'?\ /U_<O\@_U5R;_H'7WR_S/D__ (=\^'_^AMU+_P !X_\
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MW+_(/]5LF_Z!U]\O\SY:_P"'?/A__H;=2_\  >/_ !H_X=\^'_\ H;=2_P#
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MKI*J!VD^7+-^[!R".2<YS6KX'\&V7P_\,VNA:=)/-:6[2NCW+*TA,DC2-D@
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M_P 'EK_\<H_X7]\,/^BC^$O_  >6O_QRL;_A2OP\_P"A#\,_^">W_P#B*/\
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M_P <I?\ A?OPQ/ ^(_A(G_L.6O\ \<K%_P"%*_#S_H0_#/\ X)[?_P"(I/\
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MO#]JQ_$E,FG_ /#(7P,_Z([X%_\ "=M/_C= 'HW_  EFA_\ 09T__P "H_\
M&C_A+-#_ .@SI_\ X%1_XUYS_P ,A? S_HCO@7_PG;3_ .-T?\,A? S_ *([
MX%_\)VT_^-T 8/[87B+2;W]F_P :0V^IV<\SPP;8XKA&8_Z3$> #67^P_P"(
M-+L/V;_#D-SJ5G;S+-=YCFG16&;F0C@FN<_:D_9M^$W@?X"^+-<\/?#3PCH6
MLVD4)M]0T[1;:">$M<1J2CJ@9258C@]"16=^R'^SO\*_B#\!]"UOQ/\ #CPI
MXBUF>:Z6;4-4T:WN)Y L[JH9W0L<* !D\ "NK_EQ\_T,/^7OR/JS_A+-#_Z#
M.G_^!4?^-'_"6:'_ -!G3_\ P*C_ ,:\Y_X9"^!G_1'? O\ X3MI_P#&Z/\
MAD+X&?\ 1'? O_A.VG_QNN4W/1O^$LT/_H,Z?_X%1_XT?\)9H?\ T&=/_P#
MJ/\ QKSG_AD+X&?]$=\"_P#A.VG_ ,;H_P"&0O@9_P!$=\"_^$[:?_&Z /1O
M^$LT/_H,Z?\ ^!4?^-'_  EFA_\ 09T__P "H_\ &O.?^&0O@9_T1WP+_P"$
M[:?_ !NC_AD+X&?]$=\"_P#A.VG_ ,;H ]&_X2S0_P#H,Z?_ .!4?^-'_"6:
M'_T&=/\ _ J/_&O.?^&0O@9_T1WP+_X3MI_\;H_X9"^!G_1'? O_ (3MI_\
M&Z /1O\ A+-#_P"@SI__ (%1_P"-'_"6:'_T&=/_ / J/_&O./\ AD/X&?\
M1'O G_A.VG_QNE_X9"^!G_1'? O_ (3MI_\ &Z /1QXLT1C@:QIY/_7TG^-:
MBL&4,I!4C((Z&O(S^R#\#",?\*=\"_\ A.VG_P ;K O_ -DW3/!BMJ7P;UF\
M^%FNQ?.EG9RR7&B79'_+.YT]V\O:>1NB\MUSD-QB@#WRBO,_@C\7KCXE6.L:
M3K^EKX<\>^&[A;+7]$$GF)%(R[HYX7ZO;S+\\;D XW*?F5J],H **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW5EVB4L2,<GC'/&>.M:^SAB(OV:LT<WMJN FO;RNG^?8[_XC>.-:\:?%+1_
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M\D(LO^P[K_\ Z>;VO:J\5_8[_P"2$67_ &'=?_\ 3S>U[50 5\K?MF7VA_\
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M ";K\4_^Q5U7_P!)):]&KSG]I+_DW7XI_P#8JZK_ .DDM 'H/PM_Y)CX0_[
M]G_Z)2NHKE_A;_R3'PA_V![/_P!$I744 %%%% !1110 4444 %%%% !1110
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MBBB@ HHHH \+\,JK?MJ_$'(Y'@C06'_@9J@_K7?>-_&9T3]U#_K#7G_AD_\
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MH5Z+?71L=0BG[(X)^G?]*YX+F31Z%:7(U(["BD#!@"#D&EK$Z0HHHH ****
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M)&7A(GRO&._4G/&![UE^/[6P\">,OA7J%S U_9KYNAI;*%*+(\(9)>>I A<
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MW4K?3MK7+^3&W'FL/D!]SV_&@"U134D610Z,&5AD,IR#3J "BBN2^(?Q"L?
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MWPOX?TWP]8J /L^FVJ0*<=SM R?<\UOT4#"BBLO6?$FGZ'9WD]Q<Q;[6,R/
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MC6TN9W?3TM&WW._^;5AQ:C*#CHE:_KS._P!ZM_E>YA_#[_D]KQ[_ -B+H?\
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M&;]H[6+?Q/XHFN-)UG9%!<ZQ+)!,7TR)]\R$XD=2V%8_="J!TK*^&?QF\1^
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MR(X5^[&/0>_O790P\JOO/1'E8S'PP_N1UG^7J;NH:Y/X@U%KJ?@$X2,'A%[
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MP_\ LP_#SP[#XE$>E7NH7?B;3?[(UO4-4U:[N[O4;;#C;+-)*6)Q(P# A@,
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MW+P:Q?P[;$_WI!^4C"MJL3P8NWP[;#_;E/\ Y$:MNJ.4**** "BBB@ HHHH
M^<OV._\ DA%E_P!AW7__ $\WM>U5XK^QW_R0BR_[#NO_ /IYO:]JH YKXG?\
MDV\6?]@F[_\ 1+U\X:/_ ,?VG?\ 8DZI_P"BK>OH_P")W_)-O%G_ &";O_T2
M]?.&C_\ ']IW_8DZI_Z*MZC_ )B,/ZS_ /2#P,?_ !/E'_TM'6_ G_D;O"G_
M &*MQ_Z,L:^AZ^>/@3_R-WA3_L5;C_T98U]#USX3_=X_]O?^ER.W _ _E_Z3
M$****ZSTCY0^-_\ R%OC#_UXP_\ I$M1_&K_ (_OB]_UXP?^D*5)\;_^0M\8
M?^O&'_TB6H_C5_Q_?%[_ *\8/_2%*Y)_\O/\=/\ ]Q'Q5?\ Y>?]O?\ N<^L
MZ***ZS[4**** "BBB@ HHHH **** ,CQ5XGTSP?H-WJVKW"VMA;KEW;O[ =S
M7@WP<\67O@/X7>--6_LF2QTW3]0NGL--O 8Y9FGE#Q;\C* M*%QR0.F< 5T_
MQ^OKS5_$G@7PE964=PUWJ4>I7$DTFU5AMW5V 7'S$G'!XX]>1<^(&AV>H_:+
MM-0E@L_$"KIE_I<AVC=T$R,N&1UXYS@C'0\T :W@WX-SVM\_BC7M175/$<RM
M)#''"L-G9NP7<8XP,[CM0%VRW!QC)%86C^+M(\(^/-6UW4[EI+K5C%:>2<L8
M/*4AE4],$\XZGMGI2Z%X\\9>$_'$GA?4#!XGTFQA3S-5MHBDL)*%E2X&2-Q"
MDAE]1N4?>.E>>+O#NN7FJZ8D.FI;W?\ K8_*WS-(PZMC(SQW[B@#?\<1VGQ"
M\!G5M&)G>$^=!(JX8[3AUY]@?RKG-8^(T.M6MMX.@\16B:Y=HL3O%G=M)PPR
M>-^ ?ESGO@5O?#?QMX:T_P $S(+Z"TL=)#B=[@^480N682*V"C =0P'&#T(-
M>/\ @SX<:)\4-0ATW4+.X?P]9-<ZR(2Y1GGN;IWB+G.]66)5^7("A@.2,( =
MMXC^'>E>&M3^'MI'+-J-N^J/YL5Q,["1O)8B0J/E^5E&,\#=Q\V*]AKC/"/P
MD\/^#-6EU.R2\N=0D7;]HO[N2X91S]TN3MSDYQUS]*[.@ HHHH *\Y_:2_Y-
MU^*?_8JZK_Z22UZ-7G/[27_)NOQ3_P"Q5U7_ -)): /0?A;_ ,DQ\(?]@>S_
M /1*5U%<O\+?^28^$/\ L#V?_HE*ZB@ HHHH **** "BBB@ HHKC_BIX\M/A
MWX-O]6NKF.U\N)RLLIPL8"EFD;V506/TH*C%R=D>&?M5?%+5[[5M'^'G@E8[
MSQ?K=R;+3H7YC28+F6ZEQ_RQMX\NWJ<+U85;\3M%^RW\)?"_PJ^&^W4?B)XA
M:6WTZYO1O=YV^>]UB\]50L9&S]YFCC'!&.:_9Z73O!'@?Q9^TG\1F?33JUEO
MTQ+I29=/T16W01JIY\ZZ<K*5'+%X4ZKBNC^#/A;6M6U;5_BAXXM3:^-O%"(D
M6G2'=_8>F*2UO8*?[PSYDI&-TK-V5:#2<D_=CLCK?AA\.]-^%7@C3?#>F/+<
M1VJL\]Y<MNGO+AV+S7$K?Q22.S.Q]6]*ZJFO(L:[G8*O3+' ]*3SD$HB+KYA
M4L$SR0, G'IR/SH('UXY^UYOMOV??$VJ1J6?1)++7!M'(%G>073$?\!A->QU
MSOQ&\*+X\^'OB?PTY54UG2[K3B7Z 2Q-'D_]]4 >QQR)-&LD;!T8!E93D$'H
M:^6/V-_E_9C^'R'AH]/,;#T99'4C\"#7K'[+_C1OB!^SWX UF4,MZVDPVM]&
M_P!Z.[@'D7*'W6:*0?A7EG[+:?V1X!UWPL_%QX7\4ZUI$BGLHOI9H3^,$\+#
MV84$H]AHK"\:>.O#WPYT"77/%&LV6@Z1$Z1O>W\PBB5F8*HR>Y)K1T?6+#Q#
MI=KJ6EWUOJ6G748E@N[2598I4/1E=20P/J#04+K&K6?A_2;W5-1N$M-/LH'N
M;BXD.%BC12SL?8 $_A7SO8^#M.N_V6O'GQ:\?2W&D77BXOXGN(P@,\.GK%Y>
MG6(!ZMY'E_+_ ,];AQWKL/C[;M\1=8\%_"*W9BOC"^,VM;#@QZ+:;9;S)'02
MDPV__;P?2M/X[7*?$[XR>"_A7:JIT'01%XN\2(@_=E8G*Z;:,!QAYT:8J?X;
M4=FJHR<7=&52$:D>22T.,^#O[,FEV/PWT67Q5;7$?C"ZB%YJ,]O=21R0S2#=
MY(92,B,$)GOM)[UB^,=/U/X+>-K.>34+[4/"M]MA(NIFD,3$X&6/;D#\J^G:
M^2/VM_%\T'BS3--NQ(^D6[+<RQ1]7"%&"<\?,Y4$]@">U95<+2QE.<:JZ.S2
M5T^EO5V5MGL$<95RVI2G0;UDDTV^5I_$Y:[*-W?=6N>E:AJMI-OB5_W@_P"6
M;=5]!7.ZCJ%M;PRB:6..)4)=Y& "U\]>-/%&O76K6OB$:M)9SZHO^CPV_P \
M<)$D(5>1\S;3*3T[#M74?"?^SO&GQJ.G^*+8WD5Q$ MO(Y\N.51M; S_ 'E8
MYZX(]:^0CPSCJM7DKV@M;]=DI6MWL^]M'J?:2XRRJCA_:89NH[JRV3O)P4K_
M ,MUO:^JTU.;\0:>OBSX@0:3J>J'3["ZB5[2Y\L%$8L06!Z]NQ'4"OMSX2>#
M[;P/X-MM*M;]=1CC^;SE.<Y KPSXK?LI7]]A?"[QM9HQD@AF?#VS'J$/]T]U
M/'3&#U[S]G'X5^)OAO970\07@F>9?]6KEE!SQCTX_7-?<X*C3PV6K"\UG'MM
M/L][IV>OIN?G688BOB\[>-<.:,U97^*GIK&]K2C=7BT]+[)W/:ZX7]C.,ZAX
M!\8>*1_J/%'C/6-2MSW,,<_V.)OQ2T5OH16=^T#XZO\ P?X!DL/#H,_C?Q')
M_8GART3[TE],I"R>R1+NF=CP%C:NYO%T;]E?]F>X%H5_LKP1X;<QM)P9V@@)
M!/J\CCZEG]ZP/49\Q_ MV\37OB?45&X:]XVUNXC]2C:E-%'_ ..HM?>-?&G[
M'7@6YT71_!NFWF^6YTVP6[OW8'<UP5WR,?<S.37U3KWCJP\/[O/LM8N6':RT
MBZN!_P!])&1^M:*,I.T5<WQE2%&,54=K(Z*BO"?%/[6^@>'IC;Q^']<EN>RW
MEN+13_WT=W_CM><Z]^UGXHUPLFDVEIH<)Z,!Y\H_X$PV_P#CM>C3RO%5->6R
M\SY+$<19=AVX^TYGV2O_ ,#\3ZPU76+'0[1KK4+R&RMUZR3N$'TYZGVKQ_Q?
M^T-"3):^&H?-/W?MUPN%^J(>OU;\C7SE>>(-3\27GVO5+ZXO[@_\M)Y"Q'L/
M0>PK4L>U>K2RN%+6H^9_@?-XCB.MB?=H+D7?K_P/ZU.L_M"YU2\>ZNYY+FXD
M.6DD;)-;FG]JYO3^HKI-/[5M4TT1R4&Y.[.DT_M]:Z2P^\M<WI_;ZUTEA]Y:
M\RH?18<XCX9_\GE?$'_L2-#_ /2S4J^C*^<_AG_R>5\0?^Q(T/\ ]+-2KZ,K
MQI_$?64?@04445F;!4%]>PZ;9SW=S((K>"-I9)&Z*H&2?R%3UY/\>M8GOH_#
M_@G3Y"E_XDO!%(R]8[9"&D;^7U :@#6^&2S^*;J]\8WR,AO6,5A$W_+*W4X!
M^IQ^A/>O0JKZ?80:786UG;1B*VMXUBC0?PJHP!^0JQ0 4444 %%%% "'H:\E
M^*FKSZ?:7TZ8S#$SKNZ<#J:];KAOB!X=34K27>GF1R(4=?4$8->=CHN5+3H>
MA@9*-74\OUKP3K=FMC!#XGM$O;Z78DMQ"WE*F,CHX.\]AT./;->=>+O!MW\!
M?%VE75E/]HTW!GCEG*HNX$F4,H&.<\XQP1R3@5U6G_\ $EU3^S=5$GFWDB6\
M6I37.3*#(/*7GH5;8 /Q]:V?B-:V_BVVM-&OKK^TQ-)=65JGRI.T@3=N?L$Q
M&?FQTZ=JJE3I2AS4EN<>8PK5O=JOWH['2Z1HVA>/#=ZK:7VI0M=B&Y:W:<M"
MKD,H 5AC(9&!53CC/<5Y[X.N_L>L:E87\T*Z@UU/,D:87<A<+N [9*'(Z@_A
M6+\)_%-]H]YJGAN:)I].*YF.Y7VD+_KD*G@'I]1@$X-=K\0);>Q\+Z9931W%
ME>)<--;*;?<_G%@4 ?/"G+ DG^*IQ%/ZQ1:;LT7E>*<9*36NS_K^NQ[+X+OH
MY;$1@_,*ZBO*/AQ?7#?93,NR9XU,B#H&(&1^=>K+T%/ U/:45?H=..I^SK/S
M/"_V@/\ DLG[//\ V-5]_P"F34*[SQ!_%7!_M ?\ED_9Y_[&J^_],FH5WGB#
M^*O9H[G@XKX3S7Q!_%7FNO\ \5>E>(/XJ\UU_P#BKZ;#=#\[Q_4^I/ACXC_X
M2KP+I-^S;YO*\J8]_,3Y6)^I&?QKJ:\ _9=\3;FUOP_(_*E;V%?8X23_ -I_
MF:]_KYS%TO8UY0Z'WV5XGZU@Z=7K:S]5H%4M9UBUT'2[G4+R3RK:!-[MW]@/
M<G 'N:NUYC^T#-+'X-M43(CDO$63'H$<@'\1^E?-YQCI9;E];%P5W"+:]>GR
M[GT6!PZQ6)IT).RDSEH?B-XO^(FO_8?#^W3+?.254'8G]Z1R#^F/3F@?$SQ7
M\/\ Q =/\1@:C IY.T*S)_?C< 9_'Z<5@?#WQA=6]]H.A6D4=I#)J$;W4T>?
M,N?G& Q] .,#_&H/'7C"ZOIM7T6\BCNDM]1F:VN9,^; OF-E >ZGC@_X8_!?
M[9K+!+,%C:GM^;_MR]D^3DVMYVM?I;4_2/J$/K'U;V$?9V_[>M>W-S?IO;K?
M0^D]+U*WUC3[>]M)!+;SH'1QW!_D:M5YQ\!9II/ NV3.R.ZD6+/]W"G_ -"+
M5Z/7[[E.,>88"CBY*SG%-KSZGYMC:"PN)J44[J+:,";X@>%[>[>UE\2:1'<H
M_EM"]_$'#9QM*[LYSVK?KXZ^!N@2:QXN\8EOAGH_BVS_ .$JN%FUK4+B!9;)
M?,&0J/&S,%'S<$9)Q73_ !=^.'C3X;?$S4O"$%[9W;:\ELV@W4R1*-.:238X
MEX^8?>(+9Z#WKZ^66N56-&B[R:OJUY=KVWOK;1:'PE//U##SQ>*@U!2MHGWD
MNJ2=VDO=O9NSL?3U%?/GB/Q)\2-8^,MQX T#Q59Z3';Z%#?2ZE/IT<TGF [7
M94X&78C(/ &<"L+0?CEKWB#X1Z==:MXQMO"VN)J\^E3WMMI/VZXOC& 0((%!
M&X[ER=N![9Q6*R^I**E&2=[=[V=[/;RZ:^1URSRA"I*G.$E:^KY4KQ2;5W+>
MS6KLO,^H**^3;'X_^,K?X-_$74&U3[;J_AS4X+:TU*ZTU;:66)Y%'[R C"MC
M/&,C/M74^'?'/Q(\._%S1=!U_6K#Q%!XBT:?4;>TM[-;=+29$9UC5A\S+\H&
MYCSGH,54LMJQ4FY+2_?6T5+33L^MB*?$&&J.FHPE[UM=+*\W35_>_F5M+]]C
MZ#O+R#3[.>ZNIDM[:!&DEFD8*J*!DL2>@ %5]%UNP\1Z7;ZEI=Y#J%A<+NBN
M;=PZ.,XR"/<'\J^9_A_\5O$NN6?BJU\6^)V7Q%!I-[+-X/U/08X%C*J2K1R8
M_>H .5;.0?09*>%_B9XHUCPU\)/!_AR[L?#.H>(;.XNKG4K?3HBEO'$S_+%!
M@1@G:>U6\LJ1O%M75M=;6M)M[:Z1W5_*YE'B"C/EFHNS3TTYKJ4(I:2T;<TK
M2LUULCZGHKY@NOC-XW\*^%?BUI&H:K;ZGK_A V[VFLK9I'YJ2L,;XP-F0/;O
M[5I>%?'WQ$T7XI^ K+Q+KUCK&D^,;&6Y%C:V*PK8LL7F *_WGZKRQ[GCH:S_
M +.J6;4EW6^ON\^FG\O>QM_;V'4E%PE>]GHO=?/[/77^;32_?8^C:***\H^E
M"BBB@ HHHH **** "BBB@ HHHH J:LOF:5>K_>A<?^.FOG_XU9;X8ZS;J<&\
M,%ETS_KIXXL?^/U]#72^9;3+_>0C]*^4?C[\2M'\+ZCX*\-WGVF6^U?6[*9(
MK>+?^[AN8W8MSW(48&3UI=3>A&4ZL5%?TC(T'P39>+OVM-?\71:HPF\,VL%D
MUA(F_>TL#C>C9^11DC !RP;IFOHQD*V-DZ<1RO.S97G<I1.O_ 3^E?*G[+OQ
M"LOB)\2?$6K:?;7%O%>)?-(T^T>;B\62(X!/*QW"KSZ'K7UU?6_V'P]ID?SL
M6N&.>N-PD?GV_P#K4G?J;XQ3C44)_927]?,SA4H%,2I%J#A% KQ/Q4/^,HO"
MWK]EM_\ TGUBO;EKQ#Q8#_PU+X5;L+6V'YV^L_X4UU.O#_;_ ,+/;::14C4U
MJDY"%A2PH66]W?ZE+1Y6 7)RC(PQ^1_2E>K^AP_;H=7M3N7?;JH<<8W"0'!Z
MYX'Z52W ^9?VB/!-C_PLSX8>-KS4VM!8:O!IWV:),/-YCE@V_/"KM)((^[NY
M%=]\+]T)\86;'_CV\17F!C&!+LG_ /:U>;?MF>((O#>AZ1<W$$MQ'#!>RHL1
M7Y)BL4,;G)_A:;/K5OX-_&WP_P"+_BEXHTBT2\M[G6(;/7+5+B':K(UG;JPS
MG[P 4^AYP35ZM'JNG5J86,K723_!_P#!9]9^%T\O0K8?[Q_-R:U:H:"NS1[0
M?[&?SYJ_3/*"BBB@ HHHH **** /G+]CO_DA%E_V'=?_ /3S>U[57BO['?\
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MAF*:W9X4 <>E>/4PU6BI2H2LNQ[-+%4ZW+"O&_F>%>$M06.W:RU.TNKQM/\
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MV\2!8T0# 4*.  .,5X1_PFW^W^M'_";?[?ZT >F_\(A\/_\ H2?#?_@IM_\
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MMU"XDBGATR!'C8'(96"Y!![BNAU/5;+Q592:=J-A;ZO:2X+VEU L\;X((RC
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M'#F5G'W7M:\=':VENUM#Z1T_3[72;"WL;&VALK*VC6&"VMXQ''$BC"JJ@84
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M-0\E+97N''L<[1^1->D:#^RUX7T[:VH7FH:M)_$KRB*,_@@##_OJO9:,XZT
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MS1SXC#T\52E1K*\9;H^"9[/]I+PDL?@RS&J26EFH@M[JR56B:,?=VSXR%P.
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M,KM.,?=6/&7/L!7+<]*RM8\#^&UU-?:/?3*7;3QJ-TFG2NY8M;B5@G)/(Q@
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M_L6?!6>ZDN+7P'9Z'+(=S?\ "/W-QI0SZ@6LD8'X"D8.W0]MKF_$OQ*\(^#
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M1-V-H@_\?D_QKS3Q/XP?1;FTTW3K)M6UV\#-!9K)Y:JBXW2RO@[(QD#."22
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M\3A9]$F7[5X=U;<RM:Q[E40F9<-$R%T5'!&Y65<Y'+W1M&]2A&,NC=N_1O\
MK_@GN#252^PVB:E)J"V\8OI(E@:XV_.8U)(7/H"Q./>O&/'GPW^):ZEHMWX2
M\?W$MM9SKOT_5-J!X]V6WRHO[P8XPRDX/4FO1O"_B_\ M][NRO+-]+UJQ*BZ
ML9'#[0V=LB./OQM@X; Z$$ @BE8YI4N6*E&2?>W3U._\&2#_ (2O3@0"2TF.
M.G[IZ[CQ]!'-X9N7?;NB9'1F[-N"_G@D?C7 ^",OXNTS_9:0_P#D)Q_6NO\
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M1J0U5MI0?PR7Y/S/(OV@/^2R?L\_]C5??^F34*[SQ!_%7!_M ?\ )9/V>?\
ML:K[_P!,FH5WGB#^*L*.YW8KX3S7Q!_%7FNO_P 5>E>(/XJY/0O#_P#PE'C#
M3--*[HYIU,O_ %S7YG_\=!KZ.A)0CS/9'Y_BX2J34([O0]^^$?AS_A&/A_I5
MJR[9Y8_M,WKO?YL'W ('X5V-(..!P*6OEJDW4FYOJ?I%&E&A3C2CM%6"N?\
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M6UC.GWEO)J%K<X(>&4L@W 'KAV5P0>,D'@BO)-8V26[1,?O<>E>I_ &^,WQ
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M\UVN?7%8?C;QAIW@#POJ&OZL9%T^Q0/*84WO@L%&!WY(KY;\+?$GQ7\4-/\
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M6=,N(1>6B2$(%2.'(,;%7#G:RY&".3D;'C+P9HGC6U6QUNTCNK7=YOSL5,9
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M&Y<X(X!;C.<U[+X*U -&8B>16/>> _"7Q^\*Z-J6I:?)::C9[)(9H',4]I,
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MD?QJUC_A9'[6L-C ?.TWX>Z&8GP.!J6H,KLH]2EM#']//KZY\+Z2-!\/:?8
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MN-)NB/A/K7[G.R[6,?-U!,/S=.VX\>U</7HVAV+O\*=3& /,=IAQ_"I7)_\
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MG5>+M!U;3_!4=Y\/O%5U'J6GS)+%H<MPLT5PH(+V_P"\RP^4G'/4#U-:&O\
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M5_\ 226OIEHK'S#U=ST'X6_\DQ\(?]@>S_\ 1*5U%<O\+?\ DF/A#_L#V?\
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MPDMLGO Z#_9/2N\T+]LB'PLRV7Q@\+W?P_G'RC7[/?J.A3GU^THN^#/)Q.B
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M JA*7*YPKQ'^-3VQWX.""*^O_P!GWX,^)/ OP],VLV<EI>ZC-]I-E*,/%'M
M4..S'!)'49 .#D5YS^U)XG\9:U\7/ 5UXA^']QX5U.#R_LFFRZK:W37F+@$8
MDB8JF6^7YC[]*^H7^)'QAD&&_9^OR/\ L:],_P#CE>O+%3A"+74\>I@:>(;4
MNAE0>'[Z9PJ0%#ZXKJ-'^&LLS*]P<#J:R5^(7Q>CZ?L^7P_[FK3/_CE2_P#"
MS/C&.G[/]_\ ^%7IG_QRL)XR<E9:&=+*:4'>;N>CZ7X1LM- (C#,.^*W%4(N
M%&!7CO\ PLWXR?\ 1 -0_P#"KTS_ ..4?\+-^,G_ $0#4/\ PJ],_P#CE<,I
M.3NV>Q"G&FK15CV)E#*0>E<;XD\+M<2-)$N<]17'_P#"S?C)_P!$ U#_ ,*O
M3/\ XY2'XF?&,]?V?[__ ,*O3/\ XY7+6H0KQY9'91K2H2YHE'Q-\+;3Q-;P
MQZE9O*+>3S875V5XGP1N5@<@X)''8D=ZRH/AWH^DVTEL-+AN8Y"6E^V S2.?
M4N^6/XFNA;XD?&%N#^S]?_\ A5Z9_P#'*S+[Q3\6K[.[]G^_0^H\5:9_\<KR
MJF7S4;4Y_(]:GF$92O5BCE;OX<P1V\EGI5S)8:5,P:719K:.YLRW=ECD4JC'
MU'7\L:_A_P &G1[B*]N)AJ5_$GEQ22Q*H@3/W8PH^4<#ZXIPU#XL!MW_  HC
M4?I_PD^F?_'*OQ^)/BQ''L_X9^U!O?\ X2K3/_CE9K#XNI'DE+0T^LX.G+GA
M'4RK[X<V>J:Q-J$9NM.GN(_*N%L;EXTN%YXD085NO\0/\C7H?@_P1#9VUO;6
M]LEK90J$CAC7"JHZ "N4A\5?%B%LC]GR_P#_  J],_\ CE:4?Q(^,4*X7]GZ
M_ _[&O3/_CE;T\#-M>VE=+H<]7'QLU1C:YZ]9V,=G&%1<58KQS_A9OQD_P"B
M :A_X5>F?_'*/^%F_&3_ *(!J'_A5Z9_\<KV4E%61XS;D[L]CHKQS_A9OQD_
MZ(!J'_A5Z9_\<H_X6;\9/^B :A_X5>F?_'*8CV.BO'/^%F_&3_H@&H?^%7IG
M_P <H_X6;\9/^B 7_P"/BO3/_CE 'L=>$_'"Z7XR>,]%^">D$7:74]OJWC&6
M-ODL-)BE6002$=)+IT6-5Z^7YK=!SH2:?\?OB4IM/LGAOX/:5("LM\+PZ[JV
MW_IE&(X[>)O]IFE _NFO4_A/\(/#OP;\/S:9H,5Q+-=SM=ZCJFHSFXOM2N6
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M)04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,C=17ZYEN8T,TPZQ%!^JZI]F?E68X"MEM=T*R]'T:[EK^UIO^>:?K2?VM/\
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MM?0/[)OBQTU75?#$[DVUU%]K@!/"R+@,!]5(/_ *^?J]+_9Q:0?&/0=F<$7
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MQ^#M0ENM?FTN9/$$"74DDBQ"TX$Z,?DVS>6$R!Q]WBOJVF+#&DCR*BK(^-S
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M/O1NO9A^O4<&JE<7XD>72?&&F7'AT>9XFNV5)[%>(KJU!PSSG^ (,[9.N?E
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M'C>SBTW3EB=V6RNUD"2NI).W]Q(7^L5=5^T9X<TL?"FQ2\0M8Z7J&G%I9)6
MBA%Q$CLS C@(3DGIU]Z]$U7P?9ZSXHT37+F6=KC1Q-]F@##R=\JA3(PQDL%R
M!S@!FXK;DC61&1U#HPP589!'I4>TTB^J=_6ST7]=R^75]K6^]6?Z?,^<O$%Q
MX#G\::G;>*]7@@\+6^A6LGAIFU%TMY$/F>=) X?]Y*&" $$MC;CK7KWP=FU>
MX^%OA>37C,=6:PB-PUQGS2<<%\\[L8SGG.:ZQK6!EC5H8V6,@H"HPF.F/2I:
M'.\6OZZ_G?42C[U_ZZ?Y!11161H%%%% '*R+=?#V^FU33(9+K0IW,FH:9$,M
M"QZSPCU[L@Z]1SU]$TW4K76+""]LITNK2= \<T9RK*>XK%KD?"\DNE_$:?3O
M#P\_1Y%:;5H"<06<Q&5:,]G?^*,<?Q<=_,E_L<X\OP2=K=F^WEW73?:YZ4?]
ML@^;XXJ]^Z7?S[/KMO8QOVJ/&$F@^!K?2;=RDVKRF-V4X/DI@N/Q)0?0FOD.
MOH/]L!I/^$@\.J<^4+60KZ;MXS_(5\^5^+<55YULUJ1EM&R7W7_-L_8^%Z$:
M.64Y1WE=O[[?DD.CC>:18XU9Y&(5549))Z "M*^\+ZSIENUQ>:1?6D"X!EGM
MG11G@9)&*/"]]#IGB;2;RX;9;V]W#+(P!.%5P2<#V%>T_$5[OXB>'/$VMZ!X
MYGUC1;659KG19K>2 0QELJ 6/S8QGH.E>1AL%#$8:I53O.-]%;9*][-IV]$S
MU,5C)X>O3IVM"6\G>UVTDKI-)OI=H\"J:TNIK&ZAN;>1H;B%UDCD0X*L#D$>
MX-0T5Y";3NCUFDU9GWMX;\0+XP\(:+KJJ$:\MU:15Z!^C ?1@P_"KM<)^SZS
MM\%])WYVK/.$SZ>:_P#7-=W7]-9?6EB,'1K3WE%-^K1_-^848X?%U:,-HR:7
MR84445Z!P!1110 5\U^$9M2N=)\%Z+8ZQ>:-;:KXGUZ*[DL659'C66Y?:&(.
MWE1R.1VP>:^E*S;?PWI%JULT&E64)MI9)X#';HOE229\QUP/E9MS9(Y.XYZU
M<9*.Y,DY*R_K1K]3Y^T_4/$FEZ3%K,GB[6+V72_&2Z!';W$JF*:S-V(2)0%_
M>.5?[Y.?E&,<Y76M2\3RZ?K>OP>,-6M+JU\9?V-;6\;(;>.V>Y2(@QE2'($A
M(+9QM7'?/T"?#>D&!H3I=D86N?MK1_9TVF?<'\TC'W]P#;NN1G-#>&](:"2!
MM+LC#)<B\>,VZ;6G#!A*1CE]P!W=<@'-:1J)6<E?;_VV_P!]I?\ @1$H-WL_
MZ]ZWW77W'A7B+Q#KG@?2?B9IMOXAU&[BT6?2I[6\OIA)/"D[)YRE\<K@,>>@
M8]JN_%;X@ZKIVL?$:#2-::+^R_#-K<PK"ZM]FN'FERV.S%-G7MBO:;GP[I5X
M-0$^F6<W]HH(KSS(%/VE "H63CYP 2 #G@UFZ;\./"FC:?-86/AK2;6SFB\F
M6".RC"21[BVUAM^89).#W)I*:O>2_JUO^"/E:6G]:W_X!Y3K6N>(/AGJ_BV"
MTUO4?$!3PC)K<2:HZRE+M'9=R * JD$$H./EX K3^$</C(:[IU[>S7DWA^^T
MPRSOJ.K1WIFG)0I+"J@>6I!?*CY>5P*];;2;)KXWC6=N;PP_9S<&)?,\K.?+
MW8SMSSMZ9K'\._#KPMX1OI[W1/#NF:3=S*5DFL[5(G*DY*Y X&><=,T1FK:K
M7_A_\U]WH)P>EG_7N_JG]_J=%1116)J%%%% &9X@\/VWB*Q$$Y>*6-A+!<PG
M;+!(/NNC=B/UZ'BI/"'C"YDOO[ U_9%KD:EH9T&V*_C'_+1/1A_$G;J.*OUB
M>,--T[4-%EDU*?[%':_Z0E\K['M77D2*W8C]>G.:XJU-P?MZ6DEOV:\_T?3T
M.VC44E["KK%[=T_+]5U]3OJ*YGX<ZOJVN>%;:ZUFW\FZ8L$D*[#<1@_)*8_^
M698<[>WZ5TU=%&HJU.-2.S5]3GJTW1J2IRW3MH%%%%:F04R6-9HWC=0R."K*
M>A!ZBGT4 ?GKXW\+S^"_%FIZ+< [K28HK$??3JC?BI!_&L.OLOX\_!C_ (6-
MIZ:EI@6/7[-"J*V +F/KY9/8@YP>G)!ZY'Q[J6FW>CWTUG?6TMI=0MMDAF0J
MRGT(-?SOGF45<JQ,HV_=M^Z_+MZK_@G[_DN;4\TPZE?WU\2\^_H_^ =%X3^*
M7B;P-9R6NB:BME#)(9&'V6&0[B "=SH3T XSBL;Q#XBU#Q5JLNI:G,MQ>2A0
M\BQ)&#@8'RH .@]*S:*\6>)KU*<:4YMQ6R;=EZ+H>S'#T85'6A!*3W=E=^KW
M"O??V3?"SS:]JGB29<6ME";:(D?>D?!./HH_\?%>7_#OX9ZS\2=72TTZ%DM5
M8"XOG4^5 ON>Y]%')^G-?9?A_P /6'@OP[9Z#I:XM;9<-(?O2OU9F]23S_\
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MJ>G3_9KVV;?%+M5MI]<,"#^(KTCXR? V_P#A_>3:AID4E]X<D.Y)E&YK?/\
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M0;7AF 96'H0>U:=%)JZLRN:SNCRG7_V:_!.ORO*EC<:1*_).GS;5S[*P91^
M%9-E^R;X0M9@\UYJUXH_Y9O-&JGZ[4!_6O;**\2>1Y;4GSRH1OZ?IL>Q'.LQ
MA'DC7E;U_7<Y?PUX#T;P1;F+0-&M[$L-K3_>E;ZN<L?Q-:#V%U(Q9AN)[EJV
M**]>G2A1BH4DHI=$K(\NI6G6DYU'S-]6VV8G]G7/_/,?]]"D_L^Z_P">0_[[
M%;E%:6\S.Z[&%]@N_P#GB/\ OL4TV-[VMP?^V@K?HI6?<?,NQSQL[_M:@_\
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M_P".5W5%+V<OYW^'^0_;0_Y]K_R;_P"2.#.H>(>WA*\/_;Y;?_'*:=2\1?\
M0GWI_P"WRU_^.5WU%3[*?_/Q_P#DO_R)7MH?\^H_^3?_ "1Y^=4\2?\ 0FWQ
M_P"WVU_^.T[3/"VH^*-2COO$EI]AL+5PUKH[2+)OD'_+68J2IP?NJ"0.IYZ=
I]14/#\W\2;DNSM;\$BEB>6_LX*+[J]_E=L****[#B"BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>elicio-exhibit311001.jpg
<TEXT>
begin 644 elicio-exhibit311001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR')( ^4CA<\]:QO%>G:)\2X=(U7PS;RP>(5OHO,D,!BEA0'YC-V^7 (.3R
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M=.(#?:8T:5-IZ'* \'(YZ<TNG^(=*U;1!K&G70N[ @D20(SDX."-H&[/MC-
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MH6EE/:0W-PD4EW+Y,"L>9'VEL#\%-%_?V^F6,M[=LZ6\*EY&6-GVJ!DG"@G
M% %FBLC0/$^C^*+5KK1KLW5NK%#*(75<C&0"P )Y%:S,$0L<X R< D_D* %H
MKF;;X@>&[V]NK.TO+FXNK1BMQ##87#M$0<$, G'((J<>-?#YT&?6Q?-_9T$I
MBFF^SR_NV'4,NW(QGJ1B@#?HK#T_Q?H>JZ'/K5A>-/IT&[?.D$F!CK@;<G'?
M IMSXRT*ST!-=N;N6+3'P1<O:RA<'&#]W(!R,'H<\4 ;U%<U_P )_P"'!9P7
MC7=PMI<%1%</8SK&^XX7#E,<_6M76-<TSP_8-?:M>PVEL#C?*V,GT ZD^PYH
M T**Y]?&NA!86GGN;03LJ0F\LYH!*S' "[U&XG/0<T3>-O#\'B%= DO9!JS?
M=M1;2EV&"<C"X(P"<].* .@HK/GUNQM]6@TN5YA>3J7C06\A#*,9.X+MP-RY
MYXR*PIOB9X2M[."\GU.2.UN&VPS/9SA)3Z*Q3!_"@#K:*PX_%^BRM>()[A9+
M*(37$<EE,CHASAMI0$C@]!VJO:>/O#5]HMSK-KJ#S:;:DB:Y2UE*(1@G)V]@
M1GTH Z2BLO1/$6E^(]..H:3<M<VF2!*(G4,1UQD#/3M523QIH,6F7>I274R6
M=G*8;B5K28"-P<$'Y.QX/I0!OT5RY^(GAA=+75#>W T]N5NC87'E'G'W]F.O
M'6NHH **R+SQ/I%CJJZ7)=-)J!3S/LMO"\TBK_>94!*CW.*DTKQ!I6MBX&GW
M:RR6S;)X2K)+$WHR, RGZB@#3HKFHO'WAR?5+G3(+NXFO[;/G6\5C.[QX."2
M F0,D?G3F\>>&X]*NM3>_D2SM)O(N9&M9AY+\<,"N5^\O4=Z .CHKF#\0?#:
MZ?'J#7ERMC)C9<M87 B;)P,/LQ^M3S^-O#]MX@309KV1=5D^Y:_992[#!.1A
M>1@'D<<&@#H**RM;\2:1X=CA;5+Y(&F;9#& 7DE;T1%!9CTZ"H8?%NC2WEO9
MM/-;W=R<0V]U:RP228!)VJZ@G ')'2@#;HKFD\?>')=6N-*BN[B74+8$S6T5
MC.\B 8&2H3('(Y]Q5JU\6Z+>Z=>W]O=2/;V+E+H_9I0T3 ;B"A7=P#GI0!MT
M5RL7Q(\*3:=_:2:FYL-^PW9M)A"&]"Y3:#R.IKI;>X@N[:.YMIDF@E4/')&P
M964]"".HH EHJ"]O+?3K&>]NY5BMK>-I99&Z*JC)/Y5(DT<D"SQL'C9=ZLG.
MX8SD8ZT /HK!TGQIX>US5KC2M/U)9-0MP3+;/&\;K@X/# =#UJV-?T]M0NK!
M6N6N;5 \R+:2G:IS@@[<'.#C&<X/I0!IT5R=M\2_"5Y:S75OJK26T#;9IQ:S
M>7$?]IMF%_$UTUI=VU_:QW5I/%<6\J[HY8G#*P]01P: )J*P]?\ %^A>&&@7
M6;UK7SSMB)@D8.?0%5(S[4_3_%>B:I>W%C:7P:]MUW2VKQO',H]?+8!NX[=Q
M0!LT5R\'Q#\,W4]Y#;WT\TMD2+I([&=C 02#OPGR\@]?0UJV'B#2M6TDZIIM
MZEY9C.9+8&0Y'4;5!.?;&: -.BN=TGQSX=UVSNKS2KZ2[M[4?OGBM92%]ON\
MGO@<U8\/^+=!\56\\^B:C'>) P678K!E)&1E2 >?IV- &U15#3=9LM6^T?8W
ME;[/(8I?,@DCVN.H^91DCVK,B\<^'[FYGAL[J>]\AMLTMG9S3Q1GT+HI7/XT
M =%17/7/CCPW:Z*=9DU-#IHD\HW4<;R1AL@8)4'') ^O%.N/&N@6OA^/7I[R
M2/2I,%;IK:7:0<8/W<@'(P>AH WZ*YZQ\<^&]1O+6T@U-5GNT$ELD\3PF=3T
M*;U&X'VS6Q>ZA::='%)>7"0K+,D$9<_>D<X51[DF@"S14<\R6T#S2!RB#)V(
MSG\ H)/X5C^'_&&A>*A*VB7IO$B.V1UAD55/IEE S[4 ;E%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@#D?C9_R1C2_^NUM_P"BVJX/!VM>*?&WA7Q#-;IINFZ1:Q8+RJTUPP^;&%R
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M=SW#W$UP8O+W%N@"Y.   !ST%;% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !6+XC\6:+X2M([K6[I[6WD<(LHMY)%W$$@913@\'K6U7DW[1'_)-X/\
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M$=0'52&_#-%YX_\ #5AH$6NW&HD:7+(T272022(6#%2/E4XY4]:E\"VUM:>
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M+.UA>:8CU*H"0/<X%5_#$MYJ-L]]KEJEMJ4-[<1)&)-PB4M@*K<9!4*>G/7
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MLY^I)/MTJ[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MP/8@\US@\%ZP/"G_  C'_"2_\2SR?LWF_8_]*\C&-GF;]N=OR[MG3WYKM:*
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MF=8:VAT95\DBWWL[*%&6);_9Z>]3>*OAQ%XDUK2]>AU-]-UNP(Q=VT((D Y
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MKJ+I8_*%O]E^39L*]=^<X.<^O:NXHH Y3Q]X+/CO0TTF34/L=N)5F9EAWL2
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MQR-,=[_^S[FP.Z.X@@R_;@'=P,@''.#WJ'QE\.;GQOH^FZ?J6O;39-O,T=H
MTKXQN(WX''8=_P J[ZB@#F+_ ,/:WJOV.*\\01BU@N8IY8K>Q\LSB-PP5F+M
M@$J,XQ65<_#NYE^(@\9PZVD5ZL?E)";/=&%V%>?G!)P?45WE% &#IFAZA;Z]
M+JNHZS]L)M_(AMTMQ#'""P9B!N)).U>I["L;Q7\/I/%/BC1M;?5A;/I$JRV\
M2VVX$APWS'=SRHZ8KMZ* &H'"*'96?')48!/TR:=110 4444 %%%% !1110
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MMI^ZSF90V?PV_G[UUOQMCBD^$NLF4#*&%D)[-YJ#C\":Z'Q;X.TOQEIT=KJ
MECD@D$MM<P-ME@<=U/\ 0_T%9VL>"+GQ1:6NG^(]:-WIT$BR/!;VX@-RR]/,
M;<V1[*%_E0!Y#\0;B\NOV=O!TU\6:<W,8W-U*B.4(?\ OD+7L7AZ;6+_ %>_
MM=;L+>&TM[:RELUAF,JL<R$ODJN&RJ\8[#K47CCX?6WC?1[/2)+UK&PM)%DC
MCMX1G*J5 R3@* W3%=79026UG%#-*LLD:A3(J;=V/;)H 2[^R0I]NN_*1;5&
M?SI,8B7'S')Z<#K7D%CX?GTGP;\0O%,<)LY=;@N)[2UV[6CMP'(8KV8A]V.W
M%>B>,_"TOB_1UTQ=7NM-@+AY3;*-TF.0,GH,\_@*S?"OP[3P]/>RWNN:EK?V
MJ#[.5U"0N$0GY@,GOQGZ4 >/W<DL'PZ^%,EMD3KJ+&/'7=YW^-:5M)+-/\;'
MN,EPK(,_W09@O_CH6O2]-^&=C8RZ+%+>27.GZ'-+-IULZ %'=MV7?/S[3]W@
M>^:EUCX>6NHZAK-S:WLEDFN0)!J4:1AO,"]&0D_(Q!()P1STSS0!F?#R]M;#
MX.Z3J^K1JQBL6B+%-SO&)&"1@=\_* .Y(JU\)_"4WA+PI)%>(L5]?3M>36ZG
M(@# !4_ +^>?2IO$OP[77=-TK3++6[W1[#3%400V> =RC"L6ZY Z?4FK_@WP
M=_PB4%VLFL7VJSW+JS3WK[G"J.%!].2?QH Z>BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&'7W&10!J45Y@NNZY_PKGQK??VO.;[2[^^BM[GRX]P2(X4$;=O;L*[2P\06
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M"CCDG!P._;-=]I^IZ3>:MJEI8O&U]:.BWH6,J0S+E<G'S?+Z$XK3P...E(
M20 ">I]: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *J:CJ=CI%D]YJ-Y!:6R?>EF<*H_$]_:K=<C\4
M41_AEXAW*&Q9N1D=#0!UB.LD:NARK $'U%.JOI__ "#;7_KBG\A5B@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %86NR>)9)EM
MO#R:?$5CWR7.H*[(220$54(.>,DD\9'!SQNUBZ_XBM-&6*V:ZM(K^Y!$"7$H
M11CJ[$D?*/UZ#DT 5O!7B*Z\2:+--J%FEIJ%G=RV5W'&V4\V,X)4G^$UT=<Y
MH=WX>T;0)1;ZQ9RVUJY>[O6G7:99&W,SOG:&9FSC/&X>U=&"" 0<@T %%%%
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M*Y^%)-$TY;1<KX53QF8N3F-+?LI[>4)N/3(H ]KM;VTOHC+:74-Q&#@O%('
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MF1H(50N?4D#G\:232=-FOUOY-/M'O%&T7#0J9 /3=C-+)JNG17@LY+^U2Z)
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MR<'L>>:V418XU1!A5  'M7->+_%4/A_^S+475O#<ZA>QVVZ1US#&VXM)@GH
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M Z#THFU;3;>S2\FU"TCM9/N3/,H1OHQ.#5F&:*XA2:&1)(G&Y71@0P]01UH
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MH:7S9E7RP> 6R> ?>J&L>*]'T-=/-W?0*=0F2*W_ '@PX8\OG^Z!R3TZ>HH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC)ZE2>GX4 >,7^K:;<Z'HUU8W%M9V?\ PE<<HMI)-]P&^T'S))&)^4').W'
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M^BI:ZR+3;""[>[ALK:.Y?[\R1*';ZL!DT76FV%\Z/>65M<-']PS1*Y7Z9'%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/90;Y8D :0! 1EARW4]?4USWBUYO#?C72O$5I;-.NH0OI-Q$@^_(<O;D_P#
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M-K'H#VQ5_P#M/2)=?\8:+XGUYM-6]E$D:2F)$N;1X55=C.A)(PPP#P3P,YH
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MM_PK[XIPA8O+BU.[9$P,(3%'T';G/XT >K2:I8Z?:6[7^IVJ>8@(EDD6,28
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MJLUR?A*VT/\ M;6M1T74Y=2>]:)KNY61'A:0*0 NP!=V,;L>JYKK* "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9]6L(E6&T7(ELV";)"R_PJ ",G@\8Y(KT*HH[:"&626*&-))#EV50"Q]SWH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%4]5U6QT33)M1U&<06D !DE()"Y( X )ZD4 7** 00".AHH
M **AN[NWL+26[NYDAMXE+22.<!13-/O[75-/M[^RE$UK<1B2*0 @,IY!P>:
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MO%J<4"0Q^:P9#$K ;OD[[NW3'>L*+P+K47P^T+PX); SZ;=PSM,97"NL<F\
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M930]2_X6(/$3_91:G3!8&(2,7!\SS-WW<8[8_'VKIJ* "BBB@ HHHH ****
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M5V#7]4F\:ZWH@@LPEI917%L_S98N6'SGT^7H!^-3^!O#]YX6\*6NCWMU!<O
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MD()=3@#@J,#O[4 9EMXSU>+7/#]EJ,=@LFIRRPW-G""TEBX1G4-('*L<#!&
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.><[B2.*P[7X<ZCI^B>&ELM5MTUCP\9%M[AH28IXI/OHZYR,CN#QCWX]%HH
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MG=>%M0FUWPYJ/]HQRG2#.\IFC.ZX:52K$8.$ R2!SV':J<W@6[O+3QA;7-_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#\3R+=7VI6UPMTYCEMEO%.Y5PBJN6VKN'J4/6@#L-7\7:)H^@7.LS:A;26L
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ML9=/&H1WEN]D5WBX653&5]=V<8]Z2QU.PU.%IK"]M[J)&*,\$JN%8=02#P:
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MQJ%5% P  . !4E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MRO+2:W-[%!_9(MLM+&[A<B7.=^#NZ   ]<9+/!4\4GC3QRJ2HQ_M"$X5@?\
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M\*:'-JFH2 (GRQIG!D<]%'U/?MUKEO#=KIEW\4/'*R06LTB26+*&56*D0@Y
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M44 %%%% !1110 4R6&*=0LL:2*#G#J",T^J]Y?6NG6QN+RXC@A!"[Y&P,DX
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M,;^>O/6K%%% $,5K;POOBMXHVQC*( :2.RM(;A[B*UA29_OR+& S?4]34]%
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MNM)1]-BGBECMTD;S/,"#()(Q]W\/]K/'4:MJ]AH>FS:CJ5PMO:0C+R$$X'T
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ML31MN1HRV'C .#D,>">/>L6P\!:W9>%_"FDF\T^5]#OUO&?#J) -_P @X/\
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MWQCX8?Q/IELEM>?8]0L;J.]L[C9N"2IG&Y>ZD$@B@#GX(]2C^-06[N+:=_\
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M'4]-U75K)[[4(1!N@A9(($[E5+$LQ[DD=N!CGJ["*:"PMXK@QF:.,*YCSM)
MQD9H Y236O$=YXUUCP_8OID"6UI#<03RPO(1O+##*&&?N]B,>]8<7CKQ(_@G
M2_%DD6F):FY2WN[18W9Y,S>2SH^X!.>0I#?7M756^@:A;>-]3U]9K9HKNTCM
MD@(8%=A8@D]\ECD8K"'@#5!\.8?"GV^TWQW0G^T^6V"!/YV-N?7CKTH V%U[
M4[3XA_V'J+6BZ?=VC7&GRI$RN[(1OC9BQ&5!#<#D'MBM3PY?7NIZ0M_>&$K<
M.\EOY493]P6/EDY8\E<-VZXKF/&4>D^*YK#08M1B_MRWO8V9+28&6W3;^^W8
MY53&6&3CEE[UW:(D4:QQJ%10%50,  =J .)D\87$OBJ]T..[LK*_M[F)8+*\
MB8-=P$*6D1]P!/+X !QMY'/%JT\0ZK<:[XNTQC9C^R(X'M9!"W/F1LY#C?SC
M&."*B\0>#[SQ+!/8ZA+926QNUGM;K8PN+10P8JA[G@@'(P#T.*?<^%M6C\4Z
MQJ6FZA:Q6NL6\4=TDT+-)&T:E08R#CD'N#@]CTH R(?&_B"[T_P5-;6VF^;K
MZ.)@X<"-Q$SY7GIQTY)QCC.:='X\U;0YO$.G^)+>TFO=,ABN+:6S5DCN4E;8
M@*DL5(<@'K^G.9=Z)J'AR;X;:-]LM;B[L[F:-)#$R(P$#<$9)Z9&?<'':NGO
M_ L>O1Z])K$RBZU:".V!M\XMHXSN3:3@L=YW$X&>!CCD 6TUGQ&?$<5B;5;J
MPN+=V^V&PEMA;3+R P<_,K=L<YK,\.:]XX\2>%8=<MQHD8EMYRENT,K,TR2,
M$YW@!3MQUR.O.<#:T'2O%EL$_MS6[.^^S(5@$%NT1F;& \QR<\9X4 9.><"K
M'@GP_=>%_"UMHUU<0W!MV?;+$I7<&=GY!SC&['6@"CHGBB]U_0/#EW:/:B[U
M#+72M V(E0'S<#?D%7PG)/+#BJP\7:O$WC57LH;F30RGV:*W1LR!HM_S<Y)&
M>V.E:GA[PE#X?UG6;Z*<O%?7!F@A/2W# &0+_O/DGZ"JEOX9UBTU/Q-?V^H6
MT4^KR0RP,(V/D-&JJ PS\P('/3TH 71?$EQK6G7]_IFJZ7J5HELKP21Q,C)+
M\Q9)4W$C@+CH>3]:HZ9XWO=0T3P@@2V35O$*,X)0^5$J(7D8+G)XP ,]3UXJ
M[:^$9HM<U37%2QM;V]L1:-%;!O+D;))E?@9;D#IT'4YXHP> +NV\/^&88;^!
M-7\.L?LMSY9,<J$;71USD!EX.#QC/M0!)/XLU?3M3U_1+E+.74+'33J=E.(V
M6.:$9!#KN)#!AC@\YSQ56R\6^(@G@W4+]=-:QU\1120PQN)(I'A,@<.6P02#
M\NW@=SUK7N/"UW?3ZQJ=S+;#5+_3_P"SH@@8QV\7S$\\%B68D\#H!QU-1O!N
MI_V3X1L1=VF?#\D+ERK?O_+C,8&/X<@Y[\T =O7#^);C6%^)/A:RM-0ABM9X
MKN3RGMRXWH@&3AQGAR!TQ[ULZ'+K;Z]K4>H7-O<Z>LBFR>&(H8\EMT9/\14!
M<GU)'L(M?\.WNI>(]#UG3[V&WFTWST99H3('255!Q@C##:,=J *">(M9UJRU
MV^T(V:Q:9<RVT,-Q$SFY>(#?E@PV@G*C@],G.<5O>&M=A\3>&]/UJW1HX[R$
M2;&.2AZ%<]\$$5B6GA34]%NM;CT:]MEL-6F>Y*3HQ>UF<8=EQPX. =IVX/>N
M@T/1[70-#LM)L@1;VD2Q)NZG'<^Y/)^M ''3>,]<O-+_ +8T*Q-[$+ID2P%C
M*6FA60HS";(0-@%AQ@=.35AM=\47_BGQ'HNGMI< TZ"WF@FFAD<GS YVLH89
M/R@9R,8Z'/#=-\&^(=$NKK3]+U^WC\.7$[S"&2W)N+8.2S)$X8  DG!(.,]*
MT[3P]J-GXKU[6DGM634X(8DB(8&/R@P!)[YW'/2@##'Q&8^&?"^K7IATVWU>
M-OM%X\320V\@ PIY&T,<X)/ 7\1H7/B36+&?PNDDFFW":K>O;3/ C%63#LDD
M9#D#*JO!SUZTFB>%-7T3PWI&C"XT^]M;."6WN8)XV$=RK%2I[[2,,.0P.3^%
M7_A7MS8^'M&M=)O;>*\TK4GOX1+&Q@&\OF( '(4!\ YSQ[T 3W/BO6(+OQO;
MHEB[:%;17%LS1N-X:)Y"'^;G[N,C%00>*O$%KH6G:MJ8TXQZNEI'916\,K/'
M+*,L7 )W +E@%P>-N?XJE_X0S66N?%5Q+JEG(^OVD=NP^SLHB*QE-P^;I\QX
M.2<#FK5]X+N-2\!Z=H,NH"WU#35@:UOH$SLEA "/M/TY&>] %C0M7URX\17F
MGW]HTFGK LUMJ M)+<%LX:)E<DDCJ".,5G^+[C5T\=>#;2QOX8+>XGN2T;P%
MP76W<@MA@2,$X''/// K;T"Q\0Q,9_$6IVEU.J>7''90M%&!D$LV22S' ] .
M<#DU#XD\/7FJZMH6J:?>06]UI4\C@3Q&1'62,HW 8'(!R.: .4CDUJ#QQ\09
MM'EL8IH8[*5GNHFD#%;<D*%5AC/KGCT/;;@\4ZEJ.A>'-3A2TLK34K;SKNYF
M(80N4!6-$W L68G&,\+TYJ6W\,:G;ZSXGU#[5:O_ &U%$B*58&(QQF,$G^+(
M.>,>E9UAX&UK3!X8>UU6R,NC6KV;+- SQNC!1YBJ&!5_EQUY'>@#'U;Q5K6M
M?#BTU"*>&SN3K"6-SL@;$H%P$X!;* X!(//49%>HQK<K:!99(I+D+RZQE$+?
M[N20/Q-<&OP\U)?"-YHQU>W:4ZG_ &A:RFW("D3>;AP&YR>.,8KNX%N4LU$\
MD<MR%^9E4HA;V&20/S- 'FC^.?%*>!9O%3)I/EV5Z\-Q;"*3,R+/Y7RMN^0X
M]0V?;I720ZYKEGX\L]%U0V$MKJ-I+/!]FC=6@:,KE68L=XPW7"\]A66_@'4W
M^'=_X6-_:![NY>?[2(VPH:;S2-N>>>.M;5]X=U&_\7Z5K9N;>)+*UFMWC3<6
M;S=N65NV-HQQ0!C+XRUFUU30H-06Q$NHWS6EU8PJ7:TR'*9E5BI;"C((&<\
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M!E>-WA,@<.6YY!R-HP#CGK4FI^,-6^P>,+^R>VMSX>D*1VT\>[SPL:N6<Y!
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MUNHK.:^UJ&VNHXXBR.R2.,\G.W=$#M]^O%>JQ"18465P\@4!F5=H8]R!DXH
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M6\!B,7[S84.6;<.0<\56^(\^HPQ>'%L;X6R3ZY:0RKY>[?E]PSR. 5!QW]:
M.WHKE(M8U'5O$NIZ#97<-N^DV\!N;DP;C)-*I90%+8"@#)Y).[ (QDV/!?B.
M?Q)I%P][!'#?V-Y+8W:19V>;&<$KGG!!!Y]: .CHHHH **** "BBB@ HHHH
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MW$<5KLVLJLH*DL<+ASP<G..?7L:* .$E\#:K/X*TKP]+K5J6T^6W9)A9D I
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M)X% '-_\(?J2WWAR_CUB$7>E6LEI,QM,K+&X4':-_P K#8,$[O<'I2GP??\
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M,;KO^9>>N0<@5Z#10!P<_P .YM2F\3#5M66>WUZ&%9DBMO+,<D:X5E.X_*"
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M/6M:B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MPC5R)"[ A?F"_+@C!.3T%S7O!]SXAM+_ $Z_U&"73;N=941[4F6V VY$;[\
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M#J;+:6LS?:[<V@9;A'?<YWY_=!07V@9S\HYJQ\4'5/ACXA+,%S9N!DXR3VH
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M'.NI)"CP_9MI3RE*J=V[!)W'/ ]L54M?!UW91^([>#6%%KK$TTZQO:Y,,DH
M<D[AN'' ^7&><T 4]-\57^IV?A"P$J17^LZ=]MN;D(#L540ML4\;BSC&<@ '
M@U'KNK^*O#OAR6[O)[1YH]5B@@D5 ?/MI)$4%QQM<!CTXXZ4^X^'UR=&\.QV
M6M_9-8T"/R;6_2VRKQ[0K*\9;D$ =ZO:IX/NM9\*W.FW^LO+J,\D<_VX0 +&
M\;*R!8\X"@KTSDY//- $HUB^3XG?V$9$:P?2#>A2@W+()53&?3!_.N8\)WE]
M8^ +J:QEM8#_ &Y<K-/<N%6&(W+!W&>"P'0'J<=>E=%9^%=4C\71>([S6XY[
MI=/-E)$EGLC(+[\J-Q(&0.I)//(X S1\.[Q/#T.G1ZZBW-MJW]K6]P+/Y1)O
M9BKIO^9<L>XZ#TH AB\6ZN;3QO%#<)))H<"7%I/=VA1G5H3)M=/E[J0#@<$'
M!K.\32Z_??![6-4U:_M9H+W2(98[>&WV&)R 6RV?FSD=AS6^W@6_>X\2S/KX
M9M>M$@F!LAB-A&8]PPPXPQP.W&2>]O4/"%QJ'PZ'A-]3C4_94M6NA;'E% &=
MF_K@#O\ A0!#JNL:EHGB7PZ);A!H6HG[+)^Z&Z.X*YC&[^ZV".G7OS6SH=W=
MW\^I7,DP>R%TT-HNP [4^5R3W^<.![ 'O7.^,KG3+_1I/!ES>I-KUS!&;>*%
M&5@^[Y)0.=H4KN// 4UV.GV,.F:=;6-N"(;>-8TR<D@#&3ZF@#!DUB[U7QE>
M^'["Y^R1Z=:QS7,ZHK.TDA.Q5# @ !22<9.0!BN&\/ZOJF@^"H[B&>(SR^*9
M+2Y'E?(XDN=K$#.5[XY_.NVU#PG>#Q=_PDFB:K'8W4T"V]Y#/;&:*=%/RM@,
MI##US_\ 7S%^',X\*W>D'6RUP^I'4[>Y-L/W,OF^8,KGYAGKR/PH T7UC5?^
M%AWN@Q7$/V?^QUOH3)#N*2&5DP<$97"].#SUK"\/ZYXOU3P$/%<NI:<JMIDT
MRVOV,G$JDD,6#C@A2,=N.M;EMX4U6+Q4_B*?7(I;N33A8O&++;'D.S[@-^0.
M1P23UYY #M'\(7&D?#X^%1J<<N+>2VCNC;$85\\E=_)&X]Q0!C/XH\0R6/@*
M2VN+-7UR)/M1E@)^<VYD+###C/\ #@9]14EOXKUK2[;QK#?^7J=SX?19H)(X
MO*\Y7A\P*R@GH<C([5>3P1=I;^$XAJ\./#P 0FS/[_$?EC/[SY?E^O/Y53U[
M3;CPS:>,?$3ZH_\ Q-8HU_T:U(>U95\I7#;FR!G<QQQ@F@!4UW75\0>%+2WU
M&UNK;6K5[FX9[7=Y015<E-K+A6W[06W8..M6_BK-=V_PTUN:SNWMI$@.YD )
M920"N3TR#UZUSWAN2?3KZR31?%'AG64=XXY+6PTY(I3#N 9BT<AV[02V6&,C
M'4UWOB?0H_$WAG4-%EF:!;R$Q^:JY*'J#COR.E '(>(X;]/&_@.*.[C>[/VX
M">6+Y5S .=H(S@=LC-%MXTU73M+UZ#4&BO=0T_5HM.MYDB\L2^=Y>PLN<9&\
MYP1G';K6U)X5U*YUKP]JEUK4,L^D";<!9;1,9$V'H_R@ <=>?7I5.?X>+?VW
MB2VO]2WQZU<)=!H(#&]M(@4*RMN.<;%/;O0!<TB[\3+XI>UO+6>;19+;>MU<
M)%')%,#]S"-\RD<@XR/4TSQEK.M:5JGAZVTJ6T5=1O3:R">)F(^1F!R&' V]
M,9/J*N>'M$UNQ=9-=\0G5GB39"$M5@4>K, 3N;C&> ,GCFL/XBNW]M>"TAN8
MH)SK *-(NX#]T_5<C([=1UH I2>-=;\*:AXATWQ!);ZC)9:>NHV5Q#%Y'FHS
M^7L=<D##X&?3)K:MKOQ<GB.SA-O)/IES#(+F:XAB3[)*!E&4*^60GC:<D?WJ
ML7/@JWU=M8FUN87,^IVBV3&%/+6&$$D*F23G<Q8DGKCCBF^'_#6OZ8(DU3Q0
MVIPVJE;5&M!&<X*AI2&S)@'V]3DXP 9'A/5?%^O>'X];FU/34C47<;0"R)W,
MDC*C9W@@#;C'IW)/!I/C34-0T+P7 [Q+JGB)79Y_+^6)(T+N57U^Z!GCG)SC
M!W/#?A>Z\/>%9=%&I17#%I6CG-J5V^8S,<KO.<%CW%9L/P\:W\.:!8Q:J%U+
M09-]E?"WP,=&5TW<JP.#AAVZ4 5[[QO=>%-6U[3M9(O4LM,_M2TG50CR1[MA
MC?'&[?@ @#@]*I>)8]6:_P# =UJ%_'-YVKQ/+"D(58Y#$Y&PCG:!D?,23P<C
MI727/@J#6&U6?7)EN;G4;(6#-!'Y:Q0@EL("6.=S;LD]AQQ68/ VN3VVA6][
MXFBF31;M+B!UL-KR*BLH#DN03AL9 '?()/ !U/B*ZN[#PWJ5Y8O$ES;VTDT9
ME0NN54GD CT]:X^3Q/XA>T\!O;7%FK:Y$HNC+ 3\Y@,FX88<9_AP,XZBNUUF
MPDU31+W3XYU@:Z@>'S6CWA0P()QD9Z^M<VO@F[2#PI&-7A_XIX (39G]_B/R
M^?WGR_*??G\J )O">K:K<:[XCT35KF*[ETJ>'R[F.'RMZ2QAP"H)&1R,T[Q#
MJ^HZ/XK\/J9T71M1F:TF_=C<DQ4F+#>C$$=.N/6K6C^';C3/$^N:S)?1S+JI
MA8PK;E/+\M-@PVXYXZ\=:G\4>'X_$^@3Z9).]N[,DD5Q&/FAD1@RLON"* .5
MTKQ;J5TGBFQEO$DU*RNU@T]A %61)#LB8C^+YPP8CC"Y&*;=6^I2?%^2"ROH
MH+D^&XP]U)!O(_TAN0F0,D^IP/>NA_X0S3T\4:5K4):(Z?9-:+".CCC83_N@
MO_WUGM3CX<NAXXE\2)J$(WV L1;FV)PH<N&W;^3D^G3\Z .4?QKKQ^%MOKRR
M6BZA'?"TN3Y)*R 7/DEE&[Y21SSFNDEU6_UCQ+K&B:9=K9?V7;Q,\OEAV>64
M,RC!R @"C/&3G@C'.6?AW='P0_AK^VHMK7OVOS_L1SGSO.V[?,_O=\]/SJ[J
MG@[4G\3?\)#H>NC3+Z>!;>^5K0317"K]UMI8;6'.#D\?CD Q=<.MR^(_AW]N
M%G!K+278E,>YX5?[.V2!P2,<XS[9[UO^#]7U.[U'Q!I.JW$5U/I5XL27,<7E
M^8CQJXRH)&1DCBG7?A*XGU;P]?)JO.CO+(?.@WM</*I5R2&4+]XD # /MQ5G
M0_#L^D:]KFIRWT<XU65)3$MN4\LJ@0<[CG@#MUH Q?$)U%OBGX9MH=2>&VDM
M;N3R1&"H90@S[DAB/;MU-8$<^M64OQ&U'2+VWM6L;UKDB6#S3*4MT;9U 4$#
M&>3SVQSW&M^&I]3\1:/K-IJ7V.?3UFC8& 2"2.0*& R1M8;1@\CV-9Z^"[M;
M7Q5 =6A/_"0%RQ^QG]QNC$9Q^\^;Y1[<_E0!%<>*-3?5/ [0&".RUQ6:XB,9
M+@^09!AL\#..V>.M5X?%T]QXKN-&N-1&FZE%?A(K"Z@"I=6H8?/&Y&68KD\'
MKQM[U?\ ^$,N]WA1O[6A_P"*?7:O^B']_P#N_+Y_>?+\OUY_*G:AX/N=8\N#
M4]1@N+6'4?MT#?92)X@)/,$:OO( _ASC.WCW !I^+K^]TGPCJVI:>\*7-I:2
M3H9HRZG8I;& 1Z?_ %C7,C7_ !'I^EZ7>7MW;73ZXUM#:006VTV[-&SR$DL
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M)(_L*VH4-*9_+C<OD$ 'J.F/?F@#U.BN/MG\8)XBAB"32:5/;N)I[U+<&VF
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%W%ID37NFWN&M[VW <J5.<J>7&1QSSCN >@7VM:9IL"37E[##&ZEU+-U4=6
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M9XFT76KEK;3=2M[J9(4G9(VR1&XRK?B"/SI+SQ/H=A>36=UJMK'<PQ>=)"9
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M7AMA+?[1=?9+<1)M4$!5!)P>3\Q)//&.,36_C+PW=W=G:V^LVDDUX,VZ*_\
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M'K74X?$"G2T>TU6!0)7&\YMY"O#,5W8[_-S]Z@#TRT\3:1>WL-I#>#SYT,D
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M, PR.F1S7D$-P\/A3^T8H[BYL=.\67%U>16CL)!;LT@$B[2#@;PW'IGM7?\
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MZG\3IQ8PZFA2R(M6&])0(PKL0.6"'EL>G:KND:K9GXL0WQU*:\M[CP^56[>
MI$Q$X8A<* % [\X[DF@#KX/'?ABZDLD@UB!S?/Y=N0&VNV2 N<8!)!P#C/;-
M7M3\1:5I!D%[=;#%'YLNR-Y/*3GYGV@[%X/+8'!]*\BM9[:/X'^'(]\:3)JT
M+LG1EQ=%B2.HPO/TKH[?Q!IWA_QAXITWQ,K^1K$J7%E*T#31WD)B5#&NT')&
M,;>^: .ON]1TZ;Q)H<::^T<TJ2R0V4+JR7B%,[FX/"@;@<C\:GD\5:+%>"U>
M^4.;@6F_RV\OSC_RS\S&T/\ [.<YXKD]6DMH/'GP]C6".Q2**[46W ^SJT 5
M$..%Z8 ]1@9KD]<UBWO=!NR$>QDM?$4;S:;!;$"("X7,TK;22S?>SD#G !(S
M0!Z#%?7Z_%Z;36OIGL#H@N5MVV[4D,^TD8 )X'?/4UOZKKFEZ&D#ZG?0VHGE
M6&+S&QO<G  _/\*Y.&\MY?C9O60 /X=5!N^4[O/+;2#T;:<[>N*7XJ20+H>D
MI.R;3K-H[*W.460%CCT ZT =#;>+=#O;'[9:7XN(O.:W AC=W:1>654 W$@<
M\#IS3?\ A,?#OV"VO3J]LL%S/]FB9FP6ESC9M/((/4$<=\5RWC2^M]$\8Z)K
M>I"Z_L![2>VDNK1Y%%O([(RNQC(.U@F.]8WB6/P_#X4M+_2;66/3+KQ+:7,L
MTYD;[22XWR8DRV#C'O@]L$@'HNC>+-"\0W-S;:5J<-U-;8\V-<@J#T."!D>X
MXIT?BC19;N"V2^7?<.8X'9&$<S#JJ2$;7/!X!/0UQ/B#3Y/$?C2>^\-S1O+'
MX?NK66[@<%#+)_J8]XXW Y;V&/45G7<T/B+X3:+X?T_]WX@@:R@%IC$UI-$Z
M!W9>JA55SN/8CUH [Z[\<>&;&[GM;C6;=)X)8X94&6*.^=H.![?AWQFJ6G^-
MM+URQUUOM,VGP6,LMN;J2-HR@55!?+# (9C@'G@<5G^');63XL>,QOB9WBL@
MG0[MJ-N ]<'&?0XK,T6]@M=&^(=A<LT5R-1OYRCH1^[=!L.<8^;/'KVH ZZU
M\2:'IFD:-'=:\DWVNW4VUQ<MA[E=F[S#P,9 R20*O:7XDT?6K:YN+"^CDBM6
M*7!8%#$0,G<& (XYR:\TBN;7^Q/A0LDL687B\T,1^[*VY4[O3#8'/>K<WV&]
MUSXI6\\T@@GLH-QMAO=@MNP<H/XB.!CUX- '<KXOT!KBW@;4HXI+I0UN)E:/
MSP> 8RP <=.F>H]:T[Z^M=,LI;R]G2"WB&7D<X [?SXQ7EOAWQ!H6N:[X2:[
M\0:<E]I5N\$,$7F*UQ+)&J<[U7;P/NC.21SQSV/Q#OTTWP?/<2V$5Y$)H0XF
MC,B1#S%_>LHY(3[V!Z4 :<'B71YUO2+U8C8J&NDN$:%HE(R"RN 0#C@XYJM:
M^-O#=[=V5M;:M#)+>C-N &Q)QG&<8!QS@G/M7$:=J5HGC[Q%,U_/<Q7.APM'
M=31%5D"F3)!"A=O( /0YQDFLV"XM8OAI\-T\R)'AU:R:1<@&/;NWEAVQGDGU
MYH ]'\3:_9V&F:C NH26]Y%;-(9((C(8.#M9_E94!QU; ZTO@:\N=1\!Z%>7
MDS37,]E%)+(YR68J"2:XO3M9M]'N_'6D:Y(8=0O;N>ZM/,4G[5;O$%C$9Q\V
MT+C Z?G75?#:02?#?P^ '!2QB1@R%2"% /6@"C<>,XM:TKQ5!IDMW:7&EI*D
M<_D$$LD0<GYU(')Q@\D#(Z@U9\(>,--O='\/Z?=:HLNL76GPR,KYS*_E*S_-
MC!;J2,Y]JYNWO8+*/XEV-RS17,D\\Z(R$9C:W4*V<8P2,#U/%5OM-K'H'PK"
MRQ*T,UOY@! ,?^CLK;O3YC@Y[T >BW_B?1M+F,=[>B(*ZQR2%&,<;MC"NX&U
M"<CAB.H]:TKBXAM+>2XN)4BAC7<\CMA5'J37D=I=:#%+KOA7Q?!J37\VH7$D
M5LKW!2_BDD+H4"':>H';&.>^/5C&(M(\H1^6$@V[-V[;A>F3U^M &-!X^\*W
M-[9V<6MVS3WN/LZ\X<GH,XP">P)R<CUJ2[\<>&;&[GM+C6+9)[>6.*5 22CR
M$A0<#O@_3OC->86<=EKWP)T/0M.>&369'@^SPQX\R*03 M(1U4!=Q+'L?>NR
M\.RVDGQ:\9 O$SO#8K'T);:C[P/7!VY].* .FNO%&C65VMO<WHC9IA!YA1O*
M$IZ(9,; WL3FJM_XZ\,:7)=QW>LVR/9LJSJN7*%@2 0H/8'/IWQ7G6D3Z!+I
M5WX/\56FI3:TEW+FP\VY"WI,K2)(FT[<$D'/ &"3ZUT&F:AI6G_%/QL-2N+:
M#?;V(!G8#<OE-N )Z]N.] '9OXBTE+.SNEO4EBO?^/7R 96GXW?(J@EN 2<#
MBJ[^+_#\>D)JLFJ0)9/)Y*R-D'?G:4VXSN!X(QD5YKH;'PMI/A"QU"V.GI<3
MWLD%]+ 7DLD=BR1*""%=U8?>!Z$8)Z9MU<V__"K_ !592&4R_P#"2,VRXB97
M=3=1MR"!D[021V'4"@#UJ#QEX?NHV>VU))\7#6H2%&=VE"[BJJ!EL+SD C'-
M4];\=Z3I?A277K>1KN$2>0@CC8_O=VW:XQE,-USCTZD"J'B_6+.QUWPR66&&
M&Y>8IJXB$GV<^6 %0X(#2 X!.1@'@]N&E?S/A=XVMXTNGDA\0-.PDA</Y?VF
M)MQ! YV@DCMZ4 >H7.J:=<^(-#1=;FMKB3SFBT\+M^UC8<[U9=P"X)'3GUJU
M?>)]&TV65+N]$8A95FD\MFCA)Q@2. 53J/O$=1ZURNOZG97GQ!\!74,ZF$M>
ML'(*_*T.U3ST#'@'OVS6;HUY!IOAWQ?X?U\A=2>[O)!#(/GO8Y02C1CJ^<[<
M#)!&* .\O_%&AZ9>I9WFIV\5S)&95B+98J._'U&/7/&:L:1K6G:]8_;=+NEN
M+?>R%E!!5@<%2" 01Z$5YMI5K)I/B?X<Z?JDJ?;;/2+B*;>P)C<I&%4GUX('
MK@UO?#F>&2]\8+'(C;M>GE4*>J%(QN'J"0>?8T =9?ZQ8Z;(D=S*WG2*76**
M)I9"HZML0$X&1DXQR*Q/$OC&TT[P'>^(M,GCNU%N[6SQJ71G .-V.@!'.<=,
M5ER7G]A?%J]N]8E6#3]1TV**SNYCMB1XV8M$6/ )W;N>M<W?6C6/PQ\?W#$Q
MVFJ7US-I\9&-ZMM *CT9@Q [CGO0!WGAJVGEF754UJ^N;6>V5)+2ZC( FX)D
M4L 5!&1M V\\=*Z6J6CW$-UH]G+!*DD9A3#(<CH*NT %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%8'C77G\-^$-3U2%':XAMY&AVPM( X4E2VT'"Y'
M).![T ;]%><Q_8$N-"U*Z\4^(;3[9+;Q"SD,RI=7.01D.N0K9((&$(^E=+>>
M./#]C>7UG+>R-=6*JUQ#%;R2.H;." JDD<$DC('?% '0T5D-XGT?[%I]W'=^
M='J(S9B%&=Y_EW?*H&> "3QQWQ5>7QKX?AT,ZS+J&RQ68P.[1.&20-M*,N-R
MD'CD"@#?HK&T[Q3H^JZM/I=G=,UY#'YQC>%TWQYQO0L '7/&5R*;_P )=HGV
MRVMC=D&ZF-O;RF%Q#+*,_(LF-I/!Z'D@@<T ;=%<YI^JZ.NK^([A-:N)3:^6
MU[#<.1#9@(?N9  ! +'!/K5NP\3:5JE\+"VGE6Z>W%S&DL#Q%XB<;UWJ,C)'
MTR,T ;%%<=\/+N\NK37TO+R>Z:WUR[MXWG?<PC1@%'L![5O:AK^GZ9-)%</*
M9(HO/E6&!Y3''R S; < [6QZX/H: -.BN7G\:6D?BZPT..WNG%U9M=><MK(R
MXR@4# Y^\<GH.,G-7&\8:&MVEN;MOGN_L2R^2_E&?IY?F8V[L\=>O'7B@#<H
MKF[/Q?!>>--0\/+;72M9Q1,93;2;6=R^><8"X488X!).,XJR/%NBF^M;0W3J
MUVYCMI7A=8IG'\*2$;6/'&#SVS0!MT5S$_Q"\,V\-Y,U_(T=E,8;DQVLK^2P
M )+;5.%&1\QX]ZM0^,="N-7M]+BO=UQ= FW81/Y4V!DA),;&('4 YH W:*Q-
M1\6Z-I3O]LNGCBCD6*6<0.T,3G& \@!5>HZGC(SC-1WGC30;'4+FPEO':\MH
MQ+)!%;R2/M/3 53NZ'IG&.: -^BN2U7Q]IEGI^AWMD)KVWUBZCA@FA@D=0I/
MS$X&=V V%ZY'3@UJW?BC2K%96GDN-L$:R3%;65O)##(WX7Y3CG!P0.N* -BB
MF2R+#$\K!BJ*6(12QP/0#DGV'->=:)JO_"4MJ6IW&KZIIC:;JLQ5PLL5N+6%
M@I20.!&<@$G/S@D] ,4 >D45CVWBC2;J_AL5GDBN)XS+ EQ!)#YR#J4+J V!
MR0.0.>E5+3QWX<OM1BL+:_,EQ)<O:JH@DP)4&64G;A>_7&<''0T 5--\-^)-
M*5K.W\26TNGM*\@-SI^^X7>Q8_.) I.2>2A^AKIK"RATVP@L[<$10H$7/4^Y
M]Z2^U"VTZ%9+F0J'<(BJA=G8_P *J 2QP"< = 3VK(/C705TN]U![N5(+&3R
M[L-;2^9;MU^=-NY1CG)&/>@#H**R[;Q%IEW/%#;S2RR2VJWB!;>0@Q-G:V=N
M!G!P#R<=*R_#GC:QUW3;_4)(Y[.WM9Y8RUQ Z *C;<EB,;B1]T'(SC&: .HH
MK$B\6Z-)<7=NUQ+!<6D(N)8;BWDB<1=-X5E!9<\9&>>*SA\2_"1MGN!JA\A+
M879D^SR[?+)QD';R<D<=1Z4 :GB31KG6]/AAM-2>PN(+A+B.41B12R'(5T.-
MRYYQD<@'/%0V6D:K+<V]QKNHVEVUL_F0I:69@4/M*[FW.Y)PQZ$#GOQ3['Q=
MHFHZNNEVUVS7;Q&:-6A=5E08R4<@*^,C.TFDB\8:'-=6T$=VQ^U3M;P3>2XB
MEE7.463&TGY6[\X.,XH W**X[1;J\/Q0\364M[<36L5I:20PR/E(BWF9VCH.
M@]ZW-7\2:1H,MM'J=ZEL]RQ6(,I.X@$GD#C@'K0!JT5SECXZ\.ZC9:C=VU\[
M1Z=S=HUM*LD(P3DQE=V, G.,<5=/B;2%;2@;IL:L ;)O)?;+E=PYQ@';S@X-
M &M17--X_P##*WK6?]HDSK="T95@D.V4C(!(7 '/4\>]0?\ "S/".VU?^UU\
MJYD,22^3)Y88,5PS;<)R#C<1GKTYH ZRBLV_UVPTZX^SS/-)<"/SC#;P/,ZI
MG&XJ@) R#C/7!QG%,7Q'I,NG6=_;W8N+>].VV,"M(93@DA54$Y 5L\<8.<8H
M U:*RX_$.F2:?]N6:00^<8 &@<2&0$@H$(W%L@\8[&H;?Q9HUS;7DZ7;+]BD
M6*YBDA=)8W8@*IC(W98D;<#YL\9H VJ*HV&KVFI37$,!F$MN5$J30/&5W#(X
M8#/3J*S]2O-.7Q;HEI-JMW;WS"9H+*(D17(V?-YG&#M R,D8)H WJP+30]2_
MM^74-4UG[;;12O)86JVRQ"WW#;RPY<A2R@G'#'UXK3_$3PO;Q74KZBY2TG,%
MP4MI7\E@!DMA3M7D?,>/>NF1UD171@R, 58'((]: '45AIXPT.2ZMX%NV(N+
MAK6&;R7\J29<Y19,;2<JPZ\D$#D4_5/%6CZ.;C[9<NJVP5KAXX'D6 -T+E00
MOKSVYZ<T ;-%9EYX@TVQ\L/,\K20F=4MHGF8Q_W\("=OOT/:F)XFT>73++4(
M+U9[>^XM3"K.TQP3A5 +$@ YXXP<XQ0!K45A_P#"8:$-*O=2>^\NWL6*76^)
MU>!AR0R$;@<<].G-1VOC;P]>17DD-_F.S6-IF:)U&)/N;<CYR3P N3GCK0!T
M%%<%9:Z]U\7YK5+V]6R30VGDM;E&B2-_.4;PK ?P]^>_/6NALO%VBZA=VEM;
MW3[[R-Y+5G@=$N%7EBC, &P.>#TYZ<T ;E%<M-\1?"T,-Q,VI,8K:X-O<.MM
M*PA<8SOPORKR!N.!G//!K9OM:L;!XHY9)))I4,D<-O$TSL@QEMJ G'(YZ<@=
MZ -"BLB#Q/H]UI-KJ=K>"XM;L[;<PHSM*1G(5 -V1@Y&.,'.,5-I&N:?KL$L
MVGSF00RM#,CHR/%(.JLK %3]10!HT5E?\)'IG]M7&C^;,=0MX/M$D(MI"?+S
MC<#MPPSQP3SQ4-MXMT6\T)=:M[F673WE$*RK:RY9RVP +MW'YOEZ=>* -NN>
M\6^'KKQ';:?#;WD-K]DOH;TF2$R;C&VX+PPP">]1Q:MI<?B/6Y(]3U"YN;6V
MB:YL%1W2$#=@H@7[S<YP3T'2N3UOQC+K7@+1]?LKB\TWS-2M?,4*T2M$\P&"
MQ'S#;U*G'6@#U!<A1NQNQSCIFEK(TKQ/I.M7]U8V5P[75J%:2*6%XCM;.&7>
M!N4X/(R*N:AJ=GI4"37DPC6218HP%+,[L<!549))]!0!;HK&L_%.C7U[=645
MV5NK0$W$4L3QM$ ,Y;<!@8YSW'(I(/%FC3ZA%8BXDCN)HFF@6:WDC$R*,L4+
M* ^!SQGCGI0!M5F>(-);7="NM-2\ELVG4 3Q $K@@]#P0<8([@D5E)\1/"TD
M<$J:DS0S3_9Q*+>78DF[;AVVX3+<#=C/TK4U/Q!IVD&073S%HH_.D6"WDF,<
M?/S,$!VC@]>N#CH: *%OHNN77EQZ]J]E>6T4B2".VL#"TC(P92S-(_&0#A0.
MG7'%='7/W7CCPY9_8O-U-"+Z%I[8QQO()4"[B5V@Y..W4D@8R:8?'/A_[&+M
M+N62$6JWCF*VE<Q0G.'<!<J.#UP>#Z4 ='17%>*=1G_M[P7/I^HS"SO;_8Z0
MOB.>,Q.P)QU' /7%,T_5IK'X@>+Q?7UW+I]G:6DZ1D-((0PD+;449[#H">*
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M2O9:* //=,U'PWK1N-8TVPU SPV,D4MY?+.#""/]2#)]YB>RY QUY&<@*?\
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M,"EL[B"W^T!@5J^'-5T#Q%>Z;.-(U1=7L SS"_\ M &GG;A_FD.WG& !R>X
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %87BOPZ_B;3H+(7HM4BN8[@MY6\EHV#*.HP,CG^E;
MM% "(&"*'(+8Y(& 3]*6BB@ HHHH *PO%OAUO%&BG3/MGV6-I8Y6<1;R2CAU
M Y&.5&:W:* &H'$:B1E9\?,5& 3[#)Q^=.HHH *:ZEXV4,R$@C<O4>XIU% $
M-K:PV5LMO;IMC4DXR222<DDGDDDDDGJ34U%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ME !115'4M5ATVTBN6AN+B.26.)1:Q&4_.0 V!_#SDF@"]1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *XF/4M?\36NNW.A:A%9SV%_)96D$D:M%(T1 8RD
MJ6^8[L;<8&.M=M7&?\(-=VFOZA?:/XCNM-LM2E\^]LHX4?=(>&>-VYC)[D _
MRP =A%YAB3S0HDVC>%.1GOCVI]9D6FW4&M1W,6HNNFQV@MUTX1+M#ALB3?\
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MM,MK.]D9#!<Q7"R1#!!4_,!SP&4LO7^+O4?BOPK%XFL;5([R;3[VRF%Q9WD
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MM;J,Q2*#@X/<'L1U% '*:OJ^L^%[GP[=7-__ &A::E>16%W$T2*(WE!VO$5
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M ,3!)Q;I'$&7(>$HQ? /9MV1[UL>+=<ET2PLA;;!<ZA?P6$+R#*QM(V-Q'?
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M#W'V:%8A*Z@%@HP.!QVJ[0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117)?$
M+5=5T;0K6ZTFZ2"9K^W@;?$'#*\@4CGIU^M '6T5P,=[XDT7X@6>AW^LC4+/
M6;6:2WE:U2-K66/!8 +U7##&<GISZX>G>*_$=E\,1XZU+6%NA':RK]@^RHJ/
M*9O+C<L,$8/4#C'N,D ]:HKB-9U+5_"NJ>'99M2DU&SU*]33KJ*6*-=LD@.R
M2,JH( (.0<\'UYJ/3[_Q#XKT"76]%U2*TG^W2);VLT:F#RHY2A$AVE]S!2<@
MC&0!W) .[H)P,UPE[K&N:W?>(;317O()-,D%M;M;BW*-+Y:OF3S3G;E@,*!P
M"<DGB2SUO6=5\1V7AV[D&FWD.E+?:BUML<F1FV!$+!@%R&8G!/W1GK0!T.@^
M(;/Q#'?/9I.@LKQ[.43Q[#YB $X'7'S#KBM:O&K34-5\.^"?&-_::B_VVV\4
M.AE,49\T/) AW*5P.&)XQS7<W.IZDGQ-M]'CO2+&XTF6Y\IHT(259$4,#C/1
MCP30!UE%>5:3XD\20^ IO&6H:TMPEHMVAL?LJ*LS+*R1LS#!7! Z=O?)/26A
M\6Q>([!U%S<:5+$ZWHO3;+Y;XRC1>4<X)X(.>,4 =C17GOA'Q3<:KJ]KI^I:
ME=6>MQ1N;_2+R!(]QQ]Z%@OS(#T^8\<GU/3>*KN[L].MGM+^"R#7<23S2#<_
ME$_,L2[6W2'@ 8/4T ;E%>8MXGUU-"\>".]E6?1!YMG/<VZ>:%, D"LH 7KT
MR,X//-7;;5=>LO$G@_[5JQN[;7()%GMC;HBQLL/F*R$#=G((.20<\ =  =?K
MVMVOAW1;K5KU)VM[9"\@ACWM@>W^/%7;:=;JUBN$!"2H'4'K@C->6:]J=_XL
M^$WB37DU&2WMG2Y2"T2-"AAC8I\^5+;FVDY!&,C'0Y]*TL,="L@C!6-LF"1G
M!VCM0!>HKR)=:\:S^ +[Q1#X@B\[2[BY8VILX]EQ'%*P(<XR/E'&W'3J2<C7
MDU3Q%KWC%=,TW6_[,M+K08]1B(M$E:%VDQCYNO YS[].H /1J*\[EU?Q/KMK
MK+Z$]TMW87DEG;!5M_(D>+ ;S=YW_,=WW<8!&.>2SQ%XKU+2M0\C6;JYT&&X
MLHOLE]%"DMJET0=ZRN5;&&V@= 1DY[T >CT5Q5WK6I:KX@U/1]-EO(Q86T#>
M=8_9V+22AF#'S3@J !@ <\Y/2LV75?&45]X+L-0NK>PO=1-S#?QQ1)*I,<;,
MK@^I !P.,^HXH ]') !). .II%970.C!E89!!R"*\GUG4M9?P;\0M+N]8N)I
M='XAO%2..1XWA#[&VJ!W(R #CTK>_M2_M+G0O#MM<7T\EQI[WDD\8@$H5?+4
M(NX*F,N23@G ]\@ [NLF/Q%9R>*I/#HCN!>QVGVLLT>(S'N"\$]3GT&.#7(O
MKWBC2+&TTS52J7^HZP+*RO'$9<6Q!;S'5/D\P*",#C)!QUS)86MQ:?&V9)[Z
M:[#>'@R-,J!E'VCI\H (SD].] '9ZIJ0TNU2<VEW=;Y4BV6L7F,-S ;B/[HS
MDGL*NUR?C_5=2T;1[&ZTVZ$#-J-M!+^[5MZ/(JD<].#5*YNM>O?B/?Z!!K;6
M=D-+CNT,5M&SQLTC+\I8$?P]P>^ .H .YJ*6XCB60G+,B[RB#<V/8#GL:Y[X
M?:S?:]X*L;[4I%DO"TT,LBJ%#F.5TW8' R%!X]:R-"ANG^+?BK?JEX\4-O9%
M86\LKM82G9]W(4$DC!!YY)H ZKP]KUIXFT*VU>P65;:XW;!*NUOE8J<C)QRI
MJ9=2#:V^F?9+L%;<3_:3%^X.6*[ _P#?XSCTKR/PU?:SH7PR\,:O::H5MAJ*
MV\ECY"%)(Y+ID;+$%MW.000/8]:[I=6U9?B;?Z0+A9;-=&6\@MRBJ!(963EN
MI^[Z]Z .OHKS_P &^*)M8U:"ROM3N[?5X;=O[0TB^MTB82?+\\1"C<@.['S'
M@@GWTOB#JFK:1I>FSZ3=I;RRZG;6S[X@X=9'"D<]/PY^E '745PLM]K>GZ[:
M^&Y=3N]1GN(I[YKF"""*58@R*D8#$)P6)+8SP..XS-3U;QOH^@V?VRXBAN7U
MZ&TAEECC=KBVD<!3($^56Z@[<>V* /3:*\WN?$6N^#/%5U:ZSJ)UC39M*N-1
MA8P)%)$\(RR#:,%2.F<GI^)J7B'7-'\$:3XS?4#<I+]FFO;'RD$1BF*@B,A=
MP*EQ@ECG'.: /2*:KH[,%924.& /0X!P?P(/XUP4,_B;5_'/B328/$/V.UTY
MK*6+;9QN=KJS,G/8XQGKTQW!?\-HKKS?$\MQJ=W=;-<NH=LVP@[=@#$A0<X
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MYT81?*1GD'KZYKIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "N"^+<L:^$[6)KD0.^I6I5L
MC< )5)8 ^@YKO:* ,&#0WFU5-;N;Z*ZO4MF@M'2';%$C$%F"[B2S87)ST QC
MG-32_ ]G9>!G\)7L[WVG,CQY= C[68MU'&03D''&!74T4 <U:>%) =*75-3?
M48M*;?:*\00EPI57D()WL%)P0%&3D@G&*-O\/S8ZI>M8:]?6NCWTS7%SI:*A
M1G;[VUR-R*W<+CZBNSIK2(KHC.H=\[5)Y;'7% '):CX'ED\2SZYHNOWNC3WB
MHE['!''(DX485L."%8#C./ZYDOO!"-J^GZOI.I3Z;J-I;_9&EVB87$.<[9 W
MWCNYW9SDD\UU=% '%?\ "NH'\/Z]I-QJ]Y,FKW9O'D*Q@Q2[E8,N%'=%]N.@
MJU;^#[M/$5KKUSK]S<ZA!:/:DF"-8W#,#RH' R >""?7M6G'XBM9/%LOASR+
MA;N.S^V>8R@1M'OV<'.2<Y[=JV* .8TCP7:Z?X1N?#-W<-?6%QYH;>@1L2,S
M,,CW8D'M46@>#;O1Q'%>>)=0U.TME*6<%PB+Y0P5!9E&YR 2!DX'ITQUE% '
M,VGA-UOM&NM2U'[=+HZ.MK(8 DA+)L)D8$[OEST"\\G-6?$_AL>(H; I?36-
MU87:W=O/&H;#@$8*MP00QK=K+\1:[;^&M"NM7NX;B:WMDWR+ H9L>N"0/UH
MY^3X?F1?$:G7+QQKT2QW/F1QG!";"PP!R0..P]#QBY)X1DEO/#ERVI?/H:L(
M@(!B7<GEG=S_ '?3'//M7202B>".900LBA@#UP1FI* .$E^&^W3]9TFQUVZM
M=&U0R.]D(4?RG?[VQCR%)_A_(BNPLK==,TN"WDN7E2VB"F:;:"0HZG  Z>U6
MZ* /*_ 6D_\ "1>"K_3I-44Z;<:C=?:+>-!YFPS,=H?/"N/8G!.".,=I'X9,
M7C(>(8[S;BR%@+40@((@V\<YSG/?ICM7044 <;-X#EB\0WFI:/XBU#2H-0<2
M7UI J,LKXP64L#Y;$=2.:NW_ (5DNX+^RBU'R],OK=;>2U> 2"-0FS,9)X;&
M.H8<#CUZ6L>\\16MEXFTW0I(+@W&H)*\,H4>7B-<L"<YSR.W>@#%O_  _M.T
MU+0=:O-$O(+5+-VA1)5FA3[H97!!8=FJW/X/$FI:%>1ZC*&TAI9$\U [3O(I
M#LYR.N2>,8)], =/10!R3^!H[@>)TNK^22/Q"NV=4C"F(A-@*')[ =<\BHM1
M\!/?V.DLNOWL&LZ7D6VIQH@8*0%*E,;2I ''^)SV5% '):AX$CU70H[2]U:]
MEU.*Y2\CU3"K*DZ\*RJ!M"@<;<8Y/<YJ73_"5S;^*H_$5[KEQ=WBV/V)D$$<
M<;KOW] "1SCOGKSCBNHHH P_%/AW_A)M/@LS>-:I%<QW.Y(PQ+1L&4<GID<U
M&GAR>/Q=/XB&H*;B:R6S,1@^0*K%@1\V<[B>_3CWKH** ,3PIX>_X1?1%TM+
MMKJ))))%=T"L-[EV!QP>6-1?\(PT7BN\U^TU*:![R".*>W\M61VCW;&)^\,;
MCP",UT%-DD2*-I)&"HH+,Q.  .IH XI/AX(_!UCX:75Y/LUG=+<I,8!YA*R>
M8 ><8W$]NE:DGA9Y?%%SKKZ@?,GT_P#L]HEAPH3);<#G.[<3^''O4FF^*X=3
MO[."+3=06VOK<W%K>M$##*@P>H)*$@@@,!G/KQ6U+<)'Y@&9)$3>8DP7(YQQ
M[X/Y4 8-KX6?^U=+U'4K_P"W7&EQ21VTOD"-SO4*S2$$[C@=@HY)QTQ-XH\.
MGQ+9VMM]M:U6WNH[H,D88EXVW*.>V>M6/#>OVOBC0+;6+*.:.WN-^Q9E <;7
M*G(!/=3WK5H YGQ-X0_X2&73[^#4[C3-8T\L8+VV4' 8 ,K(V0RG'0_XYY;Q
M]8C2?#.CV]UK$LU]/KEI++>S[%<D.,N% "JJ@#@# QSU)/I]% &!%X<AO-1E
MU/59X[^::T-F@6+9$L+<L N2<MQDYZ 8QWH6?@9;?2K31+C4Y;K1;.9)8+:2
M,;R$;<B.^?F12!@8!^4 DC@]=10!@Z;X<?3_ !3JVN?;C(VIK$LL!B 51&"$
MVG.>A.<]?:C0_#(T+4]5N8=0N)+?4+I[LVKJNV.1\;B"!D].!G R:FTCQ%:Z
MSJ>K6$,%Q%-IDJ13><H4,67<"N">,$=<=:V* ,'6?#*:CK5AK=I=M9:K9*T:
M3! ZR1M]Z-UR-RYY&""#WJK=^"+'4-#UNPO)Y))]:.Z[NE 5BP ";1T 4*,#
MGIR22372RRQP0O-*ZI'&I9V8X"@<DFL33/%,6IW]K;QZ;J,<%Y;?:K6[>(>3
M*G'<$E3@@X8 X/KQ0!0A\&W9UW2]:O?$-U=7UA#+"&,$:)('V\%0.!\O..3G
MJ, 5H>%O#I\,V5S:B]:Z2>YDN<O&%*M(Q9AP>F3Q_6MB6X2,2 9DDC3>8DP7
M(.<<>^#^59_AO7[7Q/H%MK-E'-';W.[8LR@.-K%>0">Z^M %+Q3X3C\2&PNH
MKZ?3M3TZ0R6=[  6C+## J>&4CJ/:H+SP3!JGA]]/U34KN[O'E2X_M$[4ECE
M3[C( -JA>P QR<Y))KJ:* ,*W\/S'4XM5U"^6[U&WMWM[:3R-D<0;!9MF3EC
MM7)ST& !SG%7X>;?!=OX8&KR?9H+D7*S>0/,)$OF@'G&-Q].G%=O10!R%[X(
MG?Q)-KFE:_=Z3<WD:1Z@MO$CI<;1@, X.UL<9Y_GFY>>$UGU?0;^"]>$:*)/
M)C9-_F;TV,78G).._7.2<UT=4IM0:+5[:P%C=NL\;R&Z1 88]N/E9L\$YXX[
M&@#F;WP";F7Q!'!K=U;6.N*S7%JD2$"5H]A8,><$ $KWQUQQ5^#PQ>6<,$-K
MK+O"EBEE)'=VRRK(J[L,0-N&PQ'H1U!KI*1CM4M@G S@=: .3C\"P6K>&5LK
MV2&'P^&%NCH',A9"C%SD=B>F.3^%2+X-:SN]7;2]4DLK35W:6ZMQ$'VR,,.\
M3$_(S#KD,,\XK2\/>(;;Q)97%U:PSPK!=26KI.H5M\9PW )XS6O0!S)\&P1:
MOH%Y97'V:#0X'@MK81[E*.H5MQSG.%&#Z]<U#;>#KFT;5);?6I(YK^_6_9U@
M'R2#:-H!/*$* 0>>O-=910!C:1X?CTW5-3U621);_4C']H>./RTQ&I"@+DGN
M<DDDY],"J=]X1-UXHDUNWU:ZM#<6@M+J&-482HI)7!8$J?F/(_0\UTM% '%6
MOP]6RT/0[&#6;HW.B3&6SN)(D(&5*[63 RNTGOGOFM*3P=8WT&K#5V-]/JL*
MP74A78!&H.U$'.T DD<DY.<GC'1T4 <U9^$Y -*CU34Y-1ATEQ):*\01BX4J
MKR$'YV4$XP%&3D@G%9][\/C=#Q#;PZW=6^GZV7DGM4B0[960(S!CS@X!V^W7
M&176:A>IIVG7%[)'+(D$9D9(ERQ &3@5#HNK0:[H=EJULDB07D*SQK( &"L,
MC.">: ,63P8&O-!NXM7O([C28'MA+LC)GB8*"&^7 /RCD"MG7=(@U_0;[2+E
MW2&\A:%V3[R@C&1[U7T'Q%;>(?[1%M!<0FPO&LY5G4*2ZJI)&">/F%;% '*'
MP=<276@74VM2S3:,S-&TD"_O2R;#N Q@;>@'?DDTR;P%:7Q\2)J-T]Q;Z\4:
M>-4">4R*%0H<G&-H/.>0/I774QI8UD$9<>8REE3/) QD@?B/S% '/>'O#-]I
M+H^I^(KW6# NRV%PB((ATR=HR[8XW,3P3ZFI?%?A6#Q1:VH-W<6-]93">TO+
M<C?"^,=^"".".]6/#_B*V\1Q7TEM!<0_8KR2RE6=0K>8F-V,$\<U:N-0:#5;
M.Q%C=RK<K(QN8T!BAV@'#G/!.>..<&@#(3PO=/H&H6%YKEQ>7NH0F">]EA0$
M(01A$7"KC<Q[\DDYJK>^"9+[PAI_AQ]69(+$P;)E@&]A#M* Y..JC/'/MWZZ
MB@#E->\&2ZOJMGK5EK5QI6M6T1@-U;1*RRQ$YV-&^01GD<\'\,,U;P'%J>GV
M 75KV'5["<W,&JC:9?,888L,;2I&!MP!@ =!BNNHH Y:]\&#5?"M]H^IZM=W
M5S>[#+?,J*X*,&3:H 55!'3'<]SFI+KPK/=ZKH6HS:O))<:0TCJSPK^^:12K
M;L8 &#@ 8Q[UTM% &)JOABQU?7=(U>XW"XTQW9 O20,.C>H#!6'NHJGXE\'_
M -MZG9:O8:K<Z1J]FC1)=P*K[XV.2CHW##/(]ZZ>FB1#*T0=3(JAF7/(!S@X
M]\'\C0!RU]X,>^L]+BDU>=Y[*_347N)8U9[B9.!N P N.,*!P!@\5++X.AN]
M=U;4+VY^T0ZI9BRN+7RMJ^6-V,'.0?F//\JO:QXBMM%O]+M+B"X=M2N1;0O&
MH**Y!/S$D8X!Z9K8H Y+PYX,NM#:"*X\2:AJ5A:<6=I<*@$7&!N8#<^!TR<#
MTX&);7P@XGT634M1-]_8Q+6KF )*24*?.P)W<'H ,D G.*ZBB@#E[;P@_G:,
M^I:B;X:.Q>U=H DI;84^=P3N !Z #) )SBM'Q)X=M/$^D-I]V\D>)%FAGB.'
MAE4Y5U/J#_6M>JFJ:C'I.E76H312R16T;2NL*[F*@9.!D=J ,ZU\/R_VM!JV
MI7JWM_;0-!;N(1&D8;&YMN3EFVKDYQ@8 &3EGAOPY)X>EU-OMYN5U"\DO9%:
M(*5D?&=I!^[A1P<GWK3TC4HM9T6QU2!72&]MX[B-9  P5U# ''?!JY0!A>(/
M#0UR^TF^COY[*[TR9I898E5LAT*,I# CD'KVJM!X3EM]5U^_34R9-9CCCD5H
M<B,(A12O/)VDYSG)_*NFHH X:7X;Q_V)H=I:ZS=6FHZ(I2QU&%%WA" "KJ>&
M! &>G3ZYZ?1M+DTNT9;F_GU"[E;=-=3A59SC PJ@!5 Z #U[DDZ5% '+W7A!
MQXKF\0:5JT^G7%W$D5]&D22)<!>%;#?=<#@'GZ=<YZ?#E8O"%OX=76KDP0W@
MO!(\2%MPD\T 8QQN.3G)]Q7<5FZ_K4'AW0[O5KJ&>6"UC,DBP*&;:.IP2!^M
M &;JOABYU6+5+6;5!]AU.,1W%NUN&V?($)C)/RD@9Y# '!QZTKWP'C6XM6T+
M6KO1;K[,EI<>3&DJSQ(,+E7!&X#@-75VEPMW9P7* A)HUD4-U (SS4U '-:A
MX16[FT-XK^2(:1.;B/>GF--(002Y)&<[F)QCDTB^$GLM6U2]TC4Y+&/53ONX
M?*$@$F,&2,DC8Y'7.X$C.*Z:B@#GH?##:9'8PZ+>"SM;2U^RBVEA\V.1<@@L
M,@[ASSGN<YK.;X?6]OIFA6^E:C-8W&BRR26UP(U?/F!O,!4\8;<>F,=J[*B@
M#BI/AZ)+3Q';G6[MQKVT7!DC0[<($)& /F('T&>!6AK/@Z'7?#%II-W>SI<6
M31R6U];CRY(I4&%<=1G'7ZGIVZ6B@#%T'1+O3%>74M9N=6O74)Y\T:1A4'\*
MH@ 'J3R3QD\#&U110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ;P2R/F,E)(MN''RXR=@X^[@D 5K:=H"6>M76LW$_P!HU"YACMWD$811&A)
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M,3R !MB@  X !.!UJB?"ZIXINM>MM1NK>6[@CBG@0(8Y"F=C'(SQN/ (![T
M>9^';O5]$^&/AK6;35I4B74A;O9")/*DCDNF1MQ(+;N<@@@#CCN>NO-3US7[
M_P 1VFCRW5O+ILHMK9H'A"B7RE??('!)!+8QTP/7I93X=VZ>$+/PVNK7GV2T
MN1<QR;8_,+"3S "=N,;CZ5+J'@07'B*36]-UW4=)N[I$2]%H4VW(48!*LI ;
M'&10!T.D27[:+:/JR1)J'E+]I6$Y3S /FV^V:X.QU7Q9XBT+3?$.C-(LD\PF
M:":2$6S0;B#'C!<$ ?>ZY![<#T2TM8K*TBMH01'$H5<DDX'J3R3[GK7):?\
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MX,\4W%Y)#H^I*D&HVJHFR*5UQ'(&*[@A?@\]Q71CP8(I]7%KJUW!9ZO,T]W
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MB(ZP (F)-R;&W\?W?3%=)0 4444 %%%% !1110 4444 %%%% !1110 4444
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M&,AAC'W>.E:/C/5=2LX_%%Q::K</-I]HDUK#9 !;,A"Q,Y;Y6+'^'D[>@[T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>Y)K=KB_!>M6UCX0\':9<17<=U=V*0(K6S@*T<0+;B1\H]">#VKM* "BBB@
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M;<5 SC# ].];.H:K9Z-X]U*ZU^'5H])UBWMWLKJW%P%!12K1.L?(8YR 1W-
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MG5PS'^$,%"[NG'-8NH63G3_B=K$(;[!JMH(;,!3^_D6W*,R#ON9@ 1UVYYH
M]$\/RR3^&]+FE=I))+.)G=CDL2@))/K5:^\5Z+IS3BZNV6.W<1SS+"[10L<<
M/( 54\C.2,9&<9J3PNZOX4T@J<XLXE/J"$ (/H0>,5P&CS?V9X/\4^&=:BD.
MJ-/>>7"4):^6;<4:/^_G=CCICG% 'H,GB'2XM;M]'>X87]S&988Q"Y#H.I#
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M1Q+--)%;2.($8;@7P/EX.<'D#DC%17GCCP]8W:6DEZSW$EM]KBCA@DD,L9(
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MI%<6UJ(F:%L2%865@IQAB"0.,\UD:'?W&GZ%X$LKJPN[> 64D4]Y%8O)<02
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M5:-KI75E?&U@0>@)/M@$UT'B*[O=0U?Q#82:7J:0S:6OV VEHZ_;&*/GS9
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M =9K?Q LK+P>^N:=!/=?Z0+39Y1!AEWB,B0'D88]._&.N:ZR&5;NU$@26-9
M?E=2CCMTZBO'3I^HGX:>)K)-'U-9XM?-TL4D+,[Q?:4?*GDR':"203]37L-K
M=I=6:72QS1HZ[@LL91\>ZGD>N",^H!H \X\(>,K+1-$OEUBZOYE36;FW:Z=)
M)U@7SMB>9)R%'0<GTKL]4\5:;I5S<V\@GFEM+?[5<K;Q%S#%SAF_[Y/ R>#Q
M7F=W:WLOP?\ %EBFF:B;RYU2XDA@^Q2[Y%>X#JP7;DC:,YK>\0WEY?ZWKMB^
MF:FMO-I:_8&L[1U^V.4?(EE !7:2 $8J.3D'(% '9OXBL"MD;8R7;7L!N8$M
MTW%X1MR_.,#YU]SGBKNGW\&IZ?!>VV_R9EWIO0JV/<'D'V->7V^G0:CX7\*1
M7(UO0]4LM+5+?4X+>13$ZJBO'(N.5)' ;&[:<=>>]\'S:M/X3T^77(EBU)D/
MG!8]F?F.&*_PDK@D=B3TH H3_$308(-1F'V^5-.E,5WY=C*3#@ EF&W(4 ]3
MUP<9Q5J'QKHMQJUEI\<LY-\#]EN#;N()R%W%4D(P3CG_ .OQ7(VR3C2OB4AL
M;\->33M;*;.7,X:W5!L^7YLL".*2X2X.D?#5!8WY>RF@:Z46<N8 MNR'?\OR
MX8@<T =?/XUT:WFD5Y)C!%>"PENEB)BCG) V$_4@$XP"<$U#'XM\WQ[<>'!8
MW(6"U29IO*)#,S$ ^RC:>3U/TYX#Q'+J6J:'K44^CZLE];ZS'(MK:V;K"(%G
M0^:"HQ,S 9)RQSR  ,UU)6Y7XHW<[65^D.I:+##!.MNQ5'$CE@[#A" P/)'M
MDX% &])XRTB&YM(Y7G2"\G^S6]VT1\B27D!0_O@X/0]B:KKX^T.34Y-/B^W2
MW$5VMG*J64I\J1AD;OE^5>>IX/;.#7&>$DMUTO3_  QK'@Z\?6M/9(B\MLS6
MIV'"SB4_+C'/KG@5T?@WS(_%?C)Y;6[A2XODEADEMI$61!$JDJ2 #R#TH M:
M3XA\/V.BZOJD5_>O:1ZE(D[78D+K.64&-%8;@-Q "XZUJV>M66MW&H:4OVFW
MO+55%Q"X,<B*X)5@P/0X/(/&.U>>VUQJFG>%/$TMMH]W(\OB66?;)8,SK;O*
MI\Z.-E^<@#(X.",GI6IX;9K3XBZY>?8=8^Q76G6S17-U;RDOL,FXG<,@Y(PF
M >>% H PH[^_E^!?AW46U&]^V&[M]\PN'#2!KG:P<Y^8$'O7IL7B.PE\2R^'
MQYXU".#[0R-"P4QYQN#'@C/''>O+X;2^3X$Z'IS:9J(OH;N#S+;['+YBA;@.
MQ*[<XV\YKKO'MO>6O]D^*]%A$NI6$RP^2YV?:(9R$,9SWW%&&>A!H ZO3]4M
M]3^TFW$N+>9H'+H5!=3A@,]<'C(K,U/QEI.E2WZ3M.ZZ<J-?20Q%UM@XRI;'
M/3GC) Y-:6CZ<-*TBVLM_F/&O[R0]9)"<NY]V8D_C7FOC"34=23QMIDFE:D)
M3;8L([*U<1W2^5S(\JC#L#E=A/0 !2: .B\:>(7M=1\.:= MTUMJ-X//>W1C
MYD0C=MJLO.20I..<>QK"ME3_ (3>;PI)/K\NE/8O=1I(\H>&224*,.,-Y:!3
MM))P6/H,6]6FFGN/A_,NGZCMM[@23C['(3"ODLF7PIV\D<'FM"-W/QEENOLM
MY]E;1$MA<&UD$?F^>6V[]N,X(/6@"_#XFTK0;"RM+J]OKBV21;'^U+A"R/*#
MMP\@&,[A@MC&>"<YJ[JOBS2](%XTYGDCL5#7DD$1=;8$9!<CVYP,D#!Q@BO/
M?#L$-KIQ\):]X0O+W58)G2.5[9GM;E=Y9)3)]U0,@G//'&3Q6KIVHW/A7Q)X
MDTG5-$U*]M]4OFO;*>UM3-'.LB*IB8]%(VX^; QUP* -]_&D3>-;+0K>UN)H
M+BP-Y]ICB+*P+($*D?PX8DGIT]ZMWWC+2-.8/<O.MI]H^RM>B(F!)<[=I?M\
MWRYZ \$YK#N5N[+XGZ-?SZ;<&&717LR;6%I(XYC*C;"P&%& <%L#BN<T*"&S
MLI_"6O>$;R_U*.XD$,K6S26MVC2%TD:3[J@9&<\C'<\4 >@:WKME%'?V ^V2
MS06_F7!LE8M;J0<$LO(/!( RV!G%4OAG<SWGPWT*XNII)YY+8,\DK%F8Y/))
MY-8>EW5SX;\6>*[+4["_D75+C[78W4%J\R2J8POEDJ#M*[0/FP,<]*/!.O+X
M;\!>$M/U+3-5BFN<6A/V-@L#E@ 9,XVJ2R@'OGV- 'H5U=065I-=74J0V\*&
M221SA54#))-9-OXJTV;4;6QD%S;37B&2T^TPM&+@ 9.TGN!SM.&QVJG\1-&O
MO$'@'5],TW_C\FB!B7.-Y5@VW\0I'XUC:LS^-)?"1L[.\MI[+4HK^[\^W>+[
M,L:-NC)8#)+$+@9SUZ<T ;5IX\T2^U+[!;&]DF%X;)\64H$<H&<.2ORCL"<9
MP>P)J7QE>Z79Z&IU>ZOK:W>XB426>\/OWC:"R#Y03@<X!S65X $L=_XL$UK=
M0>?K4MQ$9[=XQ)&40!E+ 9&5-.^*44]QX+>WMK6YN9GN[9ECMX'E;"S(S'"@
M] ": -S4O$EEIDETDB7$QLX1/=?9XB_DH<X)QR<[3P,GC-:KRJD!F(8J%W85
M2QQ[ <GZ"O-_%]F9]6O]5T:;5=,UZ"V3R7BMGDM]17;N6)T*[6()*XZC(/T]
M!LYIQI5O-?1"*X\A6GCC!8*^W+ 8SG!S0!@Z;\0?#^K"-[6:Y^SO%-*;F2V=
M(D6(D/N<C"GC.#SC'J*NV_BK39]8ATN07-K=7$336ZW,+1B=%^\5)[C@D'!
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M1V[''#<Y.-PSM!QGG%(M_H\_Q 2V22\.K+IC2 ?.(#!YB\@'Y6;<1R,\9&:
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M2H9"4R0 ?O#C//2JNEK>2^./"VJ#2==>,V$\%S/=P,FR5O+ZJ<"-1@] H/\
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MTVZN+6318XHV-N_ESNI=B@;&#D,/KFJWA/2[O1_$MG#HDFJ_\(Y-;2-/8ZG
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MKUNB@#S74-6N_$&O^"[^'0-9A^R7<C7B363Q^06A9<$L ",G[PR/?M7I5%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
6%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>elicio-exhibit311002.jpg
<TEXT>
begin 644 elicio-exhibit311002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XOXB>(VT.PM(
M1<W]A%<R'S]1M+,S_98U&<G@@9.T<]MWI7:5CZGXFTK2=2AT^_DEBEN(R\9^
MSNR/@XV[@"-WMUH C\) -H$4ZZ_+KL5P3+'>R!!E3Q@!0!Q@^^<YK<KBM"6U
M\$>%]7U*XM[BWTZ2_DNX;6.%F>&-RJ@",<C)RVWL&YQ@UVBD,H89P1GD8H 6
MBBB@ HHHH *X:SO-0;XP:AI+ZC<MIT.F1W:6Q(VB1GVGG&<8'3/>NYKSVQGC
M/QQU.7)\I](B@67!V-()"2@;H6P>E &A\4+N\T[P+=7UC?3V<T,]O\\+;20T
MR(03UQACTQ6UIWBG1M5U2XTVTNRUW!&)6C>)TW1YQO4L '7/&Y<BL'XL_O/A
M[>P*K22R3VVR-%+,V)XV. .N "?PJKJ5TH^*]I=6\?VE1H$Z )RLCF1&6/=T
MRP!P* .EL_%VB7]W:6UO>,SWN_[*[0NL=QL^]L<KM; &>#R.1D5-IWB/2]6>
M^2RGED>P<QW*FWD4QL!G;AE&3CL,UY79ZBMW<> M0%O>IY%VZW%K!821P63&
M%P(D0+V/&3D]\@&NHUS2]0LO'Q_LZ%S8^)K86U\Z<""2+K)GL3"74?[06@#J
MSXDTPV5K=I)/*EW&98$BMI'DD08RPC"[L<CG&.1ZBK.E:M8:YIT6H:;<I<6L
MF=KKD<@X((/((/!!Y%<)XKN(O#OCZSU34X-070)]-%D)[%I0+:59"PW"(YVL
MK =^5KJ_"=MIT&D.^E:?+96=Q.TZ";>'EW8S(5?YEW$'@\XP>] !KVO6%G;7
MMHUW<1W,=N9)&M86E:!2#AF*JP7H>O8$]LUR_AW68+GP+X+EUG7KZWOKN6%H
MVC=BUW+D@1R'!RISR#CIUXJ'3-3'A_Q/XQT[6H[A)]1N3=V,P@=UN8C$%"*5
M!R5VXQ[UAVDFWX<?#>)XIXY+?5K5Y4DA92B+OW.01]T9'S=.>M 'J-WXDTNR
MGEBFFES#(D4K1V\CI&[8VJS*I )W+U/<>HI-4\3Z3HYG%Y<./LZ"2X,4$DH@
M4]&<HIVC@GG' )Z5P/B/SK'6M6U3PU?R)J9N(TN]#N4\R'4N$ :,$9!VX!9<
MCY><8-6;/68/#7BKQ1I/B.QNI(M6N_M5G(EH]PEVC1JAB^53R-N,'CF@#8U;
M4;C_ (6-X06TU&5M/O[>[=X8W'E2!8U*-QU^]GDGM6U>^+-%TYI_M-VRQV\@
MBGF6%VBA8XX>0*54\C.2,9&<9KF=598_B%X$_P!&%JD-M=K)$@^2WW1H$0D<
M#D$#UQQ65I$O]F^"O$_A?68I#JQEO1'"4):^$Q9D>/\ OYW8XZ8YQ0!Z'?:_
MIVGR&.:61G6'SV$$#S%(^<,VP' .#C/7!QT-)<:_IUM!!*TDLGGQ>?''!!)+
M(T> =VQ 6 Y'..X'6O-[K2)]'M-,2'79M(\3Z9HEO&TKCS+:]5=_[EE(PQ#
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M6O/[QAXG^&V@Z!9Q20ZY!+9QO;LA62S>%EWNP_A4!6P>^0!G- &WJVMC5/B
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M,,K+P<$<'V- $U%>7^"_'VF:5X7MHM>U2Z>=KVXA:ZG225$/GN$$DN"JG&,
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M)]L9.0#S?0=/M+GX6^&]/U5=4TZXBNYC'=P1O'+8R[I65V^7A2IQD\?,*DU
MZ_/X'BEU1)+]M/\ $5O(+RWM2KW5M'(A\XQJ,^HX'(7(R.:];HH X..X%Q\8
M[6]%O=+;OH+0K+);NJB0SJP4DCY6*@G!P?7FN6\:SW>JZ+XXTYM,OX;M)?\
M1K:SLW5+B,!,3O(HQ(Q (P3P% P2,U[+10!P,=T)_BY97XM[I+5O#[Q>;);N
MH5S,C!22.&*@G!YKEGM[IOAUJFRRO"T/B<WC1BW?>8?M0?>JXR1MYX%>ST4
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MR+&8RF_9C)V9/&,T[2;^/4?B[<7]M;WALYM#BC2X>TE1"PF=L991C@]^N*]
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "JFHZE::39FZO)?+B#*@P"S,S$!54#DD
MD@ "K=<;\1+#4+BPT?4-/MY;HZ5JL%]-;1#+RQ+D,%'=@&R![4 ;5IXEL;K4
M+G3BEQ!J%O#Y[6DT6)&CZ!EQD,,\<$X/!Q7(>'96\:WVJSW5QJ]I<V.LR+;2
MPL\2I%$541$?=.[G<I&3D^@QH/!_;OQ$TC7K..X2QTVQG6::2!X_-:3:%C 8
M G&&8\<<#K2_#GS8X_$23VMW;M-K=W<Q?:+9XM\;,"K#<!D&@#I]1U>UTV6V
M@D\R2ZNF*P6\2[GDP,L0.@ '4D@#(YY%>?:#K%JUAX_FU.\U5--AO&C9F,K3
MVZ>2NX+U9<'=R.!UZ5J>(WN]$^)>D^(9;2ZN=(?3Y+"5K:%IC;2%PX<HH+8.
M ,@=JPP+J?1OB8%TS4E.H&0V@:RD!FW6ZH-HQG.>W4=\4 =C)XOT/1;?1;.2
M6]=KZVWV8,$DKRJL>[E@#N<C'&222/6K \7Z?)81W4$%].7MQ=-!';-YL<9R
M 74XQT.!U.#@'%<D1/\ VS\-9?L-_LL[>5;EOL<N("UN$ ?Y?E^;CFEUECH'
MQ"U&]U;0K_4M*U6" 07%G;M.8)(P5*,J\@'.0?\ Z^ #L8_%6DW-AI]W93F\
M745+6B0*6>4 98@'& .Y. #P>36)JWQ%L;?0K?4=-@N+HRZDFG.GE$&"3S K
MJX[, 3@=SCMS6+=1S^%-?\/^(+7PY<1:(+*XLIK*R@WR68DD$BN8U[G W8S@
MYZ\9N>+VN=4\(VVH6NBW<446L6MX8%MSY[Q+(I:1HP-V>IQC. "?0 '6S^(;
M6"6*W6&ZFO)(?/\ LL<1,JQYQN8'&WGCDY)SC.*HS^//#UOH=MK+7CFRN)Q;
MJZPN=DA;;M?CY"#UW8K$AFN-(^)-YK-W:7G]E:Q80I#,+=V,$D9;Y'4 E-P8
ML,@<\=>*YS4M%OK3POJ,XL+UCJ?BA-2BMHK9W=(1*A+,J@E20I;!P>0.O% '
MH5KXPT^]PEO;W[7#22HML]JT4K"/;O;:^/E&]>?]H#KQ6MIU_!JEA%>6_F"*
M3.T2(488)!RIY!R.AKE/&FGV6K7NE>9)JNGW4<4LMIJUC&^;=ODRC@ C# ]&
MQG:1UK7\&2ZO-X4LWUU NHG>)"(O++C>VURG\)9<,1V)[=* (-'U5_$/B/5R
MCL-/TFX%FBJ<"6<*&D9O4+N50.F=QYXQ)-XTT>W1;B629;!I_L_V_P H_9Q)
MNVX+^F[C=]W/&:Q/ 5G+:-XTTJ5VBN?[;N)U;OLF561_R)_*N?MK.^E^#\_@
M>XTRY&N1QM8K&8'\ISO^6428V[,8;.>Q'7 H [?5?'>BZ1J5SIT_VV2\MX1.
M\,%G([;"V-PP/F'7)' QUK6U;6;+0]'GU6_>1+2!/,D9(F<JOJ0H)_PKDM,M
MYK3XL/N@O'@308;07;6S^6\B2,2-^,9P0>M:WQ%_Y)OXD_[!T_\ Z : $LO'
MV@WVLVNEI+<QS7B%[62:V>.*XP,D1N1AB!Z58U#QEI&F9EN6G6S2<6TEZ(B8
M(Y-VW:S=OF^4GH#P2#7+W,'_  E%KX'@L;>X$FGW5O?7$LD#1B&..,Y4D@<L
M2H '7KT&:R=&AAL(;SPKKWA"\U"^%U,;>;[,9+:[1Y"Z.S_=7&X9STQZ\4 =
MM>^/=$L=3N].?[=)=VAC\Z.&RE<J') ;A>5XY8<<CG)J\GB:QEN(HXX[EXI;
MEK6.X6(F)I5)#+GM@JPR1C(P":P=#26/XJ>(Y&M+I()K.TCBF:V=8G:,/N <
MC'&X=ZQ+:RN['Q):WOAMM2MUN]4(U/1KN!S %+G?<1EAA.F\$'#9 ]J .TOO
M%^E:>MW+*;A[6RD\N[N8H2\<#<9#$>F1G .WOBDOO&.C:?J=MITDL\ES=0&X
M@6"W>02H,?<*C#'D<#/OBN/T9+O1/#/B;PSJ5A>37LD]VUJ4MW=;U)LE2' V
MYRQ# D8[\4NEZ1>:'XI\#V4\-U,-.T::VN+B.!WB20B/"[P,?PG'/:@#L++Q
MAI%_HYU*%Y@@N?L9A>(K*)]VWRBAY#9(_GTK0TW5(=3^TK'%/#);2^3+'/'M
M*MM5OH1AAR"17FUG8V]UI/B:TU?2]6^RW?B22>.2&VF26-"%*3QX7. R]1T'
MZ]1X%768!JMIJ-Y-J%E!.BV-_<0^7+.A0%@W W;3QNQSS0!=U/QKH^E:M)I4
MWVR34$M_M MX+221W3./D 'S<YZ9Q@YQBI=.\8:+JNA1ZQ9W326TDOD*HC;S
M/-SCR]F,[L]OQZ<USMY?P6'QN1[@2;&\.[=R1,X4_:">=H.!QUZ=NXKG+OP]
MJEGIT_B&#2+BZ@/B6356TQ4(E>V:,Q%@G7><E]O7GGF@#OG\<Z+#:ZK-<M=6
M[Z4 U[!);L9(E(RK;5!RI'\0X]ZR/$'Q!MT\(:Y?:/%?&XM+0213/9N(\NA*
M.&(PRC'7I^=9FJ?8-5\%>);O1?#-[:R76G/;+)+8NEQ<.5(5 F"Q4>IXR>.A
MK2\4"6Y^#%S;06=Y)<S:8L"6ZVTAEW[0,%,9'/J* +&DMI^ER6FK&ZU@7%_
MMLNGS.[_ &B4 ,9%1LD-@'+9"XZUJ?\ "9Z,NFZG>RR3Q#2R1?0M YE@XS\R
M $X(Y##@CG-<YJBW=OK_ (.\2):W<VG6EO+:WD:V[^9!YB*!)Y>-V 5P>.!5
M'6],N;U_'>N6UK=&WO\ 1A86L:V[[[F41O\ ,$QNQEE4''//;F@#HY/B1X>B
MLIKR4WR6L2PMYS64HC<2\(5;&",\9SC/>K/_  G6CC4YM-9;];Q(O.BA:RD#
M7"9QF(8R_/I]>G-<WXKCN+KX-65K;V-[)=&.R7[.EI(9 4DC+93;D8"GJ.U:
M-ZSR?%G1[Q+6\-JNE3Q-.+638KNZ,JEMN < ]: +&J^*O#VJ> ]0U*XNM0M]
M.4O;W+01R1W$#J<,I"C<A!XYXY]ZT+SQ;I&E:C:Z5,]VUW/ 9H8TMY)&D50.
MA ^9N1P,GUKSVZMKR7X=?$*T33=1-Q>ZM<R6T7V*7=,KE-K*-O(.#S[5TERT
MDOQ'\*W:6EZ;>+3;B.27[)(%C9_+VACMX)VGK0!T%IXQT6Z\/7.M_:'AM+61
MH;@3Q,DD4BG:49,9W9(&.IR*=#XKTZ37%T22.\@U)HQ,L$ELYS&> ^Y05"YX
MR2.>.M>=W%H9?!/CN.[L-34S:Z]S;!+9TD?+Q>7(@8#>-RYP.2 1W%;GA_6=
M,U+QQ%J-_+?QZM)9_8+=)]*FM(BN?,;E\@L2N>O0<"@#H?&7B<^%M+M[A+2:
MXDN+J*V78F0F]PI)_ G [G'O6!>:U]@^*UM,\FI&VGT&2060$CDR><@&V(9P
MV!V'0$GO6C\2[:YG\+P26UK/<FVU&UN)(X(S(^Q)5+$*.3@<\55$\D_Q;L]1
M%C?I:'0I(3*]I(%#F96"DXP"5!.#R.AP>* .@LO%>DZAH46L032&WED,*HT3
M"7S=VWR]F,[L@C'X].:ETGQ%8ZO>WMC%YT-]9%1<6TZ;'0,,JWH0?4$BO+ET
M_5%\,-?1:-?7/]G>*+C4);%H'CDGMG,@W(& W'#Y %=YX4DTO4+N?4],\/SZ
M>KQ"-[F[MC#+*<YV@-\Q4>IXR1C/- &Y?ZM!I\L<!2:>YE5GCMX$W.RKC<V.
M@ R.21R0.IJE;>+]%O-&CU2"Y9H9)OLZQ^6WFF;.#'LQNWY!XQVSTYKF/& E
MTGQS8Z[=Z/=ZGHTM@;*;[)$TKVT@DWJY0<E2#@X]/IFCJD#Z9)X=\2Z7X:N8
M-+M-1GGN;*"WQ<%98O+\]HASN!R<=<$9QS@ ["/QEIKW&H6SQ7L5UIT N+F"
M2W(9(SG!'9N 3\I/3UJ3_A+M)^RZ+=>9+]GUED2RD\IL.SJ64'^Z2 3SZ5R%
MG.==\?>*#;6]Q%]IT"%(EN(S$S9,H!*MRO)[@&LB"YNI_"GP^LDT?5_/TG4K
M5;X-8R+Y12*16ZCYAWRN0.Y!(% '=VNKZ1'XC\1R03:E->6<,!O;<I(4C7#;
M3&A')(!)*YSQ5VW\5:;=^'K77+?SY;&Z=$A98CN8NVQ?EZ\L0*Q=!69?BEXK
MG>UND@N+>S6&9[=UCD**X<!B,'&X=ZJ^%M"U#2_$M_HTD!70=/NFU#3W[$S
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1110 445DZ'XALO$/]H?8TG7[#=M9S":/8?,55)P#SCYAUQ0!K4444 %%%%
M!1110 4452U;4ETC3)KYK6[NA%C]S:1&25LD#Y5'7KGZ T 7:*** "BF/*D9
MPS?-M+!1RQ ZX'4]1^8K-\/^(+/Q)I\E[8K,L23R6Y$R;&W(VUN/KZT :M%%
M% !15#6M7MM!T>ZU2\69K>VC,DGDQEVV@9)P/:K%E=QW]A;WD081W$2RH&&"
M P!&??F@">BBJ6IZDNF00RM:W=R))TAVVL1D9=QQN([*.I/84 7:*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ KS3Q9XFUO1;/6M0AU,/-8WL0BM;6%9($@+
M1C;.S+D2'<QP&R,J0,9KTNN$O_AJ+VQUW3UUZ\BL-6NS>F!8D/ES%E<G<1DK
ME1\O% '=T5EP:9>Q:Q'>/K%S-;+:>0UJZ(%>3=GS20!\V.,#BM2@ HHHH **
M** "O*O'<">*!K#0I?F\TH*FD206,TJBY1A([!U0KRRK'UX*-ZUZC.LKP.L$
MHBE(PKE=VT^N,\U0T+2GT718=/-U]I:(']^T>UG)))9@#RQ)))XSF@#&@U^'
MQ1\+9M9AP!=:9*SJ/X'",'7\&!'X5RD__)//A;_V$-+_ /11KI]'\#RZ-I.M
M:9#J[-:ZI)-+L:W&+=I?O>7@_=P3@'/.#ZY67P0\F@^'=*&J%4T.>">"3R!F
M0PC:@;YNF#SC&?:@#HM7EO8-%OI=-A6:_2WD:VB;H\@4[0?J<5R?A+Q'_P )
M#=3PV^MW0NX;;;<Z=J-LD=Q:S9'S;0JY7KZCIZUUVI6;:AI5U9+</;O<0M$)
MH_O1E@1N'N,YK)M_#<HUQ=;N[V*?4X[-K.*5+;RQM+!B7&X[CE1W '.!S0!R
M=CXRUIOA=X?UBXG!N;^_2VO+WRU MXFG93)C&T8  !(P,@G-:5KJ&OR>*_$>
MG1:MYMA86L<D,SVZ,5D=22C,H )& W3HPS67K>D1^$/!&C>'7U>\@LEO<G5$
MM0ZP*"T@\Y<,K L0!D =">G-SPS_ &C=2/::?XJ@UC3)89%DD33$B2!B."K1
MX5F/]W\>.X!FZ?XC\3+X>\%>(+G6!,-5O+>TNK3[-&J,LNX;L@;@P(!X('MZ
M]/I^I:I=?$'Q%HLU^1:065O+;>7$@:$R;P3D@Y/RCKD>U1+X!9/#F@Z*NJL(
MM%NHKF"0P#<YC)*AOFQCDYQC/'3OJ6OAR6U\5ZCKZWX:6]MXX&A,/RH$SM(^
M;/5CGU]J .*\)_VCIWP_\4ZC:ZK/Y\%WJ+QB6*-D#I(QWX"@Y..><<GBMK3O
M$>H:F?"6D_:S#<ZEI U"[NE1-YPD?RH""H+,Y)XX .!SD7M/\&2Z?X9U;1!J
MADCU%YW>5H &0S9WXP<=SCT]ZKWGP_$^EZ#':ZQ/9:IH<0AL]0AB4MLVA2KH
M<A@0!GW_ "H ==2>)=)T79?ZU8JW]J!%O"G[UK,GA0H3:TY^Z %P>PS6(WBC
M74T'QX([V03Z(/-M)[FW02[#") K* %Z],C.#R,UT&H>"9+_ $^Q#ZY=_P!J
M6EZM\-0:-"6D"E<&/ 4+M. !C'USFO)\/VD7Q(IUV[<:]$L=SYD2':1&(RPP
M!S@<=AGH>* *=OJVOV?B3P@MWJWVJVUV"59[?[.B+$RP>8K(0-V<@@Y)!SP!
MT$OPXBNC=>*9;C5+NZV:Y<P[9O+(;:L8#$A0<X & 0N.U:DGA&66]\.73:D-
M^A*PB @XEW)Y9W?-_=]._/M5K0_#/]A:KJMU#J$\EMJ%T]V;5E7:DK@;CNQD
M_=&!T'/6@"KJFLW,_C>Q\+V=PUJ7LI+^YG15+[ X147<"!EB23@\#CKD<;I>
MK7?AD^,Y/.:[O)=?M[2.5T4$F58D#$#:N0#GL"1V!KMM?\)_VMK.GZW8ZC+I
MNK62M&DZ1B19(F^\CH>H[CD8-9W_  KBUN;+7[74M4N[M-:E6>7Y4C,4BA=K
MH0.""H/IQT]0"QIR>*?^$BG@GDO/[%FM?EN+K[,+BWG!_A$8*LI'/S X/M7*
M^%7U+2_A5X@U2SU687%M)J,T:RQ1LBLDDC;L!0<G'.21SP*[30O#FI:8#)J7
MB.ZU>XCC,=LUQ"B+$#W*K@NW RQ.<=,9.:ECX)DLO!^I>'!JID@OO/W3- -Z
M><27Q@X_B.../>@"M9>(+[4[WPYHHNVMY[S1QJ5U=(B;VP$4*H(*@EG)/'0<
M8SD5?$U]XK\-> ;V\GU6V>^M[Y%AN(X5+26[S(B[P0%#X8YP,<#%7[_P$;FS
MT-[369['5M&B\BVOX8E):/:%*NAR&! 'X_E5C5?!C:OX5FT6XU>X>2YF2:YO
M'C4R2,K*PP!A5'R*, =!Z\T 0:AK&HZCXFU31-.:^@%A;0NTMFMN7,DNX@GS
MCC: HX Y).363+J_C.&Y\&66H7%M87VH2SP7T:1+*K%(W97!SQD ' [^W%;6
ML^"[B_UV'7M+UVXTC5A +>XE@A5X[A <@-&^1D$G!YQ4UQX/,M]H5TFI2[](
MDDF4RQAVGDD!#LYR.NX\ #&?3 H YIO&&K^'[+Q?;WMXNHW&DW=M!:7,\2IG
M[0J;=X0 $*7SQC(%=;;V'B&UUO)UA+K2Y+4JPN(D$L=QGADV*H*D9R">U9]Q
MX!M=0?Q*NI737%OK_EF>)8]AB:-0J%#D\C:#SGD#Z5;T'PUJ.EA6U'Q%=:M)
M#&8[4W$*(L0QC)"X+MCC<3G&>F3D YC1_&6KS>$]%^TRM<:EJ>JW%EYT4<:L
MJ1O*<JK83.V,*,^N>>AO2WGC;3;'Q XM+B\AC2.33FE$!NCR!*NV/Y6(&2O'
M/0YJ4?#:V;PDFA2:G<;[>\:^M+V)0DMO,69]P['EF_ _C6C!X7U$:7-'>>);
MR[U-S&4OFAC3R@CAPJQJ N"1\V<D]^@  (_!GB"V\0-?3V>M2WT""-3;74*Q
M7%K)\VY74*O7Y<=>AYJ77[N^CURSM8]2-K:2V\A\JTC62[EE!4+A61@(P"<M
MQ@D9.*MZ9X>6RUR]UNXFCFU"\BC@D:&'RDV)DCY<DD_,<DD] .,5!J7A:2\\
M5V_B"TU:XL;A+0V<R1QHXDBW;\#<#M.>_- '&Q>+O$=[X%\&ZK'>PPWFHZK'
M8W1-N&$BF1T)QGC.P9 QU."*T&\4ZGX7U3Q9!JM\VJ6^F:=%J%NSQ)&X+;P8
M_D !&5&"1D9[U:MOAQ]DT+2=)BUN=H-+U$:A 9(5)W!V94.,?+ESGN?4=*TK
MCP9#?:WJU_?70G@U2R%C/;>5M'EC=C#9R#\QY_E0!R_B6'4WC\!7]]JKW#3Z
MU:O+!Y2+&KM&[#9@;@!R.2<@CO7;^++N\L/".KWUA.L-U;6<L\;L@< HA8<'
MCM7/+\/;QK'1[&Y\47DUMH]Y'<VG^CQAP$5@JLQ!W$!L9QT['J.JUO3#K.A7
MNE^>81=P/ \FS<0K J2!QS@F@#A'U?Q/;MX,N_[;61=<5()X'M$\M&: N)%Q
MAMP(Y!.#GH!Q5NRUC7[:[\::0^JV]U/I4,,]G>7Z)$J>;&S8D* #:I7.<=.M
M:LO@V66W\-Q?VGC^PF5H3]G_ -:50H-WS?W3VQSS[5!J?P_BU:?Q(UUJ4@CU
MV&**5(XPIB\K[A4Y/KSGK[4 4]'US4KCQN-$.IWEQ97.C&[2XFMXXW642*A:
M/Y!E2&S\RD9''%8GA/6;_1_AKI5S]MNKNZU357LX_-\LF-GN9=S@D+EB 3\S
M$;L=N*Z^S\'W,/B6RUZZU^[NKR"T:TE!AC194+!N@'R\C)[GUQQ5)/AM9GPM
M<^'I]3O)+,SFXLV7:CV;^89 RL!DD,QY/;CB@"*XN?&&GQ^()6DE&G1:<]S9
MW-ZL#313J"2FV([64CD$CCI6=<:CXLM?A?/XJ;Q$CSR:-#=1P_8H\12; S,#
MW+9&01@'.!C@=%;^$M0.D7MKJ?B.YU*ZN;9[1;B6W1!#$PPVU%P"QX^8D]!]
M#)/X1-QX 'A)]0;R1:K9_:!"-_E* HXSC=@#G]* (-0O]2>^TN$:H;:"XL&D
M\NTC62[FG^7!"LC*(P"<G@9(R<5R=_K=YXB^$OAC5=0*&[GU6S$K(NT,5N=N
M<=L[<UV#^#IO[=L=8@UJXMKF&Q%A/Y4*$31!MPP&SL;/<9JA%\.1!X1L?#R:
MU<&WL[Q;J*1X5+#;(9%7C'&3R3DGVH [2YBDFMI8X9V@D92%E102A]0""#^(
MKRBY\::Y:^";&_GU*8:GI^IO:ZS%%!$Q,<;GS6 V?* A1@?]H=<@UZVNX*-Q
M!;') P"?I7/IX-TL:OKFH.C2'6(1#/$WW0-NU\#L6 7/KM% &9KGB6ZTJRUW
M7+>Y,UE:+#;6T)5#&T[E07W8!*CS$&-V,A_PDM&\60>(X^)Y](DMG\XZB;=6
MAF RI7R>2IZ$'..M7H/!FF)X%7PE/YD]C]F\B1R<.YZE\]FW?-]:IZ7X+NX+
M*2SUCQ+?ZO;B![>!)42,Q*RE22RC+OM) 9CW/% &+IOB76$\1>%+:;4S?QZH
M+B.]9(5%MYB1EP8'VJS $$9RP([YK.\.ZRZ^)O$?ARSO#8ZA?^(+F9+EHP5$
M:)#O5-P*LY'\/898] #T-I\/9K?_ (1\R>([V5M#++:GR(E'E%/+VD8Z[<#<
M<].,'FDN/AO'<V6I0R:HZSWFI?VI%=1PA9+6?Y1F,YX&% YSU/6@!VK7FO1^
M/]*T*UUDQ6EUI\\KNUM&T@9"@W XQGYO3'L:R['QCJ]MH$]M=3F\U!/$3Z)%
M="-%=USD/MX3?MR!T&<9SWZ<^&;J7Q+IVN3ZHLEQ96SVP46P59%<@L3\W!^4
M=./:LY_AS;7.C:OIMWJ$SC4-0;4TGA3RY+:X)!W(<G@8&,\]>: (GN/&]C_;
MK0VTUY;"R,NGF[\@3BX'6/$1PRD<C/<8JOIGBJYU;2=<N= U*XU"_MK/Y-+O
MX$BN;>X&[(90JY!^7'49!YYK9M/"FI+IUQ'J'B>]O;]XQ%#>&&.,P*&#?*BC
M!)*C);.<"EE\(/=7]YJ<^H[-4GLULTNK6 1^6@??NP2V6SCDG''3KD YZW\?
M01Z#KNLVVJW%XVGV8,FF:A"L-Q;3Y(^<*J_*<KZ@8.#6S:MXMB\16# 7-QI4
ML3K>B]^S)Y;XRC1>4<X)X(.>,58E\%VNI7M]>:U)'=SWEA_9TABA\D&$G<<_
M,26SCG/&!@"H_#_@Z]T<117OB6_U2TM5*V<$\:+Y7!4%F4;I" 2!DX]NF #*
M\(^*KC5M7M;#4=2N;/6HD<W^CWEND>3C[T)"Y9 >GS'(Y/OK?$C5=2T/P+J&
MIZ5=+;W5OY9#F,/D%U4C!XZ-Z5+:>$I!?:-=:GJ/VZ71U=;67R!'(Q9-A,C9
M.[Y<\ +SR<U;\6>'AXJ\.7.C/=M:Q7!7S)$0,V%8-QG@<@>M &+JM]KDOQ)M
M]"M-6%K8W&E2W!VVZ,Z.LB+D%L\\]\CGH:M^ M6U#5=%O4U.X%S=6&HW-BUP
M$"&41O@,5' ./2K3^')Y/%MMXA;4%\^"S:S\H0?(RLP9C][.<J/P_.I/#/AU
MO#D.H1_;#<B\O9;UB8]A5Y#E@.>F>G?W- '/K#=O\:[A/[4O!"FBQS+#^[*#
M,Q!0 IP#M!)^][XP!R5I?ZUH7P_UK7].U/R4L=;N6-IY",LZFYVL'9@2.#QM
MQCW[>E77ADS>+XO$5OJ,UM,+06DL*HK)*@<NN<\CDG..H].M8[_#SS?!^I>&
MWU9_L]_=-<R3" ;U+2>8P'.,;@.W3/X $FH:QJFJ>(M8T?3'O8#IT,.)+1;<
MDRR*6!;SC]T +P!_>R>E;_AR76)O#UD^OP10:KLQ<I"P9=P)&01QR #[9K$U
M7P3<W>O1Z[I>OW.D:HT"P7<D$*/'<HO3,;Y (YP><5TVGV2:?8Q6J222[ 2T
MDK9=V)RS,?4DD^G- 'G&LZG?^*_AOXNU:+49+6TCCO((+9(T*M%$K*Q<E2VY
ML-T(QD>ASH6.LWL\FE>'['[9'Y6AV]W))9B#S"7^11^^.W V$G )R1T[V)?A
MVR6^NV&GZ[<6>E:R)6FL_(1Q')(I#%&/(4]U_(BGWOP_=SI-WIFOWNGZMIMJ
M+-;Y8XW,T(_@D0@*0#R/ZT 9]UK_ (JT/P]IEQXCM[F-$N98]0N]/B2618@#
MY<A0!@ ?XL XQQUI=4\1ZA#X0T/4]+U^&^CNM7B@>Z2%#YT$DY4*> %8+A3@
M Y!Z5TJ>'KVV%E):ZU-]JA\PSRW,0D%T7VY+J"N,;1C;C& .G!S)_A] VAP:
M9;WIMPFI?VI(ZPC#S;]^ N<*F>,>@'/4D +_ %F^F\9ZCHK:B=)MK;3%NK>8
M*A,S$L'<EP1M3"\#U.>U<\GB3Q:_@_P=J<M]';WFKZG!!/&]H,".3=@8SG'R
M@\8.&ZBF^);N&;QO>+=^)Y- E@BAAA6[L(YH;C@L9(O,4@<MM.#G*\]!6Y!H
M6J^)=,T]M2UCS/[.U-+VUNOL/DM<A%&TNA/RC+..,9 !&,T 6?#FH:M%XVUW
M0-1U%M0AMX+>ZMY7A2-T$F\,AV  C*\<9^M6=>UNXC\5Z'X<M)C;OJ"S32W"
MJI98XU!VJ&!&22.2#@ ]R"+-GX=>U\77WB WN][R".!X/*PJJA)4@YSGYCG^
ME+K_ (:CUJ[TW4(KE[/4]-D:2UN44-@,,.C*?O*PZC(/H10!R>H^)==TIO&.
MCF^$ESI>F_VE8WKPH6,95CL=0 I(9< XY':NF\)1ZU+80ZEJNL"\2]M()$MQ
M;+&(&*Y8AARV<CKZ<8S@1W7@\7MEK8N+W-_K,'V:YNEAP$B"E0D:Y^4 ,QY)
MY))SP!M:18/I>CVE@\_G_9HEA$FS:6"C )&>N!0!=HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHKF?&>O3Z-!I-M:N(KC5=2AL%F*@^4'R68 \$X4@9X
MR1UZ4 =-17$S:AJNC^/+30&U":XLM6LII+>65$,EM-%@M@@ %2"."#@^W%<>
MOB#Q?#\+M.\>'7S/)!MDN; VT8CGC,NQ@2!D-SG((  QCN0#V:BN!NM5USQ!
M=^(;;1I+NWETZ86UJ83"%\WRE?=(),D@L^,#C ]>E>[N_%=UXIT+1I=7&FRW
MVDS27:VT4<@BG38"R%AZD\'/'OS0!Z-36D1'1&=0SG"@GECC/'X5YKXGU77=
M'TW7G37I+B[TRQBDMUM(4^0K'EY+@%=H+L#A0?N]!4UZ;O4/B7X3F_M&[@6X
MTJ>8Q1%-BG]V3@,IZYY)R?0B@#N;343=:C?6ALKN$6C(HGECVQS[ESF,Y^8#
MH>G-7:\WNO&&I:#)\0;FZG-[%HHMS9Q.BJ%,D0;!V@9&YAR><"K>LZGJ_AC_
M (1O4CJ<M_!?WD-E>P2(@4^:.)(]J@KANV2"#Z\T =[17EL^H>);FP\=3)XD
MN(3H<\C6GEV\62$A60*^5.5^@!]^U>AZ'>R:GX?TV_E 62ZM8IG"] 60$X_.
M@"_5#4]7M]+-K'(KRW%W+Y-O!'C?*^TL0,D 852220.*X6'7M9USX>ZAXQT_
M4WMIX3<SVUIY:&+RH78>6X(R2P0Y.006XP!4.KSRZ_XE^'&J1WEW:+J"S3K&
M@C/DEK4MQN0Y/.#G(],4 =[HVL+K-@]T+*\M'CD>*2"[BV2*RG!Z$@CT()!]
M:FTG4#JFEP7IL[JS,JD_9[N/9*G)&&7)QTJ::.1K1XXYVCE*8$VT$@^N",9_
M"O+;?Q/XBN?AWX)U5-5*7NI:G!;73M C+*KR,#D8&/NC[I'% 'K%-CD25 \;
MJZ'HRG(->?I=:Q!KWBGP_<:Y>7,4>F1WMO<LL:30LV\,H*J!CY1CC(_6L_PY
MJM]IG@?P1I\%S=33:Q&J[OW6Z)%A+E4+ #)( RV3@GOB@#U*BO,]=O/&6A>$
M_%=W)>R0PVT:SZ9/+Y,DZC'SHX *D ]#UQUJ3Q%+XGT/3M.OH_$TDKZAJEE"
M8GM(]D:N0'48&XJ3[YQW[T >D45PEG?ZSIOC36]$EUC[;&-)34+>6^1$$$A9
MT()15^3*@^H%5-(U_5(_%GABR?4;B^MM3L9VN99(E6*66-4;?#\JMMRQ[;2"
M",]: .OT+Q%:^('U);:&XB;3[MK243H%)<*K$@9/'S#KBM>N*\ _\A3QI_V'
MI/\ T5%5V]U2XOO'8\-0W4EI%%IOVZ62';YDA:0HJ@L#@#!)P,DE>>N0#J**
MX.;5->TJX\->&M1U**74=3NKA)+^&, B&)2XX(VB0@H"<8ZX'0U#=ZUK.E>(
M=?\ #O\ :,DH31FU6PNWC0R0[6*-&W&&&X @D9QGK0!Z%31(C2-&'4NH!90>
M0#TS^1KS&RUCQ!;6/@+6+C6Y;E=9>"VN[5H8UC(DA9]XPNX,"N2<X.>@'%/T
M6/4(=7^(4\6LWHEMKC,9<1N,_9U89!3MT &!CM0!Z;03@9KRN'7_ !!IG@'2
M_$UUKC75QJMO:6T=O);H(H9964>=D $X4DD'@GT& .@OM1U/PWXUT"Q:_GO]
M.U@RP2+<*F^&5$WJZE5'!P00>!U&* -W0/$5KXBCOWM8;B+[#>/92K.@4^8@
M4G !/'S5KUQ7PZ_UGB__ +&2[_\ 08ZLW6K7.I>/W\-0W4MI!;:<+R:2$+YD
MC,^U5!8'"@ DXY)(]#D ZRBO,7UCQ5>>'/%=A9ZBXUOP_<D0W*0QG[7%M#JK
M*5(WE<CY0.<5T-MXA&JI9ZK87DQTV#3/MUP@"'S2PRBD[>" LA.,8.WUH ZV
MBO/--OO%VK67A[7+!I2ET8IKV&=X1;FW<981X^<,N1C)R<'-/\//XBUGQ'K<
M<OB.9+;2M7$:Q+;1?OHO+5C&QQP/FX(YZ]>, '<7]];:9I]Q?7DJQ6UO&TLL
MC=%4#)-8*>,=VL6^FMX>UQ9+@H4F^SJT0C;/SLZL0H!&"#R,CBJ'Q9B>3X9:
MXR7$L02W+,J;<2#(X.0>/I@U'K]WJNAMX1CMM6N)([S5(K6X$L<1,D;(S8R%
M&,;1TQ0!W-%>=M/X@U+Q1XSTR/Q%<6MOIT5M):F*"+>A>-VQDJ05R.>,G Y'
M.7Z?X@U/5_#GA"^GU%;?[?;,]W#;)FYN9-@P(EVD!<Y9CQCCD#- 'H-%>32>
M*?$3?#?^T$U%XK^VUK[ TCPQEI(_M CPX QG!Y*XZ=:VGUO5/#?C/5;.]U*?
M4[%-"DU8)+'&C1O&^TJFU1\I'8Y/'4T =_5*SU$WEY?6YLKN 6D@C$LT>U)L
MJ#NC.?F SC/'(KF]'3Q!J5AX=UV+6D*72)/?VTD:^4T<B;@L6!D%20 2>>^:
MH6NM:V?^$[A.KVR2Z;,J6=Q>JJ16X,*OEMHZ D\G- '?NVQ&;!.!G &2:RO#
MOB"U\2Z:]]:13Q1I/);E9U"MN1BK< GN*YK0=:OS\0CH[75[<:=+HXO4:]B5
M',@E"%E  8*0>C <CCBIOA?_ ,BW?_\ 87O?_1S4 =K17 ZM+X@O_B/<>'[+
MQ!+86CZ,+M&2WC=HI/.V<9'(P.^>^,9R()-3\2^(+;6CHD]S'=Z?>R6=LRF
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M10W$JJKM&T:N VT $C)YP*DU^YOO^$@ALXM3DA@>R=DM;%0UT\VX .=RE5C
M[D@;C@YH ZJBO*H_%/B+4/!?@/4X]3%O=:K?Q6EV5@0K("),M@C@_NP<# YK
M9^UZS;Z]'X5;4K^_EAL3>RW<*P132!Y65!\WR@*!S@9)(Z<@@'>45A^$_P"W
MET01>(S&U_'*Z"1"N9(\_(S!> V#R!QQ7-V[^(M7\>>)-+C\1S6MIISV4L(2
MVB8X=69D.1]TX(SUZ<\$$ ] HKS:#5_%?B/08M=T$S+.UTYB@E>$6K0K*4*-
MU?.U3D]=W3 I/&FO:SI=KXEO+356,^GI'+:V]G&KI H4%OM!9<98Y^4'.W!
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !61XC\.V?B;2Q97;2QE)4G@GA.)()4.5=2<\C^IK7HH
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M(MN;/?)/OTXJUX:\06_B?14U2U@G@B>62,1S@!P4<H<X)'53WK7H Y#P_P"
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MQIK=PT<UDMG.D\*2!P-WS@8 #'>1_=P!QQ40\#V=G=:5>:/<RV%WIMF+&.0
M2"6W&,)(#][!&000<UU-% ')ZAX#M-0\/7FDF^N(S?70O+NY55,DT@96!Y&
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M>6<10[%X4,-Q)QA>K#DGE[SQ)KZ_#'Q->1ZE=6][I6L26D,CK&TGE"6-0KD
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MDV$([_ZJ0D*#C=\IYQR*LCX?:>?"FI>'I+Z^EM;ZX:Y:1F021R&0294A0/O
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MMN<2$EQE57@EC]*K^'? \7A^2('6M5U"UM@5M+:\F#1P#&., %L D#.< \4
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M5 XSQQ6IHVF'2-+AL3>7-YY2A1-<%=Y   'R@ 8 '0>YR230!QFEV$A^,7B
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MB5T.19+9B8R6*KL ;Y,8"G&!CUZ\UTUY;_:[*:V\UXO-0IYB8W+D8R,@C]*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^5 YVR%]A#C&4P>H.#G@<F@#JZ*R[CQ!I]K#%)*;G=(AD6%+25I=HZL8PN\
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MH?XGV*=HX/)QT/H:@N?&/A^TN8+>74XC+<0?:(5C#/YD?'*[0<YR, <G/&:
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MX^*6MF*.1DFT*.".380CR!Y"5#8P3AAQFN869I/A7X.LFLKT3V.HV(N(GM)
MR^6^9."N2% Y/3GK0!Z3;>,-&N[5)X)IV,D[V\<)MI!*\B<L A7=P.2<8'>J
M.MZ[;:MX&\0W6DW\T5Q96LX8H&BF@E1"V&# %3P.W(JAXB,^F_$30/$,J22Z
M/]DFLY944L+9W*LKL!T5MH7=T'>LN[L)9#\1M<@CE^Q:EIZV]J!&V;B1(&4L
MJXR02P4''.#CB@#M_"LTMQX/T2::1Y)9+"!W=V)9F,:DDD]234=_XLTC33<F
MXGE\NT8+=31P/)' 2 <.R@@<$$^@()P*/!Q_XHO0U*LKI80(ZLI5E8( 00>0
M017&:)*VB:1XLT#6K>=KR:\NYK<"%G^W1S9*E"!\QY(([=Z .XE\2Z5#K%CI
M37#F[OT,EJ%A=DE4#)(<#;P.>O<5(^NZ=$U\LDSI]A*K.S1. &8 JH.,,3E<
M!<GD>HKA+_PUJ>C_  P\/7$:--KGAI(KI43DN%&)801U!0LO'7:*N>*]+U3_
M (06&\@LYKG4(]0AU2\M(6(DE <,T:D<Y5<*,<_(,<T =(GC#1C)?123S036
M,0GN(9[>1)%B/1PI7++[C..]+HGB_1?$-P(-,N9)F-LET&,#JK1MT(8@ GL1
MG(.1V-<K;WF@ZQ8ZIJ^E:5J'G+IDMO)>7L4PD7(R(%\S)8YR2%R ?K70_#WY
M?A[H$+1O')#8Q12QNA1D=5 8$'D'- %#QCXB:QU_P]HP^VI#?7+_ &IK>&4L
MT:Q,P5&09R6"YVG( [ TGAY=,TCQ%J%H/$>MW]U%;>:UI>M(ZP0ER5QE<LV2
M1G); P>E,\82A/'?@N39*T=O<W#S.D;,L2M"R@L0, $D#FDAF6/XQ:A<NLBV
M_P#8D47G&-MA=978J&Q@D @XH T;;XA^&;P6#P7TCPW\ODP3_9I1&9"2H1GV
MX5B1P"0>GK5O4O%^BZ3+>1W5Q)_H01KMXX'=;</]W>5! R.?8<GBO,K:.5/@
MIX>M&M;D746J1.\'D/YB!;HN25QD +SGT-7?&%Y-J5OXXT\Z?>0S&V!M8K.S
M;%ZOE#]])*J_-C[H4D  8P30!Z#?^+M$TW4X].N;I_M<L)GCBC@>0R(,?=V@
M[CR.!D^U/LO%>C7^AOK$-YBS20Q.9(V1TD#;2A0C=NW8&W&22,=:Y"VN!/X^
M\)70@N4A31IHW>2!T",QCVALCY2=IP#7/O#J(T75[^QL;FX;3_&3:J]JL3![
MBV!'* CYO48_NT >EKXHTB[&I6QN9X)[*(/<QO"\<L:,.'"D9(]QFJ^DZ[H]
MCX:T4PZE=WT-X@CLI)PTMQ=<$Y(QDG ))(&!UQ4%MK^FZ[9:AJ5AI\ZQ?8V2
M2\GM&A=SSB-0RAGQDYQQDC&<G''Z1?SZ9X0\ V\UC<0Q!'BNKU+%I9[)Q'@(
MJ[24+DE2V.F?7( .C\8^((M2^&.O:GHFH7,$MI'*IDBW12Q2H<,C @,I!^E=
MA8N3IEM([$DPJS,>2?E%>0A)E^''Q#T\66HK/-J-T\"302%Y X39@D98G!Z9
M([XKUO2I4DT>SD4G;Y"=1C''.0>E &/9^//#M_J$=C;7DDD[W$EMC[-( LB#
M+*Q*X7H>N,X..E6(_%^C27UI:?:)$:\#&UDD@=8[C R=CD;6XY&#R.1FN3\+
MVD^H>&?'6GVZR075[J6H&W:2-H]PD&$<$@9!]1Z56\*7FDZO%HVGW?A_51KV
MG-'YL-XL_E6KH #*'8E,<';CDY QCF@#H[CXF^$[:-Y9-2?RHYS;RR"UE*Q.
M#@[SM^09XR<9P<=#6[>:Y86<L,)D>:>:,RQPVT;2NR#&6PH/R\CGIR!7FFDW
M=G)X2\?Z4T33WESK&IQ16JQDM.SL57;QSSC)_AQDXJ[H=E>>"_%VG-K)=K&;
M0+:P%X%+1Q3P_>1B/NALD@G@]* .OF\;>'H-#BUE]0'V"27R1((W.V3=MVL,
M94YX.[&.]95[\2=+CN]/M[*&]N#<WYLY'^Q2@1E5W-@;<L2,8QGKGH*X[6M+
MN(/"/B6Z%M<>5JWB&&[M;986+M&LL>Z38!D;MK-R.F/6NN\=.5O_  AJ:PSS
M6EMJ@>9X(6E**T3J"54$XR0.G>@#5BU/2F\87874K\WL6GJ\MBRR"%(]Q(D"
M%?ODG'&3QC%0V_Q$\,W:V$D%](\-]-Y$,_V:41^9N*A6?;A6)' )!Z'H:S8+
MA1\8;J\>.:.W.@11F1XF"AQ,[E,XQN"D'%<A DJ?!+1K,VMR+N/5(W>#R'\Q
M0+LN25QD#;SGTH ]5U#Q'INFW$\$TDCRV\'VB=(86D,4?/S-M!QT.!U.#@<5
M/I.KV.N6"WVG3^?;/]V38RAN <C(&1SUKSS7-7M-!\>ZU,L]Q;KJ6G6ZS2/I
M\US&S#>$=#&.,*3D'&2>V#70>&=7T#1O">@V.E3W=]9M*NGQ2I Y99,')D&
M4Z'.0,9]* .QHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,SQ%I3Z[X>O])2X%N+
MR!X'E,>_:K @X&1S@U-I-E)IND6EC),LS6T*Q>8J;-P48!QD]AZU=HH ****
M ,+2/#]S8ZE/?ZCK-SJDQ+K;>=&B+;QLP8J H&3PO)[*,8YSNT44 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5@:YX>NM2U*SU/3]9GTZ]M8W
MB4B-98W1RI8,C=\JO((/%;]% &7INE3VLWVK4+][^]V&,2M&L:HI()"JO3)
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY8_B<G\:LUR>O>#KS5[/2H+;Q+J5D]E=?:99E;+W/.2&P0!ST &T=-N,5UE
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%9D_
MB30K:X>WGUK3HIT^]')=(K+]03D5=MKJWO8%GM9XIX6^[)$X93]"* )J***
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV X[_P#UN7T71K2?XC:MK.GW@FT[9'*8HR&B%ZR%6=2/XO*VY_ZZ5U,)U?\
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M !5 &U16+_PF/A?_ *&31_\ P.B_^*H_X3'PO_T,FC_^!T7_ ,50!M45B_\
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M\)CX7_Z&31__  .B_P#BJ/\ A,?"_P#T,FC_ /@=%_\ %4 ;5%8O_"8^%_\
MH9-'_P# Z+_XJC_A,?"__0R:/_X'1?\ Q5 &U16+_P )CX7_ .ADT?\ \#HO
M_BJ/^$Q\+_\ 0R:/_P"!T7_Q5 &U16+_ ,)CX7_Z&31__ Z+_P"*H_X3'PO_
M -#)H_\ X'1?_%4 ;5%8O_"8^%_^ADT?_P #HO\ XJC_ (3'PO\ ]#)H_P#X
M'1?_ !5 &U156QU*QU2 SZ?>V]W"&VF2WE610WID$C/(_.K5 !1110 4444
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M7;:3'JLU_ FGR()%N2W[LJ1D'=TP?6JJ^+O#[",C5[3$K*J'S.&+'  /N2*
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MX/O5IF"*68X4#)- "T53TO5++6M,@U'3IQ/:3KNBD (W#..A /:KE !1102
M"2< =Z "BL=?%>@O(BKJEOM=_+27=^Z9LXVB3[I.>, UIW-S!9VTES<RI%#$
MI9Y'. H'<F@"6BL2'Q=H<[W,:7C>?;2+%+;M!(LP9@2H$97><@$C .0">U&B
M^+M!\17,UMI.HQW,\*!Y8U5E:,$D?,"!@Y!X/(]* -NBBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3WKI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA;;@G]SY.7SAERVXYZ=.12:AXLUN[AU:?P_;^=)I]T]M%;-922"Y:,@.#("
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %<EXETYK;Q7H'BA 3%8^;;7F!RL,J\/]%<*3Z D
M]JZVB@#E=4\-W^H^.-&\107=JL&FQ31K R,3*)5 )W \8P,<&M'Q9HT_B'PM
MJ&CV\\<#7D)A,LBE@@/4X&,FMA55$5$4*JC  & !2T <IXC\,7^O^!5\/_:[
M:&=A"))_+9E_=NK<+G/.P=^,U*WA_46\=0^(S<6NU-.-B;?:V22X<MN^HQC'
M2NE)P"3GCT&:PHO&6ASSW,$-Q<2RVS^7.D=E,QB;T;"<'ZT <T?AQ>R>'Y;0
MZM'!J,6K/J]C>0Q'$4K,6VLI/S+\Q'7G\.=U=%U^[T+48-6U2TFO[NV:W3R(
M&C@A4@@D*6)9CG))(Z #'.;Z^)M*DM=.N8IY)8-0N/LUN\<+D%_F!!X^7!5A
MDXZ5KT >7:MIE]HM]\--)2XMGNK*62!9&0A) EL1R,Y&0,=\$]^E;6L>!9]=
MLM?DN;](-3U:&*W62)"R011MN5.<%@Q+;CQD'&.*ZRYTO3[R=)[JQMIYH_N2
M2PJS+]"1Q5N@#C[/PQK<?C"#Q%=:I8O*---C+!#:LB8W[QL)8D<]2<^P':]X
M-\/W7AK2)K&ZN8;@O=2W"O$A7'F.7(()/0FNBHH Y+6_#.JZAXTTGQ!:7MG$
M--BFC2&6)G\SS  22&&,8J_]B\1R7+SRZC8+L@9;>*.!PGFG'SOELL  <*,=
M3[8T;+5;6_O+ZU@,AELI!%-OB91N*AA@D8;@]15QV"(SG.%&3@9/Y4 <8?!=
MY:ZSH^L:7>P6]_;1-%J+O&S?;U8[FW8(P=V6![$^G%,7PAX@TKQ!J-SX?UZW
MM=,U.<W-S;7%KYK0RM]]XCD#+8SAL@'L:Z;1=<L/$%@;W396EMQ*\6YHV0[E
M.&&& /45)J.K6.DQQO>W"Q^:^R) "SR-_=10"S'V - '+WW@_5[/Q,=<\,ZO
M!:RW%M';7L-]"TZ3!.$DX8'>!QUYJQK'A74;B;0+^PU.(ZGI,LK^9>1%DG$J
ME9,A2,=<@#@=*V['7]-U"\:SAF=+M4WFWN(7AD*]-P5P"1GN!BDU;7[#1@1<
MM*\@B:8Q00M*XC7&Y]J@G R.: .7'@*^GLO%UK>:O%(OB 9W);%3$_EA,_>Y
M''W>N/XC5F_\+:SJ%KX<6XU&R,^DWD=V[+ RK(40H% W$@88G))Y[8XJ[/X^
M\.06*7QO7DLF$9:YB@=XXA( 4WD#Y<@C@],C.,BMG2M4MM9TN#4;,R&WG7<A
MDC9&QG'*L 1TH R/$WA.'Q'J&CWC3-#)I\[,^W_EM"RD/$?9L+GV!J#Q5X7O
M]4U/3M:T/4TT_6+ /&KRQ>9%-$^-R.N0<9 ((Z?J.JHH SM&L[^UM&.J7JW=
M[*VZ1XX_+C7C 5%)) 'N2223[#-U#PS)_P ).GB72+B.WU$P?9KF.52T5U%G
M(#8.58'HPSZ$$5T=% '-GPY<:IK]CJ^N30/_ &?N:SL[<'RXY&&#(S'EVQP.
M !SU/--M/#^HVOCC4O$!N;5X;RVCMQ!L8,@C+$'=GG.XY&*Z:B@#D=%\+ZGI
M6G>(+9[RTE?5;NXNT<1LHB:4 ;2,G<!CKQ6:_P /M1B\/>&XK'5H;?6_#P*6
MMWY):.5"H5E=,YPP Z'M7?DA5)/0<UGZ-KNGZ_!<3Z=*TD=O</;2%HV0B1<;
MAA@#QF@# U7P?J&O^''M]4UD+K GCNK>[M8=D=K+&<IL0DY R<Y.3N/3@!Z:
M#XEO=#U"VUG6;.>[N;1[2+[/;M'$@<8+L-Q+-T] .@ZFM34/%>C:7J<>FWES
M(EY(I>.$6\CLZCJ5VJ<@=\5;TO6-.UNU-SIEY#=0ABC-&V=K#JI'4'V/- '-
M75CXBT'P7HVG:3?VGV^Q\FW.;<L+I$3;L S\I. 2W8 GBNPE\WRF\G9YF/EW
MYQGWQ575=5M=%L&O;PR"%71#Y<32'+,%'"@GJ15V@#F/ OAJ\\):!_95U=P7
M06:2598XRGWV+$$$GH3ZU(WA^]/Q!7Q(+FW^SC3S8&W*'<1YF_=NSC.>,8KH
MZAN[J*QLI[N?=Y4$;2OM4L=JC)P!R3@=!0!SL?AS48?%VLZVEU:E;^TCMDA9
M&S'LW88G/.=QR,"LB/P%J47@[P[H*ZA:%M&O8;KSC$V)1$VY5VYXSG!.3TKN
M+*[BO[&WO("QAN(UE3>I4[6&1D'D'!Z&IZ .)'A'7M,\1ZC?^'];MK2RU603
M7EM<6QE,4N &DB.X<G ^]D?7I5^Z\,W<OBW0M6BNX_L^E6\MOY<H9I)1(%!8
MMGJ-H[<\UTKN(XV=L[5!)P"3^0Y-4-&UG3_$>E"_TZ0SVDC/&&>,KDJQ5N&
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %>5>'[[6++Q'\0I-)TJ.^D6_W*&N!'\XB&!C!S7J
MAS@XQGMFN9\->%[S0M;US4)M1@N4U:Y%PT:6QC,9 P #O.1C':@"'Q%JU_H5
MWX9BL1;1VVI:FMM<HT1W?.'=BIS@9(.>#UK-DUKQ3>Z_XMTRSO=.MTTE()()
M6M&<G?&S[2-_L 6SVX7GC>\3>';G7KK19H;Z*V&F7RWNUX#)YC*K+MR&&!AC
MZU7@\+7UOKOB34UU&W/]LQQ((S;']SY:% <[_FX//2@"C:^*-3U3P]X8U,/;
M6-MJ5N9+R88:19-@*I$AR6+-GL2 O3G-9#^.M>;P!%K$/V/[9'JW]GS>9 RB
M5?/\L,!G*$C&<@]^*T;'P#J>EIX::SUV 3Z+;R6F9;,LDL;XY"^8-KC;US^'
M8Q?\*YOQX<N=&&O1M')JO]HI))9Y*_O?-VG#C)+=3P,= * +2^)M5T3Q9JFG
M:W<6UW:0Z.VK(]O;F)HPCE63!9MW&"#5S3;SQ1?PZ#JT364MG?JLMY:E=OV>
M-TW*4;JS#@'/![ 5)<^$Y;[Q=)K-W>026TVE-IDUH("-R,VYCOW\<\8QTJKX
M:\(ZWH4=MIMQXD-WHMD1]E@^S!)BJG*(\F>57CH!G [<4 167B/Q!<?\)E#'
M'8W%YI,XBLE(,,;9B5QO)8_WN>1T[4[0O$UW<^.'T-[R._M'TL7T=R(#'\XD
MV,%/1T.001GZFHKWX?W-_9>*[:76$0:_(DH:*V(,#*% !RYW*0@R.,Y-7+3P
MKK$?BVV\0W>MV\MPFGFRFBBLMB,-X<%<N2O(YSG/.,=@"#X7?\BQ>?\ 86O?
M_1[5GZ?*]_\ 'K6%NSN73=*B6R1NBB0J78#U)XSZ<5TOA#P[<>&=,N+*>]CN
M_-NI;D.D)CP9&+$8+-GDTFK>&/M7B"U\0Z;<K9ZM;Q&W9VCWQSPDY\N1<@\'
MD$$$'UZ4 <W\6I)+"W\,:M9Y74+;6X(X67JRR!@Z?1@!D>U2+#J+?&RZ"W\:
M@:)&P!M\XC-P_P OWNO^U^E;TGANXU;6;'4==N89UT]S+:6D$96-9<8\QB22
MS 9QT R>IYI$\.7J>/)O$G]H0&.2Q6R^S?9SD*KEP=^_KDGM0!SO@>#4QJ/C
M,K?6[,FK2)A[7*LXACP<!A@#CCVZU+H?C74=5\.>$=_D)JOB!I,R;/W<21AF
M<A<\G   SU.3G&#M:%X:U#19]=F.I6TQU2Z:[ ^RLOE.5"X^^=PPH]*Q4^&U
MQ#X0T/2[?6O)U30Y3+8ZA';X SG*NA8Y!!P>?3Z$ OWVN:]X<L+YM32VN2]]
M!:Z7,BX:42L%S(@QRI)Z$;L=NM1IJOBN#4-2B:V\S3UL&N+>^N;8)Y<Z]8V1
M7&Y2.01C'3FK%]X-NM>\-W=AKNL--?W!C=+JUB\I;9XSN0QKD]&R22<G/;C$
MEAH'B,V%S'K/B*&^N6MV@@9+/RHUW#!=U#?,WX@#GUH C\#7_B+6]*T_6M4N
MK$V=[8)(+>& JZ2G!W;B<$$9XP,<#G&3U4[2);R-"@DE"DHA; 9L<#/:N,FT
M7Q!X=^'MAI&C:Q$-1L0D4,HLMWVA5!Q&4+':3QEL\ $\=1UFHV7]I:1=V#RO
M#]I@>$R1GYDW*1D>XS0!Q.G>+-6'B3PYIUU=6URVJPSB[2&$^7;31H'VQR X
M< Y4C)/'45G3^+/%O_"->*-7CNM,0Z#J,\(C^R,1<)%M^7[_ ,G!//S')[8Y
MUK+P)K$$WAB6;Q!;LV@J\,0BL-BR1-'Y?.7/SX'7I_L^KSX#O6\-^)M';5[?
M_B>W<URTHM#^Y\T ,H'F<XP,'(H O_\ "07.K^)TT/3I5M1'IZ7US.4#L/,.
M$10>.Q))!XP!UR,_X7"==-\0K=.CW \07@D:-=JLVX9(!)P/;-3R^#=2M]=L
M==TK5K>#4([);&\6:U+PW,:G*G:'!5@?]KVK1\)>&[KPW'JB7&H)>?;K^6]^
M6#R]AD.2/O'/0>E '.^)II+?XQ^%9([:6Y86%Y^[B*AC]W^\P'ZUERVGB'PA
MIGCOQHD5M8W-\Z3P6,H\X(D8(+-M8#>V[/!(&.]=AJ/A>]O?'.F>(TU&"-+"
M&2%;9K8L7#]26WC!X&.*O>+="E\3>%[[1HKI+7[9'Y;3-$9-JGK@9'/XT <S
MXAUGQ;X?\+W.LRWNF2[Y[411+:MF-)'5&7._D@L,-CL>!G NW^K>(9?B&_AR
MRNK&"V?2OMB3/;,[QMYH3D;P&]ONCGOCFYXD\,7GB'PC'HAU&""7="TDXMBP
M;RW5QA=XQDJ.YI__  CE[_PG \2?;[?C3OL'V?[.?[^_=NW^O;'2@#!TGQOJ
M5WH&D0SBV_MB^U.;33*$/E#RB^Z3;G^ZG SU/I6K>W?BG2=*\2W$TEC+'96Y
MN-.N7C):0",LZR(I&,$8!!'!Z<5EGX;7!\.+8#6A%J%MJ;ZG97T-MM\F5F+$
M%2QW+\Q&,BMK_A'M9O/#^I6FJ:U#<7]];-;><EKLAA0@CY8]V2>222W.!T H
M Q)?%'B*0^!H[.2P#Z]:L\YFA8[)!;^9N&&Z9.=O&<8R,Y"6?B;Q3;3^)]"N
MTT^\UG3(([FSN<>1#-&^>7!;Y=N#GGG'7O5/6-.N]'U[X::3'?6[75G]H@29
MXB%<);;>5W9&0,=>"?PK:U?P$^MZ?KOVG41%J>K"%3/%%\D*1,&1 I/S#.=V
M3SN/3@4 /T'Q+=77C>ZT)KM;ZS&FQWT-UY!B))D*$#LZ' (8>XR:9\*?^1&3
M_K^O/_2B2K%GX6U>+Q>GB.ZUJWEG.G?8I88[/8APY=2OSD@9/.22>>1QB[X.
M\.S^%]#.FS7L=WB>699$A,?^L<N01N;NQH Z"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&WFA.[88_D.>AK+M_&^K+X"M+ZY\DWS:N-*N+L1XCC7SS&9BO0< <=,D=N*
M/2*KWM]:Z;92WE[<1V]M$NZ265@JJ/<US&E:GK3?$'4]#ENXKC3;.VBN!(]O
M^]S)N&PNI"@@KN'R\@_C61\1)'F\:^ M-FS_ &?/J,DLRG[KR1J#&#Z\D\4
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M&2YR,*/UJ#P]I;S>*=<\33*56]$5M:*PP?(C'W_^!.6(]@I[UU/6B@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*-#M48&<@AB>,=3S0!>\/>(+3Q+I9U"R2=(1-)#B=-K;D8J>,GN#6H2 "2<
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M2[Y%'V?01,3-_?GD4)Y8/HJY+>Y4=0<<QX2_??#WQO)><R2ZAJ9N0WKC!!_
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0!EZ=I#6UR;V]O'OK\Q^5YSHJ!$SDJJC@ D GJ3@<\ #4HHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
EBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>elicio-exhibit321001.jpg
<TEXT>
begin 644 elicio-exhibit321001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%#!+J$S1K/,((@D3R,\A!(4*@))PI[=J -"BN7C^(?AF:^N;**]N)+NV4M/
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA/91M&IC 'RLK,W."><_P^]<S^T9=7*:+H-D'9+&XNV-P0< E0-H/YL?P]J
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M":,21NO(92,@C\*YR+X@^')]6N]*AN+R74+0%I[>+3KAWC (&2 G3D?G7(?
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MC\ZW=(U:RUS3(M1T^5I;64L$9HV0Y5BI!5@",$$<CM7D>F_\G4:O_P!>"_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"*
MYF%M:S3D;A&C/@=\#->>_!2>74? T^L73>9>:EJ$]Q.Y_B;(7\@%  KT9E#*
M58 @C!![UP_@#19_!\.H^&)%80)<R7&G7!4E)(7P=I/]Y3G(XR,$<4 <U\/
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M4YZ+3M-N+:=[J]U"6\N779]T1QHO7"H.F?4DGWQQ0!Y/XZ_Y.*\%_P#7NO\
MZ'+74?&:&.+X3^(71%5I3 \A ^\?-C&3^  _"KFM_#[^VO'.G>*GU5XKK3E"
M00K "FT%C\V3D_>/0BM7QAX9_P"$O\-SZ'->&VM[C;YSQQ[F.U@PQDX'*^]
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MKW+=@..IKN* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB6^6&*TV_:#*C(8=V<;P0"N<=ZLMK&G)?VMBUW&MU=H7MXB<&50,DKZX')H
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M7&LVZ^,_"6NM<H_A^2QFM$N\_N8KA@I!+'@;@NT'U!%>F4A564JR@J>,$<4
M<3X4MC)X]\7:K9L&TJZ-LD;H<QRS)&1(RGH<94$CJ0>XK7\;QZ?-X2NXM4NY
M;.T=X5-S"VUH6,J;'SVVOM)]@:WP H    Z 4O6@#R*_GUR]\)>-](OI;76)
M;?3%,.JV4>TW"D.0CJ,C>O)PO9AZU:?Q#I.I^,OAW-8WL=Q"D5TC21Y958P*
M I/3=GJ.HR,]17J*HJ+M10H] ,4*B+C:JC'3 Z4 >4>$];T7_A'&\(^([83Z
M_;7LOF:?+$6>YE,S2)(O'(.0=W0<D\5HZ?=:?_PL;X@/-/;<6=FNYW7H(Y-X
MS[';G\,UZ/L7?OVC=C&<<XI<#TH X_X62K+\,= VR!REJJ-@YVD<8/N*["BB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\9>'5TV+4&U:W6VEF^SJS$@^;G!0J1D,#U!&1WKA]<NK#P_JGAG5Y=.N]/\
M"ZVUS:D6JR0_9#(Z,DC+'AE#!>F.,\C-5?%"^'1X(FNM'@D2SO\ 6;6X>6=Y
M&^UL)$,D@$A)*X')Z'![<D [35-5/B?PM?2>$];:.Y@F\H3VUN)CYBD$Q[6P
M.<@;N@!SG%:,_B"RTFV"ZK= 7$$"RW;10NZ1\<LQ4':"0V,XZ5K1F-T$D14H
MXW!EZ-GOGO7F7C)C9ZUK.IZ)K4=KJL-NBW>DWJAX-20)E0J]=Q#%?EYS@<9R
M0#TYU+QLJNR%A@.N,K[C((_.N(\#>)"O@BTO-=U"6:XFOKBV65T+-(PFD"KA
M!UPO0#M78VUPS:=#<W48MF,2R2H[?ZHXR03[?TKQ7P3JK^&TTS5[^5;G1KFY
MN;,@C+Z=*T\C+( /X'4C)QD #G'% 'JMWXR\/6-Q<6]QJD*3VZ*\L(#,Z@]/
ME SG@\=>#Q5Q=>TJ32(-52^B>QN ODRH<^86X 4#DL3Q@#.>,5R-C>V+?&/5
MK@7-N4_L6!5EWC'$CLP!]@03[8KCO#\TEEX6\!ZLV6TO3-2O!?JHSY'F-*L<
MC#LJ[LY[!@: /64\3Z.]G>W0O,1V'_'VKQNKP<9RZ$;E&.<D=.:0^*M%']F_
MZ9_R$P&LL1/^_&,_+QSQS].>E<[8VL6L?%.^UBQ>.XTEM%6SN98R&BGF,I8#
M(X8JG7'3<!7(OI&N+X7O--ACE67P5=M/82-_R];2)(USZ"!F4CN77TH [[QE
MK)B\*>(QIE_-;:CIUD\Y:./E"$++RRD<X[<UH6.L06OAW2I[Z=VFN+6-@%1I
M))&V L0J@L?4X%<YKI9OA-XBU&Y0PW.JV4]P8W^\"\>V*/']X($7 [@UAWNJ
M6NC:EX5UK57NAH$NBBS-W:R2!;>?*-\YC.0&"X^J^U 'HL/B/1[C1AJ\6H0O
M8D[1*#_%G;MQUW9XVXSGC%<UHVO37_Q3U6QCU"YEL(M,BE%M-%Y7D2&1@1M*
MJW0*?FR<'KBN<U8:9I,&@Z_H]C=)X<CUQKV^D;S7,A>/;]I*OE@H8GGVR.H-
M:-MJ&FZS\4M6>UG>>TNO#T<8GMD9@W[R3.U@,$XZ>XQU&* .N?QGX=B\DS:K
M#%'.6$,LH*1S;3@['(VO^!-3ZEXFT?2&<7UX(A'M\U_+9DAW=/,8 A,_[1%>
M4^'==\/7^G^#M+OO$-C;C1IDFA#+)'-*0K)&CAE"H<,-V&8$CCKFM$7^AV&N
M>)O#_C%-022_OI)[9$>X,=[!(JA541G!8 ;2,=AZ< 'K2L'4,I!4C((/!%4=
M4UK3=%BBDU*]AM5FD6*/S&P7<G  '?K6=IVNZ/8ZAI_A1=]K?BQ26*S<,VR,
M# 7><@D;3WSP36+\66B3P?;M. 85U.S+@KD%?.7/'?B@#=TWQEX>UB>[@T[4
MXKJ:T7=-'$K%@O\ > QEA[KD5*/%6B'3K'41J"&ROI!%;3A6*2.3M SC@D\#
M.*YR6&WUGXK:-JND213Q6.GW"7US P9"'*B*,L."<[VQV SW%<'::I:Q?"?P
MYI#-(=0T[5[=;RW$3%H"MR2=W'''0=^W0T >KWWC?PSIMU<6UWK-M'-;.B3)
MDDHSDA0<#V/T[XJY_P )%I?VM+;[0QD>8P(PA<HT@SE ^-I88.0#D8/H:Y70
MY[2;XO>)SNC9Y+&S6/(Y.W>7 SW&5R.W&:QK.>72]?M&\/ZHFH:9>ZLR76AW
M2AIK-VD8R2Q$?,J@Y;!XP<YYH [\>*=%.G7NH?;1]EL96ANG\M_W+J 6##&1
M@$9STJ2[\1:59"'S;DLTT)N(TAB>5S$,9?:@)"\CDC'->77VHVVG^'OB?HUR
MSKJ-Q<W=Q%;B-BSQ/ NUQQ]W@\]JUXM<M5UW1+217L#-H2;+Y;5FGN?FP;=,
MJ<8(W$8).1C'4@':S>+- M[:PN)=6M5AO\?97,G$H(SD>WOT%0KXTT&72M2U
M&WO#<0Z:";E(HG,B<9'R8SR.AQCWKRS2+NU/P_\ AO!*P5[;6H_.652NP+YN
M2<CH"5YZ FNEE=+CQG\0X+=EDEGTB!(T0Y,CK'*"!ZD94'ZB@#M_#6N1>(O#
M]EJ<<;QFXA21D9&7:S*&(!(&1SU'%4[+Q?97WB_4?#\<<XELHXBTAA<!G?>2
M,XQ@!1ST.>.E1?#R^M[WP#H8@9F\BQ@ADRA&'6-0R\CG!X-<^S2Q_$;QG8Q.
M\%]J6EVPL&V-\S*DJE@0, *Q&30!V \4:*;N&V^W*&GE,,,A1A%)(,Y19"-C
M-D$8!SP:UZ\<FDBUOX+67A>V'E>(X5MK06)XG@GCD4%RO50 I;=TQWKV( A0
M"<G'6@#D])U/5)/B3KNE75XLME;V5O-;Q+$$$9<N#SU)^4=3^59]_P")PGB[
M7-)U+6)M(^R6T<VGJBH/M"E,M(-RG>P?Y=@].AS3M)NK=OC'KZK-&2VG6J+A
MA\S*TA8#U(R,CM6?XATS3_$?B'6[3Q-='3VLQ$VBW'F>4T2[0S2QMQN;S!@C
ML%4<9R0#N?#UQJ%WX=TZYU:W%OJ$MNCW$0&-CD#(QVY[=JYK1=1U:?XI>(-)
MN-6GETZQMK>6& Q1  R YRP0,1QQSWK<\(3:K<>$=+EUM2-2:!?/W+M)/8D=
MB1@D=B37+FXA\,_%S5;[5I%M-/U:P@%O=S';%YD9(,9<\!L'(SUH Z2\>^'C
M;3;:/4IX[.6TN)I+94C*LT;0JO)4L!^\;.#Z5#X]UVZ\.>#[O4[0$/&T:O*(
M]_DHSA6DV]]JDG'3UXHM+ZVUSQ=;WVFRK<V5E93PO<QG=&TDCQ$*K=&($1SC
M.,BDO/&&EMHT]_ LEU:0WWV"Z7[.Y*G>$?Y<98#.3@$8!H ATO[5=W.D:CH_
MB675=&E=Q<B3RGR/+;:P95!'S;<K[CI@YT_%?B*W\*>%[_6[E"\=K'N$8."[
M$@*N>V6(%>?1Z/I&D^/]&O/ %\F+VX(U73[.826X@VDF1E!(C(. !QDG@=<[
M_CBUA^('@OQ'H&D2E[^TD6-E9&0><A60+D@ Y QGIS0!K:5INMWFE07FIZY=
M0:A/&)&BMHXQ# 2,[ K*2P'3+$D^W;4T)-2CT>%-7E26_5G$LB+M5\.V& [
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MRZLIN+W6;6:_V[Y=.LYD9+3/1&Q\Q8="2<9Z 5T%W=V]A:R75W,D,$8R\CG
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M(M_)(^4$@8&!^%7* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@K<BT:00N8EF.,1F0#8&Y P3U..M5X_%]M+XVG\-K;70D@MUE>4VTA4LS$
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M3Q+X=\6#4KW4)8Y_L5U$\49=K5P=Q B120IPW.><5ZA10!YO<^((/#/Q(O\
M4=5$S:/K-C;K9WT4+S(K1E\QG8"1G?N'%&NM!8W_ (%U"+2Y-/TRWOI_W45L
M1Y*O$X3**,J6)!QC()P>:](HH Y[QK87NL^!-9L=-W+>7-FZ1*>"Q(^[[9&1
M^-<EJ5Q%XN\/>$[+3%9-3M]0M)YH=I62Q$0_>%QU3 !49QDD8SFO3J* .$TR
MZA_X7%KO[P;7TVVB1C]UG5G+*#T)&X9%='XE\1VOAG23>W*2R$L$CBBC9R['
MV4$@#J3@X'J< [%% '!:+J>B^([?5-)LY;RYU#4[>1KV[>QEA0978 #(H^4
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MWN\FWSEV"J6)P.@P#R<5'X8U9]=\+:5JTL:QR7EI'.Z+T5F4$@>V:Y_Q0/\
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MTIIF6%K<N9/,38<MO&,#IQ7144 8FJZ ;O6K#6K*=+?4;-'A#/&726)\;D8
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MIN<G=("6Y/)/4Y/K5JZ\(,TNLK8:A]CM=9YO8A#N8,5V,\;;@$9E !R&Y&:
M*/PYNHX_ACHFJZBRI(FGJDD[]?+0G;^GYU3LKF#P%X5U#5+XPV,^LZK)<Q0W
M#;$@>7[BN>V$3<WN& R<5K:OX2U"Y73+?1M<72;#3HU6&V%DLP)484G<>=H
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M8W=(H?+:!HU"HRMN.<;5/(ZC\* )]+G\51^*4AN;:XGT26W)>>Z^SI)!,#P
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MNH4Y16E'+*IQ@8'0#IQ5A_!\][+I?]JZE%=QZ9>"[MW%KLFR,[5+[S\HR,X
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M90RE6 *D8((X(KD])\(ZCX9\RU\/ZQ##I+R-)'97MH9Q;ECDB-ED0A<D\'-
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M1=HY4XXSDCU-+87_ (ONYM!U*WBGFL[O8VH0S_9EA2-USOA*L7^4GHQ.1[T
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M+G95W3LNPE4A3:VYB0,C!P <4 :]_?P:;;&YN2RVZG]Y(!D1C^\WHH[GMU.
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M.//S1)#&I(]@>* /3Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU)10!RA\%O'<^(7MM6EC@UK<TD#0JPC=D$;,#P3P.!G /K49\$R'3O#-F-4
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MYZ9QC4U/2+C4=4TRZ6^6*"QE,WV<P[A*Y5ER3D= QQ[\\\5K44 <[XP\*_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5D0^)]%GOXK)+]//F5GAW*RK,J_>,;$!7 [[2:K1>.?"\]U';1:W9O++(\2
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M_P 5L2P%YIKG9R,N#;A5QZ_-D#WKUW ';K10!C^$Y4F\'Z*Z.''V&$$@YY"
M'\<UROB+6HO"OQ/LM7UDO%HMUI36<=WL+)!/YN\AL#Y=R[>>^T>E>A4$ ]:
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M<SL?EA9K=D4.?X>>.:?=ZW:1O\2[S^SO[1A:2S<030OL=/*C7>PQDJN=V.I
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M?]'CX(W' 8\$] !DYKA8+RW7X&6-LTC++#JZJZ2*5((O2Q'(ZA>3Z=Z]SHH
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M'- %3P7XVLK70UBU_69)+R34[BV2696;I,RH&91M3.,#.!Z5V>J>(--T??\
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M=HUU%XBDM8+R^B%K):MS<ONQY1&"=I/# XQCG%<E#KD?AGQ3H^LZH)?[%OM
M@LX[Q(VD6"=&+%&"@D9S^8QVXL^+9;$:!X9>RL%L+0^(K6XCB$/E'RQ+N>4I
M@%0<ECGL1G!.* .SU+Q5HVDRW$=Y>%&ME5[@I"\BP*WW3(RJ0@/^UCCGI6/X
M@O[R'Q_X-BMK^865Z]T)H$(\N4+ 64G R>>>N.E<IXPU)+P^.]-^SRVD_P!A
M!BCM;4E]0'DG$CN%.57[H (Q@Y)S@7I[Z";7OAG,K,J)'.7+H5V V^P%@1P"
MW )Z]J /2KBXAM;>2XN)4BAB4O)([!551R22>@K.L?$>EZAJ+:?!<.+Q8A/Y
M$T+Q.T9.-ZAP-RYXR,BLCXE6E_>^ []--@:XN8VBG^SIUF5)%=D'KD*>._2J
M!UK3/'.F7S^';9VU1]-G@%[+;-$UJS+Q'O9?O;L< X&"?3(!T4?BO1)+JW@6
M]P;F0Q6\K1.L4SC/RI(1L8\'@$YQQ5:[\=>&K&6^BGU1/,L2HN4CC>1H\@G.
M%!)&!DD<#OC-<)=.GB+X2:1X:LT:+Q#";.V^R%=LMK+$Z!Y&7JJA58[NA!'K
M6M8W%LGC;XB2221JDEO:A7;@/M@96 /?!(!QWXH [>77=-AL+6]-TKP7>W[,
M8E,AFW#(V*H);CG@= 37%:%XA6ZU?QX;S6[M-,M&A6*>8>6UJ&A)?"E1M(8G
MJN>!G-<WHE\^BVWP[UB_67^R+;3I;.XD"%A:3L% +@<KG&W/:M2VU"VGU;XG
M3Q^9Y%Q;0M%(865)/]%V\$C!))&/7(QG- '22^,+#1++PO:1S7VI)JBHL5XT
M$DC21B,MYC;5Y8@#C&>2<8%:=G?:?<^,+N*#6;B6[2S3S-.)_=Q+N.'QMX8Y
MP>>W2N#\Y;7PY\+KZ59/L]FT4=RZ1LWE,;8IA@ 2#NX^M:5UYFH?$O7X;*7R
MKBY\-K! [?+MFW2''^\-RDCJ* .O7Q7HC7,$'VW'VB4PP2M$XBED&?E60C8Q
MR", \X-07GC;P[87-[;3ZDGGV04W$4<;R,@.<<*"3]TYQG&.<5Y].5UWX-6/
MA6WC:'Q%$MM:?8V&)H)8Y$#2$=0H"EMW3!Z\UT>E7-K#\4_%TL\L:H;&T42/
M@ [1)O /?&1D=J .VL;VVU*Q@O;.9)[:=!)%(AR&4C(-9MWXLT2QN)8;B]V>
M3*D$T@B=HXI&QM5Y -JD[EX)'4>HK%^$QQ\,-#B;(DBA*2(PPR,&/!'8]*X?
MQEJ*W_AWQK9"VGL[F#4 18VUHP\]5>/_ $F1@OS;@,CD# '4\T >HWWB[0=.
MU&73[G4$6\BB\YH$1G?;G' 4$D^PYZ\<&IH/$FCW.@QZW#?QOITF-DP!^8EM
MH4#&=V[C;C.>,9KE8KZTG^,JW@<+"?#H022*4PWG[MISC!V\X/..:XVSFFL_
M#&B:F(I9M/TSQ-<7%]%$A9HXF>39*5')4;@WXYH [?2=<EO_ (LW]C%?7<EC
M'I"2_99XFB$4IE(/RLJG[NTY.>O6NGU;Q#I.A/;)J=]%;-<OY<0?/S'\.G0\
MGBN/TO5;/4_C)+=V+//;3:!&B3I"_ELPG<_>QCIW]B.HJS\1I85N_"(E*XCU
MZ"9P1G:@5P7/H 2.>@H WK?Q?HEYIT-_:W<EQ#,9!&L-O(\C;#M?]V%WX!X)
MQW'J*FA\3:/<Z=:W]M>"XM[MBL!@C:1I",Y 506R,'/'&.<5QWBN_@T#XA6N
MK:RM\FA76FBU6[M'E"P3+(S?/Y1SA@PYYY7ZU!>:9X??3=-_LVXO?#?F74]U
MIVHDM_K"JAFD67HKY/#8S@=-V* .U'BK1BEDYNV5;ZX-K;EX9%WRABI3E>&R
MK<''0U*=6L]0N-1TJUO9([^UC!F"QE7B#9VL-RX.<'!Y%>;ZAJ&IR^%/#FJ:
MU#$%TWQ*KW%W:Q$1RPJ9%^T!1T5BP.>ASD<&M?1-5MIOB5XHO1YRVDNFVACG
M>%E1@HDR<D<#D8SC/;- $7A[QT^F?#CPI>ZH;N]O=5FCMS*(GDR6D(8L5!Y"
MYP.I(P!UQV=YXGTFQC=[B:95BA6:4BVE;R4(R"^%^3@'AL&O+;)O(^$?@.=T
MD":?K%K)=X0DP*KODL ,C&1^8K5\5R[-3U;6= U9[/55MX_/TJ]BW0ZHGE@J
MHC.&WD-L^7G. 0,T >J5C#Q7HAN8(/MN/M$IAAE:)Q#+(,C8LI&QFR", \X-
M3WT=[J'AFYCB'V6_N+-E0;O]5(R''/L3U]J\PF*ZY\&;+PI!&T7B*%;:S^Q,
M,302QR(#(1U"@*6W],'KS0!U&N>(!=>.[;PPTNHV]JUA+/*]I#,LC2;T1,,J
MYVC<QR/ESC)[5T]DC:'H$8U75#<_98B9KZX"H64<[FQP,#O[5RUQ<PI\:K'?
M*N!H<L)<]/,,R$*3TW$ G'6K?Q.LM0OO ]RNFPO<2PS0W#V\8RTT:2*S*!W.
M!G'?&* -NU\2:3=WK627+1W(B\_RKB%X6:/NZAP-RCN1G%9<GQ(\(1"(OKD
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MEI;0,O*W4ZQ,"4_O8RJY'4Y':KM_/:MJ?PS8/&4A+%SVC'V8J,_W?FP.>_%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>,?@ =Q161X=N=7N=/E.MP0PWD=Q)'M@!V% <*RYYP1@_C6O0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'A7C**UNOVD]!M[JX>&%K#8[Q7#0LI*38PZD%3R._?WKTKPO>:;I T_P?:WT
M5Y=6MJ\CF.0.4B5@%+XZ,=PX]C6[)HNE32-)+IEF[L<LS0*23[G%.BTG38 X
MAT^TC$B[7V0J-P]#@<B@#QOX&7EK#KOCCS;F%-U\C+N<#(W2\BNF^('B&RUW
MX7^,6L9HY;:S(M?.1P5>0>6S8/?&\#Z@UW7]@Z/_ - FQ_\  =/\*D_LC33
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MRZ/@J#)#R#V^M>P7.F6%Y()+JQMIW QNEB5CCZD5&^BZ5(07TRS8@!06@4X
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M[$ C- '2T45SL7B"[;XA3^')+6%;=--%\DRR%F;,FS!& !T/KVYH Z*BBB@
MHJIJ.I6NE6GVJ\E$<6]8P3W9F"J![DD"K= !17,6'B:[\0W5X- M;=["TF:W
M:]N92JRR+]X1JH)*CIN) ST!K0TC5+Z\OK^SO].%G+:&/:4E\Q)E8$[E.!QD
M$<C.0: ->BBB@ HHHH **RO$NIW&B>&=2U6U@BGEL[:2X\N1R@8(I8\@'L/_
M -58MUXMOK>/PA(+.W:/7)(HYF,C9B+1%_E7'(X/)/X4 =?1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% 'F\EK-=_'6^6#4+BR8:!&2\"QD
MG]\>#O5A53PS:_8_BAXG\-:GMU>2^LDNY=2D&)=F0HA<#Y5QG(VA?7'3';S>
M$=%GU:357MYA?R+L:X2[E1RO]W(8<>W2I(-'L_#UC?SZ)I,37DBM*4#[7N9
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M-.Y:';=A?EY[C(/<]^@KT#3]'UW3&#6N@:,'6+R4>77;J5HX_P"ZC/ 2HX'
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M/_0&T+_P;3?_ "-1]J\8_P#0&T+_ ,&TW_R-0!T-%<]]J\8_] ;0O_!M-_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#4=9L=*:S2ZF59+R=;>!,C+L?3V R3["K_6@"O?6-OJ5G):7<?F6\JE9(]Q
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MNM2M;""*]N^9YD7#/TZ_D,^N!FLGP3XANO$'A\7FHBVBNC=W$ 2'(4^7(RC
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_=HV<[E3[H.><@5:U/1M-UJ!8-3LH;N)6W+',NY0?7![T <3XHT32%^(/@>
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%GX?T+PCH&J.ME97E]IUI"US(ZHT[&,$+N)^8YS@=>,= *[:@#R^T^(/B,^
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MX3^Z&QG'M5\YP<$ ]LUQ&A:]XCUO6?$5D;O2;9-)N_LZN;&1MX*[LG]\,=:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHMAXC@LVA\J/7[S8D1&%3<-N .V.E=9=:!HU]:P6MWI-A<6]N<PQ2VZ,L?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGJP@<$#U&3C\J +<7B>^'B/_ (1BX\5:<7D@ENH-2B$6_:618HV4_(7RS$X
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M!R>B>%S!JD&IW>CZ'IEQ &"+I:9+[A@[I"B$KC^''7!SQ75D @@C(/4&EHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
G %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>elicio-insidertradingcom001.jpg
<TEXT>
begin 644 elicio-insidertradingcom001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^UO2Y8UN+0QX26,.CAI%7GO_ !=C0!UU%><R:]XJN?A1I_B'3;BWEUFY2%Q
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MBWK@JS9'(.?EIGBOQMK?P_GTJ]U<VVI:%>R"*:6* Q36[D9S]XAAC)Q@'@T
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %8XP HSV&:U_$^AZM?:QX?UK2?L;7FE2REH+J1DCD26/8V'5201P1Q74T4
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MF62\N8O.:>0<9QD!<X&!V Q@<5H>)M#U/5=<\/WMD+3R=,NFN)!-,RL^49,
M!#_>SG-=/10!ROQ#@FU'PC<Z):<WNJE;2)?0,PWL?94W,?I[UTEK;1V=G!:Q
M9\N&-8USZ 8'\J?Y,7G^=Y:^;MV;\<[<YQGTI] !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 9FL:PFF&TMXT$M]?3>1:PYQN;!9F/HJJ"Q/MCJ15JZNX]-TR:\O9%$
M=O"99G5<#"C)(&3Z=,UQVKLY^,_AI)<^2NFW;0YZ>9E0WX[<5J^*'N;^[L-$
ML8H9I'<7=RDTIC7R8V! +!6(W/LXQR%<4 2>"_$Z^+?#D>I&W-M<++)!<VS?
M>AE1L%3[]#^-;[2(@)9U7'7)QBO-]%DO/"_Q6N[+4(;>VM/$T9NK=()C(@NH
MP!( 2J\LOS'CKBH+;P]I.I>,?B);WMC%<0*MJRQRC<JLUN26 / ;))SU&3CK
M0!ZAO4.%+#<1D#/)I&D1"H9U4L<*"<9KQ>VL;:/P-\.M=6(?VL^I6$3WK$F5
MHV)4H6/.W;QMZ5K"UM_%VI>,M*U:^L8+J&[:,"XMPTT%OL4QR1L7&T=6! ^]
MDGK0!ZF65>K <9Y/:@,&4,I!!&01WKS"+1M/OOB9I$%V3J4,GA@F22<'_2L2
MQ@-(O0Y'.#WQZ5A6]]_9GA.STLN8M&;QA+I\X+85+82N1&3V0D 'MC([T >C
MQ>(;Q_B,= V6K6!TLWJ2H29"PE"8)SC'7M72"1"Y0.I<#)7/(KS/4;:/1_BG
MJ4VC6L45W_PBDTJ1PH 'D64;3M'?@#\!47AW3=-UK2?"GB&+6[2*>&2)O,M;
M?$\\C "2&5MY+9).[([9H [;QAK-SH'A74M3LEMWNK6W>=8YR=K!1D\#DUI6
M-Q+=Z1;7)">=- LF.0NXJ#^6:\C?['XA^$/C#4]3ABFUA9+S[0T@!D@>-CY:
M ]5"J%P/<^IKUC0SG0--(Z?98O\ T$4 97@KQ#=>(=":\U!+>*Y%W<6^R'(4
MB.0J,9))X%=)D9QFO#X_#FD7GPHU_6+B+;J=G=W\MI=J["2&1)G*!#GY<M@8
M'4GUKH=6 \(ZUH'CB_MU07-HMAK3+'S&[*"LN!W#C83Z,* /3\YK/&KVTVJW
M6DVTJ/?V\"S.A/"!R0N['3.TG'I]:J>%M,_L[2!++;I!>7LC7=TJJ!B1SNVG
M'7:"%_X#7-:3I^GK\8_$DS6EJ)5L[.1',:Y#L9 6!QU/&3WH W/ _B&Y\2>%
M+74[]+>*ZFEG0QPY"_)*Z#&23T45T32(F-[JN3@9.,FO"X-,LHOA!IVN) HU
M2WU@&&Z/+Q_Z<5(4]E()R!P<YKJ9XH?$OC+Q;H>J7-BCQI$EO%=V_F,MNT0)
M>(EACYRQ) X.,]!0!Z:<XXZUQ>D^)-?U?7O$&EPV^FH=(F2+>[2#SMR[@>,[
M>/K6_P"&H%M?#>GVZ:A)J"10A$NY/O3*. WOD=^_7O7#^&=.EU#Q]X_$6J7M
ME_I<"DVIC&?W/7YD;F@#K/"?BD>)8-026T-G?Z==O9W<'F>8JNO=6P-RGMP#
M[5OJZ.6"LK%3@@'.#7A5OJFH:!X&^(&EZ?F5M+O4#:K!GS;@2N/-9VR<R*N<
MD8QZ#%=IK]C;:7XC\%WWAR&&"2YO/LLBVRA5GM&C9F+8^\%VA@3T)]Z /0?,
M3S/+WKOQG;GG'TH+HIP64'CJ?7I7C-Z]G+8:#J^E8%O-XKCV7ERX:[G+3LLG
M( VIC*A3DE0,XK<L?#>C:U\4/%T=]:)<0I%I\Z(6.W?B0[Q@]>.ON?4T =?X
MPUFYT#PKJ6IV2V[W5K;O.L<Y.U@HR>!R:T]-N'O-+M+F0*'FA21@O3)4$XKR
M-_L?B'X1^,M3U.&*;6$DO?M#2 &2!XR?+0$\J%4+@>Y]37JFCLP\-6#1@,WV
M.,J,]3L&* -#>F_9N7>1G;GG%8>MZY+9ZUI.B69B2\U+SF669"Z1+$@8DJ"I
M))*C&1U)[8/G$20ZK\#+GQ!-A?$$(FNGO ,7$=VDIP-W4'@*%_ND#I6WJVG6
MU]\1/ \FJ:=:/=7-C=M=J\*G>XBB^]D<X.<9Z4 =E9S:Z/#SRZE%8QZK&'R(
M2S0O@G:1GD9 '&3C/>N?\.>)_$_B+PA:^(;32],D^T(SI9FY=&(#$8WE2,G'
M<8]Z[*[XLI_^N;?RKBOA+/%;?"'1)YY4BAC@D9Y'8!5 D?))/04 :>D^*9/%
MGA.YU#P^L5OJ43/ UOJ((6WG7[R2;>>/;U%=*KE8E,K(&V_,0>,XYQ[5X4;+
M[=\,_B-K[0LMCJE[+=6&\%=R*<"0#_:R?RKK=>T?3]4^(OA*WO;=98;G3+M9
MD).)5"QX#>HY- 'I+2(H4LZ@,< D]:5G5%+.P51U). *\MBT^QU+Q1XC\*W,
MEA;P6=M!;V-M=V_FE+4PCYHB7&,-NR1DY"Y/ J339;2'QGH'A_4M0_M/35T5
MFL)KL K=3B7:6YX9A&!@\\$D=: /0=1U>RTI;4W4RJ;JXCMH%SS([G  ]?4^
MP-7&D1 "[JH)P"3BO*O$>@:%8V'A2QLE6[M(O$\<(,^) @;>S1*<8V X&WID
M8/(K7TI+/5_B-XFTK4[6WFMK.TM$TZWDC#1BW9#O*+TP6X)'HH[4 =^2 ,D@
M=N::98PH8R*%)P#GC/I7B1MI;GPKH-M>/++!:^,ELK&=G.]K59648;KC@C/^
MR/2NJUOPS)HM[:MX5TO3+R"U@E:?0KD[1(LK@EXB<A6RI'/&.* /1@01D<BF
MET#A"RAFZ GDUB>#+VQU#P;I-QIL,T%F;=4BAF^_&%^7:?H017!:=#:^(?AM
MXIU#5D0:S!<7K37#<2VLL18QA6ZJ$4)@#^IH ]9+ 'D@?4T*RNH92"IY!!X-
M>3V5C_;7C+PA)KML);J[\..]['(.)'_=<.O0]3D'BNA^&,:6VG:_8PC9:V>O
M7D%O$/NQ1A@0JCL!D\4 6M<\2:O8>-=(\/V=O92+J<4TBRS%U,?E@$@@9SG/
MM1/XOO-$\0V&E>(M/B@AU%_)M-0MIB\32]HW4@%&/;J#^>,_Q%_R67P7_P!>
MM]_Z M5/BMC69?#GAFQ/F:I/JD-UL3DPPQYW2MZ 9_'G% 'H[2(K*K.H+<*"
M>OTH=TC7<[*HZ9)Q7E:6EMXON?&&G:MJ%C;75O?R1DSP SV\"A3%)&Y<;5Q\
MP(&,Y/>KNE2V6J>.;[1-=E6^1-'M3I_VQ /.C96\Z0*?XB=N>_&.QH ](9E1
M2S,%4<DDX HWKM#;AM/.<\5Y?.UEIVM^%/#\6HQOHC6ES':S:BOGI-.CJ%!.
M5!(7>%/3GCM5#Q+X>LM'\'3VD&H?:T3Q!;2JD:[$M&DE0M''@G:,'.,\;J /
M7O,3YOG7Y?O<]/K7.>,_$%[X?TRQO+".VE6:^@MY#+DX21PN5P1SSZ_G7--X
M;T9/B^=/73X!976A-/<VP7]W/(LX :1>CG#'EL^M<V\2+\-KC3U++:VWB[[-
M BL1Y48NQA5(Y&,\8Z4 >VJZMG:P.#@X/0T@D0N4#J7 R5SR*\OU31T\*^/H
M9?"=KY$EUH]Y+>VT.2C-&!Y+E?[Q<XSU//O3/#VFZ;KFC>%?$$>MVD5Q#)$Q
MEMK?%Q/(P"R0RMO);<2=W';/2@#U/>F[;N7.<8SWZUEZ_>:Q:VD0T/3X;V\D
MDQMGE,<:)@DLS 'V  &3GT!KBO /AO2+G4_$-[-9H]Q8>)+HVC%C^Y^5!\HS
MQU_' ]!CTN@#DO#VN^)+OQ-=:3K>F:=;K;VB7#26=R\N"[$*IRHQD(Y_ >M=
M;7,^$&6YL]1\02L -4NGG1V. +=/W<7X%$W_ / S7103PW,"3P2I+$XRDD;!
ME8>H(ZT <AXD\0^*]+AO=3TW1+&?2K ,TJSW#)<3JGWVC4+M &#C)R<9 Y&;
M=SXO29?#T&EQJ]WKT?G6XGR%BA"!V=P.3@$#&1DGJ.M2^(IX=62?P[%<I&)D
MV7TN\#R86'*C_;89 ] =Q[ X%[%;P_%+PA>6IC.FR6%U8V[1G**Z@$*#T^ZK
M ?[IH V[/Q1<SKK-C]A$VM:5,D+V\3;4E\P Q."<[5(.3G.W:W7'-/2_$^O6
M_B^#P[XETVRBDO8'GL[FPE9XVV8WHP8 @@$'/2JF@LL7Q+\<ZQ+(L6GPQVEN
MTSG";DBW/D_[(89^M:]B;2_\01Z]>311R&(VNG6[L ZHQ#,Q7J'?:..H51G!
M+  %/6O$OB/1-0L;F;2+-]&NKV.SVI,QNDWMM5R,;<9_A!)YZ]<=G7"?$BTU
M!=*M_$.D:I.EYID\<EO9C:T-P[,$VD8R6(8@'/&>.M=Q+(D,3RR':B*68^@'
M6@!1(A<H'4N.2H/(H:1%SN=1C Y/KTKQNU^RQ/X U'3@L5K<:E((KB=PUW<1
MNDA9I6  Y.,KSVR0>*F?P]I-]_PLX75E',+=V>$2?,(G^RAMZ@]&SWZT >OL
MZHI9V"J.I)P!7-^$]?OM;N]?@OH[9#IVHM:1^1G#($1@22>3\WM7(Z)J)U3Q
M-X-TW6&$UK)X8CO8%GY6>[.P,2#]Y@F2/3<36O\ #BVMK+4?&=M:1I%#'KC[
M8TX"CRH^ .PZ\4 6/&/C:X\(:[H\<]K%+I5\Y6XN 2K6JAHTWGL5W2KZ5TVL
MZG'H^CW.H.AD\E,I&O61SPJ#W9B /<U@>*='MO$&N6VD7@S!=Z1?Q-ZC,EMA
MA[@X(]Q7/>"K_4/$-M::-JT;B?PR[QZ@S [9ITRD)!_B&W+GW"&@#J? GB.Z
M\6>$+37KN&"V^U;RL,9)V!79>6/7[N>@KHT=)%#(RLIZ$'(KQSPK-8+\$/"-
MO?>>_P!JU!(8((Y BSR_:'94D)!'EG:=W'0<9/%3B!%_X6I8S"V$:6D<P@MA
MMC20VK$E1ZY49/&2,X% 'KBNK?=8'@'@]C6=KNHS6'AW4=0L1!+-:V\DJK(3
ML)52<''TKS.]LM-\.?#_ ,-:M% ($U%M-@UBZ#'+VV 3O.?NYPI_V3CIQ74:
MOI&B:?:^);O37$=S>:-(9;:!@(=JHP63:!@,<X![@''0T =%X<U.35_#6D:A
M<>6MS>6,-S(D? != QP"2<9-:AR <#)]*\AL],LM.L_A;JEI L5_<>1#-<#[
M\D;6I)5FZE>!@'@8XQ7K] '.^%_$-UKMUKD%W9Q6SZ;?FT CE,@8!%;=D@==
MWI3CX@EU#7[G1]&BCD>SQ]MNY<^5 Q&1& .7?')&0 .ISQ65X$_Y#GC7_L-M
M_P"B8ZXS1]&!^&GBK4)+R\M-=M+Z^N99X[J1#'<(2P)4':<@+U'(/TH ]G7<
M$ <@MCD@8!/TK/UF[O[6S4:79I=7LKB.-97*1IP26=@"0H [ DG [U%H6HR7
M.CZ6-1DCCU6>RBGGMR0'#%1N.WK@,2*NW]_;:99R7=W*(X4QDGDDDX  [DG
M '))H YCP_XKU*37-3T+Q+96MG?V5NMX)[64O!- 21N&X C!!!S4$7CF?^Q;
M#Q+<6L4>A7URL*]?.AC=MD<S'H03MRH' ;J<8IT^G+J%CK\[S0_VYK-A)!#
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MI%I%<Q1^7',$RZKZ!CS26/A#P[IFL2ZM9:-9V^H2YW3QQ -SUQZ9[XZUM44
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MX;O[VYO+K1K26XNDV3NR?ZP8Q\WJ<=^M:]K:6]C:QVMI!'!;Q+M2*)0JJ/0
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M>;'OE!,:[AEP.I'KU% $E%%% !111T&30 44Q)8Y%#)(K*3@%3GFGT %%%%
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MJ#[T^@ HHHH **** "BF2S101-+-(D<:C+.[  #W)I] !1110 4444 %%%%
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MXEWQ@_*^1TR.<=J -"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ K#U7PCI&L:BNHSQW,-\J"/[39W4MO(4SG:3&PR/K6
MY10!4T_3+32[<PVD;*I.YF>1I'<],L[$LQP!R2>E6Z** "BBB@ HHHH RO\
MA'K#_A)/[?\ W_\ :'D?9M_G-M\K=NV[<XQGGI6K110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBN;E\<Z'#:/>O)=?8%)47HM)3
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M"SQRP+]U61B.1V.:-8\"OJ$&EW%KK=U:ZWILCR0ZF8UD9R_^L#IPI5O[HP
M .* ,+QPGB6T\"7JZCJJAEU2&.":V50\]L\R*HE&T -R<[< X';(.]J.IZMI
MGCCPKI(OEFLK]+K[1OA42.T<>Y3N' Y/0 =.]2:EX-EU?PK=:5?:S/-?7$D<
MS7YB4;7C963;&. H*CY?<G.3FIKKPQ=W>OZ#JTVK!Y=)$W#6P_?&5=K9PPP
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BF32I!#)-(<)&I9CZ #)KC8O%VMW?A3_A)['2+.XT^2(SQVXNB)O+Y^8_*5
MS@9*]N1DF@#M:*** "BJFI:E::1827M[*(H(\ D]R3@ >Y) 'UIMRVIC5+%;
M6.U:P/F?:WD=A(O'R; !@\]<]J +M%%% !117->.O$USX/\ "\^MP645XENR
M"2)YC&3N=5&#M/=J .EHKD_$GBC4_#UQH,']G6D[:I>I9$_:641.V3G[AW#
M/I75KNVC=C=CG'3- "T444 %%5#J5H-732_-!O&@:X\L=1&&"Y/IDMQZX/I5
MN@ HHKDX/$.L:O<3S:+9VDUE::FUA<1S.4D94($DBMG P2?E(.0.HSB@#K**
M** "BN2\2>,CI_A >(-&CM[V#[2D!:1R 09A$67 ^;GW''-=;0 45%<M,MN[
M6ZHTH&561BJD^Y ./RKD?"_BK7_%?A6UUVSTC3HDN0Y2&6^<'*NRX)$1'5:
M.SHKEKSQ-J%KX@\*:>^GQ1Q:R)//WR$R0LD)DV@8 Z@#.?7BMRU;4SJ5\MW'
M:K8@I]C:)F,C#;\^\$8'S=,=J +M%%4M-;4VCN/[3CM4<7#B 6[LP,.?D+9
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M(SG&:@U9M33396T>.UDOLKY:W3LL9&X;LE03TSCWQ0!=HHHH **** "BBB@
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M?'WRH7<&/(Y.>:J^"O"VD:M=^(;C4;=[MK/Q#=I LTSLJ+M52""<,"#@YSG
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M-MQ8H4MG61QY2GJ  <<]_7OFJS>"?#3^(#KK:1;G4BP<S8/+#HQ7.TL/7&:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0TR@8PQSD@@<COSG.34G_"+:+_Q+_P#0O^0<,6?[U_W QCY>>../IQTK8HH
MY/Q'X65M&U=M$T^VEU#40BW2W$K 72 C<I)R VS*J2/ES6'HG@JT34[6[M/"
M#^'9[>9)&N/[0WD@')141R&##*G=C@D]:](HH P]#\-VFB:EJU];010-J,PD
MDCB)*D@L=YS_ !,6).,#H.V3N444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS?3&XEU15O?#]U'OCN3Y@4S19&5X ?<,CCGIBO1M;=8]!U!G.!]GD'_CIXH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBJG]JZ<+I[4W]K]HC!9XO.7>H'.2,Y% %NBBB@ HHJ"6]
MM8+J"UEN88[BXW>3$S@/)M&6VCJ<#DXZ4 3T444 %%%(S*B%W8*JC)). !0
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MX]* )Z*** "BBB@ HJ"UOK2^61K2ZAN%C<QN8I X5QC*G'0\CCWJ>@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O(
M/%GQYL?#7C";1(]'ENX+601W-P)@A#=PBX.<>Y&3^=>OUYYXB^#'A7Q+XF;7
M+P7D<TC!IX8)0L<Q'<\$C..<$?GS0!WUK<Q7MI#=0-NAFC61&QU4C(/Y&I:9
M%%'!"D42!(T4*JJ,  < "GT %%%% !1110!'.CR6\B1R>6[*0KXSM..#7C.G
MZAI=AH:> O'NE+I=X0R6^IR)O@N9,Y$PD[/DY.>_4C.*]ENED>TF2(D2-&P4
M@XYQQS7$:WI'B'Q)X*?PYJND6,EY/"L3WWV@-"C8QYH! ?<.H&.O&['- &QJ
M_BI+/59=*M&L3>16ZSR&]NO)0!BP10<$DG:W;@8]0*IZ7XZ&LV.C_9-.DCU+
M4Q*1:W+E!"(N)&9L'(R5 P.=PZ<XHW?A_P 1^'O$<&K^&DMM2AEL8;&]M+N<
MQ,YBSLE5\'G#$$8_GP_7-!\3O>Z'XDL&LI]:L/-2XLV<I#+%+C,:OC(*X&&(
MY/)QTH K^*/%?B*V\&WUS'I2Z=>0:BED[2RMMD1I$420MMY#;NI QSU(K9OM
M9>W\8^&M-O\ 1;1KF]2Y,=VLN\VY1,L$R@/S J,\=ZJ>)-$\1>)/!-U!.EG#
MJ<D\$\-HLQ:*,1R(^PR;02QVGG '(';)EU'2M:U#Q?X5U=[.W2/3EN?M2I/G
M!E0* N0-V,<DX]J '3^,;J32]5U?2],CO-.TR62.0FX*23>5_K#&NT@XP0,D
M;L'IP3'+XYEGU?1K/2-+6]AU>Q>\M9WN?+&%"G##:2H^89/)]C5/3?#FN:!I
MNNZ#9P07-C?33RV5R\VWR!+]Y9%QD[2205SGVI]IX1O-(\1^%FLHEETW1M.D
MLGD:0!W+A/F"_P# ,GGOQ0!N>$_$4OB*QO6NK-;2\L+V6QN8DE\Q Z8Y5L#(
M(8'H*WZY;P;I&HZ1-X@-_!'&M_JLM]"4D#81PH ;T/R^XYZUU#DJC%5+$#(4
M=_:@#SKX:V%I<0^.+:6VB>&7Q'>1.A489,+\I]N33/AY>P^%-.U_PMJ#",>'
M99)D<CF2T?,B/[G[P/X"MCP)HFJZ'+X@&I6\2+J.K3ZA"T4V_"R;<*W Y&/I
M3?$7@I]7\;:/K=O.(840V^I1C_EXA5A)&ON-ZC/L: -?PKI0TW1_-EMT@O;Z
M1[R[55 Q)(=Q4^NT$+_P&M>YN(K2UFN9W"0PH9)'/15 R3^52U5U*QCU/2[O
M3YB1%=0O"Y'4!E*G^= &!:>)M4NCHUVF@N^F:J1MDBE+2VZ,NY'E7;@ CKAN
M,CK4%QXSNGT?4M;TS3$O-+TZ65)#]HVRS+$<2-&NT@@$-C)&[:>G&8/"5EXS
MTRRLM!U.+3Q9:>%C&I13EGN(D^ZHB*_*2  23TS@9YJMIWAK7-"T36_#=I!!
M<6-Y).UC=M-M\A9LY61<9.TDD;<[O]F@"_+XWGGUO2K#2-+2\BU33VOK6X>Y
M\M2!MX8;25'S#)Y/M4,'Q"5?#<VH:A9Q6=U;ZH=*G1[C,,<H8*6,FW[F"#G'
MM[TVT\)WFD>*/#DEE"LFF:1I;V#2-(!(Q;9AMO\ P#GGO4.F:!K=C8:U!<:5
M97<.HZU->26LLJLLEM(.5.1C>" <=/>@"]XA\07-CX*UO4=2T*TO(+3_ )8>
M?OANH=BMO!9.F6(Q@_=/)JW=^*!;ZS8Z+:Q6BWES9_:HDN9S$KC.!&A"G)ZY
M]!C@]N9?P)J%OX)\4:+I4/D6VJ/BPL)KC<MHI4!LMS@%@3M&<<>IQKZ]X?EU
MZUAL=6\/P7]B+- FV=5FMK@9!*L<84C;R#GCH<T 1:AX@\0_\)?X3LHK.V@B
MO[6:YFMY;AE82+&N48A#PN_CCDCMBM&Q\6S:K?W46GVMM.EIJ!LKF/[21/$
M^PR%-OW<\CGISGL,E?"_B*RNO!EVL]OJ-UI-K-:WDD\S)N,B(-X.TEL%>^":
M;J/A&]U;7K74SIT-AJ]KJ/F+JUM,%\VT$A(1U&"S&/"X(([[NU 'H-8E_KSQ
M^((=!T^".?4'MFNY/-D*)%$&"@D@$DEC@#'8G/'.W7):KH6HVWCNU\5:7&ER
M#9&PO+1I C-'OWJZ$\;@V<@D<=Z *-_XNN]2\&>*?LUHEIK&D13PW4+3G$1$
M999(V"_,",%<A??%:/@K3HY?#F@ZA>:=9QWL&G10V\\3EV$1C4\DJN,XZ<_6
MJ$OA74#H_C"X6*(ZKXB5D$0EPD*^3Y48+8Y(&2<#J<#.,UTGAJVNK'PUIME>
M1+'<6MM' X5PRDJ@!(/IQ0!)K^J/HOA^_P!4CMOM)LX'G,6_9N"J6/.#C@5R
M<?Q U"&;0+C4O#_V72-::*&&[6Z#M'+(N5#IMX4G@'/3D@=*Z'QK_P B'XB_
M[!ES_P"BFKF--TB_\3>%/!UK=6J6UI8BTO99?-#>;Y: HJ <\G!.<8 (&<YH
M T+#QCK&I:Q?V<'A^(0:=J M;N=[X )'M#&0#;R0#ROTY.>&7'CV6#PS'XJ&
MF*_A]G&Z03'SUA+[1+LVX([[=V<'/7BK'AO0K^UU+Q0=2MHTM=6NS/$4E#'8
M8U0JPQP?ESQGK6-;>$==3P#+X%G2%K;FWCU,2C'V8OG)3&?,"\8Z9P<T ='<
M^);FXO-1M-"LHKZ73H$EF,DYC#,ZETC3"MEBN#G@#<O7G$,OC)0NG6_V:*RU
M"[M/M;P:E-Y'V=<@;6X)+;C@ #^$GCH<Q]"\1^&O%]]J7ARTLK_3M4BA2:VN
M;DPM;R1($5PVULJ5 R,9XI^LZ'XHL]=TWQ)HS6=_?QVC6=_:3N84F0MO!C;!
MVE6SC.>/7N 36'Q 6^TBTD&FLFJW5^VGQV;2?(TBC<SB3;S&%&[<![8S6/:7
M5]8?$[Q1=RZ?:K<P:+#*$CF(28!W.[=MR">1T/2M'7O#_B74XM%UR/[$-<TR
M\:Y2R\P^28F38T0DQG..=Q'4GC&*=:Z%KU]XQU35;ZSM;2TO])2R*K=&22-@
M7/0* ?O>H_&@"Q_PG$AT;PIJ8TU?)U^>" K]H^:!I5+ _=^8#:?2DA\7ZS>^
M)-3TBR\/1R?V;=017$K7H4".10V\#;R0#G;['GI6!!X8\6MX>\):7)8:=&=
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M[K8&Y2""#@=: -ZBN-O/%6O/XIU/P_I6B6DUQ:6T=Q'-/>%$97+#YL)D'Y<
M#/N16<GQ+NKCP_I&H0:(/M%WJHTFZM9+C#6\^2"!\N&''7(ZB@#T.BN/;Q7J
M5M-!IFHVEC::O)').P$[RPI$K[4;(4$EO3 Z$GL#G3?$+48?"J:W)H:PI!J
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MW7_#Z6^G&#[7!=P74:SL51S'(&VD@$C('7!KHD1(HUCC5410%55&  .@ IU
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MK]??K0 NFW$]WI5G<W-N;>XF@226$]8V*@E?P/%6J** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBOFCXC?%'QKH_Q)O;*RO'L[:RF"06HB!65< AF
MR,MNSG\>* /I>BJ]A--<Z=:SW$)AFDB1Y(C_  ,0"5_ \58H **** "BBB@!
M&8*I9B H&23VKEI/'5FFDMK TO5)-(P62^2)&1UZ!@N_?M/9BH'?@<UTUPL3
MVTJSX\DH0^>FW'/Z5Y+/%XC^&6E2(57Q)X'"$,A.+FTA;J,]'0 __LB@#UZB
MN'N-:NO$/B6ZTO3I9EM(-/@NE:"X$+N9MY#Y*DX4*O'3+'.>*K66I^(DOO#G
MA?7KV)-0N8KF6\N;1@#*L6-B@X&UB&!; 'W>,9H [Z66."%Y9G6.-!EF8X %
M5;F_EM]4L;-;"YFCN?,WW,8'EP;1D;\G/S=!@'FO//'>FZK9>!+V&^UR:Y"Z
MK;M;%#M=8'G0*DA_CQEN>^!G.*W=4N=0TWQ_X0TZ+4[F2RO$O!/#($/F%(PR
MDD*#U;UQP.* .SHKSJTU35/$WA37=>M-4N+.[M;BY6RBCQY<8A)"JZD?-NVY
M.>F[C&*KVVOZQXBUSP@T6IW&GVNLZ1-<SP1(AV.H3E"5)_B/7/'09H ]-IDS
MM'"[K$\K*,A$QEO89('YFN4\ 7]]=6>MV=_>2WC:9J\]E%/-CS'C4*R[B  3
M\V,X[5UU &%X8\56?BRTN;FQM[N*.WG:WD^THJ,)%^\N Q(QD=<59L-;34-7
MU#3DLKN-K%E26:15\LLRA@%(8DG:0>G&1G%<2]Y#X!^)FHFY;RM&U^V>^0]D
MNH5S(![LGS>YP*[3PY936FD(]VNV^NG:ZNAUQ(YR5SW"C"#V44 :U%%>;^'_
M !+<-X@M-,UZXU#3M=5Y7FM9QFVOT"M@P,!C ^4@#!X.<GF@#TBF"6-IGA#J
M9$4,R \@'."?K@_E7F^FWOBSQ%H.D>)-*N%BEGE6>5)KD?9V@).Z+8%X('&[
M.<CDT[1+;4(_&'Q!DL;VXEO(6B^S1SR QM(UMN4-QT#'@#  H ])HK@_!GB%
M-3UG[%<7.IVFJ06A^V:3J0^;?N7]]&<8*_>'RG'(X%=Y0!A:MXE33KJXM+2P
MNM2O+:V%U-;VNW<L9) QN(RQVMA1R<?3.O:7"W=G!<K')&LT:R!)4*NH(SA@
M>A]17G^G6QMOBQXHN7O;QEM["UF*AE.\?O3M/'08X%5)==UJ?X5KX[M]2D74
M%0WIML@VYB#X,)7'0+QN^]D9SVH ]1JI>ZA%9VMU,$>=[:/S7AA*E]O/8D#L
M>I[5PDTVM:_X[N=+MO$%]IUE-HL-]&L4<>^%VD(P"5Z8'.<GW%1:!:2IXC^(
M#/?WDWDRHN)7!#9M@>>.V> , 4 =UH.L0^(-!L=7MXY(X;R%9D23&X ^N.]:
M->/:!/JFB^$/AWJ$&K7)BO+BVL);(J@A,4B-VQNW J#G/KT'%>PT %%<IK\]
MR_B."R34)_*:R=UL+#Y;AI-P E9C@*@&0-Q )/?I7-Z)XOU35]"\"6,]V8[W
M7?.-S=HH#;(%8L%XP&;"C(Z#.,'& #MK#Q'#?^)=4T-;6XBGTZ.*1WDV[9!)
MNVE<$\?+WQ1K'B.'1M4TFPFM;AVU.X^SQ2IMV(VTM\V3GH#T!KSV[U23P7XF
M^(&JK++>-:Z99R0+<-N()\P*I/4@,>IYQWK0\0Z?<6VN> KB?5+F[DDU(>=Y
MC H[F%SO4 ?+W&!@8/MF@#OK6_EN-2OK1["Y@2U*!+B0#RY]RY.S!SQT.0.:
M9?:H;;3X;RTM)]1262-56UVL=K$#?R0-H!R?:N*DO-2NKSXC:=/JMTT-C!$;
M5E*HT(: R$*5 [\9ZX[]ZSOM&HZ+\(O"=W8:K=1O(=.1P=C I)Y:E.5R!@]C
MGWH ]6HKCH=0N/$7C?Q!HGVRXM+;2(;<*+=MCR22JSERV,X   '3.<YXQRC>
M*/$5SX?T]3J;P7]IXI71;J9(DVW2"3&XKCC(QD*1W_  ]<H/ Z9KSZWOM5TK
MQ3XFT=M=::*/24O[>YU+9MMI"74DE54;,J"1CC%1Z+K&HQ>-=#L?ME]<65_I
M<LLKW0 6:5-G[V-3\R [CP0HP1@=Z .L\/>(H/$2:BT-M<6YL+V2QE2?;NWH
M%)(VDC'S>O:MFN*^'7^L\7_]C)=?^@QUV4L9EA>,.\992-Z'YESW'O0 12QS
M*6B=74,R$J<X()!'U!!'X4^O%;"XU31_@-<ZOI^LWL5XES*0S%7'-XR'[RDY
M(8DG.<]Z[74K;4=(EM(Y_$]U/'>WQ9X#&//D7RS^Y@V#(&X!B>R@_,.20#M:
M*\BOO$>OQ_#/QC=1ZE=VUYI&J26]O(XC:41 QX1S@@D!R,@YX'-=-Y^JZ1\2
MM.L)-7N+VVU.QN)9(9U0)')&4P8PH!488C!)]R3S0!V]%><^%?$=Q<:[9:5K
MESJ&G>($60W5E=#]Q>X4_/ P^7 Z@ CC.0<9JI#KNJVU_P"%9AJD]]]OU)[6
M\N4 %G."LA B4\_+M&&48.#R: /4:898Q,L)=1*REU3/) (!./09'YUPUG/J
M_C"PUVYT[6)-/O+34I;.S"@&.+RF /F+CYRW).>@(QC',4-K++\:92=1N2/[
M"BFQ&XV9,Q! !!PIV@_UH [33K^6^^U^;87-IY%P\"^> /.5<8D7!/RG/&>>
M*NUY8OB_5M*\)^)KB:^>YNX?$3Z9:SS(O[I"T:J2% 'RAB>G)^M;FJ7>H^&_
M&'AZUBO[JZT_6&DM9XYR':.0)N65#CCH<C[OH!0!V]%>.7.K^(XOA_KWB+_A
M([QKO2-4GCA39&$E1)@F) %YRN1Q@#TKH/&6OW>C:Q<#4Y-2L=&FM46SU2R7
M?':SG=N,R@$]TQD$<>N30!Z'3)98X4#2NJ*65 6..6( 'U)('XTEO(LMM%(D
MBRHZ!ED4Y# CJ#Z&N(^)D$DI\*[+NYA#:_:QLL3[0023D\<D$#&>* .BA\1P
MS>+KCPY]EN([F&T%WYK[=CH6VC;@D]0>H'2MFO.KC3I[OXO3V<6IW5KCPY$K
MSP[?.8"=_P"(@@'U./RJ'1->U34?!6@2WNL%)GU":VN3&G^D7JQO(H2,*.&.
MU2Q&, ,<B@#TB66."%YI75(HU+.[' 4#DDFGUXQKVHZEJ7PL\<0WEW>(=-U)
MK>'>Z^9Y7[LB.1ESN WD=>>,DU[!9P&VM4B,\LY'_+24@L?K@"@">BL+Q;<S
MVNBJT&I1Z>6N84>4H7=D+@,D8 ),C#(7 /)_&N2M]:U<'Q]9)>7ULNEVL5S8
MFX\N2:$M"[$$G<",H#@Y(![=@#TJBO,8=1UO3/"F@:M+KEU=W.NK86OERB-4
M@>1=S.AV_>(XRV1N.<'H.ET*T\1V?B2\%Y.'T6: -!%/<>;-%,#AL':,H0<\
MDX/UH ZFBD(R" 2/<=J\GC;Q3JGASQ5J,/BN]ANM&U*\2T411!9%AY"R?+R"
M!CC Y).: /6:*\OBU77/$VO^'H8M:NM-M]7\/->RQP)'F*3]WRA*D_Q=\\9Q
M@G(U](N+WQ'JVOZ8^KWD"Z.T5E%)"51WD\L,TS\8))/"_=XZ<T =!K/B.'1=
M1TFSFM;B0ZG<BVBE3;L1\$_-DYZ ] :U9Y##!)(L;RLBEA&F-S8'09[FO(I-
M;U'Q-H?@:YO)%AU%?$#6LLT:#!>-9D+J#QSC/IGMCBN@TZ\U:VU+QOHIUF[G
M&G00W%G=3"-I8S)$S$?=VD97C(Z&@#>E\6I;2Z!#=:5?6\NLOY:+($_</M+%
M7^;(. >@-=!-(8H))%C:0HI8(F-S8'09[UY1<W-_K.@_#"YEO76^NKA'>ZVA
MFW&W?+ 'C/7J,9['I6G;76NZ/XC\0>&I=<N[R%=)_M.RO9DC,T!W,A0G;M;E
M<C*]* .ZLM0%SI=K>7,$EBTZIF"YP'1FX"G!ZY.*NUY'=S7NL>&OAE?76I7?
MVBZO;?SF1PN]FA=BQ&,%LCCTYK>N+S6M>U3Q#I>FW,\+Z68[:WD2X6,B0Q*_
MF.-IW9+8QTPIXR: .^K&\/\ B*'Q"=3$-K<6[:?>O92K/MR755)(VDC'S>M<
MY9:KK&H^)]-\+ZI<I!<PZ3]NU![)\>?)YGEA5; *KD,QQ@YP.F<K\-(7MY?%
M\,D\D[)X@F'FR8W,/+BQG&!G% ';W$I@MY)5B>4HI(CCQN;V&2!GZFL[PWKU
MOXF\/6>LVL4L4%TI=$EQN #$<X)':M1_N-]*\/TEM<T#X,Z1XKT[7+@&PC#M
MIIC3[/+$92K*>-VXYSNS] * /<:*X:?6+GPY\0'35M1G;1=2LGFL_-P%MY8A
MNE3@9.4^89/8BNC\-QWJ:'!)J,LSW4^9F64@F(,<B/@?P@A??!- &J[K&C.[
M!549))P *Q=0\36VGZYHVF-;SR'5F=8+A-OEC:A<YYST'IWK,^*".WPTU\I/
M-"4M';,3;2V!T)]#W]:PM<LYDU?X>6\5].)'GFQ.X5W3-LV<<8Z=,@^X/2@#
MT6\G:ULI[A()+AXHV=88L;Y"!G:N>,GH*2SG:ZL;>X>WDMWEC5VAEQOC)&=K
M8XR.AKSV#4M8M-/\?Z<-9NY9-%7S;.[E6-I5#6_F[3\N" WMG!I][K^JV?AK
MPIJEU#J-WI4NG+)J<MAS.DC1QE9& ^8I]\G'MGT(!Z-161X7O(=0\-V5W;ZG
M_:<,JEDO,8,HW'!(P,'L1@8(-:] !1110 4444 %%%% !1110 4444 %%%%
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MVJ3:KJ#W.E"01%C&1(9!AR_R=QV& .P%:EQ?30ZI8VB6%Q-#<B0R7*%=D&T
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M\=S<3SV[)$H0$C8YX?<2%P.Q8]J[:BB@"CK.DVVNZ+>Z5>;_ +/=PM#(4.&
M(QD'UK%/@J)Y]$GEUG5)9M'9FA=VB.\E=AW#9_=XP,>O7FNHHH YAO!-LTGB
M%SJFH9UY EU_JOE 39\GR<?+QSG\ZFMO"QL8-+CL]8OXCIUJ;2,L(V$L?RXW
MC9@D;!@C'?KFNAHH S]$T:TT#28M-L@WDQEFR^,LS,69C@ <DD\ #TK0HHH
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M(?O$KC(SW (!Z=.* *MWJL_AKXA ZGJ4S:'J=F[VWF/^[MYXQN=?HR?,,^A
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)) DB<.I(Z\B@":BJ]WJ%EIZ*][=P6R,<!II @)_$T]KJW18F>>)5E(6,EP
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MXWE0.."^["_[P"Y([ B@#7HJLFHV,MZ]E'>6[W2#+0+*I=1[KG(JS0 4444
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M)QE=B@!B "W?[I[UE7-Y#I7A/X;S7$_V+2)%A^UW*(I5)#;?NF?<",;NY'!
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MN]1BU&YTNRFOH<>7<R0*TB8Z88C(HU#1-*U9X7U+3+.\>$YB:X@60H?;(.*
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M_$,XU*PN(G%K&85N!=#B1&&S>0Q+%L]1R3WKT[3M$TK2&F;3=,L[-ICNE-O
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MDZ='&]S>0F)3+)L5<]R<'^5=%10!@6@UVRTS0K6&QM28_+AO_,G/[N-4P63
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M.DV/Q(U3Q&NLV/V2[MXRL'VA,"XP5=\9X.Q5&>^YJZO_ (1W0_\ H#:?_P"
MJ?X4?\([H?\ T!M/_P# 5/\ "@#E/!&DZ5X3FUG.LV+Q7-XS6B"Y3$-ODNJ#
MGC#R2?I7>*RNH92"I&00>"*SO^$=T/\ Z VG_P#@*G^%:*JJ($10JJ,  8 %
M "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3[46.GP6P9F\M "6=G)/?EB2>?4UYW9VUU/J/Q(T^SU%[69YH([>>>5F$3/
MI'))(!9NW3/% 'IM%<%X*OU'B2^TV_T$Z)K:6D;R00,&MIXE9@)8R..K8.>>
MF<XX?\18/-O_  CB>XB\S6XH7\J9DRA20D8!QG@<]1V(H [JBO(KVYG\)7/Q
M&BT5I8HK6PM;J&,.SB&1U<.ZY)YP Q]Q6[!HAM-0TSQ)I>KV:QM;2*+>TMV
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M--$H-WY)G,8ZA-VW)],GI]#Z5:KSU=/LU^-6IW LXWF71(;A>.6D\UQG/K@
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MZ,_*;>3Y"Q'<HS*P].: .XJE+)J0U>V2&"W;3C&YGE:0B17XVA5Q@@\YY_\
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MY/*XVYSVK;H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;),Z1YVJ6&<#-;&: .9MOA]X7M#:&+3"19R&2V62XED$)_V0S$ >PX]JM_\
M"):+C4Q]ED_XF@Q>_P"D2_OAC'/S>G'TXZ5LNZQQM([!44$LS'  '<US&C>(
MM2\46K:EHUI;1:479;>:[9M]R%."P4#Y%)!P223UP* +[>$]&9=-4VTF-,Q]
MC'VF7]S@8&/F]./IQTK@E\)+<ZE>OK7@:]FU*XN9)6O=/U,0V\@+':W$J,N%
MP#\I)()Y)KT+0]2O-12]%_8"RGM;DP&,2>8& 56#!L#(.[C@>_-:O6@"AHME
M-IVC6EG<3O/+#&%:1W+D^VX\MCID\G&350^$M$)U(M9LQU/'VS=/(?.QTSEN
MV,<=N*VLT4 4+'1;'3[A[F".1KAT$9FGG>9]@)(7<Y) R2<>M-U30M.UF6TD
MOX'E>TE$T!$SIY;CHPVD<\GGWK1HS0!EQ>'=*BU.\U%;8FZO4$=RSRNXE0#
M5E)(( )XQW-4]"\$>&_#5W)=:1I<=M-("-P=VV@G)"AB0H/HN*Z"B@#GK+P-
MX:T[6WUBTTF**]=S(65FVASU8)G:&]P :;>> _#&H:[_ &U<Z1"^H$@M)N8"
M0CH70':W;[P-='10!CW7A?2+VYN[B>WD9KS:+E!<2+',  H#H&VL, #D<BBZ
M\+:/>7%U/-;2$W85;A%N)%CF  4!T#!6&!C!'2MBB@#"O/!GAZ_U&>_NM,BD
MN+B$03'<P61 , ,H.TD#H2,CM26_@S0+67398+%HWTU2EH5GD'E C!Q\W.0
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MQ7]C;(IBN)VD6*4)M9D7<4!^]R.Q/J:W;#0--TS4;R_M('2ZO2&N',SMYA'
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MA/.+B3RLH3(.C J001VQC%:5CIMIIPE^RQ%6F;?+([L[R-@#+,Q)/  Y/04
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M9#>Z=K-VUG.96+6Y28;2ASP?4]3WKJO&<5]#J-YJS:7;:_I'V!(KVT#!;FR
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MI$U34H5DB78ZH.0H88( P..E>@VOA[2[+4;K4+:W:.[N\?:)1,^Z7 P-W/.
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M^G'2@#SFZL+?34^*>EV*-;6-OI\5S!!"[(L<C6\A9E /&2JD_2DN="@TBS\
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MD9CDL3$I))KRR#POHM_\.O&%]<Q;;O3]0U%[2X\PAK9HW+)L.?EY SCKQ[4
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M]ABM:2Y@A#F6>- @!;<X&T'IGTK%UG4]8LM?T6"RM[*?3[J1H[G?(PG7C(9
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MFAZ196^ASVS1378GV&V#$A@L6T[B5)P<]3STYZB&&.V@C@A0)%&H1$4<*H&
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M(8(E"1QQJ%55'0 #H*EHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MPQH+:;;Z<VC6#65L_F0VYMU*1M_>"XP#R>?>@#B)/,L?'?C:XT6%/M9T&&:
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MYSY<R!U)^AXH \VLM-U?X=>+M$TJPU6?4O#FJS/;I8W1WRVA"%MR-U*#'(Z
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MV%NUO:VT4,3$EE10 Q/4GU)]35+3/#&A:++<2Z7I%E9O<<2M!"J%QZ' Z>U
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M@PR@# N.P!)8C;V2M?P[>7]_X?LKK5(8H;V1,RK#G83DC<N>0",$ \\UJ44
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MY^.N3WZFMR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBJ]W?V=@JM>7<%LKG"F:0("?;)H ?<6T
M%W;O;W,,<T,@P\<BAE8>A!X-4CX=T,QP1G1M/V6YS"OV5,1'U48X_"K;7MHL
M\4+74(EF&Z-#(-SCU [U2T::8:;)+>ZK:WY6:4FX@4(BJ&.%."1E1P3GM0 ]
MM T9Y;B5M)L&DN1B=S;)F4>C''S?C3H=$TJWMYK>'3;1(9@%EC6%0K@= 1CD
M#TJ2UU*RU**1M.OK6YV?*6AD$@5NV=I_2N?\%>(+O4_#M[?:U<VX>VO[F!I0
MHBC"1R%0>3QP.YH VGT#1WTLZ6VE6)T\\FU^SIY6?]W&*=8Z'I.F2>98:79V
MK[!'NA@5#M'1<@=/:F3>(=&@TFXU1M3M#8VP)EG2965<=L@]?;K3=,\0Z;J>
M@P:Q'=P):R1)([-*N(BR@[6.< C(H ?IV@Z/I$TTVFZ596<LYS*]O L9?ZD#
MFM&JD6IZ?/8&_BOK:2S )-PDRF/ Z_-G%/M+ZSOXVDL[J"Y13M+0R!P#Z9'>
M@"N="T@SW$YTJQ,MR-L\AMTW2CT8X^;\:8?#FAF"& Z-IQA@;?%&;5-L;>JC
M& ?I5B[U33]/9%O;ZVMF<9433*A;Z9/-%YJ>GZ= L][?6UM"_P!V2>944_0D
MT ,31=*COVOTTRS6];K<+ HD/_ L9IIT+26U$Z@=,LS>DAC<&!=Y(Z'=C.1Z
MU+)JNG120QR7]JCS -$K3*#(#T*C//X5*+RV:Z>U%S";A%W-$'&]1ZD=0* (
M?[(TW^T?[1_LZT^W8Q]I\E?-QZ;L9J,:%HXDN9!I5B'NABX;[.F91_M''S?C
M4EIJVFWYE%GJ%I<F'_6B&97V?7!X_&DAU?3+B01PZC:2.8S*%2=2=@."V >@
M/&>E $)\.:&UO#;G1M.,$+;XHS:IMC;U48P#]*67P[HD]Q<3S:/8237*>7/(
M]LA:5/[K''(X'!]*FM=3L=224:=J%I<N@P3%(L@0D<9"G_"L3P%K-_KOAR2[
MU.2)[E+VX@+1)L7"2,HP,GL/4T ;;:1IKS6LS:?:-+9C;;.85W0C&,(<?+^%
M%KI&FV+S/9Z=:6[3G,IAA5#)_O8'/XUA-K.I)\48M#:6$Z;)I,EVJ+%AQ()4
M3ELG(P3T Z]ZW8]6TV6^-C'J%H]V,Y@693(,=?ESGB@!ECH>DZ6S-8:99VK,
M-K&"%4R,YQP.F>U1CPYH8MYK<:-IPAG;?+']E3;(WJPQ@GZU+_;6E&.5_P"T
M[/9"0)&\]<(3V//'XU(-3L"L#"^MBMP=L!\U<2GT7GG\* )H((;6!(+>*.*%
M!A(XU"JH] !TJ2JD>JZ=+>&SCO[5[H$@PK,I<$=1MSGC!JW0!7O;"SU*V-M?
M6D%U 2"8IXPZD_0\55F\/:+<&,S:38R&*/RD+6ZG:G]T<<+R>.E$KW \1VR+
MJ=LEL;=R]BR#S9&R,.#G.!R#QWJ1M:TI&C5M3LE:24PQ@SJ"\@ZJ.>6Y''6@
M"ZB+&BHBA548"@8 'I5:^TS3]4C6/4+&VNT1MRK<1+(%/J 0>:+W4K'38UDO
M[VVM48X5IY50$_4FN?\ %&MZAINK>&$L9X/L>HZ@MM.#'N9E*,P*MG 'R^GX
MT ;G]B:4+MKL:99?:63RS-]G7>5QC;NQG&.U0_\ "-Z%]B-G_8FF_92V\P?9
M4V%O7;C&?>K(U33S'/(+^U*0'$S"9<1G_:.>/QI\E_9Q60O)+N!+4@$3M( A
M!Z'=G% $5QH^F7=BEE<:=:RVB$,D#PJ44CH0,8!I'T32I-/&GR:99O9 [OL[
M0*8\]<[2,9KF-"\17VL:MXOM?[3L6@L#$ME=11CRT#P[]S?,=V"1GGMVKI+&
M]CATS3Q>ZG:3W$T2@3HRHMPVW)9!GH>3@9XH =/HFDW-M!;3Z792V\!S#%);
MHRQG_9!&!^%+_8NE?;#>?V99?:BFPS^0N\KTQNQG'M4MEJ%EJ,!GL;NWNH@Q
M4R02!U!'49!ZTR#5M-NI#';ZA:2R#&5CF5B,\#@&@"LWAG0&LFLCHFFFT=Q(
MT'V5-A<=&*XQGWJPFCZ7$URT>G6B&Y01SE8%'FJ!M"MQ\P XP>U7"0JEF(
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M6HM6T;3VMQ(9A$;5"H<]6QC&3ZU;N[ZTL+<W%Y=06T X,DT@1?S/%207$-U
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M8)R3Y6_<&"\%QDCC.>*T?&.E:!#\/O%UWIFH/J(N+JVGFG+QM$DQE0-Y910
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M%<ZOXI\4VLFH6UW86#VXM9(%4*JO&6;D$YP>.3V[5PWAW6+>UA^&,M[<1KI
MLI8O-+#RX[O8 H<] V-P&?4TW6;Z(W?Q..DRI,V_3YI([5E9I(E5?/('(/R[
MP>HZYH ]>L=9TO4Y98K#4;2ZDB ,B03*Y4'H2 >*M3N(X)':58@JDF1NB^YS
M7$:'+X9USQ1I^MZ;K\VJZBEH\8\MX\1PGG$JHJD?-C ;G/;@X[._2*33[A9E
M1HC&VX.,C&.^: ,[2M1@MM$T[^T-?L[Z:?$:7BE(ENG)P-B@XR>F!FI%\3Z
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MH7\3:#%Y?F:UIR^;*88]UT@WR#&5'/)&1Q[UQ5U;V5KXX^'0MXH(A+:WBD(
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M*0AY9%E0-NW!T5>IR"5Z $5:\4>+9XO$]OX<TC7-&T[4/+$LG]HJ6W[CA$0
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ME=13^4VR3RVR4;&=K#L<$<'UJ"^U_2-,E,5]J5K;N &9990NT$X!;T!/ )H
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M*X'TXJPMO MPUPL,8F90K2!1N('0$]<5FKXIT![J.V36K!IY9S;I&MPI+2@
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M;CUSA0>3WH ZX:=8K;26PL[<02??B$2[6^HQ@T#3K%;(68L[<6HX$ B78/\
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MM=4N[*'498XU6!4("':<*<>_6NO?4K.PT^WFO;^+:ZJ%F<A?-.,Y '4GDX%
M"6^AZ5::A)?VVGVT-W(H1Y8XPK$ D]O]X_7OT%3'3[(WOVTV=N;O&//\I=^/
M][&:IMXFT%+>TG?6=/6&\.VV=KE )CG&%.?F.>,"KK7]FM^E@UU"+QT,BP%Q
MO91U8+UQ[T 6**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *X7XN- / K>>8P#?6F-^/^>Z9Z^V
M?PKNJ9)#%, )8T<#IN4'% '!7*V ^-NE@"VW+H4NP?+P1*FW'X%L>V:Y"^FM
M#\(?B'&LL)1-:NQ&H88&95*X_I7M7V6WW!O(BW#@'8,TGV.VVE?L\.#R1L%
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M;7T#J?(E\UFB8YX*G&.>#G\:[+P+J&J73ZS::L+.>YM+I4.HV2XCO,QKAL=
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M71? ?PXM-5E\B==?BD6.=MKI"?.* @\C"L@]L@4 >GVUW!-XLO(8M=6=X[9
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M/2JH\0:2; WHOX?LXE\C?GK)G&P#J6SQMZYXK$\=06US!I*/K3Z-?B]W6%Z
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M36EELBB8%I L9$@ '4[<K^(%;>MWEEXI7P/-X?FBDNHM3AN=L+#?!;JC><'
M^Z,84@XYP* .XLM>TK4ENC97T-P+5BL_EG=Y;#J&]#[=:CD\2Z-%;07#:A$8
MKB,S0E,L7C'5P "=HR/FZ<BN.U6TO='\?W-G8QR?8_%< 5WCZ6\\>!(_MF$D
MCU915C6=4TW3_B!:Z83#I<ITG$=[LS),GF8%O"IRN05!(PQ.0 .] %OQEKEQ
M#IWAW4-%U,"VO-7LX':$(Z3PR. 1D@]NX(ZFNSKPS3]2LQ\(? J-<QJT.N6B
MR!VV[2L[%LY]!@GTKW($,H92"",@CO0!3O\ 5K#3"@N[E8W<%E3!9F ZD*,G
M R,GH,U!+XDT2&QM;Z35K-;6[8);R^<NV8DX 7GYCGTKEEO1I'Q?U%]7E6"V
MO]-A73YYFVI^[9C)&&/&[+;L>E<7J<$-EX*U)[AXDTN]\6I<6*2$!6@\Y-S*
M#_ 2'/ICGH: /8]*UG3=<MY+C2[Z"\ACD:)WA<, XZC/XC\ZO5'"D*IO@6,)
M(=^8P,,3WXZ_6I* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *1E5U*L 0>Q%+4-W>6]A:275W.D$$
M8R\DC8"B@"7:N2<#)Z\4;5]!^5<+:>(WNOBO)8QZE.=-317N)+6>+RA#()4&
MXAE5L;3U.>IQ6UH>K:=%H#7BZ\^J6S7,BK=. Q9BY C4*/FP?E& <T ;S0Q.
MQ9HT9B-N2H)QZ?2GUBS>+-"M[&6]N-1B@@BF^SR&8,C+)@'9M8 [L,.,=Z8/
M&?APW-U;C5[?SK5!)(F3G;G&5X^89P/ESR<4 ;I (((R#VI,#&,<5S>H^(M%
MU'P;=:E!XB2QL75HQJ$; -$XX. P^][8S6E-K-AI\,"W%T[LT/F96)G8H,9=
M@H^4>Y % &BR(Z%&564\%2,@TH154*% 4<  <"LV7Q!ID4%O,;DNEQ#Y\?E1
MO(3%@'>0H)"\CDX'-)-XCTF"&UE:[WB[A\^!8HVD>2/ .\*H)VX(YQ@9% &F
M44XRH.#D<=#1M7!&T8/48ZUQ7C;79?\ A%]+U;0M5*P3ZA:IYEOM99HWE52,
MD$CKV(KM)9%AB>5R0B*68@9X'L* %P,YP,TABC:02%%+J,!B.1^->?:+K-QX
MMN+^]AUVXTU]/U25501?N6M8F"LKA@!EN3DG*Y]!BNNM/$FD7MXEI!>+Y\D9
MEC21&3S4'5DW ;U]UR* -3 SG S0 !T %84'C7PU=7T-E;ZS:RW$T[6\:(V=
MTBC)4$<=/\*UKR]MM/MS/=S+%'D*">[$X  ZDD\ #DT 6*:D4<0(C14!.3M&
M,FLN+Q-HTUE>7@U")(;)MER908VA;T=6 *DY& 1SGBEA\2:3.MX4N6#62AKF
M-X722)2,@LA 8 @$YQC@T :@4#H *6LO_A(]'\C3I_MT?DZDRI9R8.V9F^Z
M<8R>PI9_$&EVUU]FEN<2"9("1&Q19'("H7 VACN7@G/(H TMJ_W1USTHVCT'
MY5EZEXDTC2'9;^]6$)M\URC%8MW3>P!" ]MQ%:BL&4,I!4C((/!% "%%((*@
M@]1BA$2- B*JJ.@48 IU%  0#U&:0 #H,4M% #7BCD*ET5BIRI(S@^U*0#U
M-+10 F!G.!FD$:*[.J*';[S <GZTZB@#G]&T;5HM1>_UW4X;Z>,/':K!;^4L
M4;,"<\G+':HSV ]R:Z"BB@!" 3D@4;5]!^5+10 A13C*C@Y''2LG7;/6[F.V
M70]2MM/82DSM-;>;N0C^$9&#GFM>B@"MIUC#IFG6]E!N\J",(I8Y9L=R>Y/4
MGU-6:** $  Z "D6.-"Q5%4L<M@8R?>G44 ,6*-&9D159OO$#!/UH\J/<6\M
M<L02<=2.AI]% "8&<X&:  ,X &>32T4 !&>M)M7T'Y4M% "8 .0!2T44 1O!
M#(ZN\2,Z?=9E!(^E2$ @@C(/4&BB@!J1I&@1$54'15&!2[5]!^5+10!3U2VE
MNM*N[>W$8FFB:-3(2%&X8R<#WJAX2T27P_X:T_3+@P23VD"6YFB!'F*HP"<C
M(^G-;=% #2B$L2JDL,'CJ*7:,YP*6B@#(UVTUNYBMUT/4K:P<2YG>:V\[<F#
MP!D8.>:NZ=81:9IUO90%C'"@4,YRS>K$]R3DD^IJU10 $9ZTFU?0?E2T4 )M
M7T'Y5S7B+P_>ZMKV@WUN]JL.ESO,\<N<R[D*%>!QP<YYKIJ* &HBQH$10JCH
M%& *$BCC+%$52QRQ QD^].HH 8(HQ)Y@C4.1C=CG'IFE,:&02%%+@8#8Y ^M
M.HH :T:.RLR*S+RI(R1]*55"J%4 *!@ #@4M% #719%*NH93U!&11Y:; FQ=
M@Z+C@4ZB@!-JY)P.>O'6C:OH/RI:* &^6GF>9L7?C&['./3-+@9S@9QC-+10
M F .PIJ11Q)LC147^ZHP*?10 FU?[H_*FF*,NKF-"Z_=;'(I]% %--.B&JOJ
M+DO.8_*3@ (A() ]<E5R3_='2KE%% ";5]!^5&T9S@4M% #1&BNSA%#MU8#D
MTN #D 4M% #%BC3[L:C!)X'<]30T4;MN:-&;!7)4$X/:GT4 )@>@HVKZ#\J6
MB@#FM:T36IM=AU72-1LU"6YMWL[ZW,D1!;<74JP*L< 'J" *NZ-H\EC<3WUX
M]J]]<(D<AM8/*C"J6( !)).6/)/X"MBB@ (!ZC-)@8Q@8]*6B@!J1QQH$1%5
M!T51@4NU?0?E2T4 )@ Y %(L4:,S(BJ6.6(&,GWIU% "$ D$@9'2@JI() )'
M0XZ4M% ";5 QM&/3%+110 V2..5=LB*ZYSAAD4I /4"EHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *X?XG27%IINB:B(I)=/L-8M[G4%C4L1"N?F('4*VT_@#VKN** /.+
M77=*U+XR6U[8WD5Q;/X?=!<1?,A/GAL;AQP ?IS6+H@TN]^':P7>JR:<W]OW
M#6][ X!MI?-D>-VSQM(XYX(;\:]A  Z"B@#QCQ#J>H7/PS\2VFLRV5W-#J%M
M%'J-J@5+\!X26V]"RJ,-C@;2.QKJ-1N;%OC%X>=9K=@-+N0K!@<%F3:,^XW8
M]LUW^,# HH \7N+JV;X<_$V-)HB9-6NS&H8?/N";2H[Y(.,=<&MO77B>^L=0
MT;Q-#I.M0:3&R&Y*M:WD.6^1@>X93R.1N_+TVC /6@#RFZN);R+1]4M=4C\+
M>(X]'C?[+= ?99HB3^Z96Y&"O;Y@&[]I;7Q&CZQX;34+%=!NKK1-PN$@+2'+
MK_HT0(./NAL$$XP!@\UZB0#UHH \,M+VW7X(>'[=I"DL&KPK(LBE2I6[+'KZ
M+R?2O<?,C\KS=Z^7MW;\\8]<^E.HH \82.YUGX6>.;+1G$][)J]W*D,;9:6+
MSE8X'4ADR!ZYKH=;OK+Q??>#+C0+B.6XMM12[F,9&ZVMQ&WF+)C[F?E7!QD\
M=J]&HQB@#@OAM):37'BPQM"\A\07,H(P25(4*P]OO8/UI_Q#O)-'U#PQKTT4
MLNDZ??.U]Y:%O*#Q,BRD#LI8_G7=44 >;^(M?T"7PKJ^N:7I-O?6MQ-:BXO7
MMV\J5@X D88#.L0"G(X[9X.*>E745W\1-?C@O9[]K[0XO(G:+"S$&3)4A0NW
MD 'IVR37JF.,44 >(6VN:?-X$^'EG',SW%AJ]DEW&L;$P,BN&5^.#UXZX!/2
MM?4KF72M;O-0\/:I'=K+JB+?^';L!G>7S%7S(?XE/ ?N.">V*]8P/2C SGO0
M!Y&=0T.QU[Q/X?\ &+7\,FH7LDUNBO/Y=[!(JA541GYF &W'7@#MQZ#IFI:9
M8SZ=X;C$EM>#3UFBM'#.8X5PF"_()!P.N:V\44 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI8^']1>VGCU6WEDLKJ.$H4EC&71UW'(P0001Z>] &IJ/BO1=)N/(O;PQD2I
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MCR!@'GKFM*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+DE , Y.[G.>M2>$_#47A?3[NWB\M1=7DEV881B*'?CY$']T8'IR3P.E;]%
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M'5M9C6)WV'RX45"B*!G)QEB3QDGM6AX5TFYT'PSI^D7,T4[64"0++&I4.%&
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M^J&&TMK>262"WBBDF;=*R(%+GU8CJ?K0!-1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6/XEO;
M^PTV.:Q:UBS<1I<7%RX58(2WSN,D L!T'J>_2MBN?\6>'KGQ!:Z?]COUL[JP
MOH[V)I(O-C=DR-KKD9'/J.0* .:7QCJXTKQOY,L$LV@1^=;3W%JR&5#!YN'3
M*\\$9& >#CUGM/$7B&#6/"1OY[*:SUZ)E>"* JT+B'S P?=\V<$$8&*ED\":
ME*WBHOKT3?\ "0VRPRYLO]4PB\HD8?ICH.O3)/>U)X/OI)?"LG]J6X.@C_GT
M/[_]WY?_ #T^7Y3[\T <_P"(]8U'Q1\-/%6JV=S#!IZ174$,)BW&6*/*.S-G
M(8D,5Q@#C.:[_0?^1=TS_KTB_P#0!7'/\/=3M]*U[0]-UN"+1-5\YUAFM"\E
MLT@.Y48.!MR<\@G^==KI-G+I^D6EE-.L\EO$L1E5-@?:,9QDXZ>M &'XGUO4
M=)UWPU;VK6_V74;[[-<*\9+XV,V5;.!]WT_&L72+O6D\;^.9/M7VW["D'D6O
ME8WYA9TC4Y^7YF/KG-=#XC\.W.MZEHEW#?16ZZ7=_:MCP&0RG:5QD,,##'L:
MJMX3OXO$.OZE9:P+>+6($5X_L^7BE2(QJZONZ<@XQG('(H K^#?%)\2SH\.K
M07*I;G[99O!Y-Q:W&5^4J3G;]\<@\C[QKLF)"D@9(' ]:YJS\+2GQ3;>(=0F
MM&OK>U>V+VD!B\_<5^9\L>FWA><9/)KI'!9&4'!(P#Z4 <+X3\6W'B2XAA_M
M.&&_1'&HZ5-!Y<UJ^.-@)RR@\$\YR#D=*HMXVUL?"T^)=UI]NBOC;NODGRW7
M[5Y/3=D''/7K6[:^$+J36=$U35KRVN;W2(W1;J"W,<EQN0I\Y+'C!)QSD\\=
M#CW'PXU27PUJ'AR+7X8M,FO/M5M_H>9(\S"4J[;\, <XP <XR<<4 -NH=7N/
MBUK,6C7EK9SG1K8F>X@,VW]Y)@!05Z^I/'H>T4/Q#U"/PU!=:O"+-[759=,U
M>\M83*EN8P?WBKSA6.P9((&3[5TLOAS4H?%3Z_8ZA:B>>R2TN(I[9F4[&+!U
MPX(Y8\'/U%%KX7NM)M+>/2]0C\S[1-<7QN8=RWCR\OD C;STZX  YH R=8\3
MZM8>#K35[+4=-OA-J,4(N(HMR2P23!%*X; 8 \YSSG@5K?VS>:QXMU30].N4
MM$TJ&%KB8Q"1GEE!95 )P%"KD]SN &,<Y4WPY/\ PC,ND65_;VGGZH-3DVVI
M:-&#JXC1-XVK\H'7UZ9XOS^%-2MO%\WB+1=4M[:6^ACAU""XMC+'*4&%=<.I
M5@..I&* .,T'6M6\/?""'4+1[7[0NKR13AXBP(>\*';\PQ][OFNN\4ZWJVFW
M.H>3<V]I!!8&>T C\^6YE&XL&0<B-<+D@#[WWA5$?#J_'@=O#9UR$AK[[9YY
MLR2/WWG;<!QGYN_IVJ_?>#=1N=>U:_@UJ.&#5[)+6ZB:UWLFQ64&)BV%!W$D
M$'^H ,Z;Q9X@O9O! T]K"W7Q#:/-*)86?R7%OYF0=PR 3TX)QUYK0M]7\06?
MC71=!U.YL9TN=.FGG>"!D)E0J,@ECQ\W3 J&Q\#:E:/X1=M:MY#X>B>)0;(@
M3*T0BQ_K/EPH]^>>G%:]YX=N;GQOI_B%;Z)(K.VDM_LQ@)+AR"3OW<?=':@#
MG$\6>)-4TJTUS0["2ZAEN.+'R %>WWE21*6&'P-WIVP>IL3>+YV\6W>AR7\.
MF7\=U$MI:W<.$O+<["S)(>KG+@ '@@#!YIVD^!]7T2>;3[#Q(8_#<DS2K9&V
M!FB5CEHTESPI)/.,C/&#S5O7/!]UXAMKC3]1O;::QDNUN87-N?/M@&#;4?=C
M/! ; P"1@T =?7%Z3>/JOQ8\0I*?W>BV=M;P+V#3 R.WU.U!_P !KM*Y)-/.
MA_$6\U8C%EK=M%#+)V2XBR$!] RM@'U7'4B@!LOP_MGTO4;!-;UJ)+N[^UQ.
MEUAK-]Q;$1Q\H))XYZ_C6-H!>]^-GB".[=Y3H^G6UO9>:<D+(H9W_P!XG@G\
M*](KSSQ"^EIXK76],U6;3M<MD-K.6TZ::&YC!SL<*!G!Z,K?G0!W%[:VDDEO
M>W*#=8LTT;]TRC*WX;6/Z5PTWB_6V\ #QS:FW:U&;@Z<T?6V#X^_G(DV_-GI
MVQWJ_;>*K.9UDU;4C(J X@M=,N40DC&6+ EN"<#@<]S@CF[:#2K7PW<>%%UR
M9O#TKMM0Z7<>?'"S;FA#XP1R0&QD ].AH Z$Z]KNI^-I-&TZ\LH+*;1X]0@G
M>U9W3?(5Y&_#' ]AST.*PF\:>*D^'[^*'FTX'3;IH+FW6W8_:@L_E,P;=^[X
MY  /(Z\X&A'J&E0>-G\00ZJRPG3ET]+7^R+CY55RX;=]3C&.E8LEEITG@'4?
M"[>(6Q>7+SFY&B7/R;I?-(VYYYXSGI0!U&H:MXFN/'UWX;TV[TZVA&F)>QW$
MMLSM&6D9,%=X#'Y?8#/0XJGI'B_7=1\.N;I;"TO[#5VTS5+DMMC14Y,D88\D
MY0 <\MT/2L5_%5O_ ,+<DN[:_3C08X9/,L)\.WG.3A0-RXR#DY'./>I+BVTA
M;6PDL-=GBU.WU235)IIM(N'BN)I 0V8P!@ '"_-D #G/- %^3QMK2>$?&%W!
M);M=Z%.RPRSVKIYL>Q7&Y,J0WS=>G XK2BUSQ!:>+= L;ZXLY;36[:9ECA@*
MM;/&BN#N+'>""0>!]!7,SVEE/8^*;1O$TI37R&=FT2?,3%%5CQC/W>!QCONK
M4GO=/N-<\-ZFVM$?V+'*AC&CW/[[S$"$Y_AX''6@"]8>*M6BL_%%EJDENVM:
M7.([9(H2JS+(!]G8 L<[V.T\\'BNWM5G2UB6ZD22<*/,=%VJS=R!S@5YE-KW
MA#7_ ![IGB"ROYIXK*VDCGE@MY6CE?<IB1@%Y*DNWL<5V/\ PFV@_P#/Q<_^
M ,__ ,10!S_Q%D:+Q-X&=(7F9=58B-" S?NSP-Q _,U5FAO]!\4>)_B'J%B;
M.SBTL6\-F95,EPRD'>^PE5Y 4<DX-/\ $U]INO:SH=_#K+VR:5<_:5C?2+B0
MR'&,$\8&,]JV=7\0^&=<T2[TJ^GNFM[N%H9=MC.#@C&1\G![B@!EOJ7BL:_I
M\7V5KC3[J-Q=2O:B(6D@7*,OSY=">"#SWS63HOB'QGJ7AV[UY3IUPMF;V,V,
M-L^^X>,L(]IW''( V\DCOD\0^'M2ETP0P:IXNN-1M+1=ML@T:>-VP,*96P=V
M!V&,D DT[0[NRT3PM?Z1'X@E-Q/+--!=QZ/<(86D8MDJ<[L$^HH O6'CRV;0
M]3UZ+5X=2L+&R,LMOY0AN(IA_ R]@>@R.QY-2:CXCUK0+'0M9OI;>YLK^>&"
M\@CBV_9_-^ZT;9R0I(!!SGJ,=*R)(_#6IZK?ZAK%QNEO=.;3IUL],N(A*K$$
MNQ*DEN!CT]3V6VFT^73=)TK5];DO+#2YHY8RNDW"23^5_JQ(<$<<$X'S$#IR
M" 6I_$'BRXF\8Q6U[IL']AL&A8VC-YH\D2;2"_&<X+9/L!4\GBS7;R^\$K8&
MQAB\06<D\JRPLQB80"3@AAD9;IP3CKS6?'/I\<WBJ3^W"3KPZ?V-<_N/W?E_
M\"^4>W-0VG]GVMQX1D.O,P\.V[P!?[%N1YX:,1Y)S\IP/?F@#2MO&NJ:?I>N
MPZEY%WJ&GZK%IT$L41193+LV,R9/3?R ><?C6SI&H>(_^$H>SO+22?1Y+;S$
MO)(%A>*8'F,@,=RD<@XR.AS7(3V6AW]MXEM[[6[@IK-RETCV^E7$;VLJ!0A!
M(.<;%/;O6KH6O26@,FM^*)=1FBC*0>7HT\* G^-P!\S?0@#)]<T /^&VFP:K
M\*='MKG)A$TSL@ ^?%Q(<'(Z>N,>E=I'I=NFI7-^1OGGC6)BP& @S\HX]22<
MY_( 5SOPY@M]-\,1Z/;ZB;\6;,?.-E);??=GZ/G/)/2NINKJ&RM9+B=]L:#)
M.,GZ =R>@ Y)H Y'X:WLDND:MI<C%ET;5KG3X2>OE(P*#\%8+] *[2N)\/\
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MF\46?B#49K1[ZUM7MS):VYB-QNV_-)ECP-O"\XR>:Z<YP<=: /,[KQIXA@\
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M6]05HX8U'FRQ0%V([9V@G'N>!6!X,\3KXBNLPZR;@QVY^V6%S L-Q;3Y7^'
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MY;=("C1"-2%*ON//S9Z=0*E\.^&=<TMH5U7Q1+JL%JI6U1K58B."H,C DR$
MD=O4Y.".JK*USQ#8^'DM'OA/B[N8[6+RXBPWNP R>BC)[F@"KX4\.S>&[6^@
MEODNQ=7LMYE8/+VM(VYA]YLC/2KFIV.H7-W:W%C?QVXA#K+#- 94F5L<$!EP
M1C@^]:=% &-X9\.P>&=,DLX&5O-N);E]B;$5G;)"+D[5'0#)Z5F7FG'2?B!%
MXC _T.\LOL-VPZ1.K;HY#_LG+*3V^7MFMO6=;L]"TB[U.\,AM[52TODQF1E
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MM4M(;R6'3Y9898UMV\UGC^\%3J3VP<5M02B>WCF"N@D0,%==K#(S@CL?:@#
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MU*^F@:WCN)+5(TB0]<1H1DGC))[#IWST\!SQ:3X:T]-74+H,RS0N;7)E*J5
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MN,K&7N),N1WPJL0.YQ6M;VMU:_&V!;B_EO%;P]*4:9$5E_?QY'R*H([]/6K
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MP'*Y& 1]#S^%9&G1:O>>$[73HM0_LO6;)8XKAS LP)08)VMC*/C(((/N""*
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M HZC@D#@\BI9=7\3VVH>$G_M>"2/78S%+"]HNV%O)\P.I&&)X.03@^@K0E\
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M)JE_'</;HRJWD1[B"S!1Z <D=37,+XHN)H?#MA8:F^J'5C=2B_M1$)'BB.0
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MN6?4[S6_%VJZ%:W\FGQZ=:0R-)"J-)))+N(^^I&U0HZ#DGKQSSVM6^O?VUX
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MZN8-C%HXL;=HY4,VY2>#C#8QD8S_ !S:^(+/P1>)J.M-(%U: 6TD 57>W>9
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M[307 _NB+AD(]>A]J .UHKR>'7_%(\*>#?$!UP/-J=U;6MQ;/:Q^4PFR-YP
MVX'!X8#M@5TVB7VK6GQ!U+P_?:G)J-M_9\5]#)+%&CQ%G9&7Y% *_*",\^]
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MY#+'^[&Q2S9;Z#MGK7.VVL:M)JGCRQ;49"NE")K.3RH]T>Z#S"/NX;GU!XK
MEO-2UVZ^%UX;U8M1O+6XD>Y\H-AFM068+P,]<=@>QZ4 >HWMS]BL;BZ,,TWD
MQM)Y4";I'P,[5'<G& /6BSN?MEC;W0AFA\Z-9/*F7:Z9&<,.Q'0BO.TUOQ+I
M:^,M%N]5%W=Z58"_L=0:W17*,CG:Z@;<@IC..1FKT'B74KR+POIJ-<O=7^D#
M4+F:V$0D8A8QA?,PHR7)/&>.!SD '>T5YZNM^*-*MK+2]798[O4=8^QVEXXC
M,GV8J7W.J_)YF%*],9(.#C!?XMM/$%CX0\8-/KCR62V+36,B!5N$(C/F(Y"
M%2<8(^;!//2@#O4=9(U=&#(P!5E.00>XIU9'A>&2#PSIJR7,MP3;1L&E"@@;
M!P-J@8'Y^]:] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %8GBGPZ/$^DKISW;VT?G1S%D0,Q*,&4<
M\8R!FMNFR21PQM)*ZHBC+,QP * ,"3PO]H\5C7KB[$C&P.GR6WDCRWC9MS=R
M<D_ACC'>J-IX#CM]'BT&74I;C089EECLY(QOVJ^]8VD_B0,!QC.  2177T4
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MTL5FA591+ O175AAB.Q_^MCJ=-L%TVQ2V$TL[C+23S$%Y6)R6;&!D^@  Z
M"K=% '-CPF8?$&KZM:ZI/#_:B()K<QJR;U3RPW3/W>V<9Y]JIGP#"W@&#PFV
MI7'E6Q0V]TJ*)$*.'0D=&P1Z=/SKL** .2C\%3KKEQK#Z]=RW=S8"RFWQ1[6
MP6(;  QC<< =\9SSF(> MOA[0-'75'$.BW,5S!)Y(W.T>=H?G&.3G&,\=*[*
MFQR1S1)+$ZO&X#*RG(8'H0: .9O_  @^J6\]A?ZD;C39KL79A: ;T(</L1\\
M+N'H3@D CMG:A\-X[ZU\060UR^AT_69S<R6RHA"3';E@Q&XC*CY<CI7<UFZ]
MK4'A[0[O5KF&>6"UC,DBP*&;:!DG!('ZT 8.H^!IKC6+;6M.\07VG:LEN+:X
MN4CC<7,8.?G0KMR#T(''I5K4?!T5Y%HY@U*[MKK2[AIXKKY9'D9PP<MN!!+;
MB>G!Z#M706=RMY9072 JDT:R*&Z@$9Y_.HIM1ABOX;$;I+F52_EIU1 <%V]!
MGCU/;.#0!D1>%(QXEU#5Y[HSI?6BV4UM)&-IC7..<YS\QSZYZ"J=GX%2WTFV
MT.?4IKG0[6998;62,;\(VY(WD_B12!@8!X )(XKKJ* .=@\,2VVOZWJ\6HGS
M=6BCBD1H05C$894*\YSACG/4^G2J^D^$+K0M-TBST_66"Z;#+ HFMPZS(Y4_
M. 1R"O!!'7ZYZJB@#+\/:%:^'-(33[0DH)))68@#+NQ9B . ,DX Z#%44\,2
M1>(M7UF/42)=2MTMVC,(*QJ@(4CG.?F.<]:Z*B@#C$\ "/PUH>AIJL@AT>ZB
MNH)/)&]VC.4#<XQDG. ,\?CU=Y:1W^GW%E.3Y=Q$T4A7@X88./SJQ10!Q@\!
M2?V+H>F/KEQ*FC7,-S;N\*9/E#;&A Q\H!Y[GUJ[+X-@NM;U?4+VY^T0ZK9K
M97%J8]J^6N[&#G(/S'G^5=-10!R?ASP9<Z$\$5QXCU#4K&TXL[6X5 (N,#<P
M&Y\#@9.!Z<#&[K.CV/B#2+G2]2@$]I<)MD0\>X(/8@X(/J*OTV.2.:,/&ZNA
MZ,IR#0!S^GZ!K%C;)9-XFN+BS0;5:2W3[1M'0&3H>.^W/OGFB^\)Q/K5CK.F
M7+6&H6D!M0^SS$E@)SL=202 >000<^M=%10!R.I> [?4?#NHZ4;Z5)-3N5NK
MV["*7D<,I&!T4#8H YX'KS5^?PY+<^*=/U][_$UE;O;K$L/R.KX+$\YSE1CG
MCWK?HH \H\?:"GA[X=>)E;4C(^K:C%>%2@5ED::+=L]0%7..<8)S7;Q^'TU&
M_M]4U&_6_:"WDAM3"@C15D #OP3ER !D$ #. ,UT%8\OB.VA\5VWAYH+C[3<
M6[W"2[1Y952 1G.<_,.U '.6WPV-O8Z+:?\ "1Z@T>C7 EL_W<0*( R[3\O)
MPV-Q].!6BG@UD3Q(O]IL?[>R9_W(_=93R_DY_N^N>>?:M[5+YM,TRXO4L[F\
M:%=PM[5 TDGLH)&35*[\26UGXATG19;:Z%QJ:R-"^T;%\M-S!CG.<8Z ]: .
M8UU=-MO#$?P[D:>^U"?3E@M5%L^"H^1)&<#:-A4,3D?=Z<@5V^G6,.EZ;;6%
MN"(;>)8DR<D@#&2>YJ#6]7AT'1;O5;B&:6"UB:6185#-M49) ) Z#UJQ87B:
MCIUK>QJRQW$*2JK=0& (!]^: *NIZ==7=Q:7%GJ#6DMLS'!C#I*&&"KC(..A
MX(.0.:CT#0;?0+6ZCA;=)=W4EW.P4*&D<\X4=!P !STY)/-:U% ',ZQX2DUJ
M+5;*ZU(OIFINK36SP!FC 55(C?/RYV \@X))&*JZCX%>3Q%)K>BZ]>Z+<7,:
M17BVZ)(DZH,*=K@@,!QNY_GGL** .1U;P)'=7NG:CI.K7>E:I8PFW6[C"RF6
M(G)617!#Y.6R>Y)J;5/!BZCHMG:#5+J.^L[Q+Z/4'57D:=<_,RX"D$$C;@ #
M ' KJ*QX?$=M-XLG\.BWN$NX;079D=0(V0MM&TYR>0>W:@#''@5_MNLWCZY=
MR7&K6:VEP7B3;@!AN  &#AC@# '<&K<OA'SO /\ PB;:@_D?919_:/*&_P H
M+MZ9QNP.OZ5TM% ',W?A W=WH-X-4N(+O2(Y(5EAC7][&ZJK A@<'"CD>_X*
MG@ZW;5?$-W>7!N8-=B2&ZMFCVJ%1"@"D'/0G/OTQ72T4 <EX=\%W.AF&&X\2
M:CJ-A:#%G:7"H!%Q@;F W/@=,G ].!B:T\(LMSHLVI:B;YM&#?9':$)(24V9
MD8'YN#V YP3G%=/10!A^*/#B^);*TB%[-97%G=QWEO/$H8I(F<94\$8)XK*/
M@-OM&OSG7+QWUNV6WN?,CC(X0IN& ,':3@=!W!KL:* .8N_!5IJ/@FW\,WMU
M,\=M'&D%U%B.6-H\;'!'&X8'-6O#^@7NE$S:GKMWK%T$\J.6>-(Q&F02 J 9
M)(&2<DX%2^)_$5MX4T&XUB\@N)K>#&];=06&2 .I'&2*UFDC61(V=0[YVJ3R
M<=<4 <_XD\*)KM[INI6]]-IVJZ:[-;742AL*PPR,IX92.U4H? \D<WB*>36[
MF6;784AN"T,85-L?EY4 #G!..<=,@XS77T4 <E_PA+"W\-0KJK@>']OV<^0/
MWF$\L;^?[O'&/6G^(/!C:KKEOKNF:Q=:/JT,7V=IX$5UEBSG:Z,,'!Y!_P#K
M8W]3O6T[3+B\6TN+MH4+BWMEW228[*,C)J9;A"L)?]T\P^6-R V<9QCU !_*
M@#EM6\!PZE9Z:8=5O;;5M.E::WU1=K2EW^_N!&U@W=< 8  P!BI;_P %C5/#
M%SI5_JUW/=W$D<SZ@RH'WHRLF% VA05'R@=SW)-:.B>([;7;K5+>"WN(9--N
M?LTPG4+EMH;(P3Q@CK6Q0!R&K^!Y;_4+'5[+Q!?:?K=M";=[Z..-O/C)W%70
MC:0"21QQ^5.U+P+%>PZ7/#JMY!K&FRM-#J9"O([.,/O4C:588&!@   8 Q71
MWE_%96US,0TK6\?FO%%@OMY[9[X/Y5#H6L0>(-"LM7M4D2"[B$L:R !@#TS@
MD9H S-$\*R:1X@U369=6N;NXU%(EF1XXT3,:D @ 9'4]_KGK4^N>'/[6U+2M
M4@O7M+_3'D:!]@D0B1=K!E/4$>A!%;E% '-2_P!F>"[34=>U6YEDENI(S=W0
MA9B<81%"("0BYX'/4DDDYJ+P9HUK9OJ^LV]M);_VQ=FX6.12K",<+\IY7<=\
MF#R/,YYKJJ1CM4M@G S@=30!E^)-"M_$WAV^T:ZDDCANX]A>/&Y>001GW K.
MD\*7$^LZ'JMQK$T]SI2RA2\*CSC*H5]P& . , 8QWS5_P[XAMO$EE<75K#/"
ML%S):NDZ@-OC.&X!/>M>@#CI?A]9WEEX@L]0O)9X=:G%S+L01M#* H5HSSC&
MU>N>E6=+\*ZA9VDR:AXDO-4N#"T$$MQ$@$*'J=J@;F_VF)/YG.WJNJVNC6#7
MEVQ$89(U51EG=F"JH'J6('XU7TG6CJES>VTNFWUC/9NJNMR@"N&&0R,I*L/H
M>.] &%_P@0'AK0]$75)!#H]S%<P2>2-SF(Y0-SC'KC&>.G?5A\.-%XRE\1M>
MEI9;-;-H!$ H16+ @YSG)/X=JW:* ,3Q%X:@\0+92F>2UOK"<7%I=1 %HWZ$
M$'@J1P1WJM+X4^U#5+BZO?,U+4;3[$]RL(58H?F^5$R<<LQY)Y/H *Z2FM+&
MCHC.H=\[5)Y;')Q0!0T'2SH>A66E?:#<)9PK!'(RA6** !G'&<"LF^\'?:O$
MEWJ\&K7=H+ZU6UO((E0B55SM(+ E3\Q''KV/-7]"\1VWB"34TMX+B%M/NS:2
MB=0I+A58D8)X^85L4 <5:?#\V=EX=MDUJ=QH4GF6[20H=YVE-K8Q\NTX]>2<
MU;\0>#&U77+;7=,UBZT?5H8OL[7$"*ZRQ9SM=&&#@\C_ /5CJJ* *>F6"Z;8
MI;^?+<."6DGF(+RN>2S8 'X   8   K$O_"#:I!/8WVHF?3)KP7?D/"/,0B0
M2!$?/"Y'H3@D CMTLDD<2AI'5%+!06..2< ?B2!^-.H Y2\\%M/KFK:A;:Q<
MVD.KPI'>VZ1H0[*FQ6#$97Y>#CKZBHHO :VNG^'8K75[E;O00RVEQ+&C@JR;
M&5T &1MX&""/6NPILC;(V?:S;03M7J?84 <)XA33-%TW7K2XO&G\0:Y83%2T
M1!G*QE$CC &!C=@)DL<D\YS4TW@1M1\/>&@-0N-+UO1K6..&\ML,4/EJKJP/
M#*<=/;ZYZ'PWX@MO$^C)JEI%/%"\DD82=0'!1RAR 3W4UK4 <EJ/@2'5_#XL
M-0U6]FU!;A+M-3&U)DG7A64 !5 '&T#&">YS5B/PD]QH6HZ?K.L7>ISZA;-:
MRW+HD92,@C"*H"KUSGDDXST &Q?Z@UC+9(MC=W(N9Q"6MT#"$$$[WY&%XQGW
M%7: ,[0],ETC2+>QFOI;UH4">=*JJ2   ,* !P*T:** "BBB@ HHHH ****
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M-X5EBV S1N%#*P*D#.T<C!'./8 X<IJ2?\+)O].U>?3Y+&[>YC$$:'>Z6R,
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M!KTBRJEP392,RF4PGH)-H W Y&1UK"UFWGE^,.A*NHW<4;:;<N(T*[5PT><
MJ>N>3UX'(KK-%T@Z3:LDM]<W]U(=TUU<D;W/0#"@!0.P QU[DDU-5\,Q:GK^
MG:RM]=6EU9))%^X*XEC?&Y6W X^Z.1@^] 'GN-4M].^(^IZ=K$]A)I^I3W,:
MPQH?,=((VP^X'*\8P,=^3VZ0>(=0US5[;2X/M$0.D07\IM)(T=FE) P7S\J[
M>W4L,],&^/ T0T_Q#9'5+LQZ[(\ER=D>4+J$;9\O'R@#G-0W_P /HKDZ5<V>
MLW^GZIIML+2.^M]FZ6$?P2*1M8=^G6@#'U2[\9:)X0L=7U34")M-NQ_:<=LL
M;?:+3=RY^7Y7"D$[<# /M76Z;=S:GXBOKF"]=]+MXXX(XUVE))2-[.#C) 5H
MQUQG=Z51U.^TWPOIL&C7,&HZI-J*2H!Y+3-=/CYA(RC:N[('. !Z <:7A308
MO#/A;3M'BQ_HT(5R#G<YY8_F30!SOQ+BFD;PKY5[<VX?7K6)EA90#G<02"#D
M@J",\>U07H\07OQ!N_#MMXFNK2U71XKI)1!$SK(960G[N#G;S]3C%=3XD\.P
M^)+.UADNI[66TNX[R">#:621,X.&!!')X(J"V\+K;>*_^$@_M*ZEG-FMDT<@
M0JT:L6!.%SNR2<Y[]* ./\3>(-9TBQU74(-7DN;BRU.&-5M8U-M%"SQIY<I8
M#,AW,3M)()'05T46I7.O^-M<T6*]GLK;1X8 WD;0\LLRE]Q)!X50,#N2<YZ5
M5N_AI:W=CJ^GC6M2BL-1N_MOV=#'MBF+ARP)7)&Y?NDD>V>:OS^"P/$*ZYI^
ML7UC?20+;W;H(W%TJ]"X92 P[$#VQB@#BO!VL7FG>#O#FDP.[7.I:I?1/-'L
M5]J22NVW=\H)( ^A..<5W7AF+Q%;:AJD.KR&73RZ/I[32(TZ@CYU?: " >AZ
MX/-9G_"LM._X1B/13J6H[K>[:]M;M759;:8L6)0A>F6/!SU^E=!H6B2:1%(U
MUJ=WJ=Y+@27-UM!VC.%"J  !D]LDDY)H R?&6HZCINJ^%OL=Z\,-YJR6MQ"$
M4B1"CMU(R.5'0BL=I=>U/Q1XTTU/$5U:V^G16TEJ888MZ%XF?&2I^7(YXR<#
MD<YZK7_#B:_<Z7-)>SVYTVZ6[B6)5(:0 @;L@\88\#'6H(?"@@UC7-2CU*Y$
MVL)&DRE$*QA%*KLX]">N: )/!6K7.N^"M&U2\*FYN;1))2HP"V.3CMD\UO5E
M^'-$C\-Z!::/#<2SPVB>7&\H&[:.@. !^E:E !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1S316T+
MS32+'&@RS,< "I*X7XLPF3P=&PGGCVZA:#$4A4-F9!SCKU_/![4 =!+XCBB\
M86_AQK2<33VKW27!*^654J"!SG.6[@?C6U7GFKZ?)+\5-#LXK^ZA_P")/=!I
MU8&4CS(^C$'!]\=.F#R,^Q\3ZM:>'38/>O<7/_"3R:)'=SN!)Y88D$MM(W$#
M;G'<&@#U.BN7T"Q\0V'B&]%[<QOH\T*O;P27;3S12@X;#,H)0@CJ3@_6NF?=
ML;9C=@XSZT 8C>)X)M3N=/TRRNM2GM&"7+6^P1PMC.PN[*"V.PR1WQ5C2]=A
MU2]O;,6MU;7-GL\Z.X0*1OR1@@D,..H)'OUKC_@DV_X=(\I)OFO;@WN[[WG>
M8<[O?&VMOQYK;>&_#T^H6?EQWT\D%H)BH/EAY-H8@]0NYR,\9H ZJBN'U6XO
M_#7C'P[;VU]=W%AJ[R6EQ#/)YA20(665">AX.1]W':N5N+_7_P#A7OB;7/\
MA(]0%[I&IW2VY&P*RQR@ . OS CC' ]J /8J*X*6;4],\?\ AR'^V+RX@UJW
MNOM$,NWRXVC175HUQ\N,D=\CKD\USJ-XFO\ P5XAUN/Q7J$=[H][>FW4+&(Y
M%A8\2#;\V0N., >G7(!Z_17G%WK-[J]JEVM]="2708[R.PL&,;VTKJ6,LCY
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MSQ5VO+HO%.JZ7X=\6W$M_)<SVWB#^S[>>XVCR8W,* \+M 7>3TQGJ#6T-/\
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M3ZAI7[.@U;3]5O8+Q8/,#APV/WQ! W XSD\C!SWH ]G!R <$>QI:XO4-0O\
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M33@?L27;JP@^7;D84%B%) +%B 3ZT <QX6L-3UO4M?DNO$VL*NFZ[-# D<J
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M?LG;2O .J3:C=W-S<:S8R3L\[-'(S@MD)G:N#TV@<>M>@>)_^13UG_KQG_\
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M59B_F*VXDJ#D\Y)]:S;KP<D(T*'2;B_M5T^[-PS1W&V.0,X>7S5_C+?,  ,
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M9W$R@,3QR%;&1C\^:S+#4?$,_A+4WLC=:E+:>(;B%X/M)2>2UCD(\N-R<[@
M.^2 >>:[36/"UIK&K66J&ZO;.]M$>)9;2787C8@LC<'(R >,$=C5.S\":=IU
ML\-C>:C;EM0?4!(L^2DK;@0 P(VX8C!!SWS0!PGB+4-/U_X>7=Q9WVJGRM:M
M5>UO)9$FM&,D2F)P3DXY89)P3QR*Z#Q9?7?A[4@]Y%K$OAP683[787+M+93;
MF+22J&W.N"O)R!M/'-;]WX)TJ_TK4K*Z>YD?49DN+FZWA96D3;L8%0 -NQ<
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M+DOOE@)1\QEVR6&Y<@GG&>:L6TVI:=KW@2X.LW]R-8A>.\AGEW1-BW\Q2%Z
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M7;N'&.%!QQC)Z5I7MHFB_%K39XYKN>,:)=OY<\[RD%63."Y)&>.,XX^M;O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !116#XIU2]TJ'3&LGB4W.HP6LGF)N^21MI(Y&".W\J -ZB
ML/6M0U*QN)!81+<LNG7%Q';;?FEE39L4-G@$MCIZ56\+:]_;VZ:WU.WO;98\
M2Q^289[>;/*.A.5[X!&>#R: .EHKG-1U+4U\9V.CVD]O%;W%C/<LTD!=@T;Q
MJ /F'!\P_E61_P )M?1Z@_A^:"W_ +<&I)8B1 WDE&B,PFVYS]P'Y<_>'7'-
M '=45QVN>+G\(7KQ:L1=6TEA<7D$B)L?=#M+QD=#D.,'CH0<]:U[0:]):6=S
M+<6OFRF-KBW$1VHAQN"-G.0#U.<XZ#/ !M45Q6A^);_7+A[1;ZVMM3B,BWFF
MSP%);;AMC+D_.N=OS8(;.1CI6IJVN74&BZ7J%HL2&YO;2":.52Q599DC<#!&
M&&X^O(Z4 =#16-JNI7=EKV@VL1B^SWUQ+%,&0EOEA>0%3G Y0=C5;4=>N8?$
M^CZ=:I&;6XNG@NI6Z[A!)(%7W&P$GW ]< '145S5KJU^/&5QI$M]IUPOV(W(
M@12DD#;P%!^8[U()R<#! Z;@*I1>(-61/$T4<]CJMSI:(T2VT>QPY4ED9-Y)
MQ@$<C=DCJ#0!V5%<MI&L7_B33)[C1[ZV:V:8+;WTL!8E-@+YCROS!\KSCZ''
M.>_C"^L=!TN^UDQ6D$T\\%S?0Q%HQL9EB<+DD+)MSDYQD#N" #N:*XN;Q/J_
MDW2""WAO-.T:/4KN,_,KRN'(B!SP/W3\\]1Z'.WJ6L3IX6_M73;6:XEFA22&
M..+S&&_'S; 1NV@Y(R,XQF@#9HK(\,Z@^JZ#!>/?PWK.6!EBMFMP""05,;,Q
M5@0003U%:] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %9>OZ-_;=A'"L_V>>"XBNH)=NX+)&X9<KD9!Q@C(X/45J44 8\
MFEZA<+<S3:A%'>/:O;V\D$)40;NKX+$L<A3U'W?QJF/"<-WK<^J:H+6>2:T^
MR2)! 8UE7>&R_P Q)(*C'H,]<\=)10!SC>&)+?7;#4-,N;:UAL[.6UCMWMV<
M8D=&)R''=!Q[FJY\$0L&NVO';6&OUU#[<8Q_K578%V9_U>S*;<YP>N>:ZNB@
M#G+[PG#KMS+/KDB7(:SELHXHD*+&DF/,/))+':O/8#ZFKNEV&JV=O!:W>IQ7
M,4 "B1;<I+(!TW'<1GU( S[5K44 <TGABXGU+1K[4KR"XGTHL8YX[<I++E&3
M#-N/R_-D@=2 >,8-C4_#\M]9"UANTA1=1BODW1%\;)5E*_>'5U)SV#>U;M%
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M:E% %/3=/33K>1%8-)+*\\KA=H9W.20.P_PZGK5RBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
; **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>elicio-insidertradingcom002.jpg
<TEXT>
begin 644 elicio-insidertradingcom002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MEE\E_*,_3R_,V[=V>,9Z\=>*KV'BZWO_ !EJGA]+:Z5K&.',K6T@5G?>3SC
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MTRI9<XZ50NC_ ,))\*]'\-6L,D&O0M9V[6S(5DM'A= \C#^%0JL0W0Y &2:
M.WN_'7ARRN+^WFOV,VG[?M,<5O)(T88$@X522, DD<#C.,BM!O$&F?9K*XCN
M&G2]C\VV%O$\K2)@$L%4$X (Y]P.I%<?I\\,?CSQ_+*0L<EM:!'88$FV)PP4
M_P 6"0#CN<5@:59VMSX)\&12:K=Z%K%K92BWU!1A(7&P/%*K#:0V5.UL9V\4
M >LZ??VVJ6,=Y:.7@DSM8H5/!(/! (Y!ZU9KG_!5WJ5]X4M)]7MXH;UFD#^4
MA19,.P$@4\C>,-_P*N@H **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJIJ&HVVFPI)<,P\R011HBE
MFD<]%4#J>#^ )Z"@"W17/W7C31+&Q>\O)YK:*.Y%H_FV\BE93M(4C' ^9>>G
M/6ETCQGH>MZM<:79W,GVV%/-,,T#Q%X\XWKO W+GN* -^BL)?%^C-?6=L9Y4
M%\Y2TG>%UAG8<X1R-I)'3GGMFC4/&&BZ896NKEU@AF6WFN1"S0PR$@!6<# .
M2 ?3/.* -VBN>6_TQO',\"W]^=2BT[<]C\_D"+?_ *P+C!<D[<@DX&*Y&VU-
M?%DGB.6[U+7=-_L[462WFLTGC$,,:(2&7;M+$EB0P+<].!0!Z?39(TEC>.1%
M>-P596&00>H(KG]&UC2+/PGI5Q!J%W>6DZ+':37&Z2XN2<D<8W,V 3TX ).
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M#DL2I;D8^7Y03SCI69H>JZ,1K][;ZK=2PV]VYO&O68):LJ*650X&U ,'TY-
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M4$DT;0.H53T(8C!!]B: *?\ PC%S_P!#1KO_ '\A_P#C5'_",7/_ $-&N_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFCYF0#*C"[L'IN ZUZ/%X=FC\;3>(S?*?-LULS;^1@!%8L#NW=<D]L8[5OT
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M.FZV()H7LD61X)4C"-'(-P !P#G./UQ:U.'49_'O@V]FT^8):PWGVIH8V>.
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M&&]<9[54GT[4O$7PXTSPC<:9=VFIQ-:P7+O$1%$L+J6E63[K95. I)RPX'-
M'33^/=/BUF^TJ+3=7NKJRDA2=;>S+[1)G#]<[1W/OQGG%>;XDZ5%I^H7ZZ=J
MTMMIUT]M>.EK_J2F-S')'RC/;)X)QCFD\/PW,/Q(\6W4MG=1VMXEH+>=X6"2
M&.-E?!QV)'U[9KGUL-0;P-\0;/\ LR^%SJ-_>R6<9MVS,LB*$(X[D'KT[XH
M[&#QGI\^O66E?9KZ+[>CM974L.V&XVKN8*<YZ<\@ CIFHF\=:6LL9\B[-G)J
M']FB]"+Y7G[MNW&[=C<-N[;C/?'-8EY;W<NL_#Z=+"],=@)#=G[._P"YW6YC
M&[C^]Q^O2L#58/$&JZ9')?Z!JLNJ6>O13R"-0(%@6?(\E=V&RN"6P3G.3C%
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M6_M -&[,90BY*J3\JXQ_=%:=EXTL+S6[/2S:7]N]]"TUI-/#LCN H!8*<YR
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MOK.:TN;>U2*2*8 ,"!CH"?UYKIJ "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***Q?$WB6T\*Z8NH7
ML%S+ 94B)@0-M+,%!.2.,D4 ;5%<]!XK68"-M(U."[DG>&"UGC1))@BAC(N6
MQLP1R2.>.N!5>'Q[I#Z1J%].EQ;R:?<BTN;215,JS$@*@P2&W$C!!QSU&#0!
MU-%<['XNB;Q$^@OI6H)J*P"Y$>(RK1'(#!@^/O#;SW_.JR>/M-?PMI_B);2^
M-C?7"VZC8F^-C)Y8W#=TW#MF@#JZ*X:-$A^-]PP+ /X>61@6)&?M!&0#TX Z
M>E:%AXZL+^?2 MG>1VVL,ZV-S(J;)2H)Y 8LN0"1D?7% '4T5QFB>+;O5KCQ
M-'>Z/=I;:==/;J$:-CM6-"5.'R6.XGC@ @9J;0M?T.Q\&Z#)I5K<1VEZ%BTZ
MRSNE?J<?,V. "22V !UH ZVJVHV?]H:=<V9N+BW\^-H_.MGV21Y&,JW8CL:Q
M5\960;5H+BTO(+[2X1//9LJM(T1&0Z88JR\'OP1@XJI9?$&QO9=$)TW4H+76
M546MW-&HC,A3>$/S;@< \XP2.">M &YHFBP:%8_9H9[FY=FWRW-U*9)9FP!N
M=NYP /H!6E6"/%,,D\@M[&[N+>.]%A)<1["J2[@AR"V[ 8X)Q^G-;U !117G
MOA*8>/=0UO6-3+3:=;7[V-A9,Q\H+&!F1EZ,S$]\XQQ0!Z%17.C3K/PO>7^M
M/>R0:4MH/-@EE9HX-A+;D4YV@@G('H,#FE7Q=;QZCIUI?6%[8?VED6<MP$V2
M/C.P[6)5B.0& STZ\4 =#17&S?$6TCM=7N8M%U>=-(G:*\V1(#&%4,S_ #.,
MC!Z#GCICFK</CBQEU73+0V-_';:H#]BOI(U$,S!=^T#=O&0#@E0#VS0!T]%<
M3<_$RQ@AU.6+1-:N4TNX:&\,-NI\H*H)<Y897![<\$XQS6J?&%C/-80:9#/J
M,U]9F^A6#:H\D;1N)<J!DL!CKGTH Z&BN3?XA:0NB:)JZ6]]+:ZO<+;P%(<L
MCL2,,,YR"K=,].*EM?&D-R^L0-H^IQ7VEQK-+9ND9EDC8$JR8<JV=IXSGC'6
M@#IZ*Y^W\76EWX:T[7+:TNYH-0>-((4\OS"7.!D;\<=^> #GH:U-6ACN-(NX
MY5RIA;OC'!Y![&@"Y17@$.HM:_"3P_JFC:O<MXNDF18H8[QY'NF,A#(\98AE
MV\\CC ]:]>U/Q7%ID5](MA=WHTY ]\;79B'Y=Y'S,-Q"D-@9X(]0* .AHKD;
MKXA:;%<V,%G8ZCJ#W]DU[:?9801,@ .!DCYN1P<?GQ5G_A,86BN9(=*U"7[&
MD37<86-9+<N@<*RE@<A6!.,X]\' !TM%8UWXBCBU"ZL+*QNM1NK2)9;B.VV#
MRPV2H)=E!8@$@#\<9&<R7XA:,FEZ/J,,=Y<VNJW MH6AAR4D.?E<9R"-K# !
M.10!UE%<O;>-[65-;6?3-1M;G1XUEN+65$,AC92RLNUBI!"GOQBHK+X@6-[/
MH@.FZE;VVLJ/LEW-&HC+E-X0_-N!P#SC!QP3UH ZVBN9U?QK9:1:W=Z]G>3Z
M?92^3=W< 0K$V0&X+!F"D@':#CGK@XROW3_&JRGA<ND_AZ5P0Y*M^^CP0.@X
MQTH [NBLW6];MM"LXI[A)9#//';0Q1 %I)';:JC) '/<D"LIO&]E#9Z[-<6-
M]'-H8#7EN%5G"E-X92&VD%>>HZ4 =/17+V7C>UN[<W#:7J<$+K ;62:%5%VT
MOW5C^;D^N< #G..:N:5XGMM2UN]T62VN+/4K1%E>"?:=\;='4JQ!&>#W!H W
M**SM0U>.QN8+.."6ZO9T:2.WA*AMBXW,2Q  !91UZD5S\OQ'TR+PU<ZY_9^I
M2065R]K?0QQH9+212 P<;\8&1RI(P<T =C16+%XEMYQJ#PVEU+;V2!FN(PCI
M*2H;:F&RQ (SQCWK!A^*.E2Q:5=R:;JL&FZFR1Q:A+ HA21ONJQW9'IG!&>_
M!P =Q17.ZOXOMM*AU"X6QO+RVTW_ (_9K<)B'Y0QX9@6(4@G . ?7BI7\4VD
MKPQZ9!/J<TMHMZ$MMHQ"WW&)<J!NYP.IP?3- &[17"7GQ >?_A%9M'TVZN+3
M6IV4LVQ' 57)CVNPPV5Y)., X)S6UJGBV#38;^9-/O+N/3E#7K6_E_N/E#D?
M,PW,%(8A<\$?2@#H:*P3XIL;DV,.FI+J$U]:_:XH[<JI$!QAV+$!020!W)[<
M'&!\*W$FF>(6$4T2_P!OW8$4QR\8RN%/)Y'3J>E '>T5RC^)[X?$@>'5TR8V
MJZ?]I:57C^;=(%#\L"%7##^\<].!3[KQS86NGRZI]DO)='AF,,NH1JIC4AMC
M-C=N*!L@L%/3/(YH UM<TC^V]--G_:%_8?.K^?83>5(,'.-V#P>XJSI]A;Z9
M816=LK"*,'&YBS,2<EB3R22223U)-2,L5W;%<AX95ZJWWE/H17E'@3QO:>&_
MAWH8U'3]3^PEY(YM3$0,$3-,^-[$[L<C+ $9.,YH ]6MK6&T1EA3:'8NQ))+
M,>Y)Y)Z=?05-6%JOBB'3OMWDV-W?_8(Q)=_9MG[H$;L?,PRVWYL#/&/49T=,
MU.TU?2K;4[&3S;6YB$L3@=5(ST]?:@"Y17)Z?X]M-3O9+>WTG5?+@O);.YN&
MA41VSQKDESNX7J,\^^,C,W_";627FE1W%G>6]KJSB.RO) GERN1E00&++N'(
MR![XH Z:BL&V\507DD+6UC=RVDUU):I=IL*!T+!LC=N RA ..N/45BW'Q/T^
M"TU"[31=:G@TVZ>VO7CMU(@V8W,<MR.>V3@$D 8R =Q16(_BBRDFLX-/234+
MB\MOMD4=N5'[CC$A+$  D@#N?3@XS+CXB:3;>&[G6FM[TQVES]DNK<1CS;>7
M<%VN-V.K#D$@YXS0!UU%<[9^,+6XU^?1[FQOK">.U-Y&]TBJLT(.TLN&)&"1
MPP!YZ5+IOB:/4S9M%IUXMM>V[7-O<'84=  0/E8D,0P(!'KW!% &[4/V6'[7
M]K*9G"; Q).U3R0!VS@9QUP,]!7E'B>XT6\^%&JWFD6=U9Q0ZPOF)*S;O.^U
M()3@,>"2W'Z"NVL?&EG?^(O[ NM.U+3KN:)I;8WD01;E!]XH0Q(('.#@@=J
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M!;:#SM![CD@B@#HZ*YFY\;Z=%J6F65O;7EZVIVSW-G);1@I*J@' )(Y^9>N
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M;>. .>K;5"Y_2O-;#0=6N/A0/ TVEW,&H.SP2S2H/)C1IBYD#@X;Y3P!SG'
MZUZM2$@8R0,\<T >9W&G7GASQGJLLWA)_$&F:H8I;>>".*22"18UC*/O(PIV
M@YS@>_;T+38W@TR!);>&W<)EH;<?)'WVC'7'3.!GK@5;HH X'PSH][<:-XRT
MV[M;BR.IZC>RP22IC=%*H"N/UX/-5/!\>H10Z?I&H>!H[34;'8DVIM%$;=E3
M'[Q&!W%V X '!.2>*])HH \SMM"O(?$UEJVA6>HZ1>SWY.KV; _8YX<G?+@Y
M7<0 1M.<GD=34'A^ZF;3/'VG0:=<W-Q<ZU?1P!(\QNS*JX9NB@=]V.#QGI7J
M1&00"1[CM6/H/ARW\/-J!M[JZF^WW3W<PG*']Z^-Q&U1C.!QTH X[2?#6H^"
M?$>CWHAFU#3QHD6EW36ZEWADC.X.%ZE#DC@$BJ.O>&-4F\,>*[F#3[A[S7-3
MMYX+- "R11/'\S<X!(1FQGN!UXKUBB@#A]2AOI/B39ZI;Z=<2VD>C3P&1HB%
M\UF5E4@\\A>:S_#.A7&C^);*YT*VU/3='FAE?5-*N@3#!)C*^3G/S%LYV$C
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MM&.Q%>BT4 <Q\.[2]T_P!HUCJ%G+:75O;K$\4I4G([\$_KS[5T]%% !1110
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MRI%9,[R^>BKMZ\YR, YQ4,GCJ"VM]=6ZTZY34-%A^T7-HC(Q>+:6$D;$@,N
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M& (Z'W'2M"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "N5^(VFZAK/@35-*TRS>ZN[N(1QJKH@!W
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MC)3'IGU'-=?X<OM>U*59-4\.)HB1(1(&GCE:5_\ 9V=%')R>3QQUKI:.@R:
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M7=@Q(\R2\:+:@[X".Q8^G;W[' T;3]8\*:QXCBCTN;4;'4[U]1M989(QMDD
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M)EE#LNURN<KM8KP03R/?&9+X9\1)X&\6>'ETM9'OKJZDM)EN4Q()7W*<$C:
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M\+0RK"JO&Q!*D#!Y!(H YBPUK5-3^(.O:'=6-LVF6EO;@*9=V5?S"6*E>2<
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MN6"L"0&VL,9P,@_6NANM#O\ 4M?U+Q&^GRPRG1VTVUM'DC,CEF+,S$,5 SM
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?RW#;7'53CH1Z5Q6F^(O$EY\0#IMWIMM:PQZ5%=/;"[+-&SN0V2$VLP*D 9
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MM.X!L_Q D#/2@#NJ*YV3Q)<7>HZC8Z)817TNG(AG,MSY*EW7<J*0K9;;@G.
M-PYZXR&^),$VG:!>Z?I-S=)J]PUL$WJCPRJ&RC ]\J1V'?- '<,RHI9V"JHR
M23@ 4R"XANH$GMY8YH7&4DC8,K#U!'6N-M/%#Z[+KWAS6]%&GZC:VIF,#3">
M.:%@<.K8&>>",<']*'@_Q#;:'\-?",$C0?:;RU5(1/,(8_E7<S,Y!P ,#@$Y
M(&/0 ]%HKG/"WBM/$<NI6S6Z0W6G3".7R9O.BD##*O')@;@<'L"",4#Q+=MX
MLO\ P_\ V;$L\%F+RV=KD@7*%MO]SY<'@]<9'7- '1U%%=6]Q)+'#/%(\+;9
M%1P2AZX('0_6N6T7QK)KOA?3-7M-/B,M_=?9UM3=<H06#98)U4(S$8Z#@UR^
MF:M=^&=0\?W>F:(EW!:7_P!HF03K JH($9MORG+=3C 'O0!ZM17._P#"5QW=
MUIEEI=N+F\U"R^WHDLGEK'!\OS.0&.26   .>>F*E\.^)$UV74;.:V-IJ6FS
M^1=VQ?>%)&596P-RL.0< ^PH W:*Y"_\8:E'XFO] TWPZ][>6ULERC/=I$CJ
MQ(Y.#M^[QU)] ,D1Z9\0[75M(TZ:"QD35+V\>Q&GROM,<T8)D#-@X55&<@$\
MCC)Q0!V=-=%DC9'4,C AE(R"/2N73QM!9ZAJVGZY;KI]UIMI]O8I+YL<MOR-
MZ':IR",$$=>F:9+XRGL/['N=4TH6NG:K*D,4ZW&]X9)!F,2KM 7/3(9@#^=
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MX8ZFL.^\->)8]/\ &^CV>GV\UOK<L]S;W;7(7!DB53&4QG.5ZYQSGM@^F44
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MM82FL!#:@3C.5A$?S\<>O&>* &Q>/;R1/#FH/HR1Z/KDL4$4INLS1R2*64E
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M:'K46C>$O">FVMNDE]J4*QVT&[8ORQ[W=B <  9X!)) [YK6\4>&;?QAX?\
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M_.0LK.)(BA99>@X(!X&<$&NBTN:\N=+M9[^W2VNY(P\L".6$;$9VY(&<=.E
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MSG/./2DTKP]XM\.:AJ.G:5+ILFB7MW)=0W$[.)K/S#EU" 8?!)(Y'OZ5WU%
M'#76A>*=%\77VK>'&T^[L]46+[5;7\KQF.5%""164'(*@9'M78V45Q#9Q)=3
MB:X S)(J[06/)P.P]!SQCDU8HH X/QPUPGC;P,UK%'+,+RYPDC[01Y#9YP<'
M&<>],UGP!+XHC\0W&H2I:7>IP0V]L(FW_9UA;>I8X&27Y('0  'O777VAZ=J
M-]:WMW;^9<VA)MY/,8&(GJ5P>"1P?6I[_4[+2X8YK^ZBMXY)5A1I&P&=CA5^
MI- '-R:)J_B"[T&778+2W&DS_:W^SS&3SYPA52N5&U?F+<\]![U6L?#FMVR^
M,=\5D3K,KR6P%PWRYB$>'^3CIGC-=O10!YPW@WQ%9:/X2N]-DL1KGA^W^RO#
M)(Q@NHF158;MH(/R@CC@UUMG]K_LZ5O$TEC&]T?+-O&^844C&S<V"Y/))P/3
M'&3>M-6TZ_O+JTM+V">XM"HN(XG#&(MG ;'0\'BH]7T/2]?MH[;5K""]@CD$
MJ1SH& <9P<?B?SH YOX<Z(VD^'I91=-=K*[1V,DO46:,P@7/I@E@?1ZU_">H
MZOJ6CO+K<%G%>1SO$6LF9H9 ,?,I;GU4^ZFML(BQA%4! ,!0. /2E "J%4
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M H!# X!SN&,]#C! *=SXEUS4M4^'TUFUK;P:Q#)<RPL&/S_9BV"01E1NX'J
M>U;,?BG[-XI\26NH6EM;VVE6,5VUS&Q9Y(R')W<#& IXYZ]:SH_!VNVUEX*>
M&?3GO?#Z-#(KEQ'(C0^42"!DD8SC SZBKK^$KR]\3^(KG4/LITS6-.2Q812M
MYH"AP3@K@9WGOQCO0!#=>--1TS0M*\27]G;C1[YX?-C0MYUHDN-CLV</U7<
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MX$*,@D=.U3>(?"]_KEG-IM]:Z;JUB]HJ1R7<C1RQ7'S!I!A#@'*G@@C&.AH
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M?[*TO3&TX+),WFE3M^; 3'&P=^<]JK^+/!]_XJ6\MKFWTX_OD?3=1$K+<60
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M\+^[[YSSTZ<]:6S\.>+M UC48-$O=+?1-0NGNQ]K5S-:/(<N$ X<9R0"1_B
M67\4Z[=^++C0M.TRS0C3H[Z*:[E=<!V*X=0N0>#\H_/M6'J'C'6=7\(^%-4L
ME@LI+_6H;.[C.YOF68J0",?*6C.>Y!Q72P:!JEOX^N-=!M9+1],CL4#SMYI9
M'9PS?)CG=CK[^U8,'@77(/!.E:6)=._M#3-8&I1DRN8I1YSR;2=F5^^1G!Z4
M ;&I>*KZ.\O].T^*%[W3H8VG+6TTJ22LNX1KL'R\8.XD_>'!YHLO&-UJSZ-8
M6VGO8ZK?VCWD\-\C V<:,$.Y?E+$N0 /ER,GV-6Z\/>+--\4W&N:!<Z5+_:4
M42ZC:WOF*@DC7:)(RH)Z<8/I^3]1\+Z]#XATGQ)IEW:76J6]L]I>Q71:*.XB
M9M_RE0Q3:W0$'C'IR 1?#S[3_;GC3[8L2W']K@/Y1.T_N4Y&>1D<X[9[U9OO
M$OB*3Q?J'AW2=,TYI8+..ZBGN;EPA#,P^8!<Y^7H,^N>U6?">A:OI.KZ_>ZD
M]D4U.Z%RB6[,Q0[%7!) _N_CUXZ5D[[^/XSZF;&"WG_XDEN'2:8Q_P#+63!!
M"M^6._X$ @3XDZC-X>TV]CT:$7LFLKH]];/<$>3-NP=IQ@CW)&,]ZVHO$.M#
M5+/0+NWT^+6KA)KEFB=Y(8K=&"JY!VEF8L!C([G/:LJY\":FND6$-I)927@U
MX:W>O+(R(TF\L43"DXQA03Z9QS6QK?AV_E\5:7XGTIK?[=:PO:W%M.Y5)X6.
M<!PI(*L,CCGVH HCX@&SBUNTU*S4:OI5S#;>3"_R7)G($+*3RH;/(.=N#UK2
MEUS5]'N[]]:LX6TJVT]KTZA:Y4*RYW1%&8DG'(;@'T%9&J_#Z;7+/Q!<7%U'
M::OJLMO+%)"2Z6Q@QY0R0"W())P/O<#BM"WT?Q'KFD7EAXLFTZ.*>UDM3'II
M<ARXVF1BX&"!G"@8YR2>, %>U\7ZL^L:1')I3S6.HY$C06LX:R;&5WLR[74]
M"PVX]ZY[QSKM]XD^$NO:K8QVHTEU>.)9-WFRQK)L,H;.%^920N#D#J"<#I/#
M.E^-+&.VTW6K_2Y=/LP%6YM@_P!HN57A0X/RKVR1G.,=\U@-X#\3VW@;5?!5
MG-I<NE2[Q974TLBRQHS[]CH$(."3\P;\.U '5V^O7?\ PFH\.&*'RFTG[?'/
MSN!\P1[2,\COG(K!D^(6J)X6AU5-+M993K)TR2,3%?\ EMY89<CDGW(Q[UI7
M6@:_%XMT[7[!M-DE&FG3[N.=W15&\.'3 .[!!X.,^H[8J^!/$2>%ETKS],DF
M77/[3#F21 5$WF;3\IY/3V]30!MOXFUBTO(=)U&WLH=4G\Z=6MEEN8X[="H5
MBH4,6)<#' X)ST!I#X@W-MH:7.KV']E2_P!J'3GNKF&1;<+@LLX#!6V-@ 9(
MP3R:O^*/#^N7.LZ9XB\/7-G#JMG$\$L%V6,-Q"Y!*EE&005!!Q5F6P\1W&F0
MB\&E7DTL^;VS<L+<P;"OEH2K$G=M;+#GGH,4 :NC75Y=VLDEY]F;]X1#+;-F
M.:/ *N.3UR>,G&.IZUR>FZ_J<'C+QG)JES;_ -EZ3' Q55;*1>4TG'/)YY/?
M'TK8\%^&#X6L+ZV79%!<7CW$-I$Y>.V5@!L4D XR"W0 %L>YHOX0O9O$OB>2
M:2U?1M?MXXIAEA.A6(Q$ 8VX.<YSQC&.] $5UXTU'3-"TKQ)?V=N-'OGA$L:
M%O-M$EQL=FZ/U7< !C/!.*Z3Q#K<7A_1Y+^2,RMOCABC&<O([A%' )ZL,X!X
MSP:Y:/PAK-[X2L/">KR64FG6CPK)=Q2-YEQ#"P9%\LKA6.U03N/?&<\=#XO\
M/-XG\-W&FQW1M;@LDMO< 9\J5&#HV/J!0!D6_BK6AK5SI\FE?:8_L;7-O>+;
MS6\.]3S$Y=3@XY!'7T%9MAX]UN;2_"^LW6F6,>FZS<Q6C*DS&9'DR%8#&-N1
MTR3WXZ#;TRV\93VDW]NRZ0)4A:.*.R:0),Y&-[LPRH_V0#USV%8D?@K7(O!G
MA710VG&?1;ZWN97,[A9%B8G"_N\@G/?I[T :J>+I[WQ#?Z58O8BZL;R.%["X
M)6>2$["TRG., ,Q P?N]1G%2V_B:_GU/Q7IYAMA)HJQ/%)\V)0\9DPPSQZ<'
MW]JS_$/@[4/$CXO+?3DN8+Q9K+58I6%Q;1APVW&P9.,@?-CD'J.9;GPWKT'B
MCQ#>Z=)I[66N01+(T[.)('CC*<*!A@1CJ1CWZ$ K?\)WJT]CX/GM-*M';Q A
MR'N&'E/Y1?'W?N\<GKC/%7/^$HU<3?V3-!9PZQ;VJSW9CBFN(%9V<(B[ &Y"
M$DGIQ@-VSK'P9K]I9>"H6?39&T DS$32+Y@,9CPOR'L<Y./IWK1UOP_XBMO%
MW_"1^%[BP,EQ;+;7MG?EUCD"DE'5E!(8;B.F,4 ;7A;6;G7_  ];:A>:9<:;
M=/N66UG1E9&!(XR 2#C(..AK9JIIL-Y#8H-0N$GNVRTK1J50$GHH/(4=!GGC
M)YJW0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !116-XBUPZ-#8QQ1K)=ZA=I9VRN<*';)+-WP%5C[
MXQQG- &S17(:AXFU7PS8Z[?:_90R6%A$DMK=VO[L7);CRRA9BI#8&<X.<TM]
MXCU;P_JVB1:S'9RV>K3BT#VR,C6]PPRBG+'>IP1G"],XH ZZBO.I/&?B>31O
M%-_;V6DI_8%W-&ZR-(WFQQQJY QC#$$\].@QWJ^GBW6$UGPX;FTLETO7@5A1
M&8SPMY1D4LWW2"!@@#CU- ';51N-9TVUU6TTN>\B2_N]Q@MRWSN%!8D#T !Y
MKASXO\8WECXAN=-TO2#_ &+?30/'++(3.D:JQ"8 ^;!/)P.@QU-)=:Q#X@\4
M_#/6+="D=X+N94;JN;8D@_0\?A0!W=KJMC>W][8V]RDEU9,BW,8ZQEEW+GZC
MFKE<?9^)M4FU/QA:KI4$USH_E_9X;=R&N2\6\!F; ST'3CWJ/2_%M_/XM309
MVTZZDETYKL/:[D$4JLJM$QW.#]X<CD8Z4 =I17F2>/\ Q'_PB$7B>6PTQ;*&
M^-M=0JSF1E^T>3E#T!&1USGG@5TUSKFIW^JZSIVA):>=I4:>8;E&82S.F]8Q
MAEVC&W+$G[W3B@#8AT33;?5)=3BLXTOIAMDN /G<>A/<>W:K]<C+XJOS/I^F
MM9_8=5GL?MERC0278M^0H7;%][+;N<@ +[UH^$]8U'6M(>;5=,DL+R&=X'1H
MW190IXD0, =K C&?<=J -VBN:\8Z]?\ ARVL+^!+9K%KR*"]>56)AC=@OF#!
M' ) (/K[54@\6SIXVUO0[^:RB@L;,7D,JHV63&7W?-@%,KD#J&!XH Z2\U6Q
ML+JSMKJY2*:]D,5NC=9& )('X"I[FZ@LK:2YNIDA@C7<\DC!54>I)KD;CQ'K
M-E>^$;>^LK+?JTS)<$!@T#>6SX4$GD 8)SZ\52TB\UF[\4^-X+V]MY;6S,<2
M1K RD(8-ZA3N..6.<@Y/IT !V^GZA:ZK807UC,L]K.N^*1>C+ZBK->3^$/$&
ML:%X,\#%[>R;2;]X-/*Y8SJSAMKY^[C(^[@G'?L/6* ([BXAM;>2>XE2*&,;
MG=VPJCU)J'3M1L]7T^&_L)UN+68;HY4Z,,XR/RKD-"O-9NOB#XNMKJ]MY+.S
M%M&D0@8$(T3. IW8!RW)(.?;@#FO!?B#6-!^'_@J7[/9/I-W/%8.I+>>#([*
M) ?N@ _PX/'<=  >O45Q.J>+]3?^V3H5J)WTN4PB%K*>8W4BJ&95=/E3[VT9
MSSU &,]9IMV]_IEK=R6TMJ\\*R-!,,/$2 2K#U'2@"U17&ZUXB\11>,U\.Z1
M9Z:S3:;)=PS74CX#*ZK\P4=.<8&3R#D8Q4%[XOUAX-4&EVL4MWI9$4D*V<\Z
MW,XC5W1'3 0?,%!;)SU '4 [FBN5MO$U[K&H6^F6%LMC>?8([Z[^W1,QMM^0
ML10%26R&SR, =\\89\>:S'X=NM1EMK'SK/7?[)EC57VNOF)&74[L@Y8G!SV'
MO0!Z-5/3=5L=8M6N=/N4N(5D>(NG0,IPP_ BL<Z]?+\0)/#WE6[P'2S?Q/\
M,K!O,";6.2,=\@?A7-OX]U>'X=3>(H]-L?M,.HM:O"K,%Q]H\K(]3DYY(H ]
M(HKC[CQ%K>FW=OIVIQ6"WU_-*UJUG%-<+';HJDLZ !F;+!>,#G.1C%9.H>.O
M$6F>%]6OY]%C6XT^\BA26:&6"*ZBD=55T1OFS\W*D\8ZG- 'HU%<5-XA\36_
MC%- >UTHF]LWN;656DQ#L8!A)_?X88QMS[=:AL?'ET- N9-1M8?[4@UAM'VV
MZNT<DH(PX7EMNTYQR>".] '=T5PQ\5^(+:36XI=+6>.SL&O;6^-I-:PR%?O1
M,'R0PZC!Y'I4-EXRUXGPC=W]GIZZ?KZQH5A+^;%(\/F!LDXVG!XZCCDT =_1
M7G.DZ[KMK=>.K^ZDBOTTN=A%:Q0,K,$A5E53N.!SSP222?:NB\,:_+K^+JWU
M#3=0TUX0RSV:LC))GE'4LQ''/.#UX'< Z2BJ6L:I;Z'HM[JMV3]GM(6FDV]2
M%&<#W-<M>>+-6T:RT75]3@LVTS4I8H9HX58269E'R$L21( 2 >%ZY'I0!TNJ
MZ[INB1&34+H0J$,APK,50=6(4$A1D98\#-7(;F"YM8[J"9)+>1!(DJ-E64C(
M(/<8K@[1-3F^,>KQRW%H\*Z7;AD:!CF$RR?*/G^]UR>A]*[Z*&.WA2&&-(XH
MU"HB* J@=  .@H QSXR\,"22,^(=+5XVV.INT!1NF#SP:V4=9$5T8,C#*LIR
M"/45XW;^(K3P_<?$#[;ITUW#<ZQ]G VKY.YXPH$C$X523R3Q70VD6K_#/X,(
M7FM[N_TN R.LFYD(+D[ 00> P /MTH ]%JCINLZ=K*W#:;>172VTQ@E:(Y"R
M  E<]^".E9%YX@O+3QEH&D^7 UKJMO/(6P0\;1*IZYP0=WIVKF=!UN/P]9^.
M=0>,RE?$;QQQC/SR.L**. 3]YAG )QV- 'I=%<II>OZS)XI&F7=@\]A+;F5+
M^*PFMUBD!YC<29SD<@@CTQ75T 5H]1LIK^6PBNX7NX5#RP*X+HIZ%AU&?>HK
M[6=-TQT2^OK>W9U+ 2. =HZM[ 9'/3FN5TJ&*'XR:]Y4:)NTFU9MJXR?,DY/
MO47A!O[6\8^.I[Q1)B[CL%1QD"%(_NCV)9C^- '77.M:;::C9Z?/>PI>7N?L
M\!;YI, DD#TP#STJ_7AGA^^U"[T/X;/$$N+N"^O;:$SN55E1)47) )P% _*O
M0-%\0Z]>ZMK7AK58;&VUJUMUGM;FV#-!+&^0K;6.1M88(SS0!O1>)]!GU4Z5
M#K6GR:B'9#:I<H90RYR-N<Y&#GZ5JUYKX774/"WB:PT#Q#I.E22W<;BPUFQA
MVM*R+N=9<\ARH)SGGWYKNK;7M'O;O[)::M8SW//[F*X1GXZ_*#GB@"=-1LI-
M0?3TNX6O(T\QX%<%U7H"1U J2>YAM@GG2!#(X1 >K,>P'<]?R-<99PQ0_&S4
M?*C1-^A0NVU<;F\]^3[U-HE\^L_$GQ&TAS#HT<%G;+V#2+YDK?4_(OT6@#LJ
MBBN8)Y98HY%:2$[9$[J3TR/?MZUR7_"2:]JFEW.K^'K&UN[:&\:WCM)"5EN4
M23RW<2%@J<AB 0<A?? 3QC>MH7B/PKJL7'VK4%TJX4?\M(Y58KG_ '74$>F3
MZF@#KI+F&*>*!Y )9<[$[L!U./0<<^X]:S8/%.@7.L/I$&LV,FHH2&MDG4N"
M.HQGJ.X[5A>"+QM?N?$NL3,VY]2EL8"#_JX(0%4#TRQ=C[M4'BWPSI]T?#FD
MZ79PP7EO?Q7,4D2 -;PQ',CYZX/"^[,* .VBN8)I98HY%:2$@2)W7/3(]^WK
M4M<9XTO6T+7?"VKP\&?44TNX _CBF!QG_==5(].?4UV= !17%1^+-4;3_&,A
MCL_/T"1Q$0C;9@L0D^8;L@G..#44GC#6I+WPC;6EC8G^WK%[AFDD<>6ZQ*YZ
M#I\WN3C''6@#NJHR:SIL.KP:2]Y$-0G1GCM]V7*@9)QV'UKD+?Q[=VFAZU+J
MUK;OJ6FZB-.2.U++'<R/L\O&[)7.\9ZXP3STJ#4?[3B^+'A,ZG+9R(+.^97M
MXFCP=J;@0S-D#C!XZGB@#T2BN 3QQJ]U:Z7JVG:7)>:?>SJ&M8["?S8X&/$H
ME^XV!@E<=\!CC)LV7B+Q1JGBC5]+M++24ATN]@CF>660EX70.=N!]\ ]P!VY
MZ@ [:J.L:CIVEZ7-=:K=16UFHQ))(^T?3US]*NMNVG:0&QP2,C->037NL:C\
M*O'<^J7D%QMFOH1LA*$%&VC&6("X48&,^YH ]1T?3=,TNP2+2;6*VM'_ 'BI
M$NU>><@=LYS5^N(T[Q!K%CX@\/:1?V]E]AU6TD-N82QEB:)%8[R>""#V P?7
MJ:TOCK5;C3X-9TG3)+ZQDN=GV2.PG:9H=Y7S%E'R9XW;<=.,YH ] K.O]>TG
M2YEAOM0M[>5EWA'< A>FXCLON>*T:\VUNXU_P/XQU3Q%%I4FLZ#J:PFY%MS<
M69C3;D+_ !)C)QZD].X!Z%9WMKJ%LMS97,5Q Q(66)PRG!P<$<'D5/7#6'BK
M0K+PG877AMEGM]4OWBMD6)CY<LC/(X9%&[Y<.=H'/ R <TU_'&I:3'K3ZOI<
MDD%FD3V=W':RVT=RTC!!&1)DJP=E&<G@Y[8H [NBN>CN/%$6K_9;BWL9;.2U
M,BWL*%1!,#_JV0N2X(.0PQTZ5@0^.]2F\#>&_$0MK17U.]AMIX<,0HDEV94Y
MX(QGG- 'H%4[/5;&_NKRVM;E)9K*017"+UC8@$ _@:Y5_$7BB\\7ZSH>F66D
M@:>MM*LMS+)\R2;MP.!]["\<8&.<YJI>>*=9FT3QXT"65E>:('\F1%:3<! )
M,G)&6QP#C ]#0!VNH:K8Z4MNU]<I MQ.EM$6_CD<X51[FF1Z)IL6K/JL=G&M
M_(NQ[@#YV7T)[CVKCCKVKZ)X2\(2RI97GV^ZL;221U=2B2!1D#)W-UYR.<<5
M=U7Q9J+3ZS#H<"RRZ6WEE'LIY_M$NP.4#1\)PRC)SR3P .0#LZ*X:?QU*+_2
M[&<6^AW-_8+=1KJL;8:4D@P9RN&7 SG).X8%=E8O<2Z?;27<:QW+1*TR*<A7
M(&X#V!S0!5U#7]'TJ:.'4=4L[267_5I/,J%_H">:+/Q!H^H7?V2RU2SN+C87
M\J*=6;:, G .<<C\ZX[XD2-#XD\#2QP23NNK$B*,J&;]V>!N('YD5TEG>W&I
MZW<1SZ/-826ENCV\UUL8L9"X;'EN1@;%R,@_H: -ZBN$TOQ7K][KMUX=N+6S
M@UBVN=TG[IS";/'$RG=R2<#'8]>A(U+G7-3O]4UG3M!2T\[2HTWFY1F$TSIO
M6,89=HQMRQ)Y;IQ0!LRZSIL&KV^DR7D2ZA<*S16^[+LJC)..PQZU>KS?6[G5
M+GQMX!N#816NIRVE\7MYI=RPN8H\@LN=P'MU]NHTM-\5Z[=Z'K8.FVMQK.EZ
M@;%E@8I"X^0^;\QR %?)&?X3SS0!VU%<18>,;VYO_$=A&=/OI-,M8[JWN(-T
M<4P8-E3R_0H>03GVJE8^-]?>R\):K>V>G+I^N2Q6SQQ%_-C>1"RN"3C;E>G)
MQW] #T2BN'U'QEJ(A\5W.G06HC\.\/%<*VZX*QB1\$$;!@X'#9(S4R>+[RX7
M2[188H+^]L?M[LMO-=)#&2 @V( Q)W=R -IZ\4 =E16#X3UC4M9TJ635M,DL
M+N"X>!@T;HLP7I(@<;MK ]_<5LW-S#9VLUU<2".&%&DD<]%4#)/Y4 "7,$ES
M+;I,C30A3)&&RR!LXR.V<'\JEKQS2]:M])^(>DZZ=4MYE\4H;>^@2X5S;RYW
M6X(!XPI$?ID$]Z]&U+6IU\16>@:>(1>SV\ET\LREDBB0JN=H(+$LP &1T)[8
M(!NT5YOXIUCQ7%X9LC<QVVFW;:Y!9R%%\Q;B(S*%=</E%;NI).,C(SFO1(!,
M($%PZ/,!\[1J54GV!)Q^9H DI&944LS!549))P *YZXUVZN_%,_A_2FMXY[6
MU6YN9[B-I%7>2$0*&4DG!).>!CKGCDO$7B>^UWX6>+!LALM1TW[197\8#.K;
M5Y,9R" P(()SCD8/6@#N[#Q'I&J7\EC9WJ274<8F,1!5C&>CKD#<I_O#(]ZU
M*R="M'73;.XO%M9+L6ZQK-##L(CP#MY)/49ZX]JUJ "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YS
MQIX:G\2:5;+8W@L]2L+I+VSG9=RK*F<!AW4@D'^O2NCIKND<;/(RHBC+,QP
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M1U!-1LYH69S;RH%"A@0,CY/U-7?^$=\3:EXGT'6-5FTB/^SX;B*>*W$C^:)
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?*Y^8=P">:]$71M+6]2]73;,7:($6<0+YBJ.@#8R![4RRT+2--D$ECI=G:N
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M?,, ]OE&/I71^+Q?Z=>^(]7TZ2SU335@1-:TBZ^1U18\[HG'3*-G!&,@XYH
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M>,]1DGTKI0   !@#H!2T4 4KC1],N[D7-SIUI-..DLD"LP_$C-72,C!Z444
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MV6!HI%"/$KXSG &&(ZDG & +6A:1KL7CG5==U"VLH+:_M8(A'%<M(Z-'N_V
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M=4O&LI8+J1XVBD 8Y *<H=N=W7!Z$UHR:YXDMHXHM0LM-L)5M7FGO'E9[;S
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M'*3O1CM#+D$=CT_+<UGPUK_B3PVRWU_:V>M1W$5U9FV#/#;R1'*Y+#+9R<G
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M0VUP..001Z=:V/LFH:M;RPZM%!;6LL3Q/;V\QE+A@5.YBJXX)X Z\Y[5L44
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M&YF12J,0RC8,L6(RW.!F@#(D\:>)I-&\47]OI^E)_8-W-&ZR22-YL<<:N0"
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MD*O'%+&\;. 5)8@C81UYR.E '>UG6FNZ7?W5_;6EY'-+8$"Z5,GRB02 3TZ
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M8O\ ='Y4;%_NC\J6B@   Z#%,:*-W1WC5G0DHQ&2N>#CTI]% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI]RMD83:F6"]CB?:SA@"K1EN, C^+G/;&*YS1_&>MZG\*;OQ<Z:>ES%#<3I
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MIB^3\B!UPHP,G)Y8#WKC)[/4/ NM:?X95);GPUJ.J6TFF2YR;.03*[P,?[I
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\)03%"GF1:2ZMM/49$F<'TJ2Q\/ZYI<DDFGIX6M))3F1K?2WC+_4B3FNOHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHJ/[1"9O)$T?F_W-PW?E0!)14<MQ
M!!CSIHX\]-[ 9_.GJP90RD%2,@CO0 M%%% !1151M5TY-033WO[5;UQE;8S*
M)&'7A<YH MT5G2>(-%AGE@EU>P2:''F1M<H&3)VC(SQR0.>]:- !1110 444
M4 %%,EECAB:65UCC099W. !ZDU!_:5B4M7%[;;;O'V8^:N)LC<-G/S<<\=J
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M9E<-P1M..V:XSPV+_4OA[?:E=Z;I]S<VU]>7MO/+=-O2=99/F'[O@J!@<\X
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M"\98_,&X*G=U!)XZ&@".Q^(MC?:)87?DK:WMW<26K6MY.(A!+&"9 [X/ QU
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M1)&B=HG#!74X93CN#VKD[/6-<G^)VKZ88[5K&ULH'C3SF4@.S_,?E.6.T#'
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M=#L+G6+#69(T2\L"Y68  E&1E*D^G(/U%<Y/X\N(O"X\61:8DN@A\L1*?/\
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MK#S_ +1^^620L%;9MQLR,?>SSTKL=/U=+OQYK.D2:5;Q26UI#(;M6#/.C%@
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MR =I167X;UN/Q'X;T_68HFB2\@67RV.2A/49[X.>:U* "BBB@ HHHH ****
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M+=Y<8VKN<L<?4DDT <%X=T/QEX;C/AV!M.ET2.1OLVH-*PGAA9B=ACQAG&2
M<XZ9STK8T/1]3L?'/B35;F& 66I_9_)*3%G7RD*G<,8YSG@FNIJI;ZKI]W?7
M%C;7L$UU; &>&.0,T6<XW =.AZT <4/"%]>>(M(UJ6PM=.U>TN-UYJ%I-Q=P
MX(V,H W%OESD<8.">!2:?X4US1O#.L>$[5+:;3[IIQ97CRD&"*;.Y73&25+,
M1@X;C.VNVOM4T_3/)^W7L%L9Y!%")9 ID<G 50>IR1P*<=1LAJ8TTW40OFA,
MXM]PWF/.W=CTSQF@#D[3PK>Z5XPT6ZLHHFTK3='.FJ6FQ(>4(.,8Z)Z]ZHVU
MOXG\'^&M>NK>STV6ZGU>>_2.2X;:8I&W%>%!W]@.Y/?I7H=17+P0P-<7+1I%
M #(TDF,( #ELGI@9YH <C,\*L5V.5SM/8^E<%8>$;[_A)M*\0/IUKINJ0(XU
M.6SF_=W^4( V@#/S8;+ $8QSU'=6EU;WUI#=VLR36\R"2.1#E74C((/I4U '
MF,G@OQ _PPO_  WY-D+VXOFN%?[0?+"FX$W)VYS@8Z5>UCPWXDU#5_$+B*PF
MMM3TX6UI+<3MNL"8RKHJA3D,QR2"/?. *Z]->TF35!IB:C;&^;=M@$@W-M^]
M@=R.X'3O6C0!P \-:^T'@@26]EOT0@W06X."!"8L*=O)YSS@=N>M:VD:-J5G
MX^\0:Q/% ++48K:.$K+EP8@P)9<=]WJ>E=310!POQ/,RV/AMK=$>8>(;,HKM
MM5CN; )P<?7!K0_X1^YU;Q3)KE_&MJJ:>]A;0AP[?.V7=B.!T  !/<GKBMG5
M="T[6_L_]H0-,+:430CS779(.C#:1\P['M6@!M4 9P!CDYH \OM_"?BW_A&O
M"^CR6NEI_8.HV\WF?:F(N(XMWS?<^3@CCYCD]L<]/X?T;4[+QAXFU*\AMUM-
M5>!X?+F+,OEQ",AAM'7&>#717M]:Z;937E[<1V]M"N^261L*H]2:FC=)8UDC
M8,C ,K*<@@]"* .!\+Z#XO\ #5L/#49T^31896-MJ)E;SXX68ML\O;@N,D Y
MP.O.,5<M]!UB#Q!XQOS;VQBUB*%+4"<Y!2(Q_/\ +QG.>,UVE% 'F^G^%?$V
MG6OA*$P:?>0:5:M;W-G+<LL?F84).IV'<1@\$9&>/6I='\,:]IOA^72K_3]*
MU&UEU.>:X@:3(F@D+MD!EP&#%"!GL?F%>AU'#/%<(7AD61 2NY3D9'!&?K0!
MYJOP]U?3]#C.B7,5K>6&K-J&EVEQ*TD4,138T#-UP06/'3.,]Z[706U^X1[G
M7H;2T<@+':VLIE"^K,Y R3Q@ < =3GC9JM?ZA9:7:/=W]W#:VR?>EFD"*/Q-
M '.^(= OY/%6C^)M)\J6YL4DMY[:5]@GA?KM;!PRD C/!]167JW@_4M3LO%E
MX(K=-3UVU2SAA:7Y((U4@%F Y)+$G ]!D]:[V*1)HDEC8,CJ&5AT(/0U7MM1
MLKRYNK>VNHI9K1Q'<(C F)B,@,.W!H 9I$5Q;Z-9P74:)/%"D;JC[ER!C@X&
M1QZ5RWC'PQ/XF^V6EUI%I=Q&(?V==^=Y<UK-CDYQD+G:>"3P<@\5VU% 'G\O
MA[Q9H.NP:QHDMGJC7%A!::E#>RM$99(@0LRL >>3D'U[]KOB#0M?U6#PXQ^R
M37-CJD>H71\PH@50XV1\$G ; )QG&3UKLZ* .6LM&U*'XC:EK<D4 L+FQBMD
M(ERX9&9LE<8P=WKVI_C72M6U6PL%TH02B"]CFNK.>0QI=0C.8RP!XR0<$$''
M/I7344 >;R^$O$DD?C>,P::JZ];(D CG;$;>0(MI^3H/7OZ#/&A-X>UF2_\
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M12.RAU$\@8$%2,#  'H.M=;)XBEEU>PT/3XH?M\]C]ND:7/EP1 A1P.6)8X
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M\NVMXI9#"A[N[%<D],*!CCKSP 5O"7BZ\\5K;RPV4<,4<;+J(DW!K>X#$&$
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT [DT 7:*H7CZD9[!K V8MVE_P!+^T;MWE[3CR\<;LXZ\8S5XNJYRP&.N30
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M.[O86.M?9K N2=L*SQ?(">H5BRCZ8[5ZWJ.B:;JLT$UY:K)/;Y\F924DCSU
M92" >XSS3+KP]I%YI*Z5<:? ^GK@BVVXCX.1E1P>>?KS0!S.N0QI\7_"<RKB
M22SO@YSU 6/'\S^=8OAV#1O%7@VZOM=G,.KVNI2R7ES&P6XMY8YCL16P2HV!
M5"CL<#FO0GT'3)=0M;^2T5[NU7;!,S,7C'< Y[]_7O55_"'AV37QKKZ-9G5
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MJ"VT\T=O<,!;*AVJTCJ02S#HH'JV2!S766]O!:6\=O;0QPP1J%2.-0JJ!T
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M8% 'K;W$,<J1/+&LC_<1F +?0=ZDKR;4K";4_P#A/=',4.H7=]<J+6Y\Z,"
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M1_V7>>'VGO[<*/+\X.51R.@8J&'OM]JO_"W0M+MO!FA:O#9Q+J,VFQQRW/\
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M'0CTK0J#[=:?;/L?VJ#[5C/D^8-^/7;UH SF\*>'G2X1M$T\K<[1,#;KB0*
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M?UJ1O#&@O!=PMHUB8KR027*>0N)F'0L,<_C5[[?9_;/L?VN#[5C/D^8-^/\
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M>(_!]EXCXL[:X0LPF< 1L&*L"QP,9!Y[ULB[MC;I<"XB,#XVR;QM;/ P>G-
M'/>$O#,.@M>7$.F6NE+=! ;&TE+QJ5W?,3@#<=V#@=%')K:U'1]-U=85U*PM
MKQ89!)&)X@X1AW&>AI[ZE81P&=[VV6$.8S(95"AA_#G/7VJ1KJW2V-RUQ$(
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MB0/$R<K(J*#M7 ZXPV!U-=^Z+(C(ZAE88*D9!%9^G>']&T>>:;3-*LK.6?\
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M*>N3Q[<QIUQ;0>+?AT\4ME;VKZ=<K##')N=(?)0H)),_.21GH!D'KUKTS3M
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MC]SB.-AL_N\^F.@]*VSJ<;>.-/M=8U-;.*YT&%K*2=8V25R6\X9<$;B-F1W
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M8GNX=9O6BG907C*RJ1M/5>?2NEGO[:X^(FHZ=K>I1V:SZ9;FR$Z1E)HSO\T
MN",[L9 Z@#^[7;CPWH0MIK8:+IPMYFWRQ?94VNWJPQ@GW-+?>'-#U.V@M[[1
M["Y@M_\ 4QS6Z,L?^Z"./PH J>#-/LM*\)V5AIU]<7UE '2"XG8,SJ&.,$
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MF^9.D8W2D2QD%R.6ZD\GN:Z#P-J7FWVJ:=K$21>*;>3-ZQ/_ !\1Y_=R1_\
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M7O'EAKRQM.;SYTGQ@V)C CZ_P8#^V2>YH [N6[MH)(XYKB*-Y21&KN 7P,G
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M !Z=J7B?1M,\/W&MS:A;M80*298Y58,1_"I!Y8GC'K5B+6=.DTM-2:^MDM&
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MH5O()V_MMI<Q$ ,I>#+  G"DYY_6@#VV#4;&ZN9K:WO+>:X@.)8HY59HS_M
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MT;6;VQCN'M_,19'RN2P0<XZ]!6EXE\1Z?X5T&YU;4952&%254G!D;'"+ZDT
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M[*XN4N9K.WDN$0HLKQ LJGJ 2,@'TI+C4["T9%N;ZVA:16=!)*JEE R2,GD
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M<Q7!T^T,\("Q2F%=R = IQD8]JX?Q!X_6\^'EWX@\,:C;B6"=4(*K(VPW'E
ME2?EW#+#(Z5W%KJVFWUW<6EIJ%K/<VQQ/#%,K/$?]H Y'XT 7*SQH6CB.6,:
M58A)CF11;IAS[C'/XTY=9TM]1_LY=2LS?<_Z,)U\SCK\N<\5<DD2*-I)'5$0
M%F9C@ #J2: *<VC:7<V4=G/IMG+:Q',<#P*R(?4*1@4Z72=-GLX[.73[62UC
M^Y"\*E%^BXP*;;:UI5Y%/+;:G9S1VXW3-'.K",8SEB#P,<\UQ/B+X@+>?#G4
MM?\ "^HVPGM9=N"JR-M\[RMVTGY=PRPR.E '<#2--6YCN1IUH+B,!4E$*[E
MZ '&14'B.SN=1\-ZE86:QM<75K) GFN54%E*Y) /'/I4]MJVFWE[<6=KJ%K/
M=6_$\,4RL\7^\H.1^--&LZ6=1&G#4K,WQSBV\]?,XZ_+G- &;X3\.PZ)H6G1
M3:?8PZC;VL=O--;H"7*J 3NV@G)&>:TI]%TJYNWNY],LY;F2(PO,\"L[1D8*
MEB,E2#C'2FG7M'6X6W.JV(G:;R%C-PFXR8SLQG[V"..M6[FYM[.!I[J>."%?
MO22N%4?4F@"O<:/IEY:1VESIUI-;18,<,D"LB8Z8!&!3WTRPDL5L7LK9K10
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MGM:Z]9_99()&-DH1VN>F'5LYPO/0$'-6I-9TN'4$T^74K-+USM6W:=1(QQG
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M BK] .!4U8_A2_N-4\'Z+J%VX>YNK"":5@H&YV0$G X')K8H **** "BBB@
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M>PG=M\A<9]<8H FO+2#4+&XL[E!);W$;12(>C*PP1^1KQAGU>/PQ;LL3M>^
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M<;AVSVS7M-GI]EIT;1V-G;VJ,<LL$2H"?4@"FOI>GR*ZO8VS*[^8X:%2&?\
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MXYXKC=!O8K3Q_P",K36Y(HI+@PSVYG("RV@CV_+G@JIW9]V/K7'V5D+7PUX
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MCD\C=RN58X^8 XSZUKW^LZ;I047]_;VY92X$KA25'5L>@R,GH*\W\76VF0_
M.2X@AM4,NG6@\U%4%R&0CGOR3^9K3US6-,'CF>T\ZWL;MM&&;V1MSW,3.V(H
M5)VDYR2<,3D #N #4\8ZW>V,7AJZTF^C6WOM8M+:4HBN)H9&YPQSC('4>M=?
M7B=G?VLGPK^'.+F(^5K5@C_./E*N<@_0=?2O7XM7T^?5I]*BNHVOX(UEE@!^
M94;H30!=HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<GG/3(/(//>L2W\,:E?-$FM6GAZ.**1)"]C:MYCE6##!;[G('3)QTQUKLJ*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8QN>21@JJ/4D\"@"2BLN#Q+H=RZ)#JUF[.0$43+E\D ;?7)(''K6I0 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %<#\1 #XC\"Y'_,:7_P!
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MPS:FT4MLUQ(Y2(HBQ_O/E'4#/'?CFNIT:XO+K1+&XU"%8+R6!'GB4$!'(!(
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MC*%"L3EMH#%\\GA*>WB/4=-\6VGA_4XK69]1MY);"YA#1*TD8R\;J2Q'!!#
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MMZ[64J<?G7+^&='\9Z;%;:9JNIZ9/IMD L4\"2"YN%7[BOGY5Z#)&20,=R:
M,>?Q]XDC\.:YK:Z9I@AT74)K:XC,SEI4C8*VPX&#R3D_EWKI[KQ%<3>++?P]
MIZPQS2:<VH-/<(74+O"*H4$9.3DG/ '?/'/R>"=;E\&>*=$+Z>)M:OI[J.03
M/MB65@Q!^3)(Q^/M4.M1:KJ?B^SL],ET4ZCI>G@3PW,\T3(TAZI)'AV!"<C&
M!D=2> #1T?QCKFL>&$U)-(M8Y7OC9N5G+I JNRR3/D+\J[2< \YZBEL_'VW3
M?%=S=QP70T#YA+99"7*&,.N 2<'L>2.]9W]E:[K6B6VF6UMHMG+HNHQ2F"WE
M=[*Z0 DQL=NX,"0Q!!Y /?A=0T[5/#-OXSUS4M0TQ(=5AB$9$+,$F\L0J&#'
M;MR0.>#G)P.* -,^*=;@UWPWI\EMI]PFN0O*KHSQ^1L4.P_BW_*W!^7D=LU5
MO/'>IOI[ZMH^ERW]I'=-"+.*RG>::-9#&TB2 ; >"0N#P.H/ IZ-::]X<NM*
MDN=/\.W%N?+LH7M+V=YDC9@#Y0D!&T<,0".%]JO:5X7\6:!<W6EZ9JFF_P#"
M/3SR31/,CFZM0[%F1 /E/)."3QG.#TH [LLQC+( 6QE0W'/OZ5YU)X]U2V^'
MVH^((]+L1<6FHR6KP+(P7B<1[AQ\QR<_PUZ,<A#M ) X!/7\:\XE\"Z[+X!U
M7P]YFG"XO=1:\67SGVJK3"7!^3.>,?CGVH W;+Q#J\?CD:!JMK9)%<V3WEL]
ML[,R;7"LCY R?F!R /I6QKU[?V&F^;IUF+JX:6./#-A8U9@&D;G[J@DD#T[=
M:RIM#U2?Q]I^OD6:VUO8R6LD8F8N2[*Q(^3'&W'OGM4WC30]0U_1H;;3;B".
M:&[AN&BN<^3<*C9,<F,G:>.QZ4 9%KXVO)E\5PQ)87TVB0)<13PNR17"O&SX
M_BP1L(X)!]JCLO&>N%_"=U?6-@FGZ^J1XB=S+%(T1D#<\;3@C'4<<FC_ (1/
MQ"=2\47CW&EM_;=A';B-?,7RG5'3&<'Y1OSG&3CHM.;PEK1TKP9: V&[0)(G
MF8S/B79$8_E^3C(.>?I[T 7-.\57:ZIXDT_6OLEK)I,8N(VC1B);<J2)<$].
M""!T(ZUT6D2WT^D6LVI11PWDD2O+%&#B-B,[>3VZ9KD-=T[3/$WC?1)=/U"*
M2XMO-34%MY%</;J0WER8/'[T(,'J-_H:[R@#D#XFU75+;6[S0H+22#2KB2V$
M4X8M=21@%PK @(,DJ"0V2,\"L6;Q5J.O:_X&N=&N88=.U6&YN/*FC8G>D7(<
MAAD#<1@=QGGC&M8>&=9T"ZUV'1Y+*73]5N'NT^TR.KVLT@P^ %(=<@$#*^GO
M4+>!;G3&\(?V%<6P&@)-"PNPW[Q94"L_R_Q9&<< YZB@#'BO=9T[Q5\1+O1X
M+)WMY+>=S=LP#!;53M 7N<'DG XZ]N@'C;[=!HJ641BN=3TX:B2UO)<"",A<
M I'RQ)?'4#@\] 8XO#&L1WWC"X/V$C7%40CSG_=E8O*^;Y/3GCZ>]9X\%>(]
M.LO#=[HU[I\6M:18C3IDG+M;W4.%X) #*<J"..M "W'CS7[;P_;W<V@+%=G6
M$TV1)Q)"LJLX598@R@[6!XR>#ZUVFCMK#6DG]MQ64=R)6""S=F0Q_P ).X Y
M]:YK7/#GB/6M%L(I[G3WOX]2AOY?F=(4$3 B.,88D'')/<DX[#M%W% 7 #8Y
M .0#]: .%\5>--4\.6VK7\EM9PV]A(@@M[ACYM\GR[W0AOE W$<JWW><=MF?
M7+V^UV]T;1A;+/96T<\\URC.NZ3=Y<84,IY"DEL\<<'/',ZUX%\0ZC:>+;".
M^TUH-:D\V*YG#F9  N(3C@(-O!&<9/'-7;GPSXHLO$J^(=$O-*-U=VL=OJ5K
M="187*9VNA7)R <<]1Z9X *NJZUXHFU/P0CPP:5-?SR_:K.3][B1(G."RL 5
M[@=<XSTQ6RGB>6W\8ZSI^H6UK#:Z?IB7IN8R6=DRV<\# &TG'/UIFL>&M8O)
M?#M];WUK-J&EW4D\IN%98Y!(C*P4#) &[Y1Z  GO0WA6\N_%^K:A?&U?3M1T
MM=.D1)&$F 6RV-N!G>1C/'O0!3N_&VI:=X7T_P 775K;?V+<F)YH%#>=;PRD
M!)"V<,1N7*[1UX)QS))XF\277B'Q)I&G6.F*^E102Q2SRN0XD5VP0 .3M XX
M'/)XJ"+P7J]QX.M_!VISV4VE0M'&;M';SI;>-PRH8]N%8A0I.X\<XK2M- U:
MT\5>)M6 LGBU6&".%/.<,AB5E!;Y.^[/'3'>@#5\+:V/$GA;3=9\GR3>0+*T
M><[2>HSW&<UKU@>"M%N_#GA#3M'O6@>:SC\K?"Q*N >#R 1]*WZ "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH ***XSXG7FI6/A(2Z;=I;E[NWAE+1EBR/*JD Y&.O/7(R..M '9T5S
M+ZWJ$WB4>&[6:T%[#9"[NKIX&* ,VU%6/>#DX).6X '7/#_"7B2;75U.TOH(
MX-2TN[:TN5B)*.0,JZYY"L#G!Y% '1T5PVD7NMR_$SQ3!)>036MG;VGEVX@(
M.UA*P53OP&SU8@YXX&*98^,M57Q%X?TW44L/,U43+<6T )>QD2/S C.&96.
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M5 REB3NY]%Z<\ ';45YY!\1I&\$Z'KMZD%BM_=O:W-RT;O#;%3(NXC(.&:,
M9(QNY/'-_4_&%SHNB6-]?W%@+>[OC =2AC:2VCA*L4D(#$_,0J_>P"W7CD Z
M:ZT73+V_@OKJPMYKNWSY,SH"\>>NT]1^%7JS=#N[J]T\SW4UG.&D;R9[,_NY
M8_X6'S-U[\]:PT\0ZOK2Z[-H"V7EZ5<O:+'<QLS7,L:@N,AAL&3M!PW(S[4
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M.M)+N]N8K>WC&7EE<*H_$UGIXIT9I(HWO/)>9UCA6XB>$RLQ  3>!NY(Z9H
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M?JC8Y!!Y!&<'L:I7G@8:IIGB9;VY1;_7XECEEB0[(51=L:J#R0.23QDD].*
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M19Z)# H  ^K,['ZUVM<AX:TT:!K_ (ATN9?]&U.\?4K5CTD\Q0)4^JLN<>C
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MO&"<_>R?IWKNM'O_ .U=$L-1">7]KMHY]F<[=RAL?K7,)X0U);?Q=$;NT/\
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MMRZ*?DC=]V-HP <#) QP#3Y_!]YJE_I%QJLME)-I=X+F*^B1A.Z DB(YZ#D
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MR<ID$$'GH<]JPM%U_4M$LO'6M:C>K>I8:I+&L7E;-S".)4 .3M7D#&#ZY)H
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M<5L5YY%X\U"R\.>([[4$MI[JPUI],M%B0QHY)C5"V23U<D\] :T[[6]6\/\
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MLKF> LUP\JE7.0P"CYC@ '''859E\.WC>/$\2)>P"--/:Q%LT!)P7#[MV[U
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MCY8XP&)P.YSGC%4D\$WZZ%XJTTZI;'^WYYYC(+5OW'FH$(QO^;  QTYKMJ*
M.0G\(W\TOA:3^TK8'0CD_P"C-^_/EF/^_P#+P??FL'PG9ZCJ:^.;.SOK:"WN
M-=NHG<Q%I(LH@9EYP3@\9Z$9YZ5Z:0""",@]0:KVUA9V;,UK:00,WWC%&%S]
M<"@#E4\$7&G:]97NBZG':6D&F)IC6\UOYI$:MD-&VX;6]200<9(-4++X>:C9
MZ!X;TK^V[>1=$OA=HYLR/,"[L+]_CASD_3BO0:* .4&GKX;\1ZYXLU/5;6*P
MNH(4D5HBODB/(4[]QSG?Z>E5O!^E:=+XAUWQ-ILC26=_*!;$',;':OG21^SL
MJ@GN8\],5V,L4<T312QK)&PPR.,@CT(IRJJ($10JJ,  8 % "UQ__"'W_P!K
M\63C4[;_ (G\:H!]F;]QMC\L'[_S<<]N:["B@#BV\%7YTWPG:#5+8?\ "/O$
MX;[*W[_9&8QQO^7(/OS5ZR\,W=OXOUC6I[RVFMM3AB@>U^SD%5C# ?-N.<[C
MGBNFHH X:V\!7,'AF3PF^IQR>'S)A083]H$)?<8=V[!]-V,XXQGFM6V\-W5O
MXYN/$ O(/L\UDEF+58""JHQ8'=NQG+'M7244 <C!X1OX9?%,G]I6Q.NG('V9
MOW!\L1_W_FX'MS5=_!%^VA>%=-&JVP_L">"82&U;]]Y2% ,;_ER"<]>:[:B@
M#SS4?AUJ=YI?B'2X]?B2RU6]-\FZSW2QR%U;:S;\,@V  8!Z<X&#N'PS?KXR
MM_$,>JQ!S8+97<;6V?,"R%P4.[Y,DD<AN/?FNGHH X8?#S[5H7B+2M2U!9(]
M7OWOTE@A,;6\A*D8RQS@H/3/-:D?AW4+W4=+OM<O;:YETL.T @@**\K+M\QP
M6/8G"CH23GICI:* .!E^'U_-X,U[P\^KV_\ Q-KR6Z,XM&_=^8^]EV[^>>AS
M5[Q-IDWB"?0]$9DD^SWD5]?R(N%6.+)5<9."[[<#/0,>U=A2!0"2  2<G'>@
M!:Y*W\)W^D7^LMHNI006>KRM<R13P%S!.PP[H0PSNP#M/0CKVKK:* ..7P,;
M+4/"SZ7>106?A^.6..&2$NTPD38Q+!A@]^G4UV-%% '.7/AJY?QS'XBMM0CB
MC>Q6RN;=X-Y=%D+@JVX;222#D'CWY&3:^ KFS\.7?A6'4X_^$?N'<(AA/GPP
MNVYXE;=@CD@,1D ]#7<T4 ,ABCMX8X8D"1QJ$11T  P!7'ZEX+U"[UKQ!<VV
MLQPVFN6BV]Q$]KYDD95&0>6VX  [B2"#WQC.:[.B@#BK3P5J5O=>$YY-7MY#
MH$#P[?LA'G!HQ'_?^7 4>N3GZ":SMH/!-SKNM:WK-G'::G=K,6:,Q")]H0+N
M+'/"CL.]=?4<T$-S$8IXDEC."5=0P./8T <GX#T.ST^'5-2LP_V74KMY;5'Z
M)!N)4*.RLS2./9Q5>U\!W5EX?OO"]MJ<:^'[IY-J&$F>"*0DO$K;L$'+88C(
MST-=Q10!S$?A:>V\:1Z[:W5O';1:8--CM/(/RH'W@[MWJ ,8Z5B?\*WN_P#A
M'ELUUL0ZE;:E)J=E?06^/*D=F)5E+'<OS$8R.*]"HH Q]"T_5K5'FUO5$O[Q
MP%'DP^3%&H_NKDG)SR2>PX&*V" 1@C(-%% '!CX8VB>$+C0HKZ:-S>BZMKH?
M?M@LFZ-4] JDC_@3'O6QXK\+OK_AA-#LKF*QB1X6#-"9 JQ.K*H 8?W0/I72
M44 <U=>&[V3QG:>(K;48H76Q^Q7,+6Y<2)O#Y0[AM.>.<\&L>3X?W\OA'Q#H
M+:O;?\3F\FNFF%HW[KS&W,H7?STX.:[VB@#F)O#5_/XJT76VU"V']G6TENT(
MMV_>>8%W'._C[HP,&LMO 5^_A?Q+HK:M;?\ $[NYKDS"U;]SYN-R@;^<8X.1
M7=T4 5[&&6VL+>"9TDDCC",Z*5#$#&0"3C\ZQ-0\-W<_C2S\166H1V[1V;64
M\4D'F;XRX?Y3N&ULCJ0?I71T4 <(W@*_?POXET5M6MO^)Y>3732BU;]SYN-R
M@;^<8X.14E]X,UE-8M=;T/78;'4A:):7BR6OF07*+]UMNX%6&3W]O7/;T4 5
M--M);*QCAGNGNI^6EG< %V)R3@< >@[# JW110 4444 %%%% !1110 4444
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M"-UI&FW<.D:I'87-YJ/VZ>2*T4QX.T-&D9)V@JH&<YR2?8=70 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $<MO#< ":&.0#IO4
M''YT]55%"HH50,  8 %+10 4444 -V)Y@DVKO P&QSCTS3J** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS3Q$(S2H<@8 9L  _=Y(S3-6\87X;6/[$M!<OI3F(PM:S2&ZD"!V16080X8
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M )5E;D<'/M42^%[T0>)[X_93JVNH(V7S&\J%%C\M%W;<MC)8G:,DXXQ7744
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\].E=W)X@T6+4/[/DU?3TO2P06S7*"3<>@VYSDY'&.]<7'X$UF/X=6/ACS[
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MXR /7O0 @\7:XMQX3 @TZ:/Q#&6 4.AMSY?F]<MO&W(SA>1GOQK?$.]U#3?
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MBK @@@GJ*UZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *R]?T;^V[".%9_L\\%Q%=02[=P62-PRY7(R#C!&1P>HK4HH Q
MY-+U"X6YFFU"*.\>U>WMY((2H@W=7P6)8Y"GJ/N_C5,>$X;O6Y]4U06L\DUI
M]DD2" QK*N\-E_F))!48]!GKGCI** .<;PQ);Z[8:AIES;6L-G9RVL=N]NSC
M$CHQ.0X[H./<U7/@B%@UVUX[:PU^NH?;C&/]:J[ NS/^KV93;G.#USS75T4
M<Y?>$X==N99]<D2Y#6<ME'%$A18TDQYAY))8[5Y[ ?4U=TNPU6SMX+6[U.*Y
MB@ 42+;E)9 .FX[B,^I &?:M:B@#FD\,7$^I:-?:E>07$^E%C'/';E)9<HR8
M9MQ^7YLD#J0#QC!L:GX?EOK(6L-VD*+J,5\FZ(OC9*LI7[PZNI.>P;VK=HH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
;!1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>elicio-insidertradingcom003.jpg
<TEXT>
begin 644 elicio-insidertradingcom003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP1OC,2*&7/WAD$9% '0Z+JVE6?A+3;J/5KF_LY55+>ZN=TD]R23C@+N9C@\
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MUK,NW#\#*E7 ))'J3Q0!W>GZM::F]PEL9?,MV"2I+"\;(2,CA@.Q!S5VO/-
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M_N_-QSCD>U3ZU?0>'/B-?W6OQZFNE:G:P+:WEFT^R-X]P:-Q$<Y.[(X[GWH
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MK71UROPU+?\ "N-!C>*6)XK..-TEC9""!SPP''OTKJJ "BBB@ HHHH ****
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MU\7:/>:;J6H0S3FVTUWCNV:UD4QLG+#:5R2.^ : (O\ A&+G_H:-=_[^0_\
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MX((R..#0!G:[H5]K5U J:W/9Z;L:.\LXH4/VE3VWD;DXR..<'C'6MQ5"J%4
M*!@ =JP_^$OT<MJZ^;<;M( -ZOV67,0(R#C;\PP,\9XYJ:/Q'IMS8:;=Q23M
M!JC!;1UMY,ON4L#C;E1M!.3@8% &O17F?A?QG9:'::^NN:C>S)!KUU;B:1))
MQ!$&54WN 0B]AG'?WKN[[6K.PN8[5S+-=21F58+>)I'*#@MA1P,G&3U/ YH
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M?*<@_>QC!H W**Q+CQ5IEO<:I;9N9+K38!//!';N6V'.TKQALX/0_7%'A+Q
M/$WANRU3R)(6GB61D:)E W#/REA\P]QQ0!MT5R\'BN*_\9:EX:%M>1BU@C)G
M$#C+/OY#8PJ@*,,<9.<=*YWP#XULK3P?I,.LZA>37=Q=SVYNI8Y)5#FXD"*\
MN"JDC  )Z8[8H ]*HK(U7Q)IVC^?]H,[_9XQ+<>1 \ODIS\S[0<#@GUP":T;
M2[M[^SAN[29)K>=!)'(AR&4C((H FHKA/"FH7/C[[?K,]Y<P:0ET]M86MK,T
M.]4X,KNI#$DYP,X '0]:W+6&XT&[U6\U'5Y)-&6")X3=./\ 1]OF>8"W4C!0
MY;)[9.* $\6>'9_$MG96\5]':"VO(KO<T!EW-&VY1]Y<#(YK?7<%&X@MCD@8
M!/TK(MO$^F7&I1Z>6G@NYHC-!'<V[Q&9!U*;@,X[CJ.XK,E^(WAJ*TN+LW5R
MUO;7#6UQ(MG,1 ZD ^9\OR#)QDX[XZ4 =716%;^+]&N=:CTF.>7[1+&TD#-;
MNL<X7EO+<C:^!S\I-9MQ\3?"EM%)+)?S>5#.;>:1;24K"X.#O.WY!DXR<9(.
M.AH T;[0+W4=>2YGUJ8Z2HC8Z6L"!6D1MP8R8W8R =O?'IQ6]6/?>)]+L)Q
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MD?Q/B2RU5A?V"&T>XMY2TY-J4&"1G)8XV]1Z#'&G.S&Z^&C""X(M@?/(@?\
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MG'S?[1[Y 9JY;_A;?AZ413&**PNHY)1$Q1&<IM!;& 3M/>NVHH \GB#GP?\
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M]39%+QL@=D+#&Y<9'N,T 4M%U>VU[2+?4[195AF!PLR%'0@E65E/0@@@_2N
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M;YI#U8X  Z   8  ':@!--U>'4[B_AB@N8VLIS YFA*!V !RA/WEYZUH444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO&R!,8R<'"C)R?8"AO ,TGAC7]$?5U*:S=RW4LHM>8S(0651OZ<#&?UKMJ*
M.1N/!MVNOVNO:9K(L]16U6TN\VOF174:G(RFX%6'8@U>\*>&G\,VU_"VHR7O
MVN]ENR7B5-ID;)''7_. *Z"B@ KEX_"=SIVLZK?:+JBV<6JL)+F"2W\T++C!
MDC.Y=K$=<AAD9Q7444 <E/X$MX[7PY%I%[)I[:$[&W?RQ+O5D*/N![D$G/J>
ME2V_A2YMM8\0:BNJ(SZQ%%&RM;?ZKRT**0=_/!.??TZ5U%% '!O\.)$T/0;>
MQUV6SU70U,=GJ$4 .8R "CQDD," ._:KNI^"[S5O#PT^[UYY;M[F*YFO'MER
MS1L&550$!%!4<<]3W.:Z^B@!J!PBB1E9\?,5& 3[#)Q^=.HHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ KGO%FMS:2FDVMLRQW&J:A'9),PSY08,S, >"<*0,\9(SGI70UB>*O#-
MKXKT@6-Q--;R13)<6US <202K]UU]QS^= &%K^K:YX)T3Q#K-Y>1:E80Q1M8
M+,H6996(0A]BJI3<RGCG&:=K.IZQX5U7P[)-J3ZC9ZG>)I]S'+%&NR1P2DD9
M100,@Y!SQ[\U?3P=]MT6]T_Q'JEQK3WD/D22R1I$$3KA%084YP<\DD#T #K3
MPK-NTH:KJ;:C'I3>9:!H0A+A2JO(<G>P!.,!1DYP3C !QT^M^*Y/#GC/4DU\
M12:%J%PL"I9QXD2.-&V-D'Y>3TP<GKT%;VI:[JECKWA74)+UX]$U;%O<0"-,
M13NFZ+YMN[:QR#SUQ5@>!G_L;Q'IAU4F/7IY9YW^SC,9D4*P3YNF%&,Y_&M#
M4_"L.L>#/^$=O+ER!"D:7,:[71DP4<<\$%0: ,C4O$6H6%E]KCGEF75-62QL
M$V1_ND)(++D ,3L<KN)'*>^8;FZ\8:=!XAF>25=/BTY[FSN;U8&FCF4$E"L1
MVLIZ@D<<BM_7O">GZ]X:71)#+;0P^6;:6!MKV[Q_<93ZC%4H/"6H-H]]::GX
MCN=2NKJV>T6YEMT00Q,,-M1< L>/F)/0?0@'%>)O^$CNOA!+KE[XDF9;S3[*
M0VL%M'& SL@?+XR0P?D<<CT.VNOU6_U;2O&GA#3$U-Y[._DNDN1+%'ODV0LZ
MY95 &#CH!T'7FK5SX-BO?A^/"5S?2-"MM';I<H@5P(]NPD<@GY1GU]J=<^%;
MF[U;0=2GU>22XTAI7#/ O[YI%*-NP0 -IP .G?- '':79>(+JZ\<RZ%K:Z=+
M!K,KHAMDD$SB&,[7+9PIX' !YSGM4PUQ_$E[\,-9EB$4MW+/(Z+T#?9W!Q[9
M!Q73KX0FM[O6#8ZQ+;VFL2F:ZB\E6D1RH5C$^1MR .H;':GW?@Z%[SP]+8W
ML[?0L_9K=8MRD%-F&).<;3]<\\T 84^M>)]>L]6NO#OVE+BSOI;6UBQ;_9W\
MI]K"7>?,^;#?=Q@%<="3W+2WG]DF9;=!?>1N$!?*^9MSMSZ9XS7+-X#FM]>O
MK[2/$=_IEGJ,OG7ME"B,LDA^\R,P)C+=R.?IQCJ;BR272Y;")C!&\)A4IU0%
M<#'TH X+P]XV^T"XFO-3NUOM/TZ6;4=&O;=(95D4*VZ/"#*<..I^\M6M/O\
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M0V-NT@RJ/*VW<1W &3COBH8_"#RR:0-2U+[;'I,_VBU8P!)=P4J SY.5 /0
M$X&2<<Z'B?PW:>*M#ETR\>6(,RR130G#PR*<JZGU!H Y*]@N--^+>ARW6I3W
ML2Z3>./.2,,I!CW8V*H(/'&/7\%L-7\7:UIFB:]I<=PZ7<D<US:S&V%O]G?J
M$8'S ZC&"3R0<@=!KV_@Z];Q!IFM:EXAGO+FQ@D@VK;1QK*K[<[A@_W><?AB
MJ^C?#^30Y_LMKXAO_P#A'Q*98])9$*J2=VSS,;MF?X>,]\Y.0"KHMQXGUGQ-
MKEN?$"06VE:HB"-;)&\Z(QJQC)/('/4'-5[34_%6J^#O%4EEJ?\ Q.--U2Z@
MM'6WCPZ18PA4@]>>>N2.:ZC0_#DFC:KK%]]N\\ZI,)Y(S#M$;A0HVG/3 '!_
M.G>&O#K>'5U(?;3<B_OI;Y\Q;-CR'+ <_=X&._N: *6CZX_B/^P[G3KZ46LE
MD+RZ^5"6#?*B-\O!+!\[<?ZLCO7/1^)M;M=1\-F;4Q>-?ZD]G>I!"ILUR'*B
M*3:&)7:!G+#((-==X?\ "EAX<M+^VL]YBO+F2=@3_JPY)V+Z*,G ]R>]<_;?
M#5[?3='L1XDOC#H]V+BS_<Q HH##:?E^8X8C<?RH 9X4M[Z3QMXU!UB[<Q74
M4:"58V7!A4CC:#\N[@ @>N><YL7B+Q-=?!VP\51:@YOH"T]ZL<$?[^!96#@
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MF#Y%522I^]G.6.?7VH Y71O&NJW_ (:\+Q2EY-3U6XN8)9[=(PQ6 R995<A
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFF9TAZ[963[P1L88C!R 3C!JK=>-_#%FL[3ZY9*()/*E(E#;6ZX./3//IWH
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MQ:B^GR7L,=VD)N&B=MI$8P"_/\(R.:SXO&WAF:2S2+7+)S>.8[?;(")&W%<
M^[*0/7'&: -ZBLW5-8L+ &"YOOL\SQEQL7>Z(."Y&#A1ZD8KGO 'B*2\^'.F
MZOK5^)IYGE5IV !D/G.J@!1R<   "@#LZ*Q3XN\/+IDFHOJ]K':Q2&&1Y'VE
M)!_ 5/(;_9QFK>F:WIFLFY&FWT-T;64PS>4V=C^AH OT5@^(O%EAX;N-,M[H
MMYVH7*P1@*2%'5F) XP >.Y_'& GBM=+\>ZY'JVLA=(BL+:>W68*H1G+Y"X
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M!UU%17%Q#:6TEQ<2I%#&I9W<X"@=R:JVNM:=>-<K#<@-;*'G613&T2G."P8
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M2S74(C-)*T$?7:\B]45L;2PP<J#G@T^?7]+M;O[--=JLOFI ?E)42/@*A;&
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MEH'MH$5LCN40'KSU[4 ;51W$GE6TL@C:38A;8HR6P.@]ZDHH \/M-=TVYC\
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M@ YQTP:Y*.YL$^ L.V:W67^UP_# -G[=G/UV<_3VKW)45<;5 P,<#M3L#TH
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M@OCGX<^1/;A/LEVHV.N,&% HX[$C ]Q74+H&LJH5?%M^%'0"TML#_P ATO\
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MY<PSH]N'N6WL"  ;<A3SV+< ^O2L34_M%VOQ#&EHUU(FIV=W]G@8AIXXQ$9
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M02#]G!E/))SP.!W/(SZM10!Q7AKQ3I'BA]+\C2ICJ=I&1,)[-D.GDKAQO9<
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-N5=92?O;\\@C/&...N,D ["CH,FN;U37)W\86/ABRD6"::TDO9YRH8I&K!
M$!XW%CU.<!3QSQQGBCQ-K+^%/'.C372PZEHL2,+N"/'GP2KE>"?E;&02/PQV
M /1+O7]/L=:T_2)Y76\U#?\ 9E$3%7V*6;YL;1@#IG/(K3KS?Q!%J">*OA]&
MEU#)=F2[VS2185<VQY*@\X';(SZBI8/&FJ:7I_B2#4V@O;[2]0AL[>6.+RQ+
MY^S867/8OS@C(% 'H=%<9%?^+8M9N(# 9=->S:1+RZMT4P3K_"51P60C\1ZF
ML73]8\=:IX 7Q/;7VFF5]--Q'9"S)+2*<_>W<Y4'C P<=>20#TVJ6K:K;:+I
M[WUWYODHRJ?*B:1LLP4?*H)ZD5QA\:3MXB\)"*]C?2-;MPSGR?FCE9,Q@MT&
M\JXQC.5/X/\ $/B/7-,\%WFOVES;,IOD2W62WS_H[3+&""&')SN!P>"..] '
M>T5PWB?Q=)I/B-]+N=031TEM5?3[NX@W07$Y+;D=SPN,)QE3R3GH*LWFO:E>
M:W=Z+8&6*6RM(99IX8$E)DDW;1AB!M 3)[G/!&.0#L**Q_"]YK%]X=M)]>L%
ML=4((G@5@5!!(R,$\$8.,\9Q6Q0 4444 %%%% !1110 4444 %%%% !1110
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MIX%^S7>Y06#.0<-N)7&5QP><XJ[;> 6@\/\ _",R:IYWAX2AEMW@_?"(/O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!CQ1R8\Q%?
M'3<,TX * %  '  I:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I"H
M)!(!(Z''2EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=>+?#EDLS7.NZ=$(9!%*7N4&QST4\\'CI6A<:C9VL$<\]U$D<I"QL6'[PD9
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MYJ]C!);Q^;,DDZ@QKD %AGC)( ]<T :E%41K6F-IL.HK?V[6<^/*F60%9,]
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MTZ-'O+N&$29V;V&7P,G [\<\5#)KVCQ6$%_)JEFMI<$"&8SKLD). %.>3]*
M-&BLRV\1Z)>R7B6NK64S67_'R(YU;R?][!XZ'\J=%K^CS:6VJ1:I9OIZG!NE
MG4Q ]/O9Q0!HT5G7^OZ1I84W^I6ML&4,#+*%^4G 8^@SW/%)=>(=&L9FANM5
MLH9%B,[)).H(CX^8C/ Y'/O0!I45SFK^.-#TKPP->6^@N;20A(&AD#"5R=H
M(]^I[<U--J5K=ZUH_P!D\1VT:2>:WV)#&YO1M."#G< I!.1Z8- &[16=>:]I
M&GW'D7FI6L$N5!624+M+?=SZ9[9ZTMYKNDZ?<?9[S4[.WF\LR^7+,JL$');!
M/0>M &A16=;Z]I%WI)U:WU.TDT\9S<K,OEC!P<MG YXIG]JVNIZ???V5J,+3
MP*59DPS0MC(W*>A[\T :E%<YX!U2\UKP'HVI:A-YUW<VXDEDVA=QR>PP!6G>
MZ]I.FS"&]U*UMY#MRLLH7&XX7.>F3P,]: -"BL_4-=TK2GV7^H6ULVSS"))
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV'_"E_&TD9M]QU>Y(92,DBY!3GZ=*ZO7-<T_0?B9;:G-JE@HN=%\HQ7EP(4
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MA!\'? 1\ZWC9-9LW;YE!5A,=Q/N!U]JV]<NYM)U75M5T#4[>_A>^C&H^'[H
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MST%>/>,=:L+KPSXTM89(]/F@U13+81IF6<K)%FXD)!(4@ @KM P,DYQ72_\
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M* (K>,I$"\<22MS((NA;ZX&:DVKSP.>O'6EHH :T:.A1D5D/52,@TH10H4*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKO)9ONCJ!SG'&#/!X@OCKFN^%]5$,EQ;V'VRVN84*":%LJ=RDG#*PQP<'T%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\%[?HBZS<QW4,ENA#VLL84(02?FP4![=Z[NB@#EM+TCQ2MK*-;UNSO)EA:*
M06QB0DC'F2<G<V.PP!D^V,[_ (02^/PP@\)G4X5N+81B.Y6(['".' =">0<8
M(S_A7=44 <C8>&M:M_&$OB*XU.SE>?3UM98([9D7<K,R[26)"_-SG)/MVS/^
M%?ZE_P *Q/@_^TK7>9O,^U>2V,>?YV-N>N>.O2O0:* .%\<2:;KUE'X:&I1)
MXB%Q;RV\=M)^^MY-P/F@=0%7<2?3ZBNTM+6&QLH+2W0)!!&L<:C^%5& /R%
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M!B>&Y.3U/3M0!Z917DNC6B1_"NS\0WGB35[:]O-.B@>X\]Y22TBX"1YQO/W
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M[8.0!G&"2:M>&-?OO%.M>']-UEI%BD\.)J+HK&,7,S.$W'&,@*,XZ9;..!@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW"0SNH"%CVR 5!]SZU6L1''XU\9ZQ!/&FCR64*2S;QY3W"JVX@],A=H/N<4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHEMVG9MC;5PRJHSCDG<?ICGJ* )]>L=>OGM8](U6WL+<[UNR]OYDA4@8,9R
MK#GKD<CTP=2TM8;&S@M+= D$$:QQJ/X548 _(5D:+?64]UK,T&OC4(H[C]XI
M9=EGA!E P'3N<GC-6;/Q'I%]=K:6]ZC3O&98T8%/-3^^FX#>ONN10!G^,-!O
MM?BTJ.SDMX_L6HP7S&8M\_EG.P8'?U[>AKH(8DAB"1Q)$.I5!@ ]ZPIO'?A6
M"-Y)-=LA&DYMV<29"N,9!([#<,GH,]:Z$$$9'(H 8L,2.[K&BN_WF"@%OKZT
MH1 " J@'KQUIES/%;6LLT\Z01(I+2NP4(/4D\5Q&L>*D\-_"XZI9ZN=6G\G;
M;7LJ9\YB^W<=H XS^.* .YCABB+&.)$+G+%5 W'WH$,2RM*L2"1AAG"C)^IK
M%T.TG6\N+V/7+F^TZX11'!<1C,4@)#,&P#@\?+C QQZ5%_PEMA/XNN/#4;RI
M<Q6XD>41GAF.%"Y&#C!.>G0>M '0>6F2=BY/7BFO;PRILDAC=/[K*"*X+P5X
MUM5T."+Q!KD;ZC/J%Q;QM-A6?$S(@.T +G&!T!QQ78:GKVF:.";ZZ$6U/,8!
M&<HG]Y@H.U?<\4 :(    P!VIDL,4P EB20 Y =0<'UI()X;JWCN+>5)895#
MQR(P964\@@CJ*QC?V7_"821?V^/-AL"TNF;EVHH<'SF.,@\@<G&#0!N,JNNU
ME!'H12;$)R57/KBL%/'/A>1K4)KEFWVJ0Q0E7R';<5QGH,D$ GKCC-9?B7Q/
M'#XOTKP[]LEM8KB*>6ZEA4[QM5=BJ<'&2^21Z >M '9>6FTKL7:>",<&D6&)
M(UC2-%1>BA0 /PKG[75[7PYIZV.N:^+RYMO]?=O#MV*S'89=H*IQ@9.,XS5S
M4?%&A:3,D-_JUI!*\33*C2#)0#);'IC\^U &L  ,  #VH*J2"5!(Z$CI6 OC
MGPO)$9(];LY%$*SD(^X[&Z' YR?3K[4O_";>&2MBPUJT*WV/L[!\A\G Y[9(
M(YQR"* -WRX\8V+^5'EIN5MB[E^Z<=/I6;J/B+2=)D>.]O%C>./SI0%9_*CS
MC>^T'8O!Y.!P?2J&K>,],TK6M'TUW,CZEO=9$4LBQK&S;L@$')"@ =CF@#H!
M%&  (UP.@QTIP10<A0#Z@5BZ;>6MSXEU=+?7?MCQ)"LM@I4K:'YNX&<M@Y!/
M:IH/$NC7-Y#:17\9EGW"#((68CJ(V(VOC_9)H U&56^\H/U%)Y:9SL7\JPKO
MQMX9L3="XUJT4VK!)P'W%&(S@XSV'/IWQ6Y#-%<01SP2+)%(H='0Y#*1D$'N
M* $:"%T*/$C*>JE00:<(XPBH$4*HP!C@51U+7-.T@9OKD1X0R$*C.50=6(4$
MA1ZGBL^_U73KB^T(P^(DM_M,OF00PNC"^4J>.A.WOD>E &Z\,4FW?&C;#E=R
M@[3ZBE$:",QA%V'.5QQ7,1>+K36-4US1;&>:"YL$5!.(^?,*LQQN4C  ')ZY
M.*SO GC6QO?#/A^WU76(I-:OK<,5<X:1SDXX& <<XZX[4 =NL,21B-(T5%Z*
M%  _"AX8I(_+>-&0_P +*"*SM2\1Z1I#LM_?)!LV^8Q!*Q;NA=@,(#V+8JOJ
M/C'PYI,TL-]K-I#+##Y\B&3)5,@ D#W(H VT18T"(H50,  8 %! 88(!&<\T
MQ)XI+=;B-P\3)O5EYRN,Y&.M9!\8>'QI9U0ZI#]@$ODFXYV!\XVYQUSQ]>*
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M_9+UQ';2^:,2L3C"^ISU].]+;>*]#O;$WMIJ,5Q )FMP807+2+R550,L<<\
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MB@ HHHH **** "BBB@ KSBUO;./XA^/B]S"H_L^T!)<#E4D#?ED9],BO1Z*
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M_P"'KNZUOQ+X)C1X],UC&JQW(&1!NR)%'N9D0@>C,>U>J4=\T >>:#J%_?\
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MT5G:/=DCA02>%)..F.<5Y]<21Z_\'M+\,V:^5XB@%I:BS(VS6TT3H&D9>JJ
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MA_3I8HKK5K9'EA\^-0V[='Q\PQGKD8]<C&:X?1M0T>WN_B):ZB\.Z?4) 8&
MWSJ84 51U<YR,#)R?>J&EVW_  C.L_#2UUV2.&:WTN[21IB,1,5CP"3P,9VY
M_"@#T!/'7AB3P_)KJZQ;_P!FQ.8WF.1M<?PE2-P;VQFIX/%N@W*7CPZE$XLY
ME@FVALB1ONJHQ\Q/;;G/:O+O$]DO_".?$O5+4#^S]5DMDLPHXGD11YCH/X@6
M)Y'7:376^-)##<>$=>ME\[1;&^\RZ\A=RHC1E%E('\*9_#- '3Q>*-%EM[V8
MWZ1+8X-TLZM$\((R"RN P!'3CGM52U\>>%[W4K33[?6('NKR-9+=,,!(" P
M)&-V"#MSGGI7*ZO$FJ^+=:UW3)4FTZ/PS+:SW$+!HY92S,JAAPQ502<=,@=Z
MRD2S\0?#3P-I6EO%+J<4EA*%BQOMM@!DD8=5&-W)ZDCKD4 >@2>.?#,5]]B?
M6(/M'VE;78 Q_>MT7(&.XYZ#(IFD:SI$-AK.HCQ"U[9PWLGG33L-ELV%S$I
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MFCA5F"!I'"@L3@#GN3VH EHHHH **** "BBB@ HHHH ***1F5%+,0J@9))P
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M!+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MWF^8A96RY)V@],/Q[BD\(1>,]/L;'0=4T^SBM]/58CJ<=R'^T1)PH6+&0Q
M))&.2.: )[OQS+8O;SW&D/#83ZH-,1Y92DQ8OL$@C*\IN_VLXYQVI+#7M;N/
MB/K>E/:VS6-E:V[(JW!W8?S#NP5P6. ,9 &.IKFKSPOXMO-.9+G2[2ZU*#68
M[S[<]V-US"LV]448^0!<#:< 8X!)KJ+32]9L?B'J.K"SAELM0LK='=9\&)XM
M^5"D?-G=P>!ZXH S+?QO::3X#NM>L_#?V>"+4)();6&1%PYF\LN2!R2QSP#6
M[8>*;F;Q<^@:AI#6,CVAO+:3[0LGF1A@K!@!\K D< L/>N1E\*>()/AIJ>A#
M30+ZYU0W2 SIMV&Y$W)SUP,8]:Z2ZL;_ /X6-9:^]F8M-M]+EMYI9)4!1F=7
MR1NZ *030!5E^(A&A6.O0:29]*OKS[) ZW 64DN45V4K@*6'][(!''7';QLS
M1HSH48@$J3G:?3BO(=)AUBUTBVN)O![7FCQ7+:G MOJL:P+EF=9$C<*P !W!
M6;&>< ]/7()EN+>*= P61 X##! (SR/6@#'N=?E?7)]&TJTBN[VV@6>X\Z<Q
M1QAR0BY"L=QVDXQT&<]*PIOB3 GAZWU2'2;F60ZDNF75KYBA[:?>$*G^]R>,
M=<CI5A]'U/1?B!?>(+&T:_L=5MHHKJ".1%EBEBR$8;R%*E201G.?6L2^\%ZM
M'H)6VM4GO[WQ"NM7,:RJ$B42!M@8XR=J@=.3F@#N]'O-1O;2234]+.FS+,R+
M%YZS;T'1\KTSZ=16%XVUO5](N_#T&FPV[)?ZE';RM),4;HS;1A3@';R?PP<Y
M'6J2R*Q4J2,E3C(]N*Y;QMI&I:D-"NM,MX[B;3=4CNWA>41[T"NIP3QGY@?P
MH (]7B/Q FTY]"1=4CT@7'VQ70M)'YF/*4X!V[LGDCITK"'Q3N1X;M?$LGA>
MY71&E,=U<?:4+0 2&/<$QEQD#/3&<<XS6S!I>JGXG?VW-9!;)M'6R:195.)1
M*9#@9SMYQG&<]JX_PII^H^(_@U%X>ALC'%>23Q->M(GEI$;ERQVYW;L9 &,9
MQR* .MNO&FH'7]2T72O#DM_=6EO%<(QNDB25'W8.XYQ]WCN<]  36?<^.=,U
M?PCI>K3:"UU%/J45I+;7)7-I<>8%R<@Y*MR,#\J98RSZ?\6M=CM-/ENXETJS
M3;%(BLN#)M^^0".O?/3CT@O/!>K0>$+>RM[=+C4)];75[L)*JHA\[S&52V,X
M&%''.,\4 =!=>+K\>*+_ ,/V&@O<W5M:I<H\ETL:2*Q(Y.#M^Z?4^P'-1VWC
MZUN_#&B:M%9R"?6+E;2"U=\;9<L&#-CA5V-SCMTYI;;3M3A^(^HZVVGR?8I]
M-BMHR)(]Q=&9CQNX!W8'N*Y(:+JVF> ?#WA^;3(9=9CU-[B*#[8L;D*\DI>*
M09"D!E!+#&"1W% '<:/XGGU+Q-JFA3Z68)]-$;32I.'C(D&4*Y 8Y /;@BM^
MXD>&WDDCB:9U4E8U(!8^F3Q7'>%9[VWUZZBU7PW<:??ZBGGO>/>QW/G^7M7:
M=F-H 88 4#D]SSV,[.D$C)&TKA3A%(!8^G) H X.'XEW$F@:-K[>'95TO49T
M@:072F2-G<HI"8^89 !.0>>A')V;#Q9<R>)+S1-3TA[.XALOM\/ESB?S8=Q4
M\ ##@\;>>O6N5B\*:_%\+M \/G3LW]C>PRS 3ILVQS>82#GG(X'O6W?Z3KD_
MCZXUBRM_(C?0GL(9Y'0^7.7WJQ4$Y4<?CVQS0!8LO&LTVK:%8WND_9/[;ADE
MM09\RQ[$W[94*C:2OH3R"/>J&@>,=06U\5ZEKT5M%9:9J,T \F<L4V)& B@J
M,Y))W$CEN@%9FG>&_$J:CX0OYM%M8KC3&F&H2O>AY+AWA*&9FP2>><9)YQP!
M5EO!FLW>F>,M#D6&"#5;^2_M+X39.]O+**4 R,-'R?RS0!KVWCH2>([?1I;.
MWDENX'EMGL;U;A2R#)C<[5V-CD=0>>:K:1XWO_$.@C5%\*2G2I;6=W=[J,Y9
M&*^7L.,@@'GV(P>";^@WWC&Y"#7-&M;+[,A\U[>Z64WC8P-BX 09YY.> /4U
M3\(Z-JVC?#/^Q;RQQ?Q13H$25&5R[NPPV?\ :&<XZ'K0!/I'B-6\->&6T?0O
M+35(@88$.V"T0(7^=U4X&!@?+R37/>,==M_%?P>\47$EFD<MC)+;2)O$JK+&
MP&Y&P,C!!!P#S4UOX?\ $UGX=\'6']GQW5MIT;0ZGI[7*JLQ"!8WSR&53D[3
MUR..*K2^$O$;>!_&.B?V=;";5;^:>U\JY&W;(5/.0, ;<>I]!0!Z=;?\>L/^
MXO\ *I:YR75]6L];T2Q.D+]@O(RDTYN%\R&4*6 V#.1A>N>_Y]'0!P,_Q%OD
MTS7=0A\-2O#HEW)!=[KM%.Q%4LR\')PQ.WI@=><5OR^)5FU2VTS2K=+J]GL_
MMQ$LIB2.$D!2S!6.23P .QZ=^6_X1S7&\+^.=/.G$3ZU=W,MI^^CQMDC5!N.
M[@C;D]?QJU;:#K&D>)-+\0VUBUP&TI--U"R$J"1"ARLB$D*W.01D<'/7B@"6
M[^)$=IX8U'5#I,S76F7BV=]9^:H,3EU4$-_$IW*00.1V%:EAXHN9O%S:!J&D
M-9226AO+:3SUD\Q P5@P ^5@2. 6'O7,:WX,U:[\,^)#;VJMJFNZA!<F'S5"
MPQQ/&55F/!;:ASC/+8Z#-;EYI%_>_$2QU5]/?^S5TN6SF+2IN#2,K= W0!2#
MC\* .@US4SHNAWVIBV>Y%I \S1(P4L%!)Y/'05RD7Q$N$FT&?4/#T]GI.M&*
M."]-PK[99%RJL@&0I/ ;/N0*DU;P=H'ASPCXDN=(TY+6:32KF-V5W;*^63CD
MGN!6?INE7_B?P=X-L9K%K6ULQ9WD\[R(PD6) 55 "6RQVYW 8&>M &TOC24Z
M3XGO#IBB30)9$EB^T<2A(Q(2K;>.#T(ZUSVJZ@\WC_P=K.GZ5Y]W>Z3<R"%7
M5"V5B(#.>PR>>?8=JFO?#_B.#_A.-.L]-AN+;75EFM[IKE5"L\ C*%>N<C@]
M.>2*LQZ#KME>^#M3.GQW#:5I\EG=VT%PN_+*@#*7VJ?N<C(Z\9H I:_XCC\4
M?#CQE9ZAI1L=3TNVD2YLYF67RV\LLCJP&"".0<#I6O+JEI9R>";.ZT=+M[L*
MEO=.5_T9Q"22,Y.2 1QCKUJIJ7A34[O1/&=TMNIU3Q%$(8[82+B%%C\M-S'C
M/)8XSUP,XR9]0T;5[F?P5+'I[8TJ4278,J97]T8\+\W/)S]/?B@#0OO%URMO
MJEUI.CR:G;:9,8)Q'*1+(ZXWB) IWE<]RN2"!TKIHG\V)) K+N4-M<8(SV([
M&N"T[3?%OA?7=8M--TZTU#2M3O9+Z"ZENO*-H\G+JZX)8 \C;^?/'>Q*Z0HD
MDAD=5 9R -Q]<"@#G-3U6U@\>:%IT^CI+<W$-P]M?L5S"%4%U7OSE0>GXUCS
M?$:]32M<U&+PU*\&BWDEO=[KM%.U I9EX.3AB=O3 ^]SBM/6M+U&Z^('AO5(
M+0O9:?%<I/)YB@YE50N 3DXV\_7C-8/_  C>N-X2\<::=.(N-:O;F>T'G1XV
MRHJC<=W!&W)Z]>,T 6?&.I:A-XA\&1V,$$MG=7IF427#)YK"%V4, AP!D,#S
MR!P,9K2L;V.QO=6TSPUHEJ\]LXN;]!<F*,W$J[MJ'8<M@ G(4<CU.*>HZ1K%
MQ>^"YXM,8KI+E[L&:,$9B,>%^;DY.>W%3V6DZMX<\8ZWJ-I8MJ&G:SY<Y2.5
M$DMYU7:00Y *L,'()(QTH CD^)%O)I.@ZC8:7<W4>KW?V,(75'AF^;*,#W!1
MAZ=\U(OC35TU?3M(N_"TEOJ%]!/*L?VV-T7RV ^\!T((.<9&>A-8Y\%ZKINE
M^&K>VMENI[36CJU\T<JJHW>9N5-Q!.-X Z9V]LUOZGIFHS_$71-6BLRUC9VM
MQ#+)YB AI-F, G) V\_7C- &;_PL/43H6K:@GAES)HTTL6HQ&]4*GE@,QC;;
M\_RD'!"_6MVX\2SR3VD6F::;A;BQ-]]HN9#! B?+A2X5OG.[./0$US<?A[6Q
MX=\=61TYA-K5S<RV@\Z/&V2)8QN.[@@C)Z\>M20Z/XCCU/03-ID%YIMMI26S
M6LURJK;W2D9E(P0XP  0"1SP,F@!FI>.M0O_  [X2U;1+6*.'6=1AMY%GF*N
MGS,2G"D8)C8%O3MSQMQ:O;GXAC3;G1H8=072#<'4-ZL?+\Q08P<9V[B3SCIT
MYKE+'PCXDM/ /AC3VL;9K[1-6CNVA6Y'[Z-6DSAL8!^?./;\*Z*31M3N_B(N
MJ7-D%L)-$;3Y7293B1I YP."5QD9QG/:@!+CQ[Y'A]/$PTPOX>,F#<K-^^6/
M?L\WRMN-F>?O9P<X[5-/XPO7\2WNA:;H37=Q!:1W<<C72QQR*Q(!S@X'!QU/
ML!S6%:^%M>3X>3>!)[963!M8]4$B>6;<OG<4SO#A3C;C&0/FQ6Q8:-?Z=\0+
MS4DL'.F_V5#90L)4+%HV8]">A#  ^O7% &UX6U^+Q1X;L]8A@>!;A6W1.<E&
M5BK+GO@J>:R_B!K6J:'HEK-I<<)>>^M[=WDD*E5>11\N%/7IGMG//2G_  \T
MG4-"\&VNF:G;B&YADF)"NKJ0\K.,$'T8#ZT[Q[HU_K7AU(=-C26ZM[RWNEB=
M]@D$<@8KN/ ) - %B3Q!<G5AHUK96\VJ):BZN$:Y*Q0J254;]A))(.!MZ DX
MXS+X9\1P>)+&XE2![:ZM+A[2[MI""T,J=1D<$<@@]P:Q/[)UG3?'!\306(N8
M=0LEMKZSAF7S(70DHZERJL,$@C(]1FM/PGH,VD?VM>705;O5;Y[R2-6R(@0%
M5,]R !D^I/:@"_KVMVWA_2VO;A7?,B0Q1)C=+([!409[DD?3K6;_ ,)/<6OB
M.WT+4]/BMKN^@DEL9([DR13L@RR%B@*L!@]",?E2>.O#MUXD\/)!82QQ:A:7
M,5[:F3.PR1MD!L=CR*@?2K[Q!XHT+6+_ $]].CTA)G$4DJ.TDTBA.-A(V ;C
MDX)..!0!P^N:KJ7B7X)^([[6;6T)2:81,DA<H4GV@ %1@ # .<GT&:[VS\57
M(\4VVA7^DM9K=VKW%G.9U<R!-NY74#Y#A@>IKE)O"?B3_A6VO^%UT^%I9[F8
MVTRW*XD628R!B#C: #CN<]N]=#J&E:E?>./#VJ?V>ZV=I:7$-P6E3<IE" 8
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MG(&.<'I6U#K3:E)I4$=G;W%OJ-HUS*WGDJD>%Q@%/F!W@#.._I0!L6UU;WD
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M!HX!@D$@<MV'YFKNI^$[_7/$WB-KB$P:?JND+8)-O4LCJ7.XJ#T^8?E7?44
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M%W,9/ *N<@'&1U(KMK'P_INFZI>ZE:PRI=WI4W,C3R/YA487(9B.!P..E:=
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M/ >E7NA>"-+TK4(ECNK2+RG"N&4X/4$=JZ.BB@ HHHH **** "BBB@ HHHH
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M=!,EQ;QSQYV2('7/H1F@"2BBJ6H/J2/9_P!G0VTBM<*+DSN5*0X.XK@'+=,
M\4 7:**YW4O$-U8^-M$T,6L)MM2BN'\_S#O4Q*#C;C'\0YR>_ H Z*BN'O?'
M[VGA]O$B6,<FCQ7IM9QYA$\8$OE%]NW!.[!VYZ'KVKN* "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MYDG=2?F8XR<$X!.!G&,X&:9JGAO2M9O+6[O[=Y9[1_,MV$\B^4W]Y0K  ^]
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MW&<=><XS5^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M ZBD9E1"[L%4#)). !21R)+&LD;JZ,,AE.0?QH =136=4QO8+D@#)QD^E.H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.X)W4!QDY!X. <5REIX;UC4?AQIG@J]TN6T:$PQWET\D;1B..0.3'M8EBVT
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MOA#2[+4M/:RN+2UBMFC>5')*(%+94D8)''.?7% &=::[IMOKWB^:WT*XCO\
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M1D-\C,!GTSGU K3K%\*W%K-X?MX;33I].BM!]F^QS@;H=G&W()!XQR"<UM4
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M:EJ9CCV#:A5 5P.V.WI0!Z\CK(BNC!D895E.01ZBEK,\-_\ (K:1_P!>4/\
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M*03P3J"]M.DR!AD>QZCJ#7<7^N%=:70[&U2[OC;FXE227RXXHL[06;:QRQR
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MZV6J1WMP&EB4HBJZD<ORWS \<>]=C10!P5S:^*/#_C/4M4TC1X]7T[6%B>:
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M[@C'(_+-7;BP\4:'XDBU[2-'748+VPAM;ZP>Y2*6*2+=M=6)*D88@C->A44
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M&"^ETXWT(2Z+C@@%),H"ARP['O7/V7A[Q3;67C@6D8L;W5[E[G3Y_.4[,J%
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ML@);"'INX'?/)'%3Z9XPFN7\20ZE806%QH9S(GVHR"2/9O63.P84@'L3P>*
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M:W0,I (SP?45U=% '(P:!??VEXAU^6W07VI6R6MO:^:/W:(I W-TR68DXS@
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M'L[#S;1)9"_DM+;NSH"<G' ..V?>M);J2[U/PCH$\UK'9W&A^='%=1&2.XF
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MII S88X SMS@' &2 ">]3:KI-EK>FRZ?J,)FM)AB2/>RAAZ':0<>U7:YR_\
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M@*]"K!TWP5X;TC5Y-5T_1[:WO9"6,B \$]2HSA2?8"@#AM.A@\3> /$^JZF
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M-[2_<RW44C,ZRN>2Y#$_-D YZ\#TIEAX,\/:;>V]Y:Z9&+JWC,<4TC-(Z+Z
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M^IV^D?V?:V%BPO5<*N]\+Y2 *?F*MN;=TYZ\XH ]&WJ'"%AN(R!GFE+*#@L
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M/5CSU/<]:TZ1F"J68@*!DD]!0!C?\(CH']G0:=_9</V*WD\V&WYV1OG.Y1G
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MM;W:F^C@??#*[1KMD0^A55.#R._6MYM!TA].CTYM+LS91,&CM_)7RT(Z$+C
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M6\.:M=?$&'4[&U:&*_?:74?Z.#"A+I_<.<G(QT]JA\'7>H2ZUX&L_$09H9-
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MLRH\8*JS6Q)8#H&)[]>M>@VOA_1[*[-W:Z9:0W!9G\R.)00Q^\1Z$]SWI?\
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M]V;=?WL(SW9]Y3'HC5Z5X3N;?Q )?%<4.U;^-([9F7#B!!T/U=I/J-M="MM
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M#_8U@(YYO/E46Z /)_?/'+<GGK3;WP[IUSHMQI<=A9>1.P9TF@#HS9!W,O\
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M;6]I9V;1^2H5T002;O+[YP.U9FG26L'B/X;RV[6EM9R6MR(8@X:7R3!D&5^
MQ) )&,!@>37JCZ1ILFI?VD^GVK7WE^5]I:%3)L_N[L9Q[54M_"GAVT6%;?0]
M-B$$IFB"6J#9)_>''!]Z /*I="TI_ 7Q*G:PMS):ZI?&W8H/W!5$8;/[O/IC
MH/2NC>.TE^)?ABYO8X&:3099'DE5?F8&(Y)/<#O7:CPSH0M[BW&C:>(;EM\\
M?V9-LK>K#'S'ZU*^@Z1(;(OI=DWV$YM-T"GR#_L<?+T'3TH T*XOXM?\DL\0
M?]>X_P#0UKM*CG@AN8'@N(DEAD!5XY%#*P]"#U% 'G>K^'M/TOQYX0NM!M(K
M:]GEF6\\@8\^V\LEVE_O?-M^8Y.6'.<5RVH-:1?!/Q?!(84:/6;I$C. 587(
M( 'KCGZ5[%IVB:7I&?[/T^VM<J%)BC"_*.@^@].E5Y?"OA^>YN[F71-/DGNP
M!<2-;J3* 0?F..>0/RH XKQA%?6][K6KV4-CK>EFR2'5=,F.R:*-59M\3]/N
ML3@]P<<]++FTO/BMX:OX( HO-#N')= &928RH;Z UU\OAO1)I?-DTFR+E!&3
MY*_,HZ*>.5'H>*FET;3)]034)=.M7O8UVI<-"ID4>@;&0* /&+K1=,7X6>.K
MM;* 7%IJ]Y]FEV#=!MF7;L/\'X8KK;F]@NOB/?:9K-]!;++I<!L5N8T9)4._
MS@N_C).W(') 'I79CPQH M)K0:+I_P!FG?S)8?LR;)&_O,,8)]S1J'AG0M5M
MK>VU#1[&Z@M_]3'+ K"/_=!'% '!QZ'=:=8:$GA+58-6ETVWN4CM-4.5NX#(
MH;8X& 5("JW3!';JEN]WJ^D>'-4\*V]K;7=K;W2C0]0^X\?F*DBJPZ%64!6Q
MC#<X!->A7.AZ5>&W,^G6SFV79 QC&8E[A3_".!P/2DFT#2+A;99=,M2+52EO
MB( PJ>H0C[H.!P* ,_P-?VNI>#[&XL[!]/A_>)]D<@^2RR,K*"." P('MBNA
MJ.WMX;2WCM[>*.&&-=J1QJ%51Z #I4E !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(S*B%W8*JC))
M. !2UPWQ/O39:;H9N#MTJ36;9-18_=$.2?G_ -C<%S^7>@"U:>)Y[WXDC1[:
M]LKK2FTIKM3;C<PD$JI@N&(/!/0#K72IJ5C)>/9I>V[748R\"RJ74>I7.17G
MNKRQQ?%F[FTMX/[0E\*S>5Y9&7D$H\OZGICVJGX:3PWX@T3PE=GQ%<&_L98F
MBM8FA699\8D1P$WE3\Q;)Y&6)[T >GQ:C8SI(\-[;R)&,NR2J0H]3@\4V;5-
M/M[1;N:^MH[9CA9GF54)]F)Q7GT\<WAOQSJNAV<;1V_BE!<6CQKQ#.,)<'ZA
M").>XQWJ74KFRTSXE6^EWVH?V58'1TCTTD1"(D.PD0&12 =OE\<9 % &[XQU
MZ^TBWT.XTR:V,-YJMM:S%DW[HY' )1@<#CO@]:Z&[U"RT]4:]O+>V#G"F:54
MW'T&3S7F&J:;IFC^#O#=EI%]/>:?'XGM?)FF=6!S-DA"H V Y P.QK=T.5;K
MXE^,;'5D1Y##;"UCF (:T*'=M!ZKO+;O<\T =O)<0Q!#)+&@D8*FY@-Q/0#U
M-1V^H65Y"\UM=V\\2$AWBD#*I'4$@\5XG;Z?')X<\&1Z@BRV@\326UG)+R6M
M#YH1=W4J<# Z$8[5NW^@V-AXU\5P:=9P1:5+X;\R]MXXP(A<;F\L[1P&V*3^
MO>@#TV/4["6>*".^MGFEC\V.-95+.G]X#/(]Z?:WUI?*[6EU!<*C;',4@<*W
MH<=#7D+Z3IP\$_"^<6D FGO+&.64* \BO P96;J0< $=,#%6=;BFTK7?B%%H
M,(MY3H5O*L=LNSYOW@+ #^+;Z<]* /4[?4;&[N);>VO;>::+_61QRJS)]0#D
M4W^U-/#Q)]OM=\KF.-?.7+L."HYY(]*X32;?PKKNH^'=6LM>DNYXH7BMK2+R
M!F)D^=)41 =J@=#C!QW//'/IFG0?!+5+^*T@2ZM]6<PSA!OBVWP "MU4 $\#
MU/K0![ /$NE-XD;05NXC?)")9$WCY<G"K_O'DX]/J*NQZE83736L5[;/<*2&
MB652X([$9SVKC(?LD/QKU#SO(C9]%MS'OP"S&:0<>IS@5E>&I;[1=4\,Z=>+
M:ZQH]SYG]C:O!\L\8,;-ME7OE<_,.X!/- 'J54H]7TR7S/+U&T?R@3)MG4[,
M''//')'YTW6Q V@:B+F=[> VLHDF3[T:[3EA[@<UPNA/JNG:];:#KMI97LC:
M5,FG:M9# F@4IE)$['[AR..>.IH ]!^WV8$)-W!B?B+]X/WG^[SS^%)=:C8V
M3QI=WEO \IQ&LLJJ7/H,GFO&K6^LA\*OAU&US!YJ:O9$J7&5VRD,2.V.A^M=
M!IU_H=_JOCK1_%5S;Q2S76"+F41[K(QKY>PDC@?,>.A;/4T ='=:_>V?Q(AT
MB>>U327TJ6\)9-K(RR(OS.6QC!/8?C73P3PW4"3V\L<T+C*21L&5AZ@CK7GC
MV.GW?Q2T"W>V\RU3P[(8XKD%B )8]NX-U('KW]ZO_"]4AT;6K:(!(+?7+V**
M->%C02'"@=ASTH [*YNK>S@,UU/%!$.KRN%4?B::M]:-9?;5NH#:[=WGB0;,
M>N[IBN7\77ME#XE\+VTBK_:$D\[V<L\A6"(K$0[./XSAL*O')ZBN-T"-=3\/
MZU8V>N6MK?KXJFELI0H:%Y%(=04S]QB#CGKC&30!ZY:WEK>Q&6TN8;B,'&^)
MPXSZ9'UITL\,&SSI4CWL$7>P&YCT SU)]*Y7P/J5U=3ZY::GI4%AJ]M=K]M-
MLY:&=VB3;(A/(RH7(/(XSUJC\3;2VG/A-IH8V;_A(;2,,1SM.[(SUP?2@#L!
MJ^FF"><:A:>3 VV:3SEVQGT8YX/UJ5[VTBM!=R74*6Q4-YS2 )@]#NZ8K@;+
M1-)_X6_J]M_9UI]G.D6TI@\I?++[Y%W;<8SMXSC.#[U@>&KVQ@\%^#+.9 UR
MVKW2V#2RE(8622;!?^]A3A5[G R.M 'JEU=?:]$N9]+U"U5VB?R;IB)(D;!P
MQP<$ ]>:DCNX[72H;B_O;; B4R7.X)&QP/F&3@ GISWKR>T:TNO!7Q0MI)[2
M[(N;R=1&!M)^SH=ZKDX&[OD\]ZU[.Z>+Q;X!@O>-/DT5OLI;[IN]B?\ CVS(
M'U.* /11?6C67VQ;J VNW=YXD&S'KNZ8IT-W;7+RI!<12M$=LBHX8H<9P<=*
M\:\56"Q:;\4HHXD.DHEO-"A4%([HH#(4]&Y4G'<UZOH>CZ9I=J)=/LK>W>YC
MC::2) &E(7@L?XCR>3ZT 7[BX@M(&GN9HX84Y:21@JCZDTD-W;7%J+J&XBDM
MR-PE1P4(]<CBN+\5ZK#IGQ$\*G595BTF2.Y$<DIQ&MUA=A8G@';O S_>-8OB
M@Z1I>FVLFCD-HL_B:&;6)$D+P_,<OSDC9O\ +W <9X]10!Z9:7]G?QM)9W<%
MS&IP6AD#@'TR#3%U33WEAB6^M6DGSY2B929,<':,\XP>GI7'ZC8AOB[IIM8D
M:&ZTJ<:K'M!22-641%QT)W%@,]@>U<+IVGV,'P:\*:C%;0K>+JUN5N0HWC_2
MBOWNN,<8H ]>@\3:5<^(KO0XKN)KVUC1Y5#C@MNPO^\ N2.P(J['J5C-((XK
MVV=RA<*LJDE0<$XST!XSZUQ.F1:>?BUXK@NX[8^=9V6V.55^?(EW8!ZY[URV
M@6'ANP^! UG4M,64_9YX))8"$F97G*;!)U5?N@]@,\4 >P6FHV.H!S97EO<A
M#A_)E5]I]\'BA=1L7O6LDO+=KM1EH!*I<#W7.:\R:]N(OB5?&VO+![]_"S""
M.T(VB42_NTY)WD9X.!D'H*N>$KKPIK?A/PC))/')J5FT9CB2;$XNMNV4LH.X
MY)9FSU')H [/2/$NE:Y=W]M87<4SV4Y@?:X.Y@JL2/4#=C/J#6K)(D4;22.J
M(HRS,< #U)KA/A\;2+6?&$(\A+C^W9MJ<!]GEQ=!UQ6G\0KO3[7PN!J4+30S
M7=O$B"7RE,AD4KO;LF1EN#Q0!OQ:KIT]J]U#?VLENAVM*DRE%/H2#@4'5-/'
MEYO[4>:,Q_OE^?G''///%<!H(MK_ .)/B_3[^ZLKH7MA:I+'" J2';(&7&XD
MD+UYS]*YF0ZE'X7@MHH/,U#P#=&261DYFB0@(JGT: LQ]T7UH ]I^VVH>5/M
M,.^$;I5\P90>I]!]:;:ZA97T+2VEY;W$2'#/%*K@'W(-<%KMWI;^"+O7-2MG
MEAUF\MS$F_R<Q[U$ =L95" ';(XWL,51M9+>X\>>,K:]NK"Z-QI$&^.)0$=E
M$O&TDY( Z_RH ]+@U"RN9/+@N[>5]@DVQR!CL/1L ]/>N8O/%,I\?:!I6GWU
MC<:?>I=?:%BP\B/$@(!8,0,[NF >*X-[*TTKX#Z;K%E91I<RV=M#?7<2?OC;
M-(OF@L.2,<8[#Z5T^L3:3_PM'P)<6<EIMDM;Q4>)EPT?EKL QV^]C\<4 =VF
MI6$MVUI'>VSW*G#0K*I<'T*YS5JO+= EOM#U3PW9W:VNL:)=32?V1JD/RW$+
M/&[;95_BRN[)'ID\UW_B-[Z/PQJSZ8";];.8VP7J9-AVX]\XH M)J-C+>/9Q
MWMN]T@RT"RJ77ZKG(HEU&Q@D,<UY;QN&52KRJ""V=HP3U.#CUQ7E>H+!>_!O
MPO>Z+M_M6&6R^Q.GW_M)=5E!/4DYDW>N"36MHV@Z-?\ Q2\:I=Z;:3B/^SY4
M1X@0KE&)8#UR <]: /1ZK+J-BUZ;);RW-VHR8!*OF >NW.:34VN5TJ\:R&;H
M0.81ZOM.W]<5YYX0NO"NM^#O"C7$Z2:G9RQNL2S8N!><B0LH.XY)9FSP1R>*
M /0VU*P2]6R:]MENVZ0&50Y_X#G-+/J%E:^9]HO+>'RE#R>9*J[%)P"<G@9[
MUXYK^HZ?<>'+JZT^6WMK<>)T<I/)ON))Q<*'?)(\L#G"X)VXY'2NGLM+TC4?
MB_K;26=I<PR:3:RX9%='+-(-^.A)&.?0^] 'H#75NEK]J:>);?;O\TN FWUS
MTQ[TVWO+6\MA<VUS#/ <XEB<,O'7D<5XQX>U6/3?#'PWDU&4)HGVN\CGDD/[
MM) TBP;B>, YQG@$ ]JWO%TFC:;H>IW^C2L;2?5K2?6IK9_-0(6&_ Y7. I9
M<<AAG(- 'H!U&&^T^YETF^LYI(U(#JPE16 Z,%8?ED5PW_"9:XWPS\.>(4DM
M1=7US;QW(,)(*R2A3L^;Y>/7-:.EV>@R^)KK6].U^34;VXTTQS+%)"83&#E7
M<1J/FY(!)Z9]..0C(_X4/X1.1_Q^6/\ Z4"@#UVZU*PL9(X[N]MK=Y/N++*J
M%OH">:I:CXFTK2]8L-*NKN*.[O=Y1&<#:JJ26.>@R !ZD_6N!\7WNGSR_$""
MW:W@N(M*2.]DNWW&4^2[1I$A(VCYOO<Y8].](+BQEU[X97=Q-;M&=,N1++(R
MD%A;Q=2>XYH ]%M6NSKFH++?VLMJ$B,-K&F)8.#N+G/(8CC@=#5B'4;&XNI+
M6&]MY+B/[\*2J77Z@'(KS&\6ZL]?^*;:)&$OO[.LY(Q"N&WF*7+#'\7?ZU)K
M"6UUX'\#7^@;!>)>68LFB^]AAB53CMM#;A_LG/2@#TB?5-/M0YN+ZVA$;!'\
MR95VL>@.3P33[J^M+&-9+NZ@MT8X5I9 @)] 37ET>BZ5/J/Q0$MA:N(PI0-&
M"$)M025'8D\DCG-36$.LW.@^$-2T&^M)=7M] B\S3[\$I=0NL>XAARK;E ST
MY&: /3/MMK^X_P!)A_T@XA_>#]X<9^7UXYXJ>N+\/W_AK5/#WA:ZNK2TL)CD
M:;:W3KOCD7*%8\_>QC@CMCVKM" 1@\B@"I+JFG0_ZV_M8_WOD_/,H_><';U^
M]R..O-2+?6CWC6:W4#72+N: 2 NH]2O7%>/C1]+?P#\3F:QMBT&HZAY1,8_=
M;8D8;?[O//'I6Q-96EGX@^&MU;P117$_FB:95 >7=:DG<W5LGGGO0!Z*=2L!
M?"R-[;"[/2 RKYA[_=SFEN-1L;7S?M%[;P^4H:3S)578#P"<G@&O'-7U'3[C
M0+:[T^6WMK7_ (2I)!'-)ON7E%QAY"2?D'7"X/RXY&<5TVFZ3I&H_%?Q/YME
M:7,,FGV<F&161BWF9;'0DCOUP?>@#OY[ZTMK474]U!%;G!$LD@5#GIR>*=%<
MV\]L+F*>*2 KN$J."I'KGIBO(/".H6B^%_AU!*5.I,ETUG/<2D0PA RL67(W
ML%("KD=^15:"2*?X7^+((M4LT\GQ!,XRX2*5?M"D)P3M1SP.WS<\9H ]EMK^
MSO5+6EW!. <$Q2!L'TXI$U&QDO6LDO;=KM!EH!*I<#W7.:X);%-9\97_ (JL
M8[+[3#HIMK:'S(9I3<9+"3Y"P7 (4'.3D]L9RO#2>'/$/A[PI<R>(KG^T+">
M%TM8VA6=;D<2(PV;R"2Q;)Y'S$]Z /4)M4TZW#&>_M8@L@B8O,JX<C.TY/7'
M:I!?6AO39"Z@-T%WF#S!O"^NWKBO)HM&TN3P[\4=]A:MY-U=^5F,?N\6Z-\O
M]WYN>.X'I5EK*TM!\,+Z""*.[GE02SJH#R;[5BVYNK9/K0!Z=-J-C;W<=I->
MV\=S+_JX7E4._P!%)R:)]0LK7S/M%Y;P^6H=_,E5=JDXR<G@9[UY1:_V+X@T
MKQ)I'B7Q!+87B:I.UU!F%).),PO&60N?D"!2">F!6Q8:/IMS\7-3CN;**<'1
M;:1EN(U8LY=P688P7QP30!V.K^)M)T6&QDN[R$"^GC@MQO'[PN0-P_V0#DGT
MK51TDC62-E=& *LIR"#W!KQ+3Q!_PK/X?O-L,<7B1(]SX(5!-. ,GM@ 5[9"
M\3P1O R-$5!0H05([8QVH AN=1L;*2..ZO+>!Y3B-9954N?8$\T^:ZM[8J)[
MB*(OG:'<+NP,G&?0 GZ"N"\-?9M3U+Q[8>($C:?[>RRK-C_CR,8\KKT7 8_4
MD]:Y71+!KY?A5_;UND]S*EZCF=,M)$(F,0;/4;=O!]: /:89XKF%)H)4EB<;
MD=&#*P]01UJ*ZU&QL6C6[O+>W:0XC$LJH7/H,GFELK&UTVRBL[*WCM[:)=L<
M42A54>@ KSRQO]%N]?\ '6C>*KBWAEFF"XNI1'NLC$H3821P#O/'0MGJ: /1
M+N]M;"'SKRYAMXLXWS2!%S]32M=VR6RW+7$*P-C;*7 4YZ8/3FN!TN>*/XHV
M5E*LB6/_  CZ?V2MQDDX;]Y][G?M"9[X'-<CJ^GI%X4\30^6ITNW\3PC3N.(
MLRQ^:(S_  J&+#CONH ]H74K%_M.V]MV^S?Z_$JGRO\ >Y^7IWJCH_BC2-<T
MG^T[2]A^R[V7>T@& '903Z!MN1GL:YB#3[&P^,RVUG:06\,WAYC)%%&%5R+A
M0"0."<$C-<0(M.F_9WM05MS<PW$18C'F1DWNW.>JG&1GZT >VC4+(PS3"\MS
M% Q25_-7;&PZACG@CWJ"YOQ/HMS>:5=6TK+$S12_ZV/('?:1G\ZXKQ#96.@>
M-?!\-O8V]GHUU>SM<B*,)&UUY0$!?'!.<X]P#VI\5O):_$GQ7]B^73I=(CFN
MU7[HNB7 /H&,8R?P)[4 =)X*U:ZUWP7I&JWI0W-U;++)L7 R?05L75W;64!G
MN[B*WA'625PBC\37,_#'GX9>'?\ KR2J&LZO;Z=\6]*CU>9(+"72I1923L%C
M%SY@W\G@-L  /N1WH T/%OB"]TR/P]<:7<6KVU_JUM:3$IOW1R-R48-@=/0]
M:Z2VO;2\\S[+<PS^6VQ_*D#;6]#CH?:O,O$EAH4&@>'K31@&TU_%=MTD+QLS
M.2^PY^[DD<<9!I;W^R]!\8>-0UL8=-_X1Z&6XAL@(V;'FJ2N,8;;QGM0!Z3:
MZE87LDD=I>VUQ)']]8I5<K]0#Q2-JFGJ\:-?VH:20Q(#,N6<=5'/)]J\RT^Y
MME\?^#@;C3E@ET:>%+>!PP2,B/9&SD_.3VX&>PK!N=+TZ+X-^++R.TMUN+?5
MKCR)@@W1;;H;0A_A ]!ZGUH ]ONKZTL4#W=U!;HQP&FD" _G3VN(5@:9IHQ$
MHW&0L-H'KGTKA-8OH=+^*,=U<3V]Q%-HIB^RO/'&T7[W.X"1E4J_0X.?DYXK
MFO[.A\$^#O",5S<V\.GMJC/J5W9*CHI82&+<Q4AE1B@W,/X1TP* /6X-0LKJ
MT:[M[RWFMESF:.5608Z_,#CBFQ:II\]O)<0WUM)!$-TDB3*50>I(. .#^5>?
M7FA:)/%K\NF>*9?M6I/9M-<@Q26\<XD40Y5% RQ ##N#SU&;FB:B)I?$VG^,
M]-TZUN(+>$ZA=1O_ *+=0L'"N=W*G ((//2@#OD=)8UDC971@&5E.00>A!IU
M5M/%F-.M1IYA-D(E%OY)!3R\#;MQQC&,59H **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J*YMH+RWD
MM[J&.>"0;7CE4,K#T(/!J6HKBY@M(&GN9XX85^])(X51VY)H IV/A_1M,>-[
M#2;&U>-2B-!;HA52<D @<#-.M]#TFTU&74;?2[*&^FSYES' JR/GKE@,FJFJ
M:E%=>'KNXTO7K"S*_*M^Y26*%@03NY Z>I[UI7-]:6$227MW! K<!Y9 @8XS
MQDT 2/!$\T<SQ(TL>=CE02N>N#VS5;4M(TW68%@U/3[6]B5MRI<PK( ?4!@>
M:4ZOI@M?M1U&T%N,?O?.79STYSCFG6VIV%Y<SVUK?6T\]N<3112JS1'T8 Y'
MXT ,N-'TN\@@@N=-LYX8,>3'+ K+'CIM!''X4E[HNE:D8C?:;9W)A!$9F@5]
M@/4#(X%9#Z\FA^&-4U74=8L]06V>=XVBVQC"Y98>"<N ,>I]*Q;'4=<U2WTC
M5K?Q?I45C=+ ;J&2%&*3,5)AC((QD,5PQ+#CKG@ T?&?AZ[UN;P_':65K-:6
M%^ES/',X56C",NP+@@_>[X'%=#'I&F1V4MFFG6BVLQS+"(5V.?\ :&,'H.OI
M3K[5=.TP(;^_M;0/]TSS+'N^F3S1>:II^GQ)+>WUK;1O]UYIE0-QG@D\\4 0
M-X>T5H886T?3S% <Q(;9,1GU48X_"IHM)TZ"^>^BT^UCNW&&G2%1(WU;&33V
MU&R2*"5[RW6.X95A<RJ!*6Z!3GDGMBJK>(M%73[N_P#[6LFM+//VB9)U98B.
MS$'@^W6@!]GH.CZ=+<2V6E6-M)<<3/#;HAD_WB!S^-,_X1S0_LK6O]BZ=]G9
MMYA^RIL+>N,8S[T:!KMEXCT:VU*QE1XYXU<JKAC&64':V.C#/2L;7==O=*\=
M^'K%KJWBTJ]ANWN Z %?*0,"7)X'S>@Z=: .A_LO3_M4%U]@M?M%NFR&7R5W
MQ+Z*<9 ]A4=EH>DZ;*)+'3+.U< J&@@5" >HX'>IK/4++4+07=E>6]S;'.)H
M95=#CK\P.*99ZMIVHM(MCJ%K=-'C>()E<KGIG!XH LRQ1SQ/%*BR1NI5T<9#
M \$$=Q5:RTC3=-9FL-/M;4L-I,$*ID>G Z4Q=<TEY4B75+(R.7"H+A,ML^]@
M9YQW]*=;:OIEY-Y-KJ-I/+Y?G;(IU9O+SC=@'[N>_2@"!/#6A1F0IHNG*991
M/)BV0;Y!G#GCEN3S[U+=Z)I-_>07EYIEG<74'^IFF@5WC[_*2,BG6NL:9?-*
MMGJ-I<-$-T@AG5R@]3@\4S^WM'^S?:?[6L?L^[9YOVA-N[TSG&?:@"232--F
MOA?2Z?:/=@;1.T*F3'INQFG66F6&FB06%C;6HD;<X@B5-Q]3@<FE_M"R\Z&'
M[9;^;,F^)/-7,BXSE1GD>XK/TF^6WT6*;4]=L;TM,Z"\CVQ1N=Y"H.2,C[O7
MJ* +U_I>GZI'''J%C;7:1OO1;B)9 K>HR#@^]12:%H\J3I)I5BZSR"68-;H1
M(XXW-QR?<\U-::G87\T\-G?6UQ+;MMF2&57,;>C '@_6HSK.EBY:V.I68G4D
M&+SUW#'7C.>* )[2RM;"'R;.VAMXR2Q2) H)/4X'>H[W2]/U(QF^L;6Z\H[H
M_/A5]A]1D<5;!R,CI5.XU?3;2Z2UN=0M(;F0@)#),JNV>F 3DYH ;_8NE"[>
M[_LRS^TR*4>;R%WLI&""<9(Q41\-Z$UE]B.BZ<;7>)/(-JFS?_>VXQGWJQ=Z
MII]@VV\OK6W;89,33*AVCJW)Z#UJQ%+'<0I-#(DD4BAD=&!5@>001U% '+^(
M="OKR+4=.TK3M*AM-6LY+>[O"3',KE2@8J%/F *> 2/3(%;?]B:=)I%OI=U:
M0W5I B(D=Q&''RC .".O'6N7OO%$FK>*-0\.Z/KEG87%I:QO%*3')YUP[,/+
M(.<A0HR!\WS=1CG9T2^FM='N+G7=>TV[>.=O,G@VQ0P<#]V26/W?4G/(S0!H
MOHVER:>+!]-LVL@<BW:!3&#USMQBK4%O#:P)!;PQPPH,)'&H55'H .E0P:GI
M]U>36=O?6TMU ,RP1RJSQ_[R@Y'XTR/6-,EOC8QZC:/> D&W6=3(,=?ESGB@
M"2_TZQU6T:UU"SM[NW8Y,4\8=2?H>*$T^RCT\:>EG;K9!/+^SB)1'M_N[<8Q
M[5!<Z[I%F)3=:K8P")Q'(9;A%V,>BG)X)]*LW-]:65O]HN[J&"#@>9+(%7GI
MR>* (+31M+L;:2VM-.M(()!B2.*%55QC'( YXJ+_ (1S0S:I:_V-IWV=&WK%
M]E38K>H&, ^]1:K?"YT2.ZTW7+&S222,I>OMEB9=PRHY )(R!SWJY<ZMIUD\
MB76H6L#11^;()9E4HF0-QR>!D@9]Z "32--FN5N)=.M'G6(PB5H5+"/^YG&=
MOMTIL.C:7;6,MC!IMG%:2@B2!(%6-\]<J!@U,M_9O8B^6[@:S*;Q<"0&,KZ[
MNF/>FVNIZ?>L5M+ZVG()!$4JMR.HX- $=MHNE64D$EKIEE ]NACA:*!5,:DY
M*J0. ?04EOHFDVFH3:A;:99PWLW^MN(X%61_JP&35^N+U+Q6Q\=^&=,TO5+&
MXLKV2X2[BA*R."D+.N6!.!D>@Z=: .KBT^RAO9KV*SMX[N< 2SI$H>0#H&;&
M3CWIUY9VNH6LEK>VT-S;R##Q3('1OJ#P:BDU?3(M02PDU&T2]?A;=IE$C=^%
MSDTZ'4["YN9;>"^MI9XL^9$DJLR8ZY .10 VVTG3;.=9[73[6"98A"LD4*JP
MC'(0$#[H].E3_9;?]_\ N(_WYS-\H_>' 7YO7@ <]A4!U;319->G4+3[*K;6
MG\Y=@/3!;.,US?CKQ)<:?\.]0U_P]?VCO"@>.90)D8;@IP0<9YZ\].E '47%
MA9W=BUC<VD$UHRA#!)&&0J.@VGC'%5QH.CJ,#2;$#R1;\6Z?ZH'.SI]W/..E
M6+R_L].A$U]=P6T9. \\@09],DTAU&Q6S2\:]MQ:OC9.95V-GIALX.: $M]-
ML+.S:SM;*V@M6R##%$JH<]?E QS56S\-:%I[Q/9:+IULT3,T;0VR(4+8R1@<
M$X'Y"K-MJNG7LUQ#:7]K/+;G$Z13*S1'T8 \?C40U[1S);QC5K$O<L4@47"9
ME8'!"C/S$$$<=Q0 MIH>DZ?-YUEIEG;2@$!X8%0C/7D#O5^JEMJFGWMS/;6M
M]:SW%N<3113*S1GT8 Y'XTBZOICZ@=/34;1KT9S;"93(,=?ESF@!D&B:5:WS
MWMOIEG%=N2S3I JN2>I+ 9R>]/ATG3;:]DO8-/M(KN3[\Z0JKO\ 5@,FHY]>
MT>U#&XU:QB"R^2QDN$7$F,[#D_>P1QUJGJ7BW1M*UVQT>ZOH([R[#.%>4+L0
M#.6STR< >O/I0!N50@T32;74I=1M],LXKZ;_ %ES' JR/]6 R:>^KZ;'>"S?
M4+1;HL%$#3*'R>@VYSDY%7* ,U_#VB2M=-)H^GNUV0UP6MD)F(.07X^;! /-
M2?V+I7VJ2Z_LRR^T2+M>7R%WLO3!.,D54T^^6VMM2N=0UVQN;>.[DQ*NV-;9
M.,1.<D;ESR3@\CBKT&J:?<WLME!?6LMW" TD$<RLZ ]RH.1^- $0T'1QITFG
M#2K$6,AR]L+=!&Q]UQ@U-;Z;8VE@+"VLK>&S"E1;QQ*L>#U&T#&#36U;34OU
ML&U"T6\;@6YF42'C/W<YZ5SVGZ_>#QWXCT[4;NW73K&VMIH3L$8C$F_.YB>?
MNCG@>U &[9Z#H^G6<MI9:58VUM,<RPPVZ(C_ .\ ,'\::?#VB-9I:'1]/-LC
M;TA-LFQ6]0N, ^]3G5-/"V[&_M<7) @/G+^])_N\_-^%5->UBWTS3YP=2LK2
M\,3- +EQ\Q'3Y2P)YXX- $\FB:3-=?:I-+LGN/*,/FM;H7\O&-F<9VX.,=*5
MM&TMH+6!M-LS#:,&MXS NV$CH4&/E/TKG/#^L:CK'A+PKJ4^L6MI<WGER7*R
M1+_I0*G,:#(VDG!R,]*Z*YUS2;(3&ZU2R@$!42^;<(OEEL[0V3QG!QGK@T 2
M0Z5IUO>RWL%A:Q7<O^LG2%5=_JP&34=KHFE6-T]U::99V]PY):6*!58D]>0,
M\]ZL37EK;VPN9[F&* XQ*[A5.>G)XYIMKJ%E?+NM+RWN%QG,,@<>G8T 0#0=
M'!N"-)L<W(Q.?LR?O1_M<?-^-,;PYH;QQ1MHVGE(01$OV9,(#U XX'TJ]<75
MO9Q>;<SQ01Y"[Y7"C)Z#)J&TU33[^>>"SO[6XEMVVS1PS*[1GT8 \'ZT 4]3
M\.V.J/IHEMK81V$JRP_N 7C*E64(W\ RHSCJ!BM?K5./5],EU!K"/4;1[U<E
MK=9E,@QURN<U'+KVCV_^NU:QC_?>1\]P@_>8!V<G[V"..O(H :/#VBK#-"NC
MZ>(ISNE06R;9#ZL,<_C3CH.CDVY.DV)-L,0$VZ?NAG/R\?+^%6+R^M-/A\V\
MNX+6,G:'GD"+GTR2*XO0?$.IZUX;\332ZY86LMIJ<]K:Z@8E\F.-0A5L%L$<
MGDD]: .J;P[HCFY+Z/I[&Z8/<$VR'S6!R"W'S$'G)J3^Q-*^TRW/]F67GS K
M++]G7<X]&.,D?6G/J-E:B..ZO[9)3$9/GD5-R@99@">G?VI]MJ%E>V0O;6\M
MY[0@D3Q2JR$#J=P..* *I\.:$UM%;'1=.-O%)YL<1M4VH_\ > Q@'WK,\3>'
M9KO2FBT.UTN.26[2YO(+B';'>@<E9"H)R3M.2#TP>":VK;5]-O7V6NHVD[ X
MVQ3*QSC/8^E6GD2*-I)'5$499F. !ZDT <9HGA)$U>TU.;PSH6ARVK,RG36W
MR2DJ5PS"- %^;..<D#ICGIH-#TFVU*74H-+LHK^7/F7*0*LCYZY8#)I8=;TF
MXNXK2'4[*2YEC$L<*7"%W0C(8*#DC'.:<-6TTPS3#4+0Q0';*XF7;&?1CGC\
M: (E\/Z*L<Z+I%@$N.9E%LF)/][CG\:#H&C,MNITBP*V_P#J ;9,1?[O''X5
M@ZQXBNK'QKX:MH[ZU&C:C!=2RMM'2.,,&\S.-OS9XQTZU?U[7/\ BB=5UG0;
M^SF:VM)9XIT(FC)12V/E..V.M &C/H>DW.I1:E/I=E+?Q8\NY>!6D3'3#$9%
M..C:6UW)=G3;,W,BE7F,"[W!Z@MC)%9%I?WEYI'ABZ;5[:TEN4BEN(Y8U)N]
MT62B<C!R<\9Z5L7>K:;83QP7FH6EO+)C9'-,J,V3@8!//- $0T#1A8-8#2+
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M'M7&V_@>^N[ :;JVA>%-GE>4^H0QM).PQ@N%:,8<]<ES@\\T >A@!5"J  .
M!VKRO1WMK[X?^.+/7=@OH[J]-^LOW@2,Q,,]MH3:?]D8Z5ZHJA5"C. ,<G-5
M)M)TZXO4O9]/M9;J/&R=X59UQTPQ&10!Y?8Z9]I\5> 8?$%M%-?2:%.+I+A
MS2,%CX<'[Q'/7/.:]8M[>&TMXK>WB2&") D<<:A510,  #H *BDTVQFNENI;
M*W>Y7&V9HE+C'3!QFK- '#Z/Y3_%[Q3&=C'^S[+*\?\ 33/\Q^=</J$%K_PJ
M'X@H(H?+AUZ[\L!1A#YR 8]*]E72M.2Y:Y6PM5G;):40J&.>N3C-1C1-)$31
M#2[+RW8,R?9TPQ'0D8Z\T <;?VUEIGQ4\+FT@B@#Z9>JXA0 NH\M@#CKSDUR
M,>KZ7+IW@.[LKJTL]/76M\5H9M\L*,)MS2R,<Y)ZC  SC)QFO8QI.G+-',-/
MM1+$ (W$*[DQTP<<4BZ/IB A-.LU!E$YQ HS(.C]/O>_6@#S:#3-,FU/XHE[
M.V<(B[<Q@[ ;4$X],GD^X]J@T37(=+U+P!<:U<+%IDWAT1V]Q,V(TNB(\DL>
M Q0$ GU([FO4/['TS,I_LZSS-Q+^X7Y^<\\<\^M$NCZ9-8_89=.LY+3.?(>!
M3'GUVXQ0!YOXRM?#T7P]N9=$BB-J=:@F696WHTK3QF1HV)/'4<<9!K5DL+"?
MXY,);6WD;_A'A(0R Y;[01N(]<<9KMI=,L+BWCMYK&VD@BXCC>)2J?0$8%-_
MLG3O.\[^S[7S=NW?Y*[L8QC..F.* /(;4Q0?"NS=;RWMXK'Q,7CBFD"12A+M
MB(BW11WR>!@5V/AJVL-3\=ZOXF@N-/=KBWAACAAGCFE78"&D8H2%SD*,$\#G
MTK0\1>&KBXM+1-"M]*C2*X\Z>RN8-L%V-I #E1D8)##@\@<<4S0_"YM]4AU2
MZT?0],N(%9572TR7W#!WR%$)'^SCK@YXH C^*<U[;_#;69;$2&01IYGE?>\H
MNHDQ_P  W?AFL36M2T*?QW\.[NPN[(P9NEB>-U 6-K<A1[#. !Z\5Z40"""
M0>H-4;;0])LF5K72[*!D8NIBMT4ACU(P.I]: /*-(ET/7O"<VD>(M?NK?5;;
M4)&N+!&A2X-R)BRF/*;V+'&"">N*Z/Q(\_A/QY;:W96YECUV#^SI45>#=J";
M=FQZ_,A/8#-=P=+TYM1&H-86IO@-HN3"OF >F[&:L/%'*4,D:OL;<NX9VGU'
MH: /.?$DL/A?Q#X0AO=1ELM)6*XA-Z%3:MT0A#R%U906'F<X_B;G&:RO%=EH
MME\*O&LVBZC+?0W4HGFF+HT1F9TW;"@"^F<<9]\UZQ=V=K?VS6UY;0W$#_>B
MF0.K?4'BHCI>GM9)9-86IM(_N0&%=B_1<8% '(O=O%\:(HKX@6\^C$:<S?=:
M029E"_[1&TGV KA==LHX/"7BYBJ#2(_$<#63'A8\RQ>=L/\ "NXL..X:O:+C
M2M.N[5+6YL+6:VC(*0R0JR*1TP","L#QOX=O-<\++H^D164>)X9,3.8T58Y%
M? "HW7;CM0!BWV@V%M\5_#CZ/9V\*M872ZE'!&%1K?"B/>!P?G/&>N#Z5QPL
MK!?V?/M*P0+,FH@I*J@,I%_@8;J/E)'T->T6>F6-I;O'#I]I;"8?OHX8U"L<
M=#@#/XBF_P!B:3Y'D?V79>3NW>7]G3;GUQCK0!Q.J6J6'Q4LH])@AM[A_#]T
MJ+$H4,0Z% 0/0UC>&)?#GB'PUX8CN]?NCJFG7$++IZM"EPEVO#@KL#D$[BQ)
MY&23WKU,:7IZW"7 L+431@!)!"NY0.  <9%$>EZ=#?R7\5A:I>2##W"PJ)&'
MNV,F@#RD:9IC:!\5F-G;$Q3700^6OR8ME(QZ?,,\=Q[5H+>00>)?AO=WEQ''
M&^C7&996 !8Q0GJ>]>AC1M+"R*--LPLO^L'D+\_?GCFI/[,L D"?8;;9;MOA
M7REQ&WJO'!^E 'F\\U]H>IFZ@>UUOPW=Z[MDA8;;JQNFGVG:1]]0_8\X/IS7
MJ) (((R#U!JHFD:;'>&\33K1;HDL9UA4/D]3NQGN:N$ C!Y% 'B5];VO_"JO
MB5&(H?+AUN[,:A1A#F/&/0UU-]:6EA\2O!7V&&"!IK"^5O+4+O 2-AG'7G)_
M.NV&B:2(GB&F67EN0SK]G7#$="1CFG#2=-$L4HT^T$D0 C;R5RF.F#CB@#S3
MP?J7AO5O ^G:;KTD;ZU9WY>>R:7;<F]65CN"@AB23G/3!.> <;-F/,^)WC2)
M<,S:7:#;W/$O^(KLUTO3UU!M06QMA>L-IN1"OF$>F[&<4Y-.LHKMKN.SMTN6
MSNF6)0Y^K8S0!XU;ZKIW_"L_AQ$;VW\R'5K$R+Y@S&%9@Q;^[@\<UT&D:I92
M:C\0K36YH$OC.^$N& WV?E 18SU7[QX[M[UZ FBZ5$S-'IEDA:7SV*P*,R<_
M.>/O<GGKS3KG2M.O+J.ZNM/M9[B(8CEEA5G0>Q(R* /(]/:TE\&_"J9&A>5-
M1MXBX(++^ZDRN?KCCZ5N66F:9/X[^(HFL[9PMO:<-&IV[H'W?3/>N_;1],>.
M&-M.M&2$8B4P*1&/]D8X_"E.D::7E<Z?:;YAB1O)7+_7CG\: /*+&]BL_!_P
MPU.XOX%%MP;>XF6-90864D,Q"AD'3)&<XSFNO\#:=9KJ7B'6H)["5]2O/."6
MLJ2F%-H&&9<_,Q4L0"1[FIO$'AJ^FNK"31[319K&W602:7?1%(7=L8D!56PP
M (Y4\,:M>'?#:Z;?2:E+IVE:?<R1>28-,CPA&0<LVU=YX&/E&.>N: ,?XNQ6
M[>"!+<*F([^T/F-P4!F0$@]N.]9OB#15L/B%IDWA6UBMKS^Q[W[4MJ@0%-@$
M&X#C_6'CUV^U=/X\T+4?$?AY=.TX6GF&YAF8W,K(N(Y%?'RJV<[<5N6&GVEA
M$1:V-K:%\&1;= H)Q[ 9^N* /,/#,GAGQ%H?A0RZ_<OJ6GRPF+3T:%9HYU&V
M164('*_>+9/(!)-4FTS36\$_%-_L=L7BO[T(=@^3$2$8]/FYX[UZY%I6G07T
MM]#86L=W*,23I"HD?ZL!DTP:+I021!IED$D.740+AOKQS0!P&FZLL/Q'T5=6
MG5()O#D9T^29L(TQ8&7!/&\J%]\#WKG)SILWPN^)44#6LB1ZQ=RQJA4A<^7M
M8>G?!%>QSZ-I=U:QVMQIMG-;1'='#) K(A]0","E.DZ:T#PG3[4Q2/YCQF%=
MK-_>(QR?>@#A=4L[&Y^)_@WSK>"4R:;=,VY0=^!$5SZXY(KGYH(?^%?_ !$M
MH[N&RAB\02[-W$8YA;RSCHK-E3V^8^]>M#2--$L<HT^T$D0 C;R5R@'3!QQ6
M/XA\-R76DF#0HM.M)VGCEECEMQY5RBG)CDV\[3QD\^F"": ,724T_P 1?$2/
MQ$EQIA,&F?95MX[F*>5GW[B_R$@*HX!ZG<>G?J/$\,<_A35XYHTD0V<N5=<C
M[A[5AZ5X4D.IVE_?:'X>TR:TD,B-IBEI'.TK@N40JO)R,'/'/KT>MVUS>Z'?
M6EHL1GG@>)/-<HN64C)(!/?TH \F?1=/F^&7@.\TJW@76S<6!MYX5'F,_'F
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4R::*WA>:>5(HHU+.[L%50.I)/04^N%^*%V]CIFAW4P;
M^RHM9MGU(@95802<L/[H?83]!0!-9>)Y;_XHG2K35+:ZTK^R6N3%"%)242HO
M+#)^Z<XXZ_2ND37-*FU Z=#J=FU]\V(!,I?CK\N<G'?TKS[4]1M;OXJSOH]]
M:R7L_A::*WDAE4[I?-!0 @\GOCTJMX8N_#'B+1_"T,VLW4FJZ;+"8],!C2:"
M=!M?*A ^P?-DDX(Z\T =#X7\8QJ-8B\2:W8Q31:U<6-KYS)!O1 F !GGK[]:
MV[_Q?H^G>)+/0KB\@2\N(VE(>0*$48QG/=B>!WYK@;"UT*?P]\14U2&U>4ZM
M>AE=5,N"H\O'?)8_+COTJ?3FET/Q3X"CUV=8+E= F@D:9L$RCRODR>K>W4T
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M37%BTQN4:)W\\R!$BPX(SU)7&3QT[\C:RPMX.^$\KO&9!?6Z!B1G AD&,_7
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MG@$GNWJ:S--NM"U7P[J7ASQ3K-U!J<6H3&XTT&-)9I3,7C:+Y-[$Y7&#[=*
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M#JH;.UMW+P6T,3D8+(@4G\JF(# @@$'@@U3GU*ST^T@DO+V-1( $=B 93C/
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MGH*9-KND006DTNIV:17C*ELYF7$Y8@ )S\V<CI0!>"(&9@JAF^\0.3]:8UM
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M1PQ+%$BQQJ,*JC  ] *?5+3=7T[689)M,OK>\BBD,3O!('"N.JDCOR/SJ[0
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M7)M;)\]LC![X/Y&L*._T(7WBOPWXNU*YLY;C4)9%MF.U;NW?'E>7A26.T!<
MY^48KUORH]^_RTW_ -[:,TCP0R2I*\4;2)]QV4$K]#VH \MU^.72WU"^T'4X
M(Y[33(8]2T/52&6Y@6,[<-G<'P67/0GK[Z.D:JUO\3KJ?6$-E'J>CVKZ<+@[
M0@7)EBR>-P9LD=<#->@26UO+(LDD$3NARK,@)!]0:6:WAN4"3PQRJ#G:ZAAG
M\: /%=2B&G_"WQ*[2+'IMSXC$VF@G"F#[3$<I_LDAV&.W/0UUU_J=CI?QDM[
MR_O(+:VN?#YBAFE<*LCBX#%5)X)P0<"N^:.-P Z*P'0$9Q36@A<QEXHV,9RF
M5!VGV]* /$8[VV/PO,WG*$M?%0EN"W'DK]LSEP>5X/>NRU74+&Y^+'@^6"YA
M=9;*]VLK#YP1'M(]0<''KVKO?)B\HQ>6GEG.5VC'Y4&*,L&,:%AT.T9H \ET
MNYMF^%7BG0];9/[9BDO4NH)/]9+-(S-$RKU;=N3:1UP,5;T:/[-\2?#-OJ\D
M+ZG;^%=LQD8%A,'CSSZ_>Y^M>G-;P-.L[0QF91A9"HW >QI3#$S[C&A;U*C-
M '$?"Z:"32=<2WDC9(]=O0JHP(53(2,8[4RROAIGQ<\0)J\JPQWUC;-ILDS!
M5:.,-YJ*3QD.VXCK@YKNTBCCSL15SUVC%-FMX;E0L\,<J@Y =0P!]>: /%M2
MA_L[X(>+][K'87.ISR:8K' ^SM.NS:/0D,P]CFO:89HYX4EAD22-AE70Y!'L
M:<\:2 !T5@.@(S2JJHNU5"@=@,4 >5BYN='UE)M)O[?6-#O-=:*?3)P/M%G<
MM,=[1L#D@/E]I'W>>A)JM<ZG8Z?8_%/3;NZCBOIVN)(;9C^\D1K0895ZD<')
M' P2:]9%M;K/YX@B$V,>8$&['UH>V@D=G>&-G9-C,5!)7T/M[4 >4Z;XBLM$
M\0>$M2U2ZCCT:Y\-I:6]XQ_=17(*LZENBDJJCG^[BIO%+>'QHGAD:;#!#IEQ
MXHMY5W<)."S%Y &ZJ23ST(Y'!%>HRP0SQ>7-$DD?]UU!'Y&E:*-\;XT;'3*@
MXH X?2)[?_A<WB"**6+<^EVI9589+!G[>H!'YBE^)MQ#!;^&/-E2/_BH;)OF
M8#@.<G\*[<0Q*^]8T#>H49I7BCDQO16QTW#- '#1W%N?CI(BRQ>8?#JC 89)
M^T$X_+FN1M;^R_X9_P!?L&N(OM5LMZLT)8;HF,\A4,.Q.1@'DU[,(8@^\1H&
M]=HS088B"#&F&.XC:.3ZT >:ZYJ^GZ/K_@S69=3M(U^P31;+J7RXF0K'EEDP
M0'SM&.XSR,50^U:'I'@6\O/M6EZLE]KZW,KP3[[:QDDF#*792#L3 8YQD^@-
M=IK6A:U+KD6I:5=:<\(MOL[6.H6[-&OS;BZ%3D$\ Y!SM%7=&T$63W5U=QV3
M75VB1S+:V_EQ;4W%1@DDGYVR2>>.!0!P.G7MO<>+O'<46I+?S7>D0-"Z*,38
MCE!*!1@J,@9YZ@9)JG?ZIIUQ\$/#'EWENY@ETV-R'!V.KQ[E)[$ '(ZCO7L8
MC16W*BAL!<@<X'04WR(=H7RDVCD#:,"@#AM/OUT[XM>(%U69(HK^QM7TR65@
M$:*,-YBJQXSN;<1Z'-<7-:Q6?A&P2Z,2Z9<>-5ET^.7 7[(9CC /\!^8^F&S
MWKVR6V@G14FACD13D*Z @'\:<\4<F-\:MCID9Q0!P4.H6%E\8=:E>Y@CB308
M9)2&'&R20DD#T7'X5V>DZO8:[I<&I:9<I<V<X)CE3.&P<'KR.01@U8>WC*OL
MCC5RI 8H#V[^M0Z;IT&E6*VMN#L#,Y)QEF9BS'C Y)/ X':@#AO#M]:V/B#Q
MQI_B.6&&::\-R#<L%$UFT:JF,_>50I!QT)KE])MFT^P^%EGK;(LZ75PPCN2
MR1E)#$"#TP"@]C@5[1+;P3.CRPQR-&<H64$J?;TI6BC<Y>-&([E0: $A@AMH
M5A@B2*)1\J1J% ^@%>7>%[FYTK4_#EG97]MKOAN]:0V#. +O3\1L<,1PR@$J
M2>02!Z9]5J*.UMXI&DC@B1W&&94 )^IH \?Q8WWP^^)D#7RP1?VS=.9(AOQ_
MJR.!V)&#[9K>T75-(\2^.K#6#K>AFZMM/>V6TL[T2O*S$,QY .U=O QGDDXQ
MSUOB+1;C5=':UTV[CL;CS8Y YAWI(%8-L=<@E&Q@@$<?E5"S\/:A=W5O/K<>
MBK]GD$J"PM6#,XZ$NQR![ <^N,@@'FES+IX^"GC*2-[;<VKW!#*5R3]I!3].
ME=O?7=H_QET I<0LSZ1<@8<$MET(_/!Q^-=S]G@QCR8\>FT4""(,&$2 CH=H
MXH X;P=>VDGCKQV%N86_TR G#CH(%!/X$$?A7%:1J2:=\./!VJ,?,TBPUR=[
M_P H;A$AEF".P'92RM^7M7MP@A&<11C/'"BE$,01D$:!6X9=HP?K0!YSXEUG
MPG+X9\1ZW8V$&K0SK;I>W$3MY4K!PJ!G7KL!!;'08'>J^E:M8O\ %JZEEUFV
MO4N/#Z8G0*L3D3.6"8ZJ!W);'.3QQZ:D$,<'DI$BQ8QL"@+CTQ0((0 !$F N
MT?*.!Z?2@#Q#3Y;&#X->!)!);QNNLVCE@P!#"<[B?<#K[5V^AWMM;?%WQ;;3
M3HD]W!8-;QD_-*JQR;BH[@=R.E=Q]G@QCR8\>FT4X1H'#A%W ;<XYQZ4 <)\
M5'M!IGA];QH1&VO66X2D8*A_FZ]L=:J^*[ZS\.^.]%OK^>33]$N+2> 7=N J
M1W+NC9<X(&Y5Z^WIFO17BCDQO16QTW#-))#%-$8I8D>,\%&4$'\* /*-;M_#
M]EX,;4]'OV2T_P"$@@U!;FY<F"ZGWKN);'RQDYRP& 5. >^KHDVEZ[XC\0ZS
M9:OI=U=W>GI;I965TLS!4#?.W .26QTX Z\\=/XDT;4=2AL&TF]M[:2SG\WR
M+B$R03C:5"N 0<#.1CH0#C@8BTO0+H:A!J.JQZ6EQ;AO*73[<I@L,$L[')XS
MQ@#N<\8 /,K?7=*;X>_#JV6_@,UIJUB+E XS 5W@^9_<Y]<9P?2NEEU&S@^(
M'CF61!>)'HD#O;1O\\H592R#'.2"!^(KT9;:!"2L$:DOYF0@'S>OU]Z<(HP^
M\1J&_O <T >/:;K.G3^*OAU<Q:E:-;_9;F%+>VYBM<PH$A#'+%^@(8Y) ^49
MJ&ZEGN/ ?Q$TK37\S5!K5U,]I&?WI@,J%N.N&3<!Z\XKV98(4"A(D4(25PH&
M">N*<$569@H#-]X@<GZT >>Z_<V?B/5_ ]YX?N(IIH[[[1OA8$QVGEMYN['W
M0?D7![D"G?#:/3;J7Q5(B6LTR>(KMPP"LR@X (/88+?F:[V*V@A+F*&.,R'+
ME5 W'U/K4=S!*+*X6P,,%TT;"*1H\JKX^4D#&0#CB@#SS1=/N]/\1W'@4P/_
M &1!=#5;>7'RBU+%A#]1.!QW4&NV\47,%GX4U>XN;1[R".SE:2V0D&5=ARN1
MTR.,U'X?TO4+-9KS6;R&[U6X5$ED@B,<:HF=J*"2<99CD]2QZ# K:H \@T[5
M[&?QOX'GAU6TECDTZYACCM@/)@)2+;$IY8L.,AB3QG"YJ?P;K.@77A&S\-Z_
M&LOB"RO&\W3I0?.>Z$K,) .I!)W%N@R<\5ZHD$,80)$BA,[<*!MSUQZ4""$3
MF<1)YQ&TR;1NQZ9H X;0+ZTM?BGXUM;FXCBGG-G)%&[8+HMO\S =P,<GH*XO
M2[HP?"_PE?1L'TNQ\0/+J/EG(CB^T2[78#^%24;\C7MYC0L6**6(VDD<D>E(
ML4:J56-0IZ@#@T <%>B"[^*-MJ=A/"]I#HTR:C,C@QE2P,2L1QG.YA[ UQUA
M-8P?"'X?R"2WC9=:LG9@P!#"4[B??'7VKVR.V@AB\J*&../^XJ #\J7[/!C'
MDQX]-HH \MUNZN='U+5M6T34+;4K%M0B&I:%<@>8)LHH:%@<[CA" >./PKN_
M&,&H7/@O6H-*W?;Y+*58 GWBQ4\#W]/>M;[+;^<LWD1>:O"OL&X?0U+0!Y3J
M5Q:>(/ G@Z+1)(_[2BO+,V\49'F6[1X$NX=5"J&#?_7%:GA1--N_B1XZ!6UF
ME6ZLV4$*Q&V!>1]&'YBN^2W@CE>5(8UD?[[JH!;ZGO2K%&C;EC16/<* : .+
M^*DT]MX7M+H1O)8V^IVLVHJBELVROE\@=1D+GVK)O]:TS4OBKHTVE:E9S23:
M-=11312JP+ED*+D=^IQ7II (((R#U%116T$  A@CCVC V(!@=<<4 >1>%KSP
MWK?AW0='U2]OFUW39X@=*9]LL=U&<%\  XZL6SC!.:W=9AOM!^($@TV.00^*
MK<0%XQ_J+J,8\WV_=%C[F.O01!"L[3B*,3,,&0*-Q'IFGE5)!(!*G()'2@#S
M?Q'>V?ACQ]I#:C=3:9H;Z4;.UN8SB.&4."48D':"@7G_ &:S/$<6@Z=\.@VC
MS/\ 8+G7;>X2::3*S,9D+NF?X<@].."1QS7K,T,5Q&8YHDD0]5=00?P-#11L
MH5HT(7H"HXH X73[]=.^+6OKJLR117]C:OIDLK (T48;S%5CQG<VXCT.:XJ6
MSALO#.DO>"-='E\;^;9"4#RUM&9]O7@(?F/I@YZ&O;9;:"=%2:".1%.55T!
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MFGM*PO$N8H]X7RWVE615XW[<@@GIR!D'D&E_X1+XJ7?B#5D:VTG7[&%#<O\
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M\F6)XW:/^^JL 67W&15+POXML_%*7DEK',BP7,D*B2%T)"';DY& 2<\=1W%
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MB%!)QTR/6NXHZ44 >,V:VES\(=8\,/$DFMS7%W&FG$8G\UYV,;%#R  5;=T
M&<\5>EO;'PMXRU"T\7S7T5K?VEJMI>QR3B*4QQ[)(SY9^]NRP!_O'UY]8HH
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MD++NBD#<'D*?7@D9Q7<T=: ,+P9?7FI>$=.N[^RCL[J1"9(8@0G#$!E!Y 8
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MXRH(SR6%,\7ZM;W;^.].139W']G@HEO 6DU(>0<2,V#E%SM^7&,')YQ7KM%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>elicio-insidertradingcom004.jpg
<TEXT>
begin 644 elicio-insidertradingcom004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=P&W(['%<U)I=]H]F?$:6%])I'_"37&H-:VN^.46TD1B\U54AAR2V..".V:
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M=]HL$;2M.NW<2JJ"2 ""3CC(KCM.N(1XU\?SR92.:UM!&SK@/MA<, >Y!(!
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MS,<EB5&2367KGBZWT7Q'HVCO;74CZ@96+QVTD@5$0MQM!W-G;P,X&2<<5?\
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M]-Y\MO<V:S[7VA3L;<I PH !R!BM[3[!-/MC$LCRN[F2663&Z1SU8X 'Y#
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***Q/%>J/I>@R
MM SK=W++;6Q2,NP=^-P4 D[1N<@=E- %_3-5LM8MY+BPN%GBCFD@9E[.C%6'
MYC\>#5RO+?!4UEX7^(5_X;LA<1Z3JL"WMBL\,D>V9%"RH-X!)( ?->GS.T4$
MDBH9&52P0=6('2@!]%>7Q>*_$-YH'A35;/4(C<ZU?BUN+1K972 '>6*@8;,>
MS!RQ[]*W[/5-4\3W_B"#3M1^P+I5Q]BA*PH_F3! S-(&!^7+  +@X!.>1@ [
M&BO.=$\?7?B:+PQ91*+&]U1+E[QT4-Y0@)5A&&R,LW3.<#/4TW4/'E]X5D\4
M6.I[;Z72[>&YLIRH0S+*VQ5D"X (<@9 &1V% '9W_B"QT[6M-TFX,PNM19UM
M]L3%#M4L<MT' Z9S[5JUYSKMGJ-MX_\  ;7FIM>;KBYWJT*(%?[.V2FT [>O
M#9/3GK74^--:NO#O@[5-7LK<3W-K#O1""1U W$#J #D^PH W:*XA=5UF+QUI
MNE0:JE[IMSIYO9I'MU9EVL ,%-H"N#QD'D=ZH6GB#Q;K>DZ9K^BV=Q-'<S+(
M]G)]F6 VQ8CABWF!P,')XSGY: /1J*\YFU7Q3>:MXTLK?6;>U71Q$]NZ6:L3
MNA\S:=Q/'.">3Z8JQ9^,-0UF#PY:V\4R76I:3_:5R]H(MZ#Y!A/-.W!9SUSP
M,8YR #OJ*\TU/7?&^D^&8I;U8+:\&M16D<DL:,;FW>155F",51N2"!Z<8K9N
MG\0:5-8VVH>((9(+B>=I)X+55N2-H,<446'#8^8L<$X ]S0!N^(?$%CX8TB3
M4]1,PMHRJL8HF<Y) '3IR0,G K5KR+7M<O=?^!6LW.H$-<Q71MF<)L+B.Z50
M2HX!P!G'>O6W#%&"$*^/E)&0#].] #J*\UT'4_%NL:!>:S-KL$4=E+?1-#%9
M+F7RRP1MQ)VX*CC!R.^3Q8_X2G5SX;\!:G]I42ZQ=6L%XGE+M<21L[$<9!RO
M8]Z .MT_Q!8ZGK6IZ3;F;[5IOE_:!)$R ;P2N,]>%/(XK5KS<:NF@>,OB/J[
MQF1;.PLI]@.-VV*0@?CTK4LKKQ?_ &SI$PMY[C3;E2-0$_V9%ARN5>'8Y8C/
M&&W''?- ':45SOC#7Y=!L+!;8)]KU+4(-/@>096-I&QN([X 8X[G%4)M6U31
MO'.FZ#=7KWEGK%O,;:=XT66":(!F!VJ%*E3D9&<CO0!IW_B_3-/N6CD6YEBC
MN4M)[B&$O'!*V"JN1R/O+R 0,C.*W2RJ0"0"QP,GJ:X'X:6]RD_BB22_FF5=
M>NT9&1 &8;/G) SGV''M4GC%;U_'_@N"#4[BVAFFNLQQJA4,L#8;E3DX)'/'
M/K0!TVF^(;'5=6U/3+;SOM.FM&MP)(F0 N"5QG&>!G/3D5JUY@L>K-XW^(3Z
M5J26,L,5G)YI@$K,PMR0,'@#UXSZ8J]IWBW5+^[\ 3&5$BUVVE>\A"#;N2#>
M"IZCYO<\4 >@T5YOJ'BC7;;2O'SP7L1ET-P;626!2=ODB0@@8!.3U_0U-<:M
MXGM=?\+P_P!JVTD6NQ2(\3V@VV[+%Y@=2#ECP003CV'2@#L=<UNS\.Z/<:K?
MF46MNNZ0Q1-(0/H!^IXJ[!,MQ;QSIG9(@=<]<$9KRW7-5U2?P=\1M%U2[6]?
M2H0L5SY2QLZ20AP&"\9&<9'6M%M3\2^&]1\,37>H6U[I&K316+VJVPC:V=T)
M1E;)+#Y><_D,\ 'HM<_K_C?P_P"%[VUL]8O)+::[X@'V:5Q(<@8!52,Y(XSW
M%:&GV^IPW5^]_?QW,$LVZTC2$(88\#Y2<_,<YY_R.*^-7AD^(?A]<SP(3>:8
M?MD)'7"CYQ_WSD_510!T6L>.O#V@:I::;J=Y-;W=V5%O&;29O,)(  (4@G)
MQGC-:EUK%G97=E:SF837K%( L#L&(!8@D A> 3SCI7@WB[4+GXD?"W3]=L\?
M;-!MQ<7<@'S^;N", >V AD/L4KU+P+KP\;VUGX@(^2WLUMR,8'VEL&;\!M0
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MU#JZ,A1E9-W.5/4$5VU% '$2?#Z:2T\3P-KLK_V^ )F>W4^7\@0D8(R2!QT
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$U>_L+/XD^(I&B6ZB7PJ'EM8G :;;)(2HQWVX'T(K+TW6=/G\7_#ZXBU.U>
MV5S"D%M_JK;,4>R$'EB_0$,<\ X&: /1/#GB[2_$\E\NGSH_V6X>'&[YG"[0
M7QU W$@?3WJ;4[J-==TBV&NQ6<K.[&P(0O>+L/ S\P QNR/2N;^&]Y;";Q/I
M_G)]L37KV5X,_.J%QAB.P.>#WYQTI?&4]O%\0/ @DEC1_M=S]Y@#@P,/YX'U
MH ZM]=TJ*]%F]_ MP9!"$+]9#T3_ 'O;K1K@N_[&NGLKLVMQ'$SI((U<9 )
M(/4?D?>O.FN;G1]9-QI-_;ZOHEWKIBN=*G ^T6ER9SN>)@<D!P7VD?=YZ$FO
M1]:FBM]#OY9I$CC6WDRSG 'RGO0!RW@#QG/XFL)=-U>/[%XAM(U-Q$ !YB,
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MDQX/4;14E% $4EM!+%Y4D,;Q]=C*"/RJ1D5D*,H*D8*D<$>E+10 BJ%4*H
M& !VI:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8+.W>XN94BA099W. * ):*S]+UO3=9^T"PNEE>VD\N>,J4>)O1E8 C\16A0
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MGP\R><I9A#+'(,I(HY(R.JYXQUJU:^#-4TV;PWJEE-9G5-*T\:9<1N["*Z@
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M*L@'#<-C!(Z=:QK+P#K%GX.T#3/MUC)>Z+J7V^/*.(Y>9#L9NH_UA^8+VZ4
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MK)@G_MM+!9O.;R?L3.5\K V[MPSNZYQQTK1IJ%S&ID55?'S!3D ^QP,_E3J
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MR7(@\EQ&X")R<N>#D #KV! ._HKG_">JZOJ=I>+K.GFVGMKEHHY1"\27,?\
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MG(8C@]!GDX&O#KVH:UKVIZ;I!M[8:9'%Y\EU"TA::1=X3 9<!5QDY/)P,8H
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MP,-_"5/'\57?%WB[6?#T&LW82PABL522TMY5,DEZF 9&^5\H 25!*\$9/!H
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*Y[QOH%SXH\)7NBVLT4#W853+*"0@#!N@Z],=NM=#10!S$V@ZG/XVT_Q 7M
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M9;742S1/M(W(P!!P>1P:LT <7:^$]4M],\66K3V9;79YIHV&[$/F1A,'CYL
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MW8KQD'*_>%1P^#;W3]:T"^L-3C9=.TS^S)S<Q%WECRAWK@C#93OD<]Z[*B@
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M,D@8YP,Y],'- '))X$U6/P+H7AU;NS,FEW<-P9R&Q((WW@;<<9Z=3T]^#5?
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M& ./ER#GOBNWHH \XU#X?Z[=Z1KVE1ZQ9?9]0U$:A%+);LTN[S$<(YW8VC8
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M'E>XAMU:0'9%YCA-[8QP,YZC/ R*Z"N/^)%W%%X:BLI;^&Q_M"[BM_/N8@\
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M0JQ)! !.XGH>35[Q#X=OM<CU&REEL9],O81&(+J$L;=\$&13GGJ#CC!&<\T
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MS"QBN8&7>K*NX%6*9.,GD>_%\^,9QXWT+3TNK632-7LO/BD$#!Q(5W("V[:
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MD]:UZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)R8EEV<)DGMG!X(ZUZ-JGB"PT>^TZSNS,)M0G%O;[8F*ER"<%L8' /4YK4H
M\[T?5-.TOQ+KVKOJEQ,NK-$_DC1+I?*,:;%^;!SP.>!^%8LEII\O@K6/#C:]
M/C4KN2Y:X&@W68]\GF,H7OST.:]=)P"3GCT&:S=$U^Q\0P74U@TI2UN7M9/-
MB:,B1,;AAL'C/<4 >?73VD^MZK?1^(+N*+5K)+6[C_L*Y9@45E!B8CY!\QR"
M&[_4111V,&G>%8XO$%V+WP_E(YVT&X*21F+RBNS P=O?)Y[=AZ'JWB;2-"N+
M6'5+IK8W4@BAD>%_++GHID"[0?J15G5=5M-%L)+Z^>1+:/EW2%Y-H]2$!.*
M.#6YT63Q/J^IWFH7-Q::G9)8RVIT:Y4[%W?QXY)W'/RC\*IVJZ8/#]IX;O\
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MP*MT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG:>;31;JQ5G.7$<I.44\]!D9X(/- $+7_BK5/&^N:+9:M:64%G#:SQ,UGYC
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MD4$9!WMP",<8Z4_4?!*:U;:P=4OC)?ZE9_83<01^6L$0)(5%))^\23DG/L*
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MD<=Z .Q1!'&J DA0 "3DTZJ6E6]_:6$<&HWR7TZ *9U@\HO[D;B,_3 ]JNT
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5EZ]XAL/#6GM?ZF9H[1/ORQP/($YQEMH.!SUK4K \:QI-
MX0OXI45XW"*RL,A@77(- &L;^W.G"_A8SV[1B5&@&_>I&05QUX]*;IFI6^KZ
M;!J%IYAM[A!)$TD90LI&0<'G!!KSS3II?AEKRZ!>R,WA74I#_9=RYS]CE/)@
M<_W3U4G_ !(NV&MW5OH_@O0[);CS;W25G>2W$7F*D<48POF$+DEQR<\ \<Y
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M!<NUSE/DW$$##+D#CFM&^U[5$\7^#;>*X1+'5HYVN(!&"25AWCYCSC)[8Z4
M;NE^(;+5]4U33K99Q/IKHEQYL109==PQGD\=\=ZU)'$4;2,&(4$D*I8_@!R:
M\^TZ:ZM_%OQ*FL7MDNHQ:M"UTVV)6%J,%SV7/6IM#\0ZB_CBRTF34)KZRNM*
M:Z,LUNL8\U'4%HR%4E"&[@]B#0!U7A_7K/Q+HT6JV E%M*SJOFIM;*.4.1VY
M4TQ?$-D_BEO#H6<7RVAO"6B(3R]P7ACU.3V]#7E>BW'B;1?A0OB'2=6A2WTZ
M:ZF?3GME*SQBXDWAG/S ]<;<=/QKK%O8Y/B[!?D,L;>%6FP>H'GJ: .^HKSN
MPUGQ?K.G:)KNEP7$D=W)'+<VDIMA;BW?KL8-YF]1CDGD@Y Z#LO$,]U:>'-2
MN;*58KF&VDEC=DW@%5)Z=^E &E17G=A>^*G\%67B"X\262B]LK1V6>V2-;?<
M5,DBL =SE3PI&-W08XJ./QQ=Z1)XS>]>XO+31K:"ZM?M,*PRMYBM\K *O&Y1
MC*@@'G- '9ZMXALM&OM-L[I9_-U&X%O 4B)7>03RW0< ^_M5BVU)+G5+ZP%M
M=1M:",M-)$5BEWC/R-T;&,'T->?^)+?4Q>^ KN^U1[DS:O"TL/E(L:R&)SE,
M , /F&"6[<^MRX\8ZAHNI>/9;^5;JUT2WMIK2%8PF"\;-M)ZG)VC)]* /0:*
MX+5=:UKPY9^'M8GU$WUO?7,%M?6S0HJIYW1XBH##:V.&+9'OS72^*M=7PUX5
MU+66B\W[' TBQYQN;HH/MDB@#8HK@]6UG6O#4/A[5)]1-_;7]U#:7MNT2*J&
M4</$5 8;6[,6R#Z\TW1;KQ/K/B?6[=M>B@M=*U2-/+6R0^=$8U9HR2<KU^]D
MG^5 '>NZQHSNP55&2Q. !ZTM<3\6S<)\-=5DM[N:V91&&\H@;U:15*G(/!#=
ML?ED5-J&JZA'XCA\-6UQJ$TB6)O)KF%;?SF!D**/G"H ,'.%)^[[Y -K7O$-
MEX<M8+B^6<I/.ENGE1%OF=@HR>@&3W-:U>6^)9/$#_#RW7Q)"B7T>MVJ*ZE,
MS1"=-CD(2%8@\@=Q6YJ.LZQJFN:[I6D&]A?3$B1)+5;=MTKQ^8"_FG[N"HPH
M'\7/3 !VU5[^\73].N;QH9YE@C:0Q0)OD? SA5[GT%</?:UXGTA/"FI:S(MG
M!<3K9ZO;1+&ZQR,"(W#X)"EL9YXW#I5W7-4U>W\,^*M:L=0V+:1RFR5X4908
MD.\] 3EPR\Y^[GO0!UUM,+FUBG"21B5 X21=K+D9P1V/M5>]U)+&ZL8&MKJ8
MW<IB5X8BZQG:3ER/NKQC/K7&:QXLN])LO#]WJ4][:Z3=6(>[U*TMUD\J<A"O
MF JVU""_('7':I;S7=5MI_! AU>WN[?4KCR;J:&)2MP/*9MRGL"5' 'XT =W
M17$6>JZOXIA\1W&EZDUBVFWLUC:1+$CJ[Q 9:3<I)#,2,*5P,=ZR+3QEK?B&
M;P-/87,-C#KD5S]IB, ?:\49R02<XW D?09SR" >G45R7@O5-3N;SQ!I>J7G
MVV32[_R8[DQK&SQM&KC<% &1N(R *@\3ZEKL/C?P_H^FZC#:VVI0W1D+6X=D
M,:J0PR>3\W X&0,YZ$ [2BO);[Q5XJT?0_&VGW&I13:GH"PSV^H?95'G12@D
M H/E##!&<8]JWK[5-=T:YTNSN=8CN9]>O8XH"+54%D@0M)M/.\G "[AP3SGI
M0!WE%<6NN:KH_CB?P_<ROJ<$^FO?V<C(BRAT.UHCL !!R"#C/..:PX?$WB"]
MT?PA?V>JJUUK5UY%W:_9D98!M9G*C 8>65P<D]>>: /4**X&TNO%&K>-_$6E
MQ:]%:VNESV;H%LE<NCIO:,Y/ (XSG/3&.<T[SQ/K=A=Z5(^I+<R7&NK874%O
M"K6D<3NRJHDVAO, "D_,<'((Z4 >E45P27GB/5/%WBS1X=<6SAL(K:2U>.T1
MF0R([$?-D$9 SG/3C%9%MXJ\2R>$O"GBF74X]M]=VUM<V*6RB.19'V,VX_,&
MS\W! [8]0#U2BO/=2\5W-KXLN=(U'4I]&E>YB&F-+ AM;N+"%E\PJ3O)WC&1
MCY<>_H5 !17(>-]5UG3+[PY#I5W! +_45M)1+#OX*.V>O;;T&"?45A2:WXFT
M76/$6@W^K"\DAT9]7L+Y;:.-T"DJ8V4#:1N [9QW] #TRLG1?$-EKTFH)9K.
M#87)M9O.B*'>%#< \XPPZ@5R[>(]6%A\/[L7?.L-"EZGEKM?? 9"1QE3D=CB
MLC3++Q#=7_CF30=9CTZ6'5W=%:U67SG$,9VL6Z*>G SSG/:@#O\ 4/$-EIFM
M:7I5PL_VG4G9("L1*952QRW0< \=:LV^I)<:K>V MKI&M%C)FDB*Q2;P3\C=
M&QCGTKSO^W7\37'PQUF6(12W<\SNB] WV=P<>V0<5IR^+M0TC6?';WTJW5GH
MMI;W-K"L83&])&*D]3DA1D_E0!WU%<S80>)&N]'OO[6@N;&>$MJ$$D:J%+*"
MA@VKG ;C#,>/>N;D\3ZW97N@O+J2W4EYK)L+R&WA5K1%8R;523:&+J%7/S'G
M<#V% 'I&]2Y0,"P )7/(!Z?R/Y54TG4DU?3(KY+:ZMEDW8BNXC%(N&(Y4].F
M1[$5QOA>&_D\>^-0=7NG\F>W2-95C90&@# 8"@X4L< $>^3DFEH_C75;GP7X
M5:XN$;5=<OY+5KGRU C59)-S!>F=J #/<@G..0#TRBN(?6-8TSQI+X<EOC<P
MWFG/>65U-"GF0R(<,C! JLN""#@'L<U@:=XF\3GPQX-\17.KI*NIWUO:7-H+
M5%1UE8KNW8R&'!XP.V.Y /5JI:3J2:OID-\EM=6RRYQ%=Q&*1<$CE3TZ9^F*
MM3+(T+K$XCD((5RNX*?7'>O+8?%OB2?X:^&-92_A%_>ZI';7+M;J0ZM<,F .
MBC  XY]\\T >JT5QVC:CK%K\0=1\/ZCJ/]H6YT^._A=H$C,1,C(R#:.5X!&<
MGW-:GBB\O+.ULFM;Z"RCDNT2XE<;I#&0?EB7:VZ0D* ,'C- &[17)>!];O\
M59=?M;Z627^S]1,$,DT2QR&,HKC>% &1N/8=LC-+XFU34=%\2^'IQ>,FC7ER
M;*ZB\M#MD=3Y3;B,@%A@\]Q^(!UE4I-22/68=,-M=%Y86F$ZQ$PJ%(&TOT#'
M/ KA-+\5:G++XJTR749);^"=4TJ1H8U#QR-Y<; !?F D#!FZ8&1BME]4U2S^
M)&G:-+?B;3Y=*EG=6A4,TB,B[B1]3P,"@#:\1>(++POHD^K:@LYMH "_DQ%V
MY..@Z?4X%:@.Y01W&:\@\5:GJ'BKX*ZMXC&H/!;W2LT5DL:&,0K-L 8D;MQ
MW$A@,\8QUZV]UG4]1\0:EHNF->P_V?;0L9;-;=F,DH8C<)CC: HX Y)/(P*
M-W5O$-EHU[IMI=+/YNHW MX"D1*[R">6Z#@'WXZ5K5YGK,VM3V'P_?Q#;16^
MK?V[&+A(F#+D1R@$$$CD8..V:UUUZ]T3QSJ>GZYJ+-ILMB;[3G:-%"JF?.0D
M %F7Y2/]D\YH [6BLSP^-0.AVLFJ2O)>2KYD@=54Q[N0GR@#Y1@9[D&M.@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "LS7M+EUG29+"*Z%L)"NZ3R]Y !!X&1Z5IT4 9FLZ'9^(M"
MGTG5XTN(+A-LFU=O/9EY."#R*P]5\!QWVD:%#::I<V&I:)&L=GJ$*@L $",&
M4\,K!1D5U]% &5I.CR6=C+%J-_)JES<#%Q<3(J[QC&T(HPJ@9X]R>2:P5^&N
MD#PII^@-),\-E=)<K*QR[[3@J3Z&/]W_ +N/2NSJB=3QK#Z<;*\PEM]H^U"+
M,)^8C8&SR_&<8Z4 1:CI][<W]I=V6H"V:!)$>*2'S8Y0^W[PW*<C;P0>YK-M
M_!6G0>#;WPV3NM[T3&9@H4!I26)5>B@$\#M@?6K_ (>\0VGB2QFN[..>-(KB
M2V99T"MO0X;C)[U8UG58-#T>[U.YCF>"UB:600IN;:HR2!]!0!C-X'TUY?#L
MK/(7T0DQLQR9LKR7/<EPKY_O+[U9U7PZ^I^)=%UD7OE'2C*8X?*W"3S%V-N.
M?3ICOZUJZ?>QZEIEK?PJRQ7,*3('&& 8 C.._-4=+\16FK:QJVF017"3Z6\:
M3^:FT$NNY=O.2,<]!UH K:%X:?1K[6;B2]6Y35;@W,L9AVA&*A<#D\8 X/YU
ME:'X!GT*46EOXCOG\/QR^9%I3QH0G.[9YN-Q3/\ #QGH<C.>UHH Y9M-.M>/
M;36F!^Q:1;2PV[?\])Y2 Y'JJJH&>Y8^AJUX2M=7M-.NH]6U&?4";IFMI[B$
M12&(A>&4=/FWXSSC'3I6_10!RM]X,>Z\0ZCJEOK%S:QZG:K;7END:-O"A@I5
MF!V\,<X]>QK4\,Z*WAWP[9:0;V2[%I$L2RR(JG:HP!@>P]S[UK44 <S_ ,(M
M=6VN:MJ.FZNUJ-6V&Y1[<2,C*@0-$V1M. /O!AGM44G@B"*Y\.-IUT+2WT'?
M]GA\K?OW*4;<203D$^^2375T4 <]?>&&?Q/'XBTR]%EJ'V?[-.'B\V*>/.0&
M7<IW ]""/3D5GWG@"&:PMEM=2FMM0@U,ZJ;SRU?S)VR&+(>,8. .P _'L:*
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M,>1L] KY<#U8U=UOPCINN>&(]"E\V""$1_9Y87VR0-']QE/J,4 <MK:^)(=
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M$2BW>1(MX: [58J"" >001U-)X2348K+QS<IK-XT\&JW2(TRQN,K''M8_+U
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M^PMIH]0U634I'F9TEDA2,HAQA,* #CGGWK1IJ!@BAV#,!R0,9/TIU !1110
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M8'<"&#=\]?SJ>]\%VNH>&9M'NK^^EEFE2X:_=U,WG(5*OTVC&T# &,"NFHH
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MZ!X=M+6PT"SMK*Q>QM43]U;.26C4DD YY!P<X/3..U $6I>*=&TAYA>WGEB
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MOXI;&X($,L>6\QB<!5 &2V>-H&<]J9#XGT::WOIA>K&MA_Q]K,C1/#D9!9&
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M,4N_<0QSN(?E=W7!YYYP>*Y^PN;>/XP:_+)+&B?V7;IYC' RK.6&?4 @GTH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBJ][>V^GVQN+J39&"%Z$EF)P% ')))  ')H L45BVWBK2KL7ZPO<&
M>PV_:+8VLHF3=]T^7MW$'U (_*O/;/Q'=7'@"/QQ_:&L)J4%K/-+;B&9K68L
MLA12I78%7:OSKC&/F.30!ZY17%:#-!;Q6.NRZOK#?:K5()+*X29Q//M#F2.-
MEW XW?<&W&3VK<M?%6BW>FW-_'>;8;67R)UDC9)(I,@;"A ;<20 ,9.1C.:
M-FBN<N?&VD6]EJTP-T\VEP^=<VGV:19@I&0=I .#C[W0=R*SI?$NFZKX9T"^
MU"_U#2GO;BU*"".6(RS-M(BR5^:,EL$]".] ':45EP>(=-N->GT..:0ZC!&)
M9(F@D4!"<!MQ7:03W!I!XBTQK8W"RRE?M#6RK]GDWO*I(957;EL;6S@$?*?0
MT :M%9VD:[I^N1SO83%VMY3#/&\;1R1..JLK $'\.:H:EXV\/Z3?7%C=WK"[
M@C$KP1P22/M)P,!5.[H>F<8)/2@#H**P(?&GA^XT[3=0AU 26FI3K;6LJ1.5
M:5C@(<#Y3GCYL4S6=;M+BVUK2;6]G@U2TL6N&"1LC(N#M96*X(R#R,T =%17
M ^#/'NCR:#X:TZ_U21]5N[*$>9,DA664H,KYI&TOGMG.>.M6M'OKF+XD^++>
MYOKF6SM[6TECBD8LL6X2%MJCUP/<X% ':45S7A_5]&M_!]K?P:S=W^GO(Z17
M=V6>:9C(R[0-H9CNRH &< 8K2TO7].UBXO+:TF?[39LJW,$L;1R1%AE<JP!P
M1R#T- &G15#4-7L].EAMYI)#<3AC%##$TDC!>K!5!.!D<GCD#N*\[T77[6?P
M/XJNM9\0ZI;V*:S<0Q7R,XGAC!38%^4E?3&!U/K0!ZG169>:Y8:=)Y$SS/*L
M/G,L,#RLL?3<P4' )!^N#CH:9+XDTV)(6$DTOFVXN@L-O)(PB/1R%!(!]^N#
MZ&@#6HK+E\0:=%;6TX>6;[5#Y\,<$#R2/'@'=L4$@<CDCJ0.IJD?'/AL66GW
MG]J1_9]0D\JV?8V&?G*GCY2,'(;'0T =#17,KX^\/.MX%N+HS6;!9K;[%-YZ
MY&0?*V;RN.=V,>],U?7M"OM$TB^.N7-M9WUU ;2>S+*9V+#;&<*<*QX(..^<
M4 =317/WOC70;#4+NPENI6O+5!)+!#;22/M.<$!5);H>F<=\5.OBK17TS3]1
MBO!-;ZB0MGY2,[S'!.%4#=D '/'&#G% &S17):YX^TW3?!NH:_9K-=BT=K<Q
M"!PR3@XVR @% "1G./;.1FQ?ZMI5QK&@)+J6HV=S-,YMK41R0BY(1@5D5E^Z
M "1G'(!H Z6BL;4/%.DZ8]RMS/*1: &Y>*"218 1GYV4$+Q@\] <GCFFWWB[
M0M.NK*VN;]1)?1M);!$9Q*H7=E2H(/&,#J<C&<B@#;HK,T37]-\0VLMQILSR
M+#*T$J21-$\<@QE61@&!Y'4=ZTF&Y2I)&1C@X- "T5Y]X.UJ:*;QC=ZSJES+
M::7JDMO$926$4*@'HHR>O4Y/%;]EXY\/:A>:?:VUZ[/J";[5S;R+'+\N[:'*
M[=V.JYR/3- &S#8Q0WD]WN=YY@JEG/1%R0HQT +'WYY-6:JZCJ-GI&GS7]_.
ML%K"NZ21N@YP.G)))  '))JMI_B#3M3O;FR@DD2[ME5Y8)X7B=5;.UL,!D'!
MY'I0!IT5YUXQ\4Q3OX9.DZC>QI<:Y:P^9%&Z0W,9DPZ[\88<=C@C/49KHO$W
MB"RM--U2U6[N8[J"V,DDEI"[FWRI*EF52%Z9Y[<].: .CHKS_0M6M9_"7@9M
M6UN_AO[I8'C\N1B;N0H<I*<'*G))R1TK:T_QE;7WBO6-%^S748TU8MTK6TF&
M9E=FR<8"X5<$XW<XSQ0!TU%<UH&L:-;^%!J,&M75[I_GR 7=X6:1F,I78,@,
M?F^50!GH!FK]KXETNZN;JU6:2.ZM8Q++;S0/'($/1@K %E[9&>>.M &M17,6
MWQ"\,7GV P:@SQW\GDV\WV>01F0D@(7V[58D< D$\>HKIZ "BJ=_J=KIWEB=
MG,DI(CBBC:1WP,G"J"3CN>@K);QUX=32XM2:^?[+)<?9=PMI24FSCRW4+E&S
MQA@* .BHJG)J=K%J,%@[2"XGB:9%\I\;%QN);&!C<.I'450B\7:++?VMF+ET
MDO QM7D@=([C R=CD;6XYX/(Y&: -NBN5E^(WA:*&:9M1<Q07!MIY%MI2L+@
M@'>0OR#)QDX&<\\&NI+*%W%AMQG.>,4 +16'9>+]$U"[L[:WNG+7RNUH[0.J
M7 3EMC$8; YX/(Y&17*W>L_\)'XM\0:+)=:U906-K +:2Q@N(W25O,9G;:O/
MW5 #?*<'&<T >C45R7A+QE:ZSX5&J7)N(4B9XVDN+=D+A9&C4]-K.VT95,X8
MXQ5\>,=#_P!/$MU)!)I\8FN8I[>2.1(ST?:5R5]P#0!O45B:+XLT;Q!<-!IE
MTTSBWCN<^2ZJ8W^Z0Q !]"!R#D'D&G:GXITG29[B&ZGD,EM!]HN%A@>7R8N?
MG?:#M'!Z^A/:@#9HJ*"YAN;2.ZAE62"1!(DBG(92,@CVQ7+S_$SPE;1M)+JI
M$:3F"1Q;RE8G!P=Y"_*,\9. <'T- '6USUIX<NK;QO?^(6OXGCN[:.V-L+<@
MJJ%B#OWG)^8YXJ^NOZ:^L_V0MPQOC;&[6,1/AHL@;E;&UN2!P37'^-?$T-WX
M4M]4T;5KB".WU>"VG=-T/295D1]P! '.>E 'H5%8.E>+]#U^_NM,T^^?[;"F
M]HGA>)]AXWJ'4;ESW&1T]:X_1M8A7X7:E<>(M?U*VB6_N86U"*1C.BK.0NU@
M"1T Z8YQ0!Z=16??:S9:;)'!,\LD[H9%AAB>60H,9;:H)QR.?4XZU)I6JV.M
MZ9!J6FW*7-G.NZ.5.A&<'KR""",'IB@"Y16%/XPT.WN6ADNV 2Z%F\PA<Q).
M<8C,@&T') Z\$X/--O?&FA6&HW.GS74K7MM&)9+>*VDD?:>FT*I+=#TSC'-
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M7IGGMSTYH Z*BN<\ 75Q??#_ $&ZNYY)[B6RC>261BS.Q'))/4UT= !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1B[6._OE2X>"*0EH@CL55E&<DJ,@'.,^M=C'(LL:R)G:PR,@@_D:XKQPS_\
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M1&0DA4+E<!C@X!.?I755XS:V]U%\(O!MF]A?"ZMM4MGF@^R2;XU2<LS%=N0
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MT>6N1\R*3G+#'0<@=:WPVM;RPL]<M;O3+NRSK%U-%]H PR.^5VG)W<=^GN:
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MQ7<=Q92&*Y2: J(W&,KNY4GD'@G@YKSL1W.E>%_A]*=*U3^U=,1D*P6IDDB
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MLX#%2-V1R!@<\BK'C:WU&T\4>%_$EK8W%_::;)<1W=O;)OE"RH%$BJ.6VXY
MYP: *?AK5HXO'_CJYO&N[2VM8+.22.]D+>1\LI8CYF 7O\IQ730>*[-]<M](
MNK:[L;J[B::U%TBJ)U7EMI!." <E6P0.U<)J&DZKXDU+QXEGIM[;IJEA:"SF
MNH?*61X@Q*G=R,D@8([\XK6T;R?$<:PCP-)HFH)!(D]W<V*1B!F0J?)<<L22
M.1QMSGL" = WC73([C3EEBNHK34I1#97SH/)F<\J 0=PW8.TD 'L352?XB:3
M%!JDT=GJDZ:7,8KORK0YB 4,6(./E /UX. 0*YOPA$4L]-T'4_ )CU?3S'$]
M]+91FVQ'@><LO=B!D <[CV&2)K:WO!IGQ&0Z=?AK^:=K13:R9F#0*@V\<Y88
M_7I0!U$/C?2I]5TZR6.\$>I _8[QH"L$S;=VU6/.<9(XP>QIVJ^,M.TB&XNI
MX;N2PM91#=7D48:*!L@'=SN(!(!*@@=#R#CE+BVO#I'PXC&G7Y?3YH&NU%K)
MF$+ R-NX[,0/UZ56T^U;1M2U;1-8\#RZPUQ?37%E?1V<<L4T<KEP)9&^X5)(
M.>WX9 .]OM>M!<OIUO#=7]Q]G$\L=D1NCC;(5BQ9<$X. #N."0.*POA+</=?
M#C3YGEEE+37)WS,6<CSY,9)YSCUJEIXU#PI\0=:ENM*N[C3]7AM6MI["W:1(
M7BCV&)@.4'<$\8[]:T?A=;7EEX'M[2_L+FSGCN+@F.X7:2&F=P<9]&% %G3O
M%<]]XYUG0VTVXCM]/B@/G'9C+^82Q^;(4A5 [\'.*E/C?2TBM+J2.YCTR[F$
M,&HL@\AV)PO.=P!/ 8J%/'/(K#?3+]O'?BZW-G=I!K>G6\5O>HF8D*I(K%FS
MP06''4UDOINI:S\)K?P1/I=W;ZNB064C/ WDHL<B_OA+C81M7(P<YXQ0!Z)X
M@C\SPYJ2[Y$/V:0AHI&1@0I((92"*XGP9X[TZR\,>%;#48]0C:[M8($OY;=O
ML[S%!\GF'JQ/?IG//6N\U.WDN-&O+>(;Y)+=T0$]25('-><0:7>:W\-_#_A/
M^SKVWO;=K1;M[BV>-;<0LK.P<C:Y.W VDYW>F< '9ZMXPL-(BN[B6WNYK.R<
M)>7,$89+<\$[N0QP""=H;&>:V3=P_8OM:,982GF*T2ERRXR" ,D_A7F5O;-H
MFOZYIFL>"9]:CO[^6[LKV&SCFC=)3N\N1FX3:<C)XQ^OIMI$8+""$Q11&.)5
M\N$81,#&%'8#M[4 <A'\4_#TEM87GEZBFGWL@B6^>T801N6*A7?L21[X[XYK
M>@\1VUQJVJ:7';W)O--2.26/:OS*^2I4YP<[3Z5Y?H=O)XE^ ]CX:M;.Z:[N
M_P!T'>W811K]H+&0R8VX !/!SD8QFNKC%YHGQ+UB=M+O[J#4[&U2VF@BWIOC
MWAE=NB'Y@<G% %#Q'XCL]2D\"^(K&:]%E<Z@WR+OS(GER<&)2=S9''!-=#;>
M*M.\3V.M:?$E_8WUG"?/MKA&MYT!4E7&#G!QU!_G7$Z-IFK6?@CP!+<:/?H=
M(OB]Y%Y):5$*R#=Y8RQ&6' &?:NI^P37GBS6?% M;F*U_L@:? C0,);AMS.S
M>7C< ,JHR,GGM@D R]%U+3(_A9X.;7&OY/M$EJ(G@+Y,Q<;=[ CC/7)Y]Z[+
M4_$UIILMW$MO=7DEG!]HNDM54F&,Y(+;F R0I(49;CI7GYL-07X4>$-/.F7Y
MO+.]LVN(!:N7C$4@9R1CH!^?:M?[7J?A7Q]KES+HFIZEIFMB":WFL8/,:*1(
MPC)("1M!P""<#]< '<Z;J-KJ^F6VHV4HEM;F-98GP1N4C(X/2K58\>JW,%UI
M5C<:3<B2]21GD@0-#:;1D+(V>"<[01P2#6Q0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% &''X;1/&$GB3[=<&XDM1:& A/+\L,6'\.<Y)Y
MS6Y110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KSG4W:7X_Z'#=?\>\
M.C32V@/3SBY#D>^P#\*]&K$\0^%[+Q$+2662>UOK*3S;2]MF"RP,>#@D$$$<
M$$$&@#6G@AN(PDZ*Z*ZR -V96#*?P(!_"I:R+71[O=&=3U>:_$;!EC,21(6'
M1F"C)(//7&><9 Q/I^FS65YJ$\FHW5TMW,)$BF(*VXP!M3 X'>@#0HHHH **
M** "O/?%KIX8^(OAWQ0S"*SO5;2+]SP &^>)C_P('GTKT*LGQ)X>L?%.BR:5
MJ*%K:1XW..N58-^N,?0F@#S+2-7O?"GBK59;A?\ D:++^T["%AM NMVU8<?W
MBKQY]Q6_X[T_^S/!OAS3X) 6@U>PC61USN82#YB,C.3R>><UUNJ^'-/UC4]'
MO[J/,VE3M/!CIDH5P?;.UOJHIGB7PY'XEMK2"6\GMEMKJ.[4PA26>,Y7.X'C
M- '*RZ_J7A7Q+XDMKS4+C5;2TT0:O&MPJ*R.&=60%%4;3M'4<5'JFM:UHG@W
M1/%PU*2Z:5K9[ZU9%\J2.8J"(P!E2I<;3GMSFNG?PG;S^);G6KFZEG:YL/[/
MFMG1?*:')..F<Y8]^]5K'P/!:V%EI<VHW5UI-C,LMM:3!?EV'**S 995."![
M#).* .AU 2G3KCR)F@E\MBDJ@$J<=<$$?F*\[M/$VN'X<^%];G2_OH9EWZK+
M8HIG"%6PP4#[H;&=O.!]:]'NH6N+26%96B,B%=Z@$KGN,\5SNF>#FT;2M)L=
M/UB[C&F*Z1,Z(WF(V/ED&!D<9XP>!S0!<\(ZE!JWAZ*\MM7_ +5ADDD*7)4*
MVW>=JL !AE&%/ Z5R'C77-7TRU\37MGJTC3Z>L<EK#9HI2V4*"WGEA@LQ)^7
M).W! '6NXT/0[;0;2>&W9G:XN)+J>1@!OE<Y8X' '8#T'?K7/ZA\.K6__MZ+
M^U]1ALM;)DN;2,IL$I4+O!*[NPXS@X].* *^H7NLW?Q"TW2K?6)[2QO=)EN7
M2**,LCAD&4+*>?F_BW#KQZ7_  !J5_?Z3J4&HW37<VG:K<V"W#J \J1OA2V
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M)G5)HGBWQCJZ%P R^ZY%5+;Q]X6O)(T@UJW<R1RRJ<,%V1DASDC Q@_AR.*
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M[>_F:^6)=/Q]K$Z-$T((R"RN 0".1QSVJ&S\:>'M0O[.RM=3CDN+R/S;==C
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MF>*?$%G8:5J<":A-;WD-JTADMX3(8,@E2YVLJ X_BQQD^] '1T5@>"+NXO\
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M5<? S2;;49)K>W$-M%++;';+;2^:N'Z?*5?#'/IFNM_X1S4?^APUS_OBT_\
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M+]G\6VVS4D/_ "ZE#N /H?(+1\?Q#-;-_)&GQDTIS\L4>D3QE\?*CF1"%)Z
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MVGA6[\XXKSG3+Y+GQCX&OX_M\\9L[F&0BR>.&!V2/$2*% 55P1GG@<L<<3Z
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M?'+&<AA5JL?PM9V5CX?@ATW37TZS)9X;=\A@I8G)!Y4G.<'D9YYK8H ****
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M+X,F2"K<?(1@\-@\&K>D^*=*UE[^.VEEBEL"/M,=U \#Q@C*L5< A2 2#[4
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MD:R8@9A^[(RWS=.#GC&: /1:*Q-.\6:/J=A?7D5P\4=@YCNEN87A>%@ <,K
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MAMW5+F>.!WC@)Q@.P! ZC/ID9QFJ^I^//#^D7LUG=74QN(;<7+1Q6TDA,9.
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MYR>BYZ'T-7=%UNP\0Z7'J.FS&6W<LOS(4964X964@$$$$8- &A1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7&?%>.6?X:ZO;00RSSS(BQQ0QL[,?,4\  GH":[.B@#A;N99?B
MUHMVD<QMAI,Z--Y+[%9G0JI;& 2 >#7'R6^I?V'?WUI87DRV'C-M4EME@8//
M;!\[D4@;NS#'I[5[510!YE<WB^(?B+!<:;%?"WN/#]Q:I=M9RHB2/(I7)*C'
M0\GCMUJKX2ET^\L-'T+4_#&I?V[IC0J\=Q'*8(FBP//5R=@& 2,<G.!US7J]
M!SCCK0!Y9HFH6<5I\0[&>&2::?5KI4@2%F,^Z)%"+@<G/4=L@G JA!I]SX'O
M?#\NNV5_=Z;_ &'%8336(D<VLZ,S881G)4A\9_V17H?AOP[+H$^K2/?+<C4K
MU[UP(=FQV ! ^8\84>_O6_0!Y=K5O:16/A1M,T6YLK4^(XKTQ>0^\1['#2R+
M@E,DCKS@C.#D"#Q#IU_K&N^/[33HIQ->Z1;PV[F-E29T#[T#$8)P0.O>O6**
M /*=2UZ/6[?P.]OINII-9ZK";N V$V;;;$ZL#\O8GMGCFHK-K33;_6_#OB70
M-5O9KG4)Y[0PQ2R0WL4KEU&0=@(S@[L 8Y->MT4 <#8 6GQ8N)&MGAMX] AM
MPZQ.8E=)'8HKXP<*17*V4-S#\.?##O8WH_L_Q,+FYC%K(9(XO/E._9C<1AU/
M [U[110!'#*)H$E"N@=0P5UVL,^H['VKB/!ERL7B/QG++'/%'-J(FB>2!U$B
M")5+*2/F&5/2N[HH \3TR#4K#X>>"=0_L^]DBT;4Y)K^T$#>:B,TH#[",G:'
M!X'>NFMKM=7^*-[=V=O>-:7/AY8([A[25(R_FN<$LHQP>_I7HU% 'BEK=R-X
M#\#Z8NFZF;O2M7LQ?1_89<P^6S;OX?FXY^7/'7'%;^F:L?#6O^)=&UO2-0NH
M]4OWO;*2&S:=+I)%4>6<# *[<'=@8ZX%>F44 <'>>:/BAX8=K1XUBTRXCE\J
M-FBA=O+VIN P/NG'TKD;J\NM0TO1+B?2M3M[NR\20S75A;V$B06D8F8D@*N)
M"00Q;YB2QZ9Q7M5% '#>&G)^)WB^9H)XTN8[+R9)(657V1L' ;&#@D X-4]9
MT:]MO'KV5B@.E>)X@;\ X\IH=OF-CTDC.P^Y!KT6L+0O#T^EW$MUJ&L76K7;
M QQRW"HOE1EMVQ0H Y.,GOM'H* -T# P.E>.1W5QI?@/QEX7U*ROO[78W\D3
M):R2+=I+N99%=01WP<GC%>QT4 >81W)TOQ+X-U:[L[]+,Z(]DS"SE9HYOW9"
ML@4L"=IQQSBL>YMKZZ^&_C:)-,OUG;Q"]VL+6S;GC^TQL2O&&P%;[I/2O9Z*
M .!UV[%]X\\"WT-O=_9T>\:1VMI%\M7A*H7R/EW'IG%8.GFTT^XU?PSXD\/Z
MI>W,U_/-;>7%+)!?1R2&1>0=BD%N=V ,<GK7KE% 'E?B:REM-1U/4/#]Q=Z=
MKMO%%&U@86FM=541KM0*1@GDID'(QSC.:]1A:1H(VE0)*5!=0<A3CD9I]% '
MC/\ 9^JW/PYU72K33[PZCI^M27LEL\#()T6Y\P*K$8?*\C;GH/49ZN_V>*_%
M_A/4-+6;RM.>>XN9GA:/RE:/:(SN ^8DC*]0%.>V>[HH YOX@6EQ?_#[7[6T
MA>:XDLI D:#+,<= .Y]JYF_O5O\ 6/A]=0VMZ(8)I&E9[21?+!MR@+ KE1N.
M,G&?IS7I5% 'D&L6&I:C=?$(:;:7$LSW5A=6\91D%TL*QEU1L#/*$<=\5TOA
MK4-"UK4H=4L=#U&&YMH6$USJ$,J-;@CF,%\[B3U"Y& <GIGNJ* /%$CF'P:L
MK-K*\^TKK(D:W^RR;PGVPR;MNW.-ASFO:4=9(U=3E6&0?:G44 >;6NJMX6\7
M^)=/UK2[^YM=7N5NK.>WM'N$G#1JC1':#@C:!@\8]!UG_P!)T+XCVNKW]FT&
MEWNCI9J8D+I9RHY;RVVC"J0>#TR,5Z%10!XWK^DW:>#_ !G>1VMR8]8U>">S
MME@<NR))%NDV 9&[:QY'0 ]ZZN_E$GQ:T.Z2.9K==,N(VF$+;%9V0J"V, D
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M&VEED)"*I)P"3^0ZU+10!XQ:13Q?"3P3:/9W8N;75;5YH?LS[XE28LQ9<9
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M .<UTFI3S)\4+V]M;"6[ \,O%$IA;RYIA*7$6[&,D=O>O0Z* /'].NI+K7_
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M+EGWY.X'*KA1@\9.?:N;^'_C2SLO!6APZM<7TT]S<RVYO)(Y)$$C3R!%>4\
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M*AN0< C>HR!D5Z70 45SE]XVTK3U:>9;@V"70M)+Y$!ACEW;=I.=Q ;Y20"
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M9PMW<);1F.%G&]C@9(X'\^.,U!;>++:[MXVAT_4OM4K2*EE);^5,PC(#-AR
M%Y')('('7B@#?HKGK/QGI6H6$%S:>?++-=/9+:; LPG0%GC(8@ J%).3C Z\
MBF7OCC2M-LX+F_CO+99KT6(5[<DK*3CYB,@#OG/(Z9H Z2BN<TCQMI.KZG>Z
M;MN[&\M(O/>&_@,#&+_GH W\/OV[T^/QAIS:EI]G-#=VXU('[#/-&%CN"!G
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M+V,5YJ"SF&69(08HRV&8@ D] ,GO6Q7#_%9S'X1MY%1I"NJ69"+U;$R\#WH
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M5=)TFVJ6*-C;N'K@CUKE-$T'S_AYH.C>(M!U6$Q3W#_:+96\^TD\QF21=F6
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M9H21"9%0(&(R,G:?IWQ0!LZ;XLL]3BU=TM;N%M)D:*Y2<(K!E7<<?-C&,'/
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=;KTSQ63X.M-1L;6QT#4/ \4>H6.R%M5\J(V[QI@"0-G<7*CIC.>I'./3J*
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MQI/J'P@U36])M[FVF,<D$FYU62U=7\M\\\D'."/8UK&SU(_%1=9_LNX_L_\
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MW$C[PP2,9Z\4 ;MCXN-SJUKIEQIDUM<7MB;ZU#2*P=1C*-_=<;AQR/>H]/\
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M =R!L@G(/!(!')9KGCJUTEM2$$4%S_9@S=(UVD3D[0Y6-3]]@I!QP.< DY
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M,,@.S!5)]@6!JOX<\*:8OAVT?4K2'4+^XA26[N[J,222R,,DECSC)X'0#&*
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M:1=I-HD(GNF@9)5964LFSD,Q8 _PC!'- '645S5CXKEFUZ+1[S3'M[J>P-_
ML<P?<@(!1LA=K@L..GO5#2/B =4M/[1?0[JTTB+[3]JOII8]MN82005!RV=O
M49&>.>: .Q>6.+;YCJFY@J[CC)/0#WH66-Y7B61#(F-ZAAE<],CM7F?BR^GU
M34_ E_+HXMHYM9A>"=I TJH4<['&/E)X. 6'RG."*Z"UUVPB\1^+#!H,J7^G
MPV[W4JF/?=J48ICYL8"CC)!YZ4 =?17$V7Q#-U%X>NY=#NK?3M;=(8;IY4.V
M5U+*I0<X."-W'3IC!-W4/&:VQUU[.P>[AT-0UZPE"-G9O81@CYB%Y.2OH,T
M=315#1=3&M:/:ZDEO+;QW,8EC24J6V$94_*2.1@]>]<_=:_JH^)L&@1V<36!
MTQ[EB9<%\RHNXC'\/S#'?<: .L26.0N(W5]C;6VG.T^A]^:?7DGA[Q"?!^C^
M++J'1)KC3K3Q#=M<-"Z1K#'N4?*I^\1UP,#'>NYU7Q9;65Z;&U^RS78MUN66
MXNEMT",2%&X@Y9MK8&,<<D<9 .BHK'\+^([/Q9X>MM8L5D2*;(,<@&Y&4D,I
MQZ$5L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;(%3<06VY') R!GJ<5:FTS4A\48];6R9]/32&LC()$R9#*'^Z3G&!C/K[<T
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MHDD#7G[Z/&$A,9V_-SR<CVK1LM%U!O'7B2\N[!TTW5+2"VCE$J%OD5PQ(!R
M=_'7IVH C'C6'3/"UKKD.DE?#"%8DG68F6.'=L60Q[?N=/XMV"#CJ!-?^-+^
M+Q%>:)I?AR;4+JWM8[M"+J.-949BN03P.AQGD^@ZUC6_A;7C\.W\"75JI4#[
M*FJ+(GE&WWYW;<[PX7C;C&0/FQ6UI^C7]G\2+G4A8LNEMI<-C'+YJ$AHW9LE
M<YQAL>N1TH @E\=Z@W_"0+9^&Y)9-$?$ZR7:)N78'R" ><'@<^Y%2Q>/'DFT
M"X?1I8M)UMTBMKMYUWB1T+J&C X!P1G/X55M=%UB*X\<2-ISXU<[K0"6/YOW
M(C^;YN.1GZ>_%5)/#VM_\(OX%L!IK&?1;JUENQYT>-L491MIW<DYR.GOB@#6
MUCQS)H]O?W\VD.--L;U+.6664QRR%B@+QH5PZ@N.=PSAO2E_MW6F^*,FB+;6
MQL(=-6Y'[\AF#2[2Q&W&1L("YQSG/.!S/B'PMXJU?2_$UG+IEM=W5S>"6QOI
M;H#%N)$9844CY" I!Z DDY)KI?[+UN/XCPZZMC ]K<Z4EG/BXY@=96<]LL,-
M@8[CG H ATOQ;I5EHOB/56TC^SELM5DMYXHMI>YG^0;N, LS,HZ_4UI-XIGL
M?$%AI&KZ<MM)J*.;.6"X\U'=!EHV)5=K8Y'4'UKEI/!&L:IX:\4Z?)&+&[O=
M9;5+"1Y%9<@H4#[2<?<(/IGO6[<:9J7B36- OM1TQM/329'N9(VF1S+,4VJJ
M%2?E&2<M@\#CDX ,^7XEW,>AW^M?\(Y-]ATZ]DM;UFND#($<(648^8@G)' ]
M"><:7C'4/^$=OM%UV$X26^BL+T#I)#+D GW1]I!]"P[FN=G\*Z_/\.?%6B#3
M=M[JFH7%Q;@SQ[=DLF\;CNX( Y_#&:V?'-G-KMGX>T5862>ZU&&>:,D$QPQ?
M/(Q()'&%7ZL/6@#N*YBX\63R1ZO/I.F"_M])E:&X;[1Y;O(BAG6-=IW%0<<E
M<G(]ZZ>N&TG2-;\+W?B&TM=/_M"RU*[EOK283(OE22CYDE#$':&&05#'!Z9H
M FN/B#&\WA]-)TJ;48]=AEEM9!*L8RB;BIST[ D].>N,5U.FW%U=Z;;SWMD;
M*ZD0-+;&02&)NZ[AP?J*X.R\&ZAH-]X%M[.W-U::%%<)=3B15W-*F,JI.3\V
M3]/6O1J ./&NZR_Q2ET06]M_9\.FK<@^>0Q#R[2Y&WJ-A 7WSGG ;<>//*\/
MOXEBTPS^'TD*M<I-^]\L/L,HCVX*9!/WLXYQVJ2YT?5$^)?]L0VL4^G76E+8
MS.9MC1%96<G&,G*MQCOUQUK#L?"VO67P^O/ C6BR1,LMM;:GYJ>7Y#L3N=<[
MPZAB,!2"0.>] 'H\4L<\*31.'CD4,K \$'D&N;UWQ7<Z2^K&#26F@TNT6ZGF
MGF,*R ACMB.TAV 4YY') [UT%E:1V%A;6<.?*MXEB3/7"@ ?RKA?$.A>(M2U
MKQ#&;"WO[*\L/)TV6:X"K9L8V5_DP3N9CG<!TP,@4 :EWXW,=]X=MK/2+BZ&
MNV[SV[^:B8VQA\$'V(R>W.,]*K?\)Y>#PYKFH'0'-]HD[17EDER&^4*&WH^W
MYAM(."!T/XT;'0M>2^\!37&F*BZ+:2PW>RX1MI:%8QC)&>5R?0=,UK^%M)O[
M/7/%$]_9>7;:E>">$LZ-N3RU0A@"<'Y?R- &D-?:8Z&+6WBN!JB^;N2<XCB"
M!BX^7YARH[<LOKQDW'CLQZ!+XD@TPW&@0RLKW"3_ +TQJY1I5CVX*@@G[P)
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M&1@2&!_$'GO6Q533?MWV&-M1\H7;99TB.4CR>%!P,X&!G SC.!TJW0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !69K6@:=XAMH[;4HI)88Y%E54F>/YU.5/RD9P1D5IUPWQ3UF\TS
MP[8V5A.]O<:OJ,.G?:(SAHE<G<RGL<#&?>@#KH]0L!<BQ2^@:Y48\DS R<>H
MSFK2LKJ&5@RL,@@Y!%9/_"+Z)_8G]C?V;;_8-FSRM@_//7=WW=<\YS5"'47T
MR[LO"FF11WE[::>DDLD\IC1(QA%)(5CN8@\8Z G/3(!TU%<)=?$C[/X8O=4&
MD.UWIU\MA?69G \J0NJ AL?,IW @X&1Z5;?Q;K$7BAM D\/QBYGM6NK)A? H
MRJP5A*=GR$9!^7?UXS0!V%%<%+\1IK?PC=ZS-HA^TV.HG3KNV2X!"2"14RK;
M<L/F4]!5ZT\97R>+X= UK0VT]KV&2:PF2Y$PF"<LC  ;7 YP"1[^H!U]%<;:
M^.+EM3T&VO\ 2!9KK1D$,;SG[1#M4L/,C*C&0.Q.#QSUJI<>/]5%IXBN+;PV
MDBZ%.Z7'F7P7>BH')7"'+8/3I[]J .]HKE9?&+QZWX>MAIZ_V=KD>Z"]>XV[
M7V;PA3:?F(Z?-S@UKZ=J<U_J.I0?9D2VLYA"DXE+&5MH9OEVC&-P'4\@CM0!
MIT5AW>ORGQ VAZ9;17%]';"ZF,TQCCB0L54$A6)8D'C' &?0'DM>\>ZA<>#;
MB[TNUCM=0MM3CTV_AFF.Z!S(JD(0OS AAAN.#G&1B@#T(WEJ+T69N81=,AD$
M&\;RH(!;;UQR.?>IZ\XU![ZW^+FG3P:;;R:E+H4X:-9]L>1,F"TA7. .^TGV
MK5LO'\,OAQ=0O+5+2]_M!],:V>X&P7"L01YF/NX4MG'0'@GJ =E17"GXAR1Q
M:^KZ9%//I-K]L5K6ZWP7$0!)Q(5&&&,%<'M6YX;UK5-;B%S=Z,+&REMX9[:;
M[2)&DWKD@J "N./J#V.0 #>J"VO+6]1WM;F&=$<HS1.&"L.H..X]*Y276-:?
MXJ?V&(+1M-72OM!4SL"P:4*6(V$%AM("],$_-S@<IH'B.[\(^&?$-_!HR7&F
M6FOW?VE_M C9$,P7]VFT[L9S@E?;/8 ]=HKFM<\37NF37PMM+62"RLA=R7-U
M,88I"2V(T;:P+?+STQD>M49O'<A_X19K+1Y+B/Q#$7B)G5#$?*,@4C'/;)SZ
M]>A .SHKGO#/B.XUJZU:PO[!++4-+N%AFCCG\Y&#('5E;:IY!Z8J?4->:'7K
M?0K&!+C49K=[IA)(8TBB4A=S$ G)8@  =CTQ0!M45P=_\1VL/#>O7SZ03J.A
MS"*]LOM  &[&UU?;RK @CY0>O%:MMXHO1XP@T+4=(%HEY;27%G,MR)&8(0&5
MU"@*V&!X+#WH Z>BLS6]3N-,MK=K33Y;Z>XN8[=43(5-QY=V .U ,DG![51\
M-^)O[=OM8L)((HKG2[A89&@F\V-PRA@5; ]<$8X(H Z&BN:UWQ1=Z3XFTC1;
M?23=OJ:3&*3[0$"M&H8@@@\<CGZX!/!I6?CU/['U6YU6Q6RO--OQI\L"7 ='
ME8J$*N0ORG>O) QSGI0!V5%<9;^/X(M5O[/4H;=(;6Q:_%Y97!N(3&OWU)VK
MM<=<=Q^5%MX\\S7-*L9;2V:#4PPCEM+OSVMW R%E4* N>F02,\>] '6W=Y:V
M%L]S>7,-O @RTLSA%7ZD\"IJ\H^(NN3>(_A3K6H6>FP2Z224AN))OWC!9 IE
M5-N,;@<?,"1S[5ZJK *H)&<#O0 ZBN'TOQ-JG_"7>+4U5;2+2](6++K.Q\J/
MRFDW;=GS$YYY&, #..9Y_&\]CIVE:S?Z4L&C:C)&@F6XW2VXD_U;2)M  .1G
M#';GO0!V-06UY:WBR-:W,,XC<QN8G#;6'53CH>1Q[U*2IRI(.>"#7FG@S4SI
MB^([#3+.*ZOI?$EYY5H)/*"Q[D#.Q"G:J_3DX Y.* /3:*Y2^\5:G;^+(O#M
MOHD<]S+8->)*;S;'E752"=N0/FZX)Z<<\067CY+CP_#=SZ>8M2EU)M*%D)MP
M-R'*D;\?= !8MCH#P3U .RHKF$\47D?B&;P_=Z;#'J;6AN[+9<DPW*@X9=Q0
M%6!QD8/'-9)^(\@\*Z-KQTJ!(;^]6RGCDO2IM'+E/F_=\X*G/3'N.: .]J![
MRUCNX[1[F%;F4%HX6<!W ZD+U.*JV^HSW&NWEBMM']FM8XRUP)229&R=FW;Q
MA<$G/1E_#CO%K36GQ0\*7%A8+=7CVE^H3>(]^%CQN<] ,GL3Z T >A45Q5CX
M\N[C3]92?P_<)KFDS10S:=#)YN[S2/+=7"_<(.2<< 'BIXO&XBO/$5I?VD8E
MT2T%Y(;2?SA(A5B0,JI##81@^U '75#:7EM?VR7-G<0W$#YVRPN'5L'!P1P>
M016+I&O7NJQQSQ65I-:3VIGAN+2\\U&;(_=DE!@\]?8\<5A:1XVT^#P3H.HP
M:9::5#J=V]K#;M*(X(&W2'+,%P,^6>@Y9@/>@#O:*HZ7=7EW#*;ZS6UECE*!
M4E,BNN 0P; R#GTJ]0 4444 %%%% !1110 $9!'K67I'A_3M#>\?3XY8S>3-
M<3[YWDWR'&6^8G!.!T]*U** "BBB@"GJNE66MZ7<:;J,/G6EPNR6/<5W#KU!
M!'X4NF:99:/I\5AI]NEO:Q#"1K^9))Y))Y)/)JW10 4444 %%%% !1110 44
M44 %%%% !1110 5"EK"EU)<K&//D 5G/)P.@'H/8<9)-344 %%%% !1110 4
M444 %%%% !6=K>A:;XCTUM/U6W^T6K.KE-[)\RG(.5(/7WK1HH AM+2WL;2*
MTM84AMX5"1QH,!0.@%3444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI(0(3* D$<055#-W. Q.,\L!R!FMR]TS5+SQ]H.LK9;+2SM9X9]TJ[@TFW&
M#R!MY^O%=;10!S/C;3M8U+3[%=)6.=8KV.6[LY)?*%U ,YC+8/&2IP>#C!]#
M4\*Z)K&E^*_$5[>6EE!9:B;>2(6\Q;84B";,;1P,=>/IZ=C10!RNN:3J-YX[
M\-:K;VRO9Z:MR)V,@#'S4"C:.^,<]/;-<]<>"];U"U\4*OEV-W>:I%J>FS-(
M'"O&$VAP.F2G;/7VKTNB@#C5L?$WBK0=0TWQ'9V>E17%I);$6L_GF1V&/,Z#
M:HZA<DG/)&.3PTOC416VF:[::?#!:J$DOX+@NUV%&!MC*_)GC))]< 9R.RHH
M \E?P?XLMOAOJ7@6&SL[F!=R66H&ZV;HC)O 9-N0PR?;\N>VN?!.@:Q>1:IK
M&AV4NJ;4WR9+X*],-QG'T%=)10!PTGA/4;GQ%XOBGC@_LCQ#;QH;A93YD6(3
M$1LQR<X.<XQ5;_A&=<U;P;IOA+5[:&.*UD@2XO8Y@RS0PL"NQ?O!FV*#D #)
M.3TKT*B@# _X0GPTNMG7%T6V.I^89OM 'SE_7KUKA[?P1X@L+R_U_3K:&#7O
M[8FNH,SCR[BTE8%H92.F,$C@X.,=3CU>B@#CSIVK3?$2RU]]/V6D>ER6<B^<
MA<2-(K\#."ORXSP>>E<\G@?7'TF258X(-4M/$4FM6:O+F.568GRV(Y4D$C..
MN/>O4:* .7@T>[U3QC9^(K^U^QK8VDEO! TBN[/(1O8E<@ !0!SDY).*R)?A
MV;R[\3VMU,AT?4=\UG"!DPW$J 2R?4,H*_[[>M=_10!B^%--O=+\.VT6J2B;
M5)%$EY*.=\I SSWP %'LHK/\1:3J4GB[P_KUC;I=1Z<ES%-!YH20B4( RY^4
MXV\@D=:ZJB@#SW5?"FOSVFOZI8O%%JVK7%LSVHF**;:' \DR <,PW9(X^;'3
MDK9Z#XDLO$FKZI::9I=K'=Z2D%O L^5BE3?M0@( 02PR> !GK7H-% '"Z!X5
MDT?Q5/K.G:6VDVDUFRW6G1S*8Y[C<"KHH.U0 &&?E)ST'-5M#\-:KI_P_P!+
M\/ZGHMIJ$<<TJWULTJ,KQ,TCAD+<;@67KCH>>AKT.B@#B/#VB:YX4\/3VNF6
MZ3H^H[[6RN[HG[):L5!3?SDC#'&2.>I[]O110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MGMBO;=[N=LO,(XN-Q'7!SSW]Z+W4KW0]>^)=Y8O-+-::;:SP))(T@C;RY22
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M-XL1=GSL8SC=MV[O;IG^+O6KI=X=1TBROFC\HW,"3%#_  [E!Q^&: +=%%%
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M'[-?R&6XB6>0*[$[CP&^4$\D# )[5T=% &5J/AO2]6TZ"POH99K:!U>-3<R
MAE.5)8-DD'U)JIK/@GP_X@O+>\U*P,MU;IY:3I-)&^S^ZS*P+#V.>I]:Z"B@
M#(O_  OHNII8)=6"%=/.;41LT?E#;MP-I'RD<%>A':GV_AW2[75;W4XK=A=W
MJJEP[3.PD4# !4DK@ D#CC-:E-D+B-C&JLX!VAC@$]LG!Q^5 &-I_A+1=,>
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MO'')+&A94D<H&P.A(!Q^5 &)-X$\-7'AU-!FTQ9-.1@Z1O*[,C 8!#EMP('
MP>!QTJ>+P=H$/AZ;0AIL;Z=/S-%*S.9#Q\S,Q+$\#!SD8&.E<M%\2M13P+:^
M,KO0(5TB7!F%O?%YH4+[-VTQJ&Y[!N]>A0S1W$$<\3;HY%#JWJ",@T 85CX)
MT'3[^TOH;69[NTC,<$T]U+*R*<?+EV/'' [=JMZWX<TOQ'#%#JMN\\44@E1!
M/)& XZ-\K#D56\9ZY=>&_"6HZQ9VT-Q+:1&3RY7*J1^ .?IQ]:V;:4S6L4K
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M.CZ-8:!ID.FZ9;B"TA&$C#%L?B235ZBB@ HHHH **** "BBB@ HHHH ****
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M\U_>PW,\:SY#D2H[NWF/C)"GGJ>*ZVQT73[9VN4MI#/+$(F:YE:9PG79EF;
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M"T?E+@ J-I'RX &WIQTIB>#O#L=A>V*Z1;"VOI3-<1[<AW)SGVP>1C&,<8H
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M4FX-'C.-N.W_ ->O59?#&C3:G=:D]B@O;J,133*[*SJ!M'0]<<9ZXXSBH?\
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M8GGWH \Z\/:9_P )'X8\/>)QKUI;7L4L4UQ>16C>?)*3B2"1O,^8,QV[<>F
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MVLAGD)B4\$#YNA  /KBL/Q)X2C30+^#1-)ANWO[B.6_MI[AA]J0,"^&8D!R
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M8=0AGTX2QZBP>[625V\UAC#'+<$8&".1B@#CK"T">,?%NE3V5I!9RZ1!,]A
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M;V9-LORDGM\J_D*Z)K-/%?BCQ3H-Q/8Q_8UAAM(9[8R-#"T*D218==IW%OF
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC;"F!M3H,+V'&*FH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQCYC&#NV_3/-7:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK$8 #<DC)([9-<O_ ,(SXA_X5&V@?V--_:1U#S_+\^'&S[7YV=V_'W>/K^=
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#F;
M?P%H=G*QM/[0M[=F+FSAU"=+<DG)_=A]N#Z=/:NDCC2*-(XT5(T 5548"@=
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MPV=5VX'7KFKM !1110 4444 %%%0FZ@6\2S,J_:'C:41]]@(!/YL* )J***
M"BJ6GW-]<O>"]T_[(L5PT<!\X2>?& ,2<?=SD_*>1BK4K.D3LD9D< E4! W'
MTR: 'T5B>$?$(\5>&+36A:FU%P9!Y)?>5VR,G7 _NY_&MN@ HHHH **** "B
MBB@ HHK!T_Q&U]XNU;06L6A-A##,)C(#YHDW8P!T^[ZT ;U%8/B?Q&WAR+39
M/L+7*WE_#9%A($$9D8*&/4GKT'Z5HFYOO[;%K_9_^@?9_,-[YPXEW8\O9UZ<
M[NG:@"[114<[R1V\CPQ>;*J$I'NV[SC@9[9]: )**K:=/=7.FVT][:?8[J2,
M-+;^8)/*8CE=PX./459H **YC2_%-WK$NGW5CH[3:+?/(B7J7 WQ[2P#/&5&
M%;:<$,3R,@9Q73T %%%% !1110 45GW.HNVE7=UI4"ZA<0>8B0+*(_,D0D%-
MQX'((S5V%I'@C>6/RI&4%X]V[:<<C/?% #Z*** "BH;N[@L;26ZNI5B@B4N[
MMT %34 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=1GE*-?HZR-DQ9("<#;G!&!@ 5<$B^+/#?CJ^OY9_/L[B\LX(TF9/LR1)A<
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M8G_EM,H/E@?[*DEB?4*!GG!IGAV.P\5ZMK47F1B^5%D1IF<2,O\ 'M/"X&
M/4^PK6TZ2\ETVVDU""."\:,&:*)]ZH^.0&[BK- &#?>#=$U'6)M4N+>4W%Q"
M(+@)<2(DZ#.!(BD!L9/45#;^!="M%TD0Q7*_V3G[&?M<A\O(VG^+GY>.<X'
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M%U>T(G?S+=E^Z4?.X8^OMTJ<^&-->QO[619Y/[03R[N9YF\V5<;=I?.0,$C
MP!D^IJKHNL:UJ5Q93S:5 FE7MF+F.XCN,O"Q (C=2!DD'JO'!'O714 8#>#=
M':'28BESLT@@V0^U2?NB!M'?G XYSQ3XO">EQ2(<7$D,=T;Q+>6=GC68L6W@
M$_WB2!T!Y S6Y5+4)=1BDLQ86L,Z/.%N3)+L,<6#EEX.XYQQ[T 5]=\.Z=XB
M@MX]0CE)MIA/!+#,T4D3CC*LI!'!-9Q\ >'2FJ(+6<+JBA+P"ZE_>@ #GYNI
M &3U/<FNFHH Q[[POI&I^'!H%];&YT\(J!)9&9@%^Z0^=V1ZYS2Z!X:TWPW!
M)%8+.S28WRW$[S2,!T&YB3@9.!T&3ZU:U&748OLG]GVL-QON$6X\V79Y<)SN
M=>#N8<<<9JQ<O+';2/!&DDJJ2B.^P,?0G!Q^1H S1X;T]=>GUM?M"W\\(MY)
M!</@QC) "YP,$DC JG'X&T"+0(]$6UE^Q0S?:(0;B0O#+N+;T<G<IW$G@]SZ
MU8\'Z\_B?PGI^M26ZV[7<9<Q*VX)\Q&,]^E;= &;::%8VAN7VR3S72".>:X<
MR/(@! 4D]%&3P,#DGJ32:%H&G^'-.6PTU)4MTX599GE*CLH+$D*.P' K3JLU
M_;+J2:>95^U/"TXC[[%*J3[<L/U]* ,R'PEI5NVJM&MRIU4DWA^TR'S#C&1S
M\O''&.*A'@G15M=)MECN1%I+![)1=2?NB!@?Q<X!(YSQ7144 8\7AG3H-5U#
M4XOM*7FH(J7$@N7^95!"X&<#&3C&.M4E\!Z"FC:?I*PW*V6GSBXM8Q=R?NY
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M=QY.<Y)Z5Z!10!EV6B6=O<27P:XENYH1$;B>1C(L?4*,_=&3G@ D]<D5F_\
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MC.0@STV@A>/2H;R[N/!^L^.DT=IVCM]&BOX8997E"3'S 7&XD]@3ZXKT35]
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M-AT[3XFBM(%VQ1M(S[1Z L2<5=H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKA_BNA/@KS4EFCD
M2]M0K1R%?O3HIR <'@GKF@#N**\VF\/V$7Q8CTZ-9ULK_1I)KN#[0^VX=)5
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M(OB7XZE2UA62)K1HV"@%2\!+$?4DYKD-'L(;+X=?#_6X&E74?[3M8?.\UO\
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M_9P5E#GS3-N.05QC;MQSG.:NUPJ0(WQGO[=R\D$WA]'>*1RZ$F=E. 3@9 '
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M]"L%LM-MEM[<$MM!)+$]22<EC[DDTR]T+3M0U.SU*Z@9[NRW&WD$KKY>X8;
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MI&:]"F\.:3<Z3'I<]FLMG$5:*-V8^45^Z4).5([8(Q2CP_I8L+FR-L6ANO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5EZ_HW]MV$<*S_9YX+B*Z@EV[@LD;AERN1D'&
M",C@]16I10!CR:7J%PMS--J$4=X]J]O;R00E1!NZO@L2QR%/4?=_&J8\)PW>
MMSZIJ@M9Y)K3[)(D$!C65=X;+_,22"HQZ#/7/'244 <XWAB2WUVPU#3+FVM8
M;.SEM8[=[=G&)'1B<AQW0<>YJN?!$+!KMKQVUAK]=0^W&,?ZU5V!=F?]7LRF
MW.<'KGFNKHH YR^\)PZ[<RSZY(ER&LY;*.*)"BQI)CS#R22QVKSV ^IJ[I=A
MJMG;P6MWJ<5S%  HD6W*2R =-QW$9]2 ,^U:U% '-)X8N)]2T:^U*\@N)]*+
M&.>.W*2RY1DPS;C\OS9('4@'C&#8U/P_+?60M8;M(4748KY-T1?&R592OWAU
M=2<]@WM6[10!E:EI,M_JVCWJ7*1KI\[S%#&6,FZ-H\9R,<.3T/2LZ[\#Z5<:
MUI^IQHT,MK>/=NH=R)697']["_,^[@<XQWKIJ* ,1='O9K^'4+V[M)+VUBFC
MMGBMF15\S'+ N2WW1P"._MBO<^&)-1BOY;Z[C^W7EHEJTMO"40*K,P^4L202
MQR">G'')/1T4 <S-X:OD749=.O[6SN=1F22X/V1FC8*NTX42*0S<9;.< ?6I
M3X?O)ULGO;RTGFMEEC:,6>VW>-U"[1'O." ,9+'@L.AXZ&B@#DAX&C@L#:6E
M\T23:8NEW#-'N+1+NVE>?E8!W SGJ/3G9:RU."(PZ?>6<,*&-;>.2U9PD:KA
ME)#C)/8\8]#6I10!3TW3TTZWD16#22RO/*X7:&=SDD#L/\.IZU<HHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
D@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>elicio-insidertradingcom005.jpg
<TEXT>
begin 644 elicio-insidertradingcom005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ&4_Q ,#R/ZUSOA.72+G1],\,:UH^K2>(-->.,V4S7!A#QG G#9\L)CYL_@
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MB?P_H?\ IJ6]]+,UTUM!-O9$B+*J,@R?FVD[#D <X!JY9ZG8>%[*:QOM8O\
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M0"Y>(V\N]8R< E=N?J.HP<XP:SOB4'33M!N_*E>&SUVSN)VCC+E(U8Y8@ G
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4CMG!YK7HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS@QR& $?';"CT!R,X8MK\_L^7F@'2=3&IP1M;F V<FYW,Q;"C'S#'.X<<]:
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M2[BR2]N;)IEVBXM7"R1^ZG!Q3-'TF'1K$6T<T\[LQ>6XN'WR3.>K,>YP /0
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M+=(;B-DDB\OY-K*W((Q6O0 4444 %%%% !1110 4444 %%%% !1110 4444
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M%K;QF21V'W0/;N?:LI?%<$>KV6FW^GWEA-?JQM&N FV5E&2F58[7QS@XSVH
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MDM(;P'[4D.W+MSAL(^-N<-@'':O3** //=%;6_".CZW(D&JZUID$L7]EP7+
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MRW"%0MN N06R<G)X&*\ZUK6]5:V\8*VH75GKME<A='MH6_UD>U3&5CZ2[VW
MY#8]L5KW]QK&G^*O MI-JEVZW9N%O87\O$C+ SC.Q1G!]..!QGF@#NZ*\JF?
M6KNU\?NWB34HSH\SO9^444J5@$@#87E<]AC/.<]M6?Q!?3OX*DOYVM=*U.S,
MM[<1N8@9S$K(A<8* Y<\$9( ]B >@52N+V>'5;*T33YYH;A9#)=*5V0;0" P
M)S\V<# [5SG@%]6N+;59]1O[NZMAJ$T.GF<)A[93\C@A0S9Y&XDY !'6C6[V
M_MOB7X6M(KZ=;*\AO#-;#;L)C12IZ9/WCU)'2@#L*0G ) )]AWKR.>YUV;PM
MXZU$^)=26?1=1N?LA0HO$<:, V%P5[;>!R3SV]3TVX>\TNSN9  \T"2,!TR5
M!H RM#\5V^O:IJ=A!87L$FFS>3</.(PH?&<#:Y)XYZ=ZWZ\U\+^;_:_Q(,$[
MV\HO\I+&%+*1"#D;@1^8K.T_4=;@\.> M?DUV^GN-1O+:UNH)&7R7CE5L_+C
M.[(!W$YSGM@  ];JE#>SR:O<V;:?/'!#&CI=L5V2ELY4#.<C'<=ZX/4-?N--
M\526FORZEIR3:C%_9VHQ.6LY(@R_N' .%8X8$L,\YR !5F;Q#?:-XM\:RSW4
M]W9Z;I,5[!;/@*AQ(Q48 Z[1R<GWH Z;Q%XCC\.C33+9SSK?7L5DKQE=L;2-
M@%LG..O0'IVK:KR;7[>XNO"_@C6;G4KF>ZN]7TZ><&0^4YD8-A4Z*%S@8P<#
MG-:TUQKWBN3Q)'I5U]EN=/O'L[-Q>-$(71%(9T"$.&8G.[(QP #DD ]#JGJF
MH+I>G2WCP3SB/ $4"AI')(4!02 221WK@IU\0:GXXM-%N?$5S:+<>'C<7']G
ME=BSB1%+1DKG&>YR<9'&:]%AB,=O'$\C2E% +OC+$=SCC/>@#F#XX(U\:&?#
M>L_VD;7[8(-UK_JMVW=N\['WN,9S6]I.HKJVG1WBV]Q;;F=3#<*%D1E8J00"
M1U4]#7'/_P E^B_[%D_^E-2>*VU)_'GAG2[36;RRL]1AO1.D 08*(I#*2OWO
MF/)S[ 'F@#NJ*\UUY[_3K76K:/7=1O[C3=(5X!;OL>V=4<F:=@0K%B%PIR<
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MUU0V[ZM"(YM_S;\#8K;<;<;AUSCBM"_\.0:AXBTW6Y+NZ2XTY9%@CC*>7B0
M/D%23D =^W%;-% '+#P+9#2M<TXZCJ!@UJ:2:[RT>=S@*VT[. 0 /PXKH+&S
M%AIT%DDTLBPQB-9)-NX@# S@ 9_"K-% '-6'@RVTV?69H=3U$OJ[%[DN8C\Q
M&,K\G'''I4/_  @5B-%T;25U'41;:/<1W%J0T>X,F=FX[.0,G^N:ZNB@#G;C
MP?;7<<]M=:A?3V$]T+J2SD,9CWAP^ =FX+N . ?YG,J>%+(:]J6K2SW$SZC
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MPZ1)IUVT"&46DKR"4,0N3MSA-PX&!GBO6:* /)M=T"_U'2?B/JEE:7#1ZO#
MEI!Y95YO)C 9PA&>22!QD[<]Q6MJ5VVH^+_ =]!8ZB+:$W1E=[*5?+#0;%+
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MD5V+)M# 9R",5ZM10!Y>NI-JGB;X?W=MINJ?9K1+B.XDDL9$$3- $P01G ;
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M;I+'6[:YG2VB,CK& X+!1R<;ATJ"T><_%B[U)]/OXK1]$BA$C6K[?,$CN4R
M02 PZ$^@H WK3Q7I=_H=CJUI))-#?MLMHU0^9(_.4"GN-K9SP-I).!FLV_\
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MYP.O!R*Y#3="O-'^&OC/3[:UU$Z=>?:8]&LI(9'F5'B*@;<%E4MG ;!'4]:
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M)=TLMO(B#U)4@5Y@5OI?A_X%L_[&U9+C3=1T\W,;64FY%A_UC8 SM'KW[9H
M[_3/%NFZG=:C;8N;2?3U62=+V$PD1L"1(-W\/!Y[8YQ20^+M.DU6QT^6*ZMI
M-01GLI)XMJ7 49(4YR#CG# 'VKD-<TB^UOQ=XLMK:VNHDU#P^MG!<R6[I$TH
M,A*[R,?Q#\ZL^%;FVU273H;CP+/8:M9X-Q<75BJ10,!AFCD_B)[;?7)X% 'H
ME8.J^+=.TD7KR)<SQ:>H>]DMX]RVP(S\W(R<<X7) P2.16]7G&GWVH>$_$_B
M+3K[0=3U"UU2]:]L[BSM_-1]Z*K1N>B8V@?-@8]J .@EU71+KQ?HRK/>/?RV
M<LUH(]ZP21$*23T5CC&.N,]JM:=XLT_4[+5+N".Y5-,E>&Z66,(RN@RPP3V!
M!STYXS6'?QWC?$KPK<26$^R"QN8[B2&!VAB=Q'A=X&,94_UQ4=_H&H1?$*46
M<);1=>@1]28=(Y("/P_>(0A'?!/:@#5FU72+GQ;H*3?VC#J4UO-):PLKI&4*
M@MO'W20,<<D9[52\%-*/%'C2![B>6.'48UC$TK2; 85. 6)P,D\4NO1SO\4/
M"EQ':7<EO;P7BS3I;NT<9D5 F6 P,[3].]'@Z.>/Q;XQDFM+N&.YOHY8))K=
MT611$JDJ2 #R#0!V9(52S$  9)/:N=L?&VE7]SIL<2W*Q:IO%A<O'B.X* DX
MYR. 2-P&<<5O732I:3/;QB2948QH3@,V.!GW->16IU2\N/!6I3Z'KAN[6\<7
MZ&T:..!C$ZA8X^%" D .!C&,MF@#M+CXCZ'!%J4HBU*5=-E,5YY=E(?)P 2S
M @84 ]3UP<9Q6S=:_90&RCA\R[GOD,EM#;@%I$ !+\D * 1R2!R!U(K@T@NS
MHWQ+B_L[4-]_).;139RYG#6X0;?EYRPQ^O2F6']H:!XC\-Z[<:9J,VFR>'X]
M+G$-I(\MI,K!LM&!NP<8R >1]* -GX:7;WA\5,9+MD37)4C6[=FDC41Q_(=Q
M)&#GBNXEEC@B>65U2-%+.[' 4#DDGTKC/A^MTE_XK>XT^\M4N=8DN86N(3&'
M0H@!&?=36]XKTN?6_".KZ7:N$N+NSEAC).!N92!GVH K0^,M,EU"PM'2ZA_M
M)'DL998<+<A1N.W&2#CD!@"1TS5>P\?Z/J=VL%G!J<N9IH'D6QD*QO&"65N,
MJ>#@$9]N15/PKXCO=2L]/L;KPUJ5E?6<82[DNK8K%$57#&-OX]V,#;G@Y/NG
MP[$UII>N"ZL[RW+:O=W*K-:R(7C=RRLH(RV1V'- "Z3XL\-:-X-TR^MY]0?3
M+NZ:WMY+A))'+M,RG>S9VC=G&XCC\JO+X[TMM0NM.^R:F+^",2K:M9.)9XR2
M Z+W7(().,=\5P-M9:A'\)_#]@VE:F+R#6TFE@^Q2[TC%VTA8C;TVD'].M=?
M^]_X7!]O^QWOV/\ L+[/]H^RR;/,\[?MSMQG;S^G6@!VM>*?#FJ^ 7U6[FU!
M-+ED6-S;I)'-&ZR ;6V\H=XP<D#WYK5U#QAIFG:Y_8LB7LNH&V-RD4-J[[U!
M PIQACD]N!@Y(Q7G-S8ZA)\(?$.GII6I&\GU>26*#[%+O=&NED# ;>FT$_\
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M82("H^78S<_,..O-9/AW7O#]EX'L]0T[[6NFRSO%;13EGGED:5EV@,222^<
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MBY2WGA$;7$1) 9-Q]1CYMN#UH Z&BN:\#>)+CQ7X9@U6>RDMO/+LFXJ5*[V
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M-:=%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+(W1549)_(5SW_"<6:W>DV\NFZE&VKH7LB8T82  ,<X8E2%(;![?0@2:U?\
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M .UTR_74[".[6":#>6!BG #H58J00"1G(/>K=8/@V/68?"UI'KTK2WZEP9'
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KDOB9IU]J_P_U33=-M)+J\N51(XD(&<.I.22 !@&NMHH X;6%UN^\4
M"*;1[J\T2;3P((ED1(TN"3N\\%AD8VX^\!V!-9EAX8U:[^"MKHT]E)9:UI\*
MR6JNREA/$V]&!4D#)&/H:],HH \WF\'ZO)X@TK5 $635(7@\0*#E=F1*JCU
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4$8^9V);ITYX[8IC^#-$DATV-X;EAIT@EMF-Y-N5P,;B=V6../FSQQTK?HH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !12(ZR('1@RL,A@<@BEH **** "BBB@ HHHH **** "BBB@ HHIK.J
M%V"@D 9.,D]!0 ZBBB@ HHHH **** "BFNZ1H7D954=2QP!3J "BBB@ HHHH
M ***:[K&I9V"J.I)P* '444UG1"H9E4L<*"<9/H* '4444 %%-#H9#&&4N "
M5SR >AQ^!I#-$LRPF1!*PRJ%ADCV% #Z*8)HFF:$2(95&2@89 ]<4^@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 5'-;PW*!)XUD0$-M89&1TXJ2B@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"M%ER/LY;ALX'W?3\:NR>+ISXNN-$N-1&EWZ7L:VEK<P 17EME-S)(1RY!?
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M\;9 9,C</;([5GV?A#4;77=8U9M=66;5+6*&5#9@*KH& 88;.W#GY<YZ98T
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M<R#$@C?<  >2,J<$]ZLW_@]YM1\.3:?>PV=MH61!;M;&3<#'Y>"V\8 7VZT
M16^JZO+X_P!3\/R7<(MX]+CN8)(X,.KL[*2<DAC\N>P]JY;PSKNKZ5\)-/UJ
M:XN;T37+&ZEC@$DEO&9Y/,E 'WCWY!QUP<8KMX/#EQ%XXN?$;7\;+/9I9FV%
MN00JL6!W[^N6/:L[1/!VJ^']#MM,L?$"^79W)EM_,L\CRR7)C<!P6SOZY'W1
MQF@"73;_ %#Q!X7O[C0?$-E=222XL+XPA@B;4)61!CYL[QT'4'':NK4,$4,0
M6QR0, FN,F\+W>CZ1KUQI.I"PU34[A+@RVEB'1& 5=J1$G)8 Y)/5B>*ZRP^
MU?V=:_;MGVORD\_9]WS,#=CVSF@"Q1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3O#LC.,J-A''RKQ["HCX6T@"S\JWD@-G&\<#6]Q)$55R"P)5ANR0"<YR>>M
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !7.77@+PO>R7[W&D0R&_;?<@LV'?\ O8SA6X^\,$^M='10!1N-'TZ[
MTQ--GM(I+-"A6$CY048,OY$ T[4]*L=9L)+'4;9+BV?!9']0<@@]00>01R*N
M44 9]GHEA8"8P1R^9,H22:2>225E&<#S&8M@9..>,GUJD/!GAX>'WT$Z;&VE
MNQ;[,[LRJ2<Y4DY4YR<@CDYK=HH P[#P?H.F:BFHVU@/MJ0^0+B65Y7V9S@E
MR2>O4\]!T J+2O OAC1-6?4]-T>"WNW).]2V%)ZE5)VKD<?*!Q70T4 <W=^
MO#%[<7T\^EJ6O_\ CZ199$28_P!YD#!2W^UC/O2S>#].?Q!HVI06D4#Z6C)%
M(CL&V%6'E[>F/FR2<GC'?-='10 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5B^(O%N@^$[>*?7-2BLTF8K&&!9G(ZX502<<<
MX[UM5Y)\8_AAJWCFZT_4-'N(/.MHS"\$[E05)R&4X//)S^% 'J.G:C9ZOI\-
M_I]S'<VDR[HY8SE6%6JY+X;^$I_!7@NVT>ZN5GN0[RRLF=BLQSM7/8?XUUM
M!1110 4444 %8^I>*-&TAY5O;SRQ 5$[B)W2'=C;YC*"J9R/O$=16Q7EVDZU
M8:+J7B?PUXGL9Y9[[4Y[JVA-HTRWT,N"@7 ()  4@\# ]#@ [*:_TYO&-M -
M:G%XMG(_]FQ'='(F5/F, #R.,<]ZL67B?2-0TV[U"UNFDM;-F2XD\EQL9?O
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M\J7R#<UO,C12 8W9VN <8!.>G%)8^*M%U&\M[6VO"TMU&TMMOA=%G1>K1LP
M<#(/RD\'/2N)T[Q!H>K>(M8UN"^MK_56T@VT6DPK(OG)'N<C]XJEV8G& .!Z
MUE:;JD%UX@^'E^CW#Q(EQ%)##9ND%HS08$* +V/'))XR2!0!WMEKVB6AU_46
M\1/<6UO<#[2)FS':$(/D3 Z=^,]:MV7C'0-1U.WTZUU%)+JXC,L*[' D4#)V
ML1@D \@'([BN!DN(3IGQ642*3.9/*'_/3-L$&W^]\W''>K,UQ;"Y^%Y61 (0
M=^/^68-L4Y]/F^7GOQ0!W-[XJT73K@0W=YY7[T0-*8G,22'HC2 ;%/(X)'6G
M:MK>GV7FVDUY-%/Y)D8V\+2O"G3>0%8*.#RPQP?0UYEID^BK9ZCX/\5V.J3Z
MK]LG9;,-<&._5YFD1TVG8 21DG !&3WK<TC58O#GQ \3V>N^9 VHO!-82E&=
M9XUC"^6A Y92,;>ISTH V_AGJ%WJOP[T>^O[F2YNID=I)I#DL?,8?R%;=_KF
MGZ9-Y-Q+(9O+,IBAA>9U3IN*H"0N>YXKF?A$^?ACH\921&C1U97C9/\ EHQX
MR.1@CD5!9W@\/?%#Q')K4JV]IJL%K)874QVQD1(5>/<> V26V]\DT =)<>+O
M#]K8V-[-JULMK?NJ6LH;*REN!@C]2>G?%6]'UK3]?L?MNF7 GMQ(T9?8RX93
M@C# '@UY)+8-I?AC1Q=(8K>Y\9+?V]O(I!BM3*Q!*G[JX^8YZ;N:]I4J5!4@
MJ>01T- '(65[?#XLZGITE]/+9#28;B.!R-L;M*RG  '91UR:UQXKT0W,$'VT
M#SY3!#*T3B*609&Q92-C-D$8!SD&N3O!)=_%'Q!;V<XCN9O#JV\$F< 3;Y#C
M/J-P..N*PIBNM_!BS\*01F+Q'$MM9_8F&)H)HY%!D(ZA0%+;^F.] 'IMYXCT
MNPFEBN)W!A95E9()'6,MC:&95(4G(X)[CU%%[XCTO3Y98[F=P82HE9()'6(M
MC 9E4A2<C@GN/45Y]XF>;3=:UK4O#NJ?\3(2Q)>Z%=H'CU([$ ,:]0Q4@97(
MRO.,4OBAYM/UK6]4\/ZGLU,/$E[H5VHDBU+]V@'EKU#%2%RN>5P<4 >JUBP^
M+-$N+RWMH[W+W,KPP/Y3B*5USN5)"-C$8/ /8^E;&YO*W%#NVYVY[^E>)#5X
M;W3?"%V(;BU-MKR&?3;>R=8K ?O1M("Y+DD9R3DDX S0!ZY8^(-,U*]OK.TG
M>2YL2!<Q^2ZF,GD Y Y(Y'K2#Q'I9L;:\%PYBN6*P*(7+RD9)VIMW-P">!T&
M:Y/Q)9ZEI?CFTU#1XI-GB"W.FW3(/]3*H+1SGW5/,_[Y%+K:#P[\0/#>HRIY
M>@16$VGB3_EG:2$J5+'^$,$"Y/''- '0W7B#1K_PUJ-VFKFUM8DDAGN5RDEJ
MX&#E6&5<9S@C/3BIK?5M.L-#TR62_EN8[B*-;>5T9YKG*9#;5&YF(&XX'J>*
MX6[MMP^)6MP,/[,U#3UAMV'W;B5;=E9D_O9+*H(ZD'KBJ\&HC1=2\!ZU?[_[
M$71/L3SA2R6MPRQ\OC[N=NW)Z8.: -_P=X@-UK'C&6[U2:;3[*[C$3W0\OR4
M\H%@00NW#9!R >.:Z>Q\1:7J.HRZ?;W#B]BC$K6\\+POL)QO"NH)7/&1D5Y7
M?-<:FGQ!?1[:YN6_M"QO$CCC=/M$<:Q,X5L#DA3C')[=:VA/H7B^QO[SPM!J
M$^MKIEQ EU<O< VI="!&3(<;BQ' SC!.>F0"YXS\5QD^'QI&JW,?GZU;0,8H
MF$5PADPZB0KANG\+>O6N_E0R1.BR-&6! =,97W&01^8KQNZ\0:??>!/!MC#'
M.E]INIZ?'=V?V=_,MS$0'W*!D=#CUKV92&4,,X(SR,&@#S?P)X_TN/PII%OK
M^NAM5N99HR\^3N;SG"AF VJ< 8!(XQBNWM]?TRZUJXT>&X9M0ME#S0F)P44]
M"21C!['/->4V4,-]\%)O"0A#Z])+-"-/9<3)(UPS*[*>54 AMQXP.M=3XQMM
M0\/WVC>*=+A-Y>0*NF7<0.#<1RD+&3_NRE3_ ,"- ':6&I6NII*]I(SK%*T+
MEHV3#J<,/F S@\<5CW/BZUA\:Q>&?)NO.>T:X:5;=V53O15 (4@CYFRW08&3
M6KH^G#2M(MK+>9&B3]Y(>LCGEW/NS$G\:Y/4;A=/^,FGW-RLJPW&B26T3K&S
M!I?/5MN0.#CGGM0!3\,>-+/2H==3Q'K<CM#KMQ;12SJ6V1@JJ;MBX1<]S@9S
M7;ZCK5CI>!=22;RAD\N&%YGVCJVU 3@>N,5Y/-)#)\-/B/&K*TMQJUXT2C[T
MH8KL*CJP.#@CKBM*\U>ST/QDFHZX]\NC:GI=M';7UK)-LCDC+YC;RCGG?D9_
MQH ],T_4+/5;"&_L+B.XM9UW1RQG*L*LUB>%+/3K'P_#%I-A)8V#,[PPR[]V
MUF)W$/\ ,N[K@\\\X/%;= !1110 4444 %%%% !1110 4444 %%%% !1110
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M^$A'7C[K="1N7/U^M:]5A91?V@;UBSS;#&A8\1J<$A1[E03W.!Z"@"S1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS!J0TZX87!=1^^6,M$P7D'<""<8!SSB@#TNBN>D\07C:S'H=O:6S:H+7[7<
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2 2!D^E+10!Y]:>#=0OM$\8Z1JL26\.N7LUS#+%*',894"[AQR"@/''O5A]
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#+'J&4,DBM]Y7&W:5/I@8[8K3TK1K?26NY4>2:ZO)?.N;B7&^5@ HS@  !0
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MEE4$A0QP/IG.*T]*TQ],^V;M0O+S[3<O<#[5)N\D-C]VG'"#' ]Z -"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^TMG(EMH6<12[<JK/M*J3E>"0>1TR* .SHJAH4LD_A_39979Y'M8F=F.2Q*
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MJ=K?QFSMG9)Y)%:+RF7[P<. 5(XZCO1;Z[INKW-QIEK>30WR0B4QO T4JH>
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MBFEQZ/>"\T^&V2"&<-G>$&WGWXY'8UL54TZPCTZT\A':1B[222/C=([$EF.
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M=3X9=?\ A9_C1]K 3_8_*D*$+)LB(;:V,'!X.* .WDD$43R,&*JI8A5+'CT
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MUY%+*9H?MK%I(48#$>6^8@<_>YYP>E<%=V4^B6OPUTV]9Y+C3YT^U,BEQ$!
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M"62Z"VX1P!CYP#D$#Z=Z .XL_%6DWUV;2&2<7'V;[6L4EM(C20]-Z KEN<#
MYY''-5_^$Z\/'1+?6!>2G3[B?[/',+28@R;MNW&S(^;CD=>*X[2+I)OB3H-_
M%_:=U!/I$T'VF6S>-/,WQG:%V@(H /;'N31=^$K^_O\ Q/X/5)(=&NW_ +5@
MN0<!)) <1CTQ,GF<=ACO0!Z#=:]IUE<20W4[1-';&Z=GB<*D0ZL6Q@?3.?:G
M66M6=_>26D0N$N(XUE:.>W>([&) (W 9Y!Z>G-<?IOGZI\/M0U7Q3IL[37UH
ML%U:H#YGE("A  YR6,CC'/S@4SPK<:AI&L7UL^J2Z[H%OI_VB&^DBW7$#!O]
M0S ?O#M!;'WA@9 R* /0Z*JZ9J$.JZ9;:A LJPW$:R(LJ%' (SR#T-6J "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH ***Y7Q_XGN/#&@0O8HCZE?W<=C9^8,JLDAX8CN  3^5 '545
MR]_X<O(-%EEL-:U(ZQ%$7CN);AF220#.&B)\O:3P0%& >,5AZ=\48K_0?"M\
MMA.9=9F,,HBB9UB*!MX&.224.!R<<GW /1**\Z@\1)HWQ$\4?;+C4KBV6SM)
MH;5$DG:/(D+E8P"5'3/  XSVKKT\2:9-I=CJ-O.UQ!?@&U$2%GFR,\+UZ YS
MC&.<4 :U%<S+X^\/0:/<ZG-<S1P6MQ]FN%:W??#+D#:ZX^7DCD\<]:U-'UVR
MUQ;IK+S\6TQA?SH'BR< Y&X#(((P10!I45Y[>:E_PD?CS4_#L\FK6]I!8Q"%
MK030LDSNX,A9<<#:NTGY>#UR:WH/%.DZ='IUE<7MU*DKK9Q:A-"?+GF'&"X&
MW<2#SP"<XH Z2BN4\7>(;2'0]<MH)KW[1:6KF6:S1S]F8H67<R]#T.!R <G
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MQ2!HE9<Y5E!Y YR.G4U@Z_<O'>^ 9;"_O?LUQ>)&0TS?OXS"S R#^(\ \]Z
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M./>JJ?$3PW+;V%U%=3O:7KK&ERMM(8HW8X57?;A&SQ@\COB@#JJ*YTZAI?\
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MC<.HYR.>,\50DUG1[[Q)X?/VW48KNX@FEM+?9+'%.A0%C(I !(&" >03TYH
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MB29.U06*AF SCTKUFB@#@])F:/XE^*+R:UNX[>6QM%1WMGVLR!]Z@@8)&X<
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MV)_P&LC4O-:S^')6TO&^S7,3W %K(3"H@9"7&WY?F('->ET4 <K\2-(U#7/
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MO\2_#R6<MY_IYM(+DVUQ.+.0);L&"DR$CY1DXYY]JV=0\1VFGS7,7DW-R]I
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MRKX2U5=&NHX+75O.EMK> R2PQ,DBAF1,\Y()QTS7?1L7C5RC(6 )5L97V.*
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MXAM-/U!-.$4]U?/ US]FMU#.(E(!<Y(&,D#&<D] :Y3QGK,&K>%?#NM:1?7
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MS%!92,RA@6R!CI@9STY&"<U3\>QSRZCX3,%I=SBWUF.XF:"W>01QA'4LQ4'
MRPJI8B>'QIX\N)+&^$%S!:B"3['*5F*1,K!#M^;!('% ';:=?VVJZ;;:A92B
M6UN8UEB<#&Y6&0:LURWPXAGM?AYHEK=6\]O<06RQ2Q3Q-&RL.HPP!KJ: "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH ***IZGJEKI-J+BZ<@-(L4:*-S2.QPJJ.Y)_SB@"Y16!;^,-+
M>;58+OS=/GTJ-9KN.Z"C9&PW!P5+*00#T.>U+%XLLSJ5E875M>6,M^I:S:YC
M 6? R0,$X;'.UL'VH WJ*XZ;XE:-#::C="TU62#3KEK>\=+-OW.T*2S9QA1N
M^O!XQ6A?^,M,L-8M]+,=Y/=7-NUS MO;LXD48^Z>A/(Z<#N10!T-%8&G^,-+
MU'1'U1/M$2QW)M'MY8L3+.&V^45Y^;)'YT6_C#3'N]1L[P3:==:="+FXBO H
MQ"?^6@*EE*\'H>.] &_17/1>+[-]4M].DL[Z"YN[=[BS2:-1]I51DA?FX;!!
MP^T\USL7C*SUWX;ZGJNOZ=J%MIQ:>.3R!EO+65E !1L@@*,DX&>^* /0Z*R)
M=;M++[#9P17%S=7$/F06L6#(8U RQ+,  ,J,D\D]S6;<_$#1+7PY>ZU+]K$-
MC,8+J 0$RP2 @;67H.HYSCD<T =316#9>+;"]\0G1?(O8+EH3<0M<0%$GC!
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M.:VU#!%#$%L<D#&32T4 %%%% !1110!B:]X<&M7%E>0ZG>Z=?61<P3VQ4\.
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M313W$-Q=):*UN%8*[/L&XDC S_*MNO%%BG'P0\,2F\EEDFO;!E\X!A&?/'3
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MY<D;@8CVJ,*0<8.3QU-6-$_M[6='\.^(8-;5&NO+N;ZVD13"877)C0 9#*2
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(99;VYG375VW4;!0%^3R_D(&1\O'.:T/#VC?V!HUOIHOKF\2W18XY+C;N"*
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M>7NR"3C&[&5!QU(.#78CPE$=>T_67U749+NR@>!-[1D.KD%BWR=20.F ,8
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M2>6\J1[48(S88'&\\YSTYKH%GU32?B%X?MI-8NKRWU>TN6G@F"A$>,(RF,
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MWRQL "C@IMQ\HZ 'OUYH X2_OM1UOX;:?+?WUWY\'B-+0L'"LZK=;5W[>&(
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M-G%!'Y8B6(D$C!3/51W[4 9_P]U"^O-(U*WO[N2[DT[5;JQ2XEQOD2-\*6P
M"<'K5KQ3<RQ7.D0IJ#6\4UPRRVT /VB[ 1B$C(Y7!P6/& .2!5KP]X<@\.)?
MK;WEU<"]NY+R3[04.)'.6QM5>">U,U[PQ!KM]IE\;V\LKW37=K>>U90P#C:Z
MD,K @@#MVH \]O/$6OI\-?%%U'J=W;W>E:TUI [B-I/*\V(!'.#D@2$9!SP.
M:Z%[_4/#WQ"6VN-5N[ZQN=)GO)89@F(Y(F7F,*!M!#$8YJS-\-=,ETG5],_M
M/55M=4NQ=SKYR,0^58X+*>I12<Y/'7K6O+X7AG\26FN37]X]S;6S6PC/E^6Z
M-@MN&S/) Z$4 >=>));O7O@];^([K4+C[1>3VT[P(_[D(UPFV,+T^7CYOO$C
MDX.*]BKA6^%^G_V+/H<>LZM%HTDRS1V*21[("'#X1BA;&1T)(&<]>:[B-/+C
M5"[.5 &YNI]S0!Q%K?:I+XS\9Z>VJW/DVUG;2VGRQ_Z.760G:-N#R!]X$US<
M4_B+_A4+^+F\4ZC]M;1S)Y02+RPX.0PRI.<<$Y[\8X [U?"<,>M:OJJ:E?+<
M:I"D,RCRMJ*@(7:"G! 8]<]:@7P/9KX&/A'^T+\Z>8C!YA,?FB/^[G9C'OC/
MO0!B7ESJ^BII"'6;J\FU^ZAB/G%(UMP(G=A$0OR[BH7G)]\\U5UX^+M \->*
M[MM4,%K':_:-./G">>%E'SJ69.4)(P>H]:ZS6/!]AKOAJ#1;^>ZD6W*/!=JX
M2>*1/NNK*  P^E<WXM\/_P!C_#3Q#$VH:CJM_=6C0K+=OYDK\':BA0!W)X&3
MU.: (KN?7_#NN^%=1;7+J_M=8N4LKRSF1!&C.A96C &5QM.<DD]S5:ZUS5+2
M;1+N'5;B]>Y\0+97-Q%Q9O$\C+Y2*>I4 ?,H/S*<L:ZS1="@N8-&U"ZOKF^^
MQ0@VJ3! L;%-I8A5!+ 97)Z9/?FLZ/X8Z;%IUMI\>KZPMI9WJWMG$)DQ;.&+
M87Y.1DG[V2.V.<@%2UBUK6/'_B?33XDO[>TT][&:!(DCR-RLS(?E^Z<$>IXR
M3CG/U#7-4LY=,O8-5N+R27Q"EG//#Q:&%Y2GDJK=2HQEE!^8'+=J[;3?#$&E
M^(=2UF*^O9)M06-9HI60IB,%4QA0W )[G/?-8@^&.G+IT>GIJ^KI:07HOK2%
M9DQ;2!R_R_)R,D_>W8[4 9<&D7>L?$;QQ!:ZU>:7A+ ^9:!-Q;R6QDL#\H]!
MC/K68VLZAKOA+P-=:HRO?1^)XK>:5%PLK1M*F\#WV_GFN\;PE''K5YJECJE_
M93WT4<5T(BCB0(NU&RZL0P!/(/ZTV]\$Z;=6&C6,$]U96VD7*75LEN4YD7."
MQ=6)^\V?4DDT 9-QJ\_ACX@7":OJ,[Z-J%D]Q9F0C;!)$"TL? YRN&&?0@5T
MOAR&]AT.W;499I+N4&:196R8RQR(_P#@((7WQGO7/:Q]C\9:U;:')I=ZRZ5?
MI<SW-Q;LD0V D;&/#[B0,#^'<?3/;4 <E?ZI-J'Q#A\+K<2V]M%IIU"<PML>
M8F3RU4,.0HY)Q@DXYQG/*:$USIFB^,DCUK[+(/$K1F[F3?(RD0@JH4<R,ORC
M R2:[?7/"5MK&L66L0WMWIVJ6:F..ZM"FYHSR4975E9<\\C@UF/\-=-DLKZW
M;4]4\R[U!=2\_P U-\5PN,.GRX[#@@CTQ0!FV.K:J=2\:Z:EU?VT5E907-E]
MH*230,Z2$\G=D$H#ALD9/2LU;_7XO#G@/6E\0WC7.JSVMI<QNJ-$5EB8EMN,
M[P0#DGKGMQ771^!;5+_4K[^UM5:XU&U6VN7:5#OVA@'QLP#AB,8VC/ S0W@2
MT;1]#TO^T]1$&BS13VI!BW%HP0FX^7R "1VH R+2]U/2O$OBK1VUQY8;?3([
MVVN=2*D6TC"0$L0!\F5!QVP:CT75]0A\:Z#8B[OY[/4-,EDF>[^[/*FS][&I
M^9 =QXPHP1@=ZWK[P-I^I:CJUY=WE[)_:EF+*XAW($$8SC;A,@@L3G-0VW@6
MWM=0TK4I-7U>[N]+B>*)I9D_>(0/D8!0,?*.1@G^(F@#D[S7]<N= O98-2N;
M?Q5%K'V9-/B*DB(RA0HC8$%?*._>0?7..*WI[O5=7\1:OH-M=7!&EVUNHE2Y
M6"5I)%+>:VU,'H.  N0>#D8YK2%:2-Q'KWC+2M5FFDFDTM;(R)%([EBH9XBI
M7)^\7P>N1VZ^\\#?VO<V&LSZI?Z7KR6B07=SIDBH)^,LK @@C=G'_P!84 ;?
MAH:PGAVS37Y;:7544I<26QRCL"1D<#DC&>!SFL+Q-<W1UNYMHM2N2J::9(K*
MP.R6.3<?WTCDA0N   QY(;@XKJ["RATZRBM(-YCC'WG8LS$G)9B>22223W)K
M$OO!UI>^(9M96_U"VEN;86MU#;RJJ7"#.-V5+ C)Y4@T 2>"-3NM:\#Z+J5Z
MX>ZN;2.25P -S$<G ]:WZR?#>@0>&-"MM(MKBYN(+==J/<N&;'8< # ]A6M0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !117,>,]9GTQ-%M()C;G5-3BLGG'6-&#,=I/1CMV@]MV>
MHH Z>BN-U2SOM T_Q!<)XI^R6DUL'M/MH:8V3@8=PS$LX)*X'."1CK@T='O;
MX?$2;1DFU."PGT072I>2^9()!+L\Q=Q8ID'[I].0* /0**\@TC5-8L?A8/&M
MSKU_=7D5O/$(9F4P$F<HKLN,DKUSZ<=.*Z?[+XBT?5X=66\B;25M93>6LNH2
M7#3N$+(T6Z,!6R#D @8Z#B@#N**\XTE/%.L:7X<\16>HVT1G,5Q?&6_D:*:%
MQET$7E[489PN#D8Y)ZU)X5M=4U?7==DN_$>J&+2]<=(85= LB"-#L<!>5^;H
M,=SU- 'H=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MD%3&S,58$$$$]16O0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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A** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>elicio-insidertradingcom006.jpg
<TEXT>
begin 644 elicio-insidertradingcom006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHK(U'Q/I6E7KVEU+<>?'")W6&TEFV1DD!F**0!\K=?2@#7HKGK/QOH&H?93;
M7-RZW>?L[FQG5)L*6PK%,,<*> ><5H:'KECXBTM-2TV1Y+5W=%9XRA)1BIX.
M".0>M &C1110 4452LM4M[^\OK6%9A)92"*4R1,JDE0WRDC##!ZB@"[1110
M4444 %%8>L^+=*T+SS>/,5M51[IH86D%NK'"L^T<#@^^.>E;0=2@<,-IQ@^N
M>E #J*S+77]/O->O-%A>0WMG&LDR-$R@*Q(!!( ;H>F16G0 444F1D#(R>U
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MS$!R2!W'(JEI'C2^US3/","^5;7^N6TEQ-*JY$2Q*-VQ3W)(QG( SUQ5BS\
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M$ZH&<L[$(JAL@  $DX/4 8KDM<U[4M;^&7C.TO)(X-0T<W%I<O#'\EP@3(8
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MV?XD81'!QU!P/>JGC;0-8O[W2]:\-WL$&M:8)?*@N1F*XC?:'1NX^ZO/\NH
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M*BEF(50,DDX %+7E'BK6WU?X3Z[J.E^)FO;;SXUBEB1$D$3&-6BE&T8.6<]
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M(&G)+'+<QI9:Y:<Q22@_)Y@_@8X]N_&,FK,[WT?QXN#86]O/)_PCB;EGG:(
M?:#R"$;)]L4 =OIVLV>J27$=N9UDM]OFI/;20LNX9!PZ@D'!Y''%4XO%NEW*
MO):?:[NV1BK7-M:2219'!PRC#8]5R*Y#XAZCKEK\*/$M[<6T=IJ!86_^CN7
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M-DM@ G/0# '.<O0/ D^@R16J^)-0N-$MW\RVTV5$Q&0<J#)C>RJ<$+D#@=:
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M-FP*1@Y.."3GVQSG1M/";Z?J&N7-IJDR1:K(9FMVB5ECE9 C-G@GA1@9Q]:
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MQV. #]1@:[J_C;0?!6LWEQ.(9K6\A%C<3)"TDT$DB)B0)E PW'D#GCBMO4?
MLVIZ3I<4VOW:ZMI+[K+54C42KD8(<='!& >F<#/?+]2\$3ZOX8N-)O\ 7;BX
MN+J2-[B^>% [>6P=%11A44$=,'J>YS0!1U[4->\*0P7.I:G>WVF2W3O=75E8
MIYEE%L&U=N&RF[)+8) P/KTOA>^74O#]O=IJL>J1RM(R7<8 WIO;;D  !@N
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M9-,_M&UN9HD22/Y_+:-M@ /)R#B@#J] UJV\1Z#9ZQ9I*EO=IYD:R@!@,XY
M)]/6M*O*?">M75EX"\!Z19B02ZG%(&>(H'"1JS$+O^4$G')[9QS@CLO"Z>(H
M;K5(-98R60D5]/DF=#/L(^97V<<$<'J0>: .DI"< G!..PKD_B%=ZMI7A]=9
MTJ]FA2PF2:\ABC1O.MPP\P#<IP0N3D>AJ[!<W&KZK=S6.I2)816R(AC5&5I7
M7?N&5SPC1GK@[NG% &GI.H'5=+@O39W5D903]GNX]DJ<D?,N3CIG\:LSR^1
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M,=N;>&4Q!%B0D%B%'=B%R<]@!BF>&_#?_"."_5+^:Z6]NY+R02HH*R2$%L8
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MT8=K>X $D9/9@">: ,A_"B-XGM->74[U;F&T%G,/D(N(P^\;OEX.XG.W'7'
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MJV,# < GKA#SDYJ&9O&NDZ%J0D234%CO8Y+>."56NS:$_O$S@ N #@]2,\Y
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MVZE;.&[E5EM@01D84;B 2!NS@=J ,OX=?VWK.D6.N:EXAN[C;)=0O;&.,1R
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%<AXC\07C>*]+\):3,+>\O(GNKJZVAC;VZ\94'@LS?*"00.N#0!U]%
M<]>Z+J4$=O)I>M7HE2XB::.X=9%GC#@NOS#*DKG&W%=#0 4444 %%%% !117
M 17&I7?Q4U;16UJ]AT^'3XKF../R_E=F(/)4G'% '?T5S4>J6OA[3K_4M2UR
M>[TQ9L">2+>8"OR.I,:?=# \GN2,UJ6VNZ==W:6L$SO*]NMT!Y+@")L[6+$8
M&<'@G/!H T:*Q+/Q=H=]=VMM;WI+W:NULS0NB3A.6,;E0K8'/!/'/2J<WQ"\
M+06\UP^J PP3FWFD2"1A$XQG<0ORCD#<>,]^* .GHK$A\7:%<:PNE17ZF[=&
M>,%&"2!?O;'(VMCO@G%9\_Q)\(6ZAY=:B"><8"XC<JC@X^8A<*,\9.!P>>#0
M!U=%<=<WMXGQ9TRT2_F:PN-*GF-N&'E[E= &&!R<$]<UL/XKT6.^@M'NRKW$
MQ@AD:%Q%)*,_(LN-A;((QG.01U% &S164WB/2UNUM_.D+-<?9@ZV\AC,N<;-
MX7;D'(//!!'45H75U!96LMU=3)#!$I>221L*JCJ2: ):*RK/Q'I=]J']GQ3R
M)>&/SEAG@DA=T_O*'4;A],XKCX-3F\9>(?$&G0ZEJ^F/930QV,L$$L8CQ&'8
MR J%.22-LG8# YR0#T6BN)^*6HZCHW@UM0TO4)K2ZCN(8]\84Y#R*IR&!'0U
MMWGB71=$O(-,OM2VW;QM(B.K.[@=>@Y/(P.IR,"@#;HK&L_%6BW^D-JEM>[[
M19O(8^4X<2[@OE["-V[) VXSR*JZMK^CW'AW5GFU2ZTV&W4PW%RL;PS6[%00
M5#+G.""" : .CHK+;5[#3["P,MU++]H15M_D:26?Y<YVJ,DXY/''?%<OX(\0
M?:)?%MS>ZI//96FIE(Y+O*&)!&A*[2!MP21C .?>@#O**Q(_%VB/)>1/>-!+
M9Q">>*Y@DA=8ST?:Z@E<\9 //%&C^+]"U^[%KI=^+B8VZW0 C< Q,<!LD =3
MTZCO0!MT5S'B2RU-+35]4AUR\M4@LV>WM[<1[0RH6+-N0DDG'&<8'O69X/&J
MWOAKP]XBO/$5Y()+<3WL,RQ>7(K1GIM0$$,5/7L: .ZHKFK3X@^%;TKY&L1,
MK02W <HZH(XSAR6(P,8Z$YQ@]"*T-/\ $>EZG?&QMIY!=" 7 AF@DB9HB<!P
M'497/&10!JT5YY\0/%<2:%"VD:I=PS#48(!+;Q.(I3YJJZ>;MVG W<!NQ]#7
M1_VAIG_":3Q?VU<?;(=/W2Z?N_<I&'_UI&/OY.WKT[4 =!17,Q?$'PM.MH\6
MJJ\=W-Y$4@ADV;]Q7:S;<*200-Q&>U:E_K^FZ;.T%Q._G)"9WCBA>5DC!QN8
M("0.O7K@XZ4 :5%4=*UC3]<LQ>:9=QW5N3@21]"< _U%7J "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KSWQ5I]
MYHWQ&TCQK;VTUU8K:-I^H) A>2*,L660*.6 8\XY %>A44 >8_$>?2O%-CH=
MMI;6^J7?]K6SM';@2ND()WE@,E5QUS@5WMKJUE+K%UHT*R+<6<4;N/)94"MG
M;M;&#TZ"M&B@ HHHH **** "O+)6T2;XRZQ/J\-K/:#3(8XY+B$21^8&.0"0
M1D UZG10!Q<6L^';#1=0L=/LEDTQ&\L1"/9%-+.S$Q*",;><L?NJ&]CC$\)-
M+X*N]4\)7L(O95MQ=6,R!B)TV8%N2<X*[<*">5(X]?3Z* /%['4XKF^^'^HB
M.Z589Y4GMH+%XX+)F@91"JA>QXR23QG(!JRLL3?#[XE1@@R7&HW[0ICYI0Z*
M$*C^($@X(ZXKU^B@#S2]N(#KOPU='4I$)?,9>D8-L4&[^[EOEY[\5E:9=:=+
MX(\>:3(%EO;K5=2CBM N9)W9B$V#JWS8Y'3'.,5Z^VXJ=I ;'!(R :P/"GAV
MX\.0:C%-?QW8O+Z:]REN8MC2-N9?OMD9Z4 <A:6<^F^-O"NFSS@75KX;>SDF
MSD+-^[ &?4[20.IQ6;X4FT6ZT;3/"^MZ3JLGB'3G2,V,KW)BWQG"S!L^6$Q\
MV?R!XS[#10!Y4#/IOB(7'AS4'N(+O6FCO_#]VF\HQF(>XB_B0 @R9^[SG/:N
MF^)MCJ%_X(N5TV%[B:&:&X:W09:9(Y%9E [G SCOC%=?10!P.I2V_BSQ=X0O
MM%E\Y;"6:XN9D!_<QM'M\M_[K,2!M//!..*?X*N89/&GC3;(,37T3Q$\"11"
MJDK_ '@"",BN[HH \_\ C&X/@.2W7+SR75NR1("S,%E4L0!S@ 5)K-U;3_%3
MPC/'*DD2VEX#(IRJEQ&%R>@)P<>M=Y10!Y':)I=YIWBZVU&:YMX)_$IFBNK4
ME7A^6/9.IQ]T.OWNG6GW=UJS_#_QM8:E=P:HD5N8;+5(8@IO2T9^4A>&93A<
MK_,&O6:* /+WU$:+XP\+ZY?^8=#ET,V*W"H62WN"R,2^/NY"A<^H]JQKC[7?
M6'C.?3+*]N#%KUMJ A2*2-KB&/RF8(V!\WRDC!SQD=J]IHH \XM=0\+ZU#?Z
MSI-M?2W$6FRPRWMX9P801Q#^]/S,6[+G&.O(SO?#8H/ASH$:C:\5G''(F,%'
M ^8$=CFNIHH Q_%DL</A'5S(P7=9S*H[LQ0@ #N3Z5E?#F>*/X:Z'YDBH;>R
M1)@YVF-E7D-GICWKK:* /*?#5T;'X#W31:4FH7$"77F6$L1._=,Y^=.I&TAL
M=P*BAN&O?'EK/I]W?7+7GAVXM[>\>U>.,3%T("@* JCK[=R37K=% 'B%QK%O
M)\']-T)K:ZBU?3;BSANK(VSF2-HYDW-@#H<9![YQUKLQ=P?\+H:X9]D/_"/!
M"[@J WGE]I)Z-MYP><5WE% 'B.]!\"C;!2+G^U=_D[3YF/MV_.WK]SGZ5OZ[
MKUAX<^(=]?"\\H7^EPJ[3VTLD3$,^QD:-6S@9RIP#D8/7'I]<Q/X<UF'7;W4
MM)\1"VCO61IK>ZLQ<*I50HV$,I48'0Y&<GO0 OP_32+?P5IUGHFHC4+.U0P^
M?@J2X.6RIY4Y/0] 17352TW3QI\4NZ9Y[B>3S9YG !D? 7.!P  J@#T ZGFK
MM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MPO!_(XZ&M*UN8;VTAN[:0203QK)&XZ,K#(/Y&N#T>"_/Q@\1;K]61+*T++Y
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M"%R"?7'IT[^F&)J?BS4?&>NZ)9ZAIL$6G+9RI(]HS%EDW%E(W]2%^][# YR
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M+M[9)+23B.4S$[3&P QMR5YZ@'O1;7OBQ/$=I ;=I]-N89!//-;I']DE RI
M#Y9&/&.2/[U '845YMH7B#QGJ7@^3Q('L+DQ17BBPAM6WS21NZH0=W'W<;>2
M0.N3QN^$/$<7B*6:>RUJ+4+18E#Q/$(KBWER=RNO&!Z<=CR: .LHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **RU\06#>)CX?!F_M 6INRIB8)Y88+D,1@\GMGO4^EZG
M#JUHUS!%<1HLKQ%;B%HVRK%2<'MQP: +M%%% !112*P90RD%2,@CH: %KE_%
M'A:]U_5M%OK;4X+3^RK@W,:26IE\QL8P2'7C&:ZBB@#$&G:[+?P376KV9@@#
M,((+)HP[E2%+DRME1DG:,<XYXK&OO UU=1:9=Q:M%!KUE=M=/J0M"3-N&&0K
MO^Z5VKC)P%&,8KM** .)U#P-J%Y?^(I(]=6&VUZT6"ZC^R;G1A$8\HQ;A2#D
MJ0>^".M2VW@R_AU#PO=R:Q#*="MY(-OV0CS@Z*AY#_+@*,=>]=C10!R$/@Z^
MBC\4K_:MN3KS,Q/V0_N"8Q'_ ,]/F^4>W/Y5SM]IMWHWB_X;Z1#J%L]S965Y
M LKPD+(JQ1*,KNR"0O4'K^5>HU!)96LLPFDMH7E&,.T8+#'3F@#FKCP;)=:7
MXC22^C&HZ]'Y5Q<B E(T">6JJF[^%2>IY))]JJZAX&OY8-"NM-UP6.MZ1;_9
MDNUMMT<\6 "CQENAV@]>#^&.U8A5+'. ,\#-9NAZ_8^(;6>YT]I3'!</;/YL
M9C(=#AAAL$<^HH H)HNM16MJPUQ);Y;@S74DMM^ZG4H5\L(&&Q1P1R>1DYR:
ME\,>&X?#=O?)$8]U[>/=R)#'Y<:,P VHN3@84?4Y/'0;M% %+5]*M=<T>\TN
M]0M;7<312 '!P1C(/8]ZYZV\(7LMEI&GZQJD5[9Z5-'-#MMRDDS1C$?F'<1Q
MP3@#) Z<@]=10!SECX<O+/QIJ6OMJ$,D=]#%";86Q!18\[3OWG)^8YXKHZ**
M .<7PY>1^-KOQ&FH08GL5LUMVMB=H5BP8MOYY8Y&!Q6)'\/+R/P+I_A@:U!B
MSNUN1<&R.6VR^:!M\SU.,YZ5WU% '(Z]X0O/$=GJ.FZAJ%K-IU[(DBJUJ3+:
MX50?+;?C)*D@XX+'K5E_"LDOC2;79KR)[:73?[-:T,!R4W%L[]_7)(Z=*Z6H
M;JYCL[26YFW^7$I=MB,[8'HJ@D_@* //V^'&K_\ ")MX63Q)%_9,4T<EH9++
M=/&J2B0(S;P& Q@< ].W%:5[X-UB/Q+/KF@^(5TZ:^CC34(I+031S,@VK(H+
M#:V..IKIM&U>TU[1[75;%F:UND\R(NNTE?IVJ]0!RTGA.Z/B;1=735%*Z9!+
M"4F@+O/YF-[%PP .5SPN!Z5U-%% '/\ B7PY/K=UH]Y9WZV=WIET;B-I(/-5
M@4*,I7<O9NN:9I7AN[T[Q=JVN2:C'.FHQ0QM#]GVLOE A3NW8).XY^4>V*Z.
MB@#SL?#?4UT>'2T\1I]FM-474;0M8[G#"4R8D._Y^2>1M]\]*TH_!NHZ=KVI
MWVCZU'!:ZJ U[;W%KYG[T+M,D9#+M)'4$$9[=J[*J&M:Q9Z!I%QJE^9%M;="
M\ACB:0@#OA0?SZ4 <E!\/KV'PQX:T8:U"?[$O(KM96LS^],><+C?P/F///:M
M>U\-7UKXIUO6TU&W)U."*$0FU/[KRPP4YW_-]XYX'X5OV]U%=6L%Q&<).@=-
MW!((R/TJ:@#R?6-*7PQX=\+^$;KQ%:6JQRR.MY>V0-K*J D)(K-@MN<$#</N
MYZ@9Z/P7<WZWLMD-2T35-.$;2?:-*MO)6*7</E;:S*2P+'CD;>>HKLI88IXS
M'-&DB'JKJ"#^!H1(K>)414CC' 50 !0 ^N'T;P+J>A2RZ?9>(F7PV\S2K8&V
M'FQACN:-9<\(23VS@G!!YKN** . U3X=7U_9^)M/CU\16&N3&Y*-:!Y(Y"%&
M-^[E/D'& ?<=];4O#6J:G:7EE=:G9W5G>6JPRQ7-EN". 09$P_'4?*>FT<YS
MGJ:* .&NO -[9WVG:AX9UUM-N[6QCT^;[1 )TN84'REER/F'J*V6T35(UL_*
MU6.X"13)>)>6^];II"IW8# +C:0!@C#8]ZN-X@L%\2Q^'R9OM[V[7(!B8)L!
M )#$8/)'3-:E &-X7\/0^%]!ATJ!]Z(\DF0NU07<N0JY.U06P!D\#O4OB329
M->\-ZAI$5RML;VW>W:5H]^U6!!(&1S@^M:E% ')'PC>MJ7A:\.J09T**2/;]
MD/[_ 'QB,G[_ ,O ]^:IW/P[_M&V\2V]_J0:/6KA+E6@@,;VTB!0A4ECG&P'
MMWKN P+%01D=1Z4M '.Z'HVO6B^9K6OIJ5Q'&8X"EH(4&?XW4,=S<>H &<=<
MUBQ?#RXB\ VWAP:NAN+*Z6\M;P6N LBRF4;DWG(R2.HXKO*R]6\06&BW.GV]
MX9A)J%RMM!LB9E,C= 6Q@=#U/:@#!'@F[O/$%WJFL:K%=)>Z5_9MU;1VOEJR
MEF)V'<2H^;ON/7GH!GCX?ZXVAZ9HLOB6&2STJ[@N+21K'][MB.41SOP<<#@#
MI^%>A4UW"(SD$A02=H)/X <F@#C)?!FL6?B.]U/0/$G]G0:DRR7MM):+,ID
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MI# <=P1Z=:Z:B@#C+SP"K^'+>QL;_P G4(-3&K"\DAWB2YWEV+("/E.XC /
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M75I=1 %H9D^ZV#P1R01[T <W!;7MM\:@DNH-=%O#KF*2:)0R?OUX(0*",\]
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MI@'W.3G-G3=2\73^";;Q%+K.F?Z7I]M)Y<\(B2W+%2\I?/)VDG:1C./QU_\
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MH 9F#* 5S@[ 2?O>^,  '>T5YS9:YXMUS2-*U_1K>X=;F999+27[,+<VY)R
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M46EJ%1"&F\L/ODW*25W,!@8X![GBLOPR1=&AT8>(-0&G6MXMU9PJD8,&)/,
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M55&9(]\<:OO"K@ =>I.2: )=0U>_U'Q5J.AV37T*6-K#(SV7D;R\I?!/FG&
M$'0<DG/:LJ]U_P 3Z%HFB7'B:&XCB F35;K2HUE:)@1Y3LN#A"-Q;:.#CMP=
MK6O!3ZEK-MKEAK=WI6KQP?9Y;FV1"L\><X9&!!P<X]/RQ>'AZXMGL9+'5IXY
M+:.5)#<()1<F0JS-(./FRN1@C&2.G% %GPU=B_\ #]I=+J::FDH9EO$  E7<
M<$@  '& 1@8(-:M9GA_0[7PYH\6FV>XQ(SR%F &YG8LQP. ,L>!T%:= !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS>%8X8B2KQ[V0Y7[IY'KTR3CD ]!HKR.?4_$;>"?%NKCQ)=K<Z)J=VEMMBB
M=8F "R#9R,<8&.I/-;YOM7T_QOX6635Y[FWUR*X%Q:NB"*(I$)%,8 W#N.2<
MCO0!WM,$L9F:(.ID50S)GD Y ./0X/Y&O,K_ %_5[*?2[J/59;R2;Q"EE</
MH^QB%Y2GE#< 2RC&67.&!!/:M#P]:3O\4O&F=3O<1I9[5+(1AHY"!@KP%))
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MQ1X=A\5:')I-Q=7%O!*Z,[0;=QVL& ^8'NHK6>:*.2*-Y%5Y6*HI/+$ G _
M$_A3Z ,$^&0WBN+Q"=1NOM<=D;+9M384+!B2-N<[@#UK,;X>VK>%]4\/MJM^
M;74KB2XG?$>\%VW. =F "?:NQK'\4^(8O"OAV[UF>TGN8;9=SI!MW8SC/S$<
M9QZGVH K:CX3AU$:7.U]<QZEI;%K6^0('&1M96&-I5AP1C\JCNO!MM>Z;K-M
M/>W)N-8C$5Y=J$#L@7:$4;<*H!...Y.23FNC1MZ*PXW &G4 <WJ?@^+5?#5E
MH<^I7BPVK1,)D$>]S&04S\N.JCH!FIV\,JWBN+Q"=1N?M4=F;,1[4\LH6#$X
MVYSN /6MVF3.T<+NL3RLHR$3&YO89('YD4 <:WPXM/[/:W35]128:J=7AN1Y
M>^*X).X@;,%3N/!!JW#X$LH[G799M1U"Y&MVX@O$E=<-B/RRXPHP=I/'0=AT
MQI^&-?@\4>';36;:&6&&YWE8Y<;AM<KSCC^&M>@#DI/ L<VCZ/ITNM:C(NE7
M,5U#*WE;BT0P@/R8V@=@,GJ235R7PJB:_=:UINH7%A=7L2QW@B5&2;:,*Y#
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%<SXQUF?2UT:TMYO(?5=2BLFG &8U8,QVYXW';M'^]GM735D>)/#FG^*='?3
M=1$@C+K)'+"^R2*1>5=&[,* .9\3WNJ>!- \1ZS'J9O+40QM8VMSF1[>0L$9
MBY.63+*V#T]J=KMQJ'A75?#-Q;ZC=7EMJ-]'IU[%.^\2&13ME7^X05)PN!@]
M*V;3P=9)I-Y8:G=WNL"\B\F>74)0[F/G"C: %'.>!G/.>!2V'A*"T;3OM.H7
MNH)IO-FET4(B.TJ&)5068*2 6SU]>: .0;6=5'@3Q]<C4KG[1I6HW:6<V[YH
MUC12JY[@9/7-6K^;6-1\7>'],BUZ]M+;4-'EEF$ 0,KJ(_F4E>#\W?/?&.M:
MU[\/+"\.MQ_VGJ<-GK!9[FSBE41^8RA2X^7=D@#C.,]0:NQ>#K:'6-+U-=1U
M S:;;&UA5FC*M&<9#?)DYVCG(Z<8H Y36]8O/#VISV6OWNJVUB4ABT_7(CF%
M6"*&%P%X#,^XY(Q@\;<9K0N[S6/$FL^)-.TV=H&TUHX+=HKLPE':(.)& 4[P
M2V,'C"],\UNZCX2@U/\ M.*XU&^-EJ;*;FSRAC.%52%)7<H(49P?4C!JKJG@
M&QO]>_MFSU+4])O7C6&=M.G$8G1?NAP0>0. 1@T ;>A_VE_8=F-8DMY-26,+
M<O;G,;2#@D<#T]*P]?U><^--!\-QS26\-]'/<3R1G:[K&!A%;J,DY)'.%X(S
M736EK#96D5K I6*)0J@DDX'J3R3[GK6;KGANTUV6QN7EGMKZPE,MK=VY DB)
M&&'((*L."""#0!SFG7=__P )-XE\*W-[<S6L%M%>6ESO_?1H^<QE^_*G!/."
M<DU)\);;R?AKHDOG3/YMLIVN^53D_=':M^V\/0VRZA(+NY:^U *)[T[/,(48
M4 ;=H &<#;W)Y)S3O#F@0>&=$M](M+FYFMK==D7V@J65<DXRJC/7O0!A_%:-
MG^&.O%9I8BEL6S&Y7=[''4'N.]9/B"RD7Q3\/[:&]N$=I+O]^Q#NH-L<XR,9
MQTR#CT-=SK6D6NOZ)>:3>A_LUW$8I-APP![@^M9/_"&0->:+=RZMJ<L^D%S
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M!+&78LQ5@HQ\Q)Y!Q0!R,/CJ&QTC7[^(ZG!J>FZ?YDNBZH6+QR X$@)^\A)
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MEV^4C)&'4QJ!\N"2.IR.I)YJM8ZAXDGT[QQ#97<M]J%EJ1ALQ*41@FR,E%(
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MK94/MSAL$\\=N*L:9:S7?Q4\620W]Y9++!:)')%&NV7:CAL%T()4D=.F3G-
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M]KNXUDM;TE8Y2 -JIC [9R<GO3=/O=0\6Z7XEOX-3N;*YLKZXM+%87PL/D@
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M= )45LE,AC\I '^S7/+JOB"+X:GQ0_B*^DO++4VC6,A!'*GVORB) %YRI[8
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M(;!VX]L'FJ6F:I?+X5UJSN=?N(OL/B%M.AN909;B:$.A$2D?,9&#%0>OTQD
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ML;^6Q=)64L63&3\I([^IZ5S%VFK^&OB'X?":W?:A9:TTT%U;73!E1UC+J\8
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7.>(-)N)AJ&I?VK?P)%9D0P6\YC164,Q<XZDY
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MEW8VY&X=ZY#7[B]U/1-06;2=3BO;778Y&L[6QD6%(EN%/FY5<3,P^8G+')R
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC6^U*:^GL['6I%+$O.T48CC/<D[1G\*[%]>M4@TR7RYV74G5+<*F225+C//
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M^,4%ZMI>?9#H30?:#;2",2&97"EB, [03_\ 7JCIVAWEE\0+[18U4^'WF37
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M9.,*./E!R,^JT4 >>>"-9OUT72?#5]X:U"'5--6.WEDFML6RK'\OFK+T.5'
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ME4DD)^8CO@ GZXKK:Y'XB^&;OQ+X=A&FE!J>GW<=_9B0X5Y(R?E)[9!/XXH
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M.*\DL]2G%M$RQ %)2Q4(^2-IW C)XR.O2J-L;AOBO/J<FGWT5H^AQP>8ULQ
MD$K.4R 1G:1T^G6J/A;PVVL?"R\\/:I:W-I)--=$":%D:,M,[QN,@=,JWX4
M=PVJ1+K<>E>3,TSP&?> -BJ#CDYR#GIQSSZ'":GJ]MI?V9)0\EQ=2>5;V\0!
M>5L$D $@< $DD@ #DU@_#\:E>:(NM:T$_M*\1(V*'(\N,%5(/HS;Y/\ MI4'
MC"ROX?%7A?Q':VTUW:Z;)/%=P0*7D"3(%\Q5'+;2!D#)P>!0!=N/&UI%I>MS
MQV=TU]H\9DN=/<*LJC;N!SG:5(&=P)Z'OQ7*Z[KD]]HO@+6[E;NTDFU2U\Y%
M8A90T+.<(K$,"<8R,\5>OM"O-;UKQ3K=K;31Q76@G3+9)HS$UQ(0[%MK $ 9
M502!GGM6?.M]<^&/A_%_8^J1R:=?VC7*/:-NC6.$H[$ ' #''/)Z@8YH [33
M?&&F:@=561;FPDTH![N.]C\LQH5+!^I^4@'\J1/%UD-7M],NK6^L[B[A>:T\
M^(8N%098*%).X#G:0&]JX[6M"U'7-=\>6MM;7$7]HZ;;0VD\L++'))&')7<1
MCJ0/Q[UI^&;RWU*YM)9/ 4FDW]HI:YN+C3T18CM((A8?,Y)Z;1TSGL" :^B>
M.M-\0W-O%I]IJ;QS-*GVAK1EBC:,D%7;^$G' /MTK9U#58;"2"#RI;BZN-WD
MV\(!=PHRQY(  R,DD#D#J17-_#*"YM/"CVMW:7-K.M[<N4N(6C)5Y692,CG(
M(JGXYM+JT\2Z+XA70WUS3[>&:UO+2*$2R(KE&61$/WB"F#[4 :3_ !%T*+2C
M?R_:T"7W]GS0F [X)]P&U\<#J.<X/;-6K3QA9WM_?Z?'8ZBE]9P"Y%M-!Y;S
MQDD!DW$<9&.<8/7%<GXBM#>>%8)-*\+3Z>LVK6MP+>*RVS,D<BL\DBH#MX!P
M#S@>^!L"*XE^+K7RVEV+-]"%L+AK=PGF^<7VY(Z[3G].M &>?&.GZY\+)-:\
M16.H6]A< ,_V7(8@RG8%9#D8PH).W/XUNW_BJXM/'ECX>BTRYEBELY+EYEV'
M=AD48RPX&XY)]L9YKA38:LWP!E\/-HNI+J<$:V_DFW),CB;<=N,Y7:,[NG/!
M-=9J:W<?Q*T/6(M.O;BSDTV>U+Q0G]V[.C#>#C8, \G% &UI?BNRU:#5988+
MJ+^RY6AN4G548.J[B -WH1ST.>#6II]ZNHZ=;WJ12Q)/&)%25=K@'D9';CM7
M#>(="O!X^A6P*?8?$5OY.JQYP0L)!W@=]R$Q'TW+793:FT&MVFF#3[QTGB>0
MW:1@PQ;<?*S9X)SQQ0!H4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC%XU9D9"1DJV,CV.,BG4 %%4M6U!M+TR:]2QNKYH\8M[1 \KY(' )&<9SUZ
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M"EO(\I0=6,:J6 &1R1WH TJ*JZ?J-GJUA%?6%S'<VLHRDL9R#V_//&.U<O\
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M[VTC)7W Q0!OT5E)XDTF31(M92Z+Z?*5$<RQ.0VYMJX&,G)( X[UJ@Y /K0
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M'CEP\>9+BV=6./F58%!(/<!L@^AKO:* /$;J2!_@UXRB0J99M6N62,#YGW7
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXOT.*Z%NUXP)NOL7FB%S$)^GE^9MV[L\=>O'7BLE+F]'Q?N-/-_<FS?0A<+
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "N!\0WEO8_%SPU-<DK'_9UX
MN_:2%YCY)'0=LGUKOJP+SP[-=>,;#Q +Y4^QP20+;^1G<KX+9;=U^48XX]Z
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M]M=J9"Z2;L[%7D$D],>O%>P44 </:.4^,&JSM%,L!TB&(3&)MA=9'9E#8P2
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M5SWQNQ^%<"=(UFZ^'VLZ1:Z;>#4;+6I+X12PE$N4%SYBJC'A]R\C&>1SC(H
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M7.Q_XB-ZY^M8OB2]NX?&6EVTEC??V7+:RYN["W9Y6EW+B(NHS&A SD%<D#D
M&@"_)X[T"/1=.U<W,OV+4)UMX)! _P#K"VS:W'R8((.['0TQ/'>D/>7=B(=2
M%];HLGV0V,@FE0YPZ)C)7@\]N^*\]LK6_B^&^@Z<^CZHES9^(UEEC-I(S*@N
MGD+< Y 4@[NASP3S79*9!\89KW[+>?9/["6#S_LLGEF03,Y7=MQG:<T ;=MX
MNT>[T"WUJ&X<VMQ)Y,2F-O,:7<5\O9C.[<",>Q/3FE@\5:;++?V\GVB"[L(Q
M+<6LD+&41GHZJN=Z^ZYKS.PT[5H-"T?4X]-OV&D^(KF[N;1K9UD:"1W D1"
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M6@5B83T?+$  ]N<GG .#5.S\<:-?KHDEL\TD.M%ULYA'\I90Q96[J1M/4=J
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MRQGS#MSMR5P<9/.#@5>N/B/HL$.I3+;ZG,FF3&*\,=F_[G !+MG&% /?DX.
M0* .OHK*N=>MHO(6VBFOIIX?M$<-J%+&+CY\L0 .1C)R>V<&JEGXRTK4M/L;
MK3S-=-?.\<-NBA9=R9WA@Y 4KCG)],9R* -E;.%;U[S:6G9=@9CG:OHH[ D
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MGA2?3/3>)M!C\3>'[K1Y[F6W@NEV2O$!NV^@R"!^5:%K"UO:10O*96C4+O8
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&,/;26S!0W?$W^K(]]W3MVK&GM=2T7XD+K]Q:S76GW^F):3M:1-*;:9&+#Y
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M=<1KNVK'DCD #&,DF@#KM(\77&J:GXDM[O2+R&UTV;R,KL<X$88Y"L6R=W&
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MN"+5V5MRNT?=@<=\<#CBMNN4UGQ/?6'CC1M#@TR::"[AFF>5'CR^P 8 9A@
ML"2<'IC/- '5T5Y9H^O1^%M4\=3_ -FZC>V]OJ0EE^S@-Y,8A0LQ+L,XY. 2
M?;%=W+XBMR+1;&&6^GN[?[5%%"54^5Q\Y+D  [@!SD^G!P ;%%9/AWQ%9>)M
M+-]9"5 DKP2PS* \,BG#(P!(R/8FH;OQ-'#=WUK96%WJ,M@JM=+:[/W9(W!?
MF8;FV\X&>"/49 -RBO/O&GBP7G@73]0T,3W%GJ=U;Q^?"RKA&E560[F!#,-R
M]..<D5FZY:PZ+XBT.VT_0+RWM=:OO,O;)9(?*E,<4A"!/,V DX9N@.T<D\4
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MO9M,2=88F12(U5 3EF ZL !5K_A*+8PZ8([2Z>\U*,R066%64*H!8OD[5"Y
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'0[?Q)HESI-W-/%;7*[)3 5#,OID@XJ[:6_V6TBM_-DE\M0N^3&YL>N !^E
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M7&IZ<MS=:;<:=*7=3;SD%@ Q /!Q@@9_&M"BB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^# !^$^C C/,_P#Z/DK&NM8UN'P;\0YUUJ[^TZ9J$JVTY";D18XR%^[@#D]
M#[T >KT5YK?-KGA[7O"VH#7KV]M]8N%LKRUFVF-2\997C 'R[=IZYSW)YSF1
MKXCU+PIXHU2/Q7J45YHVHWPM0OEA'6$G D&WY@0,8& /3K0!Z[17G&G:_JGC
M"]BLU!@ T:TO7CCO'MG,DX8E@RJQ(7  '3GD'C"PW_B:WG\/>%]7N[6XU&>*
MYDN9[>Z:'SQ$5V*'";@VU\M@ _+UP30!Z-17.^$[/7M/CO[76[R"Y07!>S*S
M&65(3T61BJY((.#SGUXKHJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ KGM?OKN6*ZTR/0]:FBECV&ZLFM0"&'.WS) >^.5KH:*
M .(T"2Z\.:##H]GX:\3O;P(4A:9[$N@]B)0#C/<&L^TTI+;PG>^&G\+^*;G3
MKOS-XFELMRER6;:5E'\1)YS7H]% 'FMII,EMJNFZG)H?C.ZN["%H%>>[LSYD
M9Q\K@2@8&T=,9[YJA)X3B;2+S1HM"\9P:/<RB46$=Q8B.%MX?Y"92P&1]W)'
M).,X(]9HH X$QW)\20:[_P (]XK%W#:&T4>98E?+)!.<RY)) .<]O3BLYM!#
M^&+[P^^@>+S97MPUQ,?-L-^YGWM@^9P"W->GT4 >.>)=3NQXD^UWVE>/M/86
ML=O!+I20R&8 LS&3:60')X Y[GL!U'AG6->LK&5+O0_$^HPM('MI;Q;1)PA4
M95QYJ\[MW49Q7=T4 <!<17;Z]<ZS9Z!XKL+NZB2&Y^SR6)654SMR'E;!&3R,
M=:<_B!/#^EVVB6_@3Q"8ID>*"$10RHY/7S'65MN2Q)9NN2>>:[VB@#B/#$]U
MX:\,Z?H\'@[6PEK"%)5K7#-U8\S]V)/XUI7&OZE- \:>%?$,+,,"2-K/<OTW
M3$?F*Z6B@#A/"RS>$M$CTBQ\,>)Y;2(L8UN)+)BFYBQP1*,\DGG-<WXEM[G3
MO!OBJ&V\/>)WEUK?(_VC[)(HF8 9"Q.6QA1P >E>OT4 >=:5/.T6EZC=>'O$
M]]]AA_T47!L@L1*[2V!*I+8R,MD@$]R:Y[PL+V_LO$=I<:'XH-G?ZM=3RVL8
MMHE>*1\[29'#\C@[#@]CU->S44 >;:YI(UG4+/48?#7BS2K^TB\B.YTVXLXF
M,7_/,YF(*^@Q1JVCPZMI=C9MX6\5V\]A(9;:^@NK47,<A^\V\SG)8]<]:])H
MH YWPE"]K:302V&LPR[@\ESJTT4DMPQ&.L;MT  QA1Z=ZZ*BB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBEY(DE0*DI5>>,<XS@'ZT = GB_1FL]2N7GEB_LS_C]B>!_-@&,Y9 ,X(Y!
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MT,L+1BX11EBA(YP"#ZXYZ5PVH:7?:UJ7Q.L;*&=)=0M;9+5WB9$F*PE656(
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M>-='U77I-%B-U#>B/SHTNK9X1/'G&^,L!N%;UQ<0VEM+<W$J101(7DD<X55
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MJ&L7/B'PCKDD&@ZG:I)ITL*)=VI2>:5D(5509.!GJ>,GC@$T 6O"^MI'X?\
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M9(\X#%F90,G('.3@XZ$CA_!FG_\ "1?##4K/??J)M1NMFVY:*88F)4%SDCH
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M_BW;2P(#;<>^"#4=GJFDKXJ\2-9V&H2:K:P6YO  <2KA]@C5F S@-T SQUH
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M$=VD,T(<L#',H5U*L5((!/.0:MT %%%% !1110 4444 %%%% !1110 4444
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M[3VR,\9)KDH-"UJ'PEI=XFA2W=QI6LW5U-IEQ%@SP2M(,J&X+!7! _K7LE%
M'-^%FANC/>V_ADZ'"ZJH6>V2&>4C.254G"CC&>3SP!UH>/X+JY?PT+2RN;G[
M-K5O=S^3$6$<2;MS''ID<=?:NSHH XN**Y;XNOJ(LKL6+Z*MJ+@P,$\T3%]I
MR./E/7IVZUEWVA7VL>)?'=LMO<01:KI<-I;7,D3"-G5) W..@+CZ\XS7I%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*@^@W8_"NDH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MIR2Q /. !GDFD\!6>I:1X?U*'4-,N()CJ%S<1QEHV,B22%EQM8C.#W(KLJ*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>6NY\EG&,"M+1(-1M],$>K7*7-YYTK-+&FQ2ID8IA<G "E1C)QCK7&^-?/\
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MO+6\M$DV==C9E*NN>S BNZHH X.WMKZ/78M;NO#&O7VHPQ-##-<7=D/+1OO
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2P,ES8[0H8(&'R,>?F/]W([&J/ACP]K2^%?B7I3Z/J,-S>23/;)<1G]Z"&P
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MRM&PS*JGE2,C!/%+X4^(&G7D^A^'KI=035+K38YXYKF$JESA,L58G)/RL<D
M''!/% '=T5REY\0M#LKB\$AN'M+&Y2TN[U$!AMY6. K'.>"0"0"!D9Q7,6^J
MZC'^T%?Z8M[>RZ>-*\];/SV:/?\ +RJL=H/Y#F@#U*BO/H_C%X<ET:75X[35
MFT^"X%O<W M?E@8XP6YZ?,!QD^W(SWMO<17=M%<6\BR0RH'C=3D,I&01^% $
ME%<SX@\<Z7X:UO3])OX;QKG4,BV\B'S Y!QC@YSDCMWIFD^/=*UB+5Q#!>PW
M>D9^UV4\:I,@ )R!NP0<'H?YB@#J:*XC2/BIX>URXTN'3XM1E_M&5XHW%J=D
M;+GAVS@' SCDXP3@'-7(_B'H<MS"%-P;.>^.G17^P>0]QC[@.=W8@-MVDCK0
M!U=%<SI7CC3=8\1:GH-O;WB:AIREIXYD5>,@#!W<YR,'IR.:<WC73EMM(<6]
MVUUK&38V011-*H&XM@MM50O.21UH Z2BN,OOB=X?T_PO'XAE^UM8M<&UD"1
MO#,,Y1USP>#TR/S%6M+\?:3JOB2XT"."_@OHK?[2BW%N4$T?'S)SGN." : .
MIHK@/ GC^Y\7Z[K<+:;=06MM<^1"2BXCV@[O,.?O$]AD#@>]=IJ<WV?2KN8^
M< D+L3#C>.#RN>,B@"W17E_A;QKI'AKX6V^M7>JZOJ]B+EXC>7$0\W<6. 5+
M$X[=3^%=+I7Q!T?5O$RZ!'#?6]Y);"Z@-S!Y:SQGNN3GUZ@=#0!U=%<5>_%+
MP[8QM<N;F33DOO[/DOXU5HHYL9((W;\>X7'O6GK?B_3M*UFTT(PW=[J=[&TB
M6MFH+B,9RY)90HX/?/'% '145XW\./&<]IH_C+5=7N=4O['3]0(19&:62&'G
MLYR !C(ZUZ'8>,+'5-*TC4K.VNY;?593%;X5<@@,26&[@81C[8H Z&N3L?!"
MV/Q"U#Q@NHN]S?0B"2W,0V! $ P<YS\B\_7CT6X^(>AVUQ<!C<-9VUXMA<7R
MH#!%.?X"<YXR 2 0"1DU%JOQ)T/1M?N]$NXK[[?;V_VCRXH/,,JX!^0*22<'
MT& "3@"@#L**\SU7XIG^W/"MCIFEW[1:N/M+EX0)&BVGY%4G[V<9.<8'&<\=
M)J?CO2M+N+NW>&[GEL;9;N^6"-3]DC/0OEASC)VKDX&<4 =117)ZI\0]#TK4
M=)LI!=SMJT0ELI+:'S%F!Z8P<]QV[U!:?$G2;_P[KNK6MG?E]%+K=V<D069&
M4'/&2,<'G/&#0!V=%<A\./%-WXN\*0:E>VDT,TI=]Y0"-@9' 5#G)V@ '(%:
MOBCQ-9>$=&?5M1AN7M(V"R-;QARF3@$C(XS@?C0!M45BP>);>Z32GMK2[F&I
MVYN8-@3A H;+?-Q]Y?Q(%<9X$\4Z/IO@O7-:N_$6I7]E;7\AEFU),/$2%Q&H
M!.>HZ=2> * /3:*YS3/&.FZKJJZ-)#=V-_/:"[A@N@JM+"W\2E&(S[9##TK@
M_AEXP-AX3\4:MXDU:YFM;#4WC66YE:5E7"A57.3R3T]Z /7Z*YC3?'.FZCX@
MGT(V]W;:E%;"Z6&94;S8B 0R,C,#U'&<US/AOXBW'BBV\4RR6&H6MI:-)%#)
M B%H%2/DDEO]9G)QR.@^H!Z;17G/A+Q;H^A?"ZPU2ZUK4-3MWF:"&>ZC_P!(
MN)"[ (J[CZ$#)Z#J!726GC+3[NXU6S,%U!J.EQB6YL90GFA"NX,N&*L"/1OK
MB@#HJ*\_B^,7AF:ST^^$.IK8WMS]E6Z:UQ'')Z,<_CQFMK4_'&FZ;JM]IJVU
MY>7-A;"ZNUM45C#&>1D%@6..<*#C(SB@#IJ*16#*&'0C(K"U7Q;8Z9K<&BI#
M<WNJ30M<"UM54LL:]68LR@#L.<GL* -ZBO,_'GQ!5_A+<^(?"]Q,WVC;$ERB
M8-N2ZJVX'E6Y('N0?>MSX?Z;+#I*:M)?ZK+_ &C;P.;6^EWB%E3#,F23\Y^;
MKSD4 =-::?!9R7$L89IKA]\LKG+.<8'X < #@5:KA?B/XYG\(C2+2TLYI;G4
MKN.$2JH*HNX;@,]7(X ]\Y]><\7>);^P^*_@XQS:K;V=W"[7&GJSDR$;@H,:
MD@G./ZT >NT5P<_CG2O$G@7Q#>6<VIV'V%);>Z*Q!;FU8 Y8#=CCD\'/![TG
MASQ?INF^%O"]FMYJ.L7>IQ.+1I BSSA,EF;>X QTY8D\=30!WM%4]*U*+5M.
MCO88YHT<LNR9-CJ58J01V.0:N4 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q/Q4?55\%2+H^B1ZO
M=/.B^4]L+CRAR?,$9!#$$#''&<]!7;44 >/>#-+U33_C+K.K76D:S%87FF((
M[B\7S&+!8L[V4D;B4;Y1TX& .!H?!#2K_1] UF#4M.NK*XEU)YE%Q T9:,JH
M!!(YY#5ZC10!X7X>\.2Z7K'B3PUXE\,:QJ=K?7S75I+ TOV6?)R/,(8(IX4Y
M;D<^@KW&)!'$B !0J@  YQ^-/HH \MCL+]/VA)]7;3KW^S3IOV<77V9S&7P#
MC=C';KTKB;;P_K@^%OCG3CHFIB\O]32:UA-I)NE3S%;(X]%/^2*^B** /%)M
M*U1_%GPQN5TG4?)TVPCCO'^R28@;8%PW''(/\^E5=(U(:=\3/B6?L5[=F6((
MB6ENTQ+[3A2%!(SZXQZD5[K7*Z'X'@T+Q9JWB&+4+F:XU0YN(I%78,=-N!D8
M^IH \>U+P5X@L?@OX=TC^R[V?4?[6^VRVT,+2-#'AQ\V!P>5X]2?0UTNM:7>
M:7\8+[6;W1=8U+0-;LDA+:<LNZ)@JKMD5"#CY3D'CYO8U[-10!XWXS\/3Q:E
M\.8]'\/WL-CIFH?:)H88GF%M$98V^8C/. Q(!..>O%10Z7J<?CGXDWC:5J/V
M?4-.>*TD%I(1,^P+A>.>:]IHH ^>7\*^(U^$?A"6#2+]K_0M2DN+BPV/',RF
M5F!7H3QCE>?FXZ&NPUK3+74?A]XGO-%\,ZO;7NJ6\<;"[25KFX<'@%&+-A1_
M$?Y"O5J* /"/[&U?[9\*F_L?4MNE1XOC]DD_<'*CYN/]D_AS72Z/INIZ1\=O
M$>HSZ7>O8:E:Q"WNHHBT? C#9;H"-K<'DXX!R,^I44 >$:)HVKP^#_B5;2Z/
MJ23ZE/*]G&UI(#,&+ ;1CW'TJ(Z)K/V;X4#^QM2SI,Q:^'V23]P/,C^]Q_LD
M_05[Y10!X#XBU;PSHGC/QMI=SJESH\>KI'%=K)8M.925)9XB"-@(<CG=DG(]
M*]?\%2Z))X/TU?#ES]HTJ*$102'.XA>#NR 0<@YX%1)X0BM]0U"[L]0N(?[0
MF\^='CBE ? !*EU) P!P20.P%:>AZ)9>'M+33[!"L*LSDG&69B69CC R23T
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M*<!5+@$''?DXJMX6T#5Y(?BI;OIEY ^KO<-8F>!HQ,&\X+@L /XEZ^M>T44
M<+\(HKRR^'FG:9?Z=>65S9ATD6YB,>29';Y0>2,$<].?K76:SI5MKFBWNEWB
M[K>[A:%_4 C&1[CJ/I5ZB@#SOX4:#K&@^&G3Q!N,UD\MG:KL)(@1V)8=SN;I
MCJJIBO.-/\#^(=2^$'B/21IEY;ZA_;'V^&WGA:,SQ[5&%W  G@G'J!ZU]%T4
M >3P:5?Z[\6] \10V5[;:;I.D;)WN+9XBTK+(/+56 +$;P3@$<8ZUSGAZP\0
M:/\ #;QC$GA:>[O;G43-!:7MDS+)&Q4;PC#YR,9QZ@'%>]T4 >*>%=)UJ#XO
M:=J]SHNLI:SZ0(GGNT!VR8YW;3MC&0<+Q@8PHJ;P/I>K:%H_CO2[[1]02:XG
MN)876 LDJLA"["/O$G' SUYQ7LM% 'SU;>#M>D^%7A7_ (E=ZMWHFK-<75B\
M#+(T9D+;E4CYB!C@9ZFNLM=%U"^^)OBSQ8MI=QZ8^E_8[?S+=TDN'*)G;&0&
M(!4CIR<8S7K-% 'S9+X:U_\ X4SH.D#0M4.H6^MFXE@%I)N6,*WS=.GS#_(-
M=9\2?#<VI:[-KV@6^L67B2T\H6LUO:R-%>J57AB!A&7)!W8&!@YYQ[/10!!9
M?:/L%O\ :]GVGRE\[9]W?CYL>V<UYQ>Z3>Z%\;9/%,UK=W.EWFF& 26T#S&*
M1=ORE4!(R%X.,9.*].HH ^?X_!>OZ9^S]J6E2Z==R:IJ5\MU'911,[QKOCX8
M '!PA//KCK7M?AD.GA;24DBDBD2SB1TE0HRL$ ((/(Y%:M% 'F7Q?T?4M0;P
MM?6%A<7D>GZHDUPEM&9'5,@Y"CD].U5O%-GJ-_\ &#P9JT.E:@;.VB;[1+]G
M8B'=NP&(! /(SSQWKU:B@#PO0]'U>'PU\3X9='U))-3FF>R1K20&</O"[1C_
M &A],TK^#XM8^&WA;2]6T[6+#4;.VG:*^@LY7>TE5U(1T5=Q5LY!']W@U[G1
M0!S'P\&NCP)I8\2!QJFQO-\P?/C<=N__ &MN,]_7G-=/110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7(_$YY8/AUK5U!//!<06YDBE@E:-E8$<@J0:ZZN4^)-O<7WP_UBQL[:>Y
MNKF Q110QEBS$CTZ?4T >-R^(=7L?!?@F_T#6]0NO$UY,RSV9O))Q<+N;[\;
M,0.@&<#@GTX]FU/QWI^G:K>Z9':W=]=Z?:?;+U;4(1;QXSR69<M@Y"C)Q5/X
M5Z9)I?@'2[2\T][/4((V2=98=C9WL1SCGC'0FN7NM U30/&_C>_-A=WEMKFG
M,+.2VA:7][MQY;;0=O)X)P,=Z &?$_Q*+W1_!VM>']4N8[>^U%$\RWF>,21G
MJK $9Y&"#TP:WK74+)_C=>6IU#6%O$TX9LI"OV39E3O7#$YYZ$#G-<'J?@77
M],^'?@K1UT^YN[VSU'[9=I;H7$*EBQ&1QD9'3OFNF?1-1O/CCJ6H_8;R+3+K
M2#9I>&!@HD*K_@>?:@#HX_B?H<MYIT:0WALM1O&L;2_"*8995(&!\V[!)P#M
MP<'MS5K1O'VGZUK6L:1#8W\%]I*EKB.X6-,\X^4[SG/KTY'/-<?\+4UWPWIH
M\(ZSX7O9);.[9[:]"*;;8QR6\PGJ,L1@$\XP*L>+?"-\WQ8T;5]*;RX-6@DL
M=5Q_%$JY)/N5 4'L56@#TC2[\:II=M?K;SVZ7$8D6*< .H/(R 2 <=LUSVM_
M$#2]%O=2LA;W5[<Z9:B[O8[;9F&(\Y^=ESP0<#/4>HKK    !@"O'O&UAXFU
MCQ5XCL8O#MP^GR:2T5I<V@2/[1*4&#-(2&8 E@$R1D X[T =?K'Q,T+1O"VF
M>(Y8[R?3=194AD@C4E6() 92P(^ZW3/2K.B^.].UGQ3?>'1:7UGJ%I")REW$
M$$D9Q\RX)(^\O!P>>G7'E>N^'-?O/@?X6T:+0M0.HVE\'EM_*^944298XZ#Y
MQC.#[5T\&BZC<_'/5]4-C>1:9>:3]DCO&A8+O*IZ].AZ]Q0!G?$CQ_%K7P]U
M6]\/+JT45I=I!%JL#^5&SAUW %7WXP>I7:?7.*]5\/2/-X9TJ65V>1[.%F=C
MDL2@R2>YKP@>'O$MG\'-6\$MX<U&34H[\.DD4689(_,0[E?^+H>!T')[U[MX
M<CFB\,Z7%<0O!-':1))')C<K!0"#CZ4 8^M_$#2]%OM2LE@NKVYTRU^V7L=M
MLS#%US\[+G@@X&>H]1575_B?H>C^'M*UZ2"_GTW4R%AGAC7",?X7W,-IX/MP
M:Y3QM8>)M8\5^(K&+P[</I\ND/%:7-H$C^T2E!CSI"0S $L F2,@'!ZU=T;P
M=<Z[\!HO#.I6,UG?+;N(TN%"LLJN61NO S@<X.,T =Y<>(;6TOKFWN89H8K6
MS%Y/=/L\J.,[NI#9S\K=NQK&T[XCZ1?W&D(]O>6D.L[QIUQ<*@2X*G&.&)4G
M(QN SGUXK'T[PGK.I_!NXTO4I"NN:A8*KF3@H50"-&].%&[W9CWKEXO"VM:W
M:_#G2O[-N[1]!E,NHRSQ%$BV,F K'ARVTXVD]>: .I\,ZSIB>/?&DTFJ:N&M
M562Z@OBOV>V50<E"&/&!GH./6N2^(_CJ76/#WA_5M$36M.@N-36.*[\SRDN8
MAN##".3U P& )'3O5J#PIK&I>*/B3']AN;:+6;8QV5Q+$521@#QGL"?7M6'J
MFD^)-2^&/A7P_'X7U47^E:@IN0T("X7?@J2?F!!ZCCWY% 'T-7):E\1-'TV;
M4MT=U-:Z5)'%J%W"JF.W9S@ Y8,V,C.T'&:ZM&WHK;2N0#M;J/K7BFE^&[O1
MO&7BC2]<\+ZEK&F:Q=FZM9K8DPMN8MME^8*.HY;H5^E 'HG_  GFF_\ ";P^
M$VM;U;Z>+SX92J>3)'M)W*V_)'![9X-27?C?3K'3#>W5M=Q;[XZ?;PE4,ES,
M'*8C 8@C<",DCH:YKXB>#M2O?^$8U?PY$D.KZ3=11+LRRK"Q"G/<JIQG_9+5
M7^*?A+4YM \.SZ#:RWSZ%=I,ULCD22J,9((Y+97MS\Q- '2S?$'2[?2=;O9K
M:\631) E_:A4,L>>C#YMI4CD$'UJI8?%+1K_ %;1;'[%J=NNLQE[*XN(56.0
MCJOWB<]LXQR.<<UB:UI4>I_#[Q)/H_A74;&^U.W2,I<J3<W#@_Q+EB H[DCO
MVQGG_P"P-:^V_"U_['O]ND1!;X^0W[@Y4<^OW3T[4 >XNQ1&8*6(!.U>I]A7
MF7ACQW?>,H_%:RZ;>6UK;O)! Z.@$ 2,\,P;=O)Y^4$#CGC->GUY'X!T?6/#
MT'C73[_2+Q3<W4\\,RH&CD4J0NT@Y8GC@#ZXH S?AQ\3(]&\":2WB'^UKK[7
M?O;'49!YB(Q.55F9MQXYX!Q^E>F:QXQL=*U5]+2WN;Z_CM'O9H+8+F*%>K,6
M8#D\ =37B4OA/Q&?@WHFBC0M0.HV^M&YE@$!RL>UOFST_B'Z^E==X@T;4=,^
M+LGB*31-2U;0]5L5MY18A_,A8!1AE!!Q\HR#Q\Q[B@#U32-6L]=TBUU33Y?-
MM+F,21OC&1[CL1T(]JQ-;\=:;HVI7>FK!<7M]9V37]Q!;[ 8X1U/SLN3WP,G
M\Q6KX>L+?3-"MK2TTU=-@0,4M V?*!8M@XR,\Y."0"3R>M>=>-;/Q'JGC6_L
MH/#\\NF2:1)##=6FR-II67@2RD@[ <_(#R<'!H Z/4OBCH.F>#M/\5-%>SZ7
M?/Y:-#&I9'^;AE+#NK#C/3Z5;L/'FGWGBEO#DUE?V.HM!]HMTNXU47,?/*88
M\\'AL'@YZ&O%O%5A?Z5^SAHFG:E87%E=6^JE6CG4*3DS,"!GIAAUQ7H$VE:E
MXE^-FC:]'IE[9:=I%DR32W47E[Y3Y@V+_>QO'(R.#STR :(^+^CR:?J5]#H^
MM2P:7-Y-\RP1_N.<9/S\C/ID]\8YKH+KQII,,.C-;/)>RZSS80VX&Z5=NXM\
MQ 4 <G)&/K7BWAN:ZE\*?$?2[/2[Z]N;[4)88?L\.]=S$CYB/NX!SDX'O6MJ
M?@C7_#<'@+4X].NM4&CP-!J%K9.?-3>23LVD$XW,./[H[&@#T<_$?0$\/+K$
MDDL:&]_L\V[JHE6YS@QGG:#QG.[&.<U8T;QM8ZUJ6KZ7'9WD&IZ5CS[24)N8
M$9!5@Q4Y^HZUQ_B:RO[3P1O\)^#Y(GO=12::*:)9;A!CF;8Y8+)D  G)'4X/
M2OX)T;5M'^)OBC4;O1=3@L;RT1H99F$S'"@D,P9MS]> 3S0!T&D?%O0]=%@=
M.T[6)EO+P6986H*P,<8,C!B .?4G )QBI+[XK^'[&&2[:.[ETV&__L^:^B"&
M..;&>5W;]O7D+],UG? _1M1T#P3<6&JZ?<65W]M>4I-&5W*54 @]#]T_E7G_
M (KT'QCXC\/:W'-X5O(;E=6$T,5LJ)!Y6""513F20DY+D'CN.E 'L.N>/=-T
M'Q-8Z!<66H37E]&7MOL\2NK]>/O9!X[C'OC)INA_$31-;T+5-6/VBQATJ1X[
MV.[0*\17KPI(/X'KQ7+>(=-U2]^+O@W6(M*OOL5I;$7,GE$B%F# !B,C/(SC
M.*YW2O!6NZGX2^(FE-87-I<:G>_:K+ST*"91(7 R>!G '/K0!Z5I/Q!TO4];
M@TF2UO;&XN;$:A;FZ5 LL!S\V58X. 3@XI+#XB:-J%QIHCCNDL]4FDM[&]D5
M1%.Z'! ^;<,D'!(&<?3.-X4FU77O!2Z%J/AR^TS48=-?3Y;VZB5$'R; 4.=S
M9X) &!SSTS@?#?0I[;3]/T'Q#X/U ZCI-V9(;R9C]E4;]PD5MV-PR0 H.>/4
MD 'LDCI%&TDC!44%F9C@ #J37&VOQ.T.YCL+HPWD6F:A=M9VFH2(HBEE!(QC
M=N4$@@$J.ASBNEUO3VU;0-1TU9/+:[M98 _]TNI7/X9KQ!O!FO:G\.?#'@DZ
M9=6]_8ZL\MW.\9$,<0:0[Q)]ULB08 )/'2@#:\2ZCJ/B#XS1^%9CJMOIAT]E
M5+65$8.Q(^T#YL$#C&>1CA<UZU;QQZ7I444MS+)':P!7N+AMSL%7EG/<\9)K
MSJ73-1/[0,.LC3[LZ8NG?93=>2VSS.>,XZ<]>E>CWS3)I]R]M L\ZQ,8XF.!
M(V#A2?<\4 <A;?%+0[FZT51!>+::U*\%C>,J&.1U;;@@,67)( RHZ]JEU#XD
M:;I_B:]\/?V9JMQJ-K;FY*00HPD3 .5._C@_Q8Z8ZX!\I.A>++\>#M2NO"^H
MQW%AJYENHHD2.*./S%91#"& 10%.20,D\DUU\VE:FOQLUK63I=Z=.ET=K:.=
M8&*M)M4[1CZ$>F: ._\ "OBC3_&'A^#6=-\T6\I9=DJ@.C X((!(_(US'Q)O
M[.TU;PK%>7^LV7F:BOE'3]NR9LJ-DF6!QR.<'@FH_@KI.HZ'X 73]4LI[.Z2
MZD8QS(5.#@@CUJK\6M*U+5-5\(OI^GW5VMEJ*W%PT,181H&7D_D>.M &_??$
M33[+Q5<^&ETS5;G5((//$<$*,)%P#\IW\<'^+'3UQG)_X7/X>/ARWUY+'5GT
MYYA!-*(%Q;.>S_-SQS\N[@CU JDFG:C%\>K[76TV]_LMM+\A;D0,59P%.!QG
ML1]:X*#PEXC3X$W/A]M#OQJCZN)EM_(.3'M7YL],<'O0![+K7C_3=#\1Z?H<
MUEJ$]WJ$?F6IMHT=9.O'W@1T[C'?..:9I?Q#TO5-,UNZ2TOH;G1-WVZQE1!-
M'M!)(^;:1\K?Q=JX+Q7<-:_%WX>SFVN)&CLFW0HG[S[K9^4X.1SQUXXR:GT;
MP]JTMU\1_$4NFW=O%J\$MO86TD16:;Y6 ;9U&25QGU/I0!UVA_%#1_$-SI4>
MGV&JM'J/F[;AK;$4)3.1(V< X7/&>",XS1'\4=!DAAO?+NUTB>]-A%J3*ODM
M+_WUN"G!&XKCBJGPRT.\MOA'!H6H6T]A>&.XBE62,JREW<@^_##I7GS^"?$%
MU\+].\"?V9<QZE%K)>:8QGR%A^<^:)/ND?,. =WM0!ZG>_$*QM/%D_AA-*U6
MYU6*'SUC@CC*R+@'ABX X/\ %CIZXR6/Q*\.7O@VY\4&>6"RM7,4\<R8ECD&
M/D*@G+'(Q@]_K7#RW@TK]HZYE-O=7*)HRJPMXS(X&%YVCD]NF3S6$OPW\27W
MPJUYA920:C?:L-1@L'(5S&N1@CLQW$X_V1ZT >O0>-K*2?4[6:RO;>_TZU%Y
M+9RA/,:(C.Y<,5/H1D8/X5FZ)\4]&\0SZ5'IVGZO(FHR/&)C:_NX67/$C D
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M!&<T_3OB1I&H:UI6F&VO+=M7MS<6$THC,<R@$X^5B5. >"!Z=>*CTJ'4M/\
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MB-,  ,5?*MR,8SWYX./,OAM\3(]$\ V,_B,ZO>+<:B]LVH29E2)C@J&9FR>
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MI^IV4]I=Q3REHID*G!;((]: .IUSQ)9:%/86LRRSWNH2F&UM80-\I RQY(
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M7ER JQ!R,GTK6HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXEEOKV*\TY2L"1&/RP#G.05).<GO73UGZYK5EX=T2[U?49&2TM4WR%5R>N
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MMV9(=2D*M;A=^X.&W9W#)P%![9QSCUZ\M8K^QN+.==T,\;12#U5A@_H:FHH
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M+HEU+"L<SW6WS9#Q\HP22@QU;!/'%:_BG0XO$OA;4M&EQB[@:-2?X7ZJWX,
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MA5MO0'')/TS@-'A/5K'Q=X)\5?8)Y([#2UT^_MD*F6$B-U# 9PPW/@X)Z9H
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%8/BG5+W2H=,:R>)3<ZC!:R>8F[Y)&VDCD8([?RH WJ*P]:U#4
MK&XD%A$MRRZ=<7$=MM^:65-FQ0V> 2V.GI5;PMKW]O;IK?4[>]MECQ+'Y)AG
MMYL\HZ$Y7O@$9X/)H Z6BN<U'4M37QG8Z/:3V\5O<6,]RS20%V#1O&H ^8<'
MS#^59'_";7T>H/X?F@M_[<&I)8B1 WDE&B,PFVYS]P'Y<_>'7'- '=45QVN>
M+G\(7KQ:L1=6TEA<7D$B)L?=#M+QD=#D.,'CH0<]:U[0:]):6=S+<6OFRF-K
MBW$1VHAQN"-G.0#U.<XZ#/ !M45Q6A^);_7+A[1;ZVMM3B,BWFFSP%);;AMC
M+D_.N=OS8(;.1CI6IJVN74&BZ7J%HL2&YO;2":.52Q599DC<#!&&&X^O(Z4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
4B@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>elicio-insidertradingcom007.jpg
<TEXT>
begin 644 elicio-insidertradingcom007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 445YQK/Q8B\->.HO#VN:3]EM)6"KJ27&^,9 (R"@QU
M&>>,YZ4 >CT5DS:I>Q^([/38[*"2VN())_M)N2"H0H"-FPY)\P8^;L>E:U !
M1110 45R7BGQM_86OZ5H%E8?;=4U)9'B1I/+10BD\G!Y)& /S(K%D^)>JR:B
MNC6GA65]=CT[[=<V,ETJ[/F4>6K $,V&W9XXXZ\4 >CT5SGA37]7UTZB-5\.
M7.C?9I_+A$\@?SEQ]X$#'Y9'/!-='0 4444 %%%% !17(/XW>+XFQ>#9-- ,
MUJ;I+M;C/R\\%-HP?E/>M'PYKFIZQ<ZM'J.@W&EI9W1AMWE;(N4'\8X''TR.
M>M &]1110 445G-KE@OB*/01,&U![9[HQKSLC5E7+>F2W'K@T :-%%% !111
M0 4444 %%%% !17+^/O%[>!_#3:U]@%[&DJQO'Y_ED;C@$':<\UT-G<?:[&W
MN=NWSHUDVYSC(SB@">BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKD?&
M'C=O">L>'[%M-%U'K%T+42B?88F+*,[=IR/FSU'2MTZY8?\ "1KH*S!M0-JU
MTT:\[(PRKEO3);CZ&@#1HHHH **;)(D,3RRNJ1H"S,QP% ZDFJ6BZQ9Z_I,.
MIV#E[28MY;D8W!6*Y'L<9'M0!?HKD=>\;MH7C?0O#KZ:)EU<D)<B?!C(ZY3;
MSV[UH:-KFIZCK^LV%YH-Q8VMC(JVUW(V5NP<Y*C'L.A/7G!H WJ*1F"J68@*
M!DDG@50T36['Q!IHU'3I?-M6DDC20='V.4)'J"5.#Z4 :%%%<AX]\;OX'MM.
MN6TT7L-Y=+:\7'ELC$$@XVG(P#W% '7T444 %%%% !17.^)/%4>A7^D:9%$D
MVHZM,T-LDLOEQC:,LS-@X R   220*GL=7U%]=.E:AIBP-]G:X2YAG\R*0!E
M7 RH((W<@CN,$YX -NBBN1\*^-SXE\2>(M%?3A:R:+,L32"?S!+DL,@;1C[O
MOUH ZZBBB@ HKD-2\;OIGQ'TGPE)IH<:E$TL=VMQ]P*K$@IM]4]>]=?0 45R
M/CSQNW@B#3)SIHO(KVZ6UXG\LHQ&0<;3D<'N*ZZ@ HHKA'^(5TGQ.3P5_8T1
MF>/S1=?;#MV;"WW?+SGC&/UH [NBBL?1-?BU^2[EL8]^GP2M MT6XFD4X;8.
MZ@\;L\D' QR0#8HHHH **** "BBB@ HHHH ***Y"#QN\GQ,G\&R::$:.U^U+
M=K<;@R\8!7:,'GU- '7T45C^*=;D\.>&K[64M5NOL<1E:(R^7N4=<':>?PH
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MYNK:RFFB&,_.J$CCOR*S?%O@VQ\57&F27-I$9K.=9$NB[!XE#*Q"@=2VW'/
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MKBUU\%=891%) Q!_<1$$LRKCK\J], UV/CF/[7\8? ]N[RI%=P.+@12-'Y@
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MMDFKM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO]F2,3SV<5V3/%$>2<E K, <E>.AYKC/VB].N[CPSI.H1(SVMG=-]H"\[=P
M5C[9!'_ A7?>-=2L_P#A6&N7_FH;6;2Y3&V>&WQD)CZE@/QH I:_\2]*TGX>
MQ^+[-&OK:X*I;Q@["SDD;6/.W&&SUZ50O_B%K.D:K8:-J.@Q17VIWYMK&47
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MDY/4_A7T#0!YM;?$G6;[Q5X@T"T\.VDEQHT;2N6U!E$P!'"_NC@G/?CWKI/
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M]P15>+POHT&D7.E16*K9W3,UP@=LS%OO%VSN8GN23FM?K33(BYW.HP,G)Z4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6@"O\-O^2:^'/^O"+_T&NIJM8:=9Z591V>GVL-K;1C"10H%5?H!5F@ HHHH
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M:/S-.\<_"Y=&0(;C2%2Y$0P)(=@)+8Z@?,W/>@#V=]1L8XC(][;K&I +&50
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MW'XLTJ;Q;)X;BN$>]AM_/FPPQ&2P"H?]HYSCL /6K^K:M8Z%I=QJ6I7"6]I
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M3%*D@!P2C X-,N+RUM-GVFYAAWG:GF.%W'T&>M4O#^FC3-)1&A2*XG=[FY"
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M.05[C.'3ZU9WGQ0\(6^J(T.@7F@ 645T?E5Y4(.2>-^,)GW'K0![6UQ EO\
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M&#'&' \QB0% /IDCGTKB-1-Q>?M$Z=9Z@F^PBTEY+2.090L<AV /&>H/L!7
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MXP#SSTK<@GANH$GMY4EAD&Y)(V#*P]01UK"O/&>CV7BRU\./=1?;IHFED!D
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M:CI+&LD;*Z,,JRG((]0:=0 4444 %%%% !1110 4444 %%%% !1110 4444
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MS9Z9I$<+2QWJ7+M-)L4*JL,=^3N_2@#G;FV@T_\ :+\/Q:#%%#;RZ0QO$M@
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MY;%U"X!5N^>O8U>\07^E:9XLTZR35)GU;_A'#;2W=])L@>$J2/W9P6E<CIN
MZ'DC% 'L$FJ:?#IXU"6^M4LB PN6F41D'H=V<<T0ZII]Q9O>07UM+:QY+SI,
MI1<#)RP.!P0:\$\+Z9+XB^"6A65AK,=CJ]MJ[2V&]_E:9?,=4/\ =R-Q''4>
M]5_$7B+6+_X823W^FK9W%KXD6'6O)3,<[(HRQ4''+!00#@L >] 'T+9:A9:E
M"9K"\M[J(,5+P2!U!],@]:?=WEK86SW-Y<PV\"?>EF<(J_4GBN0\)6-FWBG5
MM?L_$-OJ3:I!"\T-I'MB3:-J/]YL$@'@G)Y]*P?BK]K/C+X?!MW]E?VLOG?W
M/-W)LW?AOQ^- 'H%QK^EPZ'<:PE];364",S2QS*5)'\.[.,YX^IKC?A[XO\
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M!3@RR'.%SV'!)/8#\*JZ0_C:^TB+4KJXTBWN9XQ*FG_99"J C(5I-^=WJ0N
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M\^W6GV*V'P; M8 +J;;<80?O07A!#>H.2.?4UTWAA(X/B9\3K>%4CA^S9\M
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MZ5JFF7$EM$3N-TIB1\?*'8'Y03BJOA;6;RX\'6NI^([C3(;DAO/EM9U, PQ
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MV,O[2'A,V$D#QC2G'[E@0!LG*]/]DC\,4 >IC7]&,4\HU:P,<! F87*8C).
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5E4MM8*>,X(ZUSEI\5+:Q^&NC^(-=DMUU+405CMHCL#MYA7."3A0 "2?Z@4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,]Z]6\'V>F2>)-8U_3O$*:H^J10M<);J!"A5=JG@G#$#D$YKKEL+-++[$MI
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M$V75<GY>1Z]1S7M7]E:=Y"P?8+7R4?S%C\E=JM_> QC/O3FT^R9YW:SMRTX
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M$>/5K&WO8TU !8YE# 9DER0.QX'/U]:JNT$WQ.\>:!XAU>'2HM3MXXX9;A5
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M;_SRPWWO;=M_'%>FP6\-K"L-O#'#$O1(U"@?@*=)&DL;1R(KHPPRL,@CT(H
M\LM_M$O[1LTFGG-FFC(+QD^YSR@/;/W2/:L7X&>'=&U;PYJ-[?V%O=7%OK+/
M \JAC$55"I7TY/XX'I7LMKIFGV-N]O:6-M;PR??CBB5%;MR ,&EM=/LK'=]D
MM+>WW?>\J,)GZX% $ET0+28D@ (V<_2OE Q6Z?L\0W"QQK<'Q#@R #?Q$<<]
M:^LI(TEC:.1%=&&&5AD$>A%4O[#TGR_+_LNRV9SM^SIC/KC% 'G-Q]H3]HNT
MFOVQ9OHS_8F<_)Q]_';/WB?;%>:B&^/[..JR3(_V0ZP'M,C@1;E!(_V=V[\<
MU]*7.EZ?>V\=O=6%K/!'C9%+"K*N.. 1@5,UK;M:_96@B-OMV>44&S;Z8Z8H
M H^';JVN_#]C):31RQ^0B[XV!7(49Y%:=,AABMX4BAC2.)!A410 H] !3Z "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KCX
M/B-H5SXYE\,17L'FPQ8>5I  TY8*(D_O-R<X]AZUV%>0>';F&Q_:*\6I=2K"
M]S:PB!7.#*=L7W1W[]/0^E %[PA\3%DU+Q-;^*M6L+6'3M1-G:R28B+@,XYY
MY/RC..E>BWFJV%A:QW-U=PQ0RLJQNS#]XS= O]XGL!UKYRS:MX4^+\I,1D;4
MDVMQD@W#$8/IFMK5M1FTS_A4NK75V\&D1:>D;W(4.L,K1*I+9R,X]?1O2@#W
M>QO[34[..[L;F*XMY/NR1,&4XX/(]^*XSQ[X\N/#VHZ5X?T:WAN=>U:0) LQ
M/EPJ6V[WQR1G/ ]#Z8.AX#TO2],L-1?2-5DU.UO+Z2Z:<E3'YCX+",J,%<^F
M1G(Z@UP/Q0T^YT+XI>&?'$D4DFD6YC@NY$4M]G 9LL<=!A_S'N* .\U&U\8:
M9H4US9:Q!J5^D99H9K)55O7R]A!!] V[/3OFMO4O$.CZ/,L6H:C;VTC(9 DC
M@$(.KD=E'J>*C?Q-HPAADBU&WN//($"6\@E>4GIM5<D_7H!R<"O+)#)8?%7X
M@2ZPX1)M#9[5I3A7A"*"%SV!&#[YH ]7O_$&C:7;V]Q?ZK9VT%S_ *F66956
M3C(VDG!X]*J+XU\,/]LVZ_IQ^Q#-Q_I"_NQG'//KQ]>*\!U^"\M?V>?"<.J!
ME9M7#Q1R]1"1*1P>V#GZ$5W$:V(_:7E!%N(TT<;>F%(4=/3Y?TH ],'BG0#H
MJ:S_ &Q9#3'.U;HS*(\YQC=TSGC%)9>*O#^I:E_9UEK-C<7A3S!#%.K,5QG(
MQU_"OGS1'#?LP>)DW E=37C/0;X*W[^2WU#6OA!#H4D,EY;Q(;@6Y!,<0$6_
M?CITDSGWH ]EO_%&A:7<&"^U:TMY RHPDE V,W0,>BY[9Q4M_P"(-'TNZ@MM
M0U2SM9[@9ACGF5#)_NY/-?/GCG5],N+#XA6&EA[4B_B>YBF+R27,HF 9U!XC
MC!S[G*\@8%;WB^XM+W4_@\3+#/$SQ[B6#*1F '/X@C\* /7K7Q;X>OM.NM0M
M=:L9;.U;;/.LR[(C_M'M]:EC\2Z'-IT>H1:M9O922"%+A9E*,Y. H;H3GC'K
M7F7PXCMKOXF?$NSD$<D$]PJO%G(=2T@;C\<'ZTWX8Z=J6EZ_JW@B\C9]-T.^
M^VPS-T97!,2_G^\^JF@#V.LJW\3:'=7XL8-5M)+DNR+&LH.YE^\J]B1W Y'>
MG>(XKV;PQJT6G$B^>SF6W*G!\PH=N/QQ7S]LGG^$O@#3M+S_ &TFMOMB7_61
MNLDI)(ZC&5)ST% 'OMQXIT"TN;JVN=9L(9[2/S+B)YU#1+QRPSD#D?F*T+.\
MMM0LH;RSG2>VF0/'+&<JRGH0:\?^P:=JO[2VIVU_#!<PC21^ZE 96;:@P0>#
MP3Q7L-I:6]A9PVEI!'!;PH$CBC7:J*.@ H SK_Q1H6F7'D7VK6EO('5&$DH&
MQCT#'HI/;.*EO_$&C:7=0VNH:I9VD\XS%'/,J%Q[9/-?//CC5],N=,\?V.E!
M[4+J4<ES#,7DDN)1+AY!GB.,'\22O(X6ND\87%I>^(/A"QEAGB9E+$L&4\PC
MG\0?RH ];M?%OAZ]TVYU&VUJQELK9ML\ZS+LC/\ M'M4L?B31)M/BU"+5;-[
M.:3RHYUF4H[YQM#="<\8]:\Q^&L5K>_$/XG64HCDM[B["O%GAU+3!OYX_&CX
M7Z?J>FZUJO@J]C9]/T"^-W#,W1U<'REQ^)D]B* /7YIH[>"2:9PD4:EW9CPH
M R2:\Z\)>*M=^(UU?ZAIERFD>'[6<V\#"!9+BY8 $DELJHP1P 3SUXKN=<T\
MZMH&I::K^6;NUE@#_P!W>I7/ZUY7\$=1B\.Z5J?A+7&33]6M+QI?)N&"&1&5
M1N7/WAE3R.Q'K0!Z+I4NNV^L:E!K,UM+I\,$4EK=1Q&+=DR;P^21D;5Z8&#G
MC.*M:=XCT;5YS!I^IVUS+L\P)'("63.-R_WESQD<5R?Q*OGUWX9^(X/#\C7,
ML42!Y( 65EW@R*K#AB$#9 ]<=:XN,R7WBKX2KHSAWM]+5[DQ'.R'8@;=CH.&
M'/?CK0!ZK<>./"MJMPTWB'34^SN(Y@;A<HQS\I&<@\'CV-3+XL\//J5MIRZU
M8->72AX(5G4M(",@CGN.1ZUXA;&U:[^-,C^27\MPC'&<9ES@_4+^.*J3O;0^
M$OA"\;1(PU'<Q4@'_7)DG^M 'O-YXP\-V%Q<V]WKFGPW%LNZ:)YU#H..JYSW
M'YBK<6MZ7/I U:+4;5M.*[A="5?+QG'WLXZ\?6O*8KK3[/\ :7UB749K>&/^
MR5"/.P50VV+N>^W=^&:X[19K/3?@=K%UJ]C=7.ESZUNTZ**5HLGC#;AT3*G\
M1Z\T ?0FG^(=(U1[F.QU"">2U_U\:M\T7<;EZBJ#>//"2QQR'Q)I>R23RE87
M2$%^,CK[C\Q7F/@?4X[CX^ZS<3:A!<&[TB,I-&IC28A83\@;D@ -@Y)PI-<%
M%]F/P,\4./*\YM?0!N-Q&%Q^'WOUH ^F;CQ%HUIJL6EW&JV<6H2X\NV>91(^
M>F%ZFK5OJ-G=W-Q;6]U%+/;,%GC1@6C)&0&';BO*?B;IMP/!GASQII>&U'0A
M!/N'.^(A=P/J,X/T+5Z1X<CD;2A?W$)ANM0?[7,C?>3< %4^ZH$7_@- '(?&
M'Q=K/@GP]9:IH\T0>6Z%N\<T0=<%';(Z'/RXZU')XVUK0OBEIGA/4FMM0M-4
MMQ+%/%"8Y82=_##)##*'L.#[5B_M(2(/ VFQEUWG4E8+GD@129./Q%>AZ1X4
MT"TU%==MK8SZA+$%%[/</</MQT5G8X&/3% %]O$&CIJ0TYM2MA>%Q'Y7F#.\
MC(3_ 'L<[>N.U0W'BOP_:7%W;W&M6$4]FGF7,3SJ&B7(&6&<@991^(]:\.\$
MP6.KZ+J?AOQ+KUQIVL6VMF[-L@03S3<89-P+,VX$8'L>]=#;Z?INK_M*Z];:
MA!!=0C25_=2@,K-MA&"#UX)H ]/F\6>'X(X))=8LTCGA%Q&QE&#$>CY[+[GB
MK-]KNE::D#WE_!"+C)A#-\TF!D[1U.!R<=*\@^(>G3>'=>N=>\*:A:6\VFZ?
M%#?:-. (Y;3D+M7HR]01P>.#D\W+66Y7XV>']2U*$V5E<: /LD<K86)MF7CR
M?XADY[XQ0!ZA/XBT6UTJ+5)]6LH]/EQY=TTZB)L],-G%,L?%&@ZGJ3Z=8ZQ9
M7-XB;VABF5F"^N!]17SVL=W#^SMX@DN-R6EQJX>Q#\;DWIDK[9#?D:Z>U:VB
M^-GP_6 Q(A\/*N$P!S'-@<4 >J7'CGPK:K.T_B'34^SR".4&Y7*.<_*1G(/!
MX]C6G<:MIUI81W\][ EI)M\N8N-K[ON[3W)SQCK7SZ3:M)\9Y&,1?< C'&<>
M9)G!^H7\<5-J5_/I_A7X3ZK+.\>DVK8N)T7>L+_*%8CD9 #X^AH ]-^(7C*;
M1_A[<>(_#E[;3/#,B!MHD0Y<(RD=01GZ@BNNT>ZDO=$L+N;'FSVT<CX&!EE!
M/\Z\6\>Z?I%C\*?%-WI.M/J<6I:C#<R2AD,7G-(I81E1@\8SC.,?6O8O#+*_
MA72&5@RFRAP0<@_(* $OO$NB:9=FUOM4M;><*&9)) "@)P"W]T$\ G&:EO==
MTG3KJUMKW4K6VGNR%MXY90K2DD#"@]>2.GK7A[^;8P_&.+6'"7DY#Q"4X,D;
M&01%<]1@H!CV%0>)K2X3P_\ ".PUO*SFY19DE.&6,O& #Z84@&@#WG2]:TS6
MHYI-+O[>\2&0Q2-!('"N.H)'UK@?B/XOUSPSXK\+Z?IES"MOK-SY$HEA#F/Y
MXURIX_OGKGI7?Z=I&FZ0DR:;8VUHDTAED6",('<\%B!WX%>0?&UX7\<_#^*2
M8(!>DR%9-I13)#SD'*]#S[4 ='>>--:\.?%+2O"VHO;:A8ZI$&BFCA,<T+$L
M.0"0PROH.OMSV^H>(-(TJ=8+_4K:WE*A]LD@!"DX#'T&3C)XS7C5DY^'OQI;
M_A*)&O[354VZ;K%XQ=X!T"[CT'.T_4'@$TUY+1OB9X[T3Q1K/]E0:O%'Y,TN
MP++  0 KN,#AAC'<'N* .ZUOQ9JNG?%_P]X<ADA;3=2MWEE5H\LI57^ZWI\H
M_6NHN_%.@V%V+6ZU:TAF,@AVO*!B0\A2>@8^AYKRG4(8-/\ C3\.K-+B62.W
MTLQ*]QQ(P\N0*7'&&/';K7%>,]7TR]\,^++32 ]K FMB66VF+R2RR$D-*2>(
MTSP!USU/04 >Z^)/B%HOAO7],T6YNH5NKR3]YO<*MO%@G>Y[9(  ]\ULWOB/
M1=.\K[9J=K#YL?FIOD',>0-_LN2/F/'/6O*O%M];1_%+X<ZK+<Q+8M;/_I3.
M!&?E/\73N/SJE>7-L/BYXPTSQ)JYTJSUFP2.WN)@JJ\.P#:&<87JWXJ>] 'L
MNJ:[I6C0PR:CJ-O:K.VR$R. 7/\ LCO^%<=\./&.I>)]>\665Y<6]Q:Z7>+#
M:30H!O0M( Q(.#D*IR*Y"XBA\.?%SP(;R[E.AP:2UO9W=[\@W!9!\V< -@Q^
MG5:O_!RZM)?'/Q#%O+$4EU$21*IQN3S)N0/3D?F* .S^)FNZCX8\"W^N:7,B
M7-H8R$DC#HX:14.>_P#%G@UQES\2/$.@6W@O4;]K2_L_$,:>="D!CEA8A,E"
M&P1\_0CMUYKH?C=(B?"36E9U#/Y 4$\D^?&>*9\/?"F@7GA3POKDUL;R_@L(
MO*DGN'E6!MHSL1F*H0?0#&* .RO?$&CZ==BUO-2MH)SM.R20 J&.%)_N@G@9
MQD]*+KQ#HMEJ(T^ZU6S@O#&91!+,JOL +%L$]  3GV->)V_V*Y\;?$+PYXKU
MIM*&IW"R1M($!GA!.P*S@\A2F .O/I6AX@L;.7XY> ]/NF:XACTO:PN@-S[4
MEV[QZD@9'K0!ZHOB[P\]C;7J:Q9M;71802+(")-OWL8].Y[=ZLS:_I-OIL.H
MRZC;+9SD+#-Y@*RD] G]XGL!G->9_$+PTEA?:5<>$-0MM$UG2[::>VM/ECBG
MB+9D"]LY/((P=WMD8DE]?:IJOPJUR\LEL--D>0-$H*Q1S%CM//0-@%1Z=* /
M9E\0:.^E2:H-3M?L$1*R7'FC8A!P0Q[$'J#TJM;>,/#=Y?V]C:Z[I\UU<KOA
MBCN%8N/;!KQZV6X.G_&.]5L:3,TJ0OGY'E&\-M/0GE<_45D(UO#IGP8:,Q(?
MMKERN!UFBR3^M 'TG6%XRU&ZTOPI?75C?V-C>! (+B_8+"K$C[Q/'3.,]\5N
MUP_QA95^%&O;F S$@&3U/F+0!LV7B*TL] TF;6]6T_[7=VRN9('_ '<QV@LZ
M>J<YST -;-K=6][:Q75K,DUO*H>.6-MRNIZ$$=17A>H6%U/X6\&:SX>UV.Q\
M0Z9H,<L<$K@)<PA1O4$\9!'(/!R.F*]7\!:@^J^!='OY+%+%I[<,;= 0J\GE
M0>BGJ!Z$4 4[36]0E^)&I6#ZQH[Z1;V8<64<@-U%(-NYG7J%Y/MROO5X^//"
M02)_^$DTLK+)Y2,+I""_&1U]Q^8K@])FB'[3FO9D0?\ $H4?>'4"$X_*O+8?
MLW_"@]?<>5YS>(5 /&XC8F/PY;]: /J^L&Y\;>%[,W"W&OZ=&]NVR9#<+NC;
MT(SD'@_E6EI+B71K&0,&#6\9W YS\HKQ?2KO2K3XJ?$LZI-;1(]H5'G$#<NW
MYE&>N1CCVH ]FEUG3(-)&JRZA;)IY0.+HRCRRIZ$-T.>U)9:WIFH03SVM]!+
M';DB<AP/*(&?G!Y7CGG%?.EK9:Q#\)O!-Q=K*NE1ZZ)I@V<)$7&QF]%SYG)X
M^8>HKK;BW34/BE\19IIY8_#YT407UQ!R%?RH^1V+*H?CZCO0!ZS8^)-%U+>+
M/4[68I%YS!9!Q'_?_P!WWZ&G:=XAT?5Y?*T_4;>YD\OS=D;Y.S( ;']TYX/0
M]J\;\-_;[$Z]X1\27D.HZ1;Z!+);ZS9D.\=HV!MR.HP"0IR1MXR#3?#I\4:;
M_;OA(W$&L-!X?FETC5+5MSK$V D>1ZD# /(*\$B@#V:T\0:/?WIL[34K::X
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MT8)3_=]/PJQ10!"]I;22^:]O$TG!WE 3^=!M+9EE5K>(K*<R H,.?4^M344
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M4XL].)NWMR"L4>'&U\?=ZXP>F17(7EY;Z=IOQ>TZ[E$5[<Z@'A@;[\B^<YW
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6WGT^U$TD]Y!;LY<#RP\BJ< ]2<X'IG/;GG[FXELOC$MW!I$LM[/X=):VB9
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M#&(HRQ&XC)ZG STYQD9[6[\6VJ20PV*)=7$MJMX$>=80(F^Z26[M@X'L<XH
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M<31XW$L%W$(Q.">H%=#?V6IW'Q(T/5H]+N/L-O8SPS2F2+Y&D*$#&_)QM.<
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M$; @,2,X/7M0!KMKA-QH\5O EQ_:2&3='-Q'&%#%^GS+\RCMRR^O&5%I^F^
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MM7N[>>65&$B(0'W ?<(R#@YX].E-@\7S3G2+I-&N7TO59!';W,9+N@8$H\B
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MNIGE0&W<R>4<+U<!^"1C\><6[2QU1/B3J&MOI4ZV,VF16Z,98BQD1F8C ?\
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M8)2<J&#$*^#WXKH]-M-;N?B6VOW.C/96$NCI:'SKB-G5Q*SX(0GU[''3GJ
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MR0>A/&/H-B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MSI^LK>,8[E2&B6X:4GG&"0P '/OBO5:BAN8+CS/(FCE\MRC[&#;6'4''0^U
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MA4(@=V<@#H,L23^- 'EO_"+^+IM/T@WFE6D^JV&M1WEU>O>#==HK/@K\I*J
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M'WJZ,01D$G(/:L ^"O%$MCJL\?V"TU(>(#K>G_OVD1FV!#&_RC"E<\]>>@H
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MLYG1YQ F! 2<$*Q+'MQCU([])X T;5?#WAX:/J45NJ6LTWDRQ2ES,KRN^XC
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M%5XI6;[LSKMVE1A0  .3D#M3I-)U+Q#KN@ZCJEDEBFDF28QB82&69DV#:1_
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MC[8=5$Y\PP;LA?*V_?QQG.!UYQS!J/@>_P!>F\<VUVJVUMKHMS:S+(&*-"@
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MUI%+ B)N^1?LVX 9_P![D]S^56/#?B/5=+T_P18W5A:C3-3LXK:*1)B9D=8
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M]Z@LO&6N&;PG<7]E8)I^OHB8A=S+%(T/F \\;3@C'4<<F@#NXXTAB2*)%2-
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MRHQR0>A)':NKOO%]Q_PDNI:'936$.H6BQM!:7@8/>AE#%HVW <9*XP>5.<4
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MT8;)#<MQP>@R>#FM/Q;XCU+0;O1(+"QM[K^TKT6A\V8H58JS#H.GR\GG'H:
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M7.<&NMU#4K/2K1KN_N8[:W3[TLIPJ_4]JI0>*M NI((X=9L6>XQY*^>H,O\
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MOYK>:>U0IO@!VXR3WY/7K@5T5%% !1110 4444 %%%% !1110 4444 %%%%
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MUG^#_#Q\+^%[+2Y+@W-Q$G[^<YS(_<\\X P![ 4 5_B'_P DX\2?]@V?_P!
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M&\9CWERBLS$C;(, \D#IG(E@\,ZE8M>7]K/:/J6HWPN;Y)0WE21",QB$'!.
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M=8X5C"Y8A5SM &#CUKH&\6:OIVK)_:%FUSHYM)IY[N'3Y[?[(T:[\-YAPP8
M@$8Y'O3+;P-<W&C^*=)U6:W-MKMW+=A[=FWP,P0 8(YQL!SQ]*LZ7H'B>ZLG
MT[Q5JUC=V(@>#_0X7CDN0RE"923CH3PHZX.>.0":QU7Q1>QZ)J,5G8RV&HJ'
MGB7*R6:,FY&+%\28X! 4=>*YSP_XGU73=#US4=4NH;V4Z[+I\*);NI,OFK$G
M1F^0#G: 3@=2>NUX7\.>*=&@M=)O]:L[C1['"P/%"RW,J+]Q'.=H XS@$D#'
MK5*3X>7UQI&NZ5)JL44%WJ,FI6,\,1\V"9I!(I;)P0I&..H/:@"Q)XSU+1[O
M4Y-8LI)M(M;!KQ+^*QEM@'4X,)60G+'@@@X[5E^)Y=:N;SP)=:BUD(I]9AD,
M,,;!H7,3D+N+$.,$@G"\CISQM#PSX@U_0K[3/%VIV4D<]LUNJZ=$R D_\M7W
M'EA@8   YZ\8HOX2\67MIX=MK[5-*)T6^CG6=89"TZHC*"RY #8/(!QWR,8(
M!Z#7)>(?%O\ 9'B2UT>2\L]-%S;&6"ZOHF:*:3=CRPP90I P>3SN&*ZVN<\0
M:+>ZQ+<6\EMIM_I5Q;+&UK>%EV2@M^\!"GLP]#\HP10!S=^^K2_$OP\T:6D>
MIR:#/YOF9:*-R\>[@'+ 'H,C/K5BQ\>WKZ)$EW;VO]M2:T^B*(]PA,BL<R8)
MW;0H)QG)/&1G(GTGP7J&CZWH-U'=PW-OI6EG3B96822Y*DOT(&"H '/'>J?_
M  KR_ETR[1[VVAU!=<?6[&>,,RQR,<['!QE<9!(/.>G'(!HW7B?5M+\13:#?
M?8WFGL)+RPNXX65&,?WXW0N3G&""&Z&JR^-=2;PSX-U@06@.MW=M;7$6QOD\
MT$DH=W&,=\]:UE\.7&IZZFL:S]G2:&RDLX(;9V=4\S&]]S $D@  8X&>3GCG
M(/ GB1=!\/:3+JFF"+0[^&>!U@<F5(]V-XS][! P..ISVH ?#K-MX>\9_$?5
M[L$P6EM8RL%ZMB%\ >Y.!^-1>)7UJ;5? EQJ+60CFU:-S%#&P:%S$Y"[BQWC
M!(SA>1TYP-.Z\#3ZIJ'BW^T9H/L7B""&$"(MOA,2%0W(P<DYQVQCFJ[^$_%E
M]#X=BU#4]*+:+>).)DAD+3JJ,@+#( 8@\@''?/8@'H%<EK.OZW;>-]/T#3X;
M#RKVSFF6:?>2C(5&2!C(^;IW]176US5_H-_<^.],UZ)[;[-96TMN8F9@[^85
M)/3 QM''?VH Q++Q[??V08KVWM3K/]NMH:>5N$+R Y\S!)8*%R<9SD8R,\7;
MKQ%K&G^(W\.W;V?GW=C)<Z?>QP,%W)]]'C+G) (((89K.;X>7\]CJ DO;:&^
M;7#KEA/&&80R\81P0-RX!!(QUZ<5OIX>NM1U^'6M8^SI/;6DEK;PVS,ZIYF-
M[EF ))"@ 8X&>3G@ K?#2YU&^\!:5>ZC=1W$EQ")=PC*MDDD[B6.XY[@#Z5T
M&LR74.BWLME+'%<I [1R21[U4@9R5R,_G67X)T+4/#7AJUT>_NK:X%HOE0O!
M&5R@)P6R3R<]N.*W+J 75G/;LQ42QLA([9&* /,]+\3^(]*\">#+H&QOI-6N
M+:V9I5=&'F*3DG<<G@Y; Z_=KH9-4\563P6VIMHUJ6BE=KY5=XI)-^(XDC+J
M^XK\QZ],"LR+P1K\?ASPUI3WVG2'0[V&X1PCJ)$B# *>O)#<GH,=#6WJ'A_6
M)/&UOKUC>VBQ?839R0W,;/Y7S[B\>".3P#G'04 9ND^/+C6M&\+?9[>"'5->
M61L/EHX5B!\Q\ @GH !D?>Z\5CVFLW'AOQ?X_P!1U(0W$T,>FHGD(R+(7#H@
MQEB.6 .,^H]*GL/ASK6EZ-X<-IJME_;&@22BW=HF$,T,GWD?G.2.XZ>G>K5S
M\/\ 4M9N?$TFK:A:QQZW!;(!:1MN@DAY1@Q/.&YZ<X_AH UM-UW7'\4Q:=<V
M37.G3V[.+V/3YK802#^!Q(3D$=",<\8KK*YKP]8>+(GC/B35;"X2W7;&+&%D
M,QQC?*2<=,_*H R<]A72T <<_B;55\2^)M-6VLL:;8Q75LQ+9?=O.'/_  'H
M!^-9=CXU\0M8^$=6O;?318:Y+#;20PA_-1Y$9E<,3C&5^[@GWK6E\-:H?$WB
M#58Y+,QZG8I:1HS,#'L# ,?EYSO/'MUJC_PA>K#PUX3TI9[+?H-W!<-(6?$P
MB4J !M^7(;KSC'>@#O:XCQ'=ZRGQ*\,6-I?P16EQ#=2F)[<O\Z*HRQ#C/#G'
M3'/7MV]<UK_AZ_U#Q-H6M:==V\,FG">.1)XRP9)0H)&".1M'7@YH XJTU37-
M%M?B!JFDI8&.QUB>YE6Z#L90L,995VD;3@=3GZ=ZZJ?Q=->7R6.F8AE^P17L
MDCV4UT%\W=L3;'C'W222?3 /.*@\':M_8GB_3VFLMVOSS2HX9\0>9&$(/R_-
M@+GMGVIDW@_Q%8W^FZQH.HV$&I16$>GWL%TCO;W")]UAC#!AD_GC/J =+X5U
M74=9\/P7>JZ;)IU\2R36[J1R#C<N>=I&",^M;-4],M[JVL42^NA<W;$M+(J[
M5+'LJY.U1T R>G))R:N4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !5#4-9T_2WBCO+E4FFR(H54O))CKM106;'L*OUYU\/
MIFU;QIXWU6\^:[@U$Z=%N_Y9P19VA?0$\GU/- ':66O:9J%V;.VNU:[5#(UN
MP*2HH(&61@&7J.H&:T:PO$EUI_A^RN_%=S"6ET^RD3*\%T)5MF?=E7'IDUC:
MCXDUKP^N@W^IFSGL=2N(K6XCAB9&MGE'R,K%CN4'@Y /<8Z4 =M17F\GBKQ9
M-H_BV]@?2(FT"[F4!K>1A.D<:OM^^-I()^;GKC QFKJ^*==BU7PO/<"P.FZ_
M\BV\<;^;;L8C(I,A;#9Q@C:,>_6@#NZ*\S_X2GQM>Z1XBO["/1<Z)?W$!B>*
M0FY2( D#YOE.,G/.2<8&,G0N/&.I7FEV^J6?V2QL;G2EO;9IU\Z2><@DQ"-6
M#84 9('?J,4 =Y17GP\9ZY>GP2UE!81KX@@=Y5F5SY3B'?P0>1GMU.,9&<AO
M_"3>+?['\506Z:9=:UH,XVG[.XCN8S&)  @DRKX)[D< >] 'H=9VEZ]I6MO=
MIIM]%<M9S&"X5#S&XZ@_X].*R[/Q#-J\OA\Z5/:RP7UL;RY=H6.(@ !MP_RL
M68#!ST;TJ35(_P#A&M)UW7+"S-U?O&9C&D?WMH.T87!.,D^IR>>F #H:*YKP
MIK__  D/GW5KJUAJ6G>7'Y<EO&8Y$D);>LBEB1QM(R >3UZTSQAXH'AJ33//
ME6SL;J5HY[^2$R) 0N5#8(QN/&3P,'Z@ ZBBN-?Q3>Q_V3IYFMIKV_6XG^U6
M=N\\7D1N K*BL22P=/XB!SUZ&I;>+]=B6'3M1T](=2N]3-E97,D+1Q31;2_G
M&,G<"%4C;GDXY / !WM%<'XDU_Q;X8\.^(M1FBTV6.P$4EE<-&V+A6P'5T#Y
M4J3US@^E:NHZ[J5IXXTC18OLAM=0M+B7+QMO1XPN.=V"#NZ8[=: .DED2&)Y
M9#A$4LQQG %5],U*TUC3+?4;&4R6MR@DB<J5W*>AP0"/QKB?#?B#QAKNA?VR
MQT:.WC^UQO%Y4A9GC=E1@=W ^7!'MG/.!FW'B#7=:T_X>7Z7EM;-JEP'N(A;
MED9_*=AGYP2HQ]W/7G/% 'HT6K64VL7&DQRDWMO$DTL>Q@%1B0IW8P>AZ&KM
M<3/XQO-*\0>);?4UMWL=(TR.^0P(RN^=^0<L1_!Q]:6UU_Q(=9TH&Q-WI]XI
M%ULLI(3:-MRI#N<.N>#P#W]J .UHKA_"/C"X\37%OMO;(3+O&HZ8\+1W-FP!
MP/F;) /!..>",=*V_&6H:OI/A6_U+1([:6\M(S-Y5Q&SK(B\L!M93G&2/ICO
M0!NUG:EKFFZ1<64%]<B*6]G6WMUVL=\C=!P./QKF6\9W'_"8^';%+BRDTG6;
M/SHY! _F!]NY 6W[0' ?'&?E(YZUD^+;W4;_ $_PO>/]ED\SQ1 ;,*C1@Q#S
M C,<MG< &R .".* /2II4@ADFD.(XU+,<9P ,GI6/_PENB?9-)N3>XBU9T2R
M)B<&5F^Z,8R/QQ6)9>(=?CU3Q-I%Z^GSW>FVL5W:SQ0/&C*X8[70N3P4Z@\Y
MK%U75KC7O"OPZU:[6-;B[UFRFD$8(4,4<G )/% 'J%%<)J/BS6;I-9?P_ ))
M--N&MXK=K*247+H!O!D4@)DDJ/3&3UP.RLYYKO3+>XD@:UGFA5VAE&3$Q&2I
MQU(/!^E $.LZWIWA_2Y=2U2Y%O:1??D*EL?@ 35MTBNK<I(BR12+RKKD,#Z@
MUXW>W&JWGPC\=3:E?176V\NXLB HV4D"@YW$;<* %QQZFNR3Q#K&D^+-,T[5
M6L7T_4+&:>,01L'MS"%)!8L0X(;KM7GM0!UEAIMCI=O]GT^RM[2'.?+MXEC7
M/K@ "K5<!;>+O$%];Z+JVGZ>UU9W\L9FM!92*T-NXR)!*3M8J,9&,')QZUUO
MB'68O#WAZ_U>="\=I TI0'!8@<#\3@4 :5%<9!K7B;^W["V^RBYL;N*03S_V
M?+"+*0+E3\S?.A/&.#WSVJ'1_%>LWWA_4DNA8)XAL]1.G^2D#^5O+ (VTON*
ME2'SD< ^E ';NBR(R.H9&!#*PR"/0U%9V5II]JEM96L-M;I]V*&,(J_0#BN-
MU#Q1K%RVLQ:*BO<:6_D*IL)95N9Q&KLNY6 13N"CDD=>G5D7B7Q/?^*K/1HK
M:QT\W6B_;V6YB=Y+:3>J,K , ^,GCY>N<\8(!W21I'NV(J[B6.T8R3U/UIU>
M3ZGXFU[5O!NE3&YMK6\3Q'%IUYY4)*3%+@*",MD*=H)&<GID"N]D\5:'I]ZF
MEZEKVF)JGRHT!E6-BS8QA"Q(SD8&3UH VZ*X;3_&%SJ?B&YTJ.\LK;4+:^:&
M33+F%EE>W#$"2-BPW97#\ C!QCN<S_A*?&UYI'B*_L(]%SHE_<0&)XI";E(@
M"0/F^4XR<\Y)Q@8R0#TRBN$M?'$_B$(FCAK8_P!GV]X[M9R7.UY@Q5"$(P %
MY/?/&,5)I7BO6M5DT?2;G3TTK6KFTENKQ9D+K"D;A/E7(R6+ C)X&<YH ZK5
M-6LM%M%NK^4Q0M*D08(S?,[!5&%!/4BC4=6L]+5#=.^Z3/EQQ1-+(^!D[44%
MC@=<"N1UGQ%XJT+PRMY?6VG)=KJD=H6 9EF@>54610&^1B&Z$G&*BUA=3?XQ
M:*L-Y:HG]F731![9FVKNB# XD&2<#GC'H: .G\/^*M%\4Q3RZ+>BZC@95D81
MLH!(R!\P&>/RZ&MFO/\ _A-KO2H_%OVRVM&&D7<-M:1P*8Q(TP4KN))_BD&2
M/?BNCLV\20Z^L%X+*ZTN2V+M<Q(8GBF!^YM+-N4CD'MCDT 7-6US3=#6V;4;
MD0"YF6"'Y6;?(Q  X![FKTLJ0Q/+(VU$!9CZ"N*^*1<>'--,2JT@UFRV*QP"
M?-& 3@X_*I+#7_$&G^.8/#^OBPGAU"WDN+*YLXWCVM'C?&RLQSP00?\ '@ Z
M;1]8L->TN'4M,G$]G,6\N4*5W;6*G@@'J#5ZO,/ U_?Z?\+?#S6?V6*&2ZG2
MZN[EP%MXO.E.X L-Q)"J!GJW0U=L?']VVD7_ )\4,M]%KBZ-:OY;1)*SE-CN
MI.5P')([[>,9H [C4=1M-)T^>_OIA#:P(7DD()VJ.IP.:?9W<&H6-O>VS[[>
MXB66)\$;E89!P>1P:Y'Q"WB&/0_%-MJ*VD^F?V/-)!=Q+Y;>9Y;!HV0L>,<@
M_AS47@76;G6=$T>'2+BS_L_3[&&WO7DC+NTXC0[$PXVX!Y)!Y(QGG !W5%<$
M?%NLZAX0U#Q9I(LVLK5YWAM)8V+3PPL5<EPWRL=C$<$#@'-6])\776K^+K:P
MM_L_]FWNA+JMNYB82HS.%"L=V",'/ 'UH [*BO)]2\3:_K'AK1[D75I:RMXG
MCL)A#;MMD5+C"G!?(&4!(SSTR._JD0E6!!*Z/,%^9D0JI;U R<#VR: *VG:M
M9:K]K^Q2F3[)</:S91EVR+C<.0,]1R.*NUY['XXU2'PSX@U*\@@9],UI[!GM
MX'98X%9 TI3<6; 9F(!KIO#.JOK%K/=IJ-CJ-DSC[+<V@QN7:,AQN.&!SZ=N
M!0!?N]6LK&_L;&XE*7%\[);H$8[RJ[CR!@<#OBKM<SKNNZAIOC#PSIL*VQLM
M3EFCF+*3(I2)G&TYQC(':N;G\5^+'TWQ==V[:1'_ ,(_<R@!X)&\]$B63;]\
M;203\W/I@=: /2J*JZ9>C4M)L[X)L%S DP7.=NY0<?K7$WGC#7+RPN]1\/V?
MVK[-=O!%9&RD;[2L<GEN?.!"J3AB.#C SG/ !V6I:O9:4J&ZD?<X8I'%$\LC
M!1EB$0%B!QDX[CUK*D\=^&X],34AJ7F631K,9H89)%C1B5#/M4[!D,/FQ]T^
MAKG[LZI/\8M+,=S;Q*=%FD2.6V9BBF6+<IQ(,MTYX QT-4M+N;C1_%_Q!O;V
M:SDL;&&WEN88[0CS$%NS;4S(0O?.0V23TS0!Z<CI+&LD;!D8!E93D$'N*=7#
MVWB3Q"-0TB8V7VC3;M?],"64D7V,%<JP=CAU'0\#U&.E2Z=KGB36]*TG7M+@
MLI+*]N%+V;@J\=J21O\ ,W8+@88C&.2.V2 =G17#^"+C5[GQ)XL^W7\,\4&I
M>2%%N5( B0J%.\@*,],$DY.>:[B@ HKS[Q3XQUGP];ZG?2"RC%G=1+!8[3+)
M/;LR*9696_=Y+-C( ^7'.:O76M>(Y_'E[X<L)--@B33DO(KB:%W9"TC)@J&&
M[[OJ,9[]* .SK.M-<TV_U:]TNVN1)>6(0W$85AY>[.WDC!SM/2N/T?QY?ZMH
M_AJ'RK:+6=8GN(6.TF*(6Y82N%SDYVC SU;KQ3_"J7D?Q4\7I>S132"UL=LD
M<93<N),9&3SVZ]NW2@#L=3U:RT>&&6^E,233I;QD(S9D<X4< XR>_2KM<SXT
MUW4- MM*GL5MV6YU*WM)A,I)"2.%)7!&#]<UG/K7BB^\7>(="L)=+@6P@@F@
MGE@=S^\#G#*'&3\H&<C'H<\ ';TR::.WA>:5ML: LQ]!6+X-UV3Q-X/TO69H
MEBENX \B)]T-D@XSVR#6'IMQJ\WQ;UNVDOX6L[>QMF2$VY^56:3A3OX;(Y8@
MYXX&* .LTC5['7=+AU+39Q/9SY,<H4KNP2IX(!Z@U=KQSP?K>M^'_AOX3OHC
M8MI<MXMG+;M&QE99)V7>'W  @G[NT_7L.IU'Q7K-TNLMH$ DETVX:WB@:RDE
M%S(@!8%U("9)*CTQD\'  .ZHJO87$MWIUM<S6[VTLL2N\#_>B8@$J?<'BN$/
MC/7;_3+;6M$L&O+>2XQ]A%E)N>#>5+";.W?@;L8QVY(R0#T.BN/M/$]_;>*]
M?TC6Y+**&SM%OK.2*!U,D'(=FRYSM88(&,]>]1MXDU87=GHT_EPZH]@+VZ>"
MQDF$09MJH$#$YR&RQ./EZ<\ ':45YS+XO\66^GZ";K2[2UO+W5_[-F2='02+
MAF65.254A>AR1S3-2\2>)(M-\<Z;/>6:7^CV*W=O>6ULR!D>-VQL9SA@4(!R
M>N<4 >DT5B^$A=#PGI9NYHI7-K$5,<93"[%P#EFR??CZ"MJ@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y*;PK?:=XHN]?
M\.WEO!)?JHO[*ZC+13,O"R*5.4?'!X(/IFNMJM?W]MIEC/>W;E(($,DC*C.5
M4=3A03^E &3?:!-X@TF]L==G1HKN!H##:@JB!OXLGEF! P2 !Z=<YT/A34KN
MQT;3M;OK:YM=)GCG62*-E>Y:(8CW@G"X."<9R1V%=-INH6^K:9:ZC9N7MKJ)
M9HF*D$HPR#@\C@U:H XF+P=J2:1XML3>VI.ORS2AQ&W[CS(Q&1C/S8 SVYJ2
M;PCJ,L?A-1>6H.@LK,?+;]_B,Q\<_+P<]^:[+(SCO2$!@00"#P0: /,O"EEJ
MFI6OC>QM+FUBM[K7KV%I64F2'(4,5'1C@\9Q@^O2M5? EY8:M(^D:E!!ITVE
MQ::T4\!EDA2,$ QMN &<\Y!YYYKK[/3+#3RYLK&VMC(<N88E3=]<#FK5 '!:
M9X&U:Q7P@)-3LY?^$>61<"!E\T-'Y>/O'&!SGG)["KUI;1>$-6U[7=;U:PM[
M/5KF)@9#Y8B94"!2S'!R!GMWKKZAN;2VO83#=6\4\1(.R5 RY'0X- '*?#[0
MK32[+4+ZS9S:W]U))9J_2.VWL45?1"S.X]G%=+JMO>76FS1:?=+:W9P8IF4L
MJD$'D C(XP1GO5P# P** .9T?PO]B\57OB&6.UM[FZMEMY(;,$)(0Q8R,2!E
MCD#IP!U.>-#5[+4+JXMWM'M9+8))'<V=TI*3AMN.1G!&#U!X)&*UJ* /.O\
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M&%)SR!]W/-8?A2RU34[7QO8VES:Q6]UKU["TK*3)#D*&*CHQP>,XP?7I7II
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MW>FVUNNGVU_;RSVK,0LA/RL _)P.HQCTYR&R^*O$FI:2^L^'K)KH+=/'%8F
M;9XDE,;$REAM8A2P[#I@]:WK#PQ<6'C2ZUQ+V#[+/9QVBVBVY!18R2I#[_\
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M1^6@XP%1,G:HQZDYR>] ')'Q;KD$?C3-O%=RZ-/$ENEM V2C(K%BNXEB Q.
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M-KCD'G&1TK8&L^(++QII>EWMQ8RVVKVD\D2QV[ VTD84\G=\X(;GA>G:C5_
M<NKZ1X@BDU"*/4=<$<=Q<BW+)'&@PJ(NX'CGDGDDG'0"[>>&=0NO$FAZQ_:5
MLK:7!-%Y7V5B)3(J@G/F?+C:,#F@#DD\9^*E\#Q^*II]-\JWU V]Q:I;-F9/
MM/DY#%OD(R,#!Z9)YP-_4?$6LW]UKEOH*,)=+<01#[-YJSS>6KD,2PVK\RKQ
MSU.>U5C\/+YO $WA8ZU;XEN_M/VG[$>/W_G;=OF?WN,YZ5:N?!^MVWB6ZUG0
M/$$5@=15/M]O+:>=&[JNT2(-PVG Z9/OF@"2P\0:OKFIII C72;V#3HKN^#J
M)6CED) C7G&!M8D\Y! XK%U.X\52:YX$@U*ZMK&\GN+D7,-NGF1%TADVOR02
M"I^[G@GO@5KZCX*U%-<M-<\/ZY]CU%+46=T;N#STNHP=P9@"N'!).1].!5C4
MO"-[=R:%=P:QC4M+N))VN+BW\Q9C(A5QM#+MX;C!XP!S0!GW'C6\T;5O&?\
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MFKLZP?!GA^;PKX4L=%GO$NS:J5658O+R"2<8R?7K6]0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %4H-4@N-6O--1)Q-:+&
M\C-$P0A\XVL>&Z<XZ5=KA9/$6N+KGC6R6XM-NE64%Q9$VYPI9)&(8;LL?E S
MD?2@#NJ*\VL?$OB2*V\$:K>WMK-;:X88)[5+;:5:2$N'#YZY7D8QSCMFO2:
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MC$Y^?@<#CYCTQQ4_B6_\5>&_#GB74&O;>:"SB2?3IVC4R/Q\Z2J %P#T(P:
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MO[^+3]/NKQDEF6V0N\=NGF2' S@*.IQV]ZH3>)K"#5M'TR5+E+K5E=K=6@8
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M+Q)I8U'3_-^SF22,>:A1LHQ4\'D<@]: .<MO NH:;JM^=*\1S6>C:A.US<6
MMU9U=OO^7*3E WT..V#S6A:^&+NS\3:SK,.HP#^T8(H!";0XB$88*<[^?O'/
M _"NE9E1"[L%51DDG  I: ,3PCH#^%O#%EHK78NUM%*)*(O+)7)/(W'GFMNB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M 8/A7Q7=:SJMO87FIR66MQB3[?H]Y;JF/E.&A(4%T!Q_$<CG([U;/QMJT>@
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M3CTQ[4 ;NQ<YVC/KBEKS&?5_%6C_ /")ZS<ZRMY8ZO/;6=U9"V1!$9E^61&
MR2#USP?0#@)-XFUU/AYXQU$:F_V[2-2NH+:?R8L[(V 4,-NT]>3C- '<Q^(K
M.3Q5)X=$=P+V.T^UEFCQ&8]VW@GJ<^@[&CQ#XBL_#5C'>7L=P\4DR0CR8]V&
M=@HSV R1U-<9>6^H:E\5T2RU,Z?-)X91GN$A61Q_I!^Z&^4'/<@\?F,;5]8U
M34OA]JECK4L=Q?Z3X@M[)[F- @G431,K[1P"0W(% 'JIU$#6UTS[)=Y-N9_M
M(B_<##;=F_\ O]\>E7:XN_\ $%_IGQ&N;2:Y,FE1:!+J'V=8U!#I*JYW=3QG
MVYI=&?Q)K&E^'M?M]6AV7@CN+VSEC7RA#(N[;&0N[>N0 2W/.?2@#LZ*Y+XB
M:IJNC>'(;S2;M;>?[;;Q-NB#AE>15(YZ=>W-4I+W7+#Q%#X<EU6[U"6XBGOS
M/;P012QQ!D18E#G:0"S$M@GH/>@#I/$'B*S\-V<-U>QW#QS3I ODQ[L,[!1D
M] ,D=:UJ\K\3GQ / 3Q>(E!FCURU6VF)3?+!YZ;&<)\H?J#CCBMR_P!7UG6=
M7\0:=H[WD#Z84AA>V%N0TK1B3=)YIR5^8#  Z'DY& #N**X:2_\ $;OIUOJ=
MZEA=2:<S2VFFJLL[W(8 MAE91$!W) RV":R(/'&JGP7X6U[4A=II]U!(=3O-
M/@5VA<8",RE6PAPY) X(';@@'J%%<#!XEN[VYT?2;'49=1^U6<]ZU_9"$/+&
ML@1  ^$!^;YN,@KCU-;_ (3/B$6%U%XB4&6.Y=;:8E-\L'\!D"?*'Z@XXXH
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M3^\ASP>^#6#IL/B.X_L/5$UF&:VN(?,U"WEC4)AT!4P[5R,,<?,QR/>N3O\
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MM4UO5->\3Z%;ZG=Q>1:V\]A<W5M&)8V</G<NT97*CAE#8)]J ._JI9:C!?\
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MD1@&4A0 RX8$9^GUS]!\8ZOJ/AKP?%-)-+J.M)<233P)$K[8LY"!\("<KV/
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MR1@<UJS2>3"\FQY-H)V(,LWL* ,S0]'N-+AD>^U2XU2^EP)+F9%3Y1G:JHH
M4#)/KDG)K&U+P/+-XEFUW1M?O=&N;M%2]2"-)$N HPIVN" P'&[_ .OG:\.:
M]:^)] M=9LHYH[>Y#%%F #@!BO(!/IZUJT 86M>%;+6O"KZ!*\T<)5=DRMF1
M'4A@^X\[LC.>_-,\1>$;#Q!H,&E%YK,6CQRV<]LVU[9T&$9?H./H:T=:U6'0
M]&N]4N(II8+2)II%A4,VU1DD D=@>]3:=>QZEIEI?Q*RQW,*3*K=0&4$ ^_-
M '+W/@>YU+PW?Z7JOB&[OKB]C$$EW)"BE(LYVHB@*N3U)R3^ Q>G\+RW.O:'
MJTNH_O=)CDCC180%D$BA6+<]<*,8Z'UZ5T=% &#X:\,CPU'=00ZA<3VLMQ)-
M%!(J@0[V+L 0,MR3R:BE\+-!XDN]<TG4#97%]&D=Y&T0ECE*#"OC(PX'&<XQ
MU!KH9)$B4-(ZHI8*"QQR3@#\20/QIU ')/X$MXUT)+*]DMTT>=KF/=&'::5]
MV]I#QG.YCQCD_2NGO+2"_LI[.ZC$EO<1M%*AZ,K#!'Y&I6.U2<$X&<"LGP]X
MAMO$EK=SVL%Q"+6[DM)%G4*V]#AN 3QF@#(\.^";C0?(MG\17]]IEI_QY64Z
M(%BQ]W<P&Y]O8$X''' Q6N/AW]I\/ZYH[ZO((=8OFOIW6!=R.65B%YQC*+U!
M/6NWHH YOQ)X2'B.VT^1M1FL]5TZ3S;6_ME 9&(PWRG(*D=14-]X*_M3PU<Z
M9J&L7=Q>SO'*=09$#J\;!DVH %"@C[N.Y[G-=%?7:V%C/=O')(L*%RD0RQ ]
M!5?0M8@U_0K+5[5)$@O(A+&LH 8 ],X)&?QH Q+?P==1>(UU^;7[F?4!8&R8
MM#&$8%]V=H' SC@8/').:JI\/1'X.TSPVFK2"VT^X2>.4PC>Q1]Z@\XQGVZ8
M_'=TOQ%;:KK>KZ3%!<17&EF(3&50%;S%+*5P3D8'?'6MB@#F+_PC)?\ B"YU
MAM4DBFGTM],*Q1 !$8[MZG.=P;D=O;O4@\)K=:HFHZK=B[NH[*2Q1XX1$3&^
M-Q;!.6XXQ@#)P.:Z.B@#AX/AV]K:Z"L'B*^6YT0NEI.8HSB%EV%"NW!^4#YC
MDTV;X;+)I>JZ>-<O#!J.H#4)-\:,5D#*W!P.K(N?;@ <UW"2([.J.K-&VUP#
MG:< X/IP0?Q%.H YNZ\)K?\ B4:S=W8E!T]].EMO)PDD3D%L\YR2/R_.JOAW
MP1-H!@MF\0W][I-HV;.PF5 (L?=#.!N<+V!.!@<<#&I#XEMI_$E_H2VUT+JS
MMEN78H KJQ(&WG).0>PJ_I=\VI:9;WK6=S9M,FXV]TFV2/V89.#0!RNG_#TZ
M5>SQ66OW\6@S3-,^D!4,>6.64.1N5">JC&<GGFKMYX0;4HVM+_43<Z=]O^W+
M$\(\Q&$GF!%DSPN>.F<9&0*ZBL?Q)XBMO"^EC4+N"XEA\U(CY"@E2[!03DC
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ML*7K6L;NK2E8P_F*"#L.?X3C!]1D5JT4 97B#15\0^'+S1[B8(EW"8I)!'G
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M$@B?^ -Z$'&3C%6HO"B6OBB#6K2Z$(M]._LV*U$.8UB#!AWSD$#\./>NCHH
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M@14$LJJIV@  84 =!_.M*LSP]KEMXET"SUBS25+>Z0O&LH 8#)'(!([>M:=
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ME4>6SB3=@@ D?*.I-8?A36;@>'_ 'ANUG:V-_I[3SSH!O$<:#Y5R" 6)&3V
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M>T( &QUQM8<>G6KEUX)CN5TDMJU]YVG77VWSGV,\\V"NYR5Z8.,#  P!C H
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M)2IC<8+YVJ<MUW=,#BO2><<=:XVW^'<%EJEU)9:UJ=MI5Y,T]QI4;KY+NW+
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MI&?45;D\%I'XDN]9TS5;S3FOU5;V"%4:.8J,*V&4[6QQD4 5/A/_ ,DL\/\
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MGRM^ P?2@ UOQ1:Z(FG2-!-<Q7U]'8I) 5*I([[?FR0<9!Z ]*W:\2M8)O\
MA4?@607<K2SZO8L#*=XC/FMT''UZUT-[XAU/PAK'BR!]0N=3@M-'34K<7>TE
M)2SJ1E0ORDJ#CMVH ],K&O/$<-EXHTS09+6X,NHI*\4XV^7B-06!YSGD=N]8
MEE:^)X]<TF^BO ^F2(5U!+FZ$@ER!L>(! %.>PP"#TJKXRMIKOXC^#((+R2T
M=X=0'GQ*I=1Y<>=NX$ ^Y!^E '5>(M<B\-Z!>:O/;3W$-K&9)$@V[MHZGYB!
M5^UG%U:0W"@A945P#U (S7DVK7FJVWAGXC>&M2U"74HM-L5EM;N8 2F.6-CL
M<@ $@KUQSG\*Z6YFN9+G3;)-1N/+;2 Z6%@=L_F< 3,YP%0#@!B 3G@]* .Y
MK&\2>(X?#5I;7-Q:W$\<]S'; P[<(SL%!;)'&3VS7%^&O%FI:_9>#-/N[MHY
MM4L9KJ[N(P$>7RB%"J1]W.=Q(P?EXQFD\;6FI:7X/,.H:B=2VZ[:R6OR_O4@
M,RE48_Q,.1GO0!Z=17!6OBAI?".L>-DNII4AAE>/3"<+;-&I&R08SOR,MV&>
M,_>-75M4U;0?#/A_Q/%J<]V\\MLM_ ^#'.DV =BX^0@L-NWMUS0!Z/3'FCCD
MCC=U5Y"0BD\L0,G'X"O/8M5U,V'Q"0ZC<$Z5(YLGR-T6+<2 9QR-Q[YJA;_:
MM4\7^ ;NYU&\\VZT.2:4HX W[(B2!C R6.?_ *U 'H^J7TNGVT<L-A<WK-,D
M9CMP-RAFP6.2.!U-6O.C\_R=Z^;MW[,\XSC./2N3^(=_?Z9H^GW.GWTMLQU.
MUAD"!2)$>15*G()''H167:6MU_PMCQ.]O>W!FCTVV>&.23]WN/FX4C'"@]AZ
MDT >AT5Y?I'C)[5+MM2EU.UUS3M*GGO-*O\ [MRZ -YL3#@K\K#"D##=.*TM
M-7Q5=2>']8MKQ6MIPCZ@L]R&BFC=0<QH%^5@2, $9Z$GK0!T6B>*+76H-6F\
MB:S33+N2TG^T[00R*K,WRDC'S>O:H]+\4?VI>V<<>DWZ6=];?:;6]* Q,G!
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MU@A:1$\APW#OACDKD@GJO2IO-?2_B/XSU1KJ[E6QTJ"Z$)D^5@!*VS&.%XX
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M/+E+9RJ\YR,<\=ZNUP8U#56\9>,-/&JW AMM.@GM?DC_ -'9A(3M&W!^Z/O
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M85UB< !QMY&.,# YZ4 >OT5P37>JZ;X[\,(^KW-S!K<-S]IMI0HBC9(Q(IC
M&5QR.2<CJ2>:RI-=U6TG\.W4>JSWSW>N?8KJYB %G+&YDQ'&IYRH51N48RIR
MQH ]-:X0&94/F2Q+N:)"-W.<#\<5#IEY)J&F6]W-9SV<DJ!FMYP-\9]#@D9K
M@?#EI<+XA\?21ZI?)+%=*$<NKX)@4@X92.,\#& .U0Z%XHU+4M/\!Z7<7DHG
MUFUFN;NZ&!(XC3.U3V))&2.0!QC.: /3Z*\MUO7-;T:3QEHL6J7!%CI/]J:?
M=D*TD0PP,;$J=PW+P3\V.]7;>\U?3_$_@MI=9NKN+6H)4NK>4)Y8*P>8K( ,
M@Y'.22<T >BUS;>,8CXCNM!ATC4I[ZVB6:18_)"[&. P+2#/\ZZ2O-XEOV^-
MVM?8);:-_P"R+?<9XV<$;STPPH [C3-5_M)[F-K*[LYK=PCQW*J"<@$$%68$
M<]<]0:T*Y6\LO$=UX.OX/[06V\09G>WFM0 IP[&,8;/RE=H.>F:J^'=<;Q19
M^'[BUN;B-4M3<WZAN=PS'Y3\=W#GM_JR.AH [2BO,].OO%?B7P]IOB32+A(9
MIIO/9)KH"W,&XAHBFTX( QNSG(Z]J=(VMZCKWCJR_P"$COX(=,6"2U\E8U9"
MT!?&=OW<]L9/&30!Z.\T<31K(ZJTC;$!.-QP3@>^ 3^%/KR=[F[\0WOPNU"Z
MOKF.>]BE>;R7"KO^RL2X&,9.3] <#%:&J^(;G3/%$]EKMSJ.F137D0TS44^:
MSDB^3,3XX5V(<$L,\\$ "@#T6::.W@DFF=8XHU+N[' 4 9))]*R;WQ'#8^*-
M+T*2UN#+J2RM%.-OECRUW,#SG/([=^M8'Q?1V^%^LLD\T12-2?+;;N!=05/J
M.>E5?$UC,/B!X'M(K^X1RFH#[2VUI #&N<9&,]AD'Z4 >A45YI8ZMJL.A>*+
M"7Q 8WTW5UM8;^[0/+Y+>6VP!5^:0AF5>"22.*?;:AJ%QJ?C/1WN=1@M(-.A
MN+83R#SX2ZR;L."2 =H/)R.>E 'HL,T=Q$LL+K)&PRK*<@CVI]<G\-8#%\.=
M!8SS2>980M^\8'9\@X''2N2DN]?N/"WCB_/B6_2?1-0NOLA18AD11HRJ_P F
M"O;  ZDG/8 ]9HKSL:AJ]GXC\&WCZO<3QZX'2[M&5!"O[@R*4 &5P1W))'6J
M.LZ[JM@%O[?59[N5=?CMGD@ %HD#2A/((;[S 'EE!(;/S#&* /4J*XB[U6Y\
M-_$,+JNI3-HFI6DCVOFD;+>>/YG7(&<%/F&3V(%=!X:2\&B0S7\LSW%R6G*3
M$9A5SE8_^ J0ON030!KU2FOI8M7M;);"YDBFC=VNE \N(KC"MSG)SQQVKS34
M_$.N3:%KDUOJ%Q;>*+;5C;6FGQE<F(R*$41L"&#1DOO(/<YP,5TEY=:E9?$?
MP]I9U6YGL[FPN6FCD6,;W38 YVJ.?F/MZ 4 =I17G=EJ^IZ;?^*?#]]?W%SJ
M*O')I4DA +13?)&!@#[DF0Q]*MS7>I7_ (DOO#EO<W3)IME S2I<B&6223?^
M\)VG.-HX&!DG(/& #N:*Q_"RZW'X=M8O$4UO-JL8*3RVYRKX)P>@P<8SQUS6
MQ0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[27EG$4V,S##E25+)N'7!^F#S5E?"=I%XCMM:M[JZ@DMK+[!#;Q^6(5AR#@
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MEIM44K=W9*^=(-NW&=NT +P   ,GN<U0/@*P"Z(8M0U*";1X3;VT\4JJYA(
M,;_+@C"CMGCK0!RFF>*]57PQIUI<WDJSW?B232#=2$-)'$'? W="^%V!O?/6
MMSQ'I=WI?AGQB6U>6XT^XTJ9K:TG8R/ PB8.0[$LRG*G!Z5:/PVT)M#O](D>
M^DMKRZ-X"]P2\$I8MNC;L02>3DGN35F+P5;+HE]IMQJNJW;7T)MY[NZG628Q
M$$; 2NU1@GH,\YZT 8/@'4AXA2VBDN;JS;1[2" Z>)"AE!C4K,^#RI_AQVSG
M.0%BM-0U'Q-X*USQ%!J=U9W]O/=?8TCD(C@$)(5&3[KYVY;<"?F.,8&.BC\#
MV,&H:3?P7U_%=Z9:_9(Y4:,&6'C"2?)A@,<>G7KS2MX(L%EU,6]Y?6MGJCM)
M>V4+J(I688<\J64L.NUAF@# T3Q#?ZOXL\+SO+-#!JN@O=W%J'/E^9F/!4'I
M]X]*YWQ!<7>H?#+Q;]JOKN3[#XB-M 3,V1$+B)0A/\0 8]<\\UZ/JGA"RU&]
MTR\AN;O3KC3D:*![%U3]TP ,9!4C;\H]QC@BJ8^'FC#0M8T<S7S6NJW+74VZ
M?+)(6#90XXP57KD\<YH R_%=_=^'-0@>[BUB?PXMH5DNK&=FFM9BQ)DD .YD
MVXP3D#!X-=CHD\=SH.GS17@O4>VC(NA_RV^4?/\ CUJ@?#&)C-'K.J)(]L+:
M4^9&_FJ&9MS!T/S9=N1CCC&!6IIFG6ND:7:Z=91>5:VT2Q1)G.% P.>] &'\
M0KF[LO .M7EA>36ES;VKRI+%C<"!G'(/Z<^]<Y=C5K7Q1X1CB\0:CMUJ&:.[
M5F5E&V$2 QJ1A6R,9Y/KDUW&O:-!XAT2ZTFZEFBM[I#'*82 Q4]1D@XS5";P
ME;SWVBWCZA?&;1PPMB#'@[EV$M\G.5X[?GS0!R=OJ.HV%IXYTMO$4L":9/"+
M74+[]\\*RQHQ'3+')(4<G)'7I5S2;F\E\?:CH1FU2WT^;1X[J-+FX+31N9&3
M>K%F*Y 'RD]1T'2M2\^'VEZ@FN+=7=_(-9:.2X_>(I1X\;&0A1M(VCU''.:<
M/"UEHNIOXF:ZUB^OK:Q:&1?-\QKA%)<#8 ,MGH!@9[9YH Y[0]4U&XT=_"MY
M?W)\16^J?9+BX$I#M$#YOG#T5HA@=MQ%>E* JA1G &.3DURGAVU@UCQ%=>+S
MI5Q8R3VD=G"+N+RYF1269F7MDE5&>?DST(KK* ./^(]Y?:?H%I=6%]/:N-1M
M8W\K \Q'E52I.,XP>Q%4KM-1O_BG>:*=;U"#3VT5+KRH&5"KF9D.UMN1PHYZ
M^^.*Z;Q%X=MO$MA%9W=Q<PQ1S)./(*@ED(9<Y4]" :C7PS"OB:37Q?WGVU[0
M69YCV>6"6'&SKN).?Z<4 <-H7BC4[K0/">FW=_*9M2U&ZLY[TD"1HX#)@9[,
MVU%SUZXYYK8\2Z9>:7X)\;)-JTEY9RZ?-):6\Q+26R^4P8%R26!89&>G(JXW
MPWT:3PTNAR7%^T,5T;NWG\U5FMYBQ8NC*HP<L>H/6KH\&VC>'[[29]1U*Y^W
MQF*YNYY@\\B8(VY*X P3P .I/4DT 8$-[=VGB#X>6T%U,EM>V$PN(0YV2;+=
M"O'8@D]*S;OQ7J6B:?XR9+N21[?5X;*R><[Q;B58QGGJ%W,>?:NOO?!=I>VF
MC1C4-0@N=(XM+R%T$JJ5V%3E2I!7 /R]JA7X>:&;36K2X-W<P:PP>Y2><M\P
M  93U#?*#DY.: ,75=-&F_%/P6RW=Y.K07X9;B9I?F$2Y89Z$YY P.!@"J^E
MS^*/$_AS2_$VF7T%M<2R_:)#-?OY!AW$-$T03:, 8S][(SFNCMO EM%J6DW]
MSK.L7MQI0D6V:XG7[K@ AMJC=P.O4YY)XQ%9?#G2=.U26ZM+W5(K.68SOI:W
M6+0R$Y)V8SC/.,X]L<4 =?7+>(]5E7Q7X=\/K.]O#J9N))I(VVNPB0$1JW49
M+9)'.%XQFNIK#\3>%-/\4VUO'=R7-O/:RB:VN[23RYH']5;!_(@B@#FM>O-5
M\(:8+7^VGN?[3UFWM+660;I+&"9L'+,3OQM?:6]NN*LWD]]H/Q!T32K:]NY=
M.UN"Y1TFE,K6\L2!Q(C/D\@X(.1TXK6D\%Z7<^'KC1[Z2[ODN&#RW-S,6G9Q
MC:P<8VE<#&  /3DU9M/#L<%XE]<7]Y?7L4#007%SY>Z%6QNVA45<G"Y)!)P.
MU 'F4.HZ['\,[7Q0_B'49+VVU/RPC.HCE3[88BKJ!\V5/X8&,=][Q;K=UH^N
M7XUAM3L](F2-+#5K)V,-H^WYA,BGNQSD@\$ 8ZUM?\*]TW_A%3X<^WZC]@\_
M[1]^/?N\SS.NSIOY_P#K<5=O?"4.H#48Y]3U VVI*JW=MNCV2 (J'^#*[E49
MVD>V* ,N;5+NW^*P@-_/+IK:!)=BV!&P.)4&Y<#DX]2>M<=XCFN/$?P0E\37
M5]<_:;MXYC$DI\E4-PJB+9]W &.<;LC.>U>ECPQ:+XGBUY+BY2XBM/L20J4\
MH19#;<;<]0#G/;TK#D^%^D/I5[H\>HZM!H]U()?[/BG411-O#_)E=P&1TR1S
MTSS0 R]NM3\0^)_$&C6DS0KIL4"1>7?/;LKR(7\P[5.[L #Q\IX.:S+H>)_[
M<\&:1J7B&2.XO;>]BOWT\KL=HD&&4E00W/.1@'H!BNBU;P#I^J:M!JT6HZKI
MVHQPB"2YL;GRWGC'19,@[OKU_(5:D\'V+:IH]_'=7D+Z2LBVR(ZE3O&'+EE)
M8MCDDYSSUYH Y;73?:?;ZS:1:[J5_<:=I"M"()/+>V<*Y\Z=P0KEL+A3DX4_
M+R35:Z\W6_$7PRO;JZN5FO;*>6;R9FC&[[,&) ' .6/([<5UM_X&TV_U?4M0
M:[U"'^TX!!>P03[(YPJE5)&,Y .." >X/-,_X0/319Z' M[J2/HN1:W"W'[S
M:4V%2<8P5 ' '3C% &'-XBU#1?$'Q GDN9KR#2]/M[JUMY<;4)21B!@#@D#)
MZX'6HM6U#4]#\)>'_%-MJ5U=7$LEK]NBDD+17*3;0P5.B$%@5*@=.<UUL'A6
MRAUO5-4>:XG?5(DAN8)BC1,B@A1C;G@,1UYSSFJ]AX)L+"WLK/[9?7&GV,HF
MM+.X=6CA9>4P0H=@N> S'''H, '+R+JVHZYX\LW\1:G%#IRPO:B%U0H6@W]0
MO0'L,9[YKLO!VHW&K^"]$U&[8/<W-E%+*P&-S%02<>YJ&/PC;1WNMW:7]\)=
M955N>8\#:NP;?DXPO'?\^:T=#T>'0-%M=*MI9I;>UC$41F(+!1P!D 9Q0!0\
M;:[-X:\%ZMK%O&))[6 M&K#(W$@ GV!()^E<]K=SJ'AG_A%]4M-2N[Q;V^@L
MKV*>4NDZS#'F*IX1@>0%P,'&*[F]LK;4;&>RO(5FMIXS'+&W1E(P16)I_@^T
MLET^*6^OKVWTUMUE!=.C+"0"JG(4%BJD@;B<9]>: ,#0].0?%_Q,WVF[/EVE
MG( 9VP<^9P?4>@[5Z#6):>&H+/Q->Z\E[>-<WJ)'-&Y3RRJ9V@ +D8R>_>MN
M@#AM3;4;GXJ0:2NL7L&GSZ-+.T,+*NUA*BY4XR#@]>2.<8KEI+K7!\/?$VH?
M\)'J?VKP_?W4%HX=076)^/-X_>$@X.>,=L\UZ3-X;@E\4Q^(?M=VEW';&U5%
M*>7Y9(8C!7/4 YSVK._X0*P.A:OH[7^H-:ZM/)<71+1[BTAR^#LX!_\ U8H
MH:U>7%YJ7EIJ%TY.D^<EA8.8GAD)/[]Y-P&W@ *2<X; -8_]OZQ=>#?A[JC:
ME.D]_J%I#>! JB=6#;MW&>=HZ$#D\5U3^!K!M5341?ZDDQM%LYQ'.$%S&N=N
M_"CD9/*[:YK^PH%30/"^CQ:LR:)K4-Q++?1/M$2(YRLF I7)50%[]NIH U=-
MN;CQ=K'BBW>_N[)=-NA96JVTIC,9" F4X^^2QX#9&%''7/,VGB/7]>TKP-<2
M:I/9SWU_/97OV=5"R^6) 7''4[,^@/;BN^F\*6QUNZU>QOKW3KJ\C5+O[*R;
M9]HPK,'5L,!QD8-13^"M-D714MYKJSBT9]]I';LN V",MN4EB03G)YR3UH U
M](T]]+TN"RDOKJ^:($?:+I@TKY)/S$ 9QG'3M5#Q<^K1^'+A]%B,UZKQGR5D
M$;R1AP9%5CT8IN /8GCFMRJ.K:8FK60MFN;BV*R)*DMNP5U96##&01U'((Y%
M 'EGB+5K+7?ACXP:TO=6BDMHT\[3[YW6>T;&"C9))5N3U(//T&]KD6H6WB;P
M9I5EK>HV]K?_ &I)P) Q(6 L#E@3GTR2!P<<5T,_@S3;VSUB"^DN+J35XEAN
MYW*JY100H&U0!C)(XZGG-,/@RV:\T:[?5-3DN-)WF"1Y48L77:Q;*<Y7C P/
M3GF@#GM7CO-/^W:>FO:GJ$MCI.Z)(9=DL,GSGSYY 55LX4!3G(4_*>36:[SZ
M]JGPMO[V[N1<7MK+),89FC!?[+N+ #@$DGD=CCI7:7W@K3[[7+S5#=7\#WUN
MMO>0P3[([A5!"EN,Y )'!'\Z@3P!ID6G:):1WNI(VC,3:W N/WH4IL*DXQM*
M\8 'MS0!BO+KWBS_ (2)=*N_LMS87TEG9N+YXA"T:K@O&$(<,22=V>#@ 8S5
MFZU2^7Q3I-AKUZMKILVCF5KBUG:**6\#*' D&#@*<J.,Y[X%7[WX?:;=:_-K
M%MJ&K:=-<A1=QV-V8DNMHP"XP3G'&00:P?$UM"GBY1<'Q+I%I;6,=O9W>BQ/
M)'*"261@B/MQA0 5&>>3Q@ S[N^\3V?P=GU>\UC48]1^TIY;.L:,83<!%X"
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M@Y .#[9Z=J -B#7M<;7UTV?PO,D.X%[Z.Z5X50J2#R%8G(P5QQD')KHZXCQ
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M%NC=WIET:-H[0[UP R[6W?+\V5 '/IZ\U$W@?2I;;7+>XDNIXM;.Z\5Y!RV
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MUH>(_#6GZR(/LXO(1*(B^[9GMG S^5:M !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L
M.Y\):5<ZC=7P6X@FO$"7?V>X>-;@ 8&\*>3CC(P<<9K<HH QM1\+:/J::<L]
MJR#33FT^SRM"8AMVE04(^4KP1TQ3$\):3%<ZI<(EPLNJJJ7C"YD_> +M&.?E
MPO'&.*W** .8O/A_X=OM"L='FM)?LVGD&S=;AQ+;X_NR9W#Z9[#TJ6;P1H4^
MC0:5)!.;6&87 Q=2!WE!R'9PVYFR!R2>@]*Z*B@!$78BJ"3@8R3DG\:YJZ\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO=1P)XAGC2.X+/,"1$JQX))+9(4#)KKK3Q+;3ZY_8MS;7-AJ#0^?%#<A/WR
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,DNXHH4,O "Y)SW &.M<7XK\2:AXB^#OB9Y!!:7NG2RV&H1JC,KNC*#Y9W#
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M.D%M-$S&Y6$X<EPPVEB&V\''&<YX .YJEJVKV.AZ;-J.I7 @M(1NDD*EL#Z
M$U'HFK1:_P"'['5K4%([RW69 XR5W#.#ZXZ5Y@;C5KSX8?$";4K^*ZVW%_#Q
M 4;*?*#G<0%PH 7''J: /789DN((YXCNCD4.IQC((R*?7":;K>MZ;K_A?3+T
MV,EAJ]I((DAC826[11*_+EL.",_PKC^<'_"9Z[J&F6NMZ+8->6TMQC["+*3<
MUOO*[Q-G;NP-V,8[<XR0#T*BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC@=J[6:9((GD?.U%W':I8X]@.3^%4]%UFQ\0:3!JFFS&:SGW>7(5*[L,5/!
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MU0A6=8V?!)P/N@XY('/K6E0!PUGX.U[1M7U%-%UV"WT34;EKJ6&6V+S6[O\
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MTNK1R56101R#@@@@$'ZUHT %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5YU\/)6U/QEXYU.[^:\BU,V$>[K'!%D(!Z
M ]?<\UZ+7*7'A.[LO$USK_AZ_BM+B]55OK6XA,D-P5X5^&!5P.,C(/I0!IZ]
M/8Z+:77B:YB+2:?939*_>9.'*_B47%<UJ'B?6M#T71/$5[);3V-[+ E[;)%M
M\A9L;6C;.3M) .?O=MM='+HLVJV-U;:Y<1W$=S ]NT-NACC5&&&ZDDM[GIV
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MZ#Q'X9?5]0TK5K*Z%IJNERL]O*\>]'1QM>-UR"0P[@Y'6J=YX/GU"#7IY[V
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M>'S>:0EA)I/B'PCJTFU8Q#;686YG!(W .CDY/4L1C/+8YH [;XB_\DW\2?\
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MY[5BVWCW5M9MO!MWIL=I;QZW+-!<Q3QLQBDC1\X(897<AXQDX'(S6_!X7O\
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M@C&<G.*[+I7)V_A2_P!(U36)]$U&""UU:4W$L,\!<PSD8:1"&&=W!(/<=>U
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M\RMN8BK2-N(^\V1G.*Z&B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&#+D$C![$5G:IX#AUG2M9AO;^3^T-5$0EO(HPHC$1#1JB$G"@C)!))R<GI@
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M-+XDO;VUN]+CAOH[.TFE=;AT4/<.0A*)"A5MQ)Y/!( J/0?"LGA[6-1N+._
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MQ0!ZHSHA4,R@L<*"<9.,X'X _E3J\RUK3=:MO&G@VUO/%%]<F:]O&5T@AC"
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M'9KK2K::XN(WC+I;J&E\K>/,,:G@N$W8![^O2@#<IDTHAA>4J[! 3M12S'Z
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[JY%PUN\ +QX8-M1\\ D=P3R<$=M[4M/MM6TRZTZ]C$EM<Q-%*G3*L,&K5%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8DL/#MHNJ783075[8[$RY52@W_+S\I(XQ0!D6NLZ_I<WCK3H[F;6)](@BN+
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MJ ",=LYSDUK:7HD6FW=[?/*]Q?WI0SSN ,A1A54#@*,GCW))- '.^)KO6O\
MA/=!TBPUB2SM-0MKII0L*.5,83#*6'7YCUR/8UC6>M^(;*'Q9H-YKL'VG2)[
M8P:K=1@$P38;!55(,@ ('R\L1Q5[Q4WF_%3PDL%\+:6*WO-SX#!2PCVJP/\
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MO=B@JJ>8QVC&T,=JJ.,#/2M;6;[6_".F:I<3:DE[!/=6T.F^:H\V 2NJ/O.
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MQZ4^O.K96M_BQXDO&O;N2.WTNWG$8DRI&9#M Q]WC@#N2>])I<_BO6M*\/\
MB&PNT4W#17%ZDUR# \#C+(J!?E9<@ YSQR30!W&LZHFBZ->:G+!-/%:1--(D
M.W>549.-Q Z ]Z?I=^FJZ19:C&C)'=P).JMU4,H8 _G7GEY?77BWP3XSU-K^
MXMTMC>VMM#"P"JD2$'>,?,7.<YZ C&",UVG@_P#Y$G0/^P=;_P#HM: -JF)-
M'*\BHZLT3;' .=IP#@^^"#^->=:1XAN?^$HM=)UZYU'2]8-U,0DO-I?Q8?8(
M6P5& 4..#\O.36-I^KW/A+P9XYUR*ZN+B>VUJYMXEN'WH&+QHKMW)&1WZ#%
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M+$YR,<]!Q7344 8)\*PMXDL=<;4;]KFSMFMD1FC*.K$%MWR9)) /!'MBJ2>
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%8/BG5+W2H=,:R>)3<ZC!:R>8F[Y)&VDCD8([?RH W
MJ*P]:U#4K&XD%A$MRRZ=<7$=MM^:65-FQ0V> 2V.GI5;PMKW]O;IK?4[>]ME
MCQ+'Y)AGMYL\HZ$Y7O@$9X/)H Z6BN<U'4M37QG8Z/:3V\5O<6,]RS20%V#1
MO&H ^8<'S#^59'_";7T>H/X?F@M_[<&I)8B1 WDE&B,PFVYS]P'Y<_>'7'-
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
:**** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>elicio-insidertradingcom008.jpg
<TEXT>
begin 644 elicio-insidertradingcom008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J"
MYO;2S\O[5=0P>8=J>;(%W'T&>IJ>OGCXV^!?%NN^-8M0TZQN-1L)($BA$/S>
M21]X$=LGG/3GVH ^AZ*PO!FG:CI/@S2+#5I?-O[>V5)FW;L$=L]\# S[5NT
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M30$E:*6,,LC"=AN93PQ QR<XXKD[60^'M*BADN'M_"T7BZ>*.7 =(H0K!/O
MCRQ-GD\97- 'M46H64]HUW#=V\ELN<S)("@QUY!Q2'4;%4F<WEN$AQYK&5<1
MYZ;N>,^]>6>+-&T)/"OC>^LM3_M*:ZL5GN$'E-#'(H(1P$4 .1GGJ<9]*W-2
M\,VT.D:/+X>DL-,UF6>&>)Y8MT=[*D+_ "RXY;Y2YW<G(SUH [J*[MIX#/%<
M120@9,B."H[]:2VO;6]B,MK<PSQ@X+Q2!@#Z9%>27NN32Z9IZWVDII<,7BB.
M#7(HWWP%MH8-GIY;,8R<]^O7GH=4T]/^%JJMM#&UK>:+*=4B*@QN%8")F'0M
MDL 3S@'TH [A-0LI)8HDO+=I)06C02J2X'4@9YJR3@9->'Z;IUE;_#/X>:E%
M;1)?'6+$&Y"CS"&D*D;NN,<8Z8KV?48(;G3;F&XC26%XF#HZ@J1CN#0 +J-B
M\L427ENTDP+1()5)<#J0,\_A3X+NVNFD6WN(9C$VV01N&V'T..AKQ.VTO3_^
M%2^!+P6L0NFU.R4W &)"&E*D;^N,<8S7374>F>'_ (D:YY5N+33QX6^T7,5F
M@C+;)7&X!<?,%X!H ]#AU"SNII8+:\MY9H_OHD@9D^H!R*YWPCXBN]2MM<?6
M)[5#8ZO/8HZ+Y2%$VXZD\G)[UQFG7-K#XJ^'#PS65O:M87*PP1R!GCA,*E!)
M)GYB2,] -P/7K5'3-0^P:YJSZU#'+X5D\37<<[?PPW.Y#&TPZ&// [!L$]L
M'K4LMU)K%@UO?V8L'CD\R$C,DS<;2C9Z#G/!JR^HV,9 DO+="9/* :51E_[O
M7KR..M<;K-O;K\8/"LJ11"26PO5=@HRX CP#Z@9/YUQ<^BZ6?AS\1Y_L-MYM
MMJU\('\L9AV["-G]WGTQ0![3<W=M9Q>9=7$4$><;I7"C/U-2(Z2('1U92,@J
M<@BO/;^^%EX[\/ZA<W$5RCZ+(AM7G1'C)9"9AO8*<_=/.?J,XU?AUX=B\/\
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MG8,67<>A  *CD ^@&.*WZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<YI9=5TZ"[6TFO[6.Y8@+"\RAR3TPI.>: &#1M+74#J TVS%Z>MR(%\P_P#
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M]=I/3.!TJQ!;PVL"06\20PQC:D<:A54>@ Z5PGB'Q]'/X UK6_#&H6C3V!<
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M_L;2S+-*=-L_,F!$K^0N7!Z[CCG\: /)=*FB7PC\*;BZD01K=;&DD(  \F0
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MA:18[?LFE6-OM0HOE6Z)A3U P.A]*DL](TW3Y&DLM.M+9V&&:&%4)&<X) H
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MC3#-#,=.M#+" (G,"[HP.@4XX_"@"[7!W,MK;?&Z%KAXHO,\/E4,A W/]I&
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MF1",D-&XY4E6(YX)![U%)KMDGCS5H?$&JRZ+!J6GVTEG]H\I4DAV'S(RTBD
MAF;(R.M 'I-QJ-E:6JW5Q>016[8VRR2!5;/3!/!S4*ZWI+PVTRZI9&*Z;9;N
M+A<3-G&$.?F.>,"O-K2[TGPCXF\)I)<S1^&?[.N;?3[J^?Y5F,@8,6.  T8P
MI./E/UJ7Q0-!MO#6GWNBK''I:^*+6[GN5<M$S&4&216)(VY.,CC(.* /21J>
MGFXGMQ?6QFMUWS1^:NZ-?5AG('UJA/KVE7=I<PV.OZ?%<FU:9)1,C^4IX$I7
M/*@X]C7'KJ.EWWQ:U=5NK6>*3P\BCYPRN5ED+ =FQWQTQ[51\,:9I1^ @O?L
M=H;@Z)<*\YC4O]UB06Z]0./8>E '83>+]+T1- L=2UBUN+O44 %R&6-)%$98
MS=<*K$<<]6&*TK:=I?$=VJZU;3PBWCQIR*N^$Y.9"P.<-P,$8XKSP75O:6WP
MEN[F>*&V2##32.%12;/ R3P.:MW@E/C[QF-(P+^3PY&T CX8RGS=I^N2OZ4
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M\Y^XIVGRR_HH?!R>,@5A:S>I<?$+Q.-!NH'U*?PMBW,$BEGF#/C&.K ;?TH
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M:;?6UY &*&2WE610PZC(/6K1(52S$  9)/:N'\'B*+X@^.X( B1K<VC^6F
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M4'RKE3%)L)4_=<8.1[C'&* /0H+Z"TT6TN;[4[:1#%'NO"5C29B!\PYP-W4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3X2%3X+E*Q/"IU*[Q&_WD'G-P?<=*ZC5=:ATR:VMMAFN[K=Y,(95R% +,2Q
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M@",CUYKG;SQ+J$7Q'M?#T>G2/9OI\ER\BR)ESYB+NP2,*N6]SGIQR =8""2
M0<<'VI:\G\.>(H_"-AXON!I%[<V-MX@N7GDMPFV"/$8S\S MCT7. .<<9[V_
M\20V]S]DLX&O;H6XN3&DJ1A8V)"DEB.6VM@>QSB@#;HK*\.>(;'Q3H5MJ^G%
M_L\X/RR+AT8$AE8>H((K5H **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX /..M<Y-8>*)?AO8>%Y/#5TVH:9/:H98Y8O)FCBE4AD8L#RJ]"!CG->O44
M>:>*O#]YJNIWNI:9I=_IGB.$QBPU&VD54N%V(2LV&((5MRG<.BC&>E>E)N"+
MO(+8Y(Z9I:* //[?3M8L-4\;Q?V1/-#J;>?;7$<D>U\P!-N"V=VX=P!CG/3-
M#^Q=:7PG\/[+^Q[DW&DWEM)>H&C_ ':QQLC'.[!Y8=,UZ?10!Y)XGTCQ1K>D
M>([2ZT*XO+\7ZR6$_GQ^2+99495C4MP^T'/ SSEN@KIUM-6B^)Z:Q_9,S6=Y
MI$=J\@EC_P!'=96<A_FS]UOX<Y/'O7:44 4M7^W_ -BWW]E[/[0^SR?9?,^[
MYNT[<^V<5YS8:9KC^(O!VL2^'+U9K6*XBU*>YN(FE:1XU&XG<?DW!L8Z9X4<
M9]3HH X#P_X?U"Y\.^,M)O[.:P.K7]])!)(5.8YAA6^5CS[&CPBVNB*QTO4O
M"$-E=685)]2+1-%(J<;H\?,6;'H,9SGC![^B@!&.U2<$X&<#J:\EF\/Z])\+
M-8T==%N?M]SJS7,4)>/F,W2RYSNQ]T'C/6O6Z* ..GM-0F^*.FZJNG7'V"/2
MY;>2<E $D=T8 C=GHIR0*BM?#%]:?$&^FC"CP_>-'J3IG_E\4%",>A^60G^\
M@KMJ* /.;BSUCP]XUU>X3PQ_;VF:O)'/%)$T0DMY0BHRMO(^4[0<]JF\2>'1
MK#VT>H:-=0W-O:"2TU/1V"R6TY9MT2G(.!\N"1M/.<5Z!10!YX=,\3P:OX)U
M2^LFU&[M+*>WU!H)$79+(J88Y(!&5.2,^P/ JMIEEKGAW5M4TI_"<>K6UU>S
M75CJ >,(JRL7*S;OF&TD\@$GL*],HH X"QL]:\+^.]9NO[*GU/3M92W=)K,H
M#!+''L*LK,,*<9!SQTK1^&>GZCI/@>TT_5+&2TN89)B4=U;(>5W!&TGLPZX-
M==10!R'C*QU"\USPK-9V$US%9:C]HN'0J B>6RYY()Y8<#-4;;3]4B\0>/+I
MM*N?)U*.$6; I^^*0>60/FX^;UQQ7>T4 <]X%L[O3O VC6%];/;75K:1PRQN
M02&50#R"015#5+'4X/B;INLVVG27=FVFRV4CQNB^2YD1PS;B#MP#T!/M7844
M >6MHFMOX)\>:?\ V/<BZU6_NIK.,M'^\215"G.[ ^Z<YQ4MQ8:UHOB*WUJ/
MPT^L6-[IT%K=6H,?GVTL6[! 8X*D,0<'W^OIM% %#1UN%TV-KFSALY7)8VT6
M"(@3PI(X)QC)'&<XXJ_110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %>=Z!*OCCQAXEFU11<:9H]W_ &?:6,G,6]?]9(Z]
M&8G&,]!T]:]$K@K/2=4\&^+]9OK'3I=2T7691=2I;,@FM9_XCM8@,K9SP<CT
MH W1H>FZ%JKZY"ZV-E!92I/ I*PJ,H_F!!\JD!#D@<\9Z56/C:&!-*NKW3[B
MUTW59$BMKIV4X9QE!(H.4W=CSVSBIM7L[WQ7X?U/37MY-.M[NTD@4S[3(788
M#84D!1Z$Y/H,<\Y-H^L^(O!^C>&]1TN6SGM9K;[;<ET,6R$@EHR&))?:,#'&
MXYQCD UY_'+B]UVRM/#^HW-SH^PSH&B4,K)OW EL?=Q@=3GH*;%\0;:8:)=+
MI5\NE:Q)'!!?/L $L@RJE-V[&01NQC/3(P:KV.G:M;^)O&][)I-QY&HI!]C8
M21?O2D/ED8W\<^N.*QET#7D\ ^"=-_L:X-YI6H6DUW&)8?D2(DL0=^#UXQ^E
M &_=^/GCOM9L;+PUJM[<Z2R?:$C\L?*R[]P.[!XQ@#YCGIQ5RU\;6>J6FBS:
M1;37C:Q')+;@_(J+&!O\QN=I!.W SD^W-86B:A<6?Q&\=^5IEU=EI+,J(2GW
MOLX^4[F&,^O3KDCO5T_PWK_AO3_#.D_8)-2TJ..=M0M[29$'GR/O7=O9=\0W
M,,=^I!X% &Y+\1+*+PO!KO\ 9M\T4EY]AEB4(6AE\SRSN^;D;NFW.>.*N6?B
MZ2YUN^T>71;RVU""U%Y!#*\9-Q$6*Y!5B%.X8P3W%<.GAKQ'%X$ET<: XG37
MA=HD4\6TQ"X\PE<L,#;P,X)]!77+8ZDWQ635SILZZ<=&^R&<O'@2^;OQMW;L
M8[XZT 6+#QK!J/A"/Q#!87&V280+:,RB7>9/*VD9P&W=LU8E\-13>-+3Q& T
M-Q%:F"1A.Q\P'.$*?=P"=V>I(%86F^'IK;XE:E'#*AT7*:L;<#E+QP\9_ @%
M\?WL&N]H YZR\4C49(Y+.QDFL9+R2S^T)(I*.A9277J%RI [\C(&:T-;UFVT
M'3&OKK.SS(XE&0,N[A%!)X RPR3T'-<,GAJ^_P"$GLM:TK3+O1=3>^SJFR5?
MLMW;Y.YV4,0688QQN!//K79>*+<W>A2VQTA=6AE=$GLR5&^,L-Q&X@9 ^8<C
MD"@"*7Q*MA:WT^J64EH+1HU&'5Q.9#A1&>,Y8A><<]<#FJ5OXZL/[:NM*U%!
M93P69OA)YRR1O"OWCN7H5QR#]1FN3;P/K8\/ZUI^DRW*645Q:W>BVNI2;RDD
M3;W3.21&2  ">N>W)VQ:ZQXO\/:EIU[X<7P^+BREMV>22.1FD9<#;L_@'4DX
M)XP.M &M#XL>2^TN&31[R.'54=K2<X8<+N D _U>1R,Y]\&J<WQ!M8?!^H^(
MVTZZ,&G7,EM<0ADW@H^QB.<$9]Z3PG?^*I+2RTO5M -@]FBQW-ZUPCQS!1@&
M,*2<M@'D  9[UR>I>'_$A\$^+O"]OH4TLMY?SW-M=>?&(I8Y)0X RV[=Z@@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!D:;X=M=+UG4=4AFN6N=1*-<^8X*L4&U2!CC XX_'-:]%%
M!4%Y:QWUE/:3;_*GC:-]CE6PPP<$<@\]14]% &9H>@V/A[3Q9V"R;"=SR32M
M))(V ,LS$D\ #V  %:=%% !1110 4444 %%%% !1110 4444 %1R6\,SQO+&
MKM$VY-PSM/J/?WJ2B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHK+L/$>DZGJEUIEK=9O[0!IK>2-XY$!Z':P!(]QQR/6@#4HJA+K-
ME#JT6EN\HO)D+QH()"&4$ G<%VX!9<G/&15^@ HI,C.,\^E+0 4451TK5K76
M--2_M?-6!V91YT31M\K%3E6 (Y!H O45F?V_I_\ PD8T#S)/[1-N;K88F"^6
M"%R&(P>2.A-:= !12$@ DG '4FEH **** "BLR_U_3]-U73],N9)%NM0=DMU
M$3%6(4L?FQM' Z$YJ:TU6VO;^^LX1-YMDZI+OB95RR[AM)&&X/:@"[1110 4
M44A('4XH 6BLRWU_3[K7[K1(I)#?6L2S2HT3* K' () !Z'IFM.@ HHHH **
M** "BBD!!&0<CU% "T52O=5MK"[L;:<3&2]E,46R)F&X*6^8@848'4U=H **
M3(SC//I5/3]5MM3>\2W$P-I<-;2^9$R?. "=N1\PY'(XH NT444 %%%% !11
M10 445F:OK^GZ&UDM_)(AO;E+6#;$S!I'.%!(&%_$CH: -.BBB@ HHHH **I
M:OJUGH>EW&I7[NEK;H7D=(V<J!U.%!.*GM;F.\LX+J$DQ31K(A(P<$9'\Z )
MJ*Q+OQ7I5C:ZK<W+7,<.E-MNG^RR$#Y0V1A?F&#U' K6MKB.[M(;F(DQS(LB
M$C'!&10!+15*RU6VO[R^M81,)+*012[XF49*AOE)&&&#U%)J.K6NEQVTEQYK
M+<W"6\?E1-)\SG SM!P/<\4 7J*** "BBB@ HHHH **** "BD) !). .I-+0
M 4444 %%8</BW2;FPU:\@>X>+2I'BN@+=PZLJAB I&3P1VK8@F2YMXIX]VR1
M Z[E*G!&1D'D?2@"2BBB@ HHJE;ZK;7.JWNG1B;[19K&TI:)E3#@D;6(PW3G
M'2@"[1110 44UG5 2>P)P!DX'M6?HNNV'B"TENM.D>2&*=[=B\;1D.APPPP!
MX/M0!I4444 %%1SSPVL$D]Q*D4,:EGDD8*J@=22>@K%;QEH:69O9+BXBL@N[
M[7)9S)"5]1(5VX/8YP>V: -ZBFQR++&LB'*, RGU!IU !1110 4444 %%%%
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M=#M@]S)!YF#YDG1,@<GU/'H>S](\=:AJ?AKPP6A U/5WGCD:",,%$!8.RJQ
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M/@S6[RZLI+;6KB"TGM$MRI!E1B) ^[J"O3&,''.,GTRN('@.\7PYX9TA=9@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M17 'Q;<'Q=-HMYJ3Z5?B_1;2UN(%$%Y:[ER4D(R7(W?Q<' Q0!W]%<!>:]XE
MUB+6IO#D,_G:?>26EM$%@,,SQX#"4NP<9.0-NW QUJ_;ZQJVOZUJ&D03'29]
M.LK>2<*J2M]HF5F"Y(*[%V\X&23P1CD ["BN(;5_$=AX@\&:?J<UJ)M2%Q'J
M$4"[HRT<1=60D!ADXS6=J'BG7;72_'KP7D)ET-P;5Y8 QVF$2$$# )R>OZ&@
M#N]6U.+1],EOYXKB6.+;E+:(RN<D#A1R>OY5<W ,%R-Q&0.YKSKQ!JGBW0O
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MU7:\RC\::Y<^ ?"FMK+;QW%]J<%G> 0YWJ9C&Q7G"YVD]#UXQ5[Q!XMN-/\
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MJW*LL;%U;"A<9 P0,@'UYK=\'Q2Q>$-)$UR\Y:TA8%E4;1Y:X7@#I^= &V6
M(!(!)P,GJ:6N#\6"_?XD>#K>#5)[>";[8QC1$*ADBX;D')PQ'/3M5BTU;5_%
M \0RZ1?BR.F7LEC:Q^4KK+)&H+&3<,X+' "E2 ,Y.> #M*0L 0"0">@]:P_!
MOB$>*_"&FZWY/DM=1;GC!X5@2K >V0<>U8.KK?R?%[18(]4GBMSIMQ*(51"H
M(>,'J.<^IZ=L<T =/HOB"PU\WXL3,?L-RUK-YL31D2  D88 _P 0[5/=:G#:
M:E8V+Q7#27I<(\<)9$V+N.]APN>V>IKR^*YUO3M.^(FJZ3J$-J=/U:XN2CVX
MD\XI#&Q4Y/"D#MSSU&.>JNO$>IGQ1X+AADA2PUF*:2XA\O+96#S!AB>F2.PZ
M=: .SI"< GT]*X&T\6W%SXJET:\U)],U2._98]/N8%6*ZM0^%:)RN68K@_>Z
MY&!U'?T <PWQ \.))?(US=#[ ^R[8V%QL@/^VVS"^N2:Z*VN8+VUBN;6:.:"
M50\<D;!E=3T((ZBO,-#DU ^(?B-;:?I@O9I[U47?*J1@F$#Y\G..>P-7/#MO
M>^$+?PO\/XKT?:GMI[FZNT4,44-NVQAACEGQD@\*>.> #O-5U&UTC2KK4+W?
M]EMXVDE*1-(0H&2<*">E48-8TVWT[2;JUM)A;ZJ\8A^SVQ.WS%W!GV_=&.I/
M2N3OM<OY+'QWX:U.1;B73],>>WN@@4RPR1/@.!QN4@C(P#Z"G+K&I:1X7^':
MV4T26]\]E9W"-%N9E:$MPV>/NXZ=^M 'HE%<8-3UOQ&WB(:'?1V<FEW+6=JC
MQJRS3*BLQE)!(4E@HVX/!.3G +[5]:T?Q=X?34[F-=+U2,V\B1("L5YMRJ[R
M,E&PP'?(_"@#LZ*QO#]U=7Z7M[-<&2TEN76S4HHVQ*=N<@<[F#$'^[M]R8_$
MU[>V:6'V:[@M+>6Y"7,S8,H3:2%B4@[G+ #&#QGCT -VBO+;KQIK\?P^\6:C
M!<H+W1=0DMH9I[7#21C81N3@!\/Z8XZ5MWNI^(-)U"QT^YOEO9]8N&, MK9$
M:UC2(NZKO;#G.,%N@).#TH [>BN;\+S>)#=ZI;ZY;.+6*13874IB$DR$?,'6
M-B 5/&<#(/2H/'^LZKH6C6=UI4L"227]O;N)H]VY7D"X!S\O7K@T =717GDW
MB/7O"GBXV.O7L&IZ==Z?<7L$D-L(6A>$;G3 )RNWH22>E36.J>,+Q]!U*VM)
MI[2]*-?0R_9UBAB=<AXF#[SMR.&SN'84 =[17 >'KWQ;KVH:OG6K*"'3-8FM
M"GV#=YT:HN!]\%<%@>I/7GH*Q(/%GBP_#S1_%CZC:L[W:PSVGV4!)E:X,7+=
M5(XQCTYS0!ZU67:76GZY:R7+V;!()9(C]LM]A!4X) 8?=..M8-CJ6N6GQ#DT
M"^U&&\@N=+:^B86PC\AUD"%0 <LIW9Y.>.M<GKFMZUJWP@UB]N-1,=U!JC6C
MM;Q*@DC%RL6W!R0,'UR>A.,T >N#9&%0;5'15Z?@*=7GVIPZFOQ2\.VAUNY:
M,V%U(1Y<8&X,G.-N,D''MCC&3EDWB#Q5K6F7>J>&[6>22&]DAMK9A;B"9(Y2
MC;V9PX8[6.1C' P>I /099%AB>1@Q5020BEC^ ')_"L[0=7T[Q'I<.M:<"T-
MP&5)'CV.0KE3D'D#(/!K%M=8U#Q%XCUC3;2Z;38]*2%'*(DCO/(F\@[@1L48
M&!@DYY&*K?"+=_PK'2=Y!?=<;L=,^?)0!VQ8*0"0,G R>II:X3QF+Y_'7@N"
MWU.>VAFN;C=&BJ1N6!R&Y!R<$CGCGUJU9ZKJGB:]\00Z9J/V%=*N390GR4?S
M9E0,S2;@?ERP "X/!.>> #L:*Y_P3XC?Q7X1L=8E@$$\P9)HAT61&*-CVRI(
MKH* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ KE-2\'SZQ"UGJ.I17%A]O%[&IM?WT6)/,"+)OX&>,[<[21].KHH XN3P/J
M%KXAOM0T/Q+<:7::C)YU[9BV24-)C#/&S?<8@<G!Y_##]1\#W U^+6O#VN2:
M1=&V2TN5, N$GC3[N0Q&&'][G^>>BU+5H-->WA9))KJZ9DM[:+&^4JI8XW$
M8 )R2!^)%9$7CC3[BR6:ULM1GN/*DF>R6#;/&D;;')5B.C<8!)/;.#0!'JO@
M^:[&B3V.K26^HZ3,\L=U/")O-,BE9-ZY7[VXGC&.PJA+\/KB6T\3P-KTC_V^
M%$S26RGR_P!V$)&",D@<= /0UV&G7\&J:;;7]L7,%Q&LL>]"K8(R,@\@U9H
MYC7?"EQKO@@>')=22(LD227*V^<A&5AA=W!.T=SWJ6[\,W%QXKL/$$6J&"X@
MM&M+A$@!6:,L'XR3L.1[\?G70EU#A"PWD$A<\D#&3^H_.AG5!EV"C(&2<<DX
M _.@#CCX BNK7Q+::E??:+;79A-(L</EM"X"A2IW'IM4\CJ/PJ;2_"NM6]I+
M!J_BNXU(K \-J_V983$64KO8J<NX!ZDCJ>YS7644 <W;>%Y6\0:?K6IWL%U>
MV%O)!')#:^2T@?&3(=S;NG & "Q/TV=3M);_ $NYM(+IK6:6,HDZ+DQL>C =
M\5;HH Y23P3!J6IW>H:U+!<SW6G-ILGV>W,(>)B"Q;+,2W P<\4WPWX2U;1C
M;P7_ (HN=3T^T&+6V>W2-E &%\QQS)@=.G.#V%=;10!S_A?PU)X:2\MUU%[B
MSEN99X86B"^5YCER"W5N2<'CZ58\4Z))XC\-WNCI="U6\C,4DIB\PA3UP,CG
MWK8JAJ>JQ:9IDE]Y%S=HC*OEV<1ED)+!>%'7!//H : ,74/",M\FB72ZBL.K
MZ.?]&NT@^1E*A71X]W*L!SA@?0BDN_!SWUIKK3W\9U'6;7['-<K;X6*':RA4
M3=D?>8Y+'D^@ KJJ* .7U'P@VI^ 4\,3Z@5:.*&-+N.'!!B961BA)SR@R,\\
M]*5O"]]+XFTK6Y]726:PMY8"AM<>9YA!8\-Q]T8X.!USUKIZ* ,#PSX=F\/O
MJS27R7(U&^DOF @\O8[@ @?,<CY13O%WAV3Q3H+Z4MZ+1'ECD:3R?,/R.'
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MYD@ 8;9M^,#:%+$YSQCJ:[NDVC=NP,XQF@"*TM8;&S@M+= D$$:QQH/X548
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M!MG;;BMI=ZI;6]X0<?N223GVR%KT145$"*H50,!0. /2J.M:-8>(='N=*U*
M36EPFUTS@^H(/8@X(/M67I^A:Y8VR63^)7N+1!M622T7[3M'0&3.TGW*9H I
MM?N?&$'@[3)FT^ULM+%T\D*JSXW^6B+O#   $G@_PCCFN8U;QEXBLO"GBJ);
MR)=5T"^B@%UY"GSXI&382OW0VUN<#''2NSOO"4;ZW8:UI=T;'4;2W-KN:/S4
MF@)SLD7()P>00P.?6J>I^ X=2\.:GI9OW2;5;E;F]NQ$"SLI4@*,X4#8H YX
M'<G- %*[NO$EIX^L]%&NJ]MJEE--DVB VKQLO^K]<AL?/NQUYZ5BWGBSQ)9>
M /$MRNI1RZAHNL&Q6Z>W0&:/?$ 2H^4-B3J!VZ5VUQX<GN?%6FZ\^H();*"2
M 1+!\KA\;B?FR#\HQZ>]</X^T-?#GPY\4&74UD;5M0BO,% A61IHMP7DY "@
MXYZ&@#<?4O$F@?$#1K#4=3BU+3=;$R*@MEB-K+&F_P"4CDJ1Q\Q)]ZHP^)M;
MMM4\-"?4UO&U"_DM+Y((5-HIVN0(I-H9BNT \L.#GFNICT :EJ-KJNI7\=\U
MO!)':&"/RT42 !W^\V6*C&00 "<#FL.V^&TMOI^BV7_"27C1Z-<B:SQ!$"J
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/&WE/QNG)U"\$:Z%'/Y88%?]>P*@8X4[1G'/O7;:?:?8-.M[/SY)_(C$8DD
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M^XOH=-O(Q;RW+!I DD2OM) &0"3B@#LJ*X363JMY\3K;18=<O;.PN-(EG=(
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MD@5CZIX\M=-\,:KK L+F672I#%>689%DB;CJ2<;2"I!&<@].N !;7P%8V8T
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MEN<6I<G).W&<$\E<X/ICBKUUX0M[V.XMKK4+V;3[BZ%U)9N4*;@X? .W<%W
M'&?YFNBHH YV[\(6]]'=6UUJ%[-I]U<BYELW*&/<&#X!V[@NX XS_,UM7]H-
M0T^XLVEDB6>,QL\>-P!&#C((_2K%% '*KX$LET_0K)=1U$1:)(LEI\T6<JI5
M=WR<X!(_&M&P\.0:?XCU+6X[R[DN-16-9HY"GEXC!"8 4$8!/?O6S10!@:EX
M4M=1\16VN+>WUG>16YM7-K*%$T);=L;()Z\Y7!]ZRO\ A66B_P#",PZ&+K41
M';7)NK2Y%QB:UD+%LQL!@<L>H.<\YP,=I10!S3>"=-NO#UYH^J3WFIK>J!/<
M7<NZ5MO*X( "[3R  !G)[G+]'\(6VFVTT-YJ.HZQYL)M]VI3"3;$>J   8.!
MDXR<#)XKHJ* .9L/!-G96UC9/?7MUIVGRK+:6=PR,D17[G(4,P7^$,3C ZX&
M+FE>&X-)UO5-5BO;N6;4W1YTE*;,JNU2H"@C"@#K6U10!P\WPPTQ],U'2(=4
MU6WT>^<R/I\4B>5&Q8,=A*%E&1]W./:KT_@.QGU.[OO[1U.,WUJMK>11S@+<
MJH*JS';D, 3]TC^>>JHH Y2U\!65F/#_ )>IZF3H2LMIODC;(*;#NRG]SC Q
M^?-2/X$TJX_MY;V6ZNX=<VF[BF9-N5 52NU000 ,<]@>M=/10!SFA^#K;1XF
MCN-2U+5AY1@3^T9A((XCU4  #D  DY/'6JN@_#^P\/7"?9M3U::QA<O;:?<7
M.^W@/;:N,G'8$G!YZ\UUM% "$ @@C(/4&N87P!H"^&;7P^+=C8VUTMT@)RV]
M7W\GTQE?]TXKJ** ,?Q#X<M_$<5E'<W5U MI=1W<?V<H,R(<J3N4\ ]JBE\+
M6S^)CKT=[>P7;VRV\JQ2*$E"DE2PV]02>A /0@CBMVB@#D#\/-//A-_#9U+4
MOL#W'V@G=%OW>9YO7R^F_GI^E=4\"RVC6\Q,B.A1RW!8$8.<8_2I:* ./3X>
M6*:'IND?VKJIMM.N8[BV+2QEE,9S&O*8VK],GN3Q6D?"=G)X@N]8N+BYGDN[
M/[#-!)L,3Q9)VX"@]6/?O6]10!R?A_P%9>'9X_(U35KFS@)-K8W5SOAM_P#=
M& 3C)QN)Q]>:UO$>@0>)]$N-(N[BXAMKA=LOV<J&9<YQEE..G:M:B@#G7\*/
M+I\>GS>(-7DLU54:$^0HD08^5F6(-@@8.",C-6$\-0)XIG\0K>W8NYK86K1Y
M3RQ&"2,#;G())ZUM44 <D/AWH[^&+KP_<3WEQ:7%PUT'D=1)%*6W;T95&#N.
M>_ITXJY8>$TL].NK:;5]4O9[F(PM>74RO*B?W5^7:/RR>^<#'0T4 <M_P@FF
MC0M)TQ;J]5M(97L+P,GG0$# P=NTC'!!!!'6M;3=$AT^\NKYII;J^N@BRW,V
MW<57.U0%  49)P!U))S6G10!!>6QO+.6W$\L'F*5,D6W< ?3<"/TK-\-^'+?
MPOH$.C65U=26L *Q&<H60$D]0HSR>^:V:* .0;X>:>_A:]\.MJ6I&RO+@W$I
MW1;]Q?><'9P"W/2I-8\"6FJZQ#K$6JZIIVII"();JQF6-KB,=G&TJ?P _08Z
MNB@#G9O!UE)J.C7L=Y>POI'F?9U1U8,7&'+EE+,6&<DGJ2>O-1WW@FQOM;O]
M3^VZA;G4+=;>]@@F"QSJH(4GC<" 2."/YYZ:B@#R_5=!CT;Q-X!TFSO=1\C3
M_M*&[($C0KY(5 QV[0#@+C S]>:["3P=I5UI^K6FH+)>G5L?;)9B \@ PH&T
M *%P,8'!YZDFN@HH YSP]X/AT @OJVJZF40Q0_VA<"00IW"@ #L!DY...E9D
M7PRTV/3K33O[6U<V=C=I=6<)F0"W*L6"KA>1D_Q9(Q@$<Y[:B@#"B\+6UOXD
MO-<M[R]BN+R)$GB60>6[(I5'((SN /KCU!K._P"%=:.WA(^')KB^FM!.;F&5
MI%$T$I8OO1E48.YB>AZXZ5UU% '-V_@Z*+2KBTFUC5KJYG\O-_-.IG38P90I
MV[5 (S]WGOFDO/"L<D>I73WVI2ZC>6BVGVN!HXYTC!) C("J#EB<G\P!72T4
M 9VA6EW8Z#96E]<R7%U%"J23.VYF('=L?,??'/6LW3O!\&F:EK%_!JFH&?5B
M&N2YB(W!=H*CR^, UT=% ')+\/\ 3T\.Z5H::CJ*VFEW"7-N=T6_<C;ER=G(
M!_\ KTMYX!L;CQ!/K%MJ>JZ?-=JHO8[*X$:76T8!88R#CC*D&NLHH S%T6./
M6+6^AN[N**VMC;)9))BW(R,,4Q]X8P#Z5!XI\-6OBW0YM'OKFZAM)BOFBW*J
M7PP8#+*<<@=,5M44 8.L^$[/7;"R@O+J[%S8RK-;7T3*D\;CN"%QR.",8-17
MOA"*]UBSU8:MJ4%_;VYM9)H6C4W$1;=M<;,#GG*A2/6NCHH X_\ X5SI?_"+
M7/AX7^I+8W%R;E\2H6#>9YF 2IP-P!]>.M3ZYX&M-:U2UU5-3U/3]4@B\@WE
MC*L;RQYSM<;2I&>>E=310!5T^PATRQBM(#(R(#\TCEW<DY+,QY))))/J:M44
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M7%>-O^1I\#_]A5__ $1)7:UC:QX<M]:U#3KV>[NHI-/E\ZW$)0*'(().5.>"
M1Z4 <YJH<?&SP\TN?).E70AST\S<N['OMQ7&^+PYF^+C)GR/LM@I/8R",9_'
M!'Z5Z[JFBVVJO:32-)#=6<AEMKF$@21,05.,@@@@D$$$'\JIOX1TF;0M0TBX
MCDG@U%F>\D=\23.V,L6&.>!C&    ,<4 <Q?1:KX9\7^&KB'6[^^MM6N#:7=
MI<N&0$QE@\:@#9C;R!VJ+Q7X=O/"8O?&'AW5;];B.7[5>:?/,9+>[4D;@%/W
M6QT(] *["R\.06UY;7=S>WFH7%JC1VTEVR$PAA@X"*H)( &XY.._)S!9>$X+
M60B;4]4O[<3><EM>W'F(C9W#MN8 \@,2!@'J!0 NI^*?[,U,67]@ZY=Y"GS[
M6S\R+G_:SV[UD_$'_C^\&_\ 8PP?^BY:[6L?6_#EOKT^GRW%U=1&PN%NH!"5
M $J@@,<J<\,1CIS0!L5P/Q:&/#FDX_Z#5G_Z'7>@8 &<^YK%\2>&+3Q1;6]O
M>W-U'%!.EPBP,J_O%.5))4GCTZ4 97Q0NKS3_AUJ]]I][/9W4$89)8" WW@,
M9QD=>V#5?5+&?2&LUD\2ZG,VH7ZL]J6S)/B-LQ0;=IC4D!B<X !Y Z]#KWA^
MW\1Z!-HU_<7'V:<!9FC*J[@'."=N!R!T J#5_"EIK4>FFXO+Z.ZTZ3S+>\AD
M"2@D;3DA<$$<'B@#@U\6ZMI/A?Q*IGF6>#7ETZTDN7$KVJ2>7]YCG=MWL1DG
MG R16MJ6EKI_Q7\(>7=WDJR6M\"+BX:7#!$^8%B<$YY XX'%;(^'F@M::S:3
M+=W%MJ[B2XBFN6<!\+\RYY#953DY.1^%.MO MG#J6EZA/JNL7EUIBR);O<7(
M.%< $-M49X'?D]\\8 .,N]5UF/X<>/KE=:OOM6G:M<QV]QO&]401X4'' Y/3
M%;P;4-(^(?AN'^U[ZZAU>SN?M,-Q)NC#1JC*R+C"_>(XZCKD\UJ/X!TV31M8
MTI[V_:UU>X:YNQO3+.V-V#LX!P.!Z<8JY-X7MYM6TK5)+V]>ZTN-X[?YD (<
M -N&WG( 'X<8H X.^U/7;O0=4\F^O8?%D6L&""TAD('E&50H$?W2GE'=O(//
M)->K01&&WCB:624HH4R28W-CN< #/X5Y)I=BTHD$D_CS2=4FGEFDL;57-NDC
MN6(21D:,KD]2P!Z\5ZI81WBZ1;17TX:]$"K/+&!S)M&Y@,8ZY/3'M0!Y?X7T
MW5M:T7QYI5A/:6T5YX@OX))YE9V16VAMJC )P>,D<UJWFCP>'_$_PUTBU9FA
MLS=Q*S]6Q;'D^YZUU7A[PO:^&FOC9W5W*+ZY>[G6=E8&5\;F&%!&<#CI[5)J
M?AVVU36M,U66YN8[C36=K<1,H4%UVMD%3G(X_E0!P/B35]0LK+4=4L=5O+N>
MVUJ*,7$4ACMH8S*B&W*%L2$ D%@IY)Y!&*V)X;_4OBAJFCOK>I0Z?_9,5P(K
M>41E&:1U^4@9'W1SU]\9!N7'PUT6YM=0M#=:FEK>W7VLP1W1"12[PY9!CC+#
M.#D>F*U8/"UM;:_+K,5[?"[DM5M#N=6'EJ25ZJ22"2<DDDGG- %'X;:E>ZKX
M!TZZU"X:XN@TT3S/]YQ',Z GWPHS6)=F]'QX;["L#3?\(R.)V(7'VD^@/M78
M>'?#]KX9TE=,LIKB2V1W=!.P8J68LW( ZL2?QJ >%;8>+CXE^V7GV\V_V7&Y
M/+\G=NV8V],\YSGWH XR?3KKP%I\,?\ :'F:EXH\0QI>WD4>Q8O-)+",'..%
M*@G)RV?2MIKF\T#XE:5I,-S<W&EZO:3N8;B9IC!+%@[U9B6 (8#&<9KI-=T*
MP\1:7)IVHQL\+,'5D8J\;J<JRL.0P/>HK+P_%:WOV^:\NKV^$'V=+FYV;HXR
M<D*%55&2 2<9.!GI0!YC]KO;#X(^([W3[Z>SN8-1O'26 @-_Q\D8SCCKVP:[
M::_?5OB!+X=FN9X+6VTQ+O9!,T3S.[E<[E(;"A1P#U;G.!4A\ :8WA>]\.M=
MW[6%Y,TTP,B;B6;<P!V\ MS4NM>"+#6[JQOI+W4;74K-#%'?V<XBF9#U5B!@
M@^F* .?\0VFN>'_"5CJ3:]>:E-HMP)-0,3&,W5KNRRLH/WU0@Y[[3GK72Z-<
MC6-=OM5MKJ633DCCM[<+*3%(V-[R 9P?O*OU5J@U.[B\-6%KHUGH>IZI]K25
M$\N,RH7ZGSY&/&XL<L<]ZNZ1X;M])\'6_AV"22*&.U-N98&*."0=SJ>QR2<^
MM &W15;3[)=.TVVLDFGF6WB6(2SOOD< 8RS=R>YJS0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4POS\G^'/0YQBGVGBW2+_2;+4;.62>.]D:&WC6,B1Y%W;EVG!!&QLYQC%
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MIG9)TMW($:QLW QDMD#C' R3VKJ;V^M]/T^:^N6=+>%#)(PC9BJCJ=H!/Z4
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M>5E2:-F.Y6 Z\CD'IC'K0!WU%<[:W^E/XSU.-+^\^WP6D9N+>4NL$29;#J&
M7)YR1G@4^/QEH\EY9VV^=6OD=[)V@8+=!1D^6<<\<CU'3- &_16%9^+]'O\
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M_@M 8XRP0.X#$X[[<X Y)Q[USP\0#3/B;JAGFU.:U?2(+B*R6.65@QD<';$
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M<2N=S#/<+G:/917-ZFYTSXL6FJW4,ZZ?)HKV@N$A9T$OG*X4E0=I(!ZUW%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MGY1MSU)Z5!8Z?>6/B.ROO#8U2T2[U _VIH]W;N;95);?/&S#"'^(;3AL@>U
M'87GC/2;!HY+C[0MD]Q]E^W"/, EW;=I;KC<,;L;<\9JM=?$#1K6?5(!%J,\
MVEE?M4<-E(S("N[=C ^4#G/0]LUQOARV2QT\^$];\%7%]J<$SI%=/9B2UN5+
MEDE:0\ #()SSQQD\5KVJ7">(/B),UA?B*[CA^S-]CEQ-MM]AV?+\WS<<?RH
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M4!_/1WQM!X55QD]<4 6]6E71_%&C6MG'KB6.M7):ZLW9BN(XI#MC!.5+':6
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5%<V\=W;O!+N\MQA@K%21Z9'-2T4 -1$BC6.-51% 5548
M  Z "G444 %%%% !1110 4444 %%%% !1110 4444 %%%% $%W:0WUNUO<*6
MA?ATW$!QZ''4'N._?BI^E%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MIQDX?:>#Q0!OT45D?\)%9_\ "5KX<\NX%X;1KL.8\1E P7ANYRW84 :]%%%
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M_3 !6>,X;('3/#?C5+1KW4[GQ9XVTV75+AHK,VWV1ML>8-\)<X&W!Y/<'H*
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MVKVJVK3>0'9L'S,X*;3R&SVQF@#;HK%MO%NA7L3R6>HQW(2=K<BW5I&,BC)
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?B+XYEUF32)$>XMO(>\:,A@(L-L+=<$8.*Z*74?##^#9]&MDAN]+9AIEK&9
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M7,VDZY<WGA_5(KZVGUA4OO#UT T@F\T*982/F'($F#D8!/;%>KTF!G.!GUH
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M5C<-CUQP#Z<5W=%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.(R1\PY"Y.S#<C( S7/7>H0P?"'6= =)SJEMJI,UNL+ED!OE<,>.A!&/7/%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MCF95^XLDF3D+QT S@9.,@Z/C#P[<>)]'BL(+V*TVW,5P7>$R9\MPX& R]2*
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MH7<P.$1NS#</GZ<=.M7M2\&:A=ZYKUW;:S'#::W9I;7$4EKYDD>U&0>6VX
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MC&-V<B,>9DG&,UT%GX1UA/$NDZW>:U;22V=F]G+%!9>6CH2I&W+G:<KR>1Z
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M&R,DY))!X'OD<IK6NZIJ/@[Q[HM[.B7^B02+)/%'@7,+PLR$@_=8C@X]..M
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M. ,?7K0!ZG117G-SXD\06MIXOL6O(CK&E2))8#[."L\4@_=+M')9FRA([XH
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MV0>]:/B[Q GA7PIJ.MR1>:+2+<L><;F)"J,]@210!M5BZSXJTS0_M'VHSO\
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ME&MI73*$/GY^ASD#V [-G\6:S87VC&XNX)9[O6?[/N[."+?!!&S.$Q*!_K
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M9_>XSZ?G5F?P7JD'B6[UG0_$7]FG453^T(#:+*DCJ,"2,,WR-CUW#US79T4
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M&#YG)(8_C5R7PG=S:KX9OFU2$-H:2*$%H<3;X_+/_+3Y>/KS^5=510!P^D^
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M%DQQ-Y@7SE3.5. N. N!ZUGZ5\2=9M/A5H\T/V9-4U356LHY8[9$2%-W+!%
M4GGN.^3FK&G>)/ ^D>(/$.IV'BJ^CCULF2:W?29F"R$-SNV@D9=CCCMSZYEI
M-\.K?P3#X<D\37LAM;S[;9W8TJ97AD]QM(8>W'\C0!VR^+]6L?&_B7PE-?23
MBVTPWUE>/'&)8V"*2K84*PR<CY>V.:X^'XB>,HO!7ACQ//K$<OVS53:3VHM(
MU62/+=3C.?E(XQV[]=&#Q1X&&KZYK=WXBFFUC5;7[(9DTBX2."+:%PJ8)R<
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M # YZ=001P:ZBN ^%0\-IIFJKX>O&N3+>-<W1%F]LB._18T8<* N ,GZUW]
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MWIM_HJW/E?9U00,$8_*1\Q'[ON3UK6F^%C7'PZ3P=-K\K6J.I67[,H*JK%@
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M74VMIHK6!(4EC.3@A0,<CMC.><U[!#X!E@\;ZQXI35E^TZG:FU>$VWR1KM4
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M"P1.R-A^5++U^4=<CKQ7+67Q4\0VOP4OM9N+A;C5X]3.G07+QKP"H;<5 P2
M6 X],Y[@'KEYXNTFP\467AVYDECU&]4M;KY3%9  2?F''8]:W:\1U:RO++XV
M> DO=4GU"1K5V,DZH&#;7W8V@#&>1QD>OIZ/\0_$LWA'P+J>LVR*]S"BK"&&
M0'=@H)]ANS^% %K6/%VDZ#K&F:7J$DL5SJ<@BM,1,RR/D#&1P.6'7UIUAXKT
MG4O$VI>'K:61M0TY5>=3&0H#8Z'H>H_.O'?$<>HMK?PEOM2U:?4)KVZBN'\U
M$4([- S;=JCY>0,'/2MV+Q+XG'CGX@Z=I\@O)K"R$EC$8(]V_:I RJ@OC<<
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MW\>7?BRTU.X@N;R!8KF (I23:% //('R+D \\\\UMZ_KEIX<T6XU:_$OV2W
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M=1)-;S(8Y(W&0RD8(/X5-6#X@\7Z7X<N;2TNC-->W:R-!:VZAI'5%+,>2
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MBGA&&CD (W '/')&/0_C4VH>+M,TSQ1I_AZZ\];[4 6ML1Y1P,YYSQT[UO4
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MV/TKQ,^/_$.G?#S0?'4VH23SWVK-#<V9"^28,R#8JX^4CR^&SGGG->ZR1)-
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M^TPSP2+YC2$Y+-D$9R 0<<8]* .>\,>+-;O+7XCV,U]=8T4/)82SA?/A&)2
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MI9<@[FRN,<=  !Z5-I7@.TT7QEJ'B.PO[J%]1YN;-0OD.?[V,9!SDYSU)]:
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M^',<-R[2&PNI+-'8Y)1<,OY!L?0"MB/P^GA637->M4EU#7-5VJ%CA"!W52$
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MU"RU*XO8))W"FZ_UL/0^4WJ5SU[C!YS0!U=8'BWQ=I_@O25U/4XKEK4R",O
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M8LM5\01#5BL4.D-<Z?;:=*RSP.HRTLV,#9G(^8\\  G- 'J]%>(ZGXU\31^
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M0M[;,%$)!\L?*@'!^<G/7/ITH ]OK%UCQ3IFC:!J6LR/)<6VG,4G6V7>P8$
MJ!P,@D9YXYST-7=71WT:]6.:6%S ^)(CAE.#R#V->"^%)K_3?V?-6U^SU6^B
MO4F<IB7Y58RH"V,<D@G.<]: /?-+U&'5])M-2MUD6&ZA2:,2+M8*P!&1V/-6
MZ\4UCQ%KX;X6+;:U=6[ZU!$MZZ8/F$B+YL$$9^=NWUSBJL&I^(7NOB1I1\3:
MG]GT."2YM'WKYNX*S %\9V_*.!C\.<@'NM%>))\0=:G\)?#RWDGF:YUVX:.[
MGA*K+(D<@3:I) 5GR.<@^A%>A^"QXCB;5[?7;>9+5+LMILEQ,DDK0-G"L59L
ME?4G)SU.* .CN;RVLQ$;F98_.E6&/<?ONW11ZFIZ\>^)T$T_Q7\"6_VZ[BBG
MF?Y8I-HC8$?,O'#<GDYI\FOZKK'C'QAI:ZE>6UIX>TP_9?*E*,TP7/FN1]\Y
M!X/RX[4 >O45R/PR\2W?BWP#IVK7X'VM]\<K*N [(Q7=CWP#]<UUU !1110
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M+R2=[9.1UXQ4WA?P18^%-2U>^L[Z^GDU6;S[E;EHRN_+'*[44C[QXSBNGHH
MXN7X;V"^+;KQ#I^J:IID][_Q^0V<JK'/[G*D@GU!!ZXP3FEUCX;:9J7B2V\0
M65_J&D:E!&(3+82*OF(!@!@RD'CCZ =<"NEUC6=/T#2Y]3U2Z2VM(!EY'_0
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M';@5QFBZ/<:K\8?&RI?WVFQ7<0CBN8$7$PP Z@NI!QSR.1C@]:]LHH X2_\
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MBLD4; @@!5&>"1SG .!C)J'PO\.K+PHS16>K:K+IPD,L6GSS*88V/?A03CJ
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M65;>[C$D:R@!@/< D?K6C0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7FOQV5_P#A5M](DTL>V6(%
M4<J'!< AL=1STKTJLGQ)X=T_Q7H-SHVIJ[6MP!N,;;64@@@@^H(% 'EGB2ZU
M#PW'\-XM-U;44CO[N%+E7N682(?*^7!.,<GCWIUQ>:OJ'Q7\::(->U2WT^TT
MO[3#%!<%=C[(VX/)498GC'ITXKM+[X:Z7J,.B)<ZCJKG1G$EJYF0MO&W!;*'
M.-BC P..F2:G'P_TY?$NJZ^M]J OM4MS;7!#Q[=A"C"C9Q@*N#[=Z /&I_%/
MB6+X1^'_ !6?$.HMJ":K]EV^;B-XQO.'4#YS\HY;-=SK'B#6-:^)^N^&+0WX
M2PTO=:QV5PL!,[A")7)9=P7>!CD>QK9D^$.@2^$[;PTU[J?]FV]R;J-!+'N#
MD$?>V=.3^?TK0UGX=Z9K'B"UU];_ %*PU:",1-=V4RQM,H&,.-I!_ #]!@ V
M?#!U@^&;#_A((T35A%MN0C @L#C/''( /'K7C>C6$MYXL^+$L.I7UC+;-YL;
MVDQB.\>:5)(Y(&.F<')SVQ[I:6L5E:QVT.[8@P"S%F)ZDDGDDG))/4FN4?X<
M:6+K6KFVO]1M9-:+C4/*D3]\K9^7YE.W + %<'D\T >:WGB+Q5JGP7T?QE;Z
MC>)>V$Q2^6*4HMU")"NX@=^F2/\ :/T]5\,7\/B*ZF\0V=U</IT\$45O$TK&
M/=MW.X7.,_,J'T,;>IJCJ[V?AVPT_P (VGAJ\NM)O+6:V!MT+QQX3A'(!(WD
MGYCCKDGJ1T'AO1(/#GAO3]'M\>7:0+'N'\38^9OQ.3^- 'F?QG@:7Q-X#C^T
MW*1S:JB,D<I4##IA@!T8;CSU%5_$NFE_V@?"=A'>W<0_LF1#<+)F;&)\_,<\
MD<9Z\\<UZ1XI\':;XM6P-\]S#/87 N+:>V<*\;C'J".P[=JK3^!-.N/%NG^)
M6O=0&H6$'V> ^8K+LPP.<J22=[9).>: /);#X@^(=)^$7B*Y^WSW5]::L;"V
MNK@^9)&C8Y)/4CYL9[D>F*],\+P^(H/%$K/'>'PW/8QM&U]=I-*MP,9((=CM
M9>>N,]A2V7PM\/V?A_5M$=KRYL=4E\Z=9Y%)$G]]2JC!R![<5J^&/"-MX7MD
M@BU'4K\11^5";Z<2>3'Q\J@  #@=L\#M0!YG^T8]PNE^'5;?_9IO'-SCIN &
MW/X>97M47E^4GE;?+VC9MZ8[8]JI:WH>F^(]*FTS5K5+FTE'S(W&#V((Y!'J
M*Q]/\&'3K&/3H_$>MOIT:[$MGEBX3^[Y@C$@&..&S[T <SJ>JW-U\7](\%P2
MS6>BV^G-</':RM"93M8*-RD,%7 P 1SG.:XN;QQX@N?@YKUR=2NDU'1]46UA
MO8W*O)&64#<1]XX)'Y'KS7L.H>#=-O-4T[5+=YM/U#3XC!;SVFP$1$8V%65E
M*\\<<=JS9OACH$O@QO"RM=PV$DWGSO'(OFSR9SN=BIYR!T Z =* .&^V:Y;_
M !+\):4OB356M];TH2W@>4$;MCL2@QA#\H&0,^^>:I:9XBUQ? 'Q#B?6+^6;
M1;UELKF2=C,@#D8+=2/EZ'U->F'X>Z:WB#1];:^U WFD6ZVUL=\>W8 1\PV<
MDACD_P JYGQ5X%M/#7@#Q<=*?4;NZU@>9)$P$I>4OG*A$![GVH YNZU[7= T
MCX>^(UUS4;N75'CAOK>>;=',K!>B= 0">>N<$T^UDE@^(7Q7G@FDAFATTRQR
M1.59&6/<""/<"NF\$^!;+4?#OA/4-6GU*672H%>'3[DA8X)L#)VE0Y((! )(
M';BMW_A7&EC4]=U 7^HB?7(6@O,/'@H1C"C9QQQ0!Q.D>(=:N?A?X.U&ZUX)
M]IOF2^\UY/M-ZGG.HBB*?,7.,<8[<@9J/PUXBUFXT#XGVD]]?*-&,[V)FG+3
MV^!*0ID!).#&O<]^H-=>WPET!M&T;2_M>J+%H\[SV<J7 22,LVXC<%'&X9SU
M'8U9M/AGHE@/$"VMSJ,:Z\A2[4W&_@YW$;@3D[FY.3R<8H \MM/$/B&UT?X;
M:TWB'4IY]4OVM[J*6;,3Q^=MP5QR<$\G)Y]ACJ5U#6?'/B[QMHUGK5QI=SI7
MDQ:8(I615(8[W<*?GR5 YR &Z5T)^%.B'3-#T_[=J8@T29I[+$D>5<MOR3LY
MY%6M1^&^DWWBO_A)+>]U/3=1= D[V%P(A..!\_![ =,=!WYH Y.]UW7M2^(M
MUX2>:]E>PT0.#I\RVQENF5,S$EU^4;N%R1[&O1/"9UO_ (1:P'B-$35UC*W.
MQE8,02 V5XR0 3CN:R-9^'&D:MK5CK$-UJ.FZC9Q"%+FQG"N\8& K%@V>"1G
MJ<\YKJ;.TBL+2.VAWE$'5V+,Q)R22>22223ZF@#QCX5B4?&CQV+_ #]NWOMW
M=?+\WM[8V8]L4?%<3-\8O :V&?MWFH3MZ[/-'7VQOS[9KTS4O!NG7WB"+Q!;
MRW&GZQ&GEF[M&4-(G]UU8,K#ZC/ YX%+IW@[3[+Q#+X@N);C4-8>/REN[LJ3
M$G]U%5551R>@SR>>30!YQX2TM'^//C2'[7>@);)\PN&#'<B#D]\;N/3 ]*Y[
MP7Y^F_"[Q]J5G?7D%U;7LOE/'.R[2H4AL \GU/>O8M/\$6.F>*M2\1V]]??V
MAJ*;)]S1E", # V<8P,?3G-4++X8:/8>'M6T2&^U+['JLADN0TD98L<9(.SC
M.!0!QFG^+]2O[GX<:#>:A<I#JMHUQ?7*RE))V"ML3>"",LO.#DY%6/$FH^)_
M!&B>']"OM:FOYM3UCR6O8SMF%KN7Y-[$8<Y^\3QZ]ZZG4/A5H.HZ#I.ER7&H
M1MI!_P!!O(I56>$9!P&"X(X';/%6]8^'FCZ]X;71M3FO[K;*)EO))]UP) ,;
M@Q&.G&,8]J ..\37'B[0_ _C&YGDO;.U@EAGT>9[L//&K. Z,RLQ(&>,D]?8
M8Z/P%I6L7%EI'B34_$E]>"[TF$/8OCR0S*K!Q_M8ZDY))/..*OW/@&QOO"]S
MH5]JFJW<=T$6>YGG5YG5#E5W%< 9YX [^IK4@M?^$8\,06-C%=7WV.!8+:(X
M+O@8120  . -QQ@<F@#B?@G=RMH.MZ823;Z=J\\%OZ+'D':/H23^-2:]KE]J
M'QFTGPB+BXMM+%D]W.+>5HGG?#[074A@HP. 1DYS71^ O"I\(^&4LII%EO9Y
M7NKR5/NM,_WL>PP /I5G5_"ECJVM6.M":XL]5LE:.&ZMRN[8P(*L&5E8<GJ.
M.U 'D8\:Z[=?!SQ7,^HW*ZAHFH+;V]\CE9&0RHHW$?>."P.?4=^:]#\"Z3K#
MP:;XBU+Q'>WGVS2H0UB^/)1RJMO'OC@D\DDG/0"=_AKH3>"Y_"J-=16%S*)K
MF1)%\V=]P;<S%3R2J] .@'2NDTG3H]'TBTTV&666&UB6&-I2"VU1@ X '0 =
M* .:^(E]>Z?I>G2VNK6^GP&_B6Z#EQ+<1D\Q1; 6WGT7!]QS7(>"]=U6[U#X
MAZ5<7=^+;3LO9I<SEYK;(D^7S-Q/&U?XCTKOO%O@O3/&4-BFHR7<364XG@EM
M9?+=6^N#[>_'!JGIWPYT?2M0UF]LKG48Y=7B\NYW7&\="-PW DMR>6)ZF@#Q
MN/Q-XE@^'7A?Q.?$>IRWLNLFV='F_=O'EN&7'S?=[YZUWOC/5M1\&_$_P_JE
MSJ=W_P (UJ+&WN('G;RH)L8#=<!>0V.GRM6LWPAT!O#=EH'VW5!865T;N%1+
M'N$A]3LY R?S/M3O$4<7C'4I_!^HZ'?&&UN+6X2_EC_<S*/F<A@, X!3'4E^
MF : .E\-12KI/VJ::XD-Y(]RBSR,YCC8DH@R>,+MR/7->7?&GS!X]^'9B"F3
M[>=@<X!/FPXR?2O:>E<IXE\ Z=XJUG3M4O[V_2?37\RT6!T58VRIS@H<\JO4
MGI0!YQHUP_C#X[%O%"KI>IZ''MLM/C^99\%CN\PXS]X,  ,C'H<W[C7O$7BC
MQ;XTTS2VOUN=*6.'3$MKA84C?)S)("PWY*@<A@ <8YY[CQ!\/M(\1:SIVLW$
MUY;ZIIX BN[614=L'(W?*0<'/;N>U0WOPXTNY\4GQ';ZAJFGZC)&([E[*<1B
MY  'SC;WP.F.F>O- '%:H]])\<_A\^IQ)%?G2W-RB$%5D\N7< 1VSFLCQQXG
MU_2=,UJ^AUV6XU&RUE5CGT^9Q;V\)!VP2(2$9^.0 Q'\1Z5ZK=> ]+NO%6F>
M(?M%Y%=Z9$(;6.-T\M4P0005).0QZG/-8D_P9\,7%EJ=HT^JB#4+C[2\:W9V
MQR9SE5QC/;+ G'>@#F_&T#ZA\9_ Z27=W&ES;NY$4[)Y9VMDIC[I/<]ZFO-;
MU[7_ !MXLT#3I-1\S2K)(M-2VNEBVS%0?-E)9=_S8&/F&#TYY[C5/ .E:K>Z
M-?2W-_%>Z0NVWN8I\2,I&"&)!SGVP>34&I_#G2K_ ,4)XBM[W4]-U+RQ%+)8
MW 3ST  P^0<\ #MT'I0!R,VM^(=6^)/ACPGJ]S/IX&F?:M0CLIS&9I]K<;T.
M=N5!P#ZT?!B-H?$WQ!B:5Y635BID?&YR'EY..,FNTU;P#I6J:GI>IQ3WFGZA
MIB&."ZM) '*'.5;>&##ENO/)YYJ3PMX&TOPC>ZG=:=/>N^I2F6<7$V\%LDC'
M&>-QY))]<T <]\=/^23ZG_UU@_\ 1JUEZ5X"O/%^G^!-3U:\MX=.TBPMY;>V
MMU9GE.R,Y=C@#[B\ 'OSSFN^\6>%;/QCHS:3J-Q=16;L&=+=E4N0<C)*D\$=
ML5>T72H]$T>UTR&>::"UB6&)IBI8(H 494#. /K0!Y+#K_BKQ=?>,?[%-Z-2
MTS4$M].2*Y2."!$<@^8A<;RX5LY5O;%6M>U#Q#<?&C1-!@U>[TV#4-)\VZBB
MDWK')MEW% <KGY0 >F>:ZV3X;:2/%-UK]G?:I83WG_'Y!9W/EQ7'J6&,Y/L1
MU/K5R?P/IL_C.S\4_:+N.^LX1;PQHR")8\,-NW;G'S-WSSQVH \_\8W7B+P"
MN@->WFK:WX?MH9$O[J&X:*?S'<E7<J<D $!0QVG!!YQ4USXJN=2\1^ /#EAJ
MUU-IFH6OVBYO4=HIKH*K8#,,,IRAW8(Y->B:SX9CUBXEF.HWUJ9K4VDJ0&,I
M)&2>"KHPS\QYZC\35*7P!HGV71(K59K*71/^/&X@8>9&",,#N!#!N^10!YS%
MXMUE_"OQ(TXZA=&7P]<L+&\\T^:J>8X52W5L;.IR3GFJUAKNO66L_#*[?7M1
MN3K<16]AGES&X^4#Y<8S\W7KQUKTM?AYHR>'-4T99+L)JTK37UUO7SIW8Y))
MVX'T  ':J_\ PK'1]_AY_MVI9T 8L?WD?R\@_-\G/0#Z"@#IM<U!M(\/ZEJ2
M1^8UI:RSA/[Q1"V/QQ7B!\8Z]I?P[\+^-6U.[N-0O]6>*[A>5C#+$6D&P1_=
M7 C&"H!YKWR2-)8VCD4.C@JRL,@@]0:XZU^&.A6R:?;>;>2Z;IUTUW::?*ZF
M&*0DG/W=Q )) +$<GK0!QTE@O_#340^T77_(-\__ %S=<D[?]S_9Z5Z3XP_M
M<^$-4&@,%U4P$6QR =WMGC=C./?%56\$V#>-U\6F[O?[1$7DA=R>7Y?]W&W/
MXYS[ULZKIL6KZ;-8S2S1)+C]Y"^UU(((*GL<@<T >2>%?%W]L^%O$Z?:M6L=
M9T_2F\^RNKF1VBEC5SYT;L=PR<94], =#SB?\)5X@_X5_P##O4?[9O?M=]J<
MD%U)YQ_?)Y[ !NQX&/I7K]GX,TZWO]4O[J6XO[S4[<6MQ-<; 3$!C8 BJ/J<
M9Z<\5ST7P;T&/3]/LCJ6LO#IMP;BS5KA2(6+;B -F,9YY!/O0!G7NJ:GXM^)
M?B;PK!JMQIO]G:<IL?(E:/\ ?,$8RMM(+ ;@,'C';-8_Q!L]13Q9\++/4-0,
MFHB=XYKR% "7S""R@C&?J/P[5WVM_#K2M:\26_B%+S4=.U6)!&US83"-I5 Q
MALJ<\<<8X^@J75? .EZOJ>B7\UU?I+HS;[0)*I&[()9BRDL25&<F@#FOA?JN
MI2^+?&VB7FHW5[:Z;>JMJUU(9'12T@(W'DCY13OCEJ^I:%X(M[_2K^YLKH7R
M1^9!(5RI5R00.#T%=3H'@K3_  YKNK:O:75Y)<ZJ_F72S,A4MDD$ *,8W'OW
MKD/CW9W>H^ K>TL;2YNKAK]'$=O"TC;0KY.%!P.1^= $<NI:KX8^-6BZ,NK7
MU]I^L6;//#=2>9LD <[T'1/NC@8')]L9'ACQ#XP\8Z*WB#2%O)=1363NC-TB
M6JVP S 8R_7!!W;<Y[UZ)I7@S38_$47B>6\OM0OEMA!;/>."((^>% 4'/)Y;
M)Y/-5M.^&>C:3K=YJ%A>:G;V]Y)YMQIT=QBVD;.>5QG'MG';IQ0!R$TFOZU\
M:_$?ABU\1W]AIXTT3+Y3[C$Q$1RF?NG<W;L2!C@BKXSUC6_!>NV46M7>KW/A
MXZ?':)J=G.R/#<8^:5PIP['KM;.1TR<Y](M?!5A9^-[OQ;'=7IU&[B\B569/
M+,?RX4#;D8V+SG/%&N>#;77C?K<:A?Q6^H1I'=6T3)Y<BKTX9"5/NI!Z>@P
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MWG_V:;+_ $8/V(7.>,#@D]!G.*ANY-#N+C6FB\(_$FTMM9YO;2VL%6)WY.\
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M$6QL?FM)C&Y.R7!WCYN/KSWS5;0_$^K:UI?@FPFFWS:EI\UQ<.URUNT[1;5
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M.@((^]U/<FKNE?;O&?AV]U6'7;G3-134)DB='8Q6J12X"-%N"OE%R2W/SYZ
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MU(D#E@, 9P/E/7GVKA+O5;^W;0]0L]5OKW[1XB2UFOA(R6TT3R,IB2(L00H
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M)<"<C<CD#*\ 8^G8YH WZ*X#5(;_ %+XJMHW]MZE:Z?+H9N&BMI0A#><%RI
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MO4XC#=K+;1M'(A &W;GI@ 5[%10!XIX;:R\*W3R:;X'\?"W,AE2RDPUO&_\
M>";^3_O9[=P*;IBZ?H^L7-_8>!/'D$-S)YLM@B@6KOG.2@;GGL3CMC'%>VUC
MZMKAL=2LM*M($N-2O4EDABDE,:!8P-Q9@K$<LH'!ZT <U_PLB]_Z$#Q9_P"
M:?\ Q=<U#J2Z?J%[>:-X+\<Z0]ZV^YCL[6'RY&_O;'W!3[KBO1O#NKZQJRSM
MJGAZ72%0+Y?FW*2&1N0_"] "!@GJ"#Q6Y0!Y-HNN0>'M/N;73/A[XPA>Z8R7
M%R;9'FE<]79F8Y/)]N>E9=B++3O"5YX8MO WCI=+NW+2QF",MSC(#9R <#\O
MK7MM% 'B-XME?Z)I.D3^!_'9M-*</:*(8P4(Z9.><>]/U9[/5O$<7B#_ (0C
MQ[9:HB".2XL46%IE QA\-Z<<8_05[')>0I<FU5@]UY1E$(/S%0<9]N>.?Z5E
M^$_$7_"4:$NI_9#:$SRPF)I Y!C=DZ@#KMS0!YCK;V&M7^G:A_P@?CFQO]/0
M1P75E&L<H09^4L6.>IY//)YYJ35;FTU@Z2;CP)XY4Z5+YUL5B0GS=P8NQ9B6
M8D G.:]FJ&6Z@@G@AEE59;ABD2GJY"ECC\ 30!Q;Z7I_Q,M;2?6M$UK3&TN[
M$L,=V!"TAP#G )RO3T/'&*[>5#)$Z+(\98$!TQE?<9!'Z5B>,?$;>$_#5SK(
ML6O%M]NZ-9 G#,%SDY[D=C6]0!GZ-I$6AZ7'I]O//+%&6*M.P9ADY.3@9Y).
M3D\UC6O@/3;--62&]U$+JLQN+D"8#][N#;UPHVMD#IC]!74T4 9=CH4%GJ<F
MIRW$]W?/ MO]HGV[EC!+;0%51C))/&3Z\"N<^*=O+>^%8+2"WO)W>_MF*VL+
MNRHLJEF^0$C R<UV]% &)%X<LIY9;N]EN+^:XM3:^9=8!6%N60*JJ%SWXR<#
M)X%9=K\.=(M1I.+S59#I3DVC27C$QJ5V[!C'RX...<8&<5U]8-UXC:U\9Z?X
M>:Q8B]MY9UN3(,#R\9&WK_$/2@";1/#EMH5QJ$UM<7,C7]P;F<3,I!D( +#
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ME PP]?SK<KF-,\57>KRZ?=6.CM/HM[)(BWJ3C?'L+ .\9 PK%3@AB>1D#.*
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M/$^,%E8#C/?C'MP*NZ-HUOHED;>&6YG9FWRW%U,9996QC+,>O  ] !Q6C10
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MO5,W,C.,,<X^7( '&*;_ ,(+HXOK2\#7JS6UJ++<ETZ>;"#E4DVD;@/?\<T
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MW@R[MM2O[R*^OY()[^:5D2^5DD;*PEB%48&T\8QP,'-='X:_Y*CXY_W=/_\
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MYG=A!&\S[F0,2$. 1D <G/4"O38O#-I!J^I:I%<7:7>HHD=PXD&"%!"X&,#
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MB>20"!D^U<_HX_X3+4?%L6H7%S%+9:@UC:K#.T9MT5%VR+M(^9F+-N^@Z#%
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MXSA3A@0I'&SC KT^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K/UO0].\1:5-IFJVRW
M%I+C<A)!!'(((Y!'J*T** ,'3_"&E:;I5UI\(NG2[3RYYIKJ229UP0%WD[@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8E<G' P >3@\<BI-?>[U/Q!X+OXM*U!(K>[DFG#VY+0HT3("^,XR2..H'7%
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M9P94D(V,..AP>O3O6]XQL[D^%M)U_3HBNKZ,\4]O'*#&T@;"20G/(W@X^H%
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MPFN&TZ\T^:"<P2VUX@61" K#C/0JRG\: *H\969?7(Q8WYET4!KJ/8F[:5+
MJ-WS#:,__7XJQ!XEM;W3M'NX;:Z>+5R!;[=FY04+[FPW V@GC)'3KQ6%XAT#
M49/&]I>::A^R:K:-I^JL#C9&IWJ_^\5\Q >VX>E)X'\/ZAHEY?VEZA&G:7-+
M#I)Y):&4B4_7;E4'T84 8GA;Q9:>%])U][^+4KBU@U^ZCEN40RK;IY@52[L<
MD#CID@<D5V%Y>Z/_ ,)[I5I-'=G53:S-;.NX0^7\N_/(5C]WL<>U<-<:9J4W
MPS\;:>FEW_VR_P!3NI;6$VSAI4DD!5AQTP#UZ=ZZ2[CN;CXB^%KZ.RO#:P6%
MQ'-*;=PL;2!-H;(X^Z?IWH U+SQQI=C']IDANFTX70LVOT13"LN[9C[VX@-\
MI8*1GO7-VFL#0?B)XW=K?4K]5@L95@MP9F4;)2Q&YL*/;(]A1X.NM=\-Z>WA
M&Y\/7T]S;3RBUU (#:21LY=9'?/!&[E>O''-7M/BN;?QWXTO);&\%M=VUJEO
M*+=R)3&D@<+QS@L/KVH Z_2M3M=:TFTU.RD+VMU$LL3$8)4C/([&KE<K\-[6
MYL/A[HUE>6TUM=6\ CEBF0JRL"?7K]:ZJ@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBL;Q+XC@\
M+Z?'?7=I=3V[3)"[P!/W1=@JEMS#"Y(&: -FBL2/Q+ _BY_#;65W'=+:_:Q*
M^SRWCW;<J0V3SQC%5QXP@D&G)'IUZ;G499DM8&\L%UC!+2%@Q4+@<<Y.1Q0!
MT=%<U;>-M/NM'COUAN$DDOCIPM9-JN+@,5*$YV]B<YZ>_%:^F:BVH"Z$EE/:
M26TWDNDVTY.U6W*5)!4AA^O2@"]17,ZOXTM=*EU9%L;RZ72(4GOGA" 1JP+#
M&YAN(4$G';WXI-0\<65CJ=AI\5AJ%Y/?VS7-K]GB!$J@ X&2,'YAUP!W(H Z
M>BN)_P"%G:2OAO4-8FL-1B;3;@6U[9O$HF@<D ;ANQM)(Y!J[:^.;2;Q(NAW
M.F:E8W,\3S6;7,2JMVJC+;/FR#CG# ''7% '4T5R&E?$&RU91/'I>IPV"FX6
M>]FB58K<PYW!R&..G&,CH.N<6AXTM8Y-+:\L;RTL]5=8[.ZF";&=AE%8!BR%
MATR/8X/% '2T5A:9XH@U/6=7TI;*[M[G2]GG"?RP&#@E2N'.00.IQ38_%,,]
MK8/!87375]"UQ#:L8U?RACYV.[:!\R]\_-TZX -^BN7L_'FE7ND"]CCN1<?;
M3IWV$JOG?:0>8^NW('.<XQSFL7097E^,FMF2SGM'_LF NDKAMQ\QOF4@D8(P
M.W0\4 >A9HKFO%-[I-OJ?AZ'5+"XN))M11;*6/A(I]K8+?,.V[C!JO<^.XHM
M0UFPMM$U6[NM)6-YTB2,95E+;@6<#&!TZG/ .#@ Z/4;/^T=-N;/[3<6WGQE
M/.MGV21Y'56[$>M5]$T6#0['[-%/<W+LV^6YNI?,EF; &YF[G  ^@%2Z1JEM
MK>CV>J6;,UM=PK-&6&#M89Y'8UA/X[L8W20V=X;%]2_LS[7A=HGW;/N[MVW=
M\N<=>V.: .DBM(89YIT3][-C>Y))(&<#)Z 9.!TY/K4U8.I:Y!)<WVE6]A=:
MC);0AKM+=E7RPP)5<LPRQ )P.W7&1GCO ?B>'0/AKX06ZL[R9=1D^RQSQ["J
M2/(^T.68$9YYP?SH ]/HK&U+Q+::5)J/VJ"X6#3[07D]PJJR!3NPH .XM\C<
M8_'FJ]EXKBNM8_LJ;3KRVO'LOM\2/L;S(LA2 58X8$C(/KUH Z&BN(A^)MA-
MI=IJHTC54TV>Z^RR73QH%@?S#&-PWY(+#JH(&>>>*VM2\3Q64]]!;6-U?RZ?
M")[M;;9^Z4@D#YF&6(!(4=L9QD9 -VBL%?%5I<V]B^GP3WDU[;?:XH5VQL(N
M/F;>0%Y(&.I.>P)$_ASQ%9>)]*^WV0E0+*\$L,H >*13AD8 D9'L30!KT5SM
MYXN@MUU*2UT^\OX-,8I>2VP3",%#,JAF!8J""0/IR>*P?&OB,W&E^&7TN&:[
MT[5M3M5:2%D"SQ-N;RL,P.6VC(( QD$]J /0 01D'(HK%T?2=+\.V5Y<VUNV
MG07#&[G@=QLA.T;L $JHXR=O&<U2'C>S34-,MKFRN[>+5<BRN)-FV1L;@I 8
MLI(Y ('H<'B@#IZ*XB7XF6,6FWVH_P!BZNUGIUV]K>R^7&! 5(4L?G^89/1<
MG R<<9MW/BB]3XB6F@0Z=+)9R:>]TTJ/'\YWHH89885<MGN<\#B@#K**Y74_
M'FGZ7:G4)K:Y;24N?LTM^FPQHV_86V[MQ4/\I('TR.:;<^.H8M<U#2+?1-6N
M[NQ,)E6"%2"DA.''S=!CZ\].#@ ZS-%<59^(]$TY?%VJ6VDWT4EA/OU(8!>5
MEC!W*"^,! /3Z5;LO'-K=ZII-G)IFH6T>K1&2RN9D01RL$WE<!MP..Y !QQF
M@#JJ*Y74?'=A86>JWZVEW<V&E3_9[RXA"D(XQN 4L"P7<,G\LX-=%:78N[&.
MZ$,L8D7<(Y -P'X$C]: +&<T5P5GXOT#0?">L:W9Z1J$-I!J<T=W$ &?SRX5
MV(+D %B!P?PK:M?%T5QX@DT632M0MKHVS75MYZHHNHU(!V_-\IR1P^T\\XH
MZ.BN)\-^.FO/"5QKNLV<MI&ES+&F"CAR)FC2- IRS9"KR!DGTK9M_$\)U^'1
M+ZRN;"]N(FFMA.499U7[P5E8C<N02#VY&10!NUB^)?#D/B:R@M+B\N;:.*=+
M@?9]F69&#+G<IX! JCXV\1WOAVTTQK*R>X:\U&WM6960;%>0 C#$9+#('89R
M2,<X%S>/8_&'[5%IM[/<3^'-WV2,J7+_ &@=26V+P.N[''<XH ]&0%44%BQ
MP6/4^_%+7.6'C/3M1\/VFJPPW :[G:VBM'51,9E+!DQG (V,2<XP"<U/HGB>
MVUG4]1TLV\UIJ.GE//MYBI^5QE75E)!4C\1W H W*Q+CPS!=>(DU>XU#49$0
M(5L&N#]E#J<J_EX^\#SUQD XR!575/&=OIOB$Z$FEZE=WYM#=QI;QJ1(H8+@
M$L #D]3@<=<D \EXV\1V'B_X.:_>VL5S!+:/Y,UO.-DL$RNH*L ?0^XYH ]2
MHK!U+Q-%I^I/IL-C<WMW%9F]D2': L62HY8@%B0< >G.*I3>/M,CL]!NXK6^
MG@UO M6BB!P2I;:PSD' /3/]: .KHK#T#Q-%KMUJ5DUC=V%]ITB)<6UULW*'
M7<C HS*01Z'M5;6KW28_&?ANTO;"XEU"5IS87*\1Q$1DR9^89)48Z'K0!TM%
M<9<?$6VAAUF6+0]7G71Y2E[LCC'EJ%#%^7 (P>@R?;'-=;:74-[9P7=NV^&>
M-9(V]589!_(T 345RMMX[L;E]+D%G>)8ZI<O:6EVP7:\B[NJ[MR@[&P2.W.*
MEU3QG:Z=!J-S'8WEY:::XCO)[<*1&W!8 %@6*A@3@<?4$4 =+16'=^)H8YY+
M>QL[G4+B*V6ZEC@VCRXVSMSN(^9MK87KQSBHH/&.GWEEI,UE%<7$VJQM);6V
MT))M4?,6W$!0N0"<]2,9S0!T-%<I-X^TZWT?6;Z:SO5GT9MM]9;%,T7&0WWM
MI4CD$'D5)'XVMC;2W$^EZE;1EX8[3S8E!O7E'RK%\W)]=V,=3@9P =/6)>^&
MXKWQ1I^O-?723V,<D<4*;/+*OC=G*DG.T=ZY*UOQ#\9-1NKNTN+%8?#OFS"5
M@X8";)==I/&!CURO2NBT_P :6U]?:7;/87EM_:UJ]U8O*$(E10K$$*Q*MM8'
M!]?7B@#IJ*X>7XFV,6FWVH_V-JS6>G7;VM[+Y<8%N58*S'Y_F&3T7)P,G'&>
M@O?$$<%\;"SM9K^\6#[2\4!4;(R2%)+$#YB" .IP>W- &Q17.V?C&PU'3--N
M[&"YFEU%'D@MF41R!4.'+;B H4D G/4C&<U9\.^)+/Q);73V\<L$]G</:W5O
M,!OBE7J#@D$="""0: -FBN>3Q9#)JVLZ6FF:@;O2X4F=,1_OT;.TQ_/ST/7'
MIUXHL/%]KJ>B:3JMI97DD.J2B.",>7O&0Q);Y\  *Q."2,'B@#H:*X=?$.G:
M>GC34M*T6Z_M#3V$E\DKA?/=8LJPRQ 4(!TP?8FL/7M3FO\ 1OA[K5]:W$=T
M^J6I?&&,H:!F)548C!., X/'04 >J45A:#XGBUN_U+3WL+NPOM.:/S[>ZV$[
M7!*,"C,I! /?C%4=>\3W^F>,] T:WTV:>&^6>1Y(WCRXC3[H#,,8+*23CI@9
MYH ZNBO+M,UI?#'B7Q[/'I=_?107<,TBVVTF.,0*S,2[ 'J3@$GVKMV\36DD
M-@UC%)>2W]M]J@BC*J3%A3O8L0 /F4>N3TX. #:HK(\.>([/Q-ITMU:++&T$
M[VUQ!, 'AE0X9&P2,].A(YKAK]M+@^--W;:G*([%]%281-(RH93,06P#C.!U
MH ]0HR..>M<'=0:-=^!_%-WI$DK6<EK.F/,?:)(D8%ER<CG ]/ESWJ&SO=)M
M_"OP\AU2PN+B29;-;*6/A(I_)X+?,.V[C!H ]"HS7.ZIXOM]/34I(;&[OHM+
M -Z]L$(B.T,5&Y@68*0Q Z COQ5:XU71+KQGX>5[&YDO[BTFFL+L@JBQE5+@
MC<#D@KP5X]J .KHKF+SQM9VME>ZBEC>7.F6,K17-Y"%*H5.'(4MN95.02!V.
M,X-;DPBU72)!;W&(KN B.>(Y^5UX93^.10!;HKR_7]"L+#XC^!],MUG6SNQ?
M"XB-S(?-V0@KN);)P>:?XQT>T\/7'A>6W^TM&WB.)UCWO*55HFRB@DD@LF<>
M] 'IM%<WI_C2RN3K*7UK=:7+HZK)=QW80E8V4LK@HS @@'H<Y&*%\8VZ:Y::
M3>:?>6EQ?122V?F>6PGV#+)\K':X'.#CZT =)17%V/Q)L+ZQ;41I&K1Z;$EP
MT]V\"[(3"3N5L,3DXXP".0,YSC2L?%L-UJT>F3:=>6UU-9?;X%DV-YL8(! V
ML<,"1P?7K0!/K7AN+6]3TN^DOKJ!]-F,\*0[-I<@J2VY23P2.HK;K@C\5M+&
MDP:PVD:PNDO,T,]X8%V6Q$A3Y_FSC(ZJ#C([\5T&I^)X;)[I+6SN-0>TA$UP
MMLR#8I!('S,,L0"<#MCID9 -VBN:L/'&EZG?Z/;6D=S(FKVTES:3[5V%4 W
M_-N##(&,=:R?$/Q!>V\&>(M4TO3KG[7I-PUE(LYC CDPOS\,=RC>O Y/H.M
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M@".]NV\NKQA\;L;BIZ9Z\5V6@+(--\R32XM,$KETM$"AHUP -^WY=QQDXZ9
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M\/ZC#;MILMM<SW<J-*)"Z-ND.\G'!Q^@ KTJF2\QE/-,;-\JL,9!]LY&?PH
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MM;ZQ6VN8H=N])$;*/AB,@@E3Z$#MDCG;CP9JUOX5,T=J)]3N/$2:Y=6T<BY
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MX>W!Q^M>96^G>+-/\,>(EL--N(;NZUZ6\6-9HUDEM7D4L$8,0KE0>N".W.*
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M>U>4*9+NY2U@#OL4R-G&YNPP#V/H 2: -*21(D+R.J(.K,< 4ZO-OB3<-?>
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MTB(5#NJESM4$XW'T%<A:?$32S<:S;ZB8[672K<74KQ3B>.2$_P 2,,$G/&"
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MAL;."TMT"001K'&@_A51@#\A6;:^%])L_$%UKD4#G4+G[TCRNX7@ [5)PN0
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M4XY7H<^PP >C45X[+#>7'@OQ[?/K6K_:-)U.\-DZWLB^5Y:(RC@_,.V&R/0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MVTZW6YCN$M6,*3!<)%%\N"H_B _AP #DXH:K?Z_J^A>&O$JZ!?+J&CWHEO\
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M2Z)8*!]X@=AZ5U.GW%U=?%6?5_[)U*'3Y=#2))Y;9E^83.V".H./X2-WMR*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.TN00,=>#G..AJ.Z\=6,&IZIIL.G:K=WFFHCS16]MDLK G*EB 0 O?&<C&:
M.HHJCI6K6NM:+:ZK8,TMM<Q"6+C#$$=,'H>U><ZUXEO/$_PR\87$]A=V'V-K
MF.)EF5=IB.W:2CY)R"3QM]S0!ZI17*Z+XMLY+W3-$DM;Z">YM/,MIYX=L5QL
M5=X0YSD9SR!D<C-2WWC?3=/2.ZG@NQICW/V7^T553 LF[;S\V[;N!&[;MSWQ
M0!TM%<O\0O$\OA'P;>:G;1K)>$K#;*W3S'. 3[#D_A4UEX2MXM/C6]N[VYU$
MH/-OC=2+(7QR5P<(,]%  QVH Z*BN=M+T^';#2]%NI+C4]4:)E18R#+,J=9&
M+$ <%<DD<G S4$_C_1[;0-2U::.\4:9(8KVU\G,T+CL0#C!R"&SM/K0!U-%<
MN_CK3XM7ATV6PU2.:YB:6S9K;Y;K;C<L>#G(R#\P QSG'-1-\0])B\/:GK%Q
M:ZA NF3&"[MG@S-$X /(!(P000<XYZT =;2,"4(5MK$<'&<5S%IX[TNZ\16^
MBR6VH6DUVC/9S75OY<5T%&3Y;9R<#GD#CZBE@\=:7<2:>R078LM0NVL[6]*+
MY4DJEAC[V\9*, 2H!Q]* +GAGPZGAFPGM(KR:YCEN)+C,RJ"&=BS?= XR:VZ
MY.Z^(&G6]SJ]O%IVK74VD[3=)!:\A2N[<-Q'&.><$]@>:LMXTTT76A11PW4L
M6N('LKA$7RV^7?AB6!4[><$<]LF@#HZ*R9[R+5+C5-$$5XACMP)9XF5/]8IP
M$;=D/C)Z#'![C.?I9_X0_P -:;I]]/=7EQ).UO;JT@DE<LSNL>]B 2J#&21]
MWZ"@#IJ*HZ9J2ZDDY^RW%L\$QADCN H8, #_  D@C##G-43XHMC<.D-G>3P1
MWBV,ES$$*)*6"X(W;L!F )VXH W**YW5O&-CI$%Y=26M[<65BX2\NK=%9(#P
M3D%@S8!&=H;'X'$UWXILX6D6T@N=2>*V6[E6S"'9$P)5B691\V#@ DG'2@#<
MHKG;3QII5]=Z)#;K<.FM0O-9S; $8(NY@><J0/45!<^/-+M-,UJ^GM[Y4T:;
MR;J,1!F#;0W&"1C!')(H ZFBN%U_Q9H=]X=O6U;2];338Y;<>9Y#Q";>RE&1
MPP^7=M!R1U]ZT)O%-VGQ%3PXFEW#6XL#=-,K1_-F15#8+ A5^;/<D\#C) .J
MHKD]!UOP_%:^(;^T6[MXX-2=;TW(<EI]J9V*23@Y4!0!ST%6T\8V$>JSZ;J%
MO=:;=16C7H6Z"8DA7[S*49@<=P<'VH Z&BLC3M?34;N" 6%[ +BV-U#+*$V.
M@*C@JQP?G4X.*GO]7CL;F*TCMY[N\E1I$MK?;O*+@%B695 R0.2,D\4 :%%<
MB?B)I']DVNI);WSP37O]GN!&H:WN-VW9*"PV\]^1[\BMVXUFWM=1>TFCD18[
M8W4MP2HCB0=V.<CH>W8^AH T:*YU?&5BNJ6%C=6=]:'449[*6>-=D^T;B %8
MLK8YPP4GZ\5FM\3='73Y=0^PZK]B@NFM;FX^S82W8.$R^3TR>V2.X'% ':45
M4U/4K72-+NM2O9/+M;:)I97P3A0,G@=:S+#Q5;7VK?V6UE>VUZUG]MBBG5/W
ML60N5*L1D$@8)!YH WJ*\D^W-KEMXMU/4]'U26;2=1=K62">*)[988T81AM_
MRY^8M@$'<>IP*[71?%+W7A?1KZ^LKA;[4(8_*MTV%IW,8=F3#8"XR?F*XQSC
MC(!TU%<A<_$;1K/2=3OKJ"^A?2YU@O;4P@RPLV-I.&*[3D8;=CWK<TG6EU<7
M92PO[86\OE@W<!B\X8!#)GJIS[>X% %K4+1K_3KFT6YGM6FC9!/;MMDCR,;E
M/8BJNAZ+%HED8%N;F[FD;?-=73[Y9FP!ECP.@   Z"L'P]XU?48_$%UJ=A-8
M6>F7LL'F2-&P01JF5.UB2Y)8\ CD $FM!/%]HNLKI-W8W]G>2P-<6\<T:M]H
M1?O;-C-\P_NG!]J -J*TAAN9KA4/G38#NQ)) S@#/0#)X'')]:GKB[7XF:3>
M:4=4ATW66T\6LMR;H61,8$9PRD@_>XSZ8[Y! G'Q"TO[1IB26.J11:G%OM+A
MK;*2MLW^6,$MNQTXP>Q- '6T5S5IXMT_5;36HI;/4+:735VWEI-%B8*RY4KL
M)R",X(/;M5#3_%WA_1?#7AH6MOJ(L-15(;%?*:5AE20&.2<X!X!)]J .THKF
MK7QQI<UMK4UU%>:>VC*'O(KN(!T0KN5@%)R" <8YXZ5-9^*[>\U-M,.GWT%\
M;+[=%#*(\S19Q\I#E0<D##$=1VH WZ*\ZB\8VNN?#/4=7\1Z5?Q:<S3I(MN0
M28Q*ZA04;(("@$G:,]R*ZV;7+2R>RL8(+BYN[B RPVL.TR>4N,LQ9@ !E1DG
MDGC- &Q17*7/Q"T6U\/7FLRI>".RG^S7=N(<RP2[@NUQG Y(YS@YX)J[8>++
M.^\1/HAM+ZUNO(-S";F'8L\88*63G/!(X8 \]* -ZBL_4]9M],EM8'22:[NW
M*6]M" 7D(&YL9(  '))('3N15&T\4VU_%J26]G=G4-.8+<Z>X19D)&5/+;2I
M'((;! /?B@#>HKSKX=VB>(=%T7Q-?07D.JJCR/=^:JK=^86R&"L2RKQ@,!C
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M3KL07Z0?9'\O_7%(=C >GS>N/6LC2(/$6G:#X.TV?1]1?3H;1X=0@M2J2B8
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MHT-LTJEY+JX2U@0,%WR-G R>!P"?PXR<"@#2HK"?Q-';6<TU]97%M-'=K9I
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MVHTFX_MJ+2?,%U\N)+?S>$7YNN_/4#I6=#\3;2;2+35_[%U--,FNOLLMRXC
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MS%"'\NW96X#$CGU%:(T^[\4Z5X,M_L$]M%IT]M?W$TVT >5&=JK@G<6)'(X
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M<B,Z.#R3D%21CFHO$.G:E=>._"FH6NGRSV>GM<FYE62,;/,BV+PS GGK@=*
M*Z^/[F2TU;R_#5\U]I$A6]MO.C C4*'#!\X;*G( YXYQQG47Q8EXND#2K*6Z
MDU6T-Y"9#Y<:1 *?G;!PQWJ ,'\*P[72M8BO_'<SZ1.$U7:;/][#^\Q (\??
M^7D9YQQ^54=.TKQ-9VGA2PN]$ENM+M=,%M=V0N8E"W*A0'D^;#QX!P!GKG;D
M"@"YJOCZYN/">B:QHMBV-1U.&SD69U5HCYVQU[@DE64'I@Y]JW-0\6+9SO9Q
MVT4FH0VZW$\$ETD00-G:H8_>8[3@=..2,C/%6OA;Q';_  \L-..CJ+S3-<6^
M6W2YC_?QBY:0[#D*/E88W$'@\#C.O>VWB71O&,^NV7A]=5L]6MH4N;1;F-9;
M66/(4@MA2"#@X/7Z<@%N/XEV-W:^'[C3M,OKR/7/,%OLV+M=%8LC9;@Y7&?N
M]\X%2VVMVM[XOT2+4?#=Q9:Q/8SRQ33M&QA4%0Z95CDGCL.OUJOJNG:[=>(/
M!]^=)WBQN)YKL6\L86$21LBJ-S*6(W#) YP3[5<U/3M2F^)FB:G%I\CZ?:V=
MQ#-<"2,!6D*$?*6W$?*<\4 *?',:O8SR:9/'I]]J)TV&=VP_F[F4,8R.$+*0
M#G/0X%4]*@BA^,VOF*-$,FE6SOM&-S;Y!D^_ KG)]"\67UCIDM_H#7.LV.N1
M7=Q>-=Q?OH5D) ARWRH%*_*=O3H23756MCJ\'Q(U76'TJ3[)-ID4$4@FCPTB
M,[$?>W '< "1^5 '95RVM>,O[).L.FESW%OHT:2WDFX)D,N[]V",.0O)Y'ID
MFM'PQK%WKFC"[OM,;3;M97BEMFE678RG!PZ\'^AR.U<5XIT7Q+K,OBRRFT?[
M?%<VNS2)VN8UAA'EX(V$Y$A;/S8YR!N44 =-?^,TM=;T[2K?2KR[EU"U>YMG
MC*!7"@''+<?>&2V!Z9Z5'9>.[*?P]>:G=VEQ:SV=ZVGS69*O(;@,%$:$'#%B
MRX/3FLNVTS7&\5>$K^;1I8X+'39K>Y83Q-Y;N$ 'WLG[G. >O&:QKGPCXCN=
M(UMX-/,%_'XF&N6$<TT>VX5=F$)5CM)VGK[?@ :1:>3XUZ2]UIB6D[:1<$R)
M('$HWI@%L Y'((QW&":Z'Q]J&GZ7X+U"ZU;2GU/3U4>?;+MY&X8)R1QG'3)]
MJR(H]=U3X@Z+KDGAZYLK.&PGMY_M$\)9&=D/16.1\O'?V'?2^(^EZAK?@+5-
M+TNT:ZO+I%2- Z)_$#DEB!C H BOO$6IV_Q$TW0;:P5K*2PDN&82@%B&1>G8
M+D\=\^W.YXAU=M!T&[U46<MVEK&99(HF <H!EB,\' YQ7/ZA8:O_ ,)]HFNV
MVEO-;C3YK2=3-&K6[,R,"W/(^4CY=Q]J[&2-)HGCD4.C@JRD9!!ZB@#FV\81
MKJWA^R^Q$IK<)EMK@2J4&$#E3WS@\>M2W'BR&TBN))[23"WRZ?:A'#&[F/&%
MZ8P<@YZ;6].>*_X0'7(?";Q(Z2:IHET&T LW2&.0LH8YX+JVPCT5:W_$WA34
M)/#^AG2RMQJ.BWT5_P"6[!!=L,^8,G@,VYCD]S0!JP^*&_MR;0KNP-OJBVWV
MJ"/S0T=Q&#@['P.0>H('KR.:I1^/K:7PQHFOI83_ &75;F.V5"Z[XF=]BDCH
M1GK@TJZ5=:WXVT_Q!<64UA!I]E+#''.R>9))*1GA68!5"GJ>2?09/'6^@>*8
MO FA^'?^$??S](U."5YC<Q!)T28ONC^;.,==VW\>P!TEI'!:_&K5I56.(/H4
M,LK   GSG!8_@!S[5C>/=8&O>%-*U&'2BVGRZI:FUNW8;P/.7Y]N,JK <'.>
M1D#-;5UH.I:CX\U>XEL9H-.OM"&G"Z$D9VR;G).T-NQA^N.HKGY=*\6S?#W3
MO#$OAR1KS2[BU7[0ES#Y,\4,BD,I+;LE5&00._?B@#U*_@BNM/N()XTEB>-E
M9'&0PQW%>6>"?&I\.?#OPR;[1;Y=(:-()-4!3RXW9B 2F=VW)QNP!Z9XSZNP
M:6V(*[79,;2<X)%>9V7AC6;WX8V7@:]TN6U=?+ANKMI(VB$:R!RR;6+,2!@
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MSP <C'H0#R.G2N2UKPQJFI6WC/5(M/D%YK-@EA:6ADC#A51AO<[MHRS=,D@
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MN:]%W'R]P5B<9V]_I0!Y\->A3X8^(=4\.:0^GM"U[NC+JK1RKNW2'!(SN&<
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 %8NL^%=,UR[@O;@7,-[
MI2.ZM+EX)54G)7<A&1['-;5% %#3-(M-)C<6_G/(^/,FN)WFD?'3+N2<#)P.
M@R<5?HHH **** "BBB@ HHHH **** "D90RE3T(P:6B@!D,,5O$L4,:1QJ,*
MB#  ]A3Z** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&!92 Q4D8R
M.HI:* ,K0O#]GX=@N(+%IS'/.]PXEDW_ +QCEF!/J?PK5HHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH CF@AN H
MFC60*P=0PR PZ'\*DHHH **** "BBB@ K&N/"^E7?B*+7;B*62]A140-,_EC
M:20=F=I().#CCKUK9HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
D% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>elicio-insidertradingcom009.jpg
<TEXT>
begin 644 elicio-insidertradingcom009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$[=S$G;@#!& <$]1G(I^@ZOI%KX.L[Z+6KG4+!F*17MV6>:=C(0!C:&8[OE
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M$CG  +!'(VL0#R 3BGWOB_1M/^T/<3R_9[:7R;BY2%VBA?CAW P,9&>P[XH
MW:*0,KH&5@589# ]1ZUP_@K5#:V7BVXU74I7MK'7+E!-=2EO*B58\#)Z >E
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M@DADSC:Z;=RG)'48YJQI_C30M5UQ]%MKMQ?>69(UDA>,3(.K1LP <>XSZ]*
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M>W?? =N[E0,XP<Y&1CO3++QMH>H:G:6$$\WG7D1EMF>WD6.8!=S!'(VL0#R
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV,=VTCVZ^8&<LHC+KM ^[N'RYQ^=5_B1]K'_  C"VVH3VR3:[:PR)&%PX)+
MG(.<%00.GJ#Q0!W-%<C;ZI?:UXIUC0;74I+1=&@MQ+<)%&TDTTJE@2&4J%
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M]W>^YO<;377$ C! (/8TM !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT^$_TKHZ* .:_P"$?UO(/_"2\CI_Q+H>/TH_X1[6L$?\))P>O_$NA_PKI:*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;S)&619&*J2!W(!KA[/3O$O@[P+HFDZ?-IDMY:3+%(KAV^TQDD[4& 0W(Z\
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MV,MYJ*F\N[AN7ED<DDL>^!@?05V#PQRV[02*'B92C*_.X$8(/K7(>'_#VO\
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MS70D(979@0VT]2%XQT]ZU/'>OZAX9\-/JFGPV\TB3PQLDV<$/(J<8(Y^;N:
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MT]T9I$;S;9G158!>C\*,9*X/7-5;WP+?:9=Z1J'@^_@LKK3[(:>T-[&9(KB
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MY+B2*ZB8O;S2+ARA4X(/!YZ>_?NJ* ,CPMI-QH/A?3=)NKB*XDL[=(/,CC*
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M5'?).W&2<#.3@Y &*ICP3J']A^*]-.I6O_$_GFF\P0-^X\Q A&-WS8"CTYH
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M?>(Y !;'<$ ]C0!;MO$&H:YX@N-(L=FGO8V<$]X9H_,=)9@2D8&0. I+'OD
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M)59(FC$?=S\^!UZ>Q[W+3P?J-C:>)K*'5+<VNKSW$\2M;'="\P^;<=WS <X
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M'AQDX8-N!Z=N!7H.K6VH7$,!TV[CMYHIA(WFH721,$%" 1USU[$ X.*XZ_\
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M%;PI#!$D42#"HBA54>P%<19ZS>V:>%/#L=TC7>I6IF:Y,0_<PQQJ<!<X+$D
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MN!E,XQGMD=:MV?B'Q38:[KOAR^-CJ.HP:=_:.G7"I]G2122NV0;B%PWOT[T
M>@T5PNC^)M0N/&,6B?;XKV"XTEKQ;DVQ55F5U4[","2,[NQ/3[U8<7C'Q6/
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M@/P,.!M.?N#YL\U4C\$26M]X4DM-2"V_AZ!X4CE@+M,&C$9)8,,<#CBNPHH
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M:_-$(-4U2S>'H[6=JT3R#ZF1MN>^!GT(JFOA>\T[Q+J6KZ+?P6ZZHJ&[M[B
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MRS7$?EJY> $>9C/0A<D'VKIZCG@BN;>6WF0/%*A1T/1E(P10!Q/_  EDEO\
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M56^T_2Y8Y;=/LVR20Q_ZL2/N(;;P>%7)49[@@%/0Q*WQ.\<B!T24P6&QG7<
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M1:DT,]Y:Q1RRBSVDK/Y:EE4[MH88.!D@=*ZCPMJ*ZKI+7D6K0ZI;22L8+F(
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M .P\0ZIK>GR74;:I#"8=-\Z 6EN'EGG&[<SQD.4B&%&<C[Q^:J$GBCQ#J#>
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M9^M=A7GOA">[BU:&WT_Q+HNNZ=(6^TC3K!(1!\IVL7C<KDD*NT\D'(Z&O0J
M.$NA?R?&JU@74YDMET.2980BE1^_B##D?Q8&3UXXQ7,07VN:/X;\<ZSI5_!;
MKI^O7DYA>W$GGX*95B3\HQZ<^]>@ZAX:EN?%]EXAM=2:UEAM7LYH_)#B6)G#
MX!)^4Y4<\\>E9)\!7+^'/$6CMK$937+J6YDE%H08C)C<%&_D<#&?UH EN_$&
MH:GKLVDZ8MW#]GL8;F26V6%GWREMHQ*0-H"<X!)SU&.=GPM<:Y<^'K9_$=FE
MIJHW+,D;*RM@D!AM) R,'&>*Q-1\#W\NIV.L:3X@;3-6@M5LYYEM1)%<Q Y
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M<Y$2X.Z0G  P>IKCG\5ZZGASQTT5XXN-$8O:SW-LHD*&$2 ,H &>>I'3J,T
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MY?7OS[5D:G_9.A>$8/ 5W+)J%[<Z>UM9VZV[@SJ!L7+ %5(."6)&,9[5W]%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ%9@?RK'\83:?XD\%^)K_P (0+>W,\4'VNZME/\ I*HX)B!_B(C# @=B!WH
M[ZS\0:3?W7V:VOX7G\OS0F<%T_OKG[R_[0R*I2^-_"\$1EDUZP$0F,!?S@5#
MC&1D>FX9/09KF]<N[/Q/KG@F\\/W44\T-X;EY(6!,5KY9\P/C[N3M7![\=JY
MQ;G3W^'GQ0(FMBTFI7^#N7+91=GUYSCWZ4 >I0^)-%N-8?2(=3M9-012S6ZR
M M@=?R[CM52;QOX7MX6FEUZP$23&!G$P*AQC(R/3<N3T&:XZ\O-/CUWX8&.X
MME4+, 5=0 IMB/R+8'UK-BN=.;P5\52)K8M)?7V#N7+9A7;]?FSCWS0!Z=%X
MET6?6#I$6J6KZ@%+?9UD!; ZX]2.XZT#Q)HQL+J^_M*W^RVDABN)=WRPN,95
MO[I&1G/K7G]U=V$=S\+3'<6R@$X*NHP#;%3^;<?6LV]U2RL/#?Q0TFYN$CU&
M:[O)H[4_ZQXW@3:X7J5X//0=Z /4+GQ/H5G,L5QJ]G%(T/GA&F /E\?-CTY&
M/7-4M3\0:1?^$+C4;3Q+;V%I("B:DC(1&P/8-P6X(QUKD;>]T^X\>> V\^W<
MC1IMN6&0Q6,#Z'AOR-85]>63?#/XFQI<P'=K-T44..=WEXQ]2#^1H ]@NM4L
MM-@A-W=J#(OR<9>3 R2%49/J<#BH_P#A(-(_L^VOUU""2VNCMMWC;?YQYX0#
M)8\'@<\'TKAKGQ'9>'OB-::CK%RL6D7^BQP6=\QS"LBN6=-PX!8%3GO@4:CJ
MGA_29O"J65E;:78W%S=-::E.A2.WRIW,JG #2;CMW<8YP>!0!TVM^.-&TCPK
M-KRW27-NI,<8B.=\N=NP_P!WG@YZ5-<ZI8W6LZ*MOXAC@:5I&2R7:3>@*1T/
MS *03D>E>53W$4OPM\?01S2S2Q:\\S[XR'V>?$V]@ ,9 )Z#H>.*['Q)JVFW
M?CKP!<P7L$D3W%VR2!QAE,#*"#W!/ /0]J .EN?&WABT25Y]=L%6*7R9#YP(
M5^"0<>F1GTSS6G=:G96:0O/<(//.(57YFE.,X4#);@$\=N:\OCN=.:V^*[&:
MU+.9!G<N6'V8#\1NR/K39=8T_2;;X<:W-J=M&8],:$BY<K"RF&,-^\ ;:X8+
MQCGGIB@#TW3==TG6-XTW4K2[:/\ UB0S*S)_O '*]#UJ>_U"RTJSDO-0NH;6
MVC&7EF<*H_$URWP[_LPV.K7&GZO9:@][J4U[.MG+O2!I,80=#T&<D#)R<5<^
M(DD4?PY\1F5U4-ITZKN.,L4( 'OF@"XGB_P[)>?9%UFR\_R3/L,H'R 9)Y]!
MR?05-8^)-%U+3[C4+35+66TMBPGF$@"Q$#)W9Z<<\UY_?SZ8;SX7?O;38K$C
MYEP!]G(S_P!] ?C[U1U;5M.L]3^*$LUK#J4 %@7M=_RO^["LQV\X4X+8]* /
M3K?Q'I%R+GRKZ,M;1B69""KHAZ-M(S@XX..:I>'O&.E>(= .L13I#; L6\T[
M=B[V52V>A(7./?%<EHFJ6MQ\84E75TU 76@!8YXD C=A.25CVCE0,GJQ'.3Q
M7.:;J2P?"#PY)$T\D>C:FLFKQ6V?,@C$DN<@=U)5L=> ?>@#UI/%.A/:W=R=
M5M8XK,@7)E?RS"3R-P;!&>V>O:LO5O%F@7NC:C%:^+;33I88T+W:.A:#?RIP
MW!) /'7\:Y75;CPI?^&_%FMZ->2WLTVBS6\]Z\SF,_(=D?S8!?KP.1WQD9=X
MK;3U_9]EE@-L!+I5O&K)M^8C;A<]R#GCZT >A7NM:=I0C2]O%21HS(%P68HN
M-S[5&=HR,G&!FN>\8ZW<P6GAF^T;4\6U[K%I YA".D\,C<_,0>H'4$=:SM4U
MW31XYM[7SX+&:;1PT>H ;Y+I"YQ#"#E2<C<>&)R !WKD;#4K/_A4_P /E:YC
M4PZY:+)N;&TK*Q;KZ#&?2@#W&F2RQP1/++(L<: LSN<!0.Y/:LZW\1Z1=^(+
MG0H+U'U.UB6:6W .51L8.<8/WAT/<>M:3ND4;/(RHBC+,QP /4T 8D7C/PU/
M-9Q1:Y8N]ZQ2V"R@^:=Q7 ^I! ]<<9J[J&N:9I3;;V\CB8)YC*<DJG]X@=%]
MSQ7C5M<Z?%\"-)*S6R2#5XW.&4'<+PG/UV?I[5VFBZE!I7Q$\61:U<PP+?+;
MW-E-.X6.:W6/:0K'@[3G(_VL]Z .ON?$.C6BVC7&J6<8O,?9BTR_O01G*\\C
M'.>E+I.O:3KJ3/I6H07:P/LE\I\[&]_\\UY##:IIGACP1;:@4B@?Q.9[:"XP
M"EL3-LR#T'*GVW"NJT^5[CXF^-K?2[^VM[Z6SL?+D91* ZB0$E,C=@$ \\9%
M '<ZEJVGZ/:_:=2O8+2'(4/,X4$GH!GJ?:JEEXJT'4KZ[LK+5K2XNK0$S0Q2
M!F0#@G ZX/'%<1\0K36K3X6:Y_;VJ6NH$R6Q0P6?D! )TSD;FS5[4;:RU+XD
M^$+O1&MY#90W+74ML052W:/:BL1Q@L?E'LQ'0T =7_PDVB#2X]3_ +4M?L,C
M^6EQO&PMNVXW=,YX^M<P_BQ-#\?Z[;ZYK:0Z3#9VTL"S[$".Y?(& "WW>^3Q
M7"7.K6%O\&=2T:2Y0:E:ZL?/M1S)$/MX;++U48(Y/!R!UKM(+W2[7XMZQ=7]
MQ:PQ7&D6QMY;AE59%#/OVD]1@C./:@"_XUUZ>+PWI>JZ%J@$,^H6L?F0;'2:
M*215(R0>QZC%;1NX'\8I;)KJ^<EFQ?25V$GYE_>G^(8R!Z'->6W5JNB_#6%9
ML6EI<^)TN;&&7Y"EL;D,O!Z#:"V.P-=;>74#?&JR2*YA$S>'YD3YQ]XS(5'Y
M GZ4 =8_B+1X[]+)]0@6X>7R54MP9/[F[IO_ -G.?:M.O*/!6MZ#=>%-,\,Z
MU;B7Q#I]SM?398R9?M*N2)>G3G<7Z<G->KT 82:A9CQ1> ^(8F$%HIFT[<FV
MWPQS*QZC((&">U$7C/PU/-9PPZW8O)>L5M@LH/FG)7CZD$#UQQFN?AO;./XV
MZD&N85*Z#$&RX&")G)!^@(/TKA[6YT^+X%:$5FMD<:O$YPR@AA>$D_4+^GM0
M!W^M>)HY_&T'AB/4WL8VL99Y9X<>9YN]$1 2"!]YCTYP.V<ZUKK5IHME!8ZY
MKUO<7T.V.XNB@B4N?N[\95"01P2,]NM8,VH67_"[[-?M<&3H$B >8.6,Z$#Z
MD G%8ND7EK!X&\7Z#K[HNJBXO?.@E/[RX\W)C=%ZMNR N.X H ]"U+Q/H6D3
MO!J&K6=M,D1F:.24!E08^8CJ!R/K4#>-?#*Q22_V[8E(XDE<K,&PKC*GCU'(
M'7%<)IT(LO&?@'3]9EA;4(-"FBF65@6$A6,!3GOC</?!K8TV;3H?C)KB^9;)
MY>D6R ;E&S:S[A[8&W(],4 =+_PF'ASS;&(:U9%[X*;8"4'S-WW<?7H/4U/J
M'B+1]+E>*^OX86C57EW'B)6. SD<("0<%L#BO'HKC3XOV>[?9-;)(-3!X90<
MB^SGZ[,'Z>U:WB_6M/N3X^L(I8K&Y_LX$JB[YM2_<$JXSD>6H./E&>"2PH [
M[4?&.EZ=XEL-#EF'VB[C>4MSM10!CGN22./3GTS/I-W;W.M:SY&O)?JC1AK1
M=A6R.T@KE><L02<]*X:+5;*+Q3\/]0EN56UETBXA24YP\FV+"CU)P< =>U5;
M\7&I:E\5[/1IE>_F@MA$D3 L^+?# 8[]5^IH ]*M?$6CWMY':6^H023RJ6B4
M-CS5'4H>C@=RN:J7/C;PQ:)*\^NV"+#+Y,A\X$*_!(./3(SZ9YKC=6N[/Q/H
M'@I-"EC:_BU"UE2.,CS+9$!\W>!RH494@]\#N*JQ7.G-#\5V,UJ6<N"=RY8?
M9@/RW9'UH ]91UD171@RL,A@<@BL'7O%VF^']4TK3[N3$^H2E%X.$4*S%B?P
MQCOGV-+X(F2?P)X?=)%D']G6X+*<\B-01]<UA^/+F#3_ !/X*OKN58+2+495
MDFD.%0M X7)[9/% '47WB#2=-.+R^BBQ&)6SD[$/\;8^ZO7DX'%:$4L<T22Q
M.LD;J&5U.0P/0@]Q7GOA[4[;3/%_C&UU^>*W>[G2[MWNCL6:U,84!=W4+@@C
ML36K\+["\TSX?:;;7BR(P,CQ1R ADB:1C&ISR/E(X[=.U '47=Y;6,!GNIDB
MC!"Y8]2>@'J3V ZUFGQ9X?72YM2?5[2.SAD,4LDD@78X_@8'D-[=:YSXBWG]
MDZAX:U>\:Y31K6ZD%[+;YS 7C*)(<<X!)!/^U[US7BL^&I/AUXRU31)Y+A;^
M*%9KR25F2XE4X"INX) QG'J.X. #TC_A+?#WVRYM/[9LA/;1F29#* 44'!/X
M'@^AXI$\7>'GT9]8&LV0TY',;7#2A5#CJIS_ !>W6N4UF?3&^)?@+RY;0J+:
M\V;67 !CCV8_$''Z5RFNW-M-X.^*T<,T3_Z>L@5&!ZK$"W'N#SZB@#UJS\3Z
M'J6JW&E66K6D]_ #YD$<@+KC@\=\'KZ=ZQ?!.KWES;>)7U;4/.6PUFYMTFF"
M($A14QG  XR3FLS5[?3]5\:>"I]":W>2S:6662V(Q%:^61AL= 6*@ ^^.AKE
M9Y)KWP/XY_LPB[,7B>2XG@A(9I;=7B+8 Z@A3]0#0!ZW:>(-*OIY(+:]C>:.
M/S3'R&,?]\ \E?<<4EIXBT>_TZ?4+348)[.#/FSQME$QUR?;OZ5R6KSVOB/Q
MIX,OM!NHKEK=YIYYH&#!+9H\$/CIN;: #WSZ&JEQIUYIGC._\,6\#G1_$K?;
MMZ_=@VD"Z4^SC;CT,E '<77B'2;*UCN;B^C2&6/S489.4[O@<[>1STYJ676=
M.BL8;TWD36TX!A=&W^;D9&S&=W'/&>*X#5]7T_0/B3J:^)+VXT^QU"S@%C=*
M[)$PCWAXR1P#ELX/K[BLZY?2/"-_X6N0-0L/"?V6ZMH9]\G[B22175G)RP5P
MIQGH#VP: /3(O$&DW&F)J,%_#+:._EI)&V[<^<;0!R6S_#UJQ8ZC9ZG"\ME.
MLR(YC<K_  L.JD=B,\BO.+FP\-2Z-%-HVL76E?;=9^TV>K,Y=)+PQ/E\/PR,
M-R]@3Q73> ]1U'4+'4EU6&T^UVU\T+W=GD0W>%7]XN>_13VRI^@ .GGN(;6W
MDN+B5(88U+/)(P55 ZDD]!5*SUW3+^::"VO(WFA0/)$<JZJ>C;3@[3Z]*YOX
MH+=KX6M[FWBDFM[34;:ZO8HUW%[=) SC Z@8!/L*KZ@]OK?Q*\*:EHMU#<1V
MMM=/>SV[AE$#HHC5B..7Y /HQ[4 1V.N7?C#5-8ATSQ VG36%^(;1$B61)8T
M1&<NI&6W%F'48P,=\]Y=7,-G:RW-P^R&)2[MC. /I7$?#N]M;C5O&:0W,,CG
M797"JX)*^7&,CVR",^U=S*"8G ZE30!YUK?CA]5\"V>O:#?/:E[^"-T"J28G
MF"8;<#@E>>.GK7:Z;XAT?6+JYMM.U*VNIK;'G)$X8KGH?I[]*\>34M.D^ VB
M63W,)E@O+6*XB<CY&%P"RL#W !)'8<G@BNEUV3[3\3-2MM+N(A>S^$98K?9(
M 3*924 ]^<CVH [N'Q'H]QJ*6$6H0-=2!C&F[_6;?O;#T;'?&<5J5Y3X6U#P
MIXBMO#ENTM]+K>FM&5TYY)%>TE0!7++P @&>O!&!U.*]6H XW3]<O_%GB/5[
M33;QK#2M)F^RR7$2(\MQ< 9< N&557@="23U%:]G#K5IKQCN;[[9I36Q9'DB
M594E##ARH (P>, =#G/%<;X/N(/ WB3Q'H6MS)9QW^I2:CI]U.VR*X20#*AS
MQN7 !'7FM_Q==RZ]X+UZS\.R?:KAK*15EMV#*6Q_JU8=6(SP.G&<9% &W:^(
MM'O+R.TM]0@>>52T2AL>:!U*'HX'?;FJMSXT\,VB3O/KEBJP2>5*1,#L?K@X
M[COZ=ZXO5;NS\3^'/!<>ARQG4(M0M)4BC(\RV6,?O=XZJ%&5(/? [BFV5SIQ
MO?BBS3VQW'!)9>5^S!3^&[(^M '>IXGT*35HM+CU:T>^F7='"LH)<8W<>O'.
M/3FJUYXX\+6 D-UK^GQB.7R7)G!P^,[>.XR,^G>O/&N["'P/\*RMQ;(R:A9%
ML.HV_N7#Y_X$1GW/-:FCSZ#%XF^(D6K/:*CW">:LNT%XC N0,\D9SP.YH [^
MZUK3;..W>:\CQ< M $^<R@#)*A<E@!SD5"WB;0TL[.\;5K,6]ZX2UD\X8F8G
M "^IS^5>9>'+G_A';;P9I&M%-,U#^RIBNH7 RZJTBD6\8/R^9C;U!QMP!DUD
MVM[I[?"[P]:3SQDP^*$65)AMP/M;L0P(&/E.2.P/.,T >P6OBO0+V&]FM=6M
M)H['FY9) 1$/4^W!YZ<5,/$&DMI*:JM_ =/<@+<ALHV3@8/N>/K7*6MQ9R?&
MR_B2:!O,T&%60,#N83/D8[G:1^!JCX<T^]LO$$O@F6%SI.EW(U.WF/W6MV):
M&+ZK+N/TB% 'I0.0".AH9E12S$*H&22< "LVR\1:3J.LW^D6EZDE_I^W[3"%
M(,>X9'48/X9Q1XCN([3PSJMQ+9M>116DKO;+UF 0Y3\>E !8^(M(U*Z6VL[^
M&69X_.C4$CS(\XWIG[R^XR*X^QUC6I- \>N^JRM<Z7>7"6DYBCS&J0JZC&W:
M>2>W>L#3=9L+CQC\/KJ'4H)H&LKJ%8K9,0VY,<6V%3@DL,8(8D\ X7-7--O[
M,Z!\42+J''VV[;_6#H;=5!_$@CZT =_X4NY[_P 'Z)>74ADN+BP@EE<]69HU
M)/XDUKUS_@66.;P!X>:*17 TVW4E3G!$:@CZ@UT% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%0
MW=W;V%K)<W<R0P1C+2.< =OY\4 345FVFOZ9?27,4%R?/M5#S021O'*BGD$H
MP#8/8XYKBM-UZ;Q/-JEY'K=YIS:;JKQQ)%;L\;V\952K(5Y+$GG[RY'84 >C
MT5Y19ZV_B+P;;>)KKQG=Z '$ANPJ#RPC,PC5-PP&&!RN2<'/7CTBZU6RTZ*
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MSS7 -@X7#E]QV@#!'/7@?3 GGM'^#/C=$DB+RZI>%%!&7W390@=\@9'TKV[
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M')YP&X*P'\..>>_/6NAC\7:++?VMF+EU>\#&U>2!TCN,#)V.1M;CG@\CD9H
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M9+2"Z^S2+'YK2,5^8J,?4\<$=:=X5O=&UB'1K"[T/5O[>TUHS+!>?:/+M'0
M-*&8E .#MQR<@8KU&B@#QV3Y_AS\1H%BD,UUJEZ\$?EMNF#[=A48RP.#@CTK
M=-Q]F^(7AG4&AN7M9]$DM4DB@=QYI>,[3@?*< ]<#@UZ+10!Y++>2VEE\1KB
M#2AJ+/?1R16\UN9$E39&C.%_C5<$\?W:O:-=QGXK+?J^IW-K<Z"$6]N;9T5V
M$Q8]5 0 >P'U)Y],HH XGX6$KX1DB='CD6_NF*2(58!IG93@]B"#3;^14^,>
MERL&$2:1/&\FT[%=I$8*6Z D G%=Q10!XK=!I/@]XQMDAE-Q/JMR\4(B;?(&
MG#*57&2"!D'V]JZS6[R"3XE>#;A&9H(K>\\R4*2D>]$V;FQ@9P<9KOJ* /._
M#]T/#FK>+M.UZ.0&\U&6_M7,;,+J&1% 1,#YF7;MV]>G%86D:5=>'_\ A6%A
MJ:/Y]FUT]Q\I86XDC?8&(X&"P7ZBO8:* .'GD1/C3;S,&$2Z%)"92IV!S,K!
M2W3.T$X]*Y*4%_A3X[MTBE,]QJEZT$7E-OD#R90JN,D$<@CTKV6B@#S'4]3^
MU:U>V+6EU"DVC1_9IK.T9I+]B&RC2A255"?NY'+$DXXK-L)7@\/?#&^EM+U8
M+!_)N3]ED+1L;=D'RA=V-W&<8KV"B@#S:^@GU/X@^)K>T+PS7?AU;:"5E(43
M9DXW=,C<"169<J_B'X2:9X5@MYH-?A^R6K6S1E7MGB= TI]%VHQ#=#D $DUZ
MY10!Y_IL\4/Q%\;S2Y6*2UM%21D.URB.'"G&"02 0*7X?:M#I'P^\*6-W#=+
M<7 ^R!! Q,<@R</Q\HP.I_E7?T4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?^)7=?O^,_)^[^;CGBN@MY%O;"*5D^6>(,5//##I^M</XX54\:^ %4 *-0E
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M\F"O3GKR,5GW_C'5=)M]#;Q1'+H,=U;/]KNH(UFCBN0P"HS?,%0C+?D,C!H
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MTDJR0Q-NC+B1@S(>ZL02/K6%;/:+\8M?1FA .B0&0$CM(^<_@1^E '4Q>*-
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M>)O%^A^*]9DTT7LHDC61D2.YM6A5 %9E))&&& >IXYS0!Z9>ZG9:?$CW5Y#
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M3^\R]0*\AN+=M/\ !E[=DA-%3QC'=6C?\LX[;SURR]@F[=CMW[UTT6JZ??\
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MYTN;4XM9LC8P.4EG,RA$8=B3T-+:>*=!O]5.EVFKV<U^$WFW24%\8ST^GY4
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ML=/NWOOL>"&@* 1(<<<MG:/8^E=#XU\/77B/P\VEV+V\#/-%*TDN<#RY%<#
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M!GDUT_PRGBG^&GAXQ2*X2RC1MISA@N"#[UU+PQ2.KO$C,H(#%02 >M. "@
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M#R+7XTV_$[4[>6,:5<Z8D0<,/+EN1$P;:>A(!4''<XZBKFH2Z8=4^%P\RTV
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MTI'ABDC,<D:-&?X64$?E0!Y=XAO=*TRVT'7-.@FM_#,>K2S7=Q:H0"9(V47
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MS] P]:W?AG'9'X=^'IK9("XT^*-WC R#C+*2/]K.1ZUU:0Q1Q"-(T6,=%50
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MOM(\#ZKJ>FW;6UW:0&6-@B,"1V(8$8KI:X[XISQ1?#/7EDD1&DM61 QP68]
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M-L$U&Q9O-Q&?O/&ISLE3KQC(R/J >T7>HVUA DMU(8_,.U$VEG9L9VJHR6.
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MJR@A&!.UHHQO'_ @<'U%7_ 4FK:HPFUR)ENM$1]+WMTFE#?O)1Z@JL6#ZEZ
M-S1-9DEUG4]!O7#WMALD67 'GP.#L? XW AE..,C/&<#?K@0PC^-.J:@6*VE
MEX=C2Y< D*QF9QG'?:I-=GI>IVFLZ7;:E82^;:7*"2*3:5W*>^" 10!;HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MF&@" W#:E&EJ!D73HRPM_NR$;&_ G-;:L'4,IRI&0: %HHHH **** "BBB@
MHHHH **R[GQ%I-GJL.EW%XL=_,"8K<JV^0#J5&.0/:M2@ HJ"\O;?3[8W%U*
M(XPP7."26)P% ')))  '))JKI&NZ=KB7#:?<&0VTIAG1XVC>)Q_"RL P/U%
M&C1110 4444 %%%4IM6LK?5K72Y9MMY=H\D,>QCN5,;CG&!C(ZF@"[1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6OAKQ%K2+I 70M1GMWB,4A-Q'$5! .[Y#@DY^;)[#'.A8^"=>@NO"UQ-JNG
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"K>:98:B$%]96U
MT$.4\^)7VGU&1Q5E55%"J % P !P!2T4 %%%% $ L[47AO!;0_:BFPS[!O*^
MF[KCVJ>BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M***Y_6I_$4,M[/83:=!8VUKYB_:+9Y7ED&XL/ED0*,!>QY)H Z"BN)\+ZQXK
MU_0-&UII=(\B^3=- EG(K0@AL$,92&PP7(P.,U9\#^*)-8\.6MQK%W9IJ%Q<
MW$*(I$?F;)60!%))/ 'K0!UM%5KS4;'3PAO;RWMA(=J&:54W'T&3S5D'(R*
M"BN?\9>)H_"^A-=[H?M,DD<,"2M@%G=4W$9!(7=D_3M2Z?=WE@;VYUC6M-GT
MEF0V=SD1,.NY7.=IY P1[YH WZ*YKQOK=WI'@34M:T:>V::W@\Z-W3S$8>V"
M/P/(]C5?4]=U.T\5^$;&.2#['JOG"X4Q'?E(2XPV< 9QQCMUH ZVBJMQJ5C:
MW$=O<7MO#-+_ *N.2559_H"<FGO?6D=P+=[J!9R,B)I &Q].M $]%54U/3Y(
MI)8[ZV:./&]UE4A<],G/%5A-<2:_ 8M2LS8/:,WV4*#*[;AB0-G[N#CIW'-
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M;_L5[;7/EG#^3*K[?K@\54TRZE@TZ:;5-5LKC;/(//B C1%W?*AY/S 8!]Z
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M,22<^IZUT]Y?V>G1"6]NX+:,G:'GD" GTR30!8HI$=9$5T8,K#(8'((]:6@
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MM-?\86]N,:.FIC[(H^ZLAC#3!?0!ST'&<^]:OQ @AG^'GB)9XTD5=.G<!U!
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MMA/;QV\UE;201_<B>)2J_0$8%-_LK3O/2?\ L^U\Y  LGDKN4 8 !QZ5<HH
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M^CZ9)8M8OIUHUHQW& P*8R?7;C%7:* *]M86=D6-K:00%P QBC"Y &!G [
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M[64$20I"H1\C!RN,'BK*(D4:QQJJ(H"JJC  '0 4ZB@ HHHH **** "BBB@
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MK3/*L)?M]OLU @6C>8,3DC<-GKD<\5>H **** "BBB@ HHHH **** "BBB@
MHHHH **J+J=@^IMIJ7D#7R1^:]NL@,BID#<5Z@9(JW0 4444 %%%% !1110
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M=G^TP1,Q.S9C:S#) .<#KSTJ6#0/%7A_Q+JTF@OID^E:M<?:V%X[J]K,0 [
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M=W]])<1R?:'V*KS"3D^7G(QCI0!U<^NW-WXBNM#TF*W>>R@2:[EN"=B%\[$
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M)@;BHP">^/:@!U%%<*WC;4K34-%CU"TM8#J=^;1M/+?Z3;*=_ER,<D$'8#C
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MD*70KG]:Y$^#]=-EX7OO.T]=;T >7&BL_D3PM&(W1F*Y!(7(.W@\8/6N^HH
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M3TKH!HFH77B)?$=^EG!=VEC);6D"3-(BLY!9W<JI_A P!TR<\\=100",'D4
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MQ!AS\A;=_%CKCBM"L_2$U9()QK$MI)*;AS";564"'/R!L_Q8Z]JT* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "H;JTMK^V>VO+>*X@<8>*9 ZM]0>#4
MU% %#3-#TG14=-+TRRL5?EQ;0+'N^NT#-7Z** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ML9SWIWC35+ZTTCQ/JFG:K?7-S87<?ES0RM%!9X,8,!7=B5N3N^4_>P2" *[
M^!M..D:1I?VJ^%MI,R3V@$BY1T^YD[><9/!]><U!>?#C0[Y-7BEDOUM]5D,U
MQ;I=,L?FG&9 HXW$@'G(]J (M2N;R+XK:):I?7*VESI]T[VX?]WN4H V.Y^8
M]<UQEU+JW_"">,-8_P"$AU;[7H^K72V9%R0%$;J & ^\,<8/'H!SGTD^%;,Z
MU8:M]JO?M5C"T$):4,-K8W;MP)8G R2<U4/@/3&T35-(:YOFM-4G>XNE,BY=
MW.7P=N0"0.!Z<8YH Q!9Q77QJM9WDN0S^'O/(2YD4;A.@Q@-C;ZKT/<&LJ[U
M2^@.B:A9:K?7OG^(DMI;[S62WFB>5E,21%B"%  W8'*Y!.37=R>$["75M/U1
MYKS[990?9A(LQ3S8\AML@7 89 /\\UE+\,]"2SCLTFU);:&[%Y;1+>.%MY V
M[]V.PR3[\G!% #+26\E^*>MZ:VHW9M3I4$L<?F<1,SN"4&, X4<XS7&:;>:N
MGP\\)>)I-=U.6_DU*&&57N"8Y(WG*,K)T;@]3DCL0,"O38_#%K#KUSK,5W>)
M>3VZVS'>I41KDJ "IY!).>OKFJ"^ -*3PY9:"ES?+864ZSP()5W*ZMO7YMN2
M V3S0!4MI;R3XJ:UIK:C=_9#I,,T<?F<1,TCJ2HQ@'"CG&:XS3KS5T^'7A7Q
M-)KNIRW[ZE##('N"8Y(WN"C*R=&R#U.2.Q P*]-3PS;Q^(+C6TO+P7UQ;BV=
MMR8V DC VX!!).?>J"^ -*3PW9Z ES?#3[.<3PIYJ[E<-O'S;<D!LF@#(UB^
MNF\4^([+4KN\M+>/3HI-)^RRNFYB'WD;#\TF\* ISP.!R:Z3P;#JD7A+3CK<
ML\FIR0K)<^<065R!D<#CZ=N:XO5;(R^+M4FU"+QA82N8XH+C1FD:*YB51AF\
ML$!LEN"  ,>YKN/#%K?6>CB*^N+N<^8QB-ZRM.L?\(D9>"W7\" >10!QWA_3
MX8O%'Q"D62Y)CF3:&N9&!W6P)R"V#UXSTZ#%8NB"[TCP?\.=4MM4O@]U=VME
M+;F8^0T,BME?+Z9& =W7WZ8]%?PCIYU;4M2BFO(9]10+<+',0A(38&"GC=MX
MS_7FJ_\ P@NFC2-(TL75\+729TN+,"1<HZ9V9.WD#)X/KSF@#GBVN^,%\1#3
MKS[)=V6HRV=K*NH2Q?9S'C!:)4*N#]X[LY#8XP*[<7D]KX;^VW!BN;B*T\V0
MP'Y)'"9.WV)Z5BWWP^T>]UZ;6%GU&SN+D*+M+*[:&.Z X'F!>O''&*ZE(TCB
M6)$58U4*J@8 'IB@#AO#UM=Z[X=\-^)5\0W$%U*8[F\S(SPSJX^: 1E@BX)"
M@@9&WN2:IZ?<WGBSP[XEU3^TKVSOK6]NH+3R)V1;;R>$!0':V<9;<#G=CIC&
M[I'P^T71+\SV4E^ML)3-%I[73&UBD)SN6/IG/(SD \C&!5B7P;IS7>HS03WE
MK%J9S?6]O*%CN"1@L1@E21P2A4GO0!QEGJ^J^)-6\"33:C>V::OI=Q+=P6\F
MQ6953E>.,[B<]0#P0>:DM?M%SX#\>Z;>7U[<QZ7<WL-M)+<N9/+$(=59P<L
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M& 5& (R<@[C@GKUR>] '+:;IES=^*_%GAZ37M9&GVB6T\ %Z_FHTJ-G$OW\
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M&2!S@UUMWX,TV^\-V6B3S79@L'B>TF67;-"T?"%6 Z@<9-0CP'I2SZI.MQJ
MEU.W6WNV-TS>8H4KDYS\V&(SVSQB@#E+.74;%?AWJG]LZC<2ZHL4%Y'-.6BD
M5K8OG9TW @'=U/<FK#:S=:=XJ6R\1?VE9M<:H?[/U*"=WL[B,O\ ) Z@[4;;
M\N".2,YZYZ=O!=@UMHD'VN]\O12K66'7Y"J[5S\OS87CFI1X2LBX6:ZO)[47
MAOEM)75HUF+F3(^7=@,<A<X]J .&\0:I?6MI=:I8:K?7<L.NQQ_:DE:.WCC,
MRH;<1[L28!P6VXSGG(Q70QRS>*O$WBO29-0NK/\ LT0V]L+:=XC&9(M_G':1
MN.3@ \83IR:GG^&NA3VU[:F744MKJZ^U^0EVP2*7>'+(.@R1WSCG&*GU+P#I
M.HZM%JB7&I6-ZL*P2365X\33QCHLA'+?7K[T <YJ.EEOB%X'BO-2N+VX^Q7D
M<]S%.\(E>-8P6"HV%)).<=>ASBDNO$6I:#J'Q)NA<SW8TR"VEM(IFW+$S0LQ
MP.@&XY/L*["_\(Z5?S:5*5GMWTL,EL;:9H\(RA60XZJ0![\=:6W\*Z?!JFKW
M[--.^KHJ7D4Q5HY%5=JC;C@!21[]\T <IK-Q?:!I/AC7K#4KRZEN+NU@O(Y9
MVD2[2; )"$[5;)!&T#'3IQ6=-%J-Y;?$)I/$&KH=*F=[/RKDIY;+;AQ]W&5S
M_#T]LUV^G^#M/T]+&$3WEQ::>^^RM;B0.EN0"!CC<=H) W%L=NU(O@VQ6/6T
M%W>[=:)-Y\Z_-E=IQ\OR_+QQ_/F@#E]1UO6$TOP_K5U9W^H:3+I227RZ9.T<
M\,KJK>:54@LN-PP#QR:Z;1[6#6=)\-ZG::]?W$%K"&$B2;5O<IMS,",DYYQV
M.:DM_"<%DMH+/4]1MS:VBV:%)$.8E^Z&#*02,\'&??DU4NO"$,4GAV+2GN[.
M'2),H(K@K&8\@LKKU<L 1STW,2>Q .KHHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/R_2NEUF&2#XB>(+?156*]D\($P)" I,PDD"' [CY0/PKT+^R=-\L1_V?:;
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M &E[>_NY"L5N @#C;D!F8$  GCD^Q\ZGGL9_A5XB@-Q#.\/B4D%MNY5:[3G
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MPUB(4^,^MK&$#MHMNS!<9)\Q\D^_3]*X@W-C<?LQM#YL$DUK;H)$R"T3?:.
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MUU?'MIIL5U#$UW \4#K'*VUA''G!!ZKABQP?6HM)NK2*V^)P6>%8UNYG(#@
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M53G!([ YX]>U%GK6FVEA\.XII+6UN'TD^3J=R_R0 0QAT49"EVX'S=,=#G%
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M@9Y&.?IS7%:O%'-X^US4;22(Z>OAMXK^16!C:7<3&&/3<%S[@$>HK&B>QM_
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M)[ =:@7Q)HK:;/J)U2U2TMV*32R2!!$PZJV<%3['F@"_%;06^/)ACCPH4;$
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)K:>ZM?#>DZG:VE[J<"M=ZB9E46UH,_,&)Y=MQ"CW)XZUZ)BC ]* /*-;O\
M0] E\*W&GRNGA72Y9[&XN;)]RP2-&FQRRYSU8%O5C5;Q$-(C\/3:[X=6ZO-,
M?6;.[U>X#/(MQ%&V7*@]0N$R0,?D<>OLJLI5E!4\$$<&A555"JH"@8  X H
M\X.NZ/J?Q@T*YT_4+:ZCDTBXC$L+AP6+H0N1WQDXZC\:N_%<VZ^'=*:[V?9U
MUJS,OF#*[?,YS[8S7<)%'& $C50!@;1C KG_ !AH%YXAL["WM)8(OLU]#>,T
MV3N\MMP4 >OKV]#0!R/B;3I-8\:W-WX99&N4\.W<$\]NPP7<8@0L.-V<D>@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!=()8EG*;BA&0WR,PY!Z9SZ@5I4 %%%% !1110 4444 %%%% !1110 4444
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M4'(SC'0U:UBPURV\6^'=>CTXZF8+2>UO([61$*-)L(9=Y4%<J1USC'6NWHH
M\EO/#/B:?P/XPTO^QB;S4]9>[MUCN8RK(9(VSEB,#"'K@\CBNJU"QU.Z^(V@
M:M'I<_V*UL[B*:0R1?(TFS QOR<;3G&?QKL** /*Y?"GB*YTOQ$8++[+?GQ
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M+Q )8DDV6CNNY0=K <$>]-?PX_B+Q6VL:K826MHFFO8+;2R+YDGF-ER3&Q
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M/IUK4K&\+7,5QH,$4.F2:8MKFU-G(5;R2GR[05)!&,<@_K6S0 4444 %%%%
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M8W'EO(T8S((UVD-MZ<E<D$>],/CB.2_\-_9K19=+UX'R+YIMNQMFX(R;3\Q
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MG% '8T5P$_Q,^SZ/XANFTI9[G1-C2);78>&:-QE727:,^A&W(/K6I!XMO?\
MA)K'2+W1OLJ:E;2S6,QN0Y<QA2RNH7Y.&!X+4 =717GFB>-M2@\-Z[K>NP6H
MAM-2EME,=PV$(E6)5.4&$!.2_7J=O:NPTO4+R]FG2YLX8HE2-X9X+CSHYE;/
M0[5Z8_44 :=%8FJ:U>6FJ)86>FB8FU>YDN;B4PVZ!2 %+A6^8YSC'0$UA?\
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ML%E;);VT2Q0H,*BC %3444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<BMK5_%=MI4EY''97U^]C&DMVMDBNT*/G:2"P)X!.%R<#..1G=C<2QK(N=K
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M[5R<9/H/R- '&#X>(/ 4?A$:K-]DCE$@G\E?,XE\T#T^][=./>NP:$2VQAN
MDH=-D@VX5LC!XYXK-TWQ%::GKVK:/##<)<:9Y7G&5 JMY@8KMYR>%]!UK7H
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M+FVNMJ^9%()#*#TP?F)[=#0 VYU;6HOB!JVDV=QY\:Z$+RUMI50*+@R,H&X
M'!VCJ>YJMX/\1G7-1:S?5K^WU*&S87FEZA B312Y7$J84!E^\."1RO S5_\
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M>9U*Y;DG[V1ST-;-KX7:SU_5-8BU.8SZA!'"ZO&I"",$*1WS\QSGKF@#C_\
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M[S2U9[W7[W5;I8S%!+=*@$2\?PJ!N)P,LV2<=N<@'G_A[5-0TCX4^#9["[>
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MWL]U))/(L+2Q(@:)78(X"J/O* ><YZC@UE>,-3U*V?Q');:K.9++3A<6EO8
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M[.XO'A0N+>W ,DGLH)'-<CIZ>*I+_0]2@NS)93*#J"W$Z%)5=05:(*ORD$\
M'!'7)YK2^(=[?:;X"UB_TZ\DM+NVMVECE158Y';Y@1_6@#I8W,D2.49"R@[6
MZK['WI)IH[>&2:9PD4:EW9C@* ,DFN%U6\UB3QEX6TZWUFXMK74;&X>=4CC)
M#(B$,I*GGYSUR/:L^&YU&_\  7CFPO=4N9VTJXO+:*Y.T221+"'"N0N#]X@D
M 4 ==IGBA=4OK2%-*U".UO;;[5:WK1@Q2)P>2"2A(((# 9!]>*WZ\TT[4KK2
M] \!:)!?7 ;6XHP]P^TF&-+<.43C R< $Y(!/?%6+[5=7TCQ-K7AY-2N'@;1
M7U2RN75'EMG1MK(25(92<$;@3U&: /0Z*\COKKQ+:?"+_A+%\4WIO)=*MI/*
M\F+8KDKEAE2<D-SSUYXX W=0.MV7C_2-,3Q#=FVUBUN6F5HHSY+1;"#%\OR_
M>(^;=[Y/- '?T5YM8:QJ\?AWQ19RZ^L<NF:M]DAU"\0,XA/EMC"K\TF'95^7
MDD<4^TU+4;C6/%NC-=:C#:0Z=%<VQG91/$6#AL-R0#M!^;D<]* .VU#5/LFG
M+>6MI<:@K2(@2T 9B&8*6Y(&!U/TK0KR.WNM2T;X*^'+^PU:ZCE<V*L"$8%'
M=%91E<@8/KGWKK$U*XU_QSKFA"\N+.UTFWMS_H[!7EDE#-NW8/"@  =,DYSQ
M0!V%,F=HH7=(FE91D(A&6]AD@9^IKR>3Q3XCF\.VZ'4FAU"Q\4IHMQ.L*;;I
M/,4;F7'&01D*1W]>.GT2YU*P^(VIZ#<ZI<ZA:-IT5]&;D)NB<R,C ;%4;3@'
M&.* .KL+^VU.S2[M)-\3Y&<$$$'!4@\@@@@@\@@BK->?:']JF\9_$'0+6[DM
M$W6]Q!-& Q@DFA^9@#QU4-CUS7=6<,MM8V\$UP]S+'&J/.X :1@,%B!P">O%
M $]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %<A<?#^V;Q!=ZK8:SJNF+?,'O;6SF"QSL!C=R"58CJ5(/T
M/-=?10!@Q>%K>#Q6FOQ7ERDB60L5ME">4(0VX#&W.<]\UD7_ ,-;&_M]<M#J
MVIQ6.L3&YFM8W0(DQ()=3MW<E1\I)'MTQVM% '.W/A5[A+R(ZS?&&]MQ;W,;
MB-PXVE2PRORL0>>W3C@4?\(?:)K6D:E;W=S!_9-LUI;6Z;#&(R "#E2QX5>_
M:NBHH Y$^ +5M UO1VU2_-OK%S)<W+?NMP:3&\*=F #@=C7/^)$2V\46T%YK
M&OZ2EI8+#;W]M;^;'=%FRP.(V52-J=@3GV&?3J* .<\(C4A:W/VS4;O4+4NI
MM;B]MA!,PQ\V5"K\N<8) )Y[8)KZAX#M+_4]9NQJ>HV\6LP"&^MH70))A-@;
M)4LIV^A ..<CBNKHH Y6V\#P6UWX?N?[5U"230X7AM]YC(=64*V[Y/[J@<8Z
M>N:;]FL? ::KK,]QJ=VFHW:RS(D E*R, N56-00, #O^==910!S7@[1(-,M=
M0OTLFM)=5O)+QX7&&16/R@CL<?,1V+L*Z-T62-D=0R,"&4C((/:G44 <HGP]
MT-/#.G:#Y<C6EA=)=1%FRQ96S@GN""5/L<5H:YX;BUR_TN[DO;F!]-G^T0K"
M$PSX*_-N4DC!(XQUK;HH YQ?"$2:GKU^NI7@EUJ)(IQB/"!%*KL^7@X)ZYJN
M_@.T/AW1=(34K^/^QIHYK.Z4Q^:A0%0#E-I&&(Y6NKHH Y'4? ,%SKO]LV&L
MZKI5Y+$D-T]I*O\ I*J,*7#*?F XW=:N7?A&VDOM,OK*\N;*[TZ)X(G3;('C
M;&X.'!W9(!SD'/>NBHH YNY\$:1>Z'?Z9=B:8W\OVBXNBP$S2C&UPP "E=J@
M #  QBIX/#,;7D-YJ=[/J5S! ]O"\RH@17P'("@?,P !/MQC)SNT4 <1;_#2
MUM[+2;3^W=7>+2;@360,D8\I<,-G"<C#8R<D=B*V]'\-1:/JVK:@E]=3OJ<@
MEGCF";0P4*-N%!Z #DFMRB@#A)/A?9'1+W08=:U.#0[F3S%L$,96$[PY",4+
M!<CIG'UK8O?"AOH]1@DUB]-KJ,0BNH66-@PV!"5.WY6(')Z>@%='10!!%:6\
M-BEDD2_9DC$0C/(V 8QSUXKF[/P'9VFFQZ/]NNYM$AF$T6GR;2JX;>J%L;B@
M;! )[8)(XKJZ* ,2S\-1V?BJ_P!?6^NGFOHTBE@8)Y85,[<87/&3W[U;UO1K
M'Q#HUUI6HQ>;:7*;74'!ZY!![$$ @^HK0HH P;+PR(KRQN]0U&YU*;3T9;5K
M@(-A8;2YV@;G*\9/J>.36?)\/[-M/UW3UU348[/6)99985:/$9E.9-F4SR?7
M..V,FNNHH YR3PC%+J6@WSZE>&714=(!B/#ADV-O^7GY>.,50MOAU9V6J7,U
MGJVJ6^F74QGGTJ.4?9W<\MVW!3W4$ ].G%=E10!B:?X:CT_Q-JFN)?74DVI+
M&LT+A/+ C!";<*", GOSFMNBB@#(T+PW8>'5OUT]&07MT]U)GG:S<D#T4<X'
MN:RD^'^EMH>LZ1>7%U=VNK73WDWFE R2L02R%5&,$ CKTKK** .?\/>%VT1O
M,N=:U+5IE3RHI+Z0-Y2<9 "@9)P,L<GBF_\ "%:/M\0KY38UXG[6,\#*;?E]
M.[?4UT5% '.ZEX-T_4?"=KX?$UQ;0VGDFWFA8"2-XB"K9(()R.<CG)J&V\$V
MT.LW>J3ZIJ-U->68M+E970+*!N 8A5&#AB,# [XSS7444 <QI_@JWL[/3;"X
MU"[O=/TQD>TMI@@"E/N;BJ@OM[9] 3D@&IX_"5HNO:OJDUS<3_VM MO<VTH3
MRC&H( &%!Z,W?G-=!10!R7A[P'#X>EB1-:U6[T^V.;2QN9@T4'IT +8[ D@?
M4 UL^(M#B\2:#=Z/<7$T$%TGER/#MW;>X&X$?I6I10!SS^$XY-:T?57U*\,^
ME0O#"N(]KJX ;=\O4A1TQTJ"'P3!#I^O6:ZI?;-;EDEN6(BRK.H1MGR<?* .
M<]*ZBB@#F)_!-E<>'M,TJ2\N]^E-&]C> H)H6C 53D+M/ P01@]ZL-X6BF_M
M":YOKB6_OK46CW>U T<7/RHNW &6)Y!))]AC?HH Y:X\#VMUX$3PC)J-[]A6
M)(1*/+\WRTQM7.W'8<XS5NX\,+=>(-*UJ74KLW&FQR1Q*!&$<. 'W#;G)VCH
M1BMZB@#C;CX=65S::I#)JFH;M0ODU RJ8PT,Z;=K)A/]D#!S5RS\%V]MKMSJ
M\NIZA=7%W:+:W*S.@64#=AB%48.&(P,#OC/-=-10!QO_  KRU/A.W\.-K.IM
M9V\D;Q,3%O58V#(GW,8! YQD]SBM.Z\+1R:^FNV=]<66I&W%M/)&J,MQ&#D;
MU(QD'H1@]N1Q6_10!RUWX%L+G2K/3X[N[@6WOQJ+2H4+S7 ??O<LI!RQSP!Z
M=!BK8\/P6?BB?Q/)?W;3M:"U>+:I3RU8L, +NSDGOWQ6]10!QUGX<N&L?$FH
M3RWEGJ&N2;]UHP$\$:J$B53T#;1D]@6//&:Z'0K:\L]"L;;4+A[B[BA5997;
M<S''<]SZGOUK0HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M ?,.#YA_*LC_ (3:^CU!_#\T%O\ VX-22Q$B!O)*-$9A-MSG[@/RY^\.N.:
M.ZHKCM<\7/X0O7BU8BZMI+"XO()$38^Z':7C(Z'(<8/'0@YZUKV@UZ2TL[F6
MXM?-E,;7%N(CM1#C<$;.<@'J<YQT&> #:HKBM#\2W^N7#VBWUM;:G$9%O--G
M@*2VW#;&7)^=<[?FP0V<C'2M35M<NH-%TO4+18D-S>VD$T<JEBJRS)&X&",,
M-Q]>1TH Z&BL;5=2N[+7M!M8C%]GOKB6*8,A+?+"\@*G.!R@[&JVHZ]<P^)]
M'TZU2,VMQ=/!=2MUW""20*ON-@)/N!ZX .BHKFK75K\>,KC2);[3KA?L1N1
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
:4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>elicio-insidertradingcom010.jpg
<TEXT>
begin 644 elicio-insidertradingcom010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKF".XNMK-+%Y<AV[@ &CSP!T(QU!KU73]/L]*L8K*PMHK:UB!$<,2A57)R<
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MU^[G- $"^'M$2&XA71]/6*Y.9T%L@64_[0Q\WXU=MK6WLK=+>T@B@@082*)
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KQ+QCJ>GS^%/&7V&6WM%CUE5FCFDWW$]P
MDD09UR?D0!>  >%)XZ5[;5&31=*FEN)9=,LWDN5"SNT"DR@= QQ\PX'6@#BA
M9Z7J'QL,GD6MQ')X>64':K*[?:"-WH3CC-9/A_P]_P )!\)+FPLRB7=EJ5U-
MIK\8AFCN':/'H.WT8UZ9_9&F&X^T?V=:>?MV>;Y"[MN,8SC.,<5F:EI^JZ?#
M!'X2M-%M?,E_TK[1$R@+C[RB/&6!['\Q0!G^"]3;Q:?^$GFMG@Q;K9PQ2+@H
MPP9R,]O, 3_ME[U4^(\-M<:AX.ANTC>W?6T5UDQM8&*3@YZ@],=Z[#2]/CTO
M3+>RC9G$*8+MU=NK,?<DDGW-27=G:W]LUM>6T-S _P!Z*:,.I^H/% 'F.I:-
M#:>+/&0T6U2*PD\-,MY% @$9NSOV# XW>7U'HP/>JS:KISZ1\*@M[;%HY+??
MB0?)_HS+SZ<\<]Q[5ZO:V=K8VXM[.VAMX1R(X8PBC\!Q5:#0='M0@M])L80D
MOG+Y=NB[9,8WC ^]COUH \]FFOM"U,7"&UUOPU=Z[@H?ENK"Z:?:=IZ.H?/'
M7!QTJ6"ULSXK^)T!@A\IK2T=X]@VD^0YR1ZYYKT"/1M+BO#>1Z;9I=%BYG6!
M0Y8]3NQG)R:0Z+I1DFD.F69><8F8P+F0?[1QS^- 'E-M965IX,^%EY!!#%=2
M:C9*TRJ [!H7# MU.< ?@*GBFT75_P#A,-"\4Z^^GS-J4QFMY&A0R09!A="Z
M%C\@4#!XP/45Z:=!T<QQQG2K$QQ',:FW3"'U QQ3[C1],N[V&]N-.M)KN'_5
M3R0*SQ_[K$9'X4 ><^((=0TY=6U/2IH=4LHM.ABUG2-3.V9HEC)#JXZ,59L@
MC!(;O3_$4M_NU7Q!H[6M[9OIL7]KZ)?C8_D^6S@HX^Z=KL,'C(/>O0[C1M+N
M[D7-SIMG-<#'[V2!6;CIR1GL*+C1M+N[D7-SIMG-.,8ED@5FXZ<D9[4 0M=3
MWGA@W>G1.ES-9>;;QR##*Y3*@^^<5Y=.8M2_9_L)+(G^V(&A$)'^N6_$P#>^
M\L6SWP37LE4DT?3(]0:_33K1;UCEKA8%$A[<MC- '"6>B:5J'Q:\0PZAI]G<
MYTRT=XY(E92Y9\MM/&>!SUK7^*DEY#\.=5DLED8@(9A']XP[U\W'_ -V?;-=
M,FEZ?'>M>QV-LEVV=TZPJ)#GKEL9JV0""",@]J .!\1I#=>*O M]H;1M*\SC
M?#C#V1CR^<?P?<QV!([FN=AFM4^'OQ,MA)$+D7NJMY>1O"XZXZXY'YUZI8Z1
MINF,[6&G6EH9/OF"%8]W?G YI)-'TR8SF73K1S<$&8M I\TCINXYQ[T >>_8
M[.Q\3?#*6U@AA>:&X61T4 R VNX[CWYYY[UDZ6^B:_X5O=)\1^(+FUU.#497
MNK)&A2?[0)BR&/*;V)^4#!/]T<<5ZO\ V)I6Z%O[,LLP#$)^SK^[YS\O''X4
MK:1ICZDNI/IUHU^HPMT8%,H'H'QG]: .%TK1-(O_ (K>+X[S3[2X M["0)+$
MK#<0Y+8Z9R!S71_$(@?#GQ)D_P#,-N/_ $6:V8M+T^&\>\BL;:.Z?.Z=85#M
MGKEL9-2W-K;WL!@NK>*>%NL<J!E/X&@#S.XU6+3O$?A'^T]3?3=.GT39;77[
MORQ<?(2"74J"4 P>.XSR:@U73]&TCPA#+H^L^=91^)(;S_2ID$%P^\,\2.H"
M!,Y/H&4^E>F3:-I=SIZZ?/IMG+9+R+=X%:,?\!(Q6-XGT&^O;'3X-'BTQK:T
MEWR:=>1D6\Z!2%4[0=NTG</E(R!Z4 <N\>CO?>,?%]S]FGM9=-$;6]I-')<!
M$C8.VY"=A8':,'H,FJ>G7]JOC[P2RWNGK$VDSQ106\F1$A6+RXRY.7/O@9QP
M*ZS1/":0ZDFI76A:'I<L<;Q^5IB[O,##!WOL3(_V=IYYSQ700:-I=J(!;Z;9
MP_9RQA\N!5\LM]XK@<9[XZT >=6++_PAOQ3^8<7^HYY_Z=UJSJFG3-\-O#'B
M/3HA)J>A6EO>P@#F6+RE$L>?]I,_B!7=KH>DI'-&FEV2QS?ZU1;H _\ O#'/
MXUE:OIFM.T&F:&-+L=&EB:.Z?8RS19[Q!?ESC/7H>>>A '^%)%U2"Y\1[& U
M1E:WWKAA;*,1?GEG_P"VE<_XFTW3[WXM>%X[NTMYA-97HD21 1)@1X# _>QS
M@&N^AACMX(X(4"11J$1%'"@#  JO+I>GSWB7<UC;27*8V3/"I=<=,,1D4 >;
M>;I%OXR\3^'M8U1=&M9+:".SA80QQ26?DA2J&1#P&W\ CJ>.*=IEWINA^-_#
MNGW%[+_8T>AL-)N-0<#?+YN"<D ;O+"XZ':?>O1K[2-,U-HFU#3K2[:$[HS<
M0+(4/J,@X_"G7VF6&J1)%J%C;7<:-O5+B)9 K>H!!P: /&=3^SS?#KXFO:>6
M\!UHR*8L%2/W#%ACMU.:Z_4-3TZZ^+_APPWEM*K:;=)E9%8$L8R%SZD<XK6\
M+>'[[3;KQ&-3M[-K;5+][J-(Y#(-C(J;&!4#HON.:W;;1=*L_)^RZ99P>2K+
M%Y4"KY8;[P7 X![XZT >.:G;6@^$OQ&C6&'RX==NC$H48C(>,#'I^%=3XRBT
MSPS>>&[R-(],TF6__P!.N[:).'\IEA>0E2" 3U8''!ZX-=O_ &!HWE/%_9%A
MY<C!G3[,F&([D8Y-67L+.2Q-B]I UH5V&W,8,97TVXQB@#R;Q5'IFG>'?$FI
MZ)JMSJ4=[<V;:O)$\;Q+%N ?;Y:@!BGWO8@GK6YJU[I$GQ4\$7%I<V;"2SO%
M5XG7YD*)Y8X[?>Q^.*[RUTZQLK+[%:65O!:8(\B*)53!Z_*!BH+30='L&C:S
MTFQMFB+&,PVR(4+8W8P.,X&?7 H Y7XNP02^ Y6F1"R7EKL8CE<SQ@X/;C/2
MJ-_:+IWQ3>+1K>&WN'\+W'EI"@0-(LR[.!Z$UZ!>6%GJ$8CO;2"Y13D+-&'
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MOFY8^@X&*TZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?M%WI]_;WXMMV//$;9*#/?O^%=?10!YU<2WOB#Q[HFH0:+J]M9_V==6\LUQ
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M7]A9,\L4A"MM:-F1E=&((X['M@BH?"GB&WT[PSX(TRYAN&FU/3XDAF4*4W+
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M\L;,2LWF=  &R03NRO - &QXMU6>3QOX<T9M+N+S3;A+J66%3$4NML:[>&<
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MOX1-S*+"PO? 8T_4[/:MS?R6\7D?+P7C<'<S-CC XSDGCFOHVBW=GXBTS4-
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M]OY\2R>3.FR2/(SM8=B.A%6*H:)JBZUHUMJ*V\MOYRY,,PP\; D%3CT(-7Z
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ML^;^*!;AXMIXC)*@YQCJ#QG- %VBBB@ HHK/76]-;73HBW2G4A ;@P '(C!
MW$XQU([T :%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1137=8HVD=@J*"6)Z "@!U%4=(UC3]=T];_3+E;BU9V02*" 2K%3U [@
MTLFKV,6LQ:2\X%]+ UPD6T\QJ0"<XQU([T 7:*S]*UO3M;2Y?3;I;A;6=K:8
MJ" LB@$KR.<9'2M"@ HHK/&MZ:==_L072G4O(-P8 #D1@@;B<8'+#O0!H444
M4 %%4KK5K&RU&QL+B?9=7Y=;:/:3YA1=S<@8&!ZXJ[0 4444 %%%% !116?K
M&N:;H%F+O5+I;: N$#,"<L3@   GJ: -"BD9@JEF(  R2>U4=)UK3M<MY;C3
M;E;B**9H'=00 Z_>'([9H OT444 %%%% !1110 4444 %%%% !1110 4444
M%%%4K35K&^U"^L;:??<V+(ERFTC867<O)&#D<\9H NT4V21(HVDD8*B@LS'H
M *IZ1K%AKNFQZAIEPMQ:2,RI*H(!*L5/4#N"* +U%%% !1110 4454U+4K/1
M]/FO]0N%@M85+22-G"C\* +=%16MS%>6D-U;OOAFC62-L$94C(.#[&I: "BB
ML^PUS3=3OKZRLKI9KBQ95N44']V6!(&<8/ /2@#0HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8B69@R$MD8R#DYR<\#B@"'3_ !AJW_"2>']+OC822:I#/]HAMT;-E-&@?89
MS*^.5(X.1GH<4W1_%7B.]_M6_NQI,&E:/J-U;WI"2&1XHESN3G .?7KGMCEM
MCX(U^WF\*32ZIIH.@+)"J16K!9(VC\LG[WW\#/H#S@]*U="\)SV>G>(M/U26
M">VUF[N+EA#N!19AADYZX'?]* .6\5W^L:QX2\-:Q.;2.TOM5L)Q:K&V^)'D
M5D^?=AFP1GY1UXZ<];%KNJ2>/M1T#R[000Z='=V[X;<69V7#G/3Y>PKGSX%\
M3/X9T[P])K.G/:Z9=02VMPULYE:.)@45QN R  ..OM70Q:!J47CFZ\0^=:.D
MVGI9"'YE.59G#9YZEB,=AW- '+V7CKQ-+X2T/Q/<0Z6+.ZO4M;FVC23>5:8Q
M;U8MA<<<$'/7(S@;]YXEU*?6_$>FZ=]E@;1;2*;-S&S^>[JSCHPPH"XSR<GV
MYS(_ .JQ?#_3?#(O;,R6=XES]HVMAPLWF@;>W)QUK-U5KC6O&.L266I>&]UL
MD=C-:ZM&^Y0%W,!M=2T9+_Q#!(/&!R =UX1U>[U_PMI^KWD44,EY$LRQQ X5
M6 ('/?WK$E_Y+=;?]B[)_P"E"5N>%KZ\O]$22]CLUD1VC5[(DP2JO ://.WM
M^'!(P:IW'AZ^E\?)X@6XA6W73FL/+&?,^9P^\'ID$8Q^M &*OC/6+75-"@U!
M+%9-1OFM+FPB!=[3(<IF56*EL*"00,YXQBF_\)%XTU*[\26ND0:,LND7(C3S
MED;SQY8<)PPPQS][ITX[B&U^'_B"#2= L6UG3S_8NH"YBD^R/F8?."TGS\N=
M_;'.<DTOAQ=6?Q9X[339+1=]_&OF3;LQ-Y"?. /O_P"[\O3KSP 5%\4ZKXGU
M;X?W^G74-G;:I'=2O;R0&0++'$P.XAU+ 98 <>IST'21:_K&NG77T$V2+I5R
M]FB7,3.;B9%!<$AAL7+;1P>F?:J[> Y-/3PH-#O(8#H EC'VF(N)5D3:[$ C
MYL\^F35BS\,ZIH6K:S-HMW:_9-6F-R\=RK9M[@C#2+M^^#@':=O(ZT 8\/Q
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M>//&'_""Q>,?L6D/8V\DGVNU02>;)&LS(61LX4@#H<YP3[5U\V@ZA/XZT_Q
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M9/L"EUX^8Y&X#*\YYYJS:C6K/Q9;V*7<%QHJ6(1T:,^='(N '9^A+>GU/;D
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M3:P.[: ,9YQS[7M0T#4;J(V<S66JZ?+:B*>#4 1NEW,3*" 0,[ON@#H,$8H
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M &D*V%#3>:1M[\\=:W+WP_J%]XRTG7))+18;*VFMY(,L2_F;=Q!QQC;T[^U
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M&- OF,7;'=CU/Z5)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1;B.2W+R1NL?E@HV[ !&,Y!]JIQ^ -2L;;PW<Z?K%NFKZ';?8Q+);'R;F @
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MR^:FT_-N&, >AK+7P5J TGQ98G4K;_BH)99-XMV_<>9&(R,;OFP /3FNVHH
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M;^I'4Y^@]>[8A5).< 9X&:SM%UVP\06T]QITCO'!</;.7C:,B1.&&& /!]J
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&.61)<_*I)/;(SQSS0!'=^+IU\6W>B3:BFE7JW$8L(+J$"*]A(0L5D/5R2X
M!&"!P>:[VN1USP?=>(;6\T[4+^WFTZXN5GCW6Q\ZV ()5'W8SP<''&X]:ZZ@
M!L@9HV",%<@A6(S@^N.]>5>'O$FI:%X N]5NKP7UW<:M-:0+,@ ,SW!0,Q'\
M(ZX&.!@8KU>N%7X<+)X<U30;O57DL;FZ>ZM#' $DMG:3S 2V3N(;IPO&<]>
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M<UR\HLC^Z\W&Y0/,YZ<'/YT 7_[>N=8\5'0]/G^R)!8)>7,X0.^9"0B*#P.
M220>P&.M<WX.N+RS\'>)$\U#J,VOW=LDD:[1YTDH0,!DX )W8[ &MV;P;J,&
MOV>NZ5K$%MJ"V:V5X);0R0W,:G*G8'!5AZ[CZ4[P[X+N=%NGDN=56\B;4;G4
M0@M_+(EE! YR<@!G[=2/2@!R:A(WB?\ X1'29190:=IT<TDP0.XR=L:*&X
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M*R94%0"=Q(QP/3%3Z/X;NM,\5:UK4FHQSIJ@AW0BV*&/RDVK\V\YR#SP/;%
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MI!)<R7,HRTD\@ :1B<DX' Y/ '08':K5 !1110 4444 %%%% !1110 4444
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M !1110 4UT25&21%=&&"K#((IU% " !0   !P *6BB@ HHHH **** "BBB@
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MDG)R2345YX:DG\96OB*VU%[:2.T-G/"(@XECWAQ@G[IR.N#QZ=:Z"B@#C(/
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MOA@N]"^TRHTC.'F6?:)#DDEL$@GO6!INBW^M^'/#48M[C^V(M3WZGJ",R+/
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M+IVFWL-G(UY:);F0GR@[1IE"!T#L2IQ_>-)9RS:A9>(]&73D\,>(VM[=7BW
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M44 #^!?#$GB ZZVCVYU(N)#+R SCHQ7.TMGG)&<\U?MM TVTUBYU:"!EOKH
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MN%51T %3444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MIZ=HUI;7LN=TL:8(SUP.BY[XQ4LWA?19[Z:\DT^,S3E6G )"3%>A= =KD>K
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M[ZY8?VBMI<;V9HE\UP<#.#@9;D'G)KU:YT#2KS5(M4N+&%[^*,Q1W&,.J]<
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MB&+[6HVKGH,$C'O75>*["ZL]4N+[2-.TS6-.@T]8+W19 $>.+=(=\)QM!/S
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M\F/(R0JEF8^W 'U(JX9HEE6)I$$C#(0L,G\*X+Q78Z?-\4_!S7=K;2*]O?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBD+ =2*
M%HHHH **** "BBB@ HHHH ***9#-%<1B2&5)8R2 R,&&0<'D>X(H ?14<L\,
M&SSI4CWN$3>P&YCT SU/M4E !1110 445&D\4DDD:2HTD>-ZJP)7/3([4 24
M444 %%%,AFBN(Q)#*DL9) 9&##(.#R/0@B@!]%%% !14;3PK.D#2H)G4LL98
M;F ZD#N!D?G3I)8X8FEE=8XU&69C@ >I- #J*165U#*0RD9!!R"*6@ HHHH
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M)/%"4$LJ(78(FY@-S>@]34A( ))P!U- !13(IHIXEEAD22-AE71@01[$4^@
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M96FK>))/#=W;VC2RVIN(WMKE;F&5,X96.T88>A&".]5?A$JI\,=*50 H>X
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MY\>W9]J\[.[=_=X^OMS6_8Z9JWA[QCK>I6^G2WVG:R(IRD<L:RVTRKM*L&8
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M26)ONNC8&1G@Y (-<G%X<\1)8>#-4&G(FI>'4^S26/VA29X6B6-RK?=#?+D
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MTS4X$@N[6 1.B2!^GN./RS]:Z2@ HHHH **** "BBB@ HHHH **** "BBB@
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MK"Q\.>?-HHC=S)>K&LBLA?@A3@X P,'ODCO:'CJQGT[19[?R$FU:U^UQ)>7
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M=3QP01C<\DKA54>I)X%2 AE!!!!Y!'>N/\4>)!:^&?$5W=Z%!J.G6#>4T33
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MV$9"E7<*WS;CP,<@$T =;17&6OQ#M+OPUHVK>1';OJETUFB7%P%BCD7?G=(
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M0@Z L64=AP3W-/;Q1<6/B.RT;5].CMY=0C=K*6WN/-21T&6C;*KM;'(Z@^M
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MR>X8X!.,]3S6+X@\/>(]2U?Q*GV2TO;2_L/(TZ>>XV_8B8F5U";3RS'.X=L
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS?\ )?+7_L6W_P#2@4 ;%IXP4>)(_#VL:?+INHSHTEJ6D$D-R%^]L<8Y'<$
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MS-V&>ZP80J@LK#9U!..#S[50\-_\EC\<?]>]A_Z+:C6_^2U^%?\ L'7G_LM
M&Z?$TE]KEYI.B6D=Y-8;1>3S3&*&)V&0@(5BSXY( P.YSQ26/B9[C5[K0KJS
M2UUN&$7$<#3DQ3Q$XWI)MR0#P<J"#V[US?PI1[.Y\8Z;=Y&H1:]-/*&ZLD@4
MH_T(!(I=:BDO/CIX8^RY)L=/N9KPK_#&X*(#]6Z#VH V_"/CBU\4W.I:>]N;
M'5=.G>*XM'D#\*Q7>K8&Y<@C..#^&=33M5N[S5]2LI;**&.R=$\U9RYD+*&'
MR[1C@^M</=>%[N_TE/$7A]EA\2:9J%^8&/"W,?VN;= _J#SCT/IG-:_@+Q+;
M>(QKNL"-[4>=&MQ%.-K02)"H=6SZ$'F@#7O_ !=8:?XRTOPU*#]IOX9)%?/"
M$?=4^[!7Q_N^]/\ &'B&3PIX9N];6S6[CM5#21>=Y;$$@<':<]?:N!\2:;K>
ML^$[K7;72BNI"[76+*<S#<BQ@>6FS&>8ARN?O,:U?'NLV_B'X%ZCJ]J?W-W9
M1R@9SM)=<J?<'(_"@#O=/N)[JPAN+B!(9)$#F-)"X7(SC.!_*FZI=RV&EW-W
M#"DSP1-)Y;2; P SC.#Z>E);3QVVBPSS.$BCMU=V/0 +DFF:Y_R+^I?]>LO_
M * : ./B^);P>'=*\1:IHIM=&U!D47$-R)6@W'"F12JX&1U!-:<WBS4CXTN/
M#5KH]O+/#9B]$TE\45HRVT#'EG#9[=/>N5\)^$I?%OPN\,66IZBHTA(XYWM(
M(-KS;22%>0L?ESUPH/O4NK1ZQ)\8=6&@W%O#J \-(8OM$6]6;SFP.HQSWY^E
M '8>&/%UIXDM;]S!)97.G7#VU[;SD9A=>OS#@K[U%IOB:_\ $%FVHZ%I<$VG
M%F6">[NFA-P%."R*$;"Y!P3@GTQS7(^'[.VU'X2^)$TA;G^W;V*Z&I)<,#/]
MM*$,K8  YZ8 &"/>NI^&=Q!<_#3P\UN1M2RCB8#LZ#:P/ON!H 4>-H9_"FJZ
MS:6;-<:2)1>V,\GER1/&I+KD!@3@<'H<]:LVWB.ZN/ Z>)!I\0+V?VU;8W)_
MU>S> 6V?>QVQCWKSV.&26;XQ:E#G^SY;9H$8?=:6.W<28^A//UK<TVQU,_!V
MUD&L,(O[!5A%]G3A?(^[GK[9H NWOQ"N;/X?6?BXZ+&\%SY1%N+SYU61@JG.
MS&<D9'\ZT-=\57^BZQH>F?V5;S3:M(\4;?;"JQLJ[CG]V3C'<#\*X+6_^3;M
M&_ZY6/\ Z-2ND^(,<LWC7P''#.T$AOI\2*H8K^Z]#Q0!OQ>*VM_%-KX>U?3S
M9W=[&\EG+%-YL,^P9=0V%(8#G!7\:IVWC*^N=7\2Z:FB*TVAQHS".[R;AG0N
MBJ"@QG&"3TSWKG=82[T'XM>&+S5;K^V$OQ+:689!&]BV!N<*O# @@$D9 K4\
M(_\ )5OB%_OZ?_Z(- %R?Q=K5MXFL= DT"S%Y>V\EQ&1J3%%5,9!/D]>>P--
MU3QKJ>DQ:5]IT"-+C4-2&FB,WO"2$G:V1&<H0,YZ\]*JZQ_R6WPU_P!@RZ_F
MM,^*:/)+X,2.5HG;Q';!9% )4[7Y ((_.@#J8[_6EOH(+K2+989MP\Z"\:0(
MP4D;@8UP#C&>:QM'\7ZQKEQK$5GH-M_Q*[Q[.7?J!!D=<'*_NNF".I%:MM8W
MFGZS]KO=:DNK:2(01QS(B%9"W;8HSGWZ8KG?AM_R%/''_8PS_P#H*4 ;_AOQ
M9:>(I;VT$$]EJ5@XCN[&Y $D1/0\$AE/8@\U-J.IZM!J+VUAI,-S#';B9YY[
MLPKDEAM ",2?ES^(KC]%'V_X\Z]?V/S6=II<=G=2+]TW!<,%SW(48/IC%>B7
M/_'K-_N-_*@#D?#WC/5O$.B:9K,'A^)=/OGVAA?%I(AN*;F7RQQN'8G@YJ*S
M\<ZK?0:[/;^'8Y(]%NI;6=$O_P!Y(T8!8H#& >#QDBD^#O\ R2?0/^N4G_HU
MZXA#KT6D^/KC2)B;5/$-Q]N@@C'VAX-J^88G.0&V],J>AQSB@#U[P_KMEXET
M&SUG3V8VMTF]-XPPY(((]001^%44\76#^.I/"@!^UI:"Y\S/RDYY3_>"E6^C
M4S0KC0-$\ VMUH[#^P[:T\V%E.XE "Q]RQ.<CKDUP7B:RUS2=$TSQ5)I 34M
M(O&U&[E2X5B\<G$T>,= NT#T""@#N?&?BU_!MC#J4^G&ZTXRK'/)%+B2('^(
M)M^8 #US5[5-?2U\*S:_IR17]O';&Z7$VP21A=V5;!YQ537I[;4K#0YXBDUK
M<WT#J<95T8$C\"#7GOB*.X^&NGZQI&V27PGK%O.EBPRWV"Y=&_='_88]/0_B
M2 >BW?B*ZCUNVT*TL;>;59+4WDJ27)2**(-MSNV$L2QP %['..,VM%U:[U&X
MO[:^TTV4]G(L9 E$BR94-N5L#*\XY /!X%8?B[PG:>*-5ADLM4N-*\1Z=")+
M>\MSRL;E@%9?XE)5N/\ '!A\&>(]7:[US1_%<=JFHZ,L;S7UOQ'/$ZLRN?0@
M*<]/H* -F\\76%EXVT_PO(#]JO;>297SPI7HOU(#G_@/O5SQ!K]CX:TF34;]
MG\M65$CC7<\KL<*B#NQ->;>)=.UR_P#"<OB&#2"FJ07@UNWF,PW*J ;8RF,_
MZD %>[9]:G\>ZK!JNG> ?$T;9T8:M;7,['I$&^ZS>FTY!]Z .SNM:\066DS:
MC-X>A=8HFE-K!?;Y\ 9Q@H%)]0&/MGO2UGQCJ>E:3J>KKH44NFV,:R>:][L>
M8%%8E5\L]"V.2.AKKF=40NS!4 R6)P /6N1^)91OA7K[1X\LV+%<# QQB@"Y
M9:[KEU]E9]"MTANK<S0RI?%E#8!"/^[!4D$\C(XJEHWQ!M+[P#_PF.I6XT[3
MR&*H)?-<X<IC&T<EA@ 9ZUOZ#_R+6F?]><7_ * *\/6*4_L\>$;L*S6MCJZW
M-X ,_N1<2@D^V66@#UVXU[7+/2FU6X\/H+2./S9($N]UTD>,GY-FTL!U4/\
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M;=INYC#%@OYDU'?:+8:CJ.GW]U"7N=/=I+9A(R[&9=IX!P>/7-:%% !1110
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MN2N$R23M+1DCDD\4S1]+U709[R;3O"UI$]Y*9KC=KLL@DD/5B&C(R?6NWHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFP/V.XAW'?+S\NX@ C:=V3R.IH ] U;5K31=.>]O'81J54*HRSNQ"JJCNQ)
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M>&YTR^LY+R,1',2Q(5<GUY(Z9SVK=LXKJ#XGZSJ;V-W]AETV"&.80DAW1G+
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MUW@[Q/>^([C6A=:9-:QVFH2VL99HR%"!!M.UB2V2S=,<XR:34O$]];>/]/\
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MEIXDT2VU:Q$@MYPV%E7:ZE6*L"/4$$?A7!V&LKX;\:>/IET_4;^.&2UE:.V
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M?3=0"@3P2#C=W*GD%3U]1WKSWQA8>(]=TKQ?IUSHE]=7)D_XEC1LHMA -A!
MW<R<-G()Y &!0!W%_P",+:Q\1'04T[4;J_-H;N-8(E*R*&"X#%@ <GJ<#CKT
MREIXWTN[\-QZR$N8U>X-H+5T'G_:-^SRMN<;MWOCOG&:RHTOI/B?9:M)I=Y#
M9C1'MG=H]VR4RJX4[2>=H[9&>,URZZ#KZ:%'>VVE7+76F^*)M5^Q. C7$#LW
MW">-VUL@'_#(!O:=<23_ !OG\RSN[1_[ RT<[A@Q\]?F7:S#&..,=*VXM7M;
M%M3UV[+%;B[2PM$09>78QC5%'<F4RD=L$$\#-8$UQK-QX^EU^R\/:DD)T!K6
M$W"*F)S+N4,N[('KW[XQS5_Q=X:O1X;T!=&C:ZGT&^M[M8"P#7*Q@JPR>-Q#
M$\]Z -J#Q5;OJ\^D7-E>6FHQV_VF.WE5&,\><$QE6(.#P1D$?3FJWAKQO:^*
M3:R6&EZHMI<PO*EW- %B!5MI0L&/S=_3KSD$"E+:2ZUXWTKQ$+.[M[/2K.=3
MYT)22:27:-@0\D* 3GIDC&><2_#&RO-,^'^F:=J%I-:W=L'62*5<$9=B,'H1
M@CI0!)J?B>^M/'VFZ!#I<\MO/:RW#RH\>6VE1P&88 W<]SQ@&N6T#Q%#X4;Q
MK/)I^I7EM;:U+),\ #^1%Y4>68NPR!SP,G Z8KHM<M-0A^(^A:O;Z=/=VBV=
MQ:R-"5_=.S(5+9(PORGGFL$:=J3>&OB+;?V9>";5;BY>R0Q']\KPJBD>G(/7
M&* .ZN=?A22&&RMY]0N)H/M*0VY0'RNS$NR@ DX'.3SZ'"^'O$%CXFTA-2L#
M((F9HWCE7:\;J<,K#L0:\_N=.U#2]5T77)O"\NM6#Z/#I]W:+"CSVLL9)#!'
MX(.Y@<'MG/3/H.@1LFF!VTN+2Q*Y=;1%4&-3TW[?EW'&3CIG&3C) ,JZ\>:=
M:FXE:UO'L;:_&G3WBJFR.8D+T+;BH9@"0.OK1J'CFULM:O='ATG5KV_M(5G,
M-M #O5B1E26 QP>N/09/%<5XCLO$FLZ/K,%YH.H7.HPZJDELR,GD"V69&7RA
MNY8J#DXSUR>@K;MM2-K\7M6EFLKO$FC6I98HC*T;;Y/E(3/OR,CCKTH TA\2
MM#?1=*U6..^DM]2N1:($@R\4O.4=<\,-IX&2>V<BK.E^.],O[W4[*[MKW2;O
M3H?M,\.H1JA\G_GH"I(*^O/%<+J6DW7A[1M GN;5Q<7WC(:BUI'AFB$GF$)U
MP2% S@]<@5N:_P"%KKQAK6LW\$<EI#)H+Z7;R7"&-I9'?>25/S!!@#D<[CCI
M0!TB>+[4:UI^F7EC>V3ZDK-92W"ILF*C)7Y6)5L'.& _/BH+;QYIUT^F.MK>
M+9:G=/:6EXRIY<DB[N,;MP!V-@E>W:LGPK+>736L%SX$32M1M1_I-Y+#$(=P
M&,Q,IW,6/M@ GDX //-:>)-0M?#5[J'A[4Y=8L=:2:_=FCVA0)!B$;\!.5Z8
M' R2>: .U'CNUDUN[TFWT?5[BXL[F*WN#%;@K%Y@R)#\W"8(.>OMP:=;>/-.
MN7TUUM;Q;+4KI[.TO&5/+DD4L,8W;@"4;!*]NU5?#-O>P^./&%U-8W$,%]+;
MO:RR(0LFR$(W/;YAWQGM7)/:>)-1M/#E[J/A[4Y=8L=:2>^<M'M"#S!B$;\!
M.5Y&!P,DGF@#LKKX@6D%QK-O#H^KW4VCE?M20PIPI7?N!9@,;><=3V!YK3'B
MFQFATQK%)KV74K?[3;0PA0S18!+G<0% W*.3U( S7,6UI?IK/Q N'TZ[6/44
MB^R'RB?.*VXC('_ O7''/2LC3;'7_#2^$M<CT2\O4M=&&DZC91*//B(*L'12
M0&^9<<'I0!V]CXRT^_TQ+N*"[$SW;V(LW0"8SKG<G7;P%)SNQ@$YJQHOB6UU
MG4-1TWR+BTU#3F1;FVN NY0XRK J2"I'H?KBN7\66FN:QIVD:]%H*SRZ??&X
M.CW!0R26[1E&#<E?,Y+ 9..!R16_X69;D37D7AHZ' ZJJQSPQQSR'G)8(2 H
MXQDY// XR 7;W7HK;4_[,MK6XOK\0_:'@@* I'G +%V4#)! &<G![#-<SXG\
M:B?X8ZOK>A)<^=%%+"QPJ26<J_*V\,P(*GTSV/(YJ9[._P!!^)5]K9M+BZTK
M5;.*)WMT,CV\L1. 4'.U@QY //7'6L/4?#.I1?#SQBD=C.]_K]Y/<P6<8!9
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M]12VFMX[A!)&DVW<5/0_*2.1SU[T 7Z*RM3UR*PO(K&.%KB]EC:585=4PBD
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M>%B1CD!@"5.1@U?H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3DG@CIGI4>G^&-0T+7? MM%:375KH]A<6]U=(5VAY%3! )!(RIZ#@8KTBB@
MKCC9WZ?%F75O[/N#IXT46@N!MP91,7P!G/0]<=:[&B@#R0:!KO\ PIY=#_L:
MZ_M(:AYWD;H_N?:_.SG=C[OOUJ_XGL?$6M3>*;&?1;F]M[FPVZ0PEC6"(F([
MMZEL^9O/!P>V"HR:],HH \M$]W8>,? /VK3;E)H](N8I8%VN\>%B!) //(Z
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M*RNBNC!E89!!R"*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^U0_*F![@HQ/K%[UEW&DZII?B_6)/^$5MM>T_5I4N(IV>)6MW\M49)-_.SY
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MQV!R."P7:"1W!Y/6N3\2>&;[4]7N-2TS2[K3?$45PBVNJ6TR+%<0@K_KANY
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MZ1<0V&L!OL5X\BY=@F\!D'*@J#@D_4"@#K*8\T<<D<;R(KR$A%+ %B!DX]>
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M\QP<M]T?=9B>P!QGC(!W%%<1%\2].0:W'>1QI/I,:2O]GN%FBE1R K+)@=R
M<@8KI-,U&[O+J>&YLHX52*.6.>&?S8Y@^[[IVKR-O/'\0H TZ*P=1\1OIWBG
M2]%DLLIJ2R>3=&7"AD7<4(QUQR/7GTJC9>-#=V'B"=M.$=QHUPUN]MYX+2N
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MI +>PR0/S-<!IWC73=*\ :9K&G>'9;>QNKUK9;6 H/)9IV0DXZY;)PH/7\:
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M-HCLD\<L^<@)O#Y X0CD'V/'%;NG7,UYIMO<W%L;666,.T#-N,>><$^H[^]
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M )HL!4C9#M._G.X$?2K=]97EAK7CC5K[38_[-O\ 3H883<RIY<K1HZE6"L6
M8N ,#/XUZ%574M-LM8TZ?3]0MTN+2==LD3CAAU_G@YH \WT4:IH\VAR:[X3U
M3RM.1;6WNGU"WG6U\S;&6"KACV7)W$#\<]!\6/\ DEOB#_KW'_H2UJZ;X0TG
M2YDDA^VS&,YB6[OIKA(CV*K(Y /OC-7-<T.Q\1:5-IFI)(]I-@21I(R;AG."
M5(.* .?N]+OO$FL^';BZT^2QMM*D:ZD,LB,9)"A153:QX^8DDXZ#CDXQ=.\-
M:]IOP_U'P+]@\Z-UGM;34O-3RO(E+'<X+;PRACP%.<#GN/1X(5MX$A5G94&T
M%V+$_4GK4E '$_\ "/WUCXW\-36EE))I>EZ9)8M.9$!!(0*<%LGA.>._>L>?
MP=K6K:+XTL6@-C/J6I+?V$TDB,I*>65#;22.8_3H:].HH YO0M1\47X5]8T)
M-+$,9\Q$NDF:XDQT3'"KU/)ST'3)KC[/PGXFM_ >E1VUI'!KFCZK)J$,$TJF
M.X5GD)3<I.,I(1DXY'XUZI10!R?VKQ+JNAW<E]X:MX"RK&-+EN8YC."P\S<W
MW0-N0!]<]A5;P;X8F\/:UJ364%U8:#/%&8=.N9ED\N?+%V0!F"KC;QGDY[ 5
MVM% '->.-$O-9T.)]*V#5K"ZBO+(R'"^8C<@^Q4L#]:R+?P/<V'C2TO;>8-I
ML]LKZH#P;BZB?='(1ZEG+'_<]Z[RB@#DKC3=2;XIV>KK8NVG1Z7):-/YB<.T
MBN/EW;L87'3K7,3>&/$@^&_B/PRNE*\UQ<W#6TJW,>)5DF+AL$C: #SGG..#
MV]4HH XR]T[5+OQSX6U1-,E6TL;:XCN6:6+*-*J <!N<;3G'X9JQ\1-+U'6?
M"K6&EV;7-PUS!)M$B( $E5SDL1V4BNKHH XWQ=IVO-J>A^)- M$N;S3Q+'-I
M\TJQF:*4+N ?E0P* ]<?7O)?)K.M:'C5_#4$\%S,J3:29XY&6'!RQ<D*7W;2
M #Q@<YR1UU% 'C?B+0;[PY\-==MU^TKIIU*S;3+.[G$DD">=%E2P)PI;.!DX
M'7DFNQU30+KQ7XDTV]O+.:PM-/M;J,>:Z-))).@C. C, JKNY)Y)'%=!KN@6
M'B/3_L&I+*]MO5RD<K1Y*D,N2I!X(!K1C3RXU3<S;1C+')/U- '"^$AXUTVR
MLO#NHZ1;+!8A(1JZW2E)84P!B+&[>5 '. .OL8-!L/%WA>XO]"M=*M[S39KN
M6XLM2:Z55@21BQ62/[S%22>.OJ.H]#HH Y&+2M6L_B9<ZI':+/I][I\-NUP9
ME4Q/&[DY7J<AN,#&?2I?'NDZAJVBV7]F6XN+FSU&VO/(,@0R+'(&*@G@''K7
M4T4 <3'IFLZ3X[N/$4.G-=6NJV<45W;0S)YEO+'G:07*AE()!P<Y]16GX/T&
M;18-5N;H*EUJFHRW\D2MD1;L!4SW(51DCN371T4 <"MEXG\,^,=9N=*TB/5M
M+UB1+@?Z6L+6LP0(V[=U4X!X!(QTIVJZ?XJTCQ5:>(]+LH=9,]@MEJ-FLRP'
M*LSK)&6XP"S#!YQ^8[RB@#A?$5AXBU:/PU</I@:>UU>._N(89TQ!$JNNP,Q7
M>WS ],9SSTJYXBTS5I/&OAO6M/LENH;2.Y@G0S+&4\T)M;GJ 5.<9/H#7744
M >3:SX;\5ZIIFJPW.C17FHC5$N+>]>[0;[=9E98XP?N848(.T<$Y)-=1_9^K
M'XFPZV^F/]C71C:.Z31G$ID$F "02,#&<#GMCFNQHH \ID\+^(7^$^H>'QI+
MC49[]IT0SQ;=AN1-DMN_NC'U_.O4N9K?YD:-G7E6QE<CH<$C\C4E% 'E$?AK
MQ,GPNTKPZ^BYO+"ZMR=EU&1(L<V\L"2, @# ZYSD#OU/B>UUR[UG1);;3C?:
M0HD^W6)G2,[R!L9\G#JOS97)YYP<"NNHH \E;PIXE7P1J6C?V-&)I-<^V0B&
MZC*F+[0)<C.,# P._J!72WVGZTWQ".MVNF.;<:%)9HTDD?\ KS()%!&[..,$
M^OMS7:T4 >;Z;X2U'3]<?4?#VGR^'UGLIQ>6<DR/;/<D#RF1%9@,-DDX'&!C
MDU4T_P /^)?[3\'ZE/H$:7FG/*-2GEO4>6=WA*&4L,Y7)R!DD9P% %>IT4 >
M=^'+#Q?X7^U>'+?2X+G3C<RRV6J&Z55ACD<N0\?WF92QZ<'ID=:U8-,U;3_B
M3J>J1V(N-/U"RMX_/$RJ8VB+Y!4\DG<,8X]2*Z^B@#RN/P9KT_@PP"U6VU6Q
MUYM8LXY94*3?O6<(64G&0Q'/?':NEDTR^USQ;HVO76FSV,>CV]P4@EDC:266
M554@;6*A0%/)(R2.PS77T4 >4KX7\0CX30^'_P"R'_M%+\3E//BV[/M7G9W;
MO[O'U_.M#Q=X8O/$-W>75OHL]IK,.S^RM7MKB.-D^121+A\D!]X(PW'2O1J*
M (P9([8%@9I53D( "YQVR<#/UKRV'POXAC^&6EZ(=(?[?;:JMU(@GBQY8N3-
MD'=UP<8]?SKU:B@#D4T[4F^*?]M'3Y$T]M'%GYIDCR)/-\S[H;.,'&?7VYI_
MCC2M2U :#=:9:BZDTW58KN2#S%0O&%=3@MQD;@>:ZNB@#C=/L=7@^(.KZS/I
M4@M;G3X($:.:-LR1EBP&6!Q\V 2!TYQ7,:;X6\5Z-X5\*W=EI\;ZQH4EPDUA
M+<(%N89F)8*X) /W2,XY!_'UFB@#*T.YU>]@>YU:P33F? CM!,)60#.2SKQD
MYZ#. !SR<<_K7A_4]/\ '$/B_0K=+N1[7['?V+2"-IH\Y5T8\;P0.#@$#J*[
M6B@#*M+W4K^2/.ESZ="IS(;IXV=O]E1&S#ZDGZ YR.*TWPWKVD^!-4\$+8>?
M%(+BWLM0\U/*$,Q8YD!;>&7><@*<X&#7I5% '#67AZ^TGQUI,]O92RZ58:%_
M9@G\R,$L'0@[2V<83TZG\:R7\-Z])X!\8Z3_ &3(+S5=0NI[9#-%@I*V5)._
M QW_ $S7I]% 'FYGN[3XL:21IL\LH\-NDL"/'O3]\G/+!3R!T/>FW7AKQ':V
M-[?V-L6N=3UM+R^L([A8W:T"[?*$F<;CA2V#@Y(R1U[5O#M@_B--?(G_ +02
M$VZN)FVB,G<5VYQC(!Z5JT >7_\ "-:]&/'D<.@P00:W9)'9QP7$8"M]G,6T
MC@#!.2>GINK0ET;67E\!L-*EQI'-Y^^B^3]P8N/G^;DYX[>_%>@44 <)XB\/
M/=_$'3)K.=8XM0MVCU6#'^N@A970_P#?1"'/\+D5W=8^A^%M'\.O<OIEH8GN
M7+RN\C2,>2<98D@9).!QS6Q0!YOI/A.]3Q)IFL6VDRZ%<2!_[;BCG0VUUE"/
ME16/S;R"#@8&<\]9O"=MXS\/V4/A:72K>6SM&,5OK/VI=OD9XS%]XN!QCIG'
M/<^A44 >?:;9>+/"VO:U:6&D0:EIFIWTE];W;7:Q?9GDY=9%.6(!Y&T']>+E
M[INN6'Q"M=<M;#^TX9=)&GS.LR1&.02;P[ _PG)^[DCTKM:* /)X_"_B6+P1
M9:8^D![J'7A?E8[F/!B%P92>2,$@X Y]\5U7B_3M2U+4_"\]EI\DT=CJ*W=Q
M^\C4HFQEQRPR?F[>G6NNHH Y#3=-U;3/B#XCO_L FT[4TMY(YUF4%3%$4*;3
MSN)QCH,'KVKF;+PGXGM/ ^C_ &6SCAUS1=3FOHK>:9"EPCO(2FY20"4DQD]Q
M^->JT4 <FUQXCU;0KN2_\-6\6X)&-*EN8YC.I<>86;[@^3(49^O850\,>'K[
MPQ<:W+I-E<PZ4]NKV6D75RIQ<#<6"$,PC1OE'7KDXP!7=T4 5M/FNKC3K::]
MM1:W3Q*TT D#^4Y'*[AP<'C-6:** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MDO3)<7-U'"8(I;F4NT<9()4'W(&2<DX&36K110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(FT;@.FX$>V!G% &]IWC:?4_&46DQZ-?P6[:<EX6G14<;WP"RELJ!A@>^>V
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MATS4?"6EZ=IEW/:ZG$SJY92WEI"6"_,V2WW"23T!Y)-9MG9WJ_ 9]*:PO%U
M:.]G]E,#>9YIC*@8QTR1STI+NVOX+KX>:FFEWT\6GQ2PW4<4)\R)GMP@RIQ@
M;A@D\"@#H;'4M$/C#7O+-U%?VMM";UYRRPB/YRI4,<=FR0,>]2Q^,+ ZII]C
M/;WEK_:0)L9YXP([C S@8)*G'(#!2:YB^T:^UCQ1XWMDMKF!-4T>*TM[F2%A
M&T@20,-V,8!<?7G%/\)RK>G3[2[\ MI^K6>W[1=SV4:PQE1@O%(.6)QQMZ9Y
M.!R =59^)[6^GLQ!:W;6UY*\5O=A5,3E Q/1MP'R-@D#-:US<PV=K-=7,JQ0
M0H9))'. J@9)/L!7FNBZ5>6'B'2[WP]#JNGP7=PS:MI%W"_V6(%6+21LPPIW
M8P%/.[H "*[/QEI%QK_@W5]*M'"W%U:O'$6. 6QP#[$\?C0!&GB^S_M>UTRX
ML[ZUN+V)Y;+SXU47(49(7YOE;&#M?::2P\8Z?J.@7VLPP78M[*22.:-T D#1
M\.-N>H].I[9K"\+7,>J75D)O 3:5J5KS<W-Q8QQQQ-C!\EQRQ)Z8[9R>@+T\
M.ZA:_$*\B@B_XI_4S'J=P>R7,1P4'^^?*<^NQJ -8:AI,WCZVMGAOH]9&FO(
MH?<(A#O7(/.UFW$<C/?FN7^)WB*&]^'FKR:?'J!ABE6%;^W;9%Y@D"L,A@S+
MG*YVE<]ZV+VVN9/BU9W2VUT+5='FMFNEA8HLC2*P&[&.@)]*XF2VUJW^#=]X
M*FT#4WU>T'DHT-N6AN%\X,'23H<@\CKUXZT >IZEXA@TYYXH[2[OI;:$33QV
MBJQB0YP3N89)VG"C)XZ5G-\0-"+:.(&NKD:O$\MFT%NS!PJ[B/\ >[8Z@]<=
M:YJ_2;2/'&H:EJ7A&[UC3-8A@>)X+1+B6UD1-A1U)X! !SG'ZXN7-C/%XL\#
MRP:&]E:V?VQIH;6W_=6HECPBML&W))YQD9R>G- '0V'C32;W2=0U&3[19II\
MQ@NX;J+;)$XQA=HSDG<N,9SD8YI]OXLL'U>XTN[BN-/O(;3[:4NPH!@S@N&5
MB, ]02"/2N!U'0]:U"#QFVGV%P+IM6MM1LDGB:-;H1",E02 .2A_2NENKR_\
M=^%]5T^#1+_23<6$L#2:E%Y3>:RX"*,Y*YSENG3&<G !KQ>+[%M6L-/N+:\M
M&U%6:QEN(P$N,#) P25..<,%-:^HZA:Z3IMSJ%[*(K6VC:65R"=J@9)P.M<+
MX4F6_?3[>Z\ MINJV>/M-W<6,:Q1LHP6BD'+%NVWIGD\<]5XLEU.'PGJDFC6
MR76HBW;R(74,';Z'KQGCOTH BL?%EG>:F-.>UO+6Z:S^W11S1@F6'(!9=C-R
M"1\IP>>E9<7Q+T2:QM;];;4A8SW/V9KIK4B.%_,,8WDGC+#MG&1G&:Q-+CNU
M^(6DZPNCZX;632)8)KB\C)<2%T8[E)^08!^4 9_A!K*;3=3/P7FTH:5J']H-
MJ1D%O]E?=M^V>;GITV<_IUH ]BKF]1\:Z9I<1NKB*Z_LU+C[-)J"HI@CDW;"
M#\V[ ;Y2P4@'C-=$CB2-7 8!AD;E(/X@\BO*-"L9-*CN?#&K>!6U*[6YE-MJ
M#64<EM<1NY=7ED;[N,\CD\<9/% ';77C33;+6;W2KJ&ZAN;6T:].]5"RQ*<9
M0[OF^G7UQ3M2\9:=I']F+?V]_#+J1*P1?9BS [2VT[<C<0.%&3STKG?&FDWG
MB&5[S3[:2"]\.D7%B\EJQ%U-P2@XYCPNWC^(@\!1F#Q+K+W=[X!U*?3KVVD.
MI,9K1X6\V-O(?<-N,MCU&<@<>E '2Z3XZT?5$U3>+K3YM+&Z\M[^$Q21(1D-
MCG(('&/ZBK$'BNS?78-'NK:[L;NYA:>V%TB@3HOWMI5C@@<E6P0.U<9XB\+:
MAXJO_%&IZ? ]OY^EPV5H+B,QFXD20RDE6 (7A4R0,\]N:NZ.(?$<7DIX'DT.
M^6WECGN[JQ2+R&9"I$+CYFR3U&!MSGG H WQXVTOS].W1W2VFI3_ &>SO2@\
MF:3G '.X X."5 /8XQ5#2O'0N)?$L^I6,]C8:/<-&TS[2%5(U8[MK$Y))( !
MXQWJCX(U76K;1M,\,WWAJ_@O].5+:6YDC'V7RTX\Q9,_,2HX &<GTR:I[?$.
MD)X^BT[19Y[ZYNFN[)Y(@T,JM$B\$G#-P?E_.@#KK/Q9;7>HMIQL;V&]-G]N
MB@E5,S19QE2&(SD@8)!Y%<W%XQL]=^&5_K'B#3[^WT]_.606_+&,2NH"E&R"
M H!)P,^U5](ANS\1]*U6/2-;^RS:1);R7-\GSB0R(QW@GY!@'C ']T8K.@L-
M5C^">L>'7T;4%U&,7,*IY)(E9YG9=F.HP0=W3WH ]%FUNTLC8V4$5Q<W5Q"9
M(;6+!D,:@98EF  &5&2>2>YK-N/B!HEKX<O=:E^UB&QF-O=0" F6"0$#:XZ#
MJ.<X.1S6.]O?:7XYTCQ*;.[GTV?1QIUPL4#M);.'#JQC W8/(. <=ZQ/$GA[
M4;GPYX[U"VL+MI-=N+86=HL+&0K$$!<KC*[B&/.#@#/)Q0!WUCXML+[Q"=%^
MSWMO<F W$+7$!C2>,$ E">3@D<$ \YK7O;VVTZQGO;R98;:!#)+(YX50,DUR
M-^D]Q\3_  ]?Q6=X;2*PN8Y)C;.%1G*%021Q]T_3O6A\0="N_$G@35M)L&"W
M<\0,63@,RL'VY]]N/QH GB\669U.RL+NUO+&2_4M9M<QJ%GP,E1@G:V.=K8/
MM69-\2M&BM-1NA9ZK)!IMRUO>.EF?W.T*2[9QA1N^O!XQS5/4TN?&DGA79IU
M[92V&HQ:A>FYMVB$/EJV8P6 #EF('RY&,FL@65^W@WXC6O\ 9M_Y^I7UW)9Q
MFU?,RR1(BD<=RI^G>@#U*.1)HDEC8,CJ&5AT(/0UR5GXDGUOQ-XBT&73KN"W
ML4BC\Y9 I!=&<L65MP!&W&.?7&<#>T'</#VG*\<D;K;1JR2(592% ((/(Y%<
MOIZ7FE_$+Q=-/IMZUMJ$=M+!<11%XR(X2K#(YW;N-H&><].: ,OX>^,K6R\$
M^%;74$OW:] MQ>M$6B,S,V$9R<DGID C/&:Z_5O%EGI$=[,UM>7,%A@WLULB
MLMOP&^;+ G"D,0H) (S7GUKINI0_"_P5I[Z7?_;+'5+66YA%JY:-(Y2S,>.F
M"/KVJZ(&T/Q3KEMJO@RXURTU2Z-W9WEO9I/PZJ&BDW8V $<9XY- 'IMK=07M
MI#=VTBRP3QK)'(O1E89!'U!KDKOXE:-:C42MEJUS_9LQBN_(LF/D@ $NV<87
M!ZGDX. 0#74Z=";;3;6$V\%N8XE4PP#$<>!]U?8=!7GV@:DEIKGCZ!K&[NG?
M4?D2&W:1928$&S(&%/3[V!SUZX .L;Q=ILC:?'8";49M0MFN[>.V"Y:$8RY+
ME0!\P&"<Y/3@U4E^(.A1:%I6L$W36>IW"VT++;L2KEBN'],$$'Z'&:Y?2=+U
MGPS%X8\/WEC?7.FPZ8RS2Z<N6-T7!\MW!!6,#/.0"<9X%95AIVJV_P /O"VG
M2Z'J4=SI_B%+B:,6Y;$2W,CEAC/ 5A]>V: .NN/'\S:YH5C;:#JJ+?S7"2"Y
MA6)R(D8D*K,.^TYZ8]3P.X[5Q?BR&\7Q?X0U>WT^[N[:TEN5F%O'N9/,BVH2
M#C SU)X'>NMNX&N[">W#F)IHF3<.JDC&?PH P9?'&E0VT5])'<KI,LWD+J6Q
M?(W;MH).=P4MQN*[??!!K'\2ZI-<>/\ 2- FTZZN-.DM;B:6%-FV=AL"GEAE
M5W-UQR0<' -8D6F:I=_"1O MQI=U'JZ(+'<8&-N5#C$PEQMV[1NQG=D8QFM^
M]MYX/B=X?F2TO9;2TTV>WEN1;NR!V*;06 [[30!TVGZ>GAW05L[8WMZELK&-
M99?,E<9)"[F(SC.!D] .:\WU[Q-<>)/A-;:_+#=6#M?6[J5EVHR-<A<?*WS
M+P=PZ\XKUL\BO&HK#5E^"]AH#Z)J2ZA9W4"O']G)W;+G>Q7&<J%&<]#GC- '
MI&G>++'4=;N=(,%Y:7<$ N0MW#Y8EA)V[UR>F>#G!'I4/_":::MWIL<L-W#;
M:F_EV-Y(@$,[D94 @[AN'(W 9[5A:MIUUJGQ&F>*WNX[6Y\-S6(NS;N$25Y
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M6?3Q-JMK<"VBL@LSI'(K/)(J?=. < \X'O@ '>Z/JZ:S;33)97UIY4S0E+R
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M1<0W!GU/3XQ!*H4IN2 .P8YR.!Z4 =?16!#XOTZ1M969+BW;2)4BN!*H)+.
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ML7@671Y;:%C*9K>))'?'^KA*G+ _WC@=!WX[4$$9!S2,H="IS@C!P2#^8Z4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK@]N.:JW7Q'MX#JRV^@:S=MI,OEW8AA3Y%"AB_+\C!Z#GVQS6/+I>K?\(O\
M#VT&E79GTJZM9+U %_=+'$R,>O/)[9J7P]J$MIXG\>1QZ;=7;O?J8EB4%7?R
M$&PG/R]N6P.>M '2IXRL;S^RUTJ&:_DU.V:[MUCP@$2XR6+$ '+ 8ZYJH_Q#
MTQ?#VDZTMG?O:ZE=K9H%B!:*0N4(< YX(;[N<XXZBN?TS0==\,V_AG09;&YU
M+1H+!TN4LY%4&[+[OWFYES$ 6 '0]P>*S;+0M>MO GA_2I-!N4N-/\0)=2(C
M(1Y*W#R%E^;IM8 =">>,<T =U:>,5NKW5+!]%U*#4+"%;C[(XB+SQ-G#(0Y7
MJI&"0:?:>,K2_P#"EEX@MK*[D@O)$BA@'E^:6=]@&-V.#UYXP?2J-I:7O_"U
M[W4VL;A;"728K9+A@ ID61V(QG/1ASBJ.@>'[BQ\>ZI:)(C:%:S?VE;Q#K%<
MSJ59/H ';';S5- '?%@J%F(4 9))Z5RTGCRPAL+759;2[31;F58H]1(7RQN;
M:KLN[<J,< ,1W&< YKH=1LQJ&EW=D7*"XA>(N.J[E(S^M>;#0]:U'X6IX$O-
M,FAOD6.S>YX-OY2.I\X-GGY%^[C=NXP!S0!TU]XZCM=<OM'@T/5KV\LTBE=+
M>)#N1R1N7+<@8^OMUQU$TAB@>01O*54G8F-S>PR0*Y'2K&]M_B?K%X]A<+83
MV%O;PW+8VLT9<D=<_P 0YQS77ROY43/M9]HSM09)^E 'G">++72?A_X=N_"N
MC3QZ??ZA':Q1.Z[HE:<A@0S'+-\P'.!G)(Q7577BE8)KJWBTR[N+FSM5NKJW
MC:/S(U;=A0"V&;Y#T./?FN%M/#^N0?"?P]9-I-P=0TK5(;J:TRF]D2X+G:=V
MTG:0>M:?BS19=<NI[Y-(U33M<@ME.FZC8N Y8@GR9"&VX#==WRX)PW4D ]%C
M<21(X! 8 X-85MXIBO)4:VL;F:S>\>R^U(4*K(K%6+#=N"[E(!QZ<8(-:VG"
M[73+1;]D:]$*"X9/NF3:-Q'MG->>+X?O%\3VNKZ)8W^CZE+J/_$TA!_T2ZM]
MQW2$9*[F7!&/FR>1WH K:#X@C\)OXWN!I5_>6MMK,DL[6X4B&(11Y8EV&<<\
M+D\=A7>7'B.V%U:6=E%)>W=W;FZCBB*KB$8^=BQ  RP [DGIP<<6-*U8^'?B
M';?V3=B;5KBX>R4A?WH>%44]>.1WQQ4]AI>JZ-XET/Q!_9]S-:OHD>EWL" &
M6V="&#[<_,N<@[<^M &O=?$72[3PU?ZT]I?$:?<?9KVU"+YMO)N"X8;L8RPY
M!((.:I:UXZU*UGTV&V\.ZC"MUJT=EYEP(T\Q"-^8P6YW $<XQSG!XK%\0^%M
M6NO#7C*ZMM.G>]UZ\MWM[-2NY8XB@#,<X!(5FQGN!UXKI?&]I?ZA;>'+^PTZ
MXN38ZO#=S6Z;5E$85U. Q R"PXS0!U\;,\2.R-&S*"48C*GT."1^5<=HGC.>
M[O\ Q,VJ64EE8:3<,AF9XRL:+&K$MALDG)/ ( P,YK0E\)6E_J\>LSW6KP71
M:.5K>/49%A5E ^78K;2..1T//K7+S>&=7OE\>Z(;*2%-8E,]K?,Z^4<Q( IP
M=V=RX/'3/MD Z5?&=NFMV6E7>GW=K-J$3R69<QL)B@W,GRL=K8YP?SSQ5&R^
M(T&H6C7EMH&M/9Q_:!+,(DQ$T.=RGY^IQQCCMG.<1>&+K4KI[=;[P2NDW5JN
M;NZ*1%&(!&(=IW$D_0 9Y)Q4'A:PU*Q^'FL6%UIEU%>/+>-'"0I,@E=V3&#C
M^(=3Q0!=3XC69@T6[DTC5([#5PBVUT8U*F1DW+'M#%\G!&=N">A(YK5T3Q1'
MK&JZAI4VG7>GW]DJ.\%SL):-\[64HS C@]^*XY])U<>#/ %B-)NS<Z5>V<MY
M& O[I8D*L<YP>2,8SFM_3K.]3XI:QJ+V,Z6-QI\$$5PP&UG1G+#KG^(<XH U
MO$WB:U\+6,%Y>6]S+%+<);Y@0-M9V !/(XR>V3[5GZ?XYM[S7KC1;C2=3L=0
M2 W,$-S&@-S&#C*$,1GV)!'YXH_%9VC\*6CI&TC+JMF0BD L?.7@9XY]ZGGL
M9]6\=:;K_P!BN8;32;.= 9(]LD\LNT;0IYPH4\G@EAC/- ":7\1M/U/35U8Z
M;J5KI'V:6X:_GC41)L;:5.&)W>@ .>@R0:T5\6PQ:GIUCJ.GW>GG4LBTDGV%
M7<#/EMM8[7QR >OKGBN0TWPCJNI_ M_"MQ;R6&I^4ZA9B,;Q,9%Y!(P>!^-:
MM_::CXP/AA+G2[G3Y-.U"+4+UI@ $:-6^1""=^YB.1Q@'/.!0!N6WBF*\DC:
MUL+F:S>[>S^U(4*JZ,RL6&[<%W*0#CGCC!!K%N/B;:0VNIW,6@ZU/#I=T]O>
MM'"G[G8%+.?GY'S=LG ).!C.8GA^\3Q/::OHEC?Z/J,NH_\ $TA!_P!$NK?<
M=TA&2NYEP1CYLGD=34?AVZN/LWC^QM]-N;J:?6KM(=BCRW=HXUVLV<*!P23@
M8/&3Q0!V3^*K.9+;^S(WU&2YM1>1I$Z)^Y;[K$N0!DY '7@^AJM8>.M+U72M
M/O+%+B::_E>&&TVA91(F=X;)PNW!R<XZ8SD9X]?"^I^"]0T>YCT,>(K!=)AT
MZ[BB"-+%+&682('QE3O88K1UK3]>M[KP[XGT[04WZ?).)](MV19!!,JC((.T
MN-@) ]<9.,D L^(OB!/9^$-8O[#2[I+_ $^Y%G-'/M A=BJAP<X=?G!&,Y[X
MKH9?$92]CT]-,N7U!K=KI[7S(@Z1AMH.=^TDGI@_4BN?\6P:YXK^'>JQQ:/+
M;7$IA:VL973SF"2*[%B"5!(!PN3T'.3@,\3:5'XFN+>6_P!$U:QGCMO,LM1L
MF'VFVE+-F-MC'J IQRO)R10!V^GW:ZAIMK>K')$MQ"DHCD&&4, <$>HS3[F"
M*YMI(9XUDC<896'!K T2\U^TLO#^GZQ827-Y/;'[?>QNNR"15! 8=RQXXXS[
M5OW,IAMY)!')(5'"1C+-["@#R[P%XC@\,?!.P\0W\%W=DM)]HDCP\C?Z0Z*6
M+$9 ^4>U=K8^+(KOQ,="GTV^LIWMS<V[W"J%GC#!21AB5()'# '!Z"O/K7P_
MKL?P!_X1EM&NAJZOC[/\O.;GS<AMV,;??K787EM>W'Q.T74X]/N?L,6GSPRS
M%0 CNR%01G/\)SQ0!T6MZQ:Z!HUSJEX)#!;J"RQ+N9B2  !ZDD#\:I67B>"?
M6;W2;RUFL;RTMENW$S(4:%B1N#*2."I!SC\:3QFVMKX4O#X>1GU'Y-BH5#E-
MPW[2W&[;NQGO7%-X;U'4?$VK_9]$N]/L=6\.M8BYN)49TE+/\TOSLQ;YAW8X
MQG'8 =XVUI-:L?"E[#IMVMG/KMDUM=N5"NID&"5#9 8<C(^N.*ZO6]=@N(=7
MTVVL+G4/LD'^F>0RJ(RR[@@)8%FVX.!V([D"N,GB\27O@[PUH\OA>_6_T?4+
M(W!5XO*=(6&61B_.0,]L=^V=73K?6O#FO^)K5]%O+ZSUB=KVUN;<H=CL@5HY
M,L-N,#!Y!% %#PU?:5;^ ?A[%JNGW%T\\T*V<J'Y8KC#;6;Y@>F[L:Z73/%.
MH7OCC7](?2IQ:Z=';[&1XR<LLC%C\P/S84 #.,<XS7*VFC:W%X+\ 6,NBW:W
M.EZC#/=IE#Y<:*X+<-_MCCKUXKIM/M-2TSXD^(KQ]-GDL=2@M6BNHV78OE(X
M96&=V[)&  <^U ">'?$7A^R\%V^H:;8W%I93WDD$%HW,LD[3,I4 L1EGR>N
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M/2IGO9M&N0;>(IO8B1, L2%  [D_K@5OV/CFQNM ;4YK>:VF2\;3WM)"N\7
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M2R:C*)K@3%2I<  $848X 'I67/XX==?U'1K3P]J=W=6!@,OEF, I(3\X);H
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M:F\N+P+:EMT$%TT:2JP&5D53\RG'0^_J:S]/\;17E]HD,NG7%M#K<<DEC([
MD[%WX=>J$KR.OX5B^'+NQT#Q%\0KR?;!9V]Y#(^T=,P*3@=R2?Q)H ]# "@
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MV-*TR[TC7EU!5>[AE46UY:B3EI5#'/[OL1NW8[<CT>*&.WA2*&-8XT&%1!@
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M&1,@8*VXYPA&0>2>/? /.:SX.U>;POX@:WL#)J6MZK#>?9UEC'DQQO&0&8L
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M-U\P,,_)EL[>HZ!<"M)-#UO^RO'\!TF42:S),UD/.B^</"(QGY_EY&>>WY4
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MJ"#P1U!^HKHM1TG4].^(D/B>QM'OK6XL/L%W;QNBR1X?>DB[B 1R01G/<9K
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MZ>]K)+J,]TF98W!1VR/NL>: +>G:[J,<&F:+-;K=>(AIL=S?*THCCC. I+,
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M,Y=&8GY0Q./F';M5?7=/UV[\8'=IB:EHKV.R!'N%2."XW'+R(>6XVX(#$8X
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M:!E>?/D*(0X"D 'EB6R",$UMZYK^JZ?XY\/Z)96<;VEW%/*S&;:S^6H&WD'
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MZ4 1ZUH>G>)=-%E?J\EMYBR#RIFC.Y3Q\RD&K5O%9Z9;6]E (K>%%$<,0('
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M1K(KJS=<''"\#G.><8H [&BN5@\<6M]8^&Y;*V:2YU]2UM#(^P(%3>Y=@#T
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M;6!"CY6&1P"?K5C0?$=QK@LKB.QA_L^\MFN([F"Z\W805PCC:,-ACT)QM(H
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M ZFBJ>EW5Q>V"S75H;2?>Z/"7W;=KE<@X&0<9''0U<H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I
MLC%(V949R!D*N,GV&2!3J* .3\ :9J.A^&9++4;)HIUNKB8*LB,'$DC. "#U
MP0.<4V3PP=:\1VFI7MC#96-C-]IBM5"F2XN,$"64KQA<G: 3R<D]JZZB@#EM
M6.MZW8ZOH<N@+##<I);17CW2/$T; C>RCYP<'.W'7C<.M)-\//#MTML;FWNI
M)8+6*U$B7T\19(QA<A' [GMWKJJA^UVWVT67VB+[48_-\C>-^S.-VWKC/&:
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M;[G." .3\PSCCG@FN^HH \NA\.>+K+P]X4O+.PM1J_AV,VQLI+D%;N)D"/\
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M@N1G'4&M#P[J5]JWARWOKRTBM[UPX>))-R%E8J"K=U; (/H16%X3TWQ%X?\
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MUO;SREAM$N@Z1!'#,SR;1DG&, '&!ZF@#J](O=4O#='4M*%@J2XM\7"RF5,
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M+ACYX\O:+DS<'KG!QTZT =_KFI2Z1I$U[!83W\R%52W@!+.S,%'0' &<DX.
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M#JN[=Y?/W@<8Z'\*OS:3JGB35- NM6L4L5TF8W4JB82>;-L*J$Q_ "2<G!X
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ME3GY/DP1@]>HJOH?C.?Q!X9T35+6QMS-J<YA-N;@D1!=V_+;.2H0\8 /'/-
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MQ57H"220WT"D^@.;KFNGQ+H?A+4)]/DLKE/%%K#)%("=K*S E6(&Y3P0<=Z
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MK"&VGT9(92+6<RI,DN=@!95(;<-O( R: .RCCCB39&BHN2<*,#)Y-.KDM/\
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M'T..HJA/X U2'P1J6AZ6D,<5UJ<=U:VD]RQ2TB5XW*!L'J48X' W=3U/I]%
M'$KHFOZ-XYU'6]+M[2[L]9BA^UV\]P8FMY8UVAE8*VY2.HQG-85EX'\5:;X>
MT6:SDTY-;T:\N9HHVE9HKB*=V+HQVC:<$8QGI^7J=% '!^(]&\5^)O!]S:7,
M.G0WUQ- Z6R7#&*%8Y%<DOMRS-C' P./<GNHR[1J9$".1\R@YP?K3J* /-%\
M)^)M+T/Q/X;L8;&[TS4_M,EG<2W!C>#SE.8V7:=V">#D>]7--\+:YH6M:9K4
M$5K<2_V5'INHVB3D ^7C9+&Q49/4$''!ZUW]% 'G-]X!U62SN-5L+JV@\1MJ
MXU:(,2T((3RQ"QQD@H3DXZD]JVU7Q??:1/)?66E1W+&-%T\3&2*2/>/-WN5Z
MLFX  $#N3GCJZ* .1\'^%/\ A'=4UBYMK<:?IMZ8VATU)=ZQ. =[@=%W9' _
MN_@))='U/_A9<>OI# U@FE-9<S$2%S('SMVXQQCK7544 >86_@378K"WNE^Q
MQZKI^MSZG;)YS&.:.5B7B9MN5.TXS@\BM^X\,7>MZU>ZQ?1QVDKZ5)IMM")/
M,*[R2SL0,==H &> 3GG ["B@#!\&6&J:5X4T[3=5BMHY[.WCMA]GE,@8(H7<
M25&,XSC''J:YF+PQXDT=/%&E:?!8WFEZS)<7,$TMP8WMY)5PRLNT[AGI@CW]
MO1** /-+;PKXMT'^P-4TE=-GOK32HM*OK*6=A'-''RKH^WA@<]1T/>M77]#\
M1:Q8:&T@LGO+75X-1N$$K+'&D>?W:':2Q]SC)R>. .VHH Y:QT;4X?B+J.N2
MQ0"QN;&*V3$I,@9&9LE<8P=WKVIFD^$I=,\;:KJ@G4Z9<L+J"V'\%TZ[)7_%
M5'_?;5UE% '!6>B^,/#FN:I!HPTRZT?4KM[Q)+J1TDLY)#EQM ^=<\@9'U%:
M&G:'JMK\0KS6)EADL9M/ALQ(9?WI:-F.XKMQSN[&NMHH Y_QQH5QXF\%:IH]
MI)&EQ<Q;8VD)"[@P89Q],5FSZ1K]]XQ\.:W<VEC%'807$=Q''<LQ!E"@;24&
M[&WGIU]N>RHH \RF\#>()[/69(9;2TU%M>&M:;)YA=-P4*$D&T8! .<9ZUV.
M@/XDN2UQX@@LK,A-B6UI*90Q[NS$#'3  Z9.2>,;E% ')^+- D\0R2V=]HUI
MJ>EM;@0EI1'-!/ELLIQP"-G(.1CH<UGZ5X6U[3O$?A^]N9H;V/3M(:PGG:8B
M221BIW %>0-N,DY/6N\HH \P_P"$/\416-RB16$BR^(I=4ELGN6$=S!(2?+=
MMG4'!Q@@X_"DU'P7XFO+#QI:K%I8&N^4T)6X<",B-5(/R=!M//?T%>H44 <=
MXFT#6]1M-#U327M;?7=(D,B0S.6AE5DV21E@,\CH<?EU$S0^*;[2R^HV&E.\
MLB)+IAE+Q&##;\NR<L<@XQCY0,\DUU=% '*>"_"[>&7U80Q_9-/N[A9;73Q*
M9!;#: V#T&YLG R!Q^#O%WA:?7K[1[NSN1;3VDSQSOW>UE0K*@]S\N#V(S74
MT4 <GHGA!M'\9:MJ4<JC3;C$UM:J.(IG4+*V/<1IC_>:J#^$]6NKKQV)1;10
M^(+=8K5Q*6*$0&+YQMXYYXS7=T4 >?\ _"/>))QX->>UL$;19-TZI=,=RB$Q
M_*2@R>2W;'3)ZTZY\,:Y+=>.Y%@M-NOVR0VN;@Y0K"8LO\O'7/&:[ZB@#@[?
MPUK::IX(N'@M!'H=G+;W6+@DLSQ+'E/EY VYYQUK4\*Z-J6EZQXCN;Z*!8M2
MOOM4/ERER!L5<,,#!^7/&>M=110!R'B*#Q==:U$=.T[2+C2X-KI'=7CQF24<
MAF"QD84]!GKSUQAM_H.N:WIVF7]^+"'7--OQ>010.QAVCY3&7(S\RD\XX)''
M%=C10!S>F:%</XNO?$^HHD5Q+:)8VT"/N\J%6+L6.,;F8]!T ')JGXBT'5U\
M8:9XIT-;>XGM[=[.ZM+B4QB6%F# JV#A@PSR.:["B@#S"Z\)>+IE\12Q+IT3
M:CJ-O>" 73XFC14#PNVP85@N,]^01@UM:'HVK:7XRU36KZ+3+73KRSMXRD,Y
M/D&+< @RH!'S?>X],=Z[6JFIZ99:SITVGZC;1W-I, )(I!D, <C]0#0!R7@[
MP_'8^)]?O+>X\W34NG2QB ^6%Y CW 4]QO 'L0P]:@F\(7VH^(-+U>:QM;#5
MK.\\R?4K6;!N;<$_NV4 ;F8;0<\#G!/2NWLK&UTVRAL[*WCM[:%=L<42A54>
MP%6* .;\;:5JNKZ-;PZ2T+/'>133VT\A1+J%3EHF8 X!X[$'&#P:R])T'Q!I
M_B3Q'J;VNFB'4[:W$4,,[?NWC1DV<H..<[O;[O/'<44 >;IX,UU/ACHVA;+/
M^T]*N+>=1YY\J;RI-V-VW*Y'MUJY<:/XOTKQ5<Z[HL6F72:I#$M_97$[H(I4
M&U71]IR-N > 3C./3O** .-N-"UZ;QAX;U:7[+/'I\-RETXD*$M-M^XNT_*N
MW R<D>]=/JEF=0TB]LE8(UQ \08] 64C/ZU;HH \X7POXF?P[X.T^:VTY9-"
MO+>679=,0\<4;)D$H/F;=G'08ZG/$NK^"-2US5_%AF:&VM=7M+:*VF24L\4D
M)+*S+@<;B.A[5Z%10!S'AT^,II(E\1Q:9;I;KAGLY6<W38QG! V+WQR2<=!U
ML>)=-FU46]K+I5GJFE.L@N[:=@&S\NQDR,9'S=QUSGBM^B@#S2R\%^(M(CT"
M.!K74+"QFN6;3KNZ<)$KMF'#[6WF,<<COQZB&;P3XED\#:WH173FGO-6-Y#(
M)V52AG64[AM.#\N .>O6O4:* .&O]'\4Z7XON-?\/Q6%U#J<$4=]8W<[1[)(
MP0KHX4\8.",=ORZ"+_A((+G2HG%E<0/YK:C-N96C)&4$2]QDXYYP!WK9HH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-:\,Z5JDT:QR7EI%<.B=%+H&(&>W-:=>4W6G.GPL\(^);2 RWFB65I=/$/\
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MJ+"S=H6N9 K.?,!;@^W Z#.<9Q7-06AN_#7A"'4U%\+3Q:UA;W%PH=I;93*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !12*RLH92"#T(-+0 4444 %%(K!
MAE2"/4&EH **** "BBB@ HI%8,,J01TR#2T %%%% !112!@PRI!P<<'O0 M%
M%% !12!@20""0<$ ]*6@ HHHH **:7165690S?=!/)HWIOV;AOQG;GG% #J*
M** "BBB@ HHHH **0,&Z$'G'%+0 4444 %%%% !1110 44@8,,@@C..*6@ H
MHHH **3<"Q&1D=12T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !112,ZHI9V"J.I)P!0 M% .1D=*0L%&6( ]30 M%%% !1110
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MO46MRUP\0:9%C+C8-W?U)&,$=>F/XC\*:Q>Z1XMO[73)GO==N[-H;,/&&2*
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MX<!!<F7.[?C[IQ]?SKU>HWGACECB>5%DDSL0L 6P,G [\4 <%I^G^(/#VO\
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MA@I(V[>H'.#D>G44 <)XUT&XBL?#]QH=R+?5M/N([2TD<9WQR 1NI'?"_/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MCHGV,H;:6X6-8;G?GS'4YWC;@# ;!R0* (!\1H9=#\.:K;Z1=S1:W<BV15=
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M>0#W*Y((&<5G>&=.\7^&(IO#4&G6T^FK<2/9ZL;E1Y,3N7PT6-S.I8X['@9
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M-9F(+,MS&9U(EMV5OF"X[Y7&>F.?2@#L**YB[\62_P!KZKIFFV4%W=:8B/+
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M?5M5T[3;*"ZN-,,8G@>Z\N9@RJ^Y$V'*@,.<C)!'ID Z&.[MI;F6VCN(GGA
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M9;@?.)G+ L"/E !YZG/2O0Q?V9O_ + +J WGEF7[/Y@\S9D#=MZXR1S[U8H
MX6/0=7TSQ1IOB2TM//W:6NG:A9>:H==IW+(A)VGG(()'!]:SM9\%ZM=Z+K<L
M%M&VI:SJEO>/%YH"PQ0LA52QZMA#G'&6]!D^ET4 <F=,U*3XFVVN_8BM@NDM
M9,S2+N#M(KYP#T &/K[<UI^+- 7Q1X4U+1&E\K[7"463&=K=5)]1D"MFB@#A
MYM&UKQ'9>'[+6;%+4Z9=PW=U,LRNL[Q [1&!SAFP3N"X''-9Q\,ZXWA'QMIA
ML%%QK5[<SVO[]-H2554;CG@C;SC/7O7I-% %/28YH='LXKB(Q31PHCIN!P0
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MV_[!]IA^V>5YWV?>/,\O.-VWKC/&?6@#A=2\/^();ZQ\565N%\1Q7!CEMFN
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MKBR-P'AN8"C-N5RO((4@@K_]:\OC""*ST>UMHK*VN;O3DO!'/+Y<4$9"@*,
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MQ(5.5QP"3D<FN73P?XN.E:5#<6^ES7UAK4=_/>/=-OO@K/\ ,QV97 8#'/3
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MM]GF>:6 7;C.<^F*\Z\8Z]>>(/AQXHN].MK9M+BBN+96E<[Y@F5>1<#  (.
M<[MO;-=WHH!\/Z<",C[+%_Z"* )[&_M-3LX[RQN8KFVDSLEB8,K8)!P1P>0:
MR;[P9X=U'4GU"YTJ$W;X\R5"R&3'][:1N_'-><>$O%.L^%/A9H^J'1K>?0+8
MNMU(MP?M"J9F!=4VXV@GIG)]AS7?:?XFNIO&6HZ#?6]O;I#:I>6DRR%OM,3$
M@M@@ ;2 #R>HH Z.WMX;2WCM[>)(88QM2.-0JJ/0 =*DK,\/ZA<ZKHL%_=0Q
MPFX!DC5"3F,GY"<@8)7!QVSBM.@ HHHH **** "BBB@ HHHH **** "BBB@
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M0!P4GA77HE\9VEM_9[VNN&22"229U=7>$1E6 0@ $9R"<],<Y#G\+ZXT/@E
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@!" RE6 (/!![U4TS2-.T6U^RZ78VUE 6+&
M.WB"*2>IP.]7** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBL'Q3JE[I4.
MF-9/$IN=1@M9/,3=\DC;21R,$=OY4 ;U%8>M:AJ5C<2"PB6Y9=.N+B.VV_-+
M*FS8H;/ );'3TJMX6U[^WMTUOJ=O>VRQXEC\DPSV\V>4="<KWP",\'DT =+1
M7.:CJ6IKXSL='M)[>*WN+&>Y9I("[!HWC4 ?,.#YA_*LC_A-KZ/4'\/S06_]
MN#4DL1(@;R2C1&83;<Y^X#\N?O#KCF@#NJ*X[7/%S^$+UXM6(NK:2PN+R"1$
MV/NAVEXR.AR'&#QT(.>M:]H->DM+.YEN+7S93&UQ;B([40XW!&SG(!ZG.<=!
MG@ VJ*XK0_$M_KEP]HM];6VIQ&1;S39X"DMMPVQER?G7.WYL$-G(QTK4U;7+
MJ#1=+U"T6)#<WMI!-'*I8JLLR1N!@C##<?7D=* .AHK&U74KNRU[0;6(Q?9[
MZXEBF#(2WRPO("IS@<H.QJMJ.O7,/B?1].M4C-K<73P74K==P@DD"K[C8"3[
M@>N #HJ*YJUU:_'C*XTB6^TZX7[$;D0(I22!MX"@_,=ZD$Y.!@@=-P%4HO$&
MK(GB:*.>QU6YTM$:);:/8X<J2R,F\DXP".1NR1U!H [*BN6TC6+_ ,2:9/<:
M/?6S6S3!;>^E@+$IL!?,>5^8/E><?0XYSW\87UCH.EWVLF*T@FGG@N;Z&(M&
M-C,L3A<DA9-N<G.,@=P0 =S17%S>)]7\FZ006\-YIVC1ZE=QGYE>5PY$0.>!
M^Z?GGJ/0YV]2UB=/"W]JZ;:S7$LT*20QQQ>8PWX^;8"-VT')&1G&,T ;-%9'
MAG4'U708+Q[^&]9RP,L5LUN 02"IC9F*L"""">HK7H **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
%44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>elicio-insidertradingcom011.jpg
<TEXT>
begin 644 elicio-insidertradingcom011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=JMO)#-8E@C!=ID3]YP3P<'." <UO6FE6UKH<&D8:6UBMEM<2')= NWGUR*
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M[*;S?.:)1)<R. -BQ(5;=_$6X. .U<<OC/Q'-X*T;4(KBW2\DUU=-N&DM_\
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M%1A0#][FL^36/&MQK?A[2)YK32;O4=.N)+E! LWDRQ[1N!W$,#NR!D8SSG%
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MKE1R<'GITKF/#&LN/$/B/PY878M-2O-?NIUGD0%5B01;PH(P[G^Z.@RQZ $
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MH&"*'(9\?,5& 3[#)Q7+1>#YYKC19-5U*.].CRF6WE%KY<S':5 =]QR,')
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M$N-TCGJ2!P/8#@  =JN444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-"VESZ8GB&]2R-^+^VC\J,^3)YGF$$D9<9SC/KSF@"Q8_P#)9]7_ .P+;?\
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M10BLI4[F4;I#M)&2>YXIGAWP/<:!Y-H?$5]>:/:-NM+"5$ CP<J&<#<X7L.
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MJ76U>2WU'R);86L82>,W7DD,<9!P1C;CISD\UWUQX<EF\8P^(H[X)+#9O9I
M8=R[68,23N!SD#TX_.L?_A7A/@EO"_\ :[_9FN?M/G>0/,SYOG8ZXQO]NG%
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M#L**\97Q!XPB^%MAX[.OF:6WQ)<6!MHQ%/'YI1@2!D-CN"  ,8SR?95;>BL
M1D9YH Q=8\466AZGIUA=PW)EU&3R;9HXP5=_[I.>#]<4G_"56/\ PE@\-&&Z
M743";@ Q@(8LXWALX(SQCK[5E?$_2I]1\$W%S9#_ (F&ER)J-HP'(DB.[CZK
MN'XUQNO^(#>ZKH/Q#L7 TO3'M[:YP/\ EG<KF4D]]F^$8]=WI0!Z3?>);:PO
M+RUDM+V1[2U^UR&*(,/+.X @YZDJPQUX/;FKFBZK!KFB66JVR2)!>0)/&L@
M8*PR,X)&>:P8O],T#Q%K!Y%ZDPA/_3&-"B8]B0SC_KI7(Z#=ZOHGAOX=7<>K
M2/:W[6UA+8F)!$$>%B&!QOW J.=V#Z <4 >M45YP=5\4^)-*O-2\/O/%=17T
ML5K&S0BV*12E"L@/S_,%))X()&..LL,_B'6/&'B;2?[?GLK>UM;6:$00Q,T3
M2*Y*ABI!7(YR,G P1SD ]"HKG? >LW7B#P+H^JWQ5KJXMPTK*,!F!()QVSC-
M=%0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !61XF\/P>)]#ETN>>6 .Z2)-#C<CHX=2,@@\J.M:],
MEEC@B:65U2-!EF8X % '.R>$=NLV^M6FJ7$.JI;_ &:>=T5UNH\[OG3 &0>0
M5QCITXK4T;1K;1+22"W9W>:9[B>:3&Z65SEF. !^ &  !VJNOB. ^,#X;-K<
M+<_8C>B9@OEL@<)@<YSD]P.E;- '(W?@4-XCNM8TO7-1THWX7[=!:["DY48#
M#<IV-CC<.?QJW-X1@BUN#6-)NGT^\CM19R!4$D<T*_=#*>Z]F!SV.1702RQP
M0O-,ZQQ1J6=V. H'))/I3Z .3NO =I/IUE:17MQ";?4AJCS;59Y[@,6W/D8P
M2>@ XP!@"K,GA&*?Q!J&K7%],YO['[!- %4+Y?S8P>H.6/.>]='10!QO_" @
MZ!H^DOK=[)%I-S#<6\CI'N_<\1H<*!M Z]SZUH0>%FM];UK54U*7S]6CCCE4
MQ+MC"*54K[X)ZYKHJ* .,3X>QV^BZ%8VFKW<%QH<A:RO!&C.%92K*RD;2""1
MT]*'^'&G7,6OPWU_?7<6M&-YQ(R HZ*H612%R&RN?[O;&*[.B@#GO#WAFYT=
MQ)?Z]J&L3(GEPM=[0(DXSPH&6.!EFR?ISF77O#4>N7VE7RWUS97>FRO)#+ $
M)PZE&4A@1R#Z<5N4R66."%YIG6.-%+,[' 4#J2: .<7P>+34M2NM*U.XL(]4
MPUW"BJX,F,&1"WW7(ZGD'KC-;FF:;:Z/IEMIUC$(K6VC$42#LH&/Q^M4)/$<
M$?BZ#PXUK<"XFM7NDF(7RRJD @<YSEO2MF@#D8O 5O;V-_I-OJ%Q%H=](TDM
M@%7Y0YRZ(_54;G(YZG!%:FN^%].\06EA;7<96*RN8[B)8^!\N1L_W2I*D>AK
M:JDU_(NM1Z>+"Y:)X&F-V /*4A@-A.<[CG/3H* *EMX;L+7Q7>^(HU(O;RWC
MMY/3"D\_4C:#_N"LU?!2K;^(X?[4G*Z\6:X/EIF,LFP[./[HQSFNJHH I:/I
MW]D:-9Z:)FF6UA6%)' #%5  SCC.!7+3_#BWF\/:IH0UB^33[^X:?R]L9\G=
M)YC!3MYRPZMG X'>NI2_D?69; V%RL<<*RB[('E.22-@.<[AC/3O5/7_ !'!
MX>?31<6UQ*-0O8K)'B"[4>1L MD@XZ] >E %>Y\+B\\26.M7-\[R6MM);>3Y
M2[)$?&_=WR<#I6=H7P_309TA@U[4Y=&AD\VWTN5E,<;9W ;L;BH/(7..!G-=
ME10!D>)?#EEXJT272[\R+&[*Z2PMMDB=3E74]B#6?;>#4DTJ[LM>U2[UO[5
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M^N#^5/H XI_AW#)X0OO#;:M=&UO+EKF23RT\P,TGF$ XQC</2M-M 2U\4_\
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MM;%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-+749A83Z-+.( J8CD$J*&!VY)P>^16OH.@'18W:XU2^U.ZD 5KF\<%@HZ*
MH  YSTR>Y/&&3^&HIO%D?B(7]U'=1VC6BQ+L\L(Q#'@KG.0#U[4 ><+K/B.+
MX;_\)3)XANY+NRU,Q>3Y<8CF3[7Y1$@"Y/RGL0!@8'<[OB3Q'<Z3XCOK;6;G
M4-*LIFB&EZG"NZU7*KN27 .UB^X9;L1@C&3JGX=V3>$9O#1U74?L4MQ]H9\Q
M>9N\SS<9V8QOYZ5<O_!Z:E%J-K=:K>2V.I,INK9ECP<*JG:=N5W!!GWR1@T
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M0J@#)'&3G@G&,G./:^ K&UTW^QUO;M]#$WG)IS["B_/O";MNXINYVY]LXXH
MRK5]7USQKXHTHZ_?VMG#;6DMN(DC5XC(LA(!V],CTR<#GKG#M=>\0R> _"WB
MR76[AKF:\M[>>V6-%AEC:7RVW#;G<>N<\'H!7H%OX82U\0ZKK4.HW@N=2CCC
ME4B,H@0$)M&W/&X]2>M9B_#RR3PG8>'%U3419V,ZSQ/F+S,J^]03LP0&YZ4
M921:_KWC#Q=H\?BB]LK>Q^RFV:&*+<A>,M@G;RN>HZGCYN.:WA_Q)JVO:%X<
MEU&_9)Y?M4-U:V2XGO)(FV*R$<*@P2QRHR0,XXJ?1+::[^)?C,V^JW%J)5LT
M5T1")ML)#,I92-RGC(X&>1TK<;P#I\-QI$^F7E[ILFF0/;1M;,I\R)R"ROO5
MLDD9SUR2: ..C\2>(;CP9X>N1JTT-V_B1=-F=HXR98OM#( ^!UP #M(SSZUN
MV@UD>+_$'AE?$%[(KZ;%>6MU,L9DMY69U.,* 5RH.,5:C^&UA#8064>K:HL$
M&IC4XE,B-LE#EP,LAR-Q)YY/<U>O=-M= U>_\8SW6HSR"S6"6WBB60&-6)&U
M57<3EB>M &)X>U[4-=T/1=,>\GAUN*[>'56!7>GD?ZTGC&&+1@8' D!'2NVG
MM/*-W>6J*;Z2+:C2,2,@':/89Y.*P?"NFVL^L:OXIBL9;5]5:-8Q-&4=HT4#
M>5/*ECGCN%4FNDO+9;RRGM79E2:-HV*]0",<?G0!PG@WQ$]_K<&G:E=:E9:W
M#:-]MTR_48FDRO[Z)@,%1AN%.,-TXS6MK&KSS>.M*\,13R6T,]I->3R1G#R!
M2%5%/;DDDCG@<CFKMKX82/4[#4+V_N;^XT^)XK5YU0,H< ,S%5&YB% STZ\9
MYJ36_#5MK-]I^HK/-::EI[,UO=08W ,,,C!@0RD=0?PQ0!YGXTU+4_\ A&_'
MOAV[O[F5-+CMY[:Y!"N\4W_+*0@<@$$>I'6NBU^QG_X6)X-M(M1N$<VNH W)
M"M( 5CZ9&W/8$@UT%WX*T[4-'UBPO9;B:36 /MEUE5D;: $Q@8 4 8&/KDDD
M@\(*=8TG59]8U&>ZTR.2.-I#%B3S  Y8!!U '3&,?6@#D;3Q3J]AIMYIDE[+
M=W"^)O[&M[N;8)!$RAQDXVEL94$CJ1QVJUK7_"7:+I'B>\&HO!81Z:]S9%Y4
MFGAF099<E.4(QUR0>F*V)OASI=UIVL65W=WL\>J7?VYV+(KPS\8>,JHVD;1U
MS^IIZ^!4DT*^TV_U[5K][R VSW5Q(AD2(\%4^7:,]S@DX'/ P 7/"EGJ$=DF
MH7^LW-\;VV@D\F5$"0MM^;9@9P<CJ3TZUS-]XCN;#Q9)I^N76H:49=0B_LZ\
M49L[B#*YA) (5VPX.[!R>#C KO=-LAINF6UB)Y9UMXUC627;N8 8&=H Z>U8
MMWX/BOXKBTN]1NY].N+L7;VCA" P<2;5;;N"[AG&<]>1F@#BUU*?PSJ?Q)UL
M75U<OI[Q/'#*X*NS0*5#<9P"W08P*U]9U#5?#=IX;UB/4Y[Y+R[M[6_AEVE)
M1-QO0 ?(5., <$=<UO-X+T^36-8OI9[F2#5XPEY8LR^3(0GE[NF[.WC&['?&
M0,-L/!L%K#IMM<ZC>7UGICB2S@N-F$900A8A06V@\9]B<D T 8VFW&M>+_#U
MQK.FZRUA>B_E2WC90T,444I0I(O\195)))R"PQ@"L2\UW^ROB=XGLUF-J^J?
MV=:1WY&8[9C%*0Q/]X]%!X)ZD"NIC^'ME;ZO>75IJFIVUC?3&>[TR*4""60_
M>/3< W< C/3IQ4M[X!T[4;G7YKN[NI5UN&.&YB81[4$8(0I\F05R2"2>>: ,
MCQ993Q^*_ EK'?SF;[5<K]JD"M)_Q[MDXQMSZ<8!['I67<>*]6\-VOBK3VU"
M6\ELM3M;2SNKI59HQ<*A);  .W<Q&1Z#I77#P6K3Z'--K>ISRZ,6-N\IB+/N
M78=YV?-\O&>O?K3)_ .EWC:^+ZXNKJ+7"C7,<A0!&0 (R%5!!  [GI0!4U&]
MU#PUXT\/6J7UQ>:=J[2VT\5P0S1R*F]9%. 1G!!'3T KFM,UVXT3P]JJ6CB*
MYU+QE/IT4Q4$0F6;!?!X)"AL9XSC-=]:>&A'>V=Y?ZC=:C<V,;1VLDZH/+W#
M#/\ *HRY QD]LX R<YC?#K2Y=!U+2+F[OIX;Z]:_,K,BR0SLV[?&RJ,'/KF@
M#"U8-X>^)]O?&YNKN*#P_>3B.=]Q!1D)PV,\X'';M5S3F\6:C#X>UJTN_P!U
M<^7)?K-<(89(9%!)C0+\K*2-O//0DUKV_@E?[:M-6U#6]1U"ZMK9[7]\(@DD
M;D95E5!GI]3ZU#H?P^M=!G5+;6=6DTR%_,M]-EG#0PMG(QQN(!Y )(!YY- &
M)X>_X2C5K77+Z/Q%<RW.FZG?6UK;/'$(Y]@*QB3"CHVT\8'!]<U?\%^(DU36
M39SW>IVNJ06A^V:3J2X??N7]ZAQ@K]X<''(X%;&G>#K?3=*UK3TU&^DCU:6>
M:9W*!HWE&'*%5&/49SBI4\+JU^M_=ZC=7-[%:/:07!5$>-7QN;Y5 +_*.>@Q
MP!DY -^BJFEV+:;I=M9/>7%XT$80W%RVZ23'=CW-6Z "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S
MM6U8Z7]E5-/O+Z:YD,:16H3(PI8L2[* ,#J3U(K1I,#(..10!Q\/Q CN/[4\
MCPWK<ATIS'>*@MR8V W$ >=EN/[N:U=&\30ZUK6KZ8EI/!)IAA#M*5Q)YBEE
M*[2>,8Z^O2N=^'_/BGQY_P!A<?\ HM:S#87%YXR^(GV?4[NP,,5FZM:,$8L+
M8E<D@\#'08SWH ]1HKS31_$NJ^(QX;TYWS)=:$NHW)6Y:V:9R53AE4D ')(&
M.H[#!@U0^+M'TO0K6^U_;<2^(HK,26[+(7MGR5$I* EQCMP1C.<T >I50UG5
M[70]-:]NRQ0.D:H@RSN[!54>Y8@5QJKJ4?B=_"::E>7T=O8_;3+<7I@FD,DK
M*/G1,D(% QQ][G/ K'\4Z=K<?@C2(/$.I"XOX-;M8O-M9CAT,R[2_P J_. 1
MSCW[T >B:3JMU?W5]:W>DW-C+:NH#R8:*96&0T;CK[CJ#6K7%6]U+JGCG4O#
M3WEY'9Z790R#9.R2S22ECO+C#$*  !G&2<YXQRDWB'Q%)I<%F=7GCNK#Q9'H
M[W2(G^DPE@07&/O8(! P#WSF@#V"BN (U&V\41^$TU.\OD%E)J#27-YY,S[I
M=JJ)(TSM3!X&/O#L,5T/A*VURSTB2UU^\@N[J*X=8Y8G+L8>"@D.U?G .#QS
MP>] %CQ+KJ>&O#UYK$MK/<Q6J&1XX2N['K\Q''Z^U:-M,+FUBG ($B!P#VR,
MUS/Q,_Y)GXB_Z\9/Y5CPRZCHOC+PI#_:MY<VVK6=P+BWE*^6ICB5U,:@?+U(
M[Y'7)YH ]#JCK6IKHNBWFIO;S7$=K"TSQP[=Q51DXW$#H/6N TNX\4^)O#ND
M^)M,O8+>>:47$OG7S^08=QW1&((5&!QN^]D9)I+J\G\6^"_&FI2WUU +5KVU
MM889"JQI$A'S+T8L<D[LX! &,9H ]"TG4%U;1K'4D0QI=V\<ZHQR5#J&P?SI
M-6O9].TR:ZMK":_FCQMMH"H=\D#@L0.,Y_"N"T_4Y[:+P/8WMP]GH=QHJEIT
MD,0>X$:;4:0$%1MW$#(R?7%9E]J'B:T^$^NZO+KFHK/%=LMC*Z1J7MA,$1ON
M!OF4YR3DX!!YY /7>U%<+J)U*\^*B:.FM7MOI\VB/<-%"44JPF1<J=N0<=SD
MCG&,UB6OB+7(? D+27D\RVWB!M.O;X\RI9K,5+D@=<;5+8R 2>O- 'JM1R3Q
M1/$DDBJTK;(P3RS8+8'X*3^%<=X<DU"X\;ZTL&J7=SX>MXX3;;G62,RLI\Q1
M(06;'RGAN"<>U5O&%G]I^)7@D&ZNHUD:\!$4Q4#;"2" ._)&?3B@#OJ*\ZT6
M'5M5\4^(TN/$VH1V^DZG$T* QA63RE<I)\O*<XP,=R23C%*PUC4H-9\',FIW
MEZFI330WEVQQ;W?[MG#11L<J 5&"%4$>H- 'J5%>13W&NS>&/'6H'Q+J2S:+
MJ%S]D*%%XCC1@&PN"O;;P.2>>VGXA\1WUC)!?ZLFI1:'<Z;$R7^F,2+&X.XN
M\J+R5P4P2"!CIR: /2J*\]UJ_GN#=FUUFYNQ'HR3V\6G.4,3D,?M$CY (;"[
M5).0#A3S3-"\17OB.\\,Z5>74D0NO#Z:I=/"QB>XD)1=H9<%0,LQVX[=L@@'
MH,T\5N@::145G5 6.,LQ  ^I) JL+VX.MM8G3YQ;BW$HO<KY98L1Y>,YW8YZ
M8KSKQ3I-_:P>%+74-<N+V5?$D<2RHYC81,KLH?!^9U 7YCS^?.E?:U?:#XZU
ME&O+F[L++PU]O2UD(QO5V!Y !)(0<G)Y- 'H%%>7ZGJVJZ7\-]*\;P:E<3WN
MVUN;N OF&X29E#1JG1<;Q@K@\<D\U,RZOJ?B3QS8-XBU*&WT^.WDM1"R(T9:
M%GQD+TSVZGC)- 'I5%>6_P#"3ZN?#/AC7-2MM0N])GTT/J$FF,5EBF(7$K*I
M!*8#\#@9.0<"N]\-W4-[X9TZXM]1.H1/;KMO#UFXQN(['/48X- %C3[V>\:\
M$^GSV@@N&AC,I4^<HQB1<$_*<]^>*NUY!J6M:[!\/?'-VFMW@N]-UJ2"WG^3
M<(P8@$^[@##'[N#FNE;^T--^)-AIKZQ>W5IJNGW#S1RN (W0IAH]H&SAB./U
M/- '=45YOHNHZC]CUCPM>ZC=2:Y!J8MH[EI,2-!)^\248X&(U<XZ$I@]:T-,
MN)_%&N>);!K^\M(=*E2SMA;S%'5O+#&5C_&23P&R,+TY- &]KGB./0KW2+:6
MSGE&IW:VB2H5V1N03\V3GHIZ ]*VJ\B&N7WB#P[X#O-3"F]3Q(MO-(BX61HQ
M,F\#MG'YYKH'U:?PUX\U2UU.\NI]/O=/-WIR/(3L:/B6%?5CE6'?G H ["]O
M9[:\L88M/GN8[B0I+-&5"VX"D[FR<X)&.*NUP&HOJ^C:SX'M)-5NF-U<R1WT
M9<,LK>2S=2-V 1@#., <9YK&GEUNZTKQ_<'Q)J2/HUQ,]GY91<%(%D ;"\KG
MC P.3G/8 ]8HK@)=?O+C4_"HU.X:STC4-,:>:>.0Q*]T50A&<$%1M+D#(R?7
M%:/P^?6)](N[G5KZ[NE:\ECLVN%1=UNCD1N,*#\PYRQ.< CKR =/+=)&TL:
MS7$<?F>1&1O(.0,9(')!')'2L_POK\/BGPY9ZU;P200W08K'+C< &*\XX[5R
M^B66?C!XHD-U=GR[6S<*9B5^;S?EQ_='8?6N1\.R:CH_PR\(:S:ZM=H?[1BM
MVM5*B%XI+AD967&2><Y)X[8H ]MHKSN6?Q!XL_X2(:3=_9;FPOI+.S<7C1+"
MT:KR\80APQ.3NSP< #J>GU.35/\ A [R0-&VK?V8[!K8DH9_*/*'J1NZ?A0
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MQ&5Z#&T=,=*V#J&I#5OB':1:G<QI86T$MF<AC S0,[;=P/!([_AB@#MK2_\
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M"MM.S@$ #\.*E_X1!%ADACUC4EBEM$LY4S$0Z*" <&/AL,1D8SQZ58'B-?\
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M:6]60I;21/*4,*Q%B&"C W!>JDAB<UVR>$;,-"DUY>W%K!=_;8K:9U*)+N+
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M"QP/F8$\=>3G._X5]I?_  BY\._;+_\ LXS^?M\Q-V[?YGWMN<;_ )O_ *U
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M,#TP ,8H QM)L5L/C/J<:3W$J-H<+J)YFE*?OG& S$G&1GD]S3O&ML]YX_\
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MQPZY<ZJ+F[:2XB2(P/,3"@7/*IV)SR: -"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?FQ[<D#) P2,&L/QKXI%K8Z NGR3R6^JZA;1M<6J,P>!LL0CK_$P7''."<4
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M^^P[5A^&Y]4T;X-Z= -'O/M,.H_Z4DM@SRVT37#,9DC9?F91@C@X//:O8Z*
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MI[:I$D.H&VC-S'']U)-HW ?CF@#G_#OCF'5-#U'5]1MIM/M;6XF0M*O 5'V
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MWILY_P#KUKZA_P 2;QWJMYJGAB]UC2]82"2VGMK(SM"ZQA&C=,94' //K]<
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1=JLA/W6 ]=P]J .5\/^-]5U^/PMI<\@M;Z_^U_;;B%1R+=BA\O<" 6.">.
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MCDC2-8@%D$@ <MWS\HQCI0!2\#:EJ-TVOZ=J5ZUZ^EZF]K%<R(JN\>Q&&X*
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MK%)(H5V4XR3@< G ]#44G@6-M!T#38]4N89=#DC>TND1-^%0H P(*GY21TH
MK-J]_P"'_B UEK&K2RZ/?633632QQJ(Y8N948JH)^7YA[ UT'AHW\FAP7&I3
MRRW%P3/ME55,2,<I&=H'*J0"?7-<UKPTCQEJ5KX8\FZN)],O8YKJ62!U6)%7
M)RY 5MX.S /(8GH*[N@#D_&.IZCIFJ^%Q97AB@O=52TN8O+4^8A1VZD9'W1T
MK':Y\1:EXG\9:9%XAFM(-.BMY+4Q6T19"\;/C+*05R.<C)P,$<YZCQ!X<_MZ
MYTJ8WKV_]FW:WD:H@8/( 0-V>V&/ Q]:@A\*M!K.NZG'J4GFZQ'''*IB4K&$
M4JI7\">N>: )O!FK7&O>"]'U2[V_:;JU224J, MCDX[9-;M97AO1%\-^'[/1
MX[A[B*T3RXY)% 8J.F<<5JT %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 445S'C37;C1X-(M;23RI]
M5U.&P$^T'RE?)9@#QNPI SQDC@XQ0!T]%<3+>ZEH_P 0++0/[0N)]/U>SFDA
M>0*TEK-%@DAB.5(8<,#@^W%<SIGB/7M.^%H\=ZAK<][+':S)]B>)%B>0S%$=
ML '@XS@@8X&,<@'HFJ>(K?2M;TG2YK:X>35)6BAE0+Y:LJECN.<]!V!K8KS?
MQ!IUS9^,O <D^J7-XS7DHE$NW:S^0_SJ !M[\#CI2)J/BKQ/HL^K:#,T-VE[
M*ELDDR"W"1RE"DBX+'*J23UR>,"@#TFBO/&.OZQX^UG1XO$=U8VL-E:W,0AB
MB8QLS-E02O*_+WYZ<XR#VFMH\FA7ZQSRP.8'Q+"V'7@]#V/O0!<BECFC$D3J
MZ'HRG(-/KRCP]JUWI7@3P+I\%].)=;:*$S.%/D1A"S!..IP -V>I/:NEM-2U
M#2?B0/#LUU+>:=>Z>UY;M-@R0.CA67<!RI!!YR0>* .RHKD?B1J.I:3X3-]I
M5ZUK<)=6\>0BL&5Y50@Y![-VP:RIY=?T'Q]IFEW&NW-_I^N6]Q_K(XU>UFB4
M/N0JO"D'&#G\: /0Z*\KMO$VMS?#7P9K+:E+]MO-1M8+IPB8F1YBK C;@<>F
M*T+637=1\:>*+1O$=Y!9Z1/:2Q)'#$2R-'YC1GY?NGD>O3DXH ]$K&T+Q';Z
M]<:I!#;7$#Z==?991.%!+;0V1@GC#"N=T*;7/$OAS1?$MKK0MY;B9;BXMW4-
M!]G).Z(#&0P&/FSG(/;@<Z8]2C@^).HZ?K%Q826%[+<QB!$.]TMT;#E@<KQC
M QWY/8 ]=HK@KC5M0U+^SW_M&5/M.BK<K9:> )Q,V"96)^58P.!N(!.>O%9<
M7B_6&\'>%==U&*^GTVXM';4Y]-0>;')\H20J.=G#D[>^.W! /4:*\]M_$=QJ
M5UHFD:=J<FI0W5C->M>P.D4EPJR*BC) "GYCN  (*XX&:Z+PE'K]O875OX@E
MCFECN7^RRAE,C0'[GF;0!O'() YQ0!NM+&DBQEU$C LJ9Y8#&<#\1^=97A_Q
M%;^(DU%K>WN(#87KV4JSA0=Z!22,$\?-7,W]M-+\:]/ U"[C3^Q9I!&C+M7$
MT8( (/!XSWX'/%<R#JEGX;^(.KZ=K%Q92:?K=W<1QPHA61E2,D/N!)!'&!CO
MG/& #V2BN'FUS4-:\0G2+;SXDCTR&\?[-,D;L\I8=6!X7:.G=N:WO"BZ['H$
M,7B.2"74XV9))(2,.N?E)P  V,9QQ0!-JVOV6D36UM+YDU[=DBWM(%WRRXY)
M Z #NQ( ]:A3Q)$NIV6G7FGW]E=7K,L"S1JRMM1G/SHS*.%/!.?;&37)Z0[2
M_'SQ$+O[\.E0+9ANT1(+D?\  Z[^[6 1K<3H&^SDRH<<J=I&1[X)'XT 3T5Y
M@VOZW=_"T^.K74I$O51KP6F%-N8E<@PD8S]T?>SNW=\<5?2_U;6?'YTZ+6;R
MSTZYT*._6*../?$S2;<*Q4]@.H/?&* /0**\>DUOQ+'\,;KQ(WB"X:]TB\>!
M46*,)<JEQY9\T;<DE>."O;C.2>DU!];U'XEW6@0:_=65@VD)=CR8HR\;F5D.
MUBI_NCDY[XQG( .]HKS#1_$&N7&@266IZQ''=:=K[:9<72Q?OKV)1N B50?W
MC94<#@ GCK4,WB+78_"'CLI?W=O<:-.WV2298FE1/*5]C'!!Y)YZ^] 'JM%>
M?I=ZQIWC+PM#-K5Q=6^MVMP+B"1$"1LD2NK1X7(ZD<DYJ&TUS5M,;Q/H&H:C
M/<ZQ%(C:7+(J*9(IL)"0 H'ROD,<=LT ==JOB2TT?5],TZYM[PMJ#F..>. M
M%&W  =OX<D@"MBJ4>FH8K,74LEU+:C*R2'&Y\8WE1@9ZXXXSQ7#:SXDN=-\4
M7-CK5W?Z3%-=1#2[Y4#6<D>$W1N<':Y(<$MTR,$8H ]&HI&W;#MQNQQGIFO-
M_#7BJ:34X+'6[O4+'7;>"22]TV[0".ZPI)>!@,%01P >F<YQF@#TFBO.-,O?
M%NN:3H7B'3IMIN7CN+J*:>/[.UNW+(JA<AEXP<YR#G-6[*YUOQ?I&JZAI>L'
M3[R#49;>SC*@Q1K%)M(D7&6+ $GGC<,8QR =Y17'V.H7\WQ(U?2'OY7L1ID%
MQ$@"_NW=W!*G&<84=2:Y2#Q%XBNO 7@_4%UF5+R^UM;*XD,,9$L9FD7D;>P1
M>F,\YH ].O;][2[L8%L;JX6ZE,;2PJ"L "D[GR>!QCOR:M"6-I'C5U,B %D!
MY .<9^N#7"ZB=:\/Z[X2L3X@O+V&\U":.X\^.(&1/+=U!*J#Q@#C&?2H_"-E
M<OXS\;C^UK[*7L:*24;&8%(/*GIG@=/:@#M-)OWU32X+R2QNK%Y02;>Z4+(F
M"1\P!([9Z]#5VO+]"\6ZO=^"_!RS7#S:CK5Q-'-<#8C%4\QB%R-H)VJO3IG'
M.*T9?^$WTS3-?,:M=H&AETV,RH]T$W#SDSC!.-VPG)SC.: ._JO?7UOIUF]U
M=2".%,9.,DDG   Y))(  Y)(%<UX*UZSUUM0DL]2O)EB,:26-^FRXLGP<JP(
MS@\'))Z$9XJIXNN7E^('@;2&)^S3W-S=R+_>:&'*?D6S^ H [6%VEA1WB:)F
M&2CXROL<$C]:)98X(GEE=4C0%F9C@ #N37*W>JW&I?$)O#,=S+:VUOIHO96A
M(5Y6:38HR1PH )XZDCL"#PWB;5=5O?!_B72;^_N&GT75[:!;F/:AN(9)(RHD
MP,$@-SC .!Q0!Z;/XCMX/%=IX>>VN/M%U!)<1S87RRJ8R,YSGYAVK9KSS7+&
MX?XG>&K2+4KB.0Z;>AKK:AEQNCZ<;0??:?IWJE8^*]7L]#GL);R2ZNU\3/HD
M-W($$AC^\">-N_;E02,9(.#0!ZA17G]X/%NE6?B2X:^DAT]-->YLGEDCEGAG
M122/NX*'@\Y([8K7\%6^J2Z18ZOJ.MW%Z;[3[=S;O&BI$Y0$LI SSGG)ZY/H
M  =,\L<;1J[JK2-M0$X+'!.!ZG )_ UDZ3XCM]7UC5],CMKB&?2Y(XYO."@,
M77<"N">,8ZXZUS7BZVFG^)?@M$U"[@27[9\L3+A2L/W@"",_,1DYXZ8K*:UO
MI_%7Q'ELM6N=/> 6TJM;JA9G6U!&2P/R\<@ $^M 'J=%<#:ZWJ&K:3X2N9]0
M:/\ M#3_ #[BTLUQ<7,I1""O&%0$L225 )4$\UACQ-XAG^'&CZBNJ20W_P#;
M:V,LC11GS8_M)CPX ZX SM(SSSS0!ZU5/5;Y]-TNXO([*YO7A7<+>V4-))[*
M"1DUR^CW.IV'Q)OM!N=5N-0M)-+COT-RJ!HG,K(P78J_*0 <5:^)%_?Z5\/]
M7U#3+V2TN[:'S$D15;N 1\P/K]: .I1MR*Q4KD9P>HI:X75[K6)/'N@Z7;:S
M<6MG?:?<22I''&2K)LPRDJ>?F/7(]JN^ -0O[NSUJTU"\DO'TS5I[*.XE #O
M&H4KNP "?FQG':@#K:*Y?5=5GN/&^G^&HKA[6*6REO9I(\!Y K*BHI/3[Q)(
MYX'3FLK4-1USP]#I.C7>K+<W6J:P;6*]6,!XK;!<!LC:9,#;G&.<\XH [VBN
M#N=1U72/&TGA]=1N);._TR2[M9I KRVLL9PP!(PRD$'Y@<'VK!T[6O$*>&/
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M&TCQ';ZQJ^KZ;%;7$,VER1QS><% 8NNX%<$\8QUQUKDKCQ)<VGBU],UN[O\
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MHQMC*%/+.$&1MXW?>]"*ZV]L[?4+&XLKN)9;:XC:*6-NC*PP1^1K+G\36_\
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M4P6DY+R1.(V#D.3DJ<C@]#Z5>O/ VC:AX?N](NUFE6[G-U-<[P)C/D$2!@
MPP ,#  QC'%);^#8H]'O;&YUG5;V2\@-O)=W,RO*L1!!5?EVKG/)QD\9)P,
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MI40?:HC(@!<8Z[7YVXZ>]=_>^%;6XUN#6;.YN-.U"*#[,9;4)B2'.0C*RD$
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MK7O%,_B6'2KEK6?3[IK.S9;LQ")UC5@[IL.\%F/7(P,  Y)[?2FO&TFT.HM
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M0NBHP9$!V8P"!VR>Y- $%]?:EKGBS6=$M))(H].MX"ODW9@??*&/F9"DL!@
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MUC!8XRS,%4?4D@?C6/#XC67QG/X;-E-'+%9"]$[,NUU+[!@ D]0>N.G2N?\
MB;:K<#PJ6EG3/B"TC(BF9 0Q/H1SP,'J.U5KK2S>?%^6R6^O+:,>&HE:2"4B
M5@+AQ]\Y(]<CGWZY .XU2\NK&T$UII\M_*940PQNJD*6 +98XP <_A5VO(O[
M<UI_A+IM^=6NQ>0ZLMI).K -.@N_*^<XS]W&<8SWK6\:ZO>Z1JU\^J?VI!HD
MULD=MJFFRL5L)<'<TR*03R5.2",8'K0!Z/7*R>-@/$-_HD&@:M<W=C$DTWD^
M1@HW0KNE!/?C&:Z>*6.>%)HG5XY%#(RG(8'D$5YS;'41\9?$_P#9JVIE.F6H
M_P!)9@H^]@_*.?IQ]: .T\/>(=.\4:1'J>ERM) S%&#J5>-QU5@>A%:4SM'"
M[I$\K*"1&A +>PR0/S->9PZ9-X$M] \-17\CS:]JTLM_>HOEDDH694'.S=M5
M0<YQG&#TVK"[O=)^)TGAX7-Q<Z9=Z8;Z);B1I7MY%D", [$L5((."3@]* -#
M2_%DNM^"[;Q#INCW%PUPV$LQ(@?'FE"22<< %JZ6O&;&[O=/_9\TN]L+Z>TF
MBN$&Z$@;E:\V$$XSC#'IBNU-W)X@\<:WH4MY<VL&G6D#1);3-$SO*&)D+*02
M%PH SC).<\8 .QHKSKQ NL>&]&T+6[G7+G4(]+G6+5VA)C2XA+%3(44GYD)!
M..N#FNGT21M1U;5-42YE>R,@M;9/-)C/E\/(!G&2^5_[9Y[F@#>KF;_QBMEX
MI3P\FBZE=7LEL;I#"80C1AMI.7D7G/;WKIJ\ZU<W8^..FFS6%IO[!EXF8JN/
M.'< _P J -67XB:;_P (KJNN6MI=S-I3-'>63*L<T#KU# G'X@GVS75VTPN+
M6*<#:)$#X],C->8Z]X4D\/?#GQU?WEVESJ.KQR7-PT2;(TX^5%!).!D\GDUL
M3ZA>7WB/3_#D!Q"NC)>LJWCVS2$MLX=%+?+CH,?>&<XH [NL2R\1I>>+-1T#
M[%-%)901SF5V7;('+ ;0">/E/7!]JY$7OB'29/#OA;5]4CEN-1U">-[RWE)D
M%M''YBQLY52)#E5W 9QR.3FEL+6YTSXE>+AISS7-P-&MY+9+F4R8?,FU=S')
M&X=SW]* /2*I6UY=3:I>VLNGRPV\ C\FZ9U*W&X$MM .1M/!S7G&GWFJ:K%X
M-?3M7U(WMR#_ &V@DSY8"9<LK K%B08  &0<#-:<%YJ3>)/B#9G5;O9:6UM)
M:G*Y@+1.QVC&!R/3- 'H-%>36-YJ]KHGP]UQ]<U">XU*XMK6ZBEES%(DD3$Y
M7'W@0#N/.<_07=;U746N?&<%Q?7EIJ%I$CZ)%;R,OF QY0JHXE+2 @@@^G%
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MMPMU;SVTFR2*1<@$'!'0D8(/6MBB@#E#X TLMK3"\U+.LP""\S<[MZA-A/S
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MT9G@/^K4,P8A\# -.N?&TMG/IT-SH5W ]WJBZ:PEECQ&S)O#?*3N!7GC\<4
M=9%&(HEC#,P4 99BQ/U)ZUSS^#;,WFI307U_;1:FV^]MH95"3-M"DY*EE)
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M-(^#L/C9];U.YU-[$0;9Y]\"&28+YI0]64'.3]#QP/3K?0+=9Y[Y[JZFOKB
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MT5J2ZX"L &!&.<@ <^GK4)\%Z9YNH!)KR.TU&5IKRR6;]U.[?>)R-PW8Y"D
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M9B8V^_@K@X!/3H>X/%5(KS4TT+P!XC;6-0DOM1O+2VND:<^3)'*C;@8A\N>
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MDX&2<"H_#WAK3_#-H]IIQN!;ERRQRS,ZQ@DMM0'[HRQ_.@#!^+O_ "2O7O\
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MG(YSAL$#&*L^&TD\7>#=/\2R:W=6.HFZ:YFF25MD:I(P,!C)VA-HVX(]SDT
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M=;J6TF<23L]T[2SL"""\A.X_=7OV Z5T=% &0WANQ?7;76G>Y:^MH3!&YF.
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !117G7Q)DBM?$'A"2:[EM;:?4#%=,MRT2O'L)PQ!'&10!Z
M+17*Z*/#]SXAD;1-1DGELX!YZQWCS1%9"=N<L1N!C)]<'WKJJ "BO+_B3HRZ
M+X2FU"VOM0%[-J43-,+V8862?E0H;  !VX Z"NCU5M*\ 6=YXB<ZD]FL*I-
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO($RN_)!P"3C Z@UK:E;W+_%+1+]+.Y:S@L+B&6=8F*([E"H)_X"?IWKLJ*
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M6&L6-Y9Z;&+?4[".036LP 5HR%!)!P.H(.#R,BNS\*C6!X6TX:^0=4$(^T$
M#+=LXXSC&<<9S6Q10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=I/\VXS*.>Z8R",#UR:9<6KZK\77CM]3FMXY?#43&XM"N]E,[8VL00 >N<4
M>C45YEH>NZGJ/A+0&OM8?S6O[BVN%B0_:;Y8VD553;T/RJ6;C@$DBLV[\1>(
M$^'WB*YBU.ZM[O3-?^Q0M((W?R3+$H20@') D(R#G@<T >OT5P5X^JZ5XCT_
MP^NK7E^=3-Q>,\TJ0NJH$'E(RKP,L6X&<#&>M5KE_&FB:-+]J274[>+40YBL
MY@UX;$JWRYPNY@VWD<D C/>@#T:BN<\%ZM9ZUH\UW8ZG-?P&Y95^T B6# &8
MG! .5/KV(.3UK&TV\U#Q?!XFN(-3N;&:PU">PLEA8!8C$H^9U(P^YB20V1C
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M4$H7RP5@\Q60 9!R.Y).: /1**X_XAWVI:?IVDS:;J$EH\FK6MO(%52)$>0
M@Y&<?0BLY(=6'Q%O/#A\1ZDUC/I:7Y<^7YL;^:4(1MN%4C!QCMQB@#T&BO,M
M&UO4[SPIIB7NM.)$U>>RF94S<WL<;2!43:.&.%)88P 3D<FLW4/$6OP^ /&$
MT6I7EM<Z3JPM[9I/+>18F,7R.V#G'F-R#GIS0!Z-K?B.'0[[2;6:UN)/[3NE
MM8Y8]NQ'()^;)ST4] >E;->7>.;>[\/'P_>W-_J&L'_A($N5A*)O7$$N4C
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M:U<W4<F@/*)XI,)*0T0+ 8X#=3WZ>E:OQ2#MX>TQ8W".=9L@K$9"GS1@X[T
M=Q17F&L:QK7@'Q%.LFJW6LV%UI5W>I'>!-\,T"AN"BKA&R!C'%:VGP>*7O\
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M(X(Z$$5JT4 8D/AFU:XGNM2FDU*YFMC:-)<*H A/WD"J  &[]SQS@ #.\/>
MK7P]-$(M7U:ZLK<DVMC=7 >&#TP, G&>,DX^O-=910!C>(?#D'B-+!9[RZMQ
M97<=Y']GV<R(<KG<IX'I56;P987>M:AJ5Y<7-S_:%F+*XMI-GE-$,X'"A@?F
M/.>]='10!ROA[P/#X?:,+K6KWL-NI6TAO)PZ6P((^4!1D@$@;LX!P*@_X5QI
M3^&YM$FO+^6)[PWT4Y=%EMYRQ;>C*HP<D]0>M=C10!S-AX.6U\10:]<ZSJ5[
M?Q6AM"TQC57C+;L%40#J!T].<U;\1>&H?$BV"SWMW;"RNX[R(6Y09D0Y4G<I
MX'I6W10!@7/A6&375UNTO[JRU$P"WGEA"$7"#D;U92,@]" #VZ<55N? FGSV
M>F6T5Y>VZZ?>_P!H*T3(6EN,L2[EE.22S9Z#GZ5U-% $5Q;1W=I+:SC?%+&8
MW&<94C!Z5R%K\-[*VBT:,ZUK$HT>3=9EYD&Q-I7R^$&1@XS][T(KM** ,?Q+
MX=@\3Z8MA<W5S;PB9)B;<H&+(P9?O*>,@&HW\,QOXIA\0'4;S[7%:&S"?N]A
M0D,<C9G)(!Z_I6Y10!QTOPZL9M!U/1WU74S;:E>F^G.8MWF%PYP?+X&Y0<>U
M::>&(U\3MX@_M*]-XUF+(J?*V>6&W9QLZ[B3U_2MZB@#CO\ A75B/#J:)_:N
MI_94O?MH;,6_S-_F=?+QC=SC%:D7AB.+Q-<:^NHWINY[5;1E/E[ BDD$#9G(
M))Z_I6[10!QY^'=@?![^&#JFI?8'G\\MF+S-WF>;C/EXQOYZ?I5VX\(13>(?
M[9CU34+>>6W2VNTA=%6Z122N[Y<J>3RA4_2NCHH XVQ^'-AI]AH5G#JNI^7H
MLS36NYHCEB"#NRG(^9N/>M.W\+16VMZOJT6I7HN-52-)A^Z*H$!";1LXP&/7
M/O6_10!E>&] @\,:#;:/:W%Q/;6P*Q-.5+!<YQE0 ?RK5HHH **** "BBB@
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M!<36TB+]J0=!(I4@D>H (]:N^&O#=GX6TK^SK&6YD@$CR#[1+O(+,6./Q)H
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M$Y; '7YO:LK4=,M_B7IVH+>&[M+" M'8J\3Q2+*/^7DJ0#P>%'IN)Y;"[O\
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M,QM((S(Q?:V" 3+@9 SMST();_PBG_4?UW_P-_\ K4?\(I_U']=_\#?_ *U
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MX13_ *C^N_\ @;_]:@# \=#_ (3K0U\,:-YDRWL\1N[L1D16T*N'8EB,%CM
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MH_X13_J/Z[_X&_\ UJ .-\=7":OX4\/I!IEXULFM6S+ ]K(SFVC8J7=-N5!
M)P>Q'KBKMM:MX \6/-86<LOA?77\QUMH&<V-SC[VU1GRV'M\I]!UZ7_A%/\
MJ/Z[_P"!O_UJ/^$4_P"H_KO_ (&__6H P?BX7N_ 1@M8)[F::YMW2."%I&*K
M(K$X )X KH/%MPDO@;6&B$DAGL)DB5(V9G9HV  4#.2:;_PBG_4?UW_P-_\
MK4?\(I_U']=_\#?_ *U 'GNOK)/\"-#TY+.[DO$2RCDMEM9#(IC*%P5QD8 -
M>I6>GZ5;.=1L[6" O%M9XH@FY <\@#MS^9K/_P"$4_ZC^N_^!O\ ]:C_ (13
M_J/Z[_X&_P#UJ .!TCP_)XG\)?$'0F2:VFU'6;JYM6N(7C#KE&C<9'*EE'2N
MN\->+85T6TL=9MKRPU>VB6&>UDM9&+.HP3&54AU.,C:3UK0_X13_ *C^N_\
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M6T^_00>8PMFY#XC0<*W//KQ76?\ "*?]1_7?_ W_ .M1_P (I_U']=_\#?\
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M=OJ>] $U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,D@C0NP7GG:H)/0_E7.>"-4UC5'UK^TKF*>"RU&6RMY%@V&54Q\Y(.">2IP
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M6.(+T"@ #'X5S4U^8?&%KX/TN3[#']AEU*:6-59@IEVA$# J,LS$Y!P  .O
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M\<^.]8F0R)9Z39S; <%B!+@?B<"@#M-6\06.BW6G6UYYPDU"Y6V@V1,RESG
M+=!P">3GBM6O,/$L>J2?\('?7^I>>;C6K9Y8!$BQH[1R$;"!NP!N'S%L\'BN
MM\3ZY<:;=:1IMFDC7.IW#1!HPA9$2-G8KO(7=\H SQSG!Q@@'145Q5LGC>X@
MURT:5K9H]KZ3?7*0,\F5.Z.5(R5P&XW #@Y]JA\&>*;WQ!IL^LW=PT5OI\'D
M7=IB-F-RBYE;*CA>FT=^O3&0#NZ*\^L=8\7ZG::#K6GVLTUO>O%+=VLGV=84
MMY!G=&P;S-R@CKUYX'2K%AJ?B+Q1H)UW0[ZWA<WKI!93H/)>&.4QMYC;2X<A
M6;Y2 ,@8ZD@'<TA95(!(!8X&3U-<;9:QJD_B/QGI;WI\K38[=[1Q&FY#)&SD
M'C!&0.HZ?G7,0ZGJ_B"Z^&=[-JLT$FH1W$LRPQH$\P0,=V"IYP2.>!GCF@#U
MJBO/KG7/$VLV^L3^'8[CS["\DM+:+;;F&9HB PE+L'&3N^[MP,=:Z;6KW5(/
M",UY;"SLM1$".WVR4>5 3C?N8<':"WL2!0!MT5Y[;^)=5_MSQ!IEO?23Q6^E
M)?VEQ>V@1U8EP1M 3<IVY!P/Q%4['Q)XECTSP/K5WJ4,\&M306MS:+;*H_>1
M,P<-UW KT&!SC'<@'H6JZG;:-I=SJ-WY@M[:,R2&.-G(4#).%!-/T^^AU/3;
M6_M]WDW4*31[A@[6 (R/7!K@-4U74/%/@SQC?6M^;2TM%N[2"!8D82K$A#LY
M()^8[L;2,#'6M_1YKFW^%FG3V<B1W$6C0O&[IO4$0@\C(ST]: .IHKS*P\1^
M)H?"VAZ[>ZE#=-K4=K;0VD=JB^7-(03)N+ $[0WRG SCM4NN3^,+;2/% EDO
M(=,CTB6YM;Z4VZW$<R*28\1D@J0,AL CGG.#0!Z.K*ZAE(92,@@Y!%+7G5AJ
M.J:/'X M$U%YK;4T$4\<L4?"BWWJ%(4$8(]ZBUGQ3KUC!X_%M?1[M$6&2T>6
M!6(#Q;V!Q@'D\$Y_&@#TJBO.-9U+Q?H]KH]Z=;LYEU34[*W$!L0!"LF=Z[MV
M6!..< ]<8K8T#4]7B\<ZOX?U._2^BBM(;R"40+$4WLRLF!U&5R,\^YH Z[<H
M8+D;B"0,\D#_ /6*6N!G-X/C.RMJMRMK%H?V@0A4*J// 91\N<'8"3U]^E57
M\4ZY<_#EO'5G=* H>Z&FM&IB:W5R"I;&_?M&=P.,]L4 >CD@ DG '4FLNY\1
M6%KX@T_1)#-]LOTD>#$1V$(NYOGZ=,<#)Y%<_P#$*^ENOA-JFHV%U/:^98^<
MK)@,490=IR#C(.#CGWK*UBVOE\9^ 88K\M<M;WV+B:)25!BC_A7 .!T_7- '
MI5%>;6GC+6+*PU&PO)EOM1AUY-(M[E8D0NKA6#%<A=P4L.H!(%=#H4OB=/$=
MY;ZC!/)HS0+);W-T8%F27.&C(B."N.0<#TYH V-4UO3]'\A;R8B6X8I!#&C2
M22L.2%102<=\#CO5>+Q+I\FHVVG2"YM[VZ+>3#<6[H7VJ6)!(P< <X/''K7(
MZ-(][\=_$AN^6L-.MXK-6_AC<!G(_P"!<9_"N[OX[58TOKI,_82UPC8Y0[&4
MD?\  68?C0!;HKS:X\4ZZGPZB\=PW*L-HNI-,,:>4;<OC:&QO#A>=V<9!^7%
M7;?5/$&M^,=;TFTU>*SM(K*VN;:1;16>/S-YQAB03P,Y_ #.: .\HKRF#Q;X
MGD\":%XMEU"W >ZBM[FR2V&V93-Y3,6/(;^(8P!TP:US>>+-8\7^)]$L=:M;
M&.P2V>WE^Q!V7S$8[2"<'D<GVX S0!U6J^(+'1KS3K6[\X2ZA<"V@V1,5+G)
MP6Z#@'OGBK$&IQ7&K7>G+!<K):HCM(\)$;A\X"MT8C'..E>8OX@N_$N@^!+[
M4(DBOT\2+;W*Q_=,D:S*2/8XS^-=/;ZYK;^*_&&G+-:2C3[*":P21/+17=9#
M\[9)(RJY/IV% ':45Y]I/B/5'\6:7I?]I&]AO],EF::2V C6=-GS1$!=\9W'
MUSQAJQH?%7BM? -IXJFU2W;R=1\B:U6T4+/&;HPG+=5(&,8].<YH ]:HKCO[
M2UCQ%=>(X-&OUL9-*E^RVP,:L)9Q&')DW*2$RP7"X/!.>@$<NM:W?:Q+H<8F
M@N[.P@FNY=/$+_OY=W"^<1\@V'MDY'(QR =K16/X6GURX\/6S^([2.VU4;EF
M2-E96P2 PVD@9&#C/%;% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%175U;V5K+=74T<-O$I>22
M1@JJHZDD]* ):*YY_&.FQ6B7T\%]!IKX(OI;9EB /1C_ !*O^TP ]ZU-0U6T
MTRQ6\N)?W3ND<6SDR.Y"HJ^I)( ^OI0!=HKFXO&=G+<261T_48]369H5L9(U
M620A-Y*MNV%=O.=V.@ZD V/#GBBW\2K<M;Z?J=JMN55C>VIA#,<Y"YZ[2"#Z
M&@#<HHHH *R+K2+JY\1V.IF^C%O:(ZI:F#.6< %]V[[P ('' 9NN:UZ:SJA4
M,P4L<+DXR?04 <WXJ\*2^([W1[RWU$6%QI=S]IAE6#S&)Q@J?F'RD=1W]:D;
MPW=MXT@\2'4HM\=D;(VXMCM9"X<G._(.0/H/6KFF>(K+5M7U73+=+A;C3&C2
M?S8]@RZ[EVYY/'/3N*UJ .*D^'5O<6&OZ;<ZG</I^K73WBQ(BJUO,S*VY7ZG
M#*".G?.:L6?A361IMS;:KXHEU.9[=[>"22T6-8E88+%5/SOCC)/KQR<];67J
M/B"QTZ^BL&,L]_,A>.TMXS)(5'!8@<*N>-S$#/&: #PYI#Z!X>L=)>Y%R+.%
M8$E\O82JC R,GG JGI/AN73?$>MZM)?).NK-&TD'D;0FQ-BX.XYXZY'7TJU9
M^(K*[U8:44N8-0\AK@P3PE2$5E4D-]T\L.A-:U '$Z)X"O-"E^Q6WB6[/AU9
M3)'I;0H2@)W;/-^]LSV].,\G-:?X:W$FE7FEQ^(YTLY=0_M"!#;(QBD\T2$,
MQ.7&<XZ=><UW]4+[58[);)EM[FZ2[G2%6M8_,";@2'8CHG'+>XH P$\&7=CX
MCN]7TG7)+4:@B"_ADMEE$SJNT2+R CXZ\$'TJE:?#J:S\/>'=)36RZ:+>+>1
MR/:C]XR[L+@,,+\[>I]ZZ75?$%OI<WV9;:YO;L0-<FVM%5I/*4@%L,0.I  S
MD]@<&CP]X@@\2:<U]:VE];PB0HOVRW,+2# .Y0>2ISP?8T 9D7A*YBU#Q+>#
M4XR^N*BNIMCB';'Y8Q\_/R^O?\JX_7[.'0D\->&KOQ*FF0:?:,8[Z\LD>VG(
MPBHP<E?, #'.1@'@<\>LTC*&&& (]"* .3\%3Z@XN(9-7L]7TV-$-M>6MF+=
M-V3N0;258 !3E>F<?1\W@^?^V]=U"UU=H8]9A1)H&@#A76/RPP.0<;><>H'.
M.*V]3U2/3-.:\%M<WB*ZQ^79Q^:Y)8*<*/0]?3!J_0!QG_""S_V)X:TP:L@3
M09XIXG^R\RF-2JAOG]&.<?I5A/"-Y%J7B"^AUGRI]7>&0,EOS T0 4C+<\#D
M'K^E=710!@Z=X<^S>)+C7[N>&74)[5+5C;P>2A16+9(+,2V2.<\  5!/X6N)
MO'=OXG&I(K06K6BVWV?(,9;<<MN^]G'/3VKI:;)(D,3RRNJ1HI9F8X  ZDT
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M@6,9$OEE@A)Z@@KVZCKFF#7/%$.B^!]8_MM9&UJ2VM;BVDM$\K,L);S. &W
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M5D5U7=A@ 5P<-CN" ,YZUJV.GP>&O#$-A9"8P6%MY<7R&5R%7CY1RQ]AU[4
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M'I[T 5++QAK%MI4]C=7#7E^OB-M%BNECC5V3;Y@;;\J;]H('09P<'H9]5O\
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MG[(C)&V6)SAB3DYR<D\YKC/%?@74=4\3&\MEA2&]G".UN&7:HMY%\R?YQO\
MF(3Y-IVL1GF@#TL$, 000>012U2T>S;3]%L;)X[>-H($C*6RE8E(4#" \A?3
M-7: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *R]?T;^V[".%9_L\\%Q%=02[=P62-PRY7(R#C!&1P>HK4HH QY-+U"X6
MYFFU"*.\>U>WMY((2H@W=7P6)8Y"GJ/N_C5,>$X;O6Y]4U06L\DUI]DD2" Q
MK*N\-E_F))!48]!GKGCI** .<;PQ);Z[8:AIES;6L-G9RVL=N]NSC$CHQ.0X
M[H./<U7/@B%@UVUX[:PU^NH?;C&/]:J[ NS/^KV93;G.#USS75T4 <Y?>$X=
M=N99]<D2Y#6<ME'%$A18TDQYAY))8[5Y[ ?4U=TNPU6SMX+6[U.*YB@ 42+;
ME)9 .FX[B,^I &?:M:B@#FD\,7$^I:-?:E>07$^E%C'/';E)9<HR89MQ^7YL
MD#J0#QC!L:GX?EOK(6L-VD*+J,5\FZ(OC9*LI7[PZNI.>P;VK=HH RM2TF6_
MU;1[U+E(UT^=YBAC+&3=&T>,Y&.')Z'I6==^!]*N-:T_4XT:&6UO'NW4.Y$K
M,KC^]A?F?=P.<8[UTU% &(NCWLU_#J%[=VDE[:Q31VSQ6S(J^9CE@7);[HX!
M'?VQ7N?#$FHQ7\M]=Q_;KRT2U:6WA*(%5F8?*6)()8Y!/3CCDGHZ* .9F\-7
MR+J,NG7]K9W.HS))<'[(S1L%7:<*)%(9N,MG. /K4I\/WDZV3WMY:3S6RRQM
M&+/;;O&ZA=HCWG! &,ECP6'0\=#10!R0\#1P6!M+2^:))M,72[AFCW%HEW;2
MO/RL [@9SU'ISLM9:G!$8=/O+.&%#&MO'):LX2-5PRDAQDGL>,>AK4HH IZ;
MIZ:=;R(K!I)97GE<+M#.YR2!V'^'4]:N444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
6444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>elicio-powerofattorney20001.jpg
<TEXT>
begin 644 elicio-powerofattorney20001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !161K?B?1_#KVR:I=F![G=Y*B)W+[<;N%!Z;A^=/T;Q)I'B!9C
MI=\EPT! E3!5X\]-RL 1GMQ0!J4444 %%%% !114-U=V]E#YUU/'#'N5-TC
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M\+7*)YAAEADA<IG&X*Z@D>XXH VJ*** "BJ*:SITCVBQW<<GVN22* Q_,'9
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M'XDD #O0!:HK&T?Q7HNNW4EK87A:YC3S&AEA>&39G&X*Z@D9[CBMF@ HHHH
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MA(8KI]V%B8*&()Z< C/I^%5=)\4Z)KCR)IU^DKHGFE2K(2G]\;@,K_M#(]Z
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MKI%I#>99A*D8!4M]XKV!/<CK2Q>%]"AU<ZM%I5JE^6+^<(QG<>"P[!CW/4T
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M;V$'E1'2K65R279W,L^69CDLQ]22:[JH%LK9+Z2^6!!=21K$\H'S,BDE03Z
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MO7).3G''7C.T;X=7>F_V;ISZ1I+PV-PCG4WN)&>6-&W+B' "R<#G<0,9&>E
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MYH65]B.-K%64G/(;C!K$F\!WL_P[TC1I/LLE]IMTMT(W=A#,0SY0L!D JYY
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M5.T\0:X="TOQA+JCO9WU]'&^FF&/RH[>67RD*L%W[QN5B2Q!Y&* /2J*\_\
M$-UXET2W;5I=;'VN74%AL='ABC:&>-I JIDKYA<IEBP8 <\8%4-5\4W9\4:U
M'-XCU/2=,L;B.W5[?2UFA3]VA9I)6C8+\S$<GC':@#T^BD4@J"#N!'!'>EH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'"$$ G;ZCGOGGC1\,0:QX"TKP9X4E2WO7NGG2[D$IW0XS(-@ZE1D@GH./44
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M#M;'0X(.#ZBI: "DP,@X&1P#2T4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MGRZ7X5TZVN/^/KRO-N#ZS.2\A_[[9J\FT35[K2?AA!-/X+LKS3BTT;W\\Z%
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MC_A(/$O_ $)5U_X,+?\ ^*H Z>BN8_X2#Q+_ -"5=?\ @PM__BJ/^$@\2_\
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M#7DL/BF<>!H-:_X6<C:NUBMQ]@9;1]TQ0'RO+5 _+?+@'(KUO4X)+K2;RWB
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MNGTXWLABN#(JD2[-H)49X(.>/3'>J_B2UN)_%W@^:*"62*"\G:9T0E8P;:0
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MO3([2[CCF#'56+*C@'.WR>N#TS3YO$^MWFKZG9Z!HMI=Q:7*(;A[J^,#22%
M^U%"-V8<L0"<^F:Y'PO#X:T_3]%,^B^+$U*WB@\S,&H&-95"Y^7.S;N'3&W'
M;%7]>BTB;7[]_$'A[5K;4$?%EJ>C0W!:XBP-OSP_QCD$/QP,<4 ;5YXRU)G\
M/P:7H.^[U>":8P7\YMF@\L)E6^1N?F_3WJ34O$^OZ%X8U76-6T&S1K1$:&&V
MOS)YQ+8(),:[<9'8Y]JXW4+&^F3P3/XKL=9NQ#!>BY:TCF:9-Q3RO,,'(8J!
MGU(-7]3M]-NO >OV/A[2M>6:18F:.]ANRSXD'W/.R3QG(7\: .ID\:VK^&--
MUNS@::.\N[>U:)VV-"TDHC8-P?F0DY'M5'5?%7BC3=>L=,7PWITO]H32QVLA
MU1EW!%+Y8>2=N5'3GFL;QEX?U/3]>LYM&M)+C2]4U:SGOH(E)^S3QS(QG '\
M+*I#>X![FNF\0VMQ-XV\'SQ02O#!<71FD5"5C!MW +'MDD#GO0!'=>)M;&IV
MNB6FC63ZR]H;RX2:^*P0IOV !Q&6<DC^Z,=ZU] U6[U6TG-_IDNG7=O,T$L3
MG<C$ '=&^!O0@C!P.X[5S7C./3IM:AC\1>';F[TQ80UKJ5C#+)-!+D[E8Q?.
MH(VD$<'G-'A74;G1M)O[B_\ [7?2&OXX=,_M!&:Z$;[%R^?F">83@MR!U[4
M='XG\1V7A70I=5OF41HRHJEPI=F.  3^)^@-9J>/M#36+ZSO=1L+2WA6!K>Y
MENT"W(E0ME<X& ,<@GK3_B':SW?@74HK:WEN)1Y;B*)"[L%D5C@#DG / K'M
MM/74-8\9ZA_9LIBO]/MTMVGMF5I%\ELH P!SDC*]<]: .MU/Q%HNC"(ZGJUC
M9B49C^T3JF\>HR>15*;QAI$7B?3]"^UP-/?6S7,3B9<$ J% YR2VXD8ZA37!
MVC:I:#3()[:]T]AH%G")[?26NI[IMIWPEBI6/:>S#JQ).!4_A"UO-*N/ SWV
MG7L872+FRD/V9V\F4R1%0^!\@PC8)P.* /2=1U33]'M3=:E>V]G;Y"^9<2!%
MR>@R>]12:]I$6DKJLFJ62Z<W*W1G41-]&S@UR7CNSOAXE\/ZM'->0V-HEPDD
MUI9BZ:"1PFUS'M8D$*R[@,C/H37/Q07VGV%K<Q6U^+>YUJ:Z:_N]*\V6V_=;
M1*EL@!3>P(R5XW$D<T >F0Z_HUQI3ZK#JME)IZ9WW2SJ8UQURV<"LK4?&^DV
MMGIM]:7EG>6-W?+9R7,=ROEPY1V+%AD<;>AQUK@;;3M2+7]_<6.IW=I%XBMK
M^83V/ER7, @"F01*HSA]K;0-WR\C=6UJD,'B+4]/NK/P[<):'7K666YFMG0W
M(2&3,C1LH*JIVKN8<GZ4 =]IFK:=K-J;K2[^VO8 Q4R6\H=01VR.]5[SQ+H6
MGW?V2]UG3[>XWA/*EN45MQ (&"<]&4_B/6LO0;.6V\;^*YC;/%;W#6K1N4*K
M(1$0Q!Z$\ &N5NKZQM_$_P 0+2;1[R]N;WR(8_(LWF$V;5 (RR@A>3GYB!SG
M/!H ]!U+7]'T9XDU35;*R:;_ %:W$ZQE_ID\TMYKVCZ=-%#>ZI96TLVWRTEG
M56?<2%P"><D''T->6II6KZ!J<IU:ZU-?/TFSMEEL],%\)C''MDB)V,5)?)YP
M&W=>*V_"?AV2R\2:6UW87!2U\.101R7:!FC;SF.PL!MW ;>G84 =I:^(M%OM
M1DTZTU>QGO8L[[>*X5I%QURH.>._I2P>(M%NM4?2X-6L9;],AK9+A3(,=?E!
MSQWKS70[;4+;4M)T_3(+]HH995-GJFF8;2PR/EX[H*%;D@#EBP;K4EA;R3>&
MO"OAN#1;ZWUK3;VVDN9'M'6.'RV!FE\TC8P<!L8)+;_K0!Z&GB?0'U"/3TUK
M3VO)252 7*%V()! 7.<Y!&/8U?FNK>WDACFGCC>=_+B5W ,C8)PN>IP"<#L#
M7F::%<1_#O8NERK?'Q$+HJ(#YF/[0SYF,9QY?.?[OM77^-[.>?P]]LLX))[W
M3;B*_@CC7+.8VRR@=RR;UQ_M4 :YU;3A%<2F_M1';2^3._FKB*3CY6.>#\PX
M/J*Q=&\<:1J<\EI<WME9WXO9[6.T>Y7S)/+E:,,%.#\VW.,?G7"Z-X<UB/7-
M+M+BRG%GK#PZUJ<C(=L5PC22-&WN7: 8/9#5Z70KA?A_K2)I<HO9?$+W*J(#
MYC#[<")!QDC8,Y]/:@#T"Y\1:+9ZG'IMSJUC#?28V6TEPJR-GIA2<\]O6DNO
M$6BV6I1Z;=:O8P7TF-EO)<*LC9Z84G//;UKSW4(7MM#\8Z!=:+?76K:K=W,E
MHT=H[I.)/]2WF@;5V?*#N(V[/I577+34=/NM3BM(K^;4+CR&DL+G3#>6>IR+
M&BAQ(%_=?=P=S#&W.* /3;SQ#HNG7\5C>ZM8VUW-CRX)IU1VSP, G/)J_++'
M!"\TTB1Q1J6=W8!5 ZDD]!7D.K:=?P7_ (LM;]M7SJLQ>&&STQ;E+N-HU54$
MI0["I!&&*@?>'6N]US3?-^'EQIMS;7E\?L*Q210NOGR849P>A?C/H3]: )I?
M%>EW&BWNH:/J.FZA]E7+8O46-3VWOR%'N:MWWB+1-+O$L[_5[&UN77<L4]PJ
M,1ZX)Z5Y=?Q:QJ6B^)(88KK5H7TM4COI](:TNBXDX@QM7S  2V0O!^M:&ONN
MDV7CVWU+1[N]DU$23P7$5L98WB^SJJJT@&(_+*L?F(]1G- '?7GBGP_IP4WN
MMZ=;[@I7S;E%R&&5/)Z$ D5)J7B'1='BAEU+5K*SCF&8FGG5 X]5R>?PKC/#
M&D&74M5N;BP+)+H&GP12219#_NY=Z*2.?X<@>U8VF'5=/MO#\%Q;7FFE/#]O
M#]JATE[JXE?G= 201'MP#AASGKQ0!WUSXQT>V\0:3H_VRW>75(7F@=9TVE1M
M"XYYWDG;CKM;TK535-/DMK:Y2^MF@NF"02"52LK'. IS@DX/3TKS+PK:7NEK
MX"DO=-OH_)AO[2;-LS&%WE39O"CY0=I^;A?PJ/2FNSH'@W0/[)U-;[2]3B-Z
M7LY%CA5-XW;R-K Y!!4GCDXH ])B\1Z'-//#%K%@\MO&TLR+<(3&BG:6;G@
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MW+G=R <;LBIH=#FO3;7)MM2N[:Y\2V]S(;RS$(=4B8-+Y04;%)"@E@,D9[T
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MR,.W/?CI7/3_ !#OS#86P-M:W-W=WR-<_9);A8HK>8QC$:'<S-E><@#D^@H
M]+HKG/!VOW6O:==/>0[9K6Y:#SE@DA2X4 $2*C_,H(;!!S@@\URWB+Q]J6D7
M6H30W^ER)97(C_L^*UFG=H]R@EYE.V)N2<%<#@'- 'IE%>?:KXF\3H_BRZL&
MTN.S\/ON$<T#N]RH@25E+!P%/S'!P>HX&.7ZAKFNZ^-=@T<V%O:Z?:H)$N8F
M=[AY(1(5#!@$ 5E&<-SVP* .]R,9R,=<U4M=,M+2^O;VWCVSWSI).^XG>50(
MIQT'RJ!Q7,6/_)%;;_L75_\ 2>L@^);[3M*T6QM=4TVRQI%O*J26DMY/*Q7&
M/*C(*KP/FYR2<=* /2J*\W@^(NHOHJWTMI;+)>:)'>V$8#8:Y+^6T9.>1O>'
M&,'#&J.M^+M6U[P3?QVGV6VE3P[<76I,8V8QR_-'Y:88;3F.?DYQM'![@'JD
M<B2KNC=77U4Y%+D9QD9ZXKC/!TTNFZ@OAH6^GQVUMI5O> V=L807DDE!^7<>
MR+[DY/? S/"FL7&O^+=#U6[2))[KPY+(ZQ A0?M$?0$D_K0!Z/17(^+/$-WI
M>I6ME;ZGIU@LL+2%IK:2ZF=@0 $AC(.WU;GTQ7-V.O:YXEU7P1J$=S:VGVE+
MX30FWD*L\1V,=I=2,@< \KDYSTH ]2HKRWPMK7B"+0-&TN*[LYM0U2^O]ES/
M Y6".*60N2N_+L3C:,K@$9SC)O7OC#Q%9R2:.(]-DUB+5;>Q-P8W$+QS1LZR
M;-V5(QRN3TX// !Z)17 2:SXQ?4-9T^"YT97T>TAFDF>TD(N'9&8J%\SY1\O
M7)Z]*IS?$2[OKBR@LY;?3M^F6]_+)-83WF7F!*Q@1D;0 #EB>_ ZT >ET5PV
MF>.KF1]+N=7M4L;&^T^>4ET96CG@8^8#NQ\I0%ER <*:S+WQMXBMK+2[B]^Q
MZ1!=V7VLW4VGS7$(=F)2%RC#RR$VDL>I)QC&* /3*Y[4/!>B:K>7%U<1W/\
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MU]#?S7<K)YDLD7W%("A0@'&U0*U[77M)O8+6>UU*UFBNI#% Z2@B1P"2H]2
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ME2^U/4;VXFNX+N2XF= Q:%PR*%50BKE>0%&<GG/-;FH:E8Z39M=ZC=PVMNI
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M*89&%"*RC;QP<,>N:RAX&M[9;)M+U;4=-N+:QCL&GMS&6GAC&%#AT9=PYPP
M(R:T;GQ;X=L[X65SK=A%=&3RO*>=0P?C@C/!Y'6H?$7B_2/#MO<K<ZA9K?QV
M[S16LDP5I, D#VR1@>O:@#"\3>$AJ.FZ)X6MK"[EL89TEFOY9P?+C7(D#$G<
MS.K,O Q\Y],5OZKX;:_U 7MIK&H:9,8/L\GV4QE9(\D@%9$8 C)PP /-1_\
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MN:W:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+39[/48HY;.5=LJ2' (^O;ZT >7^(;EO$'B'5ULM%OX)Y/"%]"@GMC'+,Q9
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MND\-6=K&SQ'YG"2[XQQR<[<CZ5&WA[47TOP9:VEI);30Z)<VTDGEE?L\CVZ
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M,?VB!;>\V3)_I2@$9?*'#8.,IM.*VY]'LKC09-$:(K826QM#&AQB,KMP#]*
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M,34GU, N,>:\9C(Z?=VGIZ]Z (O"VJ:E=7FM:7JLL$]SIETL0N((C&)4>))
M2I)P1NP>>U9XU7Q/K-[K$VBS:=#;Z9>&TCMKF%B;EE52Y:0-\@^; PIZ9.>E
M=+9:1;6&I:E?0F0S:C*DLP8@@%45!MXXX45CZCX'L-1NKUS>ZA;VNH,&OK*"
M55AN2 %)8%2PR  =I7('- &1=>(O$ES:>(-9TZ6PALM&GFB6SF@9VN?)&9"9
M PV9((7"GH"<YJ&;Q/XDU277[C2;FPM;/3+6&ZA6XM6D>;? )=C$.-H[9&3S
M[<[=[X#TZ\FO0E[J%K97[;KRPMY56&<X .1M++D  [67/>M%?#5@C:N4\Q1J
ML:Q3JI "JL?EC8,<?+]: .:@U_Q)X@U9[72KFPL(5TFUU#=/;M,V^7?\GWE&
MWY>O7CWXS?\ A8FH:E'HD,##3Y;S2DU&YFCTV:^P68J$5(^@RK'+'I@=>:[?
M2_#5CI%TUQ;-,7:R@L3O8$>7#NV]NOSG)K.3P'86UKIL>GW^HV%QI]K]DBNK
M>1/,>'KL?<I5AD9^[P>F* ,C3_%FOZZ^DZ7!%%IFH7$=S-=7%S:28$<+J@:.
M)RK?.74C<>!GJ:;,/$A\>^%(]1O;)'$%[YBV\+%)0C1_-RWREE*\<[3NY;/&
MXW@BP6TL([2\U"TNK$R&*^BF#3GS#F3>7#!MQP2".H&,8H@\$:=:S:7/;W5]
M%<6$TLWGB4%[AI2#+YI(.X,5&<8Z<8H YKPOKNKZQ8Z+H^C_ -GZ43IGVZ>4
M6ID10961$CCW#'*L223V]:FA\6^(=3N])TJV-A:WTMU?6=[.T+21JUOCYXUW
M \YZ$\9[XYVX_ =A:VVGII]_J-A<6,#6\=U;R)YC1,VXH^Y2K#/(^7CM5NP\
M'Z7ILNF2V_G[]/,[(SR;C*\W^L>0GEF)YSQ0 WPCJU_J=GJ$6IM!)=Z??RV3
MS0H464+@AMI)VDAAD9/->=W2ZR;/42;ZWGF_X3*W2 20LJJX:/D_,25^[\HQ
MC!YYX]6TS2+;26OFMS(3>W3W<N\@X=@ <<=/E%9)\$Z>U]<7'VJ]V3ZA%J1M
M_,7RUGC(.Y?ER <#(SVXQ0!SVI>,]:\-+KMG?O:ZA>6GV/[)-%;.@8W#L@#Q
MJS$[2I.%Y(XZU7F\=:Y8:;KC8:^^R::UY!>2Z1/9HLBD Q,LGWLY!!!Z YZ9
MKL-1\(Z7JL^IS78F9M0A@BEVR;=GDLS1LA'*L&;.<]A51_ MG=6FH0ZCJ>J:
MA)?6OV1YKB5-T<6<[4"J%'/)."3CK0!B:KXF\0:1?:?HUY?6_P!LNXY;R6ZM
M=*FN!#$"@$:Q(6+'<Q^<D# Z9-+8>.]2B%E<:Q;B"Q,EW;33/:R6_F/%'YL<
MBK)RJLBR<'/S#K75:QX;M]6N+2[6[N[&^M RPW=HZAPK8W*0RLK*< X(/(%4
M+OP%I%_X:;0KM[N:![C[3+.\V9I)"<LQ;&.1E2  ,' Q0!SVC>-]9U;3].L[
MNVM8]5>6Y_M&+82L<,<0<8&>"?-@&3ZFLC3Y]0O9K&X6>VM[.3P9YQLXK<A$
M! !5?F^7YL'..@Q[UZ)%X4TR'Q#J6MHL@O-0MUMYCN&T* !\HQP2 N?]T547
MP+IL0T\0W5]$++3CI@"2+B: KC#Y7DCKD8Y_*@#G_"FI:_I=KX*MKZYLI[#5
M;185ABMV1[?9;^8AWECOR%P>!R>*]'/0X.#6,GAJQC70E5IL:(,6N6'/[HQ?
M-QS\I/3'-6-#LKK3]*2VO;I[J<22,97<N=K2,RJ6(&<*0N<#I0!PT?Q!U-9]
M MYH;<R&XDM]:(4@0D3BW0KSQND8'G/ J*77]0UB:UN52SB:\T_59;*Y\DM)
M%"CQK&0=P^\N&/\ P'TKI[KP%HMV_B!W%P&UQ8Q<E9 -FSH8^/E.?F[\\U='
MA73%DTYE614T^QDL(8PWR^4X0$'CKB-?UH \^T"'79M2\&)::E:QW4GAAV:Y
MEM2^R,M 0 N\;F^Z,DXZG':N]\(ZO>:WX>\^^$(O8KB>UE:%2$9HI6CW $D@
M';G&>]-T3P?9:'-8S17=[</8V;V4!N'5ML+,C;>%&<;% ]O6M+2-(MM%M)+:
MU,ACDN);@^803ND<NW;IECB@#R>T37'TS0,:A;37;>++M(I);=ML9'VI68C?
MEAU(7(QP,]ZWK_QOK.AP:CIUXUO<ZC!J=O80W<5I(5*RQ"7>T*$LQ5=W"GD@
M=.:Z2V\$Z?:W4<R75ZR1:B^I0PO(I2*5Q(&"_+G:?,8X)ZXYJ2_\&Z9J$NHR
MRM<K-?3PW)ECDVM#+$H5'C.." .^<\]CB@"EX1\0ZCJ>I7]A>K-<0P1I+!?M
MILUF)-Q(9"D@^\N <C@AAZ&LSQ)HT]SXQFU2+1=,\3PI:1V[Z?<3H);,Y9MR
M*X*_.",YP?E'.*ZK1O#\>D7%S=O?7M_>7(59+B\=2VU<[5 5550,D\ 9SSFJ
MNJ^$;?4=5.JVVHZCI=\\8BEFL)57SE7.T.K*RG&3@XR,]: /.M473)_"NAV6
MG:1<W$4/B<12Z-J!0&%S'(Q@&<J$&X%>2,$<UTD5N^A:-KFJ67@2QT&\MM-F
MDAN(# S.P7<$_=C.,@'TXK8F\ :9+I%O8)>:C"\-]_:'VQ)P9Y)]I7>S,#DX
M/IV&.E7=,\-/IUT9I=>UB_0H4,%[,CQG/? 0<_C0!SVG^"/"]SX%M9KN&%9I
M;1+J76,JMR)"H<S^<>0<\YS@?3BNZMV1[:)HYO.0H"LN0=XQ][(X.>O%<D?A
MSIQMO[/_ +4U<:,3G^ROM(^S[<YV?=W[/]G=CM6_;Z?<0:[<77VEA8M;1116
MH;Y492V6"XP."H[YQVQ0!I4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 55
MU'4K+2;)[S4+J&UMDP&DE8* 3P!]3Z5:KD_&D,RW7A[44MGO(;#4/.FM(P"\
M@,4BAD4_>92P; YP#CI0!IQ>+O#LUG)>1ZU8M;1,JR2^<NU"QPH8]B2#P:AE
M\;^&(;.WNY-=L5@N5+POYH^=0<%@.N 01GI7GT\$GB'7/$1@T:YC236-'>6"
M6'#M&K*7=U[#;R<\XZXK?\0-JD?B^\6*#4+2VDLXDAGTO3DFDNVRY:-Y75EC
M"D\!L#YB<T =5?>*M TV**6\UBRA2:,2Q%IA^\0]&7^\/I5*Z\;Z/;ZQH=A'
M=P3#6 S03),"N /E(]=S<#\:Y;P%HE_9ZAX;EOM.FA-IX=:V=I8R/+E\Y?ER
M>AP#^%,T73M0TF3PC--I=YY5O?:E'*L<!8PB65_+9@.0A&#GH!0!U\/B[2[?
M2K:[U?4]-M7G$C+LN-R.$?:=I(!;&5!P.IQ5N3Q/H4.CPZN^K6@T^8A8KCS0
M5D//"^IX/ YX-<3X3T.^M]2\)2W>G3(+.TU(.TD9'E.\Z%<^A*[L>HS5>TL+
MW1M:LM3GTRYEMK?5]5/V:*/=*%F<%)D3JR@ CY<G#Y]: /1],U?3M9@>?3+Z
MWO(D;8SP2!P&P&P2.^"#^-(^L:;':7=T]] MO9N8[B0N-L3#&0Q[$9'YUR_P
M[F%S-XKN%LI+-9-;=A#( &'[F')('0GJ1V)YYKG->CU.#P_XUT&/0]3N;S4;
MV6XM7@MRT3QNJ<^9T!&UOEZYZ T =_J'B[P[I-TUKJ&M65M.K!6CEF 920",
MCL,,#D\<BHH_%VFR>,+CPYYT0N(+1+DN9!SNW97'LJAB?1A6%/HUQ)=?$20V
M#L;^W2.!C'GSP+4+A?7YLCZUAZAHFL7,=WI\5E=K-J/A.WLXI?+/EB:/S2T;
MMT0D,!SZT >AZ7XFT/6[B2WTS5;2[FC7<R0RACMSC</49[CBI-6U[2="2)M4
MU""T$I(C$KX+XZX'4X[^E<I#)+KWBGPS/9:)?Z?#I2S-<O=6Q@$:M$4$*Y^_
M\Q!^7*_(.>E2^-;:0:SIM_ NLVLT4$L::CI< N2F2A\N2':VY6VYSC@KVS0!
MT-YXGT+3[*VO;K5K2.VNAFWD\T$2C&<KC[PQZ4B:];7=UI1T^ZL;BSOQ*RRB
M?YG"C/[L#(;GKR,5P$#>(;>/0C>:=-I0%G.K7>E:0LLX8R_+&4"N(0R!7/&-
MW&1BJVC^'=;DLM(MFL[VVG$VLAI;A &B,P;RV8J-O.X'*\$]* .UG\=Z1)K>
ME:9IE[9WTMW>-;2B*8$Q 1R/N&.O*;?3FM[4]6T_1K7[5J5Y#:P%@@>5PH+'
MH!ZGV%>>6(N+J;P)8)X<U"UFT>;9=RR6I6. "VD0A7Z,K-@Y7(X&<$@5T'C=
M]0CNM%DM+>40)/(9KZVL?M<]K\A"E$P<;LD%L' ^M $VJ?$#0-/TRQU&*_MK
MFVN[U+02), $)(#$^FT')'6I=,\;Z-J-YKD/VNWA32)=DLKS *5VJ2_L 6*_
M537!V^G:O;Z?J-W-I^KW&SQ/:ZA^^MU\^:!4B!D"( ">#P!D=",@U=U33M1F
MO?$*)I-[.G]M6>K"/R3LNK=$A#(I/!<%"=AY^6@#O+3Q5H-]8W%[;:M:26UM
MCSY!*,19Z;O3/;-5O^$Y\+?9A<?V_I_DDL%83 [BI ./7!(Z>M</XKLK[Q2=
M>U'3M'OX[=M&%EMGMFBDNI3,K@"-@&(50W)'\1Q77SZ6_P#PLK2[Q+,_9+?2
M;B-91'\D;F2+ !Z [0WX T :LWB31+?2(=6EU6T73YL"*X\T%)">@4]SP>!S
MP:?:Z]I-ZEFUKJ-M,MX6%L4D!\TJ,L%]2 #D=L5YB=!U>R&C7XCU2TMK+4M4
MW_8;9)9HEEF)CD6-T;*E01E5)P_'&:M-I,]EX/U3Q"$U);FRU/\ MB%M1$<<
MDHC55D.Q%41AXPXVD9.<GK0!Z=#>6US/<0PSQR2VSA)E5LF-B P!]#@@_B*S
M&\1V=I/J/]IWNGVMO:W"P*YN!D$QA\/G 5N2<<\8/>L/0] UF7PS:W$6LSZ1
MJ%]+)?WOEV\<I9Y2&"G>#C8N%X]*Q[W0=0FUV[,EC//$WB>QN?,:+AXTMD5I
M/3 8')Z B@#O])UO2]=MWGTN_@NXXVV.8GSM;T/H:PM4\8?9O'.G^&;1K#S9
M8S/<M<S%65=R@(B@'+D$L,X&!5==&U2?Q?XGEL[NXTH7*V1CNT@1Q)M60, '
M!!ZKGN.*BN],UBV\2F<1OJTL?AVXA$T\2HEQ,9%*HVT!1G'3TH Z'3_%?A_5
M;_[#8:Q9W-S@D1QR@E@.I7^]CVS35\7>'7O9[--:LFN(%=I(Q,,J$&7^NT=1
MV[UYYIUIK5[K?A&4KK)2T,J3++IBVEO8EK9T"HH0,0"0,Y9>!SR*VO"K2VND
M^&_#T_A>Y:^TU@MQ// 4AMRJL&F24@JY8G@*<G><XYH ZGPKXDM/%GA^WU:S
MPJ2Y#1[PQC8?PD^N,'\:5?%GA]M6&E+K%F;XR&(0B49+CJG^][=:S?APEQ;>
M!]/L;NSN;6YLE-O+'<1%"6!SE<_>7G@C@UPCV^O7MII4,MEJL,UMK4%Q/IMM
MIB0VELBW(9G$FW,G'.58]22,9H ],?Q?X<CU%=/?6K%;MI3"(3,-V\$KM/H<
M@C![BJ7BKQQI'AFPU#??6CZE;6SSI9O,%9R%)53Z9QQW/:N9N]"O3X#\5VZ:
M;*;NZUN:XC01'?(OVA2K@=QM&0?056UZVO+30/&^B2:#J%_>:K-/<6DL%L9(
MY5=%V9<<*4*XP<'Y1MSF@#U#[3&EE]JG=(HA'YCN[85!C)))Z 5GZ7XHT+6I
M98M-U6UN9(DWNL<@)"_WL?W??I5/Q2E[_P (+>QV6G1W]U]F"K:S1^8K],Y0
M_>(&3M[D8KSZ_P!+UK6M2NW2XU>6.;P_>VBWNHV:V<<<C&,A H165< \MD>A
M.#0!Z5I_BWP]JMVMI8:S97-PQ(6.*8%FP"20.XP#R..#3[3Q/H5_J;Z;::M9
MS7JE@84E!8E?O >I'?'2N#N[Q]8\3^$K2WT6\TJ>.UO(EDN(A&(B;? 5"#\P
M!P<CCI@\U3\.:+J'E^%]*NE\1^?I<\;RP26L$-K;&-2&83"+,BMR %8E@W)Z
MT >B0>+_  Y<ZC%I\&M6,EW*2J1+,"S,.WUX/'6H_#?BNP\3R:FEDZ$V%TUN
MP#ABP'1_8$[L?2N0M-!O8OA_H5L--E6ZBU^.YDC\HAU7[:6+D=<;#G/I6KH>
MH/X=/B,:AIU^H;6C(CK 2DB3LJHRMT(!ZXZ4 =C<WEM9^3]IGCB\Z588][8W
MN>BCW.*KR:WI<2WS/J%LHL,?:R9!^XR,C=Z<'-4/&>FSZGX4O8[--U] %NK0
M#J9HF$B ?4J!^->>VOAK6IM6TYY=/GCM_$D@N]8#+_Q[F*=IT1_0E66+_@-
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MM]7_ .)MJ[;#=QQB3+@ 2.B*HC5BF<8SEN>M &KXU\51^$]%2Z_T<W,\\=O
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MIZ7+XXUN]GM]/O;&T_L6:R,]W;M TD[.K1X5@&(0H3G&,GCO0!WC:MIZ7%W
MU[ );.(37*%QF)""0S>@P#S[52NO%OAZRN((+K6;*&6=%>-7F )5ONGV![$]
M:\O.@^)-36#5)M,N8;OQ-))9:M&RD-;6^Z)59O0>7%(![R^]7M5T?4;+4_%5
MK*-?:'5)=]O%IME#+#<QF)4$;2/$WED8*_,0 ,$=Z /1[CQ'HMIJL6EW&IVL
M=_,P2.V:0!V)&0 .O-2ZKK>F:)"DNIWT%JDC;4\U\%SUP!U/X5S7A/1)].\4
MZO+<6LH'V#3X(YYOF+E$<,-^ &(.,D8YQ2>,9-1B\0:3);PW,%J(9@^HV.G"
M[N(W)3$8&UMBL 26VGE0.* -YO%.@)IL&HMK%DME<%A%.9EV.0"2 ?48/'7B
MEC\3Z%+HSZPFK69TZ-MKW'FC8K9QM)[')''7D5Y[X=T/4_M&AM>Z=?8A\1WM
MW(;N)=ZHT4A21]HVC+,O(XW=*LW^CZC!K^H:F-,N9[.V\1PW[01QY::/[(L9
MD1?XRKG.!SE3W% '7:!XKM?$6L:M:V+PS6MDL)2XBDW"0N&)!'8@KBK6J>*M
M!T6Z%MJ6KVEK.5#;)90"%/ )]![GBL3PD);GQ=XGU0:7=V5K>?9?)>Y@,33E
M48,VT\CL.>>GK6!XHCUJXU/Q/:16VI6XNH1';)ING(XOQY.,RSLK!<$E<$J0
M!QG- 'I,=_:2W;VL=S$]PD:S-&K D(Q(5OH=IP?8U@2>.M'_ +?L=*@N8)FO
M;*2[AE64;6VE0JCUW98C_=-<[I+WWA[5K2[N-&U.=+KP]96R"WMF<K/'OW1O
M_</SCEL#KSQ53PYIVI:5_P (>;K2[T8T*XL9=D);R96>)@'Q]T84\GB@#K/"
MWCK1_$EEIP6_LTU.[MEG:R28,R$J&91ZD9Y'6M&+Q3H,VKG2HM7LWOPQ3R!*
M"VX=5_WAW'6N-T[0[VW\(_#JW73Y8I[*YA>Y418:#-O*'+#M\S#.>YJA:V.H
M-X-T;P@-$OHM7L[V!I;IK<B"/RY@[SB;[K;@&X!W$M@CK0!VM_XRTB/[1;6.
MJZ9+J$!&^"6Y"! )1&VX@'!!)&/7 [TW3?'&C:AJ^IZ=]K@BELKQ;-=THS*[
M*I&!_O$KCU4UR\VA7P^'_B"WCTZ87=SKTMPJ"([Y$-ZK!\=2-@!SZ"K-QHEU
MJ,OCC2GMKF":ZN8[ZPNVC(BWI#%L8/TR)(^1UP* .]6\MGO9+)9XS=1QK*\0
M;YE5B0"1V!*G\C6+9>,M*N_$&M:2;B&)]*57FD>4 $8RY]@I(!)[FL_X>//J
MNEW/BF\A\JYUN03+&?\ EG B[(U^F 6_X&:P?$FE:E=ZGXNM(=,NIA=FPNX<
M1_NKF.$IYD6_IN(4C:>OTH [S2?$6CZ[YO\ 96I6UV8L;Q%("5!Z$CK@]CWI
M=5\0:/H9B&J:E;69FSY8FD"EL=3]!W/05SMB\VN^/K+6+73+ZRL[/3YK>>6\
MMF@:5G="L85L$A=C'/3G@\TNI&;1O'LVL7&F7M]97>F1VL3VEN9VB=)'9D*C
MD!@Z\]/EY(XH MZ7XWTR?PM9:WJMS;:>EV\B1J\N0Q5V7Y>[<+GBNALKVUU&
MSBO+*XBN+:4;HY8G#*P]B*\N\,6-]X<_X1[5+_0[X6L5C=VI@@MS+)9R/<;P
M=BY.&48RH/0=C78>!K*ZM=.U*XN+22S2^U*>[@MI  T4;D8# ?=)(+$=MWK0
M!?;Q9X?75AI3:Q9B^,GE>3YHSYG]S_>]NM)<>+_#EI?BQN-:L8KKS/*\II@&
M#],'TYXYKS._M]>OM-6V>RU6&>/5XYY--M-,2.UB1;D,9/-VYE)'S95LY))&
M :V=3T*]D\$_$*&/396NKZ^GDMT$1+S#9'L*^O(./I0!UGB3QEH_ARVNUGO[
M0:A%;//':R2A6<A25!]-Q&!Z]JTX-3A.A1:K=NEO";9;B5F;Y8UV[B2?0>M<
M!K$-UI\/C?3Y]#O]0FUK=+9RV]L94E4P+&J,PX0HRG[V.#D9-;WB*)X?@_J<
M4J%)$T*165A@@B Y!H V].\2:+J]U+:Z=JEK=3Q#<T<4@8[<XS[C/&1QFFV'
MB?0M5OGL;#5K.YN4!)BBE#$@'!(]<'KCI7"SVUYXJ71H=(TN\TLV.F7,3S7$
M!A2,R6_EI&A_C&XALKD?(.:@\-Z5>RWGA>UG7Q)YFE$-)%<VL$%O:%8BA D6
M(&4'.T!6.0<D\4 ;_B'XG:#IVG%M+U33+V^::&%(VN<(GF,!O<C)"@$L<>E;
M0\6Z-:O:V>I:QIL.HRQQLT2S_+N8#&,] 3TSC-<AI^A7MO\ #+PG8KITT=U!
MJ5E-<0B(AD N SLP[8&2327L%W8Z9XQT*;0;Z]O-8N;B2UEBMR\4ZRJ FZ3[
MJ;.AW$8"Y&: .WN_%&A6.H_V==:M9PWG/[AY0'X7<>/]WFJP\<^%6,P'B#3C
MY*AWQ.O ) X]>2!QW.*YS3M OK4^,O/MI);B>PMX(Y]A/VADM=IVGO\ -G\3
M4FGZ'/#?_#UCIS*FGZ;,DQ\K_4.88@ ?0DAA^= ';6&H6>J6,5[87,5S:RC,
M<L3!E8=."/>K-<UX(LKBPTF_BN+=X"VJWLB(Z[<HT[LI ]"""/K72T %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %4-6T:PURU2VU" R(D@EC*R-&\;CHRLI#*>3R".IJ_7*^
M./$=UH-KIL-DK"YU"[%NLJVSW!B4(SLPC3ESA>![Y/ - &UI&B:?H=O)#I\!
MC$KF25WD:1Y'P!N9V)9C@ <GM6A7G4/B_68M*U5;J86_V>6!;;4]1TR>V$JR
M'#*(2,O(N#@+@-E>G-4X_'FKV4>N0%S?26\=HUE-=Z>]F2T\IB&]&P2@(!R
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M+-G&2> ,GFN5MO&?B&YTY+>&:$7O_"0)I8N+JR:(F)H?,#M$2"&&>F1G';-
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MU@TZ2Z6XGTB:Q"3*0!&=XP5;.01R-ISFM/5]6\3^$=$O=6U&\T_4XDLRXB2
MPLEQN4*% )W1_-SGYA@=<T =U17G6G^)O$PO)+:.WN]5:2RFEC>?1YK%(KA%
MRB;G !1SD=<@CKS3-'\6:[.FH6ZW*7>KIISSQ:9>Z>]E.)UQ@+D[7CR<9!ST
MYYH ](HKSG2?&-]Y.JK=:Q:?:;:P:X$&JV,EA)!(#C+#D-%R.5R<\<YJO:^-
M-6AU*6V-\U_#+I5U=QS3:3)9A)8@I&S?C>AW?AQSS0!Z=574=.M-6LS:7T(F
M@+HY0L1\R,'4\<\,H/X5Q>G:YXCLK?PWJFLWUI<6.KR)'/'%;>7]F:6/,0#;
MCN&_"DG'+BNA\*ZK=:YI,NIS%!!<7,IL@JX/V<-M1CZEL%OHPH W:*\I\.ZE
MKEE8PZ7;ZA"]YJNO7\"W,MOD0+&\KR-MW?,3MX!.!GOBNQ\.:IJ3ZWK&A:I-
M%=3Z>(98[J*/R_,CE#8#+D@,"C#C@C' H Z-98W9U1U9D.' .2IQG!].*=7F
M@_M^#7_'>H:3J%I;Q6ES'*(9K?S//=;6(E6;<-JX &1SDGTQ44WCW5-7U"9-
M,:YLHH+.VG41Z1-?>;)-$)=KE!A% 91ZGD]J /4*:TL:.B,ZJSG" G!8XSQZ
M\5AP^()U\"'Q#?:?+;7$5@UW/9R*59&5"S)@\CD'K7'7,NNIK?@K5=9O[6YA
MFDFN&A@M_+,+&TE;:IW'<N,CGG('KB@#T^BO/+7Q'XCBT?0O$MY=6<MCJT]N
MCZ?'!M,$<[ (5DW99EW+G(P><8J"'Q-XG_LB'Q#+>V1L_P"V/L+62VN"\1NC
M!NW[N&&<],<>] 'I5-DECAC,DKJB#JS' 'XUY?>>.M>FNM7N=-ANI%T^\EMH
M-/BT:>=;D1-M;=.HPK,0V,<+QG/-=9XXOC:^!KV\%M%*0(CY-U$'7F1!AE/<
M9_,4 =-17G.J^(?$ZP>+M2L[ZRAM?#\S>7;O:[S.JPI(RLVX8'S$ @9Y]JZG
MQ)K\FB^#[K6H(5DF2%6BC<_+O<A5SCMEAGVH W:*X?5]3\4>%=,N;J[OM.U,
M/'%'!F$PM'<22I&,J"=T?SY/((QCG.1!J^O>(/"TEW:WU];:@TND7E[:SK;>
M48I8%4E64,04.\$=^".: ._IDD,4K1M)&CM&V]"R@[6P1D>AP2/Q-<)!KGB.
MPO\ 2?[1O;.ZBU:PGG$4=MY?V:2.-7 #;CN7D@Y],\=*@TCQ'XD2'PEJ>J7M
MG/:ZZH66VBM2AA)@:565MQ)/R8((QSQB@#T6BO+=%\=Z_J?]EZFEO>3P7]PB
MR6*:-.$A@=L!UN,;6*@AB?NGG&.*W-&U+Q-KMO%KMM?:?%827KQ+82PD?N%E
M,98R9)\SY2P&,=![T =F\L<>W?(J[FVKN.,GT'O4%]IUIJ2P+=PB403I<198
MC;(ARK<>AKS+0Y[ZRTZS-W-;WQG\73P RVPS&?,F#.O)PQ(X]!Q6@GBGQ#_P
MC,'C-KFT.FRW"9TP6_S+ THC!$F[/F<ANF.V.] 'H]%>:W?B;Q/%INMZZE[9
M+::5JLEJMF;7)GB64*=S[N#AN,#MSG/&W\4!<'X>ZF;:X\AAY>X[=VY=Z@CK
MQUH ZU98VD>-74NF-R@\KGID4ZO,_)\0IXQ\5OI^K6T$MM8V;RRR6F_SY!')
MCC< JG!SU/(P>.6-X]U35;BQ@M&GL0VE6U_/);:5+?$R3 D)A,[5&T\GDYXZ
M&@#T^BO.[/Q%XJU[4=%L(O*T:>YT^:ZNQ<V3,RM',L?RHQ4@-G(ST!]:S[?Q
M[KUZO]JVEO>3PF\,::;%HL[JT EV%OM &W?@%O[O\/O0!ZI36EC1T1G56<X0
M$X+'&>/7BO--7\>ZOI4;6Q2![RRU:5;[*8_T"/:Y<#L?+EBYZ9S5MM>O=4\2
M::52T^S3:Q=V=E,\ =HUBMI TBDGJ9%<<=5X[T =^TL:NB-(H=\[5)Y;'7'K
M3Z\7T&'6);+P$L&I1"ZEGORD\MON\I-K;OEW?,>#@D]^^.?1O"&J:AJ$&JVV
MIRQ3W.FZA)9F>./RQ*H1'#%<G!P^#CTH Z*BL3Q7JDND:$]S!>6EI(TL<8FN
MD9PNY@#M1>7?&=JCJ:XZU\7>))(O$-G9++J5S9P6UQ:R3::]M*RR.RO^Z8J7
MVA"R],]* /3*A>\MHKF.VDN(4N)03'$S@,^.N!U-<QX+U^;5Y=0M[C5$O'M_
M+(26R>TN8MP.1)&PQC(X8=>?2N4U^74-(\6^-?$$5Q;2W&F:1;RVPEM0Q3=Y
M^ &SD8P<X^]GVH ]7=U1&=V"JHR6)P *H:E8Z=K]A+IUVWG0.%:1(IV1BIY'
M*$'!QZ\C-<SXVU>YBEN-)4I]EN= U"XDROS;D"!<'TP[5S=EJ-]H[:SJE@JN
M]GHNCSRQE<[X5$ID ]#LW$>XH ]6@@BM;>*W@C6.&) D:*,!5 P !Z8IKWEM
M'=1VKW$*W$@)2)G =P.I ZFL71M;FUKQ#JHMGC;2;-8H8W49,LS+O<@^@5HQ
M]2:XG4[J\T/QKXOUX-:W5Q:6]E%:I+;CY3,SH@WYRJ@M\V/O#TH ]6HKS_6-
M>\0^%7FM[Z_M=0:XTJ\N[:5;7RC%- @;!4,0R'=]1CJ<UTWA<ZO+H\5UK%[!
M<SW2K,JP0>6L(90=G4[L'//'TH VJB%S SA!/&6+%  XR6'4?4>E>:7/C?58
M-0M[B+4X;R%]4CM)+:VTV5K9(WF$?%T0 7 (/'&<C'>H-*_Y&S2_^QIU7_T3
M)0!ZJTL:.B,ZAWSM4GEL=<>M.KFM>O6M_%OAJ 00/YQNOWDD89X]L)/R'^'/
M0^HKFM%\1^*)-,\)ZQ?WUE+!KDB6\EK':[?*WQ.RN'W$DY3D$8YP.F: /2JK
MWUE;ZE87%C=Q^;;7,;12QDD;D88(R.>AKRC2/$.KZ%X9L+1;MIKC4]8OHQ/'
M8/.T*1RRL["-"2[$CCL,\Y K4/B_Q*+#[.D;+<'5K:SM[Z^TV6V6:*7.28FP
M=RD$'!P>.F: /2(XTAA2-!M1%"J/0"GUY1XLO]>;0O%&BWFIPRR6#6,R74=M
ML+QRR8*%0V!@KU'4<5H>(?$OB#1-6GBN[Y+&T@CB^SW<NF/):W3;1O,LB$F+
MYLC'&!SDT >CT5E>(-3?3?#5YJ,%S90O'%NCFNV/DJ3C!.WDCG@#D\#O7!CQ
MMK%K)K4(O'O4@T*XU*WGN=*DLR)8L# 5L;T.X=NW4T >HTUY8XV17=59SM4$
MXW'&<#UX!K@?^$CU[0[S3YM7NK6]MK_3;B\:&"W\HP/$BR;5;<=P(8CGG(S[
M52=M?N]3\":GJM_:3PWE[YWD0V^SR&:UE8*K;CN7!()/.0#WQ0!Z;1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5FZWH=IKUI'!=&5&AE6>":!RDD,B]&5NQY(]""0:TJ
MHZIK&G:);)<:G>0VD+OY:O*V 6P3CZX!_*@#%;P'IDMI,D]UJ$UW-<17)OWG
MS.LD?W"IQM 7)P-N.3QS0O@/2';47NY;V]DU&!(+J2YG)+A&+(PQC:03QMP!
M@'&>:TK;Q/HEY9B[@U*!X?M"VQ.2"LK$!4(/(8DC@^HJ:\UW2[![E+N^AA:V
MC268.V/+1V*JQ]B01^% &.? FFS1S_;;O4+Z>81*;BYG#2*D<@D5%P  -R@G
MC)[FMH:3;#7CK/S_ &LVHM?O?+L#%NGKDUECQYX6,$<RZU;,DH8Q[<DO@X.T
M 9./;ZU<N?$^AVFF6VI3:G;"SNL"WE5]PE)[(!DL?I0!6O\ PG:7VKS:FE[J
M%G/<0K!<BTG\M9T7.T-P2"-S<J0>>M+H_A'2]#EL)+,3 V-I)9P!WR!$[JY!
MXY.5&#Z5-)XKT&+2H-3;5;8V<[[(I$;=YC<Y4 <DC!R,9&#2OXIT*/1XM6;5
M+;[#*_EQS!\AWR1M ');(/&,\&@"E)X)TPP0K!->6L\%S/<PW4$NV6-IF+2
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MHVNR21Z9J$-R\:AF120VT]&P>2I]1Q2:MXFT70Y5BU/48;:5DWK&Y.YESC(
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M6:!J]\;*PU6VN+C!*HC?? ZE3T8#N1FK,>N:9+9V5Y'>Q-;WSK';2 \2LV<
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MV1M_FJ.I4+DD#N>U.N_%>@65K:W5QJUJL%VADMW#[A,HQG9C[WWAT]: ,]?
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MR0,YFD98TST+$ G:><$ @T 1VO@/2[2XMS'<7YLK:?[1;Z>UQFWBDR2"%QG
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MV]]N)0"!CGDX+<4 >=ZKINJZI<ZOXAM=(O$A-YIDL5I(@2>=;:7?(X0G@D'
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MC,^K+# J%RO[L(D:E_NYSG:,#&<UM2:=._Q-M]2-LQMDT>2$38X5S,AVY]<
MUTU,EFB@C>261(T12S,[ !5'4D]A0!YQI.@:A:^%? MM_9\D<MEJIFN4V8,2
M%+C+'T&67\Q53P[9ZAX;O-%OKK2[FY*V-W;/:P!6G@+71</L)!*L, D=/ESU
MKU175P"K!@0",'/'K69J_AW2M<>%]0M3)+!N$4L<KQ.H.,@,A!P<#(S@XH \
M[\(6-Q?ZCHE^NFM#!!K>KR2)@,+?<74 D<=<C(X]*M7NEZG9M>7@TNZFCB\6
MK?\ EP1[G>#R44NJ]_FS^M>BZ?86>F6$-G801P6L2XCCC&% Z_\ U\]\U9H
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MFUNP&YN ,'<<YS0!RG_"::Y:VOB&(W,\S6(L9;:>]L/LTNV:8HX9,#(PIP<
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M7"-:3?:()()C&R2;2H8$>@8U2'@G1SI<]E*+F9Y[A;J2[DG8W!F7&V02=05
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MR3R!VH ]$HKSC2/%?B?Q"^AVEO)IME/?:=/=W$SP-*(S',J (N\9^]W/O[5
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M+18)U6ZNKN>XE,T]Q=.&>1B .P        QTJJ_C7PQ&MLSZ_IRK<H'A)N%
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M+/#VDW)MM0UJPM9U8*T<LZJRD@$9!/'!!S[BK6KZK;:-HMWJERX%O;1-*QW
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M 'E(TR?6[NZGDM_$>II'I%Q;.E[:Q6 <2;?W"XB4LWRY!Y52.O-:G@W^T_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ91110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445C:_9^(+M;?^PM7
MM=/*EO.-Q:>?OZ8Q\PQCG\Z -FBN+_L;X@_]#?I?_@H_^V4?V-\0?^AOTO\
M\%'_ -LH [2BN+_L;X@_]#?I?_@H_P#ME']C?$'_ *&_2_\ P4?_ &R@#M**
MXO\ L;X@_P#0WZ7_ ."C_P"V4?V-\0?^AOTO_P %'_VR@#M**XO^QOB#_P!#
M?I?_ (*/_ME']C?$'_H;]+_\%'_VR@#M**XO^QOB#_T-^E_^"C_[91_8WQ!_
MZ&_2_P#P4?\ VR@#0\8>$E\56EGY6H3Z=?V,XN+2[A4,8W'JIX8'T]JQ+3X;
MW<EYJFIZ]XCEU75;W39--CG^RK"D$3@YPBGDY.>H[^M6_P"QOB#_ -#?I?\
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MD-W+<O;+E60@D;0P&"?I@>M:W]C?$'_H;]+_ /!1_P#;*/[&^(/_ $-^E_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !169)K,4
M>NRZ:RJJ068NYYV<!8P6*J#]=KG.?X?>I)-9T]-'N=5CNX9[.WB>5Y89 ZX4
M9/(XZ"@"_16)J7B$Z3X,F\0W5DZM#9BZDM0_S*=N2F['4=,XK*G\9:GID4%U
MK/AF>ST^26.)[F.[CF\HNP52RC!QD@<9ZT =A15:;4;&WNH[6:\MX[F7_5PO
M*H=_H"<FLV'Q18-KNI:7<216LEG)%&KS2JOG-(F\!0>XSB@#;HJM=ZA96 0W
MEY;VPD.U/.E5-Q]!D\T7.H65F0+J\MX,XQYLJKG)P.I]: +-%9>@^(+#Q%9R
MW5A)NCBGD@8$@G*.5)X)X.TD>HQ67<^*[R?4[RQT'0Y=4-B_EW4YN$@C63 /
MEJ6SN8 C/&!D9- '445D:7XCLM1T,:I-NL(U9HYDO,1M"ZL596)..".N<&K_
M -OL_LT=Q]K@\B3E)?,&UN">#T/ )_"@"Q15:+4;&XMEN8;RWDMV;:LJ2J5)
MSC (.,YI;6_L[Z%IK2[@N(D)#/%(' (Z@D&@"Q16-J?B6PL?#>I:U;30WT-A
M"\KK;S*V=HSMR,X-&G^(K>^U?4-/9!"]HT*AG<?O6DCW@ >H&?RH V:*8)8S
M*T0D0R* S(#R >A(_ _E3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BL+6_$ATR_M=+LK"74=5ND:2.VC=4"QK@,[NW"KD@=R2< &L
MR?QU)I^G:M)JFBW%G?:;$D[V_F*Z2QL=H9)!P>0000",=* .PHK/FU>U-C?3
MV,UO>2VD;,\,=P@^8 G:Q)PN<8R<8J1]4L[>*V-Y=6]K)< ;$EF4%B>PY^;K
MVH N45SM]XJ2W\7V7ARVMH[BYFB\^=VN5C\E-P' .2S<YVC' I/$'B6ZTG6-
M-TJPT=]2NKZ.:556X6(*L>S.2W^^/RH Z.BL?2]6U"=)6UG25TA59%B,EW'(
M)2<\?+T/3ZYK3-S KR(T\8>-=[J7&57U/H.#S0!+15>UO[.^@,]I=P7$()!D
MAD#J"/<4R'5=.N8))X+^UEBC;:\B3*RJ?0D'@T 6Z*H:MK%EHNG7=[>3*J6L
M#7#H&&\HOH">YX'N0*KV>OP7DL+((ELYK5+A+DW"8W,VT)MSG/OTSQUH UZ*
M89HEE$1D02%2P0L,E1U./3D5%::A97ZNUG=V]RJ':QAD#[3Z'!X- %BBL+7?
M$?\ 95Y::=9V$VHZK=AGBM8F5,(N-SNS<*HR!GJ2< &J]AXNSJ$VFZYI[Z1?
M1P&Y59)EDBEB!PS)(.#@D9! (R* .EHK@+'XF_VC'HX@TJ+S]6=C;1-J$8(A
M !WOQ\K'< $Y.>]=9;:U!_8\&H:B\&GB7JLMRA53D\;P=IZ=C0!IT56N=1L;
M.!)[J\MX(7P$DEE55;/3!)P:+C4+*TC$ES>6\*,NX-)*J@C(&<D],D?F* +-
M% ((R.17)3>+=4DU_5-,TOPU+?C39(XY9A>1Q9+QJXP&]FH ZVBL/2/%>FZK
MHRZC)(+ !Y(I8KMU1HI(VV.IYQPW&0>X]:TFU*Q2[CM&O;9;F4;HX3*H=QZA
M<Y- %JBJTFHV,5XEG)>VZ74@RD#2J';Z+G)J&'5%(OY+M8[2&TF,?FO.A5EV
MJ=QP?EY;&&P>,]Q0!?HK&TWQ)9ZGJ&K6\3)Y.G>5NN1("D@>,/D'T -:$.I6
M-S:_:H+VWEM\[?-CE5DSG&,@X[B@"S165>^(]*LM'U#5#>PS6]A&SS^1(KE=
MHSMZ_>/0 ]ZNV-[#J-A!>6[AHID#J00>ON* +%%58-3T^ZN9+:WOK::>/[\4
M<JLR?4 Y%)%JFGSW(MH;ZVDG*[Q$DREBOK@'./>@"W16)KOBBPT2'F2*>Y$\
M$36R2J)%$LBQAB.N!O!K;H **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY\4QS6L#P%4*"U<.X0CA&D!/(P?QKO/^$+M?^@QX@_\ !O/_ /%4?\(7:_\
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M.UM<A58;)!U7)'/X9%:5 !1155=2M&U9]+$V;U(%N&BVGB-F*@YQCJI'7/%
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M9?-09Y C.W=W#>U ';4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% '!:YI%EKWQ2LK'4HGFMET6681B5T&\3( ?E([$_G6-K,
MJ>$I_$NC0K->:0NE0ZA%:3W,A\EC*8V17SO"G ;&>"#BNRUKPO=:AX@@UK3]
M;GTRZBM6M28X(Y0R,P8\.#W455?P%;SZ1J]M>:G=W=]JRHES?S!-^U?NJJJ
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_'\3("?U-:E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8NHZ3
M,_B32]:L]OFP+);7*L<;X'P>/=75"/;=ZU>TO2K/1K+[)8Q&*#S))=I8M\SN
M78Y/JS$U<HH IQZ7:1:K<:FD1%W<0I!*^X_,B%BHQT&"[?G533/#.DZ/):R6
M-L8VM;3[%$3(S;8=V[;R>>1U/-:]% &!+X,T62RM;9(9X/LDDLMO-;W,D<L3
M2,6?#J0V&).1G'3T%5=0\$Z:-!N[72[58KLZ==65N[RL1^^&6+$DEB6 )8Y/
M6NIHH YC0O!&E:3;VS20R3W$5I]FQ/<R31Q*5 =8U<D(IQV XXZ<4ZT\!Z#9
MS6,J17<C6#A[,37LTBV^!@! S$ 8.,>F/05TM% %33-,M-'T^.PL8C';1EBJ
M%BV-S%CR>>I-<]'\./#\"E(#JL$>YF\N'5KE%!)).%$@ Y)-=910!B/X2T6:
M._2>T,_V^!+:X::5W9HT&%4$G(QUXQSSUYJ"^\$Z+J$IEF6\1WA6WG:&]EC-
MQ&HP%EVL-_&1ELGGK7144 8%_P"#=%U!H6,$ULT4 M0;*YDM]T(Z1ML(ROH#
MT[4VZ\$:#=302?998/)MUM-EM<20I) O2-U1@&49/!SU-=#10!@IX-T2/^S?
M*MY8O[.MS:V_EW$B_N2 "C8/SC@'#9Y&:DF\)Z)<:?I-C-9![?27BDLE9V/E
MM&,)SG)P/7.>];5% &+JWA72]9O!>7 N8;H1>2TUI=20.\><[&*,-RY)X/3/
M%:5C8VNF6$%C90)!:P((XHD& JCH*L44 <Q=> /#]U<3R-!=117+E[BU@O9H
MH)F/4O$K!3GOQSWS6P=%T_[7I]RMLJ2:?&\=J$)58U8 $!1QC"@>V*OT4 9%
MMX8TFT&GB&V*_P!GRS36W[QCL:7=O/)YSO;KTS56Q\$Z%I][%<P6TV("S6\$
MEQ(\,!8$,8XV8JF02.!P"<8S70T4 <[I_@C0M,O;>YMX)_\ 12S6L,EU))#;
M$@@F.-F*KP2.!QGC%.U#P^8?!\OA_0U%M',AMPS.3Y4;M^\8$Y)(#,0/7':N
M@HH BM;:*RM(;6W0)##&L<:C^%0, ?D*EHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKFK_P 31Z;KUZES+LTZQM83
M+LC+N\\TA6-% R2<+T YWBG2>,K!M"UB_@2X2?3(F>:UN8'BD5MNY!M8 _-V
M(ZT ='15>P%TNG6HO65[L1)Y[*, O@;B!Z9S7.GQ6MEXD\20:G-%#IFE6UI,
ML@0ELR^8"#C).2J@ #.3WS0!U5%<R/'>BK%>O<_;;-K*$7$T=U9R1.(BVWS
MI'*YZD=.^*V6U6S&KPZ7YA-W+ UPJ*I(\M2%+$]!RP ]>?2@"[17/PZQ=Q>.
MKG1+L1_9IK-;NP=5P3M;;*I/<@E#]&JE:^,$5]:U"_D5-)M[X6%B(XF>6>51
MA]H7)<F0E0 /X#0!UM%<X?'&A1Z9=7US//:I:2QPW,5Q;NDL+2$!-R$9P<C!
MZ?E6;K/CR!?#>LW.EK-%J6G1QR&WOK5XF"NV%;:P!*GYN1Z4 =K16+/XLT:W
M74WDNSY6F$+=2K&S(CGH@('S/R/E&3D@=365J/C^QMM$UJY@M;U;_3K)KO[)
M=6<L3NO(5L$9*;A@D=.<XH Z^BN9'C;3H[2P::&^>\NK87!M;>RE>5$Z%V0#
M*KG@$]>V:EG\:Z-'#9R6[W-]]KA-Q$EC;/.WE @%R%&5 )QSSGCK0!T-%<_/
MXTT:.&RDMWN;YKV#[3!%96TDSM%Q\Y51E1D@<XYXZU')X[T%;739XYKBX_M)
M)'M(X+62227RR XVA<@@GD'&,'T- '2450T;6;+7M.6^L)':(NT;+)&4='4X
M965@"I!!&#6#\1-=U?P_X=AN=#CADOYKR*WC292RMNSQP1R<"@#K:*X#QMX\
MN-+\!V6M:"L,EU?QK/ )AN58@GF.Q (Z ;?JPKH_%VK7.B>#-6U:T"?:;6T>
M:/>,KN R,CTH W**X2_U7Q7X7TV'6]3O]-U/2U:/[7'%9-;RQ1N0N]3YC!MN
MX$@@9&>:[N@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **Y#6]0U^?Q
MM:Z#H]_9V4;Z<]X\D]H9R2LBI@ .N/O?I5.7Q5JNE+K>F:Y<V,%]8VL=Y#?P
MV[F*6%V*9,6XD,&!! 8]0: .[HKGW\9Z-'K5UI32S^?9Y^U2"W?RK<"/S,R2
M8VJ"O0D\X(I=,\8Z1JMTEO$US \L1G@-W;20+/&,99"X 8 $'UP<]* -^BN4
M'Q!T66%WMQ>.7@DFM6:SE5+L(,GRB5^?CGCMR,BH],\>V5QX<T6^NX+O[?J5
ML)EL[:TD>1L*"[*N"=@)X8\'(Y.: .OHKF;CQ[H$%C970GN)Q?&1+>*"UDDE
M=T^^FP#<&'<$ C!]*Z.*031)(H8*ZA@&4@\^H/(H ?1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%<-X%\8W^NW^N6FKK!&UK/(]JT:[0UNLLD63D]0T1R?]H4
M =S17GWA7X@R7UEK>HZYL@M8;V..Q2&)FDDCE17B7:,EG8.O '>MP>.]#2PU
M"\N9+FS73S$+J.ZMGCDB$AVH2I&2">XST/I0!TM%<TWCG25BMR(-3:>=7D2T
M73YC.$4X+M'MRJYZ$]>V:S&^(5HOB98(?.O=-GTJ*]M_L5I)-*Q,CJQ(4$@
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M!Z;167X=NY;_ $2WNI=2LM1,N6%S91E(G&>, LW3H>>H[5J4 %%%% !1110
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MSTZTMY"-I>&!4)'ID#IQ0!=HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MXW6[?6[/QY::YINBOJ5NNF26CJES'$59I5<'YR,C"UD:QX8\0>(;'Q%JEY90
MV^H7MC'8V5BDX<QQJY<EWX7<S$].  .37I-% '$77A.^U&Q\=6;[;?\ MJ3_
M $64L""/L\:9..0-RD8]*R+/PA?ZG<P)=Z3?V/DVD\3W-[K,EV%DDB,?[E/,
M88PQY8#C'&:].HH XG2XO$TFFZ?HD^BV]G#:6C6]S=R3)(LA$91?)"G<,G!)
M8# R,$UF:%I7B+0_["U)]!DGEM-'72+FT2YB\Q=A4K*A+!2K8.02".*])HH
M\]T7PKJ]OK^DZK=V\2,U]J%]<QI(&%MYR@(F?XCQR0.I->A444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5Y9-X)U]=)M5LXTAO)KR_M;L^:H(LKF9G+@YY9
M0$8#KR:]3HH \YO_  [X@LY==?2('CM[G4[614MID262U2!$<1LQPC97C..
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M4@L V1NSR%Z\FO78HUAB2)=VU%"C<Q)P/4GDT /HHHH **** "BBB@ HHHH
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MX'J0#7I\%E#;Z=%8JNZ".(0A6YRH&.?PIUI:6]A9PVEK$L-O @CBC08"*!@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,+67R!.< 1F7;L#9(XW=3CK5FSU*>\\3:G9*$^QV,4*EL?,9GW,PSZ!/+/\
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MF=KLH967;T.01TJK>'6]=AL[G4%M8576[6YAL?/B9[:WC/S,[ X9B<M@$XX
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M*JNO[IA%R>OS %3TSZ] :=XRNO$%MH@7PW8O=7TTJQLZ-'F",YW2 .RAF'0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB_\ B:/^$,\+?]"UH_\ X Q?_$UH07WGWEQ#Y$BQ1+&R7!*[)=V?NX.>,<Y
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M=&$=[*8$F'W5DQE5/^]@@'UP.XI=8U>ST+2I]1OY"EO"!G:I9F). J@<DDD
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** #
M...E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA.N?V2$<SBV^TLP VJN[: ><Y)#8_P!TU/=7,5G9S74SA888VD=O10,D_D*
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M2:)F&"58 @X/3@T 6:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***P?#?
MB[3?%,FI1V"SI)IURUM,LR!22"1N7!.5)# 'V- &]16'X>\5:=XFEU--/$V-
M.NFM96D4 .P[K@G*^_%;@.>E !11D>M9ZZQ;-X@ET4+)]ICM4NF8@;-C.R@9
MSG.5/;TH T**0D $DX ZFN:T[QQINI7EG$EK?PV]^S)97DT(6&Z*@G"'.1D*
M2-P&0.,T =-16+_PE6DGQ5'X;CN/-U)H7F=(\$1*N.'.>"=W Z_3C.U0 45S
M.I>-[#3;J^B^PZC=0Z?C[==6T >*V^4,=Q)!)"D$[0V >:=J7C73]/N'ABM;
M[4/)MUNKA[&(2+!$V=K,21U ) 7)P,XH Z2BN>O?&%E;W%O;V5I>ZK//;"["
M6$:OMA;[KDLRC!YP,Y.#Q44_CG3$T[2[RTM[Z_&I[_LT-I!ND.P$OE21C;C!
M]#0!TU%4],OSJ=BET;.[LRQ(\F[C"2#!QR 35R@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\"P"/$?]_!4C R?F'K7H#6MN[%FMXF8\DE 2:<]O!(8S)#&QC.4W*#M/MZ4
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M\6+8I.LT5P[C$>QQC/SD \#!H ZVBN2\92WNA?"W4WM[V?[;9Z?A;K>?,+J
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MMG-;R7'DLA1V9'#8((^=@1UZ$9HT71=9A\4'5]7EMI99-*BMI7@R!YHED<@
M_P (#J >^.E=510!@^#](N]$\'V.F73(MS"CJQC.X EF(QZ]16&^D>)]:N=#
M@UBVL(SI=XEU+J<,V6N-@( 2/:"F_(W9. ,@9KNJ* ,*_P!)N;CQIHVJQ[/L
MUG:W44N6^;=(8MN!W^XU7-,O[F]GU*.XM! MK=&&%PQ(F38C;^0,<L5QSRIY
MK1HH \^U/3O%5WXODU"XT2RU+3[1P=,MY-2\E(R!S*R>6VZ3/0D_*.@SS5RZ
MTWQ)8:MJU[I-C9SG68(C();HI]DN%382?E.],;>F#\O3FNUHH \UU'PMX@A@
MT70[;3[;4_#NFV<<<EO)>_9_M<R@#,GR-E!C.SH2><@8KHYI?%,9T^^M]*L6
M BDBNM-%R 4.1L9)=@R,#E2!U]JZ>B@# \(Z-=:/IUV;XQ"\O[V:^FCA)*1-
M(<[%) S@ <X&3DUOT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
( !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>elicio-powerofattorney20002.jpg
<TEXT>
begin 644 elicio-powerofattorney20002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1[4=MC!B.Q/ S^% '54444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*Z&BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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/ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>elicio_clawbackpolicynas001.jpg
<TEXT>
begin 644 elicio_clawbackpolicynas001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MDR,#R[<  8X'KQ@ ZYE#*5/0C!KRCP=-<WNE^._M-[>RFVN9XX&:ZD)B50Q
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,2,$8.#@?RJ[10!Q6F>&]?T7PC-X:M)[&:$+)%;WLKNKQQN2?FC"D%AN./F
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7 _&HX^$6N_2#_T?'7?5!=V-I?QB.\M8+B,'(6:
M,. ?H: .:\.>(-*L=#\)Z1<WB1W]_IL)MH2"3(%B4GD# _'K7654CTO3XG@>
M.QMD:W!$)6%08L]=O'&>^*MT %%%% !1110 5Y/\5R!X_P#AKD_\Q1O_ $.&
MO6*XWQ#X6UW5M8:[M-6TB&W 411W6CK<.F ,_.6'?)Z4 >>^,IKF3QA\0(?[
M0OHX;/18[F"*.[D1$EPAW!00/PZ<T^0QZEXT^%M[JMQ(WVK1G>>9[ADW-Y&<
MY!&"2><=<\UU\G@KQ7+))))X@T%WE&V1F\/H2XXX)W\]!^5/_P"$0\8;+=/^
M$ET39;-N@7^P5Q$?5?WGRGZ4 8?AS39?$7Q&\:VMWJ^J)::=?VLMO!!=LJJV
M&;&/[O'3ISZ@8YZ77-?&D7>L>?<CQ GC 64<(=N(MHQ!LZ;",\8YZ]>:[^#P
MGXSM;B2XM_$^C132_P"LDCT%59^_)$F333X1\8F_^W'Q+HIO.GVC^P5\SIC[
MWF9Z4 >=>+KY]3T?XG/J]W*+VRO(;>S@:=E"0[QMVIG!# 9/'/6M^\U)[/QM
MX81]0D@T^?PP[.OV@I$["-L'&<9 QSUZ5T=QX*\67EPUQ<^(="GG90C22^'T
M9BH.<$E\XR.E.F\'^+[@VYF\2:)(;<Y@WZ A\K_=S)Q^% '!:/XHOH/ 7P[?
M5+^X;2[W49TU*ZEF8E@)&$:NY.=O4D$XPOI6AXOTFSL3X M?[:N-4M$USRC=
MRW).$+ [=ZG^$<9SGCJ.E=6?!?BPV#6)\0Z$;-CEK<^'T\LGU*[\5(_A'QC+
M:1VDGB;17MHB#'"V@J43'3"^9@8H Y#5]9U;3/%/Q%71;NY<6FD6\MI&)FD6
M+*)N=02><$MG\:NZ#>WL/C#2].M+B>;3KSPG'=WH:5G'FG.)<D\.W0GO^%=%
M'X2\917;W4?B;14N9!AYET%0[?4^9DTVW\'>+K2*6.V\1Z'#',,2K'H"*'_W
M@).?QH \X\(ZCJ"Q?#/4&U2_EN=0O;R"Z,MW(XD0/@*5)QQGT_I7T/7G:>!_
M%,?E;->T!?*;='CP\@V'U'S\'@5Z&,@#)R>YH 6BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJB:59+,5\R665(((\X\R1SM49[#)R3V )JNVNVL>L1Z&]U%_:3VYFY7"@Y
MQGG.2<9S@4 :]%<WX4\40:UI.G_:[NT&JW$)E:VC8 X!/122<8Q6PNJZ>U\+
M);V W1W8BWC<2.H [D=QVH N45F7VJ26>L6%D+6>2.Z60F6.(NJLH!"DCA<\
M\GTQWXYS4O'QL=#TJ6/3Y6U?59_L]M93HT.'W;26SSM!(Y[Y'3/ !VU%8A?Q
M%:FT,IT^[625$N/)A>,Q*3RPR[;L?AZ^U6TUS2Y+\V*7\!N=YC\L.,EP,E?=
M@.2.HH T**QKGQ;X>LY)H[G6;**2!Q'*CR@&-CT!':I[?Q!I%U=7-M;ZE;2S
MVR;YHTD!*+Z\=J -*BLBU\5:!?7$%O:ZQ932W&?*6.8'?CJ!ZGVJ:77M*@O4
MLY=0MTN'D\E4+]9,9V9Z;L<XZ\T :-%9%[XIT'3IIX+S5[.":#'FQR2@,F>F
M1UJQ_;FE_;X+'^T+<W=P@DAA$@+2*1G<H[C /- %^BL674KVXU*P_LHVEQI\
MC2QW+G=O1E!P01Q@,-I!YR>.AJM9ZUJ5K:Z;)KD5M&UW.;5F@#!5D+,(V ;G
M:X '/()'KP ='16'XGU:YT>UL9[=H DM_!;S>:I.$=PI(.1@@'J<U>L]:TO4
M;26ZL]1M9[>$D22QRJRH1UR<\4 7J*YSQ#XD%KX4U74]'N;6:XL4)96^<*>.
M& ((.#FM-;S=KAM1?6A5;;S&M!_K@=P^<\\+@XZ=>] &A16>->TAEG8:E:[8
M$$DI,H 1#T8_[/OTJ=-1LI!;%+N%A<C=!AP?-&,Y7UXYXH LT52BU?39YY((
MKZW>6-#(R"09"C@M] >]26NH6=\SK:W,<K1@%PC9*@YP2/?!QZT 6:*YS5/%
M5O%'KEM83PG4=,M#.5E&5+;6;;@$$X"\X/&15W1M>LM3M8D%[;/>K;I-<1)(
M,QY R2,\#- &M16;_;^DFVN+A=0@:.WB\Z4J^=J'.&P.H.#@CKVJ72M4MM7T
MJWU&V=3#-&LGW@=N0#@^XSS0!=HKGAXGL;&QM);[4[.Y-Y=O!#+;<1GYCWR?
MN@8)SU%:.L7@L]*EG6_M+)N D]US&"3W&1G/;F@#0HJK-J=C;W"V\UW"DS,J
MA&8 Y8X4?4GH.]1:Q=_8[#S!?6EF[2(JRW7*'+#*XR,DC('/6@"_169<^(M%
MLI)8[G5K*%XF5)%>=04+= >>#P:MWU[;Z=8SWMU(([>%"[N>P% %BBN3;QA%
M_:NCO]IM(])OK*:X=W.&C9/+P"V<?\M,8QU%=!_:NG_88KT7D!M90#'*'!5\
MC/RGOP#TH N45%;74%[;1W-K-'-!(-R21L&5AZ@BI: "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M*KW5_:630)=7,4+3R"*%78 R.>B@=S0!8HHHH ***.E !14%G>6VH6D5W:3)
M/;RC<DB'*L/8U/0 5SOCJWGO/!&K6EK!+/<3V[1QQQ(6+,?I7144 <KXL@FO
M_ 3V\%K/--(( (1$Q;B1"V5QQP#UK*US3=2O-3\1OI]G,3-9V30Y5HUF:*5G
M>,-Q@E2%_'VKOZ* .<\.K;75Y<:G%H^H6,TL212R7[-YCX)(4*S'@9//OQGF
MLS4;.*;XC/>7VF3W%@-)%N)/LCR+YGFEL# /\)Z]*[:B@#S*VT+6K33)7MK.
M=-+MM:BO+33G(,OV=3EP!G^\=ZJ3GY?6M'5K.\EO-=UFRTR2X@N+>TA%M+ 0
MTKI(2TGEM@DHI& <9*UWE4_[6T_^T%L/MD/VMMVV+=RVWD@>I Y(ZB@#SW4K
M#4+C3_&$:Z;J,WV]K5X&EA!:;"H#P.A^4\8&,<XZ5T6HBXL/&.F:LEC<3Z8U
MG+;L+>$LT$C,C!R@&<$+M)QQCFNK) !)( '4FH+.^M=1MA<65Q'<0%F421,&
M4D$@X(]""* ,/P/;W%KX?>&YM)K5Q>7+A)5 .UIG92!Z8(KG[;2=2F\*:?X?
MGMKA-4L]225KHQGR]JSF0S*_0[E)XSG+8(KT2B@#F]'CF3QIXBFDMYTAG%L(
MI6B8*^Q"&P<=B:KZ\LP\<>';Q;6ZDMK2.Z$\D4#.$WJH7H.<D'I6])K.EQ3O
M#)J-HDJ':Z-,H*GT//!]JN(ZR(KHP96&00<@B@#E38W>L^-K+6YK66UT_2K>
M5;?S1B2>20 ,=@Y"A1WP2>U8FD:==Q6'@R.?3KD&SO+A[A6MV_=!EE"D\>K+
M_D5Z/10!P-[8,FM:SINHZ%J&H6.HR));-;2,(2!&B>7)A@$P4SDCH:GM([JT
MU/5])U'0I[^.\OA=VUQY8>!EPFW>Q/RE"@Z\X QFNWHH \]U33-6D/B>&VL9
MW>34;:_BX 2YC18=R!B>IV,,>W/6K.L65QJ=[K&JVEK=+#+H,EEY;P,CS2L2
M5&PC/R\C.,?/UX-=S10!Q=UIIDT/05A&H:=>00C9=6MN7,#B,+MDCP=RGD8Q
MV'UK3BMM2O\ P#):7<,=OJ,]C)$4C&U58J0,#MV..U=#10!PLL<]WX \+S6U
MK+,;2:QEFBC7+J(RH<;>N5(.1[56UBPN[N/QT4TZY,E_9Q1VP,!)D81%2 >G
M#$=\=Z[Z&VBMVD,2;/,;>P!XW'J<=B>_K3+F_M+)X$N;F*%[B010J[ &1CV4
M=S0!Q-W!,FM7J:CHVJ:AI^J6D*1FU9P%(4JT4B[EV@YSD\<FNXM(A;V<$(01
MB.-4"!BP7 QC)Y/UJ:H+.\MM0M([JSG2>WD&4DC.5;G'!H R?&<,UUX,UBUM
MX9)IY[22*..-"Q9F4@#BO-;7PSJZ:;X2&AZ5<Z?KEJ0M_=M'Y2"//*N3CS,\
M<#->ST4 >.ZKX6UR33_$VCI:SR7FIZTEU;7(4^7Y18-N+]%V@8P3GT%+X[T;
M6]3F\46UCH%UB:.U*W$ !%X4*Y9B3_". JCU)[5ZS<7]I:36\-Q<Q12W#[(4
M=@&D;&< =ZL4 >>W>D3W_P 4=$O[C2YI+"/2C%(\L.Y$D.[Y6ZC.#].:H:OH
M^HV'BKQ6\>EW-Q::IH_V>Q-M%N6,K'M\LX^[SD_RYXKU&B@#G/ =I<V'@;2;
M2\MY+>XA@"21R#!4@FH_'4#WFAVUC"";BYU"V2+'4%95=C^"HQ_"M^&_M+B[
MN+2&YBDN+?;YT:,"T>[.-P[9P:>;:)KE;AEW2HI523]T'K@=LT 87BZUO9K;
M3+FSB>=;+4(KF>!.6DC7(.!W(R& [[?6LN[L+B>7Q9J=O;W @O\ 3DMX8C$R
MO-*J.-VPC(^\J\@=#V&:ZZ2_M(;V&RDN8ENIP6BA+#>X'4@=<"BYO[2SD@CN
M;F**2X?RX5=@#(WHH[F@"MH6Z/P[IZ21R1O':QJZ.A#*0H!&*X[0]/LH8-8?
M5-#NWGDU:XNX&%@[.R&3?&0VWCIW(KT*B@#EHA<GQRM_/9SQQ'1Q&["-F59/
M,W%,@<G%<_HD.J:#8^%;V;2KV>"VL9K.YMXHB98'9D8.$ZD?)@D=C7I-% ''
MS63)J_A-[;29+2VMYKAWBCB^6!7C<+NV\ DL,@="3]:R[?2=2F\*67A^>VG3
M5+34DE-T8SY>U9_,,P?H<J3QG.3C%>B44 (S!5+'. ,\#)_*N7\"0SV7AR:*
M[MIX)%N[F79)$P)5I692!CG((Z5U-% 'G.BZ=>6VF^"D?3[F.2SNIFN1Y# Q
MAHY5R>.Y9?\ (J?P_9.K6>G:MH>HO?Z;<M*MX\CFW/+?O5.[!)5ON@9R>1U-
M=_10!Y_8VEU9_#U8QHKRW:7S-)$]OF14-T7\Q5/WB%VL!Z@>F*S-5@N(-,\0
M-=6-YY-QK-A/&UQ&,S+N@4\#J25/&..G'2O4ZHZKI-MK-JMM=^88ED24!'*_
M,K!E.1Z$ _A0!QNN:)?ZC>ZYJFDVLBB2UM46)P86NI(IO,8<X(^3" G'7VIN
MJ67]JZ!J-_I^@:G!=N;5I!=EO.F$4RN5568YP W/?.!FO00, #.?<TM 'GNI
M6FH:J?&C0:9>(NH:5%':F6/9YC*LH*X)R#\PX/XXJ]<PWFH>(-(G@M;NV']E
M74!EDA(\IW\O9N]#\I-=8;^T&H+8?:8OMAC,H@W#?L! +8],D58H XC0_,GT
M&TL;_P ,7*WNFV+VTCRH%4_)M*Q/U;?@=.W4],KH\NHZ E](\>HZGI<%K&;<
MRVNV[4[B/)YV^8%!SN[9/)KMJ9+%'/$T4J!XVX93T(]#0!3N[A;G0IIX4D=9
MK<LBJA+'<O P.<\UQ>G6%VFB> X)M/N1)83*;E6@;]UB!UR>/[S+S^/:N\-Y
M;+?+8F=!=-&91#GYB@(!;'ID@5/0!YR;35+437\&FW4T=KXBDO7MA&0\T#1E
M-Z XW$%MV/:NKLKV."%;B'0[JW6^O "JP@/EAS-*N?E'RX)//3UK;J"YO+:S
M\G[3.D7G2K#'O.-[GHH]S0!S_C*&0G0+L9,-IJ\$DWH%8-'N/T9UIUU'<6_Q
M @OC:7$EJ^F/!YL2;@KB0-@^G'Y]!S712Q1SPO%*BR1NI5D89# ]012QQK%$
ML:EBJC W,2?S/)H \\T33KRUT_P0CZ?<QR6=Q,;D>0P\H-'(N6X[EEJ?PY8R
M!K'3=5T346U#3;AG6\DE?[,>6_>J=V"6!^[C.3R,<UWU% !7"?$+PYJ-_J&@
MZ_I4!N;C1[D2O:A@&ECW*3MSQGY>GO7=U#=7=O8VLES=SQP01C<\DC!54>I)
MH I6NLB^>);>POEW?ZPW%NT(B'OO W'M\N:\OL_"NNII6D:&UM.+ZT\1&^FN
MRI\LQ#)\P/T).1QG.>HKV&*1)HDEC8,CJ&5AT(/0TZ@#Q[6M!U6X/Q%$6EW3
MMJ36HLR(3^^V-\V#[5K:7IE]#X_M;UK"YBLT\.):-*T155E&"5/X#^E>ETR6
M,2PO&Q(#J5)4X/- 'AGA?3[S6_!'@VRT^RN!+;:N;N6Z\LB-(U=LG?TST&.O
M'3I6AKVD:W>:A<FV\.W<$,/B*.[VPJ&29!D&;);<6/'  4#WKU30M"L/#FEI
MIVFH\=JA+(CN6VY.3R>>IJU9W]IJ$;R6=S%<)'(8V:)@P##J,CN* /,/$.BZ
MG<^)O&EQ%IET\=[I"6]LXB)$DF%!4'Z_AQ5C5M"U)/"/@[5-/@,>N:,+:(Q2
M@J65@L;HW?&<?AG'6O3ZS9-!T^375UIHF-\L0AW>8VTJ"2,KG!P22.* +=E:
MK964-NK;O+4 L>K'NQ]R<G\:Y_QQ ]YI=A90@F>XU*V$>.HVR!V/X*C'\*Z>
MHC;1-<K<,N954JK$YV@]<>F>/RH PO&5G->:3:>3;/<"#4+:>6-%W$QI("V%
M[\ \#FL'6-&U"\N=;UC3+.4+*+)EMCF%[LP2%W/."I*X4$X)QZ8KT"B@#S[5
M;-=3\)>(;G3M"U."[OK9(2+K>9IF&<#:6. ,]>.OM5K7=.OM4UZ_%G#/']I\
M/RVL4[1LJB5FR%)(X./\YKKX+^TNKFXMH+F*6:V($R(P)C)Z!O0\58H Y#P_
M#!J=RES<^'M0L[N.U:VG>^=BH!QF-,L0ZDC.<8X]Z;H>BZI#I5[IUPQC-C#+
M8:=,QY:-N5?\%\M?JC>M=C4%O>6UU)<1P3I(]O)Y<RJ<E&P#@^^"/SH X73+
M..]TI([_ ,,:HM]86$MO+YTK["#'M9(3N(;?@8P,#V.,[/A6#4K6]O(+B>>\
ML%BB^S75W 8KCJV8WR!OV\'=C^(]>:ZBB@#B-3M;U-2\8JMC<R+J&G1K;R1Q
M[E9A'(I7([Y(&/?/3)JNUI>176F20:3+-Y/AV>V:%XBJ-*?+*Q,<<9VL/_UU
MW]0)>6SWLEDLZ&YB19'B!^958D D>^#^5 '!6%GJ-QJDDG]GWRI<: ;4--"L
M2I("?D"_P@9P,\^YZUU?A4RIX4TN*>VGMY8+6*)XYDVL&5 #Q]0:V:* /.K:
MQOX=!TAO[.NRUKXAENI8A$=XB9YL, >HQ(OY^U=%XXMY[WP9?V]M;RS3RJ@2
M*--S$[U/;Z5T=% '%:G;7X\0R7ND"\662XM_/M)[<M;72#9^\#$?NW09YS_
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MVB"$H)?[8MMA<9 .3R0.OZ5U-4=4TJVU>WCAN#(IBE6>)XVVLDBG*L/I[Y%
M'+'Q/JVEW>HZ7J'D75W#<6L=O<11>6KK<,0-REL97:W\0SQTJS<ZKXCTZUO9
M+FQDE@CGB\N6%$>?R&!WGRU8@LI';J#G'!K6N/#&FWNGWEG>(]P+TJT\KMB1
MF7&TY&-NW QC 'XFFV_AJWMK:.-;[4'F202"ZEN#)*2 0 2V1MPQXQCD^IH
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MA"<;F./E&01DX'%4?%EK/=-HGD6LDX@U2&XEV+G8BALM^&1[UF:K9W5OXFU
MW&C7NJ:9J<$<:_99MH1E!5DD4NHVD'.>>IH Z!]6M8=6NA+J]JL$%JLLEN0
MT7)_>,^>A&!C';-/M?$6D7TS0VM_#-((?/VH<DQ_WAZ]1TZ9KG+O3;N/6M1,
M5A)Y!\/I91^4,H909#L7//1AR:--L;RWU#PC(]C.B6.E2V]R=G^K<K$ I]>4
M;IG]: +6B^(9M5B75VOH8-/6::&6VDA.<"1DC*M_>)49'.=V  :VF\0:3'9R
MW<E_#'#%((I#(=I1ST4@\AN1P1GFN/M=*U:/PMHY6QG$^G:O)>36C8#21-+*
M?EYP2!(&QGMCK1X@T6]OX?$=];64[KJ"V<4-N4PTAB?<SE3TX..<'Y?I0!UR
M^(]'DMC<1W\4D09US'ECE/O< 9P.,GH,BI)];TRWM([J2\C,$D?FI(F7!C_O
M\9^7D<].:Q-5-_I_BRWU>'3+G4+">Q-K)%;A?,A??N#%6(X(.#Z8&:HWME>:
M?K<-R=!N;C3+G3TM6M=.E"&V96<A2H95*D/@GH"OI0!U<NLZ=#L+W2%757#+
MEEVL<*21P 3T)Z]JN.ZQQL[G"J"2<9X%<'J&BWMM)')HEK<6%[%;0Q) @$MI
M<("?W4@/3;D_-QP>,]*[Z@#CKCQFES:Z'J-A,D5C=Z@;>?SXR#Y>V0@@G&/N
M ]#UKHK?6]-N[ WL%Y');AS&67/WP<;<==V>W6N*L-,U.+0_"]E-I=RLFG:H
M9)R0I 0"4;Q@G(^=??VXI+C3-7C:^O8-.N91#KYOA;H_EO<0- (R4.1\P))P
M2,X]Z .\L=0M-2@,UG.LJ*YC;'56'52#R"/0UE:CK4__  D=KX?TX1B[E@:Z
MFFE4LL,(.T':",L6.!R,8)YZ5-X>@B2WN+F+2YM/^TR^8R7#;I7. -[_ #-@
MG&.O0#Z#-U33[S3_ !K;>);6UDO('LC8W<,6/,1=^]9%!(W<Y!'7!XS0!KQ/
MJ5M?XO)K>33Q [F?9Y;(X*\-R1C!8YXZ5)#K>FSF4)>1@Q1B5P_R8C/1^<97
M_:Z5D^(X+[Q)X6U.QL()(&FMRL;7 \LNV0=N#R 0""3CKWJ"6WN=6U[3=8%C
M<6BV=C<).DB89WD"8C _B VDY''3&>P!J1^*]!E9 FJVQ,D7G)\WWEXY'KU'
M'7D4_P#X2;1/L<%V=4M5@N&9(G:0#<RYW#GN,'/IBN5TC2[ZVMO D<VGS*VG
M1R+=_)_JB82@SZY8CIGUJE/#/8_V<UU93+O\627$:%,EHV65E8#]<=>.F: .
MYMO$6D7>GF_M]0AEMA)Y)=3G]YD )CKNR1QC/(H;Q#I"6J7+ZA D3S?9P7;:
M?-SC80>0V>H/2N6NM-U""[U35;337DBOM2MI/*\M3+'&B!6F1&X#ENF><<XS
M5-=*U-;&X@;2KP9\20WP\PJY:$.C,V0QS@*<_IF@#LAXGT4V<EX-1A^SQ3"!
MWR<*YQA3Z$Y&/7(]:M7%XI,MK;RHM[Y!EC5T9@.P8@=1GMUKGHM$.IZIXMMK
MZUE2RU+RECD*XW 1!2P]"&''T!JWX/COY=+%_JK(][,JQ%T.0T<>55A_O'<_
M_ Z +MEJ,UOI-H^LM&E[(IW+#&WS8[A>2!C!/IGFM&">*YMXKB!Q)%*@='7H
MRD9!'X5S_BG3VO9[%X7U"VN(1(T-]9#>86^7Y63G<K=QC^$=.M:NB"]&A6(U
M****]$""9(@ JMCD#''Y<4 59?%F@03^1)J]HLGG>1CS!Q)Q\I/;J*M3:UIU
MO>"UENXUFWK$0<X#M]U2>@8]@3DY%</):/JMEXYT>&S>6>]U!HXWV?(&,,6&
M9NVT_-S^&33M9T_5YGO8%TFYD,.H6<T3V_EJEQ&C1;G8[@6D^5A@\  ?6@#M
MDUK3I%O62Z0BR)%R<']T0,G=Z<<_2KBRH\(E4_(5W X/3Z5R>J:5<-XN@^S;
M5M=7@VZC$3R!"5(;'?<&\MO8CTK<_LRZ&L?;O[9OC!G/V+;%Y7W<8^YO]_O=
M?;B@#&TWQ#-JMQ<WJ7T%M865Y+!/%-$0&C7Y0P<XPQ;\,'&,\ULOXATB*UN;
MF:_BBBM2!/YI*&,GD!E.",]N.>U<B=)U:70;WR;.87$.OMJ26[X7[1$)_, !
MSC)'(![@9Q2>*-'OM877M0LK*XQ=:5'910,FUYI!(S$E3T"@@9/J>V,@'<6.
MI66IQRO97,<Z12&)V0Y"N,9'ZC\ZH3^+- MIS#-J]HD@F\@@R#A^/E/IU'7U
MJ2_TVXU)8'M=7O\ 3%5>4MTB^;/]X.C8(]L5QTMJVIP^/-)ALGFGO;SRHVV?
M(&,$0!9NVT_-S^&3Q0!W%[K.G:<X2[NDA/R[BV<)N.%W'HN3P,XS4$OB318+
MXV4FI6XNA((C$&RP<@D+@=\"N6FTN[M-6U.POM&O-7L=1$312Q3XCRL21LDR
MEQ@93=G!Z]SQ6SHMI/;>+=?N);21()DMA#+M^5]B%6QWX)[]>U $&E^(IM4E
MEU$7T-O86UW-;S02PGYD5BB,K<?,6 XYX.,9Z[3^(-)CLKB[EOX8H;9MLYD.
MPQMZ,#R#R.".<UQ\>E:M_8*/'93":T\0/J+6S8#3PF9V 7G&<,& )ZK3O$6C
M7VIP>*+ZSLY\:AI\-I! 5VO,ZEB7(/3 8*,XZ'MC(!TZ^+- >1HUU:U:16=2
M@?)RN-W'?J/KD4^#Q/HEU):1P:G;R-=_Z@*WWSSQ['@\'G@UGW]O-+XN\.WD
M5G-]FMX+D2OL_P!675 H(]?E/3I6%!I>H1Z!IL!TZX$L7B!KQTV<K"9W??\
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MEW0*(EQ]X9&<CCY1S532=,OK>/P*DMA,ITZW=+KY/]4QAV<^N6],^M '4_\
M"2Z*+*WO#J=LMO<,4BD:0 ,PSD<]Q@Y],4^TU_2K^P>^M;^&6V1_+9U/W7SC
M:1USR..IR/6N$N()[&UT\W5E,N_Q8]PD93):-S*RL!]#G'7\:M:GH>IM>ZEK
MMA92NKZA;7 LP_E23QQQLCL.1M8[\@'!.P>M '7'Q)HPMUG?4;=$,_V?]XVT
MB7^X0>0>1P:?;Z[I=W:2W5O>Q20PR>4Y7.5?C"XZY.1@=\C'6N5OM.>[L;6Y
ML]!N[9I=6M;F9)SNF98V!9W^9N@& ,YXIUUI<MSJ'B7[387QMKN[M9(9;8[)
M!L1 9$/7*LN??' - '4G6].$2R?:0=\C1*@1BY=1EE"XW9 !SQQ56X\4Z7#<
M:5$DWG+J9;R)(@67:$+;L@>P&/?V-<[!#X@ADT];RTFOH5NIU^W10QQW1CV*
M(RP.-F[Y@S#!PJ],U7T;2]6L;#PBTNE7.[3KFY2>,,A8!U<*WWONY8<T =?9
MZI;E=2GEU6VG@@N"A**%$'RK^[8Y.YLG.?\ : Q3G\0Z3%:7-U+?Q116I"SF
M4[#&3R RG!!/;CFN1N=(U:0:M/;V<I9-?AU&.%L+]IA18P0N3C.5) ..0/6C
MQ+HU]JR>(M0L[.?%YI<5G% R;7FD#LQ8J>@ 8#)]^V,@'9V6L:=J-Q/;V=Y%
M--!CS$0Y*@YP?<<'GVI]_JEAI:1M?7<-LLKA$,KA=S>@K&M[><^/7O1:RI:-
MI4< E*8&\2,VW\F'M4/CI@EIHK&-I0NL6IV*,D_,>@H -;\5PGPQ/JF@W]K-
MY%S##*<;MNZ148$9&#AL\UHS>(--N-+U&6TU>UA-JA62X?YE@8CY68$C([CU
M]:Y;7-#O+Q?$5]:V,S#49;%8H=F&D\F0,\A!Z<<<X/R^XJSJUA?7%UXS:&QG
M9=0TF.WMB$QYL@252/;EUZ_TH V!JMX/%FEZ>)X9;.ZT^6X9ECP6=6C .<]"
M'/'\ZTX=9TZXNTM8KN-IG#&,<@2;?O;3T;'?&<5S4FG7UQK.CLD$\*)HT]J\
M^W_4ROY>W/\ WP?RJ"QTK4+O2O"FG364MK=:-/&UQ*1\FV.-D^1OXM^1T[$Y
MQB@#K8=6L9[@P1W"F3:SC@@%5(#$$\$ D X]:9!K>F7,C)'>1;EB\[YCMS'_
M 'QGJO\ M#BN(?P]J]Q9WNGZ8UU;6=[8W"/;7H!%I*V,"*3J48YR.0 .QP*V
MH+2[U76?#E\]C-9-IL,OVE90!\SH$\M3_$,_-D<?*.] &M:>*-#O[R*SM-5M
M9;F9"\2*^2XQGCUXYQZ<UF^'?%45TC6VJ7UL-0:^N+:)%&S>$D95&,G!(7H3
MSS7.^&+%]7\(>"XX+62,V$Z74DS)M"HH?(4_Q%B0,#WSC%6(],U!=(MH_P"S
MK@2KXD:]9=G(A,[/O_[Y(XZ]L4 =G'KFF2VMU<QW:-#:.8YW .(V'4'C@C//
MI5\$,H(Z'FN2N-*G3QL8K<I_9NHHMY>1YY62$J 0/]O* ^HC-=+!=237MU;M
M:31)!LVS/C9-D9.W!SQT.0* +-<KXNU77-"T?4=6M9;'R;?R_*AEMV9FR54D
ML'&.6/&.WO755S/C^SNM1\%W]E8VTEQ<S; D<8Y.'4GD\#@&@"+7M1UW1+$7
M,MW8O$;NUC#K;E#M>4(X.7/8@@_7CO6W:ZYI=Y!<3V]]"\5LVR9MV-AQGG/U
M&/6LSQ?;SZCH5O':VLLSF]MI3&%Y")*K,2#[ UAZOI.K7.H^(KBRLY6+3V-S
M C-Y8N?)(+H&SE3QP3CG% ':66I6>H^<+6<.T+;)4(*M&V,X93@CCGFLGQ/J
MVH:7<Z+'8O;A;^_6TD\Z(OM#*S;AAA_=_6G^'8XY);O4%T>ZTZ2X"*YO'W32
ME<]?F;@9P.<]>,8S1\;6,VH2Z"D>GR7D5OJ:7%PBH& C".#D'@\L.* +=AK=
MY_PE]SH%W]GG\NS6[6XMT*; 6V['4EL'N#GD9XK3MM9TZ[N5MX+N-Y74O&O(
M\Q1U9">& XY&:X]O#EY<>(-1DT:S;1M.NM,EMY<[46:X8$(XC4\%0>6(!/2K
M%KI]_?Q^%4>QEL[G1SNN6< *-L+1[$8?>#$@\<8'.#@4 =-#KNEW$QBBO8BV
MQI!DX#*IPS*3PP!X)&<5#;>*-#O%E:WU2VD6*(3.5?@(3@'/U_IZUR6D6NK+
MJ_AV]N=%NK?[-#=17*((UB@+;,"-%;[GRG!QD\=:+?2-6A^'FB0Q:?)]LTZ]
MBN9[(X5I524L5'.">0PYZCUH Z'1=<FU+Q3KEB94>VLX[=HE$11T+^9N#9YS
M\H["G>(-9GTG5=#7SH8[.ZN7BN#(O.!$[@AL\<J.U5]#6[D\8:UJ$FG75M:W
M=M:B)Y@JY*>9D$9SGYAVJ;Q%:W%QK?AR6*VDEBMKUI9F5<A%,3J"?^!,* -&
M+7M+GL$OHKV-[>23RD9<DL^<; O4MD'C&>*>FLZ?):1W4=RLD4KF--@+,S#.
M5"@9R-IR,9&#GI7'1VNJVJ3E=)F=)-?EN"RQH98X64XDC#< D\$]0">.]16>
MBW1TQ[:ZL]5L94U:ZN+>\MW#R0[V8JV 6WJ0VT@@YS^- '?VUS#>6T=Q;R"2
M&091UZ$5+69X>&H+H-J-56-;[:?-V*%!^8X.!P"1@D#N36G0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !117,^-7N4M-)%M=RV_F:K:QOY87Y@9!P<@]P#_/B@#<M]1L[N[NK6WN$
MDGM2JSHO6,D9 -6J\YU*ZU+2]1\:ZC87B1R6,-M.0\(?SBL.<'T!P>G//:MF
M\U?5]1OM2LM&_=W-E#$\8;85=W4L-^[G9T'RX/7GM0!UM%<A;ZEKEYXCU"W:
M^MX+:R@M+IHXX!(6#^870-GOL^]]..N5T;4M=U9=)U)&1=/OX"\ZN8_W19=R
M>5CDD'@AL^O'2@#?_MG3O[1CT_[4OVF0LJ)@X9E&64-C!8#DC.15^O.M&U"X
MTK0(3]H,LU]K\]FCRHI$1:XEW., <D ]>,D=N*LZ]XCUG1D\06<=PDDUE:PW
MEM<R1 G8[%2C 8&05.#CIVXH [RBN5GO=7@UB+16O3-//#+=B:"&.-D4,BJ@
M#D@@%B2>O3ZUKZ5/J/\ 8$<NK?94OT1O.,;_ +K<I(SGL.,GTYH TZJRZC9P
M:A;V$EPBW=P&:*(_>8*,D_A7&P>+;^QE>6\D-W;KHDFI,RQA%>2,KGRN VP[
MN-PSP#FEFENO^$E\)ZA=W?VCS;6ZF9$C 528E8[,<XYQR2>!S0!V&I:;:ZM9
M-9WL;20,0Q59&0Y!R.5(/4>M3P016T$<$$:QQ1J%1%& H'0"N-A\1ZF=(\/:
MYYJ20ZM<10RVNP;8A+D*5(YRIQG).>>E4H_$'B./1K;79+RVF@34VLY[5;;;
MYD9N#"&#9R&'&!T]<T >AT5P-KJ][I@\07#WDMP[:XEE$) FU-XA4'H.@/ S
MCIGJ35VZUC7-)8V]VT96\OK>UL9I-AD029WEU3"G&T[?7(STH Z>#4;.ZO;F
MS@N$DN+7;Y\:]4W9QGZX-33316T#S3.L<2*69F.  .]<OX?BEA\=>)TFN&G/
ME695W4!L;9.#@ ?H*9.;I_'>JQ->RFWCTB.18,+M!9I 1TS_  @^OX<4 =3:
M7<%_9PW=K();>=!)&XZ,I&0:;:7MM?Q-+:RB1$D>)B >&4E6'X$&N'\)7VI6
M5GX-M&NHY+/4-,(\GR@/**1(RD-G)SD@Y_#%3Q>(]7_L-;R9)YTCU&Z@NI+&
M%6ECBC=U5E0YR,A<]3B@#N:*R;"_:]\,1WUM>PW+O;ETN5C^5SCKMXQ].U<O
MINOZ^D'A74[VZ@N;36%6*:W2WVM&[1%PZG.3]TY'3GB@#OJSFU[2UMKRY-[&
M8;*3RKAQDB-^.#C_ 'A^=<Q#XFU%]"T/Q")%DM]1NXX9;/8,1I*^Q=I'.Y3M
MSDD'G@<8J7&HWFD:?XWO[&1(YX=30@NFX8,, /'XT >AT5S,VH:GJFI:W9:7
M=PVL^F&)(UE0,LC,@<E^,[<' VX/!.3VAO=<O=*UV\M;J?S(+JS\[2PBJ-TH
M.UH\XY.6C(]B>N* .LHJC/#J']B/%#=K_:(APLY0;3)CJ5Z8SV]*X^S\9S&Z
MT:YNKAQ87-DPNAY:_NKM0QV$X_Z9R\>H7UQ0!VAU&S&IKIOVA/MC1&80_P 6
MP$ G\R/SIUQ>VUK-;13RA)+F3RX00?G;!;'Y _E7'RP:G+XST>-[T0WS:-<&
M6;RE8J3)"2 .G!XY]*=I_B75+O3O"%R\D(.HW#0786/[Q6.0Y'/'*=/>@#M2
M0 23@#J35>PU"TU.U^TV4Z3P%F0.G3*DJ1^!!%8.C:CJ>MVECK,%Y!':S7$B
MS6LBC"QAF10I SYF0N<G')XZ5S^AWVHZ98:?-#<I]DN-?N;22W,0Y5YY?FW=
M<@@=.* /1Z*P/%FHW^F:?9RZ?)$DDM_;V[>;'N!6215/<8ZUSFK>(/$.B6_B
M6TDO(+B>QM(KVUNOLX7Y79E*,H.,@J<'TZT >A45RR7FJ#Q,- GU(%WMI+XW
M$5NJLJ[U18U!W @$L23ST'O6</$VJC1[;4[B1(X['5'L-3V1C:Z+(8_-7.2!
MG:3[;O2@#LKR]MM/@$]U*(HRZQ[B#]YF"J./4D"DU#4+32K&6]OIT@MHAEY'
MZ 5SFLZOJ5GHKZG;7*^7)J,$42O&#^Y:5(S@^^68'G@CZUD>*]1NM:\(^,6B
MN?(@T\R6@A"*?,VHI<L3SSN(&",8!YSB@#T,'(!'0U2O])L]3EM9+N-W:UE$
MT)65TVN 1GY2,\$CGUKG[S5-9O;[5+'1<)<Z<L00-L*2.R!_WF?FVD''RX/!
MY/2FW/B&\MM?BM;]Y+&&>6!;698Q);3;@N^-G )5R2P&< C;0!UDTT=O"\TT
MBQQ1J6=W. H'4DU6L=4L]1:=;6;>]N^R9&4JT;8R 5(!&0<^]87Q#61O!-\8
MYGBP8\[0/F!D48.1[TJ7E_?:UJ^E6=[Y$VG00MYS1(3-)(&(+C&-H  XP>O-
M &YJ>E6>L6HMKZ)I(0XD"K(R?,.G*D&K4<:0Q)'&BI&@"JJC 4#H *X2R\1:
MWXAFT1;.ZATY=2TN6Y?-OYACD1HQD9/(^8_A6OXY>YB\/1-;W<D#F]M4=HP/
MF5ID4CD'CG_(S0!N0:C9W-]<V4-PCW-L%,T:]4#9VY^NT_E5JO/M0?4;/Q!X
MMNK&^$4]II5K,7>$.9"@G(!'  .#G ^F*T7US5=6GEL]+S#<QZ?!=*0$(,DH
M8@-O_@&T#CGD\B@#H['2;/39KJ6UC='NY?.F+2N^Y\ 9PQ.. !QZ5=K&U&]O
M[?P;<W^8(M0BL6G.W]Y&L@3<0.F1D<5BPZKK$9T>WN+T3S:O&9D,,*(T(6-2
MRJ6)#$ELY(Z \>@!TMEHUAI]W=75K!LGNG+S.79B23GC).!GL,"KU<E:ZKK/
MV_3M#U*6*"\N!<R-<0[2S1QE=@ .5#D.">"/E..HP^'4M4.L6'A^[O(5O&M9
MKFXNK9!\P1U554," 2&!;CMQUH ZJBN'TWQ-JESJVEV=PZ!O[1N]/N2L8"R^
M5&S*Z]U)P,C..M1MXAUHVD(ANH!(WB"332\D&<QAF . 0,_+SZ^U '>52LM)
ML].N+N>UC=)+N3S9RTKOO? &<,2!P ./2N+O/$'B'3(M9LI;N":XL+NR$=T;
M<#S(IW"[2H. PYY^E6+S4M?AN/$MJFJQ9TRTCO89#:KD[ED.PC.-N8_KSUXH
M [FBN-_MW5M9::VTO]S=1:?!<K@(5:256(#;N=GR@?+SUYJ.ZU7Q!+J5]:I>
MVUJ8='BO@(X1(%E)<,H8GE<IUQT_.@#MJ*XG2[^^U7Q9H=T]W)''<Z#]K:W0
M+L#,\61R,\Y]<\<=ZVM7U2:'7M(T>"0PM?\ G.TP )58U!PN<C)+#J#P#0!L
M33Q6T#S32+'$@+,['  J"QU.SU(3?9)M[02>7*A4JT;8SAE(!'!!KA->U&_O
M_"NMV=U.5FTW5(+8S1H )T,D3*2,<'#C..,CT.*Z_7-1/AWPS?ZGC[1+;0-(
M2P \Q@,#=@?3\* ->BN7U74=4\/V-WJ,M];WEK]GC,8= K+*SA2PQ@&/YE/)
MS[\U1US4O$NC:-KEX)8Q%!:>?:R7"HTH<??4JF 5Y&#V[YH [:BN+OHM8B\6
M>'H;G67=)YKF39% J*H$0PO.<XRW)['UYI;;7]1/B#286N4N+>^NKJ"0Q1CR
M5"*[)L8@,6 0!CRN2<=* .KM;VVO1,;:42"&5H9, _*Z]1^%6*X-O$.M_8]R
MW5N)1XB_LXL8.#%O"CC/^?45N^';^^FU#6].OKA;EK"Z1(YA&$+(\2. 0.,@
ML1F@#?HKD;S5M;O[K5X]&V+-IMPD*I*4$<GR([>83\P!#$ KCIGGH&:AJ^J6
M7BR'2GOD6UU((;:;8N;=@26C;C!+@$(3CH>N.0#I-0TFSU1[5KN-W-K,)X=L
MKIM< @'Y2,]3U]:NUR5]JNM7U]J]KHNU;C39(XT639Y<A**Y\S/S $-@;<="
M>>@DBU/5-8?56T^[M[1].ND@$4H#1N B.Y<XS@AB!MQTSSV .IIKNL<;.YPJ
M@DGT%<3J?B'5+33/%DL5POF:5<QK;L8U^ZT<;$-QSRY_2K$,M^/%_BADU"3;
M;V=LT,;HK(N5E/3 /7GKSGGM0!U5I=07UG#=VT@D@F021N!]Y2,@U-7%6^OZ
MDFG>$M6N[E19:A%''>XC4!99(\HV<<*6^4_45;DUF_$VEV:R2F35//GC=5C#
MI$FTJH##&[#J3D'HWU !U5%9NAOJ;:8%U@0_;(W96,)&&7/RD@=&*XR/6L/3
M=:U&^T2R\2K=0_89(Y9KBT91\J -L5"!G>" #DX/. .* .NJEJ.DV>JBW%Y&
M[BWF6>+;*Z;77H?E(SCWKF8=?U..S\,ZI),D\&LR1Q36X08A,J%U*$<X7&#D
MG/7BJ2Z]X@^P07IO[<G^W&TUHOLPVLAG,08\YR.#P>W.: /0**X'4/$&N:;#
MKENMY#--87MG''-) !N28H"I ..-QY__ %U)>^)-8\.W^JV>H3PWJI:PW5M.
M(1'Y?F2^4589P0"0W7H#D]Z .ZHKB-<U/Q+HNC:W=^;$(H;=9K22X5&E# X=
M2J84KR"#VSSFK$^J:]9ZQJ^G1R17TZZ<EY:KY8CVN7="@YY'RC&3U[T =?37
M02(R,6 88.UB#^8Y%<=;>)7N["1K?4GCE%[%!)#>6VRZA!&3&$"X9S@E3@C&
M?0UG76K:IJ&D6RR7<UO)#XDCLF950,Z"48W8!&1QG'!QZ<4 =CH\.EZ;&VB:
M:=BV2+F NSF-6SMY8GK@]ZTZXK4_%%_HTWB8RO'/'I\%H;8&/;AI2RY?'49P
M3TX':K5]JFJ:5KG]FFY%PEUI\UQ#-)$-T4D6W((7 *D,,=P1U.: -W3M&L-*
M>X>R@\M[AS)*Q=G+$DGJQ.!DG@<#)J:YO;:S>W2XE"-<2B&($'YG()Q^0-<E
MH>MZQ+=^&&O;N*>+6-.::2-80GENJ1MD'J<[CD=/3%;'B'4;S3[W0EMI$6*[
MU!;:963)*E';@]N5H W:*X&77]=BM=0OVO8#'8ZVEEY MP!)$SQI@G.01OR,
M=QSGH-GQ])<0^#;V2VN9+=PT:EH\9*M(JD<CH0: -N+4;.;4)K".X1KJ!%>6
M(=45LX)^N#5JN"U$:A;^+=<DL[_RIX-$@D\UX5<N5>8@8X !QSQ^56T\0:GK
M!AM+#,%T^DP7^8PAR\N[ (?^ %><<_,.1W .RHK'N=5NM-\'SZK?0Q->6MFT
M\T4+90NJDD ^F15"W;Q'/,=EU&+6XLRT4T@CW)/U4J%SNC(SP<GWH Z>BN1T
MGQ'<WVCV][([^;9VDLNI0A5SYR$J4Z<?,DF,=E'K4*ZIXB?3HM4BDA^R3Z>\
M[&8(0DFS>AC"G+*>00QST.>M ':45QFDZMK$U_H45W?))'J^EO<$) JF&15C
M.5/.<[SD'C([=*N^ )+F?P987%U=27$LRL[-(!G)8YZ =^: .FJA?:SIVF.%
MO+I8B=N202%W'"EB!A03D G )%<K-XHU$^&)?$\$@,,-ZT36)08:%9O*//W@
M_P#%UQVQWJYH\$K>/O$OF74DD:I:_NV5<$%7('3/'_Z\T =;17+^*-5O[%[E
M;*Z5&AT^6Y6&*,/(77HS[AM$?![@DYQTJJNK:UJ>L6UI;WL-I%<:,M]E;<.R
M2%@.,GIS^7YT =E163X7U.;6?"VEZE<*HFN;9)) HP-Q'./QK6H **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ JEJFE6FL6BVUXKE%D25"DC(RNIRK!E((((J[5:\O[;3XT>YEV"1Q&
M@"EF=CT4 9)/!Z>AH SIO"NESKJ22).5U*-8[H>>_P ZJ-H'7CCCBF7GA'2;
MV\@O)%N4N(HA"9(;F2,RQCHCE2-P^M78];TZ6Q2\CN0T+R&)<(VXR D%-F-V
MX$'C&>#38M>TR:T2YBN=Z/*T*JJ,7,BYW)LQNW#!R,9&* '6VC6=IJEQJ,*N
MMQ<1I%)\YVE4SM 7H,9/3UJIIGA/2='NGGL8YXP2S)";AVBB+?>*(3M4G)Z#
MN:LQZ]IDUE!=PW0EBG8I$(T9F=AG< @&[(P<C'&#FB/Q!I<J6CI=JRW<IAA(
M5OFD&<H>/E8;3P<'@T 5U\*Z2NE2Z889&M9)C/AIF++(6W[U;.5.[G(/6G7/
MAG3;RQN[6Z6:9;P*+B1I6#R!?N@L.0!Z# Y/J:?+XET>""6>:^2..*Y%K(75
MEVRG&%.1_M#GIS52^\8Z5:Z)J6I1/)<+IXQ+$D3APV,J"",@'(^;ICG- %G5
MO#>GZTMJ;L3B>T),%Q#.T<J9&#AU(/(ZU>CT^UCT[[ L6;8H8RC$MN!ZY)Y)
M.3DGDYK/&KVS:S''_:)C LWG:RDMRK%0RCS"2 1C.,=]V:=8^*-%U.XMX+.^
M662YC,D.$8"11UP2,$CN,Y'I0!!:>#M&M)('2*>0P6[6J":YDD'E-C*$,2"O
M P#Q19>#])L)[*6'[638[A:J]W(RQ*PP5 )Z8&,'_"K+^)-(CFCB>\4&25H8
MVV-M>1>&56Q@D8.0#V/H:FU+6M.TAH%O[I86G8K$""2Y )P,#K@&@"O:^&]-
ML#&8(9/*@E::"W,A,<3G.2BDX'4X'09.,5E>%_#CP:<%U2WF21+^>Z2!Y@T>
MYI69&PI(R 1QT!&<9YK5D\3Z/%:1W;WF+=T23S?+?:BO]TN<?(#_ +6*LR:Q
M8Q7/V=I6,@D6([8V90[ $*6 P"00<$]QZT 5)_"NCW2ZDD]LTD>I$-<QM*^Q
MFP!N"YPK?*O(P>!4?_"(:2VDR:=,ES<12,K&6>YD>4%3E2')W+M[8(QSZFDT
M_P 6:=?VDUR?/@CCNFM5$L#AI'#%<*,9))!^49([XHO?%NFVME:W,9FN$N+Q
M;,".%R4DW;6##&5(YX(R<8H M:=H%EIE]<7L+7+W-PB)+)-</(7"YVY!..Y_
M.G7.A6-WJ9U"195N6@^SLT<S*&3)(! .#@L<$],T7.O:;9R*EQ<F/+HA9HVV
MHS8VJ[8PA.1PQ'4>M5YO%NA6[S++J"+Y$P@F.QB(W.,!B!A1\PY/'/6@!UOX
M9TVU.F&%9E_LR-H[0><Q$:D8(Z\\ #G/2BW\,V%HB+:O=0E)I)U99V)WR'+D
MYSD$\X/&:FMM?TN[DNXXKQ-UH@DFW@H%0YP^6 RO!^89''6HI/$^CPQ7<DUY
MY(M(Q+.LT3HR(>C;6 )!P>0,<4 6%L8M/T5K*QMSL2)ECC5N23GN3U).<DUD
M>$O#W]G:#HRZA%,+VQMA&(Y90ZQ/MPQ7!(YYP>P.!@'%7U\3Z3(+SRKEI6M(
M?/D1(G+&/GYE&/G'!Y7(J72M9@U30;?5MLD,,L*S$2H5*@J&[@9'/4<'M0!%
M:^&M,LY$,,3B&.8W$5N9"8HY#G+*O0<DG'0$Y %,G\*Z7<V^HV\J3F+491-=
M+Y[#>PP >O'"KTQTIUGXJT6_C:2TOEE141\JC?,')"[>/F)((P,G-31:_ID\
M!EBN"^)C;F,1/Y@D R4*8W9P"<8Z<]* *UYX4TJ^U,:A*DZW!C$4IBN'C$Z#
MHL@4@./K].E-FL[G5=>MS>Z;%%9Z;,9K:<RAVF<H5&% ^4#<V<]PM7(M<TZ>
M>W@CG)EN$>2)3&X+A#A\9'4'J.O-96IZ^TG]@7.E7:M:7FI"UE_=_>7;)N'/
M((9,4 =-64?#>DF!X39IY;W@OF'K/N#;_P Q6;-XKL[K3-:=+N;3%L)6@-W-
M:L0K *2VTC!Y8C'7C/>K][XHT;3IKB"ZO@LUM&LDR+&S%%.<,0H/'!R>W?%
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M\3[<K%(AR-S +A5(&*VCH&GSV]W'=P-<_;8Q%<&X;<SH,X7V R>G<D]>:/\
MA(M*-S#;BY)>=F2$B)RLK*"2%;&UL 'H>U+'X@TN:"SF2Z!BO)C! VQ@'D!(
M*].#E6ZXZ&@"G'X-TA-(N-,<7<UM<*$D\Z[D=M@Z(&)R%'H,59N/#EA=7DMW
M-]H,\MNML[B=E.Q6W #!X(.3D<U OB#3K-=3N;O68WMX+I86!BVBW8JO[O('
MS9)SG_:QVJPOB32GM3<1W+R1@N,1PNS?(<,=H7.!D<XQR/6@"*Y\*Z9=@FX6
M=YS-'/\ :!,RRAT!52&7&, D<>I]:9_PB&CBUGMQ%.$GNENV(N9-RR@@AU;=
MD'(SQUJ5_%.BHT2B_21I;?[3&L2M(7CR!N4*#GJ.!S2VOBC1;ZXM(+:_25[M
M=T!56VR<9(#8QNQSMSGVH 4^&M+>6_>6!I1?PK!<I)(S*Z*"%&">, GD<\TL
M/A^RBC=29Y6:#[,))9F9UB_NACR/<]3@9)P*D.O:8+V.T-T%ED9DC+(P1V7[
MRJ^-I(P<@'/!]*KVOBO0[R>VAM[])&N7:.(A&VLZYRN[& WRG@G)QD4 .M_#
M>G6LFF/$LP.F1&&T!F8A$( (Z\\ #G/2K.H:3:ZG+:27(D+6DPGAVR%=K@$
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M2ORD%LJ!C!X).*EM=7@T^."RU34UGNS+Y'V@6YC1G)RJ$CY5?!'&1D] ,XH
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M*>0MN4,S[7C4DA6&[##YCUSU- %?Q3J\FDZ3#+;L$>YNH+59B 1$)'"E^>.
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M.!/YDKLTH' #,3N(]LT 9NG7-_!XTN=,N+^2ZMY-/CNU$B(OEN9&4A=H'RX
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MD@ETZ!9[KSX6CQ&5SO&1R,5A^*M(\0>*O -Y8-I-M::E<O$3&MPK E6!9F;
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M6.:.0C!DB?."?<,K _0'O6Q7-V%J]QX]U750/W$5I#8HW9W#,[_EN4?7([4
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M';>$LK*N6$LG/S$<$Y^G'!JWIGA>_P!$G\,"%(KB.QM;BWN2)-@0RLC97(Y
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M5<W1LXV,+#]\&*E3QQRI&3QQ5?\ X2S2KB2YMXI+S="TL<LB6<A$3(N6R=N
M<'C/7WKGUT#78K>VL$L86CM==:_$[7  DB:5WX&,@@-@Y[CC/;8TG3K^UL_$
M236A5[R\FG@ D4[E=%49YX.10 MIXF@2;P_81F[O5U&S\]+QXN74*OS$ #D[
M@3Q@5:TW6;(VES,M]<W0-]) JRPE7$@/,2KM!(7!ZCH"2<#-8^FZ'JUD?"$A
MM8V;3;![.Z4S ;25C&X'G(_=GWY%5)/#>L?8I+B*Q@DN8-;FU&.UN)%V7$4@
M92I/(5L.>O (H ZB#Q+IUS$#"\CR_:&M3!Y9$@E4%F4J>F ,^F/J*T;2ZBO;
M6.YAW^6XR-ZE3Z<@\C\:Y6ZT-]1TV%+KP_%;AYS*8["=8YK9@N%D60;07SU]
MCWQSO:!;W]IH=K!J=P9[Q%(>0XR1D[<D<%MN 3W.: (D\2:;)?1VJRN6DG>V
MCD\L[&E0$L@/J-K?D<5!%XQT>>:*-)+C$ET;,2-;2*BS D;&)& 201@_U%83
MZ-XAGU/3[JYLX99;/5I)S+]IPK0,LBKL3'RX#+GN2,\]:!H.K?V4(/L1\P>(
M/[1QYJ?ZKS_,]?O8XQZT 7?&?B(V6@7YTVXGCN;:6.-YH8MR(Q9?D8D$#ANW
M3(Y%=:P+*0&*DC&X8R/SKS^_T#7UT?Q!HT%E'<QWUZUY;7)G50 \BN48'G((
M.",@CTKOMSB+<4R^W)13GGT!./Z4 <)H&N3ZEHF^[\4F'4GNI;:*+;;\L)61
M 4V;CG S^)XKI[CQ+IEK?W-C,\RW-O&DC1^0Y+*S!%*\?-ECCY<\UA^'K+5]
M'\-M83:(9[@7,UQ'F>/R\M*9$R<Y&,CL>E2:]H^JW]Y#JEK"@U'2F7[%DJ%N
M V!*&.<JI' '48SST !N:CK]AIBRFX:4^1#]HG$<9<Q1\_,V.@X/OP?0UA3>
M)AI_BO4/M%U<3Z:NF07<4<,!DV!FD#,-BYVX4')J1[;7;'Q-<ZG9:=%=6VI6
M\2312W C:VD3<,DX(92&YQD\=*2ZTG4Y-;U>Y^S>8ESI"6:.K*H:53(3P3P/
MW@_(T :EYXHTJRC,CS.Z+:B\=HHRX2 ])#CMP??@^E)>^*M+L;N6UD:XDGCM
MQ<E(;:20F,G&X8'(X/2N6N_#_B&YT$Z4UI&\)T);.-3<A!'<!&5BV,[P?EV]
MACMG-:L&F:HNMM>RV.$.BK9X253^]#,V.2.,$<^N?K0!MG7K QV;PR-<&\A-
MQ;I"A9GC !+8]/F7KZ@=:CMO$NFWMC!=V;S7"7 8PJD#AI N,D @' R.>F2!
MUKD(K/4]._X1FSM;/S-6T[2FBN$BNHT<(=BC[P*LI9"?7*CIR#)%I-VL.D76
MEZ%'*NF+-8W&FWDZ,6#%&+I)RI8,H)^I'!% ';Z;J5IJ^GQ7UC+YMO*"5;!'
M0X((/(((((/I5NJ6E6[6VG1QO:V]JQ)8P6X&Q,G.!@#)]3CDYJ[0 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !4-W=V]A:275W,D,$2[GD<X"BIJXWXA,R0^'Y93BPCUFW:[)^Z$R=
MI;_9W;?TH WAK]CO@607,/VAQ'"9K:1 ['H,D<'V.*U*BN! 8U$^TKO4KN_O
M9!7'OG%<)#KNI3^%M*\217,IN;B_2*>TZH4>;RS&%[%<CGKE><T >@45YS?Z
MAJ\6E>([]-8NA+INKK% N$V;#Y.58;>1\[>GYU<U"\U/3;GQ59Q:K=.+?2%O
MH)) A:*3]Z#CY<8.Q>,<=L4 =T    , 57N+M+::VB:.9S<2>6ICC+!3M)RQ
M'W1QU/<BN.MCJ4NO:39OK5[Y.HZ2]Q,!L!5T,>"AV_+]\Y_QYJ+3-9U2?3O!
MTTM_*S7-]-;7/RJ/.5%FP6XZ_NU/&* .^J"\NELK.:Z>.618D+E(8R[MCL%'
M)-<=;ZOJ,.K26E_+-;74RW+V=R7$EG<J 60\?<*+C(QR 3S5&ZUS4H/#?B%)
M9-0T[6K+3A,8I665<C=F6)\$%6/!'&,< 4 >BJ=RA@",C/(P:6N5CO+K5_$6
MIZ4;R:S%I9020-$0&9Y ^9#_ '@"H&#QUSGMD:5JVKZ]<^&A<7]Q:+J&ESRW
M"0!5RZ-& ZDJ2,AB?H>,=: /0:@6\@:>:%7!:$9E/9.,@$^N.<>F#W%9'@R^
MNM1\)V5S>3&:X/F(\A !?9(R@G'?"BN2\V:Z^"FKWTDLB75PMY/,R-M8MYKC
M!/I@!<>@Q0!WJZM:-K1TD,_VL6_V@C80NS=MR&Z'D]JO5P]S8R3>-TMXK^Z@
M(T-CYT;#S#^^'<@_Y%0:5KVHZU;Z!92SA)KW2/M;.)O):63*@X(4\C[V!Z^@
MH [V21(HVDD8(B LS,<  =2:A2^MW95#D,T?FX92-J>K9^[^/H?0U3TJ"XN/
M#T5KJUQ!?3M&T-S+$N$EZJ>/Y^^:I3^&- T^Q%PULZ1V5G+"'$SEEA()8<GY
MNK8SG&>* )X?$6D73VDRM(5G?R[6=K=PDA;^XY&.<?B!D9%,7QAHSZK=:7'+
M<R7UJ TT$=G,[(#C!.$]Q^=<%9Q^(_ -YI5C-<0ZYX5N[N*"V<_ZV LV4(^G
M4=1QVS4<,6IS?&#Q@NERQ1R_9[<N'0DLF(MP4@C#8S@\_P!: /2AXBTD:&=:
M>\6+3QG,TRF/!#%2"& (.01C&:BC\3Z9(+8L;J$7+K' 9[26,2,QP "RCK_+
MFN#^*,T?V[PLRE3HT&L8O]OW!)N1OF[=#)^.:]/N5MY(T%QY90R(4WG^,$%<
M>^0,4 9,7B[1IA!LN)/W]T;--T#C$HQ\IR/ESD8)P#D5K6UU#>1&2%L@,48$
M8*L.H([&F"PMO^>>?WOG'+$[G[$^N,#&>F!CH*P=.EDB^(VMVJ9,$ME;7+#L
M),NF?J55?^^10!TVY=VW<-V,XSSBEKA-3NY]+\5^)]2A>>:2TT6*XC@+DH6!
MFXQZ?*#Q5N&^O;75/##PWLMY;ZM$XN5D(()$7F"5?[O(Q@<88<9H ZBYNTM7
MMU:.9S/*(E,<98*<$Y;'W1QU/'(JQ7/>);NZM+_P]]GN7B2XU-8)HU Q(ACD
M;!XSU4=#7,W>H:Q%I.M:@FLW7FV&MK;PJ5388R\2E6 7D8<^GYT >CTR:58(
M7E?=M12QVJ6.!Z <FN"U?4-4TN/QC;PZK=,;+3HKRWED"%XW82[@/EQ@[!QC
MCG&*O0R:II_BNSMGU*>^M-1L)II8Y@O[ATV89< 84[\8.?K0!LZ;:Z'J]E#J
MMK86[17@%PK-" 7)Y#$8Z^YYK9KSCPUJ%R^B^%-%BD$27&CF8'SS"TCKL&%8
M*3P"3CO]!@WXWUHZOX?TR\UQY&GM;M;J2U55$CQL@# E<AOF(/;.< 4 =Q17
MG6GZEJRZ7H&H2ZM<S22:N^GRHX39)$))4RP Y;Y%.?6K^FWVK:R(=3AU"&V$
M6I207,3S$CRQ(R>48]OROC:0<YS['% ';4@922 P)7J >E>=PZCJT=O#?/J]
MU*R>(VL#&P0(\)G,>& 4<XQSQC'UK;\*1,NN^*7:XGDQJ6T+(^0!Y,1_KCZ4
M ='=7<-G;S3S,=D2&1PJEF"CO@<FF:;<VUYI=I=V:[;:>)98AMV_*PR..W6N
M3N(F/C+Q,QN)RJZ1"PC+_+SYXQCTXS]:HZ#=WVE0^$PEW/<07FB.[VK;=H:.
M*)DV8&0?F(ZG- 'HE%<=X=NM4U(:)K']I0&TO(#]HA\XOYKE-PV+M&PJ001G
MIG.2,U;\1W<W]H1V=M>3++]BGG^SPG8>"H65G[*I)&T Y+="!0!N7M_!8+%Y
MI8O,_EQ1H,M(V"< ?0$_0&ET^^AU.QBNX!(L<F<++&48$$@@J>0<@UP[23ZQ
M_P *]OKFZF$]TI>1HR%&XVCL6 QP23^5+<:[J4GA34/$5O<2K>V>H/$+/^ H
MDWE^4R^K+SGKEN#CB@#T"BN):YU/^V_$\_\ :=V\6D,DT%JH0+)FWWE&^7)&
M3VP?<TZPEU:YM+75(]8C%K=V#LRB42L\FW<KH"@"$8((Y'MD4 =I17GNF7.J
MW \'M)K5X?[7L6-T/DZB)7!7Y>#G///4^V%L->U II^ES71D,NIWUG]HEE\I
MY%A9@BEPIPQ'< $[?>@#T&D9E099@!D#)/<\"N&=M<M]3T'3;C7&8S7MS#*T
M 4DQB%W0,2O+KP,X [XS6?)->7EII4%SJ%U(;;Q-)9"3?AGC4R;=V!@D8'/M
M0!Z%#=I-=W-NL<RM;E0S/&55LC/RL>&]\=#5BN!U/Q!J.E2>*2+N1TMKBRBA
M=U4BW24(&;I@XW$\Y[9S5G5[W4M+U34["VO;@V[:-+>QR.0[V\J''!8'(;/0
MY^Z<8H [6BN"M=4U/3[O39GO;B]%WH4MY)!+MQYL8C(VX (SO([YH75M6M=#
MC\2Q7\%Q;-IDL[VYF,GGRB/>I0;1LQ@@@'&/<4 =A/JUK;ZM::9(7%S=J[Q#
MRSM(09;YNG<<=>:+W5K6PO+&UG+B6]E,4.$)!8*6P3T'"GK7)1HS>*O!]XU]
M+=&YL[EV9V!5F,:'<H_ASGH..E:GBG_D,>%?^PK_ .T)J .FHKB=+OM6UD6^
MJ0W\-NL>HO!<PO,2#&)&3RO+V_*_W2#G.?8XID%QK]_+:^5<7<5V-6FBNS&@
M, M5+@;2RE,C"#CYL[@>^ #L8+M)[FY@6.96MV"LSQE5;*@Y4GAASCCO46H:
MM:Z8]FER7#7<ZV\6U"P+GH"1P.G>N6DOM:>[\36UG<&YEMKZW6WADD6(M&8X
MW>-6 P"06 )_/O52YU%-2T[19%:\#Q^(8HI(;Q<2P, 3L/KC(P><@B@#T&JU
MY>QV5I-<,DLHBQN2",R/DXX"CD]0?I7&SZQ>IK%E/;7\L\$NMM92,<+'LVN#
M$J<Y*E>7X.1W%9\DUYIWA;Q??6NHW27,.JR!7+AC@&,=P>QQQT&,8H ]+HKD
MIKV[U36/$EDE[+9MID47V8QD#!:,OYC _>&?EP>/E/>L_3=0U7Q!JFE)-J%U
M91WNA?:Y8H J[9-Z#*DJ2.M '>T5A^#]1N-4\(:1>WD@>ZGME:1L ;V[G%;E
M !1110 4444 %%%% %4:=9KJ#:@+:,7C)Y9FQ\Q7^[GT]JM444 %%%% !4-U
M:6]]:R6MW!'/;RC:\4BAE8>A!J:B@".""*V@2"")(H8U"I&BA54#H !T%244
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!1U#1=+U5XWU#3K6Z:/[C31*Q7Z$CBK<,,5O"D,$211(,*B*%51Z #I3Z* "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "H[BWANK>2WN(DFAD4J\<BAE8'L0>M244 4++1=/T
MXJ;:WV[!A SLPC'HH).W\,41:)IL-VUU':1K*TAE.,[?,(P7V] Q_O8S5^B@
M#+D\.Z3+!<PO9JT5U*)IT+-B1QCYF&>3P/R'H*?-H.F3RW$DUJ'>XA$$S,[$
MR1C^$\\CD\>Y]:T:* ,]-$T])X)TM]LMO$88G#ME$/50<\#@?D/2HXO#NDPQ
MVL<=FJ):R&6!0S8C<YR5YX)R?S/J:U** ,Y-!TR/<!:(58.NUB2H#_?P"<#=
MWQC-(?#^EO:S6SVBO#,@BD5V9MR#.$R3G:,GY>G)K2HH SY]#TVY>)Y;4,\4
M9B5]S!MAZH2#DK['(I[Z38/=PW7V=1/!&8HG4E3&AZJN#P.!^0]*NT4 5K#3
M[33+46ME"L,"DL(U)P"3DX_'G\:IVVB06\5_9-''+IMX[R- XR%+\NN.A4DD
M^Q)_#5HH S8O#^EP2K+#:+&ZP^0&1F!$?4KP>F>?KSUJ&X\*Z%=Z?;6$^F02
M6MJ<P1L#^Z_W3U ]A6Q10 R&&*W@2&&-8XHU"HB# 4#H .PHFACN()()D#Q2
M*4=3T((P13Z* ,V#0-+M9(7ALT00',,8)V0G&,HF=JG!/( ZU"?"VB&^FOOL
M""[F&)9PS!W'H3G)Z#\JV** ,^/0M*BTIM+73[?[ V=UNR H<G)R#UYYI+'0
M=,TYT:VM0IC&(]SL_ECIA=Q.W\,5HT4 %9^GZ:+6ZO+Z4JUW>,ID*]%51A4'
ML!GZDD\9P-"B@"H^EV,NI+J+VD37BQ^4)BOS;.>/U/YGUJ.QT;3M-8-:6J1;
M5*H 21&I.2J \*"0.!@<"K]% %6\TVTOY+=[J$2-;R>;"22-C]-PQWP3S[FJ
MK>'=)>WG@>S5HKB83S(6;$DF<[CSR<@<^P]!6I10!SOB+PVFH:-J\>GPQ+J.
MH6AMC--(P!&"!N/.0,GMW/K6A8:/:VUJ%:W59FA$4A$C-A1_"K'D+UP!@>U:
M5% &/<>%=#NM-M]/GTR"2TMCF"-@<1?[IZC\*LC1=.6>UF2U1)+6,Q6Y0E?*
M0]0N.@.!^0J_10!EKX=TE+>&!;-1%#-]HC0,V$DSG>.>#DDY]SZT+X<T9-8;
M5TTVW74&Y,X3#$XQGZXXSUK4HH R_P#A'-)\GR?L:^7Y_P!IV[VQYN<[^OWL
M\YZYJS#IEC;W\]_#:Q)=7  EE"_,^  ,GZ ?D/2K=% %"YT73;R\-W/9Q/<&
M(P&4C#%#GY<^G)_,^M-AT+38)+.2*U56LD,=L0S?NE/!5>>!@ 8] /2M&B@#
M+L/#FC:7?37MCIMO;W,V=\D:8)SR?IGOCK4U[HNFZC<PW%Y90SS0@JCNN2 >
MH]QQT-7J* ,N/PYI$26:16,<:V6?LP0E?*)&"5P>#CC-2_V)IOVU[O[(@F=Q
M(Y&=K..CE>A88&&(SQ5^B@"I;Z99VMY<W<, 2XN2#,^23)C@9^@X'H*IV7A?
M0].:Y:RTRWMVN05E,2[<@]0,= ?08K7HH S8]!TR$V9CM0OV)2MMAF_<@C!"
M\\#''TXJ*;PQHEQI\MA-IT,EK+*9WC?)!D)R7YZ,>>1SS6O10!G)H.EQ"R$=
ME'&+(DVP3*^43U(QW.3D]\G-,/AS1VMGMWL(GA>?[2ROE@9<YW\_Q>I[UJ44
M 4!HFFAKQOL<3?;5"W(8;A* , ,#P0!P/0<4D>AZ=':S6RVP,4T8BD#,S%D&
M<*23G;R>,XY/K6A10!0BT73H)[:>.V"RVL9B@;<W[M#_  CGIP./8>E0Z?X:
MT72KB>>PTRVMY)P1(43&0>HQV!]!6K10!D6GA;0[&>":VTRWCDMRQA(7/E[N
MNW/W?H*NW>FVE]-;RW,(DDMG\R%B2-C8QD8[XR/QJU10!EIX<T:/6&U=--MU
MU!N6G"?,3C&?KCC/6N8LO!4XGW7>G:9'<^:96U.TN94E9BVXL(@H 8_[Q ]Q
MQ7=T4 9KZ!I<CW#M:*7N)%EE;<V6=?NMG/48&#VP*5]"TV2**-[566*;[0A+
M-D2_W\YR6]SS6C10!D/X7T*2=YWTJU:1Y_M#,4ZR?WOKZ^O>GS>'-'N!=B73
MX6%XP:X&,>:1C[WKT'Y"M2B@#/N=$TV[F6:>U5Y1'Y)<L<O'_<8Y^9?9LBGO
MI-C)?"],&+D1&$2*Q4B,_P (P>!WQZU=HH SK?0=+M#9&"RB3["'%KC/[D,,
M,%] 16C110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %<_XU\3'P?X6NM=-F+N*UV>9%YOEDAG51@X/=A705P7QG!D^
M%6L6\8+S2^2(XU&6<B9"<#J> 3^% "Z]\19="T'P]JLFCI*NLO%&D:W>#$TB
M[ER=G(QUKNT+%%+@!L<@'(!^M>'^/F$_@+X>1PYD>&XM'E5!DQJL8#%@.F#P
M<UZO9^)K.^\3WF@PPW7GVL"7#3F+]RZOC&U\\GG^?H: -JBBB@ HHHH *K:C
M?V^E:;=:A=OLM[:)I9&]%49/\JLUS6OW(U#5[/08&MGD/^ESQ3D[75"-J<=R
MQ#8]$.>#0!?\,Z_:^*/#ECK5GQ#=Q!]I.2C=&4^X((_"LSQ!XUAT+7=$TQ;=
M+K^U+O[(7CG ,#\?>7!]?45Y]X";4O"^H>+O L;?,JR7&D3(28][)_JPQ[C*
M\>H:N<TE+;['\-8X[.1=3L]4D&I$V[>9&WF9/F''X\]J /H9KVT3[UU"N&"<
MR ?,>@^M#7<($X26-Y(1ET#C*\9&?3\:^>_$NFP7"?%:4V2R7+7-H;-O*RQ/
MF?.8^/SQ^-='HD-O:?%"9XHTBM)_"B^<P7"22Y5CN/0OC).>>M 'I_A[6YM6
MT2UO=1L1I=U.6'V22=9",,0,$=<\'\:77=<?3?#USJ6F6JZI-'@1V\4ZIYAW
M $!CD<#)_"O"-/LQ)\.?AM:W-L2T6OG[3$Z'*1^<Q;<.RX()SV(J:^MMGP]^
M)MC!;E4;7 UG B8!4S+@QJ.V%/3L* /H!+V'$"S/'#/*@80M(-WT'KZ<53MO
M$>E7FL:AI<%W&US8+&;CYAA"^["Y]0%R?3(KR;6(KNS\5:=JVER0ZBEP-/M[
MS2;A/G;:%:.6 ]?E))./NG).0:LZ78V]CXK^)Z75@(Y9HO,M6:WZH8I-Q4XP
M 20/<D#K0![ ES!(X1)HV9EWA0P)*YQGZ9IJ7UI)'+(EU R0Y\QED!"8ZY/:
MO'_">@:/9?!0ZS<:9=2ZF-,N+>=K9F6Y*%V.P==O;MP/J<T/":3WOC'4E:TF
M\B_\+(L<;6LB([J% 4[A\S#!&XXR<XQG% 'IEQXUBN/#MOJ^@6?]KI/=>0L:
M3K$=@<H9.>WRY'J".E=*]S!%,D,DT:2R?<1G 9OH.]?/$EK$OP'\/6\=FR:A
M%JJ?:5^SE9,B24_-QDX4CZ CUK5\5VU\;GXC1W<<DNHWS6!T;:"7E0/\ODXY
M.T]=O0\F@#W&2[MH2XEN(D*#<VYP-H]3Z5*K*ZAE8,I&00<@BO#_ !'IYN/B
M,?[7MX[B5/![I.SH&4W(#DCTW=QWZ&N^^$YD_P"%7Z$DV\2QPLC*_#+AV !!
MZ<8H [.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MVB:8ETA 4R*SQD#(D9E.-P(!&"<;1SV$OA6&\&APW>I,K:A>*LUPRC SM
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MYV1;8"?/(# Q-E?DY!SG!^4^]+_PE^B><8OM4F1=?9';[/)M24X 5FVX7)(
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MFEQ-,FN'4HK2>9"+B(Q>64)!(5L$GGC(% '6P^(M,N(M\4[LWGFV,7E/Y@E
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M+^RD,EM.NZ-RI7(SCH>17,^%-5U/5$M[*^NI1J&G22IJ8VI\S XC!PN &!W
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ME,CH6&8VR%*#(P.6IB7&NW.L2Z=<:V8V31H[AWLT0KYV]U8J67[IV@X/X8H
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M<:]%H'V^XB2+2TNO.4())&9RO]W&%P.W.1G- '6U2N=6L[2]LK.:1A->NT<
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M2RG@]<'/6@#T*BL?PGJ-QJWA+2=0NF#7%Q:QO(P& 6(Y.*V* "BBB@ HHHH
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M_?K@$A./F(##('3\#4\/B?3;FTLYX&ED:\=XX81&1(63.]2IQ@KM.<XZ>XH
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MUZD?DD--".K+GW(ZXZ@]*=;>)K>32+6\E@N!++;"Y>&.)F94P"6QZ<\>O;-
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M?LP7[$Q:WV,RB,D$$C!ZD$YSZGUJ%O#6DO;3V[6K&&XG%Q*IF?#R @[CSUR
M?P'I6M10!RUGX;\SQ#KMWJ%MNM;YXC&OGL0ZI&J$2*#@\@G!SP:T]0\,:+JF
MH17][I\4MU$NP2$D97.=K8.&'L<BM:B@#-FT#3+B2^>6W+-?QB*Z_>N/-0#
M!&>F"1^)]::WA[2V/S6[%=B1LIF<JZK]T,N<,![YK4HH QI/">A2SR3/IT3/
M)<"Y;);'F_W@,X!/?'7OFI)_#6CW OA+9*1?G-R S 2'@<@'O@9QUP,UJT4
M9UQH6G74Z3RP,9EB\GS%E=6:/^ZQ!!8>QS3CHNG_ &P78@*3B#[,&21EQ%_=
M !P!]*OT4 5K"PM=+L8K*SB\JWB&V.,,2%'H,]JLT44 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MD%MN,\GZF@#JZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5Q_C_3XH_"NN:JKS+=I:'RW65E\O;TV@' /)
MYKL*RO$ND2:_X>O=*CN%M_M49C:5H]^T'K@9'/XT <SXLTFVL?!5U>6XF61U
MM=RB5B"1*O(!/!.X@^O>M&\\1&2T\16>H:20UA9^?)"MP")X75_XL#:?D8$<
M^Q-7]:T.XUCPS_9)NXHI&\O=-Y)8?(P;A=W?:.]5;WPS=7EWK<_V^%/[4L%L
MMOV<GR\!QN^]S_K#QQT% "#Q-% ]GI]I:Q>>]A'=16\MQL+J<C9'E3O8;>>G
M4>O&WJ:+)I5VKC(,+?RKG]3\(2ZKI46FW5U;20):QPHYMCYD,BY_>QMN^5B-
MO'^R.3TKH[N"2>PFMXI CO&4#NNX#(QDC(S^= 'F_AL7\MEX-N=+.H>:T8?5
M)I?,\AXMG)8O\K-G&",GKVKJT\7HUOIM^UH5TO49Q!!<"3+ L2$9DQPK$=<G
M&1D#G&AX>TA]$\.V>DS3I<BVB$(D$>S<H&.1D_SK+LO"#6VGV.DRWJS:987*
MW%NAB(DPK%D1FS@A3CG'( ]\@&*]U;Z=I/C>:ZLWO;6/4OG@\TKE3##_ !=1
MR<UT][KTT4]_#I^G-?/IZH;A%DVL2PW!4&#N;;@X.!R.?3/O/"%S=Z9XAL_[
M1B4:Q<";=]G)\KY47&-_S<(/3J:GE\.ZE%KUQJ>FZO':B^2-;V)[;S,L@VAX
MSN&UL<<[AP.#0!.?$GE:GJEE=6H@-E:"[C9I<^=&<Y(&.,$8/7!(ZYK8@EE>
MSCFG@,4I0,\2MN*G'W<\9KF=0MK#7O$VGV\#7!N-)D/VIO+=5,94$1LQ&&W,
M(S@$_=-=1<1&>VEA61HS(A4.A^9<C&1[B@#G+;Q>TMX;2;3C'<&P:^6$3@NH
M4J#'("!L?YEXY[^G,-AXTFNIM&-SHTMM:ZO#OM)O/5\R;-^QACC(S@YYQT%5
MHO"UWI$-O>7&JV[K8Z9-9,J6OEB16VD,27.&)3D\YST'6E\*:6]YX:\+W=]<
MPF'3;5)8XU3:1)Y6SYR2?N@L,>O/&,4 26GCF6>+2[N?198-.O[G[(+CSU8Q
MRERBY4#[I(QG/7MT)S4NK?3] \5R75F][;)K95H?-*\'R<'/7@D&I?!^E2:M
MX4TI+FXB-I:WKW(B6,ARRRNR!CGH#ANG/'XZ5SX0NKC2-:L/[2A7^TKX7>_[
M,3Y?*';C?S]P<\=30!8U7Q8+"6]6VL9+W["Z)<)&3YA)"L0BA3N(5E."1UJ>
M+Q(MUK4^FVT,;R6\J)*CS;)0K*K>8(RO*_,!G/8^E5Y/#NIPZ[=7^FZPMK!?
M[#>0-;^9\ZJ%WQG<-I*@#D,.,\TZ^\,-J.JVUW<3PG[)=)<6\JPD3QJN,Q[]
MW*DYSD="1CO0!-XLU6]TC2H)[&.)Y)+RW@8R.5PKR*IQP?7'MG/.,4RY\231
M#4OLU@MR=+16O LV"&*;RL?R_,0I!YV]0/7%OQ#I#ZWI7V6*X%O*D\4\<C)O
M :-U<97(R#MQU%4&\-7<5[J<]KJ$:+JL2K=*\!.) FPR)\PQE<<'/(!^H!M6
MUZFH:7#?V)65+B$30[R5#!AE<G!QU'8UP,6K:AJL/@G5[BW1KJXNY2L<4I"L
M#!*0#D  #CUX'<\5Z!864&FZ=;6-LI6"VB6*,$]%48'Z"N9T_P 'W=C!H,!U
M2&2/1YWDC'V4@NI1D )W]<.>?8<>H!9M_%Z2V*M-:>3>F^DL/LYEW*)$!+'>
M%SMVJ3G;[8K1T/5WU>VG>6SEM98)VA97R5?&,,C$#<I!'.!WK$D\&71MYFAU
M98;\:F^I6UPEOQ&S@AD92QW*02.HZUT>FV]Y;VQ^WW:W5R[;G=(_+0<8PJY.
M!QW)Y)^E '-Z3)_PDOB?7C?@R6>FW"V=O:L?W>0H9W9>C$D\9Z <=36C(T/A
MN81PM+,^IW2QVUO)*2$?9R 3G:@5"V ..<#D"AM N;/7KK5M(NXH&O0OVNWG
MB+QR,HP'4@@JV.#U!],\TNJ>'Y]3CM)WO@FHV=RMS!*(OW:D J5V9SM*D@\Y
MYZ\ 4 4[SQG]AM]2$VG,;S3IX(IX$F!!69@$=6(&0<^@.0?K1<>++^";5K?^
MPPUQIL*W+K]K&UX6#$$';]_Y&&W&./O4NH^$9=1MM19KV*.]U":W>640DJJP
ML&1 N[/4'DG^(U/<>'+J?4-:NOMT*_VG9):;?()\O:'^;.[G_6'CCH* (9?%
MES->I::7HTEY)+IZ7\1:X6(,C'&#G.#_ %]N:1/&:W.B6NJ6E@Q@FMI)W:YE
M\I(V0A3$6P?G+9 '^R>:S+*UNK#QO:6%O>6S2VV@QV[.\1PQ60XX#<'&#C/3
M\ZOKX+DM?L266I!(8+.6UD6:#S-QD;<TB?, KDY[$8.,4 3IXLFN[K3K?3]+
M:=M0T[[?"TDXC 'R?*W!Q]\<C/T[A+7Q>+FWT"Z%B8[75F,7F/+_ *B7!(0C
M'.2I /<^E)I/A:\TRZTF=M2AE.G::=/ ^S%=X)3#??X_U:\?7\,Z\TN#3?"-
MOX0FN9+C49E8V4D-LZXD#[E?/S!=K$$Y/0&@#;O+8^*--G@8/;I%=E89XIV5
MB8VP7&,="",'(R.].F\1*-?DTB"&*2XB,1>-Y]DC(YY=%P=RJ.3R.A%:ME:Q
MV-E!:Q9V0H$!/4X'4^]8FL^&6UJ[#W$\'EQW$4]O)Y/[^W*E20CYZ-M].,GK
M0!JZKJ<6DV/VF56<M(D4<:]7D=@JJ/J2*RKSQ)>:;O\ MND,@6[M[<2)-N20
M2L%#(2H)VD\@@?4U>\0Z*NOZ/+8F=[>0LDD4Z#+12(P96 [X('%9UYX>U34]
M$>WO]6B>^\V&:*6.V*Q(T3AU^3<2<D<_-],8H ;JGB\Z9#K[MI[2G1UC=@LH
M'F*ZY!Y'&/QHNO$VIVE[:6;^'V^T7CS+;K]K3#!$W@DX^7/3';'>JU[X.O[^
M#7TGU:#?K$44;E;0XB*+C*C?R/8G\:U[W1KF\UG1M0-W$AT\R%T\DGS2Z;3@
M[OE_6@"A<>,&A5W33))E@F2"Y2)R\B.=N[:H4API;GD=#@<<Q2>-)HENYVTA
MQ:6>HK87$IN%R-Q10RKCGF09&1QW/06$\.:C::S>3Z?K @TZ^E\^XMF@W.KD
M ,8WW#;NP.H..U5[CPA=3Z9JMG_:4*_;]12_W_9B?+VLC;<;^?\ 5CGCJ: +
MVEZKJ%YXIUNQFA@6ULC$L960EOF3=DC;U.?7C'?K4NN:[+HX9ELQ)&EN\[32
MR^5'\N,(&P<N<G XZ=:=9:-/9^(M1U,7:-#?+$9(/*Y#HNW(;/3';&<]ZKZS
MX=NM3U87D.H)#&UE):/%)!YFT.>70[AM;L<@Y % $7_"537%[8VNGZ6T[WVG
MF_A:2<1@#*?*W!Q]\<\_3N%L/%::S;Z<MC:;KJ^M6N6AEEV")%(4Y8 \[C@8
M'.">,4S3/#%YI][I5RVHPRM8::; +]F*[\E#N^_Q]P<?6JFF^"[W1SI=Q9:K
M"+RS@>UD:2V)CGA9]^"H?(8'D$&@"U\/2S>#8"ZE6^TW659MQ7]_)QGOBLG4
M[F*;Q!XC?7H(VTS3+6WF5DG820_ZQMT>%!#L0 <$= ,FNG\-Z/+H6D"QENEN
M2)I90ZQ;/ONSD8R>A8U0N_"7]HWFO->72/::O;QV[1)$5:,(& (;<<GYL].P
MH L_\)!/!JMMIU[I_DSWD#RVNR;>'* %D8X&U@"#W'7GBLJ'QQ=R:#;:TV@R
M+97)@6(_:4+$ROLZ8XP2/KGM6G!H5X]W8WFH7L-Q<V$$D5NZPE06< &1AN.3
M@8P,=3[8IKX1N$\&:?X?&HQ9LY(7$_V<_,(Y X&W?QDJ!G- "7/BZ^MO[91M
M#!FTJ-9YE%V-K0E2P*G;G=A6^7&./O=*GO\ Q<D*3&QLVO'AMDN7CW%6*N"0
MJ@*<O@9P<#D<\\%UX9N;FX\02_;XE&KVB6V/()\K:K+G[WS??/IVJ%/"VJ65
M]#=Z7K,5O(]K%;7B26OF)+Y8PKJ-P*M@D=2/RH G3Q1=7.M?V=9Z-+)B"WN6
M>698RL4K$$E2,[EVGY>^#T[Z>K:O'I8MD*AY[J7RH4)(!(4L22 2  I['M5:
MTT2:U\2SZJ;P21RVD5KY;1G?^[+$,7SR3O.>*7Q#HDVKQ6DMG>FRO[*?S[>?
M9O .TJ59<C*E6(/(H SI/&,T&COJ4^D2QPV]W]FNRSD")<@><N5R\>"#G /7
MC@U>D\1>386MQ-;"-[V<Q6L9D/SC#,&;Y<J"JEL8)' Z\4[^R+ZZM88-2OXK
MJ-Y"]Y&+<JDHQ@(HW':N0"0<YYSP2*RAX-O4T2VL8M:V3:?=?:--N/(R8%^8
M"-P6.]=K%>W&* +=IXK-R(X&TZ2*_ENWM8X78A)-JES(KE02FT==N<\8J1?$
M=S'=:=;WFE26TEY>2VGS2Y **S!UX^9&"<'@\]*@OO#>IW]M97#ZPB:S9W'G
MPW*6_P"Z&5*E/+W9VE2<_-G/.>U2WV@:C>0:=.=3B.I65W]J$KVY,1)1D*A
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M,^FWVFKJ=MH[PK;QSJTD]QM!#[?;#<GGYC]2 >I9IDTL=O!)-*X2.-2[L>@
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MQ=.0'@##R0^3R-I& >Q%3QQKIV@Z="TNVP7Q.AL/,?I;!^,$_P .=V#Z8[4
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M#4O*\K[7;QS^7NW;=RAL9[XS5ZL'P2ZR>!M!*L#BP@4X[$( 1^=;U !1110
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MZ2(Q\CS !@;EYZG'O0!TU!( R3BN0L/&-Y=)I-S/I4<-I?WDEEO6YW.DBF0
M[=H!4^6><@\]/7/\4:H^M:%#=6]K$UC'K%O$D[2?.2ERJ,P7'3<"O7IS[4 =
M_117,_\ "4S)K=GI\UC'&;NXF@13/F1-BLRLR@<*X0D<]".O8 Z; &>.M%<A
M8^,KRZCTJYFTJ.&TOKV2Q++=;G216D .W: 5/E]<@\]/6W#XGN'35(I+"*._
MLKM+9;?[03YN_;L?=LX!#9Z'&T^E '28&<XYK+U[1_[;T];3S_( FBF+A-Q)
MC<.!U'=16F,XY S7(Q^,KT[9I-)B2U&K?V7*XNLL'\SRPZKLY&2,Y(/UH ZX
M#@;L$XY.*4D 9)P*YJY\4RVFL6UG/9(B7%]]C0&?][@J2LNS'W"5(ZY[^U8]
MWK]Y)X9\57.JZ;:7MK97<D/V;SB R*$^7E??.?4GI0!WI&1@T5AW.NSF^U&S
MTVSCN9=.B2297E\O<S L$7Y3S@9R<#D>^,^#QA<:I=6D.CZ=%.MYIOV^&2>X
M\L#YE4JP"G!R>V>?SH ZRD.,C.,]JY=/%TMSH6G:I;V*+%>6C7!:XGV(C #$
M>0"2Q)...BD^U4WO8M7\1>"-6CA\O[7;SR@'EE5H0VTGOC- ':T5#>7'V2RG
MN?+>7R8VD\M!EFP,X'N:YVV\8Q3Z6=01+:>"1H8X&M9S)OED8J48;<J5X)X)
MP>F>* .H  & ,48!(..17,IXJN$,\-UI4T,_VJ*VMB0ZQ7)D&00S*"-N&W<'
M&.,Y%/NO$.H:?Y0O=)5-^HQ62NMQE760@"1?ESP3@@XZ=: .CI"1D9QSTKEM
M3\83:?;Z_(--65M(FBC*B?'FB158$?+P1O''ZTZXU&Y&NZ'#J>BVRW$UQ<+;
MRK<[S#MB8[A\@Y8 @^GO0!T_RH,< 4H '08K@UUZZN?",E]K&FVEY&-5^S^6
M)B ,77EJ<%?X2%(]<=NE:VH>*IK>6[^PZ7/?)93K!,L*2%V)"EM@"%3M##@D
M9P?;(!TP  P!@45@6WB47?B"?2H8X/,MYO+ECDFVS!-FX2!"/F4G X/O[5LW
M=U%8V4]W.VV&"-I7/HJC)_04 3  9P.M%<W9^(M0N[R*!=&D"7%L9H9CYBHK
M#'R2,8P%)!X(ST/XKH7BB36()IYK 6<=HKK>^9*2T$RDYCQM&[  ;/HPQF@#
MHZ 01D'(KGH-4N]5MK=I-)!TS4+1I1+YH8Q@J"HD4@?>![$X(Q[UB>"=;NK;
M1O"FFSV2"WO;#$$ZS9?<B!CN3;@ C."&/3D"@#O.G2BN9L/%4]UJ]OITUA'#
M/<VLLZ1_:-S1,A4>7)A?E.'!XSCGZFOI'C&ZU%M"EGTN.WM=7$BQ.+G>Z.JL
MV"NT#!"GG.?84 ==0 !G ZURA\83.EI/;Z>DEO=ZB^G1[IRKJZEAN8;3@$HW
M'4<>IQ*/%<TMU ;32Y[FRDO&M&EB20LF&*&3[FW8&4Y^;IS[4 =-13)94@A>
M:5@L<:EF8]@.2:YR/Q9(8M&O)K%8[#5W6.WD$N71G4M'O7'&X#L3@X'/6@#I
MJ  .@ZUR%KXRO)ELIYM)BBM+C47TYW%UN=9 [(&"[ "N5]0>>G'/7-NVG: 6
MQP"<#- "T$@=37(1^-9/L^FR7%A%"USJ+Z=<(;DDV\@8J#]SY@2!Z??7UJOX
MBNI;N^\/726<9>/6VA@/F?ZQ1%*"2<?*-R^_ SS0!VY( R3B@ #H,5QE_P"(
MQ=>&+^;4='@F:RU%+.YMO/+)N\Q-KJQ7G!=#@@=*U9M>NY);W^S--^VI8W"6
M\P$P1V8A2VP$8.T.#R1G!% &]D$D45YZNK3>'-4\7WT%A%-:07\#W&9O+*JT
M,62@"G<>2><?6O0J *NI6::CIES9R2RPI/$T;21-M901C(/8U1L]&N(YH9-0
MU)[TP'=$# D8!P1D[1R<$^@YZ=*X[Q)J%]JGA7QG%?0VYALKD10;')*X6)AP
M1_M$YSU.,8KHY/%;V%WJL&J6*P&RM4O$\F;S#)&Q90#\HPVY<8Y'/6@#IL 9
MXZT5BZ9K5Y>:M-8W.F2PHL(FCN563RVYP4)=%PPX/?(-4O'>IW6FZ%!'9RM!
M/?WL-D)UZQ"1L%A[XS@]B: .GHP,YQUK&D\,:9Y,*6]NMO)#+'*LT?$C%&#?
M,W5@<<Y)S6?=>,/L^F7&L+9K)I-M=&WEE$O[S"OY;2!<8(#9XSD@9]J .IHK
MDM3\77UBVOF+28I8]&"22LUT5,D93>2HV'YL=CQ[U)<>*[NTN;V&?3(P8M.?
M4;?;<Y,D:G!5OE^5N1TW#GK0!U-)@9S@9KE;3Q;>MJ&G07NC^3%J=LT]F\5P
M)&9E0.488 4XY')''Y.M/%LT]Y-9R6,(N4T_[=L2YW;2#AHG.WA@2.F?\0#J
M:*Y72_%=Y?S:,LVF101ZO8FZMF%R6(8*K%7&W@8;@@GIR!TJ?3?$T^HV-L_V
M".*]>]>SFM3.3Y)3=N);;S\J[AQSD<\T ;.HV]Q=V$L%K>R64[8VW$:*[)@@
M]&!!STY]:6PLTL+-+='>3!+-(^-SL22S''&223QQ6/<16WA2VUK6TC=EG=9I
M8E9BH/0N<YQUR<#@*...='1]1.J6CW ^S-#OQ#+;3>:DJ;0=P.!CDD8]J -"
MLJ31C)XFAUG[0/W=JUKY/EY!5F5B<YZY4=JBUSQ!%HMS8P2F"/[675)KF4QQ
M!E PI;!P6SQGT/T-2\\3W4(DAMM+:>]@M([F>W4NV&<$B-61&RWRGDX'3U.
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MF1%V_,HS@X/\)_'.TKQ3??V=+-J$$3SRZI-8VR0LS E&<8("Y "QDY )/H*
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M:42,%2.;S 5['.!R?3%6J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN;&;2G_MEI!ILDS1!K<9=9,Y#G/+<_>XSZ9YKJ9)"(F,6QWP=BLV Q],X/\
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MU=L6-G)9'-N#OC<@Y )^5^!SSD=JL6'A.:Q'AT?VD)1HT31+F#'FJ4"=FXP
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M + E-\'31+5X HMSF52BKGAC@X4= >:30+2UOM>OO$EM#<Q174:1HL\;1[F
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MOQ7JV@0Z7;B;34622::]*HRL 1C$9_O"@"W>>%[R_M+22XUEVU:TN!<0W@@
M12 5*^7G[I!.1G//6H9=!UBQAUJ[L=7']I:A)%*I6T7:K(BIC#,>"%QDG@'N
M:V]/U)KC3XY[Z%;&=F=6@>4-M*L5X/&1QG/O5P3PE'<2IL3[S;AA?KZ4 /7.
MT;L9QSBN3;P9<&<,-9<1IJAU*-3;J6#'.59B?F&&(!P,#'7 KJ?M$/D>?YT?
MDXW>9N&W'KGI2"Y@*QL)XRLGW"'&&^GK0!S4OA":73KZT.I(!=ZDNH%OL_W6
M#J^W[_(R@Y^M1:AX*FNH=;M;;5OL]CK&7N(6M]Y24@!F1MPP#@9!!]B*Z*^U
M:PT[3[B_NKJ*.VMU+2/N!"^WU]N]4)/$$C7FCI9V!N;6_5GEN!,J_9EVY&5[
MYY''3% &S$K)$BN^]P "V,9/KBL-_#1N-9M-1N[F.62SN))H'6#;*%8,/+9]
MQR@W=,#[H_':%U;E2PGB*@X)WC&:7SXA.(/-3S2-WE[ANQZX]* .6M/!=Q:C
M2XAK!-MIEX]Q;1BV .U@XVLV>2-YY 'T[U9TCPQ=:/.\-OK$ATD3--#9&$9C
M+$MM\S.2FXDXP#VR1UVI[Q5AN!;&*>YB0D0>:%)8#(4G^'/J:R+/Q!J-Y-8)
M_8PB6[M6F+M<@B.0'[I &2IXPXXY'% %:'P?-%IUA:?VDA%IJ3:@&^S_ 'F+
ML^W[_ RYY^E=2RJZ,C %6&"#W%5=-U"'4[,7,.Y?F:-T;[T;J2K*?<$$5;H
MYFQ\(BTL[#3I;WS]-T^X$]K$T6'&TDHK/GY@I/' / ]\Q2^#I7L[JT35-L$V
MI#445K?)1O-$I7.X9&X=?3\ZZNB@#F+[P>-1FUI[B^9?[2\AE,,>UH'AY1E.
M3DY /2B[\,ZEJ6@7&GZAKOVB><Q@SBU"*JHP;A W4D<G/X"NGHH 1=P10Y!;
M') P"?I2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,B+/(.'91U +/CT_*LO7-&M;9/ MA%-<75DFHN?-E0H1"S _4)S@9QQ7L%%
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MO_#'Q($%G*[R:@)X$,)#%=^=RJ1GIG]:V[Q;5O$WPWDLX%2%(YO-*Q; I,:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI]+18KV+:LIWE54,P.T9 R0*[;_A6_@K_H5]*_\  9:/^%;^"O\ H5]*_P#
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M)?L^"=H,BDIP,D?+^M 'JM%<MK'C.+1](O\ 57@CFLH!$L#QR\SR2 $+R,
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M4.E>/9;[Q)I^D7.F"VEOK9YEC:0^9 RY^252!@D#/XCCO0!VU%>2-XGU+5O
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M$C(8-QC;:BD@[AGA!CTR>M=0'0H'#*5/0@\&J]YJ-II]D]Y<SHD"'!;/4DX
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M=7GCFWN8(GOPT362X_>B8VT94Q_[1?&2O7OQ6ALQ<Z]9>*%5YY;& 6KR#/F
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M>N!D#UXN:CXHN4DO8]+L'O)+)8V>((Y:4LH?8I52%.T@Y/<XXZT^\\*&]7Q
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MC .D*G8 ,$@MGDBMR'P=Y.E:=9IJ4BR:?>O>0S+$N<N7W*0<C_EHWZ?B7/A
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MQFMS+]I6;+*P/0KC[I&.<]3TJ]'=6\TKQ13Q/(G#(K@E?J.U2*JHH50 H&
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M44;07DUL!$^]2$8KD' SG&:T3>V@4L;J$ ':3Y@X/I7.>!%6/3M41+>2"/\
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MXBCM,1-ME1S@L?FYVE9 <=-A^E.?Q#J]S/*^EZ>MU!;WQM98]N&8*VUV#EP
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M*PR0O7F@#>TJ&SLXGLK>Z-Q-$=T[22AY2S?Q/[G'H.G' J_7,:&JKXY\4[5
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MJ!@RATD\KD\GD>;^E6)=4\1P:Y9:1(-*\V[@N)1,JR%4$;(%^7//#C(R.>]
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M?V_V?S/*\SS!C?G&W_>SVZT 9<W@ZQN/MQDNKLR75VEZ) R!H)D "LF%XP%
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MFXDDOO+\Q)"I5=B[5Q@ ]/4FHK3PQI=GHMYI*0EK.[>5I8V/42$Y ]  <#T
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MF1CUH N^&?[8_L*'^W61KX,X9T0)N7<=K%1P"5P2.U:](K!E#*001D$=Z6@
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M=^'X;*')N+F_M4BQU!$JL3^"JQ^@-=/5))+"[U)]D\4UW: *R*X8P[L]1V)
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M:+'$UN^R4JS[L=-Q564[0<G&*[^B@#R[5K6^NK/QBJV.IW!OK:V-N\EH092
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M.OE,T0&&..,L._UK?\9VLES9:8RVLEQ%;ZE!-.B1F0B-2=QVC).,] #7244
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ML=QH[)933(+LE[F&$S/;?NV 95 /7.W)! STK;CMHH[B6X"YFD #.>3@=![
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MC[7;6DL!/=5#HP'T;_T(>M8WABT#?V99:IHVJ?VMI3MFXE:3[/G!!D5L[6W
M_='.3R.]=U+:Q3313,O[V(G8X." >H^AP,CV'H*FH \W@M+N'0M.<Z?>8MO$
MDMS)&+9]XB:24A@N,D8=3P.]-U6QN9]+\:%-,NS/=WL#VX%JY:0*D0RO'."K
M=/2O0+K4K"R=4N[VVMV8959950GZ9-,&L:88#.NHVC0B18C(LRE0[$ +G/4D
MCCWH XW4+82:YK5AJVCZK?6>J-'+;/;>8(F41HOEO@@1D,I.6QUS6IHMBH\9
M^()YK%U#FV,,TD#;6*1X)5R.<'O75T4 <SXI:[L]2T/5(K.XO+.SGD^TPVZ%
MY%#QE5D"CEMI)Z<X8U1G(BOM)EL]"N;2VFEN9#/%;%IHF?:>4P0GF'.2PX Y
MP3QVE% 'F&G6.H0^%]&$*ZEIVJV5I-&N^R:6*4;AF*1,'@X7!XZ'%:+6US-J
MVHSW6E2QO)X=B@VI SHLO[PO&K8.<;E''6NX^UV_VS['Y\?VKR_-\G<-^S.-
MV.N,\9IT\\-M \]Q*D42#<\DC!54>I)Z4 9WAA)8_"FD1SQR1S1V4*2)(I5E
M8( 00>>H-:M,AFCN((YX9%DBD4.CJ<AE(R"#Z4^@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LC7-
M7?39=-M80GVC4+H6\;.,JGRLS,1D9X4@#/4BM>J&K:1;:S;117!D1H95GAEB
M;#Q2+T93Z]>H(()!H Y?5/%6K:;;:_;A+62]TMK=TD:-@DT4QP,C=\K [N<D
M<#CM75V(OH;60ZE-;RRAV8-!&44)V&"3S^-9]WX6L[ZPO+:XGN6:]='N)P5$
MC[,;1]W  P. !W]3G;4%4"EBQ P6.,G\J .0L?$FLW5O8:P;!3HUQ UQ.?D#
M0)LW(0?,);T(VCKGCI3H]>U9Y/#4Y:T$&M,=T0B8M"#"TJX;=R> #QSVQ5[3
M/!^G:5*_D3WC6A+-'8RS;H(BV<[5QTY/!) SQ6/)X7.C:MX<2P;4;FSM+MW*
M2R>8EM&874!>.F6 YR0/:@":S\4ZE/I/A^\D6UWW^I264ZK&P&U6E 9?FX/[
ML=<]35+6=:U1M$\1^3+;V\MGJL-J)(H2"\;^3G/S?>Q)C/H.U;<?@O3XV@"W
M=_Y5M>F]@A\X!(G.XD#C."7)Y)/H0,U--X3L;BUU6WEGNF34IUN)CO4%9%V[
M64@<8V+Z]* *]SKM[I&OO::I);FSDL7N+:6*%E9I(_\ 6(<L<G!! [\^E0:]
M=7VG67A[4[GRQ?K?007'D@A2LQV.@!)XR5/7J@-6;RP;5M5LK"YTV=K739TN
MEOIW4B5@AP%P=V=S<Y & ?45=U;3&U:^T^.1=MI:7"W;D_QNH.Q1[ D,3_L@
M=S@ I>-+F]M=,L6L;D0-)J5K$Y*;MRM*H(ZCCU]1QQ6#?7>J:7K?C'4+&6T$
MMG8VUQ+YL+,)=D<C%0 PVYP><G'O79ZOI-OK5C]DN'E11(DJ21-AD=&#*0<'
MH0.U49O"MI/_ &KONKPC5+=;:Y^=3E%4J,$KD'#-S[T 9/B#Q5?Z;9W5[;BV
M,<%K#<I!L:1WW$[MY! C&,!2>ISUQBKUE<:A)\0=6MGND:SAL[9TA\OIN,N<
M'/7*C)P<\#C%)=>!].O$NXY+J_$=Y;QV]PB3!1($&%8X'W@/3@]P:TH="MX-
M9_M1)KG[0T"02 R960+NVEAW(W-^?2@"CXCU>^TZ1EM'MU"V<LX#1M+([KC
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MKA9)[BYFB2Y6Z2"1E*+(O0@[=PYYQG&?J: $UO5WT^ZTNR@""XU&Y,*.XRJ
M(SL<9&3A< 9ZFN?U#Q7J]C)J%B$M'N[*^LX?,:-@DL5PP .-WRL.0>HXSCG%
M=3JVCVVL0PI.9$D@F6>":(X>*1>C G([D8(((/(JC=>%;.[@D26XN3++<1W,
MLX*AY'C(*9^7  VC@ #\SD TK,7\6GXOI(+B[7<<P(8T;D[1@DXXQWKA;_Q9
M?WOA#7)(;R.TU&TL"\]J]LT<]M)CG@GE?1AG\:]"DB$L#Q.20ZE2>_(Q6)+X
M3L+J">.]FN;MIK,V)DE9=XB/) *J,G(!R<GCZT 9VOZ[JNC65P\<MG(]KIS7
M840LS2,N3AE#?(F!C<3R3[8+KK6]:GUJ2QL7LH8SI2WR/-"SE6+$;3AAD<=>
M,>]6KGP98W1F,MYJ!-Q9_8KG$^//3YL%N.HW-TP.<8QQ5B+PS;0W?VI+N\\W
M[$+++.I_=@D]UZY).?Z<4 9VE>)KO7GTVVMO)MI[C2H]1G9T+A=YPJJ,CC(;
M)ST ]<C)\,:C?67@W18+>2VC,D5TS?NVD<NLAP%0$';R<L3Q@=,YKH(?!MC:
M_P!G/:7=[;SV%O\ 98YHW7<\/:-\J0PX],CUIEKX(TVR%D+>YOT-I'+$K"?E
MXY&#,C''3(SQ@CUH S8?$NN:HOAU;'[!;OJ^FR73&:)W$<BB,\889!WXQVZY
M/2J7BG4[S6O!NNRQR0);6EV+0H8R6D,<B!VSGY?FS@8/ ]^.ET_PC9:9)I;P
M75X?[,A>" .ZL-C8R#\O^ROIT^M0WG@G3[S^T4%U?06VHR"6YMH90(VDR#O&
M5)!.!G! /I0 R;Q)/#XI.DW#QV9>=%MA/"VV[C*@MLDSC>"6&T^G3G-7O$>J
M76DQ:?+;"(B>_@MI!(I/RR.%)&",$9]Z=)X=MYYP\]S=31+<)=""1E*"1,;2
M#MW#D XSC/U-6=8TBWUJP^R7#RQA9$ECEA8*\;HP96!((R".X- '-:OXHU6Q
MB\1F!;1FTRXMDAWQM\R2A,AOFZC?U]NE-U/Q)K6EQ>)HY&L99],LH[V!Q RJ
M5;?E&&_)QY?7(Z]*TIO!=A/%J*27E^QU!XGN&,H)9H\;2,K@?=!_08'%37WA
M2TU&34GGNKO.HVRVMP%9 #&N< ?+P?F;GW^E %-]6UJ*_M]-D-O+=7<<EU&U
MO#_JXE\L;2'D&YMS]<C@=.>*<L^HW.L>"Y=7M$M;_P"U7*RQQL&7B"0 C!/!
M&#C)QG%;>J>&+758[$R75Y#=6.?(O+>0)*N1AAG&"" ,C':GMX<M3/IDWGW0
M?3G>2(EPQ=G!5BY())(9OSH R+/Q)J,FNZ;92FU=+[[2K&&-BD31\KM?.'XX
M;'?TZ52T'7]430=+2:47=[J-[=1HPC *A'E9C@N ?N@ 9&!ZXYV;'P7I^GRZ
M>\-U?D:>[M;(T^517ZIC'*_7GMG'%))X)TR33?L(GO41+DW5O(D^U[:0LS'R
MSCCEFZYZ\]J *\.NZTD]AI=_:PVVH7MW-''*<,K01KO\S:K'#$$#;NX.3TX+
MO!2S)-XE6=T>4:Q)ED7:#^ZBYQDXJY/X3L[BUM4>ZOA=VLWGQ7WF@SAR-I))
M!!!7@C&,=JMZ1HD&C->/#/<2O>3>?,TSALN0 2,  <** .9N?$-]HVI>+KZY
MG2XM[ 6ZP0;"N"ZC:,YX&Y^3@_AC%;*:K?V7BFTTB^,,\=[;22PS11E"CQE=
MRD$G((8$'\.:FN?"VFWEUJ4UP)9$U*)8KF O^[?:-H;'4'''7L#UYJ>QT2&S
MN8KF2YN+NXAA,$4MPRED0D$@;0.NU<DY)P.: ,'Q<TR^*_"#6\22RB[GVH[[
M ?W#=\''Y5-JM]?:;HT6HO86<%Y/J$,%Q&P,@9#.(U8'CYMI!!(_"M?4=#@U
M+4]/OY;BXCEL'9X1&5"Y92I)R#G@D5)K&D0ZU:);7$LT:)-',#$0#N1@R]0>
MX!H Y?6/$NN63>)Y8&L/)T7RY55X7+2H8PY4G?P>2,\_2K/B7Q-?Z0M[/!]F
M:.UBAE6'8TCN&;#;R"!&,?=SU.>O2M&Z\)V=XNL+-<W975E5;D!E'"KM 7Y>
M..*AOO!6GZ@U\9KJ^"WT4<=PJ2A0Y085^GW@ /8]Q0!1U;7M<@O_ !'#9R6"
M1Z591WD9E@=B^5D)0X<==G7MZ&K4>NZEK$MW;Z0+6&XMK*"XVW"E@\DJLRJ<
M$84!>3R>?;FY+X7M99-2=KJ[)U&V6UG^=3E%# 8RO7#-S[_2H9/!MBUS;7,5
MYJ%M/#;K:O);S^69XE^ZKX'./48//6@".35[^+Q+-9M%9?+I!NU))7$@;&TR
M'^#/? K-_M^\ODU73;HPRQG1?M:RQPM&-S;U8#<3N7@$'^=;MWX6T^]NIIIF
MFV36+:>T*L GDGJ!QD'WS4$?@ZS21I6OM1DE:R-BTDDP):/G&1C&1D]O?KS0
M!<\+?\BAHO\ UX0?^BUK6JMIUC'INFVUC$[O%;QK$AD(+;5&!G '859H ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ K!\8:Q>:#X<FU*R$#2121*5F0L"'D5.Q'3=G\*WJY?X@VMQ?
M^#KJSM;::YGEEA*QQ(6)"RHS?3@&@"6TUR]C\9-X>O5MYBUE]LCN+=&3: ^T
MJZDMCV.?PK6_MC3?MGV3[= +C#80N 3M^]CUQW].]<[IUC-X<\37#VUG+/I.
MJ_O3*L9:2UE P5;^(H1R/[IR.!5'PU82J;#3M5T._;4--E9EO9)F-N>H\U#N
MP2P/W<=2<\4 =3;^)=#N[N&TM]6LI;B8%HHTF4EP,YQ@\]#^56'U;3TO%M'O
M(5G9_+"%QR^,[?\ >QSCK7GVA6']K^$] M;:UD6>VU8W33F(JJ*D[EF#="2/
MEP"3SSP#5IM'U*?PI>^&YK:?^T&U$RQ7>P[&5KCS1-OZ @$\9SD8QS0!ULWB
M?0K>5XI-6M!*C,K1B4%MRKN88'.0.<57MO$-KJEOHUU9ZC:P)>D/Y$PS)*IC
M+;%Y&&&03UZ51TJQF.I>+&>TD0W5P'MY)(RH<>0J9!/^T&'X^]9EC:WW]D^!
M8I--O(I-.D1;D-%]P+;M&3QGC<0/UZ<T =6GB31)+B*W35;-I99#$B+,I+..
MJCW[5-=:SIMC(R7=];P%2 YD<*$)Z!B>!GMGK7#OI]Y_8]XJZ=<^:_B5;Q0(
M&R8A.K[^G]T'W[4W5$$FI:_9-::J^GW=Y#-+);69GRR+&6VLK97[BC!4D8/K
M@ 'HT<B2QK)&ZNC ,K*<@@]"#7,Z5XENIO&6I:!J$4*"-?,LIHU*^<H W@@D
M_,NY>G8YKI()H[FWCGA;=%(@=&]01D&N*U?3+^\%SJ>EVT@U73]3%U:"9#&)
MHS&B.F3_  L WY"@#1/B6ZE\?QZ!;Q0BS%L\DL[J2S.I7*KR!@!UYYYR.U;D
M>K:?+??8DO(6N2&(C#C+;>&QZX[XZ=ZY:+2KBR\;:2RQ3R11:=/%/=B([3/(
MZN23[D,?054\-V,Z6VGV5_X?OFU32495N9YV-N2%*[T)8@[QCC'&3GI0!V=M
MK&G7LQAMKV"60)YFU7'*9QN'J,\9'%1'7](6*25M1MTCC"L[LX 56)"G)['!
MP>AQ7$Z9:Z@;_2;F?1+T1II%Q:S0>6L<<3GRSY2 'A?E8 \D\<GLVYT;67\.
MZUIEI]KO;%K!/LHO8=EQ&X;/D[B!O  X/J<9- '?3:MIUO)<1SWUO$]M&)9@
M\@7RT/1FST''6H8?$&D7,<LD&HVTJQ,JOLD#89AD# [D=JY6_6]U'5M<O(]*
MOT@NM!%O$9(L%I-TOR[<Y!^8<8]^G-.O+.]M=&\+WL.FW<T=B@2\M+8F.< Q
M;-R@$$E3QC/()Q0!UBZSIKVD5TE["\$I(1T;<&(ZXQZ8.?3'-6H)HKF".>"1
M9(I%#HZG(92,@@^E<3/I$;6UK-86NJZ+.TT]S%<Q*T[H[;<^='\V0_)Q_LCH
M2:VM$U6Z4:;I6I:=+;WKV*S.\2#R PX* YX(X..@SUH V[FY@M(&GN94BB7&
MYW. ,G _6JAUW2A:FY;4+981+Y!9Y N)/[AST;D<=>:J>*_M(T4&UL?MC"XA
M9D$8=D42*2ZJ?O,N,@>H[]*XZZTW4)-+\16YTR_<W6K6MS$98PQD0>06/'LC
M9';IUXH [ZUUG3+V&XFM=0MI8[8D3.D@(CP,\GMQSFLNP\0/?>,[K3(9H);.
M.Q2X78A#J[.00Q)Y& ".!UKGM>TS5+N_\326%E,_G)821*4*"Y$+LTB GC)&
M!SUZ5KZ<]Q>^/)-3&FWL%K+I4<7F7$7EX<2N2I!.<X/^1S0!O:QJD6CZ;)>2
MJ7(*I'&#@R2,P5%'U8@5"]X\.I65M/J5DDC12/-;;?GDQC#)\V0J\YR#GCI6
M9XYAD?2;"Z7F.RU.UNIO^N:R#<?H <_A4FJ03R>./#]PEO*\$$-TLLJH2J%P
MFT$^^TT :L6L:;<6<=W#?026TK^5',C@JSYQ@'H3GCZU'INIFYO+[3YPHO+)
MEW[>CHXRCCTS@C'JIK'T?1KRQ\17MJT>-'CG-_:MG_EI*"&3'HK>8W_ U]*?
MIT#R_$/6[U01!'9VUJQ[-("[D?@KK_WU0!T5Q<PVL1EGE6- 0,L<<GH/K[57
M35].ELA>I>P-;%MGF!QC=G&W_>SQCKFL?QA!>[=*OK2UN+R.RN_-N+:VD*2N
MAC="4P1DC=G&>>:QI+66QN]*UJPT*_6R6]FFNK8DO<,TD803%"Q.0<C&<X.?
M6@#K8M>TF9%>/4;9E:<6P/F#_6G'[O\ WN1QUYJ/4=8M(]-U!H-5LK::U&QY
M9V#) Y&1O&1^617$I%<W=EJ]U!93NUMXIBNI(%4&38JPEL 'DXYP*GU.SU&]
MT_QULTJ\4ZC'']E5HQF0^0JX !]1^'?F@#K)/$NF0:P^ES74:SQ6PN)6;Y55
M3TZ_0GV JY'JMA+!;3QWD+Q73;;=U<$2G!.%/?@$\>E8<,-RGCI+PV<[6MQI
M,< EV85'61V(;/(X85!X9TNYLM6N["3:VFZ5,PL"#G'F@/M([&,,5'L] '63
M316\+S32)'%&I9W<X50.I)/051.OZ2MM/</J%ND-N0)G=PHCSTW9Z9[9ZU%X
MG6X?PSJ*VMC'?S-"0MM(NY9/8COQV[USVEZ9+?ZYX@CO[*_-CJ=A;Q^==(JE
M\"16! ^Z?F'&!0!UBZI8/=O:K=PFX2,2M$&&X(>C$=<>]0R:_I,4<<CZC;!)
M$617\P8V,<*V>P)X!/!KC+?1?$A;2KZ8$7A1M(O,-_R[ $>?_O;E+#V<4[QC
M8ZA=)KUA::1/LETQ([:2UC7$Y7?\KMU&W(PHZY/7I0!V-QK^D6EW]DN-3M(K
MC<B>4TH#!G.%&/4]JR];\2"TU+2+6QNK9VN=06UG0@LVW#%MI!P"" #UQGM4
M-G;S3^.+R\>RGBCETN"*.66+A9%>1B,],C<I_P#U5@65OJB:)X9TN?1[TWNE
MZFC73B,%& $@,BN3@@[L_B<^X!WZ:G927?V5+J-IR6 0'DE?O >N._IWIFLZ
MM:Z%I%UJ=XQ$%O&7; R3[#W-<SI5G?VGB2(V8NQILMQ<27-I>196V8[CYD,A
M'1F/W<GASTQ6SXQLKC4?!NL6=I$9;B:TD6.,=6;' % %*7Q7%;>)?)N;VTCT
MEM.^U+*W!W^9M(W9P>_05M7&M:9:PQS37T"Q2QF5&W@AHQC+\?P\CGIR*YU%
MFN/&":C)IUVEN=&:',D!R',F=O&>2.?TZ\5A6=EJL?A_3-.?2+M7&A-;-+%$
M/,,O3RG9ONIP#QU/?C! .X?Q#IR:[;Z1YZFXGMVN$(/R[0R@<]R=W'TK0N;J
M"RMI+FZF2&",;GD<X51ZD]JXS1K:_MM7\-74VFW2QKHALI<J,Q2;HC\_/ PC
M'_Z_%=K+$DT3Q2H'C=2K*1P0>"* (4U"SD^S;+F)OM*[H,,/W@QG*^HQS44.
MLZ9<2RQQ7UNSQ1^:X#CA/[W^[[]*YC2M!U8>']2TN=MDEK;3:=ILS-RT; E7
M/X>6OUC/K5:QM8]1TR0WWA?4X[RVT^6VF$\S$,"N&CA.\[MV."!@8]: .EU'
MQ3I.G:;<7LETKK"45D7[VYSA1CMGU].:UHI4FB62-PZ,,JPZ$5YY>:;K<GAW
M6K)3=:E;JMJ]I-<0>7<N%EW/&V0-^T#(; SN(YKT*&0S0I(8WCW#.QQAA]:
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MHDDC8,C@,K#H0>]<CJ^EW'_"61?8]OV368?*U!"<$"+!WX_VE)C/^\OI784
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MHQ&5)8;;[*BA\KY>0<$'KR <]?>HO^$9TY_[4$ZR3QZIS=QRME7.T*,<<8
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M$H:UMK:"2-#"T;HSE\AMW/15/0=:Z)W6-&=V"JHR6)P /6@##O?".F7EU<W
M-Q;M=P?9[E;:8QK,@!4;@.X!P#Z<=*U;2R@LM/BL8E8P11B-5D8N=H&,$GK5
M,^(])"7+->*HMHQ-*'5E*QGH^",E?]H<>]6EU*T<VX6;/VA#)$=IPR@ D].!
MR.OJ* ,^S\,VFGQFWM+B\BL<DBS6;]VN>R_Q*/8$#VI]QX<L9[V>Z0S6[W,(
M@N1 ^U9D&0 P]@2 1@X.,U(/$6D'SLWT2>3%Y[^9E/W?]\9QN7_:&12V/B#2
MM2NOLUG?133>4)@BYY0XY'KU /IGF@!HT&TCU.._A:6&:.U^R1K&0$2+(. N
M,=0#^'I5:#PKI]G;Z7%"USLTIF>U7S =I((.<CGAB.?6KE[>)#JNFVW]HPP/
M,[_Z,R;FN $)P#GY<8SGVQ6/9:U=ZYK=]#870MX]/O$B:*2W)$T>Q&<DG!5L
MO@<]N0<T 0^%/#LL6CPIJT-Q')#>S7*6TDB,@8RNR.-I/9@<$X!YQGFM.'PG
MIEOK$NHPFZC,TOGR6ZW#"!Y?[YCS@MD _49ZTS4/$D4=]J&E6I9;ZVL_M =X
M6* D-@=L_=/?';K2>&?$EIJ^FZ;%)>1/J<UC%<RQJ,9)5=Q';@GD#IF@!Y\)
MV#6LEL9;GRY+T7[?O!GSMP?=T_O ''3BISX=LWF5IWGGC2=[A(97!1)'# L.
M,]';C.!GI4\&M:=<WJV<5TK3LI=%((\Q0<$H2,,!WQG%-U#7M*TJ417U]#!*
MR&0(S?,5& 2!U[B@"CI_@_3--GL)H'O"UA&\5OON78)&V/DQG[HVC ]N]+#X
M0TVWM+*UB>Z6&RN/M-NGG%@CC.,9SP-QXZ<U<37]*FL;:\AO8YH+K(@,(+F0
M@$D*J@DXP<\<8.:6/7M+FDLHXKV-VOE+6NW)\T#DX/MW].] %<^&-.,]RP$J
MP74PN)[4/^ZDD!!W$>Y ) (!QR#277A>PN_[6\U[@C555+I0^ R@;0!QQQQQ
M5B?Q!I-J^VXOHHF\_P"SXD.W,F,[1GVYJN/%V@&,2?VG"%\WR3G(*/D###'R
M]1R<#D4 7Y[".YTN33Y'D,4D1A9@0&*D8/./2L]_"]D]I]D::Z-L;1;.2'S!
MMDA7.%/'HQ&1@X[U<O=:T[3I-EW=+$<J&8@[4W'"[FQA<GIG&:KW7BG0[.::
M&XU.W22!U24;L^63TW8Z=N3TR,T 6=5TBRUG2Y-.O8=]LX'"DJ5(.05(Y!!
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MK"1DNKI(RFWS"0=L>[A=[#A<]LXH HMX3TTZS+J:M=1R3LKSPQW#+#.PZ,Z
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M"/0BI6US3_["?6DG,M@L;2^9&A;*C.<#&>QH KGPQIQGN6 E6"ZF%Q<6H?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK85/E(&!Z9]:D32]6M?!GA,Q6$KW&D2PO=V0*AW"QLC;><$@MN'/./6N^HH
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MB99&0JV"#RI'!!((Z$'FH/\ A'=+%U+<"W(,TPGDC$C"-Y!C#E,[2V0#G'4
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M2Q%FMMOC $9F.TLV,9 )!_#M5G4=2U32M9GTY;UYXIM+FNX9I(TWPR1D _=
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MYCR>5&J;W.6; QD^]4KKP]IEY>7%U-;L9KF#[/,RS.@=.< @$#.&89ZX)&:
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M9I[=0.(W;=DC_OMOSJMJ'A31=4N+J>[M&=[N-8[@"9U60+]TE0P!(['&1ZT
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MH+2T@L+2.UM8Q'#&,*H[?XGWJ>@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J]W>V]C$LEP^T,X1
M%+,S'H !R3]*L5S_ (IL=2G_ ++O]*A2XN=.N_/^S.X3SD*,C $\!L.2,\4
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M:=K5CJEQ=6]K)(9K4J)8Y(7C8!LE3A@,@X.".#BH]7O8K6XTV.2_DM&GNU1
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M1BM,%VBW!=CE<A7['T.*X;2-)UX:UH%]?:=LDMH;B&\?[2A4,^S#(@. GRG
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M<L\2H^Z-E ##;E67)4XX.*R8;F^UG_A$WGOY!<MJ>H1?:51-X5!.HP,;<[5
MZ?@: /0KR\BL8!-,)"I=4_=QLYRS!1P 3C)Z]JL5Y[+J^MV6CZG"^I22RZ=K
M-O:I=F- TT4CQ95OEQD"0@D =!5Z?4-:U6YUG^S;ZWM)-,NUC"S280(%1F,B
M["2&!;G(QQCH<@':4@()(!!(X/M7*6M]?:S)J<\.J_86T_4S 8BBLGE)MW!@
M>27!)!SQD8Z'+O""2_VCXE>2[GFQJKH%D(('[N+';/MZ8[4 =3D;MN1D#.*6
MN!U'4+K1_$/C#5(YIYC9:9;S1V[$%"<38&,9 !&>".]::7U_9>(- A6]DO;3
M5(9?.\Q5^5E0.)%P!@'H1TY% '5%@N,D#/ ]ZJ:;JEIJT$LUF[.D4SP/N1D(
M=3AAA@#P:P?$22OXQ\+(EW/$C27&4C(P2(CS@@\\D?0G%<_97%]IT4E[;7TJ
M(_BJ2V>W"KL=)+@HV<C.><@@CITH ]*I"0HR2 /4UQD>H:UJ\UY=6-];VPL-
M3>"2.67Y/*1L%6783EE^8'=W';BKGCP2G0[7RKB:$G4;128B!D&=!SD>^: .
M@6\B:_>R D\U(UE),;;,$D##8P3P>,YJQ7':AJ&I6NM:[:1ZC-Y=MHJ74!*1
MDI)F0%ON\YV#KGOTJK9W.KS:CX=A?6[K9JVF/-/B./*.BQ$%/EX)WD'.?Y8
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP6_V6,KD!8L@[0.F,@5>HH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:)4&3N&TY.T],CGC/>@#JZ*K64MW+%(;VVC@<2NJ*DF\,@/RMG P2.<=JLT
M%%%% !1110!EZ)HYT=;T&X\[[5=271^3;M9SD@<]/2M2BB@!'#%"$(#8X)&0
M#]*S?#^D#0=%M],6<SI!D*[+M)!)//YUIT4 %%%% !1110 4444 %%%% !11
M10 4444 %%%% %/4[.XO;416NH36$@<,9841F('488$<_2GQ6,4&GI91%TB1
M @*M\V/KUR?7K5FB@!D4200I%$@2-%"JJC  '  I]%% !1110 4444 %%%%
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MW%?+.>IR!@\=>E '5&>$3K 94$S*66,L-Q ZD#KCD4//#%)'')*B22DB-68
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M50U+1-*UGRO[3TZUO/*.Z/SX@^T^V:OT4 (JA5"J  !@ =J6BB@ JC!IWDZM
M=:@;F61IT2/RW"[8U4D@+@9ZL>I/6KU8\NMR/JMWI]A9_:I;-$>XS*$QO!*J
MN>IP,\X'3GT *<O@ZWE;7L:A>)%K2[;F)?+VKE=A*?+P2O!)SFISX9C-_'>?
M;[KS8[!K <)C82"3]W[V5'M[5>L]7M[JVT^1PT$U]'YD4$GWQ\NX@@>G>K]
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M?J#5C:NX-M&X=\<T  =!B@!:*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MCYPV3*6W<;L ;NO:K>IZ99M<^.533T*OIT8M@MOPTGE.#LXY;.P<<]*](HH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK?\ #*NGA?2HI8I(I8K2*-TD0JRL$ ((/O0 R[\06<6IS:1#<PC4DMC.$<Y
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MG%K&FSM(L.H6KF--[A9E.U<XW'GIGO26VM:5>W*VUKJ5I/.T?FK'',K,4_O
M ]/>N'T-+M=:T:[ETN_AA31YK:2/[(4CMWW1'RU&,X 4X)SNQP33=%TZ[M['
MP+$+"Z@EM8IDN#]F8>2S0LOS<<9;'\Z .]75-/>Z:U2]MVN%#$Q"4;@%Z\9[
M=_2JUEJL(TM+J]U+3Y%>5T6>!\1MAFPHR3D@#!YZ@USWA(O]ATG3]1T&ZCU+
M28VB>YEA^1?E*L\;_P >_CISR<UGZ4EY9:5HD;Z5>)LU"]+SK:LTML'>0H54
MC@.& W$$ >G4 '3ZKKDEO/H+V$EM/::C>"W=Q\V5,;L&1@<?P>_6MUMQ4["
MV."1D _2O.-,L[Z'0O"MO+IU\DEGK,LDRM Q*)^_PQQGCYUY]^*]'9@BECG
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M2IP<$9 /-:=% $%I9PV4/EP[SD[F:1R[.>F2QR2>!^0%3T44 %%%% !1110
M4444 %%%% !1110 5GZ9H]KI/G&!IY'F;<\EQ.TK8R2%!8DA1DX'3D^M:%%
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M $2PN[N#[/<SVZ22P_W&*@D<^AJ]0 55O-1M+ QK<SJCRDB.,99WQUVJ.3^
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M)_9>I2P7Q2%<SV\<I5GQCA@HW<<<'VQU&DW4E_+>78G\RS:7R[8 #&U1AF!
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M<\0ZEIZ0WT=A%=:/#J#*+<.5<N P&3T(S^=21^)=0C%S;SSH9)/$']F13",
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "N*\;?$K3?!-[:V=S:3W4\Z>:5B(&Q
M,D9R>IR#Q[5VM<[XD\$:#XLEMY=7LS++!PCI(4.WKM)'44 ;.G7\&J:;:W]J
MQ:"YB66,D8.UAD9'XU9J.WMX;2VBMK>-8X8D"1HHP%4#  _"I* "O/\ 7[^R
MT_Q[<G5+R^ATU=&$SK!/,%5S,5W80\'&!GBO0*Y^;P])<^+9M5N'MY;.;3_L
M#VK(267>6))Z<YQC'XT 4M"U/4-&\&V,GB)V:^EE,48FD7>P9CY8=NF0O)/L
M>II\GC18;"YNGT]]MI=);W#++F-5<@"57Q\R?,,\9&#QQ4)\(:BNAQZ9%JX'
MV&Y6XTRX:,L\.TG:CY/S@*2N>.*V8M+N[[1[JSUZ>"Y:[C,4BV\9CC5",84$
MDYY)R3_*@ OM>BT]KMIXP(8&BB#AQ\\LA "<].JDG.,,#ZXRYO&Z6UM>R2:=
M+(]I/!"Q@D#QN)6"JRN<9Y.",9!_.I9/"DDOA"'2&U*07\1CF6_VY;ST8,'(
M[C( QZ<4V^T'6]7T-[34-1LS<O-!)F&!EC412!^ 6))8KR<X]N.0 N/&)L[3
M6Y;G3)8I=)5)98O-4EXW!*D$<9X/'MUJY>>)K;3M2O+6[B9([:Q%\90<@IN*
MXQ_>R/Y51U#PI/J4GB/S;J-(]8M([==J$F(H& /7YOO=..E17/A&^U:ZNIM5
MO[?;=:9]@D2VA9=IW%@ZDL>A.>?TH G?QI;V[7PNK8J+6U%UYD,@DC9<[2"P
M "L#C(]#G)K;TV^DOXI)&BC5 P$<D4OF1RJ5!W*V!D<XZ=0:R[33?$?]GR17
M^K6<\ZH(XF2U*HXR"6D!8Y) Q@8 R?7B/2_#ESHJ7ATN2ULQ=74<QMEC9H8E
M& X09&"V"<\ <<=Z .EHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+VSFNRM9A)#&&E1Y?+5GV\=1UQU //6@">BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
)HH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>elicio_clawbackpolicynas002.jpg
<TEXT>
begin 644 elicio_clawbackpolicynas002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M':VY\Q1EU64'// _>#\C2V6E:E;ZWI5X]F?+MM&:RD D7/FEHSQST_=GGW%
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MPXU+4KB[F#R;#!%(S,IQCDXV\<=?:NKH **** "BBB@ HHHH **** "BBB@
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MA'LVE(C'CRY1Z^9MP#Z$^M9<NFW^E1,+:Q9H_"]\US;%8P3/;R$,8T/^RCR
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M45]$O_.TQ!-<1AHN(BI8.#OP>%;@'/%6-1\76-C&S1J;ADMENV19$1O+;.W
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MR* QSP5#X '& .E4O#NFS:_X<N+%WM_L']LSS.ZN2Y"73.%QC R5'.>AZ=Z
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M\+G=C'((''3KG0CU#6]6EN[JPO;:W6QU)[>2*:3Y/*1MK*R["<LOS [NX[4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3?#<-%J%V+VY7_A)L>9,"3N^[QU/ XH UH)M1N?V@+RT;5)UM;71UECA"H5
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M(W!L1Y7Y/F /RX/ YH P?$_C:\U_X5WMS::M>12KJ$-K=6T\*1SQ!AAHW*J
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M* ,_Q;O&O^%E2:>-9K\QRK'*R"1?*=L, >1D#K6IJ<0;7-&;?(,RR JLC*K
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M*%,FS?@9!X&1Z57DT*XDUVXU3[;$'FL!9[/(.!AF;=][U8\>E;1D0,%+J&/
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M.1D4TR(KJC.H9ONJ3R?I0!S-EX/73I-&-M=JD6F2SRB+R?E;S=V57YOE4;B
M.<8'6DT>WL]6\3W'B.VANHXFMT@Q/$T7F2 L"^Q@#D*0N[N"1VKI]ZXSN&,X
MZT&1%8*74,>Q//\ G@T $@=HF$;!7((4L,@'Z9&:Y>'PA+#X<M-#>]M[BSAM
M3;/'<6F]9.FUL;^&']:Z@2(Q(#J2!DX/0?Y!I%EC= ZR*R'@,#D&@#FKKP<M
MW8V^GS7@EL[<0>298=T\1C"C*2;N"VWDX[FHKWP9/=+J<$6K>3:7M['?>7]G
M#,DBLA/S;N5/ECC ()ZGI717FI6=A9/>7,Z) A +9ZDG  ]R>,5;!!&0<B@#
MF_\ A&+R#6;NZL=:EMK.^<27=J(5;<^T*61\Y0D 9X/MBJE_X)FN8-:L[75O
ML^GZLYFFA:WWM'*<;F1MPP#@9!!]B*ZWS(]X3>NXYP,\G'6@R()!&77>1D+G
MDCZ4 "!EC57;<X&"V,9/KBN9?PE-)H.N:6^HH5U::65I!;X,?F8R -W/3BNC
MEE(CD$/EO.%)1&? ) Z$\X'3MWIL$[?8H9;ORHI&12X63*AB.0&.,C/0]Z ,
M=O#UPVK3Z@;^/?+IZV)3[.<#!)W??]6/%9Z>"9XK>T@36"$ATO\ LM_]'!W1
M]F7+?*W3/4' Z8%=;)(L<9=F50.[' _.LOP[J[ZWI;7<ENL#K<30%%?>/W<C
M)G.!G.W/2@"CIWABYT^^LKL:DDKVNF_V> UOC<,@AN&_V1QZ=^]4K7P1<Z;!
MI+:=K1M[W3[8VAF-L'6>$G.UD+=01D$&NO:1$*AG52QPH)QD^U#2(GWG5?J<
M?YZT 8LWA^6;5=*O3J#DV,4R'?'EY3(!N;<" #QD8&!6?I?@ZYTVXT>5M8,O
M]F12P1C[,%\Q'V_>.?O949/?T!YKI+ZX>TL+BXCC61XHV<(S;0V!G&<''Y57
MTC5%U'P_IVJ2A(/M=M%.5+<*74-C/?K0!%X>T=]"TD6+7(N )990XCV??=G(
MQD]V-5=7\-'6I_\ 2KF-K=9XIX08,RP,A4GRY-WRYV\\=S5O5=7^Q7EC8P)&
M]W>LXB$C;44*A8DD GT'XT_1M5&JVCLZ1Q74#^3<Q)*)!'( "5##KC(H QKK
MP?-,NHI#JK11W=\E^B& ,$D4H2&Y^=3L'''7O23>#99[/6(9-68MJ-U#=A_(
M'[J6/RSTSR,QCCCCN3S75;E!QD9ZXS2;UP#N&#P.>M '-MX8OXM8GO[+79;9
M;Q4^W1"W5A(ZJ%WH2?W;;0!WZ"ENO"LER?$(%^JIK-NMNP,!)B4(4R#NY.&/
MXUT8D1H_,#J4QG<#QCZTGFQ^5YOF+Y>,[\\8^M & _A;[1?6\]U=I+"FFR:=
M)"(2OF(^W<<[N#\H_6H['PSJ5MI<NG7.OR7< @:WMM]N%**1M!<@_O"!P.GJ
M03TZ3>FT-N&TXP<\'/2D\Z+:&\Q,'H=PYYQ0!@6?AF6UNM!F-\CC2;1[55\C
M'FA@@))W<']VOZU#8^%+BQT2UTC^T(+FS@C>$PW-F'22,XVAAN'(QU[Y/ KI
MO,3S/+WKOQG;GG'KBCS$\PQ[UW@9*YY ]<4 8.EZ3?:-<Z;8VUZ\FE6MEY+Q
M21#)<'A@^<Y[;>@ ^E7==TC^V;&*%9S!)#<17,4FS< \;!AD9&1D<\CZU9LM
M2M-0L_M=K.DEON=?,!X^5BI.?3(/-6/,3R_,WKY>,[L\8]<T <]?>%$U2SU9
M;RZS>:C"D+3QQ[1&J9*!5)/ 8DG)YS],,_X1:XN+Z^N[_5/.>]TX6$JQVXC4
M#+G<O)(^^>#GGOV%_0M9?6#J0D@2(V=Z]J-DF\. JMNS@==W2KTDMRM_!&D4
M1MF1S)(TF'5AC: N.0<G)SQB@"/2+*;3M*MK.>Y%P\$:Q^8(]@( P.,GL/6L
M/4?!\E]%X@@34O*@UG:9$, 8QML5"0<C/"#CMSUKIQ)&S;0ZEL9P#SBH;Z^M
MM-L)[V[E6*W@0O(['@ 4 86I^%)=5N[Z>74C$;O3?[/;R82I49+;P=Q[L>/3
M\ZC_ .$0FFDU![O5/,^WZ:-/E6*V6-0!O 91DXX<\>O?'%:']N$>*%TEH8U@
M:Q:\%QYOHZKM(QQ][KFM=Y$C3>[JJ_WF.!0!6TRTFL=-M[6>X%Q)$@0R"/8#
M@8'&3C\ZMT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5S_C+37O_#[SV\2R7U@ZWMJ",DR1G=M_
MX$ 5_&N@HH \]T^RN)?$$T+Z?MT[Q J:@ZF,#R?+(W(X]77RLCU9ZKZA&9],
M\66-Y&1KC7;R:=QB1UPOV<Q'K@$8XZ$-G&37I5% 'FNLLEE<^,;>^0?:;[18
MFB"Q$B=UCF#E<#G!(SZ<&K/G3MK=@U@<7?\ PC$R0!AC]]NC*@Y[_*3CV->@
MT4 >9:7<Z;<:CX'DMHB+N 317>8F\R.0P,&$G&02_<]<YKI_B%&DO@'6D= [
M&V;RU(R2_;'OFNFHH X'64TS1-0TFY\K[-H5PDS3S6T"R(+AA'L>0%6ZJKC=
MCJ>O)JE?65O8:59KI5T'C@M)_+L]8C^2[@9\E5. 4;@;1CH1Q@<>ET4 >:ZA
M/!!?>(1=6KVSZEH$+0P-&6+.JS;EX'++E<^G6KNEM%-XA\+I(H*'0)(W21<<
MDP_*0?7:W'?!KO::70.J%E#-DA2>3CK0!RWPY6&/P58PI%Y4T2E)U\LH0X)!
M!XY-4]62T_X3G4O-6+;)H++)N PQ\PG!]3C]*[>D9U0 LP4$@#)QDGH* /-O
M#MO:6=[X%E@CCBN)=,DCNG489CY<>%<]?O @ ],8%=7XRGAM_#<C7%N\\)FA
M5P"P5!YB_,^WDH.I'<#'>M^B@#C_  7(HU;Q)"K$JUZDR$0-&A#0QY90>@)!
M^O7GK1KUK8W'C_0!=0PR(;2[642*""/W94-G@]&P#Z&NN5U8L%8$J<, >A]Z
M=0!Y3I]M8VVA^'KF***.ZBU]XQ(!\Z0^;* N>H385XZ8(]:GBN[=]?T>XB@D
MMV36[I)XC"[2IN24?O'Q_$=I"C@#'7&1Z?10!Y8I33M(O?+MI8XK?Q#*^H+!
M;986Q=RIQM(902C8P>!4NHV>B-IEI<6,DUQ:7.NVTY>9 B9W 2&,!5PN!\Q
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M:QTZW\417&GDNVM1LP$;*$B;R<.Y4<Q@@DCO@CU->EJZNNY&##)&0<\C@TM
M'E%XD<N@^*XC&9DCU:UNEQ;,JA"8"SJI' P'/N,GGK5_5&TNYUO4].UAKR"T
MO(H3II@MLAXP@RL9V$JX?)P,=0:](HH \PU33]/FE\<BXMXI)1IL)B\T!F\T
M0N,CU?=MY'.2/6I983%JELVC!(]0N_#EP/,CP&DN/W90L>[9W')YZUZ53=Z>
M9Y>Y=^,[<\X]<4 >;68T+4M+NKVV:\-U'I4MO<V\L B2+Y<[)!L7+!NG)/4B
MI-#M;&WU;P>8884:YT:6.[(49D.V'"R>IR'P#Z&O1Z* .4^'*PQ>#+.%(?*G
MBW).OEE"'#'(/')ILBVH^)TAD6+;)HQ64L!AOWN<-Z_+Z]JZVB@#D_AU';1^
M$8?)CC20RS>9M4!O]<^W/?H1C/:FWB6MM\3;:ZN8459-+=4E:/(WB53UQP0O
M.>PKK%=&+!64E3A@#T/7FG4 >5^'8+2VMO MS'%''=F>>.XDQA]ICD&UCUQN
MV8![XJ[X<%E?7MA%?RZ@GB.PN9&FA$(4Y)8,S/L^:-@<\MSP!SBO1=Z[PFX;
MR,[<\X]:=0!S_C1KI/#$\EK'-)LEB>:.%=SO")%,@ /7Y W'<9%<=K4.AW?A
M36]0TN>YN4NGM2S/$(T\Q9 /D4(OSA<[B!TQZ5ZC10!P.HZ#X?/C71;1-.LO
MLD]I=F6-8QLD+&(KN X.<,1GTR.E4;Z(RZ-XGL+B/;KXOG?3@!B5EROV=HCU
MV@ #C@8;..:],HH XC2M,T^Z^(&MO=VUO-<11V<L;%!Q*H?<R^X..>HR*W_%
M&C#7O#MY8 +YS)O@9@#LE7E#^8'X9K8HH \VM8[Z^U6+4#IIA@\3VJV]Q'Y>
M&@* $LQ_VD,N/HE.U6/3Y->UC1];:]MUG:%M-%M #OC5%PL3;"599 QP".N:
M]'HH X&TTNTNO%GBEX[:![^)8)+1Y%!*3"(@L#TSNQDC\:;X/_LN_N]+N8Y-
M075[.V:&Z@>$1^62!N$IV#=\PR,DDDY]:] HH YGQK/):6.G7+122Z?#?QO?
MHB%OW.&Y*CDJ&V$CVK%N7T^*[TJ_T^!QX>EU*2:]<JWE&1HL))M;I&'QS@+N
MY]Z] I@FB,QA$B&4#<4W#<!ZXH \PU>SB73]7957^R9-;LY+$#H/FC,S1^BY
MW\CCAC6K<Z!H!\>V%C_9ME]B?2[C,(C C9FEC8 @<9^\1],CI7>TUW2)"\C*
MB*,EF. * /.M,%E>ZJMEJDE_'KUIJCSK''" 77S&VN)-F3%Y9 .6Z#'H*L>'
M)=.O7M[+5;29O$=G>S/*/+<-DLPWENAC*,,9..@'85WRLKH'1@RL,@@Y!%(K
MHY8*RDJ<, >AZX/YT >66LD>F>';,M!-%;6FM7']J>3;99$,DWELP*D,JED/
M0X&#Z5=D^P::NDW5J]U-X;EU22>[DFC_ '89HSL8*%&(A)STQNYKTBB@#D?!
M)MA?>)EM$"P/J9ECVH55E:&/D<8()!Z4[6UMQ\0/#SR"//V:[61F ^Z0F Q]
M/O8S[UUE% 'E.C6UC:Z3X1NH8HH[M=8F1Y N'6(F<8)ZA>4XZ<CUKT'Q-;_:
MO"NK0"+S6>SE"IMW9;8<8'KG%:M,,T2RK$9$$C#(0L,D?2@#SK38M(OM<\/1
MRP6[V:Z'*)$DCQ'OW0GD$8)X8\_W3Z51TR]6ST/PM)JDDZ:0MK/;R2+")5AF
MWJ$WAE; V!E!QQGT->K44 9/AFSMK#P]:VUDUTUJ@;R3=??V%B1Q@8'H,# Q
M7++-I\VMZQI>O6L[ZB^H)/9;4?=+$ AB\MUZ!2#GD ?,3U-=_10!Y7K3V]MI
MGC#3GB(NGU6&YBA6(DE#Y'SC Z9##/KQUK<LM.T>^\>>(9;RUMI0D=I-&9D&
M P5]S<]QQD]L\UW%% 'E6G65O8_#C2M2MK-MZS1KJ3P1!IC LC$@@@DA25."
M#P/2IK^TT.6&QN["6:XMKK6[:5I)D"1YP0Y0!5P,!=QQ@GOG->GT4 >6:I:6
ML>D>,;6VMH_LT&IVL\<,<8*HN(/,95 Z</G'H:]-MC!):1^0JB!E^10FT;?I
MZ5-2'.#@X/8T >36.F:?<Z# =.BB&OP:[)Y#1C]Y&@NVW>XC$>[(^[^-:=L+
M*]UF>PU>6_CUJ#5GN($CA ,B;R8V6383LV$*<MP 0:[30]'70[![1+AYU::2
M;<X (+N78<=LL:TZ /.-*TO1Y-$\5736=JTT=W?+&Y0$JC#@+_LGMCBG:/+#
M'=Z&-76,Z5)H$44#S@&)9QCS4.> Q7;U_ND>M>BT4 >9:0\^DW'A]=?#C2/)
MNDMFN%)6-S+^Y\S/0^5P,^I%=%\/1%'X;EAAC:..._NPJ%"N%,SE< CT(KJZ
M* .#U#R'UCQ5:ZY&"+BWC_L\NN2\?EX*Q?[8DR<#G)!]*JZ=I45YXJTJV\06
M\-S>?V!&+D2J&W3AU//JPP3Z]37HC.BLJLRAF.%!/)[\4Z@"GJ[*FC7S,0 (
M'Y/^Z:\ZM[JWMM/\,KK+S1:3)H<=N)%@$J)< *'1P5;:2,#H.A%>HT4 >?O8
M:;:ZWX,M]CR1117"*UZH,FS9^[WY''L#@]NM:?@V*WMM1\10"W6*X&IRO@1;
M3Y9"%><=#SC\:ZVB@#DM>DM['QSH-[<KL@:VNK=I=A(+MY95#@=3AL#OS7+:
M7!9SZ=X.BN+=<)J=XKI+'MPA\_ ((^Z24'H<@5ZM10!Y=%.FFV;,L);1;3Q'
M,;F&%-RI 5;8VT?\LQ(0W QQ[5I3-I]OJ&C7EE Z^'9;Z>6Y=U;RO->,;),-
MT3=N&<!=QSZ&N]9U0J&8#<<#)ZGTIU 'ENHV426D^Y%_LI_$EM)8@CA8]T?F
MLGHF[?TXZGI6L^@:#_PL""P_LVS%I_93XA$8";_.##CIGJ17=EE! ) )Z#/6
MEZT ><:0+*]U2*TU.6_C\06>IR3^4D(4L-[8?S-F3$4(SEN@QZ"I_"TFFWR6
M-KJ5I,?$EE-+]I4QN&#-N#NS=&1E/&20> *] HH \IL98M,\-:.TD,T-G:ZE
M<+J9AMLF(EI1&SJ5.0"5['&5/I5\_8-*?1)X&NI/#4FH3S3R3Q_NU=D_=MM"
MC;%O+8XP&P?0UZ/10!R7@7[.K>(5M8]D)U:22,",JI4I'RO&,$@]*-76U'Q#
MT=YEBVG3[M)F<#!!,> WM@/C/O76T4 >5^&[:SM+;P'<111Q71EFCN) ,/M,
M4@"N>N-VS /?%=EX\MC=^!-;B2'SG^R2%$"[CD#/ ]:Z*FNZ1KN=E49 R3CD
M\"@#A3%HNH^,[,20VTFG'19,))&!'GS5/W2,= 3^OO6)IE\MMHOA5]:DG32S
MIC6[2^2)5CGRHVR!E;&5! ./4=S7J]% &7X<M(+#P]9VMJUTUM&A$1NO]84R
M=N>!CC& 0"!@5J444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5FZKJG]GR6-M&BO<WT_D0ACA00K
M.S'V"J>.YP.,YK2K)U_0DUVUMU%U+:75K.MQ;7,0!:-P",X/!!!((/7- %*?
M7M3L6L$OM.BC:YU/[#E9<AD*EEE7&<9V_=/(JI=^+[RVM]0=-/AE>SU:+3\>
M<5W!_+PP^7K^\Z>W6KUYX;FO=.MHY=5F:^M[I+M+MHU_UBC&-@P-N"1C\<YY
MJK)X++PWJ'5IF-W?Q7[L\2G$D>S&,8X)C7/MTQ0 DNN^(H]6AT@:7IQO9;26
MY#?;'\O"R*H&=F>0P[=:D7Q1=W-Q!)9:;)<V;WK6CE(WW(JN4,N[;M*AE/&<
MXYSGBM)]'9_$MOK/VG#16KVWE"/AE9E8G.>N5%4K+PM)I^ISR6NKW2:;-<&Y
M:PVJ5$A.XX?&X*6Y*CW[$B@#/3QAJ6!<2Z;;):IJ_P#9DNVX9GR9!&'7Y0",
MD'G'^.AX=U'4;[5M?CO#"8;6^\B()G*CRHV _P#'B2?4U"WA!FL9;8Z@<2:F
M-3+>3TD$@DV]?N[@/?'>M/3M%_LW5=2O([N1H[Z43/ 5&U9-BJ2#UZ(./K0!
M'XBUFYT:*Q:VM([EKJ\CM</+LV[S@'H<_P">M9,?C&YMIM1L=4L(XM1M9X(D
M6WD:2.83'",#MW<8;(QGY>,U/XWCFEMM'6W68R+JMO(6CA:38JDDL0!T'>I;
MWPC;ZE;WYNKF07MX\4GVJ ;#"T7,>P<XVG)Y)R6/X %.\\5ZK86=U++H^[R;
MNW@CE8O$DZ2L%W*&7.5)P0>.^:DN-6GL]=TI=:TVP28V]W+]IAE,AA1-I(7*
M@_,I4GZ5/<^&+N^TG[)?:W-<SF>&9KAH$7_5.'4!5P!R.3R3GZ8N:AH2ZCK%
MC?S3 K:PRPF'R_ED$@ ;)S_LC'X]: *$7BF<)H=W<VD:6.LLJ0E')>%G4O&&
M['('..A]>M8VM:E)KMIX=U2*"#["^MP"!B29 HD*A_3YL=/0CGM6_8>%4M(-
M-M)KQ[FRTR3S+.-T 92%*KO;/S;0Q X';.<52C\#F"VM[&'5[B/3K6]6\MH!
M$A:(ABVS<1RN2<9&1[T ==7/>)M1U&ROM"AL3"$N[[R9?,SDCRW<#CH/EYJ_
MID&HPWFHM>7;SV\DVZV5T53&O=1MZKTQGGK3=:T8:O\ 876ZDMIK*Y%S'(BA
MN=K*00>.0Y_2@#C[75+GP[-XHO+:RMWLHM:3SP9"C8>.!3L &"06SR16[J/B
M>[BFOETW3I+W[!,L,L21N6E)56;:P4J" XZGD@]."2Y\'FYL=8M&U!@NIW27
M4C"$90KLX'/3]VO7W]>))/"TPUJYO[/6+FSBO=IO;:)%*RL%"[E)!*$@ $CT
M]>: .B!R,^OK7F5I;6J3>-/^*;?42E^VSR$CRO[I#A26# Y.?E'?CFO3L8&!
M7.VGAN\L9]4EMM8:-M1G,\A%NI*,5"_)DG'"CJ#0!F>%]>EET/P]IL%]%J-_
M<V3S/=N6VA8R%).<,3N8+S@\$GI@W;;Q3<7=GN%I%!/#?26-X\LH,<#("=PZ
M%PWR@ 8/S^U.M?!5GI<6D_V3/);3Z8LB1RR#S/-60Y<2#C.3\W!&#T]*<_A%
M%DM+BVOYH+N"[ENWE"*PE>12KY4\#@X'H!WH I1>,;ZZTW1+BVTV RZE=36A
M62=E$;IYG/W<X)C/N,]#46NZI>:IX<\0V)M+0R6-@1>JSEE,K1%RJ''\((.2
M.I P.M7;7P:;.+38TU.5TL+V6\C\R)227WY4XQQ^\;\?RJ2_\)&YOM5GM-2E
MM(]5@\J\B$:N&(38'7/W3MX/KCUYH U=!_Y%[3/^O2+_ - %8>J^*[W3&UZ,
MV4#3:;%%<01F0C[3$^1D<<'<"N.><>M='IUG_9^FVUF)7E$$2QB1P 6 &.<<
M54N]"M;W7;+5I=WG6L;QA1]V0,01N'?!&1[G- &=J.MF;1-3NHK6UOK&+3?M
M#!W(6;<A8IT/&S!_X$*HP""?QMX?G6VBB$^AS915& NZ'"_09(K5MO"MM9>%
M+K0+69TAG26,R,-S*KY&/^ KA1[**6#P\\&I:;>B]W/8V36:J8N'5MN2>>OR
M+^M %7X?(L?@RU1%"JL]T  , #[1)4VLZUJ=IKEGI6G6-M/+=VTTT;SSE #&
M4X("GCYQR,_AUJ]H&D?V%I*V N#.J22.'*;3\[ER/S8_A276CM<^(K'5A<[#
M:121"+9D,)-N[)S_ +"X_'K0!EMXHO))M]EIKW4$=X;298TD+#:VQW#;=N%;
M/&>0,Y'2F7OBNYCTJ;5[2U@DL8[T68#N0[_OA"7&!@ .3QW SD=*LP>%I+35
M[JXM-7NH;"[G-Q/8A5*M(?O$.1N4,>2![],U@^)/#<^EZ)>K8WEY-9W%_#<I
MIZ0"38QN$>0@@%MO#-CM0!J:AXMN;&R\23_8XG;1I47'F$"5617].#\^._2I
MKS53:^*;^--,MGN(-*%REP9,/(H=OW9.WY1D$]^M1ZIX-&JMK 35)[>VU=4,
M\2QJ3N50H8$\@84<>H_"KMQX=DGU6XOS?G?-8?82&B!^7).[@CYLD^WM0!GV
M?BG4)=/TRYNK&"(ZJD36:Q.\I&8C(Y=0N> . ,YR,XY-;.AZC>:C:3-?6+VD
MT4[1#<&"RJ.DB[@#@@]#T.16?/X2$WA_2].34)H+G2MAM+V) '0HNP94Y!!4
MD$=#6QIMG-9VNRYO)+R=FW232*%W'&.%' & .!^IYH R]:UK4[/6[+2M.L;:
M>6\MYI8WGG* -'MX("G@[QR,_AUJL_BB]>4M9Z:]U%%>?9)DC20MPVUW5MNW
M"MG@GD#/'2M6[T=KKQ#I^K"YV&SCEC6+9D.)-N[)S_LC'X]:HP^%I+75[JYM
M-7NH+"[F^T7%BJJ5:0_>*L1N4-CD#WZ4 9MQXD?2[;Q)>0:1:K-97\4,NR7!
MGW+'AR=O+8<#'MUJQ<>(];AO]5L1IUB9[*U2\1C<ML:-MXVGY<[LH?;G\#+>
M>$/MEMK,#:@575+F.XD(B&4*!  .?^F:]??\+4WAZ2;4]0OC>@/>V2V;*(N%
M52Q##GKEV_2@#G5O;N^\8V>J:/96QN;WP^LVVYD*  R*0"54DGG'2M32O%\F
MJ3:(HLA#_:27(D5GRT$L)VLO3##.>>.E6+7PM)82:=-::B5GL[ :?N>$,KQ
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M=;?3_$6F:>\<(M;N.=WG>3!3RP#TQC'/7-<[875C>^,_#]UI]G/'"NF3P/\
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M+A&*MDY'3K["@#OZP5\1H_BL:4C6K6OV)[EKA9LE65T7:1T'W_6H?$UM?_\
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MG)1O+)VY'R^U:-[<::D=E>Z?IEPMM=:KY[730S$)(8R#+Y74@\*,@#)W8Z9
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M>UDDAO-&B\I_LKA99 LP&,KRV2F._P"51:\_VC2KRT2RN%GD\.*B2K;O(9R
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M)+XZA'<(ZK)!,>I0A<8ZC!!X-;.FZ?\ V=;&-KJXNI6.Z2>X8%W/3G  ' '
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MWG@^\M;:&:6>5H@JPH6;B123QZ $U;;P_:WBWDEY+/=/>VAM'>0!2L)!RH
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M^X"@7:,ULX[L@!9#[X.X'N ?3E=7UNQT2""6^G6)9YXX(]QQEF8#\AG)/H*
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MG<[,)EDZ9VN1CKGMW':NZ1H7=E5%&2S'  JI!K.EW4BQV^I6<KMPJQSJQ/T
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M=[:Z?!Y]Y<Q6\60N^5PHR>@R>] &#X\MWN_"4]O%;2W+O/;D1Q1&0D"9&;@
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M)"ZD/L')!"E<@?H:]-HH X9Q)H>MZ;>IH5T-'>QDM5M[6#S6M6:0."R+G 8
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MO(L+1A6W*=NX@ $#=C/2J/A::%[[P^;^*_MI[&Q-E;B73I8DD+!/O.1MSA
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M/MD,7'R,<8*\#MQVJU+X6LFO[:^MY[NTN8(?LYD@EYECSG:^X'=SDYZY).:
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M[N%1)9I=H9E3.T84 <;F[9Y^E-_L>'_A(#K/G3?:#;_9MF5V;,[NF,YSSG-
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ML8V,9(1F$B#=D# '!]^15R;6?$;F^LK""WNM0TY(EEVQA8YI64.1\T@**00
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M@D$C @JF=O;.?F;G/>JFD^$K'1;GS+2XO?LZLSPV;SEH(2V<E%[=3P20,\4
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MH.P%3T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5%<7,-K"9;B5(XP0-S''). /J3QBI:YSQ;%?I_
M9&HV5K)>+87HFGMHL;WC*.A*@]67?D#VH UDU?3I+,W:7D+0!_++ANCYQMQU
MW9XQUS3#KNDK:K=-J-JL#2^2':4 &3.-G/\ %GMUKF[ZWN9+G2-:L]'E@MH-
M1>XN;41@32!XC'YS(.K G..6Q[\5GZMH]W-_:][%9W#P7^JV,T=OY1W%(C'Y
MDA7MD*>#R=H]: .J/B[PX(1*=;L/+*E]WGK]T-M)Z]-W%77U;3X[U+-[R%;A
MVV+&6Y+8SM_WL<XZXK&GM&?X@V5U]CD:U739HC+Y1V*[2(P!..I ;_)K(TW3
MYEOGTK5-#O[B6'4GN[>\\YOLQ4RF19/O8#*&(VXZCW- '8-J^G+>"T:]A$Y8
MJ$+CE@,E?J!SCKBH=%UVRUZUDN+*3<D<KQ'/!^5BN<>^TXKGO#D=Y;I%HFI:
M%-+<6=[+,E](BF$AG9A*K$YWX<C &<GL,UH^#8+JRTR[L[JTF@>.^N7#.!MD
M5YG=2ISR,$?G0!K7&KZ=:7 M[B\ACERH*LV,%CA0?3)X&>O:K%S<P6=M)<W4
MT<,$8W/)(P55'J2>E<%XKM=3O)-=MX=)N2&>UD@>VC7;<JK(69VSDLN"H7T
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M6PQJ>C M@Y&1A>W%9>GVFIP6/AJQ?2+W?IFK2/</L&T*1-AE.>1\Z\CZ=>*
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MTVP=EN[V" H%+F1P FXX7<>BY/3.,TT:WI;).ZZA;%+>-99F$@(1&R58^BD
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M,J& .!PISC(SZ\9C\*65_8:E!#$+LZ1]D8B"^BQ)8OE<1)(0-Z$9]<;!STH
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M_("T_P#Z]H__ $$5@Q:_=/XF;2;N=["=YI5@CE@S'<1!6VM$_0N#M)4GU&*
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M!\W)S@9 & 1WKK+II%M)FA95E"$J77< <=QD9_.@"6BN#TW7O$%Y'X7E>\M
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M&/B(:+X>U.:TN42_MK<R+NB,@4X^4-CA<XP,]?>M[SUCLQ/*3@(&;:I)_(4
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MJLV96=HU^1MK,H)90V,$C!R,\8-/O-2M+ QBYEVO)G8BJ79L#)PJ@DX'7TH
MQK3PPDRVESJ-Q>O>6ZR1HYN3YAB<@^7(RXW=!^74]3-:^$M+LTTM8?M*_P!F
M*R6Y^T/D(V,J>>5^5>/:IKGQ3H5I!!--JENL=Q"9XF#9WQ@9+#':II->TN*2
M)'O$'FLB*V#LW, 54MC )!& 2"<CUH I_P#"):;]G:+,^XWAODE\SYXYR<EU
M/;.3QTYQC%27'AFPNK*6VF,S>=.ES-+OP\LB%2I)QVVK@# X%/\ $VM#P_X<
MOM4\OS'MX6=$P2&8 X!QT&>]4;*\NAK=O%-K\,L5Q&\D-F]ILF?  8D\84'D
M<=\9/6@#5M=(M[35;O44>5KB[5%FW-D$)G;@8XQD_G1JFCVFKBU^T^:&M9A/
M$\4A1E;!7J/4,1^-9GA[7);C1Y[G5)D,B7]Q;*8XR-^R5E4*HR2<+T&36E'K
MFFRV*WD=VCPM(8EV@EC(#@IMQG=P?EQGB@"LWAC3C/<L!*L%W*)[BV#_ +J6
M08^8CWP,@$ XY!K88;E(!*DC&1U%<_X4UBXUE=8>>5)5MM1DMXBL93"!$."#
MSD%CG/-=#0!ACPGI1\.'09(Y9+'<64/(=R-NW95AR"&Y!ILGA'3)](;3KEKN
MY#.LGVB:Y=IPZ_=8/G(([8]_4YWJ* ,5O"^GR:?':2M<RM',MPES).S3"5>C
M[SSD#CTQQC%7K33+>S%P0&EDN6W3RR\M*<!>>V, #  %7** ,D>&M)_X1L>'
MS:@Z:(_+\HD],YSGKG/.?6JW_"(:>VD3:;-<7\\<Q0R23W3/(P0Y5=QY !YP
M,?J:WZ* $4%5"EBQ QD]32T44 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S?B^TOYH=-O;"VDNVL
M;OSI;6.7RWE0HZ':<CYAOR!D9Q7244 <-=Z;+-;Z7<6>@W%L#K,5[/$[*TNU
M5(,DGS$;NG ). ._ UX+2Y'Q!O;UK606LFG0P)/@;2ZR2,1UST9>V*Z*B@#S
M^ST+4Y/"^E^';FUE2ZL+^.5KS(V%(Y=_F*V>K+QCKECGCFFWFE:E)H?B&!--
MG,UUK<=U"OR_/&'A);KQQ&W!Y_.O0J* .#&FW:ZMJ>GWV@W&H6M]=_:;>Y\_
M$"@[3B52P(*$=@2<#%,N=$U.30?$?AZ2TDDDU"\EFMKK@Q[)&#!F.>"G/'^R
M,9KOZ* //=>TK5MOC"SM]-N+HZK:Q_9IE9-I*Q;"&)((.1Z<YJW?Z=J3:R-0
MTR"]M+TR6XEBDVR6UU&-NXN,D*Z#=R"#\HQFNWHH Y.RT5K^Y\6VNHVDB6>I
M7 ,;-CYT\E$)'/!#*<9]C5GP=%?OI?VW5)$EO)0(?,0Y#QQY56_X$=S_ / _
M:M?4]*LM8M!:W\/FPAU?;O9>1R.00:M1QI%$D<:*D: *JJ,  = !0!PWC'3]
M6U)M=M+?2Y9([C31';36Y1?,<;\K*Q(8XR-J]/F/X7]4TB_O-2TN^M83%]IM
MVL-01V&Y(&&[/!(W A@,9YDKK** .)L=&UC3_">J6K6T%Y=6\$EEI\,^&2:!
M2=FX'CD$*0>#L%9MWI>K7 \1-'I6H$:CH:6T33O'N,H\T;2 V%^^O P![5Z1
M10!R&H6VHV]WX8U2"PFG@L8Y(KFUCV^8F]%4. 3@[2I!P>C'%8QTO6XA+J":
M1=,(=<FO#:"94DFADC*;D*M]X9S@D9YKTBB@#A9M.O+>YTC6K#0IXH(;V6>Y
ML=ZF=Q)%Y?FM\Q!<'MN)P?7(K6\*6]Y#=:]+=6,UJEUJ)N(?-*_,ICC7HI.#
ME37244 <;I\.I6.IZGI=UHC7L%UJ#7EO>$HT*JQ#?."=P9"., YP,8ZU1GT+
M4YO#>N>&Y;61IKR^DEM[P8,9220.')SD,G/'7Y1C->@44 <+J>EZA-_PG"1V
M$SG4+-(;1OE_?,(2A[\<D=<4W5K.[%RUV;.9+:/PW<6TDA PLAVL%//HI]J[
MRH;NTAOK.:TN%9H9D*.JL5)4]1D$&@#A['2I]<LO"LL$$MH+#3G#SNH7!D@"
M!5QUY.[(X^4=Z?H%E="TM(;_ ,.7,5_IELT/VJ2<21M\FS]S\Y/S<<$  ?A7
M:6=I#86<-I;*5@A0)&I<MA1P!DDFIZ .#T?2M1MD\#I+I\R'3K:2*[^[B)C$
M%&>><D=LU4BTK6[+3;J'2[&:>R?3V"Z;J2I(+:4LO[N-C]Y-N[@DK\J\\XKT
M>B@#SFZT;5KV'Q<D>G7H_M/3(DMWNI8]SR*L@*G#84DL.!P/;I6Q=6E_J/B#
M1KI;*YM8UT^ZADD;;F%Y/+VYP3S\A/&<<5UU% '!V.CZC<:)X7TJXLI+:XT:
MYB>>;C85B5ERA!^;?QQVR<XJ&+2M231K*(Z;.)8_$37KKA<B$S.^[K_=8<=?
M:O0J* .?\;6EU?\ A.\M+.W>XN)#'LC3&3B16/4@= :S-1T[4#XD>_TJ.\MY
MWN;?SHY 'MKN(!-SL#]QU&0",'Y!P:[.B@#GO%]I<WEEIR6UM).T>I6T[JF/
ME1) S'D^@K!U71=6N[SQ%-:VDF6OK*\MT<A5N1"$W)G/&2O&<=NU=_10!Q6J
MZ/>ZU=ZSJ%O;2P_:-#DT^*.;"-+*Q8C(SP!D#)_O'MS6]9175UX52W:*6RN6
MM/* D(W1MLQGY21UYZUKT4 >?:?:ZN8O!]K-H=U#)I$ABNG#1[,"!XPZG=R"
M2#_]>IO#&F7=N+#3=3T&<W6F,0NH23AX" " Z#=G<P.,;1C)R>U=W2,H="IS
M@C!P2#^8Z4 >;>'K"76?"/ANVAM9$-IJ7VMYV4!55)78D'N6^[@<\G-7]%TV
M[MYTTS4]!N+B2TO7N(=0:?= 5WLP<+NR),,1@+U[X-=?IFEVFCV*65C&T=NA
M)5#(SXR<GEB3U-7* //;+2=2BT/PY ^FSK-:ZU)<SK\OR1EIB&Z\\2+TYZ^E
M0R:=K</AV71'TBYN+B'5TNEN8V39/&;H2[LEAAL$@@^GI7I%% '"0:9=IJE_
MIVH:#<7L-Q?-=VUWYX\A59@X\Q=_#(>F <X&/6H;[2=2ET3Q+!'IL[37>L1W
M,"_+\\8:$ELYX_U;=<'IZUZ#10!SNF6UY;>,M;GDLY1:WJ6[Q3Y7;\J%2I&<
MYS[5$UO>Z;XQU*_>SFO++4+2%$,0#&-X]_R$$]&WYSTSG.*Z>B@#A-$T"_T:
M^\+136\DJ6&GW,4\J898WD9&51W.-I&0.PK;\%6ES8>%K>UO+=[>>.68F-\9
M :5F'0D=&%=!10!Y[=:5J<G@WQ%9IIMP;F[U22>"+Y<O&TJL&SG X!Z\UUVO
M6,VL^&=1L;9S#-=6LD2,W&TLI S6I10!R$-G>ZCJ'AN\FL)K-]*BE-R&QRS1
M[/+3!^8$\Y''RCO5[P19W.G^$;*TO+9[:XBWAXWQD9=CV)'0UT-% '(:UX9N
M-1U^YB3Y=*U:S\O4&#897C/R$>[!L'V3Z53O-)UNZ^&VI6][;F?6[NW\@I&0
M=VT;%Y)Q@X+^Q<UW=% '"Z_HVIZMJVJ&SMI(EN-%2WBEDPJF59&?8><C((&>
MG)J.\LKG5_#FLR1^&;NSU*;39+/_ $F99)'9APB'>?D!R<G'7@=:[ZB@#EK.
MTNQXSL[PV<J6RZ1]G:0@ +)O5MIYST!]JGU6VO%\9:+J,-G)/;1V]S!*T97]
MV7,94D$CCY&Z9KHJ* //;32M3CT/0X&TV=9K?79+N9?E^6(R2L&Z\\.O YZU
M/HNF7<%TFEZEH4]P]M?/<PZ@\X:W*F0N)-N[(D 8C 7KWP37=T4 <[XKM;FZ
M;1#;VLEP+?4XKB78!\B*&RW)]QTYK,U2QO(/$^H-/HMUJNFZG!&BBWG"B-E!
M5DD4LHV$'.>>_%=K10!P]WH]_;ZNEQI$-Q:7*26T<D0P]G=1*$!)!^XR#(!X
M/RC&:B-IK-E:ZI#'H\DV_6_M0D B<F%F4[X@QQO&.X&*[VB@#SDZ/JRZ3JR+
MI5UN_MZ#4(D>5&>6)6A)P=QRP"-U/T)JU<:?>C6M6@O?#]SJ-EJKI-$RW $<
M9\M$:.9=X  * Y ;/;-=Y10!YWJFFZQ#IOC#25TN>[.J;YK2XB*[3NB5-C98
M%2NSCU%=Y$[IIR.\,BN(QF+@L#CIP<9_&K%% 'G]II6IQ>"_"=D^G3BYL+VW
M>YC^7,:H3N.<X(Y'3-)J.DZE-H_BR&/3IVEOM2CFM@-O[Q (03G/'^K;KC]:
M]!HH \^\0V.L7\FJ)'H]PP^V6D]NUN8T2:-&B+,^6#-(-K##< *N/6DU/2M3
MN=)\7QQZ9.9M0O(I;9/ERZA(@3G.!@HW6O0J* .-$6I6>O:S#+H<FI6.K/'/
M#(=A1"(U0I*&.0!L!X!ZGC-0ZG9:J-2\57%KI8N3<VEJENLJJR3%"^\ ,<9
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M% !1110 4444 %%%% !1110 4444 %%%<3XNN(;3QAX>:ZGNH[-XKQKE8'E
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M([Z>1)&>3:<+$[8'!],Y]L=^.?TG7)-$;6&DM)Y[/^WFMWG,P/E;S&BX!)+
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M57'S/(VU4&>,YQR3_$/6@#7HKFAXQ@B^W+=6S*]L8A&8'\Q+@R':BHV!\V[
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M)4.<@@'IGG'44:CX+U&\34(4U>)H[J.W5'N(#)+&8MO&[</E8KN/'5C7:44
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MK-$P8 $A1U! /..U=+10!S5MX>U/3]8OGL=4BCTN^N#<S0O 6EC<@;_+?<
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MX[YKB+YX(_@AIL@D\L+9V>#OV_-E ?ZY%>CU4LM/BL$DBAXMV<R)$1Q&226
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M^,=<5N>/5C.D:>9F*0KJMH97W%=B>:N26'W<>O:NG"(K,P50S=2!R:4@,""
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M>?:UW6VXQ$NKL"=XW<KQTP">M6KCPW<SWNMW/V^)?[4LTM2OV<GR]H<;OO\
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M<SI/,B!6D2/8&QZ+DX_,US-QX+NKBQ\0VK:I$!K,PE9A:G]T0%&!\_/"CTH
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MV%K^V(G#&1%(!##&$;YAT+#GK4=[X4GN_P#A)!_:$:+K4*PX^SDF$!"F?O\
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M>>1-!YT:R>5,A5TR,[6'8BN;3PCJ%D^FW&F:TEM=VUC'83L]KYD=Q&GW3LW
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M=QL23>-H8@'.!U&#CMG%3Y&,Y&/6O+](G2#2?#YEV'14U6]6\SRB$O+Y)?\
MV<D'GC)4^E)JEO%'8ZB$91I!UZS:PPV%4;HS,8R.BYW].!AJ /4<@]"*RO$>
MLMH7A^ZU6.W6Y$"AC'YFS() ZX/K7#WDNF:5=>*K5(46P^TV#>3"VR)"VT.[
M;?X,@;^.1P>M5;RXA7PKXYMDEC*_:HWB$<9C0AHXCE%[ G)'//)YH ]8I-P(
MSD8]<UC^)O)N/#-R&OA:Q2A +E5#JN77!(Z%<XSVQFN'DU&6VMXGU&V@M].A
MU0C4+K3D\RWES  DFT@X4-M##! 89SF@#U#(V[LC'7-+G(R*\V:33-&CTFXC
MGN+CPQ)?SR32S(#"C.@\LA0H B#;L<8#'/I5BZ&D:7=>%K^TS!I,=_< 7$Q(
M15DBDQ@G[J%C@=!TQQB@#T'I59IYQ?!/)C^Q^27,YEY#@CY=N.F,G.>U>7DZ
M?-9PI($6,>+7PKC9B,LV>#C"],UT/]FZ;9^/8].M;:". Z%+$( !@_O5(7'T
MSQZ4 =2FH-=VUC=:=''<VUPX+2&3;MC()WC@[N<<<=:O9&<9&>N*\MTHZ>GA
MCP"8A#'-'?1),0H4AA X?=[[MH/OBK6FG3[_ %A;;4[N\A\16FJ22B&.)0[K
MYC;2&V9,1C(!YQ@8["@#TC()(R,CM02!U('UK@O#LA@\3P1H;34;><7#Q7<8
MVW-MEMS)..XS@!N.0*=XIGL!XHEL_$,\EOIEU8+':RF)7C\S<_F+DJVUR"A&
M,=* .\I"0!DD >]>;^(;"WBM[.ZT\3SW>G6(_M 3NJS3V1 #(YQ_K" 2.A&#
MTR,VK_5=$.N61U 1?\(Y=Z7LLG:/]RLI8[EP!\K%-H'0\$4 =2VLLGBI-&:W
M4(]DUV)_,_NNJ[=N/]K.<UJD@#)( ]ZX$V>DS>+]-LKJ(/91Z%(@BO3N.!)'
MMWANIV@G!Y&,]JR=-O+2X\/>&;2\P\S:7.B27(,D9(*KY83^*7 X[@9X.: /
M5"0.I H) &20!ZUY=H@T_5+KP:+\17 ;0Y4N!/R'8>3@.#][H_7N#Z4ECJ%M
M9>%?"=S=74?V.WO+B*2&8GRV4>:$R>0"HVE0>O'UH ]3R ,D\>M .1D=*\LA
MDT_3=$TVX2^@FT=]3G:^EL@)DM]P8Q(X*G*KN4<CCY3Q@5VWA.UL+72)!IEQ
M<3V4EP\L3R@!<-@D1@ 83.<<>N.,4 ;F1G&1GTHR,XR,UYC:^9=>']-"X3Q;
M!JB_:!TFSYQ\PMW,9C)/IMQCM6SX-T[2Y=5UR\2&%[JWU:<0R Y,:,J X] >
M?R]J .U) (!(&>E+7F?CZYMGE\00!?+OHM-C>-I5+L^"[ PC^':>689[=,9K
MI/&LD%U\.=7ERKI)8NT9(^\Q7Y<>^<8H Z<$'H1Q4<UQ#;V\EQ-*B0Q*6=V.
M H'4DUYU>OIVEZQJ#VL3-%-X<:2>.S?;).X;@[AR7VD_-R<<U4/V6Y_X2>UM
M1;SPW7AY)(8[6$^6[J)0"O\ >(^4;O7 X/% 'I(NYII+)[:!)+2="\DK2;60
M8!7"XYS]1BK>1G&1GTKS^VDT\ZSX)DL?LZYM;A04 4$F)?\ V;/XYJEI^^ZT
M30#%A/%$&I(+T=)A\Y\_S.^PKD\\8VX[4 >FY&<9&:,C.,C/I7D\\&FQ:5J]
M[&L N[?Q+&;>4$;HU,T6=OH"N[.." ?2K&J7]FVM>?%B&:W\0PB;>K/-MPJE
M]W\,1' '0^O.* .\TS6'U#5M7L7MA$=/F2/<)-WF!D#@]!CAAQS6ID9QD9]*
MY?P[+&_B_P 6!74DW,!P#Z0(#^H(^HK*O9#;^,C)$;348I=0A26V<;;JTDVJ
M \9_BCQR1V^;GK0!WN1G&1GTHR,XR,CM7FWATV6H7=C]INKN/Q1932>?;B)5
M8L<AB[;,F(@@\MC[H'.!5KPC+H^IQZ6MU%(?$=HDD=]&RD.'8$2&7LRDC(SD
M<C% 'H%0W,DL=K,UM&LUPJ,8XF?:'8#@$\XR>^*\OT6[LUL_!-LSK]JL[Z:&
MY7;\T)\N8;6_NY..#UZU+9Z;I#> /$U\((&ND_M*))<Y95,CE%'MPI _$=:
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MZM];B>VDR-T9_<9*>F<-DCK@YZ4 >KD@$ D9/2H[FYAL[66ZN95B@B0O(['
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MZA'J[Z58:9;.R:>MY&TEP47!;;M("''3W_"@#I:*Y33?%UU?S:&[:;'%:ZS
MSV[?:"71UCWX8;<8(!P03T''.!7M_&>HS66EWIT> 07UX]D +LEED#.JG[F-
MN8^3UYZ<<@'9T5R\7BV1(+V.]LD2^MK];$10R-(DC.JNI!VYQM;)^7/!ZT+X
MJN8]T%UI<D5V]XEI:E@Z1W&Y2VX%E!  #9&#]WOD4 =,75=V6 VC)R>@IW:O
M.9+@Z<WC^YO-,M;E8UADFMA)B.5?)R>=O4CMCKW[UNZYXJET&VFG-C%]FMX(
MI0&FVM,&.&6-0#]T8))]1TZT =31[URD_B*[L/$FO"\6+^R]-L(KGY&._!\T
MDXQ@D[ ,9&..M5]7U:[O])UK3[W272W;2YIEN-DGEA@I^1MZ+\PX((ZX/3%
M'9 @@$$$'H12URNDZU+9MX=TR:VC6UO=/4Q77FG)D2-28]N.I7)!S_":W=*O
M9=0TZ.[DA6(2Y:,*Y;*9^5N@ZC!QVS0!=HKGM2UW4X?$/]C:=IEO<3-9FZ22
M:Y,:\.%(.%)'7MG\*SH/&MYJ$&C&PTB-I]26X4QSW.SR98<AE)"G(R#R/RH
M[*BN5G\5WB^:UMI$MT+:=+>XC@$CMN^7>4(3:0N[N1G!Z<9N)KM[=RM)IVG+
M<VD=\;.5O."N-K;7D (QA6SQG) )H WJ0D*.2!VYKFAXJN)KF!K/2YKFR>\:
MT>2-)"R!6*&3[NW:&4Y^;IS[5C:UJ;Z[;^&]3BM8?L,FM0^1*7S)M#, V,8
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M"59U(Y#8Z#.,C\.<\'ZQ<Z5H>@VC6,7V"\O+BU259?G5]\SCY-N-OR$=<^U
M'H5(2!C) SP,T/N"-L +X^4$X!->:MJ&H:KI/A+5+N"WDO7UIQ&4?&1MG&W)
M'RJ-H]> .IH ]+HKEK?Q=(;2475FJ7\>I-IPBB=I$9PN_<"%W8V<_=SQBM31
M-4NM22Z6\T^6TDMYC&&96"3+@$.NX XYQC'!% &K17)>);J6Y\6^'O#Y=DLK
MSSY[D*<&41J"L>?[I)R1W QT)K3N],TK2<:PL26<=A')+)Y";59 ASE1P2.H
M/7\S0!M45SD?B6X2YTA;NQCBAU=3]G=92QCDV;PC\=U!Y&>1CWK/M_&>HS66
MF7IT> 07U[)8X%V2RR!G53]S&W*<GKSTXY .SHKD)?&-[:VEV9M+B:[M-3AL
M)8XKDE3YNS:RDJ,\2#@XZ=:FB\4:BESJMA=Z.BZC91QSQQPW.Z.:)R0&WLJX
MVD'=D=N,T =317'W'C:2#2]:N4LX;B32YHHSY<Y"2K(%(93M[;NG3CK4\_B;
M5;>76;8Z/#+>6%LEW%#'=$B:-MXQG9PXV'C!!XYH ZFD)"@L2 !R2:RK#6AJ
M5Q:"U2.6WFLUNGF60_(&^X ,<YPWIC;3O$EPMIX8U2YDM([R**UD>2WD;:LB
M!264G!ZC/:@#4XZBBN6D\4):W-GIL,%M#-+913V\4TOEB;.08XSC!90!Q[CZ
MUU- !17)1^+[WR=2O+C2X8['3YYK>5UN2SLZ8"[5VC.XG')&*DD\67-G-<1W
MNE3*H6+[-*BNJ2R2.(Q%ET7#;B.>>#GMB@#J:*Y>\\3WVGW.K6UQ86[26&G?
MV@#'<'$BY8;>5X/R'GGM5NW\02SZQ8V M$ O-.:^1S*?E(*#81M_VQS[=* -
MP,&&5((]12XXQ7#Z9XFFCTG0(M+T.UB&IR7$<< N-B0LGF-_<Y!*DD^YX-7;
MGQ7?11W!M]'DNIK-XXKJ" 2.Q<JK.(R$VG:''4C.#TX) .J) 4EB !U)I>M<
M%XWU1]6\'>)XK6UAEMK%6@DDE<AC(%#,5&/X=PZ]3D<8R>[C_P!4G^Z* '45
MQUIXIO;==:FOXH7$6JK86D<<A!+L(E1>1TRV2WUXK8LM:E?Q#/HE[;I%=);K
M=1/$Y9)8RVT]0""&XQ[@T ;-%9/B769- T2348[47/ER1H8_,V'#N$R#@]V'
M''UK&NO&&H:=)K%O?Z3"EW8V)U"%8[HLDT(R"-VP$,",8QWH Z^H7MHY+F*=
M\LT6?+!/"DC!./7!(^A/J:Y\>)+]/LL5SI\45Q>AI+98Y'E_=*JEF<*F006
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MFDSVCW9G64%H%"AE#K@9+*?X<X(QSUJ.3Q-=65A_:M_IOEZ6;%KPS1RAFCP
M1&RG&6(/&,C((]Z .EHKG_[?N[?5K'3[VRBCDU"%Y+9DF++O0!FC;Y>.#D$=
M<'CUKZ?XMDOX?#<HL%1=:5SCSLF$K&SX^[\P.W':@"Z="NDU&ZN;76KJ"&ZD
M$DL)CC<!MH7Y2RD@84<'(K5MX(;&TC@B 2&% B@GH /6N5M?&-],ME<3:5#'
M:3ZD^FNRW)9U<.R!@-@!7*^H//3CFE=Z_>OX9\576J:=9WUK97<D/V8RD*R*
M$^7E3ZYSW)/2@#O:*YC4_$FHVFJZE86>F6\QLK)+T/)<E ZDN"N AP?D..WN
M*5O%C7'E+8VBM(^E#5,32;04/1 0#SUR>W'7- '3450T347U?1++47@$'VJ%
M9EC#EMJL,C)('.".U7Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *Q_$VAMXCT.;2_M7V9)61FD$>
M\_*P88Y'=16Q2,RH 68*"0.3CD]* ,DZ7?W,JC4-0BGM0K![>*V\L294K\Q+
M'C!/''/TJG8^%?LUOIEG<WINK+2Y/,M(VBPX(4JF]L_-M#'& .@STK>-S;JB
M.9X@CG"L7&&/H/6E>>*.18WE17;[JE@"?H* .=L_"$=K96VF&[,FE6ER+FWM
MS'\ZD-O5"^>55N1P#P!GU@_X0MTO7OX=2$5]]O:]2=8.5#J%>(C=\R$*OY9]
M,=#:ZI97DEVD%Q&YM)3%-AAA6"AB/P##/O27FK6-C8B]GN8UMRRHKA@0S,<
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M\CO89H8]K6\J*JJ1DD$849!ZY/X/N_"UUJ&GP"]UJ634[>X2Y@O%A55C=<@
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M>*[.B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M':R!HT<%&5B3R.#\HH ] HKSZU\4ZK;?%I/"@NEU73I;$W,DWEJ)+1QNX8H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK>'M$N]/U;X?S7$MBL>B6US%>,+Z$X,@8+M^;D<@FO2/^%=^#/\ H5M(_P#
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MUU+9+(F^A&?+X;=\W'J*])_X5WX,_P"A6TC_ , T_P */^%=^#/^A6TC_P
MT_PH X.TT=Y?&.GWES=6<%DOA@:1-*+V$LDN#D@!LD#/7UJKH7AN:)O ]E>7
MVGV\/AJ6YEGN5O8F6XW/E!& V[GON"X]Z]&_X5WX,_Z%;2/_  #3_"C_ (5W
MX,_Z%;2/_ -/\* /)-0\-:J;#5],@;3)8YO$W]KQ7']I0@/$<\!2<[AWSCVS
M6UXATFYU#Q-XTOK>6Q:#5M(6SM2;Z$$R *.1NX'7GVKT'_A7?@S_ *%;2/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&>12[2,O0GH!GISCK6C=BR\+M)>6\7S7\L%I#:JVU/-+$#'91\V3@?PDX)-
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M%O+&]Y;1J[QEL;=V[:">WW3^&/6GV<\DEI;M=>2ER\:LZ12;E#8YVGC(]\4
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M-<V]QY/'[UF+HR[N5.\C@@\#TJ6[\)?:H)C]L5;NXOH;Z>;R<AFB*[%"[N%
M11U/?UKH+B800L^Z,-T02/M#-V&>?Y&J'AS5FUWP[8ZH\(A:ZB$AC#;@N>V>
M] ":?H\EEKFJ:DURLGV_R\QB/;LV+M'.3GBI-4TZ74-B+-#Y&QTFM[B#S8Y0
MV.HW#D8_4U%J>MK9ZE::7;0?:=1NE9TBW[%2-?O.[8.%Y Z$DGZXDM[Z^.II
M9W=@D:M"THGBF+IE2HVG*@@_-G\/K@ R+?P:;"2P;3]3DA%M8?8)-\0D,D>=
MP()/RD'/J,'&*6R\(RZ=#H?V;4@;C2;9[5'E@W))&P7.5# @_(N#GUZUTJ2Q
MR[O+D1]IPVU@<'T-()X3G$L9PN\_,/N^OTH XZZTV)+K3-)L1<2W-OJZ7]Y*
M\+*K;@[L^[&TC) P#QP*TK#PQ<Z;J4[6VLS)I4UPUR;'RE^5V;<P63J$+<[<
M=SSS70B2,HKAU*M]U@>#]*198WC\Q)%:/&=P.1^= '/Z3X8N-'NGC@U>8Z3Y
M[3QV)B7*,S%BOF==FXDXQ^)&0;NAZ,VBK=Q"[::":YEN(T* >7YCEV&>_+'\
M*TUFB>-9%D1D8X#!@0>W6D$\1B,HE3RUSEMPP,=>: ,W4M&:^UC3-2BNV@EL
M?,& @8.C@!AST/RC!Y^E9]MX/2WL4THW>_1XKH7,5L8OG7#^8$WYY0/SC&<<
M9KHFN(%B\UIHQ'_?+#'YU!<:E:6MW:6LTZ+-=LRPIGEL*6)^F!U]QZT 69 [
M1L$8*Y'!89 /TR,US \&[?">G:,FI21W&FNDEI>QQ@,C+D E22#P2".X-=!:
MS7#FY^U)!&(YBL9CDW93 (+9 VGD\<]N:F6:)XO-65&CQG>&!&/K0!SE[X6N
M[^SM7FUN7^U[6?SX;Y85"H=I4KY><;2"<C.3GK4UQX;FN#I]V^INVJV4S2I=
M-$-K;EVLAC!'R%<< YX!SG.=Y9$=F575BIPP!S@^]0WU[;:;8SWMW*L5O A>
M1V.  * *-MH%M';ZDEUBX?4V9KMMNT/E FT#)P H ZFJ3^$8'\)6^A_;;A9+
M?9)'>C'F+,AW"3GOD=/3BK U_P#XJ9=,:*);9K W@N#+SPZK@C&!UZY-;$DT
M4*!Y)412< LP - '.W?AK4-1T9K.^ULSW#30RM/]F"J!&X=0$#8&2.3DY_+#
M?%,,&M>1X?:*[-VSQ7"W$,3JD05_F828P#M##&<_,!WK=DU&TBU*'3WF074T
M;2I'GDJI )_-A5DD $D@ =S0 B(L4:QHH5% 55 X ':L:[T&>?7+G5(M0,#R
MV!LD"Q9,?)8.#GD@GIBM@2QD@"1<GISUH::)8VD:1 B]6+# _&@#*TK04T[5
M;[4F>(W-XD:2B"'RD8IN^8KDY8[CDYZ ?B_6=&;59M.GBNVMI[&Y\]'"!P<H
MR$$'V8\^OK6F)$.W#J=PRO/7Z5D^(M:?1=%?4((8[G9+'&RF3;@.ZIG@'.-P
M..* ,ZX\(2SZ=JMF=24#4+Y;UF^S\H5*':/FY'[M?U_"4^&+N+6;J\LM:FM;
M6^827=JL*L'<*%+(QY0D 9ZUI:_JO]BZ)>WZI%++;P/,L,DFSS-BEB <'L/2
MKEG.;JRM[@J%,L:N0.V1F@"21/,B=-S+N!&5."/I7+:9X/N=-GTF7^V#(=-M
MY;:,&V4!T;;C=SG=E!D]_8\UIVNMM-XBU33)XHH8[*.!TE\W/F>9OZ@@8/R=
M.>M:KS11,JR2(A<X4,P&X^U ',V?A"2SLM!M5U%671YFE1C!S)E67!^;CAS^
ME#>#?,BN2U_BX;4_[4MYDAQY,N ,$;CN7 P1QU/MCI_,3<5WKN'49YIK3PH@
M=Y452<!BP )]* .>O_"2ZE:ZD;B\Q?WQ@)N(XL+'Y+!HP$)/ ;).3SD].,07
M/@ZXO(];^T:N6DU>UCMIB+8!4"AAE1GT8\$G\:ZRL>SUMI_$&JZ;/%%"ED(-
MDGFY\SS QZ$#!^7IS0!7F\-/<ZG)=SWH*R::VGO&D.WY2<E@=QP<^U:.C:?+
MI>D6MC+=?:3;QK&)/+"9"@ <#V%7))8XMOF2(FXX7<V,GT%#RQQLJO(BESA0
MS8W'T% &)?>')+K5KZ^AOS#]MLA:2QF(..-^U@<C^^>/8573PE\VD+/>++#I
M]A)8F/R<><CJJDD[N#A!^OX=&\T49P\B*>.K =>GYT^@# T#0+[1DB@N-;GO
MK2W79;1/$J%%Q@;V'+D#@=/H3C&CK.D6FNZ3<:;?*S03K@[3AE(.0P/8@@$?
M2K;S11G#R(O('S,!UZ4/-%$RK)(B%SA0S ;C[4 9EII^JQQ)!>:NEQ$F!O2V
M\N5P/[S;B.>^%'X5GOX00PZG8I>%=*U*<SSVQBRP9B"X5\\*Q'(P<9.".VZ9
M;D:DL7EP_93"6W^8?,WY'&W'W<'KGKVK/N]<,'B73=)CCBD2[68O()?FC:-0
M<%<=\CO^% #]2T"VU+5-,OW9DDL'8@)P)%(!VGV#*C?5:J7GANZ;7I=5TS6)
M=/:Y1([N(0K(LNWA67=]U@#C/(Z<5T!(52S$  9)/:JMGJEE?V"WUO<1M:MG
M$NX;2 <9SZ<4 4K/0C:Z]>ZB;D21W5O%;F%HSD"/=@[B>2=YSQZ50TGPE-IM
ML=.EUB>ZT9$:."S>-040@C:T@Y90"<=.WI73!@RAE((/(([U6O-1M+!K=;F9
M8VN)1%$I/+L><#\ 3^% '.V7@^[M6T9)-:::WT>0FV4VP#E"A0*[9P<*<9 '
MTKIKJ)Y[66*-UC=U*AF7<!GVR,_G69HVMMJ5SJD-Q%%;M9WQM$ EW>9A$?/(
M'/S]/:M9I8T=$>1%=_NJ6P6^E '/Z7X=U'2M"M-'BU>/[+;HL>];4B5D!Y&[
M?@$CC..*74O"\FHRB[-^(M1BNEGMKI8>8448\L#=RI!;/KN/'3'15BQ:Y+J&
MI7EII5K'.ED_E7$\TQC028R47"L20",] ,]^: *K>&+N/6;J]LM:EM+>^*O>
M6R0JP=PH4LC$YC)  /7\Z6/PQ<6NLWES9:O-;V%]*)[FS$2G,F &*N>5W #/
M!]B*U+"_EGBN6O;86;6\IC8-(&4@ '<&P.#G_'!XJYYL>Q7\Q-K<@[A@T <M
MJ7@R6_\ [8BBU9K>TU.6.>2(0!F610@R&)Z$(.,=>_:KS^')?[1U2[CU J-1
MMDAE1H0<,JE0V<CC#=/4=>U;F]<D;AD<D9Z4U9XGB$B2HT9Z,&!'YT 84WA2
M*Y\)V.A373YLEA$5S$NQU,6,,.>"0,'ZFI-:\.OJ$NGW6G7S:;>V&Y8)4B#K
ML8 ,C(< @[5^F!6RUQ L8D::,(3M#%A@GTS4.HW@L;&:<>6TB(61))-@<@9Q
MG!_D: '6-O):VJQS7+W,W)>5P 6)]AP!Z#TJQ5#1-0;5M!T[4FC$;7=M'.4!
MR%+*&QG\:OT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5R?CV&WFL]'%PB.%U:V)R.B;QN/L,=3Z5
MUE% 'G>KVVE:=KMSI6HQ36FBW=BD5E]EM0\62SF1  C;6)93QC/'H*1C86^J
M7^D^(K:]EM;NQMHK RQO([HJ8>,,@XDW\G&"<@]J]%HH \XU06<VN:MI6O\
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MA4@CU'TKU.FNZ1@%W502%!8XR3P!0!Y7>V=BFD>)KF.WA%W'K\4ELZH-ZC?
M2R=P.'R1Z'TKJ="CMX?'7B4>0%DF>"6)Q%PR>2H)#8QC<#WZUUM% '.^-Q=G
MPQ*;2.24+-"]Q%&"6> 2*9% '7*YX[C(K+\JUG\2:C?V1A;1Y-)"W)0#RGF#
M?)[%@N0>XRN>U=M10!SG@..*+P-HRQQHCBTB$JJN"'" '=[_ %JIXUD1=2\+
M L/DU9)'_P!E/+D&X^@R0,^]==10!Y5K]C920^/95MHFN%>%[5@F6#^4F2GO
MN')'.16M>W.G2^(M9L=?MYI[?4(H#I[1Q._FQA!E(V7HP?)ZCJ#7?T4 >;Z@
MMI<ZUK&E:\=1BFN)HI;$00AS*@1-HCDV$JRNK9Y&"2>Y-4=5LK(:;XQG2WB^
MU)J<4ELX0;U.V'+)_P "5LD>A]*]4+H)!&77>02%SR0.IQ^(H=UC1G=@J*,E
MF. !0!Q#162^+/%!N+>,K=:? \+F'*NH60,0V,=P#]15*&U>T\&^$/$-K:-/
M>:5;PQS1(F9'B9 DB8]5)#8_V37H45Q#/_J9HY. WR,#P>AXJ2@#A=<0Z')H
M<UZ)8]/+SO?RV\(D5+B3!5V4JWRYWKG'&15[2[#4+71K>+PQ=016.^1U_M.V
M=V(9LC8%9-JY)P".F,<5UE% '!3FP?XDZL]Y=RV\7]G01K)%</%EPSDC*D9(
M!'';-96EM)IN@P07=E)_9Z:ZPL+JXA92(\,5FF1<%\MD MC)()Z5ZE38Y$EC
M62-U=&&0RG((^M 'F6GJQT?R8K\V%U:ZU>/;->6I$#99\*ZG&T%6.,8P2/4
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M4^AIOB>T2;3_ !A<62I)I=Q:P&(1C<DET"=S1XZG;LR1W]P:].=TC7<[JJY
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MZ\9M9\/WLL;_ -BI/*)W=/D#E,12,.RYW#)XR0?0UECP[+J>B^(HK1%$(O\
M[7HVY?E6151LKZ(T@8<<$$GH:[]'21=R.K+DC*G(XX-"R(Y8(ZL4.U@#G:>N
M#^8H X34Y;J[\*KXA^PW$;74]O-=01QAIEM5(RN"#NQRY!'1B*S=7MM%N/#]
MW?:>]S<17>I64K22Q>6I=94#F-0JX.P?,0/QR#7I]% 'GVLP:7I&OK:7<+V>
M@W5B8X#;6JO$)6=C(I&QMI8,A! &=M5X_LVGWVHZ?JL5RUK)I,4.EF\C+LR!
M6WIT_P!9DKD=3@>E>DT4 8?@PG_A"-"4JZLEA"C*ZE2"$ (P?<5N444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9:GY(A>XBW-'NR%;H1GTR*X>[O=0U/PY9W=^MO-<1>)(XX=H*XV713 SG P
M*[K0-(70=%M],2=IT@!"NR@$@DGG'UK)/@X"U-M'J4PA&I#48T:-3L?S#+MS
MP2-Q[]N.* &KXLGMO[3@U"UB%W9W<%J@@9F20S!2AZ9XW<X!Z<>E:>C:E?7M
MU?07EDT2P,ODW C9$G5AGA6Y!!&".>U4;SP?!J#:PUQ>2@ZE)#+NB 1H)(@
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M@NK1I0N?W<;  K$B+AF+9/0<;3Q6EHOARXT>W6V.LW5W!!&8[2.=$Q"N,#)
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M7$B2N'9>GRC<!C'0<5%IG@S^S9](D&KW4JZ6DD4*-'& 8WQ\K$#)/RCGO[4
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MEJ;K[+]IA^T8SY6\;\?3K7%6<D!U/4](UG3+J>^;53=VK"%RDB9!B<2 84(
M <GC;CG.*SYY7DU:Q>.PO+<V_B)WEA2UD; *R+YI<@YW94@*0H!QVS0!V6C:
MS+J$VLI=1PP+I]X;<,KD@J(T?<2<?WJT4O[.1(WCNX'21MJ,L@(8^@]37GMT
M;N$ZS=1VES-;Q>(HKJXB2)BTMN(HP648^<!@#Q_<J]K(LI])35M,L+E;;^V+
M2]N)#!(&DVNH>01D;L  <@<X)]R ='XBULZ3X<U/4K,07,ME$TC1M)P"!D@X
MSS[5H&^MHO)2>XABEF V([@%B?0'K7GNJL]WI_Q!:&TN\7<,?V?-LX\W_1U7
MY<CDY[=:9XMD>ZMM>@M[&Z25[&V9)([>20W04EN#@J@0D\#!SWH ] CUBPFU
MB?2H[F-KR!%>2,,,@-G ^ORDX],>M6(+NVNFD6WN(I3&=KB-PVT^AQTKAM4B
MO)]:\3"PM[A+G4-&B%E)Y+*"X$V1NQA6^91S@\BJER@UK0]2O="MM536!I;6
MI6> P>6,@^4!M4,WWL$9QZC(R =:OB 2^+H-(@-M+;R6DL[2QR[F5T9%VD#@
M??K8GN8+6(RW$T<,8X+R,%'YFN,L+NSOO'.CWEA97$=O_94T!)M'01G?$51B
M5P,8:M'5GEM/&VEWMTCMI?V2:$.%++#.S(0S8Z952H/N1WH Z)KJW149IXE6
M0$H2X 8 9X]>.?I2PSQ7,*S02I+$PRKHP93]"*\UL]'\G5=!%S9L;3^U[Z6!
M'A)$-LR/Y888^52Q! ..HKI_!""&RU6%8FBC75;IHD*%!Y;.2I4'^$YR,<4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y#Q-J<UAXMT"V;5GL;&
M\2Y\_E "452O+ XY)KKZYW5=+O[KQAH6IP11FUL%N%E+288^8J@;1CG&WU%
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MJ-N<RS(4**=NT;6P02=QY'OD $MWK\EWXE\+_8GNTL;R6;YBH$5P@A=@?7J
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MYSW/I267A34$U73=2N[J-[B2 #5MO2=T(>+;_NL,9[CZT :\WB>QM[IH9$G
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MQOCX^1<$Y  SGH,5-K5DTFFZ'9P7T-KXALVB2)4<,X5EV2\=2NS<V<?P#TH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBN>\4ZE)92Z-:K*T$-_?K;S3*=I5=K,%![%BH7/7DXYH MCQ
M!;.VJI%;7<TNF,%FBCBR[DJ& 09YX(J74-8AT]DB\F>XN7B>9;>!09"B8W$
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M'IVK0-Y-HVK74<FK7*6C:"UX\DO[T0NK8WJO0<'[HX.!0!W=-1TEC62-@Z,
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MRLNRZ'S1[>P+#(^J^YJMHE[=:GHDJ7<LWVG2K2:UO09&(DN!E23Z\+N^DBT
M=AIU]#JFF6NH6X80W4*31[Q@[6 (S[X-6:\VT2XO-)M?"3VUS<SK=Z'(SVSO
ME"T<4;)M7L>2..3GG-:&BO<ZK:Z9J8UP/!>V;K<0).[&9RF<KR/*92#G;CKC
MTH ZBYUJTMM0TZS;>[W[ND+HN4RJECD_136C7E^D6RRZ+\.XUN)U:4LSN)26
M!-J^<$YV_AT[8-6K36KR)K72KB^?[.^KWEF+B>9E9A'DQQF0<Y.>N<G:!WH
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M94#:,X!/)XQ)J&D^(=;T0K=RV%IJ,,L4]LD):6+S(VW9<D D-TP!P/6NJHH
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M=937EY,D-O"NZ21SPHK/;7TBBAFGT^_@@FD2..1XAC+L%7(#%E&2/O 8[\T
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M/W>EW>GR0W#P6;V=U'*QC#AG\S>A ."')X/8]>*ZI+6V,XO/LL:7++S(8QO
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M?ZHM&"8_]WCC\* .1T74+JTU^*'56D=)XYY+:_BNF:WG0$,=Z$_NV5<#ICJ
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M$U]8VUR86W1F>)7V'U&1Q0!R-G:SZCXO:UN-8OY8H]+L[G,,[PK))O<%]H/
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MH5WI>GW\L4EY86MQ)#_JVFA5RGT)'%,FT32KFTBM)],LI;:$YBA>!61#[ C
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M) H,O^\0/F_&E32--0PE-/M%,&?)Q"H\O/7;QQ^% ' IJ]SINFWD&L7-Y;W
MTQI8]1M+@S172;E7S45C\DF67C@?-UP*J:]<2RZ1XZT^6X;RH+"":* 7CR^6
MQ5]WS$Y.=JDCI^=>D1:1ID,,D,6G6D<4J[)$6%0KKZ$8Y')XI8M(TV%66+3K
M1%:+R6"PJ 8_[AX^[R>.G- '-7EQ-9>+-/33YYYXCI5W(L!N&D621&CVYR3D
MY)&>O-4+*]NY-*\'ZK:7MQ/=:C-'%>QM*S+(&C9I?DSA2C*<8 QC%=K'I>GQ
M20R1V-LCP+LB985!C7T4XX'L*6'3;"WN)+B"RMHII"2\B1*K-GKD@9.: //K
M:6[BL[*__M*_>9?$KV0WW3LIA,[)L*YPW'<@D8&#77>-))8/!.M3P3RP316<
MLD<D3E&5@I(((YZU?_L;2O+$?]FV>P/Y@7R%P'_O8QU]ZLW%M!=P-!<PQS0M
MPT<BAE/U!H XG7+Z]L9Q?2&:ZTN.W@$_V6Y:.>T;)/F;,@2*V1GOP:WO&D8E
M\#Z\"6XT^=AM8J<A"1T]QT[UHG2=-,J2G3[3S$ 5'\E<J!T ..,=JMNBR(R.
MH9&&&5AD$>AH X)+*WN_$GANV6XN/);1[C<T5RX<_-!QO!W#\"/3IQ5/3-;N
M9]-\,6FH:D8H;N"Z5KF>1AYLL;A45G5E.=NX]>2/6N]CT?3(C&8].M$,2%(R
ML"C8IZ@<<#VI)-%TJ6Q^PR:99O9[MWV=H%,>?7;C&: *_AR*2'0X89=4.IM&
M707>W!<!CCG)SCIG/.,UPK_V@NA7NK6VKZB^H66NR6]O$URS(Z?:=@B9,X;*
MGOR.,&O38XTAB6*&-41%VHBC  '0 #H*PO#WAQ-*-W+=P6<EU->S723(F67S
M&+;<D9XSC/\ *@#G=U]%%XOU.WO+^>ZTNZF^QP&X9HQ_HR'!3.& +$@'H1QW
MS?MIYH=:\+RZ?>W%S;:E;R&Z$DS2*ZB,,LO).T[B!QC[V/2NL@L;2UDEDM[6
M"%Y3ND:.,*7/J2.M,M=-L;%G:TLK>W9_O&*)4+<YYP/6@#"\9&8'0EAN[BW\
M[5(H9#!*4WHP;*G'T%<WXHNFTFQUF&PU6^:?2[2 AI[Q@8F+,PQSF5F'7=Q@
M 9/(KT2YL;2]\O[5:P3^6VY/-C#;3ZC/0U%<:3IUW.T]SI]K-*T9B:22%68H
M>JDD=/:@#B[NXL[#Q/XNOY+Z>W":7!(DL4I8CY9OF5"=K$8R > ?3FKOAN\F
M7Q??6#W+&$Z?;3)"]V9R')D!.3T8@*2!QWYZUU+:;8/)YC65LS^5Y&XQ*3Y?
M]S./N^W2DMM+T^R='M;"U@9(_*4Q0JI5,YVC Z9YQ0!SFKP/?>/+73GO[Z"U
MGTN9WBM[EHMS+)& 1@Y!P3R,'\,BL?0M3U&>;0-+U.[N)+29KY%N3(5>Z,3[
M8MS#!Y3<W^U@'FNGOO#YO_%=MJEQ%:S6L-I);^5*NXY9E;<,C'&W'XUKSZ?9
M7-LEM/:02P)@K$\895QTP#P,4 >?27&HM;VUK)J%XL,7B7[##,L[!Y;?!.UF
MS\V&RN3S\OK6EIVEVUE\0KRU^U7C8TFW"-->2,[$R2@Y);GC'TZ]:ZV33-/E
MBABDL;9XX#F)&B4B,^JC''X4Z6QM)K@7$MK!).J&,2/&"P4]5SUP?2@#@?#N
MJ7=Y:^#[*^NKAH+ZSGDDF,S!IYE(VJ7!S]TN<9YQ[4S[1J3FPM9-0O1#'XDD
ML8I5G8--;B-VVL?XL,"N3S\O7/-=Z=(TTV:V9T^T-JC;EA\E=BGU"XP#3GTV
MPD2!'LK9E@.808E(C/\ L\<?A0!B>#WE']N6CW$\T5GJDD,)GE:1E39&VW<Q
M)."QZFJ5S<2:EK7BBSNKRXM/L%O$UH8IFCVJ8RQEX(W?/D<Y'RX[G/5V]E:V
MC2-;6T,+2MND,<84N?4XZFF7.FV-Y*DMU96\\D8PCRQ*Q4>Q(XH XF+S]4U?
MP+>:EYT=[<64SS*DKQ_-Y2'H",=>1^!KI?%-VEKI< >YG@,]W#"GDMM,A+CY
M"W\(.""1R!G'/%:<MA9SW,=S-:023Q?ZN5XP63Z$C(IUU:6U];M;W=O%<0-C
M='*@=3]0>* /-Y-1O&T35(UU.9)+;Q%!!$8;IG*1L\.4W'EE^=ASQVQVK4&G
MWEY=>+-$LM4OXFB$$MG(UW(6BD:,DC<3NVDJ,C..3BNL;1M+965M-LR'968&
M!>2HPI/'4#@>E17NG2QQRS:*EA:ZA*R[YY;;<'4'D-M*D\=.: ,WPQJ3^(3_
M &MBX@CCA6V-N[L )AS+D$X.#A<]?E:FZA>F?QU;:-<S20VC:>]Q&$E:/SI=
MX4C<I!.U><9_BSV&-[3[-;"RCMPY<C+.Y&"[L2S,?<L2?QI+W3;'45C6^LK>
MZ6-MR">)7VGU&1P: /-]!U$6^B>&M.>_6WLKI[Y6GDD8!Y5F.Q2RLI!(+GKR
M0*OZA8_Z)X4AN-7FU(IK/E"Z65TW+Y<V!D,<D?=W9SQUZUVLFC:7+8FQDTVS
M>T+;C T"E"?7;C&:?)I>GRI DEC:NL&/)5H5(CQTV\<?A0!Q.L:K>Z3=>,9(
M+FX*6T%BR N7\A7+"1E!S@A<M^%6==-O;^&O$=WI6NW4N=.,\:1W;2"%E5L.
MKY)&[CC/.TGUKL%L+-)YIUM(%EF&V601@,X]&..1]:AAT;2K>R>RATVSCM)#
MN>!(%",?4J!@T <A?WDFH:O=Z3<:T-+*Z=#+:R-(Z$E@VZ4$.H8@A<@Y''N<
MP7:7-S?ZY%+J]^XAT*"Y1X9W@'G8E_>!0?ESM!V]/4&NWN-'TR[$ N-.M)A;
M\PB2!6\K_=R./PI\FF:?++++)8VSR3+LD=HE)=?0G'(]C0!QEMJW]J7MMI^K
M:E+9K/H4%S!(DYA+R/GS'# C)7"$#MDG%3:A>3^'K_2]7^UWNH6%W:_9'5I&
MPT^T&*0)T!<@J< <LOO74S:+I5Q#!#/IEG+%;G,*/ K+&?\ 9!''X5!/I]_=
MZNCW%S;G2XBLL=NL)\PR#IN;=@J#A@ ,Y YXY +6F6DEEIEO;S3R3S(@$DKN
M6+-W.22<9S]*MT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MA"[;99'"@N25&T87H,_>Z\4 5[3QO!>)I<D>E:AY6J1LUHY$?[Q@N[9C?P<
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MKW$EI=$:5,L-PJA,G<JL&7YN1AQZ'VJQ?^(HK)[Q8K*ZO/L6S[3]F4,4W8(
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M,TIB(!:,@Y*.&QN&#D9R.V:?J'BBVTBR>9K.[DM[:T2ZFDXPL;9 Y8_,W!)
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M'.W/.,],U-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBI** &20Q3*%EC1U'(#*"*< %4*H  & !VI:AN;NVLT5[JXB@5F"*TCA06/
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MZ>IT=K&2[FD3:K0;4W@ [SO!&1G:.1GOQT=CIEKI^DP:9!'_ *)#$(51N?E
MQ@^M9&F^#;'38'M?M=]=6)1HHK.YFWQ0HP(*KP#C!(Y)P#Q0! NM:NNIZ##*
M;+R]5CD<JL3$PE8]X&[=\W4 G Z=L\0:9XJO[VT\*W$D5L/[7DDCG55;Y=L;
ML"IW<?<[YZU"OAV71_$?AM+>?4KVTM#.I><[Q;HT>U%R%'&>,G)]\5HVG@JS
MLWL#'?Z@8]/G>:UB:1=L6X,"O"Y*X8]<GWH Q;[6]4DTFZ:W>UM)8O$45D[1
M0G]XAEC&3\W4[N?4<<=:V)_$%]IFLW]CJ/V8J++[58M%$RF9@=KH06.2&*8
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MIY:RAP^Y<J2,L,D9Q[4  \2S?\)4VCSO#:2>=B*&XA8&YBV9W1R9VD[OX<9
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/?0!IBJQY?@EAE1GIDCH._:G2:OI\-XMI)>1+.[B,(6_C(R%STW$<@=:X_\
MLZ8:KJFEZEH=]?0W=[]IMKB.9A;%3M*^9\PVE"OH20!C-6=(CO+6[N]'U#0I
M;H_VG)>6]XR*T&QI-ZN6)R'7.,8SP,<<@ Z=M7T]+Q;1KR$3L_EA2W5\9VYZ
M;L<XZT)K&G/]KV7D+?8_^/G#?ZGC/S>G'-<2=&U*;PG=>&IK:?[?_:)ECO-I
MV,AN/-\[?T! )XZY&,<ULZAHUY_PEPFM8P=/U2 1ZCS]TQ'*G'?>I,9]L>E
M&W<:UIMH8Q<7L,7F;<%VP/F.%R>V3P,]:AG\3:':W+6\^K6:3*_ELAE&0V-Q
M!]\<US%_83#7M:LM0T._U.RU21)8'@F(A_U:(4E&X!0"F<X/!]L5K:'9R1>*
M_$<TUHZ1SO;F&5XSMD"1!#@GT.: -J/5;":"UGCNXGBNVVV[JV1*<$_*>_ )
M_"H]2O!;W%A$+^VM7FN OES#+3K@Y1!D<]#GG&.E8'AG2[FRU>\L)-K:;I4S
M"PP<X\T!]I'8H&*CV>KOBJWGN+GP^8+>640:HD\IC0ML0(X+'\6% &NFIV4E
MV+5+E&F)8!1W*_> ]<=\=.]5K_7K+3M4L=.GDVW%Z6\L8X 49)/XX'XU@:39
M7]IXDB:S%VNFRSW$EU:7D65MF.XB2&3'1F/W<GACTK0UV"Z'BCP]?0VDT\$#
M7"2F( E-Z *3DCC(ZT 1Z!XIBNFGM=4O;1+[^T+BUAC7Y-XC<JN 23DA3W]:
MVIM7T^"\2TEO(DG=Q&J,V,N1D+GIN(Y ZFN'&G7HTIE&GW(D/BC[=CR3GR?M
M&_?_ -\_CVJQ!I\PU2_TO4]#O[P2ZBUW:W2S-]FVL^]2WS#:R=,8R=HQ0!VE
M[J%GIT:27MU#;K(XC0RN%W,3@ 9ZFJJ>(M&DLYKM-3M6MH'\N642#:C=@3VZ
MC\ZS_&EK->:-;0P6TEPPO[61D1-WR)*K,3^ -86MZ5?WP\;);64S&\AMS;90
MJ)BB_, 3WXQ[T =G/K&FVKW"7%];Q-;1B6822!?+0]&.>@X/-5O^$GT/=*O]
MJVFZ)!(X\P9"G@''?GCZURVJQW^IZAK]U%I-\L-WX>^S0^9& 6DW2_+C.0?G
M'\S@5=L[2:/Q'X>N6LIUAMM(D@D?R3^[<F+"].N$;_)H M:CXIBL]8T5UOK/
M^QKVWGE><_[ 7:0^<8.[IC-;<>L:=-I\5_%>PR6DO^KEC;<'/H,=3P>!SQ7#
MZ)I][8)X6N;G3KI8[$WR3@0EFB,C90[1R01W ..](VBZEI/V?5(].NIK4ZI=
M74MA:R;)HXI1M5E (R1C)4'^,B@#LG\2:)';P7#ZK9K%.&,3&4?/M!+8^F#G
MTQ5V.]M9;!;Y+B(VC1B43;AL*8SNSZ8YS7&OI@6]\/3VFBW-M;C4Y;N9'!=T
MWQ.N]^3@EV!QD^IP<UM^,-.O-1\*75IIJ!K@&-TBR%$@1U8IGMD*1^- &A%K
M&G3K.T=W&WD -*,X* ]"1UP>Q[UD^%]7OO$%O;:JMQ;&QN(2S6PC.^%\_* V
M>1MZY'7IZ5&D,M[XLCUY+:Y@MX=->WD62%E>1V=6"[>IVX//3+<$\U8\#V\]
MGX,TJTNH)(+B" 1R1R+@JP_G^% &B^J6TKR6UM=P_:MK[ P+ E>&],X/!P>.
MG%97A3Q1;:WI&F?:+RV_M6YM%GD@C;!Y )P/Q'YUF:=:7]CK0>T2]_LV1KB2
MYL[J$M]F<Y(:%\9(9C]T9X8].E4]%TV_M+3P,C:?.LEA#,ERIC($;&(J Q]V
MQS^- ':0ZWIEQ*T45] SJC2??X**<%@>A /!(X%16WB31;SS/LVJ6DOEQB1M
MDH.%)P#]"?Z>M<?HD&I)K'AV\GT>\MTM[.YAN(UB58K=CY9"HH/W1M;!Y)XZ
M]BVTG4X/AQI$<.G3_;+"Y2:>S!\J255=BRJ<CG#;ASU'K0!VL>M:=-;M/'=Q
MNBR>2VTY8/\ W-O7=[8S5JVNH+RW6>VE66)L@.IR#@X/Z@BN+FTRVO[/[7#I
M6LZ9)<7:2?:0S-=1R+&P$K+ELKC"8/4,>,8-=#X=74O[ 1-3V+>;Y1YB1^7O
M&]MLA3^%F&&(]30!;35].>\%HMY"9V+*J;OO%?O 'H2.X'(J*V\0:1>7HL[7
M4K6:X.[$<<H8G:<-T]*Y"QTC49O#>@:)/:317^F7\4DTY4[-L;$F17Z-O7C'
M7+'(ZUN^$+62W35S/:R0/+JEQ.ADCVET=LJP^H'UH V;W5+'3O\ C[NHX?E+
MG<>BCJQ]%'J>*J7/B"P@U>STOSU^TWD32Q'&5VC !SWR6'&:S&BNM.\8ZI=W
M-I/=6.H6D*1-%&9-C1[\QD#H&WY!/'7)K+T?1=2T&X\)"XMIKA;33[BVG:+#
M^2SM&R@\] %(R/[ON* -;PMXIAU33[2/4+VT&JSO.HA0[2P21UX4DG[JYZUM
M-K&G)>K9M>0K<,2JH6QE@,E0>F0.<=<5P^GZ;>PZ)X9B;3[E)K;6I;B=?).4
MC8S?,?P=/S]C5C1["9+E-+U70[^>XM+][J&],S&V(,C.LH^;A\,1MV]?8G !
MUEGK^D:A="UL]2M;B<JSA(I Q(5MK'CT/%27FKZ?I[A+N\BA)Q]]L 9.!D]L
MG@9ZUD>#+22UTR\6XM9()6U"ZE'F1[2R/*S*?Q4K^59.HV4Z^(=8MM0T2_U.
MPU0QO UO,1&,1JC1RC< HRN<D'J: .LOM:TW32PO;V&#8H9R[8"*>A8_P@]B
M>M*VK:>KSHUY"'@C$LJEN40]&([#@\^U<#KHO]*T'QK8W6FW,B7<,EQ!>1@-
M%Y?D*NUF)R"NSIW[5J7T%[!KEW/'I]S<17NAI;1/"H($BF0D,<\<.#[\]Z .
MB?5;=]2LA#JMGY,MN\_D<,\J84JZD'A0,]CG(J'3O%NCZE:6UPEY'&+J5HH%
MD.UI"&(  /<@9QUK"TFRO8K_ ,&--8W$7V/2I(+@LF1&Y6( $C(YV-_7%16>
MCW<GPY:QGADL=0TV22X@FFP%65)&=6!S]W& 3Z,: .WCNH)KB:".56EAQYB
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M$:1:WEM+;W$%LJ/'(!N! ]!0!-::]816*37FMZ?*LUQ)'#,C!%;#'Y1\QR5
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M"OH20!C- '9#5+$W8M1<Q^<6*A<]6 R0#T) '([46NIV5](T=M<)(ZJ'PO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%<SXTENXK721:W;V_F:K:QOM4'<ID''/;('UH W;?4+.ZNKFVM[F.6:V(6
M=$;)C)&0#Z&K->=:C=ZGI6I^-=2L+F%'LH;:=A)#N\[;#G;U&T'!Z>OMSH^)
MO$FH:;!J%U:31,+2VAG2W1-Y^9CN\XGA01C: <GD\T =I17,:9)>2?$#7HY+
MQVMX;:T*0E1@;O.Z?B,Y[_@*;XJUZZT:Y3<\EI8M 2+Y8/-CCFS@"8#)5.G(
M]^1B@#H(-0L[F\N;2"YCDN+;;YT:MDQ[LXSZ9P:LUY[J-W?VFN>,=2TRZ@C:
MUT^VN<O%Y@DVI*P7J, XZUMP:S>:UJMUI]E,MFUM907&YD#[Y)0Q P?X0%YQ
MR<]1CD Z>JUQJ%I:7%O!<7$<<UR^R%&;YI&QG '?@5RN@>*+[6[_ $<.JP17
M^FSSR1A<E)8Y$3*D]OF8\Y[52&IW.L:9X)O[LH;B75FWE%P.(YQT_"@#M[W4
M+/3HTDO+B.!9)%C0NV-S,< #U)-4-6M]'M9AJ^J3>4L>Q<RSL(MP;*'9G:6!
M/!QG/TKD];U*ZU[PLFJ+.L=K_;,,*6^P'Y$NU0$GKN)7/I@XQWK>^(6?^$%U
M/'7;'C/_ %T6@#IJ*Y"76M6L=0UZRFO+%WMK&.\MYID,4<9<R*5?!)*@H#Z\
MXID.K:Y=R>(K"RD)NK*WAGLGN8 K.75SM91C@E.. 1GGI0!V5%<>_BUF\//K
MUL_F6MOIPGD1E W3-T4GMMP=P]Q6II<NM_VQ)'>)NT]X \<DGEK(LH."H",0
M4P003R.G- &FFH6<FH26"7,;7<:"1X0V652< D=JLUQFH0:C<?$2Y33+R&TG
M_L:(^;)#YO\ RVDP,9'YU%IGBO4M=MK"WAA:"]EL6N93 J-\XD,? =A\N5)[
MG!'(ZT =Q17'+K6O74J:485@U6/3UN9OL_ENOF,SH!\[#Y<H<XR?F R,<M_M
M3Q)<ZPFFM/9V4QTD74FR'S=DP?:P!W8(R/P'J>: .SHK)\.ZE/K7A;3=2D"1
MW%U:I*P RH8KD\9Z9[9KF=/\1ZW_ ,([8ZO>7-O*;^=;2."*W"[',Q7?N+X/
MRC@''..>N0#O*BN;>.[M9K:8,8I4,;A6*G!&#@CD?45RLFLZWITR6E\J(+R_
MBMK.XDV;PC(S,7525W#8P'8Y''!%3WFIZKI4EM8W,L5Q->WS0VTL(4.(?+9\
ML&PN_*$>G0X/2@#7ACTSP[8V]LK"WA>58H_,<L7D8X +')))[DUHUQUSJWB'
M3[2S%Z+='DUB&U#,H+R6[L "0K85^H.,CC(Q4SZSJ-MK.KZ3/.GVDI%+IA\L
M#<KG9R.^U^O^S@T =75:_P!0M-+LY+N^N([>WC^])(V *YFYUC6[N;4X]'C#
MS:;<) %D\L1R_(CN7)8,N0QQM'&,\]!E>*]3NM;\'>*Y(9UAM[&1[01; WF;
M I<L>HY8XQCH"<YQ0!Z)163XDUC_ (1_PU>ZH(Q(UO'E5/0L2 ,^V2,^U9MU
MJFJ:9KUOILEQ'<)?6<TL4K0X,4L6TG(!&4(88[C'4YH ZBBN>\'W>JZGH=GJ
MNI7<$JWEK#*D,4&SRV*Y;G)SG([#%59=9U&UUO5]*GF0SM%'+I9\L#<'.P[O
M7:^,_P"R0: .KHKDKS5M;NKO5+/1DWW.FM%& XCV3,45SORP8 AL#:."">>@
M23Q%=1^)$T^\D:P$TR+:%X@\%RA0$J)!TDW;N#C@# .<T ==17 :-K6H6FCV
MZRW,MU<:AK%S:*Y5 R!7F)(R0,D1@ '@9Z'&#H#6=:M;BRTJ_6.*ZOKYX8)R
M%+"!8S)N902H?@KZ=\=J .FM=0M+Y[A+6XCF:WD\J8(V=CX!P??!%6:Y3PBD
ML>L^*DFE\UQJ2_/M"Y'D18R!QG&,_P!*AU[Q#J.FW=U)!-%)%;W=K#Y,:;@$
MD9%;S6.,/\_ 4GC:2,&@#L:*X;4M8\2>?XG-E=V4:Z,5DCC>V)\Y?)$A1CNX
MZD9'MT[L77?$6K2:LVG75G:K:V=M>0)+;%R?,C9]C'=[8S^E '9G4+0:BNG?
M:(_MC1F40[OFV @%L>F2*LUP]E?R:UXH\/Z@@^SR7GA^:8#&[86> ]^N,U<T
M37-0U%+2QGE1=4@NI8]158QA5C[J.P;=$1[,?2@#I;6]MKT3&VF240RM#)M/
MW77JI]Q4]<*_B/6AISR)-:><OB :<28#M,1D"=-W!Y]_PJ6;Q%J^GVGB..0Q
M7<^F3P*DRP[0(I%1F9E!YV!F/N!0!VM-EECAB:65U2-!N9F. !ZDU@Z)J&H7
MFN:I ]Q%<Z9;",6]PL?S2,RY8;P=IV^R_P 0]*K227C?$6: WC_94TI95@VC
M +2$'\]HYH Z.SN[>_M(KNTE6:WE4-'(IX8>HJ:O.O!NHZC8:9X-MGGBDLK^
MT>/R1%AHRD>\-NSR3@@C'>MC1=9UO5QI.J0PC^S;Q2TZ2&,"-2/DV$,6+ X!
M!'//3I0!UM%<[XBO]4MM6T2RT^X@A6_GEAD:2$N5Q$[@CD="O3]:SWU;Q#<_
MVA;Z<$GO=,DC@8E$2*=_+1W+9;<@.X@8Z8ZGH #LJ*Y)O$-TGB<:;>2O8F6?
M;:^9"&AN8]F<+(/^6F[/!(X& .]4= U'4D\,64LNIAY+G4KB)V=,RE1++D1J
M 06.T=1@+D]!0!W=%>>OK.JZGIN@R/=-;RMKLEE,$1?W@C,H4L.1G]V"0#C-
M:@UG6]0EN)]+B#1VFH-;21R>6(VC1MLA+;MP;J1QCIP>M &WX@&ER:-/;ZQ.
ML5E< 0R;I"F_=QMR.><XXJTTEMIECNGG6*WA3!DF? 4#N6/\S7">(]2NM<\(
MZE>I.L=K#JD=LL&P'<L=RB$D]0Q89';&!CO78>)?^15UC_KRF_\ 0#0!)!KN
MD74T45OJEG+)-_JD2=27XSP >> 34,MGI'B:*VNV;[5#!(_EE)65"P)5@P!
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M?-6=.U:QU:.5[&X680R&.0 $%&P#@@\C@@_C0!2D\+Z=*=1YF5=1@6VN$5\
MQJ"H4<?+@$CCUIQ\.60N(+B*2XAN8K<6OG1289XAT5O7'8]1S@\U9N=:TZSN
M%@N+I8W+K'DJ=JNWW59L84G(P"03D>M1_P#"0:7YMQ%]J_>6TB13)L;<CO\
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MJ0U 27$%T8?L[R0RE=\>2=I_$GD8(SUJM?>$M*O4L0J36;V*>7;RV<S0NB'
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MADMEU)42VN&Q@X@$>>#D8;/6NNHH Y;09M0EL+>*_P##SVEU8VOD/,YC;>0
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M&PRO&?DQ[L&VGV3Z5V%% '%"RU^+P69+FSCN]9=X5FCPKG9&RKN3?\I;"M(
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!PN .O>@#3HIKNL<;2.P5%!+,QP !W-)#-'<01S1-NCD4.K>H(R#0 ^BBB@
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M"&Y0-P.3CD9KT7[-!Y;1^3'L?[R[1@_44OV>#:B^3'A!A1M'RCV]* /.K_\
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MG-&?[8M5XD*A@7&01G!'UK5TG3+FS:6>_P!0-_=R )YQB6(*@)(4*/J<GO\
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MRS^'MDEPFG%H3!AOGV<D8ZD'/'K74+!"K;EB0-C&0HSBGHBQH$10JC@ # %
M'$VIMG\0>'I=%E#V5Y9S&^57W"2/8NQW_P!O><;CR<D=JL_#Z&T31[U[98\G
M4KM24]!.^T?E751V\,6_RX8TWG+[5 W'W]:6.*.+/EQHF>NU0,T >>:==6VJ
M:F$O=76TURTU60-;HN+AT\QMJ<M\T1C*]!@#GJ":R[NUM3X$\3:G]KN#=VU[
M=PQ2_;)/D3S^%^]@\ =<UZMY$7G>=Y2>;C;OVC=CTSZ4GV: *5$,>T\D;!B@
M#D+JWM-.\5Z5I\@/]CWL=Q*?.E:1)KH[,!BQ/\(<@=,Y.,BL7]\;?2()[N?[
M)_PDLMO:/]H8&2UV28&0?F 88!] ,&O2I+>&6'R9(8WB_N,H(_*E:&)PH:)"
M%^[E1Q]* /-&U#^R=/U.%+@II=MXB$,Y8F18+=HU.#SG9YA&1G&"1TXJ?S;:
MSO--6VU1;SP_=ZFWVEHL?9XF,1V1*02-A?:2,XR0.Y%>AB"$*RB*,!QAAM'S
M?6@6\(@\@0Q^3C'E[1MQZ8Z4 >;ZFTME::V8IF72K/6+)K63?\L(+Q><JMV0
M$D8Z#+#M4\][#>:MXKAL]7MH S6#0N[;H2Q;!! /*NV$8C^\:]!\B+R/)\I/
M*QMV;1MQZ8I/LT&PIY,>Q@ 5VC! Z4 >=W-YYFD6D=Q9I87$'B2UBFC27?"7
M#1G,9X^4@@X['(K1O[:;3O$MYI4,<C6OB% 8I!D_9W7B89_A^0[U_P!H'UKL
MQ;6XB6,01"-?NKL&!]!5&TTRYCU.:]O=0-URZVT?DJ@@1B"5X^\> ,GL/<T
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M4E5=>AD#9QU/!H ]!@F2X@CFC.4D4.I]B,BGE@" 2,GH*R_#;VC^'+!K(1B
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M/3?'-E:6\(MH9K:>.")!M0[$WLJCIT.<>]>G6;6SV<36806Q7,?EKA<>P]*
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M_P"EML>)E9@ =F=WR,.F/>@#KJ*Y;6/%LNG::=0BLHVMEL!>J9IMIEX),:
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M%-,U24S7-L8\MN;&_8^?E#8Y!!ZG&*Z6B@#F+WP@;R+Q!%]N$<>LHD;!8/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@"K9Z=9Z>URUI;I";F8SS;1]^0@ L?<X%9Z^$]
M%3Q#)KZVKC59$\MKD7$F2O'RXW8QP.,8XK:HH YR/P'X:BCU6-=-.S5L_;@;
MB4^>22<MENN2>>O-;=C8VVF6%O8V<0AMK>-8HHQG"JHP!S[58HH **** "N-
MUN'Q2/$POM*T73KF.&/RX9[C4YHFVL%+@QA2O4#ZX%=E10!YCJ6B>*M6TC^R
M;SP=X>?3_,,OV==5F1"Q8L20J#/S$GZU#J'AKQ-JJZ>+SP?H4CZ>,6LHUFX6
M2(>@<*&(]B:]4HH \SN=(\67=]87LW@[PZ;C3U*6SKJ<J;%/!7A!E?8Y%4;C
MPAKUU#?PS^"]!DCU"<7%VIUJXQ+("2&/R^Y_R*]:HH \OU#0?%6JS-->^$-!
MDD>%;>5AK$Z^=&#D+)A1O&?[V>_J:74M$\5:M>6MW=^#_#YN+6,Q0R1:K-$1
M&>"AV(-R?[)R.3Q7I]% 'G.AV7C3PWIB:=I/A30+:T0EEB&JS, 3U^\A-57T
M'Q0^HF^;P=X>,QN1>%?[5F\LS@8$ICV;"^/XL9KU"B@#S:UT[QC9Z[=ZW!X5
MT)-1NU"SS?VO.?, X (*8XP,<<4S6=(\7>(+BTN-4\)Z'/+9OYEN?[8G3RWR
M#N 50,\#FO3** /,YM'\6W&OV^NR>$= _M2W01QW2ZM,K[>>#A/F')ZYJ'2O
M#WB?1-1GO]-\&^'[>>=S(X75IB@8\%E0IM4D<9 ''%>I44 >6:3X;\2:%>3W
M6F^"_#MO).S,ZC59B@)X)5"A5<CC@#CBI--T/Q5I%W#<V/@_P_'+ C1P9U:9
MQ"K'++&K(0@)_N@5Z?10!Y#_ ,(5K0G$P\#^'PXN_MJ;=9N (YNN]!MPIX'3
M X'H*HKX(\8W/B+Q!J6I>'=*N8M8:(R0'5I8D41C&T[ "X/!PPQQ7ME% 'F4
MVC^+9]5L]3?PCH*WEE$8;:2/5YT\I"""JA4  P2.E48O!VO06EE:Q>"]!2"R
MN/M5L@UJYQ%+P=X^7KQ_G->MT4 >6OX>\3OXA?7CX-\/C4GV^9*NK3*),="R
M!-K$8')!Z"H;GPGXAO!J:W'@S09%U1TDO0=9N,3LIRI;Y>QZ5ZQ10!YLNC^*
M9]:T[4;GPGH/VBR18([A=5F+I%GH?E^?'4!L\UZ3110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'1V0 G(X&6'7%;\5K96?B74+G1I5_LN329&O62;?$9MPV,3DC>5WY/I@GJ*
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M.0P'7D'(/<'/2H+'5(+;P_X?6^NE715NKVWFE<"2.-A(P@#YR-NW(&>/N^U
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M7FBVVI.OE)-;K<%2<[ 5#8SWQFO/KN\25]>LO%30K>C2H39K.0 Q\D^88O\
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MEG9=)MKB6*6;RL &8D9 ;YL#&,8XZBNQAOA=:1'J%O&6$L FC1CMR"N0">U
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M+'/'-YB,=K?+R%(8$ ],<CFC1=9E0Z?HZVJ,PT>.[24RX#8VKM(V\<GKS]*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *Q_$^AR>(M#ETQ+I;99'C9I#%YA^1U< #<.ZBMBB@# N/#L^I
MZOIU]JE]'*NGN98(8(#$ID(QN8EF)QV Q^-4-.\&W=A<:3(VL^:NFR3,@-J
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M8L#&VW X*$9!]^>E-L?%E])-HEQ>6]M'8ZM9/<HL98R0E8U?DGA@03T Q[T
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "J&I:)I>L>5_:>G6MYY1W1^?$'VGVS5^B@!  JA5   P .
MU+110 5F6^BQV^N7VJBXF=[V..*2%@NP!-VW'&?XF[]ZTZ* .;TOP=;:9&UK
M_:%]<:8 ZPV$SJ8X@P((! #$8) !) S^-9/_  C\^BZ[X7ABNM2O[.TFE"^;
M&'6VC,+(H+*HSR0,L2?H,UW5% ',#P5 IC5=3OEMX;\W\$*^7MCD+,Q .W)!
M+'KFGW/@ZWNK;5(&O[Q5U&Z2[E*[,JZ;,!?EZ?NUZYZ5TE% &7>:*EYJVFZB
M]U.LM@'\M5"[7+KM8MD9Z>F*SXO!]O%8V5HNH792TOFOT)V9,A9F(/R_=R[?
MGUKI** /.[.RU8ZC<7$$NL6FI23R.89K.&2 98X'G%<E,8Z/G' '05V6NZ/'
MKVEOI\T\T$;NCEH=N[*L&'W@1U4=JTJ* ,/5O#2ZE?6NH0ZC>6&H6\9B^T6Q
M3+QG!*LK*5(R,CC@U(WAZ(ZEIU\MW<B2PBDCC!*L'\S&YF)&225!ZBMBB@#G
M(/!]O!I^F6:W]V8]/NS=Q$[,LY+'#?+T^=NF.M++X0MIEOLWMV'NKV._WC9F
M*9-NTK\N,?(O!S7144 85WX6M+^QU&&[GFDGOU19;D85U"'*!1C "G) P>2<
MYJM/X,CN_P"TFN=6OY9-1LUL[ASY8W(-W( 3 /SD<<?CS7344 9DVD/)%;(M
M_,HAA:%@R(RS*P4?.I&,_+QC'4]CBLK_ (0BUMI+*32]1O\ 39+:V6T9K=D/
MG1+R X92,C)P0 1DUU%% &)_PC4 U&>]CN[E&ELEL=GRD+&I)!&026RQY)-1
M6_A*VMQHJB\N732(6@A1PA#HRA"'^7GY0!QBN@HH Y[1_"BZ*!%!JNH26D08
M6MM*RLEOD$?*=N6P"0 Q( I++PA;6,6B117UV4T<M]G#;/FW*5(;Y>>">F*Z
M*B@#,T;18M%CN8H+F>2&:=YUCE*XB+L68+@ XRQZYJG+X3M)&U&-;B=++4I/
M-N[1=NQV. Q!QD;@!NP>>V*WZ* ,M-$C3Q$VLBYF\UK9;7R<+Y80,6';.<D]
MZBUKP]'JUW9WT5[<V%_:;A%<VVW=M;&Y2&!# X'4=16S10!S\_A.":ZAN%U"
M^CD6U>UE*NI,Z.VYMV5."6YRN.M0_P#"&0-HRZ1+J-W/8?98[1XI0AW(F<$'
M:-K8.,CT'?FNFHH YV\\(6U['K<<E[=JFL!5G"[/D"J% 7Y>. .N:VY+=I+%
MK;SW5F3890!NZ8STQG\*GHH YRV\'V]KIVC6*7]V8M(F$MN3LRQ"LH#?+R,,
MW3'6F7'@JTN(+I3?7B337_\ :,<Z%0\$V N4^7&,#&#GO7344 <]>>$XK[3X
M(IM2OC?03BXCU!659EDQMR %VXV\;<8Q[\U(_AE)AIS3ZE>2S65U]K\U]FZ6
M3:4^8;< ;21A0*W:* .<D\'VTEO=Q_;[M7N-0741(-FZ*92N-ORXQ\HX(-7[
M31$L];N]4%U/)+<PQ0NC[=N(]VTC SGYFSSWK4HH R;'PYIUA:ZA:QQ%H+^6
M22:-SD?/]Y1Z+R>/<^M0Z'X;_L0)'_:M_>P0KLMHKEU(A7T!"@L<<98G X'>
MMRB@#*U_0H_$%C':374\$:3)-F';DLC!E^\#QD"H6\-07&K6VI7]Y=7LUJKK
M;K*45(BPPS (HRQ'&3G';%;=% '+V7@BWLCINW5=0<:=#+;P*QCP(G &TX09
MQM'/7CK4T_@ZQOEG_M*::\DFL_L32OM5S'N#9)4#+9 .>V. .<]%10!S;>#X
MKK1Y].U/5-0U#S%54GF=1)#M(92I50-P(!R<DX&?2K.G^'FL]9.JSZI=W=TU
MJMJWFK&JLJL6!PJCG+&MNB@#)U308-2O;6_CGFM-0M05BN8,;MIZHP8$,I]"
M/IBDN] @U/3;FRU2>6\2XC\MBV$VC.?E"@8.0#GDY K7HH Q5\/*[-+=7UQ<
MW7V5K1)W"!D1L;B !C<<#)([#@5%;>%8+5M$*7MT?['A:& '9\ZE0OS?+R<
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MFKZA-+;V<EDC-Y8_=MM]%'(V@YZYZYZ5TM% '/S^$X+M+XW-Y/)<7ME]ADN
MJ*_E<YZ+@L<GDCZ 55U/38]4:Q\/2V%Y+!9O#.;Z556,JF> 01EB/D(QT8UU
M5% #78(C.02 ,G:"3^0Y-<;X,T&1O#&C+J9NE:R=I5M9HMFR3+8)X!( ;(^O
M? QVE% ',6?@JWLIM/>/4[\II]Q)-;1L4PHD#;D)VY(.X\DY]#2R>"K5[.2+
M[=>+-_:#:C#<J4#PS,225^7!7DC!!X-=-10!S$WABY@MM7EL]7U#[?J)C9IE
M,2E60*H(^7 !"X/7CH,UTL898T#MN< !FQC)]:=10 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %8FNZ]<Z9(EOIVC7>K7C)YC0V[(@C
M3IEF<@#)S@<DX/I6W534+Z'3K8SR*SNQ"1Q(,O*YZ(ON?R'). ": *'A?Q-9
M^*](-_:13P-'*T$]O.NV2"5?O(P]1Q^=;58?A;1&T33IQ.4-[>W4E]=E#\OF
MR') ]@ %![[<UN4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7/
MZ[X0L?$-]!>75YJ<,L"%(_LEZ\ 4'J?E(Y/K[5T%% &3H7AZS\/P31VLMW,T
MS[WEN[AYY#@8 W,2<#T]SZUK444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
F444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>elicio_clawbackpolicynas003.jpg
<TEXT>
begin 644 elicio_clawbackpolicynas003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+4U93)(F25&PC(?& 23CJ: +GA+79+C0M/6^FFNKZXDN!N$>3M29URVT *,
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M5M.+6*1<N(I5<[G"@9(! ]/7G@ O2>(VO+K6].MX;JVDLK5)%G,7(9E9NA!
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MM:O<S0#3+0QQ11MMR&@+EV'\08DK@\87CGF@#L(=2BN);5(XIR+F#STD\H[
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MR"&. 1@8QT%7K1)+CQY92275P"VA"3 DXW&103CISQ]>* .LLKM;ZU$Z131
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MA)XN+:CX>N!*L&FZA:S2RI)$=X950@ ]3]_' Y]ZZ"/6].FT^"^ANEEMY_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@#FO#D-XOB#Q#=W%A/;07D\,D+2E,L!"BG@,2.167>Z3?2KXOT[^SGD.L/\
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M+Q8HF 4>0K!F"<C&X!=OS?Q'IVK=BT*QA:-E$[-'.;@%[B1RTA7;ELD[L#@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "H+F\M;,(;JYA@#MM4RR!=Q]!GJ:GKR_XI?#O6
M/&.IV%YIEU $AB,+PSN5"_,3O& >N<'Z"@#U"BJ.C6,FF:)86$LYGDMK=(6E
M/5RJ@$_I5Z@ J":\M;:2..>YABDD.$5W"EC[ ]:GKA;IXD\0:_IFMZ7=W<.I
M-"]F8X'=)D5%'E[E&$*N&/) &[.: .S>]M([E+9[F%9W^[$T@#-]!U[4U]0L
MHI!')>6Z.7$85I0#O/1<9Z^U>?>('EEN]15-/O(9(=7LIV6&VDE\]5:+,N_!
M&  0%7!^4YSDU!K&GI)8>.)(M-E,\MS"]J5M6W-B.+)3C)^96SCN* /2IKRU
MMI(XY[F&)Y#A%=PI8^P/6B6]M89XX);F&.:3[D;R ,_T'4UQ=S+ -?UZPUK3
M+N\MM4$+V1CMW=94" >7N4?(0X9OF( W9S5>[B2;5M9TC6[75)#>723VGV:)
MFCF4*FT"0+\A5EY)( Z]Z -J]\37MLOBHK:V['1H5EB!=OW@,9<[N..G0?G6
MO;WMQ/-8DM:+#-:F61"Y$N[Y<;1_=Y.3]*Y+4XY7/Q!5;>X8W%DB0XA8^:WD
M%<+Q\QW$#BK,42'Q7H,[VLGE?V+-%,Y@; ),1"L<=<*W!]#0!UT5_9S3+#%=
MP22LN]420$E<XR!GIGO2_;K3[08/M4'G#K'Y@W#\.O<?G7G'A^Q%I9>!773Y
M89X9YA<G[,RL@,4B_/QD DH.?:F6,FFRSZ?I^H321QV&KW%PDL]E-NE+/( K
M.4\L E\[MQS@=#T /3Y)$BC:21U1%&69C@ >YJ :A9-;"X%Y;F MM$HE7:3Z
M9SC-8GC%+K[)ID\$4DUO;:C#->11J69H1G)VCEMK%6P/[M<YK^FW-[;>,+S3
MX)9+.ZM;<HBQG]],A)=E7O\ +L&1U(QVH [RYU.PLX;B6XO((TMDWS%G'[M?
M4^E1P:WIL]A;WGVV!(;A R&251G@''7J,\UQU\[:OK?B"6SM+MXKKP\(H':V
M=1(^Z;@9 YY& >O:JUYY\FD65SIQGBNH])6)[*[LG,-ZN#NBQ@,KY!QCDY'!
M% '<PZWIT^K7.F1W<37=LBO*F\97=NX^H"Y/H"/6IXM0LIH9)HKRWDBC^^Z2
MJ57ZG/%<1J!FAU'Q6\^BW-RUYI<#);(C[9<)('3S%'49 X.3GBLZ]1[I/%F+
M>\N$O-"B$#&P=%=U$P 52N0067 .6]SUH ]+AO+6XEDBAN899(\;T1PQ7/3(
M'3-8\_B$#Q5IVDV[6LT5S'.TKI+N>-H]O! Z9W=_2N5O+&Z6^*Z+:R07,OAJ
M6%'2$H/.W*54MC ?[V,\]:L65Q;7FO\ A.6VTZZBCM[*X@G5[.1?).V,!&)7
M Y!'I^= '8V5Z3:*][<60D>5T4P2Y0@,< $_Q8'(]0:L1WUI+:_:H[J![?G]
MZL@*<<=>E>;6M@C:)X<AETZ4^3X@G=T:U;Y(2\Y!(QPIW)[<BGW"?8K/59!#
M<0I#XECNH8UMG*2(%CS\JC)7(<Y4'D9Q0!Z1!<P7*[H)XY5]8W##]*:+VU:2
M6,7,)>(9D42#*#W':N;\'-ILUWK-W:RAKJ[N?M$T9MWB,0*A5'SJK$'83G&,
MDTW6=/O;;Q5%=:=$YBUB#[#>LG'E%<LDI]PAD'UVB@#I)-1L88XI);RW1)>(
MV:50'^ASS3I;VU@F2&:YACE?&Q'D 9L\# /6N)UI(;7Q%?66J6VH'2;^QBM[
M<V=L94PNX-$0JDJ3N!'0>_%,OK>[L+^-]-$TC+]DBGTN\B,@F"[=KQRCHZ=S
MDC*Y..M '7V.NZ;J,EXEK>0R&SD,<Q#C ( )/T&<9]0:M17MI<6[7$-U#) N
M=TB2 J,=>1Q7GUS%?6]EKZ06-X[Q:XMY)'% =TUOF,G82-K'@G S]VG7\<,E
MBVLZ3::G/:RZE:W&H^; ZM/''D,5B*@G;\A.!\V.^* .JTC7CJFOZO8I]G>W
MLUA:*6&3?OWALY/3C;VK5GO+6U9%N+F&%I#A!)(%+'VSUKF?#LL<_C7Q%=0V
M\ZP7,5HR2O;O&LA57!Y8#)Y6J]TIB\0>)X=6MI9K:_M8A9E8FD$B",JT0P#\
MV\DX[[LT ==/>VEJVVXNH8CC=B20+QD#//;) _&GR7$,+1K+-&C2':@9@"Q]
M!ZUP&D:*W_"1:);ZW9"ZFCT'R;B26#S$,P="%9B""V W4UO>-4<:?IMR(I)(
M[34[:>7RT+LJ*_S-@9)QGM0!O?;;0)(_VJ'9&VV1O,&$/H?0TS^TK'9*_P!M
MMMD3[)&\U<(WH>>#[5YSK,;7UCXQ*Z?=N+B]LY+<-:/EP$B!*C'48;/<=\5M
MIHUG?^*/$6GFT,>G7VF6\1*0E49@90<'&-P#+].* .P%S TB1B>,O(N]%#C+
M+Z@=Q3(;^SN!*8+N"41?ZPI(&V?7'2N-AM=>U'P5J33PLFL1V4FGPY.#(R9#
M.I[>80/^^5-01II6M6=Y?+:ZY%*;#[)<,UNT;PKN!"*NT!V4Y/ ; !'?% '6
MWGB+2+&VCN)M0M_*DG2!6653EV( '7WR?0 FKCW]G')#&]W KS8\I3( 9,_W
M1W_"O/KL:I)ISF]B6^6UU>RF-_:VK*;F-67<QC&?F4  E>/R-2WBQ7.JZSI>
MLVFK.E_/'/9^1 VR5 B;5WA?W;*RG.2H'7N: .G\5^(!X>T&\O(FM7NX8C)'
M!-+M+@>@ZFMP'*@GTKS'7?/_ +&\:Z7?65U+?W4K2VA6V>031;$$85@"/E*G
MCL>>]=EXFCO+WP;?)IL<C7,EOE(R"C.."5P>A(R.?6@#6M[VUO YMKF&<(<.
M8I VT^AQTJ--5TZ179+^U8)RY693MZ=>>.H_.N"OUCU;1M4U31;/5I+YK6*&
MX2XA:%FC616:$*54,VSS!D9ZXSR*EN)X-<\27S:=;R_O_#<L2+);M$6._ 7#
M 'OCTH [Y;JW>58EGB:1EWA X)*^N/3WK*'B"VL;:R&JWMBEQ=S/%%Y$N4;!
M;H3Z <^AX]*YC1[@7.M>%G%I=B*'1YK>=I+2151\0Y5LC_9//3WJIIUO);>'
M?"DCV-R$M-9G:5!;.6C1OM&TE0,X.].W<4 >B+?V;QR2+=P,D7^L82 A/J<\
M5*TL:PF9I$$07<7+#;CUSZ5QUUIEQ;^+)M/MX0=,UU1<W(&/W3Q[1)D>DBE%
M/ODUK^+Y/+\-S-]A:\7S(MT:JS;1YB_.53YF"_>('7&* -,:G8& 3B^MC"6V
M"3S5VEO3.<9]J=]OL]TJ_:X-T(S(/,'R?7T_&N%MM*EUI?&%B1=*]U+#<6EQ
M/;F(&00Q[7&5 X=>G7CFBTMM8O-5@OYK%X8/$5LL5]"5Q]F\L C=_OH9%]02
MH[4 =T=0LEFBB-W;B64 QH9!EP>F!GFE:]M%G$#74(F+;1&9!N)QG&/7'->>
M^)VDDGUF*+3[N*2._L9?W-K))]H5&B_>;L$   @*N#\I)SDBKL6F"ZUWQA-:
MV 6]=(WL)I;?;B7R,;E8C&0W4B@#>O/$(A\3Z5I5NUK,EVTJSD2Y>(HA8#:.
MG([UK+?V;O(B7<#/$"9%$@)0#J3SQBN!TV>*XO\ P1Y6G7D4MBDL-RKV<@,#
M&':0QVXY;OG'>IM":6PD\J9)-1T5-.E93-:,+FU3*DV[C'[S(Z#&3M/6@#OH
MY$EC62-U=' 964Y!!Z$&H8KZTGDDCANH))(_]8J2 E/J!TJ#3[FUGT2"XTZ
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MME)90OI[:A'-(ZL#$NW?D#H1N!]QZ=* .DHKBIM0N;[QEX5N#;2V]O<PW,B
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/F1;R#(B]B"<X/;/>M'4_#L6H:QI>H+*839EDD11_KHCA@A]@Z(?P([UMT4
M<W=:%JT/B*XU/1]2MX([U$6[AN8#( R# =,,,-CC!XX%3VVF2Z9KVIZS/=(U
MM-:PQL"I+J(MYW$]\[SV[5NT4 <KX:L[.ZUK4M?T^61[&[(, *E4+E5\V101
MG#;4'U5O6M'7M)N]3;3WM;J*/[+<><\4\9>.8;2,, 1T)##W K9HH XJ/P9J
M=K%;3VFJVXU"SOKBY@=[<^6R3,2Z.-V>XY!&,"M2[T+4;J?1[UM1A-]8SO+(
MQ@/EL'1D*JN[(P#QDGISUKH:* .1N/!\]RFILU[''//J4>IVLBH3Y,B*@4,,
M_,/DYZ=33M8\)W.MV^JR3W$$5]?V2V*LBEDAC#,Q/8L26/IT'U/644 8L.D7
M2^*O[8DEAV&Q6T,2@YR'+;L_CC'ZUD7<\H^*,26DML9O['93'*Q'_+4'MSGO
MC'(].M=C10!QZ^#[W3!IMQH>HPQ7UK'+',;F$M%<+(_F/E005^?D8/'2M$Z)
M?-KVE:E+>12FS@FBES&09#*5)*\_*!M&!SQW[UOT4 <C>>$[VZTWQ!9B[@4Z
MM=K<!]A/E !!C&>?]6/3K5N\\/WEWJVI7PN($^VZ8+$)M)V$%SNSW^^>..G6
MNCHH YJT\-WEI>:#<I>0[M.L6L9@8B1*AV<KR-I_=CKGK[513P=J5MIEI%::
MK#'>:=>2W%E*8"5*R,Y9)!NY!#D9&,8!KLZ* .8O?#^K7;Z9J1U&W_MBQF>0
M'R2(&5U"M&%W%@, '.2<\]\"[X?T>[TF35)+JZAF-]>&Z BB*;"552.6.?NB
MMJB@#F+CPS=RS:]%'=Q+9ZT09B4/F1#RUC8+S@Y5>"<8)Z&JUY9Z9K'B73;2
MPE<3:0QCNU12%$.U6$3$C!RXC('H&]Z["B@!L@8QL$QOP=N[IFN+M/!>I6EG
MIMJNIVSQVE@]DPD@9@-W_+5!N&'QQSGC\J[:B@#EF\)23^&M%TV>]"W.F&("
MXA0KN15\MU&22-R%AGU.:NZ5X>CT?4-5NX)?DNY/,AA*_+!D#?@?[3#<?PK<
MHH SM#;4GTB(ZL8S>98.T490,-QVG:<D9&#@_ITKGM-\(:I976D3RZI:RMIY
MG#.+9@\XD RS'=]_@<UV5% '-Z-X9>PULZM*;:.YDMO)N?LJE%NGR#YKKT##
M!'?[QYJ2YT*^C\32:QIEW!']JMUM[J&>,L#M)*NN".1N(QT/M7044 <59>#]
M7TBTT:33=5M5O["T-G+YUNQAGBR" 0&R"",@@\UJRZ!=R:UIVHM?1R/#;2VU
MR)(3^]61E8[<-\O*X&<X![XKH** .:T#0]:T6&*PDU6"XTVT4K:KY!68J!A%
MD;<00HQT )P/H:R^$KQ?!%IX?^V0&2":.3S_ "SA@DHE VYZDC'7WKKJ* .:
MNO#EY<7?B"<7$"C5K)+55VD^5M5QN/K]\\<=*+7P]>VVJ:=>_:+=OL>F-8%-
MI&\DH=^>WW!Q[]:Z6B@#DM.\)W=C!X9A:[@<:+O#'81YP9"G'/RX#9[U+HGA
MS5=*A&E2ZI#/HD.Y8(_((GV'.(V?=C:,]0,G KJ** .+M/"&K6UIHM@=4M7M
M-'NUEMW:W;S'C"NH5OF R V,CTS['=U_2)M5CL6MYDBFLKQ+M/,4E7*AAM.#
MD9#'G]*UZ* .9NH--T:+4;[7IT)UAUMY56-F4C856(  D\;N>Y)Z<"KGA32I
M-(\.VMO/)+)<% TKRG+DX  ;'4JH5?\ @-;5% &!=Z%=R>(+O4K:ZA6.ZL%M
M)(I(R2"I<JP(/3YSGCM[\4[3PI<P#PY'+<P21:19O:. I!F#(J9'/R\+GOUK
MJZ* .<\.Z)K.C1P6%SJL-SIEFNRV"P%9F0#"K(V[!"CT )P/H9?$&BW>K7ND
MSVUQ!%_9]U]IQ(A;>=K+C@C ^:MZB@#EKCP@=6UBZU'6+I)#-I[Z>D-O&4"1
MO]XDDDLWIT ]*=!X:O)(M*BU"]C?^RD86\L*%6=RAC5V!. 0I/ SD\\8Q73T
M4 <?I/A35--O-+NGU"SD>RM);5@MNRF;<4.]CN/S$IDGW/UH3P==1>$]&TR.
M_B6_T>5)K:X\LE'901AESG!5B#@^]=A10!S-MHFMVUYK.H1W]BMWJ A*#[.Q
M2,H IS\V3D9]/7VKIJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK=+?S;.0JCX()=VV Y./N@8'///$$5_H<?B.RU3_ (2SPZ4M_#HT<I]L;)<
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MGG!'TKS2PGT&;7;B\UCQ?X=6VN_#W]BRQVMTQ9. -P+*,]/;K[<WM"UK28_
MMSX/UWQIX<>Q%K):07-K,QE9""%+!@ -N>@SG _$ [VS^(FF3K/+=6E[8V\>
MFKJJSSQC8]N>A!4GYNGR]>:AG^)NCV5A>7-];W=JUM90WXA<*7DAE8*A&&(!
MW$ @D8SZ5P^GZUI5S\/+CPAKWC3PYY"V9M+>YM)F9V QY;.&  V@ $#.?4=W
MZ-KV@VWA-M+U'6?!,MPL"6I,3';=1AEW>8Q0%254C@'YCGM0!WMY\0-.T_3[
M:ZNK>6(7=XMG;EI(_+E+('#B3=MV8/7/48Q4]QXTMH+O2[ 6%XVJ:EYIALCL
M5U6/.YG.[:!\O&"<YX]:\KL8_!MIX7N]!F\0Z!>:;<7[W"V$^H.5MHBF%$<N
MS<'#<YV]"1SDDR:5-X=T2?PIJ47C;1K[4=&MIK69+B[*I)&^XJ%<*2-F[ RO
M(':@#T"X^*6@P>'=(UU8KV:RU.Z%FACC4O#*<\.N[/&T],].,Y%2/\1+2&>P
MM;G2-2M+V_GFBM[:[5(7<1XR068#YL@*,\G\Z\O^S>&;7P=X=T:T\9Z%)/I^
MK+JEU++<%5D8$Y1 %/'.,GT]^.E^(&N^#/&6GQV1UWP_,BQ2;'FO#%)!,=NQ
MT95;@8;*GKQZ4 >KVEQ]KLH+GRY(O.C63RY!AER,X([$5-6/X4D@D\)Z7]GU
M-=3C2V2+[:K9$Y0;6;/U!K8H **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;L=<9&,T 24444 %%%% !1110 45'-<0VRJT\T<2LP12[!06)P ,]R>,5)0
M4444 %%%117,$[2+#-'(T3;) C E&ZX..AH EHHHH **BAN8+@R"&:.4QOL?
M8P;:W7!QT/(X]ZEH **** "BBHKBY@M(6FN9HX8E^\\C!5'XF@"6BF12QSPI
M+#(DD3C<KHP(8>H(ZT^@ HHHH ***C@N(;J(2V\T<L9) >-@PR#@C(]""* )
M**** "BBB@ HHHH **BFN8+8(9YHX@[!%+L%W,3@ 9[D]JEH **** "BBB@
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M[WQ-?66L0P/';&&34DLO+0,[*C+P[.#M5L_P$9Q75US,O@JUDFD<:EJ"1MJ
MU%(E=-L<V<DC*YP>>"3C/&* ,\>*]96-[J2"Q%M#K(TV5%WEV4R",,#G (+
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M(OD^:3DL.-P&>< XSV[4NF>%+?2;MVMK^]^Q&5IH[!G4PQNQR2/EW8R20I.
M><=* .4DN;[4/!UC=:E<17$O_"0Q*C+$5*[;W;W8\8 P.PXYZUT<WB&^M-3U
MFPN4MQ/!"D^GA4;_ $@.=H!^;J'PIQCJ#WI__"&VGV V2ZA?K;B^%]&@:/\
M=N)#+M&4^[O.><GMFA[1=;\3VMS/IES -(:0)<3A5$S, !L )W+QNR0,%5]\
M '0Q"01()2IDVC<4& 3WP/2N7O?$U[9:Q# \=L89-22R\M SNJ,O#LX.U6S_
M  $9Q75US,O@JUDFD<:EJ"1MJ U%(E9-L<V<DC*YP>>"3C/&* ,[4_%^I:7:
MZP9DM/M&FW<:F,1.?,MG ;S -W4+YA/;]VU;%WK-XD=S<6S6;6J7$4*2R'
M.W>_WOGQNP%&"2"*N3Z!87.L-J<T1>=K4VK*3\K(23R/7EAGT8^M4W\)6?\
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M$C2D;MH&!G  _2KU !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW%O/+,5.679MP=V<;3D]OX3S5RRURR33[>6^UG39'G:3RY8I D<@4MG;ECG
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M3?L5S CQB/*NDF,NG4A@!CG@CG-:D^N:3;10RSZG9QQSJ7B9IE D4#<2ISR
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M:.,Q@>:S)M;+'(!4'.1P33]1U+Q'IVFZY<2P0&"WL&N;:6=%R9%!+(R(YRN
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MA*0P5A@J2.H/'OQ45IX,TNRFLI(9+T"QF>6V0W+;8]^<J!_=Y/\ CCBNBHH
MP/\ A$-.%C]B26[2W%V+M4$N0CA_,&W(.!O.<?G6E<Z39WFHV-_/%ON;+?Y#
M_P!W<,-_3\JNT4 8=[X4T^]UAM3\V\MYY45+A;:X:-+A1T$@'7'3L<<5/+X?
MM9[DR2RSO%]H2Y%NS#RQ(F-I'&1@J#@'&1TZUJT4 5K*R6R295GN)?-F>4F>
M0N5+'.U<]%'8=JLT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7;8CR<D*>_LN.F:U_$_]JZ7H_A>V/B&6?S?$R0":RNG&+=SGRB^<OMZ9/H*
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MC%9>(]#MHR=Q2'1 @)]<"2E7PQXV2]>]3Q)HBW4BA'G&B .RCH"WF9(KO**
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M2B@#SS_A"_%GV![#^V_#OV)SN>W_ + 7RV/J5WX-*_@WQ;+!!!)KGAYX;?\
MU,;:"I6+_=&_C\*]"HH \^C\(>+X1<"+7O#Z"YR)PNA*/-SUW?/\W4]?6NL\
M.Z??:7H\=GJ%S:3RQD[6M+46\:KV 0$XK5HH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7<]CI%Q<VQMQ*@&TW#[8QD@$D^P.<=^G>N;3Q?=1R:C;2I&\T5_;6=M(T+1
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MG7+VC71O/LCLIC$I;?GIN(W?-@DC--NO".G7W]K"Z>XD75&1YEW@;&0 (R$
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M'L+V[OKIW=)!=RS?OT9#E&5@ %*GI@=SG.33G\*VDUE%%/=WLUS#,MQ'>R2
MS+(O (.-N,$C;C!R>.36U#-%<P1SP2))%(H9'0Y5@>A![BN7&O7*CQ0EYJ-G
M9+I\ZQ074D7R1AHD<%@6^8Y;U&: +UWX5L[VQNK::XN2]W-'-<3@J))&0J4_
MAP -J\ #I[G,U_X>@OM3M=26ZNK6^MXS$)[=E!DC)R48%2",C/3@],5:FU2R
MM95AGN560[ >#@%CA<^F3P,]:RY?%%A<VVM)!J$5E)I[-"US<)\B-M4[L'&0
M"P'7G% $=KX)L++[";>\U"-K,3*K"89=)6#.C''3(SQ@CUJ33_"%EIC:6;>[
MO?\ B6120VX=U;Y7QD'Y?]E?R^N;EQXCTBPS'>:I;),D0E=2V#M/\6WJ :LR
MZK8Q0P2M<H4G7?$4^8R+C.5 R2,<Y% &*W@?3_L5I!'>7\,UG/+/;W44BK+&
M9"2X!VX*DDY!!J:]\(V5XMDZW=_;7=GN\N\@GQ,=W+AB00P)Y((^F*U[+4+/
M4K<7%C=P74)./,AD#KGTR*9-JEE;W(MY;A5E+*F,' 9CA03T!/8'K0!-:6L=
ME:QV\9<J@^\[%F8GDDD]22236==>&],O+K4;F:$M)J%J+2?G@IST]"<CG_97
MTIEEXITN]%^ZSB..SN/L[O("NYOE'&>N6;:!W/3J*L'Q!I*VOVE]0@2+SOLY
M+MM(ESC80>0W(XZT 1WGAZTO-*LM.\R:&WLWBDB\HC.8B"F<@]P#5:]\(V-\
M=7$ES>(FJJJW,:2 *<*%R,@X)50/\*OVVN:7>6]S/;W]N\-L2)W#C$>!GD]A
MCG-9-IXD$WBO4K1[J :=:V$=R69#&8R6<-O+'IA0>@X/XT :<6B11:V-6-S<
M/<"V%J0Q7:4!W= HYSS2:MH<&L3V$TUQ<1FRG%Q$(BH&\ @$Y4YX)&/>G?\
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MUI<W0U.V^SVK!9Y-_$9/3)[ ]CT-71>VQN(8/-'FS(9(TP<LHQD_AD?F/6@
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M 9\W@RR=K"6"^U"TN;.W%JMQ;S!'DA'1'^7! ^@-;T=ND%JMO"6C1$"*0<D
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM5MX6V2R-* $;T;/0^QJL=;L[J\LX[#5].8-</%+%O#O(54DHF&X8'!/!XH
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M P;'JN.M3:A817.GV]U8Z'J$(GUBTN9UN$=Y9 C#>[*2Q4!1CGDXZ=,^@44
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M@N)Y[RP6*+[-=7=N8KCJV8WR!OV\'=@?>/7FNHJ"UO+:^B:6UG2:-7:,LAR
MRDAA]0010!SOCZVGO=!M[>WMI[AS?6\C+"C,0BR*S'CIP#3?$GAX-X:O_P"Q
M;0&]G>&>0,3YER$=6*,S<\J" ">^*ZNH+.\MM0M([JTG2>WD&4DC.5;G'!H
MYF2WEO\ Q++K<%O<Q6ZZ2]M()(&1Y79PRKM(R=H#<XQ\W'>LS2[&]CB\"1O9
MW,;V5I)%<,86_<L80@W<?WA7H%% '%^$1<+9:7I>I:#.FH:4K1M>2QCRQP5+
MQO\ Q%QC./4YJ31-+N;/Q)=Z;A3I%E*;VUP?NO,#^[QZ*?-./]M/2NNDC66)
MXVSM=2IVD@X/H1R*S;>WTOPMI#EIQ;VD?SR3W4Y8DX RSL22< #KV % %K4O
M,_LN[\FW6YE\E]D#' D.TX4_7I^-<!9V]^UZ+A],U$1R>'WM<-;;%CD!!\M4
M'( Z#.2?4]:](!#*"#D$9!J&\O+;3[62ZO+B*WMXQEY)6"JH]R: .#ATR_\
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MA;]TQA5,-QQ\P(_^M73^([2[O_#.J6=@^R[GM9(X6SCYBI Y[?6M.D)"@DD
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MKVULUHGFW#,#$<?*1Z#:/_KT 8NA:SJ1T3PWIZRO-=WNEB[:8(I8*JQC&&8
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MKNV\S6+>[G28[Y2J?>D?YCCC  R3Q0!O7GB[2+719]5CN1<00RB ^4"3YA(
M4\<=1U[&K[ZSIZ/&C7 !<H!\IP"YPH)Q\I)X .,UQNJZ3J-S;>+Q!83L;F]M
M;BW7 'FK&(=VW)Z_(W7&:M:I9ZC+K+:CI<-]:WKR0!X)E#VUU&"N2_4(Z#/(
M(/ QF@#M'=(XVDD95102S,<  =R:IV^LZ?=/*D-RK/'&)63!#;#T8 C)4]B.
M#5/Q=IEUK'A/4M/LG"W,\)6/<<!CUVD^AQC\:H)!<:KXFTG6?L=Q9I96<Z7"
MRIAF9]F(P!]X#:QR..F,T /\.ZQ>^(2FHPW,2V?FSQRVK0G(579(V5O4[<G.
M1SVQ2ZEK\D7BV'0EN[:Q:2U$\,EQ&6^T.6(V+\P'& 2.IW#&,4_P3;W-GX:C
MMKNVEMYTGN'*2#!P\SNI].C"F^(;2TU:>73M9T26\TWR4>*>./>5E)8,!M.]
M3@*00,<GF@#1MM0EM=-CDUAHH[HNZ%858A\,V-J\L?E&?I4@UK3FLH+Q+N.2
M"<$Q-%E_,QUV@9)Q@Y],5P]OIFO:3::'=W5MJ&I16OVJ"2".?%S'#(ZF)B0P
MW, @!&>_M5T6EYH>J:5JMCH-P;#R+B"6R@97F@,CJX?!;!)*_-@\9[T = _B
MG2QJ&FVD5P)CJ$;2PR1Y9"@QSN''4@5)8:K;FPGNI=5MKJ$7+QI+$N /FPL?
M!.YAP..I[5D2V5U#K_AN\@T<PVT,5U%)!;A +?S"A7< <?PG.,\^M9,.E:K#
M'!>I93D6GB"XO7MB &E@D+@.H[D!\XZ]>] '8MK^DI9/>/?P) DODNSMM*R9
MQL(/(;GH>:EL-7T_5'G2QNXIV@8+*$;.TGD?@>QZ&N+UO1+V[MO$MY;V<SC4
MYK(0V^W#,(F4NY4],C(YP?D'J*W].MYU\<ZQ>-;2I;7%I;)'*RX#,ADW#\-Z
MT 6/%NJ7>B^%M0U.Q6%I[:(R 3 E3CV!%+K6L26,^EV-L$-YJ5QY,9<95%52
M[L1D9P%X&>I%0^-K6XOO!FJV=I \]S<6[1QQH.68_P JCUNPFN;W0-8MXI';
M3KAGDBVX8QR1LC$#U&0<>QQSB@#,U?Q;J&G^'_$4D0M3J6B2JK>9&QCE1@K(
MV P()5O7J#5W7-;U;PQ9Q:I?FSO-,5T2Z,$+120JQ"[QEV# $C(X-8FO:#J%
MWX>\77,5G,]YK4L8M[<#YMD:HBENP)VLW/8COQ6MXHM;_P 5Z/\ V%;6,]O;
MW3(+JZN-JB*,,&(5<Y9CC XQSUH ZW(QG(QUS5&WUG3KN<007<;R%#(B\CS$
M'5E_O+[C(I-9L9;_ ,/7^GVLGDRSVLD,3_W"RD _K7.6EC>ZC-X6>2QFLI=)
M#&Z+K@#]T8]BD?>!)!R.,+S@X% %O2-:N]>U&XDL[J*.VM+V2WD@>$GS(U&-
MP;C#;OPQVSS6G=Z]:6VNV^BEF%W<0O*AV$JH!4#/KDMZ]NW%4O"4%Q;)JXN;
M:6 S:G//'YBXW1L<JP_PZTFI6]W%XWTK48[2:>U6SN+>1XL'RV9HV!()SC"M
MTSTH B\*>*H=4TVQBO[VV_M6X,O[I!MW;788 Y_A .,YQS6T=8TX7R61NXQ<
M2,413T9AR5!Z%AW&<UQ6FZ7J$.C>%(7T^X26SU66>X79_JT83#<?7_6+T_I4
M^AZ==13PZ5JFAW<T]G>M<17[SYMB-[,L@&_A\,1C;U/H30!TOBC4;K1_#&HZ
ME9^29[2W>91,A96VC." 0?UIEE<:K(VGR37=@Z3Q^;+"ELZ/MV=5/F'HQ3MT
M--\96\]YX.U>SM8'FN+BUDBBC09+,RD#Z53TJWMK-M/>U\/R07HB$$LWD+&$
M0A2^XCK]P8QGG'UH UX->TNZV^1>))NG-L-H)_>@9*=.H')';%/EUC3H;Q+2
M2[C69Y!$ >GF$9"9Z;B.0N<UR\-G>V/BQ->@TV4V^HN\-U;!/F@Q@+/UQEMH
M# <X*]2IR_1XK^SNKK1[[0Y+H?VE)>6]\P1H=CR%PY).0ZY(  SD#MR "UH7
MBF*6:ZM-6OK9+P:E-:0(HV;@IPHQD\GGJ>3TK:;6M.2]%HUW&)C((<<X\PC<
M$W=-V.=N<XKBY-,U Z1>1KI]QYK^)%O579R81.K[_P#OE3QU]J-2M-7N;\L-
M&N1]GUR&Y46XC6.2$$?O/O LY'7/3';N =:?$^AB<0?VI:F0S_9\"0']YQ\O
MUY ^O'6IKO7-,L'=+N]AA\LJ)&=L+&6^Z&;HI/;)&:XR]TO4)-#\20IIUP9[
MK6HKF!0G+QAH26S_ -LVZ\_G4>I1F;4M>M/[.U6;3;R\AEF>UMUEW,BQEMK;
MP5Y4*1M)&#@\X !V]SKFF6:HUQ>Q(C!6WYRH#'"DL.%![$X!K0K@KB":;6=3
M\_1;S5M*UE8IK9X)ML8'E*I252RX'RALX/4]^*[C/V:T'R%O+3[D8R3@=!0!
M@ZCXF-AXLT[2S #9W!,,MR>B3L-T:?4A6_[Z6MN[OK:R53<2;2YPB@%F8XR<
M*.3QSQ7':GX=N]6\'W<[37L6ISG[:MN%3]W<C!1?NY^7:JYST'I4L]SK*:EH
M?B%]&NY0+.2UO+.(*98'<HVY03AAE,<'IB@#:/BG2SJ.FV<,XG.H1M+#)$"R
M%!@9R..I K4NKJ"RMVGN95BB7 +,>Y. /<DD #N37+O974/B#PY>0:.8;:*&
MZBDA@V 6_F%"NX X_A.<9Y]:T_%0NSHZFSLA=N+F%G0(KNB!P6=%;@NH&1GN
M* ++>(-)2T:YDOX8XEF^SL9&VE9,@;"#R&Y''7FGVNMZ7?17,MM?021VIQ.P
M? CXSDYZ#'.>E<+<:5J;Z9K]O_95Z3=:Q:W47F%7+QJ8"Q)#'D"-L_D/2K.N
MZ1JM_=>*6L;20FYCLGM]_P JW'E,6=,GID8'/7/I0!NV6OR7OC:;3(IHWLTT
M];@+Y3(X<OCG/4$<C@=>];5W?VUB(_M$NTR-MC4 LSG!)"J,D\ GCL*YW3VO
M+WQR-4.E7EM:OI8A+SJJE7$A;:1NS_GTJWXB%Y_:6D-;V$EQ ))!-- J&:'*
M84*6(VAN02.0/3.: +K^(M&2*UE;4[4)=J6@/F#]X "21] #21^(M(E@M9H[
M^)H[N0Q0,,GS'!P5'^UP>.O!KC]%TO4K>#PE%<:9<QG3[VZ:?< VQ664*V03
MD$NOOWZ<U:CT2>Y\,:_%,C65P-3GO[.:48",'WQR>PR.>^"<T =I'=P37,UO
M'(&EAQYBX/RY&15>^UG3M-<K>721$)YC9R=B9QN;'W5SQDX%0>'H[C^RDN[V
M,1WMZ?M,Z#^!F PG_ 5"K^%<WXQL]4OY=:M+?2YI([C23%!-;! 99/G^21B0
MV!D$*.#N;.>E '27_B;1-+DDCO=4MH9(E5G1G&5!S@D?@?RI+KQ-H=D ;C5;
M1-T/VA?W@),9QAACJ#D?6N;MI_*\<2&XT^X9F\/VZ-$(P[ ^;+\IP3C/Y>I%
M4M"L9/#GB#P_8WD,DLL&AS*XB0R>63-&<<<D#.W(_E0!TM[KLAU;PW_9US;S
M:?J4LBNZC=O40NZE6SCJH[5=L=4MV@OKB75;:Y@BNFC#QKM$7W0(R<G<V3^)
M(&*Y73=!OM,/A>,V<@2WU"ZN940 BV259=BG'IO4<9[]JCDTW6(H;R\MM.FD
M>W\1'4!;'"M<0;-IVY.,]2 <<J/:@#LUUS3'MC.MVA03>05P=XE_N;<;MW^S
MC-9&L^)DM?[$N[.]MO[.NKXV]Q(XZ )(QY)^4@I@@C/TJMJ#WD\%G>6GAV2!
M);]9)QY41ND'EE?-QD@-G"YR2%S^&3:Z3J<%I9-)I5T%L_$<UZZL5=S"_FX8
M88EL;USWZ]: -[7/$Z'PC<:QH-[;3^5*D9?;O RZJRD9&&^;O^5;5YK&G6$H
MCNKN.)B5!+=%+'"[CT7)X&<9KCM8T.]FTKQ-=6UE+OU2ZMG@ME4!B(]@9R.@
M)VL>>< 9Y.*DNK"Y_MO6+2]T*\U.QU21)X)(YBL0_=HA292PV@% <X/!]1B@
M#N)98X(7EFD6.- 69W. H]2:RH/%>@W4L<<&J6\C2&,+M;()D^X,^IP<?2M*
MX^2RD 4L1&0%49)X[5PT>E7\'P\\-PC3YC=:;/:2W%LJCS,1L-^!G!/4]>:
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M, \C(ICQR:AX7DBU9H[>2>T9+IH'RL9*D.5/H.<5R^GW>JZ#JFCZ-XEM(KJ
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MK>B6VHR:?=Z>TP)-M=ILE3!(Y'OC/T(KRK3;73(/B?\ $A;N*W2?[/');"0
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M%ZR%3,!T;!)SQCG)SU[UL4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^>R8D0E,8)Z@!O3BJ-I8WFHS>%7DL9K*;2 QNBZX"_NC'L4]&#$@Y&1A><'
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M!2DT?V@R&0,2.2#R#SGK74>+K.XN[+39+>V>?[+J-O<RQH 6V*V6('<CT'-
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M2*1IH6<KMC+Y&'7TQ69X5M)F;3(]0\/WEM?Z9"86NIYR\0^7:?)^<YW8'&
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MVR(H>YNYUM[=#T+'))/L%#,?I65X<BNO^$B\1W<UA<6T%W/#)"TP4;P(44\
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MW5_$/A26VTV:]M;&\,MV%0%1&63L?O<*>!6B\4T?A_4M#TW1[N&Q2PN%A,B
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5HTB1ZA>)!(Z-(J$$EE7J0 *C/B72!9W5V;P""U*B=RC?N]P!&1C(!!!S[T
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M&EK$LTWFHR%4;.&PP!(.#R/0T 36VD6UO>F]8RW%X4\OSYVW,J9SM4=%'3.
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K-US5M.TC3))
MM2DB$4G[I8G(S,S<! #P22<>GKQ6E37C23&]%;'3(S0!XAX9D_X5-\1/[#U-
MK=-%UY1+:2J^1:R9_P!7N/.W)VY/7Y3QS6K8W,'_  TSJ)\Z/!T8(/F'WLQG
M'UQ7K+0Q,06C0X&.5%)Y$.<^4F?7:* /&_AYKFG:-XD^*&IWEPHM8-1,SLGS
M$H'EY ')KU_3M0M]5TRUU"T<O;742S1,5*DJPR#@\C@U+]GAP1Y,>",'Y1R*
M> %    '  H 6BBB@ KF?$EPFHWUKX<A%I<2S W-U;3S^7NA0C"G"L?F<KQC
M!"L*Z:N7UCP[X@OM6DN]/\72Z= P 2W33X)=F!@_,PR<\G\: .%^%5[_ ,(W
MK7B+X>ZI+"/L<C7%F#)O5HG&60$@9P"IZ=VXXKA-"\@^&? 5XURXNY_$+6T\
MWVA@_DEP&3.<A<'MCK[U[+_PA_BO<6_X3Z?)[_V3;?\ Q-'_  AWBO\ Z'Z;
M_P %%M_\30!YL+W4-/\ !GQ1MM ED06FJD0I QS#"7Q(4QT&T'ITP?2KOB06
M'_"L/%6K:1KUK=6=W%9R16MG"8H[20,BG!WMAV'WEX/&3UKO5\(^+4SM^(%P
MN>N-)MAG]*:O@WQ4D0B3Q[,L8.=HTBV _+;0!P.G3W&G^,?$$&@RO]HE\(+<
MQHDA<R7(5-K<DY?G]:SM%GT<ZU\)Y[2> W;_ &@W[A\N9BJC,G^T6R.>>GM7
MJ*^$/%BMN7Q_.#ZC2;;_ .)I$\'>*XVW)X^F4Y)RND6PY/7^'O0!X]XA,"Z!
M\0KV.<B[LO$*?8G64@P_O#]P9XXST]/:NQM)9M-^(GCJU\/R'S3H*W%O$DA?
M?<",$-R3EB3U[Y]Z[#_A#O%?_0_3<_\ 4(MO_B:5?"'BU6W+X_G!]1I-M_\
M$T <+X6:TO\ P9/JT.OV[SKX>G@U#3TB(<RJ"?-F8N?GW9PQ SGBLSP5)%!X
ME^&,L<Y\V^L;Q+QC*290 ^T-D] 1P/45Z8O@[Q6F_;X^F7><OC2+8;CZGY>:
M!X/\5@@CQ].".A_LFVX_\=H X?P'#X>LO!OCN/5_]%$6HWD5R8!B>.W(0 #
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MRZ^V1P7\?F6L8>4D$;%.<-S]Y>#R,CBH[76[.#1[*>XU$7?F6PF^T1P,/,0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4&JGV>[3Q_+?_8YC9_V8L F!7!D$A;&,YZ'KC%;%KJ5G>W-U;6\PDFM'"3J
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M%X5AN;&2SFT=PUQ(2I4[8FCVH0>0Q(/T'//%=I52QU2RU*WEGM)Q+%%(T3L
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M=R>9D$!B1]\5T]% '&ZUI>H/KTE_I,=W;WOF0J3N5K6[C!&?,4GY2HW888/
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M)+>1EU%%2Z'VF3$BJ-H'WN...,5;OM'L=2THZ;=Q-);87 \Q@P*D%2&!W9!
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M-)(UW*7WQ@!&#;LAACJ.:4^#]$:.>,VTNR>=+F0"ZE&Z5<8;[W7Y5/N0"<T
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M3UC>95&W>SH"VT $ MGMP/QK5U75=5TC5;FP6[-PDNE3WD$TL2[H9(B 0=H
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M -IV_DJ1;!"< '&1R O).<Y'2M]?#>GVR6+6<#+-IL+16.^XE*Q@C&"-W(X
MYSP*Y[0O#%Y:/9_Z+>:?+ R-+(NK22P/@@L%BSC#<C!"XS[4 ;'BC5+W2FM9
MHH[LV&V0W4EG&LDL6-NUMC Y0?-G R.*Q[2^GF\5-=KK7FVZZ!%=*[!5@)+/
MEB-N0IVACSGWP,5UUYIEO>SPSR&9985=$>*9XSM;&X':1G.T=>F.*IMX6T9G
MB;[$ ([3[$$5V5##_<*@X8#)QD'&: .>L]<U8WD]LUV\BMHOVV.:6!%_> X+
M(H .PYX#C/%,L?$.JV@T&\OKS[7!J.D27<T(A5-CQQQOE2!G)W$$'CT Z5OP
M>#]%MV1D@GWK;&U#-=RLWE'^');./3T[8J>'PWI4#Z>T=O(#I\1@M09Y"(T(
M *X+8(P .<]!0!RPGN]0U#P)JMS>&3[9*\QA5%"1E[61@%(&< '').:M6.NZ
ME+KND0F\%S;:@;I6D2)1#\F2ABX#G&,$G(/8UKVO@W1+.6U>""=!:2F6V3[5
M+LA8@@[%W8 Y/ XYHMO!VAVDEM)!:RH;61Y+<?:92(BV=P4;L!3G[HX]J .<
MM=?UN'PNFLW6I)*T]TUA'$;=52-C=&)921SPH/'0\?4RW"ZG8^,M<:SG:]O1
MHUN8!-L0D^;*-N0 N<YQD=2,UTJ>&=(31)M&^R%]/F+,\,DKORS;B06)(.[G
M@]>:B3PCI"R22E+N262%8'EDO9F<HK%E&2V<@G.>M #?"^L+JT-YFXNFEAF"
MO;WD BFM_E'RL  #SD@C@@]>*PF\3:D_A:+Q1#-F/[=Y3V!C7:8C/Y. <;M_
M0YSC.>,5V-GIUM8O-)"K&6=@TLCN69R!@9)] *J1^'-+BN'F2W8!Y_M+1>8W
ME&7.=^S.W.>>G7GKS0!CZ3!(?B+XB9KN9D6WM#Y;!-I!\[ ^[G [<_7-0>+=
M>U'3%U:>QNP386T4P@BC5@A+'=YQ8="   ISU/H:Z:#1[*VU6YU.*.07=RJK
M,YF<A@N=HVD[1C)Z#O5/4/"FC:K<7<]W;.[7<0AN L\B+*H^[N56 )&>#C(H
M Q-7U'6O[7\0V]KJ8MHK'38KR$+;HQ#GS<@E@<@[!GOZ8J63Q#=V-SH6J7]T
M(]'U&TQ*NQ=L,Y0.IW8SM(##&>N/6MH^&M+:2ZD,,Q>ZMUMIV-S+EXQG ^][
MGGKR?6J=WI$MP;70UTV'^PX!#)Y\MP7;]VVX1A"">JKR3TS0!<MWU!/#;37$
MS"]:%I<NBYC)!(4@  [>![XKG=#UK5WG\+37NH+/%J^G---&8518W6-'# CG
MG)SDX] *[2>%+FWD@E!,<BE6"L5.#[CD5F1>&-(A_L_9;R :=&T5J#<2$1H1
M@K@M@C  YS0!S^EZUJEUJ^F6LM\\L&H6$\QGCB14WH4PT.1NVX<_?!SP>:IZ
M%J6IVGA7P;,+^27^T+M([CS45BRLCL0#C/5<YY/)YKI['PCHNG36<UM;RJ]F
MK);EKF1_+5L94 L?EX&!T&.*=#X3T:"WM(([:58K.?[1;K]IEQ&_(&/FZ $X
M'09/'- '/77B;4CX8U#Q);S8%E>R1?82BE7B27RR"<;@Y&6!!QD@8J/6]:UV
MU_X2V>WU)8TT?RI8(_LZ'>#&'*,3S@Y(XP?>NJ_X1S2_M4TXMV'GS">6(2,(
MGD&"'*9VDY /3D@$\BFW'AC2;H:D)K>1QJ0 NQ]HD E & .&XXXXQ0!@>*-?
MU'3EU*XLKL-]BCMW$$4:E4W-\WG%A_$",!3D#D]:T+7_ )*9J?\ V"K;_P!&
MS59N_!^B7SW+7%M*_P!JB2*<?:90) O"E@&P6'9CS[U>@T:QMM2?48HY!=/"
ML#.9G;*+G:,$XXR><9Y- &#JFNW>G^)!;7DEQ:6,L\*6URD2R0/G;NCE."R.
M22 >!R/?++'5-<U<P:C930):KJ$D$\$S*$\I9&C('R[A)P".<$G&,8K>FT*P
MN+F6>5)&,LB2R1F9_+9TQM)3..-J]NPSFH(O"NCP:S)JL5JR7,K^:X69Q&TG
M]\QYVEO?&>_6@#/T:_U+7+&RUB'48X;>6XD2:V>-=JQAF10IQGS 0O4X))XZ
M5GV?B#5)-%\/W3W6Z6YUB2RG_=KAXQ),H[<'$:\C'>NAM?"^D66JRZC;6S1S
MR2&5E$S^7YAZN(\[0Q]<9J(>#]%$RR"WF^6Z-XBBYDVQRDDEE7=A<EB2!@&@
M#(LKW7;M->NCJZK'IUU<PQQ"U0A@L:E23UX)_'O[06-W?ZCKO@^XFU"=3=:.
M]S,B*@1I,0DG&WOO/T[8YSU,&@:=;07\,44JQW[M)<@W$AWLPP3DME<CTQ4:
M>&]*C_LW9!(O]FH8[4B>3*(< J3N^8?*O#9' H YRU\2:D\,-K+,KW%QK5S8
M+,%5-J1[R ,@C<=@'(/4U/<7_B33+ &\5[M8[QQ*U@$>Y%MMRK%"H4L"1G:.
MF"!6O+X1T2?39]/DM&:WFN#=,&GD+"8G)=6+94Y]"*FB\.Z?!!;Q1"X0P,SI
M(+F3>6(P2S9RV1_>ST'H* )="O4U'0[2[CO!>)+&")PFS?[[<#!]1V-:%06=
MG;Z?:1VMK&(X8QA5!)]SR>22><U/0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4%U=P6<0DG<J&8*
MH52S,Q[ #DGZ>E3USOB[3KZ\ATZ[T^UBO9;"[\]K.5@HG0HR, 3P&P^1GCB@
M"R?%>C+:K<M=LL37/V0DP292;(&QQMRAR1]['6K7]LV'V:6X\YA%',8"3&PW
M2!MNU1C+'/'RYYK#?2GO]$FT]_#\-A#J<I%RD9C+1)@9=\'!<XP,9QP>V*SF
MTOQ&OA[3X!9+)>:)?K) &D11?0J&4="=CE6[\9'OP :&N>)T%G97.F7WEK'J
MT%G>*\6"H+ .K!QE>#U]^*UHO$VDRV=Q="Y98[>802K)"Z.LAQM78P#9.Y<<
M<Y&*Q]6MM6U6QL)5T<P2+JEO<O )8RZHC LSG=M+<< $]!SZ5KO3M=CO?$%S
M9Z>6%W?6LL8+Q;GB145]F3A7^4X+8]>M &_)XHT>*TDNI;LQQ1W(M9"\3J4E
M.,*P(R/O#D\<BGP>(]*N+>^G6Z,:6)_TGSHWB,?&02& .".0>_:N0DT'6?L>
MKPII<F+G6+6^BW72.3&GDELEFSD>6W4]2,9'-3Z[IUP?^$NENK)OL^HPVT-K
MNF1?-E *@#!)!W,N,C!H ZF/Q%I<ES/;&X:.:WC\Z99HGCV)C.X[@,#@_D?0
MU+9ZS8WUY+9PR.+F)%D>&6)XVV'HP# 9'!&17&3V%_K":K;7>G7EGJ^H6(BA
MN+EH6B81'(7$;$C)?DD<Y^@KH/#T-Q)<&\N_#=MI%P(?*=P\;O)R#A63^#C/
M/))Z#'(!I7VMZ?IS2+<S,#%&)91'$\GEIS\S;0=HX/)]#Z&H+GQ-I%I<) ]T
MSS26_P!IC2&%Y3)'D?,NT'=U'3/'/2LUK#4=/\2:W=1V37UIJD,6S8Z#RG1"
MA5@Q'RD8.1GOQ531/#U_H>JZ*I@>XM['1FLY)U=<&0LC8 )!Q\I[>E '66=_
M;:AI\-_:2B:VFC$D;H"=RD9Z=?PZUGQ>*-(GBLI8[EVCO9F@MV^SR#?(I(*_
M=X/RMUQT/I4/@RPN]+\):?8WT!@N8$*NA96_B)ZJ2.]8.I>$M3<ZPMFZK#'<
M#4]+4-C%T<,P/H-RM[?OCZ4 :GB'7VM)M,>TNVBB_M5+.[#0\,"C,0"PYZ#E
M?6K%WXCTZYT.:[M]4ELTCN5MWF-JV^*3<N49'7()R!R/X@?2JNJZ1?&U\/QP
M6YN)+;44N[MD=5 X<NPW$9RS\ 5F:AH>KSZ5XE@CTZ1I+[58;JW'FQC=&ODY
M/WN/]4W!]10!U5_X@TS3&D%W<^6(B@E<1LRQ;CA=[ $+G(ZXZUB0^*H].U_7
M[?5[Y_LUK<0I"1 2(E>-6^8HO"[FQN;CWI([;6].U[5XXM*2]L=4E2XCG>9
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M\J*[L[B,-%(  48%MKHV <<].U '3Q^)K.37I]+VRKY-JERT[Q,(]K;OXL8
MPIY/';J#5B#Q!ID]Q+;BY,<L4/VAEGC:+]U_?&X#*^XZ5S-]X>UF^NM1BECC
MSJ6A1V;W4;@)'.OF;OE^]M)<8P.F:CGT/4M?\/7]K-X>L]'U%[)K?[1O1S(Q
MP<*4R1&<<YYY'!H U8M?DN_'-E8VUQ+]BFTZ6X:*2W*98/&%8%E!(PS=#BNE
MEW^4_E8\S:=N>F>U<I:IK-[XJTO5+G19;2.&PGMY@\\3;9&:,C&UCE?D.#U]
M0*Z6PGN+FPAFN[0VEPZY> R!S&?3<.#^% ',//K<7BZRT1]9+)-827+R"VC!
MWJR+P,=/F/\ C2'7[G1O$SVFL7S2V\>DQW#B&V+'S-[*SA44MC"Y]!5RYL+Y
M_B'8ZDEF[645A+;O-O3AV=6'&[.,*>U-O-/OV\77U]'9.]M)I M4<.@W2;V;
M&"V>C#DT :TVN:?!:Q7)F:2*:'SXS!$\I:/ ._"@G'(Y]ZLPW$.HV$=Q9W(:
M&= \4T>#D'H1GBN$M-$UC2XM"N'T)-26+2HM/NK0RQAXG3D.I8[2#D@\YZ5V
MUA!]@TF*)+**'RTXM;4 *G?:N<#CUXS[4 <';>,-43P#9>(3J,%UJ$K*#IYC
M7]\3)MV(%PP;'(Z_2NYO=;L-.9UN97#1Q^;*L<3R&-.?F;:#M'!Y/H?0UP4'
MA;4W^&]MX?;01'JR+M2[>6(+ ^\D2!U8OD ]AGM706^FZII&O:E<&W?4X-0M
M(%+JZ*RRQH5(8,1\K9SD9P<\4 ;-WXCTJR0/+=;E-N;K,2-*!#_ST.T'"^_^
M%1W?BK1K*Z6VFNV\YHEF58X7?*,0 PV@Y&2.:Y-_#.MV>BPZ'';?:[==%:U6
M:*98\7!W9#DD,4Y&T#(ZY'<:VBZ=J</B+3[NYT]X88]&2T=_-1ML@8''#9Z#
MJ!U_.@!_B;Q)]F6R33KMUE.J6]K*RP%D8-(JNF\J5!P3T.01ZUOZGJMEH]I]
MJOYO)@WJF\J2 6.!G XY(%<.NC:_;Z#!H9TMYVL]62Z2[6>,)-%]H\TG!;<'
MP2"".W6NE\86-YJ7AQ[6RMFGG:>W?8&5<!)4=N6('130 LGC+0XENB]S,#:8
M,Z?9)M\:D9WE=N=F.=V-OO5J]\1Z5IZ[I[K@0?:6,<;2!8O[YV@X7W/H?0UB
M7NF:E+JOB>=+"0QW^F1V]N?,C^9U$H(^]Q_K!R?0UF:AHVOW.C-IO]FLT;Z"
M+6,I.B;+@*RD2$-EEZ;0,KR<^H .TCUBPEU4Z8DS-=B$7&SRVP8R<!@V,$9X
MX-2VU_;WEB+V N\!!8'RF!('HI&3T].>U<KK&G7S6>@7-HRV>L1;;,J6#'RY
M%PXXX)7:)!V_=FNOMX([6VBMX4"11($11V4# % &-I/BJRU31X-1"3Q+.[+%
M&T#EWP6Q@ 9;@9.,@<^E*_B_0DM[68WI*71=8=L+EF9 2R[0N0PVGY3SGC&:
MY6VT+7+'2-#8Z,EW)I4D\4UF\T?[^.0YWH2< C"D!L'DCBM4Z3>#4_#UU;Z)
M%:0V]W-<7$,#1CR@\3("W(#,2P)QG\<9(!I/XUT".*:5KR3; B238M928U<;
ME9AMX&.<G@=\5;@\0Z9=7<UI#<,9HHO.(\EP&CSC>A(PXSW7-<]J6CZI</XT
M$5@[#4[-(;0^9& [")D/\7 RPZ]JM06&HQ^)M,OFL)?(@TA[:0^9'D2%HV Q
MN_V#STY% %FR\3:7!INF"?59+V6\A9X)A;,&N0O4A57K[ 9]JNQ>)-*GLK2[
MBN3)'=NR0*D3EW9<[ALQNR-K9R.,<US&AZ'J]BG@]9]/=?[-@GCNB)8SL+*
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M>K:!>QZW=V@T>[%VJ-H5U)YK J<$X7 ^7T[T 7_ NJS:G\0M?OM%OIY?!L4
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M.0-QQ@#GOCBF:)?^%-.U+P_<WNLWUU'X?MI(+)$T6Y0MOXW.=IR0O&!WY]J
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MS/-"+QYW62UE@6(OR$02#)4  9R>Y[T =W1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%(2%4LQ  &23VH 6BF0S17$$<\,BR12*'1U.0RD9!!
M]*?0 4444 %%5YKVVM[JVMI956:Y+"%#U<J,G'T%6* "BJMGJ-GJ'G_8[A)A
M!*892AR%< $K]>15J@ HHJ*XN8;2$RSN$0$#)[DG  '<DD  =: ):*K6&H6F
MIVHN;*=9HMQ0D<88'!!!Y!![&K- !1110 4444 %%%% !1110 4444 %%%%
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MBBB@ HHHH **** "BJQU&S&I+IQN$^V-$9A#GYM@(!;Z9(JS0 4444 %%!(
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<]G/X5I>,=1O=(\,W-]I[QI<1O&!YB;@0SJI[^_O1H]G<7&IS:YJ.FQV-])
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MJR\[31&JC=*IPT>?XB2R%?8GKBM"\\*:9?:DNH2BY6Y\L12M%</&)T'19 I
M<?7^5,N+*XU77;=;S2XXK+39_M%O<-*K&9]A484<J!N/7NH_  U[9+A+&)+B
M99+D1@/(%P"^.3CTSVKC+?Q/JO\ PB^FZG=)/)$\UPM[/8P!WB5)'56$9S\O
M S@$BNY(RI&2,CJ*Q[7PS96-O;PV<MU +<R&,K,21YAW.#G.03SSG':@"YI-
MT+[1;.Y6ZBNO-@5O/B&$D..6 [#/:N03Q%K<EAIS+<VPFGUV;3I&-OD%%:0
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M.S; QD>2-B,Y_A 4=,$DGD8K7O/"&E7D]S,PN8VNK?[/<B*Y=1.@7:-_/S$
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MUY;V6*]2TT^.]@"Q>7M9G=-AP3\N5!SUZ]:U9?!FD3I>K*+M_MR(ER6NI"9
MG3))Z^_X=*M3>'-.N;NYN;F-YWNK46DPD<E7B&3M(Z=6)SUYH Q4ANH?B1IA
MN;S[26TBX.?+"X;S(<XQ_#TP#DCU-7_$-_J-KJ^A6EC<0Q1WUQ)#*7BWG B=
MP1R.ZU-8>%=.T^\M;N-[R2>UA:"%IKIWVQG'RX)Y'RCKZ5=O=)MK^\LKJ?S/
M-LI#) 5<@*Q4J21WX)'/K0!RUEXFU%FM=+GF1KN;5[C3S=B,+\D2L^[;TW$
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M)W,  &']T@*N,8Z"EM_#-E;6L<,<]\9$D$HN)+IWEW $#+,3D ,1MZ<GCDT
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MU#7M-TLO]LN#&L>WS'$;,L6XX!=@"%'U(J;5-1ATG2KK49UD>&VB:5A$A9B
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MQ2W.B/IL-O(\>^1V+')(8J ,@=?[WMD VAXNT4S-"MS*THB$RQK;2EI$/\2
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MS:XL?+E6=H95CD1SMVY8D,$X.0O/ X(XH L2>*=&C%F?MF_[9"9[811.YE0
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M!&00FU1P!G/-1_VAK^IW5QI,%[:0:C;:?#*989 $>9]X+@-&VY 5 QQU/M@
M[6BN'DO-;N=5O;,ZQY'EZ-#>!K2.-E$Q+ABA93E#L'7GW%1V.NZK&_AN^N+U
M[F/5=,DN)K7RT5%=8DD&S W \D')/7M0!VE[96^HV<MG=Q^9;RJ5D0D@,#U!
MQVJ2&%+>!(8@1&BA5!). /<UR6C7.O:E%I6J#4K86-]:EID#JQ#LFY3$/+&"
MI!!#$\#N15#0-7UF<>$;FZU22<:O#*MQ$8HU52L1<,N%R#E><DCGH* ._!!Z
M'-+7+> 1,?#TDD]W/<,U[=#][M.,7$@SD 'GW_#%7O$VJS:78VI@9$>ZO(K;
MS'. F\]<D$#I@9!Y(X- &W17&SZAKFDW4.GWM] PU#4(X;:96#RP1LC,0WR*
MI),9"G!Z\YQ5'4]9U?3D\2I%J<K'3[FR6!GCC)"R%-ZGY>?O'GKTYH [R>9+
M>"2:3=LC4NVU2QP!DX Y/T%)!<1W,$4T9.R5!(FY2IP1GD'D=1UKE[S5-1CU
M7Q3;1WKJEGIL5S;?NT/E.1+G^'D?(O7-4=.DO=0\5:%++J5RC3>'C,X0)C>7
MAR<%2.<Y_ =N* .[HKC=&U74[F=="NK^0ZM9WC_:Y?+C!DMU&Y& VX 8/&..
M?O<\5M:_=RV_]GPP730R7%SL\N- TLRA&8JF> > 23P #[4 ;%%<#%KNL)X9
MM=7FO7"66JR6]\/+C)DMUF:/)^7@J-I)7' -3:5K>HWFI7VD/?S_ &A[M)K.
M8QQ FR.3N "X(^1UR1_$OK0!W%4K72-/LKZZO;:SABNKH[IY57YI#[FN5;7-
M176M.:*^:XM;G5I;-RL:"'8$DPB_Q%E*#+="<]>U*36]9LM(U?5I=7>06FI2
MV$<3PQA #*L:NQ !RN[/4 T =PNJ6CZN^EB1OMB0B=HRC ;"< @XP>>.#VJY
M7(V5O);?$V=9+N:YSHZ$&4+D?OFS]T#Z_C2^+-4OK1[Y;"^=);;3)+H0PQH2
MC#.)'9P1M^4@*.3SZ< '6T5QUWK.I2SVJ&66VAGT@W,<EM$'9KCCY<8/ !&!
MWR1SBJ[3>(Y+CPS87&JS6=UJ%E.]YMAB8I*JH1M^7 P6([\#UYH [FBN*@O]
M>U,W4]C?VT0T_4&MY4G<!6CC(#;P(R06'S AAC([4ZUU#7-79K^RO;:"*WU.
M2WGAED&WRDD*%2/+)#D ,#NZD=N* .SHKSL:MKHTZ*]_MB0NNOMIQC:"/8\1
MG,0+84'<!@Y!'3I5F?7]1T=M>M9;YKD6UY9PPW-PJ*8EGV!BQ50N%R2#M],Y
MH [N@G R:X;6[GQ+H^E:E.VJ0@">U-KC;)(BO*L;J_R*"IR2".>O-5-?N]3B
MTOQMITFJ7$JVFGQW$$I5$==ZR;ERJCY?D^O)YH ]$SD9%%5["-HK"!'F>9@@
M^=PH)_[Y 'Z5CW^HSR^+K30HYWMHY+*6Z:5 NYRKJH4%@0,;B3QGI[Y .@HK
MSY=;URYCTRV.H-!-_;<^ESSI"A\]$20AP"" WRCIQD'C'%=7J"ZG9^&I$LY_
MM6I1Q!4EEVH97X'IM#'MQC)% %Z\O(;"W\^??Y>]4^2-G.68*.%!/4BK%<#<
M>)+MO#=Y=6E[?07EMJ-M%+;7D"++ KO&A1N,$$,S!AZ]>*=K&HZRDWC V^KS
M0+I5M'<VRK#&<'RV<J<J<J2OU]Z .\Z"LQ/$&G.-._>RJ=18K;!X'4N0"Q!R
M/E. 3SCI6+8WNIGQ1;6<VHR20W^E/=[?+0""17C'R?+G&'/#;N@YK*M+^ZU3
M3? %]>R^;<SWC/(^T#<?(F[#@4 >A45Q%OK>HMKVCA+Y[FTOKVZMW=8T6$JB
MR,H3C=E=@!8\$YZC&+WA*35-0%Q>WNK2SQPW=U:B PQJI"3%58D*#N 7'IST
M[D ZFJEQIEG=WMM>3Q%KBU),+[V&S(P< ''(X/M7)^+=<U'3UUB>POF+6$$,
M@ABC7;$2Q)\TM][<,8"\@#/&0:FU_4]8CO\ 6;:UDGAD@L(YM.6"$2>=*2^0
MW![JHQQP2>V0 =C17&HVN3^*UTI]:G@1--ANY L,3'S/-8,N=OW2%Q_(BDT?
M4M<U>'3M:AN[9+.6=UN;>208V9*A% 3(<$ <MR<^V #IM1TC3]76%=0LX;E8
M)!+&)5R%8<9_6KM<9H=]KNM6^D:RE_;1V5XK&XA,@.W<#@1CR^'5N.6.<'-9
MNGZKKL^F>&+V3696?4KN2TG3R(MNW$I##Y<AAL'?'M0!W46F6<&HSZA'$5NI
MU"RR;V.X#H",XXR<>F35NN#@\0:G;A].DO/.D.NMIJ7<VU&V>3YJY(7;N)^4
M';W]:DOKGQ'IL5E!/JL/F2ZQ' K1A9&\AP2%?*+\P(Z@#(QF@#MR0 22 !U)
MI:\WUF\U)_#_ (@LIM4N9&L-6M88Y\(KO&[0$JVU0#CS#T SQFNTUJXDTWPY
M>3B_6"6* [;J=-P5L8#%5 R<]@.3VH U**\\U+7M9M+#Q>L=W<POIUG!<VK3
MI$9$+*^0<#;@[ ?49_ 3:SXAU/PS>:N9+QKU$TI+R)98U412F0IQM .SD'!)
M/'6@#L3JEH-772C(PO&@-P$*-@H"%)W8QU8<9S5RN/AMY;?XEV/FWTMUNT:?
M#2!1SYL62-H'7TJWXCOKN*]%M9WLD<@LII_(@13)D%0LC,^0$'(QU)/?!H Z
M6BN&L=3U?6+_ ,/P_P!J26L>HZ&;R;R8H\B3]URI93C[YZY'MW$5IK^K+X?\
M-Z_>7[?8VD\C4U$:!2"Q192=N5PVW."!@^U '?45G:)+<7-@;N>9Y%N9&EA5
ME4;(B?D' '\.#SDY-<F_B/4Y/"@\3PW#;DOS$]AL788_M'D[.FX/C#9SU]N*
M .QU/5+/1]/GO[Z4QV\"[I&5&?:/7"@FK@.0".]>8ZVLYT7XBF2]GE1&V+')
MM*@&"-N.,C&2,9Q^/-:FIZ[J?AV_UA'O&O(XM)2^B$T:@12;V0XV@'9T.#D\
M=: .ZHKB=6G\1:9I6LWRZK";==,>XMB'22594&=P_=JI0@C/7!Z=:Z318;N.
MR\V\U"2\>?;(-\:J(\J,J-H'&<GG)YZF@";3]4M-4%P;21G^SS-;R[D92KJ
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M%F7SPN[]ZH)15Y .W(ZY]J .NHK%\,:HFK:;-,L]S(R3M&\=U$(Y8&&,QN
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !63K>KW>FHJZ?HUUJER5+&*%TC"J.Y9R
M!SV R3^%:U5=1BO9[":+3[J.UNF4B.:2'S0A]=N1G\Z *?AKQ!:^*-!M]6M(
MYHHY2RM%,NUXW5BK*1Z@@UK5QWPUGO/^$:GTV_MX(KK2KV:QD> $).5(;S!G
MG+;LGWS78T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%9GB'68= T*ZU*8J%A4
M;=V=I8D!<X!(&2,G!P,F@#3HKD8?%5VGA^QO9SI=S<:E>1VMD=/G:2%M_P#$
M6(!X <D ?PXZ])9/&<&GVVJKJ"#[;IUU':&*+C[0\BJT6S)XW!QU/&&YP,T
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
7 **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>eliciotherapeuticsinc123001.jpg
<TEXT>
begin 644 eliciotherapeuticsinc123001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQQXM\--+Y0\0Z29,[=@O8\Y],;J -BBH6N[9+F*V>XB6>92T41<!G QDJ.I
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M\5^'+JXCM[?7]*FFD8*D<=Y&S,3T  .2: ->BJ;:MIJ0M*^H6BQI-]G9S,H
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MS+%(&,;?W6 Z'V- %BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KBOB46FTS1=,9
MV2SU/6+:SO-I(W0MN)3(Z!BH7\<=Z[6LW7M#LO$6D3:;?!_)DPP>-MKQNIRK
MJ>S @$&@#.U;PKX<>TLY)H+?3183QRV]S $@:%@PP V. ?ND=\XK%\,6-KKG
MC+Q7JFJ6\=S>6=^+"V690WD0+&C#:#TW%F)/>K8\#WE]/:KK_B:]U:QM)5FC
MM'ABB5W4Y4RE "^#@XX&1S5S5/"4D^M2ZSHVKW.CZA.BQW+11I+'<!?NET<8
MW <!A@XXH Y/6+6#0_%OB33M,C6"RU#PS/>W%M$,(LRDH) HX!920<==N:S/
M#UQ-X1\(QZ)>2,VDZSHQN=,F<Y\J<P;I8"?<DNOU(YKO;'P5;VUGJ_VJ_NK[
M4M6@,%U?S[=^S:5"HH 55&20 .O7-2:GX+T[5_ \7A>[9VMX;>.&*<8$B-&H
M"R#T;C^8H XZWT>^O-!\":IIUMI^JSZ?HL>[2KR4)O5XHQYB$@@,"N,D8YZT
MV2YTUK+QHC:'=Z!KDVARR7-BY0PS(J.!*A3Y6.6VD\=N*ZB?P'&MIHITW5KO
M3M2TFS6RAO851C)$%4;9$8%6!*@X[&EA\#>9'JLNK:S=:EJ.HV+V#74D:1B&
M%@<JB* !R<G.<D"@#G?#*7K^']'4_#:TEB-K"#<M<6V6&P?.01GGKCK53Q!I
M^I'XI:OKFB[GU/2-/M)4M@>+J)C*)(C[D $?[2BNGM/!WB"QLH+2V\=:@D$$
M:Q1K]AMCM51@#)3/05NV>@QVGB.]UK[1))/=VT-NZD  ",L0W'<[S0!R/AZ_
MTSQ3\0-2OH%CNK"\T.S<+(@8'][+PP/<$8([$4[P[H>D/\2/&<3Z79-'$+'R
MT-NA"9B8G QQFMW0_!.G>'O%&KZW8/(AU,+YEOQL1@225],DDD>I-:&GZ#%I
M_B'6-829VDU,0!XR!A/*4J,?7- &1\3;ZYT[X>ZI-:3-!*PCA,R'!C62149@
M>V%8\]JGO/ _AEO"\NC_ -EVD-FD)"NL8#1D#APW7<.N[.<UNZA86NJZ=<6%
M["LUK<1F.6-NC*1@BN2;P'?RV/\ 9-QXOU671-OEFU*1B5H_[C3!=Q7''J1W
MH XB'4M0U<_#6^N='&MWDNF7F^WE=%\S B&\E^,X /XUZAX9C<03R3>&8="E
M+!?+C>)S(H'4F/CN>#2OX8L_[:T748"8%TBWEMX+>,#9L<(,>V @Q6Y0!P]]
M_P EBM_^Q<N/_1\=<C\,[B;P=HN@+<2,V@^((5\MW.1:7I'W<]ED X]&'O7I
MTWA^&;Q5'KQGD$R6#V(B &W:SJ^[Z_+5.'P7IR^ X_"-RSW%DEOY'F-@/QR&
M&.C X(]Q0!YUX:MH+RP^$\%S!'/"RWVZ.5 RG$+D9!]ZZG7],L= \=>$[_2+
M2&SN;RZDLKE+= @GA,3,=P'7:5!![59'PZ%OI7AVTT_7+NSGT(2BWN5BC=F\
MQ2K9# CH3VK0TKP>;76H]9U76+W6-0@C:.W>Y"(D ;[Q1$4 $C@GDXH X;PP
M+LS>(?)\#6^LI_;M[_I4D\"'_6'Y</SQ5_Q<Z6VM> WG\-/( ]V7TFV2*4@F
M'H!D(<$YZ]JW+?P/JNGW%\VE^+[ZR@O+N6[:!;2!PKR-N."RDUIIX7EDOM"O
MM0U:XO;S27G=97B1/.\U2N&"@ 8!XP.U '-:3I=QJ'CNTUNR\,2^'K&TLIH;
M@S+%&]VS[=J[(V/"X)R?6L#X?"^_X0+1_+^'=KJ*>1Q=O<6RF7D\D,,_G7LK
M#<I'J,5PVD^ ]:T/2K?3-.\;ZA#9VZ[(H_L5NVT=>I0DT 8/BO1KZ_\ B59S
MZ-BUU;3-!%U9Q X0LLVTQ-CC:REE_$&I[+7K;Q+XWCU.U#()/"]RLD+\/#()
MT#(P[$'(KM;3P[Y'B"#6I[Z6YO(]-%@[,BJ)/G#ER , DCH.*HP> ]-M?&6I
M>)+:22*?4;-K:>%0-A9BI,@]&.T9]>M &+X+\*>']9^%.C1:AI-E()]/3S)3
M"H?)7[P;&0>^:Y."_OM3TCX874^G#6KIOMB?9YG5?/"Q,H8E^,[5#9/7'K79
MVGPZO[?18=$;QEJQTF.(0?9XH8(V,>,;?,";L8XZYK3U?P5%>#0_[*U"71WT
M4.MHUO$C[59-A&'!'W<_G0!7T]+C[/J+7'@NWT0"TDVW$<T+ESC[OR<CU_"N
M,\ 7$W@_P_HUI<R,VAZ_8K):R.<BVO#'EHB>RR<LO^UD=Z]!L?#VLPRR?VAX
MKO-0MY(GC,$EI!&.1C.44'BA_!>G3^ XO"5TSS6D5LENLIP'!4#:X]&! - '
M+:1IMA=? >VN+BRMIIX]!?9))$K,N(V(P2,CFNH\#:;86O@_0[FWLK:&>33;
M??+'$JLV8U)R0,GGFK%EX8@LO!"^%UN)&@6R:S\X@;MI4KG'3/-:.DZ>FDZ/
M8Z;&[.EI;QP*[=6"*%!/Y4 <#XI>6/XLZ<8=!.M-_8DO^C!HEVCSD^;]X0..
MGKS3/!(&M^/;_7;;28-#CLK8Z=<V 91/)*7#!I%48  'RGG.>#BNW?08G\6P
M^(3,XFBLGLA%@;2K.KY]<_+4+^&8%\81^)+:XDM[AK<VUU$@&RY7JA;_ &E/
M0^G'2@#S3X>B]_X0/2O*^'EKJ2>6V+M[BW4R_.W.&&?;GTKI[VTM]:^*&EZ1
MJ5I']@T_1OMT%BP!C$YD\O)7HVQ1@>F[(J;2? 6LZ'I<&FZ;XVU""S@!$4?V
M*W;:"2>I0D\DUJZIX1&JV^G32:K=PZSIZD0ZI $20DC#;EQM*M@97&/3% &)
M/>:#;?$'2V;0-6T[4/.ELH+N.V2*WNLJ3M8@Y=<+N''!%8MMH\FO>%?%6GP7
M%K%._BJ=XX[LXBN&21'\I\<D-MQ@5UUGX,N7UBSU37O$-[J\]DQ>UB:.."*-
MB"-VQ -S8)&2>_2B3P#I\^E:C8R75R#=ZF^J1W$3!)+:<D$%#[8[^IH Y^&Y
MMXO%.A'Q#X1DT"_2<PV5[92QR6\KLA'E,R@$!AG"L.HJSXAT/2$^)7@V%-+L
MEBE2_P#,06Z /B-,9&.<5K6W@V]FU*RNM>\27FKI82B>VMV@BA02 $!VV %B
M,G';/:M>_P!!BO\ Q%H^LO,ZRZ8)PD8 P_FJ%.?IB@#B/&%N+7XA>&(+#P];
MZFB6%YML<QQ(!NCRPW?+Q_6KUXD__"%^*&N/",&A$:7.%>.6%S+^[;(_=],8
M'7UK:\0^%)]9UJPU:RUJXTN\LHI85>&&.3<KE2<AP1_"*9'X7U6:RU&RU3Q3
M>:A;WMI);%)+6&/RRXQO!1020,\'CF@#SB[O@W@'2])NO D%N=4LXK.WU*[D
M@$(D:,!9&9=S*>XS@D^];&L65WI_CCPQ8_V0GB*XMM DADCED1-Y5H@9,R<9
MR/KS7>W'ABPO?!P\,W@,]G]D2U+' ;"J &'HP(!'N*Q[CP/?27.E7L'B>]M]
M0L+-K+[4((G:9"0<L'!&?E'- %.^2?\ X0;Q4UQX3@T)AI<X4QRQ.9AY3Y_U
M?3&!U]:8?"N@7_PJMVN-,LXY!I"3"Y2%5DC<1!@X8#(((SFMJ/POJDVG:E8Z
MKXGN]1@OK22VVR6T,?E[Q@L"BC)P3P>*S5^'MY/ID6D:CXNU2ZTA(UA:S2*&
M$21J  C.J;MN!@\\T ;O@R^N=3\$:'?7A+7-Q8PR2L>K,4!)_'K^->7^#9[:
M7P%%9GX?7FKSN;E!<_9[<13$S28S(SA@!TSCC%>TPPQV\$<,*+'%&H1$48"@
M#  K,\,Z#%X9T"WTB"9YHX&D8.X )WNSGI[MB@#A-'TJ]T/Q+\.],U&427=M
MI5['(P;(! B^4'O@<?A6[KO/Q7\(>UIJ!_2*M?Q'X937VL;F*^N-/U*PD:2U
MO+<*63<,,I5@0RD=0?056T;PG+9:VVMZMK%SJ^IB$V\4DL:1)#&2"0J(  20
M,DY/% 'E6C6U_=_"9X(/ %MJ"20W*C4#-#OYD?YPA&\E>PSD[1BNQT6XM[OQ
MSX0FM+M[N!O#4NRX<8:0!H1N([$XY]ZNV/P[U'3](&CVWC/5(=,&]?(BMX%8
M*S$L Y0L.6/-6[GP L=SI,VAZO<Z.VF6364/E11RYC)4G.\'G*CF@!OQ._Y%
MJR_["]C_ .CTJOI-G;ZW\4/%%QJD,=R^EK;6UE',H80H\>]F4'@%F)YZ_+BM
M.?PC=:CHRV&KZ_=7[)>0W:3/!%&R^6RL$P@ P2O7KS4NL>$WO=9&M:5JUSI&
MIF(02RPHDB3Q@Y =&&"1DX/!&: +&EZ'H^CZ_J,VG,L%S>I')<6<;J$XR!((
MQT)Z$]\>M<W\3M8L(O[%T"^N%AMM2NQ)>,06'V:(AV! !/S-L7\370^'O"Z:
M)=7FH7-]<:EJM[M%Q>7 4$JOW455 "*,G@=SS5B'0(H_%ESXADG>2XEM4M(H
MR!MAC#%FQ_O,03]!0!YIIGBHVGPI\66&D79EGT%98K29<AOLSY,3\\Y521_P
M"NWA\$>&&\&)I#V%K]B:V&^?8H<G;DR[SSN_BW>M7;OPK9W?B636)'8_:+!K
M"ZMB 8[B,G(W>XR1]#BL0_#Z\_L[^Q1XMU3^P=OE_8]D?F>5_P \_.V[MN./
M7'&: *BV=GK'Q-L-.O)!J&G:;H:75F)V$JRR-(4,Q[,P50,_[1/>MG5=*TK0
MKV^U_3ECMM7.FS!;>)E1;D(-P)3^(J<#/8-BIM5\&VMY_9TVF7<VD7VFQ>3:
M7%J%.V+ 'ELK ADX'![CBC1_"1LM8DUK5=5N-7U0PFWCEFC2-(8R<E411@9.
M,GDG% &=X%\-Z+/X"TV:XL;:]FU*U2YO9YXUD:XDD4,Y8GD\DCVKC8'>+1]+
MTT2/)::5XZ2RM&=MQ$*DE5R>NTL5_"NUC\"WFG))9Z%XHU#2]*D9F%FD44GD
M[CDB)V4E!SP.<=JNS>!=(?PE%X=A\^WMX76:&XCD_?),&WB7<>K[N<GUH H_
M$3[OA4?]3'9_S:N.MC=^'O%GBKQC:>;+:V^L-;:K;+D[K;RHB)5']Z,L3[J6
MKM[7P9>2ZM8W^O>([O6/L#^;:P/!'#&DF" [!!\S $XSTS6OI7A^WTJ?6)!(
MTPU2[:ZE211A245"H]1A>_K0!S/@Z'3]8U;Q@\L5M>VLFK)+&702(P-O%AAG
MCH>OO3/AUI&F;O$<W]G6GFP^(;Q8G\A=T8## 4XXQVQ6YX/\%V'@N#4+?3I9
M6M[NZ-P(Y.?*!  13Z  8S5[0=!BT%=1$4SR_;K^:^;> -K2$$J/88H \FU&
MQAU3PCJ>GW.[R+KQV\,FTX.UK@ X/T-7]5U:\31K;POK<I?6-*UG3P)FX^UV
MYG41S#W[-Z,/>NT_X02T^R26_P!LFVOKG]M$[1_K/,\S9_NY&/6IO%/@C3O%
M5]I-]</)!=Z9<I/%+%C+JK!C&WJI*@^V* ,;0K2UUGQSXLU35+9+NZTZX2SM
M(I$#^1"(E?* ]"Y8G/>G^%;W1&\;ZA%8Z+JVC7]W9+<36US D,,BH^WS JD_
M/EL$]P*UM6\(&ZUE]:TC5[K1]3EC6.>6!$DCG5?N^9&X()'0'@@4[0O"?]EZ
MO-K-_JUYJNK2P_9S<3[45(MV[:D: *HR >YH Y[XA>9_PFO@SRM(35GW7N+-
MW10_[I>[_+QUY]*DUB.3_A7/BR2?PM#H4O\ 9DZ@(\+F4>6W>/T]ZZO4-!BU
M#Q#H^L/,Z2:7YVR, 8?S$VG/TQ5C6M,CUO0M0TJ61HX[VWDMV=1RH=2I(_.@
M#S&X>6/QEX8,6@G6F_X1G_CV#1+M&^/YOWA XZ>O-6?"P&M^,-6URVTF#0X[
M&QDT^ZL0RB>24L&#2*HP  /E/.<\'%=K:>%X+37=/U5;B1I++33IRH0,,NY3
MN/O\@_.DN/"UO)XJ'B"WN)+:XDM6M;J- "ERG\);_:4]#Z<=* /-/AGJR>#?
M"=TD^3;2Z1'K5LG]YMOERH/<NL9Q_P!-*W_A5I<VCZKXKL[EB]T+BUDN6/\
M%,]NCR'_ +[9JV&^&^FR:;X:LI+J=ET(J$;@>>@*ML<?W2R(<?[-;VFZ%%IN
MM:SJ:3.\FJ2Q22(P&$*1B, ?@N: -6BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM%G&^:0(N?J:?!<074"SV\T<T+#*R1L&4_0B@"2BBB@ HHHH **** "BBB@
MHHHH **** "BFR2)%&TDCJB*"S,QP !U)-4EUS2'=435+%F8X %PA)/YT 7Z
M*** "BBB@ HJ*XN8+2!I[F>.&%?O22.%4?4FFVE[:W\ GL[F&XB)QYD,@=<_
M44 3T4UY$BC:21U1%&69C@ >YIEO<P7<(FMIHYHCT>-@RG\10!+13)IHK>,R
M32)'&" 6=@ ,G Y/N:JS:QIEM,T,^HVD4J_>1YU4CZ@F@"[15>._LYEC:*[@
M=9 Q0K("'"_>(]<=_2IHY8YHEEB=9(W&5=3D$>H- #J**C2>&2:2%)4:6/&]
M P++GID=LT 244Q9HGE>))$:2/&] P)7/3([9I] !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5IXQ\6MX3L?%MR^E?8'NHX);%+=][1M/Y.\2;\!LG.-I&.]=1\2O^2:>(_\
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M_;.A&6RG*C1HHGGE:(-CYY5?".1S@K@=#7;:5X<N;/7CK-]J?VR\?3X[*0K
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M$>-RAV,BG<,JW)QQBLFR^(&M#0-3U.^TNQF$=['I^G?8IW*7D[/L.&=1A Q
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MA(/0MN'';(S7/:=X>U36=-U&W\.?9;?PR^KB>VM+Y)$CGA5%+*H R(FE!..
M0/0G-C1;+6;B?Q_#KVGVMY9S-^_MK$.))W^SQX$6[C&T8]=U '2VGB/7['4M
M)@\1V%A!#JSF*!K25F:"787$<FX8;(4C<O<=.<UG#QWK+:+/XJ73+/\ X1J*
M5AM,K?:FA5]C2@8V]03MZX'6L#3K=-?\0^%HK'7M5UE--N/M4INH1&ME&L;
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M;2"";'E22SJJR9Y&TDX/X5//=VUK:M=7%Q%#;J-S2R.%0#U)/%<3IVEZ??\
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MD?)&O4D\#).<XI-4\*77_"KK?2=0U:Z'V#3&%TMN^T7++'PK-C=L!'08R.M
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M-@=B!Z5%::;?ZOIWC/6/#^G?9+;6+);;3;<@0FX8(RFX*G 7=O&,X)"@GJ*
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M,\D95D?9V.TC.">,@$4 6_#OA^#P[82V\<\US/<3O<W-S-C?-*WWF.  .@
M&  *Q=7\$WNH^+#XAM/$ES97"P""%!:Q2K"O\6W>#@D]2.3TZ5-I7C_1KOPE
MINN7UW%:_;$4>5\S'S=H9D48RV,]A4.M_$71M/\ "XUNPN8;V(W<=J "PVN7
M4,&&,@JI+8('3WH O7_A>?6/"3Z%JNL3W;2NC2W1A1&=5D#[=J@+CC;]*O\
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M*VEO-5MXTNHS+;D-N\Y1MY3&=WWEZ>M9&N?$/1].\*QZ[8W,-[!)=1VR[20
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M=V1+@9(7'4^W7/'6I+;Q3H=WI%QJL6IV_P!BMB5GE=MGE$=0X;!4\C@C/(H
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MCNE'EQX(&.><XQ[U'>)>:'XVUR[OM9U72H-0BMGMI;73DN5G5(@IC),;E6#
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MU/VL%F(QD<9)/I7K=% 'E-W>IX=TCQOI6JZ7?3W-_<7=U T=H\D=S%(GR_O
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M)&H+-(S<[26P N#@9JW=_#^"X:^MXM8U"VTC4)FGN]-BV>7(S'+@,5WHK'J
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM<Z3?P7D2-L=HFSM;T(Z@_6N$6[U^T^*'B]M#TFTU _9[$RK/>& C"/@+\C
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %9>MZ=J6HPQ)INMS:4Z,2[Q
M01REQZ$."!^%:E% 'GO@%O$>K:?'K.J>*YYH8[FXBDM39P(CK'(Z E@H(^Z#
MP:V+3X@:1>7%J%@U".SNY1#:ZA+;%;>=R<*%;KR>A( /8U5\(Z!>P^ +S1[Z
M-K2XN);U><$JLDLA5N/9@:Y'2_"MZ;#1]$N] UU[JUEA6YDN-7D-@JQD'S$
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %4=2TFSU=;5;V(R"UN8[J
M+#%=LB'*GCK@]NE7J* ,A/#&D1ZKJ>IK: 7FIQ+#=2!CET5=H'7CCTZX'I5&
M7P+HCBP\E;RT>QM5LX9;2\EA?R!TC9E8%AWY[UTM% '/6?@G0-/A@AM;(QQ0
M7W]H1J)7(6?;LW<GT)XZ9YZU+K'A/2];O4O9_M4%XL?D_:+.ZD@=H\YV,4(W
M+GG!Z=JW** ,BP\,Z1I=W:7-C9K ]I:&RA",<+$6#$8SR<J#D\^_-6M.TFST
MK[7]CB*?:[E[J;+$[I'QN//3H.*NT4 <YJ?@;0]6OKB[GCNHWN@%NTMKN2%+
MH 8 D56 ;CCGMQ6O<Z5976C2Z0\"K82VYMFAC^0",KMVC'3CCBKE% &-JF@)
M?:;I]C!(T$=G<V\R$,V0L3 [>#SD#;SQSGG%6=;T6Q\1:/<:5J4;R6=P )$2
M1D+ $'&5(/4"M"B@#F]*\#Z1HU_#>6DFI&6'(19M2GE3D$<HSD'@]Q1;^!-!
MM=3CO8K>?]U.;F*V:YD-O%*<Y=8B=H;DG@<$\8KI** .3N/AQX?N-2O-0(U&
M*YO)3+.T&I3QAV]<*X'M[5;O/!>D7B618WL-Q9P^1#=P7DL<_E]U:0-N8=^2
M>>:Z&B@"EI.DV.AZ=%8:=;B"VCR0H))))R22>223DD\FKM%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
;%%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 25, 2025</div></th>
<th class="th"><div>Jun. 28, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Entity Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Elicio Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">11-3430072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">451 D Street, 5th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">209-0050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ELTX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,953,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portions of the registrant&#8217;s definitive proxy statement to be filed for the registrant&#8217;s 2025 Annual Meeting of Stockholders are incorporated by reference into Part III hereof. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001601485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Baker Tilly US, LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Tewksbury, Massachusetts<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">23<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 17,618<span></span>
</td>
<td class="nump">$ 12,894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash, current</a></td>
<td class="nump">1,178<span></span>
</td>
<td class="nump">722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,897<span></span>
</td>
<td class="nump">2,732<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">20,693<span></span>
</td>
<td class="nump">16,348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">483<span></span>
</td>
<td class="nump">717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, right-of-use assets</a></td>
<td class="nump">5,706<span></span>
</td>
<td class="nump">6,563<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash, noncurrent</a></td>
<td class="nump">696<span></span>
</td>
<td class="nump">685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseOtherNoncurrent', window );">Other long-term prepaid assets</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">2,833<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">28,178<span></span>
</td>
<td class="nump">27,146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,038<span></span>
</td>
<td class="nump">4,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">8,415<span></span>
</td>
<td class="nump">3,757<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred research obligation</a></td>
<td class="nump">1,169<span></span>
</td>
<td class="nump">694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current</a></td>
<td class="nump">901<span></span>
</td>
<td class="nump">910<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent', window );">Unvested option exercise liability, current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">11,523<span></span>
</td>
<td class="nump">9,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_WarrantLiability', window );">Warrant liabilities</a></td>
<td class="nump">2,828<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, noncurrent</a></td>
<td class="nump">5,105<span></span>
</td>
<td class="nump">6,007<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible note - related party</a></td>
<td class="nump">20,034<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">39,490<span></span>
</td>
<td class="nump">15,773<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies&#8212;Note 10</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Stockholders' (deficit) equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value; 10,000,000 shares authorized; no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value; 300,000,000 shares authorized; 11,043,837 and 9,618,178 shares issued at December 31, 2024 and 2023, respectively; 11,029,382 and 9,603,723 shares outstanding as of December 31, 2024 and 2023, respectively</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock, at cost, 14,455 shares outstanding</a></td>
<td class="num">(150)<span></span>
</td>
<td class="num">(150)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">183,004<span></span>
</td>
<td class="nump">153,827<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(175)<span></span>
</td>
<td class="num">(197)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(194,101)<span></span>
</td>
<td class="num">(142,203)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' (deficit) equity</a></td>
<td class="num">(11,312)<span></span>
</td>
<td class="nump">11,373<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock, and stockholders&#8217; (deficit) equity</a></td>
<td class="nump">$ 28,178<span></span>
</td>
<td class="nump">$ 27,146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, shares outstanding (in shares)</a></td>
<td class="nump">14,455<span></span>
</td>
<td class="nump">14,455<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_WarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_WarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable within one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseOtherNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts paid in advance which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseOtherNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">11,043,837<span></span>
</td>
<td class="nump">9,618,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">11,029,382<span></span>
</td>
<td class="nump">9,603,723<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, shares outstanding (in shares)</a></td>
<td class="nump">14,455<span></span>
</td>
<td class="nump">14,455<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 33,656,000<span></span>
</td>
<td class="nump">$ 23,849,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">11,330,000<span></span>
</td>
<td class="nump">11,896,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">44,986,000<span></span>
</td>
<td class="nump">35,745,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(44,986,000)<span></span>
</td>
<td class="num">(35,745,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other (expense) income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="num">(3,886,000)<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_GainLossOnIssuanceOfWarrants', window );">Loss on issuance of pre-funded warrants</a></td>
<td class="num">(3,502,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">429,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of promissory notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">605,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain on sale of equipment</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange transaction gain</a></td>
<td class="nump">151,000<span></span>
</td>
<td class="nump">204,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOperatingAndNonoperating', window );">Interest income</a></td>
<td class="nump">777,000<span></span>
</td>
<td class="nump">373,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(455,000)<span></span>
</td>
<td class="num">(1,059,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (expense) income, net</a></td>
<td class="num">(6,912,000)<span></span>
</td>
<td class="nump">550,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(51,898,000)<span></span>
</td>
<td class="num">(35,195,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract', window );"><strong>Other comprehensive gain (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="nump">22,000<span></span>
</td>
<td class="num">(197,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (51,876,000)<span></span>
</td>
<td class="num">$ (35,392,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share, basic (in dollars per share)</a></td>
<td class="num">$ (4.25)<span></span>
</td>
<td class="num">$ (6.96)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share, diluted (in dollars per share)</a></td>
<td class="num">$ (4.25)<span></span>
</td>
<td class="num">$ (6.96)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic (in shares)</a></td>
<td class="nump">12,202,996<span></span>
</td>
<td class="nump">5,056,225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">12,202,996<span></span>
</td>
<td class="nump">5,056,225<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_GainLossOnIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain Loss On Issuance Of Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_GainLossOnIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperatingAndNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income classified as operating and nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperatingAndNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>At-the-Market Offering</div></th>
<th class="th"><div>July Public Offering</div></th>
<th class="th"><div>Conversion of Convertible Preferred Stock</div></th>
<th class="th"><div>Conversion of Convertible Debt</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>Reverse Recapitalization</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>July Public Offering</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Conversion of Convertible Preferred Stock</div>
</th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>July Public Offering</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Conversion of Convertible Preferred Stock</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Conversion of Convertible Debt</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total Convertible Preferred Stock</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance at beginning of period (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,997,920<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_TemporaryEquitySharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,997,920)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_TemporaryEquityValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (111,060)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance at end of period (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at beginning of period (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Dec. 31, 2022</a></td>
<td class="num">$ (102,145)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (107,008)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,310<span></span>
</td>
<td class="nump">41,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted common stock</a></td>
<td class="nump">67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,997,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111,060<span></span>
</td>
<td class="nump">$ 10,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111,010<span></span>
</td>
<td class="nump">$ 10,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_StockIssuedDuringPeriodSharesReverseRecapitalization', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,012,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_StockIssuedDuringPeriodValueReverseRecapitalization', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">19,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Return of common stock to pay withholding taxes on restricted stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,455)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Return of common stock to pay withholding taxes on restricted stock</a></td>
<td class="num">(150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock related to stock purchase agreement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,213,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock related to stock purchase agreement</a></td>
<td class="nump">6,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_StockIssuedDuringPeriodSharesServiceAgreement', window );">Issuance of common stock related to service agreement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_StockIssuedDuringPeriodValueServiceAgreement', window );">Issuance of common stock related to service agreement</a></td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(197)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(197)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (35,195)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,195)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (in shares) at Dec. 31, 2023</a></td>
<td class="nump">9,603,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,618,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2023</a></td>
<td class="nump">$ 11,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (150)<span></span>
</td>
<td class="nump">153,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(197)<span></span>
</td>
<td class="num">(142,203)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="num">(14,455)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,455)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance at end of period (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">703,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">510,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,635<span></span>
</td>
<td class="nump">$ 1,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,628<span></span>
</td>
<td class="nump">$ 1,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">9,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted common stock</a></td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants', window );">Issuance of common stock from the exercise of Pre-funded Warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Issuance of common stock from the exercise of Pre-funded Warrants</a></td>
<td class="nump">1,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_ReclassLiabilityClassifiedWarrantsToEquityClassifiedWarrants', window );">Reclassification of liability-classified warrants to equity classified warrants</a></td>
<td class="nump">19,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (51,898)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51,898)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (in shares) at Dec. 31, 2024</a></td>
<td class="nump">11,029,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,043,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2024</a></td>
<td class="num">$ (11,312)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (150)<span></span>
</td>
<td class="nump">$ 183,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (175)<span></span>
</td>
<td class="num">$ (194,101)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, ending balance (in shares) at Dec. 31, 2024</a></td>
<td class="num">(14,455)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,455)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ReclassLiabilityClassifiedWarrantsToEquityClassifiedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclass Liability-Classified Warrants to Equity Classified Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ReclassLiabilityClassifiedWarrantsToEquityClassifiedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock and Warrants Issued During Period, Share, Preferred Stock and Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_StockIssuedDuringPeriodSharesReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_StockIssuedDuringPeriodSharesReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_StockIssuedDuringPeriodSharesServiceAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Service Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_StockIssuedDuringPeriodSharesServiceAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_StockIssuedDuringPeriodValueReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_StockIssuedDuringPeriodValueReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_StockIssuedDuringPeriodValueServiceAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Service Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_StockIssuedDuringPeriodValueServiceAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_TemporaryEquitySharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Shares, Conversion Of Convertible Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_TemporaryEquitySharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_TemporaryEquityValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Value, Conversion Of Convertible Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_TemporaryEquityValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of preferred stock and warrants for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 118<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=angn_JulyPublicOfferingMember', window );">July Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=angn_JulyPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=angn_JulyPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (51,898)<span></span>
</td>
<td class="num">$ (35,195)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">321<span></span>
</td>
<td class="nump">382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use assets, operating leases</a></td>
<td class="nump">857<span></span>
</td>
<td class="nump">788<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_InterestExpenseNoncash', window );">Non-cash interest expense</a></td>
<td class="nump">232<span></span>
</td>
<td class="nump">1,061<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_CostsExpensedUponTheIssuanceOfWarrants', window );">Costs expensed upon the issuance of warrants</a></td>
<td class="nump">549<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of embedded derivative</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(429)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">3,886<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_GainLossOnIssuanceOfWarrants', window );">Loss on issuance of warrants</a></td>
<td class="nump">3,502<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">1,452<span></span>
</td>
<td class="nump">1,179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_ProfessionalServicesExpenseNoncash', window );">Non-cash professional services expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of promissory notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(605)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">(Gain) loss on disposal of property and equipment</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">835<span></span>
</td>
<td class="num">(729)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other long-term prepaid assets</a></td>
<td class="nump">2,233<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(3,331)<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses</a></td>
<td class="nump">4,658<span></span>
</td>
<td class="nump">2,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred research obligation</a></td>
<td class="nump">475<span></span>
</td>
<td class="num">(742)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="num">(911)<span></span>
</td>
<td class="num">(825)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(37,068)<span></span>
</td>
<td class="num">(32,694)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(87)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(84)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness', window );">Cash acquired in connection with the reverse merger</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">24,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities', window );">Merger transaction costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,364)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of promissory notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of common stock warrants from March PIPE</a></td>
<td class="nump">5,985<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_ProceedsFromIssuanceOfCommonStockWarrantsFromJulyPublicOffering', window );">Proceeds from issuance of common stock warrants from July Public Offering</a></td>
<td class="nump">11,484<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">4,555<span></span>
</td>
<td class="nump">6,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_ProceedsFromIssuanceOfCommonStockFromJulyPublicOffering', window );">Proceeds from issuance of common stock from July Public Offering</a></td>
<td class="nump">1,080<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_PaymentOfWarrantIssuanceCosts', window );">Payment of warrant issuance costs</a></td>
<td class="num">(549)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt', window );">Proceeds from issuance of senior note, net of issuance costs</a></td>
<td class="nump">19,727<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfEquity', window );">Payment of employee withholding taxes on restricted stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(150)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">42,321<span></span>
</td>
<td class="nump">38,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of foreign currency on cash</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">5,191<span></span>
</td>
<td class="nump">5,887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the beginning of the year</a></td>
<td class="nump">14,301<span></span>
</td>
<td class="nump">8,414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the end of the year</a></td>
<td class="nump">19,492<span></span>
</td>
<td class="nump">14,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Components of cash, cash equivalents and restricted cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">17,618<span></span>
</td>
<td class="nump">12,894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">1,874<span></span>
</td>
<td class="nump">1,407<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">19,492<span></span>
</td>
<td class="nump">14,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_FairValueOfPreFundedWarrants', window );">Fair value of pre-funded warrants at issuance date</a></td>
<td class="nump">13,382<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_FairValueOfCommonStockWarrants', window );">Fair value of common warrants at issuance date</a></td>
<td class="num">(6,509)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_AccretionOfPromissoryNoteDiscountFromEmbeddedDerivative', window );">Accretion of promissory note discount from embedded derivative</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_AccretionOfPromissoryNoteToFaceValue', window );">Accretion of promissory note to face value</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_SettlementOfPromissoryNotesPayable', window );">Settlement of promissory notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">897<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_VestingOfRestrictedCommonStockNoncash', window );">Non-cash vesting of restricted common stock</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Non-cash issuance of common stock from conversion of preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">111,060<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Angion Stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Non-cash issuance of stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,526<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Service Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Non-cash issuance of stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_AccretionOfPromissoryNoteDiscountFromEmbeddedDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accretion Of Promissory Note Discount From Embedded Derivative</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_AccretionOfPromissoryNoteDiscountFromEmbeddedDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_AccretionOfPromissoryNoteToFaceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accretion Of Promissory Note To Face Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_AccretionOfPromissoryNoteToFaceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_CostsExpensedUponTheIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs Expensed Upon The Issuance Of Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_CostsExpensedUponTheIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_FairValueOfCommonStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Of Common Stock Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_FairValueOfCommonStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_FairValueOfPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Of Pre Funded Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_FairValueOfPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_GainLossOnIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain Loss On Issuance Of Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_GainLossOnIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Accrued Expenses and Other Current Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_InterestExpenseNoncash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Expense, Noncash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_InterestExpenseNoncash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_PaymentOfWarrantIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment Of Warrant Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_PaymentOfWarrantIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ProceedsFromIssuanceOfCommonStockFromJulyPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance of Common Stock From July Public Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ProceedsFromIssuanceOfCommonStockFromJulyPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ProceedsFromIssuanceOfCommonStockWarrantsFromJulyPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance of Common Stock Warrants From July Public Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ProceedsFromIssuanceOfCommonStockWarrantsFromJulyPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ProfessionalServicesExpenseNoncash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Professional Services Expense, Noncash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ProfessionalServicesExpenseNoncash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_SettlementOfPromissoryNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settlement Of Promissory Notes Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_SettlementOfPromissoryNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_VestingOfRestrictedCommonStockNoncash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting Of Restricted Common Stock, Noncash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_VestingOfRestrictedCommonStockNoncash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of a business when the cash held by the acquired business exceeds the cash payments to acquire the business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 15<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/815-15/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for financing costs associated with business combinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_StockIssuanceAxis=angn_AngionStockholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_StockIssuanceAxis=angn_AngionStockholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_StockIssuanceAxis=angn_ServiceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_StockIssuanceAxis=angn_ServiceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of the Business and Financial Condition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of the Business and Financial Condition</a></td>
<td class="text">Description of the Business and Financial Condition<div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Elicio Therapeutics, Inc. (&#8220;Elicio&#8221; or the &#8220;Company&#8221;) was incorporated in Delaware as Vedantra Pharmaceuticals Inc., in August 2011. Elicio is a clinical-stage biotechnology company pioneering the development of immunotherapies for patients with limited treatment options and poor outcomes suffering from cancer. In December 2018, Elicio formed a wholly-owned subsidiary, Elicio Securities Corporation (&#8220;ESC&#8221;), a Massachusetts corporation. ESC is an investment company. Elicio, ESC, Former Elicio (as defined below) and Elicio Pty (as defined below) are collectively referred to as &#8220;Elicio&#8221; throughout these consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Reverse Merger Transaction</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On January 17, 2023, the Company entered into a definitive merger agreement (the &#8220;Merger Agreement&#8221;) with Angion Biomedica Corp. (&#8220;Angion&#8221;), a clinical-stage biotechnology company, Arkham Merger Sub, Inc., a wholly owned subsidiary of Angion (&#8220;Merger Sub&#8221;), and Elicio Operating Company, Inc. (&#8220;Former Elicio&#8221;), pursuant to which Merger Sub merged with and into Former Elicio, with Former Elicio surviving the merger as a wholly owned subsidiary of Angion (the &#8220;Merger&#8221;). Following the Merger, Former Elicio and Elicio Australia Pty Ltd. (&#8220;Elicio Pty&#8221;), an Australian subsidiary established in August 2019 for the purpose of qualifying for research credits for studies conducted in Australia, became wholly owned subsidiaries of Elicio.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 1, 2023, the Company completed the Merger in accordance with the terms and conditions of the Merger Agreement and Angion changed its name from &#8220;Angion Biomedica Corp.&#8221; to &#8220;Elicio Therapeutics, Inc.&#8221; Immediately following the consummation of the Merger, there were approximately 9.7&#160;million shares of the Company&#8217;s common stock outstanding on a fully-diluted basis, with Former Elicio equity holders collectively owning approximately 65.2% of the Company and Angion equity holders collectively owning approximately 34.8% of the Company, in each case on a fully diluted basis.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Merger was accounted for as a reverse recapitalization, with Former Elicio being treated as the acquirer for accounting purposes. See discussions of the transactions in connection with the Merger at Note 3 - Merger and Related Transactions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Liquidity and Going Concern</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has experienced net losses and negative cash flows from operating activities since inception. As of December&#160;31, 2024, the Company had an accumulated deficit of $194.1&#160;million. The Company expects that its operating losses and negative operating cash flows will continue for the foreseeable future as the Company continues to develop its product candidates. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December&#160;31, 2024, the Company had $17.6&#160;million in cash and cash equivalents. The Company&#8217;s losses from operations, negative operating cash flows and accumulated deficit, as well as the additional capital needed to fund operations for at least twelve months following the issuance of the consolidated financial statements, raise substantial doubt about the Company&#8217;s ability to continue as a going concern. The Company expects to incur substantial expenditures in the foreseeable future for the development of its product candidates and will require additional financing to continue this development. The Company plans to address this condition through the sale of Company common stock or other securities in public offerings and/or private placements, debt financings, or through other capital sources, including licensing arrangements, partnerships and collaborations with other companies or other strategic transactions, but there is no assurance these plans will be completed successfully or at all.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If the Company is unable to obtain additional capital when and as needed to continue as a going concern, it might have to further reduce or scale back its operations and/or liquidate its assets, and the values it receives for its assets in liquidation or dissolution could be significantly lower than the values reflected in its financial statements. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The accompanying consolidated financial statements have been prepared on a basis that assumes that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company's consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">guidance is meant to refer to the authoritative accounting principles generally accepted in the United States as found in the Accounting Standard Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Elicio Pty, ESC, and Former Elicio. All significant intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Since Former Elicio was determined to be the accounting acquirer in connection with the Merger, for periods prior to the Merger, the consolidated financial statements were prepared on a stand-alone basis for Former Elicio and did not include the combined entities activity or financial position. Subsequent to the Merger, the consolidated financial statements include the acquired business and assets and liabilities at their acquisition date fair value. Historical share and per share figures of Former Elicio have been retroactively restated to reflect the impact of the reverse stock split of Angion&#8217;s common stock, par value $0.01 per share (&#8220;Angion common stock&#8221;), at a ratio of 10:1 (the &#8220;Reverse Stock Split&#8221;) completed in connection with and prior to the closing of the Merger, based on the exchange ratio of 0.0181 (the &#8220;Exchange Ratio&#8221;).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Financial Statement Reclassification</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Certain account balances from prior periods have been reclassified in these consolidated financial statements to conform to current period classifications. The warrant liability was reclassified from current to noncurrent liabilities. These reclassifications had no effect on the reported results of operations or financial position.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Segments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the Chief Operating Decision Maker (&#8220;CODM&#8221;), or decision-making group, in deciding how to allocate resources and in assessing performance. The Chief Executive Officer serves as the CODM. The Company operates as a single operating and reportable segment, reflecting the integrated nature of the Company&#8217;s business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could materially differ from those estimates. Significant estimates reflected in these consolidated financial statements include but are not limited to, the accrual of research and development expenses, the valuation of stock-based awards, the valuation of warrants, the valuation of embedded derivatives and convertible debt, the operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liability, and forecasts utilized in management&#8217;s going concern assessment. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Foreign Currency Translation and Transactions</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Australian Dollar (&#8220;AUD&#8221;) is the functional currency for Elicio Pty. Accordingly, nonmonetary assets and liabilities originally acquired or assumed in other currencies are recorded in AUD at the date they were acquired or assumed. As part of the consolidation process, the Elicio Pty results are translated from AUD into the reporting currency of US Dollars using average rates for profit and loss transactions and applicable spot rates for period-end balances. The effect of translating our functional currency into our reporting currency is reported separately in Accumulated Other Comprehensive Loss.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Concentrations of Credit Risk and Off-Balance Sheet Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash, cash equivalents, and restricted cash. At times, cash balances deposited at major financial banking institutions exceed the federally insured limit. The Company regularly monitors the financial condition of the institutions in which it has depository accounts and believes the risk of loss is minimal. The Company has not experienced any losses in such accounts. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Cash and Cash Equivalents</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash and cash equivalents are comprised of deposits at major financial banking institutions and highly liquid investments with an original maturity of three months or less at the date of purchase. As of December&#160;31, 2024 and 2023, the Company&#8217;s cash equivalents were held in institutions in the United States and include deposits in a money market fund which were unrestricted as to withdrawal or use.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Restricted Cash</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Restricted cash consists of cash securing a collateral letter of credit issued in connection with the Company&#8217;s research grant and facility operating lease. See Notes 6 and 11 for further discussion. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Fair Value Measurement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company follows the guidance prescribed by ASC Topic 820, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Fair Value Measurements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, which establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The standard provides a consistent definition of fair value that focuses on an exit price which is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The standard establishes a three-level hierarchy for fair value measurements based on the nature of inputs used in the valuation of an asset or liability as of the measurement date.</span></div><div style="margin-top:6pt;padding-left:76.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Level 1:&#160;&#160;&#160;&#160;Observable inputs such as unadjusted quoted prices in active markets for identical assets or liabilities at measurement. </span></div><div style="margin-top:6pt;padding-left:76.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Level 2:&#160;&#160;&#160;&#160;Inputs (other than quoted prices included in Level 1) that are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. </span></div><div style="margin-top:6pt;padding-left:76.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Level 3:&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The carrying amounts of financial instruments reflected in the consolidated balance sheets for cash and cash equivalents, current and non-current restricted cash, accounts payable, and accrued expenses approximate their respective fair values because of the short-term maturity of those financial assets and liabilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Property and Equipment</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of the asset. Upon sale or retirement, the cost and accumulated depreciation are eliminated from their respective accounts, and the resulting gain or loss is recorded in the consolidated statement of operations and comprehensive loss. Repair and maintenance expenditures are expensed as incurred. Construction in process is not depreciated until the asset is placed into service.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:67.668%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Estimated Useful Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furniture and fixtures</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Leasehold improvements</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Shorter of useful life or lease term</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Impairment of Long-Lived Assets</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company evaluates its long-lived assets, which consist primarily of property and equipment, and right-of-use asset, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. During the years ended December&#160;31, 2024 and 2023, no impairments have occurred.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Debt Issuance Costs</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These deferred costs will be amortized and recognized as additional interest expense over the term of the Company&#8217;s convertible note using the effective interest method. The Company will present debt issuance costs as a direct deduction from the convertible note liability on its financial statements. See Note 12 for further discussion of the Company&#8217;s accounting for its outstanding debt and related issuance costs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Income Taxes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company accounts for income taxes in accordance with ASC Topic 740, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Income Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and liabilities using enacted tax rates and laws in effect in the years in which the differences are expected to reverse. A valuation allowance is provided if, based upon the weighted available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is required to recognize the financial statement effects of a tax position when it is more likely than not, based on the technical merits, the position will be sustained upon examination. As of December&#160;31, 2024, there were no accruals for interest or penalties related to uncertain tax provisions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Research and Development</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Research and development costs are charged to expense as incurred and consist of expenses incurred in performing research and development activities, including salaries and benefits, materials and supplies, preclinical expenses, stock-based compensation expense, depreciation of equipment, contract services, and other outside expenses. The Company accrues for costs incurred by external service providers, based on estimates of services performed and costs. The Company expenses all research and development costs in the periods in which they are incurred. Costs for certain research and development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and service providers. Based on the timing of payments to service providers, the Company may also record prepaid expenses for those service providers that will be recognized as expenses in future periods as the related services are rendered. Research and development costs may be offset by research grants and research and development refundable tax rebates received by Elicio Pty.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Leases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ASC Topic 842, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Leases,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (&#8220;ASC 842&#8221;) requires a lessee to recognize a ROU asset and corresponding lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the consolidated statements of operations and comprehensive loss as well as the reduction of the ROU asset. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances, the existence of an identified asset(s), if any, and the Company&#8217;s control over the use of the identified asset(s), if applicable. Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of future lease payments over the expected lease term. When the interest rate implicit in lease contracts is not readily determinable, the Company will utilize its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has elected to combine lease and non-lease components as a single component. Operating leases are recognized on the consolidated balance sheet as ROU lease assets, current lease liabilities and non-current lease liabilities. Fixed rents are included in the calculation of the lease balances, while variable costs paid for certain operating and pass-through costs are excluded. Lease expense is recognized over the expected term on a straight-line basis.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Research Grant </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company analogizes to the guidance provided by International Accounting Standards 20, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Accounting for Government Grants and Disclosure of Government Assistance </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(&#8220;IAS 20&#8221;) for funds received from grants from entities that are not customers nor government agencies. The Company recognizes the amount of grant income based on the activity in allowable expenses covered under the grant and has elected to recognize the funds earned as an offset to the related research expenses recorded in operations. Advances from the grant that have yet to be recognized are recorded as restricted cash if the grant requires the funds to be isolated from general cash and cash equivalents. The Company records a liability for any research activity that is required under the grant but has not yet been performed. The liability is recorded as a deferred research obligation on the consolidated balance sheets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Stock-Based Compensation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company issues stock-based awards to employees and non-employees, generally in the form of stock options. The Company accounts for stock-based awards in accordance with ASC 718,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> Compensation&#8212;Stock Compensation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, which requires all stock-based payments to be recognized in the consolidated statements of operations and comprehensive loss based on their fair values. The expense is recognized on a straight-line basis over the requisite service period, which is generally the vesting period. The Company has elected to account for option forfeitures as they occur. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company uses the Black-Scholes option-pricing model (&#8220;Black-Scholes&#8221;) to determine the fair value of options granted, which uses as inputs the fair value of the Company common stock, assumptions the Company </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">makes for the volatility of its Company common stock, the expected term of its stock options, the risk-free interest rate for a period that approximates the expected term of its stock options and its expected dividend yield. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Compensation cost of awards that contain a performance condition are recognized when success is considered probable during the performance period. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Prior to the Merger, there was no public market for Former Elicio&#8217;s common stock. The estimated fair value of the Company&#8217;s common stock underlying Former Elicio&#8217;s stock-based awards was determined by Former Elicio&#8217;s board of directors as of the grant date of each option grant. To determine the fair value of Former Elicio&#8217;s common stock underlying option grants, Former Elicio&#8217;s board of directors considered, among other things, input from management and valuations of Former Elicio's common stock prepared by third-party valuation firms performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants' Accounting and Valuation Guide, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Valuation of Privately-Held-Company Equity Securities Issued as Compensation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Following the Merger, the fair value of the Company&#8217;s common stock is based on the closing stock price on the date of grant as reported on the Nasdaq Capital Market.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Warrants and Derivatives</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s common stock warrants are evaluated pursuant to ASC 480, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (&#8220;ASC 480&#8221;), and ASC 815, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (&#8220;ASC 815&#8221;). The Company classifies its freestanding warrants as (i) liabilities, if the warrant terms allow settlement of the warrant exercise in cash, or (ii) equity, if the warrant terms only allow settlement in shares of common stock. Please refer to Note 9 below for the application to the Company&#8217;s pre-funded and common warrants.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Net Loss Per Share</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Basic net loss per share of Company common stock is computed by dividing net loss attributable to Company common stockholders by the weighted average number of shares of Company common stock and pre-funded warrants outstanding for the period. Pre-funded warrants are considered outstanding for the purposes of computing basic and diluted net loss per share because shares may be issued for little or no additional consideration and are fully vested and exercisable after the original issuance date of the pre-funded warrants. Diluted net loss per share excludes the potential impact of Company common stock options, warrants and unvested shares of restricted stock because their effect would be anti-dilutive due to the Company's net loss. Since the Company had net losses for the years ended December&#160;31, 2024 and 2023, basic and diluted net loss per common share are the same.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Other Comprehensive Gain (Loss)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other comprehensive gain (loss) is defined as a change in equity during a period from foreign exchange transactions and other events and circumstances from non-owner sources. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Recently Adopted Accounting Standards During the Period</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2023, the FASB finalized ASU No. 2023-07, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (&#8220;ASU 2023-07&#8221;). ASU 2023-07 requires enhanced disclosures about reportable segments and the CODM. The new guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company adopted ASU 2023-07 on January 1, 2024. There was no impact on the Company's reportable segments identified and additional required disclosures have been included in Note 17.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Recently Issued Accounting Standards Not Yet Adopted</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Except as noted below, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its consolidated financial statements and disclosures. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This ASU requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as additional information on income taxes paid. The standard requires entities to disclose federal, state, and foreign income taxes in their rate reconciliation tables and elaborate on reconciling items that exceed a quantitative threshold. Additionally, it requires an annual disclosure of income taxes paid, net of refunds, categorized by jurisdiction based on a quantitative threshold. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is permitted. This ASU will result in the required additional disclosures being included in the Company&#8217;s consolidated financial statements, once adopted. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2024, the FASB issued ASU No. 2024-03, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This ASU requires enhanced disclosures of disaggregated income statement expenses. Disclosure within the notes of the financial statements for each annual and interim period should include: employee compensation, depreciation, and intangible asset amortization, included in each relevant expense caption; certain amount that are already required to be disclosed under current GAAP in the same disclosure as the other disaggregation requirement; a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively; and the total amount of selling expenses and, in annual reporting periods, an entity&#8217;s definition of selling expenses. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning December 15, 2027. Early adoption is permitted. The Company is currently evaluating the effect that adoption of ASU 2024-03 will have on its consolidated financial statements. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2024, the FASB issued ASU No. 2024-04, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. This new guidance clarifies the accounting treatment of whether the settlement of convertible debt should be accounted for as an induced conversion or extinguishment of convertible debt. This guidance is effective for annual reporting periods beginning after December 15, 2025. The Company is evaluating the potential impact of this adoption on the consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger and Related Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_ReverseRecapitalizationAbstract', window );"><strong>Reverse Recapitalization [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_ReverseRecapitalizationDisclosureTextBlock', window );">Merger and Related Transactions</a></td>
<td class="text">Merger and Related Transactions<div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As described in Note 1, Former Elicio merged with a wholly owned subsidiary of Angion on June 1, 2023. The Merger was accounted for as a reverse recapitalization under U.S. GAAP. Former Elicio was considered the accounting acquirer for financial reporting purposes. This determination was based on the facts that, immediately following the Merger: (i) Former Elicio stockholders owned a substantial majority of the voting rights; (ii) Former Elicio designated a majority (six of nine) of the initial members of the board of directors of the combined company; (iii) Former Elicio&#8217;s executive management team became the management team of the combined company; and (iv) the Company was named Elicio Therapeutics, Inc. and is headquartered in Boston, Massachusetts. Accordingly, for accounting purposes, the Merger was treated as the equivalent of Former Elicio issuing stock to acquire the net assets of Angion. As a result of the Merger, the net assets of Angion were recorded at their acquisition-date fair value, which approximated book value due to the short-term nature of the instruments, in the financial statements of Former Elicio and the reported operating results prior to the Merger are those of Former Elicio. Historical common share amounts of Former Elicio have been retroactively restated based on the Exchange Ratio. It was concluded that any in-process research and development assets that remained as of the Merger would be </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">de minimis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> when compared to the cash and investments obtained through the Merger.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Prior to the effective time of the Merger, on June 1, 2023, in connection with the transactions contemplated by the Merger Agreement, the Company effected the Reverse Stock Split. At the effective time of the Merger, each outstanding share of Former Elicio capital stock (after giving effect to the automatic conversion of all shares of Former Elicio preferred stock into shares of Former Elicio common stock and excluding any shares held as treasury stock by Former Elicio or held or owned by Angion or any subsidiary of Angion or Former Elicio and any dissenting shares) was converted into the right to receive 0.0181 shares of Angion common stock, which resulted in the issuance by Angion of an aggregate of 5,375,751 shares of Angion common stock to the stockholders of Former Elicio (the &#8220;Exchange Shares&#8221;), and a total of 8,387,025 shares of the Company common stock being issued and outstanding immediately following the effective time of the Merger. In addition, Angion assumed the Former Elicio 2022 Equity Incentive Plan and the Former Elicio 2012 Equity Incentive Plan (the &#8220;Former Elicio Plans&#8221;) and each outstanding and unexercised option to purchase Former Elicio common stock and each outstanding and unexercised warrant to purchase Former Elicio capital stock were adjusted with such stock options and warrants henceforth representing the right to purchase a number of shares of the Company&#8217;s common stock equal to the Exchange Ratio multiplied by the number of shares of Former Elicio common stock previously represented by such options, and warrants at an exercise price equal to the exercise price of Former Elicio capital stock divided by the Exchange Ratio.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the execution of the Merger Agreement, Angion made a bridge loan to Former Elicio pursuant to a note purchase agreement and promissory notes up to an aggregate principal amount of $12.5&#160;million, issued with a 20% original issue discount, with an initial closing held substantially concurrently with the execution of the Merger Agreement for a principal amount of $6.25&#160;million in exchange for cash of $5.0&#160;million and an additional closing for a principal amount of $6.25&#160;million in exchange for cash of $5.0&#160;million upon delivery by Former Elicio to Angion of Former Elicio&#8217;s audited financial statements for the year ended December 31, 2022 (the &#8220;Bridge Loan&#8221;).</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of the recapitalization, the Company obtained the assets and liabilities listed below (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.315%"><tr><td style="width:1.0%"></td><td style="width:22.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.529%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,001&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Promissory notes</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,027&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,438)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,130&#160;</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Per the terms of the Merger Agreement, upon completion of the Merger, all obligations owed by Former Elicio related to the Bridge Loan were automatically forgiven and the amount advanced by Angion, along with any accrued and unpaid interest, was credited towards the net cash balance used to calculate the assets and liabilities listed above. Upon settlement of the Bridge Loan, the Company recognized a gain of $0.6&#160;million related to the fair value of the embedded derivatives associated with the Bridge Loan. </span></div>The Company recognized the net assets acquired, excluding the promissory notes and transaction costs of $2.9 million,<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ReverseRecapitalizationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ReverseRecapitalizationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ReverseRecapitalizationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse Recapitalization Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ReverseRecapitalizationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following tables present the Company's financial assets and liabilities measured at fair value on a recurring basis and their assigned levels within the fair value hierarchy (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Level 3</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Money market funds </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total assets</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12,100&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12,100&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Warrant liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,827&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,828&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Level 3</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Money market funds </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total assets</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,973&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,973&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Warrant liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">___________________</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Included in cash, cash equivalents, and restricted cash on the consolidated balance sheets. This balance includes cash requirements settled on a nightly basis.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash equivalents at December&#160;31, 2024 and 2023 were held in U.S. Treasury securities.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There were no transfers made among the three levels in the fair value hierarchy during the periods presented.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of the Merger transaction, Former Elicio assumed Angion&#8217;s warrant liabilities. The fair value of the assumed Angion warrants was classified as Level 3 with key Level 3 inputs of exercise price, term, and volatility. The following table presents a summary of changes in Level 3 in the fair value of the Company&#8217;s common stock warrant liability (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Balance, beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Existing Angion warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Balance, end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with assets and liabilities within the Level 3 category include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long-dated volatilities) inputs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair value of the Angion warrants assumed by the Company has been estimated using a Black-Scholes option pricing model. The underlying equity included in Black-Scholes was valued based on the equity value implied from sales of preferred and common stock at each measurement date, as applicable. The fair value of the warrants was impacted by the model selected as well as assumptions surrounding unobservable inputs including the underlying equity value, expected volatility of the underlying equity, risk free interest rate, and the expected term.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2024, the Company entered into a subscription agreement (the &#8220;March Subscription Agreement&#8221;) with GKCC, LLC (&#8220;GKCC&#8221;), an entity controlled by a member of the Company&#8217;s board of directors, providing for the issuance and sale by the Company to GKCC of pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;) to purchase up to 1,032,702 shares of the Company&#8217;s common stock, at a purchase price per Pre-Funded Warrant of $5.81 (the &#8220;March Offering&#8221;). The Company identified these warrants as liabilities and measured them at fair value on March 19, 2024, and subsequently remeasures the fair value of these warrant liabilities on a quarterly basis. The Company is able to calculate the fair value measurement based on directly observable inputs for the asset from active markets, therefore these warrants are classified as Level 2. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2024, the Company closed an underwritten public offering (the &#8220;Public Offering&#8221;), which resulted in net proceeds of $10.9&#160;million to the Company, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The Public Offering consisted of (i) 500,000 shares of the Company&#8217;s common stock (the &#8220;July Shares&#8221;) and (ii) 1,800,000 pre-funded warrants exercisable for shares of common stock (the &#8220;July Pre-Funded Warrants&#8221;), together with common warrants (the &#8220;July Common Warrants&#8221;) to purchase up to 2,300,000 shares of common stock. Each July Share and accompanying July Common Warrant were sold together at a combined offering price of $5.00 per July Share and accompanying July Common Warrant, and each July Pre-Funded Warrant and accompanying July Common Warrant were sold together at a combined offering price of $4.99 per July Pre-Funded Warrant and accompanying July Common Warrant, which represented the combined purchase price per July Pre-Funded Warrant and accompanying July Common Warrant less the $0.01 per share exercise price for each such July Pre-Funded Warrant. The July Common Warrants have an exercise price of $5.00 per share, are immediately exercisable and will expire five years from the issuance date. The Company identified these warrants as liabilities and measured them at fair value on July 1, 2024, and subsequently remeasures the fair value of these warrant liabilities on a quarterly basis. The Company is able to calculate the fair value measurement based on directly observable inputs for the asset from active markets, therefore these warrants are classified as Level 2.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At the Company&#8217;s Annual Shareholder&#8217;s Meeting in November 2024, the Company obtained stockholder approval for a shareholder, together with its affiliates, to exceed the 19.99% beneficial ownership limitation pursuant to the rules and regulations of the Nasdaq Stock Market LLC (&#8220;Stockholder Approval&#8221;). As such, the Company remeasured the July Common Warrants held by that shareholder at fair value and recognized the loss from change in fair value on the consolidated financial statements during the year ended December 31, 2024. As a result of obtaining Stockholder Approval, the Common Warrants held by that shareholder met the equity classification requirements under ASC 815. During the quarter ended December 31, 2024, the Company reclassified the July Common Warrants held by the stockholder from a liability to equity. The Company will re-assess the liability classification for the remaining July Common Warrants at each period end.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company records the change in the fair value of common stock warrants in change in fair value of warrant liability in the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair value of the assumed Angion common stock warrant liability was estimated using the following assumptions:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted average strike price</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">76.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">76.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contractual term (years)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.7</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Volatility (annual)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">74.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">94.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free rate</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dividend yield (per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text">Balance Sheet Components<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Prepaid and Other Current Assets</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Prepaid and other current assets consisted of the following (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid research and development contract services</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,206&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,883&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Advanced professional fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid insurance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total prepaid and other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,897&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,732&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net was comprised of the following (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,661&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,574&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furniture and fixtures</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Leasehold improvements</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total property and equipment</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,035&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,948&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Less: accumulated depreciation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1,552)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1,231)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">483&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">717&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Depreciation expense for the years ended December&#160;31, 2024 and 2023 was $0.3 million and $0.4 million, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Other long-term prepaid assets</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other long-term prepaid assets consisted of the advance payments for clinical trial services, totaling $0.6 million and $2.8 million as of December&#160;31, 2024 and December&#160;31, 2023, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Accrued Expenses</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Accrued expenses consisted of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued professional fees</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">945&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued research and development</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4,910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">912&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other accrued expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8,415&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,757&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research Grant<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">Research Grant</a></td>
<td class="text">Research Grant<div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2022, Former Elicio entered into a grant agreement with the Gastro-Intestinal (&#8220;GI&#8221;) Research Foundation, a not-for-profit organization focused on supporting research to treat, cure, and prevent digestive diseases. Of the $2.8 million award, $2.3&#160;million was received in September 2022 and the remaining $0.5&#160;million was received in June 2023 with the completion of the development efforts as defined in the grant agreement. The final $0.5&#160;million payment was applied as a credit to the second grant agreement described below. For the years ended December&#160;31, 2024 and 2023, the Company incurred $0 and $1.9 million, respectively, in research and development expenses related to this project. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2023, the Company entered into a second grant agreement with the GI Research Foundation for $3.1 million, with such amount received net of the $0.5&#160;million credit, described above. As of the years ended December&#160;31, 2024 and 2023, the Company incurred $2.2 million and $1.9 million, respectively, in research and development expenses related to this project. As of December&#160;31, 2024, the grant funds available for the second grant agreement were $0 and the deferred research obligation was $0, as the grant agreement was completed in the third quarter of 2024.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2024, the Company entered into a third grant agreement with the GI Research Foundation for $1.5 million. The grant funds available as of December&#160;31, 2024 were $1.2 million, which are reflected in restricted cash in the accompanying consolidated balance sheets. The deferred research obligation as of December&#160;31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> was </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$1.2 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, which was reflected in the deferred research obligation in the accompanying consolidated balance sheets. For the year ended </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December&#160;31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, the Company incurred </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$0.3 million in research and development expenses related to this project, of which</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$0.3 million was applied against the grant funds received. </span></div>The award money for the three agreements was earned and recognized as a contra research and development expense as the expenses were incurred.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock, Common Stock and Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Convertible Preferred Stock, Common Stock and Stockholders' Equity</a></td>
<td class="text">Convertible Preferred Stock, Common Stock and Stockholders' Equity<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Authorized Shares</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company's current Amended and Restated Certificate of Incorporation, as amended, authorizes 300,000,000 shares of common stock, par value $0.01 per share, and 10,000,000 shares of preferred stock, par value $0.01 per share.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Convertible Preferred Stock of Former Elicio</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Former Elicio&#8217;s convertible preferred stock consisted of Series A preferred stock (&#8220;Series A Preferred Shares&#8221;), Series B preferred stock (&#8220;Series B Preferred Shares&#8221;) and Series C preferred stock (&#8220;Series C Preferred Shares&#8221; and collectively with the Series A Preferred Shares and the Series B Preferred Shares, the &#8220;Convertible Preferred Stock&#8221;).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Conversion of Convertible Preferred Stock</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 1, 2023, Former Elicio completed the Merger with Angion in accordance with the Merger Agreement. Under the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each share of Former Elicio&#8217;s Convertible Preferred Stock was converted into a share of Former Elicio&#8217;s common stock. At the closing of the Merger, the Company issued an aggregate of 5,375,751 shares of its common stock to Former Elicio </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">stockholders, based on the Exchange Ratio. No shares of Convertible Preferred Stock were issued during the years ended December&#160;31, 2024 and 2023, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As a result of the Merger, the aggregate amount of 276,128,177 shares of Convertible Preferred Stock (retroactively restated for the reverse recapitalization as described in Note 3) were converted </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">int</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">o 4,997,920 </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">shares of Former Elicio's common stock to be exchanged for the same number of shares of the Company&#8217;s common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">At-The-Market Equity Programs</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2022, the Company filed a registration statement on Form S-3 (the &#8220;Prior Shelf Registration St</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">atement&#8221;) with the SEC that registered the offering, issuance, and sale of an amount of common stock, preferred stock, debt securities, and warrants to purchase common stock, preferred stock and/or debt securities, not to exceed an aggregate initial offering price of $100 million. Simultaneously, the Company entered into an At-the-Market Equity Offering Sales Agreement with Stifel, Nicolaus &amp; Company, Incorporated and Virtu Americas LLC, as sales agents, pursuant to which the Company was able to offer, issue or sell shares of its common stock having an aggregate offering price of up to $21 million from time to time in &#8220;at-the-market&#8221; offerings under the Prior Shelf Registration Statement and related prospectus filed with the Prior Shelf Registration Statement (the &#8220;2022 ATM Program"). During the year ended December&#160;31, 2024, the Company issued and sold a total of 650,179 shares of common stock under the 2022 ATM Program for aggregate net sale proceeds of approximately $5.4 million after deducting sales commissions. No sales were made under the 2022 ATM Program during the year ended December&#160;31, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2024, the 2022 ATM Program was terminated by the Company. In June 2024, the Company filed a registration statement on Form S-3 (the &#8220;2024 Registration Statement&#8221;) with the SEC that registered the offering, issuance, and sale of an amount of common stock, preferred stock, debt securities, warrants to purchase common stock, preferred stock and/or debt securities, and/or units consisting of any combination of such securities, not to exceed an aggregate initial offering price of $200&#160;million. Simultaneously, the Company entered into the Capital on Demand</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Sales Agreement with JonesTrading Institutional Services, LLC, as agent, to provide for the issuance and sale of up to $40&#160;million of common stock from time to time in &#8220;at-the-market&#8221; offerings under the 2024 Registration Statement and related prospectus filed with the 2024 Registration Statement (the &#8220;2024 ATM Program&#8221;). During the year ended December&#160;31, 2024, the Company issued and sold 53,795 shares of common stock, for net proceeds of $0.3 million, under the 2024 ATM Program.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Private Placement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2024, the Company entered into the March Subscription Agreement with GKCC, an entity controlled by a member of the Company&#8217;s board of directors, for purposes of the March Offering. Each Pre-Funded Warrant issued and sold in the March Offering is exercisable at an exercise price equal to $0.01 per share, subject to certain adjustments and limitations as provided under the terms of the Pre-Funded Warrants. The Pre-Funded Warrants were classified as a liability at issuance due to the need for the Company to obtain stockholder approval to settle the instruments in shares in an amount exceeding the 19.99% beneficial ownership limit. Such stockholder approval was obtained in November 2024. See Note 16 - Related Party Transactions for a discussion of the March Offering.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Public Offering</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2024, the Company closed its Public Offering, which resulted in net proceeds of $10.9&#160;million to the Company, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The Public Offering consisted of (i) the July Shares, together with the July Common Warrants, and (ii) the July Pre-Funded Warrants, together with the July Common Warrants. Each July Share and accompanying July Common Warrant were sold together at a combined offering price of $5.00 per July Share and accompanying July Common Warrant, and each July Pre-Funded Warrant and accompanying July Common Warrant were sold together at a combined offering price of $4.99 per July Pre-Funded Warrant and accompanying July Common Warrant, which represented the combined purchase price per July Pre-Funded Warrant and accompanying July Common Warrant less the $0.01 per share exercise price for each such July Pre-Funded Warrant. </span></div>The July Common Warrants have an exercise price of $5.00 per share, are immediately exercisable and will expire five years from the issuance date. Refer to Note 16 &#8212; Related Party Transactions, of our consolidated financial statements for additional information.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">2012 Plan and 2022 Plan</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the Merger Agreement, the Company assumed the Former Elicio Plans and all stock options issued and outstanding under the Former Elicio Plans. Each outstanding and unexercised option to purchase Former Elicio common stock was adjusted with such Company stock options henceforth representing the right to </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">purchase a number of shares of the Company&#8217;s common stock based on the Exchange Ratio. Any restriction on the exercise of any Former Elicio stock options assumed by the Company continued in full force and effect and the term, exercisability, vesting schedule, accelerated vesting provisions, and any other provisions of such Former Elicio stock options otherwise remained unchanged.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">2015 Plan </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2019, Angion approved an Amended and Restated 2015 Equity Incentive Plan (the &#8220;2015 Plan&#8221;) permitting the granting of incentive stock options, non-statutory stock options, restricted stock and other stock-based awards. Following the effectiveness of the 2021 Incentive Award Plan (&#8220;2021 Plan&#8221;), Angion ceased making grants under the 2015 Plan. However, the 2015 Plan continues to govern the terms and conditions of the outstanding awards granted under it. Shares of common stock subject to awards granted under the 2015 Plan that cease to be subject to such awards by forfeiture or otherwise after the termination of the 2015 Plan will be available for issuance under the 2021 Plan.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">2021 Plan and Amendment to 2021 Plan</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2021, Angion&#8217;s board of directors approved the 2021 Plan which permits the granting of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards to employees, directors, officers and consultants. The 2021 Plan provides that the number of shares reserved and available for issuance will automatically increase each January 1st by the lesser of 5% of the Company&#8217;s common stock outstanding on the immediately preceding December 31st, or such lesser number of shares as determined by the Company&#8217;s board of directors. In March 2023, Angion&#8217;s board of directors approved an amendment to the 2021 Plan to increase the cumulative number of shares of common stock reserved for issuance thereunder by 30,113 shares. The Company has a policy of issuing shares out of respective plan pools (to the extent available) to satisfy share option exercises and restricted stock vesting.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December&#160;31, 2024, 298,795 shares and 175,283 shares remain available for future grants under the 2021 Plan and Former Elicio 2022 Equity Incentive Plan, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">2024 Inducement Incentive Award Plan</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2024, the Company&#8217;s board of directors approved the Company&#8217;s 2024 Inducement Incentive Award Plan (the &#8220;2024 Inducement Plan&#8221;) which permits the granting of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock-based awards to employees as an inducement pursuant to Listing Rule 5635(c)(4) of the corporate governance rules of the Nasdaq Stock Market, LLC. The 2024 Inducement Plan provides for an overall share limit of 500,000 shares of the Company&#8217;s common stock. As of December&#160;31, 2024, 387,332 shares remain available for future grants under the 2024 Inducement Plan.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Stock Options</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes information and activity related to the Company&#8217;s stock options:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Number of <br/>Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Weighted Average <br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Weighted Average <br/>Remaining Contractual Life <br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Total <br/>Intrinsic Value <br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Outstanding as of December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,305,924&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21.27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7.43</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,511&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">798,934&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(9,757)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Forfeited (unvested)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(204,169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Outstanding as of December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,890,932&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.78</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and exercisable</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860,803&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.78</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">428&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The aggregate intrinsic value in the above table is calculated as the difference between the estimated fair value of the Company's common stock price and the exercise price of the stock options. 798,934 stock options were granted during the year ended December&#160;31, 2024. The weighted average grant date fair value per share for the stock option grants during the year ended December&#160;31, 2024 was $3.59. As of December&#160;31, 2024, the total unrecognized compensation expense related to unvested stock option awards granted was $3.1 million, which the Company expects to recognize over a weighted-average period of approximately 2.2 years.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Stock-based Compensation Expense</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes total stock-based compensation expense recorded in the consolidated statements of operations (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">582&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">552&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,452&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,179&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair value of each option is estimated on the date of grant using a Black-Scholes option pricing model with the assumptions noted in the table below. The fair value of an award with only a service condition is amortized as compensation expense on a straight-line basis over the requisite service period of the awards, which is generally the vesting period. Compensation cost of awards that contain a performance condition are recognized when success is considered probable during the performance period. The Company has elected to account for forfeitures as they occur, rather than estimating the number of awards that are expected to vest. The risk-free interest rate is estimated using the weighted average rate of return on U.S. Treasury notes with a life that approximates the expected life of the option. The expected term of options granted to employees was calculated using the simplified method, which represents the average of the contractual term of the option and the weighted-average vesting period of the option. The Company uses the simplified method because it does not have sufficient historical option exercise data to provide a reasonable basis upon which to estimate expected term. The contractual life of the option was used for the expected life of options granted to non-employees. Expected volatility is based on the weighted average of the historical volatility of a peer group of publicly traded companies, using the daily closing prices during the equivalent period of the calculated expected term of stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of the Company&#8217;s stock price becomes available, or until circumstances change, such that the identified entities are no longer comparable companies. The assumed dividend yield is based upon the Company's expectation of not paying dividends in the foreseeable future.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair value of each employee and non-employee stock option grant was estimated on the date of grant using Black-Scholes based on the following assumptions. </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.4% - 4.3%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.7% - 4.5%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">79.5% - 107.8%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">71.7% - 75.5%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected term in years (employees)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.0  -  6.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.5 - 6.1</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2021 and June 2022, certain employees of the Company early exercised options to purchase shares of the Company&#8217;s common stock. The shares had not fully vested at the time of exercise and were recorded as an unvested option exercise liability. As the shares vested, the Company recognized the shares and related expense as issuance of common stock upon settlement of restricted stock in the consolidated financial statements for the years ended December&#160;31, 2024 and 2023.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2021, the board of directors of Angion approved the Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The ESPP was effective on the date immediately prior to the effectiveness of Angion's registration statement relating to the initial public offering. The offering period and purchase period was determined by Angion&#8217;s board of directors. No offering periods or purchasing periods were active as of December&#160;31, 2024. As of December&#160;31, 2024, 165,015 shares under the ESPP remain available for purchase and no offerings have been authorized.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_WarrantsAndRightsOutstandingAbstract', window );"><strong>Warrants and Rights Outstanding [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_WarrantsAndRightsOutstandingTextBlock', window );">Warrants</a></td>
<td class="text">Warrants<div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In accordance with ASC 815, the warrants classified as liabilities are recorded at fair value at the issuance date, with subsequent changes in the fair value recognized in the consolidated statements of operations and </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">comprehensive loss at the end of each reporting period. Refer to Note 4 for changes in the fair value recognized during the periods reported. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As disclosed in Note 4, in March 2024, the Company entered into the March Subscription Agreement with GKCC, an entity controlled by a member of the Company&#8217;s board of directors, for purposes of the March Offering. Each Pre-Funded Warrant issued and sold in the March Offering is exercisable at an exercise price equal to $0.01 per share, subject to certain adjustments and limitations as provided under the terms of the Pre-Funded Warrants. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Upon issuance, the fair value of the Pre-Funded Warrants was $6.6&#160;million. The Company recorded the $0.6&#160;million difference between the proceeds and the grant date fair value as a loss on issuance of warrants in the statements of operations and comprehensive loss during the three months ended March 31, 2024. The fair value of the Pre-Funded Warrants was measured using the Black-Scholes option pricing model as of the grant date. For the year ended December&#160;31, 2024, the Company recognized a gain of $1.3 million in fair value remeasurement of the Pre-Funded Warrants. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As disclosed in Notes 4 and 7, in July 2024, the Company closed its Public Offering consisting of (i) the July Shares, (ii) the July Pre-Funded Warrants, and (iii) the July Common Warrants. Each July Pre-Funded Warrant issued and sold in the Public Offering is exercisable at an exercise price equal to $0.01 per share, subject to certain adjustments and limitations as provided under the terms of the July Pre-Funded Warrants. Each July Common Warrant is exercisable at an exercise price equal to $5.00 per share, subject to certain adjustments and limitations as provided under the terms of the July Common Warrants. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Upon issuance, the fair value of the July Pre-Funded Warrants and July Common Warrants was $6.8&#160;million and $6.5&#160;million, respectively. The Company recorded the $2.9&#160;million difference between the proceeds and the grant date fair value as a loss on the issuance of warrants in the statements of operations and comprehensive loss during the three months ended September 30, 2024. The fair value of the July Pre-Funded Warrants and July Common Warrants was measured using the Black-Scholes option pricing model as of the grant date. For the year ended December&#160;31, 2024, the Company recognized a loss of $2.4 million in fair value remeasurement of the July Pre-Funded Warrants. For the year ended December&#160;31, 2024, the Company recognized a loss of $2.8 million in fair value remeasurement of the July Common Warrants.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Following receipt of Stockholder Approval in November 2024, the Company remeasured the July Common Warrants held by that shareholder at fair value and recognized the loss from change in fair value on the consolidated financial statements during the year ended December 31, 2024. As a result of obtaining Stockholder Approval, the Common Warrants held by that shareholder met the equity classification requirements under ASC 815. During the quarter ended December 31, 2024, the Company reclassified the July Common Warrants held by the stockholder from a liability to equity. The Company will re-assess the liability classification for the remaining July Common Warrants at each period end.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes the issuances of warrants by the Company throughout 2024:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.174%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Number of Warrants Issued</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Date of Issuance</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Expiration Date</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pre-Funded Warrants</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,032,702&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">July Pre-Funded Warrants</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,800,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">July Common Warrants</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,300,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total Warrants Issued</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,132,702&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Pre-funded warrants have been purchased and have an exercise price of $.01 per share. These warrants do not have an expiration date. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes warrant activity regarding the Pre-Funded Warrants and Common Warrants outstanding at December&#160;31, 2024:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.174%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted <br/>Average <br/>Exercise <br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average Life (years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Outstanding at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">148,764&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">54.19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Issued</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,132,702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(200,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Outstanding at December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,081,466&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.5</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_WarrantsAndRightsOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants and Rights Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_WarrantsAndRightsOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_WarrantsAndRightsOutstandingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants And Rights Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_WarrantsAndRightsOutstandingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Legal Proceedings </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">From time to time, the Company may be involved in legal proceedings, or may be subject to various demands, claims and threatened litigation, which arise in the normal course of its business or otherwise. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The outcome of any future litigation is uncertain. Such litigation, if not resolved, could result in substantial costs to the Company, including any costs associated with the indemnification of directors and officers, and could lead to a diversion of management resources among other factors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company may be exposed to litigation in connection with its products under development and operations. The Company&#8217;s policy is to assess the likelihood of any adverse judgments or outcomes related to legal matters, as well as ranges of probable losses. As of the time of this report, the Company does not believe it is a party to any claim, proceeding or litigation, the outcome of which, if determined adversely to the Company, would individually or in the aggregate be reasonably expected to have a material adverse effect on its business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">License Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2016, Former Elicio entered into a license agreement to license certain intellectual property from a university, which agreement has been amended from time to time to license additional intellectual property and to adjust fees, milestone dates, and diligence requirements. The Company is required to pay certain contractual maintenance and milestone payments related to clinical trials and royalties on product sales over the term of the contract, with minimum annual royalty payments commencing in the calendar year after commercialization. The license term for the January 2016 license agreement extends until terminated by either party under certain provisions. During the year ended December&#160;31, 2024, in accordance with the terms of the license agreement, the Company achieved a milestone related to the ongoing clinical trials and recorded license expense of $0.4&#160;million. No commercialization royalties have been achieved to date. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, the Company is required to pay a total of up to $20.9&#160;million upon achievement of certain late-stage developmental and commercial milestones. The developmental milestone payment will be recorded when the milestone is achieved, and the commercial milestone payment and royalties will be recorded when the sales occur.</span></div>Future minimum annual maintenance payments are $0.1&#160;million for the year ended December&#160;31, 2024 and for each year thereafter. Future minimum annual payments are due until the termination of the agreement.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Operating Leases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2021, the Company signed an operating lease for office and laboratory space in Boston, Massachusetts (the &#8220;Boston Lease&#8221;).</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Boston Lease commenced in February 2022 with the term set to expire in February 2030. The Boston Lease has rent payments escalating annually, which total $11.1&#160;million in the aggregate. As a result, at the commencement of the Boston Lease, the Company recognized a ROU lease asset of $8.0&#160;million with a corresponding lease liability of $8.0&#160;million based on the present value of the minimum rental payments. In addition, the Company will make payments for operating expenses and real estate taxes. In June 2023, the Company secured a letter of credit for the deposit on the Boston Lease and has a deposit in the amount of $0.7&#160;million, which was reported as restricted cash, noncurrent on the consolidated balance sheets as of December&#160;31, 2024 and 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of the Merger Agreement, the Company also assumed a lease for clinical and regulatory space in Newton, Massachusetts, comprising approximately 6,157 square feet for approximately $0.2&#160;million per year, under a non-cancelable operating lease that expired on June 30, 2024. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Lease expense for all leases for the years ended December&#160;31, 2024 and 2023 was $1.5&#160;million and $1.5&#160;million, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes quantitative information about the Company's operating leases (dollars in thousands):</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating cash outflows from operating leases</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,427&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted-average remaining lease term&#8212;operating leases (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted-average discount rate&#8212;operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, maturities of lease liabilities were as follows (in thousands):</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,350&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Thereafter</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,390&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Less present value discount</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1,384)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating lease liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6,006&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Less: operating lease liability, current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(901)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating lease liability, noncurrent portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,105&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Note Payable</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with execution of the Merger Agreement, Angion made the Bridge Loan to Former Elicio pursuant to a note purchase agreement and promissory notes up to an aggregate principal amount of $12.5&#160;million, issued with a 20% original issue discount. An initial closing held substantially concurrently with the execution of the Merger Agreement for a principal amount of $6.25&#160;million in exchange for cash of $5.0&#160;million and an additional closing for a principal amount of $6.25&#160;million in exchange for cash of $5.0&#160;million occurred upon delivery by Former Elicio to Angion of Former Elicio&#8217;s audited financial statements for the year ended December 31, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The promissory notes included multiple settlement options depending on the outcome of the Merger. Former Elicio evaluated all the settlement features, included within the promissory note agreement, under FASB ASC Topic 815, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, and determined the settlement features met the definition of a derivative and required bifurcation from the promissory notes. The bifurcated embedded derivative of $0.4 million was recorded as a liability at fair value at the date of issuance based on the probability of occurrence of a triggering event taking place during the term of the promissory notes and was recorded as a discount to the carrying value of the promissory note. During the year ended December&#160;31, 2023, Former Elicio recorded other expense of $2.3 million related to the accretion of the discount of the promissory notes derivative.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the year ended December&#160;31, 2023, per the terms of the Merger Agreement, upon completion of the Merger, all obligations owed by Former Elicio related to the promissory notes were automatically forgiven and the amount advanced by Angion, along with any accrued and unpaid interest, was credited towards the net cash balance used to calculate the assets and liabilities listed above.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Senior Secured Convertible Note Financing</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2024, the Company entered into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) with GKCC, an entity controlled by a member of the Company&#8217;s board of directors, pursuant to which the Company issued a 3% Senior Secured Convertible Promissory Note due February 15, 2026 (the &#8220;Convertible Note&#8221;) in the principal amount of $20.0 million (the &#8220;Note Financing&#8221;). Unless earlier converted in accordance with </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the terms of the Convertible Note, the Convertible Note will mature on February 15, 2026. Interest on the Convertible Note accrues and is payable quarterly in cash on the principal amount equal to 3% per annum, with the initial interest payment date to be June 30, 2025. The Convertible Note is secured by a (i) first priority lien on substantially all assets of the Company and its subsidiaries, pursuant to a security agreement and (ii) first priority lien on intellectual property of the Company, pursuant to an intellectual property security agreement. The Convertible Note will be convertible into shares of the Company&#8217;s common stock, in whole or in part, at the option of GKCC at any time, based on an initial conversion price of $5.81 (the &#8220;Conversion Price&#8221;) per share of common stock, subject to adjustments and satisfaction of certain conversion conditions; provided that the Company was not able to effect any conversion of the Convertible Note and GKCC did not have any right to convert any portion of the Convertible Note until the Company received Stockholder Approval. The Company received Stockholder Approval in November 2024. If at any time from and after the date of the Securities Purchase Agreement and for so long as certain conversion conditions are satisfied, the closing price of the common stock on Nasdaq equals or exceeds 135% of the Conversion Price for 20 trading days in a 30 trading day period, then the Company has the right to require GKCC to convert all or any portion of the Convertible Note, including any accrued but unpaid interest into shares of common stock, as further described in the Convertible Note. The Convertible Note contains customary terms and covenants and customary events of default. The Company granted GKCC certain customary registration rights with respect to the shares of common stock issuable upon conversion of the Convertible Note.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company received net proceeds of approximately $19.7 million from the Note Financing, after deducting debt issuance costs. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Convertible Note includes multiple conversion features. The Company evaluated all conversion features included within the Convertible Note, under FASB ASC Topic 815, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Derivatives and Hedging,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and determined that the default interest feature met the definition of a derivative, but the value was de minimis. During the year ended December&#160;31, 2024, the Company recorded other expense of $0.1 million related to the accretion of the discount of Convertible Note debt issuance costs. As of and for the year ended December&#160;31, 2024, the Company recorded accrued interest expense of $0.2 million related to the interest due on the Convertible Note but not yet payable.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The components of the Company&#8217;s provision for income taxes for the years ended December&#160;31, 2024 and 2023 consists of the following (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:72.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.828%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">United States</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total Current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(11,236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Change in valuation allowance</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(10,859)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total Deferred</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total tax provision</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliations between the federal statutory income tax rate and the Company's effective income tax rate were as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:72.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.828%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Statutory federal income tax rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">State tax, net of federal benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Permanent differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Federal research and development credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">State research and development credits</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other differences</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(19.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(30.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Effective income tax rate</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal components of the Company's net deferred tax asset at December&#160;31, 2024 and 2023 were as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred tax assets (liabilities):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net operating loss carryforwards</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">64,646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">60,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development tax credit carryovers</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Capitalized research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13,686&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lease liability</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,732&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ROU asset</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1,470)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1,800)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total deferred tax assets</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">100,117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">90,118&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Less: Deferred tax asset valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(100,117)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(90,118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net deferred tax asset</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net operating losses (&#8220;NOL&#8221;) generated before December 31, 2017 can be carried forward 20 years under the Internal Revenue Code (&#8220;IRC&#8221;). Use of NOLs arising in tax years ended after December 31, 2017 are limited to 80% of taxable income in any one tax year, and are carried forward indefinitely. The Company has no income tax expense due to operating losses incurred for the years ended December&#160;31, 2024 and 2023. The Company has provided a valuation allowance for the full amount of the net deferred tax assets as, based on all available evidence, it is considered more likely than not that all the recorded deferred tax assets will not be realized in a future period. The increase in the net deferred tax assets and valuation allowance is primarily due to increases in federal and state NOLs, federal and state research credits, and capitalized research expenditures. At December&#160;31, 2024, Elicio has federal NOLs of $261.8 million, of which $19.1 million was generated before the tax year ended December 31, 2018, and state NOLs of $145.2 million. If not utilized, certain NOLs for federal and state tax purposes will start to expire beginning in 2032. At December&#160;31, 2024, Elicio has $12.9 million and $2.6 million of federal and state research and development credit carryforwards, respectively, that start to expire in 2027.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As the Company has not yet achieved profitable operations, management believes the tax benefits as of December&#160;31, 2024 did not satisfy the realization criteria set forth in ASC Topic 740, Income Taxes and, therefore, has recorded a full valuation allowance for the entire deferred tax asset. The valuation allowance increased in 2024 by $10.0 million due to the increase in the deferred tax assets by the same amount, primarily due to NOL carryforwards. The Company&#8217;s effective income tax rate differed from the federal statutory rate primarily due to state taxes and the Company&#8217;s full valuation allowance, the latter of which reduced the Company&#8217;s effective federal income tax rate to zero.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ownership changes, as defined in the IRC, may limit the amount of NOL carryforwards that can be utilized annually to offset future taxable income pursuant to IRC Section 382 or similar provisions. Subsequent ownership </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">changes could further affect the limitation in future years. The Company has not completed a study to assess whether a change of control has occurred or whether there have been multiple changes of control since the Company&#8217;s formation due to the significant complexity and cost associated with such study and because there could be additional changes in control in the future. As a result, the Company is not able to estimate the effect of the change in control, if any, on the Company&#8217;s ability to utilize NOL and research and development credit carryforwards in the future.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company files tax returns in the United States, Australia, California, Connecticut, Florida, Massachusetts, Michigan, Missouri, New Hampshire, New Jersey, North Carolina, Pennsylvania, and Tennessee. All tax years from 2021 to 2024 remain open to examination by the major taxing jurisdictions to which the Company is subject, as carryforward attributes generated in years past may still be adjusted upon examination by the Internal Revenue Service (&#8220;IRS&#8221;) or other authorities if they have or will be used in a future period. To its knowledge, the Company is not currently under examination by the IRS or any other jurisdictions for any tax years.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December&#160;31, 2024, the Company had $4.1 million of uncertain tax positions related to prior research tax credits that may not be substantiated upon audit. The Company does not anticipate that uncertain tax positions will decrease within the next 12 months. The Company has elected to recognize interest and penalties related to income tax matters as a component of income tax expense, of which no interest or penalties were recorded for the years ended December&#160;31, 2024 and 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text">Employee Benefit Plan<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Employee Benefit Plan</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company provides a retirement savings plan through the Vendantra Pharmaceuticals Inc. 401(k) Plan (the &#8220;Elicio Retirement Plan&#8221;), subject to certain limitations. As allowed under Section 401(k) of the IRC, the Elicio Retirement Plan allows tax deferred salary deductions for eligible employees. An employee&#8217;s interest in his or her salary deferral contributions is 100% vested when contributed.</span></div>Pursuant to the Merger Agreement, the Company assumed the retirement savings plan sponsored by Angion (the &#8220;Angion Retirement Plan&#8221;). The Angion Retirement Plan is intended to qualify for favorable tax treatment under Section 401(a) of the IRC, and contains a cash or deferred feature that is intended to meet the requirements of Section 401(k) of the IRC. Currently, no employees are contributing under the Angion Retirement Plan.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715-70/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share<div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has reported losses since inception and has computed basic net loss per share attributable to common stockholders by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock and pre-funded warrants outstanding for the period, without consideration for potentially dilutive securities. The Company computes diluted net loss per share of common stock after giving consideration to all potentially dilutive shares of common stock, including options to purchase common stock and preferred stock outstanding during the period determined using the treasury-stock and if-converted methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential shares of common stock and preferred stock have been anti-dilutive and basic and diluted loss per share were the same for all periods presented.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Basic and diluted net loss per share attributable to common stockholders was calculated for the years ended December&#160;31, 2024 and 2023 as follows (in thousands, except share and per share data):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Numerator:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(51,898)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(35,195)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Weighted-average shares used in computing net loss per share, basic and diluted</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">12,202,996</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">5,056,225</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.25)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6.96)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The table below provides potentially dilutive securities not included in the calculation of the diluted net loss per share because to do so would be anti-dilutive:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Shares issuable upon exercise of stock options</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,890,932</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">1,305,924</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Shares issuable upon the exercise of warrants</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2,448,764</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">148,764</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Unvested common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">1,933</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Total</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">4,339,696</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">1,456,621</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Consulting Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company paid $0 and $0.8 million for the years ended December&#160;31, 2024 and 2023, respectively, for consulting services provided by an entity affiliated with the Company&#8217;s former interim chief financial officer and former board member. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Private Placement and Subscription Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2024, the Company entered into the March Subscription Agreement with GKCC, an entity controlled by a member of the Company&#8217;s board of directors, for purposes of the March Offering. Each Pre-Funded Warrant issued and sold in the March Offering is exercisable at an exercise price equal to $0.01 per share, subject to certain adjustments and limitations as provided under the terms of the Pre-Funded Warrants. Refer to Note 7 for further detail about the March Offering. The gross proceeds to the Company from the March Offering were approximately $6.0&#160;million. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Public Offering</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of the Public Offering described in Note 7, Yekaterina Chudnovsky, a member of the Company&#8217;s board of directors, and Jay Venkatesan, a member of the Company&#8217;s board of directors, and trusts affiliated with Jay Venkatesan, purchased 1,600,000 July Pre-Funded Warrants and accompanying July Common Warrants and 200,000 July Pre-Funded Warrants and accompanying July Common Warrants, respectively, with such July Pre-Funded Warrants and July Common Warrants subject to the terms and conditions of the July Pre-Funded Warrants and July Common Warrants, as further detailed in Note 7 above.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Senior Secured Convertible Note Financing</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2024, the Company entered into the Securities Purchase Agreement with GKCC, pursuant to which the Company issued the Convertible Note in the principal amount of $20.0 million pursuant to the Note Financing. The Company received net proceeds of approximately $19.7 million from the Note Financing, after deducting debt issuance costs. Refer to Note 12 for further detail regarding the Note Financing.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text">Segment Reporting<div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has one reportable segment relating to the development of immunotherapies for patients with limited treatment options and poor outcomes suffering from cancer. The Company&#8217;s CODM, its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis, assesses performance for the operating segment and decides how to allocate resources based on consolidated net loss, which is reported on the consolidated statements of operations and comprehensive loss. Depreciation expense, amortization expense, stock-based compensation expense, and the change in fair value of warrants are significant noncash items included in consolidated net loss reviewed by the CODM and are reported on the consolidated statements of cash flows. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other segment items include interest revenue, interest expense, change in the fair value of derivatives, and change in the fair value of warrants. Expenditures for additions to long-lived assets, which include purchases of property and equipment, are included in total consolidated assets reviewed by the CODM and are reported on the consolidated statements of cash flows. The following table presents certain financial data for the Company&#8217;s reportable segment (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,892&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,066&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee related research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chemistry, manufacturing and controls expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract and grant reimbursements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,027)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,800)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee related general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees and other general and administrative expenses </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,455&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other segment items </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(445)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,898&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,195&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,178&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,146&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has completed an evaluation of all subsequent events after the consolidated balance sheet date as of December&#160;31, 2024 through the date these consolidated financial statements were issued to ensure that these consolidated financial statements include appropriate disclosure of events both recognized in the consolidated financial statements as of December&#160;31, 2024, and events which occurred subsequently but were not recognized in the consolidated financial statements. Non-recognizable subsequent events are summarized below.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">January Offering</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On January 29, 2025, the Company entered into a Securities Purchase Agreement (the &#8220;January Purchase Agreement&#8221;) with certain institutional investors (each an &#8220;Investor&#8221; and, collectively, the &#8220;Investors&#8221;), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Investors (the &#8220;January Offering&#8221;): (i) an aggregate of 1,261,830 shares of common stock, par value $0.01 per share, of the Company and (ii) common warrants to purchase up to an aggregate of 1,261,830 shares of Common Stock (the &#8220;January Common Warrants&#8221;). Each share of common stock and accompanying January Common Warrant were sold together at a combined offering price of $7.925. The January Common Warrants have an exercise price of $7.80 per share, are immediately exercisable and will expire five years from the initial exercise date. The aggregate gross proceeds to the Company from the January Offering were approximately $10&#160;million before deducting the placement agent&#8217;s fees and related offering expenses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Convertible Note Conversion</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As previously described, in August 2024, the Company entered into the Securities Purchase Agreement with GKCC, pursuant to which the Company issued the Convertible Note in the principal amount of $20.0&#160;million pursuant to the Note Financing. Under the terms of the Convertible Note, if at any time from and after the date of the Convertible Note and for so long as the closing price of the Company&#8217;s common stock on The Nasdaq Capital Market equals or exceeds 135% of the initial conversion price of $5.81 for 20 trading days in a 30 trading day period, then the Company had the right to require GKCC to convert all or any portion of the Convertible Note, including any accrued but unpaid interest into shares of Company common stock. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 3, 2025, the Company exercised its right under the Convertible Note to require GKCC to convert the full amount of the Convertible Note, including all accrued and unpaid interest, into shares of Company common stock. On March 5, 2025, the Company issued 3,500,573 shares of common stock to GKCC in exchange for the principal balance of $20&#160;million plus $0.3&#160;million in accrued interest, in satisfaction in full of the Convertible Note.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (51,898)<span></span>
</td>
<td class="num">$ (35,195)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We recognize the critical importance of protecting the confidentiality, integrity and availability of our business operations and systems. With this in mind, we have implemented and maintain ongoing cybersecurity risk management practices, in accordance with our risk profile and business size, under the oversight of our Audit Committee that are designed to identify, assess, and mitigate cybersecurity risk. Our cybersecurity program is informed by the National Institute of Standards and Technology Cybersecurity Framework, and other applicable industry standards. We engage third-party service providers and vendors to assist us in managing our cybersecurity programs and systems.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Cybersecurity Risk Management and Strategy; Effect of Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To identify and assess material risks from cybersecurity threats, we maintain a cybersecurity program to develop and implement effective systems and prepare for information security risks. We consider risks from cybersecurity threats alongside other company risks as part of our overall risk assessment process. We employ a range of tools and services, including regular network and endpoint monitoring to inform our risk identification and assessment, as well as undertaking the following activities: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">monitor emerging data protection laws and implement changes to our processes that are designed to comply with such laws;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">through our policies, practices and contracts (as applicable), require employees, as well as third parties that provide services on our behalf, to treat confidential information and data with care;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">employ technical safeguards that are designed to protect our information systems from cybersecurity threats, including firewalls, device encryption, multi-factor authentication, advanced threat protection for emails, anti-virus and anti-malware functionality and access controls, which are evaluated and improved from time to time; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">employ multiple backup systems for our data stored on our servers or other information systems.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We face risks from cybersecurity threats that, if realized, are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition. During the reporting period, we have not identified any risks from cybersecurity threats, including as a result of previous cyber security incidents, that we believe have materially affected, or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition. For more information, see the section in our risk factors under the heading &#8220;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Our internal information technology systems, or those of our vendors, collaborators or other contractors or consultants, may fail or suffer cybersecurity incidents, loss of data, and other disruptions, which could result in a material disruption of our product development programs, compromise sensitive information related to our business </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">or prevent us from accessing critical information, potentially exposing us to liability or otherwise adversely affecting our business</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.&#8221; which disclosures are incorporated by reference herein.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We recognize the critical importance of protecting the confidentiality, integrity and availability of our business operations and systems. With this in mind, we have implemented and maintain ongoing cybersecurity risk management practices, in accordance with our risk profile and business size, under the oversight of our Audit Committee that are designed to identify, assess, and mitigate cybersecurity risk. Our cybersecurity program is informed by the National Institute of Standards and Technology Cybersecurity Framework, and other applicable industry standards. We engage third-party service providers and vendors to assist us in managing our cybersecurity programs and systems.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cybersecurity is an important part of our risk management processes and is an area of focus for our board of directors and management. Our board of directors has delegated the oversight of cybersecurity risks to our Audit Committee, which oversees management&#8217;s implementation of our cybersecurity program.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our Audit Committee receives periodic updates from our General Counsel regarding our cybersecurity program and risks, including, as necessary, any material cybersecurity threat risks or incidents, as well as the steps management has taken to respond to such risks. Members of our Audit Committee are also encouraged to engage in conversations with management on cybersecurity-related news events and discuss any updates to our cybersecurity risk management and strategy programs. The Audit Committee reports to the full board of directors regarding its activities and risk management functions, including those related to cybersecurity.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our Audit Committee receives periodic updates from our General Counsel regarding our cybersecurity program and risks, including, as necessary, any material cybersecurity threat risks or incidents, as well as the steps management has taken to respond to such risks. Members of our Audit Committee are also encouraged to engage in conversations with management on cybersecurity-related news events and discuss any updates to our cybersecurity risk management and strategy programs. The Audit Committee reports to the full board of directors regarding its activities and risk management functions, including those related to cybersecurity.</span></div>Oversight of our cybersecurity program, which is discussed in greater detail above, is led by our General Counsel who, along with a contracted third party managed security service provider, is responsible for helping to integrate cybersecurity risk considerations into the Company&#8217;s overall risk management strategy and to help prepare for and respond to cybersecurity incidents. Our third party managed security service provider has over 25 years of experience in cybersecurity and is informed about and monitors our cybersecurity risk through participation in the cybersecurity risk management and strategy processes described above.  Additionally, our legal and operations teams review and assess potential improvements to our cybersecurity policies and procedures with input from third-party vendors, as appropriate. As discussed above, the General Counsel reports to the Audit Committee of our board of directors about cybersecurity related matters, periodically.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cybersecurity is an important part of our risk management processes and is an area of focus for our board of directors and management. Our board of directors has delegated the oversight of cybersecurity risks to our Audit Committee, which oversees management&#8217;s implementation of our cybersecurity program.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our Audit Committee receives periodic updates from our General Counsel regarding our cybersecurity program and risks, including, as necessary, any material cybersecurity threat risks or incidents, as well as the steps management has taken to respond to such risks. Members of our Audit Committee are also encouraged to engage in conversations with management on cybersecurity-related news events and discuss any updates to our cybersecurity risk management and strategy programs. The Audit Committee reports to the full board of directors regarding its activities and risk management functions, including those related to cybersecurity.</span></div>Oversight of our cybersecurity program, which is discussed in greater detail above, is led by our General Counsel who, along with a contracted third party managed security service provider, is responsible for helping to integrate cybersecurity risk considerations into the Company&#8217;s overall risk management strategy and to help prepare for and respond to cybersecurity incidents. Our third party managed security service provider has over 25 years of experience in cybersecurity and is informed about and monitors our cybersecurity risk through participation in the cybersecurity risk management and strategy processes described above.  Additionally, our legal and operations teams review and assess potential improvements to our cybersecurity policies and procedures with input from third-party vendors, as appropriate. As discussed above, the General Counsel reports to the Audit Committee of our board of directors about cybersecurity related matters, periodically.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">Oversight of our cybersecurity program, which is discussed in greater detail above, is led by our General Counsel who, along with a contracted third party managed security service provider, is responsible for helping to integrate cybersecurity risk considerations into the Company&#8217;s overall risk management strategy and to help prepare for and respond to cybersecurity incidents.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">Our third party managed security service provider has over 25 years of experience in cybersecurity and is informed about and monitors our cybersecurity risk through participation in the cybersecurity risk management and strategy processes described above.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cybersecurity is an important part of our risk management processes and is an area of focus for our board of directors and management. Our board of directors has delegated the oversight of cybersecurity risks to our Audit Committee, which oversees management&#8217;s implementation of our cybersecurity program.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our Audit Committee receives periodic updates from our General Counsel regarding our cybersecurity program and risks, including, as necessary, any material cybersecurity threat risks or incidents, as well as the steps management has taken to respond to such risks. Members of our Audit Committee are also encouraged to engage in conversations with management on cybersecurity-related news events and discuss any updates to our cybersecurity risk management and strategy programs. The Audit Committee reports to the full board of directors regarding its activities and risk management functions, including those related to cybersecurity.</span></div>Oversight of our cybersecurity program, which is discussed in greater detail above, is led by our General Counsel who, along with a contracted third party managed security service provider, is responsible for helping to integrate cybersecurity risk considerations into the Company&#8217;s overall risk management strategy and to help prepare for and respond to cybersecurity incidents. Our third party managed security service provider has over 25 years of experience in cybersecurity and is informed about and monitors our cybersecurity risk through participation in the cybersecurity risk management and strategy processes described above.  Additionally, our legal and operations teams review and assess potential improvements to our cybersecurity policies and procedures with input from third-party vendors, as appropriate. As discussed above, the General Counsel reports to the Audit Committee of our board of directors about cybersecurity related matters, periodically.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company's consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">guidance is meant to refer to the authoritative accounting principles generally accepted in the United States as found in the Accounting Standard Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Elicio Pty, ESC, and Former Elicio. All significant intercompany balances and transactions have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Financial Statement Reclassification</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Financial Statement Reclassification</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Certain account balances from prior periods have been reclassified in these consolidated financial statements to conform to current period classifications. The warrant liability was reclassified from current to noncurrent liabilities. These reclassifications had no effect on the reported results of operations or financial position.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Segments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the Chief Operating Decision Maker (&#8220;CODM&#8221;), or decision-making group, in deciding how to allocate resources and in assessing performance. The Chief Executive Officer serves as the CODM. The Company operates as a single operating and reportable segment, reflecting the integrated nature of the Company&#8217;s business.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Use of Estimates</span></div>The Company&#8217;s management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could materially differ from those estimates. Significant estimates reflected in these consolidated financial statements include but are not limited to, the accrual of research and development expenses, the valuation of stock-based awards, the valuation of warrants, the valuation of embedded derivatives and convertible debt, the operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liability, and forecasts utilized in management&#8217;s going concern assessment.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation and Transactions</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Foreign Currency Translation and Transactions</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Australian Dollar (&#8220;AUD&#8221;) is the functional currency for Elicio Pty. Accordingly, nonmonetary assets and liabilities originally acquired or assumed in other currencies are recorded in AUD at the date they were acquired or assumed. As part of the consolidation process, the Elicio Pty results are translated from AUD into the reporting currency of US Dollars using average rates for profit and loss transactions and applicable spot rates for period-end balances. The effect of translating our functional currency into our reporting currency is reported separately in Accumulated Other Comprehensive Loss.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk and Off-Balance Sheet Risk</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Concentrations of Credit Risk and Off-Balance Sheet Risk</span></div>Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash, cash equivalents, and restricted cash. At times, cash balances deposited at major financial banking institutions exceed the federally insured limit. The Company regularly monitors the financial condition of the institutions in which it has depository accounts and believes the risk of loss is minimal. The Company has not experienced any losses in such accounts.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Cash and Cash Equivalents</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash and cash equivalents are comprised of deposits at major financial banking institutions and highly liquid investments with an original maturity of three months or less at the date of purchase. As of December&#160;31, 2024 and 2023, the Company&#8217;s cash equivalents were held in institutions in the United States and include deposits in a money market fund which were unrestricted as to withdrawal or use.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Restricted Cash</span></div>Restricted cash consists of cash securing a collateral letter of credit issued in connection with the Company&#8217;s research grant and facility operating lease.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Fair Value Measurement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company follows the guidance prescribed by ASC Topic 820, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Fair Value Measurements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, which establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The standard provides a consistent definition of fair value that focuses on an exit price which is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The standard establishes a three-level hierarchy for fair value measurements based on the nature of inputs used in the valuation of an asset or liability as of the measurement date.</span></div><div style="margin-top:6pt;padding-left:76.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Level 1:&#160;&#160;&#160;&#160;Observable inputs such as unadjusted quoted prices in active markets for identical assets or liabilities at measurement. </span></div><div style="margin-top:6pt;padding-left:76.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Level 2:&#160;&#160;&#160;&#160;Inputs (other than quoted prices included in Level 1) that are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. </span></div><div style="margin-top:6pt;padding-left:76.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Level 3:&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The carrying amounts of financial instruments reflected in the consolidated balance sheets for cash and cash equivalents, current and non-current restricted cash, accounts payable, and accrued expenses approximate their respective fair values because of the short-term maturity of those financial assets and liabilities.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Property and Equipment</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of the asset. Upon sale or retirement, the cost and accumulated depreciation are eliminated from their respective accounts, and the resulting gain or loss is recorded in the consolidated statement of operations and comprehensive loss. Repair and maintenance expenditures are expensed as incurred. Construction in process is not depreciated until the asset is placed into service.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:67.668%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Estimated Useful Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furniture and fixtures</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Leasehold improvements</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Shorter of useful life or lease term</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Impairment of Long-Lived Assets</span></div>The Company evaluates its long-lived assets, which consist primarily of property and equipment, and right-of-use asset, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt Issuance Costs</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Debt Issuance Costs</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These deferred costs will be amortized and recognized as additional interest expense over the term of the Company&#8217;s convertible note using the effective interest method. The Company will present debt issuance costs as a direct deduction from the convertible note liability on its financial statements. See Note 12 for further discussion of the Company&#8217;s accounting for its outstanding debt and related issuance costs.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Income Taxes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company accounts for income taxes in accordance with ASC Topic 740, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Income Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and liabilities using enacted tax rates and laws in effect in the years in which the differences are expected to reverse. A valuation allowance is provided if, based upon the weighted available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is required to recognize the financial statement effects of a tax position when it is more likely than not, based on the technical merits, the position will be sustained upon examination. As of December&#160;31, 2024, there were no accruals for interest or penalties related to uncertain tax provisions.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development and Research Grant</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Research and Development</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Research and development costs are charged to expense as incurred and consist of expenses incurred in performing research and development activities, including salaries and benefits, materials and supplies, preclinical expenses, stock-based compensation expense, depreciation of equipment, contract services, and other outside expenses. The Company accrues for costs incurred by external service providers, based on estimates of services performed and costs. The Company expenses all research and development costs in the periods in which they are incurred. Costs for certain research and development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and service providers. Based on the timing of payments to service providers, the Company may also record prepaid expenses for those service providers that will be recognized as expenses in future periods as the related services are rendered. Research and development costs may be offset by research grants and research and development refundable tax rebates received by Elicio Pty.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Research Grant </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company analogizes to the guidance provided by International Accounting Standards 20, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Accounting for Government Grants and Disclosure of Government Assistance </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(&#8220;IAS 20&#8221;) for funds received from grants from entities that are not customers nor government agencies. The Company recognizes the amount of grant income based on the activity in allowable expenses covered under the grant and has elected to recognize the funds earned as an offset to the related research expenses recorded in operations. Advances from the grant that have yet to be recognized are recorded as restricted cash if the grant requires the funds to be isolated from general cash and cash equivalents. The Company records a liability for any research activity that is required under the grant but has not yet been performed. The liability is recorded as a deferred research obligation on the consolidated balance sheets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Leases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ASC Topic 842, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Leases,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (&#8220;ASC 842&#8221;) requires a lessee to recognize a ROU asset and corresponding lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the consolidated statements of operations and comprehensive loss as well as the reduction of the ROU asset. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances, the existence of an identified asset(s), if any, and the Company&#8217;s control over the use of the identified asset(s), if applicable. Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of future lease payments over the expected lease term. When the interest rate implicit in lease contracts is not readily determinable, the Company will utilize its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has elected to combine lease and non-lease components as a single component. Operating leases are recognized on the consolidated balance sheet as ROU lease assets, current lease liabilities and non-current lease liabilities. Fixed rents are included in the calculation of the lease balances, while variable costs paid for certain operating and pass-through costs are excluded. Lease expense is recognized over the expected term on a straight-line basis.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Stock-Based Compensation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company issues stock-based awards to employees and non-employees, generally in the form of stock options. The Company accounts for stock-based awards in accordance with ASC 718,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> Compensation&#8212;Stock Compensation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, which requires all stock-based payments to be recognized in the consolidated statements of operations and comprehensive loss based on their fair values. The expense is recognized on a straight-line basis over the requisite service period, which is generally the vesting period. The Company has elected to account for option forfeitures as they occur. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company uses the Black-Scholes option-pricing model (&#8220;Black-Scholes&#8221;) to determine the fair value of options granted, which uses as inputs the fair value of the Company common stock, assumptions the Company </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">makes for the volatility of its Company common stock, the expected term of its stock options, the risk-free interest rate for a period that approximates the expected term of its stock options and its expected dividend yield. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Compensation cost of awards that contain a performance condition are recognized when success is considered probable during the performance period. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Prior to the Merger, there was no public market for Former Elicio&#8217;s common stock. The estimated fair value of the Company&#8217;s common stock underlying Former Elicio&#8217;s stock-based awards was determined by Former Elicio&#8217;s board of directors as of the grant date of each option grant. To determine the fair value of Former Elicio&#8217;s common stock underlying option grants, Former Elicio&#8217;s board of directors considered, among other things, input from management and valuations of Former Elicio's common stock prepared by third-party valuation firms performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants' Accounting and Valuation Guide, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Valuation of Privately-Held-Company Equity Securities Issued as Compensation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Following the Merger, the fair value of the Company&#8217;s common stock is based on the closing stock price on the date of grant as reported on the Nasdaq Capital Market.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_WarrantsAndDerivativesPolicyTextBlock', window );">Warrants and Derivatives</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Warrants and Derivatives</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s common stock warrants are evaluated pursuant to ASC 480, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (&#8220;ASC 480&#8221;), and ASC 815, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (&#8220;ASC 815&#8221;). The Company classifies its freestanding warrants as (i) liabilities, if the warrant terms allow settlement of the warrant exercise in cash, or (ii) equity, if the warrant terms only allow settlement in shares of common stock. Please refer to Note 9 below for the application to the Company&#8217;s pre-funded and common warrants.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Net Loss Per Share</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Basic net loss per share of Company common stock is computed by dividing net loss attributable to Company common stockholders by the weighted average number of shares of Company common stock and pre-funded warrants outstanding for the period. Pre-funded warrants are considered outstanding for the purposes of computing basic and diluted net loss per share because shares may be issued for little or no additional consideration and are fully vested and exercisable after the original issuance date of the pre-funded warrants. Diluted net loss per share excludes the potential impact of Company common stock options, warrants and unvested shares of restricted stock because their effect would be anti-dilutive due to the Company's net loss. Since the Company had net losses for the years ended December&#160;31, 2024 and 2023, basic and diluted net loss per common share are the same.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Other Comprehensive Gain (Loss)</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Other Comprehensive Gain (Loss)</span></div>Other comprehensive gain (loss) is defined as a change in equity during a period from foreign exchange transactions and other events and circumstances from non-owner sources.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Standards During the Period and Recently Issued Accounting Standards Not Yet Adopted</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Recently Adopted Accounting Standards During the Period</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2023, the FASB finalized ASU No. 2023-07, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (&#8220;ASU 2023-07&#8221;). ASU 2023-07 requires enhanced disclosures about reportable segments and the CODM. The new guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company adopted ASU 2023-07 on January 1, 2024. There was no impact on the Company's reportable segments identified and additional required disclosures have been included in Note 17.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Recently Issued Accounting Standards Not Yet Adopted</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Except as noted below, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its consolidated financial statements and disclosures. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This ASU requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as additional information on income taxes paid. The standard requires entities to disclose federal, state, and foreign income taxes in their rate reconciliation tables and elaborate on reconciling items that exceed a quantitative threshold. Additionally, it requires an annual disclosure of income taxes paid, net of refunds, categorized by jurisdiction based on a quantitative threshold. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is permitted. This ASU will result in the required additional disclosures being included in the Company&#8217;s consolidated financial statements, once adopted. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2024, the FASB issued ASU No. 2024-03, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This ASU requires enhanced disclosures of disaggregated income statement expenses. Disclosure within the notes of the financial statements for each annual and interim period should include: employee compensation, depreciation, and intangible asset amortization, included in each relevant expense caption; certain amount that are already required to be disclosed under current GAAP in the same disclosure as the other disaggregation requirement; a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively; and the total amount of selling expenses and, in annual reporting periods, an entity&#8217;s definition of selling expenses. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning December 15, 2027. Early adoption is permitted. The Company is currently evaluating the effect that adoption of ASU 2024-03 will have on its consolidated financial statements. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2024, the FASB issued ASU No. 2024-04, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. This new guidance clarifies the accounting treatment of whether the settlement of convertible debt should be accounted for as an induced conversion or extinguishment of convertible debt. This guidance is effective for annual reporting periods beginning after December 15, 2025. The Company is evaluating the potential impact of this adoption on the consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_WarrantsAndDerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants and Derivatives</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_WarrantsAndDerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483504/205-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:67.668%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Estimated Useful Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furniture and fixtures</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Leasehold improvements</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Shorter of useful life or lease term</span></td></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net was comprised of the following (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,661&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,574&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furniture and fixtures</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Leasehold improvements</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total property and equipment</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,035&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,948&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Less: accumulated depreciation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1,552)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1,231)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">483&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">717&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger and Related Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_ReverseRecapitalizationAbstract', window );"><strong>Reverse Recapitalization [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_ScheduleOfReverseRecapitalizationTableTextBlock', window );">Schedule of Reverse Recapitalization</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of the recapitalization, the Company obtained the assets and liabilities listed below (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.315%"><tr><td style="width:1.0%"></td><td style="width:22.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.529%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,001&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Promissory notes</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,027&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,438)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,130&#160;</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ReverseRecapitalizationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ReverseRecapitalizationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ScheduleOfReverseRecapitalizationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ScheduleOfReverseRecapitalizationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following tables present the Company's financial assets and liabilities measured at fair value on a recurring basis and their assigned levels within the fair value hierarchy (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Level 3</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Money market funds </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total assets</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12,100&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12,100&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Warrant liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,827&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,828&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Level 3</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Money market funds </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total assets</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,973&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,973&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Warrant liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">___________________</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Included in cash, cash equivalents, and restricted cash on the consolidated balance sheets. This balance includes cash requirements settled on a nightly basis.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</a></td>
<td class="text">The following table presents a summary of changes in Level 3 in the fair value of the Company&#8217;s common stock warrant liability (in thousands):<div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Balance, beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Existing Angion warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Balance, end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Fair Value Measurement Inputs and Valuation Techniques</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair value of the assumed Angion common stock warrant liability was estimated using the following assumptions:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted average strike price</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">76.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">76.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contractual term (years)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.7</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Volatility (annual)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">74.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">94.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free rate</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dividend yield (per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid and Other Current Assets</a></td>
<td class="text">Prepaid and other current assets consisted of the following (in thousands):<div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid research and development contract services</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,206&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,883&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Advanced professional fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid insurance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total prepaid and other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,897&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,732&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:67.668%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Estimated Useful Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furniture and fixtures</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Leasehold improvements</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Shorter of useful life or lease term</span></td></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net was comprised of the following (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,661&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,574&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furniture and fixtures</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Leasehold improvements</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total property and equipment</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,035&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,948&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Less: accumulated depreciation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1,552)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1,231)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">483&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">717&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Accrued expenses consisted of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued professional fees</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">945&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued research and development</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4,910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">912&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other accrued expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8,415&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,757&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes information and activity related to the Company&#8217;s stock options:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Number of <br/>Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Weighted Average <br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Weighted Average <br/>Remaining Contractual Life <br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Total <br/>Intrinsic Value <br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Outstanding as of December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,305,924&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21.27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7.43</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,511&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">798,934&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(9,757)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Forfeited (unvested)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(204,169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Outstanding as of December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,890,932&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.78</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and exercisable</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860,803&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.78</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">428&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Components of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes total stock-based compensation expense recorded in the consolidated statements of operations (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">582&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">552&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,452&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,179&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used to Estimate Fair Value of Stock Option Awards</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair value of each employee and non-employee stock option grant was estimated on the date of grant using Black-Scholes based on the following assumptions. </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.4% - 4.3%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.7% - 4.5%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">79.5% - 107.8%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">71.7% - 75.5%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected term in years (employees)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.0  -  6.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.5 - 6.1</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_WarrantsAndRightsOutstandingAbstract', window );"><strong>Warrants and Rights Outstanding [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Outstanding Warrants</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes the issuances of warrants by the Company throughout 2024:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.174%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Number of Warrants Issued</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Date of Issuance</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Expiration Date</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pre-Funded Warrants</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,032,702&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">July Pre-Funded Warrants</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,800,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">July Common Warrants</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,300,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total Warrants Issued</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,132,702&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Pre-funded warrants have been purchased and have an exercise price of $.01 per share. These warrants do not have an expiration date. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes warrant activity regarding the Pre-Funded Warrants and Common Warrants outstanding at December&#160;31, 2024:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.174%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted <br/>Average <br/>Exercise <br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average Life (years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Outstanding at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">148,764&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">54.19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Issued</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,132,702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(200,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Outstanding at December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,081,466&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.5</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_WarrantsAndRightsOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants and Rights Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_WarrantsAndRightsOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock', window );">Schedule Of Quantitative Information On Operating Leases</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes quantitative information about the Company's operating leases (dollars in thousands):</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating cash outflows from operating leases</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,427&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted-average remaining lease term&#8212;operating leases (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted-average discount rate&#8212;operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Lease Liabilities</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, maturities of lease liabilities were as follows (in thousands):</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,350&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Thereafter</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,390&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Less present value discount</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1,384)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating lease liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6,006&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Less: operating lease liability, current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(901)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating lease liability, noncurrent portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,105&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Quantitative Information On Operating Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The components of the Company&#8217;s provision for income taxes for the years ended December&#160;31, 2024 and 2023 consists of the following (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:72.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.828%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">United States</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total Current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(11,236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Change in valuation allowance</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(10,859)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total Deferred</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total tax provision</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliations between the federal statutory income tax rate and the Company's effective income tax rate were as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:72.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.828%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Statutory federal income tax rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">State tax, net of federal benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Permanent differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Federal research and development credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">State research and development credits</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other differences</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(19.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(30.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Effective income tax rate</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal components of the Company's net deferred tax asset at December&#160;31, 2024 and 2023 were as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred tax assets (liabilities):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net operating loss carryforwards</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">64,646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">60,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development tax credit carryovers</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Capitalized research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13,686&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lease liability</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,732&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ROU asset</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1,470)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1,800)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total deferred tax assets</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">100,117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">90,118&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Less: Deferred tax asset valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(100,117)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(90,118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net deferred tax asset</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Net Loss Per Share, Basic and Diluted</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Basic and diluted net loss per share attributable to common stockholders was calculated for the years ended December&#160;31, 2024 and 2023 as follows (in thousands, except share and per share data):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Numerator:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(51,898)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(35,195)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Weighted-average shares used in computing net loss per share, basic and diluted</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">12,202,996</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">5,056,225</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.25)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6.96)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded From Computation of Net Loss per Share</a></td>
<td class="text">The table below provides potentially dilutive securities not included in the calculation of the diluted net loss per share because to do so would be anti-dilutive:<div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Shares issuable upon exercise of stock options</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,890,932</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">1,305,924</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Shares issuable upon the exercise of warrants</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2,448,764</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">148,764</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Unvested common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">1,933</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Total</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">4,339,696</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">1,456,621</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment</a></td>
<td class="text">The following table presents certain financial data for the Company&#8217;s reportable segment (in thousands):<div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,892&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,066&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee related research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chemistry, manufacturing and controls expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract and grant reimbursements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,027)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,800)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee related general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees and other general and administrative expenses </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,455&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other segment items </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(445)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,898&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,195&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,178&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,146&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of the Business and Financial Condition (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 01, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems', window );"><strong>Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">9,700,000<span></span>
</td>
<td class="nump">12,202,996<span></span>
</td>
<td class="nump">5,056,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 194,101<span></span>
</td>
<td class="nump">$ 142,203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,618<span></span>
</td>
<td class="nump">$ 12,894<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=angn_FormerElicioEquityHoldersMember', window );">Former Elicio Equity Holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems', window );"><strong>Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_ReverseRecapitalizationOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">65.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=angn_FormerAngionEquityHoldersMember', window );">Former Angion Equity Holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems', window );"><strong>Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_ReverseRecapitalizationOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">34.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ReverseRecapitalizationOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse Recapitalization Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ReverseRecapitalizationOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=angn_FormerElicioEquityHoldersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=angn_FormerElicioEquityHoldersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=angn_FormerAngionEquityHoldersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=angn_FormerAngionEquityHoldersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 01, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_RecapitalizationExchangeRatio', window );">Recapitalization exchange ratio</a></td>
<td class="nump">0.0181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long lived assets | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=angn_AngionCommonStockMember', window );">Angion Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split, conversion ratio</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_RecapitalizationExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recapitalization Exchange Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_RecapitalizationExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=angn_AngionCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=angn_AngionCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Property and Equipment (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life (in years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life (in years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger and Related Transactions - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 01, 2023 </div>
<div>USD ($) </div>
<div>board_member </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_ReverseRecapitalizationLineItems', window );"><strong>Reverse Recapitalization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_NumberOfMembersOfTheBoardOfDirectors', window );">Number of members of the board of directors | board_member</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_RecapitalizationExchangeRatio', window );">Recapitalization exchange ratio</a></td>
<td class="nump">0.0181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares) | shares</a></td>
<td class="nump">8,387,025<span></span>
</td>
<td class="nump">11,043,837<span></span>
</td>
<td class="nump">9,618,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares) | shares</a></td>
<td class="nump">8,387,025<span></span>
</td>
<td class="nump">11,029,382<span></span>
</td>
<td class="nump">9,603,723<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of promissory notes payable</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_ReverseRecapitalizationTransactionCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=angn_BridgeLoanBetweenAngionAndFormerElicioMember', window );">Bridge Loan Between Angion And Former Elicio | Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_ReverseRecapitalizationLineItems', window );"><strong>Reverse Recapitalization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_DebtInstrumentIssuanceDiscountPercent', window );">Debt instrument, issuance discount percent</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountInitialClosingMember', window );">Bridge Loan Between Angion And Former Elicio, Discount Amount, Initial Closing | Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_ReverseRecapitalizationLineItems', window );"><strong>Reverse Recapitalization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 6,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=angn_BridgeLoanBetweenAngionAndFormerElicioInitialClosingMember', window );">Bridge Loan Between Angion And Former Elicio, Initial Closing | Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_ReverseRecapitalizationLineItems', window );"><strong>Reverse Recapitalization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountAdditionalClosingMember', window );">Bridge Loan Between Angion And Former Elicio, Discount Amount, Additional Closing | Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_ReverseRecapitalizationLineItems', window );"><strong>Reverse Recapitalization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">6,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=angn_BridgeLoanBetweenAngionAndFormerElicioAdditionalClosingMember', window );">Bridge Loan Between Angion And Former Elicio, Additional Closing | Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_ReverseRecapitalizationLineItems', window );"><strong>Reverse Recapitalization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=angn_AngionCommonStockMember', window );">Angion Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_ReverseRecapitalizationLineItems', window );"><strong>Reverse Recapitalization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split, conversion ratio</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=angn_FormerElicioMember', window );">Former Elicio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_ReverseRecapitalizationLineItems', window );"><strong>Reverse Recapitalization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_NumberOfMembersOfTheBoardOfDirectors', window );">Number of members of the board of directors | board_member</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_DebtInstrumentIssuanceDiscountPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Issuance Discount Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_DebtInstrumentIssuanceDiscountPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_NumberOfMembersOfTheBoardOfDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Members Of The Board Of Directors</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_NumberOfMembersOfTheBoardOfDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_RecapitalizationExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recapitalization Exchange Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_RecapitalizationExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ReverseRecapitalizationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ReverseRecapitalizationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ReverseRecapitalizationTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse Recapitalization, Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ReverseRecapitalizationTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=angn_BridgeLoanBetweenAngionAndFormerElicioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=angn_BridgeLoanBetweenAngionAndFormerElicioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountInitialClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountInitialClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=angn_BridgeLoanBetweenAngionAndFormerElicioInitialClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=angn_BridgeLoanBetweenAngionAndFormerElicioInitialClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountAdditionalClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountAdditionalClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=angn_BridgeLoanBetweenAngionAndFormerElicioAdditionalClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=angn_BridgeLoanBetweenAngionAndFormerElicioAdditionalClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=angn_AngionCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=angn_AngionCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=angn_FormerElicioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=angn_FormerElicioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Merger and Related Transactions - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 01, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_ReverseRecapitalizationAbstract', window );"><strong>Reverse Recapitalization [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_CashAndCashEquivalentsAcquiredThroughReverseRecapitalization', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 24,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_OtherCurrentAssetsAcquiredThroughReverseRecapitalization', window );">Other current assets</a></td>
<td class="nump">540<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_PromissoryNotesAcquiredThroughReverseRecapitalization', window );">Promissory notes</a></td>
<td class="nump">10,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_AccruedLiabilitiesAssumedThroughReverseRecapitalization', window );">Accrued liabilities</a></td>
<td class="num">(2,438)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_NetAssetsAcquiredThroughReverseRecapitalization', window );">Net assets acquired</a></td>
<td class="nump">$ 32,130<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_AccruedLiabilitiesAssumedThroughReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities Assumed Through Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_AccruedLiabilitiesAssumedThroughReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_CashAndCashEquivalentsAcquiredThroughReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalents Acquired Through Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_CashAndCashEquivalentsAcquiredThroughReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_NetAssetsAcquiredThroughReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Assets Acquired Through Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_NetAssetsAcquiredThroughReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_OtherCurrentAssetsAcquiredThroughReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Current Assets Acquired Through Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_OtherCurrentAssetsAcquiredThroughReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_PromissoryNotesAcquiredThroughReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Promissory Notes Acquired Through Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_PromissoryNotesAcquiredThroughReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ReverseRecapitalizationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ReverseRecapitalizationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - Fair value measurements, recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">$ 12,100<span></span>
</td>
<td class="nump">$ 5,973<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">12,100<span></span>
</td>
<td class="nump">5,973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_WarrantsFairValueDisclosure', window );">Warrant liability</a></td>
<td class="nump">2,828<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">2,828<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">12,100<span></span>
</td>
<td class="nump">5,973<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">12,100<span></span>
</td>
<td class="nump">5,973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_WarrantsFairValueDisclosure', window );">Warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_WarrantsFairValueDisclosure', window );">Warrant liability</a></td>
<td class="nump">2,827<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">2,827<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_WarrantsFairValueDisclosure', window );">Warrant liability</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_WarrantsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_WarrantsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Fair Value, Liabilities, Measured on Recurring Basis, Unobservable Input Reconciliation (Details) - Warrant Liability - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, beginning of the period</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Existing Angion warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="num">(10)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, end of the period</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=angn_WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=angn_WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Pre-funded warrants outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,081,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_SaleOfStockBeneficialOwnershipLimitationPercentage', window );">Beneficial ownership limitation, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=angn_JulyPublicOfferingMember', window );">July Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross proceeds from offering | $</a></td>
<td class="nump">$ 10.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares) | shares</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=angn_JulyPublicOfferingMember', window );">July Public Offering | July Share And July Common Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share of shares issued (in dollars per share)</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=angn_PreFundedWarrantMember', window );">Pre-Funded Warrant | March Subscription Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares of common stock to purchase (up to) (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,032,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_SaleOfStockBeneficialOwnershipLimitationPercentage', window );">Beneficial ownership limitation, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=angn_PreFundedWarrantMember', window );">Pre-Funded Warrant | July Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember', window );">July Pre-Funded Warrants and July Common Warrants | July Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares of common stock to purchase (up to) (in shares) | shares</a></td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share of shares issued (in dollars per share)</a></td>
<td class="nump">$ 4.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=angn_JulyPreFundedWarrantsMember', window );">July Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=angn_JulyPreFundedWarrantsMember', window );">July Pre-Funded Warrants | July Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Pre-funded warrants outstanding (in shares) | shares</a></td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=angn_JulyCommonWarrantsMember', window );">July Common Warrants | July Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, contractual term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_SaleOfStockBeneficialOwnershipLimitationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Beneficial Ownership Limitation, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_SaleOfStockBeneficialOwnershipLimitationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=angn_JulyPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=angn_JulyPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=angn_JulySharesAndJulyCommonWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=angn_JulySharesAndJulyCommonWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=angn_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=angn_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=angn_MarchSubscriptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=angn_MarchSubscriptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=angn_JulyPreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=angn_JulyPreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=angn_JulyCommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=angn_JulyCommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Fair Value Measurement Inputs and Valuation Techniques (Details) - Level 3<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, contractual term</a></td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Weighted average strike price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="nump">76.00<span></span>
</td>
<td class="nump">76.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Volatility (annual)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="nump">0.749<span></span>
</td>
<td class="nump">0.940<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="nump">0.044<span></span>
</td>
<td class="nump">0.039<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Dividend yield (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="nump">0.000<span></span>
</td>
<td class="nump">0.000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=angn_MeasurementInputStrikePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=angn_MeasurementInputStrikePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Prepaid and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_PrepaidResearchAndDevelopmentExpenses', window );">Prepaid research and development contract services</a></td>
<td class="nump">$ 1,206<span></span>
</td>
<td class="nump">$ 1,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_AdvancedProfessionalFees', window );">Advanced professional fees</a></td>
<td class="nump">243<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">347<span></span>
</td>
<td class="nump">376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_OtherPrepaidExpensesAndOtherAssetsCurrent', window );">Other prepaid expenses and other current assets</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">173<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid and other current assets</a></td>
<td class="nump">$ 1,897<span></span>
</td>
<td class="nump">$ 2,732<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_AdvancedProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Advanced Professional Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_AdvancedProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_OtherPrepaidExpensesAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Prepaid Expenses And Other Assets, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_OtherPrepaidExpensesAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_PrepaidResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Research And Development Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_PrepaidResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 2,035<span></span>
</td>
<td class="nump">$ 1,948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(1,552)<span></span>
</td>
<td class="num">(1,231)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">483<span></span>
</td>
<td class="nump">717<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">1,661<span></span>
</td>
<td class="nump">1,574<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">242<span></span>
</td>
<td class="nump">242<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 132<span></span>
</td>
<td class="nump">$ 132<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 321<span></span>
</td>
<td class="nump">$ 382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseOtherNoncurrent', window );">Other long-term prepaid assets</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 2,833<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseOtherNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts paid in advance which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseOtherNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">$ 1,167<span></span>
</td>
<td class="nump">$ 945<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">2,312<span></span>
</td>
<td class="nump">1,849<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_AccruedResearchAndDevelopmentCurrent', window );">Accrued research and development</a></td>
<td class="nump">4,910<span></span>
</td>
<td class="nump">912<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_AccruedOtherOperatingLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 8,415<span></span>
</td>
<td class="nump">$ 3,757<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_AccruedOtherOperatingLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Other Operating Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_AccruedOtherOperatingLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_AccruedResearchAndDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Research And Development, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_AccruedResearchAndDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research Grant (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>agreement</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">$ (33,656,000)<span></span>
</td>
<td class="num">$ (23,849,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred research obligation</a></td>
<td class="nump">1,169,000<span></span>
</td>
<td class="nump">694,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash, current</a></td>
<td class="nump">$ 1,178,000<span></span>
</td>
<td class="nump">722,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_NumberOfResearchGrantAgreements', window );">Number of research grant agreements | agreement</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept2022Member', window );">Research Grant Agreement with GIRF Sept. 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_ResearchAndDevelopmentArrangementGrant', window );">Grant award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_ResearchAndDevelopmentArrangementGrantReceived', window );">Grant award received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(1,900,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFJuly2023Member', window );">Research Grant Agreement with GIRF July 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_ResearchAndDevelopmentArrangementGrant', window );">Grant award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_ResearchAndDevelopmentArrangementCredit', window );">Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept.2023Member', window );">Research Grant Agreement With The Gastro-Intestinal Research Foundation (&#8220;GIRF&#8221;) Sept. 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_ResearchAndDevelopmentArrangementGrantReceived', window );">Grant award received</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(2,200,000)<span></span>
</td>
<td class="num">$ (1,900,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred research obligation</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFAugust2024Member', window );">Research Grant Agreement With The Gastro-Intestinal Research Foundation (&#8220;GIRF&#8221;) August 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_ResearchAndDevelopmentArrangementGrant', window );">Grant award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred research obligation</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash, current</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_ResearchAndDevelopmentArrangementReimbursementFromGrantFunds', window );">Reimbursement from grant funds</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_NumberOfResearchGrantAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Research Grant Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_NumberOfResearchGrantAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ResearchAndDevelopmentArrangementCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Credit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ResearchAndDevelopmentArrangementCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ResearchAndDevelopmentArrangementGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Grant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ResearchAndDevelopmentArrangementGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ResearchAndDevelopmentArrangementGrantReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Grant Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ResearchAndDevelopmentArrangementGrantReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ResearchAndDevelopmentArrangementReimbursementFromGrantFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Reimbursement from Grant Funds</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ResearchAndDevelopmentArrangementReimbursementFromGrantFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFJuly2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFJuly2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept.2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept.2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFAugust2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFAugust2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock, Common Stock and Stockholders' Equity (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 01, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_SaleOfStockBeneficialOwnershipLimitationPercentage', window );">Beneficial ownership limitation, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.85<span></span>
</td>
<td class="nump">$ 54.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=angn_JulyPreFundedWarrantsMember', window );">July Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=angn_RegistrationStatementMember', window );">Registration Statement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_SaleOfStockAggregateInitialOfferingPrice', window );">Sale of stock, aggregate offering price (up to) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=angn_AtTheMarketEquityOfferingSalesAgreementMember', window );">At-The-Market Equity Offering Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_SaleOfStockAggregateInitialOfferingPrice', window );">Sale of stock, aggregate offering price (up to) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=angn_A2024RegistrationStatementMember', window );">2024 Registration Statement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_SaleOfStockAggregateInitialOfferingPrice', window );">Sale of stock, aggregate offering price (up to) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=angn_AtTheMarketEquityOfferingSalesAgreement2022Member', window );">At-The-Market Equity Offering Sales Agreement 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_SaleOfStockAggregateInitialOfferingPrice', window );">Sale of stock, aggregate offering price (up to) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=angn_MarchSubscriptionAgreementMember', window );">March Subscription Agreement | Pre-Funded Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_SaleOfStockBeneficialOwnershipLimitationPercentage', window );">Beneficial ownership limitation, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=angn_JulyPublicOfferingMember', window );">July Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross proceeds from offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=angn_JulyPublicOfferingMember', window );">July Public Offering | Pre-Funded Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=angn_JulyPublicOfferingMember', window );">July Public Offering | July Pre-Funded Warrants and July Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share of shares issued (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=angn_JulyPublicOfferingMember', window );">July Public Offering | July Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=angn_JulyPublicOfferingMember', window );">July Public Offering | July Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | At-The-Market Equity Offering Sales Agreement 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold in offering (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650,179<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross proceeds from offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | At-The-Market Equity Offering Sales Agreement 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold in offering (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross proceeds from offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=angn_FormerElicioEquityHoldersMember', window );">Former Elicio Equity Holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold in offering (in shares) | shares</a></td>
<td class="nump">5,375,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=angn_FormerElicioMember', window );">Former Elicio | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock (in shares) | shares</a></td>
<td class="nump">4,997,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_TemporaryEquitySharesIssuedDuringPeriod', window );">Shares issued during period (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible preferred stock | Former Elicio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares) | shares</a></td>
<td class="nump">276,128,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=angn_JulySharesAndJulyCommonWarrantMember', window );">July Share And July Common Warrant | July Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share of shares issued (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_SaleOfStockAggregateInitialOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Aggregate Initial Offering Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_SaleOfStockAggregateInitialOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_SaleOfStockBeneficialOwnershipLimitationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Beneficial Ownership Limitation, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_SaleOfStockBeneficialOwnershipLimitationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_TemporaryEquitySharesIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Shares Issued During Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_TemporaryEquitySharesIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=angn_JulyPreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=angn_JulyPreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=angn_RegistrationStatementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=angn_RegistrationStatementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=angn_AtTheMarketEquityOfferingSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=angn_AtTheMarketEquityOfferingSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=angn_A2024RegistrationStatementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=angn_A2024RegistrationStatementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=angn_AtTheMarketEquityOfferingSalesAgreement2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=angn_AtTheMarketEquityOfferingSalesAgreement2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=angn_MarchSubscriptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=angn_MarchSubscriptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=angn_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=angn_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=angn_JulyPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=angn_JulyPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=angn_JulyCommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=angn_JulyCommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=angn_AtTheMarketEquityOfferingSalesAgreement2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=angn_AtTheMarketEquityOfferingSalesAgreement2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=angn_FormerElicioEquityHoldersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=angn_FormerElicioEquityHoldersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=angn_FormerElicioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=angn_FormerElicioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=angn_JulySharesAndJulyCommonWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=angn_JulySharesAndJulyCommonWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">798,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation related to unvested stock option awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.1<span></span>
</td>
<td class="nump">$ 3.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation related to unvested stock option awards, period for recognition (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,015<span></span>
</td>
<td class="nump">165,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">3.68%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79.50%<span></span>
</td>
<td class="nump">71.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107.80%<span></span>
</td>
<td class="nump">75.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=angn_A2021PlanMember', window );">2021 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_CommonStockCapitalSharesReservedForFutureIssuanceIncreasePercentageOfCommonStockOutstanding', window );">Percentage of outstanding stock</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">298,795<span></span>
</td>
<td class="nump">298,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=angn_A2022PlanMember', window );">2022 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,283<span></span>
</td>
<td class="nump">175,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=angn_A2024PlanMember', window );">2024 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">387,332<span></span>
</td>
<td class="nump">387,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareLimit', window );">Share Based Compensation Arrangement By Share Based Payment Award, Share Limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_CommonStockCapitalSharesReservedForFutureIssuanceIncreasePercentageOfCommonStockOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Capital Shares Reserved for Future Issuance, Increase, Percentage Of Common Stock Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_CommonStockCapitalSharesReservedForFutureIssuanceIncreasePercentageOfCommonStockOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Share Limit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=angn_A2021PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=angn_A2021PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=angn_A2022PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=angn_A2022PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=angn_A2024PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=angn_A2024PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Share Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="nump">1,305,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">798,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="num">(9,757)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (unvested) (in shares)</a></td>
<td class="num">(204,169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period (in shares)</a></td>
<td class="nump">1,890,932<span></span>
</td>
<td class="nump">1,305,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options vested and exercisable (in shares)</a></td>
<td class="nump">860,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 21.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in dollars per share)</a></td>
<td class="nump">3.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in dollars per share)</a></td>
<td class="nump">3.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (unvested) (in dollars per share)</a></td>
<td class="nump">10.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period (in dollars per share)</a></td>
<td class="nump">15.69<span></span>
</td>
<td class="nump">$ 21.27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options vested and exercisable (in dollars per share)</a></td>
<td class="nump">$ 28.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock Option Activity, Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining contractual life (in years)</a></td>
<td class="text">6 years 9 months 10 days<span></span>
</td>
<td class="text">7 years 5 months 4 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options vested and exercisable, weighted average remaining contractual life (in years)</a></td>
<td class="text">4 years 9 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, total intrinsic value</a></td>
<td class="nump">$ 920<span></span>
</td>
<td class="nump">$ 2,511<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options vested and exercisable, total intrinsic value</a></td>
<td class="nump">$ 428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Components of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,452<span></span>
</td>
<td class="nump">$ 1,179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">582<span></span>
</td>
<td class="nump">552<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 870<span></span>
</td>
<td class="nump">$ 627<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Assumptions Used to Estimate Fair Value of Stock Option Awards (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.85<span></span>
</td>
<td class="nump">$ 54.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_FairValueOfCommonStockWarrants', window );">Fair value of common warrants at issuance date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,509<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_GainLossOnIssuanceOfWarrants', window );">Loss on issuance of pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,502<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Gain (loss) on fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,886)<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_SaleOfStockBeneficialOwnershipLimitationPercentage', window );">Beneficial ownership limitation, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=angn_PreFundedWarrantMember', window );">Pre-Funded Warrant | March Subscription Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_FairValueOfCommonStockWarrants', window );">Fair value of common warrants at issuance date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_GainLossOnIssuanceOfWarrants', window );">Loss on issuance of pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Gain (loss) on fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_SaleOfStockBeneficialOwnershipLimitationPercentage', window );">Beneficial ownership limitation, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1999<span></span>
</td>
<td class="nump">0.1999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=angn_PreFundedWarrantMember', window );">Pre-Funded Warrant | July Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_FairValueOfCommonStockWarrants', window );">Fair value of common warrants at issuance date</a></td>
<td class="nump">$ 6,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Gain (loss) on fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=angn_JulyCommonWarrantsMember', window );">July Common Warrants | July Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_FairValueOfCommonStockWarrants', window );">Fair value of common warrants at issuance date</a></td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Gain (loss) on fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember', window );">July Pre-Funded Warrants and July Common Warrants | July Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_GainLossOnIssuanceOfWarrants', window );">Loss on issuance of pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_FairValueOfCommonStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Of Common Stock Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_FairValueOfCommonStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_GainLossOnIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain Loss On Issuance Of Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_GainLossOnIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_SaleOfStockBeneficialOwnershipLimitationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Beneficial Ownership Limitation, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_SaleOfStockBeneficialOwnershipLimitationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=angn_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=angn_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=angn_MarchSubscriptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=angn_MarchSubscriptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=angn_JulyPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=angn_JulyPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=angn_JulyCommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=angn_JulyCommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants - Schedule of Issuance of Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jul. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_WarrantsIssuedShares', window );">Pre-funded warrants (in shares)</a></td>
<td class="nump">5,132,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54.19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=angn_PreFundedWarrantsMember', window );">Pre-funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_WarrantsIssuedShares', window );">Pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,032,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=angn_JulyPreFundedWarrantsMember', window );">July Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_WarrantsIssuedShares', window );">Pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=angn_JulyCommonWarrantsMember', window );">July Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_WarrantsIssuedShares', window );">Pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_WarrantsIssuedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Issued Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_WarrantsIssuedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=angn_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=angn_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=angn_JulyPreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=angn_JulyPreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=angn_JulyCommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=angn_JulyCommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants - Schedule of Outstanding Warrants (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_ClassOfWarrantOrRightRollForward', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding beginning balance (in shares) | shares</a></td>
<td class="nump">148,764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_ClassOfWarrantOrRightIssuedInPeriod', window );">Issued (in shares) | shares</a></td>
<td class="nump">5,132,702<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_ClassOfWarrantOrRightExercisedInPeriod', window );">Exercised (in shares) | shares</a></td>
<td class="num">(200,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding ending balance (in shares) | shares</a></td>
<td class="nump">5,081,466<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Outstanding beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 54.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceIssuedInPeriod', window );">Issued (in dollars per share) | $ / shares</a></td>
<td class="nump">2.34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Outstanding ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_ClassOfWarrantOrRightWeightedAverageLifeRollForward', window );"><strong>Weighted Average Life (years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_ClassOfWarrantOrRightWeightedAverageLife', window );">Outstanding beginning balance (in years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_ClassOfWarrantOrRightWeightedAverageLife', window );">Outstanding ending balance (in years)</a></td>
<td class="text">4 years 6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ClassOfWarrantOrRightExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Exercised In Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ClassOfWarrantOrRightExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ClassOfWarrantOrRightIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Issued In Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ClassOfWarrantOrRightIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ClassOfWarrantOrRightRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ClassOfWarrantOrRightRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Weighted Average Exercise Price, Exercises In Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Weighted Average Exercise Price, Issued In Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ClassOfWarrantOrRightWeightedAverageExercisePriceIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ClassOfWarrantOrRightWeightedAverageLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant Or Right, Weighted Average Life</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ClassOfWarrantOrRightWeightedAverageLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ClassOfWarrantOrRightWeightedAverageLifeRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Weighted Average Life</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ClassOfWarrantOrRightWeightedAverageLifeRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_LicenseExpense', window );">License expense</a></td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_OperatingLeaseFutureMinimumAnnualMaintenancePayments', window );">Future minimum payments</a></td>
<td class="nump">20.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_OperatingLeaseFutureMinimumAnnualMaintenancePaymentsDueThereafter', window );">Future minimum payments, thereafter</a></td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_LicenseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_LicenseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_OperatingLeaseFutureMinimumAnnualMaintenancePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Future Minimum, Annual Maintenance Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_OperatingLeaseFutureMinimumAnnualMaintenancePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_OperatingLeaseFutureMinimumAnnualMaintenancePaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Future Minimum, Annual Maintenance Payments, Due Thereafter</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_OperatingLeaseFutureMinimumAnnualMaintenancePaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 01, 2023 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,706<span></span>
</td>
<td class="nump">6,563<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 901<span></span>
</td>
<td class="nump">$ 910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSecuredLinesOfCredit', window );">Letter of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=angn_BostonMassachusettsMember', window );">Boston, Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=angn_NewtonMassachusettsMember', window );">Newton, Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office space (in sqft) | ft&#178;</a></td>
<td class="nump">6,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_LesseeOperatingLeaseAnnualRentExpense', window );">Operating lease, payment per year</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_LesseeOperatingLeaseAnnualRentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Annual Rent Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_LesseeOperatingLeaseAnnualRentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSecuredLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSecuredLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=angn_BostonMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=angn_BostonMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=angn_NewtonMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=angn_NewtonMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Quantitative Information about Operating Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash outflows from operating leases</a></td>
<td class="nump">$ 1,427<span></span>
</td>
<td class="nump">$ 1,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term&#8212;operating leases (in years)</a></td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate&#8212;operating leases</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Maturities of Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 1,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">1,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">1,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">1,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">1,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">7,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less present value discount</a></td>
<td class="num">(1,384)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">6,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: operating lease liability, current portion</a></td>
<td class="num">(901)<span></span>
</td>
<td class="num">$ (910)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, noncurrent portion</a></td>
<td class="nump">$ 5,105<span></span>
</td>
<td class="nump">$ 6,007<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 31, 2024 </div>
<div>USD ($) </div>
<div>day </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 01, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible debt</a></td>
<td class="nump">$ 19,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes Payable | Bridge Loan Between Angion And Former Elicio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_DebtInstrumentIssuanceDiscountPercent', window );">Debt instrument, issuance discount percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes Payable | Bridge Loan Between Angion And Former Elicio, Discount Amount, Initial Closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes Payable | Bridge Loan Between Angion And Former Elicio, Initial Closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes Payable | Bridge Loan Between Angion And Former Elicio, Discount Amount, Additional Closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes Payable | Bridge Loan Between Angion And Former Elicio, Additional Closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Embedded derivative, fair value of embedded derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Senior Secured Convertible Promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Convertible notes accrue interest, percent</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price | $ / shares</a></td>
<td class="nump">$ 5.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Percentage of stock price trigger</a></td>
<td class="nump">135.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Trading days | day</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Consecutive trading days | day</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_DebtInstrumentIssuanceDiscountPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Issuance Discount Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_DebtInstrumentIssuanceDiscountPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=angn_BridgeLoanBetweenAngionAndFormerElicioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=angn_BridgeLoanBetweenAngionAndFormerElicioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountInitialClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountInitialClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=angn_BridgeLoanBetweenAngionAndFormerElicioInitialClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=angn_BridgeLoanBetweenAngionAndFormerElicioInitialClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountAdditionalClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountAdditionalClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=angn_BridgeLoanBetweenAngionAndFormerElicioAdditionalClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=angn_BridgeLoanBetweenAngionAndFormerElicioAdditionalClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=angn_ConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=angn_ConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=angn_SeniorSecuredConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=angn_SeniorSecuredConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">United States</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total Current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(11,236,000)<span></span>
</td>
<td class="nump">7,743,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">1,192,000<span></span>
</td>
<td class="nump">3,116,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability', window );">Change in valuation allowance</a></td>
<td class="nump">10,044,000<span></span>
</td>
<td class="num">(10,859,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total Deferred</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total tax provision</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax expense (benefit) from continuing operations attributable to an adjustment of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory federal income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax, net of federal benefits</a></td>
<td class="num">(2.40%)<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent', window );">Permanent differences</a></td>
<td class="num">(3.50%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_EffectiveIncomeTaxRateReconciliationTaxCreditFederalResearchAndDevelopmentPercent', window );">Federal research and development credits</a></td>
<td class="nump">0.036<span></span>
</td>
<td class="nump">0.031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent', window );">State research and development credits</a></td>
<td class="nump">0.006<span></span>
</td>
<td class="nump">0.008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other differences</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(19.40%)<span></span>
</td>
<td class="num">(30.90%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Permanent Differences, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_EffectiveIncomeTaxRateReconciliationTaxCreditFederalResearchAndDevelopmentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Tax Credit, Federal Research And Development, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_EffectiveIncomeTaxRateReconciliationTaxCreditFederalResearchAndDevelopmentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Tax Credit, State Research And Development, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>Deferred tax assets (liabilities):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 64,646<span></span>
</td>
<td class="nump">$ 60,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Research and development tax credit carryovers</a></td>
<td class="nump">15,117<span></span>
</td>
<td class="nump">12,940<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Capitalized research and development</a></td>
<td class="nump">17,585<span></span>
</td>
<td class="nump">13,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_DeferredTaxAssetsOperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">1,548<span></span>
</td>
<td class="nump">1,897<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">2,704<span></span>
</td>
<td class="nump">2,732<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">ROU asset</a></td>
<td class="num">(1,470)<span></span>
</td>
<td class="num">(1,800)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_DeferredTaxAssetsNetBeforeValuationAllowance', window );">Total deferred tax assets</a></td>
<td class="nump">100,117<span></span>
</td>
<td class="nump">90,118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Deferred tax asset valuation allowance</a></td>
<td class="num">(100,117)<span></span>
</td>
<td class="num">(90,118)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax asset</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_DeferredTaxAssetsNetBeforeValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Net, Before Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_DeferredTaxAssetsNetBeforeValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_DeferredTaxAssetsOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_DeferredTaxAssetsOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expenses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance increase</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax positions</a></td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized tax benefits, income tax penalties and interest accrued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">261,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">12,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction | Tax Year 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">19,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">145,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_TaxYear2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=angn_EmployeeBenefitPlanMember', window );">Employee Benefit Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage', window );">Employers matching contribution annual vesting (in percentage)</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employer's matching contributions to a defined contribution plan that vests in a given year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=angn_EmployeeBenefitPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=angn_EmployeeBenefitPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Net Loss Per Share, Basic and Diluted (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 01, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (51,898)<span></span>
</td>
<td class="num">$ (35,195)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used in computing net loss per share, basic (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,202,996<span></span>
</td>
<td class="nump">5,056,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used in computing net loss per share, diluted (in shares)</a></td>
<td class="nump">9,700,000<span></span>
</td>
<td class="nump">12,202,996<span></span>
</td>
<td class="nump">5,056,225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4.25)<span></span>
</td>
<td class="num">$ (6.96)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4.25)<span></span>
</td>
<td class="num">$ (6.96)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Antidilutive Securities Excluded From Computation of Net Loss per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">4,339,696<span></span>
</td>
<td class="nump">1,456,621<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Shares issuable upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">1,890,932<span></span>
</td>
<td class="nump">1,305,924<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Shares issuable upon the exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">2,448,764<span></span>
</td>
<td class="nump">148,764<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=angn_UnvestedCommonStockMember', window );">Unvested common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,933<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=angn_UnvestedCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=angn_UnvestedCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 02, 2024</div></th>
<th class="th"><div>Mar. 19, 2024</div></th>
<th class="th"><div>Aug. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jul. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.85<span></span>
</td>
<td class="nump">$ 54.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of common stock warrants from March PIPE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,985<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_ClassOfWarrantOrRightIssuedInPeriod', window );">Issued in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,132,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=angn_SeniorSecuredConvertiblePromissoryNoteMember', window );">Senior Secured Convertible Promissory Note | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=angn_MarchSubscriptionAgreementMember', window );">March Subscription Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of common stock warrants from March PIPE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=angn_MarchSubscriptionAgreementMember', window );">March Subscription Agreement | Pre-Funded Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=angn_JulyPublicOfferingMember', window );">July Public Offering | Pre-Funded Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=angn_ConsultingServicePaymentsMember', window );">Consulting Service Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction, amounts of transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=angn_PurchaseOfWarrantsMember', window );">Purchase Of Warrants | July Public Offering | July Pre-Funded Warrants and July Common Warrants | Yekaterina Chudnovsky</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_ClassOfWarrantOrRightIssuedInPeriod', window );">Issued in period</a></td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=angn_PurchaseOfWarrantsMember', window );">Purchase Of Warrants | July Public Offering | July Pre-Funded Warrants and July Common Warrants | Jay Venkatesan and Trusts Affiliated With Jay Venkatesan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_ClassOfWarrantOrRightIssuedInPeriod', window );">Issued in period</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ClassOfWarrantOrRightIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Issued In Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ClassOfWarrantOrRightIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=angn_SeniorSecuredConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=angn_SeniorSecuredConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=angn_MarchSubscriptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=angn_MarchSubscriptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=angn_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=angn_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=angn_JulyPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=angn_JulyPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=angn_ConsultingServicePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=angn_ConsultingServicePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=angn_PurchaseOfWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=angn_PurchaseOfWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=angn_YekaterinaChudnovskyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=angn_YekaterinaChudnovskyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=angn_JayVenkatesanAndTrustsAffiliatedWithJayVenkatesanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=angn_JayVenkatesanAndTrustsAffiliatedWithJayVenkatesanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>entity</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | entity</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 33,656<span></span>
</td>
<td class="nump">$ 23,849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Employee related general and administrative expenses</a></td>
<td class="nump">11,330<span></span>
</td>
<td class="nump">11,896<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(51,898)<span></span>
</td>
<td class="num">(35,195)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total segment assets</a></td>
<td class="nump">28,178<span></span>
</td>
<td class="nump">27,146<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=angn_ReportableSegmentMember', window );">Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RecoveryOfDirectCosts', window );">Contract and grant reimbursements</a></td>
<td class="num">(1,027)<span></span>
</td>
<td class="num">(3,800)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Employee related general and administrative expenses</a></td>
<td class="nump">3,682<span></span>
</td>
<td class="nump">3,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Professional fees and other general and administrative expenses</a></td>
<td class="nump">7,648<span></span>
</td>
<td class="nump">8,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment items</a></td>
<td class="nump">6,912<span></span>
</td>
<td class="num">(445)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">51,898<span></span>
</td>
<td class="nump">35,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total segment assets</a></td>
<td class="nump">28,178<span></span>
</td>
<td class="nump">27,146<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=angn_ClinicalTrailMember', window );">Clinical trial expenses | Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">15,892<span></span>
</td>
<td class="nump">7,066<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=angn_EmployeeRelatedReasearchAndDevelopmentMember', window );">Employee related research and development expenses | Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">8,560<span></span>
</td>
<td class="nump">7,306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=angn_TranslationalMedicineAndCMCMember', window );">Chemistry, manufacturing and controls expenses | Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">4,260<span></span>
</td>
<td class="nump">7,623<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=angn_OtherMember', window );">Other research and development expenses | Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 5,971<span></span>
</td>
<td class="nump">$ 5,553<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecoveryOfDirectCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Return of or reimbursements received in relation to direct costs and expenses previously paid or incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecoveryOfDirectCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=angn_ReportableSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=angn_ReportableSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=angn_ClinicalTrailMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=angn_ClinicalTrailMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=angn_EmployeeRelatedReasearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=angn_EmployeeRelatedReasearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=angn_TranslationalMedicineAndCMCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=angn_TranslationalMedicineAndCMCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=angn_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=angn_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 05, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 29, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2024 </div>
<div>USD ($) </div>
<div>entity </div>
<div>day </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.85<span></span>
</td>
<td class="nump">$ 54.19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=angn_SeniorSecuredConvertiblePromissoryNoteMember', window );">Senior Secured Convertible Promissory Note | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Consecutive trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=angn_SeniorSecuredConvertiblePromissoryNoteMember', window );">Senior Secured Convertible Promissory Note | Convertible Debt | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Consecutive trading days | entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=angn_SeniorSecuredConvertiblePromissoryNoteMember', window );">Senior Secured Convertible Promissory Note | Convertible Debt | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Consecutive trading days | entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Subsequent Event | Pre-Funded Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares of common stock to purchase (up to) (in shares) | shares</a></td>
<td class="nump">3,500,573<span></span>
</td>
<td class="nump">1,261,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross proceeds from offering | $</a></td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_AccruedInterestPremiumForConvertiblePreferredStock', window );">Accrued interest | $</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_AccruedInterestPremiumForConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Interest Premium For Convertible Preferred Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_AccruedInterestPremiumForConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=angn_SeniorSecuredConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=angn_SeniorSecuredConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=angn_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=angn_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>115
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( /4X?UI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( /4X?UJMM5.+\@   "L"   1
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MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
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M"CS<_N\-L,+$CN'MB[\!4$L#!!0    ( /4X?UI#B=DY'0@  "DR   8
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M"+HMQ,Z#05M>P-LC; EHIV%$2## FV$G1<)SVF[EY0XG=%MG3# .,>DCM^W
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M_?K90%E(:"[M\A!\^<[Q.>8S_L9KQN]%"B#10T9S,3%2*8M+TQ1Q"AD6 U9
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M+1&M,K3F)23*3L_@@:'?N93H$GVZ?XLN?GRU]!1@T1Z]M!WWMAF73(R+"?K
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M@LW;W!)$FPA&>#%=J$BO;\3_AAU)>G;4T@L?76C@KZQ'".*4S._=G+R4M_,
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M_+8W1K6>XX0S36OGJ'!&!^<HJ>FH9J":B6H+5+-0S48U!]7<XS9R#QW41[4
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MQ+92$,[<Q9 .8+HB$0QR=@ Y"R]>48V;\.>58CJT%&*ONF*H&01PYOPZB<D
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M;T2UOV1R?M2!>\1)L"*XM(MZJ]GZEK&,GX09O^VBJKEC#E!SE\/Q-,/.50I
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M_4+H9-]],#]P^!.'V_\!4$L#!!0    ( /4X?UKO9-N5)0D  (L7   8
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MQ:PSSL!\H> M[7T:(KA*K(V+6I7656Y[)U2V0S1P26MO[):M+/0M2*\A<%!
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M>#S.(#D^:XT -UX#1-C' P2/#+F?4-+I@LT/P_2-.\:A-.2["&W1@ 97-@G
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MN;',V>3OMSKGD!#;E2#Z08;2\3K_$SB0G&+6"H:9=DN:1=6ZJ453D%)?4(!
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MU-)Z:6F7XQ67IK;/SV;ZZRSM <6#4#L.R1S#:2)R1P8*WV37'SZIIRD2T2(
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M9Y=F6R("?<^"22&P7N+01'B\K?'Q2\#=A9F(5+0:7J!)%Q4K]A?A"9P_HT"
M?'Q0GPPBF"U[EP1ES'!*W#3;1?.2"XZX]HP4V.FWLP&4>/"S+598=9 K._UV
M>'LY6 &?E9*Z/;1Z*+Y%C%SVJ/PFC0QGWIOU=_L@S4X<>S+PZ"CS;0/I*-\W
MQ75Y[LXA1?BHI+4M8WQ@V:;&Q8WQVNCRQIU0:0$>Z,TKO3?C[ZYS;?*?:#2G
M)4+#G^1EF$E5=8\/F,3W&,YY2*3S)IXN\^P7TN6X>I!=T3XW?$$5[P_(N2S/
M[E2\N0JIG#"]8G$VI&M$2["U _7#$J:C,()<<4FA-I.KH,$#T9N6WY/ZF]P
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M')V9.3-B)DNE/YH*P+*76C9F&E36MI?#H<DJJ+F)5 L-/BF4KKG%K2Z'IM7
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M1ZO-T,@\3D6,GEC/IF2.5P\J"P7YV6G[I-X8.44.8^8D!<HN!A2(1&NCLSC
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M^,><-=F*%FV:#4N'13J/_+V3RRPS-<S+:3SVZ2X$:)3Q659;%%.2*R;P7S9
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MMD'=KA^&?:"EL\5%$E62LI/]^MV1DBP[MIL,Z] OMD3='9][>_ARMI3J5B<
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M#9!-E[/9/1#5-E4?DM$;K5II8 +_79/(]=J#A$A<3716<!;)[KBP*%]FJ9)
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M*&?'XM,&E<.O]%H4/,U2/?."VUX,#_?PZRM*VVULK[STT%GVO!J1TTX(7>6
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MC0:'DUZ= >V+-V6XP.%TBNM@>%S@_DV6)^#[W(!E\\(+=#?Z\_\ 4$L#!!0
M   ( /4X?UKOHPJ71@(  )L%   9    >&PO=V]R:W-H965T<R]S:&5E=#(W
M+GAM;*U476_3,!3]*U:8$$ALSF?7E232VH+@8:A:&3R[R6UC+;&#[33;O\=V
MTM!-:840+XVO?<^YY[B^-VZY>)0%@$)/5<EDXA1*U3.,959 1>05KX'IDRT7
M%5$Z%#LL:P$DMZ"JQ+[K3G!%*'/2V.ZM1!KS1I64P4H@V505$<]S*'F;.)YS
MV+BGNT*9#9S&-=G!&M1#O1(ZP@-+3BM@DG*&!&P3Y]:;+4*3;Q-^4&CET1H9
M)QO.'TWP-4\<UPB"$C)E&(C^[&$!96F(M(Q?/:<SE#3 X_6!_;/UKKULB(0%
M+W_27!6),W50#EO2E.J>MU^@]Q,9OHR7TOZBMLN-(@=EC52\ZL%:0459]R5/
M_3T< ;S)"8#? _S7@/ $(.@!@37:*;.VED21-!:\1<)D:S:SL'=CT=H-9>9?
M7"NA3ZG&J71%GM%>HA4(^R)8!FA)959RV0A E^AAO43O+MZC"T09^E[P1A*6
MRQ@K7=LPX*RO,^_J^"?J>#ZZXTP5$GUB.>0O"; 6/2CW#\KG_EG&)617*/ ^
M(-_UPQ%!B[^'!V?D!,-%!I8O^)>+'+NOCBX<IS/-.Y,UR2!Q='=*$'MPTK=O
MO(G[<<SK?R)[X3P<G(?GV--O>M9HFZ./HD->6Z09*/OT,O*F-],8[X_ECZ0%
MD7<3#6F=,'STSBL0.]O^$F6\8:I[.,-N-V'F>L+83GRUKR?/K6TX_(>F&UMW
M1.PHDZB$K:9TKZYUHXMN%'2!XK7MI@U7NC?MLM#3$X1)T.=;SM4A, 6&>9S^
M!E!+ P04    " #U.']:+'5HOD,"  "*!@  &0   'AL+W=O<FMS:&5E=',O
M<VAE970R."YX;6R=E5MOFS 4@/^*Q:0]M>&6RY8!4M)N6AXZ16FW/3MP *O&
M9K8)[;^O;0C+IH1*>0';G//Y.T8<HI:+9UD"*/12429CIU2J7KJN3$NHL)SP
M&IA^DG-18:6GHG!E+0!G-JFB;N!Y<[?"A#E)9->V(HEXHRAAL!5(-E6%Q>L:
M*&]CQW>."SM2E,HLN$E4XP(>0?VLMT+/W(&2D0J8))PA 7GLK/SE>F'B;< O
M JT\&2-3R9[S9S/99+'C&2&@D"I#P/IV@#N@U("TQI^>Z0Q;FL33\9'^S=:N
M:]EC"7><_B:9*F/GDX,RR'%#U8ZWWZ&O9V9X*:?27E';Q8:?'90V4O&J3]8&
M%6'=';_TYW"2H#GG$X(^(;#>W4;6\AXKG$2"MTB8:$TS UNJS=9RA)F7\JB$
M?DITGDHV^G@S$.A)X(RP JV$P*P ?>Q*1J[2.Y@X-^UIZXX67*"%Z($S54KT
ME660_9OO:K-!+SCJK8-1X#VD$Q3Z-RCP@ND(+QS*#2TOO, [5^8-VK^B#<O(
M@60-IN>J[J#3\U#SW2QEC5.('?UA2! '<)*/'_RY]V5$>3HH3\?HR:ZA@'QO
M/[OU3[71*N.U^O^0.]UQ8(ZIA!&QV2 V&^7\X.SV"KEQZ'MR\T%N?M6I/8'0
M7Q&^X#;.?,]M,;@MKCZX<;]Q[D4_]Z0_5" *VP4E2GG#5-<JAM6AT:ZZ_O(W
MO.O2#U@4A$E$(=>IWF2A7Z?H.E\W4;RVW6;/E>Y==ECJGP4($Z"?YYRKX\1L
M,/Q^DC=02P,$%     @ ]3A_6CRE,S@1 @  W00  !D   !X;"]W;W)K<VAE
M971S+W-H965T,CDN>&ULI53;CM,P$/T5RT@\H3I)+Z"21&IW0:S$2M4NEP?$
M@QM/$VM]";:S6?X>VTE#0=T*B9?88\\Y<X[C<=YK\V ; (>>I%"VP(US[9H0
M6S4@J9WI%I3?.6@CJ?.AJ8EM#5 605*0+$E61%*N<)G'M9TI<]TYP17L#+*=
ME-3\W(+0?8%3?%RXXW7CP@(I\Y;6< _N<[LS/B(3"^,2E.5:(0.' F_2]781
M\F/"%PZ]/9FCX&2O]4,(;EB!DR (!%0N,% _/,(5"!&(O(P?(R>>2@;@Z?S(
M_CYZ]U[VU,*5%E\Y<TV!WV#$X$ [X>YT_P%&/\O 5VEAXQ?U0^YRCE'56:?E
M"/8*)%?#2)_&<S@!I*MG -D(R*+NH5!4>4T=+7.C>V1"MF<+DV@UHKTXKL)/
MN7?&[W*/<^6-/UX&!GTRE'%5HYT6O.)@$54,[8RN@'4&;$Z<+Q8@I!J)MP-Q
M]@QQFJ%;K5QCT3O%@/U)0+S*26IVE+K-+C)>0S5#\_05RI)L<8%O/EF?1[[Y
M_UE'WSYZ(+IQ(.WW<^<P5%F<KQ*::FU;6D&!?==8,(^ RY<OTE7R]H*'Q>1A
M<8G]GSULF&[=WW]AD'^Y@#,=G--)3JZ<!%/'QK*HTIURP^V;5J?>W0Q7]G?Z
MT/BWU-1<623@X*')[/42(S,TTQ XW<8+O-?.MT.<-O[] 1,2_/Y!:W<,0H'I
M12M_ 5!+ P04    " #U.']:)R)O\IL*   9+P  &0   'AL+W=O<FMS:&5E
M=',O<VAE970S,"YX;6SM6FN/VS86_2N$"Q2[@#,S=I[-/("\V@[0;())=O,A
MV ^T1-O$2*)*4G;<7[_G7E*4['@T<:8+M,!\2,:2^+C/<P^O=+8V]MHME?+B
M2UE4[GRT]+Y^?GSLLJ4JI3LRM:KP9&YL*3TN[>+8U5;)G">5Q?'TY.3)<2EU
M-;HXXWOO[<69:7RA*_7>"M>4I;2;EZHPZ_/19-3>N-*+I:<;QQ=GM5RH#\K_
MNWYO<76<5LEUJ2JG326LFI^/7DR>OYP\HPD\XC]:K5WOMR!59L9<T\5E?CXZ
M(8E4H3)/2TC\6:E7JBAH)<CQ>UQTE/:DB?W?[>H_L_)09B:=>F6*3SKWR_/1
MLY'(U5PVA;\RZU]55.@QK9>9PO'_8AW'GHQ$UCAORC@9$I2Z"G_EEVB(;YDP
MC1.F+'?8B*5\+;V\.+-F+2R-QFKT@U7EV1!.5^25#][BJ<8\?_%J,U/6J:RQ
MVF_$E7;7XJVLX ]8W@M9Y0*CI5>+C7BM7588UUAU=NRQ-2UPG,5M7H9MIC=L
M,YF*MZ;R2R?>5+G*MQ<XALQ)\&DK^,OIX(JO578D'D[&8GHR?32PWL-DB(>\
MWL/O,<0X66',-OG%K)2M9)4I\?DW+"0NO2K=?_?9)>SZ:/^NE'//72TS=3Y"
M4CEE5VIT\>,/DR<GIP,Z/4HZ/1I:_1;GOK<F4\XI)Y#<X@7]<KI:C,5ECL=Z
MON$+4I<GX4I\7"+SO1.?/ZHO7KPL3':]5^EAL3XIY'-F%I7^0PF_5"*#?#J3
MA=!E;:QGNYJYJ*WQE+S8F$>9:JY9-%E G['0%3S"JI&0<B5U(6>:GM%LTR!?
M&V@$M010#/X###@>ZS:.''8D/FF_Q.+:83%*KWPLUDHLY4J1+ 4;2N4\AR#.
MXY\PU<*03-F6=2U9M^RL6UL"'!B8Y 3X9,;FK-B:MB3A> 9TG.M"\0Y)6@?#
MC$6#3+&L.46;(WAI]7K1Y-J+5Z8LM?>*C"B1K%8!CS"N@L3>"!W="!^R;X,O
M,4,O$,I[Q#\2[[#V]GW(M["R%&PA*@)8>[9AJ?[%!H77+BOGM6\\.^T#W)=+
MFP=#?U39LC*% 7QL!^//6%018 >I#!:T0M9U@3B8P1YP!<#/;H1KUX.SE%#5
M @8FC]G\02TM5J*D@9U)TA54MF'CE:IR@]^P [37SHLF^+@-97.3JCL1\NT
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MD@%SFRVO,<RDDC_N5=9$X\"VH+)C4.J-A#)S3<R.8A-61IW%@R/QNK%MV@-
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M!RWKKM3:"6;9(3F(X#;.L2%:J\?0'F8G7.+:5S1MX3L"S*L]_J4\YW6Y?=7
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M!9(MHL\=\Y:\PMBA?C*,0C&A.R\5RF-$--T=0'Q6'OB@ZW7'\1/Z" :?B$[
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M?$?;A'[])?L0D@/O[5*'FI*3N+VO2;Y+0-R"@]5>M(H(?%FO>]R,$2#':&
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MA7Y/+CYQ"BGV7$GL%CHPM4+<)5+);[A3YI"L?)XR^=YRT,2@7XQO.N89_"%
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M]WCY83Q?2B-J18&3B&N%T#YC-'W[)KD>O#_!-M^QS4^A3Q=<FF6GT&=M;KE
MK7L%H4MX>.IDRR7C#C$^B7F8\8R(=>%>">+4D9-<!5C"=\*J4_#(Y43_7,(0
M7E%8@H^=U=)U%@.E2K[X,4&VV7Y$+J+:J!)DTUKSC-Z88%$;Z]#ZD+H>7\F*
M([2@O 'P7O-_L+CU? F:6:X%06$84A)S9!A7(U1&L>SXM)Y+S2NF(S:EBQ'P
M"\)FR0ZWK\@WV5XX9Y!<7E\GH1_>Y,?"2O,T?$?"2K(T?-^,$PK:@_PAO1QD
M0W;S+K]E'*(1BU71-9T*UUTB)Z20(JC8.9,9IA>^3[/DXN2-G$%^FW%[D]S
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M<X'W"G37-$P]W6 M=PLO]/83'_BV,G;"7\Y;ML4UFD_MO:(W?T0I>(-"<RE
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MWBM0EK*PE-45_+JIYBA-+-]L]Y#A;(N2AL$_'SP*S4KXO-%*DT?#BBEC2=I
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M]5+)/2BK36A6<*DZ:PJ."UN46Z/H+2<[LWZ/E)*&LSNV+5&?+WU#H/:5GW8
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M^DX/\3*N4]D( V2*3P'-QP&\@-DX@1<GJ)'TU$C^'S5D#M?,-(H;3DYHY2@
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M G@E8S7M+5;:?CS$=C@:[#0:>@,_IC8*V=VWQ]V6M@,O'O@=ZH<^]K>: D4
M<@<_5J)RU@XPJ]I15!?<MX>#,?B^"V)$W1 9&3,^L+M'4J$R1B>5><=M^@$-
MO+=Z]_;N@@7HA;OQXKFIE;35M;"9;2[5%]5=\GEY=2/_RO5"8)W-88ZF?G>
M)5I7M]SJP:K2W2QGRN(]U0V7^&, FA;@^[E2MGX@!\VOQO1_4$L#!!0    (
M /4X?UI%U2K^RP,  +,(   9    >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM
M;(U6;8_:.!#^*Z.TJA8I)>2- @6D97>K.^E:K<KVJM/I/IAD &N=.&<[P/[[
M&SLAT!Z+^H7X;9YY9OR,A^E>JF>]131P*$2I9][6F&H2!#K;8L%T7U98TLY:
MJH(9FJI-H"N%+'=&A0BBP6 8%(R7WGSJUA[5?"IK(WB)CPIT711,O2Q0R/W,
M"[WCPE>^V1J[$,RG%=O@$LVWZE'1+.A0<EY@J;DL0>%ZYMV&DT5JS[L#?W+<
MZ[,QV$A64C[;R>_YS!M80B@P,Q:!T6>'=RB$!2(:_[:87N?2&IZ/C^B?7.P4
MRXIIO)/B.\_-=N:-/,AQS6IAOLK];]C&XPAF4FCW"_OV[,"#K-9&%JTQ,2AX
MV7S9H<W#KQA$K4'D>#>.',M[9MA\JN0>E#U-:';@0G761(Z7]E*61M$N)SLS
M_T+W_H?4&AY1P7++%,+-$UL)U+UI8,B!/19D+=BB 8M> 0LC^"Q+L]7P4.:8
M_P@0$+..7G2DMXBN(MYCUH<X]"$:1,D5O+@+-W9X\2MX#TR5O-R<A_OW[4H;
M1>KXYU+ #5QR&<Y6S$17+,.91R6A4>W0F[][$PX''Z^033JRR37T^9(J,*\%
M@ES#_^_)AP73/ -6YG#/16U^3G@3P'47)XB\@8"2' GKJ")'VF6(&:/XJC96
M%F D9+(HJ*!(F]GS5HH<E88]TY QD=6"611Z+<!L$5Z0T29:-0#=)18K0CW>
MI_-+@QC(>"T%/1 :;GA)EK+6M*E]P$.&E3D2H?,G6CGIO3>!O\A%H[<+'ASZ
ME[I Q8Q4$Y=&%]U;N$E#?S0>]>PP3OUPG/8(H)149,W9[ZZB,7_/=F2^P<:M
MAEJ3*V))::AJ0VJZD#/?/A4_93:,?*+CC\=#2/U!.O2C*#T1NFI*%)-^E#JN
MP_YXV+NBKK135_K+ZKHM#7>^Z(6$)6:UXH93J ^'3-0VLY^4+.#.!<S<:WHN
MR>HHR4OZNT[BB332Z&IE^P-42NYX3IXK:9!(,2%>H&.F3\Q*:>@.6G9.,MCI
MK^5GEZZH>H49HZNT@LXE:$GMHQ8Y+5/F#7]_=#IY357+1@U<Z]H%4%?D%@^H
M,JY=4EU]@*PL'PU6; -_'$<TB@>I/R:<BQ"6]CG,GBE%C#1$?I*,_ _#!,+V
M^ZW<H;;AG5<DO'LSBL+H(_D9QS$\2<,$)'X<C_TA22_T$Y+>, HO22@X:R14
M,QO7+JFP95V:IJ=TJUU'OFT:T>EXT\X_,[7A%+? -9D.^A]("*IID<W$R,JU
MI94TU.3<<$O_*E#9 [2_EB2!=F(==/]3YO\!4$L#!!0    ( /4X?UK%VHI+
M8P,  %4'   9    >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;(U5VV[C-A#]
ME8&V6-B $-UE)6L;2+Q;=!\6#9*T?2CZ0$LC2UB*5$DJCO^^0\I64JS7R(O$
MRYPS9\B9X7(OU7?=(!IXZ;C0*Z\QIK\) ETVV#%])7L4M%-+U3%#4[4+=*^0
M50[4\2 .PSSH6"N\]=*MW:OU4@Z&MP+O%>BAZY@ZW"&7^Y47>:>%AW;7&+L0
MK)<]V^$CFC_Z>T6S8&*IV@Z%;J4 A?7*NXUN[E)K[PS^;'&OWXS!1K*5\KN=
M?*U67F@%(<?26 9&OV?<(.>6B&3\>^3T)I<6^'9\8O_5Q4ZQ;)G&C>1_M95I
M5E[A084U&[AYD/O?\!A/9OE*R;7[PGZTS5(/RD$;V1W!I*!KQ?AG+\=S> ,H
MPI\ XB,@=KI'1T[E9V;8>JGD'I2U)C8[<*$Z-(EKA;V41Z-HMR6<63_BCH[8
MP /V4IE6[&#VQ+8<]7P9&.*W5D%YY+H;N>*?<$4Q?)/"-!J^B JK_Q,$)&Q2
M%Y_4W<47&3]C>05)Y$,<QND%OF2*-G%\R;NC_?MVJXVBW/CG7+PC6WJ>S=;+
MC>Y9B2N/"D*C>D9O_?%#E(>?+FA-)ZWI)?;U(]5?-7 $6<./NK^*L2 ILWW8
M'DX6YX*XZ.9\$$\-0BTY5:SU96Q"@-L51D.)RE"U0]T*)LJ6<:@H\\A>@2'<
M1G8]$X>/'XHX6GS25+E6LZ/0QS!FA#:-'#03E9[? %TS=EM4TU7;3P(;TMJ6
MQ&^4]8(OU(DT:O@%HLPOKF,:+/PPS^%+UW-Y0"1?G!FLP$IEJFR '%"-/E/O
MZ9WGB:/PLSPD>!+FL*%&UU(6''RJ+#'4E V#LH%;=$D9K:C(7J&I'SMH3A)_
MIXC5.]QE_O4BHF^645B6D7PXZYUB9*>P[;:#TMBY$YY%?A@OYC!+_"(,YS_&
MMT.!BH[$,K"*VH*5SVQ_>W69^'D1TS=-%G"O9(W:-E("U4B[%BF=^/=P4;!I
M06>69MDQY--5M@8[#;E_3<4_2]-L/N6JH!>%2VVO*XOHN@H:))D?76?P) TY
M/%$PK=%8L[CPHX4UBQ=^E.9PKHB"-ZVN0[5S#9UR4@["C%UO6IW>C-NQ5;Z:
MCP_.-Z9VK=# L29H>+7(/%!C$Q\G1O:N<6ZEH3;LA@V]>ZBL >W74IK3Q#J8
M7M+U?U!+ P04    " #U.']:<P0M]P($   4$0  &0   'AL+W=O<FMS:&5E
M=',O<VAE970T,BYX;6S-6-]OVS80_E<(K1@2P+-^6);MS#806RF:HMV"9ET>
MACTP$FT1I4B5I.SFO]]1DA7+4;08T$/S$)/4W<?[OA///,_W0GY3"2$:_4@9
M5PLKT3J[LFT5)23%:B@RPN')1L@4:YC*K:TR27!<.*7,]APGL%-,N;6<%VMW
M<CD7N6:4DSN)5)ZF6#ZM"!/[A>5:AX4O=)MHLV OYQG>DGNBOV9W$F9VC1+3
ME'!%!4>2;!;6M7L5NIYQ*"S^IF2OCL;(4'D4XIN9W,8+RS$1$48B;2 P?.S(
MFC!FD"".[Q6H5>]I'(_'!_3W!7D@\X@560OV0&.=+*RIA6*RP3G37\3^ ZD(
MC0U>))@J_J-]9>M8*,J5%FGE#!&DE)>?^$<EQ)&#Z[_BX%4.WJE#\(K#J'(8
MO74'OW+P"V5**H4.(=9X.9=BCZ2Q!C0S*,0LO($^Y2;O]UK"4PI^>AD2%4F:
M%3D0&Z03@E:Y B.E$.8Q>D\YYA'%#*T%CVEA=Q$2C2E3E^@W]/4^1!?O+M$[
M1#GZ*Q&Y B\UMS7$9G:PHRJ.=1F']TH<KH<^"ZX3A6YX3.(F@ VD:F;>@=G*
MZT3\F/,A<MP!\AQOU!90MWM(HB$:E>Y^BWOX=O=1!YM1G:=1@3=Z!0_45X+1
M&)L,#- GDQ^=8(X>$L'8$_ISSTF,[O-'16,*!WB [K D7!</I$IHAFZY)I(H
M/4 WFPT<.V42O@:,+5$#] ?4F'\^P:[H5I-4_=M">56&Z+>':"K4E<IP1!86
ME"!%Y(Y8RU]_<0/G]S;Y^P0+>P)KI,:O4^-WH2\?BMH"ZN,=D5 K4232%(Z)
M2B #('*NE89#0?EV@&+*<F-Z00_/+]N$+C<,B@U-Y=XM9Q/'_,WMW;&&+^U<
M#UZXV2QH&H8O#<?../"\<6W7H#ZNJ8\[J5]'49[F#!M*4&QI1'4;G4Z0<]^;
M$FQRS'GFNXY[PKC%S =M1NV$@YIPT$EXC552U,7(#,CWG.XP@V/65O%6G5#G
MT@Y>\ID$[O2$=8N5-YWY[:0G->E))VGS!4LDNF&07X%N@+1^0A\$BZ&PM/'N
M1#N7=Y]@84]@#16GM8K3G[^"3_M,39]@84]@C=3,ZM3,.E_P9X4S(B/0'*IX
MFWHERNSH=#G#8.R=%.7.O<Z5I2>PABRN\WPY=-YR\J_YUMS[_O_D=\.=^W[U
MBA;VA=:4\NB>[?[\Q[^*L:_\](D6]H76S(_WG!^OEQI0P32+P,@_^2)>=^]V
MMC8]H97:V$?M(ASO;=%V*[BVYER7_56]6K;V:]/:FW;S9!U:_NNBT;6?8<K?
M"SYCN:5<(48V .D,)W =DV4+7DZTR(JF]%%H:'&+84(PU!5C ,\W0NC#Q&Q0
M_Q"R_ ]02P,$%     @ ]3A_6H1797UV P  \@T  !D   !X;"]W;W)K<VAE
M971S+W-H965T-#,N>&ULM9?;;N,V$(9?9: &Q2Z06B?'<5+;0&*W:(IN$<38
M]J+H!2./)2(4J9*TG19]^/*@:"W#UL: >F.+%.>;F9_DB)SLA'Q1!:*&UY)Q
M-0T*K:O;,%19@251 U$A-V_60I9$FZ;,0U5))"MG5+(PB:)16!+*@]G$]3W*
MV41L-*,<'R6H35D2^?<],K&;!G'PUO%$\T+;CG VJ4B.2]2?JT=I6F%#6=$2
MN:*"@\3U-+B+;Q=Q9 W<B-\H[M3>,]A4GH5XL8V'U32(;$3(,-,60<S?%N?(
MF"69./ZJH4'CTQKN/[_1?W3)FV2>B<*Y8+_3E2ZFP3B %:[)ANDGL?L)ZX2N
M+"\33+E?V/FQHZL LHW2HJR-300EY?Z?O-9"[!DDIPR2VB Y,$C3$P9I;9"^
MUV!8&PR=,CX5I\.":#*;2+$#:4<;FGUP8CIKDS[E=MZ76IJWU-CIV=+/-X@U
M+&G.Z9IFA&NXRS*QX9KR'!X%HQE%!=_!KT1*8N<)/BQ0$\K4QTFH3126%6:U
MQ[GWF)SP&"?P27!=*/B!KW#5!H0F_":'Y"V'^Z23^/.&#R"*+R&)DA0N( 15
M$(GJ6&S=I 5F T@]:0B?EPOX</&QF[AX/S']*K&5?MI,8>I<I"=<S!E1RDV@
M%MD+_/&+>0\/&DOUYY%X[SUL>!QFR\RMJDB&T\#4$85RB\'LVV_B4?3],3G[
MA"UZ@K5$'#8B#KOHL[DH2U.&E)7P$BHB84O8QBQTRF$E&"-20872S]JQ57_?
MR3]75P\;.Y@MW=M9-(CB2;C=U^LK@UHZ7#4Z7'7J\(09J:@FC/Y#7&'&UZP@
M/$>P.U\<2]P#3>EOQS$^"'?>Z?C<M=(3K*71J-%HU*G10UD1*LW'3]M=QX0I
MDLP4Q168?8A:P;]P<4RG3NBY"\3#KO<U/U@=72-::5\W:5]WIGW'<[L@ZIWB
MBLVQ-#LAYZ;9)VS1$ZPEWK@1;]QGD1[W*6*?L$5/L):(-XV(-_]SD;YY1UV=
M=P9QKEX]P5IZQ=&7TUW4J9A?;:IB5%]")O@6I3^QGRKF-2^.6Q(=*M3M]5R)
M^J)YC<*]PW"),G>7"@7N/.O/E$VOO[C,[<7%'J8/^LV%YLX=X\,O&'\;^D1D
M3KD"AFN#C ;7YFLD_07#-[2HW)'[66AS@'>/A;F4H;0#S/NU$/JM81TTU[S9
M?U!+ P04    " #U.']:2G$1#&("   K!P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970T-"YX;6R]E6UKVS 0Q[_*X<'HH(L=YVEDB:$/*RML$!JVO1A[H=CG
M1%267.G<)-^^DNQX*21^,>C>Q#KI[J_?G2[2;*OTH]D@$NP*(<T\V!"5TS T
MZ08+9GJJ1&E7<J4+1M;4Z]"4&EGF@PH1QE$T#@O&99#,_-Q")S-5D> 2%QI,
M511,[Z]1J.T\Z >'B0>^WI";")-9R=:X1/I1+K2UPE8EXP5*PY4$C?D\N.I/
MKR?.WSO\Y+@U1V-PF:R4>G3&?38/(@>$ E-R"LQ^GO$&A7!"%N.IT0S:+5W@
M\?B@?N=SM[FLF,$;)7[QC#;SX%, &>:L$O2@ME^QR6?D]%(EC/^%;>,;!9!6
MAE31!%N"@LOZRW9-'8X"^L,S 7$3$'ON>B-/><N()3.MMJ"=MU5S Y^JC[9P
M7+I#69*VJ]S&4;*L#P-4#DN^ECSG*9,$5VFJ*DE<KF&A!$\Y&O@(2]L26270
M>2^T;0Q->V R@R]/%2_M41%<W"(Q+LR'64@6SVT2I@W*=8T2GT&YQ;0'@_XE
MQ%$\?!T>VJS:U.(VM=CK#<_HM5"G4#I#W3]A:DJ6XCRPK6Y0/V.0O'_7'T>?
M.\ &+=C JP_.@!U*=PD+X8K]NH*_OUEWN"<LS)]3Y(,W(!^VY,/.DOXE+UMR
M/)!?0F4PKP0(GB-<< E[9/IT)W1O,ZHC.X!'+?"H4^FNTI)3I=&CYGSGQN84
M4:?./Y9UW%*.W[ AQF] /FG))_^G(;JW&9QOB/#H[G//R'>FUUP:$)A;J:@W
ML0>KZZNY-DB5_CI<*;*7JQ]N[&N&VCG8]5PI.ACNAFW?Q^0%4$L#!!0    (
M /4X?UH;T749# 8  ,PH   9    >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM
M;+5:;6_;-A#^*X17#"V0Q1+EU\PQX)A[Z= 60=)N'X9AH"7:%BJ)'DG'[; ?
M/U)2)-.2B:@X?TDDF?<<[R%YO$?B[,#%9[EE3*$O:9+)V]Y6J=U-OR_#+4NI
MO.8[ENE?UERD5.E;L>G+G6 TRHW2I(\];]1/:9SUYK/\V;V8S_A>)7'&[@62
M^S2EXNL=2_CAMN?WGA\\Q)NM,@_Z\]F.;M@C4Y]V]T+?]2N4*$Y9)F.>(<'6
MM[V%?T."W"!O\7O,#O+H&IE05IQ_-C=OH]N>9WK$$A8J T'UOR>V9$EBD'0_
M_BE!>Y5/8WA\_8S^<QZ\#F9%)5ORY(\X4MO;WJ2'(K:F^T0]\,.OK QH:/!"
MGLC\+SJ4;;T>"O=2\;0TUCU(XZSX3[^41!P9#/ 9 UP:X!,#/#UC$)0&P4L-
M!J7!(&>F""7G@5!%YS/!#TB8UAK-7.1DYM8Z_#@SX_ZHA/XUUG9J_IZ)#1.(
M9A%Z8 E5+$(?!<TDS8=%HA_0!RH$-8.#7A.F:)S(-^@5BC/T<<OW4AO*65_I
MGAB\?EAZ719>\1FO/D;O>::V$OV412RR ?HZA"H._!S''78B_K;/KI'G7R'L
MX0!]>B3H]:LW:,6IB/Y.6;K2,<HM%:RULVYHPL)K%!30@PKZ+!IY.5K@1+-X
M"*KQ#'+XX S\ WMB0C(]F"'=Q8HF\;\T7V!_OM,MT5O%4OE72Z_O"MA!.ZS)
M/C=R1T-VV]/I13+QQ'KS[[_S1]Z/;81"@A$@,(O.047GP(4^_[#/IPY?HV(2
M27.IMJR86>8FBH5.85S_\I\UW=HX+GR-<E\F(3_-I[/^TS%QSMYT)0X(S")N
M6!$W=!+7F'_L2[BEV88ADTQX&SL%H.\=T>-=>_[$/^'(Z;@K1T!@%D>CBJ.1
MDZ,E3U/-C,[QX>>K,@6@6,J]3L*O=8(MGKS1$^MLLKD;-:;4))B,/3P\(:W9
MSO>]03 )QG9#TFPX'>DQ&$^J=E:LXRK6<?=8=1TBE=Y!XFSSXH#'+PRXV4X'
MC*?!!)\$W&PX'7G!& ?M 4^J@"?.@'_1-1?*Y[W2X>UCN=75DC(98R=XJD>9
MBZ\HXTK3L*-?Z2IA;=$6/L9'G1MYWDFDS38G+4@;RK ]O&D5WM09WE&1@$(N
M5>M8.2&Z[BG31A!X>LH% ?)H4>)[=2WE.4FY$W&D,]P[3C-TQ]2!L0PMLHWA
M:*$++%.HZLWDIR0.8ZXG^8=\]._/C[[;75<"0=$(%)I-]5'9ZE^FSBEQH3B%
M1"-0:#:GN.84.Z<O82NE"WNIQ-[DJBNTUKX03?D^4ZU4XL:2]/&PD9_<7CMS
M!(1F<U27U[ZSW&QR9/9KFFF>HEB&ABFT8R)D9Q@KP'ULU3CXE##0\AD*S2:L
M+J!]=P7=)2=>(?),XB*?=5?H;1:KF"9HF7!IRH279$W((GH)BD:@T.S!J(MR
M?WBAK E9="]!T0@4FLUI7<3[[BJ^<]8<-:LQG35/<X#3:6>*@-!LBNK:WW<7
M_]URP+<L>:?_SM,3$HU H=G<US+$GUQHR3OU36=.(=$(%)K-::U]?+?XZ;SD
MIPV-J<NDQI*'E$L$"LU^&UM+(0PGA5JV_444Q6:6=DL#[CYUG;*@: 0*S1Z/
M6B_A"^DE#*J70-$(%)K-::V7,*Q>*N%&[IW?[;0S19>02[B62]@ME[JE@6]<
M]:"?+D#1"!2:37\MOO#@0JL>5$.!HA$H-)O36D-A]Y>-SJM^V*CW6S9_M]/.
M%%U"$N%:$F&W)"I7>/G._]&\\V]E!E+C+$'1"!2:S6"MF/#X0@L75 F!HA$H
M-)O36@EA]Q>9?!XBN4MBO6A#GAF&\],KYSY(EGB^;[VM._T<Z?;:F:-+*!M<
M*QOL5C;6AMS*">@W'5 T H5F'[RH)4_@7>CH!:AL 44C4&@VI[5L"9PE//#Y
MB]*958"?K&9W?SJS!RI0^D?'O%)S;LL<EY,H5\[%2:GJ:7$D;^G?D/SDVLGS
MA7^SR ^H]6N8XIS?>RHVNK9!"5MK2.]ZK L)41R=*VX4W^6'R59<*9[FEUM&
M(R9, _W[FNMRO;PQ#JH#C//_ 5!+ P04    " #U.']:E(*LB[@"  !J!@
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M"--"#\S2LF98X>E8\#T0)EJCF8.T-VFVKH;&9HQ/2NB[5.>IZ1=,!?B!64+
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ME$91-%/BULWR#G4OEP>ULZ"T $H+H32*HIF"M_:89[?'GG^B!37&&IK]M"V
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M#\5*%XS#3!*U*DLJ_]Q!(38CQW>V$X]LF6LSX<;#BBYA#OJYFDD<N6V4E)7
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M+PS[FN.5#M(8X'HFA-X.S*W1_DF(_P%02P,$%     @ ]3A_6B@_B.%4 P
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M,M8'()K;I9DH7M4->LF5;O?UL- 7,@ACH+_GG*O=Q/3\[HI/_@)02P,$%
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M+8*%D'D#_?TR3=7C3GZ"W?KGZ7]02P,$%     @ ]3A_6A<[SIMU#   6:<
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ME,:HH-T%J@6H%J*:0#6):HK2[*LWF.YB@'87 [2[0+4 U4)4$Z@F44U1FIU
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M\]XW7VQJ=]V+ER_$[)Y7Z_4DVGR@6HAJ M4DJBE*L_-IFH\Q^A&,,5I\H%J
M:B&J"523J*8HS4Z@*3[&_[=+4+GGU#J=6\WU85QTAB&J"523J*8H;1NY;C[7
MN@BB(KJZ+'=U[_6U3I+<FZ;K9<E7N]&[1[UR4["ZX_';L-_I/GO\??_M>[]Z
MO&N8J\M5=*\_1ME]O,R]1-^59.]L4JZUL_A^OONF2%?O.OV.=YL61;K8?#G7
MT4QGU1/*G]^E:?'T336#QS3[O%GLJ_\"4$L#!!0    ( /4X?UJ*= <Y7P@
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M+Z ^?TI3^?U-7L'V,8WSOP!02P,$%     @ ]3A_6M:SNH>[!   F14  !D
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M+,D?EP1'A.L)ZO<Y8W+[HA>H;F-'_P%02P,$%     @ ]3A_6A:LU%TE P
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MDL6_9%.V'?4Z)%C++(VK8#6".$S*O^Q;=2%V GH/!= J@!X;T*L">L<&]*N
M_K$!@RI@<&S L H8[@70P0,!HRI@5"2KO+I%:AR6L>E$I!LB\M:*EF\4^2VB
M54;"))?B=2;4KZ&*RZ:?F1 LR21Y0_[(-W-AD)<.SU@8R5?D!>D2N62"2Q(F
MY%,29O*U.JBV_UJF:\F2N9QT,S6.G-8-JCXORS[I WW:Y$.:9$M)W&3.YP?B
M'7-\[[%X]Y'^J0'051=P>Q7I_56\I$;BNW5T0GKV:T(MVB>?KAWR\L7NQ3LP
MQIF9^(&)MD0'3G3-1(<';8G>\<3><43_L<PDBFA58WR(I"6]M[UU>@6Z]P!Z
M%C$I2;H@U3U$4D&*1SGYY[UJ2MYF/);_'KH]2F[_,#=_^9S)%0OX>4>]7207
M=[PS_?47>VC]=DA'2)B#A+E(F(>$^2"8)IO^5C9]$WWJ?N,B""4G*Q$&ZEFK
MGJ7S-(J8D&3%12G/5^2'6?67QC[:2@@)<Y PMX2-"U@^J[J;]D[&@TGW;E<:
MS4:#_HE]JK?R0>/2<C[8YGQ@S+G'0D'N6+3F^?,B2.-8S<(V]Z]>EI%0RC5+
ME!SF+..'\FWDM\TW$N8@86X)&^VD<CBP]C+I-1M9>[D&C4G+]7";ZZ$QU^_3
M_*V0U"E5&5?=O%FL\\G&-NN'DFP$MTTR$N8@86X)&^[>U .+[B6YV6@_R: Q
M:4D>;9,\,B;95T4>>1FI5+_*<[W0[F]3BHW8MBE&PAPDS!TU;M$WO?%XN)?C
M ZWV9."#1J4E>;Q-\MB8Y$N>\$48A"PBZ2;A0B[#%8G".,Q87D:_SM_7 4\R
M5;(?2K41WC;52)B#A+DES+9V[U3U]CW=?VHC._5!,$T6IUM9G!IE<:4>YE[Y
M,+^?^?\@JKH*EN1Z?2,#$:X*E^7B5G >*WT<$H>QB[;B0,(<),Q%PCPDS ?!
M- 795NVZ6,]4.U9@D'*@- =*<Z$T#TKS431=/CNFG?T_U)#F3EI+R6Z48=:)
M9>MO >>H5BYT9!Z4YC]V!GI*:9U2^LPEHKF#UNFDS5)L:%G[Z43VZ4)I'I3F
MHVBZ/&JOT39Z4D^I*LWDUKJ ^HT532L!&BISH7UZ4)J/HNFZJ,U$V^PF_G0A
M:N:V5@740H32W(JVJS&[MZ\Q#]JGCZ+IJJCM1MOL-SZQ<C736VMC<%R%Z!S;
MT(6.SX/2?!1-SWQM/MIF]_%@<?IN'7TG5^N;* S(GXL%%V%R>S#O4 ,22G.@
M-!=*\Z T'T73%50[F_;HN4I3J+D)I3E0F@NE>5":CZ+I\JD]4]MLFH)*T_$1
M9>+,/)36$H':HE":!Z7Y*)HND=H_M<T&*J#4/6T6I^/]*=W,/(S6\H :HU":
M!Z7Y*)K^*57MC5*C>?;S)8V9V_;] Z4Y4)I;T7;_=Y3V&R4-M$\?1=-545N>
MU&QY%G/86?FLV'ZT>/S4UDQOK0TDS8'27"C-@])\%$W74.VQ4OI,4UL*]5:A
M- =*<Z$T#TKS431=/K4'2\T>+&9J2YN6Y]X';3/S.%KK _I1)Y3F06D^BJ;K
MH_9BJ=F+??J\EC:MRN&@,:\U#Z.U/*!F*Y3F06D^BJ;+HS9EJ=F4_?EY+=2.
MA=(<*,VM:-J\ME'7>= ^?11-5T5MV%*S85M.8!NNK7I>)'/RU$DOU,^%TAPH
MS872/"C-1]%T@=5^+GTN/Y="_5PHS8'27"C-@])\%$V73^WG4K.?^X0/#\SD
MUOJ!FKU0FEO1]"^93YLO+JB+BZ*5PNCNK"&-N;@ME@=+-8M=)UFY)FY[M%R"
M?&F?S8J5NGO'7?O,.W3\PCZ[*!;J=FM\N=[Y Q.W82))Q!>J*^MDI-[(HEQ"
M7.YDZ:I8P7J39ED:%YM+SN9<Y W4[XLTS>YW\@ZV"[FG_P%02P,$%     @
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ME&24ZP'J_HXQ^7BB'Y1W?[U$_P-02P,$%     @ ]3A_6K"NS^,P P  K0L
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MD46F;OGJ&U0.6<"89]+^HU6Y-@P=%"^DXGDEK ERRLHG>:P"L270]?<(^)6
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M(JH!LUHH7I0SVC-7>N(K+Y=Z* =A O3].>?J=6$>T(SY\3]02P,$%     @
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MW3!A/^.C4?B6(<XDGT0J2R!?Z1-H\I8\8IED%0<B<_(^S\$EF3P'D0=J@#Q
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M33R^YHMY+LT_V3>VCD7B2BI>-&#TH,A8?:7?&QTZ '=R!N U .\](#@#&#>
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M@ <,B2+S'MQ['P6;]U30_0=V_!=02P,$%     @ ]3A_6I>*NQS     $P(
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MPX)^1!WTZ[D5_]:>[?-F3^41%NTCXF@_Y5NV:=I:\W&?=4RDS4OMDZ(0$E-
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M]5O!%G597L"Y6W6E>?'R$X^7GZ><_@!02P,$%     @ ]3A_6GH$ UU< @
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M?WJ^_@U02P$"% ,4    " #U.']:1L=-2)4   #-    $
M@ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( /4X?UJMM5.+\@
M "L"   1              "  <,   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( /4X?UJ97)PC$ 8  )PG   3              "  >0!  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ ]3A_6D.)V3D="   *3(  !@
M             ("!)0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    ( /4X?UJ[*L9,/0(  +X%   8              " @7@0  !X;"]W
M;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " #U.']:5PN?/(4&  !X
M&P  &               @('K$@  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL
M4$L! A0#%     @ ]3A_6J(3,2T: P  $@L  !@              ("!IAD
M 'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( /4X?UJ1@VE
M<@4  /D5   8              " @?8<  !X;"]W;W)K<VAE971S+W-H965T
M-2YX;6Q02P$"% ,4    " #U.']:<GJN@*X1  #H#P$ &
M@(&>(@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ ]3A_
M6M;M]Z'/ @  : <  !@              ("!@C0  'AL+W=O<FMS:&5E=',O
M<VAE970W+GAM;%!+ 0(4 Q0    ( /4X?UH7W!<_XPD  .XP   8
M      " @8<W  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M" #U.']:[V3;E24)  "+%P  &               @(&@00  >&PO=V]R:W-H
M965T<R]S:&5E=#DN>&UL4$L! A0#%     @ ]3A_6HBY+?LG'0  W%<  !D
M             ("!^TH  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"
M% ,4    " #U.']:]#S_"?H(  !#%P  &0              @(%9:   >&PO
M=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( /4X?UJU\H )2PH
M  8?   9              " @8IQ  !X;"]W;W)K<VAE971S+W-H965T,3(N
M>&UL4$L! A0#%     @ ]3A_6E599/DE!   1 H  !D              ("!
M#'P  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " #U.']:
M.<ZTBH $  !.#   &0              @(%H@   >&PO=V]R:W-H965T<R]S
M:&5E=#$T+GAM;%!+ 0(4 Q0    ( /4X?UH(4=Q,#@D  /X;   9
M      " @1^%  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%
M  @ ]3A_6K<?5OG_#   X"0  !D              ("!9(X  'AL+W=O<FMS
M:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " #U.']:K:")/^0&  !R%0
M&0              @(&:FP  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+
M 0(4 Q0    ( /4X?UI4^V7"^ 4  !8.   9              " @;6B  !X
M;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ ]3A_6@M6-*1N
M!0  I P  !D              ("!Y*@  'AL+W=O<FMS:&5E=',O<VAE970Q
M.2YX;6Q02P$"% ,4    " #U.']:# "M)]H(  "6&   &0
M@(&)K@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( /4X
M?UJIV#LR* H  ),:   9              " @9JW  !X;"]W;W)K<VAE971S
M+W-H965T,C$N>&UL4$L! A0#%     @ ]3A_6ASVIR_A @  8P8  !D
M         ("!^<$  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
M    " #U.']:988RJJP$  "*"P  &0              @($1Q0  >&PO=V]R
M:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( /4X?UHN%,/2U@0  &H,
M   9              " @?3)  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL
M4$L! A0#%     @ ]3A_6JMO@6/]!   J L  !D              ("! <\
M 'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " #U.']:D4@<
M!3H&  #=#P  &0              @($UU   >&PO=V]R:W-H965T<R]S:&5E
M=#(V+GAM;%!+ 0(4 Q0    ( /4X?UKOHPJ71@(  )L%   9
M  " @:;:  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @
M]3A_6BQU:+Y# @  B@8  !D              ("!(]T  'AL+W=O<FMS:&5E
M=',O<VAE970R."YX;6Q02P$"% ,4    " #U.']:/*4S.!$"  #=!   &0
M            @(&=WP  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4
M Q0    ( /4X?UHG(F_RFPH  !DO   9              " @>7A  !X;"]W
M;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ ]3A_6K3$EH_4&@
MY%4  !D              ("!M^P  'AL+W=O<FMS:&5E=',O<VAE970S,2YX
M;6Q02P$"% ,4    " #U.']:Z5.C)?P"  "A!@  &0              @('"
M!P$ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( /4X?UKE
M"&0,K0(  ,X%   9              " @?4* 0!X;"]W;W)K<VAE971S+W-H
M965T,S,N>&UL4$L! A0#%     @ ]3A_6@4_2UBR!   D P  !D
M     ("!V0T! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /4X?UI%DD%=T 0  '8,   9              "
M@2$C 0!X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ ]3A_
M6D75*O[+ P  LP@  !D              ("!*"@! 'AL+W=O<FMS:&5E=',O
M<VAE970T,"YX;6Q02P$"% ,4    " #U.']:Q=J*2V,#  !5!P  &0
M        @($J+ $ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0
M   ( /4X?UIS!"WW @0  !01   9              " @<0O 0!X;"]W;W)K
M<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ ]3A_6H1797UV P  \@T
M !D              ("!_3,! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q0
M2P$"% ,4    " #U.']:2G$1#&("   K!P  &0              @(&J-P$
M>&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( /4X?UH;T749
M# 8  ,PH   9              " @4,Z 0!X;"]W;W)K<VAE971S+W-H965T
M-#4N>&UL4$L! A0#%     @ ]3A_6I2"K(NX @  :@8  !D
M ("!AD ! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " #U
M.']:>](TDD<$  "J&   &0              @(%U0P$ >&PO=V]R:W-H965T
M<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( /4X?UH>;-YT$ ,  &0(   9
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M970U,BYX;6Q02P$"% ,4    " #U.']:H KL[K "  ".!@  &0
M    @(%E70$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    (
M /4X?UI22C5PY (  .X'   9              " @4Q@ 0!X;"]W;W)K<VAE
M971S+W-H965T-30N>&UL4$L! A0#%     @ ]3A_6CG!#BZ2!@  "ST  !D
M             ("!9V,! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"
M% ,4    " #U.']:%SO.FW4,  !9IP  &0              @($P:@$ >&PO
M=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( /4X?UJ*= <Y7P@
M +)1   9              " @=QV 0!X;"]W;W)K<VAE971S+W-H965T-3<N
M>&UL4$L! A0#%     @ ]3A_6M:SNH>[!   F14  !D              ("!
M<G\! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"% ,4    " #U.']:
M%JS4724#  "S"P  &0              @(%DA $ >&PO=V]R:W-H965T<R]S
M:&5E=#4Y+GAM;%!+ 0(4 Q0    ( /4X?UI@(/F\Q@(  &4(   9
M      " @<"' 0!X;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%
M  @ ]3A_6F':K0ZK!@  U#T  !D              ("!O8H! 'AL+W=O<FMS
M:&5E=',O<VAE970V,2YX;6Q02P$"% ,4    " #U.']:WK8;C<4#  "&&0
M&0              @(&?D0$ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+
M 0(4 Q0    ( /4X?UJPKL_C, ,  *T+   9              " @9N5 0!X
M;"]W;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @ ]3A_6@&,XRAJ
M @  R@4  !D              ("! ID! 'AL+W=O<FMS:&5E=',O<VAE970V
M-"YX;6Q02P$"% ,4    " #U.']:[T7Y,(4$  "0'@  &0
M@(&CFP$ >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( /4X
M?UIS8N*^Z0(  , '   9              " @5^@ 0!X;"]W;W)K<VAE971S
M+W-H965T-C8N>&UL4$L! A0#%     @ ]3A_6I@D(UE# P  L P  !D
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M=#<Q+GAM;%!+ 0(4 Q0    ( /4X?UJPED?*6P0  %,7   9
M  " @:^X 0!X;"]W;W)K<VAE971S+W-H965T-S(N>&UL4$L! A0#%     @
M]3A_6I@]1#]* @  <P4  !D              ("!0;T! 'AL+W=O<FMS:&5E
M=',O<VAE970W,RYX;6Q02P$"% ,4    " #U.']:35FS-V,#  !G#   &0
M            @('"OP$ >&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4
M Q0    ( /4X?UIKUHHB=P,  /<.   9              " @5S# 0!X;"]W
M;W)K<VAE971S+W-H965T-S4N>&UL4$L! A0#%     @ ]3A_6NQO;%6&!P
M9$\  !D              ("!"L<! 'AL+W=O<FMS:&5E=',O<VAE970W-BYX
M;6Q02P$"% ,4    " #U.']:(V]H2RL%   &&P  &0              @(''
MS@$ >&PO=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+ 0(4 Q0    ( /4X?UI2
M)-1++ 8  &,O   9              " @2G4 0!X;"]W;W)K<VAE971S+W-H
M965T-S@N>&UL4$L! A0#%     @ ]3A_6A03 <%0 P  CA4   T
M     ( !C-H! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #U.']:EXJ[',
M   3 @  "P              @ $'W@$ 7W)E;',O+G)E;'-02P$"% ,4
M" #U.']:4'ZTF\@%   B,P  #P              @ 'PW@$ >&PO=V]R:V)O
M;VLN>&UL4$L! A0#%     @ ]3A_6GH$ UU< @  (2X  !H
M ( !Y>0! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @
M]3A_6BXH"M@5 @  _"P  !,              ( !>><! %M#;VYT96YT7U1Y
><&5S72YX;6Q02P4&     %8 5@"1%P  O^D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>199</ContextCount>
  <ElementCount>389</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>86</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952151 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952152 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952153 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952154 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity</Role>
      <ShortName>Consolidated Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952155 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952156 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - Description of the Business and Financial Condition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/DescriptionoftheBusinessandFinancialCondition</Role>
      <ShortName>Description of the Business and Financial Condition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Merger and Related Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/MergerandRelatedTransactions</Role>
      <ShortName>Merger and Related Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/BalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Research Grant</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/ResearchGrant</Role>
      <ShortName>Research Grant</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Convertible Preferred Stock, Common Stock and Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquity</Role>
      <ShortName>Convertible Preferred Stock, Common Stock and Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/Warrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9952171 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9952172 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9952173 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9952174 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.angn.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.angn.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Merger and Related Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/MergerandRelatedTransactionsTables</Role>
      <ShortName>Merger and Related Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.angn.com/role/MergerandRelatedTransactions</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.angn.com/role/FairValueMeasurements</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/BalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.angn.com/role/BalanceSheetComponents</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.angn.com/role/StockBasedCompensation</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/WarrantsTables</Role>
      <ShortName>Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.angn.com/role/Warrants</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.angn.com/role/Leases</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.angn.com/role/IncomeTaxes</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.angn.com/role/NetLossPerShare</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.angn.com/role/SegmentReporting</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Description of the Business and Financial Condition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails</Role>
      <ShortName>Description of the Business and Financial Condition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.angn.com/role/DescriptionoftheBusinessandFinancialCondition</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Merger and Related Transactions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/MergerandRelatedTransactionsNarrativeDetails</Role>
      <ShortName>Merger and Related Transactions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Merger and Related Transactions - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/MergerandRelatedTransactionsScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails</Role>
      <ShortName>Merger and Related Transactions - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Fair Value Measurements - Schedule of Fair Value, Liabilities, Measured on Recurring Basis, Unobservable Input Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Fair Value, Liabilities, Measured on Recurring Basis, Unobservable Input Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Fair Value Measurements - Schedule of Fair Value Measurement Inputs and Valuation Techniques (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Fair Value Measurement Inputs and Valuation Techniques (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Balance Sheet Components - Schedule of Prepaid and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/BalanceSheetComponentsScheduleofPrepaidandOtherCurrentAssetsDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Prepaid and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Balance Sheet Components - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/BalanceSheetComponentsNarrativeDetails</Role>
      <ShortName>Balance Sheet Components - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/BalanceSheetComponentsScheduleofAccruedExpensesDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Research Grant (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/ResearchGrantDetails</Role>
      <ShortName>Research Grant (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.angn.com/role/ResearchGrant</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Convertible Preferred Stock, Common Stock and Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails</Role>
      <ShortName>Convertible Preferred Stock, Common Stock and Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquity</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - Stock-Based Compensation - Schedule of Share Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Share Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - Stock-Based Compensation - Components of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Components of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - Stock-Based Compensation - Schedule of Assumptions Used to Estimate Fair Value of Stock Option Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/StockBasedCompensationScheduleofAssumptionsUsedtoEstimateFairValueofStockOptionAwardsDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Assumptions Used to Estimate Fair Value of Stock Option Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - Warrants - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/WarrantsNarrativeDetails</Role>
      <ShortName>Warrants - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - Warrants - Schedule of Issuance of Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/WarrantsScheduleofIssuanceofWarrantsDetails</Role>
      <ShortName>Warrants - Schedule of Issuance of Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - Warrants - Schedule of Outstanding Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/WarrantsScheduleofOutstandingWarrantsDetails</Role>
      <ShortName>Warrants - Schedule of Outstanding Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.angn.com/role/CommitmentsandContingencies</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - Leases - Schedule of Quantitative Information about Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/LeasesScheduleofQuantitativeInformationaboutOperatingLeasesDetails</Role>
      <ShortName>Leases - Schedule of Quantitative Information about Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9955547 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Schedule of Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9955548 - Disclosure - Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/DebtDetails</Role>
      <ShortName>Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.angn.com/role/Debt</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9955549 - Disclosure - Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9955550 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9955551 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9955552 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9955553 - Disclosure - Employee Benefit Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/EmployeeBenefitPlanDetails</Role>
      <ShortName>Employee Benefit Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.angn.com/role/EmployeeBenefitPlan</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9955554 - Disclosure - Net Loss Per Share - Schedule of Net Loss Per Share, Basic and Diluted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/NetLossPerShareScheduleofNetLossPerShareBasicandDilutedDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Net Loss Per Share, Basic and Diluted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9955555 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded From Computation of Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofNetLossperShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Antidilutive Securities Excluded From Computation of Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9955556 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.angn.com/role/RelatedPartyTransactions</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9955557 - Disclosure - Segment Reporting (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/SegmentReportingDetails</Role>
      <ShortName>Segment Reporting (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.angn.com/role/SegmentReportingTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="angn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9955558 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.angn.com/role/SubsequentEvents</ParentRole>
      <Position>78</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="angn-20241231.htm">angn-20241231.htm</File>
    <File>angn-20241231.xsd</File>
    <File>angn-20241231_cal.xml</File>
    <File>angn-20241231_def.xml</File>
    <File>angn-20241231_lab.xml</File>
    <File>angn-20241231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>angn-20241231_g1.jpg</File>
    <File>angn-20241231_g2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="682">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="40">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="6">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>122
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "angn-20241231.htm": {
   "nsprefix": "angn",
   "nsuri": "http://www.angn.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "angn-20241231.htm"
     ]
    },
    "schema": {
     "local": [
      "angn-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "angn-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "angn-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "angn-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "angn-20241231_pre.xml"
     ]
    }
   },
   "keyStandard": 319,
   "keyCustom": 70,
   "axisStandard": 30,
   "axisCustom": 1,
   "memberStandard": 31,
   "memberCustom": 52,
   "hidden": {
    "total": 26,
    "http://fasb.org/us-gaap/2024": 21,
    "http://xbrl.sec.gov/dei/2024": 5
   },
   "contextCount": 199,
   "entityCount": 1,
   "segmentCount": 86,
   "elementCount": 732,
   "unitCount": 9,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 682,
    "http://xbrl.sec.gov/dei/2024": 40,
    "http://xbrl.sec.gov/cyd/2024": 15,
    "http://xbrl.sec.gov/ecd/2024": 6
   },
   "report": {
    "R1": {
     "role": "http://www.angn.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.angn.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.angn.com/role/ConsolidatedBalanceSheets",
     "longName": "9952151 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.angn.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "9952152 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PreferredStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockSharesIssued",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
     "longName": "9952153 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CostsAndExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity",
     "longName": "9952154 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity",
     "shortName": "Consolidated Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquityParenthetical",
     "longName": "9952155 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity (Parenthetical)",
     "shortName": "Consolidated Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.angn.com/role/ConsolidatedStatementsofCashFlows",
     "longName": "9952156 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.angn.com/role/DescriptionoftheBusinessandFinancialCondition",
     "longName": "9952157 - Disclosure - Description of the Business and Financial Condition",
     "shortName": "Description of the Business and Financial Condition",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.angn.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "9952158 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.angn.com/role/MergerandRelatedTransactions",
     "longName": "9952159 - Disclosure - Merger and Related Transactions",
     "shortName": "Merger and Related Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "angn:ReverseRecapitalizationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "angn:ReverseRecapitalizationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.angn.com/role/FairValueMeasurements",
     "longName": "9952160 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.angn.com/role/BalanceSheetComponents",
     "longName": "9952161 - Disclosure - Balance Sheet Components",
     "shortName": "Balance Sheet Components",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.angn.com/role/ResearchGrant",
     "longName": "9952162 - Disclosure - Research Grant",
     "shortName": "Research Grant",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquity",
     "longName": "9952163 - Disclosure - Convertible Preferred Stock, Common Stock and Stockholders' Equity",
     "shortName": "Convertible Preferred Stock, Common Stock and Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.angn.com/role/StockBasedCompensation",
     "longName": "9952164 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.angn.com/role/Warrants",
     "longName": "9952165 - Disclosure - Warrants",
     "shortName": "Warrants",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "angn:WarrantsAndRightsOutstandingTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "angn:WarrantsAndRightsOutstandingTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.angn.com/role/CommitmentsandContingencies",
     "longName": "9952166 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.angn.com/role/Leases",
     "longName": "9952167 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.angn.com/role/Debt",
     "longName": "9952168 - Disclosure - Debt",
     "shortName": "Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.angn.com/role/IncomeTaxes",
     "longName": "9952169 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.angn.com/role/EmployeeBenefitPlan",
     "longName": "9952170 - Disclosure - Employee Benefit Plan",
     "shortName": "Employee Benefit Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.angn.com/role/NetLossPerShare",
     "longName": "9952171 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.angn.com/role/RelatedPartyTransactions",
     "longName": "9952172 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.angn.com/role/SegmentReporting",
     "longName": "9952173 - Disclosure - Segment Reporting",
     "shortName": "Segment Reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.angn.com/role/SubsequentEvents",
     "longName": "9952174 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R28": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-199",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-199",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R33": {
     "role": "http://www.angn.com/role/MergerandRelatedTransactionsTables",
     "longName": "9955513 - Disclosure - Merger and Related Transactions (Tables)",
     "shortName": "Merger and Related Transactions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "angn:ScheduleOfReverseRecapitalizationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "angn:ScheduleOfReverseRecapitalizationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.angn.com/role/FairValueMeasurementsTables",
     "longName": "9955514 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.angn.com/role/BalanceSheetComponentsTables",
     "longName": "9955515 - Disclosure - Balance Sheet Components (Tables)",
     "shortName": "Balance Sheet Components (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.angn.com/role/StockBasedCompensationTables",
     "longName": "9955516 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.angn.com/role/WarrantsTables",
     "longName": "9955517 - Disclosure - Warrants (Tables)",
     "shortName": "Warrants (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.angn.com/role/LeasesTables",
     "longName": "9955518 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "angn:ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "angn:ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.angn.com/role/IncomeTaxesTables",
     "longName": "9955519 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.angn.com/role/NetLossPerShareTables",
     "longName": "9955520 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.angn.com/role/SegmentReportingTables",
     "longName": "9955521 - Disclosure - Segment Reporting (Tables)",
     "shortName": "Segment Reporting (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails",
     "longName": "9955522 - Disclosure - Description of the Business and Financial Condition (Details)",
     "shortName": "Description of the Business and Financial Condition (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-50",
      "name": "us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-51",
      "name": "angn:ReverseRecapitalizationOwnershipPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "longName": "9955523 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails",
     "longName": "9955524 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property and Equipment (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-55",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-55",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.angn.com/role/MergerandRelatedTransactionsNarrativeDetails",
     "longName": "9955525 - Disclosure - Merger and Related Transactions - Narrative (Details)",
     "shortName": "Merger and Related Transactions - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-54",
      "name": "angn:NumberOfMembersOfTheBoardOfDirectors",
      "unitRef": "board_member",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-54",
      "name": "angn:NumberOfMembersOfTheBoardOfDirectors",
      "unitRef": "board_member",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.angn.com/role/MergerandRelatedTransactionsScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails",
     "longName": "9955526 - Disclosure - Merger and Related Transactions - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details)",
     "shortName": "Merger and Related Transactions - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-54",
      "name": "angn:CashAndCashEquivalentsAcquiredThroughReverseRecapitalization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-54",
      "name": "angn:CashAndCashEquivalentsAcquiredThroughReverseRecapitalization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
     "longName": "9955527 - Disclosure - Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-68",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-68",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails",
     "longName": "9955528 - Disclosure - Fair Value Measurements - Schedule of Fair Value, Liabilities, Measured on Recurring Basis, Unobservable Input Reconciliation (Details)",
     "shortName": "Fair Value Measurements - Schedule of Fair Value, Liabilities, Measured on Recurring Basis, Unobservable Input Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-73",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-74",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.angn.com/role/FairValueMeasurementsNarrativeDetails",
     "longName": "9955529 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-79",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails",
     "longName": "9955530 - Disclosure - Fair Value Measurements - Schedule of Fair Value Measurement Inputs and Valuation Techniques (Details)",
     "shortName": "Fair Value Measurements - Schedule of Fair Value Measurement Inputs and Valuation Techniques (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-86",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-86",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.angn.com/role/BalanceSheetComponentsScheduleofPrepaidandOtherCurrentAssetsDetails",
     "longName": "9955531 - Disclosure - Balance Sheet Components - Schedule of Prepaid and Other Current Assets (Details)",
     "shortName": "Balance Sheet Components - Schedule of Prepaid and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "angn:PrepaidResearchAndDevelopmentExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "angn:PrepaidResearchAndDevelopmentExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.angn.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails",
     "longName": "9955532 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)",
     "shortName": "Balance Sheet Components - Schedule of Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.angn.com/role/BalanceSheetComponentsNarrativeDetails",
     "longName": "9955533 - Disclosure - Balance Sheet Components - Narrative (Details)",
     "shortName": "Balance Sheet Components - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R54": {
     "role": "http://www.angn.com/role/BalanceSheetComponentsScheduleofAccruedExpensesDetails",
     "longName": "9955534 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses (Details)",
     "shortName": "Balance Sheet Components - Schedule of Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.angn.com/role/ResearchGrantDetails",
     "longName": "9955535 - Disclosure - Research Grant (Details)",
     "shortName": "Research Grant (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "angn:NumberOfResearchGrantAgreements",
      "unitRef": "agreement",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails",
     "longName": "9955536 - Disclosure - Convertible Preferred Stock, Common Stock and Stockholders' Equity (Details)",
     "shortName": "Convertible Preferred Stock, Common Stock and Stockholders' Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-113",
      "name": "angn:SaleOfStockAggregateInitialOfferingPrice",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.angn.com/role/StockBasedCompensationNarrativeDetails",
     "longName": "9955537 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.angn.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails",
     "longName": "9955538 - Disclosure - Stock-Based Compensation - Schedule of Share Option Activity (Details)",
     "shortName": "Stock-Based Compensation - Schedule of Share Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.angn.com/role/StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails",
     "longName": "9955539 - Disclosure - Stock-Based Compensation - Components of Stock-Based Compensation Expense (Details)",
     "shortName": "Stock-Based Compensation - Components of Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.angn.com/role/StockBasedCompensationScheduleofAssumptionsUsedtoEstimateFairValueofStockOptionAwardsDetails",
     "longName": "9955540 - Disclosure - Stock-Based Compensation - Schedule of Assumptions Used to Estimate Fair Value of Stock Option Awards (Details)",
     "shortName": "Stock-Based Compensation - Schedule of Assumptions Used to Estimate Fair Value of Stock Option Awards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-132",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R61": {
     "role": "http://www.angn.com/role/WarrantsNarrativeDetails",
     "longName": "9955541 - Disclosure - Warrants - Narrative (Details)",
     "shortName": "Warrants - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-139",
      "name": "angn:FairValueOfCommonStockWarrants",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.angn.com/role/WarrantsScheduleofIssuanceofWarrantsDetails",
     "longName": "9955542 - Disclosure - Warrants - Schedule of Issuance of Warrants (Details)",
     "shortName": "Warrants - Schedule of Issuance of Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "angn:WarrantsIssuedShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "angn:WarrantsIssuedShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.angn.com/role/WarrantsScheduleofOutstandingWarrantsDetails",
     "longName": "9955543 - Disclosure - Warrants - Schedule of Outstanding Warrants (Details)",
     "shortName": "Warrants - Schedule of Outstanding Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "angn:ClassOfWarrantOrRightExercisedInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.angn.com/role/CommitmentsandContingenciesDetails",
     "longName": "9955544 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "angn:LicenseExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "angn:LicenseExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.angn.com/role/LeasesNarrativeDetails",
     "longName": "9955545 - Disclosure - Leases - Narrative (Details)",
     "shortName": "Leases - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.angn.com/role/LeasesScheduleofQuantitativeInformationaboutOperatingLeasesDetails",
     "longName": "9955546 - Disclosure - Leases - Schedule of Quantitative Information about Operating Leases (Details)",
     "shortName": "Leases - Schedule of Quantitative Information about Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "angn:ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "angn:ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.angn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails",
     "longName": "9955547 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Details)",
     "shortName": "Leases - Schedule of Maturities of Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.angn.com/role/DebtDetails",
     "longName": "9955548 - Disclosure - Debt (Details)",
     "shortName": "Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AmortizationOfDebtDiscountPremium",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-158",
      "name": "us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails",
     "longName": "9955549 - Disclosure - Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)",
     "shortName": "Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails",
     "longName": "9955550 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails",
     "longName": "9955551 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.angn.com/role/IncomeTaxesNarrativeDetails",
     "longName": "9955552 - Disclosure - Income Taxes - Narrative (Details)",
     "shortName": "Income Taxes - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:IncomeTaxExpenseBenefit",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.angn.com/role/EmployeeBenefitPlanDetails",
     "longName": "9955553 - Disclosure - Employee Benefit Plan (Details)",
     "shortName": "Employee Benefit Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-169",
      "name": "us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-169",
      "name": "us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.angn.com/role/NetLossPerShareScheduleofNetLossPerShareBasicandDilutedDetails",
     "longName": "9955554 - Disclosure - Net Loss Per Share - Schedule of Net Loss Per Share, Basic and Diluted (Details)",
     "shortName": "Net Loss Per Share - Schedule of Net Loss Per Share, Basic and Diluted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R75": {
     "role": "http://www.angn.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofNetLossperShareDetails",
     "longName": "9955555 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded From Computation of Net Loss per Share (Details)",
     "shortName": "Net Loss Per Share - Schedule of Antidilutive Securities Excluded From Computation of Net Loss per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.angn.com/role/RelatedPartyTransactionsDetails",
     "longName": "9955556 - Disclosure - Related Party Transactions (Details)",
     "shortName": "Related Party Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-178",
      "name": "us-gaap:ProceedsFromIssuanceOfWarrants",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.angn.com/role/SegmentReportingDetails",
     "longName": "9955557 - Disclosure - Segment Reporting (Details)",
     "shortName": "Segment Reporting (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "entity",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "entity",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.angn.com/role/SubsequentEventsDetails",
     "longName": "9955558 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-195",
      "name": "us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
      "unitRef": "entity",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20241231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "angn_A2021PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "A2021PlanMember",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Plan",
        "label": "2021 Plan [Member]",
        "documentation": "2021 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "angn_A2022PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "A2022PlanMember",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 Plan",
        "label": "2022 Plan [Member]",
        "documentation": "2022 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "angn_A2024PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "A2024PlanMember",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 Plan",
        "label": "2024 Plan [Member]",
        "documentation": "2024 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "angn_A2024RegistrationStatementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "A2024RegistrationStatementMember",
     "presentation": [
      "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 Registration Statement",
        "label": "2024 Registration Statement [Member]",
        "documentation": "2024 Registration Statement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r841"
     ]
    },
    "angn_AccretionOfPromissoryNoteDiscountFromEmbeddedDerivative": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "AccretionOfPromissoryNoteDiscountFromEmbeddedDerivative",
     "crdr": "debit",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accretion of promissory note discount from embedded derivative",
        "label": "Accretion Of Promissory Note Discount From Embedded Derivative",
        "documentation": "Accretion Of Promissory Note Discount From Embedded Derivative"
       }
      }
     },
     "auth_ref": []
    },
    "angn_AccretionOfPromissoryNoteToFaceValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "AccretionOfPromissoryNoteToFaceValue",
     "crdr": "debit",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accretion of promissory note to face value",
        "label": "Accretion Of Promissory Note To Face Value",
        "documentation": "Accretion Of Promissory Note To Face Value"
       }
      }
     },
     "auth_ref": []
    },
    "angn_AccruedInterestPremiumForConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "AccruedInterestPremiumForConvertiblePreferredStock",
     "crdr": "credit",
     "presentation": [
      "http://www.angn.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest",
        "label": "Accrued Interest Premium For Convertible Preferred Stock",
        "documentation": "Accrued Interest Premium For Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "angn_AccruedLiabilitiesAssumedThroughReverseRecapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "AccruedLiabilitiesAssumedThroughReverseRecapitalization",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/MergerandRelatedTransactionsScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": "angn_NetAssetsAcquiredThroughReverseRecapitalization",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/MergerandRelatedTransactionsScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accrued liabilities",
        "label": "Accrued Liabilities Assumed Through Reverse Recapitalization",
        "documentation": "Accrued Liabilities Assumed Through Reverse Recapitalization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofAccruedExpensesDetails",
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "totalLabel": "Accrued expenses",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "angn_AccruedOtherOperatingLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "AccruedOtherOperatingLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accrued expenses",
        "label": "Accrued Other Operating Liabilities, Current",
        "documentation": "Accrued Other Operating Liabilities, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued professional fees",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "angn_AccruedResearchAndDevelopmentCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "AccruedResearchAndDevelopmentCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued research and development",
        "label": "Accrued Research And Development, Current",
        "documentation": "Accrued Research And Development, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r144",
      "r628"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r80",
      "r149",
      "r624",
      "r662",
      "r663"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r10",
      "r18",
      "r500",
      "r503",
      "r561",
      "r658",
      "r659",
      "r990",
      "r991",
      "r992",
      "r1002",
      "r1003",
      "r1004",
      "r1005"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r841",
      "r1123"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r678",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1068",
      "r1125"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Return of common stock to pay withholding taxes on restricted stock",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r53",
      "r406"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issuance costs",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r106"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "angn_AdvancedProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "AdvancedProfessionalFees",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPrepaidandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPrepaidandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advanced professional fees",
        "label": "Advanced Professional Fees",
        "documentation": "Advanced Professional Fees"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r889",
      "r900",
      "r910",
      "r943"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r892",
      "r903",
      "r913",
      "r946"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r893",
      "r904",
      "r914",
      "r938",
      "r947",
      "r951",
      "r959"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r448"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.angn.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt discount",
        "label": "Amortization of Debt Discount (Premium)",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r85",
      "r312",
      "r1077"
     ]
    },
    "angn_AngionCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "AngionCommonStockMember",
     "presentation": [
      "http://www.angn.com/role/MergerandRelatedTransactionsNarrativeDetails",
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Angion Common Stock",
        "label": "Angion Common Stock [Member]",
        "documentation": "Angion Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "angn_AngionStockholdersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "AngionStockholdersMember",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Angion Stockholders",
        "label": "Angion Stockholders [Member]",
        "documentation": "Angion Stockholders"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.angn.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r195"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.angn.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.angn.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.angn.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AreaOfRealEstateProperty",
     "presentation": [
      "http://www.angn.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Area of office space (in sqft)",
        "label": "Area of Real Estate Property",
        "documentation": "Area of a real estate property."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets",
      "http://www.angn.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "terseLabel": "Total segment assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r124",
      "r145",
      "r167",
      "r200",
      "r208",
      "r233",
      "r237",
      "r247",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r495",
      "r497",
      "r531",
      "r618",
      "r715",
      "r800",
      "r801",
      "r841",
      "r867",
      "r1025",
      "r1026",
      "r1082"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r150",
      "r167",
      "r247",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r495",
      "r497",
      "r531",
      "r841",
      "r1025",
      "r1026",
      "r1082"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r510",
      "r511",
      "r832"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets, Fair Value Disclosure [Abstract]",
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "angn_AtTheMarketEquityOfferingSalesAgreement2022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "AtTheMarketEquityOfferingSalesAgreement2022Member",
     "presentation": [
      "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-The-Market Equity Offering Sales Agreement 2022",
        "label": "At-The-Market Equity Offering Sales Agreement 2022 [Member]",
        "documentation": "At-The-Market Equity Offering Sales Agreement 2022"
       }
      }
     },
     "auth_ref": []
    },
    "angn_AtTheMarketEquityOfferingSalesAgreement2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "AtTheMarketEquityOfferingSalesAgreement2024Member",
     "presentation": [
      "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-The-Market Equity Offering Sales Agreement 2024",
        "label": "At-The-Market Equity Offering Sales Agreement 2024 [Member]",
        "documentation": "At-The-Market Equity Offering Sales Agreement 2024"
       }
      }
     },
     "auth_ref": []
    },
    "angn_AtTheMarketEquityOfferingSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "AtTheMarketEquityOfferingSalesAgreementMember",
     "presentation": [
      "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-The-Market Equity Offering Sales Agreement",
        "label": "At-The-Market Equity Offering Sales Agreement [Member]",
        "documentation": "At-The-Market Equity Offering Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "angn_AtTheMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "AtTheMarketOfferingMember",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-the-Market Offering",
        "label": "At-the-Market Offering [Member]",
        "documentation": "At-the-Market Offering"
       }
      }
     },
     "auth_ref": []
    },
    "angn_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.angn.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r872",
      "r873",
      "r896"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.angn.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r872",
      "r873",
      "r896"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://www.angn.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r872",
      "r873",
      "r896"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.angn.com/role/StockBasedCompensationScheduleofAssumptionsUsedtoEstimateFairValueofStockOptionAwardsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r410",
      "r411",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "angn_BostonMassachusettsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "BostonMassachusettsMember",
     "presentation": [
      "http://www.angn.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Boston, Massachusetts",
        "label": "Boston, Massachusetts [Member]",
        "documentation": "Boston, Massachusetts"
       }
      }
     },
     "auth_ref": []
    },
    "angn_BridgeLoanBetweenAngionAndFormerElicioAdditionalClosingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "BridgeLoanBetweenAngionAndFormerElicioAdditionalClosingMember",
     "presentation": [
      "http://www.angn.com/role/DebtDetails",
      "http://www.angn.com/role/MergerandRelatedTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bridge Loan Between Angion And Former Elicio, Additional Closing",
        "label": "Bridge Loan Between Angion And Former Elicio, Additional Closing [Member]",
        "documentation": "Bridge Loan Between Angion And Former Elicio, Additional Closing"
       }
      }
     },
     "auth_ref": []
    },
    "angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountAdditionalClosingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "BridgeLoanBetweenAngionAndFormerElicioDiscountAmountAdditionalClosingMember",
     "presentation": [
      "http://www.angn.com/role/DebtDetails",
      "http://www.angn.com/role/MergerandRelatedTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bridge Loan Between Angion And Former Elicio, Discount Amount, Additional Closing",
        "label": "Bridge Loan Between Angion And Former Elicio, Discount Amount, Additional Closing [Member]",
        "documentation": "Bridge Loan Between Angion And Former Elicio, Discount Amount, Additional Closing"
       }
      }
     },
     "auth_ref": []
    },
    "angn_BridgeLoanBetweenAngionAndFormerElicioDiscountAmountInitialClosingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "BridgeLoanBetweenAngionAndFormerElicioDiscountAmountInitialClosingMember",
     "presentation": [
      "http://www.angn.com/role/DebtDetails",
      "http://www.angn.com/role/MergerandRelatedTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bridge Loan Between Angion And Former Elicio, Discount Amount, Initial Closing",
        "label": "Bridge Loan Between Angion And Former Elicio, Discount Amount, Initial Closing [Member]",
        "documentation": "Bridge Loan Between Angion And Former Elicio, Discount Amount, Initial Closing"
       }
      }
     },
     "auth_ref": []
    },
    "angn_BridgeLoanBetweenAngionAndFormerElicioInitialClosingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "BridgeLoanBetweenAngionAndFormerElicioInitialClosingMember",
     "presentation": [
      "http://www.angn.com/role/DebtDetails",
      "http://www.angn.com/role/MergerandRelatedTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bridge Loan Between Angion And Former Elicio, Initial Closing",
        "label": "Bridge Loan Between Angion And Former Elicio, Initial Closing [Member]",
        "documentation": "Bridge Loan Between Angion And Former Elicio, Initial Closing"
       }
      }
     },
     "auth_ref": []
    },
    "angn_BridgeLoanBetweenAngionAndFormerElicioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "BridgeLoanBetweenAngionAndFormerElicioMember",
     "presentation": [
      "http://www.angn.com/role/DebtDetails",
      "http://www.angn.com/role/MergerandRelatedTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bridge Loan Between Angion And Former Elicio",
        "label": "Bridge Loan Between Angion And Former Elicio [Member]",
        "documentation": "Bridge Loan Between Angion And Former Elicio"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis",
     "presentation": [
      "http://www.angn.com/role/ResearchGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Project [Axis]",
        "label": "Project [Axis]",
        "documentation": "Information by project."
       }
      }
     },
     "auth_ref": [
      "r581",
      "r612",
      "r1091"
     ]
    },
    "us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAcquiredInExcessOfPaymentsToAcquireBusiness",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash acquired in connection with the reverse merger",
        "label": "Cash Acquired in Excess of Payments to Acquire Business",
        "documentation": "The cash inflow associated with the acquisition of a business when the cash held by the acquired business exceeds the cash payments to acquire the business."
       }
      }
     },
     "auth_ref": []
    },
    "angn_CashAndCashEquivalentsAcquiredThroughReverseRecapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "CashAndCashEquivalentsAcquiredThroughReverseRecapitalization",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/MergerandRelatedTransactionsScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": "angn_NetAssetsAcquiredThroughReverseRecapitalization",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/MergerandRelatedTransactionsScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash And Cash Equivalents Acquired Through Reverse Recapitalization",
        "documentation": "Cash And Cash Equivalents Acquired Through Reverse Recapitalization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets",
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r142",
      "r786"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1069",
      "r1070"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents and Restricted Cash",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r114"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash at the beginning of the year",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at the end of the year",
        "totalLabel": "Total cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r90",
      "r163"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of cash, cash equivalents and restricted cash:",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r90"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails",
      "http://www.angn.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.angn.com/role/MergerandRelatedTransactionsNarrativeDetails",
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r146",
      "r147",
      "r148",
      "r167",
      "r189",
      "r190",
      "r192",
      "r194",
      "r202",
      "r203",
      "r247",
      "r281",
      "r283",
      "r284",
      "r285",
      "r288",
      "r289",
      "r319",
      "r320",
      "r323",
      "r326",
      "r333",
      "r531",
      "r669",
      "r670",
      "r671",
      "r672",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r703",
      "r724",
      "r747",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r982",
      "r997",
      "r1006"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails",
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r202",
      "r319",
      "r320",
      "r321",
      "r323",
      "r326",
      "r331",
      "r333",
      "r669",
      "r670",
      "r671",
      "r672",
      "r814",
      "r982",
      "r997"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails",
      "http://www.angn.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.angn.com/role/RelatedPartyTransactionsDetails",
      "http://www.angn.com/role/SubsequentEventsDetails",
      "http://www.angn.com/role/WarrantsNarrativeDetails",
      "http://www.angn.com/role/WarrantsScheduleofIssuanceofWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Axis]",
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails",
      "http://www.angn.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.angn.com/role/RelatedPartyTransactionsDetails",
      "http://www.angn.com/role/SubsequentEventsDetails",
      "http://www.angn.com/role/WarrantsNarrativeDetails",
      "http://www.angn.com/role/WarrantsScheduleofIssuanceofWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Domain]",
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails",
      "http://www.angn.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.angn.com/role/RelatedPartyTransactionsDetails",
      "http://www.angn.com/role/SubsequentEventsDetails",
      "http://www.angn.com/role/WarrantsNarrativeDetails",
      "http://www.angn.com/role/WarrantsScheduleofIssuanceofWarrantsDetails",
      "http://www.angn.com/role/WarrantsScheduleofOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise price (in dollars per share)",
        "terseLabel": "Exercise price (in dollars per share)",
        "periodStartLabel": "Outstanding beginning balance (in dollars per share)",
        "periodEndLabel": "Outstanding ending balance (in dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "angn_ClassOfWarrantOrRightExercisedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "ClassOfWarrantOrRightExercisedInPeriod",
     "presentation": [
      "http://www.angn.com/role/WarrantsScheduleofOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Exercised (in shares)",
        "label": "Class Of Warrant Or Right, Exercised In Period",
        "documentation": "Class Of Warrant Or Right, Exercised In Period"
       }
      }
     },
     "auth_ref": []
    },
    "angn_ClassOfWarrantOrRightIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "ClassOfWarrantOrRightIssuedInPeriod",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsDetails",
      "http://www.angn.com/role/WarrantsScheduleofOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issued (in shares)",
        "terseLabel": "Issued in period",
        "label": "Class Of Warrant Or Right, Issued In Period",
        "documentation": "Class Of Warrant Or Right, Issued In Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.angn.com/role/WarrantsNarrativeDetails",
      "http://www.angn.com/role/WarrantsScheduleofIssuanceofWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Line Items]",
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.angn.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares of common stock to purchase (up to) (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.angn.com/role/WarrantsScheduleofOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-funded warrants outstanding (in shares)",
        "periodStartLabel": "Outstanding beginning balance (in shares)",
        "periodEndLabel": "Outstanding ending balance (in shares)",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "angn_ClassOfWarrantOrRightRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "ClassOfWarrantOrRightRollForward",
     "presentation": [
      "http://www.angn.com/role/WarrantsScheduleofOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Class of Warrant or Right [Roll Forward]",
        "documentation": "Class of Warrant or Right"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.angn.com/role/WarrantsNarrativeDetails",
      "http://www.angn.com/role/WarrantsScheduleofIssuanceofWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Table]",
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod",
     "presentation": [
      "http://www.angn.com/role/WarrantsScheduleofOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in dollars per share)",
        "label": "Class Of Warrant Or Right, Weighted Average Exercise Price, Exercises In Period",
        "documentation": "Class Of Warrant Or Right, Weighted Average Exercise Price, Exercises In Period"
       }
      }
     },
     "auth_ref": []
    },
    "angn_ClassOfWarrantOrRightWeightedAverageExercisePriceIssuedInPeriod": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceIssuedInPeriod",
     "presentation": [
      "http://www.angn.com/role/WarrantsScheduleofOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued (in dollars per share)",
        "label": "Class Of Warrant Or Right, Weighted Average Exercise Price, Issued In Period",
        "documentation": "Class Of Warrant Or Right, Weighted Average Exercise Price, Issued In Period"
       }
      }
     },
     "auth_ref": []
    },
    "angn_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward",
     "presentation": [
      "http://www.angn.com/role/WarrantsScheduleofOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price",
        "label": "Class of Warrant or Right, Weighted Average Exercise Price [Roll Forward]",
        "documentation": "Class of Warrant or Right, Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "angn_ClassOfWarrantOrRightWeightedAverageLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "ClassOfWarrantOrRightWeightedAverageLife",
     "presentation": [
      "http://www.angn.com/role/WarrantsScheduleofOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding beginning balance (in years)",
        "periodEndLabel": "Outstanding ending balance (in years)",
        "label": "Class of Warrant Or Right, Weighted Average Life",
        "documentation": "Class of Warrant Or Right, Weighted Average Life"
       }
      }
     },
     "auth_ref": []
    },
    "angn_ClassOfWarrantOrRightWeightedAverageLifeRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "ClassOfWarrantOrRightWeightedAverageLifeRollForward",
     "presentation": [
      "http://www.angn.com/role/WarrantsScheduleofOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Life (years)",
        "label": "Class of Warrant or Right, Weighted Average Life [Roll Forward]",
        "documentation": "Class of Warrant or Right, Weighted Average Life"
       }
      }
     },
     "auth_ref": []
    },
    "angn_ClinicalTrailMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "ClinicalTrailMember",
     "presentation": [
      "http://www.angn.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical trial expenses",
        "label": "Clinical Trail [Member]",
        "documentation": "Clinical Trail"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies\u2014Note 10",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r118",
      "r619",
      "r702"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r273",
      "r274",
      "r770",
      "r1017",
      "r1022"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares reserved for future issuance (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "angn_CommonStockCapitalSharesReservedForFutureIssuanceIncreasePercentageOfCommonStockOutstanding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuanceIncreasePercentageOfCommonStockOutstanding",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of outstanding stock",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance, Increase, Percentage Of Common Stock Outstanding",
        "documentation": "Common Stock, Capital Shares Reserved for Future Issuance, Increase, Percentage Of Common Stock Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity",
      "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails",
      "http://www.angn.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r857",
      "r858",
      "r859",
      "r861",
      "r862",
      "r863",
      "r864",
      "r1002",
      "r1003",
      "r1005",
      "r1068",
      "r1122",
      "r1125"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquityParenthetical",
      "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails",
      "http://www.angn.com/role/SubsequentEventsDetails",
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r703"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.angn.com/role/MergerandRelatedTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity",
      "http://www.angn.com/role/MergerandRelatedTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "periodStartLabel": "Balance at beginning of period (in shares)",
        "periodEndLabel": "Balance at end of period (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r74",
      "r703",
      "r721",
      "r1125",
      "r1126"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.01 par value; 300,000,000 shares authorized; 11,043,837 and 9,618,178 shares issued at December 31, 2024 and 2023, respectively; 11,029,382 and 9,603,723 shares outstanding as of December 31, 2024 and 2023, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r622",
      "r841"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets (liabilities):",
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r152",
      "r154",
      "r159",
      "r614",
      "r632",
      "r633"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Comprehensive Gain (Loss)",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentrations of Credit Risk and Off-Balance Sheet Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r129"
     ]
    },
    "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems",
     "presentation": [
      "http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]",
        "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable",
     "presentation": [
      "http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation, Less-than-Wholly-Owned Subsidiary, Parent Ownership Interest, Effect of Change [Table]",
        "label": "Consolidation, Less-than-Wholly-Owned Subsidiary, Parent Ownership Interest, Effect of Change [Table]",
        "documentation": "Disclosure of information about effect of change in parent's ownership interest in subsidiary on equity attributable to parent. Excludes change from deconsolidation of subsidiary."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r55"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r791"
     ]
    },
    "angn_ConsultingServicePaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "ConsultingServicePaymentsMember",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consulting Service Payments",
        "label": "Consulting Service Payments [Member]",
        "documentation": "Consulting Service Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets",
      "http://www.angn.com/role/ResearchGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred research obligation",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r337",
      "r338"
     ]
    },
    "angn_ConversionOfConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "ConversionOfConvertibleDebtMember",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of Convertible Debt",
        "label": "Conversion Of Convertible Debt [Member]",
        "documentation": "Conversion Of Convertible Debt"
       }
      }
     },
     "auth_ref": []
    },
    "angn_ConversionOfConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "ConversionOfConvertiblePreferredStockMember",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of Convertible Preferred Stock",
        "label": "Conversion Of Convertible Preferred Stock [Member]",
        "documentation": "Conversion Of Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockAmountIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockAmountIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash issuance of common stock from conversion of preferred stock",
        "label": "Conversion of Stock, Amount Issued",
        "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r26"
     ]
    },
    "us-gaap_ConversionOfStockByUniqueDescriptionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockByUniqueDescriptionAxis",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Conversion Description [Axis]",
        "label": "Stock Conversion Description [Axis]",
        "documentation": "Information by description of stock conversions."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r26"
     ]
    },
    "us-gaap_ConversionOfStockNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockNameDomain",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of Stock, Name [Domain]",
        "label": "Conversion of Stock, Name [Domain]",
        "documentation": "The unique name of a noncash or part noncash stock conversion."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r26"
     ]
    },
    "us-gaap_ConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtMember",
     "presentation": [
      "http://www.angn.com/role/DebtDetails",
      "http://www.angn.com/role/RelatedPartyTransactionsDetails",
      "http://www.angn.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Debt",
        "label": "Convertible Debt [Member]",
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r291",
      "r292",
      "r302",
      "r303",
      "r304",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813"
     ]
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleLongTermNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible note - related party",
        "label": "Convertible Notes Payable, Noncurrent",
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "angn_ConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "ConvertibleNotesMember",
     "presentation": [
      "http://www.angn.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Notes",
        "label": "Convertible Notes [Member]",
        "documentation": "Convertible Notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock",
        "label": "Convertible Preferred Stock [Member]",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r320",
      "r323",
      "r861",
      "r862",
      "r863",
      "r864"
     ]
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Costs and Expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "angn_CostsExpensedUponTheIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "CostsExpensedUponTheIssuanceOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Costs expensed upon the issuance of warrants",
        "label": "Costs Expensed Upon The Issuance Of Warrants",
        "documentation": "Costs Expensed Upon The Issuance Of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails",
      "http://www.angn.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r169",
      "r170",
      "r294",
      "r321",
      "r567",
      "r577",
      "r617",
      "r788",
      "r790"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r984",
      "r1000",
      "r1065"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Current Foreign Tax Expense (Benefit)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r984",
      "r1000"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r1000"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current:",
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r984",
      "r1000",
      "r1065"
     ]
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r881",
      "r970"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r881",
      "r970"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r883",
      "r972"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r883",
      "r972"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r885",
      "r974"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r883",
      "r972"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r876",
      "r965"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r877",
      "r966"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r877",
      "r966"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r875",
      "r964"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r875",
      "r964"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r875",
      "r964"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r878",
      "r967"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r880",
      "r969"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r880",
      "r969"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r881",
      "r970"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r884",
      "r973"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r882",
      "r971"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r879",
      "r968"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.angn.com/role/Debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r165",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r279",
      "r280",
      "r290",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r306",
      "r313",
      "r314",
      "r316",
      "r545"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.angn.com/role/DebtDetails",
      "http://www.angn.com/role/MergerandRelatedTransactionsNarrativeDetails",
      "http://www.angn.com/role/RelatedPartyTransactionsDetails",
      "http://www.angn.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r64",
      "r65",
      "r116",
      "r117",
      "r171",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r302",
      "r303",
      "r304",
      "r305",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r839",
      "r998",
      "r1018",
      "r1019",
      "r1020",
      "r1076",
      "r1078"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://www.angn.com/role/DebtDetails",
      "http://www.angn.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion price",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r293"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "presentation": [
      "http://www.angn.com/role/DebtDetails",
      "http://www.angn.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consecutive trading days",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "presentation": [
      "http://www.angn.com/role/DebtDetails",
      "http://www.angn.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of stock price trigger",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "presentation": [
      "http://www.angn.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading days",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.angn.com/role/DebtDetails",
      "http://www.angn.com/role/MergerandRelatedTransactionsNarrativeDetails",
      "http://www.angn.com/role/RelatedPartyTransactionsDetails",
      "http://www.angn.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, face amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r545",
      "r546",
      "r810",
      "r811",
      "r839"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.angn.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible notes accrue interest, percent",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r292"
     ]
    },
    "angn_DebtInstrumentIssuanceDiscountPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "DebtInstrumentIssuanceDiscountPercent",
     "presentation": [
      "http://www.angn.com/role/DebtDetails",
      "http://www.angn.com/role/MergerandRelatedTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, issuance discount percent",
        "label": "Debt Instrument, Issuance Discount Percent",
        "documentation": "Debt Instrument, Issuance Discount Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.angn.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r302",
      "r303",
      "r304",
      "r305",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r315",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r839",
      "r998",
      "r1076",
      "r1078"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.angn.com/role/DebtDetails",
      "http://www.angn.com/role/MergerandRelatedTransactionsNarrativeDetails",
      "http://www.angn.com/role/RelatedPartyTransactionsDetails",
      "http://www.angn.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r171",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r302",
      "r303",
      "r304",
      "r305",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r839",
      "r998",
      "r1018",
      "r1019",
      "r1020",
      "r1076",
      "r1078"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.angn.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-Term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r43",
      "r46",
      "r60",
      "r104",
      "r105",
      "r171",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r302",
      "r303",
      "r304",
      "r305",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r315",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r839",
      "r998",
      "r1076",
      "r1078"
     ]
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Issuance Costs",
        "label": "Debt, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCompensationShareBasedArrangementsLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested option exercise liability, current",
        "label": "Deferred Compensation Share-Based Arrangements, Liability, Current",
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable within one year (or the operating cycle, if longer)."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Prepaid and Other Current Assets",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1000",
      "r1064",
      "r1065"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1000",
      "r1064"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Deferred",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r134",
      "r1000"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred",
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1000",
      "r1064",
      "r1065"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax asset",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1060"
     ]
    },
    "angn_DeferredTaxAssetsNetBeforeValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "DeferredTaxAssetsNetBeforeValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Net, Before Valuation Allowance",
        "documentation": "Deferred Tax Assets, Net, Before Valuation Allowance"
       }
      }
     },
     "auth_ref": []
    },
    "angn_DeferredTaxAssetsOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "DeferredTaxAssetsOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "angn_DeferredTaxAssetsNetBeforeValuationAllowance",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Deferred Tax Assets, Operating Lease, Liability",
        "documentation": "Deferred Tax Assets, Operating Lease, Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "angn_DeferredTaxAssetsNetBeforeValuationAllowance",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "angn_DeferredTaxAssetsNetBeforeValuationAllowance",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "angn_DeferredTaxAssetsNetBeforeValuationAllowance",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development tax credit carryovers",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "angn_DeferredTaxAssetsNetBeforeValuationAllowance",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized research and development",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: Deferred tax asset valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "angn_DeferredTaxAssetsNetBeforeValuationAllowance",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "ROU asset",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "angn_DeferredTaxAssetsNetBeforeValuationAllowance",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Property and equipment",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "us-gaap_DefinedContributionPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanDisclosureLineItems",
     "presentation": [
      "http://www.angn.com/role/EmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Contribution Plan Disclosure [Line Items]",
        "label": "Defined Contribution Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage",
     "presentation": [
      "http://www.angn.com/role/EmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employers matching contribution annual vesting (in percentage)",
        "label": "Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage",
        "documentation": "Percentage of employer's matching contributions to a defined contribution plan that vests in a given year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanTable",
     "presentation": [
      "http://www.angn.com/role/EmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Contribution Plan [Table]",
        "label": "Defined Contribution Plan [Table]",
        "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "us-gaap_DefinedContributionPlanTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanTextBlock",
     "presentation": [
      "http://www.angn.com/role/EmployeeBenefitPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Benefit Plan",
        "label": "Defined Contribution Plan [Text Block]",
        "documentation": "The entire disclosure for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r399"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsNarrativeDetails",
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "verboseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r36"
     ]
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeGainLossOnDerivativeNet",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of derivative liability",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r1066"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r408",
      "r439",
      "r440",
      "r442",
      "r828"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on sale of equipment",
        "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal",
        "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r995",
      "r1016"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r872",
      "r873",
      "r896"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r872",
      "r873",
      "r896",
      "r939"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic Tax Jurisdiction",
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.angn.com/role/NetLossPerShareScheduleofNetLossPerShareBasicandDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per common share, basic (in dollars per share)",
        "verboseLabel": "Net loss per share, basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r187",
      "r189",
      "r192",
      "r193",
      "r194",
      "r199",
      "r491",
      "r494",
      "r507",
      "r508",
      "r615",
      "r634",
      "r792"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.angn.com/role/NetLossPerShareScheduleofNetLossPerShareBasicandDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per common share, diluted (in dollars per share)",
        "verboseLabel": "Net loss per share, diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r189",
      "r192",
      "r193",
      "r194",
      "r199",
      "r491",
      "r494",
      "r507",
      "r508",
      "r615",
      "r634",
      "r792"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r196"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.angn.com/role/NetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r195",
      "r197",
      "r198"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of foreign currency on cash",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesNarrativeDetails",
      "http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective income tax rate",
        "terseLabel": "Effective tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r831"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statutory federal income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r458",
      "r482",
      "r831"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r831",
      "r1001",
      "r1057"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other differences",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r831",
      "r1001",
      "r1057",
      "r1058"
     ]
    },
    "angn_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent",
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Permanent differences",
        "label": "Effective Income Tax Rate Reconciliation, Permanent Differences, Percent",
        "documentation": "Effective Income Tax Rate Reconciliation, Permanent Differences, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State tax, net of federal benefits",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r831",
      "r1001",
      "r1057"
     ]
    },
    "angn_EffectiveIncomeTaxRateReconciliationTaxCreditFederalResearchAndDevelopmentPercent": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditFederalResearchAndDevelopmentPercent",
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal research and development credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Federal Research And Development, Percent",
        "documentation": "Effective Income Tax Rate Reconciliation, Tax Credit, Federal Research And Development, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "angn_EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent",
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State research and development credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, State Research And Development, Percent",
        "documentation": "Effective Income Tax Rate Reconciliation, Tax Credit, State Research And Development, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.angn.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Embedded derivative, fair value of embedded derivative liability",
        "label": "Embedded Derivative, Fair Value of Embedded Derivative Liability",
        "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r1071",
      "r1072",
      "r1073"
     ]
    },
    "us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Change in fair value of embedded derivative",
        "label": "Embedded Derivative, Gain (Loss) on Embedded Derivative, Net",
        "documentation": "Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period."
       }
      }
     },
     "auth_ref": [
      "r1067"
     ]
    },
    "angn_EmployeeBenefitPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "EmployeeBenefitPlanMember",
     "presentation": [
      "http://www.angn.com/role/EmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Benefit Plan",
        "label": "Employee Benefit Plan [Member]",
        "documentation": "Employee Benefit Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation and benefits",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "angn_EmployeeRelatedReasearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "EmployeeRelatedReasearchAndDevelopmentMember",
     "presentation": [
      "http://www.angn.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee related research and development expenses",
        "label": "Employee Related Reasearch and Development [Member]",
        "documentation": "Employee Related Reasearch and Development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation related to unvested stock option awards, period for recognition (in years)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation related to unvested stock option awards",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1055"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.angn.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofNetLossperShareDetails",
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.angn.com/role/StockBasedCompensationScheduleofAssumptionsUsedtoEstimateFairValueofStockOptionAwardsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Option",
        "verboseLabel": "Shares issuable upon exercise of stock options",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails",
      "http://www.angn.com/role/MergerandRelatedTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity [Domain]",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r981"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r980"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails",
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equipment",
        "verboseLabel": "Equipment",
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity",
      "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails",
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.angn.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r137",
      "r156",
      "r157",
      "r158",
      "r172",
      "r173",
      "r174",
      "r176",
      "r181",
      "r183",
      "r185",
      "r201",
      "r248",
      "r249",
      "r260",
      "r335",
      "r480",
      "r481",
      "r488",
      "r489",
      "r490",
      "r492",
      "r493",
      "r494",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r506",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r547",
      "r549",
      "r561",
      "r631",
      "r658",
      "r659",
      "r660",
      "r678",
      "r747"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r889",
      "r900",
      "r910",
      "r943"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r886",
      "r897",
      "r907",
      "r940"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.angn.com/role/WarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Change in fair value of warrant liabilities",
        "terseLabel": "Change in fair value of warrant liability",
        "negatedLabel": "Gain (loss) on fair value of warrants",
        "label": "Fair Value Adjustment of Warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r7"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r513",
      "r514",
      "r835"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r513",
      "r514",
      "r835"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value Measurement Inputs and Valuation Techniques",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r513",
      "r835"
     ]
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByBalanceSheetGroupingTable",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r509",
      "r511",
      "r512",
      "r513",
      "r514",
      "r523",
      "r524",
      "r526",
      "r572",
      "r573",
      "r574",
      "r810",
      "r811",
      "r817",
      "r818",
      "r819",
      "r832",
      "r835"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability Class [Axis]",
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r525"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r510",
      "r511",
      "r512",
      "r514",
      "r832",
      "r1072",
      "r1074"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r519",
      "r521",
      "r522",
      "r523",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r613",
      "r832",
      "r836"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r363",
      "r368",
      "r511",
      "r524",
      "r572",
      "r817",
      "r818",
      "r819",
      "r832"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r363",
      "r368",
      "r511",
      "r512",
      "r524",
      "r573",
      "r810",
      "r811",
      "r817",
      "r818",
      "r819",
      "r832"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r511",
      "r512",
      "r513",
      "r514",
      "r524",
      "r574",
      "r810",
      "r811",
      "r817",
      "r818",
      "r819",
      "r832",
      "r835"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value by Liability Class [Domain]",
        "label": "Fair Value by Liability Class [Domain]",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r525"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r525"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r520",
      "r525"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r510",
      "r511",
      "r512",
      "r514",
      "r832",
      "r1072",
      "r1074"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r516",
      "r525"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Existing Angion warrant liability",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r525"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, beginning of the period",
        "periodEndLabel": "Balance, end of the period",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r525"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r509",
      "r511",
      "r512",
      "r513",
      "r514",
      "r523",
      "r524",
      "r526",
      "r572",
      "r573",
      "r574",
      "r810",
      "r811",
      "r817",
      "r818",
      "r819",
      "r832",
      "r835"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value measurements, recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r832",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074"
     ]
    },
    "angn_FairValueOfCommonStockWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "FairValueOfCommonStockWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.angn.com/role/WarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Fair value of common warrants at issuance date",
        "terseLabel": "Fair value of common warrants at issuance date",
        "label": "Fair Value Of Common Stock Warrants",
        "documentation": "Fair Value Of Common Stock Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "angn_FairValueOfPreFundedWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "FairValueOfPreFundedWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of pre-funded warrants at issuance date",
        "label": "Fair Value Of Pre Funded Warrants",
        "documentation": "Fair Value Of Pre Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign exchange transaction gain",
        "label": "Gain (Loss), Foreign Currency Transaction, before Tax",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r533",
      "r534",
      "r535",
      "r536",
      "r744"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency Translation and Transactions",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r893",
      "r904",
      "r914",
      "r947"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r893",
      "r904",
      "r914",
      "r947"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r893",
      "r904",
      "r914",
      "r947"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r893",
      "r904",
      "r914",
      "r947"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r893",
      "r904",
      "r914",
      "r947"
     ]
    },
    "angn_FormerAngionEquityHoldersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "FormerAngionEquityHoldersMember",
     "presentation": [
      "http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Former Angion Equity Holders",
        "label": "Former Angion Equity Holders [Member]",
        "documentation": "Former Angion Equity Holders"
       }
      }
     },
     "auth_ref": []
    },
    "angn_FormerElicioEquityHoldersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "FormerElicioEquityHoldersMember",
     "presentation": [
      "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails",
      "http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Former Elicio Equity Holders",
        "label": "Former Elicio Equity Holders [Member]",
        "documentation": "Former Elicio Equity Holders"
       }
      }
     },
     "auth_ref": []
    },
    "angn_FormerElicioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "FormerElicioMember",
     "presentation": [
      "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails",
      "http://www.angn.com/role/MergerandRelatedTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Former Elicio",
        "label": "Former Elicio [Member]",
        "documentation": "Former Elicio"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails",
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and fixtures",
        "verboseLabel": "Furniture and fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "angn_GainLossOnIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "GainLossOnIssuanceOfWarrants",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.angn.com/role/WarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on issuance of pre-funded warrants",
        "negatedLabel": "Loss on issuance of warrants",
        "negatedTerseLabel": "Loss on issuance of pre-funded warrants",
        "label": "Gain Loss On Issuance Of Warrants",
        "documentation": "Gain Loss On Issuance Of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "(Gain) loss on disposal of property and equipment",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.angn.com/role/MergerandRelatedTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on extinguishment of promissory notes payable",
        "negatedTerseLabel": "Gain on extinguishment of promissory notes",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r39",
      "r40"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.angn.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "verboseLabel": "Employee related general and administrative expenses",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r726"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r872",
      "r873",
      "r896"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of long lived assets",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r35",
      "r96",
      "r833"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r97"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r269",
      "r270",
      "r516",
      "r520",
      "r525",
      "r655",
      "r657",
      "r731",
      "r783",
      "r834",
      "r1093"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r270",
      "r516",
      "r520",
      "r525",
      "r655",
      "r657",
      "r731",
      "r783",
      "r834",
      "r1093"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction [Axis]",
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r458",
      "r459",
      "r467",
      "r475",
      "r831",
      "r1061"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction [Domain]",
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r458",
      "r459",
      "r467",
      "r475",
      "r831",
      "r1061"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r453",
      "r458",
      "r463",
      "r464",
      "r465",
      "r469",
      "r474",
      "r483",
      "r485",
      "r486",
      "r487",
      "r674",
      "r831"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.angn.com/role/IncomeTaxesNarrativeDetails",
      "http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for income taxes",
        "totalLabel": "Total tax provision",
        "verboseLabel": "Income tax expenses",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r135",
      "r184",
      "r185",
      "r200",
      "r216",
      "r237",
      "r457",
      "r458",
      "r484",
      "r635",
      "r831"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability",
        "documentation": "Amount of income tax expense (benefit) from continuing operations attributable to an adjustment of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity."
       }
      }
     },
     "auth_ref": [
      "r479"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r455",
      "r456",
      "r469",
      "r470",
      "r473",
      "r477",
      "r668"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "angn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Increase (Decrease) In Accrued Expenses and Other Current Liabilities",
        "documentation": "Increase (Decrease) In Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred research obligation",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r579",
      "r994"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r983",
      "r994"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other long-term prepaid assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r994"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r893",
      "r904",
      "r914",
      "r938",
      "r947",
      "r951",
      "r959"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r874",
      "r963"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r874",
      "r963"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r874",
      "r963"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.angn.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r310",
      "r317",
      "r812",
      "r813"
     ]
    },
    "angn_InterestExpenseNoncash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "InterestExpenseNoncash",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash interest expense",
        "label": "Interest Expense, Noncash",
        "documentation": "Interest Expense, Noncash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r993"
     ]
    },
    "us-gaap_InterestIncomeOperatingAndNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeOperatingAndNonoperating",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Interest Income, Operating and Nonoperating",
        "documentation": "Amount of interest income classified as operating and nonoperating."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r800"
     ]
    },
    "angn_JayVenkatesanAndTrustsAffiliatedWithJayVenkatesanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "JayVenkatesanAndTrustsAffiliatedWithJayVenkatesanMember",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jay Venkatesan and Trusts Affiliated With Jay Venkatesan",
        "label": "Jay Venkatesan and Trusts Affiliated With Jay Venkatesan [Member]",
        "documentation": "Jay Venkatesan and Trusts Affiliated With Jay Venkatesan"
       }
      }
     },
     "auth_ref": []
    },
    "angn_JulyCommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "JulyCommonWarrantsMember",
     "presentation": [
      "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails",
      "http://www.angn.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.angn.com/role/WarrantsNarrativeDetails",
      "http://www.angn.com/role/WarrantsScheduleofIssuanceofWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "July Common Warrants",
        "label": "July Common Warrants [Member]",
        "documentation": "July Common Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "angn_JulyPreFundedWarrantsAndJulyCommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "JulyPreFundedWarrantsAndJulyCommonWarrantsMember",
     "presentation": [
      "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails",
      "http://www.angn.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.angn.com/role/RelatedPartyTransactionsDetails",
      "http://www.angn.com/role/WarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "July Pre-Funded Warrants and July Common Warrants",
        "label": "July Pre-Funded Warrants and July Common Warrants [Member]",
        "documentation": "July Pre-Funded Warrants and July Common Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "angn_JulyPreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "JulyPreFundedWarrantsMember",
     "presentation": [
      "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails",
      "http://www.angn.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.angn.com/role/WarrantsScheduleofIssuanceofWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "July Pre-Funded Warrants",
        "label": "July Pre-Funded Warrants [Member]",
        "documentation": "July Pre-Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "angn_JulyPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "JulyPublicOfferingMember",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity",
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquityParenthetical",
      "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails",
      "http://www.angn.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.angn.com/role/RelatedPartyTransactionsDetails",
      "http://www.angn.com/role/WarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "July Public Offering",
        "label": "July Public Offering [Member]",
        "documentation": "Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "angn_JulySharesAndJulyCommonWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "JulySharesAndJulyCommonWarrantMember",
     "presentation": [
      "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails",
      "http://www.angn.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "July Share And July Common Warrant",
        "label": "July Shares And July Common Warrant [Member]",
        "documentation": "July Shares And July Common Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r559"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails",
      "http://www.angn.com/role/MergerandRelatedTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity [Axis]",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.angn.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r554",
      "r560"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.angn.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r554",
      "r560"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r553"
     ]
    },
    "angn_LesseeOperatingLeaseAnnualRentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "LesseeOperatingLeaseAnnualRentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.angn.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, payment per year",
        "label": "Lessee, Operating Lease, Annual Rent Expense",
        "documentation": "Lessee, Operating Lease, Annual Rent Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.angn.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturities of Lease Liabilities",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1080"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.angn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.angn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less present value discount",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.angn.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r548"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r64",
      "r65",
      "r66",
      "r68",
      "r69",
      "r70",
      "r71",
      "r167",
      "r247",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r496",
      "r497",
      "r498",
      "r531",
      "r701",
      "r793",
      "r867",
      "r1025",
      "r1082",
      "r1083"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities, convertible preferred stock, and stockholders\u2019 (deficit) equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r119",
      "r626",
      "r841",
      "r999",
      "r1014",
      "r1075"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities, convertible preferred stock, and stockholders\u2019 (deficit) equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r141",
      "r167",
      "r247",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r496",
      "r497",
      "r498",
      "r531",
      "r841",
      "r1025",
      "r1082",
      "r1083"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities, Fair Value Disclosure",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r511",
      "r1069"
     ]
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities, Fair Value Disclosure [Abstract]",
        "label": "Liabilities, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "angn_LicenseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "LicenseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License expense",
        "label": "License Expense",
        "documentation": "License Expense"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.angn.com/role/DebtDetails",
      "http://www.angn.com/role/MergerandRelatedTransactionsNarrativeDetails",
      "http://www.angn.com/role/RelatedPartyTransactionsDetails",
      "http://www.angn.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r1018",
      "r1019",
      "r1020"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.angn.com/role/DebtDetails",
      "http://www.angn.com/role/MergerandRelatedTransactionsNarrativeDetails",
      "http://www.angn.com/role/RelatedPartyTransactionsDetails",
      "http://www.angn.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r38",
      "r1018",
      "r1019",
      "r1020"
     ]
    },
    "angn_MarchSubscriptionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "MarchSubscriptionAgreementMember",
     "presentation": [
      "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails",
      "http://www.angn.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.angn.com/role/RelatedPartyTransactionsDetails",
      "http://www.angn.com/role/WarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "March Subscription Agreement",
        "label": "March Subscription Agreement [Member]",
        "documentation": "March Subscription Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.angn.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r275",
      "r276",
      "r277",
      "r278",
      "r402",
      "r449",
      "r514",
      "r578",
      "r654",
      "r656",
      "r664",
      "r693",
      "r694",
      "r754",
      "r756",
      "r758",
      "r759",
      "r761",
      "r780",
      "r781",
      "r806",
      "r814",
      "r827",
      "r835",
      "r836",
      "r837",
      "r838",
      "r851",
      "r1027",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield (per share)",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r1071",
      "r1072",
      "r1073"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volatility (annual)",
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r835",
      "r1071",
      "r1072",
      "r1073"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free rate",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r1071",
      "r1072",
      "r1073"
     ]
    },
    "angn_MeasurementInputStrikePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "MeasurementInputStrikePriceMember",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average strike price",
        "label": "Measurement Input, Strike Price [Member]",
        "documentation": "Measurement Input, Strike Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Axis]",
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r513",
      "r514",
      "r835"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Domain]",
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r513",
      "r514",
      "r835"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.angn.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r275",
      "r276",
      "r277",
      "r278",
      "r402",
      "r449",
      "r514",
      "r578",
      "r654",
      "r656",
      "r664",
      "r693",
      "r694",
      "r754",
      "r756",
      "r758",
      "r759",
      "r761",
      "r780",
      "r781",
      "r806",
      "r814",
      "r827",
      "r835",
      "r836",
      "r837",
      "r851",
      "r1027",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "angn_NetAssetsAcquiredThroughReverseRecapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "NetAssetsAcquiredThroughReverseRecapitalization",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/MergerandRelatedTransactionsScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.angn.com/role/MergerandRelatedTransactionsScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net assets acquired",
        "label": "Net Assets Acquired Through Reverse Recapitalization",
        "documentation": "Net Assets Acquired Through Reverse Recapitalization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r91",
      "r92"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity",
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.angn.com/role/NetLossPerShareScheduleofNetLossPerShareBasicandDilutedDetails",
      "http://www.angn.com/role/SegmentReportingDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "verboseLabel": "Net loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r92",
      "r120",
      "r139",
      "r151",
      "r153",
      "r158",
      "r167",
      "r175",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r184",
      "r185",
      "r191",
      "r247",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r491",
      "r494",
      "r508",
      "r531",
      "r630",
      "r723",
      "r745",
      "r746",
      "r865",
      "r1025"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "presentation": [
      "http://www.angn.com/role/NetLossPerShareScheduleofNetLossPerShareBasicandDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator:",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Adopted Accounting Standards During the Period and Recently Issued Accounting Standards Not Yet Adopted",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "angn_NewtonMassachusettsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "NewtonMassachusettsMember",
     "presentation": [
      "http://www.angn.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Newton, Massachusetts",
        "label": "Newton, Massachusetts [Member]",
        "documentation": "Newton, Massachusetts"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r893",
      "r904",
      "r914",
      "r938",
      "r947"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other (expense) income, net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_NotesPayableOtherPayablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayableOtherPayablesMember",
     "presentation": [
      "http://www.angn.com/role/DebtDetails",
      "http://www.angn.com/role/MergerandRelatedTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes Payable",
        "label": "Notes Payable, Other Payables [Member]",
        "documentation": "A written promise to pay a note to a third party."
       }
      }
     },
     "auth_ref": []
    },
    "angn_NumberOfMembersOfTheBoardOfDirectors": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "NumberOfMembersOfTheBoardOfDirectors",
     "presentation": [
      "http://www.angn.com/role/MergerandRelatedTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of members of the board of directors",
        "label": "Number Of Members Of The Board Of Directors",
        "documentation": "Number Of Members Of The Board Of Directors"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.angn.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r795",
      "r805",
      "r1009"
     ]
    },
    "angn_NumberOfResearchGrantAgreements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "NumberOfResearchGrantAgreements",
     "presentation": [
      "http://www.angn.com/role/ResearchGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of research grant agreements",
        "label": "Number Of Research Grant Agreements",
        "documentation": "Number Of Research Grant Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingCostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingCostsAndExpensesAbstract",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Costs and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r794",
      "r1008",
      "r1010",
      "r1011",
      "r1012",
      "r1013"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.angn.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease expense",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r1079"
     ]
    },
    "angn_OperatingLeaseFutureMinimumAnnualMaintenancePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "OperatingLeaseFutureMinimumAnnualMaintenancePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future minimum payments",
        "label": "Operating Lease, Future Minimum, Annual Maintenance Payments",
        "documentation": "Operating Lease, Future Minimum, Annual Maintenance Payments"
       }
      }
     },
     "auth_ref": []
    },
    "angn_OperatingLeaseFutureMinimumAnnualMaintenancePaymentsDueThereafter": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "OperatingLeaseFutureMinimumAnnualMaintenancePaymentsDueThereafter",
     "crdr": "credit",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future minimum payments, thereafter",
        "label": "Operating Lease, Future Minimum, Annual Maintenance Payments, Due Thereafter",
        "documentation": "Operating Lease, Future Minimum, Annual Maintenance Payments, Due Thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets",
      "http://www.angn.com/role/LeasesNarrativeDetails",
      "http://www.angn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability, current",
        "negatedLabel": "Less: operating lease liability, current portion",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets",
      "http://www.angn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability, noncurrent",
        "verboseLabel": "Operating lease liability, noncurrent portion",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.angn.com/role/LeasesScheduleofQuantitativeInformationaboutOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash outflows from operating leases",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r552",
      "r555"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets",
      "http://www.angn.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r550"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of right-of-use assets, operating leases",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.angn.com/role/LeasesScheduleofQuantitativeInformationaboutOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate\u2014operating leases",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r557",
      "r840"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.angn.com/role/LeasesScheduleofQuantitativeInformationaboutOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term\u2014operating leases (in years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r556",
      "r840"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Line Items]",
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Table]",
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.angn.com/role/DescriptionoftheBusinessandFinancialCondition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of the Business and Financial Condition",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r111",
      "r665",
      "r666"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity",
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustment",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r10",
      "r112"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive gain (loss):",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent, Alternative [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "angn_OtherCurrentAssetsAcquiredThroughReverseRecapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "OtherCurrentAssetsAcquiredThroughReverseRecapitalization",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/MergerandRelatedTransactionsScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": "angn_NetAssetsAcquiredThroughReverseRecapitalization",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/MergerandRelatedTransactionsScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other Current Assets Acquired Through Reverse Recapitalization",
        "documentation": "Other Current Assets Acquired Through Reverse Recapitalization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.angn.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professional fees and other general and administrative expenses",
        "label": "Other General and Administrative Expense",
        "documentation": "Amount of general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r1124"
     ]
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIncomeAndExpensesAbstract",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other (expense) income",
        "label": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "angn_OtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "OtherMember",
     "presentation": [
      "http://www.angn.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other research and development expenses",
        "label": "Other [Member]",
        "documentation": "Other"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "angn_OtherPrepaidExpensesAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "OtherPrepaidExpensesAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPrepaidandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPrepaidandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other prepaid expenses and other current assets",
        "label": "Other Prepaid Expenses And Other Assets, Current",
        "documentation": "Other Prepaid Expenses And Other Assets, Current"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r891",
      "r902",
      "r912",
      "r945"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r894",
      "r905",
      "r915",
      "r948"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r894",
      "r905",
      "r915",
      "r948"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Axis]",
        "label": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Domain]",
        "label": "Ownership [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "angn_PaymentOfWarrantIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "PaymentOfWarrantIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of warrant issuance costs",
        "label": "Payment Of Warrant Issuance Costs",
        "documentation": "Payment Of Warrant Issuance Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRepurchaseOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRepurchaseOfEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of employee withholding taxes on restricted stock",
        "label": "Payments for Repurchase of Equity",
        "documentation": "The cash outflow to reacquire common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r672"
     ]
    },
    "us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfMergerRelatedCostsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Merger transaction costs",
        "label": "Payments of Merger Related Costs, Financing Activities",
        "documentation": "The cash outflow for financing costs associated with business combinations."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "angn_PreFundedWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "PreFundedWarrantMember",
     "presentation": [
      "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails",
      "http://www.angn.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.angn.com/role/RelatedPartyTransactionsDetails",
      "http://www.angn.com/role/SubsequentEventsDetails",
      "http://www.angn.com/role/WarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Funded Warrant",
        "label": "Pre-Funded Warrant [Member]",
        "documentation": "Pre-Funded Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "angn_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://www.angn.com/role/WarrantsScheduleofIssuanceofWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-funded Warrants",
        "label": "Pre-funded Warrants [Member]",
        "documentation": "Pre-funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Convertible Preferred Stock",
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r857",
      "r858",
      "r861",
      "r862",
      "r863",
      "r864",
      "r1122",
      "r1125"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r319"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r703"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r319"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r703",
      "r721",
      "r1125",
      "r1126"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.01 par value; 10,000,000 shares authorized; no shares issued and outstanding",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r621",
      "r841"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPrepaidandOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPrepaidandOtherCurrentAssetsDetails",
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r989"
     ]
    },
    "us-gaap_PrepaidExpenseOtherNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseOtherNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsNarrativeDetails",
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term prepaid assets",
        "label": "Prepaid Expense Other, Noncurrent",
        "documentation": "Carrying amount as of the balance sheet date of amounts paid in advance which will be charged against earnings in periods after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPrepaidandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPrepaidandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid insurance",
        "label": "Prepaid Insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r787",
      "r807",
      "r1015"
     ]
    },
    "angn_PrepaidResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "PrepaidResearchAndDevelopmentExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPrepaidandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPrepaidandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid research and development contract services",
        "label": "Prepaid Research And Development Expenses",
        "documentation": "Prepaid Research And Development Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Statement Reclassification",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error."
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.angn.com/role/DebtDetails",
      "http://www.angn.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from convertible debt",
        "label": "Proceeds from Convertible Debt",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "angn_ProceedsFromIssuanceOfCommonStockFromJulyPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "ProceedsFromIssuanceOfCommonStockFromJulyPublicOffering",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock from July Public Offering",
        "label": "Proceeds From Issuance of Common Stock From July Public Offering",
        "documentation": "Proceeds From Issuance of Common Stock From July Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "angn_ProceedsFromIssuanceOfCommonStockWarrantsFromJulyPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "ProceedsFromIssuanceOfCommonStockWarrantsFromJulyPublicOffering",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock warrants from July Public Offering",
        "label": "Proceeds From Issuance of Common Stock Warrants From July Public Offering",
        "documentation": "Proceeds From Issuance of Common Stock Warrants From July Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfSeniorLongTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of senior note, net of issuance costs",
        "label": "Proceeds from Issuance of Senior Long-Term Debt",
        "documentation": "The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer)."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.angn.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock warrants from March PIPE",
        "label": "Proceeds from Issuance of Warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromNotesPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of promissory notes payable",
        "label": "Proceeds from Notes Payable",
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of property and equipment",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_ProceedsFromSecuredLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSecuredLinesOfCredit",
     "crdr": "debit",
     "presentation": [
      "http://www.angn.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Letter of credit",
        "label": "Proceeds from Secured Lines of Credit",
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets)."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r15"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.angn.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r241",
      "r580",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r784",
      "r815",
      "r850",
      "r851",
      "r852",
      "r855",
      "r856",
      "r1023",
      "r1024",
      "r1028",
      "r1092",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.angn.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r241",
      "r580",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r784",
      "r815",
      "r850",
      "r851",
      "r852",
      "r855",
      "r856",
      "r1023",
      "r1024",
      "r1028",
      "r1092",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121"
     ]
    },
    "angn_ProfessionalServicesExpenseNoncash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "ProfessionalServicesExpenseNoncash",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash professional services expense",
        "label": "Professional Services Expense, Noncash",
        "documentation": "Professional Services Expense, Noncash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProjectMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProjectMember",
     "presentation": [
      "http://www.angn.com/role/ResearchGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Project [Domain]",
        "label": "Project [Domain]",
        "documentation": "Planned program of work."
       }
      }
     },
     "auth_ref": [
      "r581",
      "r612",
      "r1091"
     ]
    },
    "angn_PromissoryNotesAcquiredThroughReverseRecapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "PromissoryNotesAcquiredThroughReverseRecapitalization",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/MergerandRelatedTransactionsScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": "angn_NetAssetsAcquiredThroughReverseRecapitalization",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/MergerandRelatedTransactionsScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Promissory notes",
        "label": "Promissory Notes Acquired Through Reverse Recapitalization",
        "documentation": "Promissory Notes Acquired Through Reverse Recapitalization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails",
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r559"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r143",
      "r629"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails",
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails",
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r559",
      "r616",
      "r629",
      "r841"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r130",
      "r133",
      "r627"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsTables",
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment",
        "verboseLabel": "Schedule of Property and Equipment, Net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails",
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r559"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, useful life (in years)",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "angn_PurchaseOfWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "PurchaseOfWarrantsMember",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase Of Warrants",
        "label": "Purchase Of Warrants [Member]",
        "documentation": "Purchase Of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.angn.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r275",
      "r276",
      "r277",
      "r278",
      "r361",
      "r402",
      "r434",
      "r435",
      "r436",
      "r449",
      "r514",
      "r575",
      "r576",
      "r578",
      "r654",
      "r656",
      "r664",
      "r693",
      "r694",
      "r754",
      "r756",
      "r758",
      "r759",
      "r761",
      "r780",
      "r781",
      "r806",
      "r814",
      "r827",
      "r835",
      "r836",
      "r837",
      "r838",
      "r851",
      "r859",
      "r1021",
      "r1027",
      "r1072",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.angn.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r275",
      "r276",
      "r277",
      "r278",
      "r361",
      "r402",
      "r434",
      "r435",
      "r436",
      "r449",
      "r514",
      "r575",
      "r576",
      "r578",
      "r654",
      "r656",
      "r664",
      "r693",
      "r694",
      "r754",
      "r756",
      "r758",
      "r759",
      "r761",
      "r780",
      "r781",
      "r806",
      "r814",
      "r827",
      "r835",
      "r836",
      "r837",
      "r838",
      "r851",
      "r859",
      "r1021",
      "r1027",
      "r1072",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089"
     ]
    },
    "angn_RecapitalizationExchangeRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "RecapitalizationExchangeRatio",
     "presentation": [
      "http://www.angn.com/role/MergerandRelatedTransactionsNarrativeDetails",
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recapitalization exchange ratio",
        "label": "Recapitalization Exchange Ratio",
        "documentation": "Recapitalization Exchange Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "angn_ReclassLiabilityClassifiedWarrantsToEquityClassifiedWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "ReclassLiabilityClassifiedWarrantsToEquityClassifiedWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification of liability-classified warrants to equity classified warrants",
        "label": "Reclass Liability-Classified Warrants to Equity Classified Warrants",
        "documentation": "Reclass Liability-Classified Warrants to Equity Classified Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RecoveryOfDirectCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RecoveryOfDirectCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.angn.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract and grant reimbursements",
        "label": "Recovery of Direct Costs",
        "documentation": "Return of or reimbursements received in relation to direct costs and expenses previously paid or incurred."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r886",
      "r897",
      "r907",
      "r940"
     ]
    },
    "angn_RegistrationStatementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "RegistrationStatementMember",
     "presentation": [
      "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Registration Statement",
        "label": "Registration Statement [Member]",
        "documentation": "Registration Statement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party transaction, amounts of transaction",
        "label": "Related Party Transaction, Amounts of Transaction",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r565"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Axis]",
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r565",
      "r566",
      "r1081"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Domain]",
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r727",
      "r728",
      "r731"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r562",
      "r563",
      "r564",
      "r566",
      "r568",
      "r675",
      "r676",
      "r677",
      "r729",
      "r730",
      "r731",
      "r751",
      "r753"
     ]
    },
    "angn_ReportableSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "ReportableSegmentMember",
     "presentation": [
      "http://www.angn.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reportable Segment",
        "label": "Reportable Segment [Member]",
        "documentation": "Reportable Segment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails",
      "http://www.angn.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r169",
      "r170",
      "r294",
      "r321",
      "r567",
      "r577",
      "r617",
      "r789",
      "r790"
     ]
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "presentation": [
      "http://www.angn.com/role/ResearchGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r1056"
     ]
    },
    "angn_ResearchAndDevelopmentArrangementCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "ResearchAndDevelopmentArrangementCredit",
     "crdr": "credit",
     "presentation": [
      "http://www.angn.com/role/ResearchGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit",
        "label": "Research And Development Arrangement, Credit",
        "documentation": "Research And Development Arrangement, Credit"
       }
      }
     },
     "auth_ref": []
    },
    "angn_ResearchAndDevelopmentArrangementGrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "ResearchAndDevelopmentArrangementGrant",
     "crdr": "debit",
     "presentation": [
      "http://www.angn.com/role/ResearchGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant award",
        "label": "Research And Development Arrangement, Grant",
        "documentation": "Research And Development Arrangement, Grant"
       }
      }
     },
     "auth_ref": []
    },
    "angn_ResearchAndDevelopmentArrangementGrantReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "ResearchAndDevelopmentArrangementGrantReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.angn.com/role/ResearchGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant award received",
        "label": "Research And Development Arrangement, Grant Received",
        "documentation": "Research And Development Arrangement, Grant Received"
       }
      }
     },
     "auth_ref": []
    },
    "angn_ResearchAndDevelopmentArrangementReimbursementFromGrantFunds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "ResearchAndDevelopmentArrangementReimbursementFromGrantFunds",
     "crdr": "credit",
     "presentation": [
      "http://www.angn.com/role/ResearchGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reimbursement from grant funds",
        "label": "Research And Development Arrangement, Reimbursement from Grant Funds",
        "documentation": "Research And Development Arrangement, Reimbursement from Grant Funds"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.angn.com/role/ResearchGrantDetails",
      "http://www.angn.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "negatedLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r451",
      "r783",
      "r800",
      "r1090"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development and Research Grant",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "presentation": [
      "http://www.angn.com/role/ResearchGrant"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Grant",
        "label": "Research, Development, and Computer Software Disclosure [Text Block]",
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r782"
     ]
    },
    "angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFAugust2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFAugust2024Member",
     "presentation": [
      "http://www.angn.com/role/ResearchGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Grant Agreement With The Gastro-Intestinal Research Foundation (\u201cGIRF\u201d) August 2024",
        "label": "Research Grant Agreement With The Gastro-Intestinal Research Foundation (\u201cGIRF\u201d) August 2024 [Member]",
        "documentation": "Research Grant Agreement With The Gastro-Intestinal Research Foundation (\u201cGIRF\u201d) August 2024"
       }
      }
     },
     "auth_ref": []
    },
    "angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFJuly2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFJuly2023Member",
     "presentation": [
      "http://www.angn.com/role/ResearchGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Grant Agreement with GIRF July 2023",
        "label": "Research Grant Agreement With The Gastro-Intestinal Research Foundation (\u201cGIRF\u201d) July 2023 [Member]",
        "documentation": "Research Grant Agreement With The Gastro-Intestinal Research Foundation (\u201cGIRF\u201d) July 2023"
       }
      }
     },
     "auth_ref": []
    },
    "angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept.2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept.2023Member",
     "presentation": [
      "http://www.angn.com/role/ResearchGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Grant Agreement With The Gastro-Intestinal Research Foundation (\u201cGIRF\u201d) Sept. 2023",
        "label": "Research Grant Agreement With The Gastro-Intestinal Research Foundation (\u201cGIRF\u201d) Sept. 2023 [Member]",
        "documentation": "Research Grant Agreement With The Gastro-Intestinal Research Foundation (\u201cGIRF\u201d) Sept. 2023"
       }
      }
     },
     "auth_ref": []
    },
    "angn_ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept2022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept2022Member",
     "presentation": [
      "http://www.angn.com/role/ResearchGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Grant Agreement with GIRF Sept. 2022",
        "label": "Research Grant Agreement With The Gastro-Intestinal Research Foundation (\u201cGIRF\u201d) Sept. 2022 [Member]",
        "documentation": "Research Grant Agreement With The Gastro-Intestinal Research Foundation (\u201cGIRF\u201d) Sept. 2022"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchMember",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Tax Credit Carryforward",
        "label": "Research Tax Credit Carryforward [Member]",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r1061"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r887",
      "r898",
      "r908",
      "r941"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r888",
      "r899",
      "r909",
      "r942"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r895",
      "r906",
      "r916",
      "r949"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash and Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r114",
      "r142",
      "r163",
      "r620"
     ]
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets",
      "http://www.angn.com/role/ResearchGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash, current",
        "label": "Restricted Cash, Current",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r987",
      "r996"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash, noncurrent",
        "label": "Restricted Cash, Noncurrent",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r988",
      "r996"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets",
      "http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r106",
      "r625",
      "r661",
      "r663",
      "r673",
      "r704",
      "r841"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r172",
      "r173",
      "r174",
      "r176",
      "r181",
      "r183",
      "r185",
      "r248",
      "r249",
      "r260",
      "r480",
      "r481",
      "r488",
      "r489",
      "r490",
      "r492",
      "r493",
      "r494",
      "r499",
      "r501",
      "r502",
      "r504",
      "r506",
      "r547",
      "r549",
      "r658",
      "r660",
      "r678",
      "r1125"
     ]
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetirementPlanTypeAxis",
     "presentation": [
      "http://www.angn.com/role/EmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Plan Type [Axis]",
        "label": "Retirement Plan Type [Axis]",
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r399",
      "r400",
      "r401",
      "r403",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826"
     ]
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetirementPlanTypeDomain",
     "presentation": [
      "http://www.angn.com/role/EmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Plan Type [Domain]",
        "label": "Retirement Plan Type [Domain]",
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r399",
      "r400",
      "r401",
      "r403",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826"
     ]
    },
    "angn_ReverseRecapitalizationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "ReverseRecapitalizationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse Recapitalization [Abstract]",
        "documentation": "Reverse Recapitalization"
       }
      }
     },
     "auth_ref": []
    },
    "angn_ReverseRecapitalizationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "ReverseRecapitalizationDisclosureTextBlock",
     "presentation": [
      "http://www.angn.com/role/MergerandRelatedTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger and Related Transactions",
        "label": "Reverse Recapitalization Disclosure [Text Block]",
        "documentation": "Reverse Recapitalization Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "angn_ReverseRecapitalizationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "ReverseRecapitalizationLineItems",
     "presentation": [
      "http://www.angn.com/role/MergerandRelatedTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse Recapitalization [Line Items]",
        "label": "Reverse Recapitalization [Line Items]",
        "documentation": "Reverse Recapitalization"
       }
      }
     },
     "auth_ref": []
    },
    "angn_ReverseRecapitalizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "ReverseRecapitalizationMember",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse Recapitalization",
        "label": "Reverse Recapitalization [Member]",
        "documentation": "Reverse Recapitalization"
       }
      }
     },
     "auth_ref": []
    },
    "angn_ReverseRecapitalizationOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "ReverseRecapitalizationOwnershipPercentage",
     "presentation": [
      "http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership percentage",
        "label": "Reverse Recapitalization Ownership Percentage",
        "documentation": "Reverse Recapitalization Ownership Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "angn_ReverseRecapitalizationTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "ReverseRecapitalizationTransactionCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.angn.com/role/MergerandRelatedTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction costs",
        "label": "Reverse Recapitalization, Transaction Costs",
        "documentation": "Reverse Recapitalization, Transaction Costs"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "angn_SaleOfStockAggregateInitialOfferingPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "SaleOfStockAggregateInitialOfferingPrice",
     "crdr": "debit",
     "presentation": [
      "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, aggregate offering price (up to)",
        "label": "Sale of Stock, Aggregate Initial Offering Price",
        "documentation": "Sale of Stock, Aggregate Initial Offering Price"
       }
      }
     },
     "auth_ref": []
    },
    "angn_SaleOfStockBeneficialOwnershipLimitationPercentage": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "SaleOfStockBeneficialOwnershipLimitationPercentage",
     "presentation": [
      "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails",
      "http://www.angn.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.angn.com/role/WarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Beneficial ownership limitation, percentage",
        "label": "Sale Of Stock, Beneficial Ownership Limitation, Percentage",
        "documentation": "Sale Of Stock, Beneficial Ownership Limitation, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails",
      "http://www.angn.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.angn.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds from offering",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity",
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquityParenthetical",
      "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails",
      "http://www.angn.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.angn.com/role/RelatedPartyTransactionsDetails",
      "http://www.angn.com/role/WarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails",
      "http://www.angn.com/role/MergerandRelatedTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares sold in offering (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.angn.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price (in dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.angn.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.angn.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded From Computation of Net Loss per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1063"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1060"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.angn.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Net Loss Per Share, Basic and Diluted",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r831",
      "r1057"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Stock-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1069",
      "r1070"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails",
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r559"
     ]
    },
    "angn_ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock",
     "presentation": [
      "http://www.angn.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Quantitative Information On Operating Leases",
        "label": "Schedule Of Quantitative Information On Operating Leases [Table Text Block]",
        "documentation": "Schedule Of Quantitative Information On Operating Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Table]",
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59",
      "r727",
      "r728",
      "r731"
     ]
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "presentation": [
      "http://www.angn.com/role/ResearchGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development, Contract to Perform for Others [Table]",
        "label": "Research and Development, Contract to Perform for Others [Table]",
        "documentation": "Disclosure of information about research and development arrangement accounted for as contract to perform research and development for others. Includes, but is not limited to, royalty arrangement, purchase provision, license agreement, and commitment to provide additional funding."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r1056"
     ]
    },
    "angn_ScheduleOfReverseRecapitalizationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "ScheduleOfReverseRecapitalizationTable",
     "presentation": [
      "http://www.angn.com/role/MergerandRelatedTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reverse Recapitalization [Table]",
        "label": "Schedule Of Reverse Recapitalization [Table]",
        "documentation": "Schedule Of Reverse Recapitalization"
       }
      }
     },
     "auth_ref": []
    },
    "angn_ScheduleOfReverseRecapitalizationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "ScheduleOfReverseRecapitalizationTableTextBlock",
     "presentation": [
      "http://www.angn.com/role/MergerandRelatedTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reverse Recapitalization",
        "label": "Schedule Of Reverse Recapitalization [Table Text Block]",
        "documentation": "Schedule Of Reverse Recapitalization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.angn.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r34"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.angn.com/role/SegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r34"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.angn.com/role/StockBasedCompensationScheduleofAssumptionsUsedtoEstimateFairValueofStockOptionAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r407",
      "r409",
      "r410",
      "r411",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r108"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assumptions Used to Estimate Fair Value of Stock Option Awards",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails",
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock, Class of Stock [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r102",
      "r104",
      "r105",
      "r106",
      "r146",
      "r147",
      "r148",
      "r202",
      "r319",
      "r320",
      "r321",
      "r323",
      "r326",
      "r331",
      "r333",
      "r669",
      "r670",
      "r671",
      "r672",
      "r814",
      "r982",
      "r997"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.angn.com/role/WarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Outstanding Warrants",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.angn.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r124",
      "r200",
      "r205",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r221",
      "r222",
      "r223",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r237",
      "r238",
      "r239",
      "r245",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r271",
      "r272",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r797",
      "r800",
      "r801",
      "r808",
      "r854",
      "r1092",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.angn.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r243",
      "r244",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r690",
      "r691",
      "r692",
      "r755",
      "r757",
      "r760",
      "r762",
      "r769",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r785",
      "r816",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r853",
      "r859",
      "r1028",
      "r1092",
      "r1094",
      "r1095",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.angn.com/role/SegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r200",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r220",
      "r222",
      "r223",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r241",
      "r242",
      "r245",
      "r795",
      "r798",
      "r799",
      "r800",
      "r802",
      "r804",
      "r805"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.angn.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information [Line Items]",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.angn.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other segment items",
        "label": "Segment Reporting, Other Segment Item, Amount",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r222",
      "r223",
      "r237",
      "r800"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r240",
      "r243",
      "r796",
      "r797",
      "r803"
     ]
    },
    "angn_SeniorSecuredConvertiblePromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "SeniorSecuredConvertiblePromissoryNoteMember",
     "presentation": [
      "http://www.angn.com/role/DebtDetails",
      "http://www.angn.com/role/RelatedPartyTransactionsDetails",
      "http://www.angn.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Secured Convertible Promissory Note",
        "label": "Senior Secured Convertible Promissory Note [Member]",
        "documentation": "Senior Secured Convertible Promissory Note"
       }
      }
     },
     "auth_ref": []
    },
    "angn_ServiceAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "ServiceAgreementMember",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service Agreement",
        "label": "Service Agreement [Member]",
        "documentation": "Service Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "angn_SettlementOfPromissoryNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "SettlementOfPromissoryNotesPayable",
     "crdr": "debit",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement of promissory notes payable",
        "label": "Settlement Of Promissory Notes Payable",
        "documentation": "Settlement Of Promissory Notes Payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.angn.com/role/StockBasedCompensationScheduleofAssumptionsUsedtoEstimateFairValueofStockOptionAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility, maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility, minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.angn.com/role/StockBasedCompensationScheduleofAssumptionsUsedtoEstimateFairValueofStockOptionAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r407",
      "r409",
      "r410",
      "r411",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares authorized for issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for future grants (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Option Activity, Additional Disclosures",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options vested and exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options vested and exercisable (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeited (unvested) (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.angn.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options outstanding, total intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning of period (in shares)",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r414"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Stock Options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning of period (in dollars per share)",
        "periodEndLabel": "Outstanding at end of period (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r414"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareLimit": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardShareLimit",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award, Share Limit",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Share Limit",
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Share Limit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.angn.com/role/StockBasedCompensationScheduleofAssumptionsUsedtoEstimateFairValueofStockOptionAwardsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r410",
      "r411",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (unvested) (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.angn.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r412",
      "r431",
      "r432",
      "r433",
      "r434",
      "r437",
      "r443",
      "r444",
      "r445",
      "r446"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options vested and exercisable, total intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options vested and exercisable, weighted average remaining contractual life (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options outstanding, weighted average remaining contractual life (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails",
      "http://www.angn.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price per share of shares issued (in dollars per share)",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Return of common stock to pay withholding taxes on restricted stock (in shares)",
        "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r164"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and Local Jurisdiction",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.angn.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r124",
      "r138",
      "r200",
      "r205",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r221",
      "r222",
      "r223",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r237",
      "r238",
      "r239",
      "r245",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r263",
      "r271",
      "r272",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r797",
      "r800",
      "r801",
      "r808",
      "r854",
      "r1092",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails",
      "http://www.angn.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.angn.com/role/MergerandRelatedTransactionsNarrativeDetails",
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r146",
      "r147",
      "r148",
      "r167",
      "r189",
      "r190",
      "r192",
      "r194",
      "r202",
      "r203",
      "r247",
      "r281",
      "r283",
      "r284",
      "r285",
      "r288",
      "r289",
      "r319",
      "r320",
      "r323",
      "r326",
      "r333",
      "r531",
      "r669",
      "r670",
      "r671",
      "r672",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r703",
      "r724",
      "r747",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r982",
      "r997",
      "r1006"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity",
      "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails",
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.angn.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r74",
      "r77",
      "r78",
      "r137",
      "r156",
      "r157",
      "r158",
      "r172",
      "r173",
      "r174",
      "r176",
      "r181",
      "r183",
      "r185",
      "r201",
      "r248",
      "r249",
      "r260",
      "r335",
      "r480",
      "r481",
      "r488",
      "r489",
      "r490",
      "r492",
      "r493",
      "r494",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r506",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r547",
      "r549",
      "r561",
      "r631",
      "r658",
      "r659",
      "r660",
      "r678",
      "r747"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.angn.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r243",
      "r244",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r690",
      "r691",
      "r692",
      "r755",
      "r757",
      "r760",
      "r762",
      "r769",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r785",
      "r816",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r853",
      "r859",
      "r1028",
      "r1092",
      "r1094",
      "r1095",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity",
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r201",
      "r549",
      "r580",
      "r667",
      "r689",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r703",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r722",
      "r725",
      "r726",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r747",
      "r860"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' (deficit) equity:",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity",
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r201",
      "r246",
      "r549",
      "r580",
      "r667",
      "r689",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r703",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r722",
      "r725",
      "r726",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r747",
      "r860"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r890",
      "r901",
      "r911",
      "r944"
     ]
    },
    "angn_StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock from the exercise of Pre-funded Warrants (in shares)",
        "label": "Stock and Warrants Issued During Period, Share, Preferred Stock and Warrants",
        "documentation": "Stock and Warrants Issued During Period, Share, Preferred Stock and Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock from the exercise of Pre-funded Warrants",
        "label": "Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants",
        "documentation": "Value of preferred stock and warrants for common stock issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "angn_StockIssuanceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "StockIssuanceAxis",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Issuance [Axis]",
        "label": "Stock Issuance [Axis]",
        "documentation": "Stock Issuance"
       }
      }
     },
     "auth_ref": []
    },
    "angn_StockIssuanceDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "StockIssuanceDomain",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Issuance [Domain]",
        "label": "Stock Issuance [Domain]",
        "documentation": "Stock Issuance [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash issuance of stock",
        "label": "Stock Issued",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r26"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity",
      "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of preferred stock (in shares)",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r43",
      "r74",
      "r77",
      "r106",
      "r307"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock related to stock purchase agreement (in shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r73",
      "r74",
      "r106"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity",
      "http://www.angn.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, net of issuance costs (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r73",
      "r74",
      "r106",
      "r669",
      "r747",
      "r764"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting of restricted common stock (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r73",
      "r74",
      "r106"
     ]
    },
    "angn_StockIssuedDuringPeriodSharesReverseRecapitalization": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesReverseRecapitalization",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, net of issuance costs (in shares)",
        "label": "Stock Issued During Period, Shares, Reverse Recapitalization",
        "documentation": "Stock Issued During Period, Shares, Reverse Recapitalization"
       }
      }
     },
     "auth_ref": []
    },
    "angn_StockIssuedDuringPeriodSharesServiceAgreement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesServiceAgreement",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock related to service agreement (in shares)",
        "label": "Stock Issued During Period, Shares, Service Agreement",
        "documentation": "Stock Issued During Period, Shares, Service Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity",
      "http://www.angn.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options (in shares)",
        "negatedTerseLabel": "Options exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r73",
      "r74",
      "r106",
      "r418"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of preferred stock",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r74",
      "r77",
      "r78",
      "r106"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock related to stock purchase agreement",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r73",
      "r74",
      "r106"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, net of issuance costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r73",
      "r74",
      "r106",
      "r678",
      "r747",
      "r764",
      "r866"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting of restricted common stock",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r106"
     ]
    },
    "angn_StockIssuedDuringPeriodValueReverseRecapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "StockIssuedDuringPeriodValueReverseRecapitalization",
     "crdr": "credit",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, net of issuance costs",
        "label": "Stock Issued During Period, Value, Reverse Recapitalization",
        "documentation": "Stock Issued During Period, Value, Reverse Recapitalization"
       }
      }
     },
     "auth_ref": []
    },
    "angn_StockIssuedDuringPeriodValueServiceAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "StockIssuedDuringPeriodValueServiceAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock related to service agreement",
        "label": "Stock Issued During Period, Value, Service Agreement",
        "documentation": "Stock Issued During Period, Value, Service Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r74",
      "r77",
      "r78",
      "r106"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets",
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' (deficit) equity",
        "periodStartLabel": "Balance at beginning of period",
        "periodEndLabel": "Balance at end of period",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r78",
      "r94",
      "r705",
      "r721",
      "r748",
      "r749",
      "r841",
      "r867",
      "r999",
      "r1014",
      "r1075",
      "r1125"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock, Common Stock and Stockholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r166",
      "r318",
      "r320",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r335",
      "r505",
      "r750",
      "r752",
      "r768"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://www.angn.com/role/MergerandRelatedTransactionsNarrativeDetails",
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock split, conversion ratio",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.angn.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Line Items]",
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r544",
      "r570"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.angn.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r544",
      "r570"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.angn.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Table]",
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r544",
      "r570"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.angn.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r544",
      "r570"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.angn.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r544",
      "r570"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.angn.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r569",
      "r571"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity",
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquityParenthetical",
      "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails",
      "http://www.angn.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.angn.com/role/RelatedPartyTransactionsDetails",
      "http://www.angn.com/role/WarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Components",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r986"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of noncash investing and financing activities:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Axis]",
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward, Name [Domain]",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Period [Axis]",
        "label": "Tax Period [Axis]",
        "documentation": "Information by period subject to enacted tax law."
       }
      }
     },
     "auth_ref": [
      "r1059"
     ]
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Period [Domain]",
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": [
      "r1059"
     ]
    },
    "us-gaap_TaxYear2017Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxYear2017Member",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Year 2017",
        "label": "Tax Year 2017 [Member]",
        "documentation": "Identified as tax year 2017."
       }
      }
     },
     "auth_ref": [
      "r1059"
     ]
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r283",
      "r284",
      "r285",
      "r288",
      "r289",
      "r447",
      "r623"
     ]
    },
    "angn_TemporaryEquitySharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "TemporaryEquitySharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Conversion of preferred stock (in shares)",
        "label": "Temporary Equity, Shares, Conversion Of Convertible Securities",
        "documentation": "Temporary Equity, Shares, Conversion Of Convertible Securities"
       }
      }
     },
     "auth_ref": []
    },
    "angn_TemporaryEquitySharesIssuedDuringPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "TemporaryEquitySharesIssuedDuringPeriod",
     "presentation": [
      "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued during period (in shares)",
        "label": "Temporary Equity, Shares Issued During Period",
        "documentation": "Temporary Equity, Shares Issued During Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity",
      "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning of period (in shares)",
        "periodEndLabel": "Balance at end of period (in shares)",
        "terseLabel": "Convertible preferred stock, shares outstanding (in shares)",
        "label": "Temporary Equity, Shares Outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "angn_TemporaryEquityValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "TemporaryEquityValueConversionOfConvertibleSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Conversion of preferred stock",
        "label": "Temporary Equity, Value, Conversion Of Convertible Securities",
        "documentation": "Temporary Equity, Value, Conversion Of Convertible Securities"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "angn_TranslationalMedicineAndCMCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "TranslationalMedicineAndCMCMember",
     "presentation": [
      "http://www.angn.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chemistry, manufacturing and controls expenses",
        "label": "Translational Medicine and CMC [Member]",
        "documentation": "Translational Medicine and CMC"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r960"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r960"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity",
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Stock",
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets",
      "http://www.angn.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.angn.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury stock, shares outstanding (in shares)",
        "negatedPeriodStartLabel": "Treasury stock, beginning balance (in shares)",
        "negatedPeriodEndLabel": "Treasury stock, ending balance (in shares)",
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_TreasuryStockCommonValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonValue",
     "crdr": "debit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Treasury stock, at cost, 14,455 shares outstanding",
        "label": "Treasury Stock, Common, Value",
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r77"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Uncertain tax positions",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r454",
      "r468",
      "r830"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits, income tax penalties and interest accrued",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r466",
      "r830"
     ]
    },
    "angn_UnvestedCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "UnvestedCommonStockMember",
     "presentation": [
      "http://www.angn.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested common stock",
        "label": "Unvested Common Stock [Member]",
        "documentation": "Unvested Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r31",
      "r127",
      "r128",
      "r131",
      "r132"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance increase",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "angn_VestingOfRestrictedCommonStockNoncash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "VestingOfRestrictedCommonStockNoncash",
     "crdr": "credit",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash vesting of restricted common stock",
        "label": "Vesting Of Restricted Common Stock, Noncash",
        "documentation": "Vesting Of Restricted Common Stock, Noncash"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "angn_WarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "WarrantLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant liabilities",
        "label": "Warrant Liability",
        "documentation": "Warrant Liability"
       }
      }
     },
     "auth_ref": []
    },
    "angn_WarrantLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "WarrantLiabilityMember",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant Liability",
        "label": "Warrant Liability [Member]",
        "documentation": "Warrant Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.angn.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issuable upon the exercise of warrants",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r857",
      "r858",
      "r861",
      "r862",
      "r863",
      "r864"
     ]
    },
    "angn_WarrantsAndDerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "WarrantsAndDerivativesPolicyTextBlock",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants and Derivatives",
        "label": "Warrants and Derivatives [Policy Text Block]",
        "documentation": "Warrants and Derivatives"
       }
      }
     },
     "auth_ref": []
    },
    "angn_WarrantsAndRightsOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "WarrantsAndRightsOutstandingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding [Abstract]",
        "documentation": "Warrants and Rights Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, measurement input",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r1071",
      "r1072",
      "r1073"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://www.angn.com/role/ConvertiblePreferredStockCommonStockandStockholdersEquityDetails",
      "http://www.angn.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, contractual term",
        "label": "Warrants and Rights Outstanding, Term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1071",
      "r1072",
      "r1073"
     ]
    },
    "angn_WarrantsAndRightsOutstandingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "WarrantsAndRightsOutstandingTextBlock",
     "presentation": [
      "http://www.angn.com/role/Warrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Warrants And Rights Outstanding [Text Block]",
        "documentation": "Warrants And Rights Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "angn_WarrantsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "WarrantsFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant liability",
        "label": "Warrants, Fair Value Disclosure",
        "documentation": "Warrants, Fair Value Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "angn_WarrantsIssuedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "WarrantsIssuedShares",
     "presentation": [
      "http://www.angn.com/role/WarrantsScheduleofIssuanceofWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-funded warrants (in shares)",
        "label": "Warrants Issued Shares",
        "documentation": "Warrants Issued Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails",
      "http://www.angn.com/role/NetLossPerShareScheduleofNetLossPerShareBasicandDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares outstanding, diluted (in shares)",
        "verboseLabel": "Weighted-average shares used in computing net loss per share, diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r194"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.angn.com/role/NetLossPerShareScheduleofNetLossPerShareBasicandDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares outstanding, basic (in shares)",
        "verboseLabel": "Weighted-average shares used in computing net loss per share, basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r194"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "presentation": [
      "http://www.angn.com/role/NetLossPerShareScheduleofNetLossPerShareBasicandDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator:",
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "angn_YekaterinaChudnovskyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.angn.com/20241231",
     "localname": "YekaterinaChudnovskyMember",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Yekaterina Chudnovsky",
        "label": "Yekaterina Chudnovsky [Member]",
        "documentation": "Yekaterina Chudnovsky"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4M",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4M"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-10"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715-70/tableOfContent"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480606/715-80-35-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-9"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii)(B)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479664/932-10-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477385/932-360-S50-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-18"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/210/tableOfContent"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "15",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/815-15/tableOfContent"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-1B"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>123
<FILENAME>0001601485-25-000049-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001601485-25-000049-xbrl.zip
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M,4F^4?\L&S^=,_ASL4*E&0%)=A!E,HG"H"C)GJ<GT&I/NKUQ6#^\@B?"NKL
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M.5$D"OC(F4 E&WYSA1G=Q,9;MK1R!)<^&(%TWE'X#7C/* '@ S@ W[)(X<8
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MH)H%)EU:.JDD[XPPYK#0 +L2H)802A<Y-?-0J%>09R0\%-_5/1+PO$+A9V/
M1[A6JKCY?"[LM%4HWJ/9F]/RI4!,7^.(4FILT$KK#+A4I(* 1([RRV*%@'J
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M735,I/W>,M_'DK)Y.;7:I4(2!P4S^M$4^*C&@VSI 'T58**2_!IGIAXIDZJ
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M,%MXZS@*2NI2X;.2'J:+NQ)@95^6<A\XJ84-U1-;MZW&9'%'XWO[$%!UA=D
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M+Q7\+P[64#9VF*IYW,KOHV0VM54JM19;OA] %;'-Z>4SUH#3_I+IO#9P<VJ
M0Z>1O]L#B,SUO!QXC/B2>SP><*05W,_E!F0-JA#B=C"EY?0&.517N=E626YK
M$[W#PN[44VR[)#UH&=Z;EEHG_0!O>:[H?]XQ2FM)+SUY?&^;//[,*]@FCR^3
M/%X]@7!#B;MQP%"- C9-AS()8S4/P12GQ<DM<8C<#",.2URUW#BBQ%@7,-.?
M6G]^7"*A> UP)I*63!,.PC'@3C(2"+[,CSC%.\- 3Q48HW]!IQ[PF1Y_)K\:
M56BA\F%(IC$]U8$,9AX'&*-%-9%%_0S8VXN%B56D!Q&_A^.:%D#4+TU<5A%O
M)DC#UO#R(AX/TY&&#JG--/8 ?ASG78QT<\9<*U6I\4T5LL/ ^"*(FO)X3%92
M2GF>1T:C,E7P<*X^-K^E8UVT&035C075L?>QW+<)]WT;,H/$8$:D_F@44L;>
M.A%Z_G)K;!+,-&4N$$G#M-+JT\@4[/XB4C7G07-](B72^/44%^E)[!*+$4]J
M(XF=+)UAU',K39W4)J>_T.+N0B4CXH7)E?+I46/@?U$.@$HQ3>(_,CU+C?)9
MU8@9MXNR;?!)L>4\+1H!1:;;)"HV'X9G8]RZY!U\5&XUY@HN-+R!C1G?A1F*
M%@XQC0X,U.1NZ?YJ:S<TZ#G'E&WN+\FX?'++*%?+L7?B) NZD+&Z%("@KKN=
M\1T4D*8LSY9/F@_'0T\*_]<=%@_C)K;+ZG1[G?\>=EI_3(8[@+TI_#2>J$]%
MV[9[L#^Y?UL<AX"&VRTR+FR2KXZ/3E+]K&VZ_</=R3U:?_7CX8AT#G4!$97=
M+Q8E;3?_"1;CLS#"UEOQ-QU4]N;H\ 6MB/E^IMO$SLF?<=LQ8L:M'2II!TG3
MM"R@?:HNS1,'7@;_G@63>[1&5U^DIS?(!=]'8PV;Y'"1C6VC60KF!(*FWQD@
MY!E^6"T#1VYK$7(@2IMJIR&HBA=UBHN;)$\)R)A)0^F?*#6PP2JF=X(22O&U
M_M2C-+B8%]N[OT389M0\'9O8N83V<*E49X#_M_*%Z72),JD"M%R5&<<"SF"<
M#K< %OC8083C3V&LIP068P)8'HMJH14(B- /]?CWDP2G(RI%3Y?5S'$//X@]
M3SZQ'\>>-0'I9(X50P5-U//=UMY1S3#.8U3N<&L(+3(@*U5;/<<"+PUFT<@C
MM8+;5/ILJI(BQ3 IF\?-@DJ;9U:4LC%+>9=D3F3"3+8H%A]9.WG3P7F,D-FM
M-G-0E_P7,X'X/CP$U,I C09Q>KRQ(,#^/)0H2^$68-FJ!YL9/8F1EOGTMJG2
MW W2_L8U\4>MC'.;U1!XAG_\-><?+ST&M+^- 54[C+*- 5FJ6&3N=AUSMR@Z
MYUJ^NT??:?GNM[_7\GU6KG=CI>"IFHKS#]N)[H8R-#[GF5KU=<@Z:H!3%Z7G
M#X UIX><F>B<&Y)+T0(L#4_0:6YJ?H\I:5#'Y[;O*XUSRFM-;DK5)DY"S$Q0
MX:>V\$YG#TUPDY6(1Q9A=;0?,9U%-#^YL3B:V@PGP60KTYA?-[M$:("V-J+)
MX<P7"3S6I&2K0E*;&_<RSM\A;O)&Q/PNHI3UL<9*^L4@L9JVGB=.JTF&>3V1
MB>25P12E.G\,)[KK8@2TBL?H ]<%K%3#,I6"#\F)$E@WC)S&F#(:@N%57JTE
M/IQQ#DH]CNN(!BJZPM"89@$6LJ8B' ZYF),<7N>T,S3]QHFT@R<#S^VEM7#*
M!5G I:1 IP1$63^%#K$T%0I[3S?R_A"&KG#.(0ZGITJ0[MY_4#E?%+W OJ0J
MY)?W,RL=L3MR:6[O8>-2NDN<3KTN7\1.LZK2CJ"NQ(W#XLR@AAQHRBS'=K:-
M'.8N4%6%CY.;BN $HP7'N>"KIB() Q.MC)*\;&6MT> %(/5^@%:?5:/ZFIIQ
M2\J)8!L<U5A_*K7 S^P6R9>FFG04J@L2%0$OC1O#*&<B)@EI1.7301Z>S(G&
MYA$/RO IIG[,2:;5)7%2.Z_<;-RR ]5U=15<K]CFAHO&B^!<Q,!U6D#94ZS'
M2#K'-.!WZ+[&1!VES[X0_GZ2HREV%(FG>2 G']<1QE;)L%56[DA9W6V!%[%0
ME?KX8'Z@P2Z2>/C P->?^I!IJJ=2WN=Q#Y.3P3R;YD7S-[2[66F*U%T3>&="
M.1,)I909'M- Q21#%PEVI,/V<XT"?,8AJJ1]-0L6A/B'SR=*.;)I;<"&@;\!
M-\$F6#3#,C"36 UCT^UK"H4<>C.UKG.XB)UJF*@TQ]-/8MR@-A%&H0A4OQ?4
M=[#5GRY/H[!8$3C2*?J4(Q0DVN.._4ZHI"1-(FU^,-5YF=^#S:8II&EFK&)$
MPW D4[_0=#MXE/-%J=%LG&KK'.MQE!TX4MAA1Z>X,?E"<Y=YJ3_$3)U.(HLD
M#[SP#5G[.%LS*/+3&N/(3:&_Q(PKY4G5HVY!N7(3*+/$58KS&O5"#$:/2)@=
MX/>2;/M%F6V4RN)FX=H,$\'L[!- =3%F/@$&/JH(::D5"'MX!#8V'S",KT57
MMCMOET3M9Z_RN=32YM1*FRJN5%OQQ^O!IN_(RBMT/G7GHJ"_P Q145U2:VS]
MV*%05(R+!'#+(F1@N=E!-DKGK9U_BX=C$MJ-#T UJ=,,4,D@;?5C0_38F9_G
MCJPG_0-IUBG6GN]IL2/#\ES2PT.Z4$V<Z^W3!YI?A@)//X7\9I1,2EGMSJ0R
MV^[D\_7IQ].\C>07U=E-OTU-1G6Y;W%&37%LF5&6RT/0T'?(' \#2A*ZT_@!
M,9HZE;HGE52NWB1+27)J!9#6/^;COF"QJ3577Y*Z09DV@P@+"F@VN9[:H^1$
M )J'Q.+GL?82E_MC:L^DOIR>:MH?T8>Y7=S4+S@<TWLUKPLAFR0X:SB4<*J?
M<I"KE=/VR5&C16H8EQ:=W*I*E-OB634(BZ@?AFE-F;?RPF5E<>YG+>PD[YDX
M H0 POSFNL3KK)CD>3W.K%XOD[,S>C6=R7Q,@<T%(5<K3M+#@=9%M%;-1%,^
M3(1Q2*<BBTEXVHNP\IM@@(S$=-_2%(\#[^G(J).H;FBL4@=IHGON=X<'@JF.
M#6:LPEI$"W(2NMNT*8V(@'@CEGF &=3RKM$=GP'IHAWE/$4'1[A27DU_,(,N
MI' Y_1S5VK"+A33=#<>AU(YE6]) FH33! 9[$_"8(M9F0J]^TDO/LSC8YEE4
M.U5AFV>QB;%,' T4W8Y3B<L2@S-!3,<1K2Q$?@]*AW;;V#X=IE6]8\=3RXM9
MD6#[A&C);-4\-QAJ[RT:\X[R:/K@H^](1S7_9:H@7>,KM\Y(8&G;2RF"-(><
M#&G'O-(N$Q/P9+<LC A#5>/LAZRT?(XSNJI4%\]<X/F)KA7#UG: !LW\\EP6
MFIGAI-1@=TY*"\6=&<U7GU'3G*=]2@4[02R>'>68K\]C=RW,BJ?IZK">8W)T
MG8="HF[5'&6 .<698=ZKSZ<W[=W#O5Z[<_"ZOOK;1>Q]\=,$I\)WV]T.:*I<
MMRRB](Y$ZMIZI(QNTUI>6+.M=")#AL:D,9^[EWD?1S_1M??$4W[K=#\0[L,?
M5^Z<5-)^S"G#JX'8)5"UL@W0(5IT^NNQPUP/X=9.3'1IJFSIAML[1Q$A=Y4F
M55Z29PC1I"S2RO6DK+#4'E)-"C7=GK"DQ!N[]K@;G$<&:7R7,@.N)J9V9(=A
M?]1:_&0BP@C/OD=G;Q0V8*TQ-H,U_KSN7FDM-#=<34Y6S\F&J+UB/AX]2!V3
M.K5;;#TM=5L:X)?T+34] NM'.@/$8,?/[4][2'OYS&A6P2?,^0XW,2<+#^1O
M(#2PUAA/5EG'S+L&] !S&(AFOT&P4T/>_2P%6: ;AR>4  _:OT($+YMH<U,:
M2PBM&57L<G;]Z8OV^32_F.G(8\Z-1_ #]]7KYB\"04Z_.*LH=MQZ95Y-]U((
M "4/-2UUUT/UK&"W1-1>"O'T3A50DW[ @]=+U[IN=&[A\K)GS1.WYV)\>3PA
M\?R<;Z)&HWNL@<Y!B0!YI(9H/TX4>[2:$0T;4 ,Q$QSXH-+%0), /HWSV?D3
MDB2V@'L:X*YY9,:/#"AK#X,JBOLJ6=95P()?.^U6VQL/BX.ZMG!9#UP.=_^C
M$*?*DRV5T"YUVBOG9C!O[_ >-'ZX9X@975'05,ZC@E;>!P#C<KQ7#XJ$I17$
M+9"?!N2](Q?(#@QMZ@C)NM,/NV8FBFVLN(58)<ARQ+!)9D )GJ9./S2>SWZ8
MH*\<0*3TEBVU;11VZ-VTPV;Z8-2I2HMX9LX(UE].O%>=;NM@[[]>>\P?88E(
M, /5PI0[K0&]-8$ATD7-&]03]P_^PWMU^*;3?:UOU::@-4*W>+$)O#A)J9DR
M 4I9.TT %BH\1ZT##\P0;#OVZF%[Y?7W340_Z%83.D<'@,D;A\XN)5)@R%=#
MY^K\VKO3#90%AK_R;K6*HKUY%!U@.-I5>W9;[8Z!*QLGNHA+&8\+'_#JKU=>
MNX5^CJ.]__!.+^!#>[_9;AW!-Y>_PH?.X>[KMZ D&Q;3Z1683>G)BB/<40L0
MP;FI4=*MN(6*#F\I?CT4?P",N-"AF[QA*-=%,K014PT$P] ?0;#Y?'PNK]B"
M=3U@_:1@HZFH272%79 P+X?X^7ZK9^C>L(W<,PDL8I2(= N]"HMA7>FD+J(T
M%\QU,B!&T= ];!W-@?$@PT0F O#;!Y]A[VDK'[7,^II58] ,<W7<-ZP*5RH9
M67%+>W+_GG+/Z^ %&C\'3XFK',R+JZ@\-Y.ADI>QE9-I7F'LI4&!%_KW'_3O
M*?U[0O]>-W1HIO?A->&*X'T,N^!T##O\$8RP(35',H0_228FAPO!;]9*8[D*
MI4 @,<Q#?"HBLM7'7G\ZP6ID''FHRS_FM%S;?#3S.X.*!Y<FLO6FFV?Y.Z'$
MO8/N_N'^;HT1_F9$5?VXHU"J/#Q)8XY&A1"=G93A(#F<#C('4QD F)O,A+1G
MPW%NO(W&?T_+>6CS(FR+HIL:/"=NDCOE)-".5#0.+^_LYLLP&=Y."+7GW8T2
MI9;F-(Y$L> (L##5' -65AA6D";8XERY^3&S%8BWT]H=JSS#W=;1>/@:3T1U
MNU6D9X=Y&3]SV?]<\#O3V3C<E\X'[[X #)IP0B/O [+B3PD<62),+XLP34$M
M,'SIXL,GF\&*W;Q#?L=5(^@\6\(>+7%VZFG%,32FVO3F<4XC.LRZ2Y!0P4PU
M)JD/&X)%\J#E70H]T$E,O4*8JP!5!4:"RTSX[>3Z](MW$L<97/$IC[K]#<M*
MW(B;#<-U#N>%_522IQMWVT;+UAPM0\81 .QQ;JU0V:&LP#[N3 Y L=@I#P8P
M[_]TVNW[<E" W\/^T+M4=FV9I,B"]U]1Z!;8:P>V"[>'PSA(P,9?:?EUGL#O
M>!YM!C/U?2YI3(H[801=J4Z@,5WE&M(6XNN!^%S02LV]DVCJ- LFH7>XUT+/
M\/Z;@]<TQ)($KZ.@4BTD@EA'@P[_4X>#=O_3P00M#7;1.BD)3R+P+;37 ^V;
MF:B =BQIB-O);D#2!QV \]YB.'\W#%](!OSA-@/^F5>PS8!?)@-^RS._6R="
M%=<6^(?8+H![^6!.REW'AC(A.>+)CS.KUKIJ$-8M4IHL=:)I%#//9TO%C9X%
MTG=_Y5QYBR4_A"57)AFM>.:$,5RWQX>_-5S00Y![(%3[_;DI:]934U]GU44Q
ML9<\0RR.DXP:&ZD)+T*FUL.):2IJD&TBG=I5.*)D3(2QP&?A^/^4!V+6ZQ4_
MYOA"MTC1\T7JL7%TH9==U?4N6(-ZL6[R@N.))/* 4G3'^',^G%];=X[IV2W"
M,1X4X!$E#+>\2[L:U,^<4Z 4_NYQQR-)HAMY<C27G4V_LD@%V$8M091+RWQE
M$?#@\K6G74*F>PVZA@,F E4]"R]_I;1#$ERO&\305(^0:-KR3K'8$IWDA/(3
M=#FEQA]G3]19OBY#<A[I,3'VLDE"@\ !);!4$RN*DB$ :02VB8DXXWRO\.KL
M].+ZACQKA93M$GK-3?+'0[@+*<B"@RDR\C#HW'&[5EQX-L%?>OLZA%($/8!/
MY?N:H@2:U!&.X?$LFLJ09N+B9"Q?MQG\WSU<X5[#4TX_/5^!FK<0+Z>E^;[(
M6 1O2G+/G0<B1V6YV]5A3Q9"T"1+=1Z7+G@7/,U$3.(D]^3IW5):@4Y2]EZ9
M=GH\54M,=.LG-J1 !_:?-''EUX8,'2+#"$HF"Q"DZ!-\A2$%A<X\-RV5FS7.
M"%1FPZK<S9@=RP8?-M"QXN!X+7+FB0TKO <[5F"?Q)^L8\7!CW:LF->KXFC/
MYM;AD:D&!;DCRG;D*;0 )=K/+X=E8?4X9:(3Z0MF9S#FG0J 7D=@SYE!/  9
MZ78KT#/LL&@(ZT'IZ?DZD  CT"FI76&,O$H[R,I/*+76R >U%?L!NQ/:=D&-
M++3*/*+/>6,-^N@TTFAY?\62+!T@@6?28DU5OE-VKQB%Y"9:I >TPW\EEGJ%
M>KX&[,GXFIPI%D[5OWYTR_N=&\D6T$Q:,YZ.FEE3A"DJMV0RN),/GD(!/!34
M_,X&+'YCV*JN>0%L&Z=0.9+YMPLKF,VX>N\<L4(7[M:XB\2)L@\^@ZBVP2CO
M.O%#C)CAL1:Y"S9;46*"J:"-+I4B,9M'=]RVL12HR4,S""X##\3H\B12EW=9
M65'R/,Z84*3\C+&XF,8;\HC0A!I8V,;9.B9(8I;::6:QJMNAJ2?4<'@&49"D
M87ER%$YD@P9;L;XVU:G>QZ09L$AC4VOYIJX;$%J'-1!:V!2X:?@'QCU_#L%U
MN [!A6<%RF *9)#F@J*EOJ?WZ;[EV<2>9V$6G!8BDMI""I[/]]1C@VV_%L.%
MZ<GF$71WV,]2140/RB1;Z&MR%(E";?-"<TCYWOY/+\]XG[_/N8)Y3L>H7*A9
M<4;=GWY E!P^)DHNMH)B=8+B\"%!0?QB0X+B\%D$Q::[?R,WNHQ82@V5+FTC
MC3.,TR,EUQ>G33_)B=D=-<7%N6ANAZQ\['&>EIF[B(BKD>UJ^J@9M ]TVWOM
M]5$F Z8#T;>%QYH.<DY#5<]0$OIE(FP-+-3K3T^N#%X7ANCB"V].Y_Y&2*X:
M.+A(["!E836Y RT_&72R)%D**_&Q6S 2LI\T'>;8P)-06W.( 4A+8.FFZHQ2
M(8Q_8C*A.MA3/-@;#9=+AW5ALE9]R6#&(TN<F(29RY]-8V1RZ*V]<<43 :2%
MS44^;-X(X WTKB@*L;D3 .9F$ *6-6^*U!^9SLZZFYS3,"H?41FY_>W9$.?[
MIEYA'*B2>(6T3<$'V&DQ4:V<G5<[KG#;=KJT>+TJ.XX@5V7S_M!JQH:@0+YI
MGP#Z7Q,;5K+Q6+6W=FZDEGR^"">:)>'4)/3UCL>FQV,>0S-!-JU(4$-E6CJV
M+='-*@N-?9WM<2.WZ)F.LJ!W@ZRJY9V8!'(5FBGMWVY<:8J#,$I%#A/S3+PW
M?[$T/E.EIXY#7R0\O@U%$ELOM#Y7O3TOCR$:H :A:BRAGJ$'W'RG#C,?+QU)
M4,(+&QZ9H_-0/ZR"UH,*3FU4G(^Y5#MU=T% N73$V0F8+TJ8;<C*7][6IJ23
M3Q<WGMH<S]=>7TGUQ9%4!Y@(W-G7+9=4$BJ-*8#%G)GF>!@O0^*:.0/%CSXQ
M*9D_RB1/P7R[  H+TTS%7V[R";K&#0B'F5> J)1C.T6!Z<8CR@0,QZI9+_[W
M%=)\_H39I>1=B"\S(3,T:G0T#"]_Z6E31]NTJ6IG'KW0M*D-=V^<X2+$!RDI
M@!P,I"3E34+AUT1$P1UZ%)4)AU^9JA6!#T:F(U&MU[^BUJD'24Z(B2H34_U=
M,ACO8C4F!1F64?@T#RO-<C<&=!"R88QMPAL/V=(%T]DLW*[!CU@XEJH6S_I)
MS5P:U+9<WQVL+E,&=.*,Y*%XFM8S9=Y'57==4XFPU@&JAP"@:JG-VL [B1G8
MR!*[7I,NFXR9]PV4>IG7Z9Q\_'LN-JAOJ#I5;2R;/J^V*[[JGBV=_9?[*:K5
MJD[?E,51S&7!36I/@A[/I -Q?A+_8713U6K)C'9R1\X +T4-^$8+H%G1Z5H6
MVKNG00.0F2I(PN]#TT><5/<4EL_]-%/#'"=P!E/5BU7P<-P'P<=G;L1]*#%[
MQ_5T3#)RL "RX>4^/SM62?4J!RWW5>[]=;5;-93%8@C%2LVAF6]?SWOMGUFH
M^R^$\2U%+]7+T;0"ZWB<C;$90X8T E 3QO5K?,KD $?-/QSKLC>:&:J>I8@W
M?Z"+M,J&&H^Y\,-\0APP$;@OP2ZT^6DU-'72^4NP"U4^B$G+,>2H&\(XPVH
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MM6/GC)DUN?IB! :?N8:\&4YM]EKNR@;4&O)V.BO$4QZGA6#^M(PWI[LCI6\
ML-WQ^];11Z6I&N9L' %O$.':F^K2P5F?O[1,.<U ;;/-C=_<VCVS;L:>I_NP
M=MG574>7)=986X=3XU]Z$$WWL6/<]W>Y:,K56W1.EO=I1#D.1Q:6VR?NRO86
M[9Q"TTT-^L+0(*FYR4WQVA*8X*2MI><1B4-E!]]CK>_R (DIT ;E[O<L1#8.
M!=B>6WX]^*#!&78<J/5-OKP>-0J)#S6,<Y[IA=7?4">*1GS;,;OP _6?E!3
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MQ;&3;QG #/[T&N4JE'Y36)!"@S46:UNQ^Y$U.,@ )?N'@KP[())/DS!@$<.
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MQ742*2KK#?-6.)V;OPSR0\#!,+&(LF"1WZ'T#3FMF0S'5*ZGX#UPP=WP$_J
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M@P4CR7'%MJNK_?'4A*KPAZ6$!T@LH2Q5T!-34:QN#1<\DD.RGB#$-])R-6M
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M!C!R$?2L&7(@V9Q3F#F^ND*C(H44!+BW$[W(HF7#&):FN1"5%,)2C=B"%BG
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M@!Z:0A92T"05$VC&T;\L*#^=_Q<4:;;561\$(P599/W^2>%8KSF,I&'G#X"
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MS)78-*?[HT^.W@]XP7@S%(.NKT9$S[ZMK:ELHGRBX79D0]$>-C^,BMC7QD#
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M:X<L'<DT7-@==TS8#+WOP =2,:EC8$Q-STC0:$7[XJPZ*&E3-UZ*!B00M"@
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M:\F?=;T%#7Z<(\G.A8D@HW;DTL1;+N7)^J>3?ZA%Y,5BE56.7DQ/10O!7P@
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MW)'@G)1 <N3 3!HLO#%%L=DCF/MD)8IO$?IIQXY?/& =N>U8[$N5.G.4-3T
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MIN:V'\P$.\04W8[<CRAX:0?_,4-K'(. K*?1:^YP=%:I:&A7D+P?"1"*M"E
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MQ7F@IMVI-8[&>*;J";0N(12@BP)?TZTP,)2>S%18]N3>.S "7#%00Y[^9'&
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MK!;P!_!;E0" KWM8K+B[^ 0=S!.SRD=D., W7"I*;OJ7 HU85)1%NX3$"Y6
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M]>$WR5'D4E"LMPT7):8L\0_D# 2G,00@\,QV%CHHYW/9+O8;+O5VGV<Z5K
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MTZY!%'Y+@<F0W>L(U2\F[Q\A$N^6*E&%>M7<7E2R0KV.P^^?O^XA_U1)-2(
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M<BXD.E9&&N>(ZA5""10\'E*?]M<]942(3\EM*3_]:4QKWO@J;<L<N4%60.]
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M9E )&87;HLL<3XRB+DK7PSA6%SFF5PYB5Y^U2+ZI\@ST /E0@]9W9C.QHNJ
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M[S")#C@)XE)NW6C2+9O,QEG'")IIN!APFXW\(Q)<_#FZX'0\]")D"VM9%66
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M4U\7>A?.H/8\'JVE>?BP,8EX-)Y!AT^4"\\Q3) G=(9NAXU%:JHF39U7)6Z
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M=VU:)8)H<[_#B.S,.]@3_&,,F Y_2VT5#MYP#]OPM.?HO9V2EENP]3Y$&O0
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M*-J6SE)4=4,<I",83],<)?,W@?O67CNL,0<EQI,2Y<Z%.$(*ZJ)>+Q:D2@B
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MRFJV32YNE4@SB.\/[#BE,A7!(U61?57YWUT9DP]!C(OBG1W[T\I_/(K27\M
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M);7=:[$X!OIEEC$;-?Q<N;,'JNX;C;-H^\F'1!Z4E$1F7F* (\*8.3!Y1'#
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M1^J))K^IBZK%>'!H.>;;3M5>B8A)4I[.@WPDMNS7^1Z.,,1#FLIUTU)"I"?
MYE>GWQTO4R=F*=E[[BE#62VW$I*RAO%:B;?+\ :F(V.=6I3$AWM;&/ F'Y=7
MB!<WC?ATFF=U9Y'1?B%:ZPK2SN7P2P^[B'S?QC_C*@8%*%NT00[8!'B9E+[
M',[Z$!U1/V>,$$3)EC+[RW"!4*1 U?V1SSE $>9(CK3JXO4/_=?:(J;T5(2.
M[(8!D>"AAAQC,=,6(R&:\'#4OA;D?IS28F(-3!=OU>SK1)V"02VK\"&.G\/J
M4NX45%L_VT\_)\'!"DZB>$VHAV,L%T(M_.S)LR]2;YNL09(2=+6-N,+UP28A
MT4 Y>LQ*Q:(-]JFMN[/$X1*FK3VR/(^F,G*!]TK),._!@9A,8"C_$;?7J4>G
M2#V^,'!5]%"B?7SYX,F9JL;[++O6TGJ->>-/<.TA1N>I#;NT@13Z,-(F\8!6
M_]>%Z5O"-"*@:[?4WP$1S20AU8^%6VUD7.]SW-S3W%:RS5 S#KYYCODKNS03
MI\>T_R\"K39"UBE:P8R3\H(P=C]%WTU!>7IFO:WG:ZSC3<Y=N,']/\%H_GR"
MT3QL),H)1O,QKM'HTOS(!O,%&<R+Q2[U7+A8H#:U5R@9*A7[4B1 )M08@EXS
MZ74!O*;6-/DR6+&:.UWST8]H.Y= #+U,'-5VBFN5V'[VY$D6IFE4)$2$(T:>
ML89B^BT>04UO=7)IQ+9W05;+M,2>^N3B1K2*(!JBV['5<#<F^#P^!.NR4%H&
M7&E=7K$Z\/ ;*\T_]'_@7!=]>$MBJJ+R-+4(2=ZZZ'8Q!.=4"@?AE,=!_6-T
MYL=_ARHPNPHBWMRD1[%Z<-QK0%G#K48? )VFE,<;$-E2?[.JP_'67.T%I]Y<
MYVVX_GI"T+0,U">=OV=.2FBD<@07G/+V;$6:2#E1-W>:^]+MC^=W4V_ QP1D
MJK1@ "CM%+##GU9 O0/F\K/ I,V'8E%!2VN[GP=O)T'.3Z^1#[RNB#JU/L27
M"W.'_2X%&![-OM4SHX6]?ND?*+I>[?\!^80W8J7BEL6&)X;BJ:T7MFY'VQFT
M]X:,1GZS;,-V3YJC)0HP)9$9<]2$65Y3I.MIQ]5^Q=BMY('T2ZU9/]Z5PP"K
M*:/6?W6NG.:D-D5>N[A9+35*EJ*,$N,>E^9+O$4<VLSU?@.CG6^*.)'Z7OC;
M*/8F0!;* AV*G-*]88S%%J5<X"(IN/3M)W:$<X3\4I>/=2YA@99<M9\:%BMS
MR^AF0[!0]/;!;BS=A%PV%8B'^"1.?5TYK(7,&"VG\,:U[HO: YMIX\QV+'..
M3&/DEVA>52R38([X4&PP-.7;L2LO[I]D+O(85!#3]D5D9H[8@N.  MOK,M)D
M;^E66N#4TE5C,CL,]0ROU?D[I-.3AASPLEPQ*?W$ 9'F)/@$FLGK;ZS&2 -Z
MV7L_-ACKD3=P]-NQ7.OTH?S:0>.I+Y#Q6*R=+W9.QKIT1(GEF:Q751W9$V%-
MK#-#GN9U'9.]R+Y/KDV"80:W5;XG-*E2W4>5R+#>W,@<&:%<>A?<4.,^BQ3*
MU9)(X<:K $L\[7<.)(?5C_-GT0Z,_[06,^AGR$LKHRR-8C4$,N.LBGA ^'$_
MU70N(Y26/-K(73>V)54"^9@E<7UVM[$BDPYV#Y22.VAZK\)X;"--YRNT,8E8
MPZ;1J _H8/TZ>#'Y]R)XHMLRX1C5:JYW$X:Y.=H/Z1ZTO'R^Q9#^18BP4;*\
M-CF4V).R@:5]H%D)\W_3CI]9C70<:I?3B(_)T?M&"FO7!5\[NAHQ<."C70<_
M&-Z_+1/VZJI9[%'4&;+(BQK-C6(+,*QJ+]V:].YCE3H+B[-N<*\A(8R-PN7/
M-)QA1V?BG*7**8.-P":+KVJMR>IJCW4'&I$^9H:NAT;V)-7K.\.->5*A\9TJ
MLB%#(H1.6)5T4XJ+F;RSB*C0R?I_[+UK;R/'M37\5_CE 1* H]B3Y.2<&'B!
M\<1)?!X['M@)C/-\:Y)-J3UD-]/-ELS\^K?VVI?:55U-2<[(ELXP")*11/:E
M+KOV9>VUX!&VB_78]]H O1UQ9MM$,3=' @\\.W%S\V2>,E-Y<V9U(H1@[Z%$
M--(?4U'7!3<_&M1"2I*%)LQ>VAHSGKXS-L(63D\:(?\<F^%F@?N Y90/S:/P
M]I4*$XS&C-P)L/K!U-7M@#$V48SN%,X"TMSHB1[0BN $)APBMC"L5$=2!;$7
MF!N+-:ERR\X=\U,@6TV\G@]H:(^O4ZYE/".;],A3XPU1#?'ZG5F95MG+3N'8
M>#&8F^UW%<LGKNM8U*%PMNM:=7TBB<=SPEW^=.D<UFAA1$!1[B[C72N5Q&X(
M!-UMDV(84$IG"*DG@XQ,6YB2(9PX;NL.LVDO0MB<D:SBU@=.''+<O[*L3)V4
MI<M+P22LYE:0>.)E536<0Q4K0M-]"(>EB#K@$.HV!$V1!#1\XMW;+T/\A6-E
M P#5:D69(_SHX91'KP-)A)1QS!B4'HXE)B6%42NM<M.<JM 7V3"E!)LQN%X(
M--?V9KX\C^=<%A%>_E&FMU6&.L]KX69A#!MKM_CT-:<\%I4E"KM@QQK0,-EC
M%2Y.08)=EG$,DC6ET=Y5=\*LP")S-$Z#!.%,Z&EB[1C\\&?Z),U/\I29$T*I
M1P.OAV]4E-NW;\KI (>IKL#REO$-C=1G2B;]&%;%]UC'2M<M?^"LN-IOUG%.
M2@!V-UE RM4H&D'=(7V!94((*-=;/Y G$0D\-KNI1R*=D&? OB_$5'X?.T>,
M/7$^LK?UALQ;85&Z=4A9,!KE$(KNU,VE\?ST]2M:\-H0D):6?1&C.[O^@YG\
M:W=7WXI8G<8D41T+)7-_Z;6VK5H?@?8:A^ 6("T&]E1KS1P9"G9IJ$O=O-:7
MH!C(N2%3,WSF31+;V1R'N#43I*Q_%YH&\:L3:ZJMYIP3B98]8?;T^;+H/_,,
M:?&!]6)>=:TW<0]Q$19?!W>NTVD)#TTW!B:)>PL+)]Z2*/6BC5QZ5%_8$<?Q
MJ%TWM#AC.G)BM05U2>>&R4K*K5 [C 1W^IIV!S7I;=>^<E/TT2,=_NN"='C>
M8($+TN$7DOT2@\,5GQ/0P>%8$R>:#!B38+'3V8[[%=>//(TPMT]8$"*]#A%/
MRNZ:J_;'6IL2YE;./Y$P!%[[P-ELYQESP:E8EU<CV96J/</$%Z;3_Z[>(:0<
MT!8N6I;4EWA'D4I+5$Y3MSR/=/"2KK/2K+$)CG*6_)P7W%#^F<]EW%'Z,/58
MO &]8CB0.7*^Q5%-9)SA>*6VH!4YE=[GGM[#.1J5I-48C\T7H-GP6:Z-DJ\R
MA]V/TNHJ*?97]A!\6(3OA(".2^7Z&6LHL&R34B@B8;\LOM1@S,;AN8X]XZ41
M8OH'+4T"T(#A(;>O@N-5[Z1;(<_S^P6V%D JMWEVFI-$G.9BN+RSRCEW6R[Z
M31>$Q)W:S0,^,FWIT3GGL(T6/<=,BMZG#4)YPKNVV/28:'QKU^.7K3(SAP-Y
MM #FE'A;,;_B]T4>X)/*4#!(*%V-V8[AG!>+H*(9VMH.9$@Q4ZX;V%[6]F8O
M&>,U9RE TS+=#[0E.S(Y@P16ZE6]E( D3,@78]\=I$3+_PXW?QOB+^F-H#*[
M]L7,4)<J-4;8M;RG)RO-^]QA\FML4]8QWJ49X%TUA+<QJKF1Z.%1Q\L6L2YW
M.A0&$CZ!,!QJ;]3FOJWO.-+/=I:P&<5%Y.S]S'95GOFQ#<M82PJ\*7E)"<&M
M7ZTJU?"R%L/6I]>8;2N%3Y=$FY-I&>S\F"=PXMQ:FE_5Z8"PL<M@3#)X,!_N
M?E'3 .&$DZ)VE>-JR,_'9:R]5D?*=M#:3(#V%*'"Z'EV(4M:T#$*!-(:G<;T
M4.FWD[>*(A1[.ENX_I"LG1$KK:XH9Y_B=":6,#>$R*M(Z?99-G[_I&Z ,+*T
MX:!"075V2H/5@_01(MK6(GK#'.F3;K'DETDU@ZK[7+6S)(6R\/HTA$XV);J0
MHWHY.]F5O9G!.AW%,&0*I>4!5:'TPD"*WWI;A0LQA$JZU#CS*3V764M?=@GN
M[^GZ3>1_9XQ)6*O'+@S%H!RV*8\IT;-<P\/-^Z'YL>DHB2B,Z/6+ 6$>^+ZF
M-@SU$AE3RLE@IDI6U0ON0"T(QT":_*BX#,AL:2,>+<32>,U!=0IH$M1NA>KI
M[$N9MV-O1\ %U"*9])W?<*C-V^(Z@,VO1YXXRF#H&%OCM\4\%[;P)V0+C[-:
M7#US, )9PT#='1VK=UA158QCI0J/H+!H 3EJSG94<ASAE'5/9$MNZM63)W_1
MW'W2U0+'VD/3!2C&84_"=,4A'3+!1*-)YI86F> R(FGH9;Z><+XBD2O51WC3
M:+_?+/=2WB2?^)S2]2#X6O^+.28GKCIR, [!&4V P)OG9);O8 FVI+ELXZ?=
MQA+6\$'.AM=XX;2/2DR\.D9+G_TK6>QVH-E6^XR/1UF=I8/S@A9,M .Z_GB9
MZ:><:4!92'*A0I"KNW32OG:9A:<TPWWW(\%+F90F;P0I>3&:]S3I*]U7EWEZ
M4ND<2M3H)L%T^,-0ZS3&LMMSXD5B42%!J0AI,@C=S*YNKRDAQU=DKA.XO.UU
MQXSM+:6X<IZ:RRP_T2SK-E+1<<:1J=L:)M?^D)YN7N/*88&'8S^N.>\,KT::
ME2VZCX<GD;M0"JE;CQEB2LCQB\[391T\T3K(')B^7O<$IL],<;(R7)XVTX^K
M*;S12E/,=%TF[XDF3[T7)/A[;#/*I*XY"CG<G(9FW5!?JX6@ROL$;0/Z#%JD
MV>VM%26;)T#X(.[KZZJW6 A_NDSL$Y[!;E=6FW D<HE"SLF8_MF,O=(@"(#6
M=$U4Q5(BDG#1_24:>59SJPAZ7ZD_\7Y;+MY^^XU TI.N<\X.-+V0.M9#IE @
MZ?^89;[,Y,\SD\7P)19&8HT G8;4@DHHFJG$MXDO64'H1_V(P'6#L>^@"OF@
M6?Y(D)J__^2"U/R9G^""U'P(4O-B5O^MD$39*-&$+.1]FK=M6J*@9+7<X9(O
M>#9G72QJCT+-3F&&PC;K?=U?2Z1(V;TPM?4>"GA(SE)EM!F@7D(,P\=JNT7A
MA)I6F&C*"K(LX';1R7WBB8\]1>;$&'NX+VA+O,C@[[X[+ B8[).(@S*=I>"4
MF!(4Q%A?AW7 8"M0)/,?I25G/"P7-7)/Z.:Q1VI +'T,ST6*?>,A+!19?@*/
MT7SE,C:ZW4IV$@(\6Q<[)9%R")/"@KX>(U FWP#268?E'*Z,%AN ((G):5<S
M+&4*#O'RD9.H^T"LR#V'Y%F?+3_''+<"<P06R( &+5F]W':]!#E:PD9A\:4@
M4 :+%E =<P/("FKSP(XSX[B47(NTGBI04@3[PH>9W$#0)OBLBCN;T4Q: ,=P
M2>6^!_M0I*JYZ80J'WA#[ON,-EBP8_*ZA*)2\:KPR?1SE:QBKE +D$H67FR'
M<.OO:J&L(2ETAEL=&\^$G:8.P[ (OXC1,BB!.E,K;8N3ZI=S^>B!<?)7<)L%
MM$E"#U">AX0!* PK<+8)5G_FJ6!12D_DVP"]=$&108R0K4C8$ @L6 @J4#(>
M7FSE'@TE(W5J[^OC#3$2H]$1JK71:KDV1[>:./?7(.>.\1 $;(,. 5XS(P-H
MHX:7X0^BEN+ZIMYW_/O3<A'\Z1MM?\Q/?:%7EJG0_IRL\^"%&!PB5&G:Q^,<
MYQ;-G2B.J% ;%=JHB$)H9Q;#<(3CJ3)(M0I_H1.S92KK;CJJ=*)TUT!?^Q58
M);>)3ZLT^:W#9QJ*/BS 1G8X]G7,5X5U6UTMOH@X1GGP&;@JDZ_H"RL3>\H]
M TK1,T!-DUE+YL(4/S(F][EKB+R;TQ^A3Q(;C/#-8T<L18IZ)A")RF)"D41:
MUQR>&&,9,0,T?7X%[JXX0CNN;L=G=>K^!#Z6*<3I3GALUNA%ZXHK02B06M;S
M@8%-W3&::3[1%'097*JCM7FP"!*D 'IK)N)NZ"F;25<4"^C=!!?9G)[/M)Q7
M;1!'<$^$>T5"$ZFISIP\AK5W,N\,-J6^-G:!,1VYOZPRB2V!T %J-4 DGUM-
M"]K]2FK"V%O5\4;*S XP@(^',)Y_P9I6JMO.?9=#TV.1),^$100'!6Q3 J;L
M\AX6MS3]IO<KA9NF-(^.GI1^/!R7<8W=!)LZM;/.1D?-39AD;3\DIYX;"I7+
M5J\8XLJ&F5Q*:]8QI$1RJ>(3 Q^O8'@2V1R$!Y:^_^;K=U]]^>?_>?7ZDT_%
M,9&%\/K5(6P\&DU*GCCF[R^^^O+5)Y^\IE?Y)G@*=$:\_N3UIQ&;_(=[OKE,
M;OR'=XH<6=77Q(/(CQ>N_N;0-SLHNF1OD$+CZ6+O;@A6^SI_*;TV7>V_JW:D
M51BN]SME\(']T+[D>/UB(X71^A:B(O]F)LM*$]]'L,)TH,-">C->$\LW/=.2
M&5V(<3/8C8/TVQJQ,4G+#F-_VW#K%H6XB_$@A3E0UH38=VDEW,D(T-X"6!6L
MR$R\2PL9/FXP-?#O]MV&3QZ_B[Q,-L+;93"NNPIT'TU+[@!X+AH<6+J5<="=
MJMUU4UU]R S%PU(CBY\[*:+-3]9R4O9FLY7T (,T),TK*/+>B@I>,LDR_=S+
M"J+)DQ&Q]%%4I16AG>B<)/8R-_!TD[-GP]7B6]BU82XD4^-W6Q,>>G$31HQ1
M//Y@MU.!^TG9KJ]UYPSI<G2]R*T*)KL(-K+7C" X%"5 <,I6""AUBSS <LK5
MA(4@OAS17..[/>'X10^0]ZFH >:>)JSY*:'G*C&FV?I@[F F,4P8=+5I,3WG
M\)B0*N2&MT7$? "IH[KS67[6TG,6DWEO.>*R<$KK^>6"1VLTUVNN@UW8$R-G
M>XJSUZUYH:^E[]$YP*AA9LUZW+(M JO,2&D<HY&I6ZBX7IC[?-:$"._V<K*)
M^*@/;RJHY/'8".?>4-%<&1XN#^L=8#D<H2SGH<2MA9P&C:G^V>D6$$:KHY;:
M)=,=0X*/MFSF;<VL:9IR)"96Y,^K?@8.NR3@)*(Y6N]]\=&8L@^"#1E3?4+S
MB\L6O\7=D*+R'4FU" ?Q4A;(E]LDJ'\ V_RT[=O8"]7T#<)B:SR[X_W>M*<-
M3:0-#&9TPDB_(KL;$_(A-@YO?LOK2J: %%5":*6&VF#!2+SZ9)M)?%GR?1RR
M5G5*J_K%X\B\DL1&?2VY=-<+GKCIEV[*IZ\8S9RX9"U,EM%"<#9_D3DBD^&[
M%'1_@5G2K"-\"G$H:6(0S'(/6S L NPW$/A=U1/AI?FU?>5\FPLZZ=,+.NEY
M WPNZ*2+W7R W92JI<BWP:.AT KH^>"D?/O%U]]16-FFQ0;V.FK3>6&A/&)2
M(HP$106"J^?V9#T%$R]MRZW&(718C=HVK(Z4\)/MQU8O3L^ KQ2YTN L_B;B
M:';"5^^T5$@JFE2@+P?PS[J0P(>$I4"$<8DOI/)VO +8K:XVX30@7H&>,B!T
M],8+V'F==E5=?*JGQ$I)\HGI JM> 00U]5,6?*Y3XG%)PDDEY6,R+T\<P,<:
M*+)V$O*P(02VD'X0RBK7S6[':<7.>D<82K&M)2]74QF[6I\NR^3GW?F1/C)$
MP!4Z!/QF-VGMA#!5.?*94$WI["Y3]713Y?+.(A1P0RHWN\:P09"%EQP*EUZ:
M<,J.M$]=9@O2->_SQ,8%N_K$2/*^/HQ"(P^%OY$D%5],7C!AH)4B_)E"N ,J
MIHIF2J+9M)IJ%@;5653 !&)1A%?,0VTLO9,)1VP;CK)8383%%+A*?@_XIPR9
M*J?\SA"^<<X2E .3%.I+619)$49 ,U+0DLD:Y?R(6C^46Y;VB?CR"ZG5Q9J<
M\2H6U2\,] "BZDISL KIDND>N&3@@3?GJ$<=+2OGL-/2 8NLY+6@*&FT.R5W
MFH59TI6?<P7ID0"L[TT-;[\0RO/P*/1R)#-,*-+PJD2M#6<1"2_&9#FO,JJ8
MY:)E1]-]L;*"\C"&F<8PTT<\A197;G?A7,061(:W=/EG-.3GBW;POZ@IFLI2
MX?^] N%#QCR1C'O\+$B=/FGT%>5$%:PQK+OH 5'<,5[O%1!WOUX<MWK+O7HT
M51S/G S:F#J/:= G9/\6M^>:,5:'9WP?"H%/L",C*Y $CWCLK;%=0!4W5$3D
MJA2;&WK,MA85K%B68FG1AIZ1/DUM&&&NP@6;.(J;AI+%N )X^3BMW:W?L]"U
M\KH1% P?8OU+&TJM8H/1$X@R_V:HUZ>HUTH.5-E;#\*K"CFI4# S/RB,^T&4
MF02V%%;'20*^]4WR2Q.U/[ 8N.[;A]U>L_"Z(KH) "+R]H99MA6].RU%!-)O
M@.6\21#0\2KAF3; _[0<7%C8![8[CMZO6^V$@7%@QK9X%Q[7N[H7U"^N-E=Z
M9DQS=]=>+;YC02?VM'1C"B&.R0_Z3>[/Z>2%63@II=-Q_?W.U_)L2$LI[R+^
M4\\NCIC[5DV-D>O:)DEP%=.O.Y9E\1U4-8'ASF5'R:O2Z3-/AHXW_L,7 3T1
M14M)J1?SF1,QF@_WQWE]HDOH]&^%3A]@C7?;8]TR$C-I<FB&8+ZQ))O65,%U
M:O5$8F48TX,6P-N)C[P*2O-B(]P]381<MA=%(*Y+(]&7SLS@TJWR,F@\9::*
MW6->KB:U7N[)/KLLU"?+N7H/22?_4/?PTAA>D!T%IA"*F"B8P1XL_QY-J+B$
MZ[[V[M@XI'3T)N$L&5O^EC-Y+%GO#%XDND\B&,'%5\K>PA(TE[3>$UHW;MU+
M99V="S]_4G$>*86W63O)<%,Q@"M"]J*WC%#)\KH.DWM@Y>VE&;#4+W;*U1[Z
M5%"Q!E)7P,>E6'L"\515\0-I"1"*_EBO;UITDG 0!YT9%8H%.SUM$F?T:+MM
MJ]NNCQVKEW7[LQD[!B>S%]LAL3%_QLT>;//A!W/D\J98W#8$,I\)#5V_\VTB
M*$$-"=EBR[Y\62Y/M%R(1B,[P9(5E  \D\]"N<F;!38Q2T%V@7HEE6CML\Z8
MU+="FSHW7TFOJ#MMG7OUD-7ZT4/)7E^@9,\;C76!DLV:YU]"I'1"S\'F*";G
M=O6U<KC4&]8WDE!7,T;( U.):=RCW1LHG&IM4 ND' <R,Y>S[.=R?2B1A]J0
ML-8"^*35BZ9WF?EMM^;(S7%ZA/V!F>Q<2U(X;E9R(-%U;KO=K>0E]B7N /H]
M7*\P[[U/+U0$W8I^ODL#7%;'S[4ZJ*>\420<.2L[HF$:>9\3H8#Z-'" A<LD
M\8UXPD6TC?*2'(SMFD39)T94UBQWF>4GQ-?E^61?=;LONRSBP&+UPW3&\K@6
MA'V^,$RV3(*J;X7WD3[HRQP_T1RO3IQ=9JH M-_VX%WYB1/OJ[:DT=P=#EU_
M'%NC?(C73?C"4HM"?6J;#@OHCM(PX7L%VHRDFH@+O.+L^;1(?,%]/:FX!4$1
M\MU/;IQUB]/P WKB&\CSDBVIC:/4)6FXBB5((RJW.A!>@QDN>RHS%[O$SY03
MSM;/7@A0(@&IW5%2?)U6?#P1'JABZO=63!3UB.D&L6[^-NQ:HEY 4X/0+#8#
M//)7YI'',G#]HR>^NDOT0V/*7:FJM-Q$O%X#<1;0YJ[*H([(*>!I&WUB^ SL
M;!7Y\ESMM=XS-I1L"9TWX2FJ?G?BANN!V$ZS5 K3OB7U!7X%XQTL%$/NR=O=
M5.KE<MH9A!_1K4%N<=^U/"8EX/C5@CDR)$F<9/NJ-2>RU<>NAWQ2-&U<P!49
MK,B?O$7)UJ280M[>=:^2!P733/Z?EH-DW3"-T(XR]5RWEI?9E-YFXUX'KP+
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MU+#P4N=O!S2C4ANK]E]/4YUALVBZ_$]HF,9(LU5"_YIFG@@5X6JR+AW#C_2
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M,PFCG:2PU$+8>@N6VJMRJF/Z8G+,;\ZI5_K!2A(1U3 (T;_%1@\\(%@8+JI
M/X0EH_)&6IM=5Z>$%!0GI(/>%U92Z?QTO'YETUH['78O=R)^1<,=+AY(%]<V
MX51 4GX_C>-WX7KK&QEG%ES)GI3YLLFO2%.'$G9*KSEO<:Q:@V-!FPU5Y3""
MU$9/.Z$R@D!0!7%=A_OM.%?#?#N^F0*O "(/JI%G=I3=&(.EN5$K*WD,$T0B
M8W"]49W9@VHVG:B<F,B2";(B-3AX"4PCC460_BBO%#MFHKO(53$J0@%GZ7O)
M)7\ ;Y)+W=K%[4I<D<$CK3]WO15 $^56]U6[\!SB1&&8*>)DO@QHQ]CR3.[X
MA=BO;W@&!9.<9VZW73^WBB039:WFN?<_U.[3.0V^E>E3]#0(YGGKABEER?NM
M>+EL$1NSJ>Q$Y<YRUD:C/NB2!30]SDP8@,": TV0M!K?G1T7PS/31TAH9+2$
M963/S[#?]K("$PA>*=!G%57M8SP5W&'.%S]T:#1R>,#(*&5JS'VQ'4365%:V
M^.Q;VUAT^0R'*D( S% [E\GOZ_,/])>OWF6-A 3)B8W27B3)-_H^F#M_D4K4
M>P2&4=J&1_O+VW=N[K<Q;H/+SQVPUHH<.^X8^V0[?Q*IIO3M"*GB!>IH-3!.
M5!'&.4A^(*(QH=XP<(>J6QM0T%JCM^RC5L;C =O&5"/-H6KE'@?6QR"3GN15
M2TEV;;&/\^=I1B9]; B^I4JZ*5,5_SNL -;%[AO6[45%(L-C4FE@_)),4KU9
MQ55:G_E2C8*2[FH%(>DF.^N$*V_/XZ#$2[G-T0ENN49^'WN9B\TZP)7B3"U:
MU[C'(DL7,T<=+\+SD0;HKK;H3*#D#]]4C'_V&\OH4R;=/1X#D'8^1&?%9BDI
MO 6#%"/(4NWLH(R>44E*]MNI&WE9HD(2UPQYO&&@&N*V+L&-E]H$6D BPS(;
M3X2N^N7]2V,Y]>%YF9&]!A%!Q/\7NG<>TOG^0AR-O)A3@MNQ<32@9?2_ .2
MND9A/Z:5G&9KML3[I90 )136Y-+!RM2#H=@YH\?M_F'FR4]D/.E/VB?$*,6
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MB[O;2(DO,_!!9J!%YY27H0.(#%N%3]KHK5R&_$,,N??OR*D[$OE:=0<H!UQ
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MK7R-*J.DM?!4ZQNT\*SZKMIH@<:I4X6E0Z1^-Z<AK.2*SM58+$HJJM5)F63
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M'N2%B9N0NP<FA+@N%_]2,EU<(_-UKH>G?Z?YDFDM8#GMA=1\\3+!J!BY9W3
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MF,DJO!E5'O;=!@8<%58RL+ATIR<5Z15F:1\:J/I'CH8/';D&DT8OG-2&'V0
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MKG]?1QIU--RW@V;5#%"C@,%Q<*L=!ZFJG$LM@Q?EADM3>%(1J$;F3T[=(;<
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M%,L%3_YX$PZG]S3ZVUT'(>2;<'318005[-/AIL,CA@&CS$HXRRM!R,79V3:
M%Z+YF2H'_9%;) _@A8CX0_,XF+US<']2E97ZT"#.\*2K;176C#'5M:_ '+]I
M!FH ZI-V@60)<C]P>'Z\28A[UR$6#9X\*@,:N9-#,>*QY9&>:"K@R=Z..W)U
M5)M5.TG#2VX-**@M>!3Y+8FM,2S2&F[*V%K%0UDN**KO^_"K84_#WR>OB3>A
MGSLB0HO"&C;F#QQA&DCC:T8J1]O F)V]\HH3:0\>W$:X<,*4VO./(F3>,;NV
M>B!*WF5?=_&537$G O%RKYNZVH0%W/-S<CL-41DDS9@.)^'BT*$.3AKY5X@7
M?,F-W&3)9@"4R?7A5KK'*NB%2K]TF&!ZQ9K[9PIY,F!J@/% 3B\UDDU"A]VU
M5K]/>CU+4?*R!#U(*JD*,LF@H@X7&]G,_>?%0L>ZOY."=!_CN@?1,$C!($Q(
MG#GI$1H4$=LD:J1):[M?AY$:VNZ49;]]YB@#0(08NA+]@$D_U12+<JY*4@JX
ME:,9!<"$!+]P)HE*^RV;)V+HZXSNB![SI9Q37S7OZSO4->YJ9=UW&CK&3I#W
M>LPC3C0Y,J7FP;B&)Z]ZWF<#4^&1)8[;S8JI#<OT5&$S'&[R='?33XZ:8!E#
M !5Q"BY=Y%)JC^L:"O:FDU(?:\";RJAUK2'-JG:& @4D:=E8Q-57Z9)&6I;/
MA? )SK-B65,8R04X,1.HMV!QAK&@X)+J-3MIA44Y9\NL2-QLPY^KCQ72! 3B
MJF)WN&OU3P-IMF(]MN;]V)9YJ)%Y(=AFK-Q3[0Q^H*(0SPJE^5C6I! )[-N&
MJ3V4.#M,K<$GK_M:>B1]_P3GHR*"PR+Z.!&L$Q1.2CK91RY-(CE"$TDVN.;N
M3JP3R8X9HHW-*F>1G]'@WNL<N^$J,+)()(#L4<,#KT ^/_PL9VN5$5R3*X;\
M%106]B+?@SPRT^GR L6& !0UK5YQAPS]Z_Y9B<41EU=,K!7M!-_M;E63BB_;
MK794VI062_1%-7&IJ5B0]CS^&^@,AQ-S&(V$T8&[E!Q;#DL2QW1_7+28-"(P
M$;<+'I1[%TLNAN6UVQ5:L^U2G"(CMIOQJ% $MQSNOU72$)K8<T.:\82$SU)!
M3-:;<J3(73A3%C\FZU):9C4%J-)95F2A*='^_WAL/+N-6+9IW\(O_E8H^\/0
MTL[\TB_Z=[+HG\\+_82R@Y+!P;_Q@G7E_2U%"#M.?0NMD<Y+X!%;M[1LP;09
MA>N^).M<&#$P;'#?)N,V.R]:R6%$!!<1UST',W):L;N!WKS@+O5U\C=M+YEQ
M*=GA<YT%_.LQIU7.>@ZW=:NUX*&6)XKJ'K[J&!4BLA:]L,;J=H!>DE A.H^,
M1:O(^1-@BE4,IF\__X83821/\Y^*(<F+S(K"%5) ;K5FY0VMP:/@<FR0PL !
MM:_>"QF?3FRXY$X18QPG:EU&X//;2##!JYV'YJ@] ^5]UM.BFR!9RF_XF)[_
MQY7A7\BNU(:7@<[J8V&%S>H:(2'1"LJ(15+5W M*(C9JFZD[Y73E>R)2IQ05
M830&C/T/XVT%1<J1SG12,0Q/_9OC35]W+3T_'BX\5EA.%#Q__NV;/_,VX<__
M_=WO?^LP ?J"@ QM;+N&[[\A"J(P\M5R\?8F7&NY^"N5\_YO1ZOTRZ&OJ#_]
MOZLP%<O%WYIK6AK+Q;?C,-#_?U>-FV;QAOH1Z*>PSJH#T#+_>$]YC3I"]3/B
M=P3W24-'85FN1E[@.AU='\9QUW2D%VB$?[$R"O,I1'W!)Z2^+[%1/O;C4JM<
MTOW!$$+-4"3]C%FNJ"MC1]81F3S2^5O5!:&[:/+4M3%VX6A5I5']*.#I&8N]
M.F7G0K3$,JF:QIMY8//\N0UBMP-0_8\O0I'[89OY>2AR_^[J]_3>AV1RDI5H
MYX;+9!"P1?;FJD95'!OVL\OT/-'TR& SCX'(R[*-1 S[BGV4*&MKS@Q<MMLP
ML&B1#':ZVX0HFOX5CO[N/?V#FSC(#Z"?MJQVU;%C6U,6:5VS$'#";Y)3YZVJ
MO@<7$7!71^859.I*]BT:CLR"U:^NZ\M*>:*58ESTVYBS!*H*0.H$.IZPALTT
M:X5%TH10E^"\'E[(!E\;B0_=P/RE6)XK:,^6/J\G3^+00O,H.B1B@ !6^O'0
M]+SL^GK/6"(.PFM%/P$;5G$Q4D'C=EB4.I\A2" QO/)C\FN?XN(TR6D\R_Q2
M_5A ,K^_@&2>-\[D(P7)7,Z&QYT-G'6V2!]%XU-4RN#0,I&CO2;V_=J1FC*%
MUCA, H5-9RUN^24!,_#H1^[EV6MH%S,*:9(-B>.Z?K]D(BRB 0B/LSDE,;#3
MUEXN$C=)>,+VU,F \)=R_LCG+E/&\BSUPNT4K/4J>8],QT\3'Q<GYJD6*GF9
M@Z#D:>6H""LON2,C^5&@<4U;WM%,5U(DJ ,__""K<PNAF(@T 2' NCO$+CI9
M3U;?.9?#NJR&IU\-)@'$T "0L.C<K*HXLPK\0&EP;'D>^9",*R@)<A%&:9SD
M)_\RK4\TK9R,4NR6.QZ\'"]R<E??78F@C.$2XG:TK*;[2/AAU2E=DB/TU+T]
M39Q"S+%I80F89(JMPC2;BLB)!<JB.(T<.6!>\+DR%)7WU?$HDEOC:@>Y+Y'K
MOJ[ 7$Y@N=WFCNZG*MH=Y<+:R^)[JL6'-AANF&%P"C.#EE30X&W(B@&I,?KP
MMM5M9QA/_FNM[A'#F<8#B.57I^R:X=;]D57*.$Q5ODE?A*G"IN!58[K$3-@#
MAVP9F\<B=*]0F4%/S&^Z_K**GF85Q1*PZ!YMN#YZ-XS-<4@*PL2XC51:[EC$
M1(-1YEK!<4+:X?1&*)_S"ICDO>9MQC::GI=2TD*58UK_6)B^L[:V<[T(]2.I
M%S%IPRNKLKSM^I:<]7]P>0JHDNGOH&+/@B@4/XC#'S;4FO%$OF76?DE'43PT
M4.W5@B)/%HJEM"F@V\ \$*/5..)U9+ELZF!\Y*0" TO2MMP5:;JL ESE@T%[
M_:7,M^-!BI:3@4)"4B7(4X<2&"9HC/=M=_?JIKM+D4LLDAQFLU46Z!21,;VF
MNH9A >DE_4P@U\9-?]SQ:VA+8"?/H=>T.< !-!TB4VJRE'-G)$-V*8-8)VT'
M#*ZW[H0I6HYA5M)/+%(W\9Y,R%DSZ@5_!64H85<%D>L_[1;S+K9'3G4;-0[C
M N(RQ?9G71/Z[.QMQ\WB^BRL$LGMJM>,D:5*93.@'1@P;AQ^9\J/W)'0=^TU
MXT 81TM @2,7805'R_9EU,!PDRT1BRUF@+42- HNI;87[]6R-\8TO6N>&7G.
M(R%4-O\+G&(;]JR%D 4E'SG=>BGUSF.@)%Y>BG-R/S@D/Q:?T2C>!]?XP&-F
MP*4$?KHZI6F]B@MX9TR?7"7I-1J)52V8YV"$-QW.,]F%AUTE;LL,5.YHXF)2
M#/8%1P["Z?J38B(B,RYAME7?=W?L/W&8)NJ(T1BT8?#"AJZARC3*UM6N:V"-
M&,N4$^$@B5?M!# ?4T01OO1G!K_3P!F:*"UVRZR)%36;(+I/@]:\?)!*[5P-
MP,;,EHO@XKMW?_]FZ0:UA/SPX]EV[2NJ\Q)&PSVGI3/;=>V?@^*"OKEU0!']
M/1TTQUVMS47N#S_B!*$7INX;84M:/HV2Z*S-*>^?ACG8Z/&&GU_9]#(BA1&A
M:C!U? Y'TEAHC_8K)$T.1CG@-P=E10AI0'8J]5FHJ;/G//[J%'>((@<T,-9\
M74(HZ8R @1WD*&$9"\)O+X'!DG_"4V'K O,#(R7*$5E05L@0!E?3F@JIG3$K
MM$]Y&D"<+O1JIUAY1\&C;27O!&^O;%:CS5D*<*M!BX*Q>X .19X]<31S;SES
M M.SP!%"[L.7]HT00+E.HXT0V)'+>#QQ"BT^729$*1@SO:JDO(C+C/!=>XUS
M,\;1F[KJV2#MN]C[Y+)\8>;\FDKA"W+F-5OMPF(^HVIW$DDIKCB1>QG&EOGE
M&66JC\!XE[:^1NT>P(8$;9I,;U%L/(SVVDT'J-7#+=?OE>,I.4+\N_"-TL);
MTFW865^N-+ P2,-Z#6-UKKJM@B-O0H9%0G+;7:X#=!G;/[DY36E9$:NX+LWO
M,[(81ZT4$;<V<PFCL/8$#N='(Y[H8>"2%1ZS8PIU-O&"02*>6E7$MO?=!JS;
M/(-APB%]$,SHG:(C_=X.3KS60>,[NC&G#%R'5+;Y&S+R]69F;QM&%)K!'O98
MH+ANVO 6,6P4%GD+0#0U>8^+\ACP=)IZ",->1]I'6B9P7IZ1%_[X6 ;C(#XU
MN9RTT,I3!5.+CZ_JNO6$F2K3D*9WG0](O/Q,Q!S9((\WHU('6@B]K3>@1O)*
M>>HV(M_YR6=[:A-_U;3X\=//+(12J>F^1G=^)M0H"F_D&JNW2'8!!155=7U&
MT_@@[/N'FK2LJ/0RYFJ1JU;CUKF:=&S5@Q(OX'_Z$/HJW(N*?'(XN:6?.!JU
MO-WNW#,[(D!O-X2@$E>B. 9O\M%CZ?[C@J5[WG"TCQ1+]PM;]X0S-SI^]Z8&
M/?2=,[G1ZJN2233ZQZ@.7[+_6D>K6-FEYZ2.SW6+!2\< AF!"9!%#WC^[.&Y
MESTF.^M8&6!#^O67?R^^(??IE5Z* M?8VKXL(BJH)&:G$S\8&NA+#U[O :TP
MOO I"XNAK3)1X,7GU>GFU9^ZL+W>L%[.I__UGY]HC2Q_IGC.ZY.Y>DGTKWG$
MXO=>Y0>Y]A%5.(3L0%SBQW!$M<.6R9I"T-=33P2SWT=(ALX$9JCV3Z$<KPGP
M)+PTD3U,H^+BJ">%R)3]D?,K[H&1-1$^"?LEY4[]>^GC,AVO*<FD#P[]*]_W
MWO!2=0^WJ9FO0\@]_[CX5?/KR'')Y34L1.XH):YZ%-XFU<J8D@FW_BQ<)ES'
MYTFE<7$(P3>5KM%KW3&CKN0.!!-#=2I6IB;^^.$S^D6XVL,OETB8@R^9KP\U
M#2RCDG/W*RE+AE722\YYXNG)8A6'[]?<NS>!+3'U3#;G-&H+Y&9CZZN;*=91
MI=;:I8(%G$2#5D3P@0&Z9EK82L===V!\'.$0XULK)Q^H[9,R/%;E=0,*MGEC
M)MQ/HI%*HT3-)O +AP=L!&![UZ(/,S\4K;03C>@N"C\R.*(J=4DV3% .;;![
M'Z_T2LZT8FG<%R\T0DA=."WF?.=<>R-J($5#<&[6E]&#3_)3YL4_8.A-Z,)8
MC<QZP]"?E$==WRLN*1.9*1^PY2^MDMK,-.L5'Q(]Y6[ M'GHKFJ L^$[(+U[
M_J2E[Y'.T4)$DZNA8[X&ZMOUD!DC_XH'+*#K9HO-M%)J3TKF9"49:&#P</F8
MT2)K*E24LC(6K?(()"D%T6!8RE)$FBL57MH$?VD@D1!_9=D#T1P3CW9X?6K5
MDO$M!9N9K&,23[H SX[%=''*7M3*+2LZVN'$RN#\&KH]DE=Y*=D()HA _,C@
M$/%]JKZOI"P[""B,1G'J:#H.D?>)F<MXB!#@VW?NK0\K,XYF/!09DM(CYG,6
MR91D)R6>6DZ YO1;I\[?#%O2\).\\:5DUL\^'B-?>#ON0.6W$SJA^D=:]^$.
M4EQR-Z!:L*P_HG@B!@H>P(QC*2D82XYA^=.9EYZC+-;CDZ?5Q&PYW%MK=;2[
MZ#LCEQUBEUBGX>R\!#^IT=A5Z_>+77W-=(R"GB3=8..'JI@W@>V(OY0+ERJ!
M4]A-%$$1'M[0!K"LC85AM$XC3=URX53<N""0=#'M#U73LRC(!+$WS]_BEMW+
M5C3\QHL+,!M%<44PW"QRBMB$Z**X6KQS@>+YX)<I*JG"B",9Y#8^')J$;;D>
MC#G> YQ__HC1 K6;<G.(0DPI_,ZH4R04>+,_W#3AO[M:T[[NE56H:]-4UVVP
M(N2J:^N D\*1@HYT%Z04('F^0 >/*4J<D%F;E/V8? 2!ZFZ76^U=726!\N(X
M[AF99V_.W+^"-V7V%P<^Y<X\Q^12H?%[TS>W(AS.KY(0--D-.6?Q]O 7G'FM
MD<DP%R*Q&0MEK8GT2DKF$6Q)I./<GY-;]>O#)*#O,7!@IW7VB:3:ZL%.)YJ5
MF5E3!ZX9,DN5%_72CUQ)WB>+'55WB0_)FHA2^0 *88_FLCQ<.6EKSYA&!3-F
M[%4.ENYH<(Z3!1F-O%N3[C4G6SF9QSN3.5M%RRBL? E?U\S&5'H:H^""TC:_
M@A!?">ALPPRL>]*K!UQB (_ ,:JBKFK@ZDB->HB@PTCG%UP^>C>$VLE0X0"R
ML6*:R7IP'AGW@YR'ERSCU Z&9<Y9/;CFOTG:5_DMS8,YOQV<ZV86@R,_$;-6
M)[$[?T2?(9Q/R/%^&MT8V'3GV<9H%LK)%-T00%.R9\G23H H5\-0<QPNN1&'
M_^'E-O.V%1'?01">TS$T6 =R$XYR#B#1*9!%N;=?VR)#Q? $\PCIMCC]OI_=
M!/2F6.+4*[1&XBWB+6*Q#B=( \U@3K@UO?9GR^I7G]<M50O1%*CL!HWE$WV#
M;<)JR!M$!=Z*8W:U^"(=+T@92K;1LCML1$40.H%?=N,10/,9RE-#:!#K.F9?
ME]8H*TH,JO13F'\W7RW6%2O:E#Q-=6X#?#ZEFK0>E-9B-@.%(8LTJ67Z/G80
M?@AGU)J]$%/0!JI=?V#S%*D2*5$6+B3FM.O>*^84K;-"2DO51:C+#=)')(_]
M4IS0O\?A+)5*HJRK]&/([DK9F\L'58R;!U)[;E012F4>L1,.I ;L"-MH4^[L
MM.5\I13"T\]#=\%N9;Q.B&QDU7.4DG(5W,E2785?U;>UX-8FC>O^[)DU:\Q^
MS#"SPG4_^E+]'RZE^N==[;Z4ZG\)D[NJ,X)5@QMZ.NZ8JIX8UN!+-?SY;=+?
M^CA9AH\Q]Y;0$AOU#D>K0NHFC4%PH]L'M59E;8N&?%XQF'8G(A%)N[& U=HP
MS;$17GTV*=3E -R?,LG/:*H>3)>-T(3S!0,GOWRV0HEF]6?Q$N3<5AV;1%,J
M1G1>YJ=6S';&4E30FVW(3ST6EH9O$IA9$%>+ORFU+)+THFV+OHR,I9?5@&9Y
M1+69G9:K)=2RQ0=V/XTLMDV]VPRQT"N1A.O^U)AP:;T0L8;J>83)@Y8'\^VJ
ME-7858>8 M#H-S)VS!=<9KF\KQ:?2W!2REA0-1(U?Q!EG>J*)Q@/JLT3RN%I
ME,&E-C&J!E+/<JL-Y/'5=\K9)1ULV3R9-&Q9$'R.]5[T.+CO$ O[:O&=EEVR
M1\_N2'+DMRZ_6[KQ-IUEQ(MWX5\OQ01DI?9):_98:R9VL@\;ZSV:A,TI[W(D
M479I#4B4>(D89)K+P;PI6IM=%VUZP@.EA!)H >'@$G$O"H"W$L56_L&XKRI[
MC-ACFH2WU@9U[/Y=+N<+!0DS Z<:P2(W^.\2!UT&E]Y["*,D.4G+RWF+R-KO
MX73=7 ;\PPUXQ$W-J",*3N<RY!]BR+58@%;S>#)YRD1=XA^&3>HR[" U9)*6
MKD4\A_Y!@Y=)YY_WPE^*$[2U$]X70"KF\SMUH^7:M7*GI2$9#U]T8OC8FI*O
M_"F"VJ' 1@6KW4YE>DKQK[A"IGM8M\"-UJG\6-0#99_)\:'G#!*/$$)D\)%O
MW[Z[$0G$KL "Y@LQG1*!J/=$C>V:4M&ATU<4A561+[(NLS1XSXG"HLBV.GCT
MJI4X;2Q.QUW7>T*MPFFOAO<O9@6^&23IO^]:KG?([*Z:S@O;D.M+9:7PB?$(
M91=MLL.J82(?0"%NF\U(8K)W-QTC3ZC41&J/!,1GOI\-K4AA(4UN0^%4>A<6
M56Y2X$'>W]QYMF'WAZ(4:2JF7/4I&1VA%BA#,[CHV["K6IK6BON)7]!_G_]0
M8#CR7OT,'10V<R83G=(P)8H2H'/@YG/E9J)$">V G\3,Q-#)G)C)2(=X,SWH
MH7[Z<UPMOHH9,!FMI#,AV^\N6%MF7+8:S7L#AF[W)>RH#]@$8ZR[&DQGNV '
MF"CG_A0<Q6SUPP)1]\#/R$0\,J_Z]T?8AT97,B'OPT_M.H6Q^Y1G9*I-._%!
M[BJ\<N?YL0J9!*$#T.IYPIU :Y0!#KRZV1JH4Q=.M6:(VG5*]A 7>S!K*L.&
M/7_^\8"_EYQOELJ'=HSZ\7K@2(E>Q<^3.Z<$[<G!&CE49N* 9[3N[DT21S?"
M\L6/217S0>&3PY&"\@&I8L=H+U@WMT0C@I'!=_AM=6@4B/B8#4+K;AW^&FY?
M,[O8ZN2T:-P6B23(/HU\/]NZ1Q16F^#9P/HIL9?M"'()E1[(W<0?OIY,RQ-H
M+9\#X=/B&3$^+::,3PE%5HD1+>%TBOQ0?I;A$?7:B& 7:%JK,_PP]LVP:=:"
ML_B^Y'>HD=': 1=2A*Y284?2304REU8:PY9R_E5]DUE3,-2Y\M6#K/:$.8&V
MK-M:IK+(!;13L6!3B_2![.3R6DUYW*:47)?E^_\E:[5,C3==J#"1XB$_9$$:
M_8=?WNZJ7XRT0L(KO^-P[QM"\-6+7PEP_(MWW\2^T0]5:XN@SG*E[;&%MC.Z
MO$G2/RTS,."RWKA:P*1X3:H-&_(Y35U[@I--9>\4]Y]L]*6<([L(PVXH;]4W
M+X88^<WPJ#"5)_' 5D0(J&QQ]%J!4U3Q\-Z@7J[^EZB^"D2BI"I\S00RW -?
MKCIEV')'W$HVGD"[X0')BU/-.*2% )4*5ZPY&-4(G%?INCE4V5$=RYSZJMS]
M<!N,-^T:(J?3^6?797F!L?WG!<;VO)%@%QC;+V%O?8%#CPN4.9BZG]/R,80"
MBPI\.P WHHU^Q2=8A*(D0 B?H9T[IY>49E%[;17Z<%[VH_";PLB1G]RUM=.)
M>(#]EFX;D4\;NO(S#1XAX\0H$G<@PE'&%L@,'@XY#ZQ%"&S3B?H6'EP<HZ4?
MY21"[?()>"D']^<I$2SDO4F/>R6:/ZIAS@[<7"<3,U4T*EY/#ED)1L)92,[5
M>F$:.7"IS!&BJ6&8=]J6:0D[#CLH ?+;P8-+TDF<28TYHB)<Z&2@,R48CPDQ
MNBZH1N312PXDA5ZJHN*!)-(]+(_BI8I34(WA#PMK?0:.LB DA: GB*NO&NIR
MT8<QE7:W^,[+*$:XJ-+6Y_@L'(MZM);V2!EU*X)-Q]G@*"N8;2)6P%[(%OGF
MG)S)3&Q19,* N[OJN\I:X@K],KQ I/08\];HXD2RO;#BRG-W[TR 'D>Q;06S
M*@WDM_4\6- !OJSYPEUIAM-$.MK$"--&0[!C],O,E=)V7'H%QPR'A"P_):0D
MVZ:--H>J1/3&_QR)2D1:BM)RJG;,+1=&Y8])7;H6-.)>D)L8X3Z-LX^9%0O<
M[3:^V[,T@O2*N*UOYL0,T,^1J2461='RG!9/M-0AF+=\S9R7V]%,J9!]63Z_
M% R?_4"7'HP+I205=@J+E@O#  1>UV^XAIRLZ93\W/<TFA%$,L&LK;%<89*X
MH9[[C;3U+3P6TF8@(QW&_4%-GUX=SA"ZIE9C>*B6F<EOPHX'H(&M*@=LTO8Y
M\%:C0$_:G6]#6 >-'5*/I_596;]2VII9? W=M4<E1I]?ZO.KD%_;R3ZB0]/B
MV]*-/>;@S/'C;3UE=S[]PV?# XH]<N&$E C5MCW<02W-"%.3[SO6NB]V"HG9
MI&(;=XZ1W9]Y#SNMM)VQ:4>?%?(E!H<L$![Q1^V;W&F\6ORUNZN1+BAW$NN#
MMXY9_\%6VR%(G/5%Z;L$1ZD<EX1KCLCH!+$25TB6E$KZ,=^=.G45%X%DY4.0
M*848#JHCYIYB&[T%!7RDW($@%4J+DJ)2QFG[[E3M8%U.>S$OV[CX\C%V!6O'
MA5B58IO[AM[[7O%&4W\@B6RZ.6O*M>>)CZ8T7E-I4;@ N^H$=)(['T!]T;?9
M1R==QR@]((JR1<#< CY'!3$>V!TRUTLF@JN&>S>.?P_M41?,P>Y4=CC+(Y-U
M*?NMSQ9KUYA"@.>S"3:&O7AS@AUS2EC:X2OR%S[JCD?2UCL-8M_"L8+O3,TC
MBW$UNQT?6/&DAJ74E?, B>6KQ=M$;$SDQ7U-6\ :L[IK$_F+O-\EDWV0.L 3
M]*0MGVU3VKT-UZZYP-N N7Z$%'1  T+B*PPU8+_BGA:U(_P[8)*&.:@%*V,J
M5D_9*5*T'TM \BTS>(RBE)@:DDN;2J_ H+C$#H"?>!J=WZ=)(;WH!<F&!\E1
MQ*@_):=1=8HYXD<Z)<=_4V4B4\'ZB6H2?=4(92"HB?]_]MZ]N7'C^A;]*JQS
MS[TUKH+TFQDG<1)7G:KQV$[&\<0NSSCY&R)!$1D08 !",O/I;^^U'[T;#TIR
M+)LZPW\2CT2!C7[LWH^UUTJA4.9B.,T3H3G@KXMPD<=K%1T>2\F?\0 T@_9$
M16W@L?]BLC:G8[ >B/;Z#GZ-^D)*XV,9LY$VN )TV+E)*%NU\(157(7HHR(N
MSF4/NQ(F-YB^CAF9BD*]K<SY@@DE,2%N17S),15JLE#TY#+SE\<#=2[^%$_0
M6KBBAR^AFR8.Y836]NAE]'WXLV8%VE,Z3S7>B?V0MJB+V["K^5_AI/9D@O1?
M*ULY7@=//5D4G6<QG$O8HD+>*P/'+B^-$2[""(8"9JH)J.KR8C(&;*\WUCB_
M+G =R>GC4G[3COACYL;(G/3<PGIQWS^"Q\ADG>S!LQZO%^#,F(E/<J:\?3!M
M,A]Q DSW8S #GR\V+KX+D[2]ZLGV@&"+"S+ZS+R+$5XX&<?I >,;\V3-O9]_
M*UT,S2P(;<YL_C'*M:N$/ 5<34UQG@Q\5>2K"MSI*L69SM/MIH#.9HDB#R4M
MG\J)>W^O_:W!Z-#2*!O?E+G,"7D_8R8='.=&5;J]KJ:GB?8<Z-P?S81'.>6Z
M3,ENJCF;AR5A'AO]X<[O(F7[Q@.Y(^P:KWR8,ZR3Z# [F9-N<*8S?8]M+7K)
MNH43^/&ZP%64,WG=IJBHL_&.X8:9 &@M*C 83GY1Y3L"DTBF>=G+^935.\,N
M_G2&79PV<N$,N_@M+A"0!Q!!!6P]"<!J:GA;Y*+RL SSLTK\4\]6WO80K.3,
M/[<S[?O<-"(XKS?P<\E*.45GE5+AT))B<FJG:!@[F%;4Q0VP*I\O(-!%T:JR
MC/LVT:$.UGT9[&(VEJ\$1Z!+%L \X7N$TH5O2[GU*-1#+FO)UT*$K;C2\\.(
ME*BN_G]7TNJ!,>#K#='T8WDU&9/?SOM\X1?FRJ;@7Y[Q58D.A(W6X/HB@7ZH
M4E,5RP3,'JY!ITN1)*KM0[*!I\L6SGV9R(:!;Q!=/KYC<@KKZIHE&\>P%!ZT
M*?*;<LC+?,1_8D1ISQ(!5E1-,P%<,?,0J-@Z.M,KJFG)1?!/-FZYEJ+"S"U:
MDO8K=3"IOMATGZYL._J48*[$"7LJ"^Y.F-"].:^;P#V<PDHX,5,0,3ZD!1KA
MJ:1?IZE,3E922JSKV[81&3=AM_+4UY-!O+18)22M"14NHN<$>W]$Q/*T5B#)
M ;<%.<%<RG[7[\C!7[Q&G2K<I\@^LIJ7*B,DE*+C5%-$*SF!MD3)10K:) HF
MCXN@<*WY0)O=/R%>Y4D*F\'AV ) %=@&.&A 1>#_"1D&*6$.SK/V#$@^='NE
M#4QA:+B[.U;$0UI]-?5U%K\EF(L$H6(]>Y$9G'P#'E$(^!=?%HJX#-^L\C%R
MJP@D!*L57+WK%O<TQN[!&]8C*D%Y)@C$6Y4(CS)FG.'RQDUT+7!,:6;Z.NP*
MNM=8_XZ0^4[_@E=R9G[KXM8C20<T!Z/.CIAYBJ4\>5*R0D_%U/UH7)??%OGF
M</%N2[OD%2&REGG8Q[RE2*I&FWY>O7FE33_9E,NQ:G;HFU%UB779=L2<0D]J
MVO#>%VNG--$=NGVQ%<GW98D]I6T25$CK-IH8-M$,/8+(1.UO&R,AF4MU,C[U
MBF@CUFA V\>**=7]3"<LWSHY(\*")4 26FU^%$D&A?_HIO7;S/&79!-XJM^"
M#>C%'[+%R^<O/H5^E_19W>H !_)UO'?C7>ND,X<S80#FW"E-R@W0^6[X#<"'
MJZ'"GHRD#'.:=_P!.<5N H@Q#ZU[$[,\ZWQNJ?=2>R4UYPA$MJ]RY]#S")]\
M\4?*1NXWG<P:BT$<TUI0\ OW@H6=!J%K5@.<@JU["90Y6.,3.;J4SPR'D2M[
M2"^N>$MR*E RB'F7-#)*6Z&=YC??_Q!/,Q\\NC^PSWJIZ'#70%(QIFRA@??8
MW3,DFOD:-,#P?!N0M$Y!DDUQRVQ)Y0"L-92DUZ*M6!!%O"#/;P?G(<$=CU1!
MNZ+X( 3Z;FB.KM2E]I4Q@@E%(N^FV W^NO0 1Z),3@H$OZ,5.&#8T<&Y)D]B
M11=[V*AL!Y*65]:F"9-CIV'5LP(%MQ1'C9[9A]+XTQLU+4G[UTZ@A]E@JMC0
M&&E+==#-%/&-2#P,7\,+.JA*$'^&DK2$C\V%7U'!?3K+JJ &@VM?8F*#9>V>
MG+Z)H1S)H/%Y%X2FJJ2,YV6A3)"OD)P)(Z>0)9T#- SLPTVTVZM8;GP=3?F#
MY?7R^A)J#V'MLL'@7&734\D(0K79)Y!?_:M5?!,[4:L)\WO7VYV.T7I@.D-:
MBQG>J!RLM<GU#M(*4Z)V6NF80-JQS'$4_\VW= LA6 LAZPE-VO%:L9A)28ZI
M :4B*PV"+:W@0]>.^,GLJU2$6,[,%*#H+UA,.(TQXDUM.4G =_(H7880!Y>[
M?7BH5I8X PS\K*I1M9L3"F$MD-LHI>LWQ#1482-D5!D59\R,F20C&:N7SX6*
M&' @R@Z&?U4E*2)1WLOJ;E109VTI'%9Y5Y><%75>A]_%!RPE8_$C8317(F>B
M0Z*:?&'Z+2SSBY(:_E.[^!U;"BY5PE$V[6CJJ!<XAE]9&M"6VCJ<7Q<R1+X&
M+6J3V*EI#Q?J[0A_B8DU#?^$-P1%UBM9]]SEG>R--&*[(VR,B9#+Q3\$K!!'
MX%YV%\]^_(#Y)M^__TI]$U_QQZ=)<*UC$;KX<0M,#-$6H<;D<3,RX8;[K)GA
MR\V+OEQ<ZD[V/1:<I=7D[(7+Q"GH@!!0)'+)\9A^K^@F*T'"@$1QFJ*!707W
M)M$9UGN:MI)U$#@]9"^9-!R+DAA&+<(5#FG79+ )I#I<A? ]XLR3OO5CS IM
M3!5(YL!GQH+1@HN)LRU<B[)<88=;(1I&GK(+?**<U;=N50=<+ANI.'#8 >M0
M+H,/^I>2?8ZAZ8_ #!,X]!2*^X+#?I>*:(AHGIWG\ RD#28:%'62=!/-3Q-7
M4G@6U,DD6/.F:4%P#6=X0C)A*%%//FM"X!A%>#-7=X]D2[$(3RR)ZZ8J&VM3
MT!W52[G?NWB<YHGR/&@@("00:!)LH1(DN)5\)@M"'(.=4AW@9XE:I*T'ZJT,
ML=R.!BN!<6>I.IC@Z<=.CB'D*)W_=% W@U2HQF46^<GVOD>Y")8"P:Y"H/P\
M.K.=2'8.E\" 5^%YY!\(X 893/N5AK22'Z&FY.M:J.'M,\;V]K'C13Y[?L:+
MG#;DXHP7^2U,G]''9N#$"!=RKK9EE$WS,2XE[B[(__)$<SY=RN9QBK,U6Z"^
MPVD<]AR#T5PUTH/(/=KCDACUP,8^I-A/3MOFR5PTB OA*@679LD]&P+F3'B&
M:37:70.)S(20,C,\;0>7A[K+AI]X_<-W]+]OOTL7%4Q\98>/S+5+PF6"TN^1
M2RG&Z'"EZJB^R>-G]U2^65E0PXS=4*L#7RWA=YMR)_>3-&!VR>T6@V?U]SAD
MJ*KY[C/'(9CX*XV74PN14EZVG?K2 GMNN:1@BC^H4EB.@H#^X>O"+#B$*Z6V
MM$LKWP^:D?UKZEL"H0$X^X=BMQ^?%]K_CIRY2=>&U)N(JSVIY](Y6I?ATTEM
MV 1E@ 6Q=2D*C:SC-(\FUSP*(=(M;V*J+\Z(1J+"@C<H6*@ .J5M*E*$7B5K
M,2L\H:L@DUS3PE:D.0]W;$/SG<5$6K$M.VY4[8V/A<Z2/6O6_N1ZW+2]V- L
MHYD;&D5W:"XTB\\;6V:RG9]C#5A,@,/"E,'$DTIITCPFWV&/6G$"F-<%!0%'
MI*Z;==3G+1'Y=9\CGB[2/D_X9(R2;@3]/? CB]Q*GL88B#^E4)S^GTIWL>%Z
M%$4<5;^2"X/^&!&B^.-D 61"HX-[5TNC:VCOBFI]P29-+=&TIRSA/3E_R\U
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M(_"B>=H)J"QR94JJGM[9U.Y9KLJ\+;7)D)VL4L3@S481]]HJ6#)P93,?170
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M):/YGG[3T=M%,K?:9CHJ%:1NUS+.<#<1@=9W+-7 9W-"QDZ5+7PUM_P,@DD
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M)UJ^NR-P &E@YJYQPB)9PY0]D2NW^JS/S\OY.,NII8"H G<OCCR7]'8D4])
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MLCG!/[A&H $7]HIS&LA(]$2*79$7<;VA][TJ*O#*L0*->U-RBDV'!ND392\
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M*3&U)BH1JI9&[%TL=+^+6541R7GQIT\_1>)6W_89?4YBHO3C&AU=+O[:W!8
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MU43AVIZ),I4_;JAC^RK%:QS.6!*4&+/P].2Q2*JK2*INH[@L^B[6GF%_'3
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M [,-$K2/BQ)[W<HDG<?"B4)*D5\("-.<@ZDE#S1_>O^M4UNUV_"'NM0GC8<
MI6%8C(10G/SBB *E<<S7FD*6SB[*#>7U@M/LB^:#Q#%RJW 7AJ"!)IZR,REQ
M<RNK3SK]-CZ^TU<3KRY\&%BR^M!72!"\2V:5BB?C'[AW%73267 H=)&=+/$\
M)G/4')BJ.MPXPWJR2LEH>\-/RA(E<SB'#*'!+HW=&?-($%PA3">RDW4X 75U
MA.DF97X@/G:WJC@.S?#*%B!*& (QKYTR[GH#,"7*Z$DQ&T-QE%.HTOO\:UR5
M00V>_K;Q:=%MY%A0OD7AD710Q$IK"5':!))R@[->(XTPTPU:7\S_<#,*)HT*
MESY. \LHV9EYR[\_X_NAO",Z?%C#1XPM4.J5]WF%"1P [LS(2S'O6/*DM ]T
MDEB>UUA!)-#>S(T)3:N')4N8I1RS(QU5R-.RI#O/?AD&[\^R*M@=__?1>BNU
M-3@JUMO"FP/5G=3DSZ2V,Z8*NFA7$9M;K5]!LA.N+\VTF$SX_<3:CW C^T/4
M1;?;C=ZS;:0@&.7G56[LXA3;[0,YQ8N&=;&$$7,$.;9,;MC]\<'SO:\QCBFA
M8J0?T0WX6Z/CUI'E.7-8YG+\(?&,&S?\_KN:5O<-9C^!"?/9#\[1%>&R[0J.
MG)N;_)_GWA@_S/]YA]-@PCO^DE^AV?H(J3TY[O)W23ML?![1KV !+!PY"PA9
M!#$XTCM=+D2X[M$*R:ZGG7GU)C;V2[/]G^"OC?Q[#U0'5IE!A [R(-R-\H-(
MXJW)0E=5'>]-W#&-BG1A\I:+%))3*T0#LC*CDI66R>*&<!ER[H,YXY13<VE6
MD L-T"JSH)U'8;^['F$Z>_<^9G_-0Z1QZL;PQ@5FZT<,\WN08O&#L1[:@K47
M\ WT 6;D(:C5 C%MHTK&QU'<.+6,]G4.&4"4=M2,H)**-#"$3$17\+@M/'!2
M,W,U(RFS_(;U7!S\>>;<'X$=S*UY+KY^1!\F[@\V/D;FE4S=(2<TN2X)>DJU
MH?P!NC+TJR. ?"3^*#+-K:I>AMW>Z0GUB15;G_E#V:,?B))-LA6,!"YG!9CO
MN33JNW]YGZ#.&20&=T*PNZD;C+\!CL2E=\]_5XY<78C)P,>W681^];7D,2X/
MA70$]"Q.82U RRRK!XTU_*''"(R1IEF&AJ$(VXLR6P&NP2W[L:Q6"K&M-0[5
M)%_IFN<R2O)^IR)LJ;4<4'0FR;QP<I;F']SR+0ZCO5]^M"X5<@=\[NFAF)=6
M$W=:A)& ISBBRHN R))8!@GRT%"W4%1X"*GM% @6K*'52)-*Z@L %' F!3=)
MZ)\%SKK"JCJZ"PCL8PK2D'!DQ3RXM0NU'"A6@<]:B;9_\44G1) 9A6 B8JBH
M/H@F0N'@-<57TT00<)$D-E7D^S-Q-P0^LUEW(FJ7+8]%(!/%%*@Q^H_<N_2@
MW$3@!-"FM0)S$[+".*@Y%E)A!0[,TA(M-!$--*8Q C/NXF @!>B,?MZ'XOQ3
ME7 &RC%P-;H=NW1QQ2GJLJRQ$SE&+Y&.L>LK8.1FL<I'*H)\>\,L4U(3;4KW
MM]7GN=EY2DPI/!B$?&)87""L3M'I[&'1:&B]<\QRS)]MA:-GSFW65Q4U.$H=
M5;(F^V"D^$@/T(7\/<[2-,WTA(B$%2'3$3@)9Y^:.9Z).83\C\#Z1<<J="8,
M9AZ."^ZND -XH@FU)E3?*BVKU<B$<]0CUTTAM,"@6<>\4; 4&$@XBI7O?(2U
MBS%7 3 [2 RMP0+,$<)K(A<9@@G!B^;0?&/CN*'C!S<035WXXQQR[Z"28V]$
M'H%R"4<@KV2;D^KGP'X3J&-SI&_'11X6^V7'(U2J%_^5LJF:T3MT1M_CA68Z
M.6L-A :DX:"TAJ0.(M":(]=RF':++.1+F[Y_XC!5MMYR5".I^8\0B8?$-Z;#
MG= 'E&&8!/A=U&Z9B6M=Y:1O+QJ71@)<AR.$:U&8*O=S,^M;AA/D8L]%N/LZ
MN%&[^H*;NO/3G[J!@@2(^$=%ONK$F87:63TY.OND2T%U?3>E.W0L"%*^TM!%
MD;$LX7T8(+');(6L,J8O:M>!?P%?@BB5E/T=LAFFBG$5F0-D!%*\U8EO?<H9
ME_ZS3(09=]*&X;?4PL[T[#WI0Y!.,)OLIXQ:5T2Z[EG$5:$+GG\GKU$UBJI#
M4]Q$.L8D)(]HGS6&7HB !@"QSV;.$,J(?%-\24M-_!)<1WX$-(8"LE30>XK#
M)&.<I)+D.(-O(%F/N&!<9)J1K;$;!K'$&<CO:C0J#O6GY?JY>H0L=6),G8RX
MV&CY\XL LRM"F'A*W4\&B6393@IRTBH=GWDCQ8>#9EU\6.WZO5==?,COGTAS
MB4*+L4IU531:6CBC5Z 30]P8=32Y IBV4<DF4STM_(A<UAG.'O+QHS&&/G2V
M7HKK1YHEE4S(IQ7J_CM7%8(1"?A$][(H0!  +IA#48.; )>:N>D6P_<I;J@H
M!Y2)E_^F< (^&F'S7:6:17Z$FSU7R%&<$?1+K@.5I0MO)(#7C&53NH-LBGFP
MTQ3SC3]CUQ,CZY190C^[A/Y.E_ KP)9>3SY)O"Z5<\JNY?2@,]Q)]@,@84_E
MMJ-$-#^;-I8Q5HQ+X#?YY75P]J4_BK57G(,!2VEJ^2RJUMI-2E?83V$!.]^@
MYW3GXP&721/VFD=GN(&,]Y#8T!3[@F?LGJS'="H\F\)6L>I4AEP:O?AUAJ5?
M<F\:3%Z!HYN6;V[6:$UB<:>R!&FJ-G(=W,9#A1-H' '_2O%UZK4S5[O7WOW5
MWG:5V04=TJ6_SBG,X(P,4X-"W2$=+\98=(M6"3#8;U1.RK\4>]R<,'JN"]F/
M6B& W0UO'@/X'@/V<:A@7?=\YH8HQ(7!1*9R(!-) *AE90OSLM"T"N<[\\3(
M/7ZP8]5,)W*?OV,]=%A4K(*M\C"[@-L>_.]0\(#-P53,0",D@$=$O0YF"XP5
M0,>=N9MCZ5QZ[)$F98A6<[!_8D## ( )074A'5:7[E!A.D5#E)=+V%;9\Q6
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MIP)$7%8T0#1@1CTP\DJ*M0G4SR&3P)\PWM68HQ9A)XUL!28X,G%YR/JQ#8
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M5"I)K/_$*<I9+';#J;3L1%X2;@1<50 [EA@9)#O3[TE+A( =S[FHB(,$KK&
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M<PU@U)\5!NA!0/"?\I-ZY<#R@];:$0,Y)1WR7#R?*YH7^50->)\L)*D$86N
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M)++MDFE(H]02EZQJ+355<-\DJM?):<-NH4A'HG4L?2"'G#<6OCK7WI!X6,$
M:9ZBNFQ@(PGK; E$YQ.;6(7R'OQS8V>I,[ !I$NXCN;'A]#0_*VJ)4;4\488
M<$8GC2\B#%6!+DUI:G=ZUE B-@>8O\8WBE=2F8KQ5,IXLSFI=+!+K*,9#*?
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M-P= .!>,WC)([,Q"WU@-80$;,*LYSA?B5J+#G@L5/G>X=3=<)J:.F^B;R5<
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M"G]P9HF:*7&<F^R\:5669W_::E_F?K"Z^^4W](O[XX/G>Y]AE@[$0V//C6[
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MZKTT; OQ\;R;<,*]_(H8%;7A^>R&YU/YIKP&/JV:._-V3-7/?L!_!%-U1!&
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M\_W8F?"-?7!FC\XRA&MA\AUG.I/8:3H54F,RV24UN)XDGN>RWB=TF@^ $QW
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M9V/J<-^!,L&;#?<=YG'59U*?27TF]9G49U*?R5LZDXW\^L%JQ_XZFK( _/6
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MXW%] @B,^BON!FB;8)0"="SY*)Y-*.3S#Z#J)0EU;K'< 5V[WLQ:WC,734.
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M5[+RDET $1G D/D]5V1"GI*1IS;.R%.K4V79C2S-H']$SEY?I>8FK]I$-/L
MT611P& JT=O;F1QQV1F\"S.A*7<ZTJ3$DU&+0*-!&PL+#=:<UEP6%(]@^C8%
MP2)*"\Z16(&Y [; YI(UVD6JK#V,/26/38K0C,UY=G:"W#-2&,BUQ"VU $#H
M:\+-@UX%"/ G"!LJE>',@EZPLB-L4"<7,\+#=,$,F^.!P22J;P5FR"J(4C9+
MV>Q,X#/+GFNW5/:<RIX[L^RY# \S?-JK66)3KN:-RDZ4%9*H$>JR)[5D45Z'
M)BZO9/-1;05YY\,_(KJV1?UH\Y)IDE(M< 8^41B2/&2ZP2.1"4]:ENZ(C08X
MW@SHM^TVV<VR["KL09"L4BKF(],ME](N_H!]@(J.2+@E8#BLC46*A]/H=%KD
M>/75$Z/6"2_FY>9,D#"Z="D[8H)92VOM^N%&>W26@ 2C3JOQ-L6)NS<*WG C
MWIML;>-&9#U:V,T*8X=3%XCCQ7'_)%);T ZI=560Q-6000SX'R\26O%$A#9\
M4OQ<5A+BW7DRGW;I.L^62:\4O B#!+)I&[=T(RN1CV#J +VC\]&FL/ OB\Q]
M[/S$S5^."OPC^L&+K(<4Y91BF #6E=NB-HT:,UKT!3G;,*:B1Q(F+)L;!Z@P
MK*/>/5C6?\%T#J%:HW/2,JRE;ON!B1 Y/YD+"1C$(4^VQN4<0R9@K@!S!,;)
M';4Y$(WG4(416\M>KC "X87YSK%P2?3LX4'U(-*5VO6N[$)T$;_$YO(?A@-D
M#MM8R&5O?' >\HU W/[ #;3T?^\F&&XGO5" DGLYJ+"8LK  L/]9.?@_A&S<
MTC)XKT'"!E&WBT>D7$?A18\ 7(09([#>O=2V5G#NY,+YE@/W'8\44'ER$JID
MT!(6BTM[+T+!@.G,$EH $+?/R][AL,%?X27*3@AII)=I3=)RCK^>&O-9  [=
MS;G ]+4C:TRO$B+"+DO*M8*3H@N.O^=$<:2;BR,_;2=%C0%<O-52Q#8FZ-K!
M >((3MN1/#E(EN:A>?FS2'!<A'\B'%8PP<S;J7/K,$=DVI*<)5B$0L&*R)*%
M8[*YQZDI#FYR?D6N ]U#\>OAXH-@WQ#-1WAVOIXATD7ZAP=OA,7_O3*?.!>,
MA2+Y(MBL$7\M'X)C,-<@AZ#,YY+='^S@G7&M!<_X1)W./)_39"0"@7E:3XXK
MX_4"*6$K$==B^'S8\X:>0^M'MF$)7Q=*<"LAJ+$;@^>+'Y,X7G-0BS9.WA8$
MC8J,&N,CQG!%)Z-HHDP6P-.9*_&\%1&JT3P,J'&.F]N]J!$DNU)K+)Q")?Y.
M!(0:8?!DJ:\1P1NR79&+)G"0Q1-IFR@J(&"E)6^N&+DWCYJXKKR PW@SX%V7
MB*L)ES/F\H1@R [ EQF:O7?1%O?7]W.L_;=-#"@L0RLXP_XM4 )V9/M7GHVW
M 98'JR_9Q,[#Y'GBN14ZME[W?)&!!0:Q81&9\!0&0CVP8RCI"5\ # 5P#MC3
M,^-ZDDP8PU^PZ6H.>#>-R\6F]G.))24ZEP(N\RW.D&25D7A[O+67V EEXZ#^
M%M:MB22V!.U(^@O[X_!T#LJ[Q;1[%,XB?!E-+$GQAR";+9&'SE/$HED/N%Q3
M^\&62+;X]4+'I%B;V$NL\1:=@+, BIQ8/&W>;)*#$ZB"&XE6D)O".SKY\1L!
MK7 >T4WA$6I<)1IKB[%W^Q64Y-!V!E6/,R*EXX+9%R+!6,8_T&R^)'_BTF,?
MY#\^FI8'YUQ_L&S"</K11[&6")J@OIH8-T6DQ[\6P83QN#EL#='Y*48DBA>+
M4$.S]=?XO#3^^6#8' Q&F5^UFNV"GW='@T*_R-M4!W3OWN:EMLR"/.+(Q^TQ
M (KZ7!.2WV %27) V8;S1.?>%3LVCPP<]^ T%NY+P%%_<H[Z#5-48S!X[:AJ
M06-B()!&3$_#<[QZ!.BFT%S)$HU@DRV4-R!&H8F_;P[+-Y\\N",<-\J%?JJ[
M:*Y@X!CZ#41^K+<H;,OX8*[<-=-=*3)ZV "KGU0^-7QD3^3><XKM@5'XZ\JU
M+=XC%R-< "U4$?; YPV3/TL"7SVP=O V6-N^N.J^!=9FSWRN*M9^P[ KS@/
M8GD7M/^,RL)C<.$:8.T#FNX\+AXSD5Q1%8)&?1J5XO-1L_*/7FW"WR[08L$+
MO',_@W+M@&EV-_WFV$^H:9BD>.65>/1:Z?9!\%F]4R1#@. E(2 N"1(:!\7)
M)USS"XR%RT41+/67Q7[=&!P@D,@NM$%[TG0B]3+3[2 2J:/E4[06[Z9BA5>
MS7:QH82&57#<J\X[)_!!$99KK!88%>5!'YRNX[.PP6K"34@58SP@1YZQA;XF
MPWH2:4XZ9VC%QSJ5AA6"O$\,Y5;B_GF<U)-^57(IZ[QILVMY8<YUQC:"2*KT
MTO+6V\#3+$^.YL"I")&.Y[RU=]"MAK>H\D-'MO"OW,;/R)-@X6),Y@:_Y0!F
M9B/H>"+ S;]&8#S9W*<=/UW8A!7_XM>><\+0-\&3VKU-X9*L')[/88TC25B-
MV>BFV9HD6Z21?GM+JY4(=TSRQ+\!%GQU7% ?TGJ#O5J\@$7@,3O=(Z37ZA:;
M]CTXQAY[%U>VD^IADFYJ$N*.Z%/A&,*;M8?KZ3.;Y'F0>ZU^G84+GDR[E<,#
M;AROSIGW/ )NR@F:Z+L-.\P#(P!=Z[_,%"4S 4?!/@-A4W7J689!+>$1#7W)
M%-[(G>,55N=BM].(@YI7P*%'-EB:>ZGC]2FTS27O7\O;_ <C'?@YJ!T"SPF
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MCP#D[[SWH-A165*8>)\1NO%=9Q[&>2)U+;D+!HT0FY'&VW%BD1HDKP6(DU6
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MBP_NM5=8ST/!F( 0,G=#:2PA+@>$':W6EV0AC<O[C.<3G5LR?[YREXX7$"5
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M"0/=C+C:KL7'XPH5'P>Q.*U7J/A8\J2OP UPNA.+=(E))S-TA^F06G>83F;
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M>Y^&:_J7L:_GCOUTR?/J@NP8"Q?B]U'C-*;L3*-DAI',/)JL4R@T8<S6 +3
MT1 \*P_]QKKV:0[,XO+!F#ES@*>S),:(J4;X]<(QV9QG.?%\T35^BDEW?H ,
ME$L77P7SG&B;F,/L\4QDW([X(3^!M5C.$9^GKK/0/)W>/L4$H"ES7<R.LLUX
M\@X@%].-F;8(&:Z&5]W 1"I]":L9B -Y25FQ+"QXN4[)UP)0=%#-8W-&G^I(
MN?,Y+8P077+2A-<25T4@9%$[AXA,HDM#C/8#9L>O)7]-F, E-YGZ34-S+>]/
M !)C<>+@*6 $5;D<<I<:8_BMK?V!F8B4D-*(X2\ECA"F 3/!U+")9[@6QU7]
M"6!#R/ .?X+.\T[K(U_I(?K@M7R0'FE_?,_9X.__W\U-0_OV[49[)WZ+G\AG
M$,SX>KPC%%>N,Y]SM-$!$2F1)"?Q;.+H+IF7IN7"_3BNUP#L=IXM0I"IX]*O
M+$ ORN?'VT0J2)(N'!CW(VCC$N=1(0.7R!P]\SU\_Y5_+YLV!$>%998K  F0
MH[9:XI^YRI WTUWT'B?TH=CTVMOO7U/-]%%$W4W%F^_<'WBUWU<(HKOI0Y!=
M>Z,C #^MY0[%@]YN31A;@5XTPI*;1JO;:0Q;:8^)Q@^Q2U)@ QF+'D*'TBS1
M'Z"EX8GK_663%GG/W =\\V;H=9*P>X## 9!P._?X^G"9]+G;%U?]YBBM$6:@
M_]T4>"E@F\0"SAHE9EE(Z%RG@%]Z+"I%8AH!HJ9@NO3H B$69;"2<-OCAB!>
MPF8@/F!B\)+Y6D-^32MXV7F;X>MCKZ82EO^L=-='MBB*6.*G@/T)+0- 9:R
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MTF-NKO:.8D7OLP7LJT_?%3#?I33W2*21$YD;E!*90Z"&F-^_N.HVA[E]'/<
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M.(GJLVCW<N-XOG>C+PE<_\7B-H(&\$."!0=!B&D9B-;+N/%>&M&B8'8(S(8
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MUHO9P[]V9$:X06C@)<62-,KBD</F\-!,,G8.DMO#C]0)*3A\ AWC79(>X*V
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MOCZRE]/MJ%T,7YFR.IC_UPGWAMV'*E72>[7"+A"(5CAV;C%$&WR0#-R8U["
MA7><KKBC&PHH68$0"\5%4AXE;.;P]_'WGBFUB"X>'\D$)AK;@C0 %=U0Q$9&
MY4EQRYU%5_S$0!CBS.20H20C'#2[']_:]#0E>YHF34]3T]/TFGJ:2(>E:;9:
M]S3Y E/;JMH[OPOJVES[$Q\IK&F*V4+"_!<%%E%9'96_4L]$@SX!F3' -O=
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M/6"W0XLALF#?46]]>#!ZF-M/:<P.#CH(XSK+ULIG:JT4P(C:U'IF8@J"X2A
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M-)_W+R7OK^C(:7H[SA#[2;)KL<['-4I89GLC#^?(SY8M/L+O%3'*L$^QW4U
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M]'FRQ'9354]F0?- /4AU[7"8#P.4O;[#%%P/1Q=7:?76.=7 5&[AA+K*=2O
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M@4F\NWGRCZ'@=E(PC=(AU10?FH &N0NP*1IE'R 2:$!>>+%('PIH!QQO2Q#
MPN:)C_Q'O%$?T$!(//P:'88+1@[<,!K:_TQ0C=J?^!^K!4XSUP-,O3":8.*N
MXSDFU^W/"Q!@>#/-MM?XO C\0.QAI8#\>G$D2G\!'"1W:T2]P22?(4 IV:Y
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M-*Q_VJR_ 8JV0M;OUHKU]V61U$UC_6%2A3=5Q+QF;,6MI3Y1[MK4OUBS'2]
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M[!?GR5@I,[HI:'@Z"KE\_-J2__K]!F7:FKN6]%'@ B18F6L#X1U+@P%8S?2
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M#'.8!X<F&[H8[OY=8(+<F1&HS'*@9D-$[=B :08&'CR4A0 Z"&TE0%I\%'8
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MS?YOJMX(ZC7"I1M]7+PZP-(-\Q(E!:J21FN\:JW1>Z>^,JVA=DY;;=2ZSF3
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M&:-+D3R.B3Q2'>"(LEM<=L#DA)-K$K7%:Q*ECN\,X7^]J.^^_S]02P,$%
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M#!TD]$#.HYX7Q1]^[SE,P,,)C^#75QI&BZ->7)QP/.\Y7!:/GPCVHB5=B.?
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M6]3S-YS6UCVG.=7I/K7X^SYRW\A)UR%WBJ&<AEFW/'DBC)):22:(;T=YK ^
M,5L(*$J,J22A>YLWMR/:NP/$R:?_2JP(<'9]P-)9IV2(H%P*O#820;"Z AD3
M>"G:@+5WGN,.2&.*@71DR[66#QT%TZ^?_RFHQ9)G=WX=5(JB>F0?6-'FKE;)
M+DI-[0:9+#?_)>K>)>1V2&.*8!R +3T$TYLM;]>X;F?L7O(?W$!DX]AU=;&
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M\JU@SD'U;23=PVI_D?-"F&'T+@SSZ_'+\&DX#Z-K<)DG3;-"\$S5*9<"T>H
MH<3(@K#21-68!H\".@<JM)/X0SJ(@^F0TM7EU:BZZ&_G%SBM$Y_B13TI/^/K
M,?GR> V49\Z4YAF43)P<J2P@Y$1_+<4*]%)+V7J'Z SN+&C2BR8>4D8>2IGW
M.*>Y8OXI3,?#\<?9-2K+$S<J(#!%,U:8(WCK+40G/1HEF!:M3<;-2,Z!# UD
M_%#SZE#-WXW676-26J/@HH!T3! E-6UEA<XSJ7VA/4QP*WUCO6_"<0Y:/UB^
M#W6N#_<.QM<WBV_+ M8/7_X^'O[W%?Z(LS0=?EK(N/I%PM!!IHF16N@"RM9
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M[8KW*2IN6N<^/@GH-\FYAKK;D%![6$6+Q]-></IYF/#%QRDNGB<, K-%!N^
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M'E([_X'#CQ=SS"\^XS1\Q%^O*JBWY<?AZ*J^H'E0.HC,VF*$$J!M?<$F2H&
MNH!+AG'IE;3-@V][0CQ!6NBS]2OZU&[K?69+^X4;8;TC4YJ$1],8R*)LM-Z
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M=G<VL[MSOUGOB\\:<!$5TTR"MACIB*+E[K XR,;1CDJ'%*([0CK-P1/YJE=
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M=0\!I+N@%E&'M^7OLUH%"N<#8S@O:"-HP^ITR10-Q2HZI!1:KG1.MG7VRZ.
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M3=P*GG?P91,Y_^:_[D+<O!1#0)YB+AZAR&!@TQJ,=72XF$H!E?>,X6 I-<X
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MLOGKDN&KI&(4RA+NHD+B4T\LXB5.6RN8B,JEVIUSG@3TPGC57ED-3B=TJB)
M6I8&':^7RW49%/@=YI415"G("L]?2G%7QI<@*%J2B92WC@DJ0NU,J\<171AG
M*HJ_8NG/;5WB/CH7C)!>S]]"-UND*P=).!4TR<%*4NH12(CHPV5FK/!&)^6&
M30\8\+ +T7P3V39(T+T?U_G-QV\M>I*3?=-X$R,K$XD]<=%QDF+ G2QKXTWM
MGH^'L%P():J*O&(:SKY-:L?4O@I.9"TE)5FQDI&&>U6 $ F>:I0&#L&DVFQX
M!,Z%$:*6X ]>C%7KE/7^MI/-._BRZ$HI^X@.68<^:F1GK$$(*W7$VGW6ZWE>
M=)_]?6*$9&7RVA(F;(E<&TFLMII8%Z@"&ZF@M/*;,P17O<Y8CSSMEYO-'V]C
MOPJMF:1L()P;%(60G 0C!.%&>^UI1)'4CH,] >947;&JL^=P9ZPV*CIW7ZR2
MYH);9UI'-*TV335N2R-<RIP!)V7OQ$64W))H.(G2"? EXAA5A=R_?<\^_V5,
M(UTO*LJ\<E+H!D_)<]\@6FYKG : JI@R?!#(]"G"XW7T4.&5!#R9]EF225MO
MB<HV$YG1)'/>4OR"F+U!K@_S8)Z7UA])^9U(Z:?(M7I;*OSM+/IKM,%GUYL+
M !^LUX!;F(UH<$M$1VPJOK3F,@D3A.7#&@CL^?!IDS8KR7Q146"ULW>W7>DW
M#M4[\$LHG0QPR;_"5[A>?+G3PL#J@,9.9H0JBDY52HHX[01A2EL K955;I!F
M3WGJ#Z_R9B*N_3+WCO1U;YIXY&::1;1[$>7+/UYNT)7<8TLI6B=412)!9A(R
M1VF8*+Q/DFL9!A'@Z*-^>*W7%6;M*/.;U2?HML4#5DO!2_V)*5^$E,0E;HGQ
M.BBE0V P3*EW/O2'5]]3!=0@)/Q^A=M&V2)^62^10\OEQFNXG5/C@K0>K,/3
MPO;Y?IHXF@+!7\F8'1.\>M;;HX NW>.JKY46S>-NL6S'H0\ TZI/W%T@9VH)
M5T]1NQ08+>46'>#N@<(MKHS#%KAU4?0V$O4DQ-(,UWO)5!8^5$^/GT#EQ_JZ
M3:3Q4X1;VU:[W=W*+K;!M#VK,L5U!$YD4*Q,&,+509DEY;22D0L!<EC'A@,/
M.$,_KZ?+?%%98$W2U?8Y Z_^_()<ARL0(3%6LI^*T2%SN8$T$0AU*L@H,SH)
MN?+K^RB@LVF_752^G@*:L",NOD)W\R;_.NL@KEXNEB4]14O%A*+H+@B*H%Q&
M> J(]#Y8H0UEN?85UEX@%\F&L0)O<*3_#\RA\]?(T!?I,\IXN>I\F?>T)2D'
MS;5@B>18CC6C^IB!0=,H!"^\AB1JS[<Y ND"F5%3"0TL_MY?/8:1<JL-EX9X
M:PT>>%"6[B,Q+%F@.H(-M?.=A^"Z0+945T>+N,*.$'K,9>F;]"?-0@3@0+(3
M"O>Z4D*JDR,V6F95-I[*Z@WI'X=T@42IJ80&.6A_A=7K>5Q\AM\7R^45KB10
M:3FAE.,YZ!DE+C&TA@QW+M) HZB=EGP/P 7J_^D";M!VX<5R"6CN0.9X6J5(
MLBF.EC,&72(MB<YXBGEJJ5:U0XJW3[Y _3Y!I >K8NNE#:[#$OZU+G[.UQ(7
M&9,V>."CQJ8-#D%8*VWP_K.^Z]T[H**$!D1IY"JC]\3FTF3)NS(@P$@1J\^-
M/("EQMB9.Y][&_YV,F1N<R3>E?6E0(F5#GU=Q3W([''9M0N6]N&8+,&OAI[W
MS8\9)=AS9^T]")J^^M=ZMBK=2;\LYM^"ILDK (O&AQ']/5CT) CTA<%9S_"<
MBG2W$6R]6Z9]@,YVRS1:W8>ND4:+O4'@80?3)@0[!%2CZZ2]@,Y\K31><8M6
M4I^,$K380T%'8@V+I>50)(%G?!>\UB(G"C'5WAXFI,+0ZZ:)F'"*L)LT5BA]
MJ_OY*MO\-<J#49D3[S,:MS8K8KDH.1<ARI2- *A]2_$ Q/2N0P7E/.BG,$:R
M#:X?=D^[;;<0S6)D269$E-!-=;P'""1K!S$GAV[2H(3^$8;CN9LM5;<#*HBZ
M12+)0UC;QH #@+5**CD$ZGPS!T>K[C@=1LB]19K)08#H.2GIK2 VX39XVU$F
MX#;HK-1>.NMP*_RQ"3%@K.!T?#A%W.UYL!UC <:;6')9G2QG'X+RB(\P4"HP
MZB'6=Q?W 3E#0+&.HAY7_Q.D/%67G)[ID*36*9>$B9)7:9,CCD&IP)999R4%
M8JMM$#Z[H7.U+80ZXFYPC_C8Y)PAT/Y_IMQ)"CQA=MA3I-_"8WP$HE>!4TM+
M$5PI@L!7@OC,#1%2.H88(>X6'_QXQ'CR3+E6O#A%Z+435P^,17,NY>QY)!I*
MY5O,@02;-4&3B5D:O4?/>5#>ZH\P4^XD^0^8*7>*\!H8 GMZD,NHJ&4(QCOE
M2UOA<J7B "T5R,"M8<K5CA \HPD.M8_^D0)ND!=RL/WX$%P_ZX"&DW0VM#'_
M4P0^Y8 &YB*/EDJBR@Z'>YU&!PA=WRPI-<Q0'5QM5_"Y#VAHPH-3Y'S6 0U2
M9,NDH82KB&LN<RZ#L2@"I[V-@><$%SV@X21%/7E PRE2GFI @TXT:1=*[(ME
M/ (1F/46T$Q)3JN8K<NU[XF>U8"&VF;!:"$W2"$\T&9\"*J?=?["21H;UGO_
M*>*>;OZ"H%Q(E2P!52*A"7!O*I?C5!CJ%;>:L]K.P7.?O]"  Z=(>;+Y"]XK
M7"$3)(-#TT<I](%=Z8.D1%#*NN!=[0SRYSU_X20M#9J_<(J(*Y[\_9!+M%,V
M@VVM"E3(3%+*:'X86V:0,4N<YK@PE54>UI_VV+C?[0-_^#/]Z>([F"X^0H=;
M(W( C)HCOK\_>OH.?4\4_J[Z1DBN<B.^NW!H+(VKP1 C2Q*:58FX@#_:[)7G
M7BH^K'#GW I\I-E>7?V=(K#*>OL#)?5Y_7D;VM521 .2&"=+X4B4Q'MT'FT.
M/G#E=1"#&G@<T=R]ATX\&?FI8E_4D%GE$_ /_^==("%'"KG4C?O2Y@LL"0SI
MR*AT@0.UX ;5VQY3WMV'_H#*>[+,IKJK_.NZ0"N=I>*Z0VG"\J6_OH;TR\WN
M8)DKH-)F8&B^]S,#;H>OVDB2]4Q(G]&.K]UP9R3DL^?(_%ZE$&=*Q;5(IOF>
M^_O6=V^Z/JD\_<U?K^$M=.\_^0ZN#&.6A2Q(0!N>R,P5<64  2*74K&$[U[M
MS+H!L"Z%/Y45T"+7SO?M[7J(9:[5-US!:H@:-TE3EBSQ)^)%T 1<6;=6-OKJ
MA8H'L%P(&ZJ(ND$^]M.&G1EAF'<4-[-4AI88'HA7UN.9BG:1 X5':^U.#C_(
M9+KICJ*J2FJ0Q7=P"E(V%DQ"7%GY,O'&(N-C1(,,T,\R,F>A:F\NSV?P5!-^
M5!%U\Z2..]'%#ZC7Y:?%=<)M,.*?_,=[F^.';O;Q(YKNR47(C$<2O$Y$@A/$
M"0@$5^4E '.Z^ESED9 ODE!M%=?@SO @_-MO2^BGA\NN;.;,)L%(DL!12**D
MT%&*[CU0*FRR5$W&L%UPE\ZE4<JH&*0>3GK\W1(=O])RZT/G4YD^YF_PI(V"
M2@@ADZQS+"$&70*$0'+D,N&2(A[$D^]3!\!>.JNJ*NLARTQ%GZL@G.&G]MV!
MWD$$A)K>S._.K8X\6UON>YPK=5Z":Q*XH20G$[2DD>M0O?;M%( 7PJ9V2GG(
M(#LJ,^Y%C%T_778%R//5VPX^S]:??UMT]_*W($/70>H7=!5I<, @$MMW!4R"
MDD!])L+E*!1Z X;O[$X'\N-.?_8/3H\I)/Z0(.[1YER;7Y<OP2_AO__K_P!0
M2P,$%     @ ]CA_6L[Q]<1[Y0  <A(! !0   !A;F=N+3(P,C0Q,C,Q7V<Q
M+FIP9^R[=U23S]XO&J1+DXZTH" =$:E2;70! >DE*IT(D1X@ 4&:M"@**"!(
M[T1Z#])1I/?>.TA""8&$</CM^^[W/??LO=8]]ZRSWW/7NN_D^?R3>6;6?+XS
M\VTSS\7DQ2+@FHZ&M@: A(0$\./R![B8 3P"D%ZY\M=S6<@N'W(J<G(R,O*K
ME)045+17:6EIKM+0T-$S7:.C9Z2GH;G&=HV1F865E966@9V#C86#B865Y:].
M2$@OVY"14Y.34[/0T="Q_+\N%S\ C%0D.+)%4I*;@"N,)*2,)!<= "  0$).
M\K<"^+="<N5RC!245-17:2Y?J+X&N$)"2GJ%C/2O45_6PB_K 62,Y$PWI!Y0
M,!N^H+SIP7(WY$,F%?_#\E96HR&T@/1+SU#JJVSL'-<Y;PD*"8N(RLC*R2O<
M4WST6%U#4TM;Q_B9B:F9N86EG;V#HY.SBZN7MX^O']0_X&U8>$1DU+OHA(^?
M$I.2/W])R<K.R<W++R@LJJBLJJZIK:MO:&OOZ.SJ[OGY:WAD=&Q\8G)J>FEY
M975M?6-S:QMS<'ATC#W!G9[]Q8L$0$KR]_)/>3%>\KI"1D9*1OD7+Y(K?G^]
MP$A&?D.*@NF!(>4+#^:;=T.H6!Y^R"QOI>:7-D*SOO0<NLHF(+-T"_,7M;\Q
M^Y\C%OJ_Q.S?B?T'KVD +2G)Y>21,@+4 .?&6='"@/_"?^&?@$1X5JSG N R
M$+^%5R7<4[UA=:-@?N!U35+-[LRSGA]IY4< 3HSD% *[VX+KQ%R5I(;&/*S]
MGHXQG[:>JA>K?W#+'/A4X>;7^&VHZ+%P P;1@*@HR&&)70I(8S#66N)1E[4W
MM7[[84^'2P909:@.8/DO_$_!/WB/&2UO@+L H+$@NODYV=CBN[/3<Z(;OQ(]
M2?CK6F71%X!=,S2VMS6XNJ9Z:>%:RY>23=_#W)@;TX@[?,SQ%P!^9E!6N@S&
M)".$(%8$GG[+6CFR-[W\Q(>/_NUL&D-7B[#R"PR_"<:I,^[1,F^&>#KGV)\,
M;\%6]%#>G;MSDTC+P_(OX>)7;4<*3[A5DNVD74U>']EDNQ$&)KCP..]>KICB
M2/-OH7))FG9O6&@_IA#BSS/5P SLA.>8\*W*,?>C8#JK7T-3+MAACH-O*[ P
M^+KL5C>V"5>Y(DG=THZG8P.R@@.JC*S@%1Q:7S/%WH99T_WP0WYJLECB<?H1
ML-<?LTPG!Q=[%D; GM!$;*3A$;D^2QXLF&=C6J]\GE>X..#>&7?=ZJ\!%6Y=
M ,B"72&<,%Z,S=<%;-]X;F;5&]NMB80O_-"?UU^DQU+R3>RL1Q:UEFUB.1.+
MW6N::N.7I;?+,B,WP>CN-B++*,P#.>6LJ-<X!YKO^7Y30][.HVME5Y'(B@]9
MA-,1I!?W:+0^U/Y\84=>?&?3@M]$Z)!UA/_GP)9AV/+6EE!]H_H-I @N$:^'
MXUHRBV)^/.Z^+S2FG*F<-.V3/5LE', ^<^(UD?(I=?)4;,9K;+-D@6$'&R0\
M6'5NI_^^[P7\RNR#&T8T_+2%K5NMI73=P^^[#?5^EEP &,&&4,B#41^+H9R(
M7W-_>-CWKQ5IDRY$ X:SFHPFL'F#$!D(P%4DSS:*X #'TJ@+.++-Q0WL'2$U
M<.$8&@T<:$EI@1%\6(WZXDSY>2C35R -P.(C6)P8O;GE7*:V%-D)H8<]1_=,
MP*0"W'=A7>$=449::3YFQCT*?.=49<'MP55^H<HV&,&3'PTF1R>*QYD>@GPO
MJ$7B?F@/KLAXHEJ] \)9YKKJ@$PP^Q&8-,:IW98D?7A93].F)FF;*ZP[*82>
M"A*@+?]]X'Y6ZL?T-,.Z,R.242/'[P2WY1YEAB4)JPYV#^7Q:9]&ZY_<P?Z)
M&EHL[KMOYK+J#2+4KKFI"N. NAC5#(A$=5XF\ NW\?GQ!H="6;['47[-&\5H
MO3D1%X"A.LO_KV'6=P&HF=B[7D(<(-(-14;N+<.MK%.LH&5Y7$FS-PO%V>M/
M(Z0[X3=L_3'%BY (566H@PR$^7)/M@NE0CQ>X05#\(FO>)MQ>?%I,H5M50X6
MMBH& WV2V"^X&;PFU(W(Y9+$UM"W-OP22Z2Z\N3%[%W0U^AZ?@':,[,ON/RV
ML^XW/MI5"":70Q?Y\6Z[D@)?.:5L[^?PXJ.51=#NV.+"%+;_6/D>74=M\B1>
M_7@W5/NKIGH/Z=6[4-95$/KI/B=4HWWI<3K7:!F_JG"+F$285!>GB<ES76:"
MV,Q\4VR[1,0+IT"9H) $#%<O1C^>*6$U>6'[M=IWIS8>HPM %QWFZL&\K@WO
M_-3>T8D'HEH)W:\V1<JO6GV\T $*5:7$(:^!6*&^(R;/&TV=C"H*CNAS[A!V
M5A<FV[$=Z/F,)00=3 %S(ZF-R(BUTCWIGEK(^$!-9)Z1/;'\_N)#C^Q$6%LW
MI;;1NT/_=4G6J.X!1@O/VNI&;LKVC#>H*SA]7:A5NV^*?<[S?I($ZP#(2ZOC
ML@N ,P^Y!.LX;#=?I/'G7-38@5\G!( [7 )V&C#!3- F>1G+</ZGM<#I:3W,
M[X*"NS,,.[&8?9"YG*>4+?G*P)2BVG5HZK-1-X+?LAYON^F7?-3P8OT<325\
ML66.S'>]*O^V6>&GQ*'5"P S2M[U G"M20UM]PPMF.FS).RS<_K*DNR'^1?]
M+G)-VF]OHTOS</++8C 'C'P[%5$4#)RZYK)3J V_0>?9%QMF2B3YV*]T]:14
M%VN#;AJ?)ZT:R:T;WFVZX>GN]B*&LL^NEUVH7OGCOLTM9.N<XL1R?^E*J[\2
MR%6.YL6M&LJD(K4HH.7,M+H$[2G(>.T"0 XS'95L<5+JA7# [H]6^>_"'I^Y
M;G/";-VSX4SI-V+J7^K[^?SHU$3O=W-60%N6S<*RQPF:Q3BW)@D) O5RW2];
M#;R6$"4.CI\H&\!S0-T-J+2S\RH+'@6D-.[(!:1!#R7R7M(#-LU"3DU;(BX
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M_E2?M'Z+XXKM%_?3D\S^*X9.C'"U:%4@P0^GNR36PC:_(W=@-4?SQ=XMPP5
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MW0-1!R^F!TEC?)&YMCL3IJ:\;)\U7Y_(';ZS3^&/F'[C+>"W9WL//8!UPUP
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M0$S_Y#WJ)RGS(".!/R0^S2PS#4-.F_XT-EDZ>3%>O%:PP]'==D#?=F/K:DW
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M%5.^_:OSSDV3]H>-D6/G'2,,-QKF%D+SOB7%Z<*5:+0-+M*;")B3V$Q;+=N
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M@G]*?*C[C_)"_B8OSY]\P?^CN']HJ/\4<)ET%C!!D:> 6;$4!=9.Y/8WD5/
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M-E6G6:8M8"'@<2?DOIKUB$/@)>>J5O#'?@CVB3:!<1YZ<=2M6<XZL.'&_"F
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M%>7=!9+L7XC)U^S5+Y/?+JNMX4*DOQ$";^4<:]&<.8VD)7\KR%JK9+-4;DK
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MCH(EJXP6?N/,^X9;9O<T_62V>:&Z$B_27F1J/+>1L,J8^%T5=^*/ISXJABH
M+$C$!CJ.!N[=S'C<27>;8:\#,(_K=D*?7X<G"?YDWW+NMB#UQ6=55O;O.DM9
M1/>^/ (NVM80;#-. 9960N=KU*50&MY;UU9A]/OC_@D*+&$T&J8&6W]\7<-^
M4UIST*@, '<X?N(]U0<7) 3DPZ3@M)3Y7AD,/R5&M<A8%\.@KMU5#-/A=;F_
MD+2P8RQZ(Q+;90*2%! 3#6OW52]2BXT]7-7?79F.L.?=U6J%%@.;P(&FH%J\
M6Z"SM8N<^GIVLI0],))K^*IPVACEW@KI)@X<0+SV72&3X*E4,L W;Y)+FR<O
M>2 'F=?[Z3GTX(LQ'TVV9IWZ.AXUKK>O>Y9G6$Y?W]SLM&'EKP^]5O,37@0\
M7&*KR-Z"/J0:B;/:34W'K^DFN5?'L$S*4N^'G7Q9!PD]$C,1;7N)M=*R45>\
MZ7+K8S1;RAJ4S6KF'B'A6'AM],;GZH'YZ2#^3>VZ]$HYI9=[#&)'[J6LPZI:
M_:(G%FP\I,Z9;<'-J2<%8 W3&7K1&";OUE)WS#B2]NO;#5D=A_R7%BLZF]5'
MR.3XMHVT>9-7]V_WK^].WSU:"[)_8]<$N;/'FKD6'X(!KW?-@T.KYX;AC_>[
MP<J1Q [45H<(I.?I0W<B@?9@.JX)36%=XEX^<2F!XMLF96S69= W;/7%,(VW
MWRXN PJR+7 9]+<X.2\=[<D2WG:_45.0[;VQRCF8XC>'(%L! ^$2UJE6(]B)
MSG'7K,VV&NJI^,G*LN!5QKOQ8K'<FBCF]SH?5B]O\ACR+BYP<W?S]]9F7AX(
M_D@;!99$V*#&' QPFT4NV-X <8AGAMK]9"^!,:RM(C=G*LNH7 ![F?O2>X0]
M)!AQ192P>UUA?OAN&51 LBQK#,+ <L[,'QQNN^=+ZYL#!^-ZJD34LF"(9W5?
MJSODTM^TX=E%C8]X#%*=AV5UQ$3K=WXYC/7N)^)GVWI#)J:D3YIY4R>M+?3S
M^>],WE1=S.JP3Y]+/@7X>17PBOS^V@>#:U(=6-^=F_5<+^1P/]HX7XI73M;E
MRN/57LQDU1D3@<K:LA43V6[6BQ$26L W^/-=3*[,^4\JEOIC%6##>DN"H2^6
MY*ZL09]HOM *37258H(X+;2? LR#B&+X:\U"!&V#%220J)1:GN1E,U@#N5#9
M'D-&5O.)G+\O?I!@@$// _W@8+NY#4MMW#%!5;TPN7-ZHZ*LN_,S[XWHVQ=;
MWSWM53EZ?#Y4YUA9KN.7JMDO7L0X6\L(^F(M>X:1C8<+*HPHF&N\ZOHN5\3H
M*<?G0D6[JEM4D_DNWD"""!X$"8N=I9+5RUDNGA$(<<SDH[M3;B1CUC5Q^7"4
MG2-*>G1 GR9!*8-U0+?P'?LB/_L<,%SV,3ZAR508+PMB[%?TWV(WAL&E>[/,
M;UQ(LR)#H3.\9$OM6#^7W8R.7>#\EQI<8F.*&4$_;B6.)L)RL:+9CIP%\8]R
M<(,'1-X2_+-6('!6>H\J_G"PN9YG0)8Y72W'-OZCM,MG%?TND0_(%S+QAU.C
MM+K183Q&14GO\=]+<\@GD] 3]NBP=]&D?D.=BF#JIF)"=8_<ZP"Z_-L]7J"R
MG;VV9D$64C_UU J)S,?A*@$LPX6GQ=K%N_3>I94#E0U,DMJ3 1$-Q585=)K3
MT,X9VS6'.\>6"2>X$R6YW,;]LMMH+XW9]ESV9<=Y$ZO0D,6V@3@2M9HE:M)H
M&Q4]VLQ&A;;HIV$:TB(<_.A/RLUZ*&%JR'ULEGMNS71^#ATX<XO@FRJ0F[+:
M9VJX,7UGBJQE]1;K1UVM[*#PH@0K/K=3 "[>%KQS-!OC-"-(6'&8NR9:C0<&
MW1[ 1OID)OX0H5[F;8:['RO6]53">7&CD+,#54USJ&N'(QO1P]"U"_TX0@5R
M@=1-96HS (O#OMXB<IG>3;I\+$N<,/0!K5L/1A@.B/$J..EFC7[*\[J6052I
M'<U[53]8]K&NY*L;1U_A:W!@+A(7OR8'FIB-@:.RX-1XAP:31TO&!*TLYGRQ
MCJBEQ@G?V* VQ#UDM1=O)<'@^)$5F(K+C@?/@3L(OG/(W;]WKNC ;0PR0RN2
M;3JUNSA!-GD*P(B.0(CU%0L:4[ =G1*_1:3&]DOYN*A' (VU^.V(8#"SK CN
M>S.+^DJ!B[(B_VX-9,989?J]QD!M 1L94?XD338!S63<,3=[J6B6SL]BK*K2
M-*W;?E8EWN7!=:<>N]M%NTI^""L6<.MHG&L\??!&&6^"[B3?\TH^X&!E ?+,
M.K8DQ)EU$HEFQSS+U(8K!_7DD;7T6+D'CR9F#6Y>J-RX1^([X,J&2>S[#,NR
MHY0P;,'[X#&/%!G^LLJ&8Y;9%VZ(*V+OLG53ZYC"#BG;!L%G-H+^MA$[;%+_
MN0&J_;F4V8?@.=G7>/:FY'.X8UNFF5P'6[.2=T(ONB6^/03AQ3#=;O.G@ E/
MN"O:"B?8U/:&L9W7$YX\/42EH0X+\AQ,>,KG!4PE]1U! ^'R3JG6,WRE-</\
M/1SEX?(UH)FR842C==X2"0S=1B7MS8YS-]![,Q8/[CZUP)%RS78,UW3#%7I.
M 5LR+F>'=^0@20C6.^>==BD,K]*]QW\E,'RVQ?6>@6.?>Z<TF\?P<+:&]V*:
M0Z'^T3?8H,$I -E*S&9NK1XEDBI6C%^C0TN9>X&G /N6/(/ZL!+WNIV S^15
M*,H1D @L=QZ4ZX@YBX*Z^0X9N0R;M3JN?J_D^PX?GLQOZ3=^YX$8B'[*\YPI
M.GYB;<J*IRT/R"(4CXSJ5&)EK#F8T6R0UNH8?&MAY]59^@OF0K^HH+(PQ+X2
MS@3I+^A\8G\?_CC7AOQGU4A!8@)2Y+A]MJECF3=6B/CTY&O?98H9$(["\K-#
M_%$W>/_%1?O5'INAU1K2[_(6!#47Y"$1T>F/_UXR<7@*X-EQ"$#2RDK@E9[2
M'U&FQC'K"4^VNZI>V62!L-,VG)%+VW#VTH=9-K@"L:< NJ>N(9[0>&:S-?9P
M\H&JX6=&<8(B9).R.O@46>!W\104S(=?N!\1[DH&EI_)MT+06N(5OU*F9=AJ
MK-*)4*3W";T6VT'[(2QY>^EL;;'($*;W>*X"Q9<#S[&=DW+T#HIW2\IZ?4G<
M!+8<$U@TQKC;+:T=WC5[=>J!^<O$:$H/-IO?_RW2@4K,T8&RSI;RH.':?BOQ
MCRN#-J)W(9&WC723^!9W"F@)$5<U8%,?O2UCOQO24 PS=IG;8\56 P/9J)R!
M_H:WJ@O0");TJV W5B>._'$-CRC;K\,MV>^<9$(W4=ZW;0R]\BHD/+Y5E >Y
M*?.E\^2$_QIA^PB2-821&#/.J =]&Z:CN\\=]:,X<I5WL0M!26C;_UX9?-!\
M=ZD13#FBAK.V4C&&AG=SI\8OR[X^%N4*\[3#@OT.5#&0&^.*-$9*+678K.-B
MP>R] J2UY'%)SJ%/VT!::WPOI!R]H$3DBC_;V^)&B'[P8US%_L> 9J82F%&K
MJQH&RGB6VY3U=M%VL+50LU)Z\8[LA;UJ:SIZ,^&?X78]YC./J?+BBQQ @?5P
MRR/C@F?1F6>:&34 G (RA8BY,8.G "LO$6V\*(FU%/\Z[^@GV'O8G+ED64X-
MOI-%E,<';+!YN:00*-0PLY?2&+9D585IW4=E Y70^<X5Z&+@!PN<5WF,+4LK
M,M>(35S.X\KE&A&7J>XIRS+GG!*?,L/P>5 PJ^A(!:)MS5L;?;;DI4X!$2/$
MW 49:#"K)(',Y5(<GFX$<@-F=E=25NV57[+8QM*]K2U3? :LZ]%H*>U(GIBM
M4=B]S"_VS=_NAEHB55HSGFF+:=E=#(_0'"XH,Z!3K8*/DIT+7*P'$<JP&\R-
M;*7(0.X1!VQ1,.*:7.W9KC,@) G-=R5QG*2((5ALW\$L,>)?3XI<,U^WUKU-
M-S#R^(0(#*Z;BQB'/BI+WC+ _\QL)7&A'Y5,0^']M\%-3/MM9A,%T?O\P\UR
MT!FY,/ XOR_\ FYDX')SHB]I'&4_Z#*Y<<? CGO[L=>ZWD]J^!T\ZH=J2!($
M$[9CR\IFL<.%*SNVGY!&<D8\WC"9]05;15#"HALK/,ISXD"W*@L=KR_$["J8
MAS\F\H CY(H,M#677+*ZWEI6(AHM\TX!O3M4^G$W1?W=;VU:Z/)OOG4O #>B
MZ6KOS]]#,:L-TQIVRW8%%@PU<"B?8/-[Y-8Z92'XDF8PK5@'D1.7"A3FY.*=
MI3'F/I(E2Z%:VF)"SHX@:CT$YJR\V\';G+!H4E,%^(@*Y7H*8,*0@'#^<H(2
MYD+_M]JXY\G*AMC%5?MBE5G8_$"-;P\OTX!FSM03SS9_Q*]S9J< XQ8;74M_
M>9-+S:Q@5UYUM$H&4?+HIN,I@(;$M0*^3+PC&+A7)+$/=U(@\TJ2$%]AX,'O
MB0T93&5LY$E0+9GGL#B-7C#7\R5-C4@8QJV? A 7DVHKM)(4VP,QC[H_2$>]
MY9V2!64XLX@];;IFU4!>T<F;VA7[:]:(Z>RP(R__GRS3R31/Y,<K*>$MPV15
M,2&",L=*#\U5T0^$OKZ,+#TH:*UW)W!F3AN1!J",!9SEL;SNF>7;"\YWH%3A
M 77&FM93L?L@__2,U&]I721AV-M50]7.H%A36#:(G/!MC951VJNA92817GSE
M5R8.N4+0\\S7YTK+[+I&X7^IWKN\'HEQ:#[W[GG"_82N1.=#"**QSA"!3EW9
M,V(#!YZ=:UL4T>,>(LM'ACXCJS+M9O'<>L$*4Z&9/D"/Y-JT6?75Y7NIP9?^
M76Y->VN'0Z@T2DA;H[)H_?YB+6H^+B(%1XJF"W*0O@[1ZN2A.^>#H#K:S[?6
M<K%(#7^C8(59D8Y:?DLUK8JGQRIT[P_NOX[N"C(JSOY!7%M.$A\R&&]C8/B!
M$B"(S)T"UB>IG$1AKDN+MT;S"V3T+(1M5A-=E9)B!Z)\\^46LDHU%-S;2O]-
MY3_A>]\N_C?/$/['<;X@TT+LVI6-7M97,:@PN->QZ#@A&GL6CXP\W;/')\_M
MR]$IMN29(ZC(MBSJAW(,_2,L<[@FL^@TQ@J7=E BC!]A?C"9IY:]L;&?QB;;
M+I8J7Z!ZGTUC0ZOM > QW#?#[3SB!I]Y=UL$X???XVK[T$L_$;-*1-LE<)'M
M@;Q3BZE8)"/+A<C*)EX*']ZF6J=C+@*BN7I^U9 KPQ/#[NJ8)9]1]70SNG)"
MFAIJ=T:A[F\4%",(>M7TQ+.-=;Z-:&OCKLX3UR!4M8/Z &(A(##U(71?,2?2
MO PT@)^YQQW 7 E--6>7]5D<2E3P<.>?T/2> EC!\P9=W,W*TQV42Z%.D_GN
MLRV0#_5,A*(W3*1+1<.IA_E[1B+%,'UG*1:ED?K<WU7@4A"]2)(LHC6:1+OH
M=PH (0CXLQ7_M@,O.CW/00]Z2# ZEH(A,-V#JW'O>K%0JHZ#/;NGA^%RGUEC
MUA@V@O?_1!]QO'P*"&/[&RRV@_XS&MD+#/'AVU'7DA_HFS[ J8?,;]!Y\9H,
M8H?X,HQI/[W+'(8\MUT&$_0\SJ8#_Y@N2.2=OD:"MYWL(EI3I<3O"JP^U0/=
MQ4'6(S!H"D*0&+^>1CU>5#R Q#DB_=D/4VJ\Q PAI]V,;"W,2;WW1,-/AP'@
M\:HN[9\D 6-,EJ$[2V<;"QL^G^>U?D[!;T@B.F7\XH/Z1?$]I!'>+@,]LR9A
M?UWR(:8#X#\8PQJ,,;7Z^]R\6%73,SQN((;JD[#:!XY807$65<UR7%/'4C>F
M??'EFVV/>3FYW&E1$[JFIFIG<:;7B;KB;\.*&JY>? Z*V43B4,[@OVL&\C>A
M_V9Q@P583O# )V-\LO?GA,?G+[?+O1,Q/;/EU:U'9T?'!Z< +S9\QI^6^G(*
MJ \S.PDQ/5A\5(5'-"/&W1[B8U$G16DS)H3'NG$+594#"5WTE[VWB\.E6-:J
M" ZXS";DU=*/17UO="_)=KMP=XNV55G(QA]!2;2;OY5D1CH2/<,FRMX[]H?:
M*V+U0J(6G/K<9"V"]QW^ :?5&02WOSM+(:D%-7WN=QURU/BQ&O[DE^%FV%L2
M,SXL>]HA9YSHU[[,0;9U]0=.<'TIVX:5 T)+U!R.;O'89>//R#GSV8Q"%@;!
M1[-^7@UG8A[\EYAI?X*"G0(^L.$+8F*Q0^[N9YIQ>1Y,JTCS-D?ZW(;J7ZB
M_^IQB^Z<;C6/0"\(&3BWIEFZTDB[W$F&K5>+D\\#%I(OK3_V\M3[;(TH40J1
MU<@R-( KX3UM9^@'POGR7G :_J+T?R<=?SQ)HIWYF_,<_N4\B^"M-!.A+D?G
M^<[T *>FW6GA0:4BG\[6"1E526V.MXTI.@_W:6WC_T%=2W^HZZ^U584NLNV8
M+F5O1O%]&^(W+Z_V^?WF:318A^)W"8VYB=YU!TS2XV:@7&QV]@HK:V5T=VV?
MG06O@PA9\M<Y3[VIWZO]SBE X&\>#3US4;8_V+169,9@LXDBUY+),:AKUJ;
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M;B%(Y*Z/AU[:D-,3KM!<"E\CS:P5U:^W",$/4&J-2B%P%CPQWJX/UU/$U1A
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MS]@F_U_$O7=8TUO6-ASE( H(%GJ+"D@'$>DEH@<0$9 BH2,B4B*]0R "TIN
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M*-.28NV1K/6]PJ$P6L>7,J8T<VI7&4O95*J#/U3I/SP<#%V[2?>W3ZH /WT
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MD$)KJU_) %02#$=AQTE?,H 4<BAP3*14\9&( 5I!TDSG;YO)[G6#$H^7EL@
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MQ9?I0CM::P507%YE$JJ$C_,2D=XS#&(W>B8LKBR9'STU3?D<&G2V_A+RYJZ
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MI+:V\]S E7ZM'1%'(*7H6=#WQFI*KW1Z<)8,S470ZHSJ!YXI6[(D!!<3)CJ
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M=^J=TONDS7N,2(I?X",*H8\(B3D$C7:5*PW:S"7(R_YCM>4=<8N.JB:R3!O
M[GD>O'D)6"7E_8XCR]CX.5517*=TLPC3TT\WGM._R&FB]JW>;T-P^!9C2L>?
M$R6O9N2;70US*:$K)J0;&5SN^,* 3#0?*YH',A$.=<-\:NX;KTSSDX9&Q,0Y
MW"U/9UX6W@0L-#RFE3<V/S1]O73YR<U5"_]"I826.N#SH!NC2&W&R!L;KA,]
M[Y?]0XU[W1S#KKQZ>/T#3<$O3Y!V;1<M"5+S+M&D2Z:Z\E5#FQLE>(A%>PY$
M_KS'U>EV3AJ5YP,Y@2<J5W]-?-PW=C:>@?&V+B)C%Q@I&\0^#'7RRCZ0/0PO
MQ?1_6"F52F98L8F- *V']=@TNCC"68C:6-3]\:HMEN,8,,3I/#Y&I$?PBVIW
MW>V+")?7P?UY7"7R5<K9:X:5Y74U(9A%P:L-CUYH\#X;^L!^6<,CX6ZEU75"
MJBX')8/Z0I 'Q=@-;3Z"W\_"2!7P7@[KK;\J!4>^\]CQ'WU^G.U5JH/9,AI^
M4I6A&V$($?14JT[<%+]L0N\D\$K.2/GF2GR5^[7ZW>?)?"+UW_0"*KE.:(<O
MBH1-,<4(DP%^;.</P8FDT618>_0X\+-?J'*-M0Y[\^OKJ,AY7!G57- [R!R*
MV[??:MA3,8%FV50G/'^IM1;(EW8Q$%]W?FF!4]5\OY=6%DP'UQU,/QAOL>)2
M>E ,L>2(=Q#U8B.J\K;S9Z;D9E1EWZ]R'N+A5@7(CD?GS5I%\HAC02%!?+X)
M;1SM31]/99183IB9'3PMZ#.I27BUFY#%6B.T?6U1Y55NKZ_&\R!)0HC3HQU=
M9-:$6>3RCJ-(@)T]MA-RP^:J0/\T3:P/YO4<&1 %/V=3AV7)*;N:?)R"J0_J
M$A-[@)PPLG\]_Z)\KK(V<>)&O?%F '(X#^G$%U^>'6+R:A:@F*Q%_]GMPN>+
M)8D?NBO>A"BK(C))P&G?&I>S4*,Z'$NI \+!VS\\QUET,:S>-HYA0/<.UJUV
M<NPX(A:I4:0]!Z3SM;BQP:(5=]9+<_-))-+M[646P>%5_ZP1]RBI"4'$&V>0
MO023"CQ_Q;L&[4/DUR,4D\X'WOYBQ#+1Q6]K21 )#=XM6YJ3:!,+,,75QBD!
M,5(.7H4$?RUWB9(7G5R#O6RN,EG/[9CJ3;G['_SY#UCY;7TA)%7*E&R1^^,L
MI^.853CJ.\<,'JU[?'I,=_ZF(Z6L*.21.C*%@L:#!*"<'P>0\O:U#6_2:BI%
MQ:YTT.:^_^+N.TN+C[O 6CVX_C#%^S/7Z5CET_?//H*J$^+>$46Q;0UD0&1!
MTL2]>.,Y!][8KMN*U'I5'B/C:A#7M%2<+FLO4S2WYGS(=>&R@Z?:*9NZ:DR&
M+]UGF$#?;X[#UD;)@!0(P86D=JQ(:IRG(%1[#+U/B:94E+0$ 28]0,RA#EAW
MMP[W$WYLDVY!3<,)X,6^-"+U*AG YZ"GQCSI\=O/KM?5SX=TOF4O&)'5>_TP
MD8;S13 A^K5,-IICQJ#M47D#80-CH8DH6ZK$QF>Z.F&J0[3#5]6.VB/7A9?B
M@YB(<EA4!&G8CV;OZA"+2#'86M+Y:Z<H) L;'R8;B90O\GU$MS\(U7Z[>GW2
M3*&<NJ(]Y94/C5Q96C,9P.A%!ER$W"=$8.C:^=L3)^SR.SQHSY,!8KI/LYI&
M<55D0""G G0X#1T@3DI52<W9TQ\J$+49=#[RGZS')K2CH]<4(IY7%X<CD>6_
M9HWA.C@P4Q'=QO[1>,68R VQA2P[X^PXK8_EG^Z?TI2>;V+WQ%EU]IH95;1^
M=?"&/!D6)B*$5M_NM_O 6#SIMIBA4CB5Q'R9WEO[NNFG.>4.NE_((WQ$7N:I
M=>BLR"1O*[UQOYOM8%*586DG27&%^(AVUK$*AZ;S8YM0>0]0(@NR,.LVK.:B
MXAZL.A:<HUUB/#&M82>V@/1QI\\]*\@PHSHR_A+*2:B>\PWB(1C<22>8K&)5
M&5Z+9X@^K<QK$332?X6GR4J9]\<WA7IACS!,#41'RC!7;5)G"-KX5T0 ;;<9
MS6U<=!3&:WL\>NOQ"XNE=@5%D(Q"IT^7+HH&N^JJ]I<^@5C*#T)!12O>K/N#
M9E..^C>\NSJWSN7%ZUH'CXPG^/K,Y;_&T5&J[>'_I[WKC(HJ6]8]HB(",B Y
MYQQ$$)#0K2!91$#)004DB>0<&D1 @C1!8,A9)$L. BT@.6=H8I,SW<0&FN8U
MSG5&9WSOOOOGK?7NNC\.B].UJ^JKJGW.WG7JG+U;G$DL-1K25@4E1>]/D&L%
MJ HB![LN,B1\:"]D;I5!3$Y?1PGENKYO@<VQ55>55-4-L?#>MXQ\$S&V&^K?
MXN$KSXU?NC;Q5KUGN)^])H##^4KNUB^\[K]L6:1,D+,\/,&K]3&TGCH WW#[
M;7]BI-9/$7$M:LXH9%IL1.!%0)I;ME>X1;M#3 #%#@[OFVR?J<O;2DC7)P.%
MF.LA(6W1&,&*"H)N2I"U7DI9,NG^V'5$,^T'?B\=> HE](VD_)R!8$$,V0 _
MR:5PD?L)X2(*FR-5V$Z$]E(E0I7J]ENCN?*M!%<^M@+3/$Q8N"Z(L=)E58I<
M2/8K-T19YM<#4?Y5Q)@D(E9;L'WY<@A<RJ4YA0;(I;T:O[XB$DM><6-2H:)1
M+D*'ELZ_AM;$;EVIXSA09F(/3&>NNQRXUVTYH>YC 7MGQ99?4J5Z0_0^SG2%
M[!=KCIC" G91,@*AL%;ZZ%VB+TD43894-BCIM %A;:8!24F2"?71>Y&=S+NO
M?020..W ]Z7\M<JY: $$11/#&[N"YB&7> )=_IS$+0%F'&L6L\2@:U)NV>U>
MKTY[T\L9Z/A2(&5$UYI('5IS]*;N'UX]$A26 .H38:_P+$<<K1+1ELY-6Z^/
MA"TS7?3/I9SWBW 0,Z_YT41%GJ(?Y6+F'XNS%SC9"45N'*J_R;3'3K*LPWBZ
M'*N$\8!7QQZP&*'T(;D$;3+X9X *KP];!.Z;.Z6;P9X?]%O'U:W('T[+6[ M
MUA@H=D@/ #;WJ+K5D/+!?))"608&*L(\PK:*O \5&37?Y4;Y)M?Q+-J$P-['
MY1J@FMH'A:UY# ;+)5R[OP3Q6+IH",3H:@<C<GIP7^#H820#&UVF^5 !TZ*R
MR2CSBIGQ"YLZ]3)XDT_/ #9=+7;=M!G5VU BM(FG!>)$#LDS@:_Q08=OW%?/
MN2MT7FJ]9P\$"U0>8AHL)Y1IBF\)@6]*(\9TU[6812K=*M]==2[FB5'_A;D2
M<RE/_@2$DM71T7'4;M"D?+KCKM4S3=6WM0?U/]\[O&!R<IV>L'QT0?3X>L/.
M'96N$+K/,%$Q^0:FJJ-2Z>!/=YV]HNWR=,8G92\U#]U0$?QBU\ZH"4Z5LDJI
M1):J(+G7&UN&[]FN=GKRN]C;GSC/'X]V>S,/R =)>B&9B8@MW=G",O@ZFI_:
M%<H**1(6O7O/4?[$V8>R>#ZI*7[K%H^7EBJ2(HBYI#KAX3 3XO*8 +,ZM87/
MD0$8QH$[$LN-GWQHE3=NI*]RJ6[R>C?>E^)6QN>J'^BXF$9>\ NPE@7LX+W,
MH')5OV/@G5'@V8QPD2Z%:"+"BBSR5]3TQU=WO?)4!^#1 @(.Q+Q1+T&N(JI2
MZZ!&\<*$//0=E%>>A;MW2+J^@9$^7G[9V")%<<NC!7W!>:E>J))G\$G(;\?U
M4KH]>N.\ VL4GT)-4W5^<<*MILMA'M[(KHOIX:DR^?3&=!;[(_U\N>?P+,K:
MDV>^LT!4WEJ@6;3FE:6H2/R7*TUJ)5$63Z*N-_'/ES%8-J($X/TYBK,>X_MU
MN ^0=.43RAZT@DJW:(*NG0%N<BF*W0;6VG+9ITT>'\1$> R,F'Y?#:1W^TM!
MTVW["]$1@R>VMQJIGP%6R%:DJVZ< 9KSUH_I;GE?<?=.QX[&TPY7'O T8TC1
M$J.UHLC6N< WY?BR?HHC6;X;STEXJ"ZDXOJVH:U@U-4VA&BEOMK'<W7@IGBO
M+Y&6-33,,W+]9%>T39Y"<"%*F5-)KWMR@SESJ +G4XZN.T&_O@!\YU8O&JL^
M4A%N=(R '&G=G8=@:47_H/DBA#"* O[@]4;0HIX '*H1<0:@<Q?ZE![,<SW_
MKR^I<4E9F*<2Q;P4]J)H!%-*VL!5J?1R71U:-BHK8J-HY09] U1F&IL^ (<'
MT*#3Q">([3=\^V!25+#J]7'SV?>!A!.+?,QK^&8!3_L8E/:W:5"XTJB@]/8L
MJQ'B&=CM-J(F%O><-:*J(K;S%]T1)XRE45^2F:)DB: G-V9$HR&J^EH%M/=-
M:6Z+U=<882B/XF8Y'F3!550,U_7TV@\Y1<J@5%#S@JLJ>)A^[&!W.3-R<HW8
MQ]@CEN:>I0=RE#YZSRCKJ:M$ S6'CZ.V8P&^:J!J24BF';\HP_;UR10-O?(F
MW?0$)0D^(F-\N4?&7(^\]Y+&=Z>*&AA(T'>,J->\&4?VB0A5BR;;<0],^&B#
M#A[1,%T*+.*@*[W?5S;#@#*TN>0:<-BX66"X6O,"1I]A08#$^ZS9I44<:1?P
MN:WGSJT]D?Y0]4V<+-.NGAZ-^22;1O=#?T_"#XIS4D I?NQL#15HD=-D0=O)
M-;;CYR.O[W"DE8YJDD'6)^1[*@\*@Z\F/2,BXU8V^X"?&<9)%%XLWH$WE5@H
MU^<0?U"GVB@N4IZG;>ER;%J^E/9$65=?A=+,)WE-54;WDRSPJ7V*).H$#@F!
M(WI?V4@*6=#6[-?'GOKE2 ]<G+#A?6K0Y)[!"7JK.F]S&?5)$=/;Y_@).ZMN
M$C1/[[FR)S&V:>=XF2J;KUUF<]OHCC6I-9EDE[.DQ&<PX7[WM=[9/=&88*+
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MLO(J["U)H4?O:QEL^>]EL'Q(4(?>9_%9'(Z-HM99*[TF>0S7'SFQ;>OIZK'
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M-:(?A*, 3:<)V/\W6P_B5\?)QP%'K+X[1W%H.^5W_!Z3[LWO8HFN3D^4Y2;
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M:8CMB^/MS;Y\&QY5RB \0G9DN8)8@U1>4CFR<<I3?JB6Y\ ::CSX=$BEWRZ
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M(N5^>G3 <"#= :7$1'7X!XWZ)EC4($17W\FQB<@*(R/<XS[=X&M8XSV&*OT
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MZJK,])O Q;&_$S8&/93C7NJ+ +<T\<Z:.UT=$-UIBHW5W3))V0'70-O)AZ-
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MAUZ* RD%ES46'D5EA]7'\@]F!%4U^2Q:(-Z G,KMNRROHEPS^3^PFPY'B>7
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MX8&<.GT\T.J+![IA7W*;(+6WY_</SP>P"0+GC_O@ZQQ!>WC@SO*%17V&H_#
MNLLX',4)0N?A./8OS'S*YBV&)4G .F]=$<3][($,(X[%]J@/C?GQP"?OXP'L
M</)%J_H'*0G_D1.T3##OS)H##X# ,_!>T _S#%PH8EYL_Q]4.&$[U@=[#O'
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M@1V;D2.\^F5].J/H$_5S5'"*>P[&3.M+TUMM;[?GB?T#8R_80W]1$_XTZO*
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M\+G\M"1TK_A<%TO.L#_?GLUDB57!N.5APO4N^O2O.[L+CIPS]J[2-"R>0Q/
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M5F(?&0L_,OM"Y<&ZZ6EA?]._+G3E]^U%2OS[9X)!6BW-?_(X8V+"%4/BTU*
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M3J;^A)BSFE]$G"C;UG3;ZI=AXOZFM.FY+X/?OS((D23/72?PO?:[/\X$*LD
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MB6&!C"X<UQ!PB_7@/Z@1P4QG?TFMIE<S#2;*M_:_]O@\9)=I5RTB VAV\7U
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MJY:1<7Y+'E'!X )\DD2SPX1'0<['L/IOW>6G#PPDIQ1%,/<H^E@5Y1MCI*M
M-N/7U @.*K%ZU"UV[,,#'(;O;+0'G=KA0RHAM#OF?IG>R]=C&3P[2;YCHUNX
M^.3$K]&>-N_\#VLV=1<PWOP^S1\@I_0IW*:9+,X'"C+J^Y%B&ZT.!/,MO?UQ
M8"V.50_'4:A!@=TM2AFMQ5)Q0F;;]X7') 7^I>7SH B-9Y!^T$I:_37=T8G]
MO *PX@M7@@06LORR86+U7\ZN "HMM.J1<V)B,_&#-GCG=MGUF%XD%;P8V!.R
M8C'O!$KPWR5;-^*+!SGON+> ?RX:;865FVU> 1X,Q9,8J2%8"0$M-K66P9#1
M*B@9 >&R=.=ENT>O13,7&7H0I&VA/X-:F2[D;\-ULV;V6-E5V.!73^" NU>
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MX[!QP0W)S;E-352PE#XVLC(=N=<^,:O/Q:#S:<JJT%;N%?-]S>,'\2SAF"M
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M[+^@FO"RIT$3BN*K2K+FDXHJ5?C< ^VHJN.>J7V&\:$[<WY1+S+Z6$"CAE>
MKB=X")$AYPH0CIC]%F9OC6;[RWM4>-0=-85E&YQO%)2O]ERJEJMD=\R.#ZQ
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M=R\F_,!"S,6LS'J3)YU2,-TQ%;$G8K/8O.4O:S [/^CI*:AR2],^U>S_+?(
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MUX2KLAC1"OHH1?JG?M$*RRM(&!%PV<)WOA"C/R]?I#M_L*'[Z:OC]?2(_0V
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M7UFBTI>.$RP,?_'A4>JKYYST=_9#YDR>Z59EZ-9%PLY=29!!\Y[WT</7:RG
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MV,O@S10#EW3>G U7TID76A/6?78_3Y@V9UMLL<5>#+VW9 3H.6.KO;@>[Q.
M3"^ KF6LLE2[,_UJ\B+,=#C3]U JWFETZ;2U$<NJH%E@N?XKL:=8)J!]*]IM
M5].YE[H$Y2T+C>ZGV[U0+_IW)W!=NAU@YDQ*9G,&M>3M+M$4/'VYJF0[:W?I
M9#TW;'U4?SS_->T+,%N'*U=\]&ES24ZVK7.#_<;X#O]PSGYIQ&A;*\%3NU*1
MAXB9G*IF@]ZFH$?417V9=Z1\Z\_M=N,9ZX$8]E(O>YBEHT#P >W9?/G/BU]%
M,ST.OF^_+_]X5^)1_(MW@??]A=I<3VOC'G78#8"7;*0"P7ZE\0HD['4WNMM[
M9&O\CPK7/[QG@/N8;8^MT<)%JQ"R20RC@EI5KQP7,9)HK;*,^U"I;SK(<N^
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MRA#,T*"3[2DX;MO" E7M@C^N-M =@;M!V#/!CGZ,-$K,\W=V@\Q_O%ME97R
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M."( ;J8UC5Y:DDU?+:(UNI'CQA#PU0$N-H8+7D8 H+[CR @ F6HHEGH,TB:
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M2%063@;#=+EAP^EL=(XKZ+!6LG>S;\I?QW!5=9%0M >ZR]$<5K?*AKD%6$[
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M?#N4HD3XI#H!^"-O-C2I23#0S5@_HZJ*V^Q%>T\F ; V1QMO\G"B_TS2U6"
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M>_^0<ILAT.%@5QIU68G6^!9@$)3N+*58*/Q[<5&YEVSQ#+/&%N*!9&DP<</
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M;[<I#F#<Y"I,>5(YGB=Z7'4E2:=Q.R2/\[EG=KK/,._EQ3;^U (KVU(G^RE
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M"D&,[O[T3P]?W.]BY+:Q/ 9,=M:%X:CKU<+:^\F@7TJ=/6D"D:"$<RW4I&R
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M1%I?\4Y-SM.@D5'(:_1[FV-H\C*?8N1OVD+HX;&5SK1?SGX$5W9M="S)/V5
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MAQM1W543JN: _BS]_=\9Q_\U@?-=_0PP80U&90HI,6YCG3?:);X:@L?)AJI
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MC^]Y22KAPWKL6>/+2*VI^(CD>55>@=&61.#XR5R6>DFQNO"(>6;!SY27S!D
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M<N$E-\_MLM:7GG<UP"N]FR_JX_K3;B[%J4S>".<+XDUD-+@!5CH*_1_M[;4
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M\@\V:/F ;X3K94/Z6O:NQ8X=CMDE$L+PBCF$25.#@!F#(=:!WYF#L<&-F79
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MX,-QB-#(/BS_H:G*HT]37:I?IMXFJ!4!8ILD.E^M'UU"?7![QY82:?G;X,R
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M9M^=*4VX:. % <_)%<28#EYU'!SZ"CJXQ;3-JWQ [?_*!>";&-XSZWI64=-
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MX>N_EGAGDD@E05]R+M;>#=5VGKIMWWXY_-K1&-II8&3RWV&SS0=U=>Y_%RQ
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MPSWZB3R?$_P.[9%MIN'Q37;Q,K,QZFO$DM86"]-HHU$!DT/:NTUP< Z2NY>
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M%B%)\@#Q  99D$$4BQA2A@A,<D)0&$A$N=6%UA1,3NP8]%@&FS4H.Z;!2FS
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M3 )$*4MAG&7*"^$1@KG@'&9)D.19EF#&U?Y>JP/:;'^;D[;:[CL&C+_KBA'
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MCD\,UV6<Z\F9$+SZJ,3Y)MBV%/Q3L5(4Y#OUUV*S0(B1D/,,RH3H3)DL@GE
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M00@A.K4M"*@+!V%E<1TX 0(P#;@?G'#[:G!"CX>;L3)Q=XA 60_>H7+-?_
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MQ#ZR8D=SZH!)RX3)Z+HT90:F,R!X6D1#_*,$O/;H +I_"X  H0C_0+E%&&P
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M7G",(.Y8)?^UT]_\P[-)]ZF;-,0RDP71:IXQ03"A/,<TT3Y)3HH@DRHV#85
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M^HUOMVOQ7C[+U>:I[FMPZ'KP12X?V4YK/_,OY@KC;R9/]^-N+:H%XX'(HCC
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MD@USP EH5B#;*23?T,&44$T=_:V'SS$#J.7 G\Z!R.M)SUB1G%6W0$!XK4]
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M7\$2@#.=%FS?=&F</)CR\&RVWA?9SKQ8_D^3(*G-[JB0+,$B+G),0L%Q+J(
MIVE"I4P#2A2W[Y\,9V!BY?&IUU^EGWAU@]9-0M"^ 0O?5+:3B)S!'M8G<T (
MO%VTR;>J>4*OF9H824BCY6D1=>RW/ &RP ;,[K ,]V%V6'?&=LSN4A]W9;YB
M'=?D6VU('ILG+(VB+*#4?(4"$\DY9D$F<$120E5$>)&!3+U3$E,'HCJ"5YAQ
M9W"Q#/=<)2U4D8($=<A O22+MYS2$P(S9XE>$O T[_/BD_ZJU-N+.LD"114-
M,"M2C@G-$LSR.,=Q:&8]%AE)8BOC:9S4Q!OQ4K6VTZWF &!V.],/#+ =ZHJ
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M29+!8_ODI?D.Z4O\'AW)%Q_RG!A[.([2/&!%Q!BFG&7: <GUG[*BP%R)@-)
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M)C=[D3!4)#$+](N^7<F,[PN$#67 =J0-?&#70JWA(IP00#.=LV4,#/JY*=[
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M898'.-4^TNA2];PC*#:V145F &]= ,N>"?#<YE+]LGX&JZ5).6MM6#6.+S[
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M2PA$>9Y ' 88TA3+XP0-@TB%9ZM6%WKGB7%R1@MV2U3[6]LU-QET;#(['5R
M2N]4X X LQ4[H#L;.,0&>7GN3@!Z,CJR_"\0F]3BUQ/\T-+7?,O2;\ ?E$7U
MC3\O:Q6!8]J7]LSK'H^M'46P)>FG ^P%N5P=2\^1F?8@>D'8HZ/GI>?MOHHW
M[%_K9K7I5+AMJWJ'2_:YZKN)#4Z]&Z_/>^73F1<)93E+.0RX.I0FF7)L)0@F
M."<\XSBGA5&>T#7,3!*_M>_3,MNIKD):3S%,A9_A:7C'5=OJ=-=26C&F.A'V
MK&W"NSKN9F#K8GP_BK:QGG$!DR-==!4KD^HK%Z =ZC0G8UINP:W+3E'ZM*SO
M\0]5.$+%HDG-*G]QNC_U/(E2$:1%"D7!*$0LD(9WCN41N8C"N @I+5!BD$A_
M#2]:R_7J#/MO?+6NJT,7OUK%S_BU[?_<\PE6^ =OU#6@'&U5EW2UB3V[PO%O
M,T6:%I0OQ.VL*T4/M@0W3:'!H!?Z-DBMY9(O&!#+NNU),6 ;W))%^3!^!VYN
MD%T!DRMCS8:%:0VY*T Z,O*N&<O6'?B>JUY8B\\5XS_^#W^=\S@D(F8(IEDJ
MK3K,4I@3FL.4!"QEA(2,Q&:.P ,*T[@ >Z*@I0HD65/GWR$NNFZ_*Z2U<OCI
M"VKAZCLCS!5.OL,1)W;OG1'HV+%W[D$W1_[;U2.O/Z_X4Q==.*=!D-(49U!D
M.8%(K;P\2P()($UC:6A$@@JC&(%Q>IZ78$L--+W7H)1D3?L_7(#+SE%R!0A7
M^DMFH(-D\X%BPEUDJ:&\GOPHA]3>U)UR1O1+7I5SK]DM^M]XI3I1W53LACV5
M5:D\-JORA?=1J_UU;I;1C)"$PRA)4XB2,(<D2SGD,<\9C?,DR)#)TM>BZED!
M]#RTA9#Q'A=F>D /03UMX!P7,YTPA&2?@6WDN?N:#48R.](+>C0GU0Y&,!SJ
M"+.7KX@DE!0V99Z.8XS:&XC]')G!\W-,@K205@*,2!A"A#($,8E"2!->B(+E
M7.1:1KLKACSKEW/1AT#-/9!*'/ ?O*9EE\XAN81B+0TY9EC#S=GT:-HK$X)N
M:-"TX"K5M:%U)HBQ#Q(_R+/;>]-Q5*,#O%S&.U[#SO21D [ .QDCZ6)<FT*H
MR_J)UQ\7)2V7O6U 4I+E7%6]E_H1HD*:6#DN0N770"'+,8UR@V*=1^-[UG,=
M0=!1-*D[>0S$N IR()Z91MF3S"8Z\H2()N4TKQ+5LH2FUF0:%LL\*\=X@<SC
MUR8LBGF6Y_U"F.<?LPRKXDW#^1>.&_Z!-[0NG]MDD+:83IQS%?=(H$B*7!["
M\ASF,4Y@S!G!:2ZDJC!*_Q^AY5EE=)1GH*4] P/J=F6(QE#3,VL<86&F7ZZ
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MC*1VY<K2(SJMB\L(B"/7E]G;=BKDCZKN@C+_F[-[_.,=K^3Y?-7,<\9R)K(
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M-]@#WF= <0]6D@O0\0]: <!.@K99H=J9MD)LLV5GH)=#.=M[269 G2'_5-*
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M?X&;9GN9?%M_*Q\>5__@ZD_.;N3W&3_PCS]X3<M&:H22<G7?K-KH=4U8YK'
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M;,4K58MB<]<^CS,>A&G,89KEB=0*201QAA.8%DD6$<)"$6M5C[#FP+/JZ)@
M3QT7X+FG:K#>K&#5T#:^P3)324>1-SUP/4<ST/$$!DQM:FYY!]- P_D&U4X-
M>@'73'-> \RH>K4:>#H=?(W<>XKZJH'LSL"W]0.N^I*1[Y=5LUR4K*M,5K$[
M^77;? ]OQ:=2T2WQ8MN(T;29IQ-:'M73@+T9V&.P[^Z^8[%-1]TP"79<>KFW
M=HJ;HX.1&YXF/3XYA?'PD.5V<+.UK'K;W]?LIJZ_JRS%-I'QYN'AY@67BYNG
ME8YI=6$(WQ?K#P]U>Z\,6H(JDU)OO[\D^;A><BBTF::YKS%3._6@^N,,['@
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MF:,B"DA"& SBC$(4B  2FC,8AC%/TT3$861V^:9#U?-R/E<"8@:J+IJ[W#Q
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ME$.LHF**D*0YS],PS(Q./!?H>5Z*+770DS3LNGH!*+T=TJ'X9@MS3_(9Z.H
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M)F%:XIS3 L=A$I-(9 $OC&Y*7:N([_JB3C+B.]$W2.HCX":[KB>$.'UD3\4
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M$IZ'(A68R%"W4.(YSIE,U%8[$R+-0AI34"0_)M#S;.WU08/WK!L%RW3.NH,
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MNMM'L-AN+K]SO:$>0]>Q-N)RC6>;#8KUBLL<I.:62B)DX'C0\4!"=)H8FKD
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M:.<YR8+J4@@BB'<)I:6S54H*RGCMBO@?D#3M9<ZXT*JIC0; M2^CF;21Z1B
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M.^/Z$L)VYF5*/,A /%.JW%H+$E@J0VBITRRCDZ!JYV!_2-2TA5 CXJNN.AK
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M@,D]78$N&!%*@C32HUB8(Y)EC9O'*$*%#1YBI$A.9;@<)&;:QT_U85-'Z@W
MY\#8M@MF$HL*I0#$45E$E#,IS]^)SR%0SXW0H791QX,$3?O6J3Z,ZDF_!2C]
M>!#;!6,L,2I5Z<LI=DT5.?&I=&K)V7!P0HGJ/<1[$S=M'=$($!M%*PW ;7\
MVP47AD6FI0=")4I(EIH\9YPAP0H'6G*J^-C#\!X!I-&J@>H#J8*\&T#-[?S;
M!0]2*>",9R(LY>4=*9K<C&>V4"ZCK>7,B-JU9O?1,6VU07W$#)9U WC9I6XW
MJ(.++-GS[[\OY_\\AY>PB>OY6:>=$J]RC8>U0O0KKC*11J1RG\3QKX:9H+B-
MKO[(\WZT-3)Z97AJ:!1EM BR=_X4+C9@-,)J(P1!SP_MJZ61."TRH?@Q5+ $
MVMNQ<75-SK3A_SCZ_Q'(CE3&A+CJ.G/<Y./@!=2%4:9, =/6$^N,1[[*! :.
M.S,DZ6S,94;WWH7/@08HCUBT,2@=J^75$XB\42B5'@D7W&B=?4:.2*8,N3&R
MW)JS0$!'2YWTW(<P!$#72TU[F#TE;(X4;P/GV:?SL)FGN5]__^07<"&ISC"[
M;A8HVN10K+/4'(BE%*--"8I3J6E2M5N9'B2FD>%A%6[,JHB[!=Q<DU_VU?M\
MHS[^8I/1Z)*B41#!N,--5M*KV9?FFBQY!E)K7SM4^S%5$]^CU5'_/JCJZF+J
M(^PC%!,+'R'N4JSS_^KT<QF4(JU@A"<T&8&<"&1"0B)*4B.CLC%DV^OX>G"9
MB6%26:&K4:0[-4Z>;3^?P-_\^A_E400N/U]^N>#"FJ2DRXX( " R&4E"C([8
M*!E33M&\/^GD $8.+C%QG#XB/NI(=6IL_#_GB^\?SL-B'O>8<#QI!@:/;,<U
M6E>6B(\YDL2]S"* M4GV@L:A%29V549$1A69MN"Z7+IS;^=+>(-?;F8<0S@;
ME$0A@"PM A)&>*51?,HZ@P@F^=K-_.Y2T<@8TXIE8<<)N &(O%G&4C6 <=WN
MOV^6G^'T;+5&QVV7>_^X6BQ>K]9_^'6:.66L$"X0D9/"#64BL9XJ$J.)6D8,
M V7M^=V/H:^1RK$CL7"W'\<XBFD ='N<W'V#$*E*-&A)J*(H.*\C\1JC!6L<
M4"-B!ED[O_PCFB:?A#02&O9KB&JJYFBHG>&ANRJO%=;;,0#WPJ_7WTLOM]/5
M^7)[[^MU<#Y''2A)AGHBF63$6FU0ACP:"CQ(6KL,_]%$3CY[8A)(5E;>Y!CM
M/,Y[M]V!%.PGB.?K^78.FYD.A@9A,RDOP(@44I9[:T%BL#H@K\GN/Q ^X.,?
MM_[D<RO&!>!3:6;Z1G[W<=I-6O@QHT%EJ;W$O69+0Q)K'?$L)#P>E#."IA"L
M.@:"_9:?O,'6TR-P!+U,#\#>[H<P0EL6#&$6,%IC%F-Z[CQA68 %FHSQU>O'
M:WB&8W;8:L0S?(QJ!IZZKY9I(K^0VAQ<9AKW49EJ'!R&=-X 2>CY6L<S3Z+V
M7>$X?N&8#8):]0L?H[Q&$'I7FG>?Q=X4J*4QL"A-V7J<2%G:)2E%2Z&^419T
MF4TR>HKF01(;*?P;*TM33ST-)&IN/$2[:^\3RVCDHR9:E%L2H]'%9<*1Q).1
MR>72Q[IZ$>!A>EI+T%0$PN'G@<.T,GGL>[TK]V4U$\*7IXV..*T=D8[C_HRQ
M/+K%[V;+762U!Q[<I:*U#,MXF!JH@6:0=,\;R-T>F>7 0XCE$9'@N#&8!N)#
MY@1"SE)ZS;FHW4SM(#&M)4[&PU4=?0P-4#^,8:_*;$%(+\_+_?#% AUG[^"/
M[D>;61(H'-"9)&=RJ3%!P5F?268L)1?!<%/[OJP?9:VE34:V:W4UU8!?=H"K
M+C5TS12:;\\9.K8Y,)16>0KG4I)$&701?/0VN]JW:+T(:RUA\N3H&Z"G=L&W
MVU+=#]]WCUXVK[[!.LXWD&9!\:2%H22:C*Z$L99XH3P*TD<GHF62U>]+]%@J
M6TN;3&04AVNP78QV&^\ @U8DW'6*<*U3&0M<FG!Z09)DCJ&(6:K>Q^;11$[>
MOGEJA%;27[L W6W!C[#9KN=Q>_$XZUD19]<0'46;8;X]+_XS8]QH11.)$H\.
MF2@G(0=:6L?R%'/FW-:^"1E,].1MI*<&\$CZ;1?0W8[MQ2]/(0MA\' !A7_D
MR(G7%D4>N1:9!TO34QK@:G >LUWUU' >1[M3E]3OV%BFO_OUVB^WFP/;^/8+
MVAN_/Z,L&N60Q=BU4%8!_22!!U+RC*FLI-)^[Q+F0$W$4$JF;V<].D*?7F.M
M&-L'^>UVYF%^5;32,&KQ2-$>)6W0G0^)DBQ"IJ$\ 6=\#&,[@.9^6/Y37/ \
MJ7JGMK8?(2[\9O-V[L-\4>[QR]_F>0Y7['Q>7=SPW_G)+(-1P99YN>C]E[Z8
MY4$.1**L5MRR\H3#];*T0ZCHA\R?^IKH:375BH4]Y+_W*/\TVFF*>T]1S3 :
M=8%X*RQ!5J7D3G,%U5^$#Z*X'X;_%%=23ZC:=H'<LXH4(\WDP"52[GR)#!&/
M%.O0+TI:)U#29%.[G&@0P?U@_&>^V1I!L5-["#_(I=S[RG^FE=8TT4B8+-UI
MN!0D, L$I2HH5Y1FW:][U#&K]X/A3WW%]32::11Z%WF/^_FS+ G1#6LJ^6=I
MI2>>>TLTC8IA:(F!Y2.B_\<MW@]X/_4EUI/HI86#N]M$I04W2NNS__;W^?:D
M"!*9Q6]<#KN$5)JCPG*SXS%9;IBDH912HQBSR\1YZCH#;XR1$7+U).H1=/:#
MZ9_C)FML-;;S>.=Z/C3:_JZY]^=57XYEE@YYU430LCD5'@K.^D18L-(E!%U(
MM8N)!Y#;#[]_BHNLIU)J.S!^T*EY=7JV6'V'W27TA_-U/$&N/RS\<C,S'IUF
MCY$@54J4YC"<.$H]T3)3@7+P>K]?U[@Q_V%2^\'WSWQQ5569+3@+#_A#![F<
M*8418$!//#IN\*P)DC@I\)A1-CL7@V2Z=DGT483V*\/_J:^QGDZ1C894%\5G
ML/XZC_#LRQJZ5UHS3TT6WEG"<M"E,[\BGLI(4)*"<85>?.)#@JG[E^T'N)_Z
MKFED732*LET!V1W&1+ ZXWZQ/."FT4X2*Z4F1OI$-=6..3H$9/>NV@]C/_^M
MT6B::.#8O>$<?UX=F)O5;::P[QM_!)3P9KZ]%,%.*!\AKKXLNT_IY#-CW-KH
MK"#&0$99^T!"3I&8X"Q$Y1A4KTH=FZ=^N/]3W#0U!8\&MLNA65\H:YA_6;XX
M1YJ6\?N-3I[/EJG[VV('D"MY=O5E&(9^6*V[']SWVE]1'GG(>#[QTOY3>D5<
M0/79J+RVGCM+:]]=/2F#_3;2G^*NJUW@-+"KD*6=--ZN-IN92-(ZD2U14F#@
MJDN_VT@344Z+P)E6RM6N/+A%0#]4_M177\,%WP!J'FPBH#0&DZ),#7$9/7VK
M& G<2$(E\.A3#+9ZEYO!K1WX3WVK55TMC?2ON:>O ')O:> E(9Q0/%&7X8R2
M$6 YAJ0B6M_JXU:.[.SPY[B!&J:"1H!TN)$ ]Y)K*_&0[GI(*>&)->5>EZN@
MF0H^U&_5.JBQ _]37 S544B=S@ZW0?9OO]V1_EO\1O>C[B?E SY"_J7\]_>/
M;VXM57(6?\%#?;?*B]5RLUK,D^]>MURTCMJL#@]20TM]4^0O(<_C?+N3_,Z]
M/('M//K%;0%LYJ=GB[T+SKLYIA&I^>U:.OMRNR#J#E"GD11\V\(R0?JUTFB$
MBQD2M[;(L[#9KC&.F*E@C/&02'"E5(YJ1:Q7Z.)I+FRT3#-;^U:Z%V'5!D/L
M1B#8)+7PG!,'4(9LXX;U1@")SKF@8G1:U7]*>I."1CKW5\/"P3D1CY=W Z'"
MX5E>W&7K7=0DBU+*5TZ2X)4APEIGK>$>'8G:P!DT.6]\#!VAX=Z3\QXC[A9P
M\^,1/3PI:J.+Q*C2,Y;B5]9&2:)D&#1;$9RMWB'IIYV<]RCU/WYRWF-T,?7U
MWL$)31&]2ZU4(* ,;CR4"[&1*9*<U!(2!QO[M2,?-/5JRGEYCU)CKZE7CY%I
M"V;G;HM7EKB))3<7.IE8SXB3 <IC="]RYHZJ^J591TV]>JJ)]X,.J&$";@ B
MO2[FKN^MRY]^&>'%:K-%7K.1*6=-DN2!E%F1)&B:"4^4&2>%]D96!M,0>AOQ
MBX[$RC$WJC44UP!(;Z2",1Y^O^Y$>?'R&W8EMS/K=#0H,R)"SB6!XTB@X(@/
M+'/O'0JZMF'K058CEJX.Y&JKH1JRGB+-Y3<GKQ>K/S95LU57'SI>TNE^NNOG
MCJX6NDH3<&$@Q@1$9 ,7C?*R _3&-)2APH9*,9:K<0\]%2Z7RV=^6*^^SE%R
MS[__OD&SNGQ_!FO4U?++,W0]OW9/2J\D4)+'94@<4:GT^U$8H3BF6.E +A1X
M4%K63@H\GLI&3L6A"+KG2GI,=35P*MZ^= ]9 90F:32!(#)%0[Q+F03GP06(
M!L+TU0ZCP6AL;3]8[_ 8T3> FUN>8RFD6\;Y FZQ]'GU6&DJ9-B6AJB&0]SU
M, _)*A*,28D9[YD?-12HQ,>T_MH3HWAR(#2P&5X"KASG%X]-!64I)DLRLYS(
M0'D9@"V(#M$Q'2&&4+L>X^;ZTYK0Z=&PJJ2:!F!U)9.WI?C@X_S+"3HX**YG
MFPULGYV6DLO=6_Q7WTJE,\R,DLZRD(F7$<^0+ 7QT:*T8K29&RLMK?T [;$T
M3FL;FX/GJ"IN ,(W67B?7T+8OIQO8IDH]V$-I_/STQE5GK-R[#!:^O*"P[,G
MX=E#2\->II60OG;KQ!\2->T\F>9 6E>)4]]UO5GB!\%F>[&CWJ%X49:S+%B(
M@(>!BZE4;"G<8ARC1I>LX8F!%?N/=P_<=-W_^=..B&D&4K4T,#6(N@SX!?WI
M][/5\O,)7&;'W^>K+HTV&I:2CR1#>4CLRH0'ALQYCSN"2JOO3%T[ *I^ZTT[
M":8MD(V@H0;.TU>G 1**[B6LYU]19E_AKWZ^+*)]O[S[,Y3]C/$L*5"&#D.Y
M;681OZ*,DAA+WWN6E%:I\OGZ:"*G'173#&Z?1LGM=(9Y[>?K[N+G6@,W=B:W
M/'7#FZ0M5^J.6N(3DT1I*P+5SN?J590/$C3MM)CF0%I/>5.?Y=>;ZY[S@7''
M0A"!."C#Q,I;^D"9(I&G%"3^+,9^';$?6F7:.2[-0*NN-H;:N7I=!^]V\O(Y
M6AV$)1:))C) N4JW&9G)/HJ818JU$]T#.J^-UKFJ&>155-?4U@Q%E6&SZ>IX
M+KH=;/8"+<ND%S09XH/%791D)"Y#)@:TCC)3 !UZV;0?KS7QQ)1F #:&:AH(
M1XJQWA0I0G%-OQ6!G<\W)SMGH"2*9DP:FB ;XHQGI0,-(^C  M'1 1AKF7"U
M7Q/^D*B)1Y\T \IQM-A.?''M2NSJO%&>*,'M]]+CK7L9=]8U2>+69DVE)]DI
M3B3-*#6PEBAJ?7(VB21K3U/M1]G$@U":Q&EE?;8#UKMOC:_$>%&(>R5#[Y)1
M2G#">=+(H!<D"*6)PD!?*N1.V-HIG?[433SYI#G0CJ37!@[_NYQ]6,.9GZ>7
M%_1<^#;/EJEK.-3=:6YF(DB6-/5$))Y+L0ER*;4D3G-O%!)J=>U'P,=1.FTE
MQ5BX^2$\JRNQ:1M;>"K.=]?R:GO!'9X9SL:<2([*$_3((VYU;4BP2E"(/)GJ
M'D%/TJ8MGY@,D\/5U#((G\7N,GWSP7_O'I-Y1UED#,7FHBFMKP3Q%BRA ;20
M00IC:M>\_Y"H:4LB)@/>$-5,G0FZEYOU^95)WUS:]%V_O^WE(,(RSTHP0Q4S
MD6@32J4<L\2:DL2/-,DLDJ%Z+T%YL!KB:"*F+9D8&7)/JJ$FG<47JV4GOC+Z
MX@7Z[.B=KZ]F8<ZR"#0)KTFT9;ZE88)8FB@)3((%%*ISM;N-/I+$:8LM)K.(
M]=36)"IO%V1>,^8\@*"JO':TZ/!J*8EGE)/D Y4NH1><G\ EO)^X:<LGIG,*
M*ZBJ 0SV?Z\Q\Q*RD9229%@B,G,@3H(G6N68N78.J@\8Z4_=M![BT[_=&D-I
MQ\-QA?ML3#B^67Z%S0%!:J^"< %9XAQ=$9,-\2DD I!E]%92MU_E.!8L'Z"R
MD4?T3_1"M9:Z&K"/&'I=-JB(_SR?K^%6VA\]Y!N9?Z<]3]+B9F:,2.X4\<$H
M E$D!2QK'VK;Q_[4-?FVM1I.5D^BM':R.,A/!$B;URCI>VZC;G$8HV,Q6DXH
MH&<L$XK4A6@(QF_)!20RY^JP[$]>DZ]51\/E2&IKP$[VE^2LE)'(R#6QJO17
M2381ET4D0DH:K$^1L]H)QO[4->E'CH7'D936KA_Y>K[TRWB_(*E7*>N@"1<T
MXG&0-09N>#" S4PH@^*TM6/LQU,Y+3R?VH^LI:X&[&-A[\(90<9>?8NPV:#Y
MWW=4GI]OYDO\T2SEJ&Q&&1HJ*+*'.]IKF4BPFD:@68OJMS"/)+%)C[(:8O;[
MAHVHO@;0><G(^_PW6'^!]<5PZ.X5VSTBG0%S,@>'1XVUI2(/76?'J"4N,1J
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M )7E^=\^"U2A[^"5)-$+9 $4)<YF22BW5@B-83^K#;I[R.B'J9_MFF&HO!N
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M2*]7Z]\W,--1H76U4 :@ Y'!>^*93X3I*+V!).K'7KT(FS@17MT0U=?&SYO
MOG195_ER1H>_,9YC]*QVO^6?*-5]A"S&SW\GA6&@8P9QQQ&&UF2,-SGB7FD)
MCB8,0VL;A:?(?Q^>"--%2Q:84Q*/?AH!MS?SAC@6-1%)^"!XQIU9.Y[L2UNS
MF?''(.5P9KRB8AHX> ]R\_S[9_R(+JMGP1J=)!X@W5&2*"4VJD0B1CW:265
MU*[&[$%6*ZGSFGCH.Q7J2.6TC+?"T&4&,0KAF9($8YF$(LN2.*=4&88!FF'(
MHU3MT+,'6=/BK3H4>@\@.TXO#4#MBH6+/#*&RA1*$:7B@B/1&G<B%4 P&$K9
M6F.#J6W&]DAH%$+'JGA53]X-P.7U^7HYWY9>9.7)^+?RU>7;#)&D$Y*CT8:R
ML2R:;Z^I)+ST*U;6ZVAK]VLX3,VT6:^Q051)"PW@Z:"DKF-T;P4>_]H1K5TI
MU3"!6(F\6?05%,1HM*H]$.W'5+5R0S2%7W6<:EH&V^\;R.>+M_.,$K/<Y.0H
MD=GZTE!,EVV)+,7$).-2!:F?"FW79#5Z)AZ)A+Y .U(M+:;1_@;K+[#VRW0Q
M/.DS?KW!<+L,*ZI1_?FHSQ^<"#N>FQJS@0Z\QOC_V7O7YK9R'5WX%V$.[Y>/
MZ71GGYY*=_*F,S-U/JEX 1.=<:2,9*=WYM<?4)*OL>QEB4N+RKR[:J<=VQ%Q
M>0@"( C<9# B!D0R;N1(*54?W4GP.9.'511+CL7"W;"!%<\LU&@LQYY5M@:<
M.Q9XX!$(_$@&7-=.K]8 YB0M#T@QC![$R[#U)AS?TU*K>P9N-)/TA&=9QOGL
M+7X*%[_5V2'?-R&MB)G<.RO(E13D0 9G:Z]" <Y*[3092UV>.K/6F/[ET_+;
M_Z*/WAY7],7M*?7(@A.B9 QE+MM(=F)0;*G>!1>8E-+%:K#.2SHSD3:+M0RB
M8<PG'4+.3Z7[GT?$W=6F@</1ZEHVD-W4]0)WVVA<!X!$1DF9L.XUD:_)'?,1
M(UBN,&FN5+)JT(GQXV=/I^C#%;2OZ<@!TNH@@ME?5&PB!?@B:)">$_19??S,
M:">(E$RD;<%D\PN^X^KUFP?'8Y\/;770 9@>*4N64@54FH/3B;:#BHF^VM0M
M")4<^5SB80>C_T%U^R]2[_-U^R^1]=3GS-ZJ<^64JFV:=(X1E L>'%<"K+8*
M99*)_OBIZO9?I+1!=?LOD& '-N-7C)>_+R@DN]K,8J[;(LBL @D%BBNT+:(3
M$)0(](="95-P[?L#_$C%-$6+ISIRCI1Z=[CY,WRYO@:)*CMK9 !>/*_=".J,
M+F8A%C*VC+8#<ZW]EGVT3&MLCM7QDY Y4.!3'SN_K.;Y$[Y=AL4O>/DWXF)K
M1>NMUX^NO/#"*4?G<371)"W+(7H6H$2!RI./[XP8=!:]9-6>,'.HDI>GD/AY
M0*G.VJJ%<:^^U#]_7\PO:T?TB^5ZOOBT8QH+-['4I(*K@T^EB+0?38&BA8H^
M!'('0D.8/4_1M%>14T&PL:;. YZ/LFE%<LH[<BQ4?6,E4IVVP(EK8E9C3'74
M94- '@S!T9Z,3 7!H[5Q'J"[O]->Y>UTB(=\.SH+"B/A&O)O09E4-M,(H9CB
MF7$9BY"CF<4]1$W[XJ0/R]A"7^>!TWV<"N4U^281>/8"E"8OVDEE(-*6U(6'
MF%E+^W@,%O7/AL46.ND@>JW/N^C3OE0QWA021YYUU$R!B[GR@ R<<0Y0Z**2
M\,5CZTY+C]$QC9$[5>;C:,EWB)[=UN-UL""S"@2O3=)]3K6DR8-,DF14O$:4
M(^.GA[S'\1I^!C('B+L#T-1'[>OWX7O=0>\N/^-J]_5UG2]%U]$7ET '17XF
MTE>>XF[@7HO@A0Z<J<;H>8:DOF!TB-:7XZE@:A=JCX%^>U/ J9CUGH0$(K%(
M1IKX\,IE2*)D95!$_] :O:QH[NV+*J>;.T)CGU?MA3PU8JY[KF_!OGY7/G[&
M7Y9AE6L;]A4F^J?KF:P[2$</SG$%BMPV"-P8VEY:Z.P5=VY8WZXAJ_57G'B@
M9I=CBGEJW#S=<2,%G4N*->+TF>QQ[><;M(%B&>H<C8L/'W.,UL)DG *4\9#2
M3K =N#<O[N*38F!,H28H.#+**4>*&)DFMS ZQFWBB;>O;QJAT](X=]"CH.XD
MNNH!B^&FU]ZU-=Y.&/E]O;["_/OBSO.&F50Q,E][[QG%:9^A!>>9!%>XT5E:
M=&'0U+^7X/ %]$V8#1@7@V/IJ /\W2D*NLO3S,GL*;308%E-DL62(& N$%,1
M,A0*/D3[^5Z/DC*ASSXJJEI(OD< W1V-)&3MO9@Y1+0)E)4,/!9.QEA)E8(S
MJ%L_:'R*GD%0,C\!E [500=XNG];\"8DW-XES1)SHLXW N,\Q2$)"T4D4M;&
M:38Z%,&;UDFG?;0,PI$]/QPUD?W4,>!])JI1#8N$UQ>3NVE9LTBH9\X[")$Q
M$I/-%-62O15>Z\R],UX.:V<Y:+E!@''G YB1!-V!^?E'F"_6;Y?K-1E1BG)K
ME[*K^?KSMM-BY7@6'&85A 0OA*A3@31$$S)X(W-T.M<L76,[]"Q1@_#ESP=?
MXVAC:LNT+_%[&SV\7JXOU[/@G8U"TXDMZY8IR4,L.4/6FEO'4XKLJ#?D#Q<<
MEMMDYP.?T:1];MT=;MN!DAB6GQ;S_Z9P-=.*\S*_[A?[*OW7U9SXH$]X.P]Q
M?C&_K"T9R9Q_J7/[1ND*T8RN4;M)C".]4W2AR 6U+\$!#XZ\-,<-^*(8Y!BE
MT+EP;=PQ%J1)%XH]0_AV OWX>;6\^O1Y#P$S%6+V'.-FW%]MK$YFP8@ 7"N?
M:V=M*8;Y;\=0T=^ET$$(N&<V3Z:5J4_CS:WZZZM5%?7]O?P,D\PQ[9TSP%TQ
MH%0($)G@P$3FA00MZ3P9!+U#*>COANEXV)U$&U-#[CT)<[Y>+U>;2XRA'/(B
M-'DZ'#@*XK 8<E5R[2Z!AH=H&&8QK W/0<OW=[%T/-C&U\/42'N5TNH*'W%)
MGN%1<.9]G41@!?G8J@@+03#Z:TDL11.#8<,>&!U(0']72,>C[12Z.'96]L=&
M=3OX,N.=;(E98@)F8P**XQU$[0.X:+0426KZZ; 2GI<MW-^=TO$P&U/VAYNS
M):TX3MS[)LQ7FX%??V!87ZTV;3/NA&PW/]X*Y7Y\MOLG>;D@L9#3,5]\^B6L
MY^LCPMTQR3DZRCV9K!H-$[DAJ&:3+Y9U_=LA$2F%Q&V,@)KB"Y6Y!"]C )]T
M<DDE+YHWGW^*GJ.[6E]_]B_??PD7-87^UV?$RW_0YOU*LMZ6A291K(SDX$I5
M:](=^1Y!" 3&<LXFJ"39:#P_0=>T9=?-4/)#B^O6*NG@8N,.3S=?_N\YKHBH
MS]_?TAEQL7G\D*.0-AL+NKX>596UP.L#^Z*,EPYCYJWK/H91U@G4FB%B/^1:
MJ:<GT-T]=W[D;_=>PB1.3H_E($UM'V^9!>]$K:2*R(3TR:0R%O:&$-@-!)LA
M9!\(FZNK)RS^OOAZ=;G>2(Q?=V*,-B?A.?G"C%A))*_(6 %37&)<&2Y2ZS;_
M3Y#3"<[:@V ?W([42*?@$M>L!*]M\ FTK(&617)"2I+@DO62,2YS;/W6\@ER
MINW8,BVX#M%(I^"2UZT41$$99 %9) <*1VNY._D<(CCCHR/7P[>>,O@$.=/V
M8ID67(=HI"=P_?+]CMC>K/"_KG"1=JVMA3+.%5]YH/V2O $O(@,6 A:6;.:E
M]?N7 61U8LE.$!$T44Q/6'N,H=VV]()K2\(!7\NX5*TR]5)ZX"&+8!R9YM"Z
ML\4 LCIQR5I!88#??XQ>.H7:^B:!>=W_5B83!'$2+5*$9 OQA!%!9FLE3UH*
MW;J4<PA=G8"M%1B&!)G':*8GM#UV%+R9+^A[\W!QV]T[?-T4F+V]J7*4),\2
M(CD-6.HH .XA)DNA.W'*-J\TV&A6[T":._'UQC]^3Z#2#B"\O?IY)*5^DU$7
M.7,TUH! :4!%8\#%J$$(B3HDS%RV?LSU+%&=F,J38&0YIL(Z0.#CE8>/,#BS
M/B27@R1?IX98TG%BC&F2G5-")24X:QV/#"9N6D0V!L7#=X:C:*@#Z.T5VRSY
MX"*Z6N]5&+G54D#,R8$3/!06%-';VD7<2\RT >^XT&JC@69U*D<TW+NMG'A*
M5ED;6:07P$TB!]?0+G&H+9A0DBH8:PNOQK@:1EDO694)3M015#=U'>A_U(&H
M>VRTR9)'(SCXVIE.Q:(@UI'=&;-D*<M@U+!V2$\L,G%?OA$4NAQ!NAV<@$^+
MBD14(VZ;H5! #LJG CY$"2G7GLU2HY'^I.9J6C,U(K!&4,@Y5V\.*$3\M\4R
MKG'UK8;\F_N8^EJ/SHF+^8;"$]1TMB/R9)6>(\GU%/6?@J/ B!),"@$4QD2G
M>PE@C/;&%1T\MFX$<I+ZST=4\NYE*MEFO8(O ;5F$+FI%Y"RUG0G"3RE$$5&
MJYKG:5KST$E:YUCT[<TI3J'J#IR,.TG;:PE\W\PYW-Q@%:5\4=F#B''3TEB
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MPHTQWC;7,"EC;53J,\6'RM I')QWP"0Q1<Z@T:%U>]F]Q$Q;LSK:4=5$]CV
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MH?R[0]/>/:*Y0E6#0RD=Q8H\:XC9:F)-^*3(TPRA_92](91UX8./AJXF^N@
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MTCI WS.C'U")$', +JJW4T2"8(J$R)7@<E/\W[QQ_=%S5DXQ,FQ"![*=QCJ
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M%OD@-.Q;8=I4Q"AX:"+,'A#Q$-C5O]O+G/7,26LC\.0T*,45!7),  H3,(G
MTL,'RT\@Y24K3_NZ>#0$C2;\#AR8OZ[B>I[G8?7]K[#) ]9$\N9@=LATP81
M1K(.J6<<0O$12N LY")D#K*Q^[*7F Y-T_%.<!O1]X"A6_+KM<:[\I'DM*9
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MRSEQ4(6T8T+RC#9[1DS4^NR@+812$J2<>#"9"RV;#U]ZC)")2UK:H^=X<7>
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M0#[E)9 RQL4@9EI1CG3R\GYGB)?@R4!89C9N_<U,K[JBST'Y#V$@9*&#U"&
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MS2\AE)P,]GYT&H!![JC,V[#85O/X:NV+:[[/C+M2]UW?\DV$23'EM%1 T?B
MK3(6: 450(QKKQVF2L!3WE>?#Q7)DR%XUA,I-S=1KE:-^:K:8+/7(<C-)$PE
M./=: RQ,6$<PG#DTK22@ACF%*T.L[-=9^] 7\L9%)J)&$G46L!M]6>DVG%E5
M<_]%Q0V]BT%V]E5+QJE6$G!L8T\.X6(ZI !"T<H3;7"86VJG^Y PI8367LO=
M28-*"?1Z%#_&RR_]RR58,8*D"F<1![&)K>8XD$0Z0+7EE=>&0)ZZ5M]IJ3+[
MUVG@WR556BQR;VB_A4]_C9HRS:R[>[VX;5Q7>65MB1%T!$.)@<<TV'9<$: )
MMX!9&M05=FPH^UU+G?I29K(DAK6>2L>Y"?./U?S^:J7G,W/IP]>#5[>9A%*"
M05L!7>D8<'44:$$$L*Y"@IHP"<IZ$>70%S)O7Q,2)(E."]BGWLY5VVY]N<OF
M<WPY\)!Q9*71!G)0F3@1(:N@FM@@4UB.I/.>L]1QGX/"Y+T&?WTW* TJI=)K
ML_:<"(M"Z7#FD#"L/4V!5-&BZC W9#21R;MB'Q$G<XG/-(#WH=$ [>?>P*X:
M]V$5+YZ>)Q%5DD#FH056.P%(%7,BC1: ,V.PI9004_7:OO:/7R CAF!7IU5D
M;BYT&^_.-&(%[?CSAVRBG;@$)-XX;SR(!:W"ADPM$&%?!\9B#Z&$V!G2W\DY
MX\MYG9])^#.I\C,RJVV6-UT?>-=\BSMX=!<[ZTL,=UHK"QSE%! 2MG/I%(Q_
M@ZKBD$G1ZU8B?.#)_A3^ZW%O.O3MO$](7\_G2:+[S-SY[+ZMPZ+;<^+NE-9+
M#T(NN:LP,#06JF3* QGL*PC6EWI/'*>H5]#G!*%Z"Y1GDTN#>3TU +GWNC_<
MO\,""X=+]?;KRB[J[^V_[]>&57/!J((5P-[)V"X,A6D(#JS%RAC&#?:XUZYV
M^!OYJ#$1FG5ZU>9FR#_4_>]N$:?2JM@;X+I9M6%']GXVGT7;_*_9\NNS?[.I
MH,RMX%Y5  D9YBBH!"(6958\;,L0*^]V6TL<<HJ&"9#'-WHE;KT&* 6<[=\Y
MO?RX:)?-*BJQ,]_,:8\H@T#RF)J K 2*A+\)RF%8322F\"<^TK^4(F^;J]</
M%HW$H3@F/5F"'I&*,1.6@/?Q[7O\&U$$"%Y5F")(O4J=$GY(EMP5I,=A?)0R
M Q6>>^_[XA:SNNG2S;NBU]]=LYR%Q705M#=KV[JY_U0OW=JV2BT\-(@ 2;0
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M*J4JVK1'FO38E$"T!]G72RVL)H84Q&&5P.#(6ZB -K&4J5($48^53OZ^XYD
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M^J%V,8Q3LX*58+PB'"@A>' J7526,H C*QQDQ@F=^DE''[DR5\R:FFO)H2G
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M>B^/0)N.(8XK;F(ZK"31 H=)J#"?<'2@5".HG$GO'.\3I#CB# 'Y.'4&:+P
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MBJ'?'0Q&SH'HN]S=KM_^N\H/_%Y!52Q-N<@](ZMACZ!LINCN#] J&3O_A^*
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M]_$727Y!/PG3%))QJIN&QQ0'QIC4BALK%A,IM3\IF,B;Y#NN-9?"A:PNRSU
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M_78IMKH:G6#^^V/W<K.F[1_ OU!+ P04    " #V.']:T!%NJ!8H   ?B0
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MF9<$0/J1+("OX=EN \#_E63$.B\*@ CKR,L%O;KHLD)P]Z\O7B7W01)8]'0
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MGC\'>=-V6M*WFU6^X3VU=0?!OF,S4J&4KSO*I=D7^,LR%\YJWGP!-?.[-U]
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M>%,]SV5I\H+',#9U ;E&EX8+[GFFGH"$$(H=>_ S!%^\51:A6VQ6FE,.:DC
MO7"X0_-7ZC\9Q*[<P8@!6I Z2)>C$*A[<';GWFV"8OHTO?1@=%07O8H$VQ^:
M*)Z)#G$YT'ULSC/<$K%>$]PPC8$H@-FS-&%:+^C9)04C^:.U&Y.WWB/5YA)C
MP%#KO"%%N:XV-4?>>N'(H+VP_DO[RS<;_/5!/A>I0 $AB25C1!M\!@\(YBT
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M,&HP$(L)%]+G[(9X469D57V_Z_:(@X1%'Y%#=Y^G4..@WH!#TA599L3B(Y\
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M[W1HF"&?^;FIBAO76NNA??2_)[0D7$9&L;>O?*GXB.2.1#8,%::#AJL0W9=
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M)H ?6H4-RXYYF_G!W-<FQ0/S:&EODFS/R,@H_M(LY)#>2JVW=U*5.<O "%/
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M4R8;OT<##<Z)ONIEH&UG_A4N ]')4NN!<S0JN"^X2[G1=Z@T2*9TO_0-/F;
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M\*OZS+>J&%QH_OYG+H7RCC"7T!]02P,$%     @ ]CA_6N1&%U.P @  &A
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M@Y;M6R4:-8S>JJ#YL3-PNH*",F;\'P;%#?&-Q!N.XI#>DKQ1^V_9S/K]$\V
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M23:4YKRA<04[I]MV\O-^E-#8G*A*?;MD)XBM]V8V[]O_!+X#4$L! A0#%
M  @ ]CA_6KN%.P?DT@, @0\? !$              ( !     &%N9VXM,C R
M-#$R,S$N:'1M4$L! A0#%     @ ]CA_6DTC8R]B%@  *0\! !$
M     ( !$],# &%N9VXM,C R-#$R,S$N>'-D4$L! A0#%     @ ]CA_6JZ*
M#N;((@  9UD! !4              ( !I.D# &%N9VXM,C R-#$R,S%?8V%L
M+GAM;%!+ 0(4 Q0    ( /8X?UK=+$\0*6L  />B!  5              "
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M &%N9VXM,C R-#$R,S%?<')E+GAM;%!+ 0(4 Q0    ( /8X?UI^U?I^L08
M /$0   5              "  <TZ"0!E;&EC:6\M97AH:6)I=#,Q,2YH=&U0
M2P$"% ,4    " #V.']:$/W_:V@#   '!@  %0              @ &Q00D
M96QI8VEO+65X:&EB:70S,C$N:'1M4$L! A0#%     @ ]CA_6M 1;J@6*
M'XD  !P              ( !3$4) &5L:6-I;RUI;G-I9&5R=')A9&EN9V-O
M;2YH=&U02P$"% ,4    " #V.']:>:6%%,<$  #W"P  '
M@ &<;0D 96QI8VEO+7!O=V5R;V9A='1O<FYE>3(P+FAT;5!+ 0(4 Q0    (
M /8X?UI^77&#8 \  '$Q   <              "  9UR"0!E;&EC:6]?8VQA
M=V)A8VMP;VQI8WEN87,N:'1M4$L! A0#%     @ ]CA_6I.69(>K @  BP0
M !P              ( !-X() &5L:6-I;W1H97)A<&5U=&EC<VEN8S$R,RYH
M=&U02P$"% ,4    " #V.']:Y$874[ "   :$   $@              @ $<
KA0D 97AH:6)I=#(Q,3(P,C0N:'1M4$L%!@     /  \ _ ,  /R'"0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>angn-20241231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:angn="http://www.angn.com/20241231"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="angn-20241231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
        </entity>
        <period>
            <instant>2024-06-28</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
        </entity>
        <period>
            <instant>2025-03-25</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:JulyPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:JulyPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:JulyPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">angn:ConversionOfConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">angn:ConversionOfConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">angn:ConversionOfConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">angn:ConversionOfConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">angn:ConversionOfConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:ReverseRecapitalizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="angn:StockIssuanceAxis">angn:AngionStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="angn:StockIssuanceAxis">angn:AngionStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="angn:StockIssuanceAxis">angn:ServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="angn:StockIssuanceAxis">angn:ServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-01</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">angn:FormerElicioEquityHoldersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-01</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">angn:FormerAngionEquityHoldersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-01</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">angn:AngionCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-01</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
        </entity>
        <period>
            <instant>2023-06-01</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">angn:AngionCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-01</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">angn:FormerElicioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-01</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">angn:FormerElicioEquityHoldersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-01</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">angn:BridgeLoanBetweenAngionAndFormerElicioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-01</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">angn:BridgeLoanBetweenAngionAndFormerElicioDiscountAmountInitialClosingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-01</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">angn:BridgeLoanBetweenAngionAndFormerElicioInitialClosingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-01</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">angn:BridgeLoanBetweenAngionAndFormerElicioDiscountAmountAdditionalClosingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-01</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">angn:BridgeLoanBetweenAngionAndFormerElicioAdditionalClosingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-01</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">angn:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">angn:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">angn:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">angn:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">angn:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:MarchSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:JulyPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:JulyPreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:JulyPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:JulyPreFundedWarrantsAndJulyCommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:JulyPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">angn:JulySharesAndJulyCommonWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:JulyPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:JulyCommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:JulyPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">angn:MeasurementInputStrikePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">angn:MeasurementInputStrikePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">angn:ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">angn:ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">angn:ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">angn:ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">angn:ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFJuly2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">angn:ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept.2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">angn:ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept.2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">angn:ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept.2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">angn:ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">angn:ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">angn:ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">angn:FormerElicioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-01</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">angn:FormerElicioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-01</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:RegistrationStatementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:AtTheMarketEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:AtTheMarketEquityOfferingSalesAgreement2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:AtTheMarketEquityOfferingSalesAgreement2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:A2024RegistrationStatementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:AtTheMarketEquityOfferingSalesAgreement2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:AtTheMarketEquityOfferingSalesAgreement2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:MarchSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">angn:A2021PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">angn:A2021PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">angn:A2021PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">angn:A2022PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">angn:A2024PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">angn:A2024PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:MarchSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:MarchSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:MarchSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:JulyPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:JulyPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:JulyCommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:JulyPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:JulyPreFundedWarrantsAndJulyCommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:JulyPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:JulyPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:JulyCommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:JulyPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:JulyPreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:JulyCommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:JulyPreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">angn:BostonMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">angn:BostonMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">angn:NewtonMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-01</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">angn:NewtonMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-01</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">angn:ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">angn:ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">angn:SeniorSecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-31</instant>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">angn:SeniorSecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-31</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-31</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">angn:SeniorSecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">angn:EmployeeBenefitPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">angn:UnvestedCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">angn:UnvestedCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">angn:ConsultingServicePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">angn:ConsultingServicePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:MarchSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-19</startDate>
            <endDate>2024-03-19</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">angn:YekaterinaChudnovskyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:JulyPreFundedWarrantsAndJulyCommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">angn:PurchaseOfWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:JulyPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-02</startDate>
            <endDate>2024-07-02</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">angn:JayVenkatesanAndTrustsAffiliatedWithJayVenkatesanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:JulyPreFundedWarrantsAndJulyCommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">angn:PurchaseOfWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:JulyPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-02</startDate>
            <endDate>2024-07-02</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">angn:ClinicalTrailMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">angn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">angn:ClinicalTrailMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">angn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">angn:EmployeeRelatedReasearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">angn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">angn:EmployeeRelatedReasearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">angn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">angn:TranslationalMedicineAndCMCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">angn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">angn:TranslationalMedicineAndCMCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">angn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">angn:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">angn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">angn:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">angn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">angn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">angn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">angn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">angn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-29</instant>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-29</startDate>
            <endDate>2025-01-29</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">angn:SeniorSecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-31</endDate>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">angn:SeniorSecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-31</endDate>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-05</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-05</startDate>
            <endDate>2025-03-05</endDate>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="board_member">
        <measure>angn:board_member</measure>
    </unit>
    <unit id="agreement">
        <measure>angn:agreement</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="day">
        <measure>angn:day</measure>
    </unit>
    <unit id="entity">
        <measure>angn:entity</measure>
    </unit>
    <dei:SecurityExchangeName contextRef="c-1" id="f-36">NASDAQ</dei:SecurityExchangeName>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-37">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-38">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-39">0001601485</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-40">false</dei:AmendmentFlag>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="c-57"
      decimals="INF"
      id="f-414"
      unitRef="number">0.1</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="c-57"
      decimals="INF"
      id="f-436"
      unitRef="number">0.1</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-131" decimals="4" id="f-630" unitRef="number">0.034</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-131" decimals="4" id="f-631" unitRef="number">0.043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-131" decimals="4" id="f-632" unitRef="number">0.034</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-131" decimals="4" id="f-633" unitRef="number">0.043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-134" decimals="3" id="f-634" unitRef="number">0.037</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-134" decimals="4" id="f-635" unitRef="number">0.045</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-134" decimals="4" id="f-636" unitRef="number">0.0368</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-131" decimals="3" id="f-637" unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-132" decimals="3" id="f-638" unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="c-131" decimals="4" id="f-639" unitRef="number">0.795</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="c-131" decimals="4" id="f-640" unitRef="number">1.078</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="c-6" decimals="4" id="f-641" unitRef="number">0.717</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="c-134" decimals="4" id="f-642" unitRef="number">0.755</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="c-134" decimals="4" id="f-643" unitRef="number">0.7170</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="c-134" decimals="4" id="f-644" unitRef="number">0.7550</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-135" id="f-645">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-136" id="f-646">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-137" id="f-647">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-138" id="f-648">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-4">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-3">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-39990</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">Elicio Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">11-3430072</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">451 D Street, 5th Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">02210</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">209-0050</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common Stock, par value $0.01</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">ELTX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-19">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-20">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-21">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-22">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-23">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-24">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-25">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c-1" id="f-26">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-27">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-28">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-29">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="-5" id="f-30" unitRef="usd">33200000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-31" unitRef="shares">15953524</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-32">&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Portions of the registrant&#x2019;s definitive proxy statement to be filed for the registrant&#x2019;s 2025 Annual Meeting of Stockholders are incorporated by reference into Part III hereof. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.&lt;/span&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorName contextRef="c-1" id="f-33">Baker Tilly US, LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-34">Tewksbury, Massachusetts</dei:AuditorLocation>
    <dei:AuditorFirmId contextRef="c-1" id="f-35">23</dei:AuditorFirmId>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="c-1" id="f-41">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We recognize the critical importance of protecting the confidentiality, integrity and availability of our business operations and systems. With this in mind, we have implemented and maintain ongoing cybersecurity risk management practices, in accordance with our risk profile and business size, under the oversight of our Audit Committee that are designed to identify, assess, and mitigate cybersecurity risk. Our cybersecurity program is informed by the National Institute of Standards and Technology Cybersecurity Framework, and other applicable industry standards. We engage third-party service providers and vendors to assist us in managing our cybersecurity programs and systems.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Cybersecurity Risk Management and Strategy; Effect of Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;To identify and assess material risks from cybersecurity threats, we maintain a cybersecurity program to develop and implement effective systems and prepare for information security risks. We consider risks from cybersecurity threats alongside other company risks as part of our overall risk assessment process. We employ a range of tools and services, including regular network and endpoint monitoring to inform our risk identification and assessment, as well as undertaking the following activities: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt"&gt;monitor emerging data protection laws and implement changes to our processes that are designed to comply with such laws;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt"&gt;through our policies, practices and contracts (as applicable), require employees, as well as third parties that provide services on our behalf, to treat confidential information and data with care;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt"&gt;employ technical safeguards that are designed to protect our information systems from cybersecurity threats, including firewalls, device encryption, multi-factor authentication, advanced threat protection for emails, anti-virus and anti-malware functionality and access controls, which are evaluated and improved from time to time; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt"&gt;employ multiple backup systems for our data stored on our servers or other information systems.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We face risks from cybersecurity threats that, if realized, are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition. During the reporting period, we have not identified any risks from cybersecurity threats, including as a result of previous cyber security incidents, that we believe have materially affected, or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition. For more information, see the section in our risk factors under the heading &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Our internal information technology systems, or those of our vendors, collaborators or other contractors or consultants, may fail or suffer cybersecurity incidents, loss of data, and other disruptions, which could result in a material disruption of our product development programs, compromise sensitive information related to our business &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;or prevent us from accessing critical information, potentially exposing us to liability or otherwise adversely affecting our business&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;.&#x201d; which disclosures are incorporated by reference herein.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="c-1" id="f-42">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We recognize the critical importance of protecting the confidentiality, integrity and availability of our business operations and systems. With this in mind, we have implemented and maintain ongoing cybersecurity risk management practices, in accordance with our risk profile and business size, under the oversight of our Audit Committee that are designed to identify, assess, and mitigate cybersecurity risk. Our cybersecurity program is informed by the National Institute of Standards and Technology Cybersecurity Framework, and other applicable industry standards. We engage third-party service providers and vendors to assist us in managing our cybersecurity programs and systems.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="c-1" id="f-43">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="c-1" id="f-44">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="c-1" id="f-45">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="c-1" id="f-46">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-49">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Cybersecurity is an important part of our risk management processes and is an area of focus for our board of directors and management. Our board of directors has delegated the oversight of cybersecurity risks to our Audit Committee, which oversees management&#x2019;s implementation of our cybersecurity program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Our Audit Committee receives periodic updates from our General Counsel regarding our cybersecurity program and risks, including, as necessary, any material cybersecurity threat risks or incidents, as well as the steps management has taken to respond to such risks. Members of our Audit Committee are also encouraged to engage in conversations with management on cybersecurity-related news events and discuss any updates to our cybersecurity risk management and strategy programs. The Audit Committee reports to the full board of directors regarding its activities and risk management functions, including those related to cybersecurity.&lt;/span&gt;&lt;/div&gt;Oversight of our cybersecurity program, which is discussed in greater detail above, is led by our General Counsel who, along with a contracted third party managed security service provider, is responsible for helping to integrate cybersecurity risk considerations into the Company&#x2019;s overall risk management strategy and to help prepare for and respond to cybersecurity incidents. Our third party managed security service provider has over 25 years of experience in cybersecurity and is informed about and monitors our cybersecurity risk through participation in the cybersecurity risk management and strategy processes described above.  Additionally, our legal and operations teams review and assess potential improvements to our cybersecurity policies and procedures with input from third-party vendors, as appropriate. As discussed above, the General Counsel reports to the Audit Committee of our board of directors about cybersecurity related matters, periodically.</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="c-1" id="f-48">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Cybersecurity is an important part of our risk management processes and is an area of focus for our board of directors and management. Our board of directors has delegated the oversight of cybersecurity risks to our Audit Committee, which oversees management&#x2019;s implementation of our cybersecurity program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Our Audit Committee receives periodic updates from our General Counsel regarding our cybersecurity program and risks, including, as necessary, any material cybersecurity threat risks or incidents, as well as the steps management has taken to respond to such risks. Members of our Audit Committee are also encouraged to engage in conversations with management on cybersecurity-related news events and discuss any updates to our cybersecurity risk management and strategy programs. The Audit Committee reports to the full board of directors regarding its activities and risk management functions, including those related to cybersecurity.&lt;/span&gt;&lt;/div&gt;Oversight of our cybersecurity program, which is discussed in greater detail above, is led by our General Counsel who, along with a contracted third party managed security service provider, is responsible for helping to integrate cybersecurity risk considerations into the Company&#x2019;s overall risk management strategy and to help prepare for and respond to cybersecurity incidents. Our third party managed security service provider has over 25 years of experience in cybersecurity and is informed about and monitors our cybersecurity risk through participation in the cybersecurity risk management and strategy processes described above.  Additionally, our legal and operations teams review and assess potential improvements to our cybersecurity policies and procedures with input from third-party vendors, as appropriate. As discussed above, the General Counsel reports to the Audit Committee of our board of directors about cybersecurity related matters, periodically.</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="c-1" id="f-47">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Cybersecurity is an important part of our risk management processes and is an area of focus for our board of directors and management. Our board of directors has delegated the oversight of cybersecurity risks to our Audit Committee, which oversees management&#x2019;s implementation of our cybersecurity program.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="c-1" id="f-50">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-52">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Our Audit Committee receives periodic updates from our General Counsel regarding our cybersecurity program and risks, including, as necessary, any material cybersecurity threat risks or incidents, as well as the steps management has taken to respond to such risks. Members of our Audit Committee are also encouraged to engage in conversations with management on cybersecurity-related news events and discuss any updates to our cybersecurity risk management and strategy programs. The Audit Committee reports to the full board of directors regarding its activities and risk management functions, including those related to cybersecurity.&lt;/span&gt;&lt;/div&gt;Oversight of our cybersecurity program, which is discussed in greater detail above, is led by our General Counsel who, along with a contracted third party managed security service provider, is responsible for helping to integrate cybersecurity risk considerations into the Company&#x2019;s overall risk management strategy and to help prepare for and respond to cybersecurity incidents. Our third party managed security service provider has over 25 years of experience in cybersecurity and is informed about and monitors our cybersecurity risk through participation in the cybersecurity risk management and strategy processes described above.  Additionally, our legal and operations teams review and assess potential improvements to our cybersecurity policies and procedures with input from third-party vendors, as appropriate. As discussed above, the General Counsel reports to the Audit Committee of our board of directors about cybersecurity related matters, periodically.</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-51">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Our Audit Committee receives periodic updates from our General Counsel regarding our cybersecurity program and risks, including, as necessary, any material cybersecurity threat risks or incidents, as well as the steps management has taken to respond to such risks. Members of our Audit Committee are also encouraged to engage in conversations with management on cybersecurity-related news events and discuss any updates to our cybersecurity risk management and strategy programs. The Audit Committee reports to the full board of directors regarding its activities and risk management functions, including those related to cybersecurity.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-53">Oversight of our cybersecurity program, which is discussed in greater detail above, is led by our General Counsel who, along with a contracted third party managed security service provider, is responsible for helping to integrate cybersecurity risk considerations into the Company&#x2019;s overall risk management strategy and to help prepare for and respond to cybersecurity incidents.</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="c-1" id="f-54">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="c-1" id="f-55">Our third party managed security service provider has over 25 years of experience in cybersecurity and is informed about and monitors our cybersecurity risk through participation in the cybersecurity risk management and strategy processes described above.</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-56" unitRef="usd">17618000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="-3" id="f-57" unitRef="usd">12894000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent contextRef="c-4" decimals="-3" id="f-58" unitRef="usd">1178000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c-5" decimals="-3" id="f-59" unitRef="usd">722000</us-gaap:RestrictedCashCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-60" unitRef="usd">1897000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-5" decimals="-3" id="f-61" unitRef="usd">2732000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-62" unitRef="usd">20693000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-5" decimals="-3" id="f-63" unitRef="usd">16348000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-64" unitRef="usd">483000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-3" id="f-65" unitRef="usd">717000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-66" unitRef="usd">5706000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-67" unitRef="usd">6563000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-4" decimals="-3" id="f-68" unitRef="usd">696000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-5" decimals="-3" id="f-69" unitRef="usd">685000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:PrepaidExpenseOtherNoncurrent contextRef="c-4" decimals="-3" id="f-70" unitRef="usd">600000</us-gaap:PrepaidExpenseOtherNoncurrent>
    <us-gaap:PrepaidExpenseOtherNoncurrent contextRef="c-5" decimals="-3" id="f-71" unitRef="usd">2833000</us-gaap:PrepaidExpenseOtherNoncurrent>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-72" unitRef="usd">28178000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-5" decimals="-3" id="f-73" unitRef="usd">27146000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-74" unitRef="usd">1038000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-5" decimals="-3" id="f-75" unitRef="usd">4369000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-76" unitRef="usd">8415000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-77" unitRef="usd">3757000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-4" decimals="-3" id="f-78" unitRef="usd">1169000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-5" decimals="-3" id="f-79" unitRef="usd">694000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-80" unitRef="usd">901000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-81" unitRef="usd">910000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent contextRef="c-4" decimals="-3" id="f-82" unitRef="usd">0</us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent>
    <us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent contextRef="c-5" decimals="-3" id="f-83" unitRef="usd">25000</us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-84" unitRef="usd">11523000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-85" unitRef="usd">9755000</us-gaap:LiabilitiesCurrent>
    <angn:WarrantLiability contextRef="c-4" decimals="-3" id="f-86" unitRef="usd">2828000</angn:WarrantLiability>
    <angn:WarrantLiability contextRef="c-5" decimals="-3" id="f-87" unitRef="usd">11000</angn:WarrantLiability>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-88" unitRef="usd">5105000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-89" unitRef="usd">6007000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="c-4" decimals="-3" id="f-90" unitRef="usd">20034000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="c-5" decimals="-3" id="f-91" unitRef="usd">0</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-92" unitRef="usd">39490000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-5" decimals="-3" id="f-93" unitRef="usd">15773000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-94" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-5" id="f-95" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-96"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-97"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-5" decimals="INF" id="f-98" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-99" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-5" decimals="INF" id="f-100" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c-4" decimals="INF" id="f-101" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-102" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-103" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="-3" id="f-104" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-5" decimals="-3" id="f-105" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-106"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-107"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-5" decimals="INF" id="f-108" unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-109" unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-110" unitRef="shares">11043837</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c-5" decimals="INF" id="f-111" unitRef="shares">9618178</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-112" unitRef="shares">11029382</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-113" unitRef="shares">9603723</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-114" unitRef="usd">110000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-5" decimals="-3" id="f-115" unitRef="usd">96000</us-gaap:CommonStockValue>
    <us-gaap:TreasuryStockCommonShares contextRef="c-4" decimals="INF" id="f-116" unitRef="shares">14455</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares contextRef="c-5" decimals="INF" id="f-117" unitRef="shares">14455</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue contextRef="c-4" decimals="-3" id="f-118" unitRef="usd">150000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue contextRef="c-5" decimals="-3" id="f-119" unitRef="usd">150000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="-3" id="f-120" unitRef="usd">183004000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-5" decimals="-3" id="f-121" unitRef="usd">153827000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-122" unitRef="usd">-175000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-5" decimals="-3" id="f-123" unitRef="usd">-197000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-124" unitRef="usd">-194101000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-5" decimals="-3" id="f-125" unitRef="usd">-142203000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-126" unitRef="usd">-11312000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-127" unitRef="usd">11373000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-128" unitRef="usd">28178000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-5" decimals="-3" id="f-129" unitRef="usd">27146000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-130" unitRef="usd">33656000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-6" decimals="-3" id="f-131" unitRef="usd">23849000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-132" unitRef="usd">11330000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-6" decimals="-3" id="f-133" unitRef="usd">11896000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses contextRef="c-1" decimals="-3" id="f-134" unitRef="usd">44986000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-6" decimals="-3" id="f-135" unitRef="usd">35745000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-136" unitRef="usd">-44986000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-6" decimals="-3" id="f-137" unitRef="usd">-35745000</us-gaap:OperatingIncomeLoss>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-1" decimals="-3" id="f-138" unitRef="usd">3886000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-6" decimals="-3" id="f-139" unitRef="usd">2000</us-gaap:FairValueAdjustmentOfWarrants>
    <angn:GainLossOnIssuanceOfWarrants contextRef="c-1" decimals="-3" id="f-140" unitRef="usd">-3502000</angn:GainLossOnIssuanceOfWarrants>
    <angn:GainLossOnIssuanceOfWarrants contextRef="c-6" decimals="-3" id="f-141" unitRef="usd">0</angn:GainLossOnIssuanceOfWarrants>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="c-1" decimals="-3" id="f-142" unitRef="usd">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="c-6" decimals="-3" id="f-143" unitRef="usd">429000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-1" decimals="-3" id="f-144" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-6" decimals="-3" id="f-145" unitRef="usd">605000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal contextRef="c-1" decimals="-3" id="f-146" unitRef="usd">3000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal contextRef="c-6" decimals="-3" id="f-147" unitRef="usd">0</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-1" decimals="-3" id="f-148" unitRef="usd">151000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-6" decimals="-3" id="f-149" unitRef="usd">204000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:InterestIncomeOperatingAndNonoperating contextRef="c-1" decimals="-3" id="f-150" unitRef="usd">777000</us-gaap:InterestIncomeOperatingAndNonoperating>
    <us-gaap:InterestIncomeOperatingAndNonoperating contextRef="c-6" decimals="-3" id="f-151" unitRef="usd">373000</us-gaap:InterestIncomeOperatingAndNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-1" decimals="-3" id="f-152" unitRef="usd">455000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-6" decimals="-3" id="f-153" unitRef="usd">1059000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-154" unitRef="usd">-6912000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-6" decimals="-3" id="f-155" unitRef="usd">550000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-156" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-157" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-158" unitRef="usd">-51898000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-159" unitRef="usd">-35195000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-160" unitRef="usd">22000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-6" decimals="-3" id="f-161" unitRef="usd">-197000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-162" unitRef="usd">-51876000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-6" decimals="-3" id="f-163" unitRef="usd">-35392000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-164"
      unitRef="usdPerShare">-4.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-165"
      unitRef="usdPerShare">-4.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-6"
      decimals="2"
      id="f-166"
      unitRef="usdPerShare">-6.96</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-6"
      decimals="2"
      id="f-167"
      unitRef="usdPerShare">-6.96</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-168" unitRef="shares">12202996</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-169" unitRef="shares">12202996</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="0" id="f-170" unitRef="shares">5056225</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-6" decimals="0" id="f-171" unitRef="shares">5056225</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding contextRef="c-7" decimals="INF" id="f-172" unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-7" decimals="-3" id="f-173" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-8" decimals="INF" id="f-174" unitRef="shares">9618178</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-3" id="f-175" unitRef="usd">96000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares contextRef="c-9" decimals="INF" id="f-176" unitRef="shares">14455</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity contextRef="c-9" decimals="-3" id="f-177" unitRef="usd">-150000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-10" decimals="-3" id="f-178" unitRef="usd">153827000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-3" id="f-179" unitRef="usd">-197000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-12" decimals="-3" id="f-180" unitRef="usd">-142203000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-181" unitRef="usd">11373000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-1" decimals="-3" id="f-182" unitRef="usd">118000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-13"
      decimals="INF"
      id="f-183"
      unitRef="shares">703974</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-13" decimals="-3" id="f-184" unitRef="usd">7000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-14" decimals="-3" id="f-185" unitRef="usd">5628000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-15" decimals="-3" id="f-186" unitRef="usd">5635000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-13"
      decimals="INF"
      id="f-187"
      unitRef="shares">9757</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-14" decimals="-3" id="f-188" unitRef="usd">39000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-1" decimals="-3" id="f-189" unitRef="usd">39000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c-13"
      decimals="INF"
      id="f-190"
      unitRef="shares">1928</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-14" decimals="-3" id="f-191" unitRef="usd">25000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-1" decimals="-3" id="f-192" unitRef="usd">25000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-16" decimals="-3" id="f-193" unitRef="usd">517000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-17"
      decimals="INF"
      id="f-194"
      unitRef="shares">510000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-17" decimals="-3" id="f-195" unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-18" decimals="-3" id="f-196" unitRef="usd">1075000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-16" decimals="-3" id="f-197" unitRef="usd">1080000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <angn:StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants contextRef="c-13" decimals="-3" id="f-198" unitRef="shares">200000</angn:StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants contextRef="c-13" decimals="-3" id="f-199" unitRef="usd">2000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants contextRef="c-14" decimals="-3" id="f-200" unitRef="usd">1014000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants contextRef="c-1" decimals="-3" id="f-201" unitRef="usd">1016000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <angn:ReclassLiabilityClassifiedWarrantsToEquityClassifiedWarrants contextRef="c-14" decimals="-3" id="f-202" unitRef="usd">19944000</angn:ReclassLiabilityClassifiedWarrantsToEquityClassifiedWarrants>
    <angn:ReclassLiabilityClassifiedWarrantsToEquityClassifiedWarrants contextRef="c-1" decimals="-3" id="f-203" unitRef="usd">19944000</angn:ReclassLiabilityClassifiedWarrantsToEquityClassifiedWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-14" decimals="-3" id="f-204" unitRef="usd">1452000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-205" unitRef="usd">1452000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-19" decimals="-3" id="f-206" unitRef="usd">22000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-207" unitRef="usd">22000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="c-20" decimals="-3" id="f-208" unitRef="usd">-51898000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-209" unitRef="usd">-51898000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-21"
      decimals="INF"
      id="f-210"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-21" decimals="-3" id="f-211" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-22"
      decimals="INF"
      id="f-212"
      unitRef="shares">11043837</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-3" id="f-213" unitRef="usd">110000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c-23"
      decimals="INF"
      id="f-214"
      unitRef="shares">14455</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-3" id="f-215" unitRef="usd">-150000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-216" unitRef="usd">183004000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-3" id="f-217" unitRef="usd">-175000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-218" unitRef="usd">-194101000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-219" unitRef="usd">-11312000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-27"
      decimals="INF"
      id="f-220"
      unitRef="shares">4997920</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-27" decimals="-3" id="f-221" unitRef="usd">111060000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-28"
      decimals="INF"
      id="f-222"
      unitRef="shares">320281</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="-3" id="f-223" unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c-29"
      decimals="INF"
      id="f-224"
      unitRef="shares">0</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="-3" id="f-225" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-30" decimals="-3" id="f-226" unitRef="usd">4860000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-3" id="f-227" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-3" id="f-228" unitRef="usd">-107008000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-3" id="f-229" unitRef="usd">-102145000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-34"
      decimals="INF"
      id="f-230"
      unitRef="shares">16349</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-34" decimals="-3" id="f-231" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-35" decimals="-3" id="f-232" unitRef="usd">126000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-6" decimals="-3" id="f-233" unitRef="usd">127000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c-34"
      decimals="INF"
      id="f-234"
      unitRef="shares">5310</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-35" decimals="-3" id="f-235" unitRef="usd">67000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-6" decimals="-3" id="f-236" unitRef="usd">67000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <angn:TemporaryEquitySharesConversionOfConvertibleSecurities
      contextRef="c-36"
      decimals="INF"
      id="f-237"
      unitRef="shares">4997920</angn:TemporaryEquitySharesConversionOfConvertibleSecurities>
    <angn:TemporaryEquityValueConversionOfConvertibleSecurities contextRef="c-36" decimals="-3" id="f-238" unitRef="usd">111060000</angn:TemporaryEquityValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-37"
      decimals="INF"
      id="f-239"
      unitRef="shares">4997920</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-37" decimals="-3" id="f-240" unitRef="usd">50000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-38" decimals="-3" id="f-241" unitRef="usd">111010000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-39" decimals="-3" id="f-242" unitRef="usd">111060000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-243"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-6" decimals="-5" id="f-244" unitRef="usd">2400000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <angn:StockIssuedDuringPeriodSharesReverseRecapitalization
      contextRef="c-34"
      decimals="INF"
      id="f-245"
      unitRef="shares">3012854</angn:StockIssuedDuringPeriodSharesReverseRecapitalization>
    <angn:StockIssuedDuringPeriodValueReverseRecapitalization contextRef="c-34" decimals="-3" id="f-246" unitRef="usd">30000</angn:StockIssuedDuringPeriodValueReverseRecapitalization>
    <angn:StockIssuedDuringPeriodValueReverseRecapitalization contextRef="c-35" decimals="-3" id="f-247" unitRef="usd">19496000</angn:StockIssuedDuringPeriodValueReverseRecapitalization>
    <angn:StockIssuedDuringPeriodValueReverseRecapitalization contextRef="c-6" decimals="-3" id="f-248" unitRef="usd">19526000</angn:StockIssuedDuringPeriodValueReverseRecapitalization>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-40" decimals="-3" id="f-249" unitRef="usd">10027000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-41" decimals="-3" id="f-250" unitRef="usd">10027000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c-42"
      decimals="INF"
      id="f-251"
      unitRef="shares">41005</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="c-43"
      decimals="INF"
      id="f-252"
      unitRef="shares">14455</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-43" decimals="-3" id="f-253" unitRef="usd">150000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-6" decimals="-3" id="f-254" unitRef="usd">150000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-34"
      decimals="INF"
      id="f-255"
      unitRef="shares">1213000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-34" decimals="-3" id="f-256" unitRef="usd">12000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-35" decimals="-3" id="f-257" unitRef="usd">6987000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-6" decimals="-3" id="f-258" unitRef="usd">6999000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <angn:StockIssuedDuringPeriodSharesServiceAgreement
      contextRef="c-34"
      decimals="INF"
      id="f-259"
      unitRef="shares">11459</angn:StockIssuedDuringPeriodSharesServiceAgreement>
    <angn:StockIssuedDuringPeriodValueServiceAgreement contextRef="c-35" decimals="-3" id="f-260" unitRef="usd">75000</angn:StockIssuedDuringPeriodValueServiceAgreement>
    <angn:StockIssuedDuringPeriodValueServiceAgreement contextRef="c-6" decimals="-3" id="f-261" unitRef="usd">75000</angn:StockIssuedDuringPeriodValueServiceAgreement>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-35" decimals="-3" id="f-262" unitRef="usd">1179000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-6" decimals="-3" id="f-263" unitRef="usd">1179000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-44" decimals="-3" id="f-264" unitRef="usd">-197000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-6" decimals="-3" id="f-265" unitRef="usd">-197000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="c-45" decimals="-3" id="f-266" unitRef="usd">-35195000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-267" unitRef="usd">-35195000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding contextRef="c-7" decimals="INF" id="f-268" unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-7" decimals="-3" id="f-269" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-8" decimals="INF" id="f-270" unitRef="shares">9618178</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-3" id="f-271" unitRef="usd">96000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares contextRef="c-9" decimals="INF" id="f-272" unitRef="shares">14455</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity contextRef="c-9" decimals="-3" id="f-273" unitRef="usd">-150000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-10" decimals="-3" id="f-274" unitRef="usd">153827000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-3" id="f-275" unitRef="usd">-197000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-12" decimals="-3" id="f-276" unitRef="usd">-142203000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-277" unitRef="usd">11373000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-278" unitRef="usd">-51898000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-279" unitRef="usd">-35195000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation contextRef="c-1" decimals="-3" id="f-280" unitRef="usd">321000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-6" decimals="-3" id="f-281" unitRef="usd">382000</us-gaap:Depreciation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-1" decimals="-3" id="f-282" unitRef="usd">857000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-6" decimals="-3" id="f-283" unitRef="usd">788000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-1" decimals="-3" id="f-284" unitRef="usd">75000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-6" decimals="-3" id="f-285" unitRef="usd">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <angn:InterestExpenseNoncash contextRef="c-1" decimals="-3" id="f-286" unitRef="usd">232000</angn:InterestExpenseNoncash>
    <angn:InterestExpenseNoncash contextRef="c-6" decimals="-3" id="f-287" unitRef="usd">1061000</angn:InterestExpenseNoncash>
    <angn:CostsExpensedUponTheIssuanceOfWarrants contextRef="c-1" decimals="-3" id="f-288" unitRef="usd">549000</angn:CostsExpensedUponTheIssuanceOfWarrants>
    <angn:CostsExpensedUponTheIssuanceOfWarrants contextRef="c-6" decimals="-3" id="f-289" unitRef="usd">0</angn:CostsExpensedUponTheIssuanceOfWarrants>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet contextRef="c-1" decimals="-3" id="f-290" unitRef="usd">0</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet contextRef="c-6" decimals="-3" id="f-291" unitRef="usd">429000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-1" decimals="-3" id="f-292" unitRef="usd">3886000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-6" decimals="-3" id="f-293" unitRef="usd">2000</us-gaap:FairValueAdjustmentOfWarrants>
    <angn:GainLossOnIssuanceOfWarrants contextRef="c-1" decimals="-3" id="f-294" unitRef="usd">-3502000</angn:GainLossOnIssuanceOfWarrants>
    <angn:GainLossOnIssuanceOfWarrants contextRef="c-6" decimals="-3" id="f-295" unitRef="usd">0</angn:GainLossOnIssuanceOfWarrants>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-296" unitRef="usd">1452000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-6" decimals="-3" id="f-297" unitRef="usd">1179000</us-gaap:ShareBasedCompensation>
    <angn:ProfessionalServicesExpenseNoncash contextRef="c-1" decimals="-3" id="f-298" unitRef="usd">0</angn:ProfessionalServicesExpenseNoncash>
    <angn:ProfessionalServicesExpenseNoncash contextRef="c-6" decimals="-3" id="f-299" unitRef="usd">75000</angn:ProfessionalServicesExpenseNoncash>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-1" decimals="-3" id="f-300" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-6" decimals="-3" id="f-301" unitRef="usd">605000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-1" decimals="-3" id="f-302" unitRef="usd">3000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-6" decimals="-3" id="f-303" unitRef="usd">-105000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-304" unitRef="usd">-835000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-6" decimals="-3" id="f-305" unitRef="usd">729000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-1" decimals="-3" id="f-306" unitRef="usd">-2233000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-6" decimals="-3" id="f-307" unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-308" unitRef="usd">-3331000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-6" decimals="-3" id="f-309" unitRef="usd">23000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <angn:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities contextRef="c-1" decimals="-3" id="f-310" unitRef="usd">4658000</angn:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities>
    <angn:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities contextRef="c-6" decimals="-3" id="f-311" unitRef="usd">2216000</angn:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-3" id="f-312" unitRef="usd">475000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-6" decimals="-3" id="f-313" unitRef="usd">-742000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-314" unitRef="usd">-911000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-6" decimals="-3" id="f-315" unitRef="usd">-825000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-316" unitRef="usd">-37068000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-6" decimals="-3" id="f-317" unitRef="usd">-32694000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-318" unitRef="usd">87000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-6" decimals="-3" id="f-319" unitRef="usd">66000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-320" unitRef="usd">3000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-6" decimals="-3" id="f-321" unitRef="usd">34000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-322" unitRef="usd">-84000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-6" decimals="-3" id="f-323" unitRef="usd">-32000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:CashAcquiredInExcessOfPaymentsToAcquireBusiness contextRef="c-1" decimals="-3" id="f-324" unitRef="usd">0</us-gaap:CashAcquiredInExcessOfPaymentsToAcquireBusiness>
    <us-gaap:CashAcquiredInExcessOfPaymentsToAcquireBusiness contextRef="c-6" decimals="-3" id="f-325" unitRef="usd">24001000</us-gaap:CashAcquiredInExcessOfPaymentsToAcquireBusiness>
    <us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities contextRef="c-1" decimals="-3" id="f-326" unitRef="usd">0</us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities>
    <us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities contextRef="c-6" decimals="-3" id="f-327" unitRef="usd">2364000</us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities>
    <us-gaap:ProceedsFromNotesPayable contextRef="c-1" decimals="-3" id="f-328" unitRef="usd">0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="c-6" decimals="-3" id="f-329" unitRef="usd">10000000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c-1" decimals="-3" id="f-330" unitRef="usd">5985000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c-6" decimals="-3" id="f-331" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfWarrants>
    <angn:ProceedsFromIssuanceOfCommonStockWarrantsFromJulyPublicOffering contextRef="c-1" decimals="-3" id="f-332" unitRef="usd">11484000</angn:ProceedsFromIssuanceOfCommonStockWarrantsFromJulyPublicOffering>
    <angn:ProceedsFromIssuanceOfCommonStockWarrantsFromJulyPublicOffering contextRef="c-6" decimals="-3" id="f-333" unitRef="usd">0</angn:ProceedsFromIssuanceOfCommonStockWarrantsFromJulyPublicOffering>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-334" unitRef="usd">4555000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-6" decimals="-3" id="f-335" unitRef="usd">6999000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <angn:ProceedsFromIssuanceOfCommonStockFromJulyPublicOffering contextRef="c-1" decimals="-3" id="f-336" unitRef="usd">1080000</angn:ProceedsFromIssuanceOfCommonStockFromJulyPublicOffering>
    <angn:ProceedsFromIssuanceOfCommonStockFromJulyPublicOffering contextRef="c-6" decimals="-3" id="f-337" unitRef="usd">0</angn:ProceedsFromIssuanceOfCommonStockFromJulyPublicOffering>
    <angn:PaymentOfWarrantIssuanceCosts contextRef="c-1" decimals="-3" id="f-338" unitRef="usd">549000</angn:PaymentOfWarrantIssuanceCosts>
    <angn:PaymentOfWarrantIssuanceCosts contextRef="c-6" decimals="-3" id="f-339" unitRef="usd">0</angn:PaymentOfWarrantIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt contextRef="c-1" decimals="-3" id="f-340" unitRef="usd">19727000</us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt contextRef="c-6" decimals="-3" id="f-341" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt>
    <us-gaap:PaymentsForRepurchaseOfEquity contextRef="c-1" decimals="-3" id="f-342" unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfEquity>
    <us-gaap:PaymentsForRepurchaseOfEquity contextRef="c-6" decimals="-3" id="f-343" unitRef="usd">150000</us-gaap:PaymentsForRepurchaseOfEquity>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-344" unitRef="usd">39000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-6" decimals="-3" id="f-345" unitRef="usd">127000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-346" unitRef="usd">42321000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-6" decimals="-3" id="f-347" unitRef="usd">38613000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-3" id="f-348" unitRef="usd">22000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-6" decimals="-3" id="f-349" unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-350" unitRef="usd">5191000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-6" decimals="-3" id="f-351" unitRef="usd">5887000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-352" unitRef="usd">14301000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-33" decimals="-3" id="f-353" unitRef="usd">8414000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-354" unitRef="usd">19492000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-355" unitRef="usd">14301000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-356" unitRef="usd">17618000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="-3" id="f-357" unitRef="usd">12894000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="c-4" decimals="-3" id="f-358" unitRef="usd">1874000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="c-5" decimals="-3" id="f-359" unitRef="usd">1407000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-360" unitRef="usd">19492000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-361" unitRef="usd">14301000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <angn:FairValueOfPreFundedWarrants contextRef="c-1" decimals="-3" id="f-362" unitRef="usd">13382000</angn:FairValueOfPreFundedWarrants>
    <angn:FairValueOfPreFundedWarrants contextRef="c-6" decimals="-3" id="f-363" unitRef="usd">0</angn:FairValueOfPreFundedWarrants>
    <angn:FairValueOfCommonStockWarrants contextRef="c-1" decimals="-3" id="f-364" unitRef="usd">6509000</angn:FairValueOfCommonStockWarrants>
    <angn:FairValueOfCommonStockWarrants contextRef="c-6" decimals="-3" id="f-365" unitRef="usd">0</angn:FairValueOfCommonStockWarrants>
    <angn:AccretionOfPromissoryNoteDiscountFromEmbeddedDerivative contextRef="c-1" decimals="-3" id="f-366" unitRef="usd">0</angn:AccretionOfPromissoryNoteDiscountFromEmbeddedDerivative>
    <angn:AccretionOfPromissoryNoteDiscountFromEmbeddedDerivative contextRef="c-6" decimals="-3" id="f-367" unitRef="usd">10027000</angn:AccretionOfPromissoryNoteDiscountFromEmbeddedDerivative>
    <angn:AccretionOfPromissoryNoteToFaceValue contextRef="c-1" decimals="-3" id="f-368" unitRef="usd">26000</angn:AccretionOfPromissoryNoteToFaceValue>
    <angn:AccretionOfPromissoryNoteToFaceValue contextRef="c-6" decimals="-3" id="f-369" unitRef="usd">130000</angn:AccretionOfPromissoryNoteToFaceValue>
    <angn:SettlementOfPromissoryNotesPayable contextRef="c-1" decimals="-3" id="f-370" unitRef="usd">0</angn:SettlementOfPromissoryNotesPayable>
    <angn:SettlementOfPromissoryNotesPayable contextRef="c-6" decimals="-3" id="f-371" unitRef="usd">897000</angn:SettlementOfPromissoryNotesPayable>
    <angn:VestingOfRestrictedCommonStockNoncash contextRef="c-1" decimals="-3" id="f-372" unitRef="usd">25000</angn:VestingOfRestrictedCommonStockNoncash>
    <angn:VestingOfRestrictedCommonStockNoncash contextRef="c-6" decimals="-3" id="f-373" unitRef="usd">67000</angn:VestingOfRestrictedCommonStockNoncash>
    <us-gaap:ConversionOfStockAmountIssued1 contextRef="c-1" decimals="-3" id="f-374" unitRef="usd">0</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:ConversionOfStockAmountIssued1 contextRef="c-6" decimals="-3" id="f-375" unitRef="usd">111060000</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:StockIssued1 contextRef="c-46" decimals="-3" id="f-376" unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="c-47" decimals="-3" id="f-377" unitRef="usd">19526000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="c-48" decimals="-3" id="f-378" unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="c-49" decimals="-3" id="f-379" unitRef="usd">75000</us-gaap:StockIssued1>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c-1" id="f-380">Description of the Business and Financial Condition&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Elicio Therapeutics, Inc. (&#x201c;Elicio&#x201d; or the &#x201c;Company&#x201d;) was incorporated in Delaware as Vedantra Pharmaceuticals Inc., in August 2011. Elicio is a clinical-stage biotechnology company pioneering the development of immunotherapies for patients with limited treatment options and poor outcomes suffering from cancer. In December 2018, Elicio formed a wholly-owned subsidiary, Elicio Securities Corporation (&#x201c;ESC&#x201d;), a Massachusetts corporation. ESC is an investment company. Elicio, ESC, Former Elicio (as defined below) and Elicio Pty (as defined below) are collectively referred to as &#x201c;Elicio&#x201d; throughout these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Reverse Merger Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On January 17, 2023, the Company entered into a definitive merger agreement (the &#x201c;Merger Agreement&#x201d;) with Angion Biomedica Corp. (&#x201c;Angion&#x201d;), a clinical-stage biotechnology company, Arkham Merger Sub, Inc., a wholly owned subsidiary of Angion (&#x201c;Merger Sub&#x201d;), and Elicio Operating Company, Inc. (&#x201c;Former Elicio&#x201d;), pursuant to which Merger Sub merged with and into Former Elicio, with Former Elicio surviving the merger as a wholly owned subsidiary of Angion (the &#x201c;Merger&#x201d;). Following the Merger, Former Elicio and Elicio Australia Pty Ltd. (&#x201c;Elicio Pty&#x201d;), an Australian subsidiary established in August 2019 for the purpose of qualifying for research credits for studies conducted in Australia, became wholly owned subsidiaries of Elicio.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On June 1, 2023, the Company completed the Merger in accordance with the terms and conditions of the Merger Agreement and Angion changed its name from &#x201c;Angion Biomedica Corp.&#x201d; to &#x201c;Elicio Therapeutics, Inc.&#x201d; Immediately following the consummation of the Merger, there were approximately 9.7&#160;million shares of the Company&#x2019;s common stock outstanding on a fully-diluted basis, with Former Elicio equity holders collectively owning approximately 65.2% of the Company and Angion equity holders collectively owning approximately 34.8% of the Company, in each case on a fully diluted basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Merger was accounted for as a reverse recapitalization, with Former Elicio being treated as the acquirer for accounting purposes. See discussions of the transactions in connection with the Merger at Note 3 - Merger and Related Transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Liquidity and Going Concern&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company has experienced net losses and negative cash flows from operating activities since inception. As of December&#160;31, 2024, the Company had an accumulated deficit of $194.1&#160;million. The Company expects that its operating losses and negative operating cash flows will continue for the foreseeable future as the Company continues to develop its product candidates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As of December&#160;31, 2024, the Company had $17.6&#160;million in cash and cash equivalents. The Company&#x2019;s losses from operations, negative operating cash flows and accumulated deficit, as well as the additional capital needed to fund operations for at least twelve months following the issuance of the consolidated financial statements, raise substantial doubt about the Company&#x2019;s ability to continue as a going concern. The Company expects to incur substantial expenditures in the foreseeable future for the development of its product candidates and will require additional financing to continue this development. The Company plans to address this condition through the sale of Company common stock or other securities in public offerings and/or private placements, debt financings, or through other capital sources, including licensing arrangements, partnerships and collaborations with other companies or other strategic transactions, but there is no assurance these plans will be completed successfully or at all.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;If the Company is unable to obtain additional capital when and as needed to continue as a going concern, it might have to further reduce or scale back its operations and/or liquidate its assets, and the values it receives for its assets in liquidation or dissolution could be significantly lower than the values reflected in its financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The accompanying consolidated financial statements have been prepared on a basis that assumes that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-50" decimals="-5" id="f-381" unitRef="shares">9700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <angn:ReverseRecapitalizationOwnershipPercentage contextRef="c-51" decimals="3" id="f-382" unitRef="number">0.652</angn:ReverseRecapitalizationOwnershipPercentage>
    <angn:ReverseRecapitalizationOwnershipPercentage contextRef="c-52" decimals="3" id="f-383" unitRef="number">0.348</angn:ReverseRecapitalizationOwnershipPercentage>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-5" id="f-384" unitRef="usd">-194100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-5" id="f-385" unitRef="usd">17600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-386">Summary of Significant Accounting Policies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company's consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;). Any reference in these notes to applicable &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;guidance is meant to refer to the authoritative accounting principles generally accepted in the United States as found in the Accounting Standard Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Elicio Pty, ESC, and Former Elicio. All significant intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Since Former Elicio was determined to be the accounting acquirer in connection with the Merger, for periods prior to the Merger, the consolidated financial statements were prepared on a stand-alone basis for Former Elicio and did not include the combined entities activity or financial position. Subsequent to the Merger, the consolidated financial statements include the acquired business and assets and liabilities at their acquisition date fair value. Historical share and per share figures of Former Elicio have been retroactively restated to reflect the impact of the reverse stock split of Angion&#x2019;s common stock, par value $0.01 per share (&#x201c;Angion common stock&#x201d;), at a ratio of 10:1 (the &#x201c;Reverse Stock Split&#x201d;) completed in connection with and prior to the closing of the Merger, based on the exchange ratio of 0.0181 (the &#x201c;Exchange Ratio&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Financial Statement Reclassification&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Certain account balances from prior periods have been reclassified in these consolidated financial statements to conform to current period classifications. The warrant liability was reclassified from current to noncurrent liabilities. These reclassifications had no effect on the reported results of operations or financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the Chief Operating Decision Maker (&#x201c;CODM&#x201d;), or decision-making group, in deciding how to allocate resources and in assessing performance. The Chief Executive Officer serves as the CODM. The Company operates as a single operating and reportable segment, reflecting the integrated nature of the Company&#x2019;s business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company&#x2019;s management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could materially differ from those estimates. Significant estimates reflected in these consolidated financial statements include but are not limited to, the accrual of research and development expenses, the valuation of stock-based awards, the valuation of warrants, the valuation of embedded derivatives and convertible debt, the operating lease right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liability, and forecasts utilized in management&#x2019;s going concern assessment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Foreign Currency Translation and Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Australian Dollar (&#x201c;AUD&#x201d;) is the functional currency for Elicio Pty. Accordingly, nonmonetary assets and liabilities originally acquired or assumed in other currencies are recorded in AUD at the date they were acquired or assumed. As part of the consolidation process, the Elicio Pty results are translated from AUD into the reporting currency of US Dollars using average rates for profit and loss transactions and applicable spot rates for period-end balances. The effect of translating our functional currency into our reporting currency is reported separately in Accumulated Other Comprehensive Loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Concentrations of Credit Risk and Off-Balance Sheet Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash, cash equivalents, and restricted cash. At times, cash balances deposited at major financial banking institutions exceed the federally insured limit. The Company regularly monitors the financial condition of the institutions in which it has depository accounts and believes the risk of loss is minimal. The Company has not experienced any losses in such accounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Cash and cash equivalents are comprised of deposits at major financial banking institutions and highly liquid investments with an original maturity of three months or less at the date of purchase. As of December&#160;31, 2024 and 2023, the Company&#x2019;s cash equivalents were held in institutions in the United States and include deposits in a money market fund which were unrestricted as to withdrawal or use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Restricted cash consists of cash securing a collateral letter of credit issued in connection with the Company&#x2019;s research grant and facility operating lease. See Notes 6 and 11 for further discussion. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Fair Value Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company follows the guidance prescribed by ASC Topic 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, which establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The standard provides a consistent definition of fair value that focuses on an exit price which is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The standard establishes a three-level hierarchy for fair value measurements based on the nature of inputs used in the valuation of an asset or liability as of the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:76.5pt;text-align:justify;text-indent:-49.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Level 1:&#160;&#160;&#160;&#160;Observable inputs such as unadjusted quoted prices in active markets for identical assets or liabilities at measurement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:76.5pt;text-align:justify;text-indent:-49.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Level 2:&#160;&#160;&#160;&#160;Inputs (other than quoted prices included in Level 1) that are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:76.5pt;text-align:justify;text-indent:-49.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Level 3:&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The carrying amounts of financial instruments reflected in the consolidated balance sheets for cash and cash equivalents, current and non-current restricted cash, accounts payable, and accrued expenses approximate their respective fair values because of the short-term maturity of those financial assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of the asset. Upon sale or retirement, the cost and accumulated depreciation are eliminated from their respective accounts, and the resulting gain or loss is recorded in the consolidated statement of operations and comprehensive loss. Repair and maintenance expenditures are expensed as incurred. Construction in process is not depreciated until the asset is placed into service.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.668%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.386%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Asset Class&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Estimated Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Shorter of useful life or lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company evaluates its long-lived assets, which consist primarily of property and equipment, and right-of-use asset, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. During the years ended December&#160;31, 2024 and 2023, no impairments have occurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Debt Issuance Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;These deferred costs will be amortized and recognized as additional interest expense over the term of the Company&#x2019;s convertible note using the effective interest method. The Company will present debt issuance costs as a direct deduction from the convertible note liability on its financial statements. See Note 12 for further discussion of the Company&#x2019;s accounting for its outstanding debt and related issuance costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company accounts for income taxes in accordance with ASC Topic 740, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. Deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;and liabilities using enacted tax rates and laws in effect in the years in which the differences are expected to reverse. A valuation allowance is provided if, based upon the weighted available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company is required to recognize the financial statement effects of a tax position when it is more likely than not, based on the technical merits, the position will be sustained upon examination. As of December&#160;31, 2024, there were no accruals for interest or penalties related to uncertain tax provisions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Research and development costs are charged to expense as incurred and consist of expenses incurred in performing research and development activities, including salaries and benefits, materials and supplies, preclinical expenses, stock-based compensation expense, depreciation of equipment, contract services, and other outside expenses. The Company accrues for costs incurred by external service providers, based on estimates of services performed and costs. The Company expenses all research and development costs in the periods in which they are incurred. Costs for certain research and development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and service providers. Based on the timing of payments to service providers, the Company may also record prepaid expenses for those service providers that will be recognized as expenses in future periods as the related services are rendered. Research and development costs may be offset by research grants and research and development refundable tax rebates received by Elicio Pty.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;ASC Topic 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Leases,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; (&#x201c;ASC 842&#x201d;) requires a lessee to recognize a ROU asset and corresponding lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the consolidated statements of operations and comprehensive loss as well as the reduction of the ROU asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances, the existence of an identified asset(s), if any, and the Company&#x2019;s control over the use of the identified asset(s), if applicable. Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of future lease payments over the expected lease term. When the interest rate implicit in lease contracts is not readily determinable, the Company will utilize its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company has elected to combine lease and non-lease components as a single component. Operating leases are recognized on the consolidated balance sheet as ROU lease assets, current lease liabilities and non-current lease liabilities. Fixed rents are included in the calculation of the lease balances, while variable costs paid for certain operating and pass-through costs are excluded. Lease expense is recognized over the expected term on a straight-line basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Research Grant &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company analogizes to the guidance provided by International Accounting Standards 20, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Accounting for Government Grants and Disclosure of Government Assistance &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(&#x201c;IAS 20&#x201d;) for funds received from grants from entities that are not customers nor government agencies. The Company recognizes the amount of grant income based on the activity in allowable expenses covered under the grant and has elected to recognize the funds earned as an offset to the related research expenses recorded in operations. Advances from the grant that have yet to be recognized are recorded as restricted cash if the grant requires the funds to be isolated from general cash and cash equivalents. The Company records a liability for any research activity that is required under the grant but has not yet been performed. The liability is recorded as a deferred research obligation on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company issues stock-based awards to employees and non-employees, generally in the form of stock options. The Company accounts for stock-based awards in accordance with ASC 718,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt; Compensation&#x2014;Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, which requires all stock-based payments to be recognized in the consolidated statements of operations and comprehensive loss based on their fair values. The expense is recognized on a straight-line basis over the requisite service period, which is generally the vesting period. The Company has elected to account for option forfeitures as they occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company uses the Black-Scholes option-pricing model (&#x201c;Black-Scholes&#x201d;) to determine the fair value of options granted, which uses as inputs the fair value of the Company common stock, assumptions the Company &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;makes for the volatility of its Company common stock, the expected term of its stock options, the risk-free interest rate for a period that approximates the expected term of its stock options and its expected dividend yield. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Compensation cost of awards that contain a performance condition are recognized when success is considered probable during the performance period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Prior to the Merger, there was no public market for Former Elicio&#x2019;s common stock. The estimated fair value of the Company&#x2019;s common stock underlying Former Elicio&#x2019;s stock-based awards was determined by Former Elicio&#x2019;s board of directors as of the grant date of each option grant. To determine the fair value of Former Elicio&#x2019;s common stock underlying option grants, Former Elicio&#x2019;s board of directors considered, among other things, input from management and valuations of Former Elicio's common stock prepared by third-party valuation firms performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants' Accounting and Valuation Guide, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Valuation of Privately-Held-Company Equity Securities Issued as Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. Following the Merger, the fair value of the Company&#x2019;s common stock is based on the closing stock price on the date of grant as reported on the Nasdaq Capital Market.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Warrants and Derivatives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company&#x2019;s common stock warrants are evaluated pursuant to ASC 480, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Distinguishing Liabilities from Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; (&#x201c;ASC 480&#x201d;), and ASC 815, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Derivatives and Hedging&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; (&#x201c;ASC 815&#x201d;). The Company classifies its freestanding warrants as (i) liabilities, if the warrant terms allow settlement of the warrant exercise in cash, or (ii) equity, if the warrant terms only allow settlement in shares of common stock. Please refer to Note 9 below for the application to the Company&#x2019;s pre-funded and common warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Basic net loss per share of Company common stock is computed by dividing net loss attributable to Company common stockholders by the weighted average number of shares of Company common stock and pre-funded warrants outstanding for the period. Pre-funded warrants are considered outstanding for the purposes of computing basic and diluted net loss per share because shares may be issued for little or no additional consideration and are fully vested and exercisable after the original issuance date of the pre-funded warrants. Diluted net loss per share excludes the potential impact of Company common stock options, warrants and unvested shares of restricted stock because their effect would be anti-dilutive due to the Company's net loss. Since the Company had net losses for the years ended December&#160;31, 2024 and 2023, basic and diluted net loss per common share are the same.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Other Comprehensive Gain (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Other comprehensive gain (loss) is defined as a change in equity during a period from foreign exchange transactions and other events and circumstances from non-owner sources. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Recently Adopted Accounting Standards During the Period&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In November 2023, the FASB finalized ASU No. 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; (&#x201c;ASU 2023-07&#x201d;). ASU 2023-07 requires enhanced disclosures about reportable segments and the CODM. The new guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company adopted ASU 2023-07 on January 1, 2024. There was no impact on the Company's reportable segments identified and additional required disclosures have been included in Note 17.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Recently Issued Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Except as noted below, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its consolidated financial statements and disclosures. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In December 2023, the FASB issued ASU No. 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;This ASU requires disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation as well as additional information on income taxes paid. The standard requires entities to disclose federal, state, and foreign income taxes in their rate reconciliation tables and elaborate on reconciling items that exceed a quantitative threshold. Additionally, it requires an annual disclosure of income taxes paid, net of refunds, categorized by jurisdiction based on a quantitative threshold. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is permitted. This ASU will result in the required additional disclosures being included in the Company&#x2019;s consolidated financial statements, once adopted. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In November 2024, the FASB issued ASU No. 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;This ASU requires enhanced disclosures of disaggregated income statement expenses. Disclosure within the notes of the financial statements for each annual and interim period should include: employee compensation, depreciation, and intangible asset amortization, included in each relevant expense caption; certain amount that are already required to be disclosed under current GAAP in the same disclosure as the other disaggregation requirement; a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively; and the total amount of selling expenses and, in annual reporting periods, an entity&#x2019;s definition of selling expenses. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning December 15, 2027. Early adoption is permitted. The Company is currently evaluating the effect that adoption of ASU 2024-03 will have on its consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In November 2024, the FASB issued ASU No. 2024-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Debt &#x2013; Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. This new guidance clarifies the accounting treatment of whether the settlement of convertible debt should be accounted for as an induced conversion or extinguishment of convertible debt. This guidance is effective for annual reporting periods beginning after December 15, 2025. The Company is evaluating the potential impact of this adoption on the consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-387">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company's consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;). Any reference in these notes to applicable &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;guidance is meant to refer to the authoritative accounting principles generally accepted in the United States as found in the Accounting Standard Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-388">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Elicio Pty, ESC, and Former Elicio. All significant intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-53"
      decimals="INF"
      id="f-389"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <angn:RecapitalizationExchangeRatio
      contextRef="c-54"
      decimals="INF"
      id="f-390"
      unitRef="number">0.0181</angn:RecapitalizationExchangeRatio>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="c-1" id="f-391">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Financial Statement Reclassification&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Certain account balances from prior periods have been reclassified in these consolidated financial statements to conform to current period classifications. The warrant liability was reclassified from current to noncurrent liabilities. These reclassifications had no effect on the reported results of operations or financial position.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c-1" id="f-392">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the Chief Operating Decision Maker (&#x201c;CODM&#x201d;), or decision-making group, in deciding how to allocate resources and in assessing performance. The Chief Executive Officer serves as the CODM. The Company operates as a single operating and reportable segment, reflecting the integrated nature of the Company&#x2019;s business.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-393">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;The Company&#x2019;s management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could materially differ from those estimates. Significant estimates reflected in these consolidated financial statements include but are not limited to, the accrual of research and development expenses, the valuation of stock-based awards, the valuation of warrants, the valuation of embedded derivatives and convertible debt, the operating lease right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liability, and forecasts utilized in management&#x2019;s going concern assessment.</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c-1" id="f-394">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Foreign Currency Translation and Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Australian Dollar (&#x201c;AUD&#x201d;) is the functional currency for Elicio Pty. Accordingly, nonmonetary assets and liabilities originally acquired or assumed in other currencies are recorded in AUD at the date they were acquired or assumed. As part of the consolidation process, the Elicio Pty results are translated from AUD into the reporting currency of US Dollars using average rates for profit and loss transactions and applicable spot rates for period-end balances. The effect of translating our functional currency into our reporting currency is reported separately in Accumulated Other Comprehensive Loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-395">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Concentrations of Credit Risk and Off-Balance Sheet Risk&lt;/span&gt;&lt;/div&gt;Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash, cash equivalents, and restricted cash. At times, cash balances deposited at major financial banking institutions exceed the federally insured limit. The Company regularly monitors the financial condition of the institutions in which it has depository accounts and believes the risk of loss is minimal. The Company has not experienced any losses in such accounts.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="c-1" id="f-396">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Cash and cash equivalents are comprised of deposits at major financial banking institutions and highly liquid investments with an original maturity of three months or less at the date of purchase. As of December&#160;31, 2024 and 2023, the Company&#x2019;s cash equivalents were held in institutions in the United States and include deposits in a money market fund which were unrestricted as to withdrawal or use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;Restricted cash consists of cash securing a collateral letter of credit issued in connection with the Company&#x2019;s research grant and facility operating lease.</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c-1" id="f-397">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Fair Value Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company follows the guidance prescribed by ASC Topic 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, which establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The standard provides a consistent definition of fair value that focuses on an exit price which is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The standard establishes a three-level hierarchy for fair value measurements based on the nature of inputs used in the valuation of an asset or liability as of the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:76.5pt;text-align:justify;text-indent:-49.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Level 1:&#160;&#160;&#160;&#160;Observable inputs such as unadjusted quoted prices in active markets for identical assets or liabilities at measurement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:76.5pt;text-align:justify;text-indent:-49.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Level 2:&#160;&#160;&#160;&#160;Inputs (other than quoted prices included in Level 1) that are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:76.5pt;text-align:justify;text-indent:-49.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Level 3:&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The carrying amounts of financial instruments reflected in the consolidated balance sheets for cash and cash equivalents, current and non-current restricted cash, accounts payable, and accrued expenses approximate their respective fair values because of the short-term maturity of those financial assets and liabilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-398">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of the asset. Upon sale or retirement, the cost and accumulated depreciation are eliminated from their respective accounts, and the resulting gain or loss is recorded in the consolidated statement of operations and comprehensive loss. Repair and maintenance expenditures are expensed as incurred. Construction in process is not depreciated until the asset is placed into service.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.668%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.386%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Asset Class&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Estimated Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Shorter of useful life or lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-399">&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.668%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.386%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Asset Class&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Estimated Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Shorter of useful life or lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net was comprised of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.291%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total property and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1,552)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1,231)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-55" id="f-400">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-56" id="f-401">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c-1" id="f-402">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;The Company evaluates its long-lived assets, which consist primarily of property and equipment, and right-of-use asset, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-1" decimals="INF" id="f-403" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-6" decimals="INF" id="f-404" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:DebtPolicyTextBlock contextRef="c-1" id="f-405">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Debt Issuance Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;These deferred costs will be amortized and recognized as additional interest expense over the term of the Company&#x2019;s convertible note using the effective interest method. The Company will present debt issuance costs as a direct deduction from the convertible note liability on its financial statements. See Note 12 for further discussion of the Company&#x2019;s accounting for its outstanding debt and related issuance costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-406">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company accounts for income taxes in accordance with ASC Topic 740, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. Deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;and liabilities using enacted tax rates and laws in effect in the years in which the differences are expected to reverse. A valuation allowance is provided if, based upon the weighted available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company is required to recognize the financial statement effects of a tax position when it is more likely than not, based on the technical merits, the position will be sustained upon examination. As of December&#160;31, 2024, there were no accruals for interest or penalties related to uncertain tax provisions.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-407">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Research and development costs are charged to expense as incurred and consist of expenses incurred in performing research and development activities, including salaries and benefits, materials and supplies, preclinical expenses, stock-based compensation expense, depreciation of equipment, contract services, and other outside expenses. The Company accrues for costs incurred by external service providers, based on estimates of services performed and costs. The Company expenses all research and development costs in the periods in which they are incurred. Costs for certain research and development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and service providers. Based on the timing of payments to service providers, the Company may also record prepaid expenses for those service providers that will be recognized as expenses in future periods as the related services are rendered. Research and development costs may be offset by research grants and research and development refundable tax rebates received by Elicio Pty.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Research Grant &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company analogizes to the guidance provided by International Accounting Standards 20, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Accounting for Government Grants and Disclosure of Government Assistance &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(&#x201c;IAS 20&#x201d;) for funds received from grants from entities that are not customers nor government agencies. The Company recognizes the amount of grant income based on the activity in allowable expenses covered under the grant and has elected to recognize the funds earned as an offset to the related research expenses recorded in operations. Advances from the grant that have yet to be recognized are recorded as restricted cash if the grant requires the funds to be isolated from general cash and cash equivalents. The Company records a liability for any research activity that is required under the grant but has not yet been performed. The liability is recorded as a deferred research obligation on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-408">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;ASC Topic 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Leases,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; (&#x201c;ASC 842&#x201d;) requires a lessee to recognize a ROU asset and corresponding lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the consolidated statements of operations and comprehensive loss as well as the reduction of the ROU asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances, the existence of an identified asset(s), if any, and the Company&#x2019;s control over the use of the identified asset(s), if applicable. Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of future lease payments over the expected lease term. When the interest rate implicit in lease contracts is not readily determinable, the Company will utilize its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company has elected to combine lease and non-lease components as a single component. Operating leases are recognized on the consolidated balance sheet as ROU lease assets, current lease liabilities and non-current lease liabilities. Fixed rents are included in the calculation of the lease balances, while variable costs paid for certain operating and pass-through costs are excluded. Lease expense is recognized over the expected term on a straight-line basis.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-409">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company issues stock-based awards to employees and non-employees, generally in the form of stock options. The Company accounts for stock-based awards in accordance with ASC 718,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt; Compensation&#x2014;Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, which requires all stock-based payments to be recognized in the consolidated statements of operations and comprehensive loss based on their fair values. The expense is recognized on a straight-line basis over the requisite service period, which is generally the vesting period. The Company has elected to account for option forfeitures as they occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company uses the Black-Scholes option-pricing model (&#x201c;Black-Scholes&#x201d;) to determine the fair value of options granted, which uses as inputs the fair value of the Company common stock, assumptions the Company &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;makes for the volatility of its Company common stock, the expected term of its stock options, the risk-free interest rate for a period that approximates the expected term of its stock options and its expected dividend yield. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Compensation cost of awards that contain a performance condition are recognized when success is considered probable during the performance period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Prior to the Merger, there was no public market for Former Elicio&#x2019;s common stock. The estimated fair value of the Company&#x2019;s common stock underlying Former Elicio&#x2019;s stock-based awards was determined by Former Elicio&#x2019;s board of directors as of the grant date of each option grant. To determine the fair value of Former Elicio&#x2019;s common stock underlying option grants, Former Elicio&#x2019;s board of directors considered, among other things, input from management and valuations of Former Elicio's common stock prepared by third-party valuation firms performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants' Accounting and Valuation Guide, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Valuation of Privately-Held-Company Equity Securities Issued as Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. Following the Merger, the fair value of the Company&#x2019;s common stock is based on the closing stock price on the date of grant as reported on the Nasdaq Capital Market.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <angn:WarrantsAndDerivativesPolicyTextBlock contextRef="c-1" id="f-410">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Warrants and Derivatives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company&#x2019;s common stock warrants are evaluated pursuant to ASC 480, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Distinguishing Liabilities from Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; (&#x201c;ASC 480&#x201d;), and ASC 815, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Derivatives and Hedging&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; (&#x201c;ASC 815&#x201d;). The Company classifies its freestanding warrants as (i) liabilities, if the warrant terms allow settlement of the warrant exercise in cash, or (ii) equity, if the warrant terms only allow settlement in shares of common stock. Please refer to Note 9 below for the application to the Company&#x2019;s pre-funded and common warrants.&lt;/span&gt;&lt;/div&gt;</angn:WarrantsAndDerivativesPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-411">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Basic net loss per share of Company common stock is computed by dividing net loss attributable to Company common stockholders by the weighted average number of shares of Company common stock and pre-funded warrants outstanding for the period. Pre-funded warrants are considered outstanding for the purposes of computing basic and diluted net loss per share because shares may be issued for little or no additional consideration and are fully vested and exercisable after the original issuance date of the pre-funded warrants. Diluted net loss per share excludes the potential impact of Company common stock options, warrants and unvested shares of restricted stock because their effect would be anti-dilutive due to the Company's net loss. Since the Company had net losses for the years ended December&#160;31, 2024 and 2023, basic and diluted net loss per common share are the same.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c-1" id="f-412">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Other Comprehensive Gain (Loss)&lt;/span&gt;&lt;/div&gt;Other comprehensive gain (loss) is defined as a change in equity during a period from foreign exchange transactions and other events and circumstances from non-owner sources.</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-413">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Recently Adopted Accounting Standards During the Period&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In November 2023, the FASB finalized ASU No. 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; (&#x201c;ASU 2023-07&#x201d;). ASU 2023-07 requires enhanced disclosures about reportable segments and the CODM. The new guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company adopted ASU 2023-07 on January 1, 2024. There was no impact on the Company's reportable segments identified and additional required disclosures have been included in Note 17.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Recently Issued Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Except as noted below, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its consolidated financial statements and disclosures. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In December 2023, the FASB issued ASU No. 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;This ASU requires disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation as well as additional information on income taxes paid. The standard requires entities to disclose federal, state, and foreign income taxes in their rate reconciliation tables and elaborate on reconciling items that exceed a quantitative threshold. Additionally, it requires an annual disclosure of income taxes paid, net of refunds, categorized by jurisdiction based on a quantitative threshold. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is permitted. This ASU will result in the required additional disclosures being included in the Company&#x2019;s consolidated financial statements, once adopted. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In November 2024, the FASB issued ASU No. 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;This ASU requires enhanced disclosures of disaggregated income statement expenses. Disclosure within the notes of the financial statements for each annual and interim period should include: employee compensation, depreciation, and intangible asset amortization, included in each relevant expense caption; certain amount that are already required to be disclosed under current GAAP in the same disclosure as the other disaggregation requirement; a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively; and the total amount of selling expenses and, in annual reporting periods, an entity&#x2019;s definition of selling expenses. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning December 15, 2027. Early adoption is permitted. The Company is currently evaluating the effect that adoption of ASU 2024-03 will have on its consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In November 2024, the FASB issued ASU No. 2024-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Debt &#x2013; Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. This new guidance clarifies the accounting treatment of whether the settlement of convertible debt should be accounted for as an induced conversion or extinguishment of convertible debt. This guidance is effective for annual reporting periods beginning after December 15, 2025. The Company is evaluating the potential impact of this adoption on the consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <angn:ReverseRecapitalizationDisclosureTextBlock contextRef="c-1" id="f-415">Merger and Related Transactions&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As described in Note 1, Former Elicio merged with a wholly owned subsidiary of Angion on June 1, 2023. The Merger was accounted for as a reverse recapitalization under U.S. GAAP. Former Elicio was considered the accounting acquirer for financial reporting purposes. This determination was based on the facts that, immediately following the Merger: (i) Former Elicio stockholders owned a substantial majority of the voting rights; (ii) Former Elicio designated a majority (six of nine) of the initial members of the board of directors of the combined company; (iii) Former Elicio&#x2019;s executive management team became the management team of the combined company; and (iv) the Company was named Elicio Therapeutics, Inc. and is headquartered in Boston, Massachusetts. Accordingly, for accounting purposes, the Merger was treated as the equivalent of Former Elicio issuing stock to acquire the net assets of Angion. As a result of the Merger, the net assets of Angion were recorded at their acquisition-date fair value, which approximated book value due to the short-term nature of the instruments, in the financial statements of Former Elicio and the reported operating results prior to the Merger are those of Former Elicio. Historical common share amounts of Former Elicio have been retroactively restated based on the Exchange Ratio. It was concluded that any in-process research and development assets that remained as of the Merger would be &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;de minimis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; when compared to the cash and investments obtained through the Merger.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Prior to the effective time of the Merger, on June 1, 2023, in connection with the transactions contemplated by the Merger Agreement, the Company effected the Reverse Stock Split. At the effective time of the Merger, each outstanding share of Former Elicio capital stock (after giving effect to the automatic conversion of all shares of Former Elicio preferred stock into shares of Former Elicio common stock and excluding any shares held as treasury stock by Former Elicio or held or owned by Angion or any subsidiary of Angion or Former Elicio and any dissenting shares) was converted into the right to receive 0.0181 shares of Angion common stock, which resulted in the issuance by Angion of an aggregate of 5,375,751 shares of Angion common stock to the stockholders of Former Elicio (the &#x201c;Exchange Shares&#x201d;), and a total of 8,387,025 shares of the Company common stock being issued and outstanding immediately following the effective time of the Merger. In addition, Angion assumed the Former Elicio 2022 Equity Incentive Plan and the Former Elicio 2012 Equity Incentive Plan (the &#x201c;Former Elicio Plans&#x201d;) and each outstanding and unexercised option to purchase Former Elicio common stock and each outstanding and unexercised warrant to purchase Former Elicio capital stock were adjusted with such stock options and warrants henceforth representing the right to purchase a number of shares of the Company&#x2019;s common stock equal to the Exchange Ratio multiplied by the number of shares of Former Elicio common stock previously represented by such options, and warrants at an exercise price equal to the exercise price of Former Elicio capital stock divided by the Exchange Ratio.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In connection with the execution of the Merger Agreement, Angion made a bridge loan to Former Elicio pursuant to a note purchase agreement and promissory notes up to an aggregate principal amount of $12.5&#160;million, issued with a 20% original issue discount, with an initial closing held substantially concurrently with the execution of the Merger Agreement for a principal amount of $6.25&#160;million in exchange for cash of $5.0&#160;million and an additional closing for a principal amount of $6.25&#160;million in exchange for cash of $5.0&#160;million upon delivery by Former Elicio to Angion of Former Elicio&#x2019;s audited financial statements for the year ended December 31, 2022 (the &#x201c;Bridge Loan&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As part of the recapitalization, the Company obtained the assets and liabilities listed below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.315%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.463%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.708%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.529%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Promissory notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,438)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Per the terms of the Merger Agreement, upon completion of the Merger, all obligations owed by Former Elicio related to the Bridge Loan were automatically forgiven and the amount advanced by Angion, along with any accrued and unpaid interest, was credited towards the net cash balance used to calculate the assets and liabilities listed above. Upon settlement of the Bridge Loan, the Company recognized a gain of $0.6&#160;million related to the fair value of the embedded derivatives associated with the Bridge Loan. &lt;/span&gt;&lt;/div&gt;The Company recognized the net assets acquired, excluding the promissory notes and transaction costs of $2.9 million,</angn:ReverseRecapitalizationDisclosureTextBlock>
    <angn:NumberOfMembersOfTheBoardOfDirectors
      contextRef="c-58"
      decimals="INF"
      id="f-416"
      unitRef="board_member">6</angn:NumberOfMembersOfTheBoardOfDirectors>
    <angn:NumberOfMembersOfTheBoardOfDirectors
      contextRef="c-54"
      decimals="INF"
      id="f-417"
      unitRef="board_member">9</angn:NumberOfMembersOfTheBoardOfDirectors>
    <angn:RecapitalizationExchangeRatio
      contextRef="c-54"
      decimals="INF"
      id="f-418"
      unitRef="number">0.0181</angn:RecapitalizationExchangeRatio>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-59"
      decimals="INF"
      id="f-419"
      unitRef="shares">5375751</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-54"
      decimals="INF"
      id="f-420"
      unitRef="shares">8387025</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-54"
      decimals="INF"
      id="f-421"
      unitRef="shares">8387025</us-gaap:CommonStockSharesIssued>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-60" decimals="-5" id="f-422" unitRef="usd">12500000</us-gaap:DebtInstrumentFaceAmount>
    <angn:DebtInstrumentIssuanceDiscountPercent
      contextRef="c-60"
      decimals="INF"
      id="f-423"
      unitRef="number">0.20</angn:DebtInstrumentIssuanceDiscountPercent>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-61" decimals="-4" id="f-424" unitRef="usd">6250000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-62" decimals="-5" id="f-425" unitRef="usd">5000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-63" decimals="-4" id="f-426" unitRef="usd">6250000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-64" decimals="-5" id="f-427" unitRef="usd">5000000</us-gaap:DebtInstrumentFaceAmount>
    <angn:ScheduleOfReverseRecapitalizationTableTextBlock contextRef="c-1" id="f-428">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As part of the recapitalization, the Company obtained the assets and liabilities listed below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.315%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.463%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.708%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.529%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Promissory notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,438)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</angn:ScheduleOfReverseRecapitalizationTableTextBlock>
    <angn:CashAndCashEquivalentsAcquiredThroughReverseRecapitalization contextRef="c-54" decimals="-3" id="f-429" unitRef="usd">24001000</angn:CashAndCashEquivalentsAcquiredThroughReverseRecapitalization>
    <angn:OtherCurrentAssetsAcquiredThroughReverseRecapitalization contextRef="c-54" decimals="-3" id="f-430" unitRef="usd">540000</angn:OtherCurrentAssetsAcquiredThroughReverseRecapitalization>
    <angn:PromissoryNotesAcquiredThroughReverseRecapitalization contextRef="c-54" decimals="-3" id="f-431" unitRef="usd">10027000</angn:PromissoryNotesAcquiredThroughReverseRecapitalization>
    <angn:AccruedLiabilitiesAssumedThroughReverseRecapitalization contextRef="c-54" decimals="-3" id="f-432" unitRef="usd">2438000</angn:AccruedLiabilitiesAssumedThroughReverseRecapitalization>
    <angn:NetAssetsAcquiredThroughReverseRecapitalization contextRef="c-54" decimals="-3" id="f-433" unitRef="usd">32130000</angn:NetAssetsAcquiredThroughReverseRecapitalization>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-50" decimals="-5" id="f-434" unitRef="usd">600000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <angn:ReverseRecapitalizationTransactionCosts contextRef="c-1" decimals="-5" id="f-435" unitRef="usd">2900000</angn:ReverseRecapitalizationTransactionCosts>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-437">Fair Value Measurements&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following tables present the Company's financial assets and liabilities measured at fair value on a recurring basis and their assigned levels within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.268%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.642%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Money market funds &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;12,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;12,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;12,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;12,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.268%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.642%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Money market funds &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;___________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1) Included in cash, cash equivalents, and restricted cash on the consolidated balance sheets. This balance includes cash requirements settled on a nightly basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Cash equivalents at December&#160;31, 2024 and 2023 were held in U.S. Treasury securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;There were no transfers made among the three levels in the fair value hierarchy during the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As part of the Merger transaction, Former Elicio assumed Angion&#x2019;s warrant liabilities. The fair value of the assumed Angion warrants was classified as Level 3 with key Level 3 inputs of exercise price, term, and volatility. The following table presents a summary of changes in Level 3 in the fair value of the Company&#x2019;s common stock warrant liability (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.346%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Balance, beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Existing Angion warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Balance, end of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with assets and liabilities within the Level 3 category include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long-dated volatilities) inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The fair value of the Angion warrants assumed by the Company has been estimated using a Black-Scholes option pricing model. The underlying equity included in Black-Scholes was valued based on the equity value implied from sales of preferred and common stock at each measurement date, as applicable. The fair value of the warrants was impacted by the model selected as well as assumptions surrounding unobservable inputs including the underlying equity value, expected volatility of the underlying equity, risk free interest rate, and the expected term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In March 2024, the Company entered into a subscription agreement (the &#x201c;March Subscription Agreement&#x201d;) with GKCC, LLC (&#x201c;GKCC&#x201d;), an entity controlled by a member of the Company&#x2019;s board of directors, providing for the issuance and sale by the Company to GKCC of pre-funded warrants (the &#x201c;Pre-Funded Warrants&#x201d;) to purchase up to 1,032,702 shares of the Company&#x2019;s common stock, at a purchase price per Pre-Funded Warrant of $5.81 (the &#x201c;March Offering&#x201d;). The Company identified these warrants as liabilities and measured them at fair value on March 19, 2024, and subsequently remeasures the fair value of these warrant liabilities on a quarterly basis. The Company is able to calculate the fair value measurement based on directly observable inputs for the asset from active markets, therefore these warrants are classified as Level 2. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In July 2024, the Company closed an underwritten public offering (the &#x201c;Public Offering&#x201d;), which resulted in net proceeds of $10.9&#160;million to the Company, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The Public Offering consisted of (i) 500,000 shares of the Company&#x2019;s common stock (the &#x201c;July Shares&#x201d;) and (ii) 1,800,000 pre-funded warrants exercisable for shares of common stock (the &#x201c;July Pre-Funded Warrants&#x201d;), together with common warrants (the &#x201c;July Common Warrants&#x201d;) to purchase up to 2,300,000 shares of common stock. Each July Share and accompanying July Common Warrant were sold together at a combined offering price of $5.00 per July Share and accompanying July Common Warrant, and each July Pre-Funded Warrant and accompanying July Common Warrant were sold together at a combined offering price of $4.99 per July Pre-Funded Warrant and accompanying July Common Warrant, which represented the combined purchase price per July Pre-Funded Warrant and accompanying July Common Warrant less the $0.01 per share exercise price for each such July Pre-Funded Warrant. The July Common Warrants have an exercise price of $5.00 per share, are immediately exercisable and will expire five years from the issuance date. The Company identified these warrants as liabilities and measured them at fair value on July 1, 2024, and subsequently remeasures the fair value of these warrant liabilities on a quarterly basis. The Company is able to calculate the fair value measurement based on directly observable inputs for the asset from active markets, therefore these warrants are classified as Level 2.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;At the Company&#x2019;s Annual Shareholder&#x2019;s Meeting in November 2024, the Company obtained stockholder approval for a shareholder, together with its affiliates, to exceed the 19.99% beneficial ownership limitation pursuant to the rules and regulations of the Nasdaq Stock Market LLC (&#x201c;Stockholder Approval&#x201d;). As such, the Company remeasured the July Common Warrants held by that shareholder at fair value and recognized the loss from change in fair value on the consolidated financial statements during the year ended December 31, 2024. As a result of obtaining Stockholder Approval, the Common Warrants held by that shareholder met the equity classification requirements under ASC 815. During the quarter ended December 31, 2024, the Company reclassified the July Common Warrants held by the stockholder from a liability to equity. The Company will re-assess the liability classification for the remaining July Common Warrants at each period end.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company records the change in the fair value of common stock warrants in change in fair value of warrant liability in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The fair value of the assumed Angion common stock warrant liability was estimated using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.274%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Weighted average strike price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;76.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;76.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contractual term (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Volatility (annual)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;74.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;94.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Risk-free rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Dividend yield (per share)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-438">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following tables present the Company's financial assets and liabilities measured at fair value on a recurring basis and their assigned levels within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.268%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.642%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Money market funds &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;12,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;12,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;12,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;12,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.268%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.642%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Money market funds &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;___________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1) Included in cash, cash equivalents, and restricted cash on the consolidated balance sheets. This balance includes cash requirements settled on a nightly basis.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-65" decimals="-3" id="f-439" unitRef="usd">12100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-66" decimals="-3" id="f-440" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-67" decimals="-3" id="f-441" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-68" decimals="-3" id="f-442" unitRef="usd">12100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-65" decimals="-3" id="f-443" unitRef="usd">12100000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-66" decimals="-3" id="f-444" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-67" decimals="-3" id="f-445" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-68" decimals="-3" id="f-446" unitRef="usd">12100000</us-gaap:AssetsFairValueDisclosure>
    <angn:WarrantsFairValueDisclosure contextRef="c-65" decimals="-3" id="f-447" unitRef="usd">0</angn:WarrantsFairValueDisclosure>
    <angn:WarrantsFairValueDisclosure contextRef="c-66" decimals="-3" id="f-448" unitRef="usd">2827000</angn:WarrantsFairValueDisclosure>
    <angn:WarrantsFairValueDisclosure contextRef="c-67" decimals="-3" id="f-449" unitRef="usd">1000</angn:WarrantsFairValueDisclosure>
    <angn:WarrantsFairValueDisclosure contextRef="c-68" decimals="-3" id="f-450" unitRef="usd">2828000</angn:WarrantsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-65" decimals="-3" id="f-451" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-66" decimals="-3" id="f-452" unitRef="usd">2827000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-67" decimals="-3" id="f-453" unitRef="usd">1000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-68" decimals="-3" id="f-454" unitRef="usd">2828000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-69" decimals="-3" id="f-455" unitRef="usd">5973000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-70" decimals="-3" id="f-456" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-71" decimals="-3" id="f-457" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-72" decimals="-3" id="f-458" unitRef="usd">5973000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-69" decimals="-3" id="f-459" unitRef="usd">5973000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-70" decimals="-3" id="f-460" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-71" decimals="-3" id="f-461" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-72" decimals="-3" id="f-462" unitRef="usd">5973000</us-gaap:AssetsFairValueDisclosure>
    <angn:WarrantsFairValueDisclosure contextRef="c-69" decimals="-3" id="f-463" unitRef="usd">0</angn:WarrantsFairValueDisclosure>
    <angn:WarrantsFairValueDisclosure contextRef="c-70" decimals="-3" id="f-464" unitRef="usd">0</angn:WarrantsFairValueDisclosure>
    <angn:WarrantsFairValueDisclosure contextRef="c-71" decimals="-3" id="f-465" unitRef="usd">11000</angn:WarrantsFairValueDisclosure>
    <angn:WarrantsFairValueDisclosure contextRef="c-72" decimals="-3" id="f-466" unitRef="usd">11000</angn:WarrantsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-69" decimals="-3" id="f-467" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-70" decimals="-3" id="f-468" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-71" decimals="-3" id="f-469" unitRef="usd">11000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-72" decimals="-3" id="f-470" unitRef="usd">11000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c-1" id="f-471">The following table presents a summary of changes in Level 3 in the fair value of the Company&#x2019;s common stock warrant liability (in thousands):&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.346%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Balance, beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Existing Angion warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Balance, end of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-73" decimals="-3" id="f-472" unitRef="usd">11000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-74" decimals="-3" id="f-473" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues contextRef="c-75" decimals="-3" id="f-474" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues contextRef="c-76" decimals="-3" id="f-475" unitRef="usd">9000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-75" decimals="-3" id="f-476" unitRef="usd">-10000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-76" decimals="-3" id="f-477" unitRef="usd">2000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-77" decimals="-3" id="f-478" unitRef="usd">1000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-73" decimals="-3" id="f-479" unitRef="usd">11000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-78"
      decimals="INF"
      id="f-480"
      unitRef="shares">1032702</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-78"
      decimals="2"
      id="f-481"
      unitRef="usdPerShare">5.81</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-79" decimals="-5" id="f-482" unitRef="usd">10900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-79" decimals="0" id="f-483" unitRef="shares">500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c-80" decimals="0" id="f-484" unitRef="shares">1800000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c-81" decimals="0" id="f-485" unitRef="shares">2300000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c-82"
      decimals="2"
      id="f-486"
      unitRef="usdPerShare">5.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c-81"
      decimals="2"
      id="f-487"
      unitRef="usdPerShare">4.99</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-80"
      decimals="2"
      id="f-488"
      unitRef="usdPerShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-83"
      decimals="2"
      id="f-489"
      unitRef="usdPerShare">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-83" id="f-490">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <angn:SaleOfStockBeneficialOwnershipLimitationPercentage contextRef="c-4" decimals="4" id="f-491" unitRef="number">0.1999</angn:SaleOfStockBeneficialOwnershipLimitationPercentage>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="c-1" id="f-492">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The fair value of the assumed Angion common stock warrant liability was estimated using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.274%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Weighted average strike price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;76.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;76.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contractual term (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Volatility (annual)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;74.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;94.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Risk-free rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Dividend yield (per share)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-84"
      decimals="2"
      id="f-493"
      unitRef="usdPerShare">76.00</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-85"
      decimals="2"
      id="f-494"
      unitRef="usdPerShare">76.00</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-86" id="f-495">P3Y8M12D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-87" id="f-496">P4Y8M12D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-88" decimals="3" id="f-497" unitRef="number">0.749</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-89" decimals="3" id="f-498" unitRef="number">0.940</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-90" decimals="3" id="f-499" unitRef="number">0.044</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-91" decimals="3" id="f-500" unitRef="number">0.039</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-92" decimals="3" id="f-501" unitRef="number">0.000</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-93" decimals="3" id="f-502" unitRef="number">0.000</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="c-1" id="f-503">Balance Sheet Components&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Prepaid and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; Prepaid and other current assets consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.291%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Prepaid research and development contract services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Advanced professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total prepaid and other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net was comprised of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.291%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total property and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1,552)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1,231)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Depreciation expense for the years ended December&#160;31, 2024 and 2023 was $0.3 million and $0.4 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Other long-term prepaid assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Other long-term prepaid assets consisted of the advance payments for clinical trial services, totaling $0.6 million and $2.8 million as of December&#160;31, 2024 and December&#160;31, 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Accrued Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.876%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accrued professional fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accrued research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other accrued expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;8,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="c-1" id="f-504">Prepaid and other current assets consisted of the following (in thousands):&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.291%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Prepaid research and development contract services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Advanced professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total prepaid and other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <angn:PrepaidResearchAndDevelopmentExpenses contextRef="c-4" decimals="-3" id="f-505" unitRef="usd">1206000</angn:PrepaidResearchAndDevelopmentExpenses>
    <angn:PrepaidResearchAndDevelopmentExpenses contextRef="c-5" decimals="-3" id="f-506" unitRef="usd">1883000</angn:PrepaidResearchAndDevelopmentExpenses>
    <angn:AdvancedProfessionalFees contextRef="c-4" decimals="-3" id="f-507" unitRef="usd">243000</angn:AdvancedProfessionalFees>
    <angn:AdvancedProfessionalFees contextRef="c-5" decimals="-3" id="f-508" unitRef="usd">300000</angn:AdvancedProfessionalFees>
    <us-gaap:PrepaidInsurance contextRef="c-4" decimals="-3" id="f-509" unitRef="usd">347000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance contextRef="c-5" decimals="-3" id="f-510" unitRef="usd">376000</us-gaap:PrepaidInsurance>
    <angn:OtherPrepaidExpensesAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-511" unitRef="usd">101000</angn:OtherPrepaidExpensesAndOtherAssetsCurrent>
    <angn:OtherPrepaidExpensesAndOtherAssetsCurrent contextRef="c-5" decimals="-3" id="f-512" unitRef="usd">173000</angn:OtherPrepaidExpensesAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-513" unitRef="usd">1897000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-5" decimals="-3" id="f-514" unitRef="usd">2732000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-55" decimals="-3" id="f-515" unitRef="usd">1661000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-94" decimals="-3" id="f-516" unitRef="usd">1574000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-56" decimals="-3" id="f-517" unitRef="usd">242000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-95" decimals="-3" id="f-518" unitRef="usd">242000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-96" decimals="-3" id="f-519" unitRef="usd">132000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-97" decimals="-3" id="f-520" unitRef="usd">132000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-4" decimals="-3" id="f-521" unitRef="usd">2035000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-5" decimals="-3" id="f-522" unitRef="usd">1948000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-523" unitRef="usd">1552000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-524" unitRef="usd">1231000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-525" unitRef="usd">483000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-3" id="f-526" unitRef="usd">717000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c-1" decimals="-5" id="f-527" unitRef="usd">300000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-6" decimals="-5" id="f-528" unitRef="usd">400000</us-gaap:Depreciation>
    <us-gaap:PrepaidExpenseOtherNoncurrent contextRef="c-4" decimals="-5" id="f-529" unitRef="usd">600000</us-gaap:PrepaidExpenseOtherNoncurrent>
    <us-gaap:PrepaidExpenseOtherNoncurrent contextRef="c-5" decimals="-5" id="f-530" unitRef="usd">2800000</us-gaap:PrepaidExpenseOtherNoncurrent>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-531">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.876%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accrued professional fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accrued research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other accrued expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;8,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-4" decimals="-3" id="f-532" unitRef="usd">1167000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-5" decimals="-3" id="f-533" unitRef="usd">945000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-534" unitRef="usd">2312000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-535" unitRef="usd">1849000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <angn:AccruedResearchAndDevelopmentCurrent contextRef="c-4" decimals="-3" id="f-536" unitRef="usd">4910000</angn:AccruedResearchAndDevelopmentCurrent>
    <angn:AccruedResearchAndDevelopmentCurrent contextRef="c-5" decimals="-3" id="f-537" unitRef="usd">912000</angn:AccruedResearchAndDevelopmentCurrent>
    <angn:AccruedOtherOperatingLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-538" unitRef="usd">26000</angn:AccruedOtherOperatingLiabilitiesCurrent>
    <angn:AccruedOtherOperatingLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-539" unitRef="usd">51000</angn:AccruedOtherOperatingLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-540" unitRef="usd">8415000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-541" unitRef="usd">3757000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock contextRef="c-1" id="f-542">Research Grant&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In September 2022, Former Elicio entered into a grant agreement with the Gastro-Intestinal (&#x201c;GI&#x201d;) Research Foundation, a not-for-profit organization focused on supporting research to treat, cure, and prevent digestive diseases. Of the $2.8 million award, $2.3&#160;million was received in September 2022 and the remaining $0.5&#160;million was received in June 2023 with the completion of the development efforts as defined in the grant agreement. The final $0.5&#160;million payment was applied as a credit to the second grant agreement described below. For the years ended December&#160;31, 2024 and 2023, the Company incurred $0 and $1.9 million, respectively, in research and development expenses related to this project. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In September 2023, the Company entered into a second grant agreement with the GI Research Foundation for $3.1 million, with such amount received net of the $0.5&#160;million credit, described above. As of the years ended December&#160;31, 2024 and 2023, the Company incurred $2.2 million and $1.9 million, respectively, in research and development expenses related to this project. As of December&#160;31, 2024, the grant funds available for the second grant agreement were $0 and the deferred research obligation was $0, as the grant agreement was completed in the third quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In August 2024, the Company entered into a third grant agreement with the GI Research Foundation for $1.5 million. The grant funds available as of December&#160;31, 2024 were $1.2 million, which are reflected in restricted cash in the accompanying consolidated balance sheets. The deferred research obligation as of December&#160;31, 2024&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; was &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$1.2 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, which was reflected in the deferred research obligation in the accompanying consolidated balance sheets. For the year ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, the Company incurred &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$0.3 million in research and development expenses related to this project, of which&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$0.3 million was applied against the grant funds received. &lt;/span&gt;&lt;/div&gt;The award money for the three agreements was earned and recognized as a contra research and development expense as the expenses were incurred.</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <angn:ResearchAndDevelopmentArrangementGrant contextRef="c-98" decimals="-5" id="f-543" unitRef="usd">2800000</angn:ResearchAndDevelopmentArrangementGrant>
    <angn:ResearchAndDevelopmentArrangementGrantReceived contextRef="c-98" decimals="-5" id="f-544" unitRef="usd">2300000</angn:ResearchAndDevelopmentArrangementGrantReceived>
    <angn:ResearchAndDevelopmentArrangementGrantReceived contextRef="c-99" decimals="-5" id="f-545" unitRef="usd">500000</angn:ResearchAndDevelopmentArrangementGrantReceived>
    <angn:ResearchAndDevelopmentArrangementGrantReceived contextRef="c-99" decimals="-5" id="f-546" unitRef="usd">500000</angn:ResearchAndDevelopmentArrangementGrantReceived>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-100" decimals="-3" id="f-547" unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-101" decimals="-5" id="f-548" unitRef="usd">1900000</us-gaap:ResearchAndDevelopmentExpense>
    <angn:ResearchAndDevelopmentArrangementGrant contextRef="c-102" decimals="-5" id="f-549" unitRef="usd">3100000</angn:ResearchAndDevelopmentArrangementGrant>
    <angn:ResearchAndDevelopmentArrangementCredit contextRef="c-102" decimals="-5" id="f-550" unitRef="usd">500000</angn:ResearchAndDevelopmentArrangementCredit>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-103" decimals="-5" id="f-551" unitRef="usd">2200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-104" decimals="-5" id="f-552" unitRef="usd">1900000</us-gaap:ResearchAndDevelopmentExpense>
    <angn:ResearchAndDevelopmentArrangementGrantReceived contextRef="c-105" decimals="0" id="f-553" unitRef="usd">0</angn:ResearchAndDevelopmentArrangementGrantReceived>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-105" decimals="0" id="f-554" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <angn:ResearchAndDevelopmentArrangementGrant contextRef="c-106" decimals="-5" id="f-555" unitRef="usd">1500000</angn:ResearchAndDevelopmentArrangementGrant>
    <us-gaap:RestrictedCashCurrent contextRef="c-107" decimals="-5" id="f-556" unitRef="usd">1200000</us-gaap:RestrictedCashCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-107" decimals="-5" id="f-557" unitRef="usd">1200000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-108" decimals="-5" id="f-558" unitRef="usd">300000</us-gaap:ResearchAndDevelopmentExpense>
    <angn:ResearchAndDevelopmentArrangementReimbursementFromGrantFunds contextRef="c-108" decimals="-5" id="f-559" unitRef="usd">300000</angn:ResearchAndDevelopmentArrangementReimbursementFromGrantFunds>
    <angn:NumberOfResearchGrantAgreements
      contextRef="c-4"
      decimals="INF"
      id="f-560"
      unitRef="agreement">3</angn:NumberOfResearchGrantAgreements>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-561">Convertible Preferred Stock, Common Stock and Stockholders' Equity&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Authorized Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company's current Amended and Restated Certificate of Incorporation, as amended, authorizes 300,000,000 shares of common stock, par value $0.01 per share, and 10,000,000 shares of preferred stock, par value $0.01 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Convertible Preferred Stock of Former Elicio&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Former Elicio&#x2019;s convertible preferred stock consisted of Series A preferred stock (&#x201c;Series A Preferred Shares&#x201d;), Series B preferred stock (&#x201c;Series B Preferred Shares&#x201d;) and Series C preferred stock (&#x201c;Series C Preferred Shares&#x201d; and collectively with the Series A Preferred Shares and the Series B Preferred Shares, the &#x201c;Convertible Preferred Stock&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Conversion of Convertible Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On June 1, 2023, Former Elicio completed the Merger with Angion in accordance with the Merger Agreement. Under the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each share of Former Elicio&#x2019;s Convertible Preferred Stock was converted into a share of Former Elicio&#x2019;s common stock. At the closing of the Merger, the Company issued an aggregate of 5,375,751 shares of its common stock to Former Elicio &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;stockholders, based on the Exchange Ratio. No shares of Convertible Preferred Stock were issued during the years ended December&#160;31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As a result of the Merger, the aggregate amount of 276,128,177 shares of Convertible Preferred Stock (retroactively restated for the reverse recapitalization as described in Note 3) were converted &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;int&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;o 4,997,920 &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;shares of Former Elicio's common stock to be exchanged for the same number of shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;At-The-Market Equity Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In May 2022, the Company filed a registration statement on Form S-3 (the &#x201c;Prior Shelf Registration St&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;atement&#x201d;) with the SEC that registered the offering, issuance, and sale of an amount of common stock, preferred stock, debt securities, and warrants to purchase common stock, preferred stock and/or debt securities, not to exceed an aggregate initial offering price of $100 million. Simultaneously, the Company entered into an At-the-Market Equity Offering Sales Agreement with Stifel, Nicolaus &amp;amp; Company, Incorporated and Virtu Americas LLC, as sales agents, pursuant to which the Company was able to offer, issue or sell shares of its common stock having an aggregate offering price of up to $21 million from time to time in &#x201c;at-the-market&#x201d; offerings under the Prior Shelf Registration Statement and related prospectus filed with the Prior Shelf Registration Statement (the &#x201c;2022 ATM Program"). During the year ended December&#160;31, 2024, the Company issued and sold a total of 650,179 shares of common stock under the 2022 ATM Program for aggregate net sale proceeds of approximately $5.4 million after deducting sales commissions. No sales were made under the 2022 ATM Program during the year ended December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In May 2024, the 2022 ATM Program was terminated by the Company. In June 2024, the Company filed a registration statement on Form S-3 (the &#x201c;2024 Registration Statement&#x201d;) with the SEC that registered the offering, issuance, and sale of an amount of common stock, preferred stock, debt securities, warrants to purchase common stock, preferred stock and/or debt securities, and/or units consisting of any combination of such securities, not to exceed an aggregate initial offering price of $200&#160;million. Simultaneously, the Company entered into the Capital on Demand&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; Sales Agreement with JonesTrading Institutional Services, LLC, as agent, to provide for the issuance and sale of up to $40&#160;million of common stock from time to time in &#x201c;at-the-market&#x201d; offerings under the 2024 Registration Statement and related prospectus filed with the 2024 Registration Statement (the &#x201c;2024 ATM Program&#x201d;). During the year ended December&#160;31, 2024, the Company issued and sold 53,795 shares of common stock, for net proceeds of $0.3 million, under the 2024 ATM Program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Private Placement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In March 2024, the Company entered into the March Subscription Agreement with GKCC, an entity controlled by a member of the Company&#x2019;s board of directors, for purposes of the March Offering. Each Pre-Funded Warrant issued and sold in the March Offering is exercisable at an exercise price equal to $0.01 per share, subject to certain adjustments and limitations as provided under the terms of the Pre-Funded Warrants. The Pre-Funded Warrants were classified as a liability at issuance due to the need for the Company to obtain stockholder approval to settle the instruments in shares in an amount exceeding the 19.99% beneficial ownership limit. Such stockholder approval was obtained in November 2024. See Note 16 - Related Party Transactions for a discussion of the March Offering.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Public Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In July 2024, the Company closed its Public Offering, which resulted in net proceeds of $10.9&#160;million to the Company, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The Public Offering consisted of (i) the July Shares, together with the July Common Warrants, and (ii) the July Pre-Funded Warrants, together with the July Common Warrants. Each July Share and accompanying July Common Warrant were sold together at a combined offering price of $5.00 per July Share and accompanying July Common Warrant, and each July Pre-Funded Warrant and accompanying July Common Warrant were sold together at a combined offering price of $4.99 per July Pre-Funded Warrant and accompanying July Common Warrant, which represented the combined purchase price per July Pre-Funded Warrant and accompanying July Common Warrant less the $0.01 per share exercise price for each such July Pre-Funded Warrant. &lt;/span&gt;&lt;/div&gt;The July Common Warrants have an exercise price of $5.00 per share, are immediately exercisable and will expire five years from the issuance date. Refer to Note 16 &#x2014; Related Party Transactions, of our consolidated financial statements for additional information.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-562" unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-563"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-564" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-565"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-59"
      decimals="INF"
      id="f-566"
      unitRef="shares">5375751</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <angn:TemporaryEquitySharesIssuedDuringPeriod
      contextRef="c-109"
      decimals="INF"
      id="f-567"
      unitRef="shares">0</angn:TemporaryEquitySharesIssuedDuringPeriod>
    <angn:TemporaryEquitySharesIssuedDuringPeriod
      contextRef="c-110"
      decimals="INF"
      id="f-568"
      unitRef="shares">0</angn:TemporaryEquitySharesIssuedDuringPeriod>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-111"
      decimals="INF"
      id="f-569"
      unitRef="shares">276128177</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-112"
      decimals="INF"
      id="f-570"
      unitRef="shares">4997920</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <angn:SaleOfStockAggregateInitialOfferingPrice contextRef="c-113" decimals="-6" id="f-571" unitRef="usd">100000000</angn:SaleOfStockAggregateInitialOfferingPrice>
    <angn:SaleOfStockAggregateInitialOfferingPrice contextRef="c-114" decimals="-6" id="f-572" unitRef="usd">21000000</angn:SaleOfStockAggregateInitialOfferingPrice>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c-115" decimals="0" id="f-573" unitRef="shares">650179</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-115" decimals="-5" id="f-574" unitRef="usd">5400000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-116"
      decimals="INF"
      id="f-575"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <angn:SaleOfStockAggregateInitialOfferingPrice contextRef="c-117" decimals="-6" id="f-576" unitRef="usd">200000000</angn:SaleOfStockAggregateInitialOfferingPrice>
    <angn:SaleOfStockAggregateInitialOfferingPrice contextRef="c-118" decimals="-6" id="f-577" unitRef="usd">40000000</angn:SaleOfStockAggregateInitialOfferingPrice>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c-119" decimals="0" id="f-578" unitRef="shares">53795</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-119" decimals="-5" id="f-579" unitRef="usd">300000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-120"
      decimals="2"
      id="f-580"
      unitRef="usdPerShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <angn:SaleOfStockBeneficialOwnershipLimitationPercentage contextRef="c-78" decimals="4" id="f-581" unitRef="number">0.1999</angn:SaleOfStockBeneficialOwnershipLimitationPercentage>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-79" decimals="-5" id="f-582" unitRef="usd">10900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c-82"
      decimals="2"
      id="f-583"
      unitRef="usdPerShare">5.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c-81"
      decimals="2"
      id="f-584"
      unitRef="usdPerShare">4.99</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-80"
      decimals="2"
      id="f-585"
      unitRef="usdPerShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-83"
      decimals="2"
      id="f-586"
      unitRef="usdPerShare">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-83" id="f-587">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-588">Stock-Based Compensation&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;2012 Plan and 2022 Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Pursuant to the Merger Agreement, the Company assumed the Former Elicio Plans and all stock options issued and outstanding under the Former Elicio Plans. Each outstanding and unexercised option to purchase Former Elicio common stock was adjusted with such Company stock options henceforth representing the right to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;purchase a number of shares of the Company&#x2019;s common stock based on the Exchange Ratio. Any restriction on the exercise of any Former Elicio stock options assumed by the Company continued in full force and effect and the term, exercisability, vesting schedule, accelerated vesting provisions, and any other provisions of such Former Elicio stock options otherwise remained unchanged.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;2015 Plan &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In June 2019, Angion approved an Amended and Restated 2015 Equity Incentive Plan (the &#x201c;2015 Plan&#x201d;) permitting the granting of incentive stock options, non-statutory stock options, restricted stock and other stock-based awards. Following the effectiveness of the 2021 Incentive Award Plan (&#x201c;2021 Plan&#x201d;), Angion ceased making grants under the 2015 Plan. However, the 2015 Plan continues to govern the terms and conditions of the outstanding awards granted under it. Shares of common stock subject to awards granted under the 2015 Plan that cease to be subject to such awards by forfeiture or otherwise after the termination of the 2015 Plan will be available for issuance under the 2021 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;2021 Plan and Amendment to 2021 Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In January 2021, Angion&#x2019;s board of directors approved the 2021 Plan which permits the granting of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards to employees, directors, officers and consultants. The 2021 Plan provides that the number of shares reserved and available for issuance will automatically increase each January 1st by the lesser of 5% of the Company&#x2019;s common stock outstanding on the immediately preceding December 31st, or such lesser number of shares as determined by the Company&#x2019;s board of directors. In March 2023, Angion&#x2019;s board of directors approved an amendment to the 2021 Plan to increase the cumulative number of shares of common stock reserved for issuance thereunder by 30,113 shares. The Company has a policy of issuing shares out of respective plan pools (to the extent available) to satisfy share option exercises and restricted stock vesting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As of December&#160;31, 2024, 298,795 shares and 175,283 shares remain available for future grants under the 2021 Plan and Former Elicio 2022 Equity Incentive Plan, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;2024 Inducement Incentive Award Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In February 2024, the Company&#x2019;s board of directors approved the Company&#x2019;s 2024 Inducement Incentive Award Plan (the &#x201c;2024 Inducement Plan&#x201d;) which permits the granting of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock-based awards to employees as an inducement pursuant to Listing Rule 5635(c)(4) of the corporate governance rules of the Nasdaq Stock Market, LLC. The 2024 Inducement Plan provides for an overall share limit of 500,000 shares of the Company&#x2019;s common stock. As of December&#160;31, 2024, 387,332 shares remain available for future grants under the 2024 Inducement Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table summarizes information and activity related to the Company&#x2019;s stock options:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.268%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%"&gt;Number of &lt;br/&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%"&gt;Weighted Average &lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%"&gt;Weighted Average &lt;br/&gt;Remaining Contractual Life &lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%"&gt;Total &lt;br/&gt;Intrinsic Value &lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,305,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;21.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7.43&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;798,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(9,757)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Forfeited (unvested)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(204,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Outstanding as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,890,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;15.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6.78&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;860,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.78&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The aggregate intrinsic value in the above table is calculated as the difference between the estimated fair value of the Company's common stock price and the exercise price of the stock options. 798,934 stock options were granted during the year ended December&#160;31, 2024. The weighted average grant date fair value per share for the stock option grants during the year ended December&#160;31, 2024 was $3.59. As of December&#160;31, 2024, the total unrecognized compensation expense related to unvested stock option awards granted was $3.1 million, which the Company expects to recognize over a weighted-average period of approximately 2.2 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Stock-based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table summarizes total stock-based compensation expense recorded in the consolidated statements of operations (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.876%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The fair value of each option is estimated on the date of grant using a Black-Scholes option pricing model with the assumptions noted in the table below. The fair value of an award with only a service condition is amortized as compensation expense on a straight-line basis over the requisite service period of the awards, which is generally the vesting period. Compensation cost of awards that contain a performance condition are recognized when success is considered probable during the performance period. The Company has elected to account for forfeitures as they occur, rather than estimating the number of awards that are expected to vest. The risk-free interest rate is estimated using the weighted average rate of return on U.S. Treasury notes with a life that approximates the expected life of the option. The expected term of options granted to employees was calculated using the simplified method, which represents the average of the contractual term of the option and the weighted-average vesting period of the option. The Company uses the simplified method because it does not have sufficient historical option exercise data to provide a reasonable basis upon which to estimate expected term. The contractual life of the option was used for the expected life of options granted to non-employees. Expected volatility is based on the weighted average of the historical volatility of a peer group of publicly traded companies, using the daily closing prices during the equivalent period of the calculated expected term of stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of the Company&#x2019;s stock price becomes available, or until circumstances change, such that the identified entities are no longer comparable companies. The assumed dividend yield is based upon the Company's expectation of not paying dividends in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The fair value of each employee and non-employee stock option grant was estimated on the date of grant using Black-Scholes based on the following assumptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.028%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.4% - 4.3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.7% - 4.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;79.5% - 107.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;71.7% - 75.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected term in years (employees)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.0  -  6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.5 - 6.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In March 2021 and June 2022, certain employees of the Company early exercised options to purchase shares of the Company&#x2019;s common stock. The shares had not fully vested at the time of exercise and were recorded as an unvested option exercise liability. As the shares vested, the Company recognized the shares and related expense as issuance of common stock upon settlement of restricted stock in the consolidated financial statements for the years ended December&#160;31, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In January 2021, the board of directors of Angion approved the Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;). The ESPP was effective on the date immediately prior to the effectiveness of Angion's registration statement relating to the initial public offering. The offering period and purchase period was determined by Angion&#x2019;s board of directors. No offering periods or purchasing periods were active as of December&#160;31, 2024. As of December&#160;31, 2024, 165,015 shares under the ESPP remain available for purchase and no offerings have been authorized.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <angn:CommonStockCapitalSharesReservedForFutureIssuanceIncreasePercentageOfCommonStockOutstanding contextRef="c-121" decimals="2" id="f-589" unitRef="number">0.05</angn:CommonStockCapitalSharesReservedForFutureIssuanceIncreasePercentageOfCommonStockOutstanding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-122"
      decimals="INF"
      id="f-590"
      unitRef="shares">30113</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-123"
      decimals="INF"
      id="f-591"
      unitRef="shares">298795</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-124"
      decimals="INF"
      id="f-592"
      unitRef="shares">175283</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <angn:ShareBasedCompensationArrangementByShareBasedPaymentAwardShareLimit
      contextRef="c-125"
      decimals="INF"
      id="f-593"
      unitRef="shares">500000</angn:ShareBasedCompensationArrangementByShareBasedPaymentAwardShareLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-126"
      decimals="INF"
      id="f-594"
      unitRef="shares">387332</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-595">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table summarizes information and activity related to the Company&#x2019;s stock options:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.268%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%"&gt;Number of &lt;br/&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%"&gt;Weighted Average &lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%"&gt;Weighted Average &lt;br/&gt;Remaining Contractual Life &lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%"&gt;Total &lt;br/&gt;Intrinsic Value &lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,305,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;21.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7.43&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;798,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(9,757)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Forfeited (unvested)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(204,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Outstanding as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,890,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;15.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6.78&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;860,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.78&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-5" decimals="INF" id="f-596" unitRef="shares">1305924</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-597"
      unitRef="usdPerShare">21.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-6" id="f-598">P7Y5M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-5" decimals="-3" id="f-599" unitRef="usd">2511000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-600" unitRef="shares">798934</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-601"
      unitRef="usdPerShare">3.59</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-602" unitRef="shares">9757</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-603"
      unitRef="usdPerShare">3.92</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-1" decimals="INF" id="f-604" unitRef="shares">204169</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-605"
      unitRef="usdPerShare">10.43</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-4" decimals="INF" id="f-606" unitRef="shares">1890932</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-607"
      unitRef="usdPerShare">15.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-608">P6Y9M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-4" decimals="-3" id="f-609" unitRef="usd">920000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c-4" decimals="INF" id="f-610" unitRef="shares">860803</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-611"
      unitRef="usdPerShare">28.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-612">P4Y9M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-4" decimals="-3" id="f-613" unitRef="usd">428000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-614" unitRef="shares">798934</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-615"
      unitRef="usdPerShare">3.59</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-4" decimals="-5" id="f-616" unitRef="usd">3100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-1" id="f-617">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-618">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table summarizes total stock-based compensation expense recorded in the consolidated statements of operations (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.876%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-127" decimals="-3" id="f-619" unitRef="usd">582000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-128" decimals="-3" id="f-620" unitRef="usd">552000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-129" decimals="-3" id="f-621" unitRef="usd">870000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-130" decimals="-3" id="f-622" unitRef="usd">627000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-623" unitRef="usd">1452000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-6" decimals="-3" id="f-624" unitRef="usd">1179000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-625">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The fair value of each employee and non-employee stock option grant was estimated on the date of grant using Black-Scholes based on the following assumptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.028%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.4% - 4.3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.7% - 4.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;79.5% - 107.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;71.7% - 75.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected term in years (employees)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.0  -  6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.5 - 6.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-131" decimals="3" id="f-626" unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-132" decimals="3" id="f-627" unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-133"
      decimals="INF"
      id="f-628"
      unitRef="shares">165015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-133"
      decimals="INF"
      id="f-629"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <angn:WarrantsAndRightsOutstandingTextBlock contextRef="c-1" id="f-649">Warrants&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In accordance with ASC 815, the warrants classified as liabilities are recorded at fair value at the issuance date, with subsequent changes in the fair value recognized in the consolidated statements of operations and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;comprehensive loss at the end of each reporting period. Refer to Note 4 for changes in the fair value recognized during the periods reported. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As disclosed in Note 4, in March 2024, the Company entered into the March Subscription Agreement with GKCC, an entity controlled by a member of the Company&#x2019;s board of directors, for purposes of the March Offering. Each Pre-Funded Warrant issued and sold in the March Offering is exercisable at an exercise price equal to $0.01 per share, subject to certain adjustments and limitations as provided under the terms of the Pre-Funded Warrants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Upon issuance, the fair value of the Pre-Funded Warrants was $6.6&#160;million. The Company recorded the $0.6&#160;million difference between the proceeds and the grant date fair value as a loss on issuance of warrants in the statements of operations and comprehensive loss during the three months ended March 31, 2024. The fair value of the Pre-Funded Warrants was measured using the Black-Scholes option pricing model as of the grant date. For the year ended December&#160;31, 2024, the Company recognized a gain of $1.3 million in fair value remeasurement of the Pre-Funded Warrants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As disclosed in Notes 4 and 7, in July 2024, the Company closed its Public Offering consisting of (i) the July Shares, (ii) the July Pre-Funded Warrants, and (iii) the July Common Warrants. Each July Pre-Funded Warrant issued and sold in the Public Offering is exercisable at an exercise price equal to $0.01 per share, subject to certain adjustments and limitations as provided under the terms of the July Pre-Funded Warrants. Each July Common Warrant is exercisable at an exercise price equal to $5.00 per share, subject to certain adjustments and limitations as provided under the terms of the July Common Warrants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Upon issuance, the fair value of the July Pre-Funded Warrants and July Common Warrants was $6.8&#160;million and $6.5&#160;million, respectively. The Company recorded the $2.9&#160;million difference between the proceeds and the grant date fair value as a loss on the issuance of warrants in the statements of operations and comprehensive loss during the three months ended September 30, 2024. The fair value of the July Pre-Funded Warrants and July Common Warrants was measured using the Black-Scholes option pricing model as of the grant date. For the year ended December&#160;31, 2024, the Company recognized a loss of $2.4 million in fair value remeasurement of the July Pre-Funded Warrants. For the year ended December&#160;31, 2024, the Company recognized a loss of $2.8 million in fair value remeasurement of the July Common Warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Following receipt of Stockholder Approval in November 2024, the Company remeasured the July Common Warrants held by that shareholder at fair value and recognized the loss from change in fair value on the consolidated financial statements during the year ended December 31, 2024. As a result of obtaining Stockholder Approval, the Common Warrants held by that shareholder met the equity classification requirements under ASC 815. During the quarter ended December 31, 2024, the Company reclassified the July Common Warrants held by the stockholder from a liability to equity. The Company will re-assess the liability classification for the remaining July Common Warrants at each period end.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table summarizes the issuances of warrants by the Company throughout 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.174%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.613%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.514%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Number of Warrants Issued&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Date of Issuance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Expiration Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Pre-Funded Warrants&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,032,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;July Pre-Funded Warrants&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,800,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;July Common Warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,300,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total Warrants Issued&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5,132,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; Pre-funded warrants have been purchased and have an exercise price of $.01 per share. These warrants do not have an expiration date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table summarizes warrant activity regarding the Pre-Funded Warrants and Common Warrants outstanding at December&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.174%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.613%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.514%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted &lt;br/&gt;Average &lt;br/&gt;Exercise &lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted Average Life (years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;148,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;54.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Issued&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5,132,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(200,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5,081,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</angn:WarrantsAndRightsOutstandingTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-78"
      decimals="2"
      id="f-650"
      unitRef="usdPerShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <angn:FairValueOfCommonStockWarrants contextRef="c-139" decimals="-5" id="f-651" unitRef="usd">6600000</angn:FairValueOfCommonStockWarrants>
    <angn:GainLossOnIssuanceOfWarrants contextRef="c-140" decimals="-5" id="f-652" unitRef="usd">600000</angn:GainLossOnIssuanceOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-141" decimals="-5" id="f-653" unitRef="usd">-1300000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-142"
      decimals="2"
      id="f-654"
      unitRef="usdPerShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-83"
      decimals="2"
      id="f-655"
      unitRef="usdPerShare">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <angn:FairValueOfCommonStockWarrants contextRef="c-143" decimals="-5" id="f-656" unitRef="usd">6800000</angn:FairValueOfCommonStockWarrants>
    <angn:FairValueOfCommonStockWarrants contextRef="c-144" decimals="-5" id="f-657" unitRef="usd">6500000</angn:FairValueOfCommonStockWarrants>
    <angn:GainLossOnIssuanceOfWarrants contextRef="c-145" decimals="-5" id="f-658" unitRef="usd">2900000</angn:GainLossOnIssuanceOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-146" decimals="-5" id="f-659" unitRef="usd">-2400000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-147" decimals="-5" id="f-660" unitRef="usd">-2800000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c-1" id="f-661">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table summarizes the issuances of warrants by the Company throughout 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.174%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.613%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.514%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Number of Warrants Issued&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Date of Issuance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Expiration Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Pre-Funded Warrants&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,032,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;July Pre-Funded Warrants&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,800,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;July Common Warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,300,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total Warrants Issued&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5,132,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; Pre-funded warrants have been purchased and have an exercise price of $.01 per share. These warrants do not have an expiration date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table summarizes warrant activity regarding the Pre-Funded Warrants and Common Warrants outstanding at December&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.174%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.613%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.514%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted &lt;br/&gt;Average &lt;br/&gt;Exercise &lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted Average Life (years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;148,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;54.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Issued&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5,132,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(200,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5,081,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <angn:WarrantsIssuedShares
      contextRef="c-148"
      decimals="INF"
      id="f-662"
      unitRef="shares">1032702</angn:WarrantsIssuedShares>
    <angn:WarrantsIssuedShares
      contextRef="c-149"
      decimals="INF"
      id="f-663"
      unitRef="shares">1800000</angn:WarrantsIssuedShares>
    <angn:WarrantsIssuedShares
      contextRef="c-150"
      decimals="INF"
      id="f-664"
      unitRef="shares">2300000</angn:WarrantsIssuedShares>
    <angn:WarrantsIssuedShares contextRef="c-4" decimals="INF" id="f-665" unitRef="shares">5132702</angn:WarrantsIssuedShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-151"
      decimals="2"
      id="f-666"
      unitRef="usdPerShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-152"
      decimals="2"
      id="f-667"
      unitRef="usdPerShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c-5" decimals="INF" id="f-668" unitRef="shares">148764</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-5"
      decimals="INF"
      id="f-669"
      unitRef="usdPerShare">54.19</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <angn:ClassOfWarrantOrRightWeightedAverageLife contextRef="c-5" id="f-670">P5Y6M</angn:ClassOfWarrantOrRightWeightedAverageLife>
    <angn:ClassOfWarrantOrRightIssuedInPeriod contextRef="c-1" decimals="INF" id="f-671" unitRef="shares">5132702</angn:ClassOfWarrantOrRightIssuedInPeriod>
    <angn:ClassOfWarrantOrRightWeightedAverageExercisePriceIssuedInPeriod
      contextRef="c-1"
      decimals="INF"
      id="f-672"
      unitRef="usdPerShare">2.34</angn:ClassOfWarrantOrRightWeightedAverageExercisePriceIssuedInPeriod>
    <angn:ClassOfWarrantOrRightExercisedInPeriod contextRef="c-1" decimals="INF" id="f-673" unitRef="shares">200000</angn:ClassOfWarrantOrRightExercisedInPeriod>
    <angn:ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod
      contextRef="c-1"
      decimals="INF"
      id="f-674"
      unitRef="usdPerShare">0.01</angn:ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c-4" decimals="INF" id="f-675" unitRef="shares">5081466</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-4"
      decimals="INF"
      id="f-676"
      unitRef="usdPerShare">3.85</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <angn:ClassOfWarrantOrRightWeightedAverageLife contextRef="c-4" id="f-677">P4Y6M</angn:ClassOfWarrantOrRightWeightedAverageLife>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-678">Commitments and Contingencies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Legal Proceedings &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;From time to time, the Company may be involved in legal proceedings, or may be subject to various demands, claims and threatened litigation, which arise in the normal course of its business or otherwise. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The outcome of any future litigation is uncertain. Such litigation, if not resolved, could result in substantial costs to the Company, including any costs associated with the indemnification of directors and officers, and could lead to a diversion of management resources among other factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company may be exposed to litigation in connection with its products under development and operations. The Company&#x2019;s policy is to assess the likelihood of any adverse judgments or outcomes related to legal matters, as well as ranges of probable losses. As of the time of this report, the Company does not believe it is a party to any claim, proceeding or litigation, the outcome of which, if determined adversely to the Company, would individually or in the aggregate be reasonably expected to have a material adverse effect on its business. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In January 2016, Former Elicio entered into a license agreement to license certain intellectual property from a university, which agreement has been amended from time to time to license additional intellectual property and to adjust fees, milestone dates, and diligence requirements. The Company is required to pay certain contractual maintenance and milestone payments related to clinical trials and royalties on product sales over the term of the contract, with minimum annual royalty payments commencing in the calendar year after commercialization. The license term for the January 2016 license agreement extends until terminated by either party under certain provisions. During the year ended December&#160;31, 2024, in accordance with the terms of the license agreement, the Company achieved a milestone related to the ongoing clinical trials and recorded license expense of $0.4&#160;million. No commercialization royalties have been achieved to date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In addition, the Company is required to pay a total of up to $20.9&#160;million upon achievement of certain late-stage developmental and commercial milestones. The developmental milestone payment will be recorded when the milestone is achieved, and the commercial milestone payment and royalties will be recorded when the sales occur.&lt;/span&gt;&lt;/div&gt;Future minimum annual maintenance payments are $0.1&#160;million for the year ended December&#160;31, 2024 and for each year thereafter. Future minimum annual payments are due until the termination of the agreement.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <angn:LicenseExpense contextRef="c-1" decimals="-5" id="f-679" unitRef="usd">400000</angn:LicenseExpense>
    <angn:OperatingLeaseFutureMinimumAnnualMaintenancePayments contextRef="c-1" decimals="-5" id="f-680" unitRef="usd">20900000</angn:OperatingLeaseFutureMinimumAnnualMaintenancePayments>
    <angn:OperatingLeaseFutureMinimumAnnualMaintenancePaymentsDueThereafter contextRef="c-1" decimals="-5" id="f-681" unitRef="usd">100000</angn:OperatingLeaseFutureMinimumAnnualMaintenancePaymentsDueThereafter>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-682">Leases&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In July 2021, the Company signed an operating lease for office and laboratory space in Boston, Massachusetts (the &#x201c;Boston Lease&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Boston Lease commenced in February 2022 with the term set to expire in February 2030. The Boston Lease has rent payments escalating annually, which total $11.1&#160;million in the aggregate. As a result, at the commencement of the Boston Lease, the Company recognized a ROU lease asset of $8.0&#160;million with a corresponding lease liability of $8.0&#160;million based on the present value of the minimum rental payments. In addition, the Company will make payments for operating expenses and real estate taxes. In June 2023, the Company secured a letter of credit for the deposit on the Boston Lease and has a deposit in the amount of $0.7&#160;million, which was reported as restricted cash, noncurrent on the consolidated balance sheets as of December&#160;31, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As part of the Merger Agreement, the Company also assumed a lease for clinical and regulatory space in Newton, Massachusetts, comprising approximately 6,157 square feet for approximately $0.2&#160;million per year, under a non-cancelable operating lease that expired on June 30, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Lease expense for all leases for the years ended December&#160;31, 2024 and 2023 was $1.5&#160;million and $1.5&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table summarizes quantitative information about the Company's operating leases (dollars in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.268%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;For the year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating cash outflows from operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Weighted-average remaining lease term&#x2014;operating leases (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Weighted-average discount rate&#x2014;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, maturities of lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.673%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Less present value discount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1,384)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Less: operating lease liability, current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(901)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating lease liability, noncurrent portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeaseExpense contextRef="c-153" decimals="-5" id="f-683" unitRef="usd">11100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-154" decimals="-5" id="f-684" unitRef="usd">8000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-154" decimals="-5" id="f-685" unitRef="usd">8000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ProceedsFromSecuredLinesOfCredit contextRef="c-155" decimals="-5" id="f-686" unitRef="usd">700000</us-gaap:ProceedsFromSecuredLinesOfCredit>
    <us-gaap:AreaOfRealEstateProperty contextRef="c-156" decimals="0" id="f-687" unitRef="sqft">6157</us-gaap:AreaOfRealEstateProperty>
    <angn:LesseeOperatingLeaseAnnualRentExpense contextRef="c-157" decimals="-5" id="f-688" unitRef="usd">200000</angn:LesseeOperatingLeaseAnnualRentExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-1" decimals="-5" id="f-689" unitRef="usd">1500000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-6" decimals="-5" id="f-690" unitRef="usd">1500000</us-gaap:OperatingLeaseExpense>
    <angn:ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock contextRef="c-1" id="f-691">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table summarizes quantitative information about the Company's operating leases (dollars in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.268%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;For the year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating cash outflows from operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Weighted-average remaining lease term&#x2014;operating leases (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Weighted-average discount rate&#x2014;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</angn:ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-3" id="f-692" unitRef="usd">1427000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-6" decimals="-3" id="f-693" unitRef="usd">1380000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-4" id="f-694">P5Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-5" id="f-695">P5Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-4" decimals="3" id="f-696" unitRef="number">0.080</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-5" decimals="3" id="f-697" unitRef="number">0.075</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-698">&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, maturities of lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.673%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Less present value discount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1,384)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Less: operating lease liability, current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(901)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating lease liability, noncurrent portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-4" decimals="-3" id="f-699" unitRef="usd">1350000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-4" decimals="-3" id="f-700" unitRef="usd">1383000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-4" decimals="-3" id="f-701" unitRef="usd">1425000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-4" decimals="-3" id="f-702" unitRef="usd">1467000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-4" decimals="-3" id="f-703" unitRef="usd">1512000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-4" decimals="-3" id="f-704" unitRef="usd">253000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-4" decimals="-3" id="f-705" unitRef="usd">7390000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-4" decimals="-3" id="f-706" unitRef="usd">1384000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-4" decimals="-3" id="f-707" unitRef="usd">6006000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-708" unitRef="usd">901000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-709" unitRef="usd">5105000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-710">Debt&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Note Payable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In connection with execution of the Merger Agreement, Angion made the Bridge Loan to Former Elicio pursuant to a note purchase agreement and promissory notes up to an aggregate principal amount of $12.5&#160;million, issued with a 20% original issue discount. An initial closing held substantially concurrently with the execution of the Merger Agreement for a principal amount of $6.25&#160;million in exchange for cash of $5.0&#160;million and an additional closing for a principal amount of $6.25&#160;million in exchange for cash of $5.0&#160;million occurred upon delivery by Former Elicio to Angion of Former Elicio&#x2019;s audited financial statements for the year ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The promissory notes included multiple settlement options depending on the outcome of the Merger. Former Elicio evaluated all the settlement features, included within the promissory note agreement, under FASB ASC Topic 815, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Derivatives and Hedging&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, and determined the settlement features met the definition of a derivative and required bifurcation from the promissory notes. The bifurcated embedded derivative of $0.4 million was recorded as a liability at fair value at the date of issuance based on the probability of occurrence of a triggering event taking place during the term of the promissory notes and was recorded as a discount to the carrying value of the promissory note. During the year ended December&#160;31, 2023, Former Elicio recorded other expense of $2.3 million related to the accretion of the discount of the promissory notes derivative.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During the year ended December&#160;31, 2023, per the terms of the Merger Agreement, upon completion of the Merger, all obligations owed by Former Elicio related to the promissory notes were automatically forgiven and the amount advanced by Angion, along with any accrued and unpaid interest, was credited towards the net cash balance used to calculate the assets and liabilities listed above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Senior Secured Convertible Note Financing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In August 2024, the Company entered into a securities purchase agreement (the &#x201c;Securities Purchase Agreement&#x201d;) with GKCC, an entity controlled by a member of the Company&#x2019;s board of directors, pursuant to which the Company issued a 3% Senior Secured Convertible Promissory Note due February 15, 2026 (the &#x201c;Convertible Note&#x201d;) in the principal amount of $20.0 million (the &#x201c;Note Financing&#x201d;). Unless earlier converted in accordance with &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;the terms of the Convertible Note, the Convertible Note will mature on February 15, 2026. Interest on the Convertible Note accrues and is payable quarterly in cash on the principal amount equal to 3% per annum, with the initial interest payment date to be June 30, 2025. The Convertible Note is secured by a (i) first priority lien on substantially all assets of the Company and its subsidiaries, pursuant to a security agreement and (ii) first priority lien on intellectual property of the Company, pursuant to an intellectual property security agreement. The Convertible Note will be convertible into shares of the Company&#x2019;s common stock, in whole or in part, at the option of GKCC at any time, based on an initial conversion price of $5.81 (the &#x201c;Conversion Price&#x201d;) per share of common stock, subject to adjustments and satisfaction of certain conversion conditions; provided that the Company was not able to effect any conversion of the Convertible Note and GKCC did not have any right to convert any portion of the Convertible Note until the Company received Stockholder Approval. The Company received Stockholder Approval in November 2024. If at any time from and after the date of the Securities Purchase Agreement and for so long as certain conversion conditions are satisfied, the closing price of the common stock on Nasdaq equals or exceeds 135% of the Conversion Price for 20 trading days in a 30 trading day period, then the Company has the right to require GKCC to convert all or any portion of the Convertible Note, including any accrued but unpaid interest into shares of common stock, as further described in the Convertible Note. The Convertible Note contains customary terms and covenants and customary events of default. The Company granted GKCC certain customary registration rights with respect to the shares of common stock issuable upon conversion of the Convertible Note.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company received net proceeds of approximately $19.7 million from the Note Financing, after deducting debt issuance costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Convertible Note includes multiple conversion features. The Company evaluated all conversion features included within the Convertible Note, under FASB ASC Topic 815, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Derivatives and Hedging,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; and determined that the default interest feature met the definition of a derivative, but the value was de minimis. During the year ended December&#160;31, 2024, the Company recorded other expense of $0.1 million related to the accretion of the discount of Convertible Note debt issuance costs. As of and for the year ended December&#160;31, 2024, the Company recorded accrued interest expense of $0.2 million related to the interest due on the Convertible Note but not yet payable.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-60" decimals="-5" id="f-711" unitRef="usd">12500000</us-gaap:DebtInstrumentFaceAmount>
    <angn:DebtInstrumentIssuanceDiscountPercent
      contextRef="c-60"
      decimals="INF"
      id="f-712"
      unitRef="number">0.20</angn:DebtInstrumentIssuanceDiscountPercent>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-61" decimals="-4" id="f-713" unitRef="usd">6250000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-62" decimals="-5" id="f-714" unitRef="usd">5000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-63" decimals="-4" id="f-715" unitRef="usd">6250000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-64" decimals="-5" id="f-716" unitRef="usd">5000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="c-158" decimals="-5" id="f-717" unitRef="usd">400000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-159" decimals="-5" id="f-718" unitRef="usd">2300000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-160" decimals="2" id="f-719" unitRef="number">0.03</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-160" decimals="-5" id="f-720" unitRef="usd">20000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-160" decimals="2" id="f-721" unitRef="number">0.03</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-160"
      decimals="2"
      id="f-722"
      unitRef="usdPerShare">5.81</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger contextRef="c-161" decimals="2" id="f-723" unitRef="number">1.35</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays contextRef="c-161" decimals="INF" id="f-724" unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1 contextRef="c-161" decimals="INF" id="f-725" unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c-162" decimals="-5" id="f-726" unitRef="usd">19700000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-163" decimals="-3" id="f-727" unitRef="usd">100000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestExpenseDebt contextRef="c-163" decimals="-5" id="f-728" unitRef="usd">200000</us-gaap:InterestExpenseDebt>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-729">Income Taxes&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The components of the Company&#x2019;s provision for income taxes for the years ended December&#160;31, 2024 and 2023 consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.451%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.827%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.828%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Deferred &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(11,236)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(10,859)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total tax provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliations between the federal statutory income tax rate and the Company's effective income tax rate were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.451%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.827%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.828%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Statutory federal income tax rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;State tax, net of federal benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Federal research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;State research and development credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other differences&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(19.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(30.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Effective income tax rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The principal components of the Company's net deferred tax asset at December&#160;31, 2024 and 2023 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.876%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Deferred tax assets (liabilities):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;64,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;60,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Research and development tax credit carryovers&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;15,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;12,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Capitalized research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;17,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;13,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Lease liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;ROU asset&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1,470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1,800)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;100,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;90,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Less: Deferred tax asset valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(100,117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(90,118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Net deferred tax asset&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Net operating losses (&#x201c;NOL&#x201d;) generated before December 31, 2017 can be carried forward 20 years under the Internal Revenue Code (&#x201c;IRC&#x201d;). Use of NOLs arising in tax years ended after December 31, 2017 are limited to 80% of taxable income in any one tax year, and are carried forward indefinitely. The Company has no income tax expense due to operating losses incurred for the years ended December&#160;31, 2024 and 2023. The Company has provided a valuation allowance for the full amount of the net deferred tax assets as, based on all available evidence, it is considered more likely than not that all the recorded deferred tax assets will not be realized in a future period. The increase in the net deferred tax assets and valuation allowance is primarily due to increases in federal and state NOLs, federal and state research credits, and capitalized research expenditures. At December&#160;31, 2024, Elicio has federal NOLs of $261.8 million, of which $19.1 million was generated before the tax year ended December 31, 2018, and state NOLs of $145.2 million. If not utilized, certain NOLs for federal and state tax purposes will start to expire beginning in 2032. At December&#160;31, 2024, Elicio has $12.9 million and $2.6 million of federal and state research and development credit carryforwards, respectively, that start to expire in 2027.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As the Company has not yet achieved profitable operations, management believes the tax benefits as of December&#160;31, 2024 did not satisfy the realization criteria set forth in ASC Topic 740, Income Taxes and, therefore, has recorded a full valuation allowance for the entire deferred tax asset. The valuation allowance increased in 2024 by $10.0 million due to the increase in the deferred tax assets by the same amount, primarily due to NOL carryforwards. The Company&#x2019;s effective income tax rate differed from the federal statutory rate primarily due to state taxes and the Company&#x2019;s full valuation allowance, the latter of which reduced the Company&#x2019;s effective federal income tax rate to zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Ownership changes, as defined in the IRC, may limit the amount of NOL carryforwards that can be utilized annually to offset future taxable income pursuant to IRC Section 382 or similar provisions. Subsequent ownership &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;changes could further affect the limitation in future years. The Company has not completed a study to assess whether a change of control has occurred or whether there have been multiple changes of control since the Company&#x2019;s formation due to the significant complexity and cost associated with such study and because there could be additional changes in control in the future. As a result, the Company is not able to estimate the effect of the change in control, if any, on the Company&#x2019;s ability to utilize NOL and research and development credit carryforwards in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company files tax returns in the United States, Australia, California, Connecticut, Florida, Massachusetts, Michigan, Missouri, New Hampshire, New Jersey, North Carolina, Pennsylvania, and Tennessee. All tax years from 2021 to 2024 remain open to examination by the major taxing jurisdictions to which the Company is subject, as carryforward attributes generated in years past may still be adjusted upon examination by the Internal Revenue Service (&#x201c;IRS&#x201d;) or other authorities if they have or will be used in a future period. To its knowledge, the Company is not currently under examination by the IRS or any other jurisdictions for any tax years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As of December&#160;31, 2024, the Company had $4.1 million of uncertain tax positions related to prior research tax credits that may not be substantiated upon audit. The Company does not anticipate that uncertain tax positions will decrease within the next 12 months. The Company has elected to recognize interest and penalties related to income tax matters as a component of income tax expense, of which no interest or penalties were recorded for the years ended December&#160;31, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-730">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The components of the Company&#x2019;s provision for income taxes for the years ended December&#160;31, 2024 and 2023 consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.451%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.827%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.828%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Deferred &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(11,236)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(10,859)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total tax provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-731" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-732" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-733" unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-734" unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-735" unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-736" unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-737" unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-738" unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-739" unitRef="usd">-11236000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-740" unitRef="usd">7743000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-741" unitRef="usd">1192000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-742" unitRef="usd">3116000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-743" unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-744" unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability contextRef="c-1" decimals="-3" id="f-745" unitRef="usd">10044000</us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability>
    <us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability contextRef="c-6" decimals="-3" id="f-746" unitRef="usd">-10859000</us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-747" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-748" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-749" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-750" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-751">&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliations between the federal statutory income tax rate and the Company's effective income tax rate were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.451%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.827%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.828%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Statutory federal income tax rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;State tax, net of federal benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Federal research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;State research and development credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other differences&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(19.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(30.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Effective income tax rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="INF" id="f-752" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-6" decimals="INF" id="f-753" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="3" id="f-754" unitRef="number">-0.024</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-6" decimals="3" id="f-755" unitRef="number">0.062</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <angn:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent contextRef="c-1" decimals="3" id="f-756" unitRef="number">-0.035</angn:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent>
    <angn:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent contextRef="c-6" decimals="3" id="f-757" unitRef="number">-0.003</angn:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent>
    <angn:EffectiveIncomeTaxRateReconciliationTaxCreditFederalResearchAndDevelopmentPercent contextRef="c-1" decimals="3" id="f-758" unitRef="number">0.036</angn:EffectiveIncomeTaxRateReconciliationTaxCreditFederalResearchAndDevelopmentPercent>
    <angn:EffectiveIncomeTaxRateReconciliationTaxCreditFederalResearchAndDevelopmentPercent contextRef="c-6" decimals="3" id="f-759" unitRef="number">0.031</angn:EffectiveIncomeTaxRateReconciliationTaxCreditFederalResearchAndDevelopmentPercent>
    <angn:EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent contextRef="c-1" decimals="3" id="f-760" unitRef="number">0.006</angn:EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent>
    <angn:EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent contextRef="c-6" decimals="3" id="f-761" unitRef="number">0.008</angn:EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-1" decimals="3" id="f-762" unitRef="number">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-6" decimals="3" id="f-763" unitRef="number">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="3" id="f-764" unitRef="number">-0.194</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-6" decimals="3" id="f-765" unitRef="number">-0.309</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-766" unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-6" decimals="3" id="f-767" unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-768">&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The principal components of the Company's net deferred tax asset at December&#160;31, 2024 and 2023 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.876%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Deferred tax assets (liabilities):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;64,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;60,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Research and development tax credit carryovers&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;15,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;12,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Capitalized research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;17,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;13,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Lease liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;ROU asset&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1,470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1,800)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;100,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;90,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Less: Deferred tax asset valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(100,117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(90,118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Net deferred tax asset&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-4" decimals="-3" id="f-769" unitRef="usd">64646000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-5" decimals="-3" id="f-770" unitRef="usd">60696000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c-4" decimals="-3" id="f-771" unitRef="usd">15117000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c-5" decimals="-3" id="f-772" unitRef="usd">12940000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-4" decimals="-3" id="f-773" unitRef="usd">17585000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-5" decimals="-3" id="f-774" unitRef="usd">13686000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <angn:DeferredTaxAssetsOperatingLeaseLiability contextRef="c-4" decimals="-3" id="f-775" unitRef="usd">1548000</angn:DeferredTaxAssetsOperatingLeaseLiability>
    <angn:DeferredTaxAssetsOperatingLeaseLiability contextRef="c-5" decimals="-3" id="f-776" unitRef="usd">1897000</angn:DeferredTaxAssetsOperatingLeaseLiability>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-4" decimals="-3" id="f-777" unitRef="usd">2704000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-5" decimals="-3" id="f-778" unitRef="usd">2732000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-4" decimals="-3" id="f-779" unitRef="usd">1470000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-5" decimals="-3" id="f-780" unitRef="usd">1800000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-781" unitRef="usd">13000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-782" unitRef="usd">33000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <angn:DeferredTaxAssetsNetBeforeValuationAllowance contextRef="c-4" decimals="-3" id="f-783" unitRef="usd">100117000</angn:DeferredTaxAssetsNetBeforeValuationAllowance>
    <angn:DeferredTaxAssetsNetBeforeValuationAllowance contextRef="c-5" decimals="-3" id="f-784" unitRef="usd">90118000</angn:DeferredTaxAssetsNetBeforeValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-4" decimals="-3" id="f-785" unitRef="usd">100117000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-3" id="f-786" unitRef="usd">90118000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-4" decimals="-3" id="f-787" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-5" decimals="-3" id="f-788" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-6" decimals="INF" id="f-789" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="INF" id="f-790" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:OperatingLossCarryforwards contextRef="c-164" decimals="-5" id="f-791" unitRef="usd">261800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-165" decimals="-5" id="f-792" unitRef="usd">19100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-166" decimals="-5" id="f-793" unitRef="usd">145200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-167" decimals="-5" id="f-794" unitRef="usd">12900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-168" decimals="-5" id="f-795" unitRef="usd">2600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-1" decimals="-5" id="f-796" unitRef="usd">10000000.0</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-797" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-4" decimals="-5" id="f-798" unitRef="usd">4100000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c-4" decimals="INF" id="f-799" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c-5" decimals="INF" id="f-800" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:DefinedContributionPlanTextBlock contextRef="c-1" id="f-801">Employee Benefit Plan&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Employee Benefit Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company provides a retirement savings plan through the Vendantra Pharmaceuticals Inc. 401(k) Plan (the &#x201c;Elicio Retirement Plan&#x201d;), subject to certain limitations. As allowed under Section 401(k) of the IRC, the Elicio Retirement Plan allows tax deferred salary deductions for eligible employees. An employee&#x2019;s interest in his or her salary deferral contributions is 100% vested when contributed.&lt;/span&gt;&lt;/div&gt;Pursuant to the Merger Agreement, the Company assumed the retirement savings plan sponsored by Angion (the &#x201c;Angion Retirement Plan&#x201d;). The Angion Retirement Plan is intended to qualify for favorable tax treatment under Section 401(a) of the IRC, and contains a cash or deferred feature that is intended to meet the requirements of Section 401(k) of the IRC. Currently, no employees are contributing under the Angion Retirement Plan.</us-gaap:DefinedContributionPlanTextBlock>
    <us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage
      contextRef="c-169"
      decimals="INF"
      id="f-802"
      unitRef="number">1</us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-803">Net Loss Per Share&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company has reported losses since inception and has computed basic net loss per share attributable to common stockholders by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock and pre-funded warrants outstanding for the period, without consideration for potentially dilutive securities. The Company computes diluted net loss per share of common stock after giving consideration to all potentially dilutive shares of common stock, including options to purchase common stock and preferred stock outstanding during the period determined using the treasury-stock and if-converted methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential shares of common stock and preferred stock have been anti-dilutive and basic and diluted loss per share were the same for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Basic and diluted net loss per share attributable to common stockholders was calculated for the years ended December&#160;31, 2024 and 2023 as follows (in thousands, except share and per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.876%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Numerator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(51,898)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(35,195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Weighted-average shares used in computing net loss per share, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;12,202,996&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;5,056,225&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4.25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6.96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The table below provides potentially dilutive securities not included in the calculation of the diluted net loss per share because to do so would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.876%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Shares issuable upon exercise of stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,890,932&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;1,305,924&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Shares issuable upon the exercise of warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;2,448,764&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;148,764&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Unvested common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;1,933&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;4,339,696&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;1,456,621&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-804">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Basic and diluted net loss per share attributable to common stockholders was calculated for the years ended December&#160;31, 2024 and 2023 as follows (in thousands, except share and per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.876%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Numerator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(51,898)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(35,195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Weighted-average shares used in computing net loss per share, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;12,202,996&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;5,056,225&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4.25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6.96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-805" unitRef="usd">-51898000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-806" unitRef="usd">-35195000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-807" unitRef="shares">12202996</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-808" unitRef="shares">12202996</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="0" id="f-809" unitRef="shares">5056225</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-6" decimals="0" id="f-810" unitRef="shares">5056225</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-811"
      unitRef="usdPerShare">-4.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-812"
      unitRef="usdPerShare">-4.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-6"
      decimals="2"
      id="f-813"
      unitRef="usdPerShare">-6.96</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-6"
      decimals="2"
      id="f-814"
      unitRef="usdPerShare">-6.96</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-815">The table below provides potentially dilutive securities not included in the calculation of the diluted net loss per share because to do so would be anti-dilutive:&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.876%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Shares issuable upon exercise of stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,890,932&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;1,305,924&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Shares issuable upon the exercise of warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;2,448,764&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;148,764&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Unvested common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;1,933&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;4,339,696&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;1,456,621&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-170" decimals="0" id="f-816" unitRef="shares">1890932</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-171" decimals="0" id="f-817" unitRef="shares">1305924</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-172" decimals="0" id="f-818" unitRef="shares">2448764</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-173" decimals="0" id="f-819" unitRef="shares">148764</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-174" decimals="0" id="f-820" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-175" decimals="0" id="f-821" unitRef="shares">1933</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-822" unitRef="shares">4339696</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-6" decimals="0" id="f-823" unitRef="shares">1456621</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c-1" id="f-824">Related Party Transactions&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Consulting Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company paid $0 and $0.8 million for the years ended December&#160;31, 2024 and 2023, respectively, for consulting services provided by an entity affiliated with the Company&#x2019;s former interim chief financial officer and former board member. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Private Placement and Subscription Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In March 2024, the Company entered into the March Subscription Agreement with GKCC, an entity controlled by a member of the Company&#x2019;s board of directors, for purposes of the March Offering. Each Pre-Funded Warrant issued and sold in the March Offering is exercisable at an exercise price equal to $0.01 per share, subject to certain adjustments and limitations as provided under the terms of the Pre-Funded Warrants. Refer to Note 7 for further detail about the March Offering. The gross proceeds to the Company from the March Offering were approximately $6.0&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Public Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As part of the Public Offering described in Note 7, Yekaterina Chudnovsky, a member of the Company&#x2019;s board of directors, and Jay Venkatesan, a member of the Company&#x2019;s board of directors, and trusts affiliated with Jay Venkatesan, purchased 1,600,000 July Pre-Funded Warrants and accompanying July Common Warrants and 200,000 July Pre-Funded Warrants and accompanying July Common Warrants, respectively, with such July Pre-Funded Warrants and July Common Warrants subject to the terms and conditions of the July Pre-Funded Warrants and July Common Warrants, as further detailed in Note 7 above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Senior Secured Convertible Note Financing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In August 2024, the Company entered into the Securities Purchase Agreement with GKCC, pursuant to which the Company issued the Convertible Note in the principal amount of $20.0 million pursuant to the Note Financing. The Company received net proceeds of approximately $19.7 million from the Note Financing, after deducting debt issuance costs. Refer to Note 12 for further detail regarding the Note Financing.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-176" decimals="-5" id="f-825" unitRef="usd">0</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-177" decimals="-3" id="f-826" unitRef="usd">800000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-78"
      decimals="2"
      id="f-827"
      unitRef="usdPerShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c-178" decimals="-5" id="f-828" unitRef="usd">6000000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <angn:ClassOfWarrantOrRightIssuedInPeriod contextRef="c-179" decimals="0" id="f-829" unitRef="shares">1600000</angn:ClassOfWarrantOrRightIssuedInPeriod>
    <angn:ClassOfWarrantOrRightIssuedInPeriod contextRef="c-180" decimals="0" id="f-830" unitRef="shares">200000</angn:ClassOfWarrantOrRightIssuedInPeriod>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-160" decimals="-5" id="f-831" unitRef="usd">20000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c-162" decimals="-5" id="f-832" unitRef="usd">19700000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-833">Segment Reporting&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company has one reportable segment relating to the development of immunotherapies for patients with limited treatment options and poor outcomes suffering from cancer. The Company&#x2019;s CODM, its Chief Executive Officer, manages the Company&#x2019;s operations on a consolidated basis, assesses performance for the operating segment and decides how to allocate resources based on consolidated net loss, which is reported on the consolidated statements of operations and comprehensive loss. Depreciation expense, amortization expense, stock-based compensation expense, and the change in fair value of warrants are significant noncash items included in consolidated net loss reviewed by the CODM and are reported on the consolidated statements of cash flows. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Other segment items include interest revenue, interest expense, change in the fair value of derivatives, and change in the fair value of warrants. Expenditures for additions to long-lived assets, which include purchases of property and equipment, are included in total consolidated assets reviewed by the CODM and are reported on the consolidated statements of cash flows. The following table presents certain financial data for the Company&#x2019;s reportable segment (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.876%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trial expenses &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee related research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Chemistry, manufacturing and controls expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract and grant reimbursements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,027)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,800)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee related general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees and other general and administrative expenses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other segment items &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(445)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total segment assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments contextRef="c-1" decimals="INF" id="f-834" unitRef="entity">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-835">The following table presents certain financial data for the Company&#x2019;s reportable segment (in thousands):&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.876%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trial expenses &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee related research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Chemistry, manufacturing and controls expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract and grant reimbursements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,027)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,800)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee related general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees and other general and administrative expenses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other segment items &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(445)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total segment assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-181" decimals="-3" id="f-836" unitRef="usd">15892000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-182" decimals="-3" id="f-837" unitRef="usd">7066000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-183" decimals="-3" id="f-838" unitRef="usd">8560000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-184" decimals="-3" id="f-839" unitRef="usd">7306000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-185" decimals="-3" id="f-840" unitRef="usd">4260000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-186" decimals="-3" id="f-841" unitRef="usd">7623000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-187" decimals="-3" id="f-842" unitRef="usd">5971000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-188" decimals="-3" id="f-843" unitRef="usd">5553000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:RecoveryOfDirectCosts contextRef="c-189" decimals="-3" id="f-844" unitRef="usd">-1027000</us-gaap:RecoveryOfDirectCosts>
    <us-gaap:RecoveryOfDirectCosts contextRef="c-190" decimals="-3" id="f-845" unitRef="usd">-3800000</us-gaap:RecoveryOfDirectCosts>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-189" decimals="-3" id="f-846" unitRef="usd">3682000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-190" decimals="-3" id="f-847" unitRef="usd">3437000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="c-189" decimals="-3" id="f-848" unitRef="usd">7648000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="c-190" decimals="-3" id="f-849" unitRef="usd">8455000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-189" decimals="-3" id="f-850" unitRef="usd">6912000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-190" decimals="-3" id="f-851" unitRef="usd">-445000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:NetIncomeLoss contextRef="c-189" decimals="-3" id="f-852" unitRef="usd">51898000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-190" decimals="-3" id="f-853" unitRef="usd">35195000</us-gaap:NetIncomeLoss>
    <us-gaap:Assets contextRef="c-191" decimals="-3" id="f-854" unitRef="usd">28178000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-192" decimals="-3" id="f-855" unitRef="usd">27146000</us-gaap:Assets>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-856">Subsequent Events&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company has completed an evaluation of all subsequent events after the consolidated balance sheet date as of December&#160;31, 2024 through the date these consolidated financial statements were issued to ensure that these consolidated financial statements include appropriate disclosure of events both recognized in the consolidated financial statements as of December&#160;31, 2024, and events which occurred subsequently but were not recognized in the consolidated financial statements. Non-recognizable subsequent events are summarized below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;January Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On January 29, 2025, the Company entered into a Securities Purchase Agreement (the &#x201c;January Purchase Agreement&#x201d;) with certain institutional investors (each an &#x201c;Investor&#x201d; and, collectively, the &#x201c;Investors&#x201d;), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Investors (the &#x201c;January Offering&#x201d;): (i) an aggregate of 1,261,830 shares of common stock, par value $0.01 per share, of the Company and (ii) common warrants to purchase up to an aggregate of 1,261,830 shares of Common Stock (the &#x201c;January Common Warrants&#x201d;). Each share of common stock and accompanying January Common Warrant were sold together at a combined offering price of $7.925. The January Common Warrants have an exercise price of $7.80 per share, are immediately exercisable and will expire five years from the initial exercise date. The aggregate gross proceeds to the Company from the January Offering were approximately $10&#160;million before deducting the placement agent&#x2019;s fees and related offering expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Convertible Note Conversion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As previously described, in August 2024, the Company entered into the Securities Purchase Agreement with GKCC, pursuant to which the Company issued the Convertible Note in the principal amount of $20.0&#160;million pursuant to the Note Financing. Under the terms of the Convertible Note, if at any time from and after the date of the Convertible Note and for so long as the closing price of the Company&#x2019;s common stock on The Nasdaq Capital Market equals or exceeds 135% of the initial conversion price of $5.81 for 20 trading days in a 30 trading day period, then the Company had the right to require GKCC to convert all or any portion of the Convertible Note, including any accrued but unpaid interest into shares of Company common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On March 3, 2025, the Company exercised its right under the Convertible Note to require GKCC to convert the full amount of the Convertible Note, including all accrued and unpaid interest, into shares of Company common stock. On March 5, 2025, the Company issued 3,500,573 shares of common stock to GKCC in exchange for the principal balance of $20&#160;million plus $0.3&#160;million in accrued interest, in satisfaction in full of the Convertible Note.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-193"
      decimals="INF"
      id="f-857"
      unitRef="shares">1261830</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-193"
      decimals="INF"
      id="f-858"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-193"
      decimals="INF"
      id="f-859"
      unitRef="shares">1261830</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-193"
      decimals="3"
      id="f-860"
      unitRef="usdPerShare">7.925</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-193"
      decimals="1"
      id="f-861"
      unitRef="usdPerShare">7.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-194" decimals="-6" id="f-862" unitRef="usd">10000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-160" decimals="-5" id="f-863" unitRef="usd">20000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger contextRef="c-161" decimals="2" id="f-864" unitRef="number">1.35</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-160"
      decimals="2"
      id="f-865"
      unitRef="usdPerShare">5.81</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="c-195"
      decimals="INF"
      id="f-866"
      unitRef="entity">20</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="c-196"
      decimals="INF"
      id="f-867"
      unitRef="entity">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-197"
      decimals="INF"
      id="f-868"
      unitRef="shares">3500573</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-198" decimals="-6" id="f-869" unitRef="usd">20000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <angn:AccruedInterestPremiumForConvertiblePreferredStock contextRef="c-198" decimals="-5" id="f-870" unitRef="usd">300000</angn:AccruedInterestPremiumForConvertiblePreferredStock>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-199" id="f-871">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-199" id="f-872">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-199" id="f-873">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-199" id="f-874">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c-1" id="f-875">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c-1" id="f-876">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
